<SEC-DOCUMENT>0001193125-22-276311.txt : 20221103
<SEC-HEADER>0001193125-22-276311.hdr.sgml : 20221103
<ACCEPTANCE-DATETIME>20221103061822
ACCESSION NUMBER:		0001193125-22-276311
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		39
FILED AS OF DATE:		20221103
DATE AS OF CHANGE:		20221103

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Acrivon Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001781174
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				825125532
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-267911
		FILM NUMBER:		221356016

	BUSINESS ADDRESS:	
		STREET 1:		480 ARSENAL WAY, SUITE 100
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
		BUSINESS PHONE:		617-207-8979

	MAIL ADDRESS:	
		STREET 1:		480 ARSENAL WAY, SUITE 100
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>d383050ds1a.htm
<DESCRIPTION>S-1/A
<TEXT>
<HTML><HEAD>
<TITLE>S-1/A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>As filed with the Securities and Exchange Commission on November&nbsp;3, 2022. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>Registration No. 333-267911 </B></P>  <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES
AND EXCHANGE COMMISSION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT NO. 1 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>TO
</B></P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT STYLE="white-space:nowrap">S-1</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>UNDER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>THE SECURITIES
ACT OF 1933 </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Acrivon Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">(Exact name of registrant as specified in its charter) </P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2834</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">82-5125532</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">(State or other jurisdiction of</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">incorporation or organization)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">(Primary Standard Industrial</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Classification Code Number)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">(I.R.S. Employer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Identification No.)</P></TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>480 Arsenal Way, Suite 100 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Watertown, Massachusetts 02472 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(617) <FONT STYLE="white-space:nowrap">207-8979</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">(Address, including zip code, and telephone number, including area code, of registrant&#146;s principal executive offices) </P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Peter Blume-Jensen, M.D., Ph.D. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Chief Executive Officer and President </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Acrivon Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>480 Arsenal Way, Suite 100 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Watertown, Massachusetts 02472 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(617) <FONT STYLE="white-space:nowrap">207-8979</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">(Name, address, including zip code, and telephone number, including area code, of agent for service) </P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><I>Copies to: </I></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Ryan Sansom</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Mark Ballantyne</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Divakar
Gupta</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Katherine Denby</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Cooley LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>55 Hudson
Yards</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>New York, New York 10001</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(212) <FONT STYLE="white-space:nowrap">479-6000</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Edwin O&#146;Connor</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>William A. Magioncalda</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Goodwin Procter LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>620
Eighth Avenue</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>New York, New York 10018</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(212) <FONT STYLE="white-space:nowrap">813-8800</FONT></B></P></TD></TR>
</TABLE>  <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman" ALIGN="justify"><B>Approximate date of commencement of proposed sale to the public: </B>As soon as
practicable after this Registration Statement is declared effective. </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman" ALIGN="justify">If any of the securities being registered on this Form
are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman" ALIGN="justify">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b)&nbsp;under the Securities Act,
please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman" ALIGN="justify">If this Form is a post-effective amendment filed pursuant to Rule&nbsp;462(c)&nbsp;under the Securities Act, check the following
box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman" ALIGN="justify">If this Form is a post-effective amendment filed pursuant to Rule&nbsp;462(d)&nbsp;under the Securities Act, check the following
box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman" ALIGN="justify">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <FONT
STYLE="white-space:nowrap">non-accelerated</FONT> filer, smaller reporting company, or an emerging growth company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting company,&#148; and
&#147;emerging growth company&#148; in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. </P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt">Large&nbsp;accelerated&nbsp;filer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt">&#9744;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt">Accelerated&nbsp;filer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt">&#9744;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt"><FONT STYLE="white-space:nowrap">Non-accelerated&nbsp;filer</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt">&#9746;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt">Smaller&nbsp;reporting&nbsp;company</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt">&#9746;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt">Emerging&nbsp;growth&nbsp;company</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt">&#9746;</P></TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman" ALIGN="justify">If an emerging growth company, indicate by check mark if the registrant has elected not to use
the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;&#9744; </P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman" ALIGN="justify"><B>The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective
date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933 or until the Registration
Statement shall become effective on such date as the Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Arial Narrow" ALIGN="justify"><FONT COLOR="#de1a1e"><B>The information in this preliminary prospectus is not complete and
may be changed. These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and we are not soliciting offers
to buy these securities in any jurisdiction where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><FONT COLOR="#de1a1e"><I>SUBJECT TO COMPLETION, DATED NOVEMBER&nbsp;3, 2022 </I></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><FONT COLOR="#de1a1e"><I>PRELIMINARY PROSPECTUS </I></FONT></P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><I>5,900,000 Shares </I></P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383050g44x13.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><I>Common Stock </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Bodoni MT" ALIGN="justify"><B><I>We are
offering 5,900,000 shares of our common stock. This is our initial public offering, and no public market currently exists for shares of our common stock. We expect the initial public offering price to be between $16.00 and $18.00 per share. We have
applied to list our common shares on the Nasdaq Global Market under the symbol &#147;ACRV.&#148; </I></B></P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B><I>We are an
&#147;emerging growth company&#148; and a &#147;smaller reporting company&#148; as defined under federal securities laws, and, as such, will be subject to reduced public company reporting requirements for this prospectus and future filings. See the
section titled &#147;Prospectus Summary&#151;Implications of Being an Emerging Growth Company and a Smaller Reporting Company.&#148; Investing in our common stock involves risks. See the section titled &#147;<A HREF="#toc383050_4">Risk
Factors</A>&#148; beginning on page&nbsp;13. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Bodoni MT" ALIGN="justify"><B><I>Neither the Securities and Exchange Commission nor any state securities commission
has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </I></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Bodoni MT; " ALIGN="center"><B><I>Per&nbsp;Share</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Bodoni MT; " ALIGN="center"><B><I>Total</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Initial Public Offering Price</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Underwriting Discounts and
Commissions&nbsp;<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Proceeds, before expenses, to us</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>(1)</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><I>We refer you to &#147;Underwriting&#148; for additional information regarding total underwriter
compensation. </I></P></TD></TR></TABLE>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>We have granted the underwriters an option for a period of 30 days to purchase up to an
additional 885,000 shares of our common stock. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>The underwriters expect to deliver the shares of common stock against payment in New
York, New&nbsp;York on or about November &nbsp;&nbsp;&nbsp;&nbsp;, 2022. </I></P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:14pt" ALIGN="center">


<TR>

<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="29%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:14pt">
<TD VALIGN="top"><I>MORGAN&nbsp;STANLEY</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><I>JEFFERIES</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><I>COWEN</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><I>PIPER&nbsp;SANDLER</I></TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Prospectus dated November &nbsp;&nbsp;&nbsp;&nbsp; , 2022 </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc383050_1">Prospectus Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc383050_4">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc383050_5">Special Note Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc383050_6">Market and Industry Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc383050_7">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc383050_8">Dividend Policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc383050_9">Capitalization</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc383050_10">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc383050_11">Management&#146;s Discussion and Analysis of Financial Condition and Results
 of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc383050_12">Business</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
</DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc383050_13">Management</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc383050_14">Executive Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc383050_15">Certain Relationships and Related Party Transactions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc383050_16">Principal Stockholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc383050_17">Description of Capital Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc383050_18">Shares Eligible for Future Sale</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc383050_19">Certain Material U.S. Federal Income Tax Consequences to <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc383050_20">Underwriting</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc383050_21">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc383050_22">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc383050_23">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc383050_24">Index to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  </div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Neither we nor the underwriters have authorized anyone to provide any information or to make any representations other than
those contained in this prospectus or in any free writing prospectuses we have prepared. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may provide you. We
are offering to sell, and seeking offers to buy, shares of common stock only in jurisdictions where offers and sales are permitted. The information contained in this prospectus is accurate only as of the date of this prospectus, regardless of the
time of delivery of this prospectus or of any sale of the common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For investors outside of the United States: We
have not, and the underwriters have not, done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than the United States. Persons outside of
the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus outside of the United States.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">OncoSignature is our trademark and is used in this prospectus. This prospectus also includes trademarks, tradenames and
service marks that are the property of other organizations. Solely for convenience, our trademarks and tradenames referred to in this prospectus appear without the&nbsp;<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> and <SUP
STYLE="font-size:75%; vertical-align:top">&#153;</SUP>&nbsp;symbol, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights, or the right of the applicable
licensor to these trademarks and tradenames. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Through and including
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022 (25 days after the date of this prospectus), all dealers that buy, sell or trade our common stock, whether or not participating in this offering,
may be required to deliver a prospectus. This delivery requirement is in addition to the obligation of dealers to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc383050_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>This summary highlights, and is qualified in its entirety by, information contained elsewhere in this prospectus. This
summary does not contain all of the information you should consider before investing in our common stock. You should read this entire prospectus carefully, especially the sections titled &#147;Risk Factors&#148; and &#147;Management&#146;s
Discussion and Analysis of Financial Condition and Results of Operations&#148; and our financial statements and the related notes appearing elsewhere in this prospectus, before making an investment decision. As used in this prospectus, unless the
context otherwise requires, references to &#147;we,&#148; &#147;us,&#148; &#147;our,&#148; &#147;the company,&#148; &#147;Acrivon&#148; and &#147;Acrivon Therapeutics&#148; refer to Acrivon Therapeutics, Inc. and, where appropriate, our
subsidiaries. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are a clinical stage biopharmaceutical company developing precision oncology medicines that we match to patients whose
tumors are predicted to be sensitive to each specific medicine by utilizing our proprietary proteomics-based patient responder identification platform. Recently approved targeted oncology treatments, such as kinase inhibitors, have transformed the
cancer treatment landscape, and while the therapeutic benefit of these agents has provided significant benefit to patients, these targeted oncology treatments unfortunately only address the less than 10% of patients with cancers that harbor certain
easily-identifiable genetic mutations. Our approach is designed to overcome the limitations of genomics-based patient selection methods. We do this by using our proprietary precision medicine platform, Acrivon Predictive Precision Proteomics, or
AP3, to develop our pipeline of oncology drug candidates. Our AP3 platform enables the creation of drug-specific proprietary OncoSignature companion diagnostics that are used to identify the patients most likely to benefit from our drug candidates,
which we refer to as patient responders. We are currently advancing our lead candidate, <FONT STYLE="white-space:nowrap">ACR-368,</FONT> a selective small molecule inhibitor targeting CHK1 and CHK2 with sub single-digit nM and single-digit nM
potency, respectively, in a potentially registrational Phase 2 trial across multiple tumor types, which our AP3 platform predicts will have a high proportion of patient responders based on OncoSignature-predicted sensitivity to <FONT
STYLE="white-space:nowrap">ACR-368.</FONT> Our <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature test, which has not yet obtained regulatory approval, has been extensively evaluated in preclinical studies, including in two separate,
blinded, prospectively-designed studies on pretreatment tumor biopsies collected from patients with ovarian cancer treated with <FONT STYLE="white-space:nowrap">ACR-368</FONT> in past Phase&nbsp;2 clinical trials conducted by Eli Lilly and Company,
or Lilly, and at the National Cancer Institute, or NCI, demonstrating robust enrichment of responders through our method. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The AP3 approach is proteomics-based and designed to enable identification and treatment of the patients whose tumors are
sensitive to a specific drug or drug candidate based on direct protein measurement of critical tumor-driving mechanisms and independent of underlying genetic alterations. We believe our approach is applicable across stages of drug development and
across therapeutic modalities. Accordingly, the AP3 method is not limited to the typically very small subset of cancers driven by single gene driver mutations or susceptible to a synthetic lethal approach. Rather, we believe our method is broadly
applicable to the vast majority of cancers, in particular the majority of solid tumors, for which genetics-based approaches have proven insufficient to identify patient responders in many cases. In principle, we believe a much larger percentage of
tumors can be addressed therapeutically using agents attuned to the specific biochemical signaling pathways found in these tumors, which our AP3 platform was purposefully designed to enable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">By applying our highly specific patient selection approach to drug development, we seek to both accelerate clinical
development and significantly increase the probability of successful treatment outcomes for patients. Our pipeline includes the Phase 2 lead program, <FONT STYLE="white-space:nowrap">ACR-368,</FONT> also known as prexasertib, a targeted oncology
asset that targets CHK1 and CHK2, or CHK1/2. <FONT STYLE="white-space:nowrap">ACR-368</FONT> has been dosed in more than 400 patients at the recommended Phase 2 dose, or RP2D, with reported deep, durable responses, including complete responses, or
CRs, in a proportion of patients with solid tumors in past single center and multi-center Phase 2 clinical trials in tumor indications with high unmet need. <FONT STYLE="white-space:nowrap">ACR-368</FONT> has also demonstrated a favorable safety and
tolerability profile with </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
primarily reversible hematological toxicity and very limited <FONT STYLE="white-space:nowrap">non-hematological</FONT> toxicity. We have received clearance from the U.S. Food and Drug
Administration, or FDA, for an Investigational New Drug, or IND, application to advance <FONT STYLE="white-space:nowrap">ACR-368</FONT> in Phase 2 single arm clinical trials conducted under the FDA program known as the master protocol, which was
developed to help expedite drug development in multiple tumor types for drugs with an established RP2D within the same overall trial structure. Initially, patients with platinum-resistant ovarian, endometrial, or bladder cancer will be treated in
this trial. Patients will be stratified for treatment based on OncoSignature-predicted sensitivity to <FONT STYLE="white-space:nowrap">ACR-368</FONT> across multiple sites in the United States in this trial with registrational intent. Through the
use of our OncoSignature test, we believe we can significantly increase the overall response rate, or ORR, observed in previous trials that were conducted without a prospective patient responder identification method. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We also plan to study <FONT STYLE="white-space:nowrap">ACR-368</FONT> in additional indications, such as human papilloma virus
positive, or HPV<SUP STYLE="font-size:75%; vertical-align:top">+</SUP>, squamous cell carcinomas, including squamous cell cancer, or SCC, of head and neck, or SCCHN, anal, and cervical cancer, based on demonstrated clinical single agent activity in
SCCHN and anal cancer and OncoSignature-based prediction of sensitivity to <FONT STYLE="white-space:nowrap">ACR-368</FONT> in a proportion of patients. In addition to <FONT STYLE="white-space:nowrap">ACR-368,</FONT> we are also developing
internally-discovered preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response, or DDR, and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine
kinase.</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our AP3 Platform </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our AP3 platform is based on our proprietary approach developed to enable treatment of the patients who are most likely to
respond to any particular drug candidate based on dependency in the tumor on the upregulated specific biochemical pathways that each drug modulates. Hence, our approach is tumor-agnostic: if the pathways the tumor depends on for its survival and
growth, and that the drug candidate modulates, are upregulated, we predict that individual patient&#146;s tumor will be sensitive to the drug candidate. This applies regardless of the tumor origin and is independent of underlying genetic
alterations. We are applying AP3 broadly to clinically active drug candidates as well as carefully selected preclinical lead series with a strong clinical rationale, and for which there is no obvious patient selection path through standard companion
diagnostic approaches. We also intend to explore the use of AP3 with approved drugs to improve the ORR and outcomes for patients through our patient selection approach. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">One of the key outputs of our AP3 platform are our proprietary, response-predictive clinical tests that we refer to as
OncoSignature tests. These are drug-tailored, automated, quantitative proteomic tissue imaging tests applied to pretreatment tumor biopsies as a companion diagnostic, or CDx, to select and treat the patients predicted to benefit from the drug
candidate. Our OncoSignature test, which has not yet obtained regulatory approval, is being developed with Akoya Biosciences, Inc., or Akoya, pursuant to a companion diagnostic agreement. Our OncoSignature tests encompass a signature of three
classes of functionally-defined protein biomarkers assembled into a single signature assay. The quantitative levels for each of the three biomarkers are defined to determine whether a patient&#146;s individual tumor has upregulated the biochemical
signaling mechanisms that the drug modulates and that the tumor depends on for growth and/or survival. For example, in the case of ACR-368, which is a selective CHK1/2 inhibitor, the three biomarkers we quantify with our ACR-368 OncoSignature assay
measure the level of activated DNA repair downstream of the activated drug targets and whether the tumor likely depends on it. Our company name, Acrivon, is derived from Greek for &#147;accurate.&#148; We chose it to embody how our OncoSignature
tests are designed to accurately match our therapies with patients who will benefit. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The tumor-agnostic application
of OncoSignature tests enables us to identify and focus on tumor types for which a high unmet need for a treatment exists and that are predicted to be highly sensitive to our drug candidates. We achieve this by deploying our OncoSignature screening
of human cancer samples across various tumor types. Through this process, we can identify new tumor types predicted to be sensitive to a drug candidate </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
and even estimate the percentage of predicted responders before entering clinical trials. For example, we have identified endometrial cancer and bladder cancer as two highly sensitive cancer
types for <FONT STYLE="white-space:nowrap">ACR-368,</FONT> and therefore will include patients with these tumor types in our Phase 2 trials. Moreover, we have found through this approach that a proportion of patients with HPV<SUP
STYLE="font-size:75%; vertical-align:top">+</SUP> cancers are predicted to be responsive to <FONT STYLE="white-space:nowrap">ACR-368</FONT> consistent with previously demonstrated clinical activity in a proportion of patients with SCCHN and anal
cancer. Furthermore, we predicted that patients with squamous <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer, or sqNSCLC, would not respond to <FONT STYLE="white-space:nowrap">ACR-368,</FONT> consistent with an observed 0% ORR in
patients with this tumor type in a past trial with <FONT STYLE="white-space:nowrap">ACR-368.</FONT> Hence, through our OncoSignature screening approach, we can specifically avoid running clinical trials in cancer types predicted to have limited
sensitivity to the drug candidate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are not only using our AP3 platform to generate drug-tailored, response-predictive
clinical OncoSignature tests, but we also use our AP3 platform to provide unbiased, quantitative analyses of <FONT STYLE="white-space:nowrap">off-target</FONT> effects on intracellular signaling using phosphoproteomic profiling, potentially enabling
us to discover inhibitors that are both highly potent and highly selective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe that by leveraging our AP3
platform and clinical OncoSignature tests, we will profoundly alter precision oncology drug development and the treatment landscape of patients suffering from cancer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Pipeline </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383050g05s67.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Lead Clinical Candidate <FONT STYLE="white-space:nowrap">ACR-368</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">ACR-368</FONT> is a selective small molecule inhibitor targeting CHK1/2. CHK1/2 are key
regulators of the cell cycle and of DDR and inhibition of CHK1/2 has been demonstrated to have anti-tumor activity in multiple preclinical models as well as in clinical trials in humans. Several CHK1/2 inhibitors including <FONT
STYLE="white-space:nowrap">ACR-368,</FONT> also known as prexasertib, have been investigated in the clinic; however, none have been approved by the FDA. <FONT STYLE="white-space:nowrap">ACR-368</FONT> has shown deep, durable single agent clinical
activity, including CRs and partial responses, PRs, in a proportion of patients with solid tumors with high unmet need for a treatment, such as platinum-resistant ovarian cancer, and SCCs, including SCCHN and anal cancer. More than 400 patients with
these tumors have been treated with <FONT STYLE="white-space:nowrap">ACR-368</FONT> monotherapy at the RP2D in advanced single- and multi-center clinical trials conducted by Lilly, NCI, and at MD Anderson Cancer Center, or MDACC. The ORR in these
trials without a predictive biomarker was 29% at the single center Phase 2 ovarian cancer trial at NCI in the intent to treat, or ITT, </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
population, and approximately 12% across the platinum-resistant ovarian cancer cohorts in the large Phase&nbsp;2 multi-center international trial sponsored by Lilly. The median duration of
response, or mDoR, at the RP2D across trials to date have ranged from almost six months to 12 months, and <FONT STYLE="white-space:nowrap">ACR-368</FONT> monotherapy demonstrated a generally favorable safety and tolerability profile with primarily
reversible hematological toxicity and very limited <FONT STYLE="white-space:nowrap">non-hematological</FONT> toxicity. Based on these two trials, encompassing over 200 patients with ovarian cancer, primarily platinum-resistant, we believe the
unenriched background ORR in a larger patient population of platinum-resistant ovarian cancer is somewhere between 15% and 20%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Using our AP3 platform, we have developed a predictive OncoSignature test for <FONT STYLE="white-space:nowrap">ACR-368,</FONT>
called <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature, that we believe can predict patient response to <FONT STYLE="white-space:nowrap">ACR-368</FONT> monotherapy and therefore substantially improve the clinical ORR and, furthermore,
that, we believe, has the potential to enable expedited drug development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">By applying our
<FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature test for indication finding and expansion across human cancer types we have found that approximately 30% of samples from patients with ovarian cancer are
<FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature-positive. Moreover, we observed that between 30% and 40% of patients with endometrial and bladder cancer are predicted highly sensitive to <FONT STYLE="white-space:nowrap">ACR-368.</FONT>
Patients with these two types of cancer were not previously treated in clinical trials. All three tumor types are therefore included in our upcoming Phase 2 clinical trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have also used our AP3 platform to identify resistance mechanisms to <FONT STYLE="white-space:nowrap">ACR-368.</FONT>
Through phospho-proteomic profiling of human tumor cell lines that are either highly sensitive or highly resistant to <FONT STYLE="white-space:nowrap">ACR-368,</FONT> we uncovered key resistance mechanisms and found that very low dose gemcitabine,
or LDG, could be used to overcome resistance and further sensitize human tumor cells to <FONT STYLE="white-space:nowrap">ACR-368</FONT> through inducing increased DDR stress. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Based on these results, we are initiating a Phase 2 clinical trial where we intend to treat patients with all three tumor
types: platinum-resistant ovarian, endometrial, and bladder cancer. <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature-positive patients, which we believe will represent 30% to 40% of patients of each tumor type, will receive <FONT
STYLE="white-space:nowrap">ACR-368</FONT> monotherapy in a single arm Phase 2b trial for each of the three tumor types. The <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature-negative patients with these three tumor types will receive <FONT
STYLE="white-space:nowrap">ACR-368</FONT> combined with LDG in a Phase 1b trial, followed by expansion into a Phase 2 trial with the combination in all three tumor types. As a result, all patients biopsied with these tumor types will have the
opportunity to receive therapy. This Phase 2 clinical trial design and protocol has been cleared by the FDA and we have begun enrolling patients. Akoya will procure and manufacture the necessary supplies to perform the OncoSignature tests used in
the Phase 2 clinical trial. Based on our communications with the FDA to date, we believe this trial, if successful, has the potential to be registrational for <FONT STYLE="white-space:nowrap">ACR-368</FONT> in each of the three tumor types. We
believe that use of our <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature test to select patients predicted to be sensitive to <FONT STYLE="white-space:nowrap">ACR-368</FONT> for treatment will significantly increase the ORR, which has
the potential to lead to accelerated approval for multiple cancers while avoiding treatment of patients with tumors that are not likely to respond. However, we cannot guarantee that the FDA will permit us to utilize an expedited approval process or
that our intended approach will be sufficient for regulatory approval. We are planning to file an IND application amendment to add three additional cancer types under the same trial protocol design at a later time, including head and neck cancer,
anal cancer, and cervical cancer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Preclinical Programs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We also have two preclinical drug programs designed to take advantage of our AP3 platform and the ability to predict tumor
sensitivity based on custom OncoSignature tests. Both of these programs are structure-guided with rational medicinal chemistry efforts based on <FONT STYLE="white-space:nowrap">co-crystallography</FONT> of lead series with their respective targets.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The first of these is directed at WEE1, a critical node in the DDR pathways. WEE1 inhibitors have demonstrated promising
anti-tumor activity in early clinical trials conducted by competitors; however, the ORRs have been limited across key trials and we believe a patient selection method is required to achieve a sufficient
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
ORR for ultimate approval. The second, equally advanced preclinical program is directed at PKMYT1, a closely related protein serine/threonine kinase also serving critical functions in the cell
cycle and DDR pathways. Based on mechanism of action and preclinical studies there is a rationale and data suggesting that inhibition of PKMYT1 will result in clinical activity. Currently one company has advanced a PKMYT1 inhibitor into phase 1
clinical trials. We believe the compound is in need of a patient selection method in the clinic and that genetics-based patient selection methods will be challenging. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Based on results from our AP3 platform, we believe that we can predict drug-sensitivity using our proteomics-based approach
for patient responder identification with our OncoSignature tests. We anticipate advancing our WEE1 inhibitor and PKMYT1 inhibitor into <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies in 2023. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our goal is
to be the leading biopharmaceutical company leveraging proteomic and phosphoproteomic data, which we access through our proprietary AP3 platform, to unlock insights beyond genomic based approaches and discover and efficiently develop medicines to
benefit patients with cancer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The key elements of our strategy summarized below are to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Advance <FONT STYLE="white-space:nowrap">ACR-368,</FONT> our CHK1/2 inhibitor, through clinical development in
ovarian, bladder, and endometrial cancer by enrolling <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature-positive patients. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Selectively pursue AP3 identified rational drug combinations with our drug candidates in
OncoSignature-negative patients, initially <FONT STYLE="white-space:nowrap">ACR-368</FONT> with <FONT STYLE="white-space:nowrap">low-dose</FONT> gemcitabine. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Discover and develop a pipeline of proprietary drug candidates by leveraging our AP3 platform and predictive
OncoSignature tests. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Acquire rights to drug candidates for which we believe our OncoSignature tests can increase the likelihood of
clinical success. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Opportunistically enter into strategic <FONT STYLE="white-space:nowrap">co-development</FONT> partnerships
around predictive OncoSignature tests to maximize the full potential of our AP3 platform. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Team </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We were founded and are led by pioneers in oncogenic signaling, oncology precision medicine and the use of proteomic technology
to uncover intracellular biochemical signaling pathways with the goal of applying this knowledge to develop drug candidates and clinical diagnostics. Our founders have pioneered and established <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">proof-of-concept,</FONT></FONT> including clinical implementation, for the underlying technologies in our AP3 platform. Our scientific advisors are thought leaders from leading global cancer and academic centers and are
actively involved in our drug development process. We are supported by leading healthcare investors, Wellington Management, Surveyor Capital, RA Capital, Perceptive Advisors, Sands Capital and Chione. Prospective investors should not rely on the
past investment decisions of our investors, as our investors may have different risk tolerances and have received their shares in prior offerings at prices lower than the price offered to the public in this offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Associated with Our Business </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our business is subject to numerous risks that you should be aware of before making an investment decision. These risks are
described more fully in the section titled &#147;Risk Factors&#148; and include, among others: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have incurred significant losses since our inception. We expect to incur losses over the next several years
and may never achieve or maintain profitability. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have a limited operating history and no history of commercializing products, which may make it difficult
for an investor to evaluate the success of our business to date and to assess our future viability. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Even if this offering is successful, we will need additional funding to meet our financial obligations and to
pursue our business objectives. If we are unable to raise capital when needed, we could be forced to curtail our planned longer-term operations and the pursuit of our growth strategy. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are highly dependent on the success of our lead drug candidate, ACR-368, as this is our first drug
candidate being developed for clinical development and regulatory approval. We may never obtain approval for <FONT STYLE="white-space:nowrap">ACR-368</FONT> or any other drug candidate. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our business substantially depends upon the successful clinical development of drug candidates using our AP3
platform and OncoSignature companion diagnostics. If we are unable to obtain regulatory approval for, and successfully commercialize, drugs developed through the application of our AP3 platform and OncoSignature tests, our business may be materially
harmed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time
consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our drug candidates, on a timely basis or at all, our business will be substantially harmed. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The successful clinical development of our drug candidates depends on the co-approval of the OncoSignature
test as a companion diagnostic test. If we or our companion diagnostic collaborator are unable to obtain regulatory approval for our OncoSignature companion diagnostic tests for our drug candidates, we may not obtain regulatory approval and realize
the commercial potential of our drug candidates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our relationships with customers, healthcare providers, including physicians, and third-party payors are
subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, health information privacy and security laws and other healthcare laws and regulations. If we are unable to comply, or have not fully complied,
with such laws, we could face substantial penalties. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We rely, and expect to continue to rely, on third parties, including independent clinical investigators,
contracted laboratories and contract research organizations, or CROs, to conduct our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be
able to obtain regulatory approval for or commercialize our drug candidates and our business could be substantially harmed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The targeted oncology space is competitive, which may result in others discovering, developing or
commercializing products before or more successfully than we do. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our future success depends on our ability to retain key executives and to attract, retain and motivate
qualified personnel. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our success depends in part on our ability to obtain intellectual property rights for our proprietary
technologies and drug candidates, as well as our ability to protect our intellectual property. It is difficult and costly to protect our proprietary rights and technology, and we may not be able to ensure their protection. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We depend on intellectual property licensed from a third party and termination of this license could result in
the loss of significant rights, which would harm our business. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have identified material weaknesses in our internal control over financial reporting. If we are unable to
remediate these material weaknesses, or if we identify additional material weaknesses in the future or otherwise fail to maintain effective internal control over financial reporting, we may not be able to accurately or timely report our financial
condition or results of operations, which may adversely affect our business. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Developments&#151;Preliminary Balance of Cash, Cash Equivalents and Short-term Investments
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We estimate that we had cash, cash equivalents and short-term investments of approximately $76.8 million as of
September&nbsp;30, 2022, which excludes cash of approximately $0.4 million as of that date that is restricted as to use. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our actual consolidated financial results as of September&nbsp;30, 2022 are not yet available. Our financial closing
procedures for the nine months ended September&nbsp;30, 2022 are not yet complete and, as a result, our final results upon completion of those procedures may differ materially from our preliminary estimates. The preliminary consolidated financial
data presented above as of September&nbsp;30, 2022 is not a comprehensive statement of our financial position or operating results; reflects our preliminary estimates based on information available as of the date of this prospectus; and is subject
to change, and those changes may be material. Accordingly, you should not place undue reliance upon these preliminary estimates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This preliminary consolidated financial data has been prepared by, and is the responsibility of, our management.
PricewaterhouseCoopers LLP has not audited, reviewed, compiled or applied agreed-upon procedures with respect to this preliminary consolidated financial data. Accordingly, PricewaterhouseCoopers LLP does not express an opinion or any other form of
assurance with respect thereto. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an Emerging Growth Company and a Smaller Reporting Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We qualify as an &#147;emerging growth company&#148; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS
Act. For so long as we remain an emerging growth company, we may take advantage of relief from certain reporting requirements and other burdens that are otherwise applicable generally to public companies. These provisions include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">being permitted to provide only two years of audited financial statements, in addition to any required
unaudited interim financial statements with correspondingly reduced &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; disclosure;</P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exemption from compliance with the auditor attestation requirements of Section&nbsp;404 of the
Sarbanes-Oxley Act of 2002, as amended, in the assessment of our internal control over financial reporting;</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced disclosure about our executive compensation arrangements in our periodic reports, proxy statements and
registration statements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exemptions from the requirements of holding <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory votes
on executive compensation or golden parachute arrangements; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exemption from compliance with the requirements of the Public Company Accounting Oversight Board regarding
the communication of critical audit matters in the auditor&#146;s report on financial statements. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We
may take advantage of these provisions until the last day of the fiscal year ending after the fifth anniversary of the completion of this offering or such earlier time that we no longer qualify as an emerging growth company. We will cease to qualify
as an emerging growth company on the date that is the earliest of: (1)&nbsp;the last day of our fiscal year following the fifth anniversary of the date of the completion of this offering, (2)&nbsp;the last day of the fiscal year in which we have
more than $1.24&nbsp;billion in total annual gross revenues, (3)&nbsp;the date on which we are deemed to be a &#147;large accelerated filer&#148; under the rules of the U.S. Securities and Exchange Commission or (4)&nbsp;the date on which we have
issued more than $1.0&nbsp;billion of <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt over the prior three-year period. We will be deemed to be a &#147;large accelerated filer&#148; at such time that we (a)&nbsp;have an
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
aggregate worldwide market value of our common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> of $700&nbsp;million or more as of the last business day of our most recently
completed second fiscal quarter, (b)&nbsp;have been required to file annual and quarterly reports under the Securities Exchange Act of 1934, as amended, or the Exchange Act, for a period of at least 12 months and (c)&nbsp;have filed at least one
annual report pursuant to the Exchange Act. We may choose to take advantage of some but not all of these reduced reporting burdens. We have taken advantage of certain reduced reporting requirements in this prospectus. Accordingly, the information
contained herein may be different than you might obtain from other public companies in which you hold equity interests. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such
time as those standards apply to private companies. We have elected to take advantage of the extended transition period to comply with new or revised accounting standards and to adopt certain of the reduced disclosure requirements available to
emerging growth companies. As a result of the accounting standards election, we will not be subject to the same implementation timing for new or revised accounting standards as other public companies that are not emerging growth companies, which may
make comparison of our financials to those of other public companies more difficult. As a result of these elections, the information that we provide in this prospectus may be different than the information you may receive from other public companies
in which you hold equity interests. In addition, it is possible that some investors will find our common stock less attractive as a result of these elections, which may result in a less active trading market for our common stock and higher
volatility in our share price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are also a &#147;smaller reporting company&#148; as defined under the Exchange Act. We
may continue to be a smaller reporting company for so long as either (i)&nbsp;the market value of our common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250&nbsp;million as of the last business day of our most
recently completed second fiscal quarter or (ii)&nbsp;our annual revenue was less than $100&nbsp;million during the most recently completed fiscal year and the market value of our common stock held by
<FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700&nbsp;million as of the last business day of our most recently completed second quarter. If we are a smaller reporting company at the time we cease to be an emerging growth
company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company, we may choose to present only the two most recent fiscal years of
audited financial statements in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and have reduced disclosure obligations regarding executive compensation, and, similar to emerging growth companies, if we are a smaller reporting
company with less than $100&nbsp;million in annual revenue, we would not be required to obtain an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We
were incorporated under the laws of the State of Delaware in March 2018. Our principal executive offices are located at 480 Arsenal Way, Suite 100, Watertown, Massachusetts 02472, and our telephone number is (617)
<FONT STYLE="white-space:nowrap">207-8979.</FONT> Our website address is <I>www.acrivon.com</I>. The information contained on, or accessible through, our website is not incorporated by reference into this prospectus. We have included our website in
this prospectus solely as an inactive textual reference. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc383050_2"></A>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock offered by us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5,900,000 shares</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriters&#146; option to purchase additional shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">We have granted the underwriters an option for a period of 30&nbsp;days to purchase up to 885,000 additional shares.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock to be outstanding immediately after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:pt"><BR></P> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">18,809,823 shares (or 19,694,823 shares if the underwriters exercise
in full their option to purchase additional shares)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Use of proceeds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We estimate that the net proceeds from this offering will be approximately $90.4&nbsp;million (or approximately $104.4&nbsp;million if the
underwriters exercise in full their option to purchase up to 885,000 additional shares of common stock), assuming an initial public offering price of $17.00 per share, which is the midpoint of the price range set forth on the cover page of this
prospectus, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">We currently intend to use the net proceeds from this offering, together with our existing cash, cash equivalents and short-term investments,
<U></U><B></B>(i)<B></B>&nbsp;to fund the advancement of <FONT STYLE="white-space:nowrap">ACR-368,</FONT> including chemistry manufacturing and controls, or CMC, and companion diagnostic development, in Phase&nbsp;2 clinical trials across our three
lead indications into potential registrational phase, pending the results and discussions with the FDA, as well as to potentially initiate Phase&nbsp;2 trials in patients with HPV+ tumors, (ii)&nbsp;to complete IND-enabling studies for at least one
of our preclinical programs and (iii)&nbsp;the remainder for continued development of our AP3 platform, other research and development activities, working capital and other general corporate purposes. See the section titled &#147;Use of
Proceeds&#148; beginning for additional information.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk factors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">You should read the section titled &#147;Risk Factors&#148; for a discussion of factors you should consider carefully, together with all the other information included in this prospectus, before deciding to invest in our common
stock.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proposed Nasdaq Global Market symbol</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#147;ACRV&#148;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The number of shares of our common stock to be outstanding after this offering is
based on 12,909,823 shares of our common stock outstanding as of June&nbsp;30, 2022, after giving effect to the conversion of all outstanding shares of our preferred stock into an aggregate of 11,140,262 shares of common stock, and excludes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,072,851 shares of our common stock issuable upon the exercise of options outstanding as of June&nbsp;30,
2022 under our 2019 Stock Incentive Plan, or the 2019 Plan, at a weighted-average exercise price of $2.85 per </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
share (of which (i) options to purchase an aggregate of 25,039 shares of common stock were exercised subsequent to June 30, 2022 and (ii) options to purchase an aggregate of 65,392 shares of
common stock were canceled subsequent to June 30, 2022), which does not include options to purchase an aggregate of 166,259 shares of our common stock, at a weighted-average exercise price of $4.07 per share, that were granted subsequent to
June&nbsp;30, 2022; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,003,666 shares of our common stock available for future issuance as of June&nbsp;30, 2022 under the 2019
Plan, which shares will cease to be available for issuance under the 2019 Plan at the time our 2022 Equity Incentive Plan, or the 2022 Plan, becomes effective and will be added to, and become available for issuance under, the 2022 Plan;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an additional 2,555,571 shares of our common stock reserved for future issuance under our 2022 Plan, which
will become effective on the date of the underwriting agreement related to this offering (of which we will grant certain options to purchase shares of common stock at an exercise price equal to the initial public offering price and certain
restricted stock units, as described in &#147;Executive Compensation&#148;), as well as any automatic increases in the number of shares of common stock reserved for future issuance under the 2022 Plan and any additional shares of our common stock
that may become available under our 2022 Plan, as more fully described in &#147;Executive Compensation&#151;Equity Incentive Plans&#148;; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">215,000 shares of our common stock reserved for future issuance under our 2022 Employee Stock Purchase Plan,
or the ESPP, which will become effective on the date of the underwriting agreement related to this offering, as well as any automatic increases in the number of shares of common stock reserved for future issuance under the ESPP.
</P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Unless otherwise indicated, all information contained in this prospectus, including the number of
shares of common stock that will be outstanding after this offering, assumes or gives effect to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the conversion of all outstanding shares of our preferred stock into 11,140,262 shares of our common stock,
which will occur upon the closing of this offering; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-2.466</FONT></FONT> reverse stock
split of our common stock effected on November&nbsp;1, 2022; </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the filing and effectiveness of our amended and restated certificate of incorporation upon the closing of this
offering; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise of the outstanding options referred to above after June&nbsp;30, 2022; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise by the underwriters of their option to purchase additional shares of our common stock.
</P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc383050_3"></A>SUMMARY CONSOLIDATED FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">You should read the following summary consolidated financial data together with our consolidated financial statements and the
related notes appearing at the end of this prospectus and the &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; sections of this prospectus. The summary condensed consolidated statements of
operations data for the six months ended June&nbsp;30, 2022 and 2021 and the condensed consolidated balance sheet data as of June&nbsp;30, 2022 have been derived from our unaudited condensed consolidated financial statements appearing at the end of
this prospectus and have been prepared on the same basis as the audited consolidated financial statements. We have derived the consolidated statement of operations data for the years ended December&nbsp;31, 2021 and 2020 from our audited
consolidated financial statements appearing at the end of this prospectus. In the opinion of management, the unaudited data reflect all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of the financial
information in those statements. Our historical results are not necessarily indicative of the results that may be expected in any future period and the results for the six months ended June&nbsp;30, 2022 are not necessarily indicative of the results
to be expected for the fiscal year ending December&nbsp;31, 2022 or any other future period. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Statement of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating Expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,448</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,466</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,137</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,243</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,184</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,168</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,099</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of preferred stock tranche rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(71</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of anti-dilution right</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(208</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(217</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(59</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,138</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,040</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,460</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,243</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,306</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders &#150; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,040</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,460</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,243</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,306</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share &#150; basic and
diluted<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> (7.37</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5.50</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> (9.32</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> (3.70</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average common stock outstanding &#150; basic and diluted<SUP
STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,769,561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,718,569</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,743,382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,432,480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share &#150; basic and
diluted<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> (1.01</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.26</TD>
<TD NOWRAP VALIGN="bottom">) &nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted-average common stock outstanding &#150; basic and diluted<SUP
STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,909,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,883,644</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">See Note 13 to our audited consolidated financial statements and Note 11 to our unaudited condensed
consolidated financial statements appearing at the end of this prospectus for details on the calculation of basic and diluted net loss per share attributable to common stockholders. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Pro forma basic and diluted net loss per share attributable to common stockholders has been prepared to give
effect to adjustments to our capital structure arising in connection with the completion of this offering </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
and is calculated by dividing pro forma net loss attributable to common stockholders by the pro forma weighted-average common shares outstanding for the period. The unaudited pro forma net loss
attributable to common stockholders used in the calculation of unaudited pro forma basic and diluted net loss per share attributable to common stockholders is equal to net loss attributable to common stockholders. The unaudited pro forma basic and
diluted weighted-average common shares outstanding used in the calculation of unaudited pro forma basic and diluted net loss per share for the six months ended June&nbsp;30, 2022 and year ended December&nbsp;31, 2021 have been prepared to reflect
the conversion of all of the outstanding shares of our convertible preferred stock into an aggregate of 11,140,262 shares of our common stock as if the offering had occurred on January&nbsp;1, 2021. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of June&nbsp;30, 2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma,<BR>As<BR>Adjusted<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">83,861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">83,861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">174,251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">173,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">185,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,841</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholder&#146;s (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(36,576</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;85,942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;176,321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Gives effect to the conversion of all of the outstanding shares of our preferred stock into an aggregate of
11,140,262 shares of our common stock upon the closing of this offering. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Gives further effect to the sale of 5,900,000 shares of common stock in this offering at an assumed initial
public offering price of $17.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting fees and commissions and estimated offering expenses payable by us. This pro
forma as adjusted information is illustrative only and will depend on the actual initial public offering price and other terms of this offering determined at pricing. Each $1.00 increase or decrease in the assumed initial public offering price of
$17.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase or decrease the pro forma as adjusted amount of each of cash and cash equivalents, working capital, total assets and total
stockholders&#146; equity by $5.5 million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts and commissions and estimated
offering expenses payable by us. Each increase or decrease of 1.0&nbsp;million in the number of shares we are offering would increase or decrease the pro forma as adjusted amount of each of cash and cash equivalents, working capital, total assets
and stockholders&#146; equity by $15.8 million, assuming no change in the assumed initial public offering price per share and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">We define working capital as current assets less current liabilities. See our consolidated financial
statements and related notes included elsewhere in this prospectus for further details regarding our current assets and current liabilities. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc383050_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Investing in our common stock involves a high degree of risk. You should consider carefully the risks and uncertainties
described below, together with all of the other information in this prospectus, including our financial statements and related notes, before deciding whether to purchase shares of our common stock. The risks and uncertainties described below are not
the only ones we face. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become important factors that affect us. If any of the following risks are realized, our business, financial
condition, results of operations and prospects could be materially and adversely affected. In that event, the price of our common stock could decline, and you could lose part or all of your investment. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Financial Position and Capital Needs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We have incurred significant losses since our inception. We expect to incur losses over the next several years and may never achieve or
maintain profitability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Since our inception, we have incurred significant losses, and we expect to continue to
incur significant expenses and operating losses for the foreseeable future. Our net losses were $16.2&nbsp;million and $5.3&nbsp;million for the year ended December&nbsp;31, 2021 and 2020, respectively, and $13.0&nbsp;million and $9.5&nbsp;million
for the six months ended June&nbsp;30, 2022 and 2021, respectively. As of June&nbsp;30, 2022, we had an accumulated deficit of $37.9&nbsp;million. Since our inception, we have financed our operations with aggregate net proceeds of
$119.8&nbsp;million from the issuance of convertible notes and the sale of our Series A-1 convertible preferred stock and Series B convertible preferred stock. We have no products approved for commercialization and have never generated any revenue
from product sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">All of our drug candidates are still in clinical and preclinical testing. We expect to continue to
incur significant expenses and operating losses over the next several years. Our net losses may fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially as we: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue to conduct our ongoing clinical trials of <FONT STYLE="white-space:nowrap">ACR-368,</FONT> as well as
initiate and complete additional clinical trials of future drug candidates or current drug candidates in new indications or patient populations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue to advance the preclinical development of our other drug candidates and our preclinical and discovery
programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek regulatory approval for any drug candidates that successfully complete clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pursue marketing approvals and reimbursement for our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">manufacture material under current good manufacturing practices, or cGMP, for clinical trials and potential
commercial sales at our contracted manufacturing facilities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">develop, establish and validate our commercial-scale cGMP manufacturing process; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain, expand, enforce, defend and protect our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">comply with regulatory requirements established by the applicable regulatory authorities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish, either alone or with a third party, a sales, marketing and distribution infrastructure and scale up
external, or establish internal, manufacturing and distribution capabilities to commercialize any drug candidates for which we may obtain regulatory approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">hire and retain additional personnel, including research, clinical, development, manufacturing quality
control, quality assurance, regulatory and scientific personnel; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">add operational, financial, corporate development, management information systems and administrative
personnel, including personnel to support our product development and planned future commercialization efforts; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">incur additional legal, accounting and other expenses in operating as a public company. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To date, we have not generated any revenue from the commercialization of any drug candidate. To become and remain profitable,
we must succeed in developing and eventually commercializing drug candidates that generate significant revenue. This will require us to be successful in a range of challenging activities, including completing preclinical testing and clinical trials
of our drug candidates, validating manufacturing processes, obtaining regulatory approval, and manufacturing, marketing and selling any drug candidates for which we may obtain regulatory approval, as well as discovering and developing additional
drug candidates. All of our drug candidates are in clinical or preclinical development. We may never succeed in these activities and, even if we do, may never generate any revenue or revenue that is significant enough to achieve profitability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Because of the numerous risks and uncertainties associated with drug candidate development, we are unable to accurately
predict the timing or amount of expenses or when, or if, we will be able to achieve profitability. If we are required by regulatory authorities to perform clinical trials or preclinical studies in addition to those currently expected, or if there
are any delays in the initiation and completion of our clinical trials or the development of any of our drug candidates, our expenses could increase. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Even if we achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our
failure to become and remain profitable would depress the value of our company and could impair our ability to raise capital, expand our business, maintain our development efforts, obtain product approvals, diversify our offerings or continue our
operations. A decline in the value of our company could also cause you to lose all or part of your investment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We have a limited
operating history and no history of commercializing products, which may make it difficult for an investor to evaluate the success of our business to date and to assess our future viability. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are a clinical-stage biopharmaceutical company with a limited operating history. We commenced operations in March 2018, and
our operations to date have been largely focused on organizing and staffing our company, business planning, raising capital, building our AP3 platform, developing our manufacturing capabilities and developing our clinical and preclinical drug
candidates, including undertaking preclinical studies and conducting clinical trials. To date, we have not yet demonstrated our ability to successfully complete pivotal clinical trials, obtain regulatory approvals, manufacture a product on a
commercial scale, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful commercialization, and we may not be successful in doing so. Consequently, any predictions you make about our
future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing and commercializing products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, as a business with a limited operating history, we may encounter unforeseen expenses, difficulties,
complications, delays and other known and unknown factors. We will eventually need to transition from a company with a research and clinical focus to a company, if any of our drug candidates are approved, capable of supporting commercial activities.
We may not be successful in such a transition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Even if this offering is successful, we will need additional funding to meet our
financial obligations and to pursue our business objectives. If we are unable to raise capital when needed, we could be forced to curtail our planned longer-term operations and the pursuit of our growth strategy. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our operations have consumed substantial amounts of cash since inception, and we expect to continue to incur significant
expenses and operating losses over the next several years as we continue to develop our drug candidate pipeline and, to a lesser extent, build out our manufacturing capabilities for our drug candidates, which, if approved, may not achieve commercial
success. Our revenue, if any, will be derived from sales of products that may not be commercially available for a number of years, if at all. If we obtain marketing approval for any drug candidates that we develop or otherwise acquire, we expect to
incur significant commercialization expenses </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
related to product sales, marketing, distribution and manufacturing. We also expect an increase in our expenses associated with creating additional infrastructure to support operations as a
public company. Accordingly, we will need to obtain substantial additional funding in order to continue our operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of June 30, 2022, we had cash and cash equivalents of $83.9 million. We believe that the anticipated net proceeds from this
offering, together with our existing cash and cash equivalents as of June 30, 2022, will be sufficient to fund our operating expenses and capital expenditure requirements at least into the fourth quarter of 2024. This estimate is based on
assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. We plan to use the net proceeds from this offering to fund the advancement of ACR-368, including chemistry, manufacturing and
controls, or CMC, and companion diagnostic development, in Phase 2 clinical trials across our three lead indications into potential registrational phase, pending results and discussions with the FDA, as well as to potentially initiate Phase 2 trials
in patients with HPV+ tumors, to complete IND-enabling studies for at least one of our preclinical programs and the remainder for continued development of our AP3 platform, other research and development activities, working capital and other general
corporate purposes. The net proceeds from this offering, together with our existing cash, cash equivalents and short-term investments, may not be sufficient to fund any of our drug candidates through regulatory approval. Changes may occur beyond our
control that would cause us to consume our available capital before that time, including changes in and progress of our development activities, acquisitions of additional drug candidates and changes in regulation. The timing and amount of our
funding requirements will depend on many factors, including: </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate of progress in the development of <FONT STYLE="white-space:nowrap">ACR-368</FONT> and our other drug
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, progress, results and costs of <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies,
preclinical development, laboratory testing and clinical trials for <FONT STYLE="white-space:nowrap">ACR-368</FONT> and future drug candidates and associated development programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which we develop, <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire other drug
candidates and technologies in our pipeline; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, progress, results and costs as well as timing of process development and manufacturing <FONT
STYLE="white-space:nowrap">scale-up</FONT> and validation activities associated with <FONT STYLE="white-space:nowrap">ACR-368</FONT> and our future drug candidates and other programs as we advance them through preclinical and clinical development;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability of our AP3 platform to identify patient responders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number and development requirements of drug candidates that we may pursue; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs, timing and outcome of regulatory review of our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our headcount growth and associated costs as we expand our research and development capabilities and establish
a commercial infrastructure; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and costs of securing sufficient capacity for commercial supply of our drug candidates, or the raw
material components thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales
and distribution, for any of our drug candidates for which we receive marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs necessary to obtain regulatory approvals, if any, for products in the United States and other
jurisdictions, and the costs of post-marketing studies that could be required by regulatory authorities in jurisdictions where approval is obtained; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our
intellectual property rights and defending any intellectual property-related claims; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the continuation of our existing licensing and collaboration arrangements and entry into new collaborations
and licensing arrangements, if at all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the need and ability to hire additional research, clinical, development, scientific and manufacturing
personnel; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs we incur in maintaining business operations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the need to implement additional internal systems and infrastructure; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of competing technological, product and market developments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the revenue, if any, received from commercial sales of our drug candidates for which we receive marketing
approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of operating as a public company; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">business disruptions affecting the initiation, patient enrollment, development and operation of our clinical
trials, including a public health emergency, such as the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, or geopolitical events, including the ongoing Russian invasion of Ukraine, and related sanctions against Russia.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We will require additional capital to achieve our business objectives. Additional funds may not be
available on a timely basis, on favorable terms or at all, and such funds, if raised, may not be sufficient to enable us to continue to implement our long-term business strategy. Any additional fundraising efforts may divert our management from
their <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities, which may adversely affect our ability to develop and commercialize our drug candidates. Further, our ability to raise additional capital
may be adversely impacted by potential worsening global economic conditions and the recent disruptions to and volatility in the credit and financial markets in the United States and worldwide resulting from the ongoing Russian invasion of Ukraine
and related sanctions against Russia, and the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. If we are unable to raise sufficient additional capital, we could be forced to curtail our planned operations and the pursuit of our
growth strategy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to
relinquish rights to our technologies or drug candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Until such time, if ever, as we can generate substantial
revenue, we may finance our cash needs through a combination of equity offerings, government or private-party grants, debt financings and license and collaboration agreements. We do not currently have any committed external source of funds. To the
extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of such securities may include liquidation or other preferences that adversely affect your
rights as a common stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making
capital expenditures or declaring dividends. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If we raise additional funds through collaborations, strategic alliances or
marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights to our technologies, future revenue streams or drug candidates, grant licenses on terms that may not be favorable to us or commit
to future payment streams. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights
to develop and market drug candidates that we would otherwise prefer to develop and market ourselves. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to the Design and Development of
Our Drug Candidates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We are highly dependent on the success of our lead drug candidate, ACR-368, as this is our first drug
candidate being developed for clinical development and regulatory approval. We may never obtain approval for <FONT STYLE="white-space:nowrap">ACR-368</FONT> or any other drug candidate. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our future success is highly dependent on our ability to obtain regulatory approval for, and then successfully commercialize or
identify a strategic partner to commercialize, our lead drug candidate, <FONT STYLE="white-space:nowrap">ACR-368.</FONT> <FONT STYLE="white-space:nowrap">ACR-368</FONT> has been dosed in more than 400 patients at the RP2D in past single center and
multi-center Phase 2 clinical trials. We have received clearance from the FDA for an IND application to advance <FONT STYLE="white-space:nowrap">ACR-368</FONT> in Phase 2 single arm </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
clinical trials conducted under the FDA program known as the master protocol. We currently have no products that are approved for sale in any jurisdiction.
<FONT STYLE="white-space:nowrap">ACR-368</FONT> or any of our other future drug candidates may not achieve success in their clinical trials or obtain regulatory approval. If we do not obtain regulatory approval for
<FONT STYLE="white-space:nowrap">ACR-368</FONT> and successfully commercialize <FONT STYLE="white-space:nowrap">ACR-368</FONT> in one or more indications or if we experience significant delays in doing so, we may never generate any revenue or become
profitable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our ability to generate product revenues, which we do not expect will occur for several years, if ever, will
depend heavily on the successful development and eventual commercialization of <FONT STYLE="white-space:nowrap">ACR-368</FONT> or other future drug candidates identified through the application of our AP3 platform and OncoSignature companion
diagnostics. The success of <FONT STYLE="white-space:nowrap">ACR-368</FONT> or any other future drug candidate will depend on several factors, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successful completion of preclinical studies and clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">timely and successful enrollment of patients in, and completion of, clinical trials with favorable results;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">demonstration of safety, efficacy and acceptable risk-benefit profiles of
<FONT STYLE="white-space:nowrap">ACR-368</FONT> and our future drug candidates to the satisfaction of the FDA and other regulatory agencies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability of our AP3 platform-based OncoSignature tests to identify patient responders;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the AP3 platform may not work equally well for all therapeutic targets; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability, or that of our collaborators, to develop and obtain clearance or approval of companion
diagnostics, on a timely basis, or at all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">receipt and related terms of marketing approvals from applicable regulatory authorities for <FONT
STYLE="white-space:nowrap">ACR-368</FONT> and our future drug candidates, including the completion of any required post-marketing studies or trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">raising additional funds necessary to complete the clinical development of and commercialization of <FONT
STYLE="white-space:nowrap">ACR-368;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successfully identifying and developing, acquiring or <FONT STYLE="white-space:nowrap">in-licensing</FONT>
additional drug candidates to expand our pipeline; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acceptance of an IND application by the FDA or other similar clinical trial applications from other regulatory
authorities for clinical trials for future drug candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining and maintaining patent, trade secret and other intellectual property protection and regulatory
exclusivity for <FONT STYLE="white-space:nowrap">ACR-368</FONT> and our future drug candidates and our OncoSignature companion diagnostics; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">making arrangements with third-party manufacturers, or establishing manufacturing capabilities, for both
clinical and commercial supplies of our drug candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing sales, marketing and distribution capabilities and launching commercial sales of our products, if
approved, whether alone or in collaboration with third parties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acceptance of our products, if approved, by patients, the medical community and third-party payors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">effectively competing with other therapies available on the market or in development; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining and maintaining third-party payor coverage and adequate reimbursement; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintaining a continued acceptable safety profile of any products following regulatory approval.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Many of these factors are beyond our control, and it is possible that none of our drug candidates,
including <FONT STYLE="white-space:nowrap">ACR-368,</FONT> will ever obtain regulatory approval even if we expend substantial time and resources seeking such approval. If we experience significant delays or are otherwise unable to successfully
commercialize our drug candidates, it would materially harm our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our business substantially depends upon the successful clinical development of drug
candidates using our AP3 platform and OncoSignature companion diagnostics. If we are unable to obtain regulatory approval for, and successfully commercialize, drugs developed through the application of our AP3 platform and OncoSignature tests, our
business may be materially harmed.</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Using our AP3 platform, we have developed predictive OncoSignature tests for our
clinical drug candidate, <FONT STYLE="white-space:nowrap">ACR-368,</FONT> as well as for two other clinical stage drug candidates. Negative results in the development of <FONT STYLE="white-space:nowrap">ACR-368</FONT> may also impact our ability to
successfully develop other drug candidates, either at all or within anticipated timeframes because, although other drug candidates may target different indications, the underlying technology platform, and specifically the use of an OncoSignature
test, to identify patient responders is the same for all of our drug candidates. Accordingly, a failure in any one program may decrease trust in our AP3 program. In addition, if <FONT STYLE="white-space:nowrap">ACR-368</FONT> shows unexpected
adverse events or a lack of efficacy in the indications we intend to treat, or if we experience other regulatory or developmental issues, our development plans and business could be significantly harmed. We cannot guarantee the successful clinical
development, approval and commercialization of ACR-368. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>The regulatory approval processes of the FDA and comparable foreign
regulatory authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our drug candidates, on a timely basis or at all, our business will be substantially harmed.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our lead drug candidate is currently in Phase&nbsp;2 clinical development under a master protocol designed for
expedited drug development using our ACR-368 OncoSignature test. Although we are using our OncoSignature test to specifically treat patients predicted to be sensitive to ACR-368, we cannot guarantee that we will achieve sufficient ORR for marketing
approval. For our preclinical drug candidates, we must complete preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our drug candidate in humans before obtaining marketing approval from
regulatory authorities. Clinical testing is expensive, difficult to design and implement, can take many&nbsp;years to complete and is uncertain as to the outcome. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The length of time necessary to complete clinical trials and to submit an application for marketing approval for a decision by
a regulatory authority may be difficult to predict. The clinical trial requirements of the FDA and other comparable foreign regulatory authorities and the criteria these regulators use to determine the safety and efficacy of a drug candidate vary
substantially according to the type, complexity, novelty and intended use and market of the drug candidate. As a result, the regulatory approval process for drug candidates such as ours is uncertain and may be more expensive and take longer than the
approval process for drug candidates based on other, better known or more extensively studied technologies. It is difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for our drug candidates in either
the United States or other comparable regions of the world or how long it will take to commercialize our drug candidates. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential drug
candidate to market would adversely affect our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our
drug candidates, including ACR-368, could fail to receive regulatory approval for many reasons, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our
clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities
that a drug candidate is safe and effective for its proposed indication; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the results of clinical trials may not meet the level of statistical significance required by the FDA or
comparable foreign regulatory authorities for approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be unable to demonstrate that a drug candidate&#146;s clinical and other benefits outweigh its safety
risks; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from
preclinical studies or clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the data collected from clinical trials of our drug candidates may not be sufficient to support the submission
of a New Drug Application, or NDA, to the FDA or other submission or to obtain regulatory approval in the United States or elsewhere; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or
facilities of third-party manufacturers with which we contract for clinical and commercial supplies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we or third-party collaborators may fail to obtain regulatory approval of companion diagnostic tests, if
required, on a timely basis, or at all; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly
change in a manner rendering our clinical data insufficient for approval. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prior to obtaining approval
to commercialize a drug candidate in the United States or elsewhere, we or our collaborators must demonstrate with substantial evidence from one or more well-controlled clinical trials, and to the satisfaction of the FDA or comparable foreign
regulatory agencies, that such drug candidates are safe and effective for their intended uses. Results from nonclinical studies and clinical trials can be interpreted in different ways. Even if we believe the nonclinical or clinical data for our
drug candidates are promising, such data may not be sufficient to support approval by the FDA or comparable foreign regulatory authorities. The FDA may also require us to conduct additional preclinical studies or clinical trials for our drug
candidates either prior to or post-approval, or it may object to elements of our clinical development program. Depending on the extent of these or any other studies required by the FDA or comparable foreign regulatory authorities, approval of any
regulatory approval applications that we submit may be delayed by several years, or may require us to expend significantly more resources than we have available. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Of the large number of potential products in development, only a small percentage successfully complete the FDA or comparable
foreign regulatory approval processes and are commercialized. The lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our drug candidates, which
would significantly harm our business, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, as of May&nbsp;26, 2021, the
FDA noted it is continuing to ensure timely reviews of applications for medical products during the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic in line with its user fee performance goals and conducting mission critical
domestic and foreign inspections to ensure compliance of manufacturing facilities with FDA quality standards. However, the FDA may not be able to continue its current pace and approval timelines could be extended, including where a <FONT
STYLE="white-space:nowrap">pre-approval</FONT> inspection or an inspection of clinical sites is required and due to the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and travel restrictions the FDA is unable to complete such
required inspections during the review period. Since March 2020 when foreign and domestic inspections of facilities were largely placed on hold, the FDA has been working to resume routine surveillance, bioresearch monitoring and <FONT
STYLE="white-space:nowrap">pre-approval</FONT> inspections on a prioritized basis. Since April 2021, the FDA has conducted limited inspections and employed remote interactive evaluations, using risk management methods, to meet user fee commitments
and goal dates. Ongoing travel restrictions and other uncertainties continue to impact oversight operations both domestic and abroad and it is unclear when standard operational levels will resume. The FDA is continuing to complete mission-critical
work, prioritize other higher-tiered inspectional needs (e.g., <FONT STYLE="white-space:nowrap">for-cause</FONT> inspections), and carry out surveillance inspections using risk-based approaches for evaluating public health. Should the FDA determine
that an inspection is necessary for approval and an inspection cannot be completed during the review cycle due to restrictions on travel, and the FDA does not determine a remote interactive evaluation to be adequate, the agency has stated that it
generally intends to issue, depending on the circumstances, a complete response letter or defer action on the application until an inspection can be completed. During the <FONT STYLE="white-space:nowrap">COVID-19</FONT> public health emergency, a
number of companies announced receipt of complete response letters due to the FDA&#146;s inability to complete required inspections for their applications. Regulatory authorities </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
outside the United&nbsp;States may adopt similar restrictions or other policy measures in response to the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and may experience
delays in their regulatory activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, even if we were to obtain approval, regulatory authorities may
approve any of our drug candidates for fewer or more limited indications than we request, may impose significant limitations in the form of narrow indications, warnings, or a post-marketing risk management strategy such as a Risk Evaluation and
Mitigation Strategy, or REMS, or the equivalent in another jurisdiction. Regulatory authorities may not approve the price we intend to charge for our products, may grant approval contingent on the performance of costly post-marketing clinical
trials, or may approve a drug candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that drug candidate. Any of the foregoing scenarios could materially harm the commercial
prospects for our drug candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Depending on our clinical trial results, we may seek NDA approval for ACR-368 in the United
States under the FDA&#146;s accelerated approval pathway, but this pathway may not lead to faster development, regulatory review, or approval process and does not increase the likelihood that ACR-368 will receiving marketing approval. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Depending on our clinical trial results, we intend to seek approval for ACR-368 for one or more indications, and we may seek
approval of our future drug candidates, where applicable, under the FDA&#146;s accelerated approval pathway. A product may be eligible for accelerated approval if it is designed to treat a serious or life-threatening disease or condition, generally
provides a meaningful advantage over available therapies, and demonstrates an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit or on a clinical endpoint that can be measured earlier than irreversible morbidity or
mortality, or IMM, that is reasonably likely to predict an effect on IMM or other clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease, such as
IMM. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of
clinical benefit. The accelerated approval pathway may be used in cases in which the advantage of a new product over available therapy may not be a direct therapeutic advantage, but is a clinically important improvement from a patient and public
health perspective. If granted, accelerated approval is usually contingent on the sponsor&#146;s agreement to conduct adequate and well-controlled post-marketing clinical trials to confirm the product&#146;s clinical benefit. These confirmatory
trials must be completed with due diligence. If the sponsor fails to conduct such studies in a timely manner, or if such post-approval studies fail to verify the product&#146;s predicted clinical benefit, the FDA may withdraw its approval of the
product on an expedited basis. In addition, for products being considered for accelerated approval, the FDA currently requires, unless otherwise informed by the Agency, pre-approval of promotional materials, which could adversely impact the timing
of the commercial launch of the product. There can be no assurance that the FDA would allow ACR-368 or any of the drug candidates we may develop to proceed on an accelerated approval pathway, and even if the FDA did allow such pathway, there can be
no assurance that expedited development will occur or that the FDA will review and approve such submission or application on a timely basis, or at all. Moreover, even if we received accelerated approval, any post-marketing studies required to
confirm clinical benefit may not show such benefit, which could lead to withdrawal of any approvals we have obtained. In addition, receiving accelerated approval does not assure that the product&#146;s accelerated approval will eventually be
converted to a traditional approval. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may incur additional costs or experience delays in completing, or ultimately be unable to
complete the development and/or commercialization of <FONT STYLE="white-space:nowrap">ACR-368</FONT> or our other future drug candidates identified through the application of our AP3 platform and OncoSignature companion diagnostics. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any delays in the commencement or completion of our ongoing, planned or future clinical trials could significantly increase our
product development costs. We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to obtain marketing approval or commercialize
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
<FONT STYLE="white-space:nowrap">ACR-368</FONT> or our future drug candidates identified through the application of our AP3 platform and OncoSignature companion diagnostics, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulators, institutional review boards, or IRBs, or ethics committees, or ECs, may not authorize us or our
investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA may disagree as to the design or implementation of our clinical trials or with our recommended doses
with respect to <FONT STYLE="white-space:nowrap">ACR-368,</FONT> or any of our future drug candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may experience delays in reaching, or fail to reach, agreement on acceptable clinical trial contracts or
clinical trial protocols with prospective contract research organizations, or CROs, and prospective trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical trials for <FONT STYLE="white-space:nowrap">ACR-368</FONT> or our future drug candidates may produce
negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials, delay or halt clinical trials or abandon product development programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">lack of adequate funding to continue clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of patients required for clinical trials may be larger than we anticipate, enrollment in these
clinical trials may be slower than we anticipate or may be lower than we anticipate due to challenges in recruiting and enrolling suitable patients who meet the trial criteria, participants may drop out of these clinical trials at a higher rate than
we anticipate or the duration of these clinical trials may be longer than we anticipate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">competition for clinical trial participants from investigational and approved therapies may make it more
difficult to enroll patients in our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may experience difficulties in maintaining contact with patients after treatment, resulting in incomplete
data; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we or third-party collaborators may fail to obtain regulatory approval of companion diagnostic tests, if
required, on a timely basis, or at all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our third-party contractors may fail to meet their contractual obligations to us in a timely manner, or at
all, or may fail to comply with regulatory requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may have to suspend or terminate clinical trials for various reasons, including a finding by us or by a
Data Monitoring Committee for a trial that the participants are being exposed to unacceptable health risks; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">ACR-368</FONT> or our future drug candidates may have undesirable or
unexpected side effects or other unexpected characteristics, causing us or our investigators, regulators or IRBs or ECs to suspend or terminate the trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of clinical trials may be greater than we anticipate; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes to clinical trial protocols; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the supply or quality of <FONT STYLE="white-space:nowrap">ACR-368</FONT> or our future drug candidates or
other materials necessary to conduct clinical trials may be insufficient or inadequate and result in delays or suspension of our clinical trials; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, which may slow potential
enrollment, reduce the number of eligible patients for clinical trials, or reduce the number of patients who remain in our trials. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Delays, including delays caused by the above factors, can be costly and could negatively affect our ability to complete a
clinical trial or obtain timely marketing approvals. We do not know whether any of our planned preclinical studies or clinical trials will begin on a timely basis or at all, will need to be restructured or will be completed on schedule, or at all.
For example, the FDA may place a partial or full clinical hold on any of our current or future clinical trials for a variety of reasons, including safety concerns and noncompliance with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
regulatory requirements. If we are not able to complete successful clinical trials, we will not be able to obtain regulatory approval and will not be able to commercialize <FONT
STYLE="white-space:nowrap">ACR-368</FONT> or our future drug candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Significant preclinical or clinical trial delays
also could shorten any periods during which we may have the exclusive right to commercialize our drug candidates or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize our drug
candidates, which would limit our future revenues and harm our commercial prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The successful clinical development of our drug candidates
depends on the co-approval of the OncoSignature test as a companion diagnostic test. If we or our companion diagnostic collaborator are unable to obtain regulatory approval for our OncoSignature companion diagnostic tests for our drug candidates, we
may not obtain regulatory approval and realize the commercial potential of our drug candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A key part of our
development strategy for our drug candidates is to identify subsets of patients with specific types of tumors. Identification of these patients will require the use and development of companion diagnostics. According to the FDA&#146;s 2014 guidance
document on In Vitro Companion Diagnostic Devices, for novel therapeutic products that depend on the use of a diagnostic test and where the diagnostic device could be essential for the safe and effective use of the corresponding therapeutic product,
the premarket application for the companion diagnostic device should be developed and approved or cleared contemporaneously with the therapeutic, although the FDA recognizes that there may be cases when contemporaneous development may not be
possible. However, in cases where a drug cannot be used safely or effectively without the companion diagnostic, the FDA&#146;s guidance indicates it will generally not approve the drug without the approval or clearance of the diagnostic device. The
FDA also issued a draft guidance in July 2016 setting forth the principles for <FONT STYLE="white-space:nowrap">co-development</FONT> of an in vitro companion diagnostic device with a therapeutic product. The draft guidance describes principles to
guide the development and contemporaneous marketing authorization for the therapeutic product and its corresponding in vitro companion diagnostic. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We do not have experience or capabilities in developing or commercializing diagnostics and plan to rely in large part on our
collaboration partner Akoya to perform these functions. Akoya has not commercialized or submitted or obtained Premarket Approval Application, or PMA, for any companion diagnostic, and any setbacks they encounter could delay any commercial launch of <FONT
STYLE="white-space:nowrap">ACR-368,</FONT> if approved. It may be necessary to resolve issues such as selectivity/specificity, analytical validation, reproducibility, or clinical validation of companion diagnostics during the development and
regulatory approval processes. Moreover, even if data from preclinical studies and early clinical trials appear to support development of a companion diagnostic for a drug candidate, data generated in later clinical trials may fail to support the
analytical and clinical validation of the companion diagnostic. We and our future collaborators may encounter difficulties in developing, obtaining regulatory approval for, manufacturing and commercializing companion diagnostics similar to those we
face with respect to our drug candidates, including issues with achieving regulatory clearance or approval, production of sufficient quantities at commercial scale and with appropriate quality standards, and in gaining market acceptance. If we are
unable to successfully develop companion diagnostics for our drug candidates, or experience delays in doing so, the development of these drug candidates may be adversely affected, these drug candidates may not obtain marketing approval, and we may
not realize the full commercial potential of any of these therapeutics that have or may obtain marketing approval. We may not be able to enter into arrangements with another diagnostic company to develop and obtain regulatory approval for an
alternative diagnostic test for use in connection with the development and commercialization of our drug candidates or do so on commercially reasonable terms, which could adversely affect and/or delay the development or commercialization of our
therapeutic candidates or therapeutics. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Companion diagnostics are subject to regulation by the FDA and comparable foreign
regulatory authorities as medical devices and will likely require separate regulatory approval prior to commercialization. If we or third parties are unable to successfully develop companion diagnostics for our drug candidates, or experience delays
in doing so: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the development of these drug candidates may be delayed because it may be difficult to identify patients for
enrollment in our clinical trials in a timely manner; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">these drug candidates may not receive marketing approval if their safe and effective use depends on a
companion diagnostic; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not realize the full commercial potential of these drug candidates that receive marketing approval if,
among other reasons, we are unable to appropriately identify patients or types of tumors targeted by these drug candidates. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Even if our drug candidates and any associated companion diagnostics are approved for marketing, the need for companion
diagnostics may slow or limit adoption of our drug candidates. Although we believe companion diagnostic testing is becoming more prevalent in the diagnosis and treatment of cancer, our drug candidates may be perceived negatively compared to
alternative treatments that do not require the use of companion diagnostics, either due to the additional cost of the companion diagnostic or the need to complete additional testing prior to administering our drug candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If any of these events were to occur, our business and growth prospects would be harmed materially. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may not be able to file INDs or IND amendments to commence additional clinical trials on the timelines we expect, and even if we are
able to, the FDA may not permit us to proceed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Although we received clearance from the FDA for an IND to advance <FONT
STYLE="white-space:nowrap">ACR-368</FONT> in Phase 2 single arm clinical trials conducted under the master protocol, we may not be able to file INDs for our other drug candidates on the timelines we expect. For example, we may experience, or our
partners may experience, manufacturing delays or other delays with <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies. Moreover, we cannot be sure that submission of an IND will result in the FDA allowing further clinical trials to begin,
or that, once begun, issues will not arise that suspend or terminate clinical trials. Additionally, even if such regulatory authorities agree with the design and implementation of the clinical trials set forth in an IND, we cannot guarantee that
such regulatory authorities will not change their requirements in the future. These considerations also apply to new clinical trials we may submit as amendments to existing INDs or to a new IND. Any failure to file INDs on the timelines we expect or
to obtain regulatory approvals for our trials may prevent us from completing our clinical trials or commercializing our products on a timely basis, if at all. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If we experience delays or difficulties in enrolling patients in our ongoing or planned clinical trials, our receipt of necessary
regulatory approval could be delayed or prevented. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may not be able to initiate or continue our ongoing or
planned clinical trials if we are unable to identify and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or comparable foreign regulatory authorities. In addition, some of our competitors
currently have ongoing clinical trials for drug candidates that would treat the same patients as our lead clinical drug candidate, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our
competitors&#146; drug candidates. We rely on our external companion diagnostic partner, Akoya, to perform <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature testing in our clinical trial. If Akoya encounters delays or technical
challenges, enrollment in our clinical trials may be substantially delayed. Patient enrollment is also affected by other factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the severity of the disease under investigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to recruit clinical trial investigators of appropriate competencies and experience;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the incidence and prevalence of our target indications; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">competing studies or trials with similar eligibility criteria; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">invasive procedures required to enroll patients and to obtain evidence of the drug candidates&#146;
performance during clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">availability and efficacy of approved medications for the disease under investigation; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">eligibility criteria defined in the protocol for the trial in question; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the size and nature of the patient population required for analysis of the trial&#146;s primary endpoints;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">efforts to facilitate timely enrollment in clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether we are subject to a partial or full clinical hold on any of our clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reluctance of physicians to encourage patient participation in clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to monitor patients adequately during and after treatment; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain and maintain patient consents; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">proximity and availability of clinical trial sites for prospective patients. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our inability to enroll and maintain a sufficient number of patients for our clinical trials would result in significant
delays or may require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials, including due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, may result in increased development costs, which
would cause the value of our company to decline, limit our ability to obtain additional financing and delay or limit our ability to obtain regulatory approval for our drug candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Unexpected adverse side effects or other safety risks associated with <FONT STYLE="white-space:nowrap">ACR-368</FONT> or our other
future drug candidates could delay or preclude approval, cause us to suspend or discontinue clinical trials or abandon further development, limit the commercial profile of an approved product or result in significant negative consequences following
marketing approval, if any. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As is the case with small molecule therapeutics generally, side effects and adverse
events associated with <FONT STYLE="white-space:nowrap">ACR-368</FONT> have been observed. Although <FONT STYLE="white-space:nowrap">ACR-368</FONT> has been evaluated in approximately 1,000 patients in clinical trials to date with a generally
favorable tolerability profile, unexpected side effects may still arise in our ongoing or any future clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our
trials will be primarily based on the established RP2D dosing regimen used in over 400 patients in past trials. In these trials, the most frequent treatment related adverse events greater than or equal to Grade 3, which are considered serious
adverse events, were primarily reversible, manageable hematological toxicities, including neutropenia and thrombocytopenia and there was only limited non-hematological toxicities. In one of the clinical trials (a cohort of 58 platinum-sensitive
patients), there were three deaths deemed possibly related to study treatment. In addition, our trials will also, in part, include testing of ACR-368 at RP2D in combination with low dose gemcitabine, which could result in greater severity and
prevalence of side effects or unexpected characteristics. Undesirable side effects could result in the delay, suspension or termination of clinical trials by us or regulatory authorities for a number of reasons. Furthermore, clinical trials by their
nature utilize a sample of the potential patient population. With a limited number of subjects and limited duration of exposure, rare and severe side effects of our drug candidates or those of our competitors may only be uncovered with a
significantly larger number of patients exposed to the drug. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, due to the high mortality rates of the cancers
for which we are initially pursuing development and the pretreated and advanced nature of disease in many patients in our ongoing clinical trials of <FONT STYLE="white-space:nowrap">ACR-368,</FONT> a material&nbsp;percentage of patients in these
clinical trials ultimately will die during a trial for reasons unrelated to the drug. For example, in the Phase 1b/2 combination arm of our Phase 2 trial for ACR-368 we recently dosed a patient who had previously failed three lines of prior therapy.
The patient died prior to receiving a second dose of ACR-368 and the death was determined by the trial investigator not to be drug related, but instead related to the subject&#146;s disease progression. If we elect to, or are required to, delay,
suspend or terminate any clinical trial, whether due to a patient death or otherwise, the commercial prospects of <FONT STYLE="white-space:nowrap">ACR-368</FONT> or our future drug candidates could be harmed and our ability to generate product
revenues could potentially be delayed or eliminated. Serious adverse events observed in clinical trials could hinder or prevent market acceptance of our drug candidates, which would harm our commercial prospects our financial condition and our
reputation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Moreover, if <FONT STYLE="white-space:nowrap">ACR-368</FONT> or any of our
future drug candidates are associated with undesirable or unexpected side effects in clinical trials, we may elect to abandon or limit their development to more narrow uses or subpopulations in which the undesirable side effects or other
characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective, which may limit the commercial expectations for the drug candidate, even if it is approved. We may also be required to modify our trial plans based
on findings in our clinical trials. Side effects could also affect patient recruitment or the ability of enrolled patients to complete a trial. Many drugs that initially showed promise in early stage testing have later been found to cause side
effects that prevented further development. In addition, regulatory authorities may draw different conclusions, require additional testing to confirm these determinations, require more restrictive labeling or deny regulatory approval of the drug
candidate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">It is possible that, as we test our drug candidates in larger, longer and more extensive clinical trials,
including with different dosing regimens, or as the use of our drug candidates becomes more widespread following any regulatory approval, illnesses, injuries, discomforts and other adverse events that were observed in earlier trials, as well as
conditions that did not occur or went undetected in previous trials, will be reported by patients. If such side effects become known later in development or upon approval, if any, such findings may harm our business, financial condition, results of
operations and prospects significantly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, if <FONT STYLE="white-space:nowrap">ACR-368</FONT> receives
marketing approval, and we or others later identify undesirable side effects caused by treatment with such drug, a number of potentially significant negative consequences could result, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may withdraw approval of the drug; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to recall a product or change the way the drug is administered to patients;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may require additional warnings in the labeling, such as a contraindication or a boxed
warning, or issue safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to implement a REMS, or create a medication guide outlining the risks of such side effects
for distribution to patients; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additional restrictions may be imposed on the marketing or promotion of the particular product or the
manufacturing processes for the product or any component thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we could be sued and held liable for harm caused to patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be subject to regulatory investigations and government enforcement actions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the drug could become less competitive; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reputation may suffer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any of these events could prevent us from achieving or maintaining market acceptance of our drug candidates, if approved, and
could significantly harm our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Preliminary, interim and topline
data from our clinical trials that we announce or publish from time to time may change as more patient data becomes available and is subject to audit and verification procedures that could result in material changes in the final data. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">From time to time, we may publicly disclose preliminary, interim or topline data from our clinical trials, such as futility
analyses, ORR, or various primary and secondary clinical endpoints. These updates will be based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more
comprehensive review of the data related to the particular study or trial. Additionally, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient
data becomes available. Therefore, positive interim results in any ongoing clinical trial may not be predictive of such results in the completed study or trial. We also make assumptions, estimations, calculations and conclusions as part of our
analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline results that we report may differ from future results of the same studies, or different conclusions or
considerations may qualify such results, once additional data has been received and fully evaluated. Topline data also remains subject to audit and verification procedures that may result in the final data being materially different from the
preliminary data we previously published. As a result, topline data should be viewed with caution until the final data is available. In addition, we may report interim analyses of only certain endpoints rather than all endpoints. Adverse changes
between preliminary or interim data and final data could significantly harm our business and prospects. Further, additional disclosure of interim data by us or by our competitors in the future could result in volatility in the price of our common
stock after this offering. See the description of risks under the heading &#147;Risks Related to our Common Stock and This Offering&#148; for more disclosure related to the risk of volatility in our stock price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations,
conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular drug candidate or product and our company in
general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is typically selected from a more extensive amount of available information. You or others may not agree with what we determine is
the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise
regarding a particular product, drug candidate or our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, other future clinical trials we conduct may
be open-label trials in which both the patient and investigator know whether the patient is receiving the investigational drug candidate or either an existing approved product or placebo. Open-label clinical trials typically test only the
investigational drug candidate and sometimes may do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware when they
are receiving treatment. Open-label clinical trials may be subject to a &#147;patient bias&#148; where patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. In addition, open-label
clinical trials may be subject to an &#147;investigator bias&#148; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the
treated group more favorably given this knowledge. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If the preliminary or topline data that we report differs from late,
final or actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, <FONT STYLE="white-space:nowrap">ACR-368,</FONT> or any other future drug
candidates may be harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may in the future seek to engage in strategic transactions to acquire or <FONT
STYLE="white-space:nowrap">in-license</FONT> additional products, drug candidates or technologies. If we are unable to realize the benefits from such transactions, it may adversely affect our ability to develop and commercialize an expanded pipeline
of drug candidates, negatively impact our cash position, increase our expenses and present significant distractions to our management. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">From time to time, we may consider strategic transactions, such as additional collaborations, acquisitions of companies, asset
purchases, joint ventures and <FONT STYLE="white-space:nowrap">in-licensing</FONT> of new products, drug candidates or technologies that we believe will complement or augment our existing business. For example, in 2021, we acquired our lead drug
candidate, <FONT STYLE="white-space:nowrap">ACR-368,</FONT> pursuant to worldwide license agreement with Lilly which maintains certain open INDs with the FDA for prexasertib being supplied to investigator-initiated studies. If we acquire assets with
promising markets or technologies, we may not be able to realize the benefit of acquiring such assets if we are not able to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
successfully integrate them with our existing technologies. We may encounter numerous difficulties in developing, testing, manufacturing and marketing any new products resulting from a strategic
acquisition that delay or prevent us from realizing their expected benefits or enhancing our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Following any such
strategic transaction, we may not achieve any expected synergies to justify the transaction. For example, such transactions may require us to incur <FONT STYLE="white-space:nowrap">non-recurring</FONT> or other charges, increase our near-term and
long-term expenditures and pose significant integration or implementation challenges or disrupt our management or business. These transactions would entail numerous operational and financial risks, including, but not limited to, exposure to unknown
liabilities, disruption of our business and diversion of our management&#146;s time and attention in order to manage a collaboration or develop acquired products, drug candidates or technologies, incurrence of substantial debt or dilutive issuances
of equity securities to pay transaction consideration or costs, higher than expected acquisition or integration costs, write-downs of assets or goodwill or impairment charges, increased amortization expenses, difficulty and cost in facilitating the
transaction or combining the operations and personnel of any acquired business, impairment of relationships with key suppliers, manufacturers or customers of any acquired business due to changes in management and ownership and the inability to
retain key employees of any acquired business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Accordingly, although there can be no assurance that we will undertake or
successfully complete any transactions of the nature described above, any transactions that we do complete may be subject to the foregoing or other risks and could have a material and adverse effect on our business, financial condition, results of
operations and prospects. Conversely, any failure to enter any strategic transaction that would be beneficial to us could delay the development and potential commercialization of our drug candidates and could have a negative impact on the
competitiveness of any drug candidate that reaches market. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may expend our limited resources to pursue a particular drug
candidate or indication and fail to capitalize on drug candidates or indications that may be more profitable or for which there is a greater likelihood of success. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Because we have limited financial and managerial resources, we focus on research programs and drug candidates that we identify
for specific indications. As a result, we may forego or delay pursuit of opportunities with other future drug candidates or for other indications that later prove to have greater commercial potential. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market
opportunities. Our spending on current and future research and development programs and drug candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target
market for a particular drug candidate, we may relinquish valuable rights to that drug candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development
and commercialization rights to that drug candidate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our clinical development is focused on the development of precision oncology
medicines utilizing our proprietary precision medicine platform, which is based on a novel scientific approach and may never lead to marketable products. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The development of precision oncology medicines for patients whose tumors are sensitive to a specific product or drug candidate
based on direct protein measurement is a rapidly emerging field, and the scientific discoveries that form the basis for our efforts to develop drug candidates are relatively new. Furthermore, our OncoSignature companion diagnostic is based on new
technology, which makes it difficult to predict the time and cost of development and of subsequently obtaining regulatory approval, if at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The scientific evidence to support the feasibility of developing drug candidates based on these discoveries is both
preliminary and limited. Although we believe, based on our clinical work, that our approach is applicable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
across stages of drug development and therapeutic modalities, clinical results may not confirm this hypothesis or may only confirm it for certain tumor types. Therefore, we do not know if our
approach will be successful, but if our approach is unsuccessful, our business will suffer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Efforts to identify, acquire
or <FONT STYLE="white-space:nowrap">in-license,</FONT> and then develop drug candidates require substantial technical, financial and human resources, whether or not any drug candidates are ultimately identified. We apply our AP3 platform and
OncoSignature companion diagnostic in our efforts to discover potential precision targets for which drug candidates may be developed. Our efforts may initially show promise in identifying potential drug candidates, yet fail to yield drug candidates
for clinical development, approved products or commercial revenues for many reasons, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the methodology used may not be successful in identifying potential drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">competitors may develop alternatives that render any drug candidates we develop obsolete;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any drug candidates we develop may nevertheless be covered by third parties&#146; patents or other exclusive
rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a drug candidate may be shown to have harmful side effects or other characteristics that indicate it is
unlikely to be effective or otherwise does not meet applicable regulatory criteria; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a drug candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at
all; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a drug candidate may not be accepted as safe and effective by physicians, patients, the medical community or
third-party payors. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Increasing demand for compassionate use of our drug candidates could negatively affect our
reputation and harm our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are developing drug candidates for the treatment of indications for which
there are currently limited or no available therapeutic options. It is possible for individuals or groups to target companies with disruptive social media campaigns related to a request for access to unapproved drugs for patients with significant
unmet medical need. If we experience a similar social media campaign regarding our decision to provide or not provide access to any of our current or future drug candidates under an expanded access policy, our reputation may be negatively affected
and our business may be harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Recent media attention to individual patients&#146; expanded access requests has resulted
in the introduction and enactment of legislation at the local and national level referred to as &#147;Right to Try&#148; laws, such as the federal Right to Try Act of 2017 signed into law on May&nbsp;30, 2018, which are intended to allow patients
access to unapproved therapies earlier than traditional expanded access programs. A possible consequence of both activism and legislation in this area may be the need for us to initiate an unanticipated expanded access program or to make our drug
candidates more widely available sooner than anticipated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, some patients who receive access to drugs prior to
their commercial approval through compassionate use, expanded access programs or right to try access have life-threatening illnesses and have exhausted all other available therapies. The risk for serious adverse events in this patient population is
high, which could have a negative impact on the safety profile of our drug candidates if we were to provide them to these patients, which could cause significant delays or an inability to successfully commercialize our drug candidates, which could
materially harm our business. If we were to provide patients with any of our drug candidates under an expanded access program, we may in the future need to restructure or pause any compassionate use and/or expanded access programs for a variety of
reasons, which could prompt adverse publicity or other disruptions related to current or potential participants in such programs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our business and operations may be adversely affected by the evolving and ongoing <FONT
STYLE="white-space:nowrap">COVID-19</FONT> global pandemic. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our business and operations may be adversely affected
by the effects of the recent and evolving <FONT STYLE="white-space:nowrap">COVID-19</FONT> virus, which was declared by the World Health Organization as a global pandemic, including the current resurgences as a result of the Omicron variant and
related subvariants in various regions in the United States and globally and other future resurgences. The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic has resulted in travel and other restrictions in order to reduce the spread of the
disease, including public health directives and orders in the United States and globally that, among other things and for various periods of time, directed individuals to shelter at their places of residence, directed businesses and governmental
agencies to cease <FONT STYLE="white-space:nowrap">non-essential</FONT> operations at physical locations, prohibited certain <FONT STYLE="white-space:nowrap">non-essential</FONT> gatherings and events and ordered cessation of <FONT
STYLE="white-space:nowrap">non-essential</FONT> travel. Future remote work policies and similar government orders or other restrictions on the conduct of business operations related to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic
may negatively impact productivity; disrupt our ongoing research and development activities and our clinical programs and timelines; and cause disruptions to our supply chain, to the administrative functions of clinical trial sites and to the
operations of our other partners, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. In the event that government
authorities were to enhance current restrictions, such orders also may impact the availability or cost of materials, which would disrupt our supply chain and manufacturing efforts and could affect our ability to conduct ongoing and planned clinical
trials and preparatory activities. We may also face difficulties in obtaining access to manufacturing slots for our drug candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Although our ongoing and planned clinical trials have not been impacted by the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic to date, we may experience related disruptions in the future that could severely impact our clinical trials, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays, difficulties or a suspension in clinical site initiation, including difficulties in recruiting
clinical site investigators and clinical site staff; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays, difficulties or interruptions in shipping and delivering in a timely manner supplies, samples or
products required for our clinical trials due to the impact of the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on the United States Postal Service, FedEx, United Parcel Service and/or other commercial shipping organizations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays, difficulties or interruptions in obtaining the raw materials and other resources needed for our
operations, including due to <FONT STYLE="white-space:nowrap">government-led</FONT> diversion, reprioritization or appropriation of such resources; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays or interruptions in third-party or collaborator services, including due to <FONT
STYLE="white-space:nowrap">government-led</FONT> diversion, reprioritization or appropriation of such services; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interruptions in our ability to manufacture and deliver drug supply for trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of
hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in local regulations as part of a response to the ongoing
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic that may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue the clinical trials altogether;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interruption of key clinical trial activities, such as clinical trial site monitoring, and the ability or
willingness of subjects to travel to trial sites due to limitations on travel imposed or recommended by federal or state governments, employers and others; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limitations in employee resources that would otherwise be focused on the conduct of our clinical trials,
including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interruption or delays in the operations of the FDA or other regulatory authorities, which may impact review
and approval timelines; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in necessary interactions with local regulators, ethics committees and other important agencies and
contractors due to limitations in employee resources or forced furlough of government employees; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal of the FDA to accept data from clinical trials in these affected geographies. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The spread of <FONT STYLE="white-space:nowrap">COVID-19,</FONT> including new variants of the virus, such as the Omicron
variant and related subvariants, which has caused a broad impact globally, may materially affect us economically. While the potential economic impact brought by, and the duration of, <FONT STYLE="white-space:nowrap">COVID-19</FONT> may be difficult
to assess or predict, a widespread pandemic could result in significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market
correction resulting from the spread of <FONT STYLE="white-space:nowrap">COVID-19</FONT> could materially affect our business and the value of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Since the beginning of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, several vaccines for <FONT
STYLE="white-space:nowrap">COVID-19</FONT> have received Emergency Use Authorization by the FDA and a number of those later received marketing approval. Additional vaccines may be authorized or approved in the future. The resultant demand for
vaccines and potential for manufacturing facilities and materials to be commandeered under the Defense Production Act of 1950, or equivalent foreign legislation, may make it more difficult and/or more costly to obtain materials or manufacturing
slots for the products needed for our clinical trials, which could lead to delays in these trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The global <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic continues to rapidly evolve. The extent to which the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic impacts our business and operations, including our clinical development and regulatory
efforts, will depend on future developments that are highly uncertain and cannot be predicted with confidence at the time of this prospectus, such as the ultimate geographic spread of the disease, the duration of the outbreak, the duration and
effect of business disruptions and the short-term effects and ultimate effectiveness of the travel restrictions, quarantines, social distancing requirements and business closures in the United States and other countries to contain and treat patients
with the disease. Accordingly, we do not yet know the full extent of potential delays or impacts on our business, our clinical and regulatory activities, healthcare systems or the global economy as a whole. However, these impacts could adversely
affect our business, financial condition, results of operations and growth prospects. In addition, to the extent the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic adversely affects our business and results of operations, it may
also have the effect of heightening many of the other risks and uncertainties described in this &#147;Risk Factors&#148; section. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to
Government Regulation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our relationships with customers, healthcare providers, including physicians, and third-party payors are
subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, health information privacy and security laws and other healthcare laws and regulations. If we are unable to comply, or have not fully complied,
with such laws, we could face substantial penalties. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Healthcare providers, including physicians, and third-party
payors in the United States and elsewhere will play a primary role in the recommendation and prescription of any drug candidates for which we obtain marketing approval. Our current and future arrangements with healthcare professionals, principal
investigators, consultants, customers and third-party payors subject us to various federal and state fraud and abuse laws and other healthcare laws, including, without limitation, the federal Anti-Kickback Statute, the federal civil and criminal
false claims laws and the law commonly referred to as the Physician Payments Sunshine Act and regulations promulgated under such laws. These laws will impact, among other things, our clinical research, proposed sales, marketing and educational
programs, and other interactions with healthcare professionals. In addition, we may be subject to patient privacy laws by both the federal government and the states in which we conduct or may conduct our business. The laws that will affect our
operations include, but are not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Anti-Kickback Statute, which prohibits, among other things, individuals or entities from knowingly
and willfully soliciting, receiving, offering or paying any remuneration (including any </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind in return for, or to induce, either the referral of an individual, or the purchase, lease, order or
arrangement for or recommendation of the purchase, lease, order or arrangement for any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid
programs. The term &#147;remuneration&#148; has been broadly interpreted to include anything of value. Although there are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, the exceptions
and safe harbors are drawn narrowly. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. A
person does not need to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation. In addition, the ACA, signed into law in 2010, provides that the government may assert that a claim including
items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal civil and criminal false claims laws, including, without limitation, the federal False Claims Act,
which can be enforced by private citizens through civil whistleblower or qui tam actions, and the federal civil monetary penalty law which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented,
claims for payment or approval from the federal government, including Medicare, Medicaid and other government payors, that are false or fraudulent or knowingly making, using or causing to be made or used a false record or statement material to a
false or fraudulent claim or to avoid, decrease or conceal an obligation to pay money to the federal government. A claim includes &#147;any request or demand&#148; for money or property presented to the United States federal government. Several
pharmaceutical and other healthcare companies have been prosecuted under these laws for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. Other companies have been
prosecuted for causing false claims to be submitted because of the companies&#146; marketing of products for unapproved, and thus <FONT STYLE="white-space:nowrap">non-reimbursable,</FONT> uses; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional
federal criminal statutes which prohibit, among other things, a person from knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors and knowingly and
willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal
Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or
HITECH, and their implementing regulations, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information on health plans, healthcare clearinghouses and certain healthcare
providers, known as &#147;covered entities&#148;, and their respective HIPAA &#147;business associates&#148;, which are independent contractors that perform certain services for or on behalf of covered entities or other business associates involving
the use or disclosure of individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys
general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorneys&#146; fees and costs associated with pursuing federal civil actions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal transparency laws, including the federal Physician Payments Sunshine Act, which requires certain
manufacturers of drugs, medical devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the State Children&#146;s Health Insurance Program, with specific exceptions, to report annually to Centers for
Medicare&nbsp;&amp; Medicaid Services, or CMS, information </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
related to: (i)&nbsp;payments or other &#147;transfers of value&#146;&#146; made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain other
healthcare providers (such as physicians assistants and nurse practitioners), and teaching hospitals, and (ii)&nbsp;ownership and investment interests held by physicians and their immediate family members; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">state and foreign laws and regulations that are analogous to each of the above federal laws; state laws that
require manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers, marketing expenditures or drug pricing; state laws that require pharmaceutical companies to comply with the
pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or that otherwise restrict payments that may be made to healthcare providers; state and local laws that
require the registration of pharmaceutical sales representatives; and state and foreign laws that govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not
preempted by HIPAA, thus complicating compliance efforts. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Because of the breadth of these laws and the
narrowness of the statutory exceptions and regulatory safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. It is possible that governmental authorities will
conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of
these laws or any other governmental regulations that may apply to us, we may be subject to significant penalties, including, without limitation, civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment,
exclusion from participating in federal and state funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve
allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws, contractual damages, diminished profits and future earnings, reputational harm and the curtailment or restructuring of our operations, any of which could harm our
business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The risk of our being found in violation of these laws is increased by the fact that many of them have not been
fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and
regulations will involve substantial costs. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#146;s attention from the
operation of our business. The shifting compliance environment and the need to build and maintain robust and expandable systems to comply with multiple jurisdictions with different compliance and/or reporting requirements increases the possibility
that a healthcare company may run afoul of one or more of the requirements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Even if we obtain FDA approval of any of our drug
candidates in the United States, we may never obtain approval for or commercialize any of them in any other jurisdiction, which would limit our ability to realize their full market potential. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In order to market any products in any particular jurisdiction, we must establish and comply with numerous and varying
regulatory requirements on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis regarding safety and efficacy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Approval by the FDA in the United States does not ensure approval by regulatory authorities in other countries or
jurisdictions. However, the failure to obtain approval in one jurisdiction may negatively impact our ability to obtain approval elsewhere. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other
countries, and regulatory approval in one country does not guarantee regulatory approval in any other country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Approval
processes vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approval could result in difficulties and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
increased costs for us and require additional preclinical studies or clinical trials which could be costly and time consuming. Regulatory requirements can vary widely from country to country and
could delay or prevent the introduction of our products in those countries. We do not have any drug candidates approved for sale in any jurisdiction, including in international markets, and we do not have experience in obtaining regulatory approval
in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and
our ability to realize the full market potential of any product we develop will be unrealized. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Even if we receive regulatory
approval of our current or future drug candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense, and we may be subject to penalties if we fail to comply with
regulatory requirements or experience unanticipated problems with our drug candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any drug candidate for
which we obtain marketing approval will be subject to ongoing regulatory requirements for, among other things, manufacturing processes, submission of post-approval clinical data and safety information, labeling, packaging, distribution, adverse
event reporting, storage, recordkeeping, export, import, advertising, promotional activities and product tracking and tracing. These requirements include submissions of safety and other post-marketing information and reports, establishment
registration and drug listing requirements, continued compliance with cGMP requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of
samples to physicians and recordkeeping and GCP requirements for any clinical trials that we conduct post-approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
FDA and other federal and state agencies, including the Department of Justice, closely regulate compliance with all requirements governing prescription drug and biologic products, including requirements pertaining to their marketing and promotion in
accordance with the provisions of the approved labeling and manufacturing of products in accordance with cGMP requirements. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#146;s FDA
approved labeling. The FDA imposes stringent restrictions on manufacturers&#146; communications regarding <FONT STYLE="white-space:nowrap">off-label</FONT> use and if we market our products for uses beyond their approved diseases, we may be subject
to enforcement action for <FONT STYLE="white-space:nowrap">off-label</FONT> marketing. Violations of the Federal Food, Drug, and Cosmetic Act, relating to the promotion of prescription drugs for unapproved uses may lead to enforcement actions and
investigations alleging violations of federal and state health care fraud and abuse laws, as well as state consumer protection laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, later discovery of previously unknown adverse events or other problems with our products, manufacturers or
manufacturing processes, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on manufacturing such products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the labeling or marketing of a product; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on product distribution or use; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">requirements to conduct post-marketing studies or clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">warning or untitled letters, or holds on clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withdrawal of the products from the market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal to approve pending applications or supplements to approved applications that we submit;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recall of products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, restitution or disgorgement of profits or revenues; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">suspension or withdrawal of marketing approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal to permit the import or export of our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product seizure or detention; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA&#146;s policies, and the policies of foreign regulatory agencies, may change and additional government regulations may
be enacted that could prevent, limit or delay regulatory approval of our drug candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We also cannot predict the
likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. For example, executive orders or other actions could impose significant
burdens on, or otherwise materially delay, the FDA&#146;s ability to engage in routine oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. If such executive
actions were to impose restrictions on the FDA&#146;s ability to engage in oversight and implementation activities in the normal course, our business could be negatively impacted. If we are slow or unable to adapt to changes in existing requirements
or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained which would adversely affect our business, prospects and ability to achieve or
sustain profitability. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Enacted and future healthcare legislation may increase the difficulty and cost for us to progress our
clinical programs and obtain marketing approval of and commercialize our drug candidates and may affect the prices we may set. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the United States, the European Union and other jurisdictions, there have been, and we expect there will continue to be, a
number of legislative and regulatory changes and proposed changes to the healthcare system that could affect our future results of operations. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state
levels that seek to reduce healthcare costs and improve the quality of healthcare. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA,
was enacted, which substantially changed the way healthcare is financed by both governmental and private insurers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Since
its enactment, there have been judicial, Congressional and executive branch challenges to certain aspects of the ACA. For example, on June&nbsp;17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is
unconstitutional in its entirety because the &#147;individual mandate&#148; was repealed by Congress. Thus, the ACA will remain in effect in its current form. It is possible that the ACA will be subject to judicial or Congressional challenges in the
future. It is unclear how any such challenges and the health reform measures of the Biden administration will impact the ACA and our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In
August 2011, the Budget Control Act of 2011, among other things, led to aggregate reductions of Medicare payments to providers of 2% per fiscal year. These reductions went into effect in April 2013 and, due to subsequent legislative amendments to
the statute will remain in effect until 2031 unless additional action is taken by Congress. However, pursuant to <FONT STYLE="white-space:nowrap">COVID-19</FONT> relief legislation, these Medicare sequester reductions were suspended from May&nbsp;1,
2020 through March&nbsp;31, 2022 due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. Under current legislation the actual reduction in Medicare payments will vary from 1% in 2022 to up to 4% in the final fiscal year of this
sequester .In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers,
and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. It is also possible that additional governmental action is taken in response to the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Moreover, payment methodologies may be subject to changes in healthcare
legislation and regulatory initiatives. For example, CMS may develop new payment and delivery models, such as bundled payment models. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set
prices for their marketed products, which has resulted in several U.S. presidential executive orders, Congressional inquiries and proposed and enacted federal legislation designed to, among other things, bring more transparency to drug pricing,
reduce the cost of prescription drugs under Medicare, and review the relationship between pricing and manufacturer patient programs. For example, in July 2021, the Biden administration released an executive order, &#147;Promoting Competition in the
American Economy,&#148; with multiple provisions aimed at prescription drugs. In response to Biden&#146;s executive order, on September&nbsp;9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug
pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. No legislation or administrative actions have been finalized to
implement these principles. Additionally, on March&nbsp;11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#146;s average
manufacturer price, for single source and innovator multiple source drugs, beginning January&nbsp;1, 2024. In addition, Congress is considering drug pricing and other health reform initiatives. We expect that additional U.S. federal healthcare
reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our drug candidates or additional pricing
pressures and could negatively affect our customers and accordingly, our financial operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Individual states in the
United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product
access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other
restrictions could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products
and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our drug candidates or put pressure on our product pricing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the European Union, similar political, economic and regulatory developments may affect our ability to profitably
commercialize our drug candidates, if approved. In addition to continuing pressure on prices and cost containment measures, legislative developments at the European Union or member state level may result in significant additional requirements or
obstacles that may increase our operating costs. The delivery of healthcare in the European Union, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for
national, rather than European Union, law and policy. National governments and health service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement of products in that context. In
general, however, the healthcare budgetary constraints in most EU member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing European Union and
national regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our drug candidates, restrict or regulate post-approval activities and affect our ability to commercialize our drug
candidates, if approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In markets outside of the United States and the European Union, reimbursement and healthcare
payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or
administrative action in the United States, the European Union or any other jurisdiction. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our drug candidates may lose any regulatory approval that may have been obtained
and we may not achieve or sustain profitability. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If we or our third-party manufacturers and suppliers fail to comply with
environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory
procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Although we do not currently manufacture our drug products or drug candidates on site, our research and development activities do involve the use of
biological and hazardous materials and produce hazardous waste products at small quantities. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these
materials, which could cause an interruption of our commercialization efforts, research and development efforts and business operations, environmental damage resulting in costly <FONT STYLE="white-space:nowrap">clean-up</FONT> and liabilities under
applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. Although we believe that the safety procedures utilized by our third-party manufacturers for handling and disposing of
these materials generally comply with the standards prescribed by these laws and regulations, we cannot guarantee that this is the case or eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be
held liable for any resulting damages and such liability could exceed our resources and state or federal or other applicable authorities may curtail our use of certain materials and/or interrupt our business operations. Furthermore, environmental
laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. In addition, we may incur substantial costs in order to comply
with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development, or production efforts. Failure to comply with these laws and regulations also may result
in substantial fines, penalties, or other sanctions.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Although we maintain workers&#146; compensation insurance to cover us
for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials or other work-related injuries, this insurance may not provide adequate coverage against potential liabilities. We do not carry
specific biological waste or hazardous waste insurance coverage, workers compensation or property and casualty and general liability insurance policies that include coverage for damages and fines arising from biological or hazardous waste exposure
or contamination. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Changes in funding for the FDA and other government agencies could hinder their ability to hire and retain key
leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner, which could negatively impact our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget
and funding levels, ability to hire and retain key personnel, accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government
funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by
necessary government agencies, which would adversely affect our business. For example, over the last several years, including for 35 days beginning on December&nbsp;22, 2018, the U.S. government has shut down several times and certain regulatory
agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. Our business depends upon the ability of the FDA to accept and review our potential regulatory filings. If a prolonged government shutdown occurs,
it could significantly impact the ability </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our ability to advance clinical development of our drug candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process
our regulatory submissions, which could have a material adverse effect on our business. Further, future shutdowns of other government agencies, such as the U.S. Securities and Exchange Commission, or SEC, may also impact our business through review
of our public filings and our ability to access the public markets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If we obtain approval to commercialize any products outside of
the United States, a variety of risks associated with international operations could adversely affect our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If <FONT STYLE="white-space:nowrap">ACR-368</FONT> or any of our other drug candidates are approved for commercialization, we
may seek to enter into agreements with third parties to market them in certain jurisdictions outside the United States. We expect that we would be subject to additional risks related to international pharmaceutical operations, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">different regulatory requirements for drug and companion diagnostic approvals and rules governing drug and
companion diagnostic commercialization in foreign countries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced protection for intellectual property rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">foreign reimbursement, pricing and insurance regimes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unexpected changes in tariffs, trade barriers and regulatory requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">economic weakness, including inflation, or political instability in particular foreign economies and markets;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and
other obligations incident to doing business in another country; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">business interruptions resulting from geopolitical actions, including war and terrorism or natural disasters
including earthquakes, typhoons, floods and fires, or from economic or political instability; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">greater difficulty with enforcing our contracts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential noncompliance with the U.S. Foreign Corrupt Practices Act, or FCPA, the U.K. Bribery Act 2010 and
similar anti-bribery and anticorruption laws in other jurisdictions; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities
abroad. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have no prior experience in these areas. In addition, there are complex regulatory, tax,
labor and other legal requirements imposed by individual countries in Europe with which we will need to comply. If we are unable to successfully manage the challenges of international expansion and operations, our business and operating results
could be harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may develop our current and future drug candidates in combination with other therapies, and safety or supply
issues with <FONT STYLE="white-space:nowrap">combination-use</FONT> products may delay or prevent development and approval of our drug candidates.</I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may develop our current or future drug candidates in combination with one or more cancer therapies, both approved and
unapproved. Even if any drug candidate we develop were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risks that the FDA or similar regulatory
authorities outside of the United States could revoke approval of the therapy used in combination with our drug candidates or that safety, efficacy, manufacturing or supply issues could arise with these existing therapies. Combination therapies are
commonly used for the treatment of cancer, and we </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
would be subject to similar risks if we develop any of our drug candidates for use in combination with other drugs or for indications other than cancer. Similarly, if the therapies we use in
combination with our drug candidates are replaced as the standard of care for the indications we choose for any of our drug candidates, the FDA or similar regulatory authorities outside of the United States may require us to conduct additional
clinical trials. The occurrence of any of these risks could result in our own products, if approved, being removed from the market or being less successful commercially.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may also evaluate our drug candidates in combination with one or more cancer therapies that have not yet been approved for
marketing by the FDA or a similar regulatory authority outside of the United States. We may be unable to effectively identify and collaborate with third parties for the evaluation of our drug candidates in combination with their therapies. We will
not be able to market and sell any drug candidate we develop in combination with any such unapproved cancer therapies that do not ultimately obtain marketing approval. The regulations prohibiting the promotion of products for unapproved uses are
complex and subject to substantial interpretation by the FDA and other government agencies. In addition, there are additional risks similar to the ones described for our products currently in development and clinical trials that result from the fact
that such cancer therapies are unapproved, such as the potential for serious adverse effects, delay in their clinical trials and lack of FDA approval.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If the FDA or a similar regulatory authority outside of the United States does not approve these other drugs or revokes
approval of, or if safety, efficacy, manufacturing, or supply issues arise with, the drugs we choose to evaluate in combination with any drug candidate we develop, we may be unable to obtain approval of or market such product. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may not be able to obtain or maintain orphan drug designation or exclusivity for our drug candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Regulatory authorities in some jurisdictions, including the United States, may designate drugs for relatively small patient
populations as &#147;orphan drugs.&#148; Under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is intended to treat patients with a rare disease or condition, which is generally defined as a patient population of fewer than
200,000 individuals in the United States, or if the disease or condition affects more than 200,000 individuals in the United States and there is no reasonable expectation that the cost of developing the drug for the type of disease or condition will
be recovered from sales of the product in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Orphan drug designation entitles a party to financial
incentives, such as opportunities for grant funding towards clinical trial costs, tax advantages and user fee waivers. Additionally, if a product that has orphan designation subsequently receives the first FDA approval for the disease or condition
for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same indication for seven&nbsp;years, except in certain
circumstances, such as a showing of clinical superiority (i.e., another product is safer, more effective or makes a major contribution to patient care) over the product with orphan exclusivity or where the manufacturer is unable to assure sufficient
product quantity. Competitors, however, may receive approval of different products for the same indication for which the orphan product has exclusivity, or obtain approval for the same product but for a different indication than that for which the
orphan product has exclusivity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">ACR-368 has been granted orphan drug designation, or ODD, for the treatment of anal
cancer. We may apply for an ODD in the United States or other geographies for <FONT STYLE="white-space:nowrap">ACR-368</FONT> for the treatment of other diseases or conditions or for our future drug candidates. However, obtaining an orphan drug
designation can be difficult, and we may not be successful in doing so. Even if we obtain orphan drug designation for a drug candidate in specific indications, we may not be the first to obtain regulatory approval of the drug candidate for the
orphan-designated indication, due to the uncertainties associated with developing drug products. In addition, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan-designated
indication or may be lost if the FDA later determines that the request for orphan designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare
disease or condition. Orphan drug designation does not ensure that we will receive </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
marketing exclusivity in a particular market, and we cannot assure you that any future application for orphan drug designation in any other geography or with respect to any other future drug
candidate will be granted. Orphan drug designation neither shortens the development time or regulatory review time of a drug, nor gives the drug any advantage in the regulatory review or approval process. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>A Fast Track designation by the FDA, even if granted for our lead drug candidate, or any of our future drug candidates, may not lead to
a faster development or regulatory review or approval process and does not increase the likelihood that our drug candidates will receive marketing approval. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">At various times, we may seek Fast Track designation for one or more of our drug candidates. If a drug candidate is intended
for the treatment of a serious or life-threatening condition and the drug candidate demonstrates the potential to address unmet medical needs for this condition, the drug sponsor may apply for FDA Fast Track designation for a particular indication.
We may seek Fast Track designation for our lead drug candidate and/or certain of our future drug candidates, but there is no assurance that the FDA will grant this status to any of our proposed drug candidates and we might only be successful in
receiving a Fast Track designation from the FDA for a drug candidate after applying on more than one occasion. Marketing applications filed by sponsors of products in Fast Track development may qualify for priority review under the policies and
procedures offered by the FDA, but the receipt of a Fast Track designation does not assure any such qualification or ultimate marketing approval by the FDA. The FDA has broad discretion whether or not to grant a Fast Track designation, so even if we
believe a particular drug candidate is eligible for this designation, there can be no assurance that the FDA would decide to grant it. Even if we do receive a Fast Track designation, we may not experience a faster development process, review or
approval compared to conventional FDA procedures, and receiving a Fast Track designation does not provide assurance of ultimate FDA approval. In addition, the FDA may withdraw a Fast Track designation if it believes that the designation is no longer
supported by data from our clinical development program. In addition, the FDA may withdraw any Fast Track designation at any time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>A Breakthrough Therapy designation by the FDA, even if granted for any of our current or future drug candidates, may not lead to a
faster development or regulatory review or approval process and it does not increase the likelihood that our drug candidates will receive marketing approval. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may seek Breakthrough Therapy designation for our lead drug candidate and some or all of our future drug candidates. A
Breakthrough Therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate
substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drug candidates that have been designated as Breakthrough Therapies,
interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as
breakthrough therapies by the FDA may also be eligible for other expedited approval programs, including accelerated approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Designation as a Breakthrough Therapy is within the discretion of the FDA. Accordingly, even if we believe a drug candidate
meets the criteria for designation as a Breakthrough Therapy, the FDA may disagree and instead determine not to make such a designation. In any event, the receipt of a Breakthrough Therapy designation for a drug candidate may not result in a faster
development process, review or approval compared to candidate products considered for approval under <FONT STYLE="white-space:nowrap">non-expedited</FONT> FDA review procedures and does not assure ultimate approval by the FDA of a drug candidate. In
addition, even if a drug candidate qualifies as a Breakthrough Therapy, the FDA may later decide that the drug candidate no longer meets the conditions for qualification. Thus, even though we intend to seek Breakthrough Therapy designation for our
lead drug candidate and some or all of our future drug candidates for the treatment of various cancers, there can be no assurance that we will receive Breakthrough Therapy designations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Reliance on Third Parties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We rely, and expect to continue to rely, on third parties, including independent clinical investigators, contracted laboratories and
CROs, to conduct our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our drug
candidates and our business could be substantially harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have relied upon and plan to continue to rely upon
third parties, including independent clinical investigators, contracted laboratories and third-party CROs, to conduct our preclinical studies and clinical trials in accordance with applicable regulatory requirements and to monitor and manage data
for our ongoing preclinical and clinical programs. We rely on these parties for execution of our preclinical studies and clinical trials, and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each
of our studies and trials is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards, and our reliance on these third parties does not relieve us of our regulatory responsibilities. We and our
third party contractors and CROs are required to comply with good laboratory practices, or GLPs, as applicable, and GCP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for all of
our products in clinical development. Regulatory authorities enforce these GLPs and GCPs through periodic inspections of laboratories conducting GLP studies, trial sponsors, principal investigators and trial sites. If we, our investigators or any of
our CROs or contracted laboratories fail to comply with applicable GLPs and GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform
additional preclinical studies or clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our preclinical studies or
clinical trials comply with applicable GLP or GCP regulations. In addition, our clinical trials must be conducted with drug products produced in compliance with applicable cGMP regulations. Our failure to comply with these regulations may require us
to repeat preclinical studies or clinical trials, which would delay the regulatory approval process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Further, these
laboratories, investigators and CROs are not our employees and we will not be able to control, other than by contract, the amount of resources, including time, which they devote to our drug candidates and clinical trials. If independent
laboratories, investigators or CROs fail to devote sufficient resources to the development of our drug candidates, or if their performance is substandard, it may delay or compromise the prospects for approval and commercialization of any drug
candidates that we develop. In addition, the use of third-party service providers requires us to disclose our proprietary information to these parties, which could increase the risk that this information will be misappropriated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our CROs have the right to terminate their agreements with us in the event of an uncured material breach. In addition, some of
our CROs have an ability to terminate their respective agreements with us if we make a general assignment for the benefit of our creditors or if we are liquidated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If any of our relationships with these third-party laboratories, CROs or clinical investigators terminate, we may not be able
to enter into arrangements with alternative laboratories, CROs or investigators or to do so in a timely manner or on commercially reasonable terms. If laboratories, CROs or clinical investigators do not successfully carry out their contractual
duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our preclinical or clinical protocols, regulatory
requirements or for other reasons, our preclinical or clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our drug candidates. As a result, our results of
operations and the commercial prospects for our drug candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Switching or adding additional laboratories or CROs or investigators involves additional cost and requires management time and
focus. In addition, there is a natural transition period when a new laboratory or CRO </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we carefully manage our relationships with our
contracted laboratories and CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and
results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, clinical investigators may serve as scientific advisors or consultants to us from
time to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or the FDA concludes that the financial relationship
may have affected the interpretation of the preclinical study or clinical trial, the integrity of the data generated at the applicable preclinical study or clinical trial site may be questioned and the utility of the preclinical study or clinical
trial itself may be jeopardized, which could result in the delay or rejection by the FDA. Any such delay or rejection could prevent us from commercializing our clinical-stage drug candidate or any future drug candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We rely on third parties to supply and manufacture our drug candidates, and we expect to continue to rely on third parties to
manufacture our products, if approved. The development of such drug candidates and the commercialization of any products, if approved, could be stopped, delayed or made less profitable if any such third party fails to provide us with sufficient
quantities of drug candidates or products or fails to do so at acceptable quality levels or prices or fails to maintain or achieve satisfactory regulatory compliance. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We do not currently have the infrastructure or capability internally to manufacture all our drug candidates for use in the
conduct of our preclinical studies and clinical trials or for commercial supply, if our products are approved. We rely on, and expect to continue to rely on, contract manufacturing organizations, or CMOs. Any replacement of our CMOs could require
significant effort and expertise because there may be a limited number of qualified CMOs. This could be particularly problematic if we rely on a single-source supplier. Reliance on third-party providers may expose us to more risk than if we were to
manufacture our drug candidates ourselves. We are dependent on our CMOs for the production of our drug candidates in accordance with relevant regulations, such as cGMP, which includes, among other things, quality control, quality assurance and the
maintenance of records and documentation. Moreover, many of the third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting product development
activities that could harm our competitive position. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our third-party manufacturers may be subject to damage or
interruption from, among other things, fire, natural or <FONT STYLE="white-space:nowrap">man-made</FONT> disaster, war, disease outbreaks or public health pandemics, power loss, telecommunications failure, unauthorized entry, computer viruses, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">denial-of-service</FONT></FONT> attacks, acts of terrorism, human error, vandalism or sabotage, financial insolvency, bankruptcy and similar events. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If we were to experience an unexpected loss of supply of or if any supplier were unable to meet our demand for any of our drug
candidates, we could experience delays in our research or ongoing and planned clinical trials or commercialization. We could be unable to find alternative suppliers of acceptable quality, in the appropriate volumes who could meet our timelines at an
acceptable cost. Moreover, our suppliers are often subject to strict manufacturing requirements and rigorous testing requirements, which could limit or delay production. The long transition periods necessary to switch manufacturers and suppliers, if
necessary, could significantly delay our preclinical studies, our clinical trials and the commercialization of our products, if approved, which could materially adversely affect our business, financial condition and results of operation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In complying with the applicable manufacturing regulations of the FDA and comparable foreign regulatory authorities, we and
our third-party suppliers must spend significant time, money and effort in the areas of design and development, testing, production, record-keeping and quality control to assure that the products meet applicable specifications and other regulatory
requirements. The failure to comply with these requirements could result in an enforcement action against us, including the seizure of products and shutting down of production. We </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
and any of these third-party suppliers may also be subject to audits by the FDA and comparable foreign regulatory authorities. If any of our third-party suppliers fails to comply with cGMP or
other applicable manufacturing regulations, our ability to develop and commercialize the products could suffer significant interruptions. We face risks inherent in relying on CMOs, as any disruption, such as a fire, natural hazards, vandalism or an
outbreak of contagious disease affecting the CMO or any supplier of the CMO could significantly interrupt our manufacturing capability. In case of a disruption, we will have to establish alternative manufacturing sources. This would require
substantial capital on our part, which we may not be able to obtain on commercially acceptable terms or at all. Additionally, we would likely experience months of manufacturing delays as the CMO builds or locates replacement facilities and seeks and
obtains necessary regulatory approvals. If this occurs, we will be unable to satisfy manufacturing needs on a timely basis, if at all. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our current and future partnerships will be important to our business. If we are unable to enter into new partnerships, or if these
partnerships are not successful, our business could be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have existing partnerships and
license agreements, including with Lilly for ACR-368 and with Akoya to co-develop, validate and commercialize our OncoSignature test. Moreover, a part of our business strategy is to carefully evaluate and, as deemed appropriate, potentially enter
into partnerships in the future, including with major biotechnology or pharmaceutical companies. We have limited capabilities for product development and do not yet have any capability for commercialization. Accordingly, we may enter into
partnerships with other companies to provide us with additional drug candidates and funding for our programs and AP3 platform. If we fail to enter into or maintain partnerships on reasonable terms or at all, our ability to develop our existing or
future research programs and drug candidates or to identify future drug candidates through the application of our AP3 platform and OncoSignature companion diagnostics could be delayed, the commercial potential of our product could change and our
costs of development and commercialization could increase. Furthermore, we may find that our programs require the use of intellectual property rights held by third parties, and the growth of our business may depend in part on our ability to acquire
or <FONT STYLE="white-space:nowrap">in-license</FONT> these intellectual property rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our current partnerships, and
any partnerships we may enter into in the future, may pose a number of risks, including, but not limited to, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">partners have significant discretion in determining the efforts and resources that they will apply;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">partners may not perform their obligations as expected; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">partners could independently develop, or develop with third parties, products that compete directly or
indirectly with our products and drug candidates if the partners believe that the competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">partners may fail to comply with applicable regulatory requirements regarding the development, manufacture,
distribution or marketing of a drug candidate or product; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disagreements with partners, including disagreements over proprietary rights, contract interpretation or the
preferred course of development, might cause delays or terminations of the research, development or commercialization of drug candidates, might lead to additional responsibilities for us with respect to drug candidates, or might result in litigation
or arbitration, any of which would be time-consuming and expensive; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">partners may not properly maintain or defend our intellectual property rights or may use our proprietary
information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">partners may infringe the intellectual property rights of third parties, which may expose us to litigation and
potential liability; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if a partners of ours is involved in a business combination, the partner might deemphasize or terminate the
development or commercialization of any drug candidate licensed to it by us; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">partnerships may be terminated by the partner, and, if terminated, we could be required to raise additional
capital to pursue further development or commercialization of the applicable drug candidates. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If our
partnerships do not result in the successful discovery, development and commercialization of drug candidates or if one of our partners terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments
under such partnership. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">All of the risks relating to product development, regulatory approval and commercialization
described in this prospectus also apply to the activities of our partners. Additionally, if one of our partners terminates its agreement with us, we may find it more difficult to attract new partners and our perception in the business and financial
communities could be adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may not be able to negotiate partnerships on a timely basis, on acceptable
terms, or at all. Our ability to reach a definitive agreement for a partnership will depend, among other things, upon an assessment of the partner&#146;s resources and expertise, the terms and conditions of the proposed partnership and the proposed
partner&#146;s evaluation of a number of factors. These factors may include the design or results of preclinical studies or clinical trials, the likelihood of regulatory approval, the potential market for the subject drug candidate, the costs and
complexities of manufacturing and delivering such drug candidate to patients, the potential of competing products, the existence of any uncertainty with respect to our ownership of technology (which can exist if there is a challenge to such
ownership regardless of the merits of the challenge) and industry and market conditions generally. The partner may also consider alternative drug candidates or technologies for similar indications that may be available to collaborate on and whether
such a partnership could be more attractive than the one with us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Commercialization of Our Drug Candidates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Even if any of our current or drug candidates receive marketing approval, they may fail to achieve the degree of market acceptance by
physicians, patients, third-party payors and others in the medical community necessary for commercial success. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If <FONT
STYLE="white-space:nowrap">ACR-368</FONT> or our future drug candidates receive marketing approval, they may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. For
example, current cancer treatments, such as existing targeted therapies, chemotherapy, and radiation therapy, are well established in the medical community, and doctors may continue to rely on these treatments. If our drug candidates do not achieve
an adequate level of acceptance, we may not generate significant product revenues and we may not become profitable. The degree of market acceptance of our drug candidates, if approved for commercial sale, will depend on a number of factors,
including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the efficacy, safety and potential advantages compared to alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the acceptance of our drug candidates as front-line treatments for various indications; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prevalence and severity of any side effects, in particular compared to alternative treatments;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limitations or warnings contained in the labeling approved by the FDA or other regulatory authorities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the size of the target patient population; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the willingness of the target patient population to try new therapies and of physicians to prescribe these
therapies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to offer our products for sale at competitive prices; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the convenience and ease of administration compared to alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the strength of marketing and distribution support; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">publicity for our drug candidates and competing products and treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the existence of distribution and/or use restrictions, such as through a REMS; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of third-party payor coverage and adequate reimbursement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of any marketing approval in relation to other product approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">support from patient advocacy groups; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any restrictions on the use of our products together with other medications. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If the market opportunities for our drug candidates are smaller than we estimate or if any approval that we obtain is based on a
narrower definition of the patient population, then our revenue potential and ability to achieve profitability will be adversely affected. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The total addressable market opportunity for <FONT STYLE="white-space:nowrap">ACR-368</FONT> and any other future drug
candidates we may develop will ultimately depend upon, among other things, the proportion of patients identified as sensitive to our treatments based on our OncoSignature tests in our target indications, acceptance by the medical community, patient
access, drug and any related companion diagnostic pricing and their reimbursement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may initially seek regulatory
approval of <FONT STYLE="white-space:nowrap">ACR-368</FONT> or our future drug candidates as therapies for patients with platinum-resistant ovarian, bladder or endometrial cancer. The number of patients in our targeted commercial markets and
elsewhere may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our drugs or new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect our results of
operations and our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We currently have no marketing and sales organization and may have to invest significant resources to
develop these capabilities. If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our products, we may not be able to generate revenue. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We currently have no sales or marketing infrastructure or experience in the sale, marketing or distribution of drug products.
Our operations to date have been focused on developing and extensively evaluating in preclinical studies our AP3 platform and our proprietary predictive OncoSignature tests, acquiring the rights to ACR-368, advancing our preclinical drug candidate
programs, organizing and staffing our company, business planning and raising capital. To achieve commercial success for any product for which we obtain marketing approval, we will need to establish sales, marketing and distribution capabilities,
either ourselves or through collaboration or other arrangements with third parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There are risks involved with
establishing our own sales and marketing capabilities. For example, recruiting and training a sales force is expensive and time-consuming and could delay any product launch. If the commercial launch of a drug candidate for which we recruit a sales
force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. These efforts are expected to be costly, and our investment would be lost
if we cannot retain or reposition our sales and marketing personnel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Factors that may inhibit our efforts to
commercialize our products on our own include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to recruit, train and retain adequate numbers of effective sales and marketing personnel;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to raise financing necessary to build our commercialization infrastructure;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability of sales personnel to obtain access to physicians or educate an adequate number of physicians as
to the benefits of our products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unfavorable third-party payor coverage and reimbursement in any geography; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the lack of complementary products to be offered by sales personnel, which may put us at a competitive
disadvantage relative to companies with more extensive product lines; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unforeseen costs and expenses associated with creating an independent sales and marketing organization.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Furthermore, developing a sales and marketing organization requires significant investment, is
time-consuming and could delay the launch of our drug candidate. We may not be able to build an effective sales and marketing organization in the United States, the European Union or other key global markets. If we are unable to build our own
distribution and marketing capabilities or to find suitable partners for the commercialization of our drug candidate, we may have difficulties generating revenue from them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If we enter into arrangements with third parties to perform sales and marketing services, our product revenues and our
profitability, if any, are likely to be lower than if we were to market and sell any products that we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to market and sell our drug candidates or
may be unable to do so on terms that are acceptable to us. We likely will have little control over such third parties, and any of these third parties may fail to devote the necessary resources and attention to sell and market our products
effectively. If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing any drug candidate for which we receive marketing approval.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>The targeted oncology space is competitive, which may result in others discovering, developing or commercializing products before
or more successfully than we do. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The development and commercialization of drug products is highly competitive. We
face competition with respect to our current drug candidates and will face competition with respect to any drug candidates that we may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty pharmaceutical
companies and existing or emerging biotechnology companies, academic research institutions and governmental agencies and public and private research institutions worldwide. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We anticipate several biopharmaceutical companies will aim to develop precision oncology approaches for the larger subsets of
cancers where genetics has proven insufficient for patient responder identification over the next decade. We expect that the broader biopharmaceutical field will eventually recognize proteomics as the next era of precision medicine. We are aware of
several competitors with CHK1/2 inhibitors and WEE1 inhibitors, including Sierra Oncology (SRA737), Astrazeneca/Merck (Adavosertib), Zentalis <FONT STYLE="white-space:nowrap">(Zn-c3),</FONT> Debiopharm (Debio0123), Impact Therapeutics (IMP7068) and
Shouya Holdings <FONT STYLE="white-space:nowrap">(SY-4835),</FONT> and one company with a PKMYT1 inhibitor, Repare Therapeutics (RP-6306). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Many of the companies against which we are competing or against which we may compete in the future, either alone or through
collaborations, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do.
Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early-stage companies may also prove to be significant
competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific, management and sales and marketing personnel, establishing
clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Furthermore, we also face competition more broadly across the oncology market for cost-effective and reimbursable cancer
treatments. There are a variety of available drug therapies marketed for cancer. In many cases, these drugs are administered in combination to enhance efficacy. While <FONT STYLE="white-space:nowrap">ACR-368</FONT> or our future drug
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
candidates, if approved, may compete with these existing drugs and other therapies, to the extent they are ultimately used in combination with or as an adjunct to these therapies, our drug
candidates may not be competitive with them. Some of these drugs are branded and subject to patent protection, and others are available on a generic basis. Insurers and other third-party payors may also encourage the use of generic products or
specific branded products. As a result, obtaining market acceptance of, and gaining significant share of the market for, our drug candidates may pose challenges. In addition, many companies are developing new oncology therapeutics, and we cannot
predict what the standard of care will be as drug candidates progress through clinical development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our commercial
opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient to administer, are less expensive or with a more favorable
labeling than <FONT STYLE="white-space:nowrap">ACR-368</FONT> or our future drug candidates. Our competitors also may obtain FDA, foreign regulatory authority, or other marketing or regulatory approval for their products more rapidly than any
approval we may obtain for ours, which could result in our competitors establishing a strong market position before we are able to enter the market, thereby limiting our potential for commercial success. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Even if we are able to commercialize any drug candidates, the products may become subject to unfavorable pricing regulations,
third-party reimbursement practices or healthcare reform initiatives, which would harm our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
regulations that govern marketing approvals, pricing, coverage and reimbursement for new drug products vary widely from country to country. Current and future legislation may significantly change the approval requirements in ways that could involve
additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is
granted. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our drug candidate to other available therapies. In some foreign markets, prescription
pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a drug candidate in a particular country, but then be subject to price regulations
that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenues, if any, we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability
to recoup our investment in one or more drug candidates, even if such drug candidates obtain marketing approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our
ability to commercialize any drug candidates successfully also will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from third-party payors, including government
healthcare programs, private health insurers and other organizations. Third-party payors decide which medications they will pay for and establish reimbursement levels. In the United States, the principal decisions about reimbursement for new
medicines are typically made by the CMS, which decides whether and to what extent a new medicine will be covered and reimbursed under Medicare. Private payors often, but not always, follow CMS&#146;s decisions regarding coverage and reimbursement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Third-party payors have attempted to
control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the
prices charged for medical products. Coverage and reimbursement may not be available for any product that we commercialize and, even if these are available, the level of reimbursement may not be satisfactory. Reimbursement may affect the demand for,
or the price of, any drug candidate for which we obtain marketing approval. Obtaining and maintaining coverage and adequate reimbursement for our products may be difficult. We may be required to conduct expensive pharmacoeconomic studies to justify
coverage and reimbursement or the level of reimbursement relative to other therapies. If </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
coverage and adequate reimbursement are not available or reimbursement is available only to limited levels, we may not be able to successfully commercialize any drug candidate for which we obtain
marketing approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, companion diagnostic tests will be required to obtain coverage and reimbursement
separate and apart from the coverage and reimbursement we seek for our drug candidates, if approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There may also be
significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA or similar regulatory authorities outside of the United States.
Moreover, eligibility for coverage and reimbursement does not imply that a drug will be paid for in all cases or at a rate that covers our costs, including research, development, intellectual property, manufacture, sale and distribution expenses.
Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may
be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or
private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Third-party payors often rely upon Medicare coverage policy and payment
limitations in setting their own reimbursement policies, but also have their own methods and approval process apart from Medicare determinations. Our inability to promptly obtain coverage and adequate reimbursement rates from third-party payors for
any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or
administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, our drug
candidates may lose any marketing approval that may have been obtained and we may not achieve or sustain profitability, which would adversely affect our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>The market opportunities for any current or future drug candidate we develop, if and when approved, may be limited to those patients who
are ineligible for established therapies or for whom prior therapies have failed, and may be small. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cancer
therapies are sometimes characterized as first-line, second-line, or third-line, and the FDA often approves new therapies initially only for third-line use. When cancer is detected early enough, first-line therapy, usually chemotherapy, hormone
therapy, surgery, radiation therapy or a combination of these, is sometimes adequate to cure the cancer or prolong life without a cure. Second- and third-line therapies are administered to patients when prior therapy is not effective. We expect to
initially seek approval of our drug candidates we develop as a therapy for patients who have received one or more prior treatments. Subsequently, for those products that prove to be sufficiently beneficial, if any, we would expect to seek approval
potentially as a first-line therapy, but there is no guarantee that drug candidates we develop, even if approved, would be approved for first-line therapy, and, prior to any such approvals, we may have to conduct additional clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The number of patients who have the cancers we are targeting may turn out to be lower than expected. Additionally, the
potentially addressable patient population for our current programs or future drug candidates in both oncology and non-oncology indications may be limited, if and when approved. Even if we obtain significant market share for any drug candidate, if
and when approved, if the potential target populations are small, we may never achieve profitability without obtaining marketing approval for additional indications, including to be used as first- or second-line therapy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Product liability lawsuits against us could cause us to incur substantial liabilities
and to limit commercialization of any products that we may develop. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We face an inherent risk of product liability
exposure related to the testing of our drug candidates in human clinical trials and will face an even greater risk if we commercialize any products that we may develop. If we cannot successfully defend ourselves against any claims that our drug
candidates or products caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">decreased demand for any drug candidates or products that we may develop; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injury to our reputation and significant negative media attention; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">initiation of investigations by regulators; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withdrawal of clinical trial participants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significant time and costs to defend the related litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">diversion of management and scientific resources from our business operations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">substantial monetary awards to trial participants or patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">loss of revenue; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced resources of our management to pursue our business strategy; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability to commercialize any products that we may develop. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our current product liability insurance coverage for the United States and certain other jurisdictions may not be adequate to
cover all liabilities that we may incur. We likely will need to increase our insurance coverage as we expand our clinical trials or if we commence commercialization of <FONT STYLE="white-space:nowrap">ACR-368</FONT> or our future drug candidates.
Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. A successful product liability claim or series of claims brought
against us could decrease our cash and adversely affect our business and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Employee Matters and Our Operations
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are highly dependent on the management, development, clinical, financial and business development expertise of
our executive officers, particularly Peter Blume-Jensen, M.D., Ph.D., our <FONT STYLE="white-space:nowrap">co-founder,</FONT> President and CEO, the inventor of our AP3 platform and OncoSignature patient selection method and a member of our board of
directors and Kristina Masson, Ph.D., our co-founder and President and CEO of our phosphoproteomics subsidiary in Lund, Sweden. Each of our executive officers may currently terminate their employment with us at any time. We do not currently maintain
&#147;key person&#148; insurance for any of our executives or employees<SUP STYLE="font-size:75%; vertical-align:top">.</SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Recruiting and retaining qualified scientific and clinical personnel and, if we progress the development of our product
pipeline toward scaling up for commercialization, manufacturing and sales and marketing personnel, will also be critical to our success. The loss of the services of our executive officers or other key personnel, including any of our scientific
founders, could impede the achievement of our development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult
and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize products. Competition to
hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also
experience competition for the hiring of scientific and clinical personnel from </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our development and
commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to
continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We expect to
expand our clinical development, manufacturing and regulatory capabilities and potentially implement sales, marketing and distribution capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our
operations. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of October 31, 2022, we had 39 full-time employees and three part-time employees. As our
development progresses, we expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of clinical product development, regulatory affairs and, if any of our drug candidates
receives marketing approval, sales, marketing and distribution. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and
train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our
operations or recruit and train additional qualified personnel. Our choice to focus on multiple therapeutic areas may negatively affect our ability to develop adequately the specialized capability and expertise necessary for operations. The
expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our employees, independent contractors, consultants, collaborators,
principal investigators, CROs, suppliers and vendors may be improperly classified and may engage in misconduct or other improper activities, including <FONT STYLE="white-space:nowrap">non-compliance</FONT> with regulatory standards and requirements.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our endeavors to properly classify our employees as exempt or <FONT STYLE="white-space:nowrap">non-exempt</FONT>
with respect to wage and hour laws, including, but not limited to, for purposes of minimum wage, overtime and applicable meal and rest periods, and we monitor and evaluate such classifications. Although there are no current, pending, or threatened
claims or investigations against us asserting that any employees have been incorrectly classified as exempt, the possibility nevertheless exists that certain job roles could be deemed to have been incorrectly classified as exempt. In addition, we
endeavor to classify our workforce properly, and we monitor and evaluate such classifications. Although there are no current, pending, or threatened claims or investigations against us asserting that any independent contractors have been incorrectly
classified, the possibility nevertheless exists that certain contractors could be deemed to be employees </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are exposed
to the risk that our employees, independent contractors, consultants, collaborators, principal investigators, CROs, suppliers and vendors may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include
intentional, reckless and/or negligent conduct that violates FDA regulations, including those laws requiring the reporting of true, complete and accurate information to the FDA, manufacturing standards, federal and state healthcare laws and
regulations, and laws that require the true, complete and accurate reporting of financial information or data. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations
intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and
other business arrangements. Misconduct by these parties could also involve the improper use of individually identifiable information, including, without limitation, information obtained in the course of clinical trials, which could result in
regulatory sanctions and serious harm to our reputation. We have adopted a code of business conduct and ethics, but it is not always possible to identify and deter misconduct, and the precautions we take to detect and prevent this activity may not
be effective in controlling unknown or unmanaged risks or losses or in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against
us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, including, without
limitation, damages, fines, disgorgement, imprisonment, exclusion from participation in government healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity
agreement or similar agreement to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws, and the curtailment or restructuring of our operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our business and operations would suffer in the event of system failures, cyberattacks or a deficiency in our or our CROs&#146;,
manufacturers&#146; contractors&#146;, consultants&#146; or collaborators&#146; cybersecurity. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Despite the
implementation of security measures, our internal computer systems, as well as those of third parties on which we rely, are vulnerable to damage from, among other things, computer viruses, malware, unauthorized access, natural disasters, terrorism,
war, telecommunication and electrical failures, system malfunctions, cyberattacks or cyber-intrusions over the Internet, attachments to emails, phishing attacks, persons inside our organization, or persons with access to systems inside our
organization. The risk of a security breach or disruption, particularly through cyberattacks or cyber intrusion, including by computer hackers, foreign governments and cyber terrorists, has generally increased as the number, intensity and
sophistication of attempted attacks and intrusions from around the world have increased. If such an event were to occur and cause interruptions in our operations, it could lead to the loss, destruction, alteration, prevention of access to,
disclosure, dissemination of, or damage or unauthorized access to, our data (including trade secrets or other confidential information, intellectual property, proprietary business information and personal data) or data that is processed or
maintained on our behalf, and cause interruptions in our operations, which could result in a material disruption of our drug candidate development programs. For example, the loss of preclinical study or clinical trial data from completed, ongoing or
planned trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of or damage to our data or
applications, or inappropriate disclosure of personal, confidential or proprietary information, we could incur liability and the further development of our drug candidates could be delayed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the ordinary course of our business, we collect and store sensitive data, including intellectual property, clinical trial
data, proprietary business information, personal data and personally identifiable information of our clinical trial subjects and employees, in our data centers and on our networks. The secure processing, maintenance and transmission of this
information is critical to our operations. Despite our security measures, we cannot ensure that our information technology and infrastructure will prevent breakdowns or breaches in our or their systems or other cybersecurity incidents that cause
loss, destruction, unavailability, alteration, dissemination of, or damage or unauthorized access to, our data, including personal data, assets and other data processed or maintained on our behalf, that could have a material adverse effect upon our
reputation, business, operations or financial condition. Although, to our knowledge, we have not experienced any such material security breach to date, any such breach could compromise our networks and the information stored there could be accessed,
publicly disclosed, lost or stolen. Any such access, disclosure or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, significant regulatory penalties, and
such an event could disrupt our operations, damage our reputation, and cause a loss of confidence in us and our ability to conduct clinical trials, which could adversely affect our reputation and delay clinical development of our drug candidates.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To the extent that any disruption or security breach were to result in a loss of or damage to our data or applications,
or inappropriate disclosure of confidential or proprietary information or personal data, we could incur material legal claims and liability and damage to our reputation, and the further development of our drug candidates could be delayed. Any such
event could also compel us to comply with federal and state breach notification laws, and foreign law equivalents, subject us to mandatory corrective action and otherwise subject us </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
to substantial liability under laws, rules, regulations and standards that protect the privacy and security of personal data, which could result in significant legal and financial exposure and
reputational damages that could potentially have an adverse effect on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Notifications and <FONT
STYLE="white-space:nowrap">follow-up</FONT> actions related to a data breach or other security incident could impact our reputation and cause us to incur significant costs, including significant legal expenses and remediation costs. We expect to
incur significant costs in an effort to detect and prevent security incidents, and we may face increased costs and requirements to expend substantial resources in the event of an actual or perceived security incident. However, we cannot guarantee
that we will be able to detect or prevent any such incidents, or that we can remediate any such incidents in an effective or timely manner. Our efforts to improve security and protect data from compromise may also identify previously undiscovered
instances of data breaches or other cybersecurity incidents. To the extent that any data breach, disruption or security incident were to result in any loss, destruction, or alteration of, damage, unauthorized access to or inappropriate or
unauthorized disclosure or dissemination of, our data, including personal data, or other information that is processed or maintained on our behalf, we could be exposed to litigation and governmental investigations and inquiries, the further
development and commercialization of our drug candidates could be delayed and we could be subject to significant fines or penalties for any noncompliance with applicable state, federal and foreign privacy and security laws, rules, regulations and
standards. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Business disruptions could seriously harm our future revenue and financial condition and increase our costs and
expenses.</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our operations, and those of our CROs, CMOs and other contractors and consultants, could be subject to
earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or <FONT STYLE="white-space:nowrap">man-made</FONT> disasters or
business interruptions, for which we are predominantly self-insured. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. We rely on third-party
manufacturers to produce our drug candidates. Our ability to obtain clinical supplies of our drug candidates could be disrupted if the operations of these suppliers are affected by a <FONT STYLE="white-space:nowrap">man-made</FONT> or natural
disaster or other business interruption.</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We are subject to a variety of privacy and data security laws, rules, regulations,
policies, industry standards and contractual obligations, and our failure to comply with them could harm our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We maintain a large quantity of sensitive information, including confidential business and personal information in connection
with the conduct of our clinical trials and related to our employees, and we are subject to laws and regulations governing the privacy and security of such information. In the United States, there are numerous federal and state privacy and data
security laws and regulations governing the collection, use, disclosure and protection of personal information, including federal and state health information privacy laws, federal and state security breach notification laws and federal and state
consumer protection laws. The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing focus on privacy and data protection issues, which may affect our business and is expected to
increase our compliance costs and exposure to liability. In the United States, numerous federal and state laws and regulations could apply to our operations or the operations of our partners, including state data breach notification laws, state
health information privacy laws and federal and state consumer protection laws and regulations, including Section&nbsp;5 of the Federal Trade Commission Act, that govern the collection, use, disclosure and protection of health-related and other
personal information. In addition, we may obtain health information from third parties, including research institutions from which we obtain clinical trial data, that are subject to privacy and security requirements under HIPAA, as amended by the
Health Information Technology for Economic and Clinical Health Act, and the regulations promulgated thereunder. Depending on the facts and circumstances, we could be subject to significant penalties if we obtain, use or disclose individually
identifiable health information in a manner that is not authorized or permitted by HIPAA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In Europe, the General Data Protection Regulation, or GDPR, took effect in
May 2018. The GDPR governs the collection, use, disclosure, transfer or other processing of personal data of individuals within the European Economic Area, or EEA, including clinical trial data. Among other things, the GDPR imposes requirements
regarding the security of personal data and notification of data breaches to the competent national data processing authorities, requires having lawful bases on which personal data can be processed and requires changes to informed consent practices,
as well as more detailed notices for clinical trial subjects and investigators. In addition, the GDPR increases the scrutiny of transfers of personal data from the EEA to the United States and other jurisdictions that the European Commission does
not recognize as having &#147;adequate&#148; data protection laws; in July 2020, the Court of Justice of the European Union limited how organizations could lawfully transfer personal data from the EEA to the United States by invalidating the <FONT
STYLE="white-space:nowrap">EU-U.S.</FONT> Privacy Shield and imposing further restrictions on the use of standard contractual clauses, which could increase our costs and our ability to efficiently process personal data from the EEA. The GDPR imposes
substantial fines for breaches and violations (up to the greater of &#128;20&nbsp;million or 4% of our consolidated annual worldwide gross revenue), and confers a private right of action on data subjects and consumer associations to lodge complaints
with supervisory authorities, seek judicial remedies and obtain compensation for damages resulting from violations of the GDPR. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Relatedly, following the United Kingdom&#146;s withdrawal from the EEA and the European Union and the expiration of the
Transition Period, companies must comply with both the GDPR and the legislation similar to the GDPR as incorporated into UK national law, which provides for significant fines of up to the greater of &pound;17.5&nbsp;million or 4% of global turnover
and exposes companies to two parallel regimes with potentially divergent enforcement actions for certain violations. On January&nbsp;1, 2021, the United Kingdom became a third country for purposes of the GDPR. The relationship between the United
Kingdom and the European Union in relation to certain aspects of data protection law remains unclear, for example with respect to how data can lawfully be transferred between each jurisdiction, which exposes us to further compliance risk. Pursuant
to the <FONT STYLE="white-space:nowrap">EU-UK</FONT> Trade and Cooperation Agreement of December&nbsp;24, 2020, transfers of personal data from the European Union to the United Kingdom may continue to take place without a need for additional
safeguards during a further transition period, which expires on the earlier of (i)&nbsp;the date on which an adequacy decision with respect to the United Kingdom is adopted by the European Commission; or (ii)&nbsp;the expiry of four months, which
shall be extended by a further two months unless either the European Union or the United Kingdom objects. On February&nbsp;19, 2021 the European Commission published its draft decision finding the United Kingdom to be adequate under the GDPR, though
it remains unclear whether the European Commission will formally adopt an adequacy decision with respect to the United Kingdom. In the absence of such decision, after the expiry of the additional transition period we may need to put in place
additional safeguards for transfers of personal data from the European Union to the United Kingdom, such as standard contractual clauses approved by the European Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Compliance with these and any other applicable privacy and data security laws and regulations is a rigorous and time-intensive
process, and we may be required to put in place additional mechanisms ensuring compliance with the new data protection rules. If we fail to comply with any such laws or regulations, we may face significant fines and penalties that could adversely
affect our business, financial condition and results of operations. Furthermore, the laws are not consistent, and compliance in the event of a widespread data breach is costly. In addition, states are constantly adopting new laws or amending
existing laws, requiring attention to frequently changing regulatory requirements. For example, California enacted the California Consumer Privacy Act, or CCPA, which took effect on January&nbsp;1, 2020, became enforceable by the California Attorney
General on July&nbsp;1, 2020 and has been dubbed the first &#147;GDPR-like&#148; law in the United States. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information
sharing and receive detailed information about how their personal information is used by requiring covered companies to provide new disclosures to California consumers (as that term is broadly defined) and provide such consumers new ways to opt out
of certain sales of personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Further, the California Privacy Rights Act,
or CPRA, recently passed in California and will impose additional data protection obligations on companies doing business in California, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk
data and opt outs for certain </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
uses of sensitive data. It also created a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security
enforcement. The majority of the provisions will go into effect on January&nbsp;1, 2023, and additional compliance investment and potential business process changes may be required. Although the CCPA currently exempts certain health-related
information, including clinical trial data, the CCPA and the CPRA may increase our compliance costs and potential liability. Similar laws have been proposed in other states and at the federal level and, if passed, such laws may have potentially
conflicting requirements that would make compliance challenging. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">With the GDPR, CCPA, CPRA and other laws, regulations
and other obligations relating to privacy and data protection imposing new and relatively burdensome obligations, and with the substantial uncertainty over the interpretation and application of these and other obligations, we may face challenges in
addressing their requirements and making necessary changes to our policies and practices and may incur significant costs and expenses in an effort to do so. We are currently in the process of developing and updating our policies and procedures in
accordance with requirements under applicable data privacy and protection laws and regulations. We do not currently have any formal data privacy policies and procedures in place and have not completed formal assessments of whether we are in
compliance with all applicable data privacy laws and regulations. Additionally, if third parties with which we work, such as vendors or service providers, violate applicable laws, rules or regulations or our policies, such violations may also put
our or our clinical trial and employee data, including personal data, at risk, which could in turn have an adverse effect on our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks
Related to Intellectual Property </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our success depends in part on our ability to obtain intellectual property rights for our
proprietary technologies and drug candidates, as well as our ability to protect our intellectual property. It is difficult and costly to protect our proprietary rights and technology, and we may not be able to ensure their protection. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our commercial success will depend in large part on obtaining and maintaining patent, trademark and trade secret protection of
our proprietary technologies and our drug candidates, their respective components, formulations, combination therapies, methods used to manufacture them and methods of treatment, as well as successfully defending these patents, trademarks and trade
secrets against third-party challenges or violations. Our ability to stop unauthorized third parties from making, using, selling, offering to sell or importing our technologies and drug candidates is dependent upon the extent to which we have rights
under valid and enforceable patents that cover these activities. If we are unable to secure and maintain patent protection for any product or technology we develop, or if the scope of the patent protection secured is not sufficiently broad, our
competitors could develop and commercialize products and technologies similar or identical to ours, and our ability to commercialize any drug candidates and technologies we may develop may be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The patenting process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable
patent applications at a reasonable cost or in a timely manner. In addition, we may not pursue or obtain patent protection in all relevant markets. It is also possible that we will fail to identify, or to file on, patentable aspects of our research
and development output before it is too late to obtain patent protection. Moreover, in some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering drug
candidates and technologies that we license from or license to third parties and are reliant on our licensors or licensees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can
be uncertain. The patent applications that we own or <FONT STYLE="white-space:nowrap">in-license</FONT> may fail to result in issued patents with claims that cover our drug candidates, technologies or uses thereof in the United States or in other
countries. Many of our technologies relate to diagnostics, such as for identifying subjects who are likely to respond to a particular drug due to biological characteristics of their tumors. Recent court decisions in the United States, such as
<I>Athena Diagnostics v. Mayo Collaborative Services, </I>915 F.3d 743 (Fed. Cir. 2019),<I> cert. denied, </I>140 S. Ct. 855 (2020) have invalidated certain patents in the diagnostics space as covering laws of nature. Some or all of our technologies
may similarly be found not eligible for patent protection. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Even if we do successfully issue patents that cover our products or
technologies, third parties may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable. Furthermore, even if they are unchallenged, our patents and patent
applications may not adequately protect our intellectual property or prevent others from designing around or otherwise avoiding our claims. If the breadth or strength of protection provided by the patent applications we hold with respect to our drug
candidates is insufficient or is threatened, it could dissuade companies from collaborating with us to develop, and threaten our ability to commercialize, our drug candidates and our technologies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Further, patents have limited terms. We may not be able to issue patents whose terms provide sufficient protection during the
commercial lifetime of our drug candidates or of our technologies. For example, if we encounter delays in our clinical trials, the period of time during which we could market our drug candidates under patent protection could be reduced. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Some or all of our patents may have claims whose infringement is difficult to detect or to prove. Courts place the legal
burden of proving infringement on patent holders. If we cannot convince a court that we have met this burden of proof, then our patent may not provide useful protection even if valid and enforceable against infringers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Since patent applications in the United States and most other countries are confidential for a period of time after filing, we
cannot be certain that we were the first to file any patent application related to our drug candidates or technologies. Furthermore, for United States applications in which all claims are entitled to a priority date before March&nbsp;16, 2013, an
interference proceeding can be provoked by a third-party or instituted by the United States Patent and Trademark Office, or USPTO, to determine who was the first to invent any of the subject matter covered by the patent claims of our applications.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We cannot be certain that we are the first to invent the inventions covered by pending patent applications or issued
patents (collectively, our &#147;patent filings&#148;) and, if we are not, we may be subject to priority disputes or derivation challenges. We may be required to disclaim part or all of the term of certain patent filings. There may be prior art of
which we are not aware that may affect the validity or enforceability of a patent claim. There also may be prior art of which we are aware, but which we do not believe affects the validity or enforceability of a claim, which may, nonetheless,
ultimately be found to affect the validity or enforceability of a claim. No assurance can be given that if challenged, our patents would be declared by a court or patent office to be valid or enforceable or that even if found valid and enforceable,
a competitor&#146;s technology or product would be found by a court to infringe our patents. We may analyze patents or patent applications of our competitors that we believe are relevant to our activities, and consider that we are free to operate in
relation to our drug candidates and technologies, but our competitors may achieve issued claims, including in patents we consider to be unrelated, which block our efforts or may potentially result in our drug candidates, our technologies or our
activities infringing such claims. The possibility exists that others will develop products which have the same effect as our products on an independent basis which do not infringe our patents or other intellectual property rights, or will design
around or otherwise avoid the claims of patents that we have had issued that cover our products and technologies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">It is
possible that we do not perfect ownership of all of the patents, patent applications or other intellectual property upon which we rely. This possibility includes the risk that we do not identify all inventors, or identify incorrect inventors, which
may lead to claims disputing inventorship or ownership of our patents, patent applications or other intellectual property by former employees or other third parties. There is also a risk that we do not establish an unbroken chain of title from
inventors to us. Errors in inventorship or ownership can sometimes also impact priority claims. If we were to lose ability to claim priority for certain patent filings, intervening art or other events may preclude us from issuing patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications
and the enforcement or defense of our issued patents. Under the enacted Leahy-Smith America Invents Act, or America Invents Act, enacted in 2013, the United States moved from a &#147;first to invent&#148; to a
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;first-to-file&#148;</FONT></FONT> system. Under a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;first-to-file&#148;</FONT></FONT> system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled
to a patent on the invention regardless of whether another inventor had made the invention earlier. The America Invents Act includes a number of other significant changes to U.S. patent law, including provisions that affect the way patent
applications are prosecuted, redefine prior art and establish a set of new patent office procedures for reviewing patents after issuance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The degree of future protection for our intellectual property rights is uncertain because legal means afford only limited
protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may be able to make or use compounds or formulations similar or equivalent our drug candidates, or to
develop technologies similar or comparable to ours, but that are not covered by the claims of any patents, should they issue, that we own or control; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the active ingredients in our current drug candidates will eventually become commercially available in generic
drug products, and is it possible that patent protection may not be available with regard to formulation or method of use; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we or our licensors or collaborators, as the case may be, may fail to meet our obligations to the U.S.
government in regards to any patents and patent applications funded by U.S. government grants, leading to the loss of patent rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we or our licensors or collaborators, as the case may be, might not have been the first to invent, or the
first to file patent applications for our inventions, or may be found to have derived these inventions from others; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may independently develop similar or alternative technologies or duplicate any of our technologies
without infringing our intellectual property rights in a way that we can detect and prove; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is possible that our pending patent applications will not result in issued patents in jurisdictions where
we or our competitors operate commercially, in time to provide useful commercial protection, or at all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitors might conduct research and development activities in the United States and other countries
that provide a safe harbor from patent infringement claims for certain research and development activities, as well as in countries where we do not have patent rights, and then use the information learned from such activities to develop competitive
products or technologies for sale in our major commercial markets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is possible that there are prior public disclosures that could invalidate our patents or our
licensors&#146; patents, as the case may be, or parts of our or their patents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is possible that others may circumvent our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT>
patents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is possible that there are unpublished applications or patent applications maintained in secrecy that may
later issue with claims covering our products or technologies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the laws of foreign countries may not protect our or our licensors&#146;, as the case may be, proprietary
rights to the extent required for us to benefit commercially, or at all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the claims of our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> issued patents or patent
applications, if and when issued, may not cover our drug candidates or technologies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> issued patents may not provide us with any
competitive advantages, may be narrowed in scope, or be held invalid or unenforceable as a result of legal challenges; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not be able to detect or to prove infringement of our owned or
<FONT STYLE="white-space:nowrap">in-licensed</FONT> patents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inventors of our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents or patent
applications may become involved with competitors, develop products or processes which design around our patents, or become hostile to us or the patents or patent applications on which they are named as inventors; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is possible that our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents or patent
applications omit individual(s) that should be listed as inventor(s) or include individual(s) that should not be listed as inventor(s), which may cause these patents or patents issuing from these patent applications to be held invalid or
unenforceable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we have engaged in scientific collaborations in the past, and will continue to do so in the future. Such
collaborators may develop adjacent or competing products or technologies to ours that are outside the scope of our patents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not develop additional proprietary technologies for which we can obtain patent protection;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may choose not to file for patent protection in order to maintain certain trade secrets, and a third party
may subsequently obtain a patent covering such intellectual property; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is possible that drug candidates or technologies we develop may be covered by third parties&#146; patents
or other exclusive rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the patents of others may have an adverse effect on our business; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be unable to protect the confidentiality of key information, including trade secrets, that are required
for us to achieve or maintain our business goals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not be able to detect breaches of confidentiality obligations to us before significant damage is done
to our business; or </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not be able to build brand identity in the marks we use to label our products or technologies, or third
parties may misuse them or create brand confusion, and our business may be negatively impacted. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Should
any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We rely in part on trade secrets to protect our technology, and our failure to obtain or maintain trade secret protection could harm our
business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We rely on trade secrets to protect some of our technology and proprietary information, especially where
we believe patent protection is not appropriate or obtainable, or may not provide effective protection. However, trade secrets are difficult to protect. It can be difficult or impossible to detect trade secret breaches. Furthermore, litigating a
claim that a third party had illegally obtained and was using our trade secrets would be expensive and time consuming, and the outcome would be unpredictable. Moreover, if our competitors independently develop similar knowledge, methods and <FONT
STYLE="white-space:nowrap">know-how,</FONT> our business could be harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Patent terms may be inadequate to protect our competitive
position on our drug candidates for an adequate amount of time. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have issued patents covering the
composition-of-matter and the salt form of ACR-368 through 2030 and 2037, respectively, without extension, and also seek protection through our OncoSignature method-of-use patents. We expect to seek extensions of patent terms in the United States
and, if available, in other countries where we are prosecuting patents. In the United States, the Drug Price Competition and Patent Term Restoration Act of 1984 permits a patent term extension of up to five years beyond the normal expiration of the
patent, which is limited to the approved indication (or any additional indications approved during the period of extension). However, the applicable authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory
authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. If this occurs, our competitors may be
able to take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data and launch their drug earlier than might otherwise be the case. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Patent term extensions in other countries may also be subject to certain
procedural or administrative requirements including adherence to certain strict timelines. A failure to meet such requirements may result in a loss of the extension in those countries. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and
other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these requirements. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The USPTO and various <FONT STYLE="white-space:nowrap">non-U.S.</FONT> governmental patent agencies require compliance with a
number of procedural, documentary, fee payment and other similar provisions during the patent application process. In addition, periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents and/or applications
will have to be paid to the USPTO and various government patent agencies outside of the United States over the lifetime of our owned patents and/or applications and any patent rights we may own or license in the future. We employ reputable law firms
and other professionals to help us comply with such requirements and fee payments. <FONT STYLE="white-space:nowrap">Non-compliance</FONT> events that could result in abandonment or lapse of a patent or patent application include, but are not limited
to, failure to respond to official actions within prescribed time limits, <FONT STYLE="white-space:nowrap">non-payment</FONT> of fees and failure to properly legalize and submit formal documents. If we fail to maintain the patents and patent
applications covering our products or technologies, we may not be able to stop a competitor from marketing products or technologies that are the same as or similar to our drug candidates or technologies, which would have a material adverse effect on
our business. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which <FONT STYLE="white-space:nowrap">non-compliance</FONT> can
result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market and this circumstance
could harm our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may be subject to claims challenging the inventorship or ownership of our future patents and other
intellectual property. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may also be subject to claims that former employees, collaborators, or other third
parties have an ownership interest in our patent applications, our future patents, or other intellectual property. We may be subject to ownership disputes in the future arising, for example, from conflicting obligations of consultants or others who
are involved in developing our drug candidates and platform discovery. Although it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning
such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own, and we cannot be certain that our agreements with such
parties will be upheld in the face of a potential challenge, or that they will not be breached, for which we may not have an adequate remedy. The assignment of intellectual property rights may not be self-executing or the assignment agreements may
be breached, and litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property
rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in
substantial costs and be a distraction to management and other employees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may become involved in lawsuits to protect or enforce
our patents or other intellectual property rights, which could be expensive, time consuming and unsuccessful. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Competitors may infringe our present or future issued patents, trademarks, copyrights or other intellectual property. To
counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming and divert the time and attention of our management and scientific personnel. Any claims we assert against perceived
infringers could provoke these parties to assert counterclaims against us, including claims alleging that we infringe their patents, trademarks, copyrights or other intellectual </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
property. In addition, in a patent infringement proceeding, there is a risk that a court will decide that a patent of ours is invalid or unenforceable, in whole or in part, or that we do not have
the right to stop the other party from using the invention at issue. There is also a risk that, even if the validity of such patents is upheld, the court will construe the patent&#146;s claims narrowly or decide that we do not have the right to stop
the other party from making, using, selling, offering to sell or importing the invention at issue on the grounds that our patents do not cover the invention. An adverse outcome in a litigation or proceeding involving our patents could limit our
ability to assert our patents against those parties or other competitors, and may curtail or preclude our ability to exclude third parties from making, using, selling, offering to sell or importing similar or competitive products. Similarly, if we
assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that another party has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of
such trademarks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In any infringement litigation, any award of monetary damages we receive may not be commercially
valuable. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. In
addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect
on the price of our common stock. Moreover, there can be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded. Some of our
competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Even if we ultimately prevail in
such claims, the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit we receive as a result of the proceedings. Accordingly, despite our efforts, we may not be
able to prevent third parties from infringing, misappropriating or successfully challenging our intellectual property rights. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a
negative impact on our ability to compete in the marketplace. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Third parties may initiate legal proceedings alleging that we are
infringing their intellectual property rights, the outcome of which would be uncertain and could have a negative impact on the success of our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our commercial success depends, in part, upon our ability and the ability of future collaborators, if any, to develop, use,
manufacture, market and sell our drug candidates and our proprietary technologies without infringing the proprietary rights and intellectual property of third parties. The biotechnology and pharmaceutical industries are characterized by extensive
and complex litigation regarding patents and other intellectual property rights. We may in the future become party to, or be threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our drug
candidates and technology, including interference proceedings, derivation proceedings, ex parte reexamination, post grant review and inter partes review before the USPTO or equivalent foreign regulatory authority. Third parties may assert
infringement claims against us based on existing patents or patents that may be granted in the future, regardless of their merit. There is a risk that third parties may choose to engage in litigation with us to enforce or to otherwise assert their
patent rights against us. Even if we believe such claims are without merit, a court of competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed, which could have a negative impact on our ability to
commercialize our current and any future drug candidates. In order to successfully challenge the validity of any such U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to
present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. Foreign courts will have similar burdens to
overcome in order to successfully challenge a third party claim of patent infringement. If we are found to infringe a third party&#146;s valid and enforceable intellectual property rights, we could be required to obtain a license from such third
party to continue developing, manufacturing and marketing our drug candidate(s) and technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could
be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
thereby giving our competitors and other third parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. We could be
forced, including by court order, to cease developing, manufacturing and commercializing the infringing technology or drug candidate. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#146; fees, if
we are found to have willfully infringed a patent or other intellectual property right. A finding of infringement could prevent us from manufacturing and commercializing our drug candidates or force us to cease some or all of our business
operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business, financial condition, results of operations
and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may need to license intellectual property from third parties, and such licenses may not be available or may not
be available on commercially reasonable terms. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A third party may hold intellectual property rights, including
patent rights, that are important or necessary to the development of our drug candidates and technologies. It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our drug candidates or our
technologies, in which case we would be required to obtain a license from these third parties. Such a license may not be available on commercially reasonable terms, or at all, and we could be forced to accept unfavorable contractual terms. If we are
unable to obtain such licenses on commercially reasonable terms, our business could be harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We depend on intellectual property
licensed from a third party and termination of this license could result in the loss of significant rights, which would harm our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are dependent on patents, <FONT STYLE="white-space:nowrap">know-how</FONT> and proprietary technology, both our own and
licensed from others. In particular, we are dependent on our license agreement with Lilly. Any termination of this license could result in the loss of significant rights and could harm our ability to commercialize our drug candidates. See the
section titled &#147;Business&#151;Licensing and Collaborations&#148; for additional information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Disputes may also arise
between us and our current licensor or future licensors regarding intellectual property subject to a license agreement, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of rights granted under the license agreement and other interpretation-related issues;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether and the extent to which our drug candidates and technologies infringe intellectual property of the
licensor that is not subject to the licensing agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our right to sublicense patent and other rights to third parties under collaborative development
relationships; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our diligence obligations with respect to the use of the licensed technology in relation to our development
and commercialization of our drug candidates, and what activities satisfy those diligence obligations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from the joint
creation or use of intellectual property by our licensors and us and our partners; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our payment obligations with respect to licensed technology. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current or future
licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected drug candidates and technologies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are generally also subject to all of the same risks with respect to protection of intellectual property that we license, as
we are for intellectual property that we own, which are described below. If we, Lilly, or any future licensors fail to adequately protect any licensed intellectual property, our ability to commercialize products could suffer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may be subject to claims asserting that our employees, consultants or advisors have
wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Many of our employees, consultants or advisors are currently, or were previously, employed at universities or other
biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or
<FONT STYLE="white-space:nowrap">know-how</FONT> of others in their work for us, we may be subject to claims that these individuals or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any
such individual&#146;s current or former employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or
personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, we may in the future be subject to claims by our former employees or consultants asserting an ownership right in
our patents or patent applications, as a result of the work they performed on our behalf. Although it is our policy to require our employees and contractors who may be involved in the development of intellectual property to execute agreements
assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own, and we cannot be certain that our agreements with
such parties will be upheld in the face of a potential challenge or that they will not be breached, for which we may not have an adequate remedy. The assignment of intellectual property rights may not be self-executing or the assignment agreements
may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby
impairing our ability to protect our future drug candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The United States Congress periodically enacts
legislation that significantly impacts the patent system. The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent
owners in certain situations. Various decisions by the U.S. Supreme Court and other U.S. federal courts are widely considered to have reduced patent protections available to developers of diagnostic technologies. In addition to increasing
uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents once obtained. Depending on actions by the U.S. Congress, the federal courts, and the
USPTO, the laws and regulations governing patents could change in unpredictable ways that could weaken our ability to obtain new patents or to enforce patents that we own or have licensed, or that we might obtain in the future. Similarly, changes in
patent law and regulations in other countries or jurisdictions, changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new
patents or to enforce patents that we own or have licensed or that we may obtain in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may not be able to protect our
intellectual property rights throughout the world, which could negatively impact our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Filing, prosecuting
and defending patents on drug candidates and technologies in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States could be less extensive than those in
the United States. In some cases, we may not be able to obtain patent protection for certain technologies outside the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as
federal and state laws in the United States, even in jurisdictions where we do pursue patent protection. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, even in
jurisdictions where we do pursue patent protection or from selling or importing products made using our inventions in and into the United States or other jurisdictions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Many companies have encountered significant problems in protecting and
defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, which could make
it difficult for us to stop the infringement of our patents, if pursued and obtained, or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result
in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third
parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights
around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Reliance on third parties requires us to share our proprietary information, which increases the possibility that such information will
be misappropriated or disclosed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Because we rely on third parties for aspects of development, manufacture, or
commercialization of our drug candidates and technologies, or if we collaborate with third parties for the development or commercialization of our future drug candidates and technologies, we must, at times, share proprietary information with them.
We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with our advisors, employees, third-party
contractors and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information. Despite the contractual provisions
employed when working with third parties, the need to share confidential information increases the risk that such information become known by our competitors, is inadvertently incorporated into the technology of others, or is disclosed or used in
violation of these agreements. Given that our proprietary position is based, in part, on our <FONT STYLE="white-space:nowrap">know-how,</FONT> a competitor&#146;s discovery of our <FONT STYLE="white-space:nowrap">know-how</FONT> or other
unauthorized use or disclosure could have an adverse effect on our business and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, these
agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to our <FONT STYLE="white-space:nowrap">know-how.</FONT> Despite our efforts to protect our <FONT
STYLE="white-space:nowrap">know-how,</FONT> we may not be able to prevent the unauthorized disclosure or use of our technical <FONT STYLE="white-space:nowrap">know-how</FONT> by the parties to these agreements. Moreover, we cannot guarantee that we
have entered into such agreements with each party that may have or have had access to our confidential information or proprietary technology and processes. Monitoring unauthorized uses and disclosures is difficult, and we do not know whether the
steps we have taken to protect our proprietary technologies will be effective. If any of the collaborators, scientific advisors, employees, contractors and consultants who are parties to these agreements breaches or violates the terms of any of
these agreements, we may not have adequate remedies for any such breach or violation. Moreover, if confidential information that is licensed or disclosed to us by our partners, collaborators, or others is inadvertently disclosed or subject to a
breach or violation, we may be exposed to liability to the owner of that confidential information. Enforcing a claim that a third-party illegally obtained and is using our proprietary information, like patent litigation, is expensive and time
consuming, and the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing to protect proprietary information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Trademarks we own, license or may obtain may be infringed or successfully challenged, resulting in harm to our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We rely on trademarks and expect to rely on future trademarks as one means to distinguish our drug candidates that are approved
for marketing and technologies from the products of our competitors. OncoSignature is trademarked. Once we select trademarks and apply to register them, our trademark applications may not be approved. Third parties may oppose our trademark
applications or otherwise challenge our use of the trademarks. In the event that our trademarks are successfully challenged, we could be forced to rebrand our products, which could result in loss of brand recognition and could require us to devote
resources to advertising and marketing new brands. Our competitors may infringe our trademarks, and we may not have adequate resources to enforce our trademarks. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, any proprietary name we propose to use with <FONT
STYLE="white-space:nowrap">ACR-368</FONT> or any future drug candidate in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. The FDA typically conducts a review of
proposed product names, including an evaluation of the potential for confusion with other product names. If the FDA objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in an effort
to identify a suitable proprietary product name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. Comparable foreign regulators may have similar requirements, and it
is possible that different proprietary or <FONT STYLE="white-space:nowrap">non-proprietary</FONT> names may be required in different jurisdictions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If we are unable to protect the confidentiality of our proprietary information, our business and competitive position would be harmed.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to seeking patent and trademark protection for our drug candidates and technologies, we also rely on
unpatented <FONT STYLE="white-space:nowrap">know-how,</FONT> technology and other proprietary information, to maintain our competitive position. We seek to protect our proprietary information, in part, by entering into
<FONT STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants,
advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary
information. Monitoring unauthorized uses and disclosures of our intellectual property is difficult, and we do not know whether the steps we have taken to protect our intellectual property will be effective. In addition, we may not be able to obtain
adequate remedies for any such breaches. Enforcing a claim that a party illegally disclosed or misappropriated proprietary information is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and
outside the United States are less willing or unwilling to protect trade secrets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Moreover, our competitors may
independently develop knowledge, methods and <FONT STYLE="white-space:nowrap">know-how</FONT> equivalent to our proprietary information. Competitors may be able to obtain or reverse engineer information about our products or technologies that would
permit them to replicate some or all of the competitive advantages we derive from our development efforts for technologies on which we do not have patent protection. If any of our proprietary information were to be lawfully obtained or independently
developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our proprietary information were to be disclosed to or independently
developed by a competitor, our competitive position would be harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We also seek to preserve the integrity and
confidentiality of our data and other confidential information by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations
and systems, agreements or security measures may be breached and detecting the disclosure or misappropriation of confidential information and enforcing a claim that a party illegally disclosed or misappropriated confidential information is
difficult, expensive and time-consuming, and the outcome is unpredictable. Further, we may not be able to obtain adequate remedies for any breach. In addition, our confidential information may otherwise become known or be independently discovered by
competitors, in which case we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If we do not obtain patent term extension for patents covering our drug candidates, our business may be materially harmed, and in any
case, the terms of our patents may not be sufficient to effectively protect our drug candidates and business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Patents have a limited term. In most countries, including the United States, the expiration of a patent is generally 20 years
after its first effective <FONT STYLE="white-space:nowrap">non-provisional</FONT> filing date. However, depending upon the timing, duration and specifics of FDA marketing approval of <FONT STYLE="white-space:nowrap">ACR-368,</FONT> our other drug
candidates or any future drug </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
candidates, one or more of any U.S. patents we may be issued or have licensed may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act
of 1984, also known as the Hatch-Waxman Amendments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Hatch-Waxman Amendments permit a patent restoration term of up to
five years as compensation for patent term lost during product development and the FDA regulatory review process. The Hatch-Waxman Act allows a maximum of one patent to be extended per <FONT STYLE="white-space:nowrap">FDA-approved</FONT> product as
compensation for the patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only those claims covering such
approved drug product, a method for using it or a method for manufacturing it may be extended. Patent term extension may also be available in certain foreign countries upon regulatory approval of our drug candidates. However, we may not be granted
an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope
of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or restoration or the term of any such extension is less than we request, our competitors may obtain approval of competing products
following our patent expiration, and our competitive position, business, financial condition, results of operations, and prospects could be harmed, possibly materially. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If there are delays in obtaining regulatory approvals or other additional delays, the period of time during which we can
market our drug candidates under patent protection could be further reduced. Given the amount of time required for the development, testing and regulatory review of new drug candidates, patents protecting such drug candidates might expire before or
shortly after such drug candidates are commercialized. Once the patent term has expired, we may be open to competition from similar or generic products. The launch of a generic version of one of our products in particular would be likely to result
in an immediate and substantial reduction in the demand for that product, which could have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to This Offering, Ownership of our Common Stock and our Status as a Public Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>An active trading market for our common stock may not develop and you may not be able to resell your shares of our common stock at or
above the initial offering price, if at all. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prior to this offering, there has been no public market for our
common stock. The initial public offering price for our common stock was determined through negotiations with the underwriters and may not be indicative of the price at which our common stock will trade after the closing of this offering. Although
we anticipate that our common stock will be approved for listing on the Nasdaq Global Market, an active trading market for our shares may never develop or be sustained following this offering. If an active market for our common stock does not
develop or is not sustained, it may be difficult for you to sell shares you purchased in this offering at an attractive price or at all. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>The trading price of the shares of our common stock may be volatile, and purchasers of our common stock could incur substantial losses.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our stock price may be volatile. The stock market in general and the market for biopharmaceutical companies in
particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, investors may not be able to sell their common stock at or above the price paid for
the shares. The market price for our common stock may be influenced by many factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the reporting of unfavorable preclinical results; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the commencement, enrollment or results of our clinical trials of
<FONT STYLE="white-space:nowrap">ACR-368</FONT> or any future clinical trials we may conduct, or changes in the development status of our drug candidates; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any delay in our regulatory filings for <FONT STYLE="white-space:nowrap">ACR-368</FONT> or any other drug
candidate we may develop, and any adverse development or perceived adverse development with respect to the applicable regulatory authority&#146;s review of such filings, including without limitation the FDA&#146;s issuance of a &#147;refusal to
file&#148; letter or a request for additional information; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse results from, delays in or termination of clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse regulatory decisions, including failure to receive regulatory approval of our drug candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unanticipated serious safety concerns related to the use of <FONT STYLE="white-space:nowrap">ACR-368</FONT> or
any other drug candidate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in financial estimates by us or by any equity research analysts who might cover our stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conditions or trends in our industry; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the market valuations of similar companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">stock market price and volume fluctuations of comparable companies and, in particular, those that operate in
the biopharmaceutical industry; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">publication of research reports about us or our industry or positive or negative recommendations or withdrawal
of research coverage by securities analysts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements by us or our competitors of significant acquisitions, strategic partnerships or divestitures;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our relationships with our collaborators; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements of investigations or regulatory scrutiny of our operations or lawsuits filed against us;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">investors&#146; general perception of our company and our business; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recruitment or departure of key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overall performance of the equity markets; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">trading volume of our common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disputes or other developments relating to proprietary rights, including patents, litigation matters and our
ability to obtain patent protection for our technologies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significant lawsuits, including patent or stockholder litigation or employee or independent contractor
litigation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the structure of healthcare payment systems; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general political and economic conditions; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other events or factors, many of which are beyond our control. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The stock market in general, and the market for biotechnology companies in particular, have experienced extreme price and
volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies, including recently in connection with the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, the Russian invasion
of Ukraine, rising inflation and increasing interest rates, which have resulted in decreased stock prices for many companies notwithstanding the lack of a fundamental change in their underlying business models or prospects. Broad market and industry
factors, including potentially worsening economic conditions, may negatively affect the market price of our common stock, regardless of our actual operating performance. The realization of any of the above risks or any of a broad range of other
risks, including those described in this section, could have a significant and material adverse impact on the market price of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, in the past, stockholders have initiated class action lawsuits against pharmaceutical and biotechnology companies
following periods of volatility in the market prices of these companies&#146; stock. Such litigation, if instituted against us, could cause us to incur substantial costs and divert management&#146;s attention and resources from our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>A significant portion of our total outstanding shares are restricted from immediate
resale but may be sold into the market in the near future. This could cause the market price of our common stock to drop significantly, even if our business is doing well. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the
perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. After this offering, we will have 18,809,823 shares of common stock outstanding based on the number of
shares outstanding as of June&nbsp;30, 2022. This includes the shares that we are selling in this offering, which may be resold in the public market immediately. Following the consummation of this offering, substantially all of our shares
outstanding prior to this offering will be subject to a <FONT STYLE="white-space:nowrap">180-day</FONT> <FONT STYLE="white-space:nowrap">lock-up</FONT> period pursuant to <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements executed in
connection with this offering described in &#147;Underwriting&#148; and restricted from immediate resale under the federal securities laws as described in &#147;Shares Eligible for Future Sale.&#148; All of these shares will, however, be able to be
resold after the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period, as well as pursuant to customary exceptions thereto or upon the waiver of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement by on behalf of the
underwriters. We also intend to register shares of common stock that we may issue under our equity compensation plans. Once we register these shares, they can be freely sold in the public market upon issuance, subject to the <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements. As restrictions on resale end, the market price of our stock could decline if the holders of currently-restricted shares sell them or are perceived by the market as intending to sell them. </P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We intend to file a registration statement on Form S-8 under the Securities Act to register shares subject to outstanding
stock options issued under the 2019 Plan and shares of common stock reserved for issuance under the 2022 Plan and the ESPP. Both the 2022 Plan and the ESPP provide for annual automatic increases in the shares reserved for issuance under the plans
which could result in additional dilution to our stockholders. Once we register the issuance of shares under these plans, they can be freely sold in the public market upon issuance, subject to the vesting of the equity awards, other restrictions
provided under the terms of the applicable plan or equity award, and the lock-up period with respect to this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If you
purchase shares of common stock in this offering, you will suffer immediate dilution of your investment. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
initial public offering price of our common stock will be substantially higher than the pro forma as adjusted net tangible book value per share of our common stock. Therefore, if you purchase shares of our common stock in this offering, you will pay
a price per share that substantially exceeds our pro forma as adjusted net tangible book value per share after this offering. To the extent outstanding options are exercised, you will incur further dilution. Based on an assumed initial public
offering price of $17.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, you will experience immediate dilution of $7.63&nbsp;per share as of June&nbsp;30, 2022, representing the difference between
our pro forma as adjusted net tangible book value per share, after giving effect to this offering, and the assumed initial public offering price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To the extent that stock options are exercised, new equity awards are issued under our equity incentive plans or we issue
additional shares of common stock in the future, there will be further dilution to investors participating in this offering. In addition, we may choose to raise additional capital because of market conditions or strategic considerations, even if we
believe that we have sufficient funds for our current or future operating plans. If we raise additional capital through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our
stockholders. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If equity research analysts do not publish research or reports, or publish unfavorable research or reports,
about us, our business or our market, our stock price and trading volume could decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The trading market for our
common stock will be influenced by the research and reports that equity research analysts publish about us and our business. As a newly public company, we have only limited research coverage by equity research analysts. Equity research analysts may
elect not to provide research coverage of our common </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
stock, and such lack of research coverage may adversely affect the market price of our common stock. In the event we do have equity research analyst coverage, we will not have any control over
the analysts or the content and opinions included in their reports. The price of our stock could decline if one or more equity research analysts downgrade our stock or issue other unfavorable commentary or research. If one or more equity research
analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which in turn could cause our stock price or trading volume to decline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our executive officers, directors and their affiliates, if they choose to act together, have the ability to significantly influence all
matters submitted to stockholders for approval. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the closing of this offering, based on the number of
common stock outstanding as of June&nbsp;30, 2022, our executive officers, directors and stockholders who owned more than 5% of our outstanding common stock before this offering and their respective affiliates will, in the aggregate, hold common
stock representing approximately 54.0% of our outstanding common stock, without giving effect to any purchases by our officers, directors and their affiliated entities in this offering. As a result, if these stockholders choose to act together, they
would be able to control or significantly influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, would control or significantly influence
the election of directors, the composition of our management and approval of any merger, consolidation, sale of all or substantially all of our assets or other business combination that other stockholders may desire. Any of these actions could
adversely affect the market price of our common stock. This concentration of ownership control may: </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delay, defer, or prevent a change in control; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">entrench our management and board of directors; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delay or prevent a merger, consolidation, takeover, or other business combination involving us that other
stockholders may desire. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Concentration of ownership of our common stock among our existing executive officers,
directors and principal stockholders may prevent new investors from influencing significant corporate decisions. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our executive officers, directors and current beneficial owners of 5% or more of our common stock and their respective
affiliates beneficially own over 78.6% of our outstanding common stock prior to this offering and will continue to own a majority of our common stock following this offering. As a result, these persons, acting together, would be able to
significantly influence all matters requiring stockholder approval, including the election and removal of directors, any merger, consolidation, sale of all or substantially all of our assets, or other significant corporate transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Some of these persons or entities may have interests different than yours. For example, because many of these stockholders
purchased their shares at prices substantially below the current market price of our common stock and have held their shares for a longer period, they may be more interested in selling our company to an acquirer than other investors, or they may
want us to pursue strategies that deviate from the interests of other stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We are an &#147;emerging growth company&#148;
and a &#147;smaller reporting company&#148; and, as a result of the reduced disclosure and governance requirements applicable to emerging growth companies and smaller reporting companies, our common stock may be less attractive to investors.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are an &#147;emerging growth company&#148; as defined in the JOBS Act and we intend to take advantage of some
of the exemptions from reporting requirements that are applicable to other public companies that are not emerging growth companies, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">being permitted to provide only two years of audited financial statements, in addition to any required
unaudited interim financial statements with correspondingly reduced &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; disclosure;</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exemption from compliance with the auditor attestation requirements of Section&nbsp;404 of the
Sarbanes-Oxley Act of 2002, as amended, in the assessment of our internal control over financial reporting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and
registration statements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exemptions from the requirements of holding <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory votes
on executive compensation or golden parachute arrangements; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exemption from compliance with the requirements of the Public Company Accounting Oversight Board regarding
the communication of critical audit matters in the auditor&#146;s report on financial statements. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We
cannot predict if investors will find our common stock less attractive because we will rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and
our stock price may be more volatile. We may take advantage of these reporting exemptions until we are no longer an emerging growth company. We will remain an emerging growth company until the last day of our fiscal year following the fifth
anniversary of the completion of this offering or, if earlier, (i)&nbsp;the last day of the fiscal year in which we have total annual gross revenue of at least $1.24&nbsp;billion, (ii)&nbsp;the date on which we are deemed to be a large accelerated
filer, which means the market value of our common stock that is held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700&nbsp;million as of the prior June&nbsp;30th, or (iii)&nbsp;the date on which we have issued more than
$1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt during the prior three-year period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In
addition, we have elected to take advantage of the extended transition period to comply with new or revised accounting standards and to adopt certain of the reduced disclosure requirements available to emerging growth companies. As a result of the
accounting standards election, we will not be subject to the same implementation timing for new or revised accounting standards as other public companies that are not emerging growth companies, which may make comparison of our financials to those of
other public companies more difficult. As a result of these elections, the information that we provide in this prospectus may be different than the information investors may receive from other public companies in which they hold equity interests. In
addition, it is possible that some investors will find our common stock less attractive as a result of these elections, which may result in a less active trading market for our common stock and higher volatility in our share price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Even after we no longer qualify as an emerging growth company, we may, under certain circumstances, still qualify as a
&#147;smaller reporting company,&#148; which would allow us to take advantage of many of the same exemptions from disclosure requirements, including reduced disclosure obligations regarding executive compensation in our periodic reports and proxy
statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We will have broad discretion in the use of proceeds from this offering and may invest or spend the proceeds in ways
with which you do not agree and in ways that may not increase the value of your investment. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We will have broad
discretion over the use of proceeds from this offering. You may not agree with our decisions, and our use of the proceeds may not yield any return on your investment. We expect to use the net proceeds to us from this offering, together with our
existing cash, cash equivalents and short-term investments, to fund the advancement of ACR-368, including CMC and companion diagnostic development, in Phase 2 clinical trials across our three lead indications into potential registrational phase,
pending results and discussions with the FDA, as well as to potentially initiate Phase 2 trials in patients with HPV+ tumors, to complete IND-enabling studies for at least one of our preclinical programs and the remainder for continued development
of our AP3 platform, other research and development activities, working capital and other general corporate purposes. See the section titled &#147;Use of Proceeds.&#148; In addition, we may use a portion of the proceeds from this offering to pursue
our strategy to <FONT STYLE="white-space:nowrap">in-license</FONT> or develop additional drug candidates. Our failure to apply the net proceeds from this offering effectively could compromise our ability to pursue our growth strategy and we might
not be able to yield a significant return, if any, on our investment of these net proceeds. You will not have the opportunity to influence our decisions on how to use our net proceeds from this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We have identified material weaknesses in our internal control over financial
reporting. If we are unable to remediate these material weaknesses, or if we identify additional material weaknesses in the future or otherwise fail to maintain effective internal control over financial reporting, we may not be able to accurately or
timely report our financial condition or results of operations, which may adversely affect our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A
material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that it is reasonably possible that a material misstatement of the annual or interim financial statements will not be prevented or
detected on a timely basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Effective internal control over financial reporting is necessary for us to provide reliable
financial reports in a timely manner commensurate with the financial reporting requirements of an SEC registrant. Prior to the completion of this offering, we have been a private company and therefore have not designed or maintained internal
controls over financial reporting commensurate with the financial reporting requirements of an SEC registrant. Accordingly, we have identified the following material weaknesses: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We did not design and maintain an effective control environment commensurate with the financial reporting
requirements of a public company. Specifically, we lacked a sufficient complement of resources with (i)&nbsp;an appropriate level of accounting knowledge, experience and training to appropriately analyze, record and disclose accounting matters
timely and accurately as a public company, and (ii)&nbsp;an appropriate level of knowledge and experience to establish effective processes and controls. Additionally, the lack of a sufficient number of professionals resulted in an inability to
consistently design and maintain formal accounting policies, procedures and controls or establish appropriate authorities and responsibilities in pursuit of our financial reporting objectives, as demonstrated by, among other things, insufficient
segregation of duties in our finance and accounting functions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We did not design and maintain effective controls in response to the risks of material misstatement.
Specifically, changes to existing controls or the implementation of new controls were not sufficient to timely respond to changes to the risks of material misstatement to financial reporting due to changes in the complexity in the business.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These material weaknesses contributed to the following additional material weaknesses: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We did not design and maintain effective controls to achieve complete, accurate and timely financial
accounting, reporting and disclosures, including controls over the preparation and review of account reconciliations and journal entries and the identification of and accounting for certain <FONT STYLE="white-space:nowrap">non-routine,</FONT>
unusual or complex transactions in a timely fashion, including the proper application of U.S. GAAP to such transactions.&nbsp;Specifically, we did not design and maintain controls to timely identify and account for preferred stock tranche rights,
convertible notes and the anti-dilution right valuation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We did not design and maintain effective controls over information technology general controls for information
systems that are relevant to the preparation of its financial statements. Specifically, we did not design and maintain: (i)&nbsp;program change management controls to ensure that program and data changes are identified, tested, authorized and
implemented appropriately; (ii)&nbsp;user access controls to ensure appropriate segregation of duties and to adequately restrict user and privileged access to appropriate personnel; (iii)&nbsp;computer operations controls to ensure that processing
and transfer of data, and data backups and recovery are monitored; and (iv)&nbsp;program development controls to ensure that new software development is tested, authorized and implemented appropriately. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">None of the material weaknesses described above resulted in misstatement to our consolidated financial statements. However,
the material weaknesses described above could result in a misstatement of one or more account balances or disclosures that would result in a material misstatement to the annual or interim consolidated financial statements that would not be prevented
or detected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prior to the completion of this offering, we have been a private company with limited accounting personnel
to adequately execute our accounting processes. We are in the process of implementing measures designed to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
improve our internal control over financial reporting and remediate these material weaknesses. Such measures include, but are not limited to: hiring additional finance and accounting personnel,
upgrading our financial systems and implementing information technology general controls, establishing controls to identify, assess, and respond to the risks of material misstatement, and establishing controls to identify and account for certain
non-routine, unusual or complex transactions in a timely fashion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">While we are currently in the process of remediating
the material weaknesses, we cannot assure you that these efforts will remediate our material weaknesses in a timely manner, or at all. If we are unable to successfully remediate our material weaknesses, or identify any future material weaknesses,
the accuracy and timing of our financial reporting may be adversely affected, we may be unable to maintain compliance with securities law requirements regarding timely filing of periodic reports, the market price of our stock may decline as a
result, and we could be subject to sanctions or investigations by the Nasdaq Global Market, the SEC, or other regulatory authorities. Failure to remediate any material weakness in our internal control over financial reporting, or to implement or
maintain other effective control systems required of public companies, could also restrict our future access to the capital markets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware and the federal
district courts of the United States of America will be the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders&#146; ability to obtain a favorable judicial forum for disputes with us
or our directors, officers or employees. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated certificate of incorporation provides that the
Court of Chancery of the State of Delaware is the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any derivative action or proceeding brought on our behalf; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any action asserting a breach of fiduciary duty; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any action asserting a claim against us arising under the Delaware General Corporation Law, our amended and
restated certificate of incorporation, or our amended and restated bylaws; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any claim or cause of action seeking to interpret, apply, enforce or determine the validity of our restated
certificate or our amended and restated bylaws; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any claim or cause of action as to which the Delaware General Corporation Law confers jurisdiction on the
Court of Chancery of the state of Delaware; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any action asserting a claim against us that is governed by the internal-affairs doctrine.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This provision would not apply to suits brought to enforce a duty or liability created by the Exchange
Act. Furthermore, Section&nbsp;22 of the Securities Act of 1933, as amended, or the Securities Act, creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have
jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our amended and restated certificate of
incorporation further provides that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. While the Delaware courts have
determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert
the validity and enforceability of the exclusive forum provisions of our amended and restated certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be
no assurance that the provisions will be enforced by a court in those other jurisdictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These exclusive forum
provisions may result in increased costs for investors to bring a claim. Further, these exclusive forum provisions may limit a stockholder&#146;s ability to bring a claim in a judicial forum that it finds
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
favorable for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers and other employees. If a court were to find
either exclusive-forum provision in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving the dispute in other
jurisdictions, all of which could seriously harm our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Provisions in our corporate charter documents and under Delaware law
could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Provisions in our certificate of incorporation and our bylaws that will become effective upon the closing of this offering may
discourage, delay, or prevent a merger, acquisition, or other change in control of our company that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions could
also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members
of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other
things, these provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish a classified board of directors such that directors are elected at the annual stockholder meeting;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">allow the authorized number of our directors to be changed from time to time by our stockholders or our board
of directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limit the manner in which stockholders can remove directors from our board of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish requirements for stockholder proposals that can be acted on at stockholder meetings;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require that stockholder actions must be effected at a duly called stockholder meeting and allow actions by
our stockholders by written consent, with certain requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limit who may call stockholder meetings; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authorize our board of directors to issue preferred stock without stockholder approval, which could be used to
institute a &#147;poison pill&#148; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section&nbsp;203 of the Delaware
General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15%
of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We could be subject to
securities class action litigation. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the past, securities class action litigation has often been brought against
a company following a decline in the market price of its securities. This risk is especially relevant for us because biopharmaceutical companies have experienced significant stock price volatility in recent years. If we face such litigation, it
could result in substantial costs and a diversion of management&#146;s attention and resources, which could harm our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General Risks </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We are subject to U.S. and certain foreign anti-corruption laws and regulations, export and import controls, sanctions and embargoes. We
could face liability and other serious consequences for violations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are subject to anti-corruption laws and
regulations, including the FCPA, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act and other state and national anti-bribery laws in the countries in which we may conduct activities in the future.
Anti-corruption laws are interpreted broadly and generally prohibit companies and their employees, agents, contractors and other third-party collaborators from offering, promising, giving, or authorizing others to give anything of value, either
directly or indirectly through third parties, to any person in the public or private sector to obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions
of the corporation and to devise and maintain an adequate system of internal accounting controls. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our business is heavily
regulated and therefore involves significant interaction with public officials, including officials of <FONT STYLE="white-space:nowrap">non-United</FONT> States governments. Additionally, in many other countries, the healthcare providers who
prescribe pharmaceuticals are employed by their government, and therefore will be considered foreign officials for purposes of the FCPA. We also expect to rely on third parties for research, preclinical studies and clinical trials and/or to obtain
necessary permits, licenses, patent registrations and other marketing approvals. We can be held liable for the corrupt or other illegal activities of our employees, agents, CROs, contractors and other collaborators and partners, even if we do not
explicitly authorize or have actual knowledge of such activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are also subject to export control and import laws
and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations and various economic and trade sanctions regulations administered by the U.S. Treasury Department&#146;s Office of Foreign Assets Controls. Compliance
with applicable regulatory requirements regarding the export of our products may create delays in the introduction of our products in international markets or, in some cases, prevent the export of our products to some countries altogether.
Furthermore, U.S. export control laws and economic sanctions prohibit the shipment of certain products and services to countries, governments and persons targeted by U.S. sanctions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There is no certainty that all of our employees, agents, suppliers, manufacturers, contractors or collaborators, or those of
our affiliates, will comply with all applicable anti-corruption, export and import control, and sanctions laws and regulations, particularly given the high level of complexity of these laws. Violations of these laws and regulations could result in
fines, criminal sanctions against us, our officers, or our employees, the closing down of facilities, including those of our suppliers and manufacturers, requirements to obtain export licenses, cessation of business activities in sanctioned
countries, implementation of compliance programs, and prohibitions on the conduct of our business. Any such violations could include prohibitions on our ability to offer our products in one or more countries as well as difficulties in manufacturing
or continuing to develop our products, and could materially damage our reputation, our brand, our international expansion efforts, our ability to attract and retain employees, and our business, prospects, operating results and financial condition.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If we are unable to design and maintain effective internal control over financial reporting in the future, investors may lose
confidence in the accuracy and completeness of our financial reports and the market price of our common stock may decline. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Ensuring that we have adequate internal control over financial reporting in place so that we can produce accurate financial
statements on a timely basis is a costly and time-consuming effort that needs to be <FONT STYLE="white-space:nowrap">re-evaluated</FONT> frequently. Our internal control over financial reporting is a process designed to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements in accordance with generally accepted accounting principles. In connection with this offering, we intend to begin the process of documenting, reviewing and
improving our internal control over financial reporting for compliance with Section&nbsp;404, which will require annual management assessment of the effectiveness of our internal control over financial reporting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Implementing any appropriate changes to our internal control over financial
reporting may distract our officers and employees, entail substantial costs to modify our existing processes, and take significant time to complete. These changes may not, however, be effective in establishing and maintaining the adequacy of our
internal controls, and any failure to maintain that adequacy, or consequent inability to produce accurate financial statements on a timely basis, could increase our operating costs and harm our business. If we fail to remediate our identified
material weaknesses, or identify additional material weaknesses, in our internal control over financial reporting; if we are unable to comply with the requirements of Section&nbsp;404 in a timely manner; or if we are unable to assert that our
internal control over financial reporting is effective, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our common stock could decline, and we could also become subject to
investigations by the stock exchange on which our common stock is listed, the SEC or other regulatory authorities, which could require additional financial and management resources. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may not be able to utilize a significant portion of our net operating loss carryforwards and other tax attributes. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December&nbsp;31, 2021, we had approximately $13.9&nbsp;million federal net operating loss carryforwards and
$12.3&nbsp;million in state net operating loss carryforwards. The federal net operating loss carryforward can be carried forward indefinitely while the state net operating loss carryforward will begin to expire in varying amounts in 2038. The net
operating loss carryforwards subject to expiration could expire unused and be unavailable to offset future income tax liabilities. Under the 2017 Tax Cuts and Jobs Act, or the Tax Act, as modified by the Coronavirus Aid, Relief and Economic Security
Act, or CARES Act, federal net operating losses generated in taxable years beginning after December&nbsp;31, 2017 and in future taxable years, if any, will not expire and may be carried forward indefinitely, but the deductibility of such federal net
operating losses in taxable years beginning after December&nbsp;31, 2020 are limited to the lesser of the net operating loss carryover or 80% of the corporation&#146;s adjusted taxable income (subject to Section&nbsp;382 of the Internal Revenue Code
of 1986, as amended, or the Code). There is variation in how states are responding to the Tax Act and CARES Act. In addition, for state income tax purposes, there may be periods during which the use of net operating losses, or NOLs, is suspended or
otherwise limited. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Separately, under Section&nbsp;382 of the Code, and corresponding provisions of state law, if a
corporation undergoes an &#147;ownership change,&#148; which is generally defined as a greater than 50 percentage point change, by value, in its equity ownership by certain stockholders over a rolling three-year period, the corporation&#146;s
ability to use its <FONT STYLE="white-space:nowrap">pre-change</FONT> NOL carryforwards and other <FONT STYLE="white-space:nowrap">pre-change</FONT> tax attributes to offset its post-change income or taxes may be limited. The completion of this
offering, together with private placements and other transactions that have occurred since our inception, may trigger such an ownership change pursuant to Section&nbsp;382 of the Code. We have not completed a Section&nbsp;382 analysis, and
therefore, there can be no assurances that the NOLs carryforward are not already limited. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, we may experience
ownership changes as a result of subsequent shifts in our stock ownership, some of which may be outside of our control. If an ownership change occurs and our ability to use our NOL carryforwards is materially limited, it could harm our future
operating results by effectively increasing our future tax obligations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>New or future changes to tax laws could materially
adversely affect our company. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The tax regimes we are subject to or operate under, including with respect to income
and <FONT STYLE="white-space:nowrap">non-income</FONT> taxes, are unsettled and may be subject to significant change. Changes in tax laws, regulations, or rulings, or changes in interpretations of existing laws and regulations, could materially
adversely affect our company. For example, the Tax Act, together with the CARES Act, made broad and complex changes to the U.S. tax code, including changes to U.S. federal tax rates, additional limitations on the deductibility of interest, both
positive and negative changes to the utilization of future NOL carryforwards, allowing for the expensing of certain capital expenditures, and putting into effect the migration from a &#147;worldwide&#148; system of taxation to a territorial system.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
In addition, many countries in Europe, as well as a number of other countries and organizations (including the Organization for Economic Cooperation and Development and the European Commission),
have recently proposed, recommended, or (in the case of countries) enacted or otherwise become subject to changes to existing tax laws or new tax laws that could significantly increase our tax obligations in the countries where we do business or
require us to change the manner in which we operate our business. Recently, in the United States, Congress and the Biden administration proposed legislation (which has not yet been enacted) to make various tax law changes. These proposals,
recommendations and enactments include changes to the existing framework in respect of income taxes that could apply to our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Unfavorable global political or economic conditions could adversely affect our business, financial condition or results of operations.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our results of operations could be adversely affected by general conditions in the global economy and in the
global financial markets. The global credit and financial markets have experienced severe volatility and disruptions in the past several years. A severe or prolonged economic downturn, such as the global financial crisis, could result in a variety
of risks to our business, including our ability to raise additional capital when needed on acceptable terms, if at all. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will
not occur. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for our services. In addition, the current military conflict between Russia and Ukraine
could disrupt or otherwise adversely impact our operations and those of third parties upon which we rely. Related sanctions, export controls or other actions have been or may in the future be initiated by nations including the United States, the
European Union or Russia (e.g., potential cyberattacks, disruption of energy flows, etc.), which could adversely affect our business and/or our supply chain, our CROs, CMOs and other third parties with whom we conduct business. Any of the foregoing
could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We will incur increased costs and demands upon management as a result of being a public company. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As a public company listed in the United States, we will incur significant additional legal, accounting and other expenses that
we did not incur as a private company, including the cost of director and officer liability insurance. These additional costs could negatively affect our financial results. In addition, changing laws, regulations and standards relating to corporate
governance and public disclosure, including regulations implemented by the SEC and Nasdaq, may increase legal and financial compliance costs and make some activities more time-consuming. These laws, regulations and standards are subject to varying
interpretations and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. We intend to invest resources to comply with evolving laws, regulations and standards, and this
investment may result in increased general and administrative expenses and a diversion of management&#146;s time and attention from revenue-generating activities to compliance activities. If notwithstanding our efforts to comply with new laws,
regulations and standards, we fail to comply, regulatory authorities may initiate legal proceedings against us and our business may be harmed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Failure to comply with these rules might also make it more difficult for us to obtain some types of insurance, including
director and officer liability insurance, and we might be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these events could also make it more difficult
for us to attract and retain qualified persons to serve on our board of directors, on committees of our board of directors or as members of senior management. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon completion of this offering, we will become subject to certain reporting requirements of the Exchange Act. Our disclosure
controls and procedures are designed to reasonably assure that information required to be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
disclosed by us in reports we file or submit under the Exchange Act is accumulated and communicated to management, recorded, processed, summarized, and reported within the time periods specified
in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the
control system are met. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These inherent limitations include the realities that judgments in decision-making can be faulty,
and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by an unauthorized override of the controls. Accordingly,
because of the inherent limitations in our control system, misstatements or insufficient disclosures due to error or fraud may occur and not be detected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc383050_5"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This prospectus contains forward-looking statements that involve substantial risks and uncertainties. The forward-looking
statements are contained principally in the sections titled &#147;Prospectus Summary,&#148; &#147;Risk Factors,&#148; &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations,&#148; &#147;Business&#148; and
elsewhere in this prospectus. In some cases, you can identify forward-looking statements by terms such as &#147;anticipate,&#148; &#147;believe,&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;may,&#148;
&#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;should,&#148; &#147;target,&#148; &#147;will,&#148; or &#147;would&#148; or the negative of these terms or other similar expressions intended to identify
statements about the future. These statements speak only as of the date of this prospectus and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially
different from any future results, performance or achievements expressed or implied by the forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and
financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements include statements about the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing, progress and results of our preclinical studies and clinical trials of our drug candidates,
including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of any IND submissions, initiation of clinical trials and timing of expected clinical results for <FONT
STYLE="white-space:nowrap">ACR-368</FONT> and our other future drug candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of any submission of filings for regulatory approval of, and our ability to obtain and maintain
regulatory approvals for, <FONT STYLE="white-space:nowrap">ACR-368</FONT> and any other drug candidates for any indication; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, including new variants of the virus,
which could adversely impact our business, including our preclinical studies and clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to identify patients with the cancers treated by our drug candidates, and to enroll patients in
trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the size of the patient populations, market acceptance and opportunity for and
clinical utility of our drug candidates, if approved for commercial use; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our manufacturing capabilities and strategy, including the scalability and commercial viability of our
manufacturing methods and processes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the scope of any approved indication for
<FONT STYLE="white-space:nowrap">ACR-368</FONT> or any other drug candidate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully commercialize our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to leverage our AP3 platform to identify and develop future drug candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates of our expenses, ongoing losses, future revenue, capital requirements and our need for or
ability to obtain additional funding before we can expect to generate any revenue from drug sales; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish or maintain collaborations or strategic relationships; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to identify, recruit and retain key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reliance upon intellectual property licensed from third parties and our ability to obtain such licenses on
commercially reasonable terms or at all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to protect and enforce our intellectual property position for our drug candidates, and the scope
of such protection; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial performance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expected use of proceeds from this offering; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitive position and the development of and projections relating to our competitors or our industry;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates regarding future revenue, expenses and needs for additional financing; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of laws and regulations; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the time during which we will be an emerging growth company under the JOBS Act.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The foregoing list of risks is not exhaustive. Other sections of this prospectus may include additional
factors that could harm our business and financial performance. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and
uncertainties. As a result of these factors, we cannot assure you that the forward-looking statements in this prospectus will prove to be accurate. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking
statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. You should, however, review the factors and risks and other information we describe in the reports we will file from time to
time with the SEC after the date of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Because forward-looking statements are inherently subject to risks
and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. Although we believe that we have a reasonable basis
for each forward-looking statement contained in this prospectus, the events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the
forward-looking statements. You should refer to the &#147;Risk Factors&#148; section of this prospectus for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our
forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">You should read this prospectus and the documents that we reference in this prospectus and
have filed as exhibits to the registration statement, of which this prospectus is a part, completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking
statements by these cautionary statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc383050_6"></A>MARKET AND INDUSTRY DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We obtained the industry, statistical and market data in this prospectus from our own internal estimates and research as well
as from industry and general publications and research, surveys and studies conducted by third parties. All of the market data used in this prospectus involve a number of assumptions and limitations, and the sources of such data cannot guarantee the
accuracy or completeness of such information. While we believe that each of these studies and publications is reliable, the industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of important factors,
including those described in the section titled &#147;Risk Factors.&#148; These and other factors could cause results to differ materially from those expressed in the estimates made by third parties and by us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc383050_7"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We estimate that the net proceeds from our issuance and sale of 5,900,000 shares of our common stock in this offering will be
approximately $90.4 million (or approximately $104.4 million if the underwriters exercise in full their option to purchase up to 885,000 additional shares), assuming an initial public offering price of $17.00 per share, which is the midpoint of the
price range set forth on the cover page of this prospectus, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each $1.00 increase (decrease) in the assumed initial public offering price of $17.00 per share would increase (decrease) the
net proceeds to us from this offering by approximately $5.5 million, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts and
commissions and estimated offering expenses payable by us. Each increase (decrease) of 1.0&nbsp;million in the number of shares we are offering would increase (decrease) the net proceeds to us from this offering, after deducting the estimated
underwriting discounts and commissions and estimated offering expenses payable by us, by approximately $15.8 million, assuming the assumed initial public offering price stays the same. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We intend to use the net proceeds from this offering, together with our existing cash, cash equivalents and short-term
investments, as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $80.0 million to $90.0 million to fund the advancement of ACR-368, including CMC and companion
diagnostic development, in Phase 2 clinical trials across our three lead indications into potential registrational phase, pending the results and discussions with the FDA, as well as to potentially initiate Phase 2 trials in patients with HPV+
tumors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $15.0 million to $20.0 million to complete IND-enabling studies for at least one of our
preclinical programs; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the remainder for continued development of our AP3 platform, other research and development activities,
working capital and other general corporate purposes. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of June 30, 2022, we had cash and cash
equivalents of $83.9 million. Based on our current operational plans and assumptions, we expect our cash and cash equivalents, together with the net proceeds from this offering, will be sufficient to fund our operating expenses and capital
expenditure requirements at least into the fourth quarter of 2024. We believe that the net proceeds from this offering, together with our existing cash and cash equivalents as of June 30, 2022, will be insufficient to fund any of our drug candidates
through regulatory approval, and we anticipate needing to raise additional capital to complete the development of and commercialize our drug candidates. It is difficult to predict the cost and timing required to complete development and obtain
regulatory approval of, and commercialize, our drug candidates due to, among other factors, our limited experience with initiating, conducting and completing clinical trials, obtaining regulatory approval and commercializing our drug candidates, the
rate of subject enrollment in our clinical trials, filing requirements with various regulatory agencies, clinical trial results and the actual costs of manufacturing and supplying our drug candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our expected use of the net proceeds from this offering represents our intentions based upon our current plans and business
conditions. As of the date of this prospectus, we cannot predict with certainty all of the particular uses for the net proceeds to be received upon the completion of this offering or the amounts that we will actually spend on the uses set forth
above. We believe that opportunities may exist from time to time to expand our current business through licenses with or acquisitions of, or investments in, complementary businesses, products or technologies, and we may use a portion of the net
proceeds for these purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our management will have broad discretion over the use of the net proceeds from this
offering. The amounts and timing of our expenditures will depend upon numerous factors, including the results of our research and development efforts, the timing, cost and success of preclinical studies and clinical trials, the timing of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
regulatory submissions, our ability to obtain additional financing, the amount of cash obtained through our existing collaborations and future collaborations, if any, and any unforeseen cash
needs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pending any use described above, we intend to invest the net proceeds of this offering in short- and
intermediate-term interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc383050_8"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have never declared or paid, and do not anticipate declaring or paying, in the foreseeable future, any cash dividends on our
capital stock. We currently intend to retain all available funds and any future earnings to support our operations and finance the growth and development of our business. Any future determination related to our dividend policy will be made at the
discretion of our board of directors and will depend upon, among other factors, our results of operations, financial condition, capital requirements, contractual restrictions, business prospects and other factors our board of directors may deem
relevant. </P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc383050_9"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table sets forth our cash and cash equivalents, and our capitalization as of June&nbsp;30, 2022: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on an actual basis; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on a pro forma basis to give effect to: (1)&nbsp;the conversion of all outstanding shares of our preferred
stock into an aggregate of 11,140,262 shares of our common stock upon the closing of this offering; and (2)&nbsp;the filing and effectiveness of our amended and restated certificate of incorporation upon the closing of this offering; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on a pro forma as adjusted basis to give effect to: (1)&nbsp;the pro forma adjustments described above; and
(2)&nbsp;our issuance and sale of 5,900,000 shares of common stock in this offering at an assumed initial public offering price of $17.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after
deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The pro forma and pro forma as adjusted information below is illustrative only, and our capitalization following the closing
of this offering will depend on the actual initial public offering price and other terms of this offering determined at pricing. You should read this information in conjunction with our financial statements and the related notes appearing at the end
of this prospectus, the sections of this prospectus titled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and other financial information contained in this prospectus. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD ROWSPAN="3" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of June&nbsp;30, 2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma<BR>As&nbsp;Adjusted</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands, except share and per<BR>share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">83,861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">83,861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">174,251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock, $0.001 par value per share; 27,471,911 shares authorized; 27,471,911
shares issued and outstanding, actual; no shares authorized, issued or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">122,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; (deficit) equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock, $0.001 par value per share; no shares authorized, issued or outstanding, actual;
10,000,000 shares authorized and no shares issued or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.001 par value per share; 40,013,683 shares authorized, 1,769,561 shares issued
and outstanding, actual; 500,000,000 shares authorized, 12,909,823 shares issued and outstanding, pro forma; 500,000,000 authorized, 18,809,823 issued and outstanding, pro&nbsp;forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">123,834</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">214,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37,905</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37,905</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom" ALIGN="right">(37,905<BR></TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;<BR></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(36,576</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">176,321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">85,942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">85,942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">176,321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each $1.00 increase (decrease) in the assumed initial public offering price of $17.00
per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted amount of each of cash and cash equivalents, additional paid in capital, total stockholders&#146;
equity (deficit) and total capitalization by approximately $5.5&nbsp;million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts
and commissions and estimated offering expenses payable by us. Similarly, each increase </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
(decrease) of 1.0&nbsp;million shares in the number of shares offered by us at the assumed initial public offering price per share of $17.00 per share, which is the midpoint of the price range
set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted amount of each of cash and cash equivalents, additional paid in capital, total stockholders&#146; equity (deficit) and total capitalization by
approximately $15.8&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The number of shares of our common stock to be outstanding after this offering is based
on 12,909,823 shares of our common stock outstanding as of June&nbsp;30, 2022, after giving effect to the conversion of all outstanding shares of our preferred stock into an aggregate of 11,140,262 shares of common stock, and excludes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,072,851 shares of our common stock issuable upon the exercise of options outstanding as of June&nbsp;30,
2022 under the 2019 Plan, at a weighted-average exercise price of $2.85 per share (of which (i) options to purchase an aggregate of 25,039 shares of common stock were exercised subsequent to June 30, 2022 and (ii) options to purchase an aggregate of
65,392 shares of common stock were canceled subsequent to June 30, 2022), which does not include options to purchase an aggregate of 166,259&nbsp;shares of our common stock, at a weighted-average exercise price of $4.07 per share, that were granted
subsequent to June&nbsp;30, 2022; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,003,666 shares of our common stock available for future issuance as of June&nbsp;30, 2022 under the 2019
Plan, which shares will cease to be available for issuance under the 2019 Plan at the time the 2022 Plan becomes effective and will be added to, and become available for issuance under, the 2022 Plan; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an additional 2,555,571 shares of our common stock reserved for future issuance under the 2022 Plan, which
will become effective on the date of the underwriting agreement related to this offering (of which we will grant certain options to purchase shares of common stock at an exercise price equal to the initial public offering price and certain
restricted stock units, as described in &#147;Executive Compensation&#148;), as well as any automatic increases in the number of shares of common stock reserved for future issuance under the 2022 Plan and any additional shares of our common stock
that may become available under our 2022 Plan, as more fully described in &#147;Executive Compensation&#151;Equity Incentive Plans&#148;; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">215,000 shares of our common stock reserved for future issuance under the ESPP, which will become effective on
the date of the underwriting agreement related to this offering, as well as any automatic increases in the number of shares of common stock reserved for future issuance under the ESPP. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc383050_10"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If you invest in our common stock in this offering, your ownership interest will be immediately diluted to the extent of the
difference between the initial public offering price per share and the pro forma as adjusted net tangible book value per share of our common stock after this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of June&nbsp;30, 2022, we had a historical net tangible book deficit of $36.8&nbsp;million, or $20.80 per share of our
common stock. Our historical net tangible book deficit per share represents total tangible assets less total liabilities and the carrying values of our convertible preferred stock, which is not included within stockholders&#146; deficit divided by
the 1,769,561 shares of our common stock outstanding as of June&nbsp;30, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our pro forma net tangible book value as
of June&nbsp;30, 2022 was $85.7&nbsp;million, or $6.64 per share of our common stock. Pro forma net tangible book value represents the amount of our total tangible assets less our total liabilities, after giving effect to the conversion of all
outstanding shares of our preferred stock into an aggregate of 11,140,262 shares of our common stock, as if such conversion had occurred upon the closing of this offering. Pro forma net tangible book value per share represents pro forma net tangible
book value divided by the total number of shares outstanding as of June&nbsp;30, 2022, after giving effect to the pro forma adjustment described&nbsp;above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">After giving further effect to the sale of 5,900,000 shares of common stock in this offering at an assumed initial public
offering price of $17.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us, our
pro forma as adjusted net tangible book value as of June&nbsp;30, 2022 would have been $176.3&nbsp;million, or $9.37 per share. This amount represents an immediate increase in pro forma net tangible book value of $2.73 per share to our existing
stockholders and immediate dilution of $7.63 per share to new investors in this offering. We determine dilution by subtracting the pro forma as adjusted net tangible book value per share after this offering from the amount of cash that a new
investor paid for a share of common stock in this offering. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table illustrates this dilution on a per
share basis: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed initial public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical net tangible book deficit per share as of June&nbsp;30, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(20.80</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma increase in historical net tangible book value per share attributable to the pro forma
transactions described in the preceding paragraphs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net tangible book value per share as of June 30, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in pro forma net tangible book value per share attributable to this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma as adjusted net tangible book value per share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The dilution information discussed above is illustrative only and will change based
on the actual initial public offering price and other terms of this offering determined at pricing. Each $1.00 increase (decrease) in the assumed initial public offering price of $17.00 per share, which is the midpoint of the price range set forth
on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted net tangible book value per share after this offering by approximately $0.29, and dilution in pro forma net tangible book value per share to new investors by
approximately $0.71, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable
by us. An increase of 1.0&nbsp;million shares in the number of shares we are offering would increase the pro forma as adjusted net tangible book value per share after this offering by $0.33 and decrease the dilution per share to new investors
participating in this offering by $0.33, assuming no change in the assumed initial public offering price per share and after deducting the estimated </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
underwriting discounts and commissions. A decrease of 1.0&nbsp;million shares in the number of shares we are offering would decrease the pro forma as adjusted net tangible book value per share
after this offering by $0.36 and increase the dilution per share to new investors participating in this offering by $0.36, assuming no change in the assumed initial public offering price per share and after deducting the estimated underwriting
discounts and commissions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If the underwriters exercise their option to purchase additional shares of our common stock in
full, the pro forma as adjusted net tangible book value after this offering would be $9.66 per share, the increase in pro forma net tangible book value per share would be $3.02 and the dilution per share to new investors would be $7.34 per share, in
each case assuming an initial public offering price of $17.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes, as of June&nbsp;30, 2022, on the pro forma as adjusted basis described above, the differences
between the number of shares purchased from us, the total consideration paid to us in cash and the average price per share that existing stockholders and new investors paid for such shares. The calculation below is based on an assumed initial public
offering price of $17.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, before deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P>
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Consideration</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average&nbsp;Price<BR>per&nbsp;Share</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,909,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">120,252,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9.31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,900,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,809,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">220,552,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The number of shares of our common stock to be outstanding after this offering is
based on 12,909,823 of shares of our common stock outstanding as of June&nbsp;30, 2022, after giving effect to the conversion of all outstanding shares of our preferred stock into an aggregate of 11,140,262 shares of common stock, and excludes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,072,851&nbsp;shares of our common stock issuable upon the exercise of options outstanding as of
June&nbsp;30, 2022 under the 2019 Plan, at a weighted-average exercise price of $2.85 per share (of which (i) options to purchase an aggregate of 25,039 shares of common stock were exercised subsequent to June 30, 2022 and (ii) options to purchase
an aggregate of 65,392 shares of common stock were canceled subsequent to June 30, 2022), which does not include options to purchase an aggregate of 166,259&nbsp;shares of our common stock, at a weighted-average exercise price of $4.07 per share,
that were granted subsequent to June&nbsp;30, 2022; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,003,666&nbsp;shares of our common stock available for future issuance as of June&nbsp;30, 2022 under the
2019 Plan, which shares will cease to be available for issuance under the 2019 Plan at the time the 2022 Plan becomes effective and will be added to, and become available for issuance under, the 2022 Plan; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an additional 2,555,571 shares of our common stock reserved for future issuance under the 2022 Plan, which
will become effective on the date of the underwriting agreement related to this offering (of which we will grant certain options to purchase shares of common stock at an exercise price equal to the initial public offering price and certain
restricted stock units, as described in &#147;Executive Compensation&#148;), as well as any automatic increases in the number of shares of common stock reserved for future issuance under the 2022 Plan and any additional shares of our common stock
that may become available under our 2022 Plan, as more fully described in &#147;Executive Compensation&#151;Equity Incentive Plans&#148;; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">215,000 shares of our common stock reserved for future issuance under the ESPP, which will become effective on
the date of the underwriting agreement related to this offering, as well as any automatic increases in the number of shares of common stock reserved for future issuance under the ESPP. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To the extent that stock options are exercised, new equity awards are
issued under our equity incentive plans or we issue additional shares of common stock in the future, there will be further dilution to investors participating in this offering. In addition, we may choose to raise additional capital because of market
conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans. If we raise additional capital through the sale of equity or convertible debt securities, the issuance of these
securities could result in further dilution to our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc383050_11"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>You should read the following discussion and analysis of our financial
condition and results of operations together with our consolidated financial statements and related notes and other financial information included elsewhere in this prospectus. Some of the information contained in this discussion and analysis or set
forth elsewhere in this prospectus, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including
those factors set forth in the &#147;Special Note Regarding Forward-Looking Statements&#148; and &#147;Risk Factors&#148; sections of this prospectus, our actual results could differ materially from the results described in or implied by the
forward-looking statements contained in the following discussion and analysis. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are a clinical stage biopharmaceutical company developing precision oncology medicines that we match to patients whose
tumors are predicted to be sensitive to each specific medicine by utilizing our proprietary proteomics-based patient responder identification platform. Recently approved targeted oncology treatments, such as kinase inhibitors, have transformed the
cancer treatment landscape, and while the therapeutic benefit of these agents has provided significant benefit to patients, these targeted oncology treatments unfortunately only address the less than 10% of patients with cancers that harbor certain
easily-identifiable genetic mutations. Our approach is designed to overcome the limitations of genomics-based patient selection methods. We do this by using our proprietary precision medicine platform, AP3, to develop our pipeline of oncology drug
candidates. Our AP3 platform enables the creation of drug-specific proprietary OncoSignature companion diagnostics that are used to identify the patients most likely to benefit from our drug candidates, which we refer to as patient responders. We
are currently advancing our lead candidate, ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 with sub single-digit nM and single-digit nM potency, respectively, in a potentially registrational Phase 2 trial across multiple tumor
types, which our AP3 platform predicts will have a high proportion of patient responders based on OncoSignature-predicted sensitivity to ACR-368. Our ACR-368 OncoSignature test, which has not yet obtained regulatory approval, has been extensively
evaluated in preclinical studies, including in two separate, blinded, prospectively-designed studies on pretreatment tumor biopsies collected from patients with ovarian cancer treated with ACR-368 in past Phase 2 clinical trials conducted by Eli
Lilly and Company, or Lilly, and at the National Cancer Institute demonstrating robust enrichment of responders through our method. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Since our inception in 2018, we have devoted substantially all of our resources toward conducting discovery and research
activities, organizing and staffing our company, business planning, acquiring or discovering drug candidates, establishing and protecting our intellectual property portfolio, developing and progressing <FONT STYLE="white-space:nowrap">ACR-368</FONT>
and the <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature, preparing for and conducting preclinical studies and clinical trials, establishing arrangements with third parties for the manufacture of
<FONT STYLE="white-space:nowrap">ACR-368,</FONT> the <FONT STYLE="white-space:nowrap">ACR-368</FONT> Oncosignature and component materials, as well as raising capital. We do not have any drug candidates approved for sale and have not generated any
revenue from drug sales. Since inception, we have funded our operations primarily through equity and convertible debt financings and have received aggregate net proceeds of $119.8&nbsp;million from the issuance of convertible notes and the sale of
our Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock, or Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, and Series&nbsp;B convertible preferred stock, or Series B Preferred Stock, which we refer to
collectively as our Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have incurred operating losses since inception. Our net losses for the six months
ended June&nbsp;30, 2022 and 2021 were $13.0&nbsp;million and $9.5&nbsp;million, respectively. Our net losses for the years ended December&nbsp;31, 2021 and 2020 were $16.2&nbsp;million and $5.3&nbsp;million, respectively. As of June&nbsp;30, 2022,
we had an accumulated deficit of $37.9&nbsp;million. These losses have resulted primarily from costs incurred in connection with research and development activities and general and administrative costs associated with our operations. We expect to
continue to incur significant and increasing expenses and operating losses for the foreseeable future, particularly if and as we: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue to conduct preclinical studies and clinical trials for
<FONT STYLE="white-space:nowrap">ACR-368;</FONT> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">initiate and conduct additional preclinical studies and clinical trials for
<FONT STYLE="white-space:nowrap">ACR-368;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue to discover and develop additional drug candidates and the
<FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature tests; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acquire <FONT STYLE="white-space:nowrap">or&nbsp;in-license&nbsp;other</FONT> drug candidates and
technologies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain, expand, and protect our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">hire additional clinical and scientific personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">further develop and refine the manufacturing processes for <FONT STYLE="white-space:nowrap">ACR-368,</FONT>
the <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature or any future drug candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek regulatory approvals and pursue commercialization for any drug candidates that successfully complete
clinical trials; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">add operational, financial, and management information systems and personnel, including personnel to support
our drug development and planned future commercialization efforts, as well as to support our transition to a public reporting company. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Following the closing of this offering, we expect to incur additional costs associated with operating as a public company,
including significant legal, accounting, insurance, investor relations and other expenses that we did not incur as a private company. Furthermore, we will not generate revenue from drug sales until we successfully complete clinical development and
obtain regulatory approval for a drug candidate. In addition, if we obtain regulatory approval for a drug candidate and do not enter into a third-party commercialization partnership, we expect to incur significant expenses related to developing our
commercialization capability to support drug sales, marketing, manufacturing and distribution activities. Our net losses may fluctuate significantly from
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">quarter-to-quarter</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-year,</FONT></FONT> depending on the timing of our planned clinical
studies and our expenditures on other research and development activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As a result, we will need substantial
additional funding to support our continuing operations and pursue our growth strategy. Until such time that we can generate significant revenue from drug sales, if ever, we expect to finance our operations through the sale of equity, debt
financings or other capital sources, including potential collaborations with other companies or other strategic transactions. If we are unable to raise capital as needed, this could have a negative impact on our financial condition and ability to
pursue our business strategies including requiring us to delay, reduce or eliminate drug development or future commercialization efforts. The amount and timing of our future funding requirements will depend on many factors including the successful
advancement of <FONT STYLE="white-space:nowrap">ACR-368,</FONT> the <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature, or any future drug candidates. Our ability to raise additional funds may also be adversely impacted by potential
worsening global economic conditions, and disruptions to, and volatility in the credit and financial markets in the United States and worldwide, such as those resulting from the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and
the hostilities in Ukraine. There can be no assurances that the current operating plan will be achieved or that additional funding will be available on terms acceptable to us, or at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of June&nbsp;30, 2022, we had cash and cash equivalents of $83.9&nbsp;million. We believe that the anticipated net proceeds
from this offering, together with our existing cash and cash equivalents as of June&nbsp;30, 2022, will enable us to fund our operating expenses and capital expenditure requirements at least into the fourth quarter of 2024. We have based this
estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. See the section titled &#147;&#151;Liquidity and Capital Resources.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>License Agreement with Eli Lilly and Company </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In January 2021, we entered into a license agreement and stock issuance agreement, or, collectively, the Lilly Agreement, with
Lilly, pursuant to which we have been granted an exclusive, royalty-bearing sublicensable license to certain intellectual property rights owned or controlled by Lilly, to commercially develop, manufacture, use, distribute and sell therapeutic
products containing the compound prexasertib. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the terms of the agreement, we paid Lilly an initial upfront fee
payment of $5.0&nbsp;million. In connection with entering into the agreement, we also entered into a common stock issuance agreement with Lilly pursuant to which we issued Lilly 336,575 shares of our common stock and 46,058 shares of Series B
Preferred Stock, which will convert into 18,677 shares of common stock immediately upon the closing of this offering. As additional consideration for the license, we are required to pay Lilly aggregate&nbsp;development and commercial&nbsp;milestone
payments of up to $168.0&nbsp;million, of which $5.0&nbsp;million is due prior to NDA.&nbsp;No development or commercial milestones have been achieved to date under the Lilly Agreement. We are also obligated to pay a tiered percentage royalty on
annual net sales ranging from a low single-digit up to&nbsp;a maximum of 10%,&nbsp;subject to certain specified reductions. Royalties are payable by&nbsp;us on a licensed
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-licensed</FONT></FONT> product and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis until the later of the
expiration of the last valid claim covering the licensed product in such country, expiration of all applicable regulatory exclusivities in such country for such licensed product and the tenth anniversary of the first commercial sale of such licensed
product in such country, provided, that our obligation to pay royalties for a given licensed product in a given country will expire earlier upon achievement of certain sales thresholds by generic products in such country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For a more detailed description of this agreement, see the section titled &#147;Business&#151;Licensing and
Collaborations&#148; and Note 7 to our consolidated financial statements included elsewhere in this prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Companion Diagnostic Agreement
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In June 2022, we entered into a companion diagnostic agreement with Akoya Biosciences, Inc., or Akoya, pursuant to
which we agreed to <FONT STYLE="white-space:nowrap">co-develop,</FONT> validate, and commercialize our proprietary <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature test, the companion diagnostic that will be used to identify patients
with cancer most likely to respond to <FONT STYLE="white-space:nowrap">ACR-368.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to the agreement, we paid
Akoya a <FONT STYLE="white-space:nowrap">one-time,</FONT> <FONT STYLE="white-space:nowrap">non-refundable,</FONT> <FONT STYLE="white-space:nowrap">non-creditable</FONT> upfront payment in the amount of $0.6&nbsp;million. We are obligated to pay
Akoya up to an aggregate of $10.3 million upon the achievement of specified development milestones. As of October&nbsp;17, 2022, development milestones have been achieved under the agreement, resulting in payments of $2.3&nbsp;million by us to
Akoya. Other than certain specified pass-through costs, each party is responsible for its own costs associated with the development of the companion diagnostic.&nbsp;Akoya will procure and manufacture necessary supplies to perform the <FONT
STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature test to support our clinical development and commercial requirements, in accordance with a supply agreement to be mutually agreed upon by the parties. We may terminate the agreement at our
convenience, subject to the payment of a termination fee in the amount of $1.0 million.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For a more detailed description of
this agreement, see the sections titled &#147;Business&#151;Licensing and Collaborations&#148; and &#147;&#151;Contractual Obligations.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Impact <FONT
STYLE="white-space:nowrap">of&nbsp;COVID-19&nbsp;on</FONT> Our Business </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The extent of the impact of the novel
coronavirus, or <FONT STYLE="white-space:nowrap">COVID-19,</FONT> pandemic on our business, operations and development timelines and plans remains uncertain, and will depend on certain developments, including the duration and spread of the outbreak
and its impact on our CMOs, CROs, and other third parties with whom we do business, as well as its impact on regulatory authorities and our key scientific and management personnel. While we continue to conduct our research and development
activities, the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic may cause disruptions that impact the timing of our preclinical studies and clinical trials of <FONT STYLE="white-space:nowrap">ACR-368</FONT> and affect our ability to
complete preclinical studies, future clinical trials or to procure items that are essential for our research and development activities. We expect to continue to take actions as may be required or recommended by government authorities or as we
determine are in the best interests of our employees and other business partners in light of the pandemic. To date, there has not been a significant impact on the development of <FONT STYLE="white-space:nowrap">ACR-368</FONT> and the <FONT
STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature or the rest of our pipeline; however, we cannot at this time predict the specific extent, duration, or full impact that the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic could
potentially have on our ongoing business plan, financial condition and operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Components of Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To date,
we have not generated any revenue, and we do not expect to generate any revenue in the foreseeable future from drug sales. We may in the future generate revenue from payments received under collaboration agreements, which includes payments of
upfront fees, license fees, milestone-based payments and reimbursements for research and development efforts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and Development </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The majority of our expenses has been research and development expenses, which consist primarily of costs incurred in
connection with our research and development activities, including our drug discovery efforts and the development of <FONT STYLE="white-space:nowrap">ACR-368</FONT> and the <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature. We expense
research and development costs as incurred, which include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">direct cost for conducting internal research and development to generate preclinical validation data for <FONT
STYLE="white-space:nowrap">ACR-368</FONT> including the <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature, and for our internal preclinical drug discovery programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost to obtain and maintain licenses to intellectual property, such as those with Lilly and related future
payments should certain milestones be achieved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">external research and development expenses incurred under agreements with CROs, as well as investigative sites
and consultants that conduct our clinical trials and other scientific development services; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs related to manufacturing material for our clinical trials, including fees paid to CMOs;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">manufacturing&nbsp;scale-up&nbsp;expenses</FONT> and the cost of acquiring
and manufacturing clinical trial materials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">employee-related expenses, including salaries, bonuses, benefits, stock-based compensation and other related
costs for those employees involved in research and development efforts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs of outside consultants, including their fees, stock-based compensation and related travel expenses;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses to acquire technologies, such as intellectual property, to be used in research and development;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upfront and maintenance fees incurred under license, acquisition and other third-party agreements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs related to regulatory activities, including filing fees paid to regulatory agencies and compliance with
regulatory requirements; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">facilities, depreciation, and other expenses, which include direct and allocated expenses for rent,
maintenance of facilities and equipment and software. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Costs for certain activities are recognized based
on an evaluation of the progress to completion of specific tasks using data such as information provided to us by our vendors and analyzing the progress of our discovery studies or other services performed. Significant judgment and estimates are
made in determining the accrued expense balances at the end of any reporting period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We characterize research and
development costs incurred prior to the identification of a drug candidate as discovery costs. Once a drug candidate has been identified, research and development costs incurred are allocated as drug candidate costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our direct, internal research and development costs consist primarily of costs for reagents and material supplies for our <FONT
STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature test and for cellular and human tissue samples and reagents necessary for our preclinical drug discovery programs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our external research and development expenses consist primarily of fees
paid to outside consultants, CROs, CMOs and research laboratories in connection with our process development, manufacturing, and clinical development activities. Our direct external research and development expenses also include fees incurred under
license and intellectual property purchase agreements. We track these external research and development costs on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">a&nbsp;program-by-program&nbsp;basis</FONT></FONT> once we have
identified a drug candidate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A significant portion of our research and development costs to date have been third-party
costs, which we track on an individual drug candidate basis after a clinical drug candidate has been identified. Currently, our sole clinical drug candidate is <FONT STYLE="white-space:nowrap">ACR-368.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our indirect research and development costs are primarily personnel-related costs, facilities, which is offset by a portion of
our allocable sublease rent income, and other costs. Employees and infrastructure are not directly tied to any one program and are deployed across our programs. As such, we do not track these costs on a specific program basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We do not allocate employee costs associated with our discovery efforts, or facility costs, including depreciation or other
indirect costs, to specific programs because these costs are deployed across multiple programs and, as such, are not separately classified. We use internal resources and third-party consultants primarily to conduct our research and discovery
activities as well as for managing our process development, manufacturing and clinical development activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
successful development of our <FONT STYLE="white-space:nowrap">ACR-368</FONT> and <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature test or any other future drug candidates is highly uncertain. We plan to substantially increase our
research and development expenses for the foreseeable future as we continue the development of <FONT STYLE="white-space:nowrap">ACR-368</FONT> and manufacturing processes and conduct discovery and research activities for our clinical programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We cannot determine with certainty the timing of initiation, the duration, or the completion costs of current or future
clinical trials of our drug candidates due to the inherently unpredictable nature of preclinical and clinical development. Clinical development timelines, the probability of success and development costs can differ materially from expectations. We
anticipate that we will make determinations as to which drug candidates to pursue and how much funding to direct to each drug candidate on an ongoing basis in response to the results of ongoing and future clinical trials, regulatory developments and
our ongoing assessments as to each drug candidate&#146;s commercial potential. We will need to raise substantial additional capital in the future. Our clinical development costs are expected to increase significantly with our ongoing clinical
trials. We anticipate that our expenses will increase substantially, particularly due to the numerous risks and uncertainties associated with developing drug candidates, including the uncertainty of: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, rate of progress and expenses of our ongoing research activities and clinical trials and other
research and development activities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">confirming the appropriate safety profile established in past clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successful enrollment in and completion of clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether our drug candidates show efficacy with an increased objective response rate through patient responder
identification in our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">receipt of marketing approvals from applicable regulatory authorities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our drug
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which we establish additional collaboration or license agreements; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">commercializing drug candidates, if and when approved, whether alone or in collaboration with others; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continued acceptable safety profile of the products following any regulatory approval. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any changes in the outcome of any of these variables with respect to the development of our drug candidates in clinical
development could mean a significant change in the costs and timing associated with the development of these drug candidates. We may never succeed in achieving regulatory approval for any of our drug candidates. We may obtain unexpected results from
our clinical trials. We may elect to discontinue, delay or modify clinical trials of some drug candidates or focus on others. For example, if the U.S. Food and Drug Administration, European Medicines Agency or another regulatory authority were to
delay our planned start of clinical trials or require us to conduct clinical trials or other testing beyond those that we currently expect or if we experience significant delays in enrollment in any of our planned clinical trials, we could be
required to expend significant additional financial resources and time on the completion of clinical development of that drug candidate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General and
Administrative </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">General and administrative expenses consist primarily of employee-related costs, including salaries,
bonuses, benefits, and stock-based compensation expenses for personnel in executive, finance, accounting, human resources and other administrative functions. Other significant general and administrative expenses include legal fees relating to
patent, intellectual property and corporate matters, fees paid for accounting, audit, consulting and other professional services, and expenses for rent, insurance and other operating costs. An allocated portion of sublease rent income is recorded as
an offset to general and administrative expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We anticipate that our general and administrative expenses will increase
in the future as we increase our headcount to support our continued research activities and development of our drug candidates. We also anticipate that we will incur significantly increased accounting, audit, legal, regulatory, compliance and
director and officer insurance costs as well as investor and public relations expenses associated with operating as a public company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Total Other
Income (Expense), Net </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Income </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Other income primarily consists of interest income, which is earned on cash equivalents that generate interest on a monthly
basis. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Change in Fair Value of Convertible Notes </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The convertible notes, or the Notes, were related to our obligation to issue shares of Preferred Stock to investors, which were
converted into Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock in October 2020. We elected the fair value option to account for the Notes. The Notes were classified as a liability on our consolidated balance sheets and initially
recorded at fair value. The Notes were subsequently revalued with changes in fair value for each reporting period recognized in other income (expense), net until converted. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Change in Fair Value of Preferred Stock Tranche Rights </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The preferred stock tranche rights, or Preferred Stock Tranche Rights, were related to our obligation to issue shares of Series
<FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock in subsequent second and third closings upon the occurrence of one of four milestones. This obligation was fully satisfied in January 2021 when the third and final tranche of the Series <FONT
STYLE="white-space:nowrap">A-1</FONT> Preferred Stock was closed. The Preferred Stock Tranche Rights were classified as a liability on our consolidated balance sheets and initially recorded at fair value. The Preferred Stock Tranche Rights were
subsequently </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
revalued until the tranches were settled, with changes in fair value for each reporting period recognized in other income (expense), net. Upon the issuance of the Preferred Stock Tranche Right
shares, the fair value of the related Preferred Stock Tranche Rights was reclassified to Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Change in Fair Value of Anti-dilution Right </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The anti-dilution right, or Anti-dilution Right, related to our obligation to issue capital stock to Lilly for no consideration
upon a future financing. We determined that the Anti-dilution Right was a freestanding financial instrument, and it was classified as a liability on our consolidated balance sheets and initially recorded at fair value. We determined that the Lilly
Agreement represented an asset acquisition of in process research and development, or IPR&amp;D, assets with no alternative future use and recognized the aggregate acquisition cost as acquired IPR&amp;D expense in the consolidated statements of
operations and comprehensive loss. The Anti-dilution Right was subsequently revalued until anti-dilution shares were issued and the Anti-dilution Right was settled, with changes in fair value for each reporting period recognized in other income
(expense), net. Upon issuance of the anti-dilution shares in November 2021, the fair value of the Anti-dilution Right was reclassified to Series B Preferred Stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Since our inception, we have not recorded any income tax benefits for the net losses we have incurred or for the research and
development tax credits earned in each year and interim period, as we believe, based upon the weight of available evidence, that it is more likely than not that all of our net operating loss carryforwards and tax credit carryforwards will not be
realized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December&nbsp;31, 2021, we had $13.9&nbsp;million and $12.3&nbsp;million of federal and state operating
loss carryforwards, respectively. The federal NOLs are not subject to expiration and the state NOLs begin to expire in 2038. These loss carryforwards are available to reduce future federal taxable income, if any. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the Six Months
Ended June&nbsp;30, 2022 and 2021 </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes our results of operations (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2022&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,448</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,137</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,243</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,894</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of preferred stock tranche rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of anti-dilution right</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(208</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(217</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,040</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,460</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,580</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes our research and development expenses (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2022&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Direct research and development expenses by program:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">ACR-368</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,657</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unallocated research and development expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel related (including stock-based compensation)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">871</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other drug discovery programs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facilities, supplies and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">565</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">559</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,448</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Research and development expenses were $10.1&nbsp;million for the six months ended
June&nbsp;30, 2022, compared to $8.4&nbsp;million for the six months ended June&nbsp;30, 2021. The increase of $1.7&nbsp;million was primarily due to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $1.7&nbsp;million decrease in costs related to the development
<FONT STYLE="white-space:nowrap">of&nbsp;ACR-368,</FONT> primarily due to a $5.5&nbsp;million decrease from the upfront fees associated with the Lilly Agreement in the prior year, offset by increased costs of $3.8&nbsp;million related to the
development of ACR-368, which included $2.0&nbsp;million from increased activity in the outsourcing of manufacturing and the development of clinical trials, and an increase of $1.8&nbsp;million in costs related to the onboarding of CROs in clinical
trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $2.1&nbsp;million increase in personnel-related costs, including $0.5&nbsp;million of recruiting expense and
$0.1&nbsp;million of stock-based compensation expense, primarily due to an increase in headcount in support of research activities; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $1.3&nbsp;million increase in costs related to discovery activities as a result of increased efforts toward
identifying drug candidates. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General and Administrative Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes our general and administrative expenses for each of the periods presented (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2022&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel related (including stock-based compensation)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,724</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal and professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">765</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facilities, supplies and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total general and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">General and administrative expenses were $3.0&nbsp;million for the six months ended
June&nbsp;30, 2022, compared to $0.8&nbsp;million for the six months ended June&nbsp;30, 2021. The increase of $2.2&nbsp;million was primarily due to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $1.4&nbsp;million increase in payroll and personnel-related costs, primarily due to an increase in
headcount, including the hiring of our chief financial officer; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $0.8&nbsp;million increase in legal, accounting and professional fees, primarily due to preparation for our
initial public offering, or IPO. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Total Other Income (Expense), Net </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Total other income, net was $0.1&nbsp;million for the six months ended June&nbsp;30, 2022, compared to total other expense, net
of $0.2&nbsp;million for the six months ended June&nbsp;30, 2021. The change of $0.3&nbsp;million is primarily </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
attributable to a $0.2&nbsp;million loss attributable to the change in the fair value of the Anti-dilution Right upon remeasurement as of June&nbsp;30, 2021 prior to settlement in November 2021,
a $0.1&nbsp;million loss attributable to the change in the fair value of the Preferred Stock Tranche Rights upon remeasurement immediately prior to settlement in January 2021, and an increase of $0.1&nbsp;million in other income, net primarily
related to an increase in interest income on our cash equivalents. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the Years Ended December&nbsp;31, 2021 and 2020 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes our results of operations (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Year&nbsp;Ended&nbsp;December&nbsp;31,&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,466</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,184</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,168</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,016</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,099</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of preferred stock tranche rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(71</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of anti-dilution right</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(59</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,138</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,243</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,306</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,937</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes our research and development expenses (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Year&nbsp;Ended&nbsp;December&nbsp;31,&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Direct research and development expenses by program:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">ACR-368</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unallocated research and development expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other drug discovery programs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,876</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">577</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel related (including stock-based compensation)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,965</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facilities, supplies and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">981</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">729</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Research and development expenses were $13.7&nbsp;million for the year ended December&nbsp;31,
2021, compared to $1.9&nbsp;million for the year ended December&nbsp;31, 2020. The increase of $11.8&nbsp;million was primarily due to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $7.3&nbsp;million increase in costs related to the development
<FONT STYLE="white-space:nowrap">of&nbsp;ACR-368,</FONT> primarily due to costs associated with the Lilly Agreement, including the upfront payment to Lilly of $5.0&nbsp;million, the initial fair value of the Anti-dilution Right of $0.2&nbsp;million,
and the issuance of common stock to Lilly of $0.3&nbsp;million, an increase of $1.1&nbsp;million due to the increased activity in outsourcing of manufacturing and the development of clinical trials, and an increase of $0.7&nbsp;million due to
increased costs related to the onboarding of CROs in clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $2.3&nbsp;million increase in costs related to discovery activities as a result of increased efforts toward
identifying drug candidates; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $1.5&nbsp;million increase in personnel-related costs, including $0.4&nbsp;million of stock-based
compensation expense, primarily due to an increase in headcount in support of research activities; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $0.7&nbsp;million increase in facilities, supplies and other expenses, primarily due to a $1.0&nbsp;million
increase in facilities, rent, travel and equipment driven by an increase in headcount in support of research activities, offset by a $0.3&nbsp;million increase in allocated sublease rent income, which is recorded as an offset to research and
development expenses. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General and Administrative Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes our general and administrative expenses for each of the periods presented (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Year&nbsp;Ended&nbsp;December&nbsp;31,&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel related (including stock-based compensation)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal and professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facilities, supplies and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total general and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,466</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">General and administrative expenses were $2.5&nbsp;million for the year ended
December&nbsp;31, 2021, compared to $1.3&nbsp;million for the year ended December&nbsp;31, 2020. The increase of $1.2&nbsp;million was primarily due to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $0.7&nbsp;million increase in payroll and personnel-related costs, including $0.1&nbsp;million of
stock-based compensation, primarily due to an increase in headcount; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $0.2&nbsp;million increase in legal, accounting and professional fees; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $0.3&nbsp;million increase in facilities, supplies, and other expenses, primarily due to a $0.4&nbsp;million
increase in facilities, rent, travel and equipment driven by an increase in headcount, offset by a $0.1&nbsp;million increase in allocated sublease rent income, which is recorded as an offset to general and administrative expenses.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Total Other Expense, Net </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Total other expense, net was $0.1&nbsp;million for the year ended December&nbsp;31, 2021, compared to total other expense, net
of $2.1&nbsp;million for the year ended December&nbsp;31, 2020. The decrease of $2.0&nbsp;million is primarily attributable to a $2.1&nbsp;million loss attributable to the change in the fair value of the Notes upon remeasurement in October 2020,
prior to conversion. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sources of Liquidity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Since our inception, we have not recognized any revenue and have incurred significant losses in each period and on an aggregate
basis. We have not yet commercialized any drug candidates, and we do not expect to generate revenue from sales of any drug candidates or from other sources for several years, if at all. As of June&nbsp;30, 2022, we had $83.9&nbsp;million in cash and
cash equivalents, and we had an accumulated deficit of $37.9&nbsp;million. We have funded our operations primarily with net proceeds of $119.8&nbsp;million from the issuance of convertible notes and sales of our Preferred Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash Flows </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes our cash flows for each of the periods presented (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Year&nbsp;Ended&nbsp;December&nbsp;31,&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2022&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14,242</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,041</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,982</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,803</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,489</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(101</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(238</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash (used in) provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112,221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (decrease) increase in cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(15,742</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">98,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Net Cash Used in Operating Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net cash used in operating activities was $14.2&nbsp;million for the six months ended June&nbsp;30, 2022, reflecting a net loss
of $13.0&nbsp;million and a net change of $2.0&nbsp;million in our net operating assets and liabilities, partially offset by <FONT STYLE="white-space:nowrap">non-cash</FONT> charges of $0.8&nbsp;million.
<FONT STYLE="white-space:nowrap">Non-cash&nbsp;charges</FONT> primarily consisted of <FONT STYLE="white-space:nowrap">non-cash</FONT> lease expense of $0.4&nbsp;million, stock-based compensation expense of $0.3&nbsp;million, and depreciation of
$0.1&nbsp;million. The change in our net operating assets and liabilities was primarily due to a $2.5&nbsp;million increase in prepaid expenses and other current assets and a $0.3&nbsp;million decrease in operating lease liabilities, partially
offset by a $0.4&nbsp;million increase in accounts payable and a $0.4&nbsp;million increase in accrued expenses and other liabilities. The increase in prepaid expenses and other current assets was primarily due to the timing of payments to vendors,
the decrease in operating lease liabilities was due to lease payments on our leases, the increase in accounts payable and accrued expenses and other liabilities was primarily due to an increase in research and development costs and an increase in
headcount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net cash used in operating activities was $8.0&nbsp;million for the six months ended June&nbsp;30, 2021,
reflecting a net loss of $9.5&nbsp;million, partially offset by <FONT STYLE="white-space:nowrap">non-cash</FONT> charges of $1.3&nbsp;million and a net change of $0.1&nbsp;million in our net operating assets and liabilities. <FONT
STYLE="white-space:nowrap">Non-cash&nbsp;charges</FONT> primarily consisted of <FONT STYLE="white-space:nowrap">non-cash</FONT> lease expense of $0.3&nbsp;million, the cost of the Lilly Agreement paid for in common stock of $0.3&nbsp;million,
stock-based compensation expense of $0.2&nbsp;million, the cost of the Anti-dilution Right assumed with the Lilly Agreement of $0.2&nbsp;million, and the change in the fair value of the Anti-dilution right of $0.2&nbsp;million. The change in our net
operating assets and liabilities was primarily due to a $0.2&nbsp;million increase in accrued expenses and other liabilities and a $0.1&nbsp;million increase in accounts payable, partially offset by a $0.2&nbsp;million decrease in operating lease
liabilities. The increase in accounts payable and accrued expenses and other liabilities was primarily due to an increase in research and development costs and an increase in headcount, and the decrease in operating lease liabilities was due to
lease payments on our leases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net cash used in operating activities was $14.0&nbsp;million for the year ended
December&nbsp;31, 2021, reflecting a net loss of $16.2&nbsp;million, partially offset by <FONT STYLE="white-space:nowrap">non-cash</FONT> charges of $1.9&nbsp;million and a net change of $0.3&nbsp;million in our net operating assets and liabilities.
<FONT STYLE="white-space:nowrap">Non-cash&nbsp;charges</FONT> primarily consisted of <FONT STYLE="white-space:nowrap">non-cash</FONT> lease expense of $0.8&nbsp;million, stock-based compensation expense of $0.5&nbsp;million, the cost of the Lilly
Agreement paid for in common stock of $0.3&nbsp;million, and the cost of the Anti-dilution Right assumed with the license agreement of $0.2&nbsp;million. The change in our net operating assets and liabilities was primarily due to a $0.9&nbsp;million
increase in accrued expenses and other liabilities and a $0.8&nbsp;million increase in accounts payable, partially offset by a $0.8&nbsp;million increase in prepaid expenses and other current assets and a $0.6&nbsp;million decrease in operating
lease liabilities. The increase in accounts payable was primarily due to an increase in research and development costs, the increase in accrued expenses and other liabilities was primarily due to an increase in research and development costs and an
increase in headcount, the increase in prepaid expenses and other current assets was primarily due to the timing of payments to vendors, and the decrease in operating lease liabilities was due to lease payments on our leases. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net cash used in operating activities was $2.8&nbsp;million for the year
ended December&nbsp;31, 2020, reflecting a net loss of $5.3&nbsp;million, partially offset by <FONT STYLE="white-space:nowrap">non-cash</FONT> charges of $2.2&nbsp;million and a net change of $0.3&nbsp;million in our net operating assets and
liabilities. <FONT STYLE="white-space:nowrap">Non-cash&nbsp;charges</FONT> primarily consist of a change in fair value of the Notes of $2.1&nbsp;million and the change in the fair value of Preferred Stock Tranche Rights of $0.1&nbsp;million. The
change in our net operating assets and liabilities was primarily due to a $0.4&nbsp;million increase in accrued expenses and other liabilities and a $0.1&nbsp;million increase in accounts payable, partially offset by a $0.1&nbsp;million increase in
prepaid expenses and other current assets. The increase in accrued expenses and other liabilities was primarily due to an increase in research and development costs and an increase in headcount. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Net Cash Used in Investing Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net cash used in investing activities was $1.5&nbsp;million and $0.1&nbsp;million for the six months ended June&nbsp;30, 2022
and 2021, respectively, and resulted from our purchases of property and equipment, consisting largely of laboratory equipment purchases to support our expanded headcount and continued research and development activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net cash used in investing activities was $0.2&nbsp;million and $15,000 for the year ended December&nbsp;31, 2021 and 2020,
respectively, and resulted from our purchases of property and equipment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Net Cash (Used in) Provided by Financing Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net cash used in financing activities was $11,000 for the six months ended June 30, 2022, resulting from the payment of
deferred offering costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net cash provided by financing activities was $12.5&nbsp;million for the six months ended
June&nbsp;30, 2021, resulting from proceeds received from the issuance and sale of shares of our Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, net of issuance costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net cash provided by financing activities was $112.2&nbsp;million for the year ended December&nbsp;31, 2021, resulting from
proceeds received from the issuance and sale of shares of our Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, net of issuance costs, of $12.5&nbsp;million and from the issuance and sale of our Series B Preferred Stock, net of
issuance costs, of $99.8&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net cash provided by financing activities was $2.9&nbsp;million for the year ended
December&nbsp;31, 2020, resulting from proceeds received from the issuance and sale of shares of our Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, net of issuance costs of $2.8&nbsp;million and proceeds from the issuance of our
payment protection program loan of $0.1&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Funding Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of June&nbsp;30, 2022, our cash and cash equivalents were $83.9&nbsp;million. We believe that the net proceeds from this
offering, together with our existing cash and cash equivalents as of June&nbsp;30, 2022, will enable us to fund our operating expenses and capital expenditure requirements at least into the fourth quarter of 2024. We have based this estimate on
assumptions that may prove to be wrong, and we could expend our capital resources sooner than we expect. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We expect
to incur significant expenses and operating losses for the foreseeable future as we advance our drug candidates through clinical development, seek regulatory approval and pursue commercialization of any approved drug candidates. We expect that our
research and development and general and administrative costs will increase in connection with our planned research and clinical activities. In addition, upon the completion of this offering, we expect to incur additional costs associated with
operating as a public company, including significant legal, accounting, investor relations and other expenses that we did not incur as a private company. If we receive regulatory approval for any of our drug candidates, we expect to incur
significant commercialization expenses </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
related to drug manufacturing, sales, marketing and distribution, depending on where we choose to commercialize. We may also require additional capital to
<FONT STYLE="white-space:nowrap">pursue&nbsp;in-licenses&nbsp;or</FONT> acquisitions of other drug candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Because of
the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical drug candidates, we are unable to accurately predict the amount of our operating expenditures. Our future capital requirements will
depend on many factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, timing, progress, results and costs of preclinical and clinical development activities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs, timing and outcome of regulatory review of drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of future activities, including drug sales, medical affairs, marketing, manufacturing and
distribution, for any drug for which we receive marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of establishing and maintaining arrangements with third party manufacturers for the commercial
supply of products that receive marketing approval, if any; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the revenue, if any, received from commercial sale of our products, should any drug candidates receive
marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cash requirements of any future acquisitions or discovery of drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost and timing of attracting, hiring and retaining skilled personnel to support our operations and
continued growth; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of implementing operational, financial and management systems; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual
property rights and defending intellectual property-related claims; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish and maintain collaborations, strategic partnerships or marketing, distribution,
licensing or other strategic arrangements with third parties on favorable terms, if at all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing, receipt and amount of sales of, or milestone payments related to or royalties on, current or
future drug candidates, if any; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs associated with operating as a public company. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A change in the outcome of any of these or other variables with respect to the development of
<FONT STYLE="white-space:nowrap">ACR-368,</FONT> the <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature, or any drug or development candidate we may develop in the future could significantly change the costs and timing associated with our
development plans. Further, our operating plans may change in the future, and we may need additional funds to meet operational needs and capital requirements associated with such operating plans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Until such time, if ever, as we can generate substantial drug revenues to support our expenses, we expect to finance our cash
needs through a combination of equity offerings, debt financings, collaborations and other similar arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our
stockholders will be or could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and equity financing, if available, may involve
agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through collaborations, or other similar
arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or drug candidates or grant licenses on terms that may not be favorable to us and/or may reduce the value of
our common stock. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our drug development or future commercialization efforts or grant rights to develop
and market our drug candidates even if we would otherwise prefer to develop and market such drug candidates ourselves. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Contractual Obligations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Leases </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We lease
laboratory and office space in Watertown, Massachusetts. This lease is classified as an operating lease, and will expire in April 2028, with an option to extend the term for an additional five years at then-market rental rates. Additionally, we also
lease laboratory and office space in Lund, Sweden. This lease is classified as an operating lease, and will expire in September 2023, with an option to extend the term for an additional three years. Future minimum commitments under these leases are
$7.2&nbsp;million as of December&nbsp;31, 2021. Of the $7.2&nbsp;million, $1.1&nbsp;million is due in less than 12 months. See Note 6 in our unaudited condensed consolidated financial statements appearing at the end of this prospectus for more
information on our lease obligations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>License Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may incur contingent royalty and milestone payments that we are required to make under our license agreement with Lilly,
pursuant to which we have <FONT STYLE="white-space:nowrap">in-licensed</FONT> certain intellectual property. We are required to pay Lilly aggregate&nbsp;development and commercial&nbsp;milestone payments of up to $168.0&nbsp;million, of which
$5.0&nbsp;million is due prior to NDA. Due to the uncertainty of the achievement and timing of the events requiring payment under our license agreement with Lilly, the amounts to be paid by us are not fixed or determinable at this time. We are also
obligated to pay a tiered percentage royalty on annual net sales ranging from a low single-digit up to&nbsp;a maximum of 10%,&nbsp;subject to certain specified reductions. For additional information, see the section titled
&#147;Business&#151;Licensing and Collaborations.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Companion Diagnostic Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may incur contingent milestone payments that we are required to make under our companion diagnostic agreement with Akoya
pursuant to which we agreed to <FONT STYLE="white-space:nowrap">co-develop,</FONT> validate, and commercialize our proprietary ACR-368 OncoSignature test. We are obligated to pay Akoya up to an aggregate of $10.3 million upon the achievement of
specified development milestones. Due to the uncertainty of the achievement and timing of the events requiring payment under our companion diagnostic agreement with Akoya, the amounts to be paid by us and when are not determinable at this time.
While the achievement and timing of such milestones are uncertain, it is reasonably possible that up to $2.0&nbsp;million in milestone payments could be achieved in the next 12 months. As of October&nbsp;17, 2022, development milestones have been
achieved under our companion diagnostic agreement, resulting in payments of $2.3&nbsp;million by us to Akoya. For additional information, see the section titled &#147;Business&#151;Licensing and Collaborations.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Purchase and Other Obligations </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We enter into contracts in the normal course of business with CROs and other third-party vendors for clinical trials and
testing and manufacturing services. These contracts do not contain minimum purchase commitments and are cancellable by us upon written notice. Payments due upon cancellation consist of payments for services provided or expenses incurred, <FONT
STYLE="white-space:nowrap">including&nbsp;non-cancelable&nbsp;obligations</FONT> of our service provided up to one year after the date of cancellation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies and Significant Judgments and Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our consolidated financial statements are prepared in accordance with&nbsp;accounting principles generally accepted in the
United States, or U.S. GAAP. The preparation of our consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">liabilities, costs and expenses, and the disclosure of contingent assets and liabilities in our consolidated financial statements. We base our
estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and
liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">While our significant accounting policies are described in more detail in
Note&nbsp;2 to our audited consolidated financial statements appearing elsewhere in this prospectus, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our consolidated
financial statements.</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued research and
development expenses as of each balance sheet date. This process involves reviewing open contracts and purchase orders, communicating with our personnel and with vendors to identify services that have been performed on our behalf and estimating the
level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. The majority of our service providers invoice us monthly in arrears for services performed or
when contractual milestones are met. We make estimates of our accrued expenses as of each balance sheet date based on facts and circumstances known to us at that time. We periodically confirm the accuracy of our estimates with the service providers
and make adjustments if necessary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We base our expenses related to research and development activities on our estimates
of the services received and efforts expended pursuant to quotes and contracts with vendors that conduct research and development on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and
may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the research and development expense. In accruing service fees, we estimate the
time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or prepaid balance <FONT
STYLE="white-space:nowrap">accordingly.&nbsp;Non-refundable&nbsp;advance</FONT> payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have
been received rather than when the payment is made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Although we do not expect our estimates to be materially different
from amounts incurred, if our estimates of the status and timing of services performed differ from the actual status and timing of services performed, it could result in us reporting amounts that are too high or too low in any particular period. To
date, there have been no material differences between our estimates of such expenses and the amounts incurred. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preferred Stock Tranche Rights and
Anti-dilution Right </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The initial fair value of the Preferred Stock Tranche Rights recognized in connection with the
issuance of our Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock in August 2020 and the Anti-dilution Right issued to Lilly in January 2021 were determined based on significant inputs not observable in the market, which represent
Level&nbsp;3 measurements within the fair value hierarchy. These obligations were remeasured prior to the issuance of subsequent tranches in January 2021 and anti-dilution shares in November 2021 and at each interim reporting period. See Note 9 to
our audited consolidated financial statements included elsewhere in this prospectus for additional information regarding our issuances of Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Preferred Stock Tranche Rights and Anti-dilution Right were valued as forward contracts. The values were determined using
a probability-weighted present value calculation. In determining the fair values, estimates and assumptions impacting fair value included the future value of our Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, risk free interest
rates, estimated years to liquidity and probability of each milestone being achieved. We determined the per share future value of the shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock by back-solving to the initial
proceeds of the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock financing. We remeasured each Tranche Right and Anti-dilution Right at each reporting period and prior to settlement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Convertible Notes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We issued the Notes in 2018 and 2019 to investors, which were subsequently converted in October 2020. We elected the fair value
option to account for the Notes. The fair value of the Notes was based on significant inputs not observable in the market, which represented a Level&nbsp;3 measurement within the fair value hierarchy. A change in the assumptions related to the
valuation of the Notes could have a significant impact on the value of the obligation. The value was determined using a probability-weighted present value calculation. In determining the fair value of the Notes, estimates and assumptions impacting
the fair value included the estimated future values of our Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, discount rates, estimated time to conversion, and probability of conversion upon certain events. We remeasured the Notes
at each reporting period and prior to the conversion of the Notes. There were no convertible notes outstanding during the year ended December&nbsp;31, 2021. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We measure stock-based compensation based on the grant date fair value of the stock-based awards and recognize stock-based
compensation expense on a straight-line basis over the requisite service period of the awards, which is generally the vesting period of the respective award. Forfeitures are accounted for as they occur.
<FONT STYLE="white-space:nowrap">For&nbsp;non-employee&nbsp;awards,</FONT> compensation expense is recognized as the services are provided, which is generally ratably over the vesting period. At inception, prior to the issuance of any stock option
grants, we adopted the guidance of Accounting Standards Update, or ASU, <FONT STYLE="white-space:nowrap">No.&nbsp;2018-07,</FONT><I>&nbsp;Compensation&#151;Stock Compensation</I>&nbsp;(Topic 718):<I>&nbsp;Improvements to</I><I></I><I><FONT
STYLE="white-space:nowrap">&nbsp;Non-employee</FONT></I><I></I><I>&nbsp;Share-based Payment Accounting</I>, <FONT STYLE="white-space:nowrap">ASU&nbsp;2018-07,&nbsp;and</FONT> account for awards
<FONT STYLE="white-space:nowrap">to&nbsp;non-employees&nbsp;using</FONT> the grant date fair value without subsequent periodic remeasurement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Stock-based compensation expense is classified in our consolidated statements of operations based on the function to which the
related services are provided or in the same manner in which the grantee&#146;s payroll costs are classified or in which the grantee&#146;s service payments are classified. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model,
which requires inputs based on certain subjective assumptions, including the expected stock price volatility, the expected term of the option, the risk-free interest rate for a period that approximates the expected term of the option, and our
expected dividend yield. As there is currently no public market for our common stock, we determined the volatility for awards granted based on an analysis of reported data for a group of guideline companies that issued options with substantially
similar terms. The expected volatility has been determined using a weighted-average of the historical volatility measures of this group of guideline companies. We expect to estimate expected volatility based on the group of guideline companies until
we have adequate historical data regarding the volatility of our own traded stock price. The expected term of our stock options granted to employees and <FONT STYLE="white-space:nowrap">non-employees</FONT> has been determined utilizing the
&#147;simplified&#148; method for awards that qualify as &#147;plain-vanilla&#148; options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods
approximately equal to the expected term of the award. We have not paid, and do not anticipate paying, dividends on our common stock; therefore, the expected dividend yield is assumed to be zero. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Determination of Fair Value of Common Stock </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As there has been no public market for our common stock to date, the historical estimated fair value of our common stock has
been determined by our board of directors, considering our most recently available independent third-party valuations of common stock. In accordance with the guidance outlined in the American Institute of Certified Public Accountants&#146;
Accounting and Valuation Guide,<I>&nbsp;Valuation of Privately-Held-Company Equity Securities Issued as Compensation</I>,&nbsp;a third-party valuation firm prepared valuations of our common stock using either an option pricing method, or OPM, or a
hybrid method, both of which used market approaches to estimate our enterprise value. The OPM treats common stock and preferred stock as call options on the total equity value of a company, with exercise prices based on the value thresholds at which
the allocation </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
among the various holders of a company&#146;s securities changes. Under this method, the common stock has value only if the funds available for distribution to stockholders exceed the value of
the preferred stock liquidation preferences at the time of the liquidity event, such as a strategic sale or a merger. A discount for lack of marketability of the common stock is then applied to arrive at an indication of value for the common stock.
The hybrid method is a probability-weighted expected return method, or PWERM, where the equity value in one or more scenarios is calculated using an OPM. The PWERM is a scenario-based methodology that estimates the fair value of common stock based
upon an analysis of our future values, assuming various outcomes. The common stock value is based on the probability-weighted present value of expected future investment returns considering each of the possible outcomes available as well as the
rights of each class of stock. The future value of the common stock under each outcome is discounted back to the valuation date at an appropriate risk-adjusted discount rate and probability-weighted to arrive at an indication of value for the common
stock. These third-party valuations were performed at various dates, which resulted in valuation of our common stock of $3.88 per share as of November&nbsp;9, 2021, $3.63 per share as of April&nbsp;15, 2022 and $4.07 per share as of July&nbsp;22,
2022. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to considering the results of the third-party valuations, our board of directors considered
various objective and subjective factors to determine the fair value of our common stock as of each grant date, which may be a date later than the most recent third-party valuation date, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prices at which we sold Preferred Stock and the superior rights and preferences of the Preferred Stock
relative to our common stock at the time of each grant; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to raise future financings; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the progress of our research and development efforts, including the status of clinical studies for our drug
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the lack of liquidity of our equity as a private company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our stage of development and business strategy and the material risks related to our business and industry;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the achievement of enterprise milestones, including entering into collaboration and license agreements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the valuation of publicly traded companies in the life sciences and biotechnology sectors, as well as recently
completed mergers and acquisitions of peer companies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any external market conditions affecting the biotechnology industry and trends within the biotechnology
industry; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the likelihood of achieving a liquidity event for the holders of our Preferred Stock and holders of our common
stock, such as an IPO, or a sale of our company, given prevailing market conditions; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the analysis of IPOs and the market performance of similar companies in the biopharmaceutical industry.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There are significant judgments and estimates inherent in these valuations. These judgments and
estimates include assumptions regarding our future operating performance, the stage of development of our drug candidates, the timing of a potential IPO or other liquidity event and the determination of the appropriate valuation methodology at each
valuation date. The assumptions underlying these valuations represent management&#146;s best estimates, which involve inherent uncertainties and the application of management judgment. As a result, if factors or expected outcomes change and we use
significantly different assumptions or estimates, our stock-based compensation expense could be materially different. Following the completion of this offering, the fair value of our common stock will be determined based on the quoted market price
of our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Options Granted </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table sets forth, by grant date, the number of shares underlying options granted from January&nbsp;1, 2022
through the date of this prospectus, the per share exercise price of the options, the fair value per share of common stock on each grant date and the weighted-average estimated per share fair value of the options granted during the period: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Grant Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number
of<BR>Shares<BR>Subject to<BR>Options&nbsp;Granted</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Per&nbsp;Share<BR>Exercise&nbsp;Price<BR>of<BR>Options</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Per&nbsp;Share&nbsp;Value&nbsp;of<BR>Common&nbsp;Stock on<BR>Grant
Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B><FONT
STYLE="white-space:nowrap">Weighted-Average</FONT><BR>Estimated Per<BR>Share Fair Value<BR>of Options</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March&nbsp;22, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">710,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">June&nbsp;27, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">486,613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">August&nbsp;5, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166,259</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.07</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.07</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The fair value of our common stock of $3.88 per share on March&nbsp;22, 2022 was
determined by our board of directors, based, in part, on the $3.88 per share value indicated in the third-party valuation prepared as of November&nbsp;9, 2021. In particular, the valuation determined our enterprise value using an OPM backsolve
approach that was based on the $5.71 price per share paid by new and existing investors in the closing of our Series B Preferred Stock financing in November 2021. A DLOM of the common stock was then applied to arrive at an indication of fair value
for our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The fair value of our common stock of $3.63 per share on June&nbsp;27, 2022 was determined by us,
based, in part, on the $3.63 per share value indicated in the third-party valuation prepared as of April&nbsp;15, 2022. In particular, the valuation determined our enterprise value using the hybrid method, which included a PWERM, with an IPO
scenario, and a sale scenario. Our enterprise value in the IPO scenario was based on guideline IPO transactions identified within the last one to two years, which was adjusted by a risk-adjusted discount rate. The IPO scenario also assumed an
estimated timeline for the IPO to occur. Our enterprise value for the sale scenario was based on an OPM market-adjusted backsolve method based on the $5.71 price per share paid by new and existing investors in the closing of our Series B Preferred
Stock financing in November 2021. The negative market adjustment that was applied to the equity value considered the performance of guideline public companies and the biotech indices since the most recent sale of our preferred stock through the
valuation date. A DLOM of the common stock was then applied to arrive at an indication of fair value for our common stock. In addition, the board determined that the fair value of our common stock remained at $3.63 per share through June&nbsp;27,
2022. The decrease of $0.25 from the previous valuation performed at November 9, 2021 is primarily the result of a negative 20% market adjustment. The negative market adjustment applied was developed based on the share price declines noted for a
range of comparable companies. The selected market adjustment applied to the enterprise value estimates the decline in enterprise values experienced in the market from November 2021 to April 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The fair value of our common stock of $4.07 per share on August 5, 2022 was determined by us, based, in part, on the $4.07 per
share value indicated in the third-party valuation prepared as of July 22, 2022. In particular, the valuation determined our enterprise value using the hybrid method, which included a PWERM, with an IPO scenario, and a sale scenario. Our enterprise
value in the IPO scenario was based on guideline IPO transactions identified within the last one to two years, which was adjusted by a risk-adjusted discount rate. The IPO scenario also assumed an estimated timeline for the IPO to occur. The
increase of $0.44 from the previous valuation performed as of April 15, 2022 is primarily the result of a probability increase for the IPO scenario. In particular, we began the formal process to prepare for a potential IPO, prior to our July 22,
2022 valuation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On the effective date of the registration statement of which this prospectus forms a part, assuming we
issue 5,900,000 shares in connection with this offering at an assumed price of $17.00 per share, we will issue certain directors and employees, including our executive officers, stock options to purchase an aggregate 1,008,493 shares of our common
stock, under the 2022 Plan, subject to continued service through such grant date. Based on an assumed exercise price of $17.00 per share, which is the midpoint of the estimated price range set forth on the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
cover page of this prospectus, we estimate that the aggregate grant-date fair value of the options to be granted in connection with this offering is $12.5 million, which is expected to be
recognized as stock-based compensation expense over a period of three to four years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, on the effective date
of the registration statement of which this prospectus forms a part, assuming we issue 5,900,000 shares in connection in this offering at an assumed price of $17.00 per share, we will grant certain employees, including our executive officers, an
aggregate of 1,638,006 restricted stock unit awards, or RSUs, under the 2022 Plan, subject to continued service through such grant date. Based on an assumed fair value of $17.00 per share, which is the midpoint of the estimated price range set forth
on the cover page of this prospectus, we estimate that the aggregate grant-date fair value of the RSUs to be granted in connection with this offering is $27.8 million, which is expected to be recognized as stock-based compensation expense over a
period of three to four years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The actual number of options and RSUs that we will grant upon the IPO is illustrative only
and will change based on the actual initial public offering price and the actual number of shares that we issue in the offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">See the sections titled &#147;Management&#151;Non-Employee Director Compensation Policy&#151;Director IPO Option Grants&#148;
and &#147;Executive Compensation&#151;Outstanding Equity Awards at Fiscal Year End&#148; for additional information. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Accounting
Pronouncements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A description of recent issued accounting pronouncements that may potentially impact our financial
position and results of operations is disclosed in Note 2 to our unaudited condensed consolidated financial statements appearing at the end of this prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Internal Control Over Financial Reporting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In connection with the audit of our financial statements for the year ended December&nbsp;31, 2021 and 2020, we identified
material weaknesses in our internal control over financial reporting that existed as of those periods. See the section titled &#147;Risk factors&#151;We have identified material weaknesses in our internal control over financial reporting. If we are
unable to remediate these material weaknesses, or if we identify additional material weaknesses in the future or otherwise fail to maintain effective internal control over financial reporting, we may not be able to accurately or timely report our
financial condition or results of operations, which may adversely affect our business.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Qualitative and Quantitative Disclosures about Market
Risk </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest Rate Risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our primary exposure to market risk is interest rate sensitivity, which is impacted by changes to the general level of U.S.
interest rates, particularly because our cash equivalents are in the form of money market funds that are invested in U.S. Treasury securities. As of June&nbsp;30, 2022 and December&nbsp;31, 2021, we had cash and cash equivalents of
$83.9&nbsp;million and $99.6&nbsp;million, respectively. Interest income is sensitive to changes in the general level of interest rates; however, due to the nature of these investments, an immediate 10% change in interest rates would not have a
material effect on the fair market value of our investment portfolio. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of June&nbsp;30, 2022 and December&nbsp;31,
2021, we had no debt outstanding, and therefore we are not subject to interest rate risk related to debt. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Foreign Currency Exchange Risk
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our reporting currency is the U.S. dollar, or USD. Our functional currency for Acrivon AB, our wholly-owned
subsidiary in Sweden, is the USD. Adjustments that arise from exchange rate changes on transactions </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
denominated in a currency other than the functional currency are included in other income (expense), net in the consolidated statements of operations and comprehensive loss as incurred. We have
not recognized material currency transaction gains or losses during the six months ended June&nbsp;30, 2022 and year ended December&nbsp;31, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We do not currently engage in currency hedging activities in order to reduce our currency exposure, but we may begin to do so
in the future. Instruments that may be used to hedge future risks may include foreign currency forward and swap contracts. These instruments may be used to selectively manage risks, but there can be no assurance that we will be fully protected
against material foreign currency fluctuations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Effects of Inflation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Inflation generally affects us by increasing our cost of labor and clinical trial costs. We believe that inflation has not had
a material effect on our consolidated financial statements included elsewhere in this prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Emerging Growth Company and Smaller Reporting
Company Status </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The JOBS Act provides that, among other things, an &#147;emerging growth company&#148; can take
advantage of an extended transition period for complying with new or revised accounting standards. This provision allows an emerging growth company to delay the adoption of some accounting standards until those standards would otherwise apply to
private companies.&nbsp;As an emerging growth company, we have elected not to &#147;opt out&#148; of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards and, as a result, we will
comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required&nbsp;for&nbsp;private companies on
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">a&nbsp;case-by-case&nbsp;basis</FONT></FONT> until such time that we either (i)&nbsp;irrevocably elect to &#147;opt out&#148; of such extended transition period or (ii)&nbsp;no longer
qualify as an emerging growth company. As a result, our consolidated financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates. We may choose to early adopt
any new or revised accounting standards whenever such early adoption is permitted for private companies. We intend to rely on&nbsp;certain of&nbsp;the other exemptions and reduced reporting requirements provided by the JOBS Act. As an emerging
growth company, we are not required to, among other things, (i)&nbsp;provide an auditor&#146;s attestation report on our system of internal controls over financial reporting pursuant to Section&nbsp;404(b), and (ii)&nbsp;comply with any requirement
that may be adopted by the Public Company Accounting Oversight Board regarding a supplement to the auditor&#146;s report providing additional information about the audit and the financial statements (auditor discussion and analysis). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are also a &#147;smaller reporting company,&#148; meaning that the market value of our stock held <FONT
STYLE="white-space:nowrap">by&nbsp;non-affiliates&nbsp;plus</FONT> the proposed aggregate amount of gross proceeds to us as a result of this offering is less than $700&nbsp;million and our annual revenue was less than $100&nbsp;million during the
most recently completed fiscal year. We may continue to be a smaller reporting company after this offering if either (i)&nbsp;the market value of our stock held <FONT STYLE="white-space:nowrap">by&nbsp;non-affiliates&nbsp;is</FONT> less than
$250&nbsp;million or (ii)&nbsp;our annual revenue is less than $100&nbsp;million during the most recently completed fiscal year and the market value of our stock held <FONT STYLE="white-space:nowrap">by&nbsp;non-affiliates&nbsp;is</FONT> less than
$700&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If we are a smaller reporting company at the time we cease to be an emerging growth company, we may
continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial
statements in our Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K&nbsp;and,</FONT> similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc383050_12"></A>BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are a
clinical stage biopharmaceutical company developing precision oncology medicines that we match to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing our proprietary proteomics-based patient responder
identification platform. Recently approved targeted oncology treatments, such as kinase inhibitors, have transformed the cancer treatment landscape, and while the therapeutic benefit of these agents has provided significant benefit to patients,
these targeted oncology treatments unfortunately only address the less than 10% of patients with cancers that harbor certain easily-identifiable genetic mutations. Our approach is designed to overcome the limitations of genomics-based patient
selection methods. We do this by using our proprietary precision medicine platform, Acrivon Predictive Precision Proteomics, or AP3, to develop our pipeline of oncology drug candidates. Our AP3 platform enables the creation of drug-specific
proprietary OncoSignature companion diagnostics that are used to identify the patients most likely to benefit from our drug candidates, which we refer to as patient responders. We are currently advancing our lead candidate, <FONT
STYLE="white-space:nowrap">ACR-368,</FONT> a selective small molecule inhibitor targeting CHK1 and CHK2 with sub single-digit nM and single-digit nM potency, respectively, in a potentially registrational Phase 2 trial across multiple tumor types,
which our AP3 platform predicts will have a high proportion of patient responders based on OncoSignature-predicted sensitivity to <FONT STYLE="white-space:nowrap">ACR-368.</FONT> Our ACR-368 OncoSignature test, which has not yet obtained regulatory
approval, has been extensively evaluated in preclinical studies, including in two separate, blinded, prospectively-designed studies on pretreatment tumor biopsies collected from patients with ovarian cancer treated with ACR-368 in past Phase 2
clinical trials conducted by Eli Lilly and Company, or Lilly, and at the National Cancer Institute, or NCI, demonstrating robust enrichment of responders through our method. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The AP3 approach is proteomics-based and designed to enable identification and treatment of the patients whose tumors are
sensitive to a specific drug or drug candidate based on direct protein measurement of critical tumor-driving mechanisms and independent of underlying genetic alterations. We believe our approach is applicable across stages of drug development and
across therapeutic modalities. Accordingly, the AP3 method is not limited to the typically very small subset of cancers driven by single gene driver mutations or susceptible to a synthetic lethal approach. Rather, we believe our method is broadly
applicable to the vast majority of cancers, in particular the majority of solid tumors, for which genetics-based approaches have proven insufficient to identify patient responders in many cases. In principle, we believe a much larger percentage of
tumors can be addressed therapeutically using agents attuned to the specific biochemical signaling pathways found in these tumors, which our AP3 platform was purposefully designed to enable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">By applying our highly specific patient selection approach to drug development, we seek to both accelerate clinical
development and significantly increase the probability of successful treatment outcomes for patients. Our pipeline includes the Phase 2 lead program, <FONT STYLE="white-space:nowrap">ACR-368,</FONT> also known as prexasertib, a targeted oncology
asset that targets CHK1 and CHK2, or CHK1/2. <FONT STYLE="white-space:nowrap">ACR-368</FONT> has been dosed in more than 400 patients at the recommended Phase 2 dose, or RP2D, with reported deep, durable responses, including complete responses, or
CRs, in a proportion of patients with solid tumors in past single center and multi-center Phase 2 clinical trials in tumor indications with high unmet need. <FONT STYLE="white-space:nowrap">ACR-368</FONT> has also demonstrated a generally favorable
safety and tolerability profile with primarily reversible hematological toxicity and very limited <FONT STYLE="white-space:nowrap">non-hematological</FONT> toxicity. We have received clearance from the U.S. Food and Drug Administration, or FDA, for
an Investigational New Drug, or IND, application to advance <FONT STYLE="white-space:nowrap">ACR-368</FONT> in Phase 2 single arm clinical trials conducted under the FDA program known as the master protocol, which was developed to help expedite drug
development in multiple tumor types for drugs with an established RP2D within the same overall trial structure. Initially, patients with platinum-resistant ovarian, endometrial, or bladder cancer will be treated in this trial. Patients will be
stratified for treatment based on OncoSignature-predicted sensitivity to <FONT STYLE="white-space:nowrap">ACR-368</FONT> across multiple sites in the United States in this trial with registrational intent. Through the use of our OncoSignature test,
we believe we can significantly increase the overall response rate, or ORR, observed in previous trials that were conducted without a prospective patient responder identification method. We also plan to study
<FONT STYLE="white-space:nowrap">ACR-368</FONT> in additional indications, such as human papilloma virus positive, or HPV<SUP STYLE="font-size:75%; vertical-align:top">+</SUP>, squamous cell carcinomas, including squamous cell cancer, or SCC, of
head and neck, or SCCHN, anal, and cervical cancer, based on demonstrated clinical single agent activity in SCCHN </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
and anal cancer and OncoSignature-based prediction of sensitivity to <FONT STYLE="white-space:nowrap">ACR-368</FONT> in a proportion of patients. In addition to
<FONT STYLE="white-space:nowrap">ACR-368,</FONT> we are also developing internally-discovered preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response, or DDR, and cell cycle regulation pathways, including WEE1, a
protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We were founded and are led by pioneers in
oncogenic signaling, oncology precision medicine and the use of proteomic technology to uncover intracellular biochemical signaling pathways with the goal of applying this knowledge to develop drug candidates and clinical diagnostics. Our founders
have established <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept,</FONT></FONT> including clinical implementation, for the underlying technologies in our AP3 platform. Our scientific advisors are thought leaders
from leading global cancer and academic centers and are actively involved in our drug development process. We are supported by leading healthcare investors, including Wellington Management, Surveyor Capital, RA Capital, Perceptive Advisors, Sands
Capital and Chione. Prospective investors should not rely on the past investment decisions of our investors, as our investors may have different risk tolerances and have received their shares in prior offerings at prices lower than the price offered
to the public in this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our AP3 Platform </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our AP3 platform is based on our proprietary approach developed to enable treatment of the patients who are most likely to
respond to any particular drug candidate based on dependency in the tumor on the upregulated specific biochemical pathways that each drug modulates. Hence, our approach is tumor-agnostic: if the pathways the tumor depends on for its survival and
growth, and that the drug candidate modulates, are upregulated, we predict that individual patient&#146;s tumor will be sensitive to the drug candidate. This applies regardless of the tumor origin and is independent of underlying genetic
alterations. We are applying AP3 broadly to clinically active drug candidates as well as carefully selected preclinical lead series with a strong clinical rationale, and for which there is no obvious patient selection path through standard companion
diagnostic approaches. We also intend to explore the use of AP3 with approved drugs to improve the ORR and outcomes for patients through our patient selection approach. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">One of the key outputs of our AP3 platform are our proprietary response-predictive clinical tests that we refer to as
OncoSignature tests. These are drug-tailored, automated, quantitative proteomic tissue imaging tests applied to pretreatment tumor biopsies as a companion diagnostic, or CDx, to select and treat the patients predicted to benefit from the drug
candidate. Our OncoSignature test, which has not yet obtained regulatory approval, is being developed with Akoya Biosciences, Inc., or Akoya, pursuant to a companion diagnostic agreement. Our OncoSignature tests encompass a signature of three
classes of functionally-defined protein biomarkers assembled into a single signature assay. The quantitative levels for each of the three biomarkers are defined to determine whether a patient&#146;s individual tumor has upregulated the biochemical
signaling mechanisms that the drug modulates and that the tumor depends on for growth and/or survival. Our company name, Acrivon, is derived from Greek for &#147;accurate.&#148; We chose it to embody how our OncoSignature tests are designed to
accurately match our therapies with patients who will benefit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The tumor-agnostic application of OncoSignature tests
enables us to identify and focus on tumor types for which a high unmet need for a treatment exists and that are predicted to be highly sensitive to our drug candidates. We achieve this by deploying our OncoSignature screening of human cancer samples
across various tumor types. Through this process, we can identify new tumor types predicted to be sensitive to a drug candidate and even estimate the percentage of predicted responders before entering clinical trials. For example, we have identified
endometrial cancer and bladder cancer as two highly sensitive cancer types for ACR-368, and therefore will include patients with these tumor types in our Phase 2 trials. Moreover, we have found through this approach that a proportion of patients
with HPV<SUP STYLE="font-size:75%; vertical-align:top">+</SUP> cancers are predicted to be responsive to <FONT STYLE="white-space:nowrap">ACR-368,</FONT> consistent with previously demonstrated clinical activity in a proportion of patients with
SCCHN and anal cancer. Furthermore, we predicted that patients with squamous non-small cell lung cancer, or sqNSCLC, would not respond to ACR-368, consistent with an observed ORR of 0% in patients with this tumor type in a past trial with ACR-368.
Hence, through our OncoSignature screening approach, we can specifically avoid running clinical trials in cancer types predicted to have limited sensitivity to the drug candidate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are not only using our AP3 platform to generate drug-tailored,
response-predictive clinical OncoSignature tests, but we also use our AP3 platform to provide unbiased, quantitative analyses of <FONT STYLE="white-space:nowrap">off-target</FONT> effects on intracellular signaling using phosphoproteomic profiling,
potentially enabling us to discover inhibitors that are both highly potent and highly selective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe that by
leveraging our AP3 platform and clinical OncoSignature tests, we will profoundly alter precision oncology drug development and the treatment landscape of patients suffering from cancer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Pipeline </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383050g05s67.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 1</B>. Acrivon&#146;s internal pipeline including the clinically advanced <FONT
STYLE="white-space:nowrap">ACR-368</FONT> and two preclinical programs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Lead Clinical Candidate <FONT STYLE="white-space:nowrap">ACR-368</FONT>
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">ACR-368</FONT> is a selective small molecule inhibitor targeting CHK1/2. CHK1/2 are
key regulators of the cell cycle and of DDR and inhibition of CHK1/2 has been demonstrated to have anti-tumor activity in multiple preclinical models as well as in clinical trials in humans. Several CHK1/2 inhibitors including <FONT
STYLE="white-space:nowrap">ACR-368,</FONT> also known as prexasertib, have been investigated in the clinic; however, none have been approved by the FDA. <FONT STYLE="white-space:nowrap">ACR-368</FONT> has shown deep, durable single agent clinical
activity, including CRs and partial responses, or PRs, in a proportion of patients with solid tumors with high unmet need for a treatment, such as platinum-resistant ovarian cancer, and SCCs, including SCCHN and anal cancer. More than 400 patients
with these tumors have been treated with <FONT STYLE="white-space:nowrap">ACR-368</FONT> monotherapy at the RP2D in advanced single- and multi-center clinical trials conducted by Lilly, NCI, and at MD Anderson Cancer Center, or MDACC. The ORR in
these trials without a predictive biomarker was 29% at the single center Phase 2 ovarian cancer trial at NCI in the intent to treat, or ITT, population, and approximately 12% across the platinum-resistant ovarian cancer cohorts in the large Phase 2
multi-center international trial sponsored by Lilly. The median duration of response, or mDOR, at the RP2D across trials to date have ranged from almost six months to 12 months, and <FONT STYLE="white-space:nowrap">ACR-368</FONT> monotherapy
demonstrated a generally favorable safety and tolerability profile with primarily reversible hematological toxicity and very limited <FONT STYLE="white-space:nowrap">non-hematological</FONT> toxicity. Based on these two trials, encompassing over 200
patients with ovarian cancer, primarily platinum-resistant, we believe the unenriched background ORR in a larger patient population of platinum-resistant ovarian cancer is somewhere between 15% and 20%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Using our AP3 platform, we have developed a predictive OncoSignature test for <FONT STYLE="white-space:nowrap">ACR-368,</FONT>
called <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature, that we believe can predict patient response to <FONT STYLE="white-space:nowrap">ACR-368</FONT> monotherapy and therefore substantially
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
improve the clinical ORR and, furthermore, that we believe, has the potential to enable expedited drug development. Predicted patient responders are referred to as
<FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature-positive and predicted <FONT STYLE="white-space:nowrap">non-responders</FONT> are referred to as <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature-negative. The <FONT
STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature test has been extensively evaluated in preclinical studies in both patient-derived xenograft, or PDX, mouse tumor models as well as in two separate blinded, prospectively designed preclinical
studies of <FONT STYLE="white-space:nowrap">pre-treatment</FONT> tumor biopsies collected from patients with ovarian cancer that received <FONT STYLE="white-space:nowrap">ACR-368</FONT> in previous clinical trials. Based on the preclinical study
results, we believe the ORR in the <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature-positive patients will be increased significantly when compared to the unenriched ORR observed in previous trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">By applying our <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature test for indication finding and expansion across
human cancer types, as described below, we have found that approximately 30% of samples from patients with ovarian cancer are <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature-positive. Moreover, we observed that between 30% and 40% of
patients with endometrial and bladder cancer are predicted to be highly sensitive to <FONT STYLE="white-space:nowrap">ACR-368.</FONT> Patients with these two types of cancer were not previously treated in
<FONT STYLE="white-space:nowrap">ACR-368</FONT> clinical trials. All three tumor types are therefore included in our upcoming Phase 2 clinical trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have also used our AP3 platform to identify resistance mechanisms to <FONT STYLE="white-space:nowrap">ACR-368.</FONT>
Through phospho-proteomic profiling of human tumor cell lines that are either highly sensitive or highly resistant to <FONT STYLE="white-space:nowrap">ACR-368,</FONT> we uncovered key resistance mechanisms and found that very low dose gemcitabine,
or LDG, could be used to overcome resistance and further sensitize human tumor cells to <FONT STYLE="white-space:nowrap">ACR-368</FONT> through inducing increased DDR stress. Moreover, the use of LDG was observed to enhance sensitivity to <FONT
STYLE="white-space:nowrap">ACR-368</FONT> in the already sensitive cells. We expect this may enable <FONT STYLE="white-space:nowrap">ACR-368</FONT> in combination with LDG to be an important treatment for
<FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature-negative patients who would otherwise be excluded from <FONT STYLE="white-space:nowrap">ACR-368</FONT> treatment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Based on these results, we are initiating a Phase 2 clinical trial where we intend to treat patients with all three tumor
types: platinum-resistant ovarian, endometrial, and bladder cancer. <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature-positive patients, which we believe will represent 30% to 40% of patients of each tumor type, will receive <FONT
STYLE="white-space:nowrap">ACR-368</FONT> monotherapy in a single arm Phase 2b trial for each of the three tumor types. The <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature-negative patients with one of these three tumor types will
receive <FONT STYLE="white-space:nowrap">ACR-368</FONT> combined with LDG in a Phase 1b trial, followed by expansion into a Phase 2 trial with the combination in all three tumor types. As a result, all patients with these tumor types that have been
biopsied will be eligible to receive therapy. This Phase 2 clinical trial design and protocol has been cleared by the FDA and we have begun enrolling patients. Akoya will procure and manufacture the necessary supplies to perform the OncoSignature
tests used in the Phase 2 clinical trial. Based on our communications with the FDA to date, we believe this trial, if successful, has the potential to be registrational for <FONT STYLE="white-space:nowrap">ACR-368</FONT> in each of the three tumor
types. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are carrying out our trial under the auspices of the master protocol guidance issued by the FDA in March 2022
to enable expedited drug development. This guidance provides sponsors of drugs or biologics for the treatment of cancer and for which the RP2D has been established in prior studies, the opportunity to simultaneously evaluate more than one
investigational drug and/or multiple cancer subpopulations within the same overall trial structure under master protocol in adult and pediatric cancers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe that use of our <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature test to select patients predicted to
be sensitive to <FONT STYLE="white-space:nowrap">ACR-368</FONT> for treatment will significantly increase the ORR, which has the potential to lead to accelerated approval for multiple cancers while avoiding treatment of patients with tumors that are
not likely to respond. However, we cannot guarantee that the FDA will permit us to utilize an expedited approval process or that our intended approach will be sufficient for regulatory approval. We are planning to file an IND application amendment
to add three additional cancer types under the same trial protocol design at a later time, including head and neck cancer, anal cancer, and cervical cancer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Preclinical Programs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We also have two preclinical drug programs designed to take advantage of our AP3 platform and the ability to predict tumor
sensitivity based on custom OncoSignature tests. Both of these programs are structure-guided with rational medicinal chemistry efforts based on <FONT STYLE="white-space:nowrap">co-crystallography</FONT> of lead series with their respective targets.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The first of these is directed at WEE1, a critical node in the DDR pathways. WEE1 inhibitors have demonstrated promising
anti-tumor activity in early clinical trials conducted by competitors; however, the ORRs have been relatively low and we believe will be insufficient for approval without a patient selection method. Similar to the case with <FONT
STYLE="white-space:nowrap">ACR-368,</FONT> to our knowledge, no genetic biomarkers have been identified that can reliably predict drug sensitivity. Multiple lead compounds have been synthesized and
<FONT STYLE="white-space:nowrap">co-crystallized</FONT> with WEE1 at high resolution, resulting in four novel lead series with single-digit nM potency that have preclinical pharmacokinetic, or PK, studies ongoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The second, equally advanced preclinical program is directed at PKMYT1, a closely related protein serine/threonine kinase also
serving critical functions in the cell cycle and DDR pathways. Based on mechanism of action and preclinical studies there is a rationale and data suggesting that inhibition of PKMYT1 will result in clinical activity. Currently one company has
advanced a PKMYT1 inhibitor into phase 1 clinical trials. We believe the compound is in need of a patient selection method in the clinic and that genetics-based patient selection methods will be challenging. Similar to the WEE1 program, many high
resolution <FONT STYLE="white-space:nowrap">co-crystals</FONT> have been generated between our lead series and PKMYT1, resulting in two promising, equally potent, novel lead series with PK studies ongoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Based on results from our AP3 platform, we believe that we can predict drug-sensitivity using our proteomics-based approach
for patient responder identification with our OncoSignature tests. We anticipate advancing our WEE1 inhibitor and PKMYT1 inhibitor into <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies in 2023. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>AP3 Potential for Broad Clinical Impact </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our AP3 platform is based on two integrated technology pillars, mass spectrometry-based proteomic profiling and our automated
tumor imaging biomarker platform. Mass spectrometry, or MS, enables a systematic, unbiased quantitative analysis of the proteins inside a cell or entire tissues and is used to identify our biomarker candidates. These are validated using our
biomarker platform which is also used to run our OncoSignature tests. AP3 is designed to generate multiple clinically-actionable, valuable outputs: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Predictive biomarkers and patient responder identification:</U> Our OncoSignature tests are designed to
enable identification and treatment of patients predicted to be sensitive to the drug candidate, while avoiding treatment of patients predicted not to benefit. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Indication finding and expansion:</U> OncoSignature screening of human patient tumor samples is used to
predict what proportion of various tumor types are expected to be highly sensitive to our drug candidates. This enables indication expansion and could potentially increase the response rates in clinical trials. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Identification of resistance mechanisms:</U> AP3 is a powerful technology to identify either <FONT
STYLE="white-space:nowrap">pre-existing</FONT> (intrinsic) resistance or acquired (therapy-induced) resistance to drugs demonstrated in prior studies. We intend to apply this technology to develop combination therapy candidates that target the
druggable resistance mechanisms and <FONT STYLE="white-space:nowrap">re-sensitize</FONT> tumors and to prevent resistance development. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Identification of rational drug combinations:</U> Through our AP3 platform, we uncover the entire protein
signaling pathways underlying resistance. The druggable targets on such pathways are a basis for rational drug combinations and we believe can efficiently overcome resistance demonstrated in multiple prior studies. We intend to apply this for
indication expansion and confirmatory trials for our drug candidate pipeline. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Unbiased drug target engagement and pharmacodynamic biomarker discovery:</U> Through our high resolution
phosphoproteomic drug profiling, we uncover thousands of <FONT STYLE="white-space:nowrap">on-</FONT> and <FONT STYLE="white-space:nowrap">off-target</FONT> interactions and drug-regulated pharmacodynamic, or PD, biomarkers for each drug candidate.
These can be used to guide selectivity optimization of preclinical lead series and to measure drug target engagement in patient tumor tissues during clinical trials, and hence guide dose optimization. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our AP3 platform deploys high resolution, high throughput MS resulting in large datasets reflecting differentially
drug-regulated phosphorylation sites and signaling pathways inside sensitive and resistant cells for each drug candidate we profile. The data are highly structured and amenable to machine learning, which has enabled us to create a streamlined
process and to integrate all the analytical steps into a single workflow. We intend to apply our AP3 platform to both our existing and future pipeline of drug candidates addressing prevalent, high unmet need cancers and where patient responder
identification has proven challenging, as further described below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center"><U>


<IMG SRC="g383050g03a33.jpg" ALT="LOGO">
 </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 2</B>. AP3 has potential for broad impact across the drug discovery and development process.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Team </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We were
founded and are led by pioneers in oncogenic signaling, oncology precision medicine, and the use of proteomic technology to uncover intracellular biochemical signaling pathways and to apply this knowledge to develop drug candidates and clinical
diagnostics. Peter Blume-Jensen, MD, PhD, our <FONT STYLE="white-space:nowrap">co-founder,</FONT> President and Chief Executive Officer, is the inventor of our AP3 platform and OncoSignature patient selection method. He has extensive experience in
oncology drug discovery and development at leading pharmaceutical companies including Serono, Merck&nbsp;&amp; Co. and Daiichi Sanyo. While Chief Scientific Officer at Metamark Genetics, Dr.&nbsp;Blume-Jensen led the development of an automated,
proteomics-based predictive clinical diagnostic for prostate cancer which was validated through blinded clinical trials and included as the only stand-alone test under National Comprehensive Cancer Network, or NCCN, guidelines and reimbursement in
2015. Kristina Masson, PhD, <FONT STYLE="white-space:nowrap">co-founder,</FONT> Executive Vice President, Business Operations and head of our discovery research site in Sweden, previously founded and operated OncoSignature AB, a biotech company
which established the phosphoproteomics and drug discovery infrastructure, and which we subsequently acquired. Jesper Olsen, PhD, our academic <FONT STYLE="white-space:nowrap">co-founder,</FONT> is Professor of Quantitative Proteomics at the
University of Copenhagen and Vice </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Director of the Novo Nordisk Foundation for Protein Research and a recognized pioneer of <FONT STYLE="white-space:nowrap">MS-based</FONT> quantitative phosphoproteomics. Rasmus Holm-Jorgensen,
our Chief Financial Officer, has over 20 years of experience in the biopharmaceutical industry, most recently as Chief Strategy&nbsp;&amp; Portfolio Officer and part of the founding team at Kiniksa Pharmaceuticals. Erick Gamelin, MD, PhD, our Chief
Medical Officer, has led over 100 Phase 1 through Phase 3 oncology clinical trials and most recently served as Chief Medical Officer of Step Pharma. Eric Devroe, PhD, our Chief Operating Officer, has extensive experience in operations and business
development leadership from his time at Metamark Genetics, MDACC, and several <FONT STYLE="white-space:nowrap">start-up</FONT> companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our founders have pioneered and established
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept,</FONT></FONT> including clinical implementation, for the underlying technologies in our AP3 platform. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our goal is
to be the leading biopharmaceutical company leveraging proteomic and phosphoproteomic data, which we access through our proprietary AP3 platform, to unlock insights beyond genomic-based approaches and discover and efficiently develop medicines to
benefit patients with cancer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">While our AP3 approach is broadly applicable across disease areas, we are initially
committed to oncology. Our goal is to treat patients with cancer with clinically active therapeutics that have a high likelihood of success based on predicted sensitivity to our drug candidates. Oncology is an area of high unmet clinical need, in
which only a small fraction of patients currently benefit from existing predictive biomarkers, such as next-generation sequencing, or NGS. We are currently applying the AP3 technology to both <FONT STYLE="white-space:nowrap">in-licensed</FONT>
clinical stage and to internally developed drug candidates for tumors that do not harbor single gene driver mutations, which is estimated to be more than 90% of all human cancers. The relevant drug target classes in these tumors that we believe are
well-suited for our AP3 approach include but are not limited to DDR pathways, DNA replication stress, super enhancers, and cell cycle and transcriptional regulators. We are initially focused on expedited clinical development of our clinically
advanced asset <FONT STYLE="white-space:nowrap">ACR-368,</FONT> in our upcoming Phase 2 trial in patients with platinum-resistant ovarian, endometrial, or bladder cancers, followed by staggered development of
<FONT STYLE="white-space:nowrap">ACR-368</FONT> in HPV<SUP STYLE="font-size:75%; vertical-align:top">+</SUP> cancers. This trial is based on OncoSignature-predicted sensitivity to <FONT STYLE="white-space:nowrap">ACR-368</FONT> and has recently been
cleared by the FDA to be conducted under a master protocol. In addition, we intend to leverage AP3 for our internally developed preclinical programs targeting WEE1 and PKMYT1. The key elements of our strategy summarized below are to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Advance <FONT STYLE="white-space:nowrap">ACR-368,</FONT> our CHK1/2 inhibitor, through clinical development
in ovarian, bladder, and endometrial cancer by enrolling <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature-positive patients</B>. Our lead program, <FONT STYLE="white-space:nowrap">ACR-368,</FONT> has already demonstrated deep, durable
anti-tumor activity, including CRs, in patients with ovarian cancer in past clinical trials. Based on our robust preclinical data, including in two blinded, prospective studies on pretreatment tumor biopsies from past ovarian cancer trials with <FONT
STYLE="white-space:nowrap">ACR-368,</FONT> we believe that our <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature test will lead to significant improvement in ORRs in ovarian cancer as compared to the ORR seen in the previous trials.
Based on human tumor sample profiling, we expect around 30% of patients with ovarian cancer to be <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature-positive and these patients will receive <FONT STYLE="white-space:nowrap">ACR-368</FONT>
monotherapy in a single arm Phase 2 clinical trial. Additionally, through screening with our <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature test we predict that patients with other solid tumor types of high clinical unmet need,
including 30% to 40% of patients with endometrial and bladder cancer, could benefit from <FONT STYLE="white-space:nowrap">ACR-368</FONT> monotherapy. We have further confirmed this prediction in preclinical studies on PDX models of these two tumor
types where we observed that these tumors were highly sensitive to <FONT STYLE="white-space:nowrap">ACR-368,</FONT> and that our <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature test was able to prospectively identify which models are
the most sensitive. We have begun enrolling patients in Phase 2 clinical trials in these tumor types and expect to report initial clinical data from this trial during the second half of 2023. Pending the results and discussions with the FDA, we
intend to enter the registrational phase during 2024. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Selectively pursue AP3 identified rational drug combinations with our drug</B> <B>candidates in
OncoSignature-negative patients, initially ACR-368 with LDG</B>. Our AP3 platform is able to elucidate pathways of underlying tumor resistance mechanisms, both <FONT STYLE="white-space:nowrap">pre-existing</FONT> (intrinsic) and
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
acquired (therapy-induced). This allows us to identify rational drug combinations that can <FONT STYLE="white-space:nowrap">re-sensitize</FONT> <FONT STYLE="white-space:nowrap">ACR-368</FONT>
OncoSignature-negative patients to our drug candidates in resistant tumors. For example, we have shown that LDG was highly synergistic with <FONT STYLE="white-space:nowrap">ACR-368</FONT> in resistant human tumor cell lines and was able to <FONT
STYLE="white-space:nowrap">re-sensitize</FONT> <FONT STYLE="white-space:nowrap">ACR-368</FONT> resistant tumors to <FONT STYLE="white-space:nowrap">ACR-368,</FONT> in ovarian, bladder, and endometrial cancers. Based on these findings, we will
conduct a clinical trial with <FONT STYLE="white-space:nowrap">ACR-368</FONT> in combination with LDG for patients that are <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature-negative within these tumor types, and subsequently in patients
with HPV<SUP STYLE="font-size:75%; vertical-align:top">+</SUP> cancers. We have begun enrolling patients into a Phase 1b dose escalation arm, in order to determine the optimal dosage of LDG with the RP2D of
<FONT STYLE="white-space:nowrap">ACR-368,</FONT> and then expand into a Phase 2 trial. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Discover and develop a pipeline of proprietary drug candidates by leveraging our AP3 platform and
predictive OncoSignature tests</B>. We are applying our AP3 platform in multiple ways to build and advance a pipeline of structure-guided, wholly owned precision oncology drug candidates. Our first earlier stage pipeline program is targeting WEE1.
While WEE1 inhibitors have shown single agent clinical activity across patients with solid tumors of high unmet need, the ORR so far has been insufficient for approval and, despite significant efforts in identifying patient responders, these efforts
have not been fruitful to date. We believe that with our AP3 platform and OncoSignature patient selection strategy, we can significantly enrich the ORR for responders sufficient for approval. Our WEE1 program is currently in preclinical stage and we
expect to enter <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies during 2023. We are also developing an additional preclinical stage lead series in parallel against PKMYT1. Based on mechanism of action and preclinical studies there is a
rationale and data suggesting that inhibition of PKMYT1 will result in clinical activity. Currently one company has advanced a PKMYT1 inhibitor into phase&nbsp;1 clinical trials. We believe the compound is in need of a patient selection method in
the clinic and that genetics-based patient selection methods will be challenging. We expect to enter <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies for that program in 2023. All of our internally derived drug candidates will leverage
AP3 phosphoproteomic drug candidate profiling to guide and optimize drug potency and selectivity. We believe that this approach will help ensure that our drug candidates directly affect the pathways of interest while minimizing <FONT
STYLE="white-space:nowrap">off-target</FONT> effects, an approach that is highly differentiated from traditional drug discovery programs. Secondly, by developing OncoSignature tests tailored for our pipeline drug candidates we believe we can
identify patients with highly sensitive tumor types of high unmet clinical need for treatment before initiation of our clinical trials. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Acquire rights to drug</B> <B>candidates for which we believe our OncoSignature tests can increase the
likelihood of clinical success</B>. We <FONT STYLE="white-space:nowrap">in-licensed</FONT> <FONT STYLE="white-space:nowrap">ACR-368</FONT> after successfully developing a predictive <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature test
to increase the probability of clinical success. We intend to take a similar approach and <FONT STYLE="white-space:nowrap">in-license</FONT> other attractive drug candidates where genetics-based patient selection is challenging or impossible, and
develop drug-tailored OncoSignature tests for these drug candidates. We intend to pursue only the opportunities that, similar to <FONT STYLE="white-space:nowrap">ACR-368,</FONT> have high clinical potential and where we believe we can successfully
select patients who are likely to respond to such specific drug candidates, based on our proprietary OncoSignature tests. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Opportunistically enter into strategic <FONT STYLE="white-space:nowrap">co-development</FONT> partnerships
around predictive OncoSignature tests to maximize the full potential of our AP3 platform</B>. We believe that there are opportunities to partner with organizations that have approved drugs or drug candidates in development under competitive pressure
and where the availability of a highly predictive OncoSignature test to achieve high ORRs can potentially provide an advantage in obtaining regulatory approval and market share. Moreover, we believe that identification of rational drug combinations
for such drugs to improve ORR and clinical benefit are of high value to prospective partners. We intend to pursue such partnerships where we can realize the value that OncoSignature and our AP3 platform can bring to the drug candidate through early <FONT
STYLE="white-space:nowrap">co-development.</FONT> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Urgent Need for Precision Oncology Approaches that Transcend the Limitations of Genomics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cancer is a disease of dysregulated protein activity, which occurs as a result of underlying genetic changes. The majority of
precision medicine efforts in oncology have been focused on identifying patients who are most likely to respond based either on genetic changes in their tumors, such as specific mutations, gene amplifications, and gene translocations, or on the
patient&#146;s own genetic background. The availability of genomic sequences from tens of thousands of tumors has begun to transform oncology treatment away from the use of broad cytotoxic drugs approved based on tumor location towards precision
medicines that address tumors with specific genetic alterations. However, while this approach has led to the recent approval of a number of targeted therapies, their use is limited to a very small fraction of patients with these mutations. It is
estimated that only 9% of all patients with cancer have tumors with genetic profiles that make them eligible for an available precision oncology medicine, <FONT STYLE="white-space:nowrap">so-called</FONT> genetically-defined cancers, and only 5% of
all patients with cancer are likely to benefit from available therapies. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center"><U>


<IMG SRC="g383050g20a23.jpg" ALT="LOGO">
 </U></P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 3. </B>Proteomic biomarkers have the potential to be broadly applicable across the vast
majority of cancers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Proteomic biomarkers have the potential to be broadly applicable for the vast majority of cancers
where more traditional genetics-based approaches have proven challenging. In this small subset of genetically defined cancers, most often the alterations in the gene lead to drug target protein dysregulation that drives the cancer, which are
potential targets of cancer therapies. There are three main types of such recurrent single driver <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">gain-of-function,</FONT></FONT> or GOF, gene alterations known in human cancer: point
mutations, gene fusions, and amplifications, which represents less than 10% of all cancers. These most easily addressable GOF mutation-driven cancers have been the obvious focus of drug discovery and development for more than two decades. Examples
of such approved drugs include Vemurafenib for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">B-RAF-V600E-mutant</FONT></FONT> melanoma, Imatinib for KIT and PDGFR-alpha mutant GIST, Crizotinib for
<FONT STYLE="white-space:nowrap">EML4-ALK+</FONT> lung cancer, Trastuzumab for HER2 amplified breast cancer, and recently Larotrectinib for solid tumors with <FONT STYLE="white-space:nowrap">N-TRK</FONT> fusions. However, more than 90% of cancers
have tumor-driving targets that do not harbor underlying single genetic alterations. Such tumor-driving drug targets are activated through post-translational modifications, including phosphorylation, due to complex genetic alterations elsewhere in
the genome of tumor cells, rather than in the drug target itself. Successful clinical development of inhibitors for these targets is highly challenging as prevailing predictive methods such as NGS, polymerase chain reaction, or PCR, fluorescent <I><FONT
STYLE="white-space:nowrap">in-situ</FONT></I> hybridization, or FISH, immunohistochemistry, or IHC, and transcriptomics have not been successful in identifying patients that would significantly benefit from the drug. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Accordingly, while a powerful tool to uncover underlying mechanisms of disease, the utility of genomics for patient selection
is limited when it comes to drug response prediction in oncology. Additionally, the lack of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
therapeutic efficacy for a given drug, due to inability to identify patient responders, is still a top attrition factor in drug development. The vast majority of cancers contain multiple, complex
genomic alterations resulting in the dysregulated, tumor-driving protein activity. Relatively few genetic alterations are common to a broad percentage of patients with cancer, such as mutations in the <FONT STYLE="white-space:nowrap">K-RAS</FONT> or
p53 genes. However, precision medicines against these targets have been difficult to develop and, because of the complex genetic alterations often <FONT STYLE="white-space:nowrap">co-existing</FONT> in tumors, treatment often does not elicit
expected clinical benefit. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The AP3 Solution: Matching Drug Action to the Disease-driving Mechanisms in Patients&#146; Tumors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our AP3 platform has been developed over the last decade to be an efficient process and workflow to determine sensitivity to
drugs based on the biological signaling pathways that are activated in diseased cells and are required for their survival. Our AP3 platform leverages proteomic biomarkers which enable direct measurement of disease-driving mechanisms independent of
target gene alterations, and allow for accurate matching with the mechanism of action of a particular drug. For example, in the case of ACR-368, which is a selective CHK1/2 inhibitor, the three biomarkers we quantify with our ACR-368 OncoSignature
assay measure the level of activated DNA repair downstream of the activated drug targets and whether the tumor likely depends on it. One biomarker is a specific phosphorylation site in the drug target and another is a specific phosphorylation site
in a key DNA repair protein, which together inform us about their functional activity. The third is a protein that drives premature DNA replication, which implies that the tumor is dependent on the upregulated DNA repair measured by the two other
biomarkers. We have designed our proprietary AP3 platform to be agnostic to the underlying genetic alterations in the genome and enable identification and treatment of patients based on direct measurement of the disease-driving mechanisms that are
regulated by and sensitive to the drug. Hence, in contrast to measuring genetic alterations in a patient&#146;s tumor, which is only a surrogate <FONT STYLE="white-space:nowrap">read-out</FONT> for protein dysregulation, and having to infer whether
the drug will act on the inferred protein dysregulation, the AP3 method directly reveals the dysregulated proteins and pathways driving the tumor that the drug acts on. The AP3 method is drug-centric, and we believe enables an accurate match
<I>(</I>Acrivon is derived from Greek for &#147;accurate&#148;)<I> </I>between the mechanism of the drug action with the disease-driving mechanisms in the patient&#146;s tumor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383050g23s23.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 4.</B> We are applying AP3 to develop drug candidates with the potential to serve the high unmet
clinical needs of the 95% of patients currently unaddressed by precision oncology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our AP3 platform is fundamentally
different from genetics-based methods to identify patient responders and we believe it is particularly applicable to the majority of cancers without genetic alterations in the drug target itself. It specifically focuses on the proteins and pathways
that drive tumor growth and survival and enable drug action, rather than exploring complex biology and accumulated genetic alterations that have proven very difficult to connect to drug response. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">While the principles and technology behind AP3 are not limited to cancer, we are initially committed to oncology, where we are
applying AP3 to develop drug candidates with the potential to transform the treatment of solid tumors of high unmet clinical need. Strategically, we are applying AP3 to drug classes where genetics has proven difficult or insufficient for response
prediction, and that are active in major fractions of solid tumors, but where the ORR is insufficient for approval without a prospective patient responder identification method. In addition to DDR pathway inhibitors such as ATR, ATM, WEE1, and
CHK1/2, examples of drug classes that we believe would benefit from our AP3 platform include cell cycle regulators (such as CDK2, 4, 6), mitotic regulators (such as Aurora kinases), transcriptional regulators, DNA replication modulators, such as
CDC7, super enhancer kinases (such as CDK7, 9, 12), and inhibitors of mutated forms of <FONT STYLE="white-space:nowrap">K-RAS.</FONT> We believe our ability to apply AP3 to these drug classes allows us to open up the potential of precision medicine
approaches to a much </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
larger fraction of patients than has been possible using exclusively genetics-based approaches. We are initially progressing a pipeline of DDR drug candidates, but intend to broaden our pipeline
to some of these other drug classes and targets through OncoSignature patient responder identification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our AP3 platform
is based on two underlying technology pillars typically executed in two sequential steps: the first step, a high-resolution MS for biomarker identification which is integrated with, the second step, our automated tumor biopsy-imaging biomarker
platform that enables biomarker validation and which is also used to run our OncoSignature tests. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383050g41w28.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 5. </B>Our AP3 platform is based on unbiased biomarker identification using global
phosphoproteomic profiling by MS and an automated biomarker platform for our clinical OncoSignature tests. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">MS enables a
systematic, unbiased quantitative measurement and analysis of the proteins inside a cell or entire tissues. We specifically use it to identify and measure in an unbiased manner the effects of any given drug or drug candidate on the activity state of
the protein signaling networks inside a cell through analysis of the phosphorylation state and levels of proteins inside a tumor cell. Phosphorylation is the best-studied, allosteric <FONT STYLE="white-space:nowrap">on-off</FONT> switch regulatory
mechanism for protein activity involved in all forms of intracellular signaling. Analysis of the entire phospho-proteome before and after drug treatment, <FONT STYLE="white-space:nowrap">so-called</FONT> phosphoproteomic drug profiling, enables us
to objectively identify the global effect of any drug on the activity state of the protein signaling network. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our MS
efforts allow us to identify attractive drug-regulated biomarker candidates, which include identifying changes in overall protein levels as well as in post-translational modifications of proteins, such as those that involve phosphorylation and are
involved in activation or inhibition of protein function in biological signaling pathways. Our data-independent acquisition, label-free phosphoproteomic methods provide for very high resolution. Starting with lists of thousands of potential
biomarker candidates that correlate with drug sensitivity and resistance, our proprietary algorithms and workflows distill biomarker candidates into three functionally defined classes. The biomarkers are further validated in tumor models and through
quantitative measurements on PDX models as well as on patient tumor samples and, when available, clinical trial biopsies, as we have done with <FONT STYLE="white-space:nowrap">ACR-368.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of our AP3 platform to develop drug-tailored, predictive OncoSignature tests </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">One of the key outputs of our AP3 platform are our drug-tailored OncoSignature tests, which are based on an assembly of
biomarkers from each of the three classes selected by the process described above, resulting in a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
single, quantitative signature test. They are automated, quantitative protein imaging tests designed to be applied to pretreatment tumor biopsies as a CDx to select and treat the patients
predicted to benefit from the specific drug candidate for which they are developed. The tests are developed for routine-processed, paraffin-fixed biopsy tissue and stained with fluorescently labeled antibodies against the OncoSignature biomarkers.
Digital images of these stained tissues are then processed by proprietary software that identifies both tumor cells and tumor cell nuclei. They are quantitatively measured in only defined tumor tissue regions of a patient biopsy where they function,
called the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;region-of-interest,&#148;</FONT></FONT> or ROI. A proprietary algorithm assesses the quantitative level of each biomarker and combines them to predict the likely
response to a drug or drug candidate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The AP3 approach is designed to provide a streamlined, rationale-driven workflow to
identify and validate biomarkers. Every OncoSignature test is drug-tailored. Our process to generate an OncoSignature test, including technical biomarker validation, can be completed in approximately two to three months. It measures three
functionally defined classes of biomarkers that in combination are predictive of sensitivity to the particular drug. Each biomarker class can contain more than one biomarker, but we typically measure only one in each class for a total of three
biomarkers. A key rationale is that patients whose tumors do not harbor the specific protein disease-driving mechanisms that are sensitive to the drug are predicted to be unlikely to respond to a particular drug or drug candidate and hence can be
excluded from treatment. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center"><U>


<IMG SRC="g383050g52e38.jpg" ALT="LOGO">
 </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 6</B>. AP3 approach for streamlined development and validation of predictive OncoSignature
tests. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In order to create an OncoSignature test that can be readily performed on clinical samples, we qualify monoclonal
antibodies for the prioritized set of three biomarkers. These antibodies are chosen based on our systematic evaluation of their specificity and sensitivity including correlation in changes in biomarker levels with drug sensitivity in cell lines and,
most importantly, their technical performance on human intended use FFPE-processed cancer tissues as well. This technical validation ensures specificity (that it only recognizes the biomarker of interest), dynamic range (the fold changes of the
biomarker level across tumor samples), and proper intensity. The technically qualified antibodies are then assembled into a final drug-tailored predictive </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
OncoSignature test that is functionally validated in a blinded, prospectively designed manner in various preclinical studies. These include prediction of drug sensitivity across human tumor cell
lines, in PDX models, and across human tumor samples, and, when available, on pretreatment tumor biopsies collected from past trials with the drug or drug candidate. Using our AP3 platform workflow, we have developed and evaluated in preclinical
studies an OncoSignature predictive test for <FONT STYLE="white-space:nowrap">ACR-368,</FONT> as further described below. We have also developed and done preliminary validation for two prototype OncoSignature tests for two other clinical stage
assets, a CDK7 and a CDC7 inhibitor, for which genetics-based patient selection has also proven challenging. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The <FONT
STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature test will be conducted under an exclusive license with our external companion diagnostic partner, who will also commercialize the test, pending approval. The tests are performed on a standard,
routine processed <FONT STYLE="white-space:nowrap">pre-treatment</FONT> tumor biopsy with an anticipated turnaround time of five to seven business days. We intend to protect all our drug-tailored OncoSignature tests via patents for their
tumor-agnostic usage across cancers. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383050g06a01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 7.</B> Our OncoSignature tests are applied to pretreatment tumor biopsies and will be offered by
our CDx partner with an anticipated turn-around time of five to seven business days. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Enablement of AP3 through our team&#146;s expertise
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The enablement of the AP3 approach as a means to realize the potential of proteomic drug profiling and protein
signature tests in precision medicine is the result of the vision of our founders and their long-standing expertise in the field, including pioneering the underlying AP3 technologies and implementation experience. Three critical aspects behind AP3
are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Founding concept and vision</B>. Our founders are leaders and respected authorities in the understanding of
oncogenic kinase signaling, protein dysregulation through tyrosine phosphorylation, and the relationship of each to human cancer. Our vision was embedded in the 2001 <I>Nature</I> review article, &#147;Oncogenic kinase signaling,&#148; by our
founder Peter Blume-Jensen, which became a citation classic in the field of medicine. It described how cancer and other diseases are inevitably driven by dysregulated protein signaling resulting from either very simple or complex underlying genetic
alterations. The paper linked simple GOF mutations in a class of proteins called tyrosine kinases with their disease-driving dysregulation and involvement in a certain small subset of human cancers. Our founding vision is that proteomic biomarkers
enable direct measurement of the disease-driving mechanisms and allow for accurate matching with drug action, independent of underlying genetic alterations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Technical expertise and implementation experience</B>. The two underlying technologies used in a stepwise
manner in our AP3 platform, (1)&nbsp;high resolution MS for quantitative protein and protein </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
phosphorylation analysis and (2)&nbsp;the automated biomarker platform, have been pioneered and established by our founders and team and integrated into a content system and approach. Jesper
Olsen, our academic <FONT STYLE="white-space:nowrap">co-founder,</FONT> is a recognized world leader in the use of <FONT STYLE="white-space:nowrap">MS-based</FONT> phosphoproteomics, or the study of protein phosphorylation and its impact on biology.
Dr.&nbsp;Olsen is one of the most highly cited authors in this field. Our <FONT STYLE="white-space:nowrap">co-founder,</FONT> Kristina Masson, has established the entire infrastructure for phosphoproteomics at our subsidiary in Medicon Village,
Lund, Sweden in close proximity with Dr.&nbsp;Olsen&#146;s laboratory in Copenhagen, Denmark. Our OncoSignature technology is enabled by this comprehensive proteomics infrastructure and demonstrated <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> for the first unbiased MS step in the AP3 approach, resulting in identification of resistance mechanisms and rational drug combinations with the potential to be tested in controlled clinical
trials with the drug selinexor in acute myeloid leukemia. This work was published in <I>Cell Reports </I>on August&nbsp;9, 2022. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Peter Blume-Jensen, led the first
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> for unbiased identification of drug-regulated PD biomarkers for PI3&#146;K pathway-targeted agents through an
<FONT STYLE="white-space:nowrap">MS-based</FONT> phosphoproteomics approach. Under his leadership, our team also led the establishment of our automated biomarker platform and the research and development of ProMark, a proteomics eight biomarker
imaging test for prostate cancer outcome prediction launched by Metamark. That test was validated in a blinded trial and was subsequently included in the NCCN Clinical Practice Guidelines. Through this experience, we understand the technical and
regulatory challenges involved in developing and implementing a clinically meaningful proteomic test, and we fully leverage and factor these insights into the design of our OncoSignature tests. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">ACR-368,</FONT> Our Phase 2 Lead Candidate </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our lead drug candidate, <FONT STYLE="white-space:nowrap">ACR-368,</FONT> also known as prexasertib, is a selective inhibitor
with sub single-digit potency against CHK1 and single-digit potency against CHK2. <FONT STYLE="white-space:nowrap">ACR-368</FONT> was originally discovered by Array BioPharma and acquired by Lilly, who evaluated the compound in over 1,000 patients
across 18 clinical trials, where it demonstrated deep, durable single agent activity, including CRs, in a proportion of patients across several Phase 2 studies of platinum-resistant ovarian cancer and other solid tumors. Despite the demonstrated
clinical activity in a proportion of patients, there was no obvious patient selection strategy to improve responses sufficient for approval. We chose to <FONT STYLE="white-space:nowrap">in-license</FONT>
<FONT STYLE="white-space:nowrap">ACR-368,</FONT> prioritizing it over other carefully evaluated candidates, based on multiple criteria, including its proven clinical single agent activity, extensive safety data set and extensive comparison work and <FONT
STYLE="white-space:nowrap">in-house</FONT> AP3 profiling. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have begun enrolling patients in a Phase 2 trial of <FONT
STYLE="white-space:nowrap">ACR-368</FONT> in patients with ovarian, endometrial, or bladder cancer based on OncoSignature-predicted sensitivity to <FONT STYLE="white-space:nowrap">ACR-368.</FONT> Akoya will procure and manufacture the necessary
supplies to perform the OncoSignature tests used in the Phase 2 clinical trial. We expect to report initial clinical data from this trial during the second half of 2023. Pending results and discussions with the FDA, we intend to enter the
registrational phase during 2024. Patients who test <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature-positive will receive <FONT STYLE="white-space:nowrap">ACR-368</FONT> monotherapy in a single arm Phase 2 trial, while <FONT
STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature-negative patients will receive <FONT STYLE="white-space:nowrap">ACR-368</FONT> in combination with LDG in a Phase 1b/2 single arm trial. We also plan to study
<FONT STYLE="white-space:nowrap">ACR-368</FONT> in additional indications, such as HPV<SUP STYLE="font-size:75%; vertical-align:top">+</SUP> squamous cell carcinomas, including SCCHN, anal, and cervical cancer, based on demonstrated clinical single
agent activity in SCCHN and anal cancer and OncoSignature-based prediction of sensitivity to <FONT STYLE="white-space:nowrap">ACR-368</FONT> in a proportion of patients. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">ACR-368,</FONT> a selective inhibitor of CHK1 and CHK2, key DDR regulators </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">CHK1 and CHK2 are checkpoint proteins that prevent cell replication when DNA damage is present. In the absence of DNA damage,
CHK1 and CHK2 are largely inactive. Most normal tissues, other than certain dividing cells such as those in bone marrow, are not reliant on DDR mechanisms such as CHK1 and CHK2, and hence not subject to the negative side effects from such
inhibitors. In contrast, inhibition of the kinase activity of these proteins or knockdown of their expression by RNA interference in certain G1/S checkpoint-deficient tumor cells has been shown to prevent repair of double-strand DNA breaks resulting
in cell death. Treatment of cells with DNA damaging agents or inhibitors of other proteins involved in the DDR, sensitizes them to cell killing by CHK1 and CHK2 inhibitors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383050g28m28.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 8.</B> CHK1 functions as a cell cycle checkpoint to inhibit DNA replication when DNA damage is
present. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">ACR-368</FONT> is a selective CHK1/2 inhibitor with a potency of less than 1 nM
against CHK1 and 8 nM against CHK2. In preclinical studies, <FONT STYLE="white-space:nowrap">ACR-368</FONT> inhibited growth with a potency of less than 100 nM in over 75% of 600 cancer cell lines screened, including a potency of less than 50 nM in
16 of 23 tested ovarian cancer cell lines. <FONT STYLE="white-space:nowrap">ACR-368</FONT> as a single agent led to complete tumor regression in approximately 40% of 38 ovarian cancer PDX models tested. Significant anti-tumor activity was also
observed in other tumor models such as sarcomas and neuroblastoma. The anti-tumor activity of <FONT STYLE="white-space:nowrap">ACR-368</FONT> was enhanced in preclinical models when it was combined with DNA damaging agents such as cisplatin and
gemcitabine. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Clinical development of <FONT STYLE="white-space:nowrap">ACR-368</FONT> for patients with ovarian and other solid
cancers of high unmet treatment need </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are developing <FONT STYLE="white-space:nowrap">ACR-368</FONT> for the
treatment of patients with advanced solid tumors including ovarian, endometrial, and bladder cancers. <FONT STYLE="white-space:nowrap">ACR-368</FONT> has demonstrated deep, durable single agent anti-tumor clinical activity, including CRs, in a
proportion of more than 400 patients treated at RP2D in past clinical trials conducted by Lilly, its previous sponsor, and in several investigator-initiated trials, including at the NCI and at MDACC. Importantly, ACR-368 was well-tolerated in these
trials, exhibiting primarily reversible, manageable hematological toxicities and limited dose-limiting <FONT STYLE="white-space:nowrap">non-hematological</FONT> toxicities. Accordingly, there have been no clinical or regulatory holds reported and
less than 2% drug-related discontinuations across all trials to date. While the ORR in the single center Phase 2 study at NCI was 29%, the confirmed ORR in a <FONT STYLE="white-space:nowrap">169-patient</FONT> Phase 2 trial conducted in 46 centers
across eight countries in platinum-resistant ovarian cancer was only approximately 12%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">By pairing <FONT
STYLE="white-space:nowrap">ACR-368</FONT> with our compound-specific OncoSignature test, we believe we can significantly increase the ORR by targeting treatment to the patients that are predicted to be most dependent on CHK1/2, and therefore more
likely to respond. Based on our preclinical studies, which include blinded, prospective studies of <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature test on pretreatment tumor biopsies collected from patients treated with <FONT
STYLE="white-space:nowrap">ACR-368</FONT> in the past ovarian trials, we expect 30% to 40% of patients in our three lead indications, platinum-resistant ovarian, endometrial, and bladder cancer, will be
<FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature-positive. We expect the ORR to be significantly amplified and, if the data are sufficient, we will aim for single-agent, <FONT STYLE="white-space:nowrap">single-arm</FONT> approval. These
patients will be treated with <FONT STYLE="white-space:nowrap">ACR-368</FONT> in a Phase 2 trial at the RP2D. The remaining 60% to 70% of <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature-negative patients will receive <FONT
STYLE="white-space:nowrap">ACR-368</FONT> at the RP2D with LDG, which we have found to be highly synergistic with <FONT STYLE="white-space:nowrap">ACR-368</FONT> using our AP3 platform in preclinical studies. The IND application for our Phase 2
master protocol trial has been cleared. We have begun enrolling patients in Phase 2 clinical trials in these three tumor types and expect to report initial clinical data from this trial during the second half of 2023. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ovarian cancer background </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Ovarian cancer is the fifth deadliest cancer in women. An estimated 19,880 women in the United States are projected to be
diagnosed with ovarian cancer and approximately 12,810 will die from this disease in 2022 based on projections from the NCI. The overall five-year survival rate in patients with ovarian cancer is 50% but drops to 31% in patients with metastatic
disease. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surgery and cytotoxic chemotherapies are widely used to treat patients with
ovarian cancer. One of the primary chemotherapies involves the use of platinum containing regimens such as carboplatin or cisplatin. Approximately 85% to 90% of patients with ovarian cancer initially respond to these drugs, but in over 80% of cases,
these cancers return and are considered platinum-resistant. For these patients, there are few remaining treatment options, including bevacizumab with chemotherapy or PARP inhibitor as maintenance therapy for some patients. Only about 12% of
platinum-resistant patients achieve tumor shrinkage and, on average, people with platinum-resistant ovarian cancer survive for no longer than a year. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Endometrial cancer background </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Endometrial cancer is a cancer of the lining of the uterus that primarily affects post-menopausal women. The American Cancer
Society estimates that in the United States there will be 65,950 new cases of endometrial cancer and approximately 12,550 patients will die of this disease in 2022. First-line treatment for patients with localized, early-stage disease is surgery.
Patients with more advanced disease, stages III or IV, are treated with chemotherapy, typically with platinum-based drugs. Approximately 60% of patients with endometrial cancer initially respond to these treatments; however, similar to ovarian
cancer, resistance develops to these drugs. These platinum-resistant patients are treated with radiation therapy or may be eligible for immunotherapy treatments with lenvatinib, an angiogenesis inhibitor. Five-year survival for patients with
metastatic endometrial cancer is approximately 20%. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bladder cancer background </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Bladder cancer is the most common malignancy involving the urinary system, and 90% of bladder cancer cases are urothelial
carcinomas. The five-year survival for patients with early-stage disease is 96%; however, for patients with advanced metastatic disease the five-year survival drops sharply to less than 10%. The NCI estimates that there will be 81,180 new cases of
bladder cancer and 17,100 deaths in the United States in 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The most common treatment for patients diagnosed with
advanced or metastatic bladder cancer is chemotherapy with platinum-based drugs such as carboplatin or cisplatin in combination with gemcitabine. Patients with metastatic disease that progress during or after platinum-based chemotherapy are
increasingly being treated with immune checkpoint inhibitor therapy. A number of <FONT STYLE="white-space:nowrap">PD-1</FONT> and <FONT STYLE="white-space:nowrap">PD-L1</FONT> checkpoint inhibitors have been approved by the FDA for use in refractory
bladder cancer. Objective ORRs in clinical trials with checkpoint inhibitors have been approximately 15%. On July&nbsp;9, 2021, enfortumab vedotin, a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">nectin-4-directed</FONT></FONT>
antibody drug conjugate was approved for patients that have progressed after treatment with immune checkpoint inhibitors <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> and a platinum-containing
chemotherapy. The ORR is about 40%, but eventually the disease progresses and the median overall survival is approximately 12 months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Only an estimated 20% of patients with bladder cancer have alterations in the FGFR2 or FGFR3 genes. In clinical testing,
erdafitinib, an FGFR-targeted drug, has demonstrated a 32% ORR with 2% of patients achieving CRs. Despite the availability of these therapies, the prognosis for patients with metastatic bladder cancer is still poor with a five-year survival rate of
only 8%. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>HPV<SUP STYLE="font-size:75%; vertical-align:top">+</SUP> squamous cell carcinoma background </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Squamous cell carcinomas are cancers that develop in the squamous cells that make up the outermost layer of the skin. More than
90% of anal cancers and cervical cancers and about 70% of SCCHN in the oropharynx, or the back of the throat, are linked to infections with HPV. There are over 46,000 HPV<SUP STYLE="font-size:75%; vertical-align:top">+</SUP>-associated cancers
diagnosed in the United States each year and up to 5% of cancers worldwide are potentially caused by HPV<SUP STYLE="font-size:75%; vertical-align:top">+</SUP> infections. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Unlike many cancers, HPV<SUP STYLE="font-size:75%; vertical-align:top">+</SUP> cancers are not typically driven by high levels
of genomic instability but rather by alterations in cell cycle regulation, including upregulation of DDR pathways. Certain HPV<SUP STYLE="font-size:75%; vertical-align:top">+</SUP> cancers, primarily SCCHN and cervical cancer, respond to <FONT
STYLE="white-space:nowrap">PD-1</FONT> or <FONT STYLE="white-space:nowrap">PD-L1</FONT> immune checkpoint inhibitor therapies with ORRs of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
approximately 20%. While these and other targeted therapies are still in development for these cancers, the primary treatment is with surgery and chemotherapy regimens typically composed of a
backbone of <FONT STYLE="white-space:nowrap">5-fluorouracil</FONT> and cisplatin, and radiation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sarcoma background </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to previously demonstrated clinical activity in the above tumor types as monotherapy, <FONT
STYLE="white-space:nowrap">ACR-368</FONT> has also shown clinical activity in patients with sarcomas in combination with various chemotherapeutic agents. Patients with sarcomas have very limited treatment options, primarily surgery, chemotherapy,
and radiation. The five-year survival for patients with metastatic soft tissue sarcomas is approximately 17%. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Previous clinical trials of <FONT
STYLE="white-space:nowrap">ACR-368</FONT> have demonstrated compelling, durable single agent activity </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT
STYLE="white-space:nowrap">ACR-368</FONT> has demonstrated deep, durable single agent activity, including CRs, in a proportion of more than 400 patients with high-grade serous, primarily platinum-resistant, ovarian cancer and SCC treated at RP2D.
Overall, <FONT STYLE="white-space:nowrap">ACR-368</FONT> has been tested in 18 clinical trials as monotherapy or in combination with both targeted agents and chemotherapy in over 1,000 patients across primarily solid tumor types and has shown a
generally favorable safety profile. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Phase 1a/b trial in squamous cell carcinoma established single agent clinical activity and the RP2D </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A <FONT STYLE="white-space:nowrap">146-patient</FONT> Phase 1 multicenter trial was conducted in patients with refractory or
recurrent squamous cell carcinoma and led by Dr.&nbsp;David Hong at MDACC. The trial included patients with SCCHN, sqNSCLC, and anal cancer. The primary objective of the Phase 1b expansion cohorts was to determine the safety, toxicity, and RP2D of <FONT
STYLE="white-space:nowrap">ACR-368.</FONT> In addition, the ORR according to Response Evaluation Criteria in Solid Tumors, or RECIST, version 1.1 for patients with specific types of SCC was recorded. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The RP2D was established at 105 mg/m<SUP STYLE="font-size:75%; vertical-align:top">2</SUP> given as an intravenous infusion
every 14 days, and used in the expansion phase for 101 patients. The study demonstrated clinical monotherapy activity of <FONT STYLE="white-space:nowrap">ACR-368,</FONT> with a 5% ORR in SCCHN and 15% ORR in anal cancer. The mDoR was seven months
and over 12 months, respectively, including a CR in anal cancer. Based on these results and the lack of highly effective treatments, <FONT STYLE="white-space:nowrap">ACR-368</FONT> has been granted FDA Orphan Drug Designation, or ODD, for the
treatment of anal cancer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Of note, approximately half of the patients with SCCHN were HPV<SUP
STYLE="font-size:75%; vertical-align:top">+</SUP> and showed a significantly higher ORR of 19% in response to <FONT STYLE="white-space:nowrap">ACR-368&#151;a</FONT> similar finding to the ORR recorded in patients with anal cancer, which is almost
obligate HPV<SUP STYLE="font-size:75%; vertical-align:top">+</SUP>. This was reflected in a markedly longer progression-free survival, or PFS, in HPV<SUP STYLE="font-size:75%; vertical-align:top">+</SUP> compared to
<FONT STYLE="white-space:nowrap">HPV-negative,</FONT> or HPV<SUP STYLE="font-size:75%; vertical-align:top">-</SUP>, patients, with some HPV<SUP STYLE="font-size:75%; vertical-align:top">+</SUP> patients benefiting from therapy well over 12 months
while no HPV<SUP STYLE="font-size:75%; vertical-align:top">-</SUP> patients had benefit beyond five months (Fig. 9.). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383050g29k08.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 9.</B> <FONT STYLE="white-space:nowrap">ACR-368</FONT> treatment resulted in a significant
improvement in progression-free survival in patients with HPV<SUP STYLE="font-size:75%; vertical-align:top">+</SUP> SCCHN compared to patients with HPV<SUP STYLE="font-size:75%; vertical-align:top">-</SUP> SCCHN. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In this trial, as in most of the other clinical trials with <FONT STYLE="white-space:nowrap">ACR-368,</FONT> an attempt was
made to identify biomarkers predictive for response to <FONT STYLE="white-space:nowrap">ACR-368</FONT> in pretreatment tissue samples by NGS. In an analysis of genetic changes in 24 genes involved in DDR or increased replication stress, no obvious
correlation with clinical response was observed. This lack of correlation between genetic changes and clinical response underscores the need for an alternative patient responder identification method, such as AP3. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383050g22j00.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 10.</B> Maximal percentage change in tumor size from baseline by best ORR across all expansion
cohorts. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Phase 2, single center NCI trial in patients with high-grade serous ovarian cancer </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A Phase 2 trial of <FONT STYLE="white-space:nowrap">ACR-368,</FONT> led by Dr.&nbsp;Lee at NCI, enrolled 28 women with
high-grade serous ovarian cancer. <FONT STYLE="white-space:nowrap">ACR-368</FONT> was administered at the RP2D every 14 days until disease progression, an event of unacceptable toxicity, or withdrawal of consent. Twenty-four women had evaluable
responses after three withdrew consent because of travel inconvenience and one developed an intervening illness that prevented radiological evaluation of tumor progression. All patients in this trial had failed at least one round of prior cytotoxic
chemotherapy and three quarters of the patients had failed three or more prior lines of therapy. The primary endpoint in this single center trial was investigator assessed tumor response based on RECIST v1.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the analysis of the ITT population of 28 patients, an ORR of 29% was achieved. For the 21 patients in the ITT population
with platinum-resistant disease, an ORR of 29% was achieved. The mean duration of response in patients with platinum-resistant ovarian cancer was over ten months, with some patients remaining on <FONT STYLE="white-space:nowrap">ACR-368</FONT>
therapy for over 16 months (Fig. 11). </P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383050g19a20.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 11.</B> Duration of response with <FONT STYLE="white-space:nowrap">ACR-368</FONT> in a <FONT
STYLE="white-space:nowrap">28-patient</FONT> ovarian cancer Phase 2 trial. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Similar to the findings reported for
<FONT STYLE="white-space:nowrap">ACR-368</FONT> in SCC, there was no correlation observed between clinical response and alterations or the expression of potential biomarker genes (Fig. 12). </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383050g93i64.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 12</B>. No correlation was observed between <FONT STYLE="white-space:nowrap">ACR-368</FONT>
response and genetic alterations or potential biomarker expression in patients with ovarian cancer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Phase 2 multicenter trial in advanced, high-grade
serous ovarian cancer </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A large Phase 2 trial of <FONT STYLE="white-space:nowrap">ACR-368</FONT> in patients with
platinum-resistant and platinum-refractory ovarian cancer sponsored by Lilly was conducted in 46 centers across eight countries. The 169 patients enrolled in this trial had failed two to four prior systemic therapies and 90% of patients had stage
III or stage IV disease. The trial included patients with either an altered BRCA1 or BRCA2 gene, or BRCA-positive, or unaltered BRCA1 or BRCA2 gene, or BRCA-negative, ovarian cancer and was divided into four cohorts. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cohort 1: patients with platinum-resistant, BRCA negative ovarian cancer with at least three lines of prior
therapy </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cohort 2: patients with BRCA negative platinum-resistant ovarian cancer with no more than two lines of prior
therapy </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cohort 3: patients with platinum-resistant BRCA mutant ovarian cancer with any line of prior therapy, but with
obligatory prior PARP inhibitor therapy </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cohort 4: patients with platinum-refractory BRCA negative or BRCA mutant ovarian cancer and any line of prior
therapy. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383050g13p30.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 13. </B>ORR and Disease Control Rate in each of the four cohorts of patients with
platinum-resistant and platinum-refractory ovarian cancer. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The primary outcome in this study was ORR. Results from
this trial showed that a subset of patients with ovarian cancer treated with <FONT STYLE="white-space:nowrap">ACR-368</FONT> across all four cohorts achieved durable PRs. The ORR in the 140 patients with platinum-resistant ovarian cancer was 12.1%,
not including unconfirmed responders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Secondary outcomes included Disease Control Rate, or DCR, which is the percentage
of patients with a best overall response of CR, PR, or stable disease, or SD, for at least four months. The DCR was over 30% across all four cohorts, varying from 31% in patients with platinum-refractory disease to 45% in patients with
platinum-resistant disease with at least three lines of prior failed therapies. In the three cohorts of patients with platinum-resistant disease, the median duration of response was 5.6 months (95% confidence interval: 3.9 months; 7.6 months), and
the median duration of overall survival was 11.9 months (95% confidence interval: 9.9 months; 14 months). </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Consistent
with previous observations, retrospective analyses of patient pretreatment tumor samples by both NGS and by IHC failed to identify biomarkers that strongly correlated with clinical response. Despite the demonstrated clinical activity, these data
underscore the need for an effective patient responder enrichment method. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">ACR-368</FONT> has been generally
well-tolerated with manageable side effects </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There have been eight Lilly-sponsored clinical trials with <FONT
STYLE="white-space:nowrap">ACR-368.</FONT> In these trials, <FONT STYLE="white-space:nowrap">ACR-368</FONT> was administered to a total of 681&nbsp;subjects, to 479&nbsp;subjects as monotherapy and to 202&nbsp;subjects in combination with other
treatments. In addition, there have been 10 Investigator-Initiated Trials, or IITs, where <FONT STYLE="white-space:nowrap">ACR-368</FONT> was administered to a total of 283&nbsp;patients as either monotherapy or in combination. The primary adverse
events observed in these trials were hematological, including transient neutropenia and thrombocytopenia, both of which were generally reversible and manageable. The neutropenia and thrombocytopenia are thought to be part of the mechanism-based
suppression of cells in the bone marrow, or myelosuppression, which is also seen with other DDR inhibitors. However, by dosing <FONT STYLE="white-space:nowrap">ACR-368</FONT> at the established RP2D once every 14 days it was found that in most
patients who experienced drug-related hematologic toxicities such as neutropenia had already begun to recover by the 14th day after dosing. Hence, granulocyte colony-stimulating factor and platelet infusions to correct for neutropenia and
thrombocytopenia, respectively, were not mandated but were used at the discretion of the treating physicians in these trials. Nonhematologic toxicities deemed related to ACR-368 treatment occurred at a much lower frequency and severity as summarized
below, with fatigue, nausea, and diarrhea being the mostly commonly observed events. In addition, in a few patients, an association was identified between increasing ACR-368 plasma concentration following monotherapy and transient QTcF prolongation.
None of these episodes led to clinical manifestations. Accordingly, drug-related discontinuations were between only 1% to 2% across all patients. A proportion of patients experienced very durable responses, and in a few cases remained on therapy for
several years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary of adverse events from published reports on clinical trials with ACR-368 monotherapy dosed at
RP2D </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Study Number <BR>NCT Number <BR>Status</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Study Design<BR>Monotherapy</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">ACR-368&nbsp;Dosing</FONT><BR>Regimen and<BR>Schedule</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number&nbsp;of<BR>Subjects</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Summary of Safety Data*</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" COLSPAN="9"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><I>Ovarian Carcinoma</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top">NCI Phase 2 single center study in platinum-resistant or refractory recurrent ovarian cancer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Single arm study in BRCA-negative, primarily platinum-resistant, recurrent high-grade serous or high-grade endometrioid ovarian carcinoma (Lee et al, Lancet Oncology, 2018)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">RP2D: 105 mg/m<SUP STYLE="font-size:75%; vertical-align:top">2</SUP> every 14&nbsp;days</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">28 intent to treat platinum resistant (N=21), platinum-sensitive (N=6), and platinum-refractory (N=1) patients.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Most frequent treatment related AEs &#8805; Grade 3: neutropenia measured at day 8, 26 (93%), leukopenia 23 (82%), thrombocytopenia 7 (25%),
anemia 3 (11%), febrile neutropenia 2 (7%); most frequent treatment related non hematological AEs &#8805; Grade 3: fatigue 2 (7%), vomiting 1 (4%), diarrhea 2 (7%).</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">No deaths and no treatment discontinuation due to AEs reported. Note: in this trial, neutropenia and thrombocytopenia were measured at day 8 after infusion,
which is nadir for neutropenia, to specifically assess highest degree of neutropenia, not at end of each dosing cycle, which is standard clinical practice.</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" COLSPAN="9"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><I>Other Cancer Types</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">I4D-MC-JTJA</FONT></FONT> (JTJA)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">NCT01115790 Completed</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">Phase 1 open-label, multicenter</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Non randomized, cohort expansion in subjects advanced squamous cell carcinomas (Hong et al, Clin Cancer Res 2018)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">RP2D: 105 mg/m<SUP STYLE="font-size:75%; vertical-align:top">2</SUP> every 14&nbsp;days</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Total: 101</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Anus: 26</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">H&amp;N: 57</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">NSCLC: 16</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">+ 2 subjects skin and vaginal</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Most frequent treatment related AEs &#8805; Grade 3: 93/101&nbsp;(92%) subjects; neutropenia at day 8, 90 (89%), leukopenia 26 (26%),
thrombocytopenia 16 (16%), febrile neutropenia 12 (12%), anemia 14 (14%). Most frequent treatment related non-hematological AEs &#8805; Grade 3: fatigue 2 (2%), and headache 1(1%).</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Dose reductions in 10 subjects (10%) and dose delays in 22 (22%) due to neutropenia. No deaths and no treatment discontinuation due to AEs reported.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">Note: in this trial, neutropenia and thrombocytopenia were measured at day 8 after infusion, which is nadir for neutropenia, to specifically assess highest
degree of neutropenia, not at end of each dosing cycle, which is standard clinical practice.</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">I4D-MC-JTJH</FONT></FONT> (JTJH)</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">NCT02735980 Phase 2 multicenter, nonrandomized</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Parallel cohort study in subjects with extensive-Small Cell Lung Cancer who had either</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">platinum-sensitive or platinum-resistant/refractory disease (Byers et al, Clin Lung Cancer 2021)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Cohort 1: platinum-sensitive</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Cohort 2:
platinum-resistant/refractory</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">RP2D: 105 mg/m<SUP STYLE="font-size:75%; vertical-align:top">2</SUP> every 14&nbsp;days</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Total: 116</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Cohort 1: 58</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">Cohort 2: 60</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Treatment related AEs &#8805; Grade 3: 89/116&nbsp;(76.7%) subjects; neutropenia 75 (64.7%), leukopenia 30 (25.9%), thrombocytopenia 30
(25.9%), febrile neutropenia 12 (10.3%), anemia 14 (12.1%). <FONT STYLE="white-space:nowrap">Non-heme</FONT> AEs: fatigue 5 (4.3%), and decreased appetite 2 (1.7%).</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Dose reductions in 8 subjects (13.3%). Dose delays in 19 (31%) due to neutropenia or thrombocytopenia, and 2 possibly drug related treatment discontinuations
due to Gr3 pneumonia and Gr2 leukopenia. Mean relative dose-intensity 98.26%. </P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">Three deaths (5.4%) in cohort 1 deemed possibly related to study
treatment.</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Adverse events greater than or equal to Grade 3 are considered serious adverse events </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Using Our <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature Test For Prediction of Sensitivity to
<FONT STYLE="white-space:nowrap">ACR-368</FONT> in Our Upcoming Phase&nbsp;2 Trial </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Using the AP3 streamlined process
as described above, we have developed a predictive OncoSignature test for <FONT STYLE="white-space:nowrap">ACR-368,</FONT> called <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature. We will be using this in our upcoming Phase&nbsp;2 trial
to treat patients with ovarian, endometrial, or bladder cancer based on predicted sensitivity to <FONT STYLE="white-space:nowrap">ACR-368.</FONT> We have extensively evaluated our <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature test in
various preclinical studies and models demonstrating the ability to predict sensitivity to <FONT STYLE="white-space:nowrap">ACR-368.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Prediction of sensitivity to <FONT STYLE="white-space:nowrap">ACR-368</FONT> across multiple human
ovarian tumor samples </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Two key questions facing companies entering clinical trials is whether the chosen tumor
types in a particular trial will be sensitive to the drug candidate and, if so, what percentage of patients with each of these tumor types are expected to be sensitive to the drug candidate. To acquire this important information, we use our
OncoSignature tests to screen across human patient tumor samples and multiple tumor types to predict not only which tumors are sensitive to our drug candidates, but also what percentage of patients with these tumor types are predicted to respond. We
have used our <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature test in this manner to screen across commercially available human patient tumor samples and across tumors that have been routine-processed by formalin-fixation and paraffin
embedding, or FFPE, just like the pretreatment tumor biopsies collected from patient tumors will be processed in our upcoming clinical trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Using automated image acquisition software, the biomarkers in our <FONT STYLE="white-space:nowrap">ACR-368</FONT>
OncoSignature tests are measured quantitatively within the ROI, which is where they are informative and exert their biological function. Patient tumor samples with a minimal predictive threshold of each of the three biomarkers present predicts
sensitivity to <FONT STYLE="white-space:nowrap">ACR-368.</FONT> Conversely, patients without presence of any of the three biomarkers are predicted to not benefit from <FONT STYLE="white-space:nowrap">ACR-368</FONT> and will be excluded from the
monotherapy arm in our upcoming clinical trials. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383050g07a02.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 14.</B> Screening with our
ACR-368 OncoSignature across human patient tumor samples is used to predict which patients are believed to be sensitive and resistant to ACR-368, in this example using human ovarian and anal tumor samples. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Through our analysis of patient tumor samples acquired from biorepositories,
we have found that in high-grade serous ovarian cancer approximately 30% of all patient tumor samples have each of the three biomarkers present above the minimal predictive threshold. This result, combined with the results described below, suggests
that approximately 30% of patients could potentially benefit from treatment with <FONT STYLE="white-space:nowrap">ACR-368</FONT> monotherapy. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383050g23n00.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 15.</B> Our <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature provides quantitative
scores that we use to objectively predict tumor response. Patient tumor samples with all three biomarkers above a certain minimum level on the heatmap are predicted to benefit from <FONT STYLE="white-space:nowrap">ACR-368</FONT> therapy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Prediction of sensitivity to <FONT STYLE="white-space:nowrap">ACR-368</FONT> in human tumor cell lines </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Human tumor cell lines are very different from human intact tumor tissue, but are still widely used to assess anti-tumor
efficacy. To date, it has been very challenging to predict sensitivity to DDR inhibitors with prevailing genetics-based methods in human tumor cell lines. However, by applying our <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature to a
small panel of human tumor cell lines, we demonstrated our ability to predict sensitivity to <FONT STYLE="white-space:nowrap">ACR-368</FONT> with a high degree of certainty. The presence of all three biomarkers above a minimal level predicted
sensitivity to <FONT STYLE="white-space:nowrap">ACR-368</FONT> in all cells that are highly sensitive to <FONT STYLE="white-space:nowrap">ACR-368</FONT> in viability assays, except for one. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383050g08k08.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 16</B>. Prediction of <FONT STYLE="white-space:nowrap">ACR-368</FONT> sensitivity across human
tumor cell lines. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">EC<SUB STYLE="font-size:75%; vertical-align:bottom">50</SUB>: concentration of
<FONT STYLE="white-space:nowrap">ACR-368</FONT> resulting in 50% inhibition of tumor cell survival. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">R = predicted responder and NR = predicted <FONT
STYLE="white-space:nowrap">non-responder.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Prediction of sensitivity to <FONT STYLE="white-space:nowrap">ACR-368</FONT> in ovarian PDX models
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To demonstrate that we can also predict responders to <FONT STYLE="white-space:nowrap">ACR-368</FONT> in PDX
models, we obtained untreated tumor tissue samples from 20 PDX models of ovarian cancer and generated quantitative biomarker scores with our <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature test. Using the same approach, we assessed
whether the tumor samples with a minimal level of each of the three biomarkers would predict sensitivity to <FONT STYLE="white-space:nowrap">ACR-368.</FONT> We found that our <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature was able to
capture 80% of responders in PDX models while improving the ORR to approximately 55% compared to an approximated 20% baseline response rate.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383050g35a01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 17.</B> Our <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature accurately distinguished
responders from <FONT STYLE="white-space:nowrap">non-responders</FONT> in PDX models; sensitivity and specificity plotted as an area under receiver operator curve, or AUC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Blinded, prospectively designed prediction of
<FONT STYLE="white-space:nowrap">ACR-368</FONT> sensitivity in two separate studies of pretreatment tumor biopsies from past Phase 2 trials with <FONT STYLE="white-space:nowrap">ACR-368</FONT> in patients with high grade serous ovarian cancer
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our OncoSignature tests are developed using only tumor cells independent of any input from clinical results. The
tests are dictated by a mechanistic, functional definition of each of the three classes of biomarkers based on a strong scientific and clinical rationale as well as on our insights into biological signaling. Based on our approach, we believe we can
predict that if all three classes of biomarkers are present at a minimal level in a tumor sample, the tumor depends on upregulation of the drug target signaling axis for its growth and survival. Moreover, from our phosphoproteomic drug profiling of
tumor cells, we have found that this upregulated signaling axis is modulated by the drug candidate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To test our <FONT
STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature for its ability to identify the patients that benefit from monotherapy with <FONT STYLE="white-space:nowrap">ACR-368,</FONT> we conducted two separate studies on pretreatment tumor biopsy
samples collected from patients treated with <FONT STYLE="white-space:nowrap">ACR-368</FONT> in past trials. Importantly, the studies were blinded to any treatment outcome annotation, the analyses were prospectively defined, and results were
analyzed by an independent third-party statistician. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We were able to obtain
<FONT STYLE="white-space:nowrap">pre-treatment</FONT> biopsy samples from a subset of patients with ovarian cancer treated with <FONT STYLE="white-space:nowrap">ACR-368</FONT> in the prior clinical Phase 2 trials: patients treated at NCI and in the
multi-center trial sponsored by Lilly. We generated OncoSignature scores on these biopsy samples blinded to treatment outcome and handed these over to the third-party biostatistician, who received the treatment outcome annotation separately. The
results of both of these studies showed that use of our tumor-agnostic <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature test was able to significantly improve the response rate, to 47% and 58%, respectively. Moreover, the results also
demonstrated that a negative <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature largely eliminated patients who are less responsive to <FONT STYLE="white-space:nowrap">ACR-368,</FONT> hence sparing these patients from a <FONT
STYLE="white-space:nowrap">ACR-368</FONT> single-agent treatment from which they would not benefit. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383050g24m45.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 18.</B> Blinded OncoSignature scoring of <FONT STYLE="white-space:nowrap">pre-treatment</FONT>
tumor biopsies from prior clinical trials of <FONT STYLE="white-space:nowrap">ACR-368</FONT> was able to segregate responders from <FONT STYLE="white-space:nowrap">non-responders.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Patients predicted to be sensitive to
<FONT STYLE="white-space:nowrap">ACR-368</FONT> had a median PFS, or mPFS, of 7.9 months compared to 2.2 months for those predicted to be <FONT STYLE="white-space:nowrap">non-responders.</FONT> This reflects the fact that not only the patients with
PR or CR, but also with SD predicted by <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature to be responders to <FONT STYLE="white-space:nowrap">ACR-368</FONT> treatment did indeed benefit for longer periods of time than the predicted <FONT
STYLE="white-space:nowrap">non-responders.</FONT> This could be valuable for confirmatory trials where mPFS is typically a primary endpoint. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383050g09m65.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 19.</B> Patients with OncoSignature positive scores had improved PFS compared to OncoSignature
negative patients. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Prediction of <FONT STYLE="white-space:nowrap">ACR-368</FONT> clinical activity in additional cancer indications </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To identify tumor types predicted to be sensitive to <FONT STYLE="white-space:nowrap">ACR-368,</FONT> we used our <FONT
STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature test to screen across large numbers of human patient tumor samples across tumor types obtained from biorepositories. Through this tumor-agnostic usage of
<FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature we found that between 30% and 40% of samples from patients with endometrial cancer and bladder cancer were predicted to be sensitive to <FONT STYLE="white-space:nowrap">ACR-368.</FONT> In
addition to confirming the positive predictive value of our <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature test, we have also demonstrated the high negative predictive value of our <FONT STYLE="white-space:nowrap">ACR-368</FONT>
OncoSignature test. For example, in sqNSCLC our <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature test predicted that none of the patient samples would be sensitive to <FONT STYLE="white-space:nowrap">ACR-368,</FONT> which is consistent
with the Phase 1 trial that was conducted in SCC types and described above, which showed an ORR of 0% in sqNSCLC. Based on these findings, which were further confirmed in PDX models of endometrial and bladder cancer, as described below, we predict
that a significant proportion of patients with endometrial and bladder cancer will also be sensitive to <FONT STYLE="white-space:nowrap">ACR-368</FONT> monotherapy, and these two tumor types are therefore included together with ovarian cancer in our
upcoming Phase 2 trial. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383050g28s66.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 20.</B> ACR-368 OncoSignature screening across human routine-processed FFPE patient tumor samples
predicts which tumor types and what proportion thereof are sensitive to ACR-368. Each line in the four heat maps for each of the four tumor types&#151;ovarian cancer, sqNSCLC, endometrial cancer, and bladder cancer&#151;represents an individual
tumor sample and the three columns from left to right represent the quantitative level of each of the three biomarkers in the OncoSignature test. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Confirmation of activity in PDX models of predicted tumor types </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In order to confirm our prediction based on screening of human patient tumor samples that a proportion of patients with bladder
and endometrial cancer are sensitive to <FONT STYLE="white-space:nowrap">ACR-368</FONT> monotherapy, we generated PDX models of these two tumor types and assessed anti-tumor activity of <FONT STYLE="white-space:nowrap">ACR-368</FONT> in these
tumors. Fresh tumor tissues from mice bearing established primary human endometrial and bladder cancer tissues from 20 and 18 patients, respectively, were harvested and small pieces inoculated into mice randomized into two groups, receiving vehicle
control and <FONT STYLE="white-space:nowrap">ACR-368,</FONT> respectively, as well as a PD group used to predict <FONT STYLE="white-space:nowrap">ACR-368</FONT> sensitivity on the tumor tissue prior to treatment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Mice were treated in a <FONT STYLE="white-space:nowrap">three-days-on,</FONT>
<FONT STYLE="white-space:nowrap">four-days-off</FONT> weekly schedule for four weeks at 10 mg/kg. Mice were sacrificed either four days after last dosing or when the tumor volume in one of the arms reached 2,000 mm, whichever came first. <FONT
STYLE="white-space:nowrap">ACR-368</FONT> demonstrated anti-tumor single agent activity in a proportion of models while others were less sensitive, consistent with the prediction obtained from screening of human patient tumor samples. This result in
these preclinical studies confirmed the predicted single agent activity of <FONT STYLE="white-space:nowrap">ACR-368</FONT> in endometrial and bladder cancer. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383050g17s56.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 21.</B><B><I> </I></B>Assessment of anti-tumor activity of
<FONT STYLE="white-space:nowrap">ACR-368</FONT> in PDX models of endometrial cancer (left two columns) and bladder cancer (right two columns) confirm that a proportion are sensitive to <FONT STYLE="white-space:nowrap">ACR-368.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Blinded, prospectively designed prediction of sensitivity to <FONT STYLE="white-space:nowrap">ACR-368</FONT> in endometrial PDX models </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To further demonstrate the predictive power of our <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature test, we were
able to obtain <FONT STYLE="white-space:nowrap">de-identified</FONT> FFPE tissue samples from the PD arm of the endometrial cancer PDX model study. <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature biomarker scores were generated for 18
out of 20 PDX models, as two PDX models lacked cytokeratin expression. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Using the same minimal biomarker levels established and evaluated in all our
other studies summarized above, we found that eight PDX models were <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature-positive and predicted to be sensitive to <FONT STYLE="white-space:nowrap">ACR-368.</FONT> After unblinding of the data
and analysis by a third-party biostatistician, we showed that these models all were sensitive and experienced tumor growth inhibition, or TGI, in response to treatment with <FONT STYLE="white-space:nowrap">ACR-368.</FONT> The <FONT
STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature-negative models, which are predicted less sensitive to <FONT STYLE="white-space:nowrap">ACR-368,</FONT> contained all the <FONT STYLE="white-space:nowrap">non-responsive</FONT> PDX models as
well as some models with overall less pronounced TGI. The segregation of <FONT STYLE="white-space:nowrap">non-responders</FONT> from responders was statistically significant, and a sensitivity and specificity analysis demonstrated an AUC of 0.88.
Despite the well-known observation that PDX models in general tend to show a much higher percentage of responders compared to human patients, as also demonstrated in our ovarian PDX model study above, this result nevertheless confirmed the ability
of our <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature test to segregate the most sensitive from <FONT STYLE="white-space:nowrap">non-sensitive</FONT> PDX models in a blinded, prospectively designed manner. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383050g91s91.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 22</B>.<B> </B>Blinded, prospectively designed prediction of
<FONT STYLE="white-space:nowrap">ACR-368</FONT> sensitivity with our OncoSignature test demonstrates segregation of responders and <FONT STYLE="white-space:nowrap">non-responders</FONT> with a p-value = 0.003 and an AUC of 0.88. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>AP3 Platform Prediction of LDG as a Rational Combination to Circumvent <FONT STYLE="white-space:nowrap">ACR-368</FONT> Resistance </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Not all tumors are sensitive to <FONT STYLE="white-space:nowrap">ACR-368,</FONT> and those that are sensitive can develop
resistance to treatment. We used our AP3 platform to identify pathways that drive resistance to <FONT STYLE="white-space:nowrap">ACR-368</FONT> and to propose potential combination therapies to circumvent these resistance pathways. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As an example, we generated <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ACR-368-resistant</FONT></FONT>
ovarian cancer cell lines by growing five different human tumor cell lines, including OVCAR3, that are normally sensitive to <FONT STYLE="white-space:nowrap">ACR-368</FONT> in the presence of a clinically relevant dose (50 nM) of <FONT
STYLE="white-space:nowrap">ACR-368</FONT> for over ten weeks. While most cells died, a few cells developed resistance to <FONT STYLE="white-space:nowrap">ACR-368</FONT> and were able to grow in the presence of the drug candidate. In general,
resistant cells were at least <FONT STYLE="white-space:nowrap">1,000-fold</FONT> less sensitive to <FONT STYLE="white-space:nowrap">ACR-368</FONT> than the parental cell lines. Removal of <FONT STYLE="white-space:nowrap">ACR-368</FONT> for up to two
months in the cell lines did not alter this level of resistance, and resistance was maintained in the presence of drug efflux inhibitors, suggesting that the resistance was not due to drug efflux from the cells, but rather permanent change in cell
signaling in these cell lines drove the development of resistance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Using AP3, we conducted global proteomic analyses
comparing <FONT STYLE="white-space:nowrap">ACR-368</FONT> sensitive and resistant OVCAR3 cells, identifying thousands of differentially expressed proteins and phosphoproteins in these cells. Pathway mapping and analyses of these proteins and
phosphoproteins showed that the activity state of proteins involved in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
DNA damage repair were significantly downregulated, with a compensatory upregulation of proteins involved in cell cycle progression. These changes demonstrate a low level of active DNA damage
repair and hence we believe that they allowed these <FONT STYLE="white-space:nowrap">ACR-368</FONT> resistant cells to continue to progress through the cell cycle regardless of the presence of the drug. Furthermore, we found that cells treated with
low doses of gemcitabine led to reversal of these changes, upregulating the activity of the core DNA damage repair pathways, consistent with potentially identifying a means of reversing <FONT STYLE="white-space:nowrap">ACR-368</FONT> resistance.
This was in line with our quantitative phosphoproteomic data, which showed that treatment of <FONT STYLE="white-space:nowrap">ACR-368</FONT> resistant cells with LDG resulted in an upregulation of the three OncoSignature biomarkers, rendering the
tumor cells more <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature-positive after treatment with LDG. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383050g14s30.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 23</B>. Proteomic analyses of <FONT STYLE="white-space:nowrap">ACR-368</FONT> sensitive and
resistant ovarian cell lines identified activation of proteins that regulate cell cycle progression and inactivation of proteins in the DNA damage repair pathways. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These findings suggested that tumor cells that are resistant to <FONT STYLE="white-space:nowrap">ACR-368</FONT> should be
sensitized by treatments such as gemcitabine that function by disrupting cell cycle progression. We tested this hypothesis in cell-killing assays. The five parental human ovarian tumor cell lines were highly sensitive to <FONT
STYLE="white-space:nowrap">ACR-368</FONT> killing with a concentration required for 50% inhibition, or EC<SUB STYLE="font-size:75%; vertical-align:bottom">50</SUB> between ten to 30 nM. The
EC<SUB STYLE="font-size:75%; vertical-align:bottom">50</SUB> for OVCAR3 was 15 nM <FONT STYLE="white-space:nowrap">ACR-368.</FONT> By contrast, the resistant OVCAR3 cells had an EC<SUB STYLE="font-size:75%; vertical-align:bottom">50</SUB> of over 10
&micro;M, which means they were over <FONT STYLE="white-space:nowrap">1,000-fold</FONT> less sensitive to <FONT STYLE="white-space:nowrap">ACR-368.</FONT> Treatment of these cells with 0.53 nM gemcitabine, lowered the EC<SUB
STYLE="font-size:75%; vertical-align:bottom">50</SUB> for <FONT STYLE="white-space:nowrap">ACR-368</FONT> to 100 nM. A further increase in gemcitabine concentration to 2.7 nM lowered the EC<SUB STYLE="font-size:75%; vertical-align:bottom">50</SUB>
for <FONT STYLE="white-space:nowrap">ACR-368</FONT> to 6 nM. Likewise, treatment of the parental cells with the same low doses of gemcitabine increased the sensitivity to ACR-368. Treatment of these cells with 0.53 nM gemcitabine lowered the EC50
for ACR-368 to 2.7 nM. A further increase in gemcitabine concentration to 2.7 nM lowered the EC50 for ACR-368 to 0.2 nM. These findings of synergy between <FONT STYLE="white-space:nowrap">ACR-368</FONT> and LDG were extended into other human tumor
cell lines, including endometrial and bladder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Support for the synergistic action of
<FONT STYLE="white-space:nowrap">ACR-368</FONT> and gemcitabine comes from the observation that gemcitabine alone does not induce potent cell death in OVCAR3 cells: at 0.53 and at 2.7 nM of gemcitabine there was no effect on cell survival, and more
than half of treated cells survived at concentrations exceeding 30 &micro;M. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383050g14s40.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 24.</B> Low concentrations of gemcitabine sensitize a highly resistant ovarian cancer cell line
to <FONT STYLE="white-space:nowrap">ACR-368.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Based on these results, we intend to treat patients who are predicted
to be resistant to <FONT STYLE="white-space:nowrap">ACR-368</FONT> in our clinical trials with LDG in combination with <FONT STYLE="white-space:nowrap">ACR-368</FONT> to potentially overcome resistance to
<FONT STYLE="white-space:nowrap">ACR-368.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Upcoming Phase 2 Clinical Trials of <FONT STYLE="white-space:nowrap">ACR-368</FONT> Based on <FONT
STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature-predicted Drug Sensitivity </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The IND for our upcoming Phase 2
clinical trial of <FONT STYLE="white-space:nowrap">ACR-368</FONT> with cohorts of patients with advanced or metastatic recurrent platinum-resistant high-grade ovarian, endometrial, and bladder cancers has cleared. The trial will be conducted under
the master protocol guidance by the FDA published in March 2022, which aims to enable expedited drug development in multiple cancer types of drugs for which the RP2D has been established in prior studies. The Phase 2 trial will be based on <FONT
STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature prediction of sensitivity to <FONT STYLE="white-space:nowrap">ACR-368</FONT> monotherapy on freshly sampled pretreatment tumor biopsies. Patients with
<FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature-positive tumors of all three tumor types will be enrolled in an arm to be treated with <FONT STYLE="white-space:nowrap">ACR-368</FONT> monotherapy at RP2D in a Simon <FONT
STYLE="white-space:nowrap">two-stage,</FONT> single arm design. Patients who have OncoSignature negative tumors of all three tumor types are predicted not to be highly sensitive to <FONT STYLE="white-space:nowrap">ACR-368</FONT> monotherapy. These
patients will be treated with <FONT STYLE="white-space:nowrap">ACR-368</FONT> at RP2D plus LDG in a single arm design based on our expectation that LDG will increase <FONT STYLE="white-space:nowrap">ACR-368</FONT> sensitivity in a proportion of
these <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature-negative patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the <FONT
STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature-positive arm, up to 23 patients of each of the three tumor types will receive <FONT STYLE="white-space:nowrap">ACR-368</FONT> monotherapy at RP2D. Although not expected to be necessary, the
trial does incorporate an opportunity to refine the OncoSignature biomarker patient selection threshold based on the first 12 patients treated with <FONT STYLE="white-space:nowrap">ACR-368</FONT> monotherapy. An interim futility analysis will be
used to exclude the <FONT STYLE="white-space:nowrap">non-interesting</FONT> response rate and assess the ORR. Based on this result, the study is designed to enroll up to an additional 48 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
patients with these tumor types with a registrational intent. The <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature-negative patients of all three tumor types will receive <FONT
STYLE="white-space:nowrap">ACR-368</FONT> at RP2D with increasing doses of LDG in a Phase 1b dose escalation component of the trial. Once the RP2D for LDG with <FONT STYLE="white-space:nowrap">ACR-368</FONT> has been found, the plan is to expand the
<FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature-negative patients at the RP2D for the combination into a Phase 2 trial component for all three tumor types in a single arm design. Anti-tumor activity will be assessed by RECIST. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383050g23a01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 25</B>. Design of the single arm Phase 2 ACR-368 monotherapy and single arm Phase 1b/2 ACR-368
with LDG combination trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We intend to expand our master protocol, at a later point to include patients with HPV<SUP
STYLE="font-size:75%; vertical-align:top">+</SUP> squamous cell carcinomas, including SCCHN, anal, and cervical cancer. The prior studies in SCCHN and anal cancer, described above, have demonstrated an unenriched ORR of 19% in patients with HPV<SUP
STYLE="font-size:75%; vertical-align:top">+</SUP> SCCHN, and 15% in patients with anal cancer. Moreover, the mDoR was seven months for SCCHN and above 12 months in anal cancer. The FDA has granted ODD for
<FONT STYLE="white-space:nowrap">ACR-368</FONT> for anal cancer. Preclinical screening on human patient tumor samples suggests that approximately 25% of cases of these cancers have activated biochemical signaling pathways that are consistent with
sensitivity to <FONT STYLE="white-space:nowrap">ACR-368.</FONT> We plan to file an IND application amendment to add three additional tumor types under the same master protocol and clinical trial design described above at a later date. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patients with additional tumor types, including sarcomas, have been observed to be sensitive to <FONT STYLE="white-space:nowrap">ACR-368</FONT>
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Several investigator-initiated trials, or IITs, have demonstrated clinical activity of <FONT
STYLE="white-space:nowrap">ACR-368</FONT> in combination with various chemotherapeutic agents in patients with different types of sarcomas. These are of high unmet need for improved treatments, and only 17% of patients with metastatic soft tissue
sarcomas survive more than five years. Importantly, these IITs have not only demonstrated clinical activity of <FONT STYLE="white-space:nowrap">ACR-368,</FONT> but have also demonstrated that combination with chemotherapy is generally well-tolerated
in these patients. For example, in a Phase 1/2 trial in patients with relapsed/refractory desmoplastic small round cell tumor and rhabdomyosarcoma conducted at Memorial Sloan Kettering Cancer Center it was reported that <FONT
STYLE="white-space:nowrap">ACR-368</FONT> in combination with irinotecan resulted in a 32% ORR and mPFS of over 5.5 months. The combination was generally well-tolerated, leading to primarily hematological adverse events, which were manageable. We
intend to initiate certain carefully selected trials in patients with sarcomas that have demonstrated promising preliminary clinical results in past trials at a later date. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Proprietary, Internal Preclinical Programs Targeting Critical Nodes in the DDR Pathways </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We intend to leverage our AP3 platform and OncoSignature tests to aim for enrichment of patient responders for our internal
preclinical programs. We strategically work on drug targets for which early-stage </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
clinical programs from other companies have demonstrated clinical activity or where there is a strong rationale for clinical activity, and where we believe genetics-based approaches are
insufficient for patient responder identification. Our programs include WEE1 and PKMYT1. The field designing drugs that target the DDR pathway is rapidly expanding to include a number of drug candidates in development against targets such as ATR,
ATM, <FONT STYLE="white-space:nowrap">DNA-PK,</FONT> CHK1/2, and WEE1. Although several of these candidates have demonstrated anti-tumor activity in the clinic, the ORRs to treatment with these candidates have been relatively low. We believe that
our AP3 platform provides us with the opportunity to not only develop OncoSignature tests to improve the response rates of existing drug candidates but can also guide the design and optimization of novel drug candidates as described above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are using <FONT STYLE="white-space:nowrap">co-crystallography-guided</FONT> drug design and use of cellular drug target
engagement imaging assays that incorporate insights derived from our AP3 platform, aiming to accelerate the advancement, and maximally improve the likelihood of success of, these internal programs. We are not only using our AP3 platform to generate
drug-tailored, response-predictive clinical OncoSignature tests, but we also use our AP3 platform to provide unbiased, quantitative analyses of <FONT STYLE="white-space:nowrap">off-target</FONT> effects on intracellular signaling using
phosphoproteomic profiling, potentially enabling us to discover inhibitors that are both highly potent and highly selective. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In our WEE1 program, we have multiple lead compounds synthesized and <FONT STYLE="white-space:nowrap">co-crystallized</FONT>
with WEE1 at resolutions observed between 2.1 &Aring; to 2.6 &Aring;. As a result of these experiments, we have synthesized over 400 compounds and discovered four novel lead series. Multiple compounds have been identified with IC<SUB
STYLE="font-size:75%; vertical-align:bottom">50</SUB>&#146;s less than 10 nM. We have observed encouraging drug target engagement in cells and evaluation of their PK properties is currently underway. In parallel, we are developing a target and drug
tailored OncoSignature test for patient selection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our second, closely related preclinical program directed at PKMYT1 is
equally advanced as our WEE1 program. We have synthesized multiple lead compounds and <FONT STYLE="white-space:nowrap">co-crystallized</FONT> these compounds with the target providing resolutions between 1.65 &Aring; to 2.1 &Aring;. As a result of
these experiments, we have identified two novel lead series. Multiple compounds have been identified with IC<SUB STYLE="font-size:75%; vertical-align:bottom">50</SUB>&#146;s less than 10 nM. We have also observed encouraging drug target engagement
in cells and evaluation of their PK properties is currently underway. In parallel, we are developing a target and drug tailored OncoSignature test for patient selection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We anticipate nominating a development candidate and entering <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies for
either of these programs by the end of 2023. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Expansion of Our Pipeline Through Application of AP3 and OncoSignature Tests </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have shown that our AP3 platform is capable of generating OncoSignature tests that can predict preclinical sensitivity to a
number of potential cancer therapies. We are applying the power of this technology to expand our pipeline in several ways: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Selectively pursue carefully selected in-licensing candidates for which we believe a genetics-based patient
selection method is challenging and where we believe an OncoSignature predictive test can be developed that will significantly improve response rates, similar to how we identified ACR-368. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Develop our own proprietary inhibitors of targets that we believe are highly amenable to use with an
OncoSignature test. We have found that a number of DDR targets fall into this class. We have already initiated preclinical programs for two such targets. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Establish carefully selected <FONT STYLE="white-space:nowrap">co-development</FONT> partnerships with leading
biopharmaceutical organizations that either have approved products or attractive drug candidates under competitive pressure where the availability of an OncoSignature test could significantly increase response rates, leading to new drug approvals,
label expansions and the ability to deliver effective therapies to the right patients. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Broad Utility and Applications of Our AP3 Platform </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Based on our extensive studies, we have demonstrated that our AP3 platform has many high impact applications, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Predictive biomarkers and patient responder identification. </U>Our AP3 platform enables identification of
predictive biomarkers that are assembled into OncoSignature tests used to select patients to be treated that are predicted to be sensitive to a drug or drug candidate, <FONT STYLE="white-space:nowrap">so-called</FONT> patient responders. This
capability has been demonstrated in the studies described above. Using this approach, we have also developed predictive OncoSignature tests for a clinical stage CDK7 inhibitor and a clinical stage CDC7 inhibitor. The goal is to only treat patients
most likely to benefit from the drug and avoid overtreatment of patients that do not benefit from it with the potential for side effects. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Indication finding and expansion</U>. The drug-tailored OncoSignature tests are also used to identify tumor
types predicted to be sensitive to a drug or drug candidate. By screening across human patient tumor samples across tumor types, one can estimate the proportion of predicted responders within these samples in a matter of weeks. The goal is to
identify and treat patients with attractive, high unmet need tumor types with an appropriate proportion of predicted responders and to avoid treatment of patients with tumor types that are predicted to be unresponsive to the drug or drug candidate.
This is applicable to both clinical stage drug candidates and preclinical lead series. For example, through this approach we were able to identify endometrial and bladder cancer as two predicted highly <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">ACR-368-sensitive</FONT></FONT> tumor types, which are now included in our upcoming Phase 2 clinical trials. Conversely, we also found that sqNSCLC is predicted <FONT STYLE="white-space:nowrap">non-sensitive</FONT> to the
drug candidate, consistent with the clinical trial conducted by Lilly, which showed 0% ORR in their prior clinical trial in sqNSCLC. Likewise, for preclinical stage lead series, our AP3 platform enables us to know and plan for exactly which tumor
types to include in any future clinical trials. This enables indication expansion and could potentially increase the response rates in clinical trials. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Identification of resistance mechanisms.</U> The AP3 approach is also used to identify resistance
mechanisms in human cancer, preventing a desirable drug response. Resistance mechanisms can be divided into two main categories: na&iuml;ve, or intrinsic, resistance and therapy-induced, or acquired, resistance. For example, we have shown that the <FONT
STYLE="white-space:nowrap">IRS-2</FONT> adaptor protein is a key mediator of <FONT STYLE="white-space:nowrap">ALK-driven</FONT> tumor cell survival in neuroblastoma and can serve as an intrinsic resistance mechanism to ALK inhibition. As an example
of therapy-induced resistance we have shown that protein kinase <FONT STYLE="white-space:nowrap">C-delta,</FONT> or <FONT STYLE="white-space:nowrap">PKC-</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT>, is a resistance mechanism to Notch1
inhibition in leukemia. Moreover, in studies deploying advanced MS with <FONT STYLE="white-space:nowrap">so-called</FONT> spatial phosphoproteomics to quantify phosphopeptides with high accuracy in the nucleus and cytoplasm of cells, a method
developed in <FONT STYLE="white-space:nowrap">co-founder</FONT> Jesper Olsen&#146;s lab, we found that upregulated <FONT STYLE="white-space:nowrap">AKT-Foxo3</FONT> signaling and p53
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">loss-of-function</FONT></FONT> are acquired and intrinsic resistance mechanisms to selinexor, a selective inhibitor of the nuclear export protein XPO1, in patients with AML.
Understanding of resistance mechanisms is often clinically actionable, as such patients can either effectively be excluded from therapy or, as described in next paragraph, receive rational drug combinations. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383050g46m46.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 26. </B>Spatial phosphoproteomics conducted in two human AML cell lines quantifies the nuclear
and cytoplasmic levels of more than 35,000 phosphopeptides and identifies upregulated, nuclear signaling of <FONT STYLE="white-space:nowrap">AKT-FOXO3A</FONT> as a resistance mechanism to Selinexor. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Identification of rational drug combinations.</U> To the extent that identified resistance mechanisms
include druggable targets, these can be the basis for rational drug combinations. For example, in the studies referenced above, the uncovered resistance mechanisms included the druggable targets <FONT STYLE="white-space:nowrap">PKC-</FONT><FONT
STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT>, AKT, and MDM2. Accordingly, it was demonstrated that (i)&nbsp;combination with the PKC inhibitor sotrastaurin overcame Notch inhibitor resistance in leukemia, (ii)&nbsp;combination with the AKT inhibitor <FONT
STYLE="white-space:nowrap">MK-2206</FONT> overcame selinexor resistance, and (iii)&nbsp;combination with the MDM2 inhibitor, nutlin, which enhances p53 activity, enhanced selinexor sensitivity in AML. These results demonstrate the wider
applicability of our AP3 platform to a number of drug target classes beyond DDR, including targets for which there is currently only limited understanding of their biological mechanisms of action. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Unbiased drug target engagement and PD biomarker discovery.</U> Through our high resolution
phosphoproteomic drug profiling we uncover and quantify typically in the order of approximately 6,000 statistically significantly regulated phosphoproteomic changes that correlate with drug exposure. This provides a rich source of potential
clinically useful biomarkers that can be developed to quantify PD drug target exposure. Such biomarkers can be used for dose-optimization through measure of the drug target engagement in patient tumor tissue in dose-finding Phase 1 clinical trials.
Moreover, they can inform whether the drug candidate elicits the predicted changes in biological signaling pathways in a patient&#146;s tumor. Typically at least one of our three classes of biomarkers in our OncoSignature tests is a key PD biomarker
for our drug target. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In summary, the AP3 method is broadly applicable across products and drug
candidates and is developed and designed to be a transformative, efficient method to accurately match the right therapy to the right patient. Given the highly structured data resulting from AP3, we have been able to engineer it as a machine learning
pipeline, aiming for high throughput and reproducible results. We expect this to be highly beneficial in our pursuit of expanding our proprietary pipeline and portfolio through continued <FONT STYLE="white-space:nowrap">in-licensing</FONT> and <FONT
STYLE="white-space:nowrap">co-development</FONT> pharmaceutical partnerships. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Business Protection </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our AP3 platform and OncoSignature methodology has been developed and implemented for over a decade by our founding scientific
team as an expert system. As such, we have multiple layers of protection. Firstly, we </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
have over the years established a number of tools and trade secrets that we keep as proprietary <FONT STYLE="white-space:nowrap">know-how</FONT> <FONT STYLE="white-space:nowrap">in-house.</FONT>
Secondly, we file concrete, tumor-agnostic <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">method-of-use</FONT></FONT> patents for our drug-tailored OncoSignature tests. For example, we have filed an
<FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">method-of-use</FONT></FONT> patent claiming treatment of patients with <FONT STYLE="white-space:nowrap">ACR-368</FONT>
OncoSignature-positive tumors with <FONT STYLE="white-space:nowrap">ACR-368</FONT> monotherapy based on predicted sensitivity to the drug. Finally, through an exclusive license arrangement with our CDx partner who will be conducting the clinical
development for our test and, pending successful market approval, commercialize it, we believe we have ensured that the test cannot be offered for other DDR inhibitors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Manufacturing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We
acquired sufficient <FONT STYLE="white-space:nowrap">ACR-368</FONT> drug substance and drug product from Lilly to treat several hundred patients. Aside from this material, we expect to rely on, for the foreseeable future, third-party contract
manufacturing organizations, or CMOs, to produce our drug candidates for preclinical studies and clinical trials, as well as for future commercial manufacture of any drugs, if approved. We require all our CMOs to conduct manufacturing activities in
compliance with current good manufacturing practice, or cGMP, requirements. We have assembled a team of experienced employees and consultants who provide the necessary technical, quality and regulatory oversight to ensure the cGMP compliance of our
CMOs. Currently, we have manufacturing agreements in place with three CMOs for the manufacture of <FONT STYLE="white-space:nowrap">ACR-368.</FONT> To date we have successfully completed three familiarization campaigns, one GMP engineering campaign
and three registrational campaigns for the drug substance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We plan to continue to rely on third-party manufacturers for
any future trials and commercialization, if approved, of <FONT STYLE="white-space:nowrap">ACR-368</FONT> and any future drug candidates. We anticipate that these CMOs will have the capacity to support commercial scale production, but do not have any
formal agreements in place at this time. If needed, we believe we can identify and engage additional CMOs to provide active pharmaceutical ingredient and finished drug product without significant disruption to our business or clinical development
timelines. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Licensing and Collaborations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>License Agreement with Lilly </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In January 2021, we entered into a license agreement and stock issuance agreement, or, collectively, the Lilly Agreement, with
Lilly, pursuant to which we have been granted an exclusive, royalty-bearing sublicensable license to certain intellectual property rights owned or controlled by Lilly, to commercially develop, manufacture, use, distribute and sell therapeutic
products containing the compound prexasertib. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the terms of the agreement, we paid Lilly an initial upfront fee
payment of $5.0&nbsp;million. In connection with entering into the agreement, we also entered into a common stock issuance agreement with Lilly pursuant to which we issued Lilly 336,575 shares of our common stock and 46,058 shares of Series B
convertible preferred stock, which will convert into 18,677 shares of common stock immediately upon the closing of this offering. As additional consideration for the license, we are required to pay Lilly aggregate&nbsp;development and
commercial&nbsp;milestone payments of up to $168.0&nbsp;million, of which $5.0&nbsp;million is due prior to NDA.&nbsp;We are also obligated to pay a tiered percentage royalty on annual net sales ranging from a low single-digit up to&nbsp;a maximum
of 10% subject to certain specified reductions. Royalties are payable by&nbsp;us on a licensed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-licensed</FONT></FONT> product and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis until the later of the expiration of the last valid claim covering the licensed product in such country, expiration of all applicable regulatory exclusivities in such country for such
licensed product and the tenth anniversary of the first commercial sale of such licensed product in such country, provided, that our obligation to pay royalties for a given licensed product in a given country will expire earlier upon achievement of
certain sales thresholds by generic products is such country. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We also&nbsp;have provided Lilly&nbsp;with certain,
limited rights of first negotiation with us for reacquisition of the <FONT STYLE="white-space:nowrap">ACR-368</FONT> program with such right expiring 45 days following the completion of certain clinical milestones.&nbsp;The right to first
negotiation expressly does not restrict any potential Change of Control transaction or IPO of our company (as each such term is&nbsp;contractually&nbsp;defined in the agreement). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Companion Diagnostic Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In June 2022, we entered into a companion diagnostic agreement with Akoya pursuant to which we agreed to <FONT
STYLE="white-space:nowrap">co-develop,</FONT> validate, and commercialize our proprietary <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature test, the CDx that will be used to identify patients with cancer most likely to respond to <FONT
STYLE="white-space:nowrap">ACR-368.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to the agreement, Akoya, in partnership with us, will develop,
clinically validate, seek regulatory approval for, and, pending <FONT STYLE="white-space:nowrap">ACR-368</FONT> approval, commercialize the OncoSignature test required for prescribing <FONT STYLE="white-space:nowrap">ACR-368.&nbsp;Development</FONT>
of the CDx will be overseen by a joint steering committee.&nbsp;Each party is required to use commercially reasonable efforts to carry out its activities under the agreement.&nbsp;The agreement contains certain mutual exclusivity obligations of the
parties with respect to the biomarkers and drug target, subject to certain specified limitations, including in the event that Akoya is unable to sufficiently supply commercial needs of such CDx.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to the agreement, we paid Akoya a <FONT STYLE="white-space:nowrap">one-time,</FONT>
<FONT STYLE="white-space:nowrap">non-refundable,</FONT> <FONT STYLE="white-space:nowrap">non-creditable</FONT> upfront payment in the amount of $0.6&nbsp;million. The Company is obligated to pay Akoya up to an aggregate of $10.3 million upon the
achievement of specified development milestones. As of October&nbsp;17, 2022, development milestones have been achieved under the agreement, resulting in payments of $2.3&nbsp;million by the Company to Akoya. Other than certain specified
pass-through costs, each party is responsible for its own costs associated with the development of the companion diagnostic.&nbsp;Akoya will procure and manufacture necessary supplies to perform the <FONT STYLE="white-space:nowrap">ACR-368</FONT>
OncoSignature test to support our clinical development and commercial requirements, in accordance with a supply agreement to be mutually agreed upon by the parties. We may terminate the agreement at our convenience, subject to the payment of a
termination fee in the amount of $1.0 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The agreement shall, unless terminated early, continue in
perpetuity.&nbsp;Either party may terminate the agreement in the event of an uncured, material breach by the other party or insolvency of the other party.&nbsp;Additionally, we may terminate the agreement for any reason subject to a specified notice
period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent License Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In April 2018, we entered into a patent license agreement, or the Blume-Jensen License Agreement, with Peter Blume-Jensen, our
Chief Executive Officer and President, that granted us an exclusive, worldwide, irrevocable, perpetual, royalty-free license under certain licensed patents relating to broad aspects of the general discovery process for biomarkers in our
drug-tailored OncoSignature tests, such as our ACR-368 OncoSignature test, for any and all purposes and uses, including without limitation and rights to sublicense through multiple tiers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the terms of the Blume-Jensen License Agreement, we issued 871,857 shares of our common stock to Dr. Blume-Jensen. In
addition, we were obligated to reimburse Dr. Blume-Jensen the sum of $150,000, which represented the parties&#146; agreed upon estimate of unreimbursed past expenses incurred by Dr. Blume-Jensen with respect to the preparation, filing, prosecution,
protection and maintenance of the licensed patents, within 30 days following the closing of an equity financing by us with gross proceeds of at least $2,000,000. Following the closing of our Series A-1 Preferred Stock financing, we paid Dr.
Blume-Jensen $150,000 in October 2020 to satisfy this obligation. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Unless otherwise terminated pursuant to its
termination provisions, the Blume-Jensen License Agreement will expire upon the expiration of all claims under the licensed patents. We have the right to terminate the Blume-Jensen License Agreement at any time upon written notice to Dr.
Blume-Jensen. Dr. Blume-Jensen may also terminate the Blume-Jensen License Agreement in the event of our dissolution, liquidation, bankruptcy or if we cease operations for a continuous period of 12 months. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We pursue a layered intellectual property strategy, including patents, trademarks, and trade secret rights, to protect our AP3
platform, the OncoSignature<SUP STYLE="font-size:75%; vertical-align:top"> </SUP>tests we develop with it, and the drug candidates<SUP STYLE="font-size:75%; vertical-align:top"> </SUP>we work to commercialize. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Given the early stage of development of our drug candidates, we cannot be certain that any of our intellectual property rights
will provide protection for any drug candidate that may ultimately be commercialized. <FONT STYLE="white-space:nowrap">ACR-368</FONT> is our only drug candidate that has advanced to clinical testing, and there can be no certainty that its clinical
development will be successful, or that significant modification or adjustment will not be required for successful commercialization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our future commercial success depends, in part, on our abilities to obtain and maintain patent and other proprietary
protection for commercially important technology, inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> related to our business; to defend and enforce our patents and other intellectual property; to preserve the confidentiality of our
trade secrets; and to operate without infringing, misappropriating or violating the valid and enforceable patents and other intellectual property rights of third parties. Our ability to stop third parties from making, using, selling, offering to
sell or importing our products, or from developing competing diagnostic technologies, may depend on the extent to which we have rights under valid and enforceable patents, trade secrets or other intellectual property rights that cover these
activities. We cannot be sure that patents will issue with respect to any of the owned or licensed pending patent applications or, with respect to any patent applications that we may file or license in the future, nor can we be sure that any of our
owned or licensed patents or any patents that may be issued now or in the future will be commercially useful in protecting any products that we ultimately attempt to commercialize, or any method of making or using such products. Moreover, we may be
unable to obtain patent protection for certain of our drug candidates, or for our OncoSignature<SUP STYLE="font-size:75%; vertical-align:top"> </SUP>tests or AP3 platform. See the section titled &#147;Risk Factors&#151;Risks Related to Intellectual
Property&#148; for a more comprehensive description of risks related to our intellectual property. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patents </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">An issued patent provides its owner (or its licensee) with a right to exclude others from making, using or selling that which
is claimed in the patent, for a specified period of time (the &#147;term&#148; of the patent), in the jurisdiction in which the patent is issued. In the United States, and in many other countries, patents have a presumptive term of 20&nbsp;years
from their effective filing date (which is the earliest <FONT STYLE="white-space:nowrap">non-provisional</FONT> filing date to which the patent claims priority). However, many jurisdictions, including the United States, require the payment of
periodic maintenance fees in order for patents to remain in force for the full <FONT STYLE="white-space:nowrap">20-year</FONT> term; some jurisdictions require periodic annuities to be paid even to maintain pendency of an application. The United
States also has provisions that require a patent term to be shortened if its claims are too similar to another patent owned by the same party that has a shorter term. The United States and certain other jurisdictions also have provisions that permit
extension of patent term for patents that claim a drug or drug product, or its approved use, if the patent was issued before clinical trials were completed and certain other requirements were satisfied. In the United States, such extension is called
a Patent Term Extension, or PTE, and it is limited to a period of not more than five years, or a period that would extend the patent so that the total patent term including the PTE does not exceed 14 years after the date of regulatory approval; only
one patent can be extended per product approval. The United States also offers a different form of patent term extension, known as Patent Term Adjustment, or PTA, whereby a particular patent&#146;s term is automatically extended beyond the <FONT
STYLE="white-space:nowrap">20-year</FONT> date if the United States Patent and Trademark Office, or the USPTO, caused delay during its examination; however, potentially available PTA is reduced by any amount of any delay caused by the patent
applicant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our patent portfolio includes both <FONT STYLE="white-space:nowrap">in-licensed</FONT> and owned patent
filings, as discussed in more detail below. Particularly given our <FONT STYLE="white-space:nowrap">pre-commercial</FONT> state of development, we cannot be certain that any of the patent filings in our portfolio will provide meaningful protection
for any drug or OncoSignature test we ultimately attempt to commercialize. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have <FONT STYLE="white-space:nowrap">in-licensed</FONT> from Lilly a
portfolio including three families of patent filings relating to <FONT STYLE="white-space:nowrap">ACR-368.</FONT> See the section titled &#147;Business&#151;Licensing and Collaborations.&#148; The first family, with a presumptive twenty-year term
extending into 2029, includes issued patents in the United States (US patent 8,314,108, which, due to PTA, will expire in 2030) and including in Europe, China, Hong Kong, Japan, Macao and Taiwan. The second family, with a presumptive twenty-year
term extending into 2036, includes issued patents in the United States (US patent 11,123,326, which, due to PTA, will expire in 2037) and in Europe, Japan and Taiwan and a pending application in the United States, that claim use of <FONT
STYLE="white-space:nowrap">ACR-368</FONT> to treat certain particular types of cancer. The third family, with a presumptive twenty-year term extending into late 2036, includes issued patents in the United States (US patent 10,189,818, which, due to
PTA, will expire in 2037) and in Europe, China, Hong Kong, Japan and Taiwan. We may be able to pursue patent term extension in one or more jurisdictions for patents in this <FONT STYLE="white-space:nowrap">in-licensed</FONT> portfolio to provide
extended protection to <FONT STYLE="white-space:nowrap">ACR-368.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have also
<FONT STYLE="white-space:nowrap">in-licensed</FONT> from our founder a patent family with a presumptive twenty-year term extending into 2028 that includes issued EP and pending US filings that claims aspects of our AP3 platform relating to methods
of identifying responder populations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We own a provisional patent filing in the United States directed to our
OncoSignature<SUP STYLE="font-size:75%; vertical-align:top"> </SUP>test for <FONT STYLE="white-space:nowrap">ACR-368,</FONT> including claims to methods of treating patients identified by the OncoSignature<SUP
STYLE="font-size:75%; vertical-align:top"> </SUP>test with <FONT STYLE="white-space:nowrap">ACR-368;</FONT> non-provisional filings in the United States that claim the benefit of this filing and filings in other jurisdictions that claim priority to
this filing would have a presumptive twenty-year term extending into 2043. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We intend to pursue patent protection, whether
through <FONT STYLE="white-space:nowrap">in-licensing</FONT> or our own development, for future drug candidates and OncoSignature<SUP STYLE="font-size:75%; vertical-align:top"> </SUP>tests. We may also pursue additional patent protection for
features of our AP3 platform, though we will rely on confidentiality and trade secret protections for certain aspects of that platform. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Trademarks
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have registered our rights in the OncoSignature<SUP STYLE="font-size:75%; vertical-align:top"> </SUP>mark in
the United States and various other jurisdictions. We expect to pursue trademark protection for additional marks in the future for products and assays that we commercialize. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Trade Secrets and Confidential Information </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For certain of our technologies, including aspects of our AP3 platform and how we use it to develop OncoSignature<SUP
STYLE="font-size:75%; vertical-align:top"> </SUP>tests, we rely on unpatented trade secrets and confidential <FONT STYLE="white-space:nowrap">know-how</FONT> to develop and maintain our competitive position. However, trade secrets are notoriously
difficult to protect. Breaches of trade secret or confidentiality provisions can be challenging to detect, and even more challenging to prove. We seek to protect our proprietary information, in part, through confidentiality and <FONT
STYLE="white-space:nowrap">non-competition</FONT> agreements with employees, consultants, partners, and other advisors. These agreements may be breached and we may not be able to successfully defend our rights. Moreover, we may not be able to secure
adequate remedies for harm caused by such breach. Furthermore, our trade secrets or confidential information may be independently developed by a third party, and we may not have any ability to restrain or secure any remedy from them. As a result, we
may be unable to meaningfully protect our trade secrets and proprietary information. See the section titled &#147;Risk Factors&#151;Risks Related to Intellectual Property&#148; for a more comprehensive description of risks related to our trade
secrets and confidential information. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The biopharmaceutical industry is characterized by the rapid evolution of technologies and understanding of precision medicine
in oncology, intense competition and a strong emphasis on intellectual property. As one of the first companies to adopt a phosphoproteomics-based approach with a platform designed to develop predictive
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
protein signature tests for patient responder identification, we believe that our differentiated approach, strategy, as well as our scientific capabilities,
<FONT STYLE="white-space:nowrap">know-how</FONT> and experience provide us with significant competitive advantages. However, in the future, we expect competition from multiple sources, including major pharmaceutical, specialty pharmaceutical, and
existing or emerging biotechnology companies, academic research institutions and governmental agencies and public and private research institutions worldwide. Many of our competitors, either alone or with their collaborators, have significantly
greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. These competitors also compete with us
in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient enrollment in clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. As a
result, our competitors may discover, develop, license or commercialize products before or more successfully than we do. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">At present, we do not believe we face competition from segments of the pharmaceutical, biotechnology and other related markets
that pursue the development of targeted oncology therapies for the smaller subsets of patients with genetically-defined cancers. However, we anticipate several biopharmaceutical companies will aim to develop precision oncology approaches for the
larger subsets of cancers where genetics has proven insufficient for patient responder identification. We expect that the broader biopharmaceutical field will eventually recognize proteomics as the next era of precision medicine, but we believe it
will take some time before significant competition will truly emerge in this space. There are several competitors with CHK1/2 inhibitors and WEE1 inhibitors, including Sierra Oncology (SRA737), Astrazeneca/Merck (Adavosertib), Zentalis <FONT
STYLE="white-space:nowrap">(Zn-c3),</FONT> Debiopharm (Debio0123), Impact Therapeutics (IMP7068) and Shouya Holdings <FONT STYLE="white-space:nowrap">(SY-4835).</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We, like other targeted oncology precision medicine companies, face competition more broadly across the oncology market for
cost-effective and reimbursable cancer treatments. The most common methods of treating patients with cancer are surgery, radiation and drug therapy, including chemotherapy, hormone therapy, biologic therapy, such as monoclonal and bispecific
antibodies, immunotherapy, cell-based therapy and targeted therapy, or a combination of any such methods. There are a variety of available drug therapies marketed for cancer. In many cases, these drugs are administered in combination to enhance
efficacy. While our drug candidates, if any are approved, may compete with these existing drugs and other therapies, to the extent they are ultimately used in combination with or as an adjunct to these therapies, our drug candidates may not be
competitive with them. Some of these drugs are branded and subject to patent protection, and others are available on a generic basis. Insurers and other third-party payors may also encourage the use of generic products or specific branded products.
As a result, obtaining market acceptance of, and gaining significant share of the market for, any of our drug candidates that we successfully introduce to the market may pose challenges. In addition, many companies are developing new oncology
therapeutics, and we cannot predict what the standard of care will be as our drug candidates progress through clinical development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We could see a reduction or elimination in our commercial opportunity if our competitors develop and commercialize drugs that
are safer, more effective, have fewer or less severe side effects, are more convenient to administer, are less expensive or with a more favorable label than our drug candidates. Our competitors also may obtain FDA or other regulatory approval for
their drugs more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. The key competitive factors affecting the success of all of our drug
candidates, if approved, are likely to be their efficacy, safety, convenience, price, the level of generic competition and the availability of reimbursement from government and other third-party payors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government Regulation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries impose substantial
requirements upon the clinical development, manufacture and marketing of pharmaceutical and diagnostic products. These agencies and other federal, state and local entities regulate research and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
development activities and the testing, manufacture, quality control, safety, effectiveness, labeling, storage, packaging, recordkeeping, tracking, approval, import, export, distribution,
advertising and promotion of drug and diagnostic products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Government Regulation of Drug Products </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA, and its implementing
regulations. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to
comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant to a variety of administrative or judicial sanctions, such as the FDA&#146;s refusal to
approve a pending New Drug Application, or NDA, withdrawal of an approval, imposition of a clinical hold, issuance of untitled or warning letters, product recalls or withdrawals from the market, product seizures, total or partial suspension of
production or distribution, injunctions, debarment, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The process required by the FDA before drug candidates may be marketed in the United States generally involves the following:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">nonclinical laboratory and animal tests that must be conducted in accordance with applicable regulations,
including good laboratory practices, or GLPs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submission to the FDA of an investigational new drug, or IND, application, which must become effective before
clinical trials may begin; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approval by an independent institutional review board, or IRB, for each clinical site or centrally before each
trial may be initiated; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adequate and well-controlled human clinical trials to establish the safety and efficacy of the proposed drug
candidate for its intended use, performed in accordance with good clinical practices, or GCPs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submission to the FDA of an NDA and payment of user fees; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of an FDA advisory committee review, if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection of manufacturing facilities and selected
clinical investigators for their compliance with cGMPs and GCPs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of FDA audits of clinical trial sites to assure compliance with GCPs and the integrity
of the clinical data; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FDA review and approval of an NDA to permit commercial marketing for particular indications for use; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with any post-approval requirements, including the potential requirement to implement a Risk
Evaluation and Mitigation Strategy, or REMS, and the potential requirement to conduct post-approval studies. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The testing and approval process requires substantial time, effort and financial resources. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preclinical Studies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Preclinical studies include laboratory evaluation of drug substance chemistry, pharmacology, toxicity and drug product
formulation, as well as animal studies to assess potential safety and efficacy. Prior to commencing the first clinical trial with a drug candidate, a sponsor must submit the results of the preclinical tests and preclinical literature, together with
manufacturing information, analytical data and any available clinical data or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
literature, among other required information, to the FDA as part of an IND. Some preclinical studies may continue even after the IND is submitted. The IND automatically becomes effective 30 days
after receipt by the FDA, unless the FDA, within the <FONT STYLE="white-space:nowrap">30-day</FONT> time period, raises safety concerns or questions about the conduct of the clinical trial and imposes a clinical hold. In such a case, the IND sponsor
and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA also may impose a partial clinical hold that would limit a trial, for example, to certain doses or for a certain length of time or to a certain number of
subjects. As a result, submission of an IND may not result in FDA authorization to commence a clinical trial. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clinical Trials </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Clinical trials involve the administration of the investigational new drug to human subjects under the supervision of qualified
investigators in accordance with GCP requirements. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development, as well as amendments to previously submitted clinical trials.
Further, an independent IRB for each institution participating in the clinical trial must review and approve the plan for any clinical trial, its informed consent form and other communications to study subjects before the clinical trial commences at
that site. An IRB is charged with protecting the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated
benefits. The IRB must continue to oversee the clinical trial while it is being conducted, including any changes to the study plans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Regulatory authorities, an IRB or the sponsor may suspend or discontinue a clinical trial at any time on various grounds,
including a finding that the subjects are being exposed to an unacceptable health risk, the clinical trial is not being conducted in accordance with the FDA&#146;s or the IRB&#146;s requirements, or if the drug has been associated with unexpected
serious harm to subjects. Some studies also include a data safety monitoring board, which receives special access to unblinded data during the clinical trial and may advise the sponsor to halt the clinical trial if it determines that there is an
unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In general, for purposes of
NDA approval, human clinical trials are typically conducted in three sequential phases that may overlap. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Phase 1</I>. Studies are
initially conducted to test the drug candidate for safety, dosage tolerance, structure-activity relationships, mechanism of action, absorption, metabolism, distribution and excretion in healthy volunteers or subjects with the target disease or
condition. If possible, Phase 1 clinical trials may also be used to gain early evidence of product effectiveness. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Phase 2</I>.
Controlled studies are conducted with groups of subjects with a specified disease or condition to provide enough data to evaluate the preliminary efficacy, optimal dosages and dosing schedule and expanded evidence of safety. Multiple Phase 2
clinical trials may be conducted to obtain information prior to beginning larger and more expansive Phase 3 clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Phase
3</I>. These clinical trials are generally undertaken in larger subject populations to provide statistically significant evidence of clinical efficacy and to further test for safety in an expanded subject population at multiple clinical trial sites.
These clinical trials are intended to establish the overall risk/benefit ratio of the product and provide an adequate basis for product labeling. These clinical trials may be done at trial sites outside the United States as long as the global sites
are also representative of the U.S. population and the conduct of the study at global sites comports with FDA regulations and guidance, such as compliance with GCPs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA may require, or companies may pursue, additional clinical trials after a product is approved. These <FONT
STYLE="white-space:nowrap">so-called</FONT> Phase 4 studies may be made a condition to be satisfied after approval. The results of Phase 4 studies can confirm the effectiveness of a drug candidate and can provide important safety information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We intend to proceed with the design and conduct of certain of our clinical
trials under the FDA&#146;s master protocol guidance. This guidance is intended to provide recommendations to sponsors of drugs or biologics for the treatment of cancer to expedite the development of such products by simultaneously evaluating more
than one investigational drug and/or more than one cancer type within the same overall trial structure (master protocols) in adult and pediatric cancers. In general, the RP2D should have been established for an investigational drug or drugs
evaluated in a master protocol. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Clinical trials must be conducted under the supervision of qualified investigators in
accordance with GCP requirements, which include the requirements that all research subjects provide their informed consent in writing for their participation in any clinical trial, and the review and approval of the study by an IRB. Investigators
must also provide information to the clinical trial sponsors to allow the sponsors to make specified financial disclosures to the FDA. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the
trial procedures, the parameters to be used in monitoring safety and the efficacy criteria to be evaluated and a statistical analysis plan. Information about some clinical trials, including a description of the trial and trial results, must be
submitted within specific timeframes to the National Institutes of Health for public dissemination on their ClinicalTrials.gov website. Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and
the IRB and more frequently if serious adverse events occur. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The manufacture of investigational drugs for the conduct of
human clinical trials is subject to cGMP requirements. Investigational drugs and active pharmaceutical ingredients imported into the United States are also subject to regulation by the FDA relating to their labeling and distribution. Further, the
export of investigational drug products outside of the United States is subject to regulatory requirements of the receiving country as well as U.S. export requirements under the FDCA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional
information about the chemistry and physical characteristics of the drug candidate as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable
of consistently producing quality batches of the drug candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected and
tested, and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Special FDA Expedited Review and Approval Programs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA has various programs, including fast track designation, breakthrough therapy designation, accelerated approval, and
priority review, which are intended to expedite or simplify the process for the development and FDA review of drugs that are intended for the treatment of serious or life threatening diseases or conditions and demonstrate the potential to address
unmet medical needs. The purpose of these programs is to provide important new drugs to patients earlier than under standard FDA review procedures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the fast track program, the sponsor of a new drug candidate may request that the FDA designate the drug candidate for a
specific indication as a fast track drug concurrent with, or after, the filing of the IND for the drug candidate. To be eligible for a fast track designation, the FDA must determine, based on the request of a sponsor, that a product is intended to
treat patients with a serious or life threatening disease or condition and demonstrates the potential to address an unmet medical need. The FDA will determine that a product will fill an unmet medical need if it will provide a therapy where none
exists or provide a therapy that may be potentially superior to existing therapy based on efficacy or safety factors. Fast track designation provides additional opportunities for interaction with the FDA&#146;s review team and may allow for rolling
review of NDA components before the completed application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable,
and the sponsor pays any required user fees upon submission of the first section of the NDA. However, the FDA&#146;s time period goal for reviewing an application does not begin until the last section of the NDA is submitted. The FDA may decide to
rescind the fast track designation if it determines that the qualifying criteria no longer apply. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, a sponsor can request breakthrough therapy designation for a
drug if it is intended, alone or in combination with one or more other drugs, to treat patients with a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial
improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Drugs designated as breakthrough therapies are eligible for intensive guidance from
the FDA on an efficient drug development program, organizational commitment to the development and review of the product including involvement of senior managers, and, like fast track products, are also eligible for rolling review of the NDA. Both
fast track and breakthrough therapy products may be eligible for accelerated approval and/or priority review, if relevant criteria are met. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the FDA&#146;s accelerated approval regulations, the FDA may approve a drug for a serious or life threatening illness
that provides meaningful therapeutic benefit to patients over existing treatments based upon a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible
morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of
alternative treatments. A drug candidate approved on this basis is subject to rigorous post marketing compliance requirements, including the completion of Phase 4 or post approval clinical trials to confirm the effect on the clinical endpoint.
Failure to conduct required post approval studies, or confirm a clinical benefit during post marketing studies, will allow the FDA to withdraw the drug from the market on an expedited basis. In addition, for products being considered for accelerated
approval, the FDA generally requires, unless otherwise informed by the agency, that all advertising and promotional materials intended for dissemination or publication within 120 days of marketing approval be submitted to the agency for review
during the pre-approval review period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Once an NDA is submitted for a product intended to treat patients with a serious
condition, the FDA may assign a priority review designation if the FDA determines that the product, if approved, would provide a significant improvement in safety or effectiveness. A priority review means that the goal for the FDA to review an
application is six months, rather than the standard review of ten months under the Prescription Drug User Fee Act, or PDUFA, guidelines. Under the current PDUFA performance goals, these six and ten month review periods are measured from the <FONT
STYLE="white-space:nowrap">60-day</FONT> filing date rather than the receipt date for NDAs for new molecular entities, which typically adds approximately two months to the timeline for review from the date of submission. In addition, the FDA may
review applications under Real-Time Oncology Review, or RTOR, which, according to the FDA, aims to explore a more efficient review process to ensure that safe and effective treatments are available to patients as early as possible, while maintaining
and improving review quality. Drugs considered for review under RTOR must be likely to demonstrate substantial improvements over available therapy, which may include drugs previously granted breakthrough therapy designation for the same or other
indications, and must have straightforward study designs and endpoints that can be easily interpreted. RTOR allows the FDA to review much of the data in a NDA earlier, before the applicant formally submits the complete application. This analysis of
the <FONT STYLE="white-space:nowrap">pre-submission</FONT> package gives the FDA and applicants an early opportunity to address data quality and potential review issues and allows the FDA to provide early feedback regarding the most effective way to
analyze data to properly address key regulatory questions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Even if a product qualifies for one or more of these programs,
the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. In addition, the manufacturer of an investigational drug for a serious or
life threatening disease is required to make available, such as by posting on its website, its policy on responding to requests for expanded access. Furthermore, fast track designation, breakthrough therapy designation, accelerated approval and
priority review do not change the standards for approval and may not ultimately expedite the development or approval process. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>NDA Submission and Review by the FDA </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Assuming successful completion of the required clinical and preclinical testing, among other items, the results of product
development, including chemistry, manufacture and controls, nonclinical studies and clinical trials are submitted to the FDA, along with proposed labeling, as part of an NDA. The submission of an NDA requires payment of a substantial user fee to the
FDA. These user fees must be filed at the time of the first submission of the application, even if the application is being submitted on a rolling basis. Fee waivers or reductions are available in some circumstances. One basis for a waiver of the
application user fee is if the applicant employs fewer than 500 employees, including employees of affiliates, the applicant does not have an approved marketing application for a product that has been introduced or delivered for introduction into
interstate commerce, and the applicant, including its affiliates, is submitting its first marketing application. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In
addition, under the Pediatric Research Equity Act, an NDA or supplement to an NDA for a new active ingredient, indication, dosage form, dosage regimen or route of administration must contain data that are adequate to assess the safety and efficacy
of the drug for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric
data until after approval of the product for use in adults or full or partial waivers from the pediatric data requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA must refer applications for drugs that contain active ingredients, including any ester or salt of the active
ingredients, that have not previously been approved by the FDA to an advisory committee or provide in an action letter a summary of the reasons for not referring it to an advisory committee. The FDA may also refer drugs which present difficult
questions of safety or efficacy to an advisory committee. An advisory committee is typically a panel that includes clinicians and other experts who review, evaluate and make a recommendation as to whether the application should be approved and under
what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA reviews applications to determine, among other things, whether a product is safe and effective for its intended use
and whether the manufacturing controls are adequate to assure and preserve the product&#146;s identity, strength, quality and purity. Before approving an NDA, the FDA will inspect the facility or facilities where the product is manufactured. The FDA
will not approve an application unless it determines that the manufacturing processes and facilities, including contract manufacturers and subcontracts, are in compliance with cGMP requirements and adequate to assure consistent production of the
product within required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical trial sites to assure compliance with GCPs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Once the FDA receives an application, it has 60 days to review the NDA to determine if it is substantially complete to permit
a substantive review, before it accepts the application for filing. Once the submission is accepted for filing, the FDA begins an <FONT STYLE="white-space:nowrap">in-depth</FONT> review of the NDA. Under the goals and policies agreed to by the FDA
under PDUFA, the FDA has set the review goal of 10 months from the <FONT STYLE="white-space:nowrap">60-day</FONT> filing date to complete its initial review of a standard NDA for a new molecular entity, or NME, and make a decision on the
application. For priority review applications, the FDA has set the review goal of reviewing NME NDAs within six months of the <FONT STYLE="white-space:nowrap">60-day</FONT> filing date. Such deadlines are referred to as the PDUFA date. The PDUFA
date is only a goal and the FDA does not always meet its PDUFA dates. The review process and the PDUFA date may also be extended if the FDA requests or the NDA sponsor otherwise provides additional information or clarification regarding the
submission during the review period that amends the original application. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Once the FDA&#146;s review of the application
is complete, the FDA will issue either a Complete Response Letter, or CRL, or an approval letter. A CRL indicates that the review cycle of the application is complete and the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
application is not ready for approval. A CRL generally contains a statement of specific conditions that must be met in order to secure final approval of the NDA and may require additional
clinical or preclinical testing, or other information or analyses in order for the FDA to reconsider the application in the future. Even with the submission of additional information, the FDA ultimately may decide that the application does not
satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA&#146;s satisfaction, the FDA may issue an approval letter. An approval letter authorizes commercial marketing of the drug with specific prescribing
information for specific indications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA may delay or refuse approval of an NDA if applicable regulatory criteria
are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product, or impose other conditions, including distribution restrictions or other risk management
mechanisms. For example, the FDA may require a REMS as a condition of approval or following approval to mitigate any identified or suspected serious risks and ensure safe use of the drug. The FDA may prevent or limit further marketing of a product,
or impose additional post-marketing requirements, based on the results of post-marketing studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and
additional labeling claims, are subject to further testing requirements, FDA notification and FDA review and approval. Further, should new safety information arise, additional testing, product labeling or FDA notification may be required. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If regulatory approval of a product is granted, such approval may entail limitations on the indicated uses for which such
product may be marketed or may include contraindications, warnings or precautions in the product labeling, which has resulted in a boxed warning. A boxed warning is the strictest warning put in the labeling of prescription drugs or drug products by
the FDA when there is reasonable evidence of an association of a serious hazard with the drug. The FDA also may not approve the inclusion of all labeling claims sought by an applicant. Once approved, the FDA may withdraw the product approval if
compliance with <FONT STYLE="white-space:nowrap">pre-</FONT> and post-marketing regulatory standards is not maintained or if problems occur after the product reaches the marketplace. In addition, the FDA may require Phase 4 post-marketing studies to
monitor the effect of approved products, and may limit further marketing of the product based on the results of these post-marketing studies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Orphan Drug Designation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat patients with a rare
disease or condition, which is a disease or condition that affects fewer than 200,000 individuals in the United States, or 200,000 or more than individuals in the United States for which there is no reasonable expectation that the cost of developing
and making available in the United States a drug or biologic for this type of disease or condition will be recovered from sales in the United States for that drug or biologic. Orphan drug designation must be requested before submitting an NDA. After
the FDA grants Orphan Drug Designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. The Orphan Drug Designation does not convey any advantage in, or shorten the duration of, the
regulatory review or approval process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If a product that has Orphan Drug Designation subsequently receives the first FDA
approval for the disease for which it has such designation, the product is entitled to orphan drug exclusive approval (or exclusivity), which means that the FDA may not approve any other applications, including a full NDA, to market the same drug
for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or if the holder of the orphan drug exclusivity cannot assure the availability of
sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. Orphan drug exclusivity does not prevent the FDA from approving a different drug or biologic for the same disease
or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of Orphan Drug Designation are tax credits for certain research and a waiver of the NDA application fee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A designated orphan drug may not receive orphan drug exclusivity if it is
approved for a use that is broader than the indication for which it received orphan designation. In addition, exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially
defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Post-Approval Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any products manufactured or distributed by us pursuant to FDA approvals are subject to continuing regulation by the FDA,
including periodic reporting, product sampling and distribution, advertising, promotion, drug shortage reporting, compliance with any post-approval requirements imposed as a conditional of approval such as Phase 4 clinical trials, REMS and
surveillance, recordkeeping and reporting requirements, including adverse experiences. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">After approval, most changes to
the approved product, such as adding new indications or other labeling claims are subject to prior FDA review and approval. There also are continuing, annual program fee requirements for approved products, as well as new application fees for
supplemental applications with clinical data. Drug manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies and to list their drug products, and are subject to periodic announced
and unannounced inspections by the FDA and these state agencies for compliance with cGMPs and other requirements, which impose procedural and documentation requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented, or
FDA notification. FDA regulations also require investigation and correction of any deviations from cGMPs and specifications, and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may
decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain cGMP compliance. Manufacturers and other parties involved in the drug supply chain for prescription
drug products must also comply with product tracking and tracing requirements and for notifying the FDA of counterfeit, diverted, stolen and intentionally adulterated products or products that are otherwise unfit for distribution in the United
States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity
or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in withdrawal of marketing approval, mandatory revisions to the approved labeling to add new safety information or other limitations,
imposition of post-market studies or clinical trials to assess new safety risks, or imposition of distribution or other restrictions under a REMS program, among other consequences. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA closely regulates the marketing and promotion of drugs. A company can make only those claims relating to safety and
efficacy that are consistent with the FDA approved labeling. Physicians, in their independent professional medical judgment, may prescribe legally available products for uses that are not described in the product&#146;s labeling and that differ from
those tested by us and approved by the FDA. However, manufacturers and third parties acting on their behalf are prohibited from marketing or promoting drugs in a manner inconsistent with the approved labeling. The FDA and other agencies actively
enforce the laws and regulations prohibiting the promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses and a company that is found to have improperly promoted <FONT STYLE="white-space:nowrap">off-label</FONT> uses may be subject to
significant liability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Failure to comply with any of the FDA&#146;s requirements could result in significant adverse
enforcement actions. These include a variety of administrative or judicial sanctions, such as refusal to approve pending applications, license suspension or revocation, withdrawal of an approval, imposition of a clinical hold or termination of
clinical trials, warning letters, untitled letters, modification of promotional materials or labeling, product recalls, product seizures or detentions, refusal to allow imports or exports, total or partial suspension of production or distribution,
debarment, injunctions, fines, consent decrees, corporate integrity agreements, refusals of government contracts and new orders under existing contracts, exclusion from participation in federal </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
and state healthcare programs, restitution, disgorgement or civil or criminal penalties, including fines and imprisonment. It is also possible that failure to comply with the FDA&#146;s
requirements relating to the promotion of prescription drugs may lead to investigations alleging violations of federal and state healthcare fraud and abuse and other laws, as well as state consumer protection laws. Any of these sanctions could
result in adverse publicity, among other adverse consequences. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Marketing Exclusivity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA provides periods of <FONT STYLE="white-space:nowrap">non-patent</FONT> regulatory exclusivity, which provides the
holder of an approved NDA limited protection from new competition in the marketplace for the innovation represented by its approved drug for a period of three or five years following the FDA&#146;s approval of the NDA. Five years of exclusivity are
available to new chemical entities, or NCEs. A drug is an NCE if the FDA has not previously approved any other new drug containing the same active moiety. An active moiety is the molecule or ion, excluding those appended portions of the molecule
that cause the drug to be an ester, salt, including a salt with hydrogen or coordination bonds, or other noncovalent, or not involving the sharing of electron pairs between atoms, derivatives, such as a complex (i.e., formed by the chemical
interaction of two compounds), chelate (i.e., a chemical compound), or clathrate (i.e., a polymer framework that traps molecules), of the molecule, responsible for the therapeutic activity of the drug substance. During the exclusivity period, the
FDA may not accept for review or approve an Abbreviated New Drug Application, or ANDA, or a 505(b)(2) NDA submitted by another company that contains the previously approved active moiety. An ANDA or 505(b)(2) application, however, may be submitted
one year before NCE exclusivity expires if a Paragraph IV certification is filed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Regulation of Companion Diagnostics </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe that the success of ACR-368 and certain of our drug candidates may depend, in part, on the development and
commercialization of OncoSignature, a companion diagnostic candidate. Companion diagnostics identify patients who are most likely to benefit from a particular therapeutic product; identify patients likely to be at increased risk for serious side
effects as a result of treatment with a particular therapeutic product; or monitor response to treatment with a particular therapeutic product for the purpose of adjusting treatment to achieve improved safety or effectiveness. Companion diagnostics
are regulated as medical devices by the FDA. In the United States, the FDCA and its implementing regulations, and other federal and state statutes and regulations govern, among other things, medical device design and development, preclinical and
clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import, and post-market surveillance. Unless an exemption or FDA exercise of
enforcement discretion applies, diagnostic tests generally require marketing clearance or approval from the FDA prior to commercialization. The two primary types of FDA marketing authorization applicable to a medical device are premarket
notification, also called 510(k) clearance, and approval of a premarket, or PMA approval. We intend to seek PMA approval of our OncoSignature companion diagnostic candidate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">PMA applications must be supported by valid scientific evidence, which typically requires extensive data, including technical,
preclinical, clinical and manufacturing data, to demonstrate to the FDA&#146;s satisfaction the safety and effectiveness of the device. For diagnostic tests, a PMA application typically includes data regarding analytical and clinical validation
studies. As part of its review of the PMA, the FDA will conduct a <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection of the manufacturing facility or facilities to ensure compliance with the Quality System Regulation, or QSR, which
requires manufacturers to follow design, testing, control, documentation and other quality assurance procedures. The FDA&#146;s review of an initial PMA application is required by statute to take between six to ten months, although the process
typically takes longer, and may require several years to complete. If the FDA evaluations of both the PMA application and the manufacturing facilities are favorable, the FDA will either issue an approval letter or an approvable letter, which usually
contains a number of conditions that must be met in order to secure the final approval of the PMA. If the FDA&#146;s evaluation of the PMA or manufacturing facilities is not favorable, the FDA will deny the approval of the PMA or issue a not
approvable letter. A not approvable letter will outline the deficiencies in the application and, where practical, will identify what is necessary to make </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
the PMA approvable. Once granted, PMA approval may be withdrawn by the FDA if compliance with post-approval requirements, conditions of approval or other regulatory standards is not maintained or
problems are identified following initial marketing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On July&nbsp;31, 2014, the FDA issued a final guidance document
addressing the development and approval process for &#147;In Vitro Companion Diagnostic Devices.&#148; According to the guidance document, for novel therapeutic products that depend on the use of a diagnostic test and where the diagnostic device
could be essential for the safe and effective use of the corresponding therapeutic product, the premarket application for the companion diagnostic device should be developed and approved or cleared contemporaneously with the therapeutic, although
the FDA recognizes that there may be cases when contemporaneous development may not be possible. However, in cases where a drug cannot be used safely or effectively without the companion diagnostic, the FDA&#146;s guidance indicates it will
generally not approve the drug without the approval or clearance of the diagnostic device. The FDA also issued a draft guidance in July 2016 setting forth the principles for <FONT STYLE="white-space:nowrap">co-development</FONT> of an in vitro
companion diagnostic device with a therapeutic product. The draft guidance describes principles to guide the development and contemporaneous marketing authorization for the therapeutic product and its corresponding in vitro companion diagnostic.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Once cleared or approved, the companion diagnostic device must adhere to post-marketing requirements including the
requirements of FDA&#146;s QSR, adverse event reporting, recalls and corrections along with product marketing requirements and limitations. Like drug and biologic makers, companion diagnostic makers are subject to unannounced FDA inspections at any
time during which the FDA will conduct an audit of the product(s) and the company&#146;s facilities for compliance with its authorities </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Regulation
Outside the United States </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In order to market any product outside of the United States, we would need to comply
with numerous and varying regulatory requirements of other countries and jurisdictions regarding quality, safety, and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of our
products. Whether or not we obtain FDA approval for a product, we would need to obtain the necessary approvals by the comparable foreign regulatory authorities before we can commence clinical trials or marketing of the product in foreign countries
and jurisdictions. Although many of the issues discussed above with respect to the United States apply similarly in the context of the European Union, the approval process varies between countries and jurisdictions and can involve additional product
testing and additional administrative review periods. The time required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country or
jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Healthcare Laws and Compliance Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our business activities, including but not limited to, research, sales, promotion, distribution, medical education and other
activities are subject to regulation by numerous regulatory and law enforcement authorities in the United States in addition to the FDA, including the Department of Justice, the Department of Health and Human Services, or HHS, and its various
divisions, including Centers for Medicare&nbsp;&amp; Medicaid Services, or CMS, and the Health Resources and Services Administration, the Department of Veterans Affairs, the Department of Defense and state and local governments. Our business
activities must comply with numerous healthcare laws and regulations, including those described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The federal
Anti-Kickback Statute prohibits, among other things, any person or entity, from knowingly and willfully offering, paying, soliciting or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward,
or in return for, the referral of an individual for, or purchasing, leasing, ordering, or arranging for the purchase, lease or order of, any good, facility, item or service reimbursable under </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">156 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Medicare, Medicaid or other federal healthcare programs. The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and
prescribers, purchasers, and formulary managers on the other hand. The term remuneration has been interpreted broadly to include anything of value. There are a number of statutory exceptions and regulatory safe harbors protecting some common
activities from prosecution. The exceptions and safe harbors are drawn narrowly and require strict compliance in order to offer protection. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchasing or
recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal
under the federal Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis based on a cumulative review of all of its
facts and circumstances. Additionally, the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the ACA, amended the intent requirement of the federal
Anti-Kickback Statute, and other healthcare criminal fraud statutes, so that a person or entity no longer needs to have actual knowledge of the federal Anti-Kickback Statute, or the specific intent to violate it, to have violated the statute. The
ACA also provided that a violation of the federal Anti-Kickback Statute is grounds for the government or a whistleblower to assert that a claim for payment of items or services resulting from such violation constitutes a false or fraudulent claim
for purposes of the federal civil False Claims Act, or FCA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The federal civil and criminal false claims laws, including
the FCA, prohibit, among other things, any person or entity from knowingly presenting, or causing to be presented, a false claim for payment to, or approval by, the U.S. federal government, including the Medicare and Medicaid programs, or knowingly
making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim or to avoid, decrease or conceal an obligation to pay money to the federal government. As a result of a modification made by the Fraud
Enforcement and Recovery Act of 2009, a claim includes &#147;any request or demand&#148; for money or property presented to the U.S. government. In addition, manufacturers can be held liable under the FCA even when they do not submit claims directly
to government payors if they are deemed to &#147;cause&#148; the submission of false or fraudulent claims. The FCA also permits a private individual acting as a &#147;whistleblower&#148; to bring actions on behalf of the federal government alleging
violations of the FCA and to share in any monetary recovery. FCA liability is potentially significant in the healthcare industry because the statute provides for treble damages and mandatory penalties. Government enforcement agencies and private
whistleblowers have investigated pharmaceutical companies for or asserted liability under the FCA for a variety of alleged promotional and marketing activities, such as providing free products to customers with the expectation that the customers
would bill federal programs for the products; providing consulting fees and other benefits to physicians to induce them to prescribe products; engaging in promotion for <FONT STYLE="white-space:nowrap">&#147;off-label&#148;</FONT> uses; and
submitting inflated best price information to the Medicaid Rebate Program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The federal Health Insurance Portability and
Accountability Act of 1996, or HIPAA, created additional federal criminal statutes that prohibits, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by
means of false or fraudulent pretenses, representations or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of whether the payor is public or private, knowingly and
willfully embezzling or stealing from a health care benefit program, willfully obstructing a criminal investigation of a health care offense and knowingly and willfully falsifying, concealing or covering up by any trick, scheme or device a material
fact or making any materially false, fictitious or fraudulent statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. Additionally, the ACA amended the intent requirement
of some of these criminal statutes under HIPAA so that a person or entity no longer needs to have actual knowledge of the statute, or the specific intent to violate it, to have committed a violation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, the federal Open Payments program pursuant to the Physician Payments Sunshine Act, created under
Section&nbsp;6002 of the ACA and its implementing regulations, requires certain manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program
(with specified exceptions) to report annually information related to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">157 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
specified payments or other transfers of value provided to physicians, as defined by such law, certain other healthcare providers (such as physician assistants and nurse practitioners) and
teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, the physicians and teaching hospitals and to report annually specified ownership and investment interests held by physicians and their immediate family
members. Failure to submit timely, accurately and completely the required information for all payments, transfers of value and ownership or investment interests may result in civil monetary penalties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, we may be subject to data privacy and security regulation by both the federal government and the states in which
we conduct our business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their implementing regulations, impose requirements relating to the privacy, security and transmission of
individually identifiable health information held by covered entities and their business associates. Among other things, HITECH makes HIPAA&#146;s security standards directly applicable to business associates, defined as independent contractors or
agents of covered entities that create, receive, maintain or transmit protected health information in connection with providing a service for or on behalf of a covered entity. HITECH also created new tiers of civil monetary penalties, amended HIPAA
to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek
attorneys&#146; fees and costs associated with pursuing federal civil actions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Many states have also adopted laws similar
to each of the above federal laws, which may be broader in scope and apply to items or services reimbursed by any third-party payor, including commercial insurers. We may also be subject to state laws that require pharmaceutical companies to comply
with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, and/or state laws that require drug manufacturers to report information related to payments and other
transfers of value to physicians and other healthcare providers or marketing expenditures and pricing information, state and local laws that require the registration of pharmaceutical sales representatives, and state laws governing the privacy and
security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Ensuring that our internal operations and business arrangements with third parties comply with applicable healthcare laws and
regulations will likely be costly. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare
laws and regulations. If our operations were found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines,
disgorgement, imprisonment, possible exclusion from government funded healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, additional reporting obligations and oversight if we become subject to a
corporate integrity agreement or other agreement to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws, and curtailment of our operations, any of which could substantially disrupt our operations. If the
physicians or other providers or entities with whom we expect to do business are found not to be in compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusions from government
funded healthcare programs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Coverage and Reimbursement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our ability to commercialize any products successfully will also depend in part on the extent to which coverage and adequate
reimbursement for the procedures utilizing our drug candidates, performed by health care providers, once approved, will be available from government health administration authorities, private health insurers and other organizations. Government
authorities and other third-party payors, such as private health insurers and health maintenance organizations, determine which procedures, and the products utilized in such procedures, they will cover and establish reimbursement levels. Assuming
coverage is obtained for procedures utilizing a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">158 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
or may require <FONT STYLE="white-space:nowrap">co-payments</FONT> that patients find unacceptably high. Patients who undergo procedures for the treatment of their conditions, and their treating
physicians, generally rely on third-party payors to reimburse all or part of the costs associated with the procedures which utilize our products. Treating physicians are unlikely to use and order our products unless coverage is provided and the
reimbursement is adequate to cover all or a significant portion of the cost of the procedures which utilize our products. Therefore, coverage and adequate reimbursement for procedures which utilize new products is critical to the acceptance of such
new products. Coverage decisions may depend upon clinical and economic standards that disfavor new products when more established or lower cost therapeutic alternatives are already available or subsequently become available. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Government authorities and other third-party payors are developing increasingly sophisticated methods of cost containment,
such as including price controls, restrictions on coverage and reimbursement and requirements for substitution of less expensive products and procedures. Government and other third-party payors are increasingly challenging the prices charged for
health care products and procedures, examining the cost effectiveness of procedures, and the products used in such procedures, in addition to their safety and efficacy, and limiting or attempting to limit both coverage and the level of
reimbursement. Further, no uniform policy requirement for coverage and reimbursement exists among third-party payors in the United States, which causes significant uncertainty related to the insurance coverage and reimbursement of newly approved
products, and the procedures which may utilize such newly approved products. Therefore, coverage and reimbursement can differ significantly from payor to payor and health care provider to health care provider. As a result, the coverage determination
process is often a time-consuming and costly process that requires the provision of scientific and clinical support for the use of new products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied
consistently or obtained in the first instance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, we may develop, either by ourselves or with collaborators,
companion diagnostic tests for our lead drug candidate for certain indications. We, or our collaborators, if any, will be required to obtain coverage and reimbursement for these tests separate and apart from the coverage and reimbursement we seek
for our drug candidates, if approved. While we have not yet developed any companion diagnostic test for our drug candidates, if we do, there is significant uncertainty regarding our ability to obtain coverage and adequate reimbursement for the same
reasons that are applicable to our drug candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There may also be significant delays in obtaining coverage and
reimbursement for newly approved products, and coverage may be more limited than the purposes for which the product is approved by the FDA. Moreover, eligibility for coverage and reimbursement does not imply that a product, or the procedures which
utilize such product, will be paid for in all cases or at a rate which the health care providers who purchase those products will find cost effective. Additionally, we expect pricing pressures in connection with the sale of any of our drug
candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, and additional legislative changes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We cannot be sure that coverage and reimbursement will be available for any product that we commercialize, or the procedures
which utilize such product, and, if reimbursement is available, what the level of reimbursement will be. Coverage and reimbursement may impact the demand for, or the price of, any drug candidate for which we obtain marketing approval. If coverage
and reimbursement are not available or reimbursement is available only to limited levels, we may not successfully commercialize any drug candidate for which we obtain marketing approval. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Healthcare Reform </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The United States and some foreign jurisdictions are considering or have enacted a number of legislative and regulatory
proposals to change the healthcare system in ways that could affect our ability to sell our products profitably. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare
systems with the stated goals of containing healthcare costs, improving quality or expanding access. In the United States, the biopharmaceutical industry has been a particular focus of these </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">159 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
efforts and has been significantly affected by federal and state legislative initiatives, including those designed to limit the pricing, coverage, and reimbursement of pharmaceutical and
biopharmaceutical products, especially under government-funded health care programs, and increased governmental control of drug pricing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">By way of example, in March 2010, the ACA was signed into law, intended to broaden access to health insurance, reduce or
constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add transparency requirements for the healthcare and health insurance industries, impose taxes and fees on the healthcare industry and impose additional health
policy reforms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There have been executive, judicial and Congressional challenges to certain aspects of the ACA. For
example, on June&nbsp;17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#147;individual mandate&#148; was repealed by Congress. Thus, the ACA will remain
in effect in its current form. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Other legislative changes have been proposed and adopted in the United States since the
ACA. For example, through the process created by the Budget Control Act of 2011, there are automatic reductions of Medicare payments to providers up to 2% per fiscal year, which went into effect in April 2013 and, following passage of the BBA and
the Infrastructure Investment and&nbsp;Jobs Act, will remain in effect until 2031 unless additional Congressional action is taken. However, <FONT STYLE="white-space:nowrap">COVID-19</FONT> relief support legislation suspended the 2% Medicare
sequester from May&nbsp;1, 2020 through March&nbsp;31, 2022. Under current legislation the actual reduction in Medicare payments will vary from 1% in 2022 to up to 4% in the final fiscal year of this sequester. In January 2013, the American Taxpayer
Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period
for the government to recover overpayments to providers from three to five years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The heightened governmental scrutiny in
the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics, also has resulted in executive orders, congressional inquiries and proposed and enacted federal and state legislation designed to,
among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. For example, in July 2021, the Biden
administration released an executive order, &#147;Promoting Competition in the American Economy,&#148; with multiple provisions aimed at prescription drugs. In response to Biden&#146;s executive order, on September&nbsp;9, 2021, HHS released a
Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to
advance these principles. No legislation or administrative actions have been finalized to implement these principles. Additionally, on March&nbsp;11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the
statutory Medicaid drug rebate cap, currently set at 100% of a drug&#146;s average manufacturer price, for single source and innovator multiple source drugs, beginning January&nbsp;1, 2024. In addition, Congress is considering drug pricing and other
health reform initiatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">At the state level, individual states in the United States have increasingly passed
legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and
transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Some third-party payors also <FONT STYLE="white-space:nowrap">require&nbsp;pre-approval&nbsp;of</FONT> coverage for new or
innovative devices or therapies before they will reimburse healthcare providers that use such therapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We expect that
these initiatives, as well as other healthcare reform measures that may be adopted in the future, as well as the trend toward managed healthcare and increasing influence of managed care organizations, may result in more rigorous coverage criteria
and lower reimbursement, and in additional downward pressure on the price that we receive for any approved product. It is also possible that additional governmental action is taken </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">160 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
in response to <FONT STYLE="white-space:nowrap">the&nbsp;COVID-19&nbsp;pandemic.</FONT> Any reduction in reimbursement from Medicare or other government-funded programs may result in a similar
reduction in payments from private payors. The implementation of current and future cost containment measures or other healthcare reforms may adversely affect our operations and prevent us from being able to generate revenue, attain profitability or
commercialize our drug candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Data Privacy and Security </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the ordinary course of our business, we collect, process and store confidential and sensitive information, including
personal information, intellectual property, trade secrets, and proprietary information owned or controlled by ourselves or other third parties. We, and third parties upon whom we rely, use sophisticated information technology, software and services
to process, store, use, generate, transfer and disclose information, as well as other sensitive information controlled by ourselves or other third parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may also be subject to federal, state, and foreign data privacy and security laws and regulations. In the United States,
numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws and regulations (e.g., Section&nbsp;5 of the FTC Act), govern the
collection, use, disclosure, and protection of health-related and other personal information could apply to our operations or the operations of our partners, vendors, or other third parties on whom we rely. The legislative and regulatory framework
related to the collection, use, retention, safeguarding, disclosure, sharing, transfer, security and other processing of personal data worldwide is rapidly evolving. The number and scope of data protection laws and regulations is changing, subject
to differing applications and interpretations, and may be inconsistent among jurisdictions, or in conflict with other rules, laws or other data processing obligations. Efforts to ensure that our current and future business arrangements, including
our relationship with our CROs or other vendors who process data on our behalf, comply with applicable data privacy and data security laws and regulations will involve substantial costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For example, HIPAA, as amended by HITECH, and its implementing regulations, impose requirements relating to the privacy,
security and transmission of individually identifiable health information on certain health care providers, health plans and health care clearinghouses, known as covered entities, as well as their business associates and covered subcontractors that
perform certain services that involve creating, receiving, maintaining or transmitting individually identifiable health information for or on behalf of such covered entities. Entities that are found to be in violation of HIPAA as the result of a
breach of unsecured protected health information, a complaint about privacy practices or an audit by HHS, may be subject to significant civil, criminal and administrative fines and penalties and/or additional reporting and oversight obligations if
required to enter into a resolution agreement and corrective action plan with HHS to settle allegations of <FONT STYLE="white-space:nowrap">HIPAA&nbsp;non-compliance.&nbsp;Further,</FONT> entities that knowingly obtain, use, or disclose individually
identifiable health information maintained by a HIPAA covered entity in a manner that is not authorized or permitted by HIPAA may be subject to civil and criminal penalties. Even when HIPAA does not apply, according to the FTC, violating
consumers&#146; privacy rights or failing to take appropriate steps to keep consumers&#146; personal information secure may constitute unfair acts or practices in or affecting commerce in violation of Section&nbsp;5 of the FTC Act. The FTC expects a
company&#146;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce
vulnerabilities. Individually identifiable health information is considered sensitive data that merits stronger safeguards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Likewise, we expect that there will continue to be new proposed laws, regulations and industry standards relating to privacy
and data protection in the United States, the EU and other jurisdictions, such as the California Consumer Privacy Act of 2018 (CCPA), which has been characterized as the first &#147;GDPR-like&#148; privacy statute to be enacted in the United States.
Although the CCPA exempts certain data processed in the context of clinical trials, the CCPA, to the extent applicable to our business and operations, may increase our compliance costs and potential liability with respect to the personal information
we maintain about California residents. The CCPA among other effects, creates individual privacy rights for California consumers (as defined in the law), places </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">161 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
increased privacy and security obligations on entities handling certain personal data of consumers or households, requires covered companies to provide disclosures to consumers regarding data
collection, use and sharing practices, requires covered companies to allow users <FONT STYLE="white-space:nowrap">to&nbsp;opt-out&nbsp;of</FONT> certain sales or transfers of personal information, and provides consumers with a private right of
action for certain data breaches. The CCPA became effective on January&nbsp;1, 2020, and the California Attorney General&#146;s authority to begin bringing enforcement actions began July&nbsp;1, 2020. As currently written, the CCPA may impact our
business activities and exemplifies the vulnerability of our business to the evolving regulatory environment related to personal data and protected health information. Further, the California Privacy Rights Act (CPRA) was recently voted into law by
California residents. The CPRA significantly amends the CCPA, and imposes additional data protection obligations on covered companies doing business in California, including additional consumer rights processes and opt outs for certain uses of
sensitive data. It also creates a new California data protection agency specifically tasked to enforce the law, which would likely result in increased regulatory scrutiny of California businesses in the areas of data protection and security. The
substantive requirements for businesses subject to the CPRA will go into effect on January&nbsp;1, 2023, and become enforceable on July&nbsp;1, 2023. A similar law, the Consumer Data Protection Act (CDPA), was recently passed in Virginia and goes
into effect on January&nbsp;1, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We also are or will become subject to privacy laws in the jurisdictions in which we
are established or in which we sell or market our products or run clinical trials. For example, in the EU, we are subject to Regulation (EU) 2016/679, the GDPR, in relation to our collection, control, processing, and other use of personal data (i.e.
data relating to an identified or identifiable living individual). We process personal data in relation to participants in our clinical trials in the European Economic Area (EEA), including the health and medical information of these participants.
The GDPR is directly applicable in each EU and EEA Member State, however, it provides that EU and EEA Member States may introduce further conditions, including limitations which could limit our ability to collect, use and share personal data
(including health and medical information), or could cause our compliance costs to increase, ultimately having an adverse impact on our business. As noted above, the GDPR imposes onerous accountability obligations requiring data controllers and
processors to maintain a record of their data processing and implement policies as part of its mandated privacy governance framework. It also requires data controllers to be transparent and disclose to data subjects (in a concise, intelligible and
easily accessible form) how their personal information is to be used, imposes limitations on retention of personal data; defines for the first time pseudonymized <FONT STYLE="white-space:nowrap">(i.e.,&nbsp;key-coded)&nbsp;data;</FONT> introduces
mandatory data breach notification requirements; and sets higher standards for data controllers to demonstrate that they have obtained valid consent for certain data processing activities. We are also subject to EEA rules with respect to
cross-border transfers of personal data out of the EEA. As noted above, recent legal developments in the EU have created complexity and uncertainty regarding transfers of personal data from the EEA to the United States, e.g. on July&nbsp;16, 2020,
the Court of Justice of the European Union (CJEU), invalidated <FONT STYLE="white-space:nowrap">the&nbsp;EU-U.S.&nbsp;Privacy</FONT> Shield Framework, or the Privacy Shield, under which personal data could be transferred from the EEA to U.S.
entities who had self-certified under the Privacy Shield scheme. While the CJEU upheld the adequacy of the standard contractual clauses (a standard form of contract approved by the European Commission as an adequate personal data transfer mechanism,
and potential alternative to the Privacy Shield), it made clear that reliance on them alone may not necessarily be sufficient in all circumstances. Use of the standard contractual clauses must now be assessed on <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">a&nbsp;case-by-case&nbsp;basis</FONT></FONT> taking into account the legal regime applicable in the destination country, in particular applicable surveillance laws and rights of individuals and additional measures and/or
contractual provisions may need to be put in place, however, the nature of these additional measures is currently uncertain. On June&nbsp;4, 2021, the European Commission adopted new standard contractual clauses under the GDPR for data transfers
from entities that are subject to the GDPR to transfer personal data outside of the EEA. The new standard contractual clauses impose additional obligations, including the obligation to conduct a transfer impact assessment and, depending on a
party&#146;s role in the transfer, to implement additional security measures and to update internal privacy practices. If we elect to rely on the standard contractual clauses for data transfers, we may be required to incur significant time and
resources to update our contractual arrangements and to comply with new obligations. Additionally, on September&nbsp;8, 2020, the Swiss Data Protection Authority (the Federal Data Protection and Information Commissioner) concluded that <FONT
STYLE="white-space:nowrap">the&nbsp;Swiss-U.S.&nbsp;Privacy</FONT> Shield does not provide an adequate level of protection for personal data transfer from Switzerland to the U.S. pursuant to the Swiss Federal Act on Data Protection. As
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">162 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
supervisory authorities issue further guidance on personal data export mechanisms, including circumstances where the standard contractual clauses cannot be used, and/or start taking enforcement
action, we could suffer additional costs, complaints and/or regulatory investigations or fines, and/or if we are otherwise unable to transfer personal data between and among countries and regions in which we operate, it could affect the manner in
which we provide our services, the geographical location or segregation of our relevant systems and operations, and could adversely affect our financial results. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are subject to the supervision of local data protection authorities in those EU jurisdictions where we are established or
otherwise subject to the GDPR. Fines for certain breaches of the GDPR are significant: up to the greater of &#128;20.0&nbsp;million or 4% of total global annual turnover. Further, following the withdrawal of the United Kingdom from the EU on
January&nbsp;31, 2020, pursuant to the transitional arrangements agreed between the United Kingdom and the EU, we will have to comply with the GDPR and separately the GDPR as implemented in the United Kingdom, each regime having the ability to fine
up to the greater of &#128;20&nbsp;million / &pound;17&nbsp;million or 4% of global turnover. Following December&nbsp;31, 2020, and the expiry of the post-Brexit transitional arrangements between the United Kingdom and EU, although it is likely that
the data protection obligations of the GDPR will continue to apply <FONT STYLE="white-space:nowrap">to&nbsp;UK-related&nbsp;processing</FONT> of personal data in substantially unvaried form and fashion, for at least the short term thereafter, the
relationship between the United Kingdom and the EU in relation to certain aspects of data protection law remains unclear. For example, it is not yet clear whether the United Kingdom will be the subject of
<FONT STYLE="white-space:nowrap">a&nbsp;so-called&nbsp;adequacy</FONT> decision of the European Commission, and it is therefore unclear how data transfers between EU/EEA Member States and the United Kingdom will be treated. Any changes relating to
the UK and EU position regarding aspects of data protection law may lead to additional compliance costs and could increase our overall risk. In addition to the foregoing, a breach of the GDPR or other applicable privacy and data protection laws and
regulations could result in regulatory investigations, reputational damage, orders to cease/change our use of data, enforcement notices, an inability to process personal data or to operate in certain jurisdictions, or potential civil claims
including class action type litigation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Moreover, we use third-party service providers and subprocessors to help us
operate our business and engage in processing on our behalf. If we, our service providers, partners, or other relevant third-parties have experienced, or in the future experience, any security incident(s) that result in any data loss, deletion or
destruction, unauthorized access to, loss of, unauthorized acquisition or disclosure of, or inadvertent exposure or disclosure of sensitive information, or compromise related to the security, confidentiality, integrity of our (or their) information
technology, software, services, communications or data, it may result in a material adverse impact, including without limitation, regulatory investigations or enforcement actions, litigation, or an inability to process data in some jurisdictions.
Furthermore, applicable data protection laws, privacy policies and data protection obligations may require us to notify relevant stakeholders of security breaches, including affected individuals, customers, and regulators. Such disclosures are
costly, and the disclosure or the failure to comply with such requirements, could result in a material adverse impact, including without limitation, regulatory investigations or enforcement actions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For more information on the potential impact of the GDPR, and associated EEA data protection laws, on our business, see the
section titled &#147;Risk Factors&#151;Risks Related to Employee Matters and Our Operations&#151;We are subject to a variety of privacy and data security laws, rules, regulations, policies, industry standards and contractual obligations, and our
failure to comply with them could harm our business.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Additional Regulation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to the foregoing, state and federal laws regarding environmental protection and hazardous substances, including the
Occupational Safety and Health Act, the Resource Conservation and Recovery Act and the Toxic Substances Control Act, affect our business. These and other laws govern the use, handling and disposal of various biologic, chemical and radioactive
substances used in, and wastes generated by, operations. If our operations result in contamination of the environment or expose individuals to hazardous substances, we could be liable for damages and governmental fines. Equivalent laws have been
adopted in other countries that impose similar obligations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">163 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Foreign Corrupt Practices Act </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Foreign Corrupt Practices Act, or FCPA, prohibits any U.S. individual or business from paying, offering or authorizing
payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in
obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring the companies to maintain books and records that accurately and fairly reflect all
transactions of the companies, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Facilities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our principal
executive office is located in Watertown, Massachusetts, where we lease a total of 13,711 square feet of office and laboratory space that we use for our administrative, research and development and other activities under a lease that currently
expires in April 2028, with an option to extend the term for an additional five years at then-market rental rates. Additionally, we also lease laboratory and office space in Lund, Sweden, which will expire in September 2023, with an option to extend
the term for an additional three years. We believe that our facilities are sufficient to meet our current needs and that suitable additional space will be available as and when needed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees and Human Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of October&nbsp;31, 2022, we had 39 full-time employees and three part-time employees. Of our 42 full- and part-time
employees, approximately 24 have Ph.D. or M.D. degrees and 34 are engaged in research and development activities. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with
our employees to be good. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our human capital resources objectives include, as applicable, identifying, recruiting,
retaining, incentivizing and integrating our employees. We believe our success depends on our ability to attract, retain, develop and motivate diverse highly skilled personnel. In particular, we depend upon the personal efforts and abilities of the
principal members of our senior management to partner effectively as a team, and to provide strategic direction, develop our business, manage our operations and maintain a cohesive and stable work environment. We also rely on qualified managers and
skilled employees, such as scientists, engineers and laboratory technicians, with technical expertise in operations, scientific knowledge, engineering skills and quality management experience in order to operate our business successfully. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our compensation program is designed to retain, motivate and, as needed, attract highly qualified employees. Accordingly, we
use a mix of competitive base salary, cash-based annual incentive compensation, performance-based equity compensation awards and other employee benefits. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Proceedings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">From
time to time, we may become involved in legal proceedings arising in the ordinary course of our business. We are not currently subject to any material legal proceedings. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">164 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc383050_13"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers and Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table provides information regarding our current executive officers and directors, including their ages as of
October 31, 2022: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="59%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Age</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Position(s)</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Executive Officers</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Blume-Jensen, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">60</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Executive Officer, President and Chairman of the Board</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rasmus Holm-Jorgensen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">51</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Erick Gamelin, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">65</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Medical Officer</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kristina Masson, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">42</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Executive Vice President, Business Operations, Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eric Devroe, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">44</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Operating Officer</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derek DiRocco, Ph.D.<SUP STYLE="font-size:75%; vertical-align:top">(1)(2)(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">42</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sharon Shacham, Ph.D.,
M.B.A.<SUP STYLE="font-size:75%; vertical-align:top">(1)(2)(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">52</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Tomsicek, M.B.A.<SUP STYLE="font-size:75%; vertical-align:top">(1)(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">56</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Member of the audit committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Member of the compensation committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Member of the nominating and corporate governance committee. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Peter Blume-Jensen, M.D., Ph.D.</I></B>, is our main founder and has served as our Chief Executive Officer, acting Chief
Scientific Officer, President, and as a member of our board of directors since March 2018, including as chairman of our board of directors since October 2020. Dr.&nbsp;Blume-Jensen previously served as Chief Scientific Officer at XTuit
Pharmaceuticals, Inc., a biopharmaceutical company, from 2014 to March 2018 and before that as Chief Scientific Officer at Metamark Genetics, Inc., a biopharmaceutical company, from 2010 to 2014. Prior to that he held several leadership positions in
various pharmaceutical companies, including most recently as Vice President, External Scientific Affairs and Global Therapeutic Area Advisor for Oncology at Daiichi Sankyo from 2008 to 2010. He was Department Head, Senior Director, Molecular
Oncology at Merck&nbsp;&amp; Co., Inc. from 2005 to 2008 and before that Department Head, Director of Molecular Oncology at EMD Serono, a biopharmaceutical division of Merck KGaA, from 2001 to 2005. He received an M.D. from Copenhagen University
Medical School, Denmark, a Ph.D. from The Ludwig Institute for Cancer Research, Uppsala University, Uppsala, Sweden, and conducted his Post-Doctoral Fellowship under Tony Hunter at the Salk Institute. Our board of directors believes that
Dr.&nbsp;Blume-Jensen is qualified to serve as a director based on his knowledge of our business as our main founder and chief executive officer, inventor of the founding AP3 platform and his extensive experience in oncology research and development
and oncogenic kinase signaling. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Rasmus Holm-Jorgensen</I></B> has served as our Chief Financial Officer since April
2022. Previously, he served as Senior Vice President, Chief Strategy&nbsp;&amp; Portfolio Officer at Kiniksa Pharmaceuticals, Inc., a biopharmaceutical company, from 2015 to April 2022. Prior to that, Mr.&nbsp;Holm-Jorgensen served as Group Vice
President and General Manager at Synageva BioPharma Corp. from 2011 to 2015. Mr.&nbsp;Holm-Jorgensen received an M.S. in economics from the University of Copenhagen. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Erick Gamelin, M.D., Ph.D.</I></B>, has served as our Chief Medical Officer since March 2021. Previously, he served as
Chief Medical Officer at Step Pharma, a biotechnology company, from November 2019 to January 2021, Vice President, Oncology at Dynavax Technologies Corporation, a biopharmaceutical company, from March 2018 to October 2019, Vice President at
MacroGenics, Inc., a biopharmaceutical company, from August 2017 to March 2018, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">165 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
and in various leadership positions in the Oncology Vaccine department at Pfizer Inc., a pharmaceutical company, from 2015 to July 2017. Dr. Gamelin is a medical oncologist, former professor of
Medical Oncology and CEO of a University Cancer Center, ICO, and a Knight of the French National Order of Merit, appointed by the French Minister of Health. He has co-authored more than 135 international scientific articles in peer-reviewed journals
and has founded and led an academic research team: &#147;Genomics and mechanisms of cancer resistance.&#148; Dr.&nbsp;Gamelin received a Ph.D. in molecular pharmacology from Bordeaux University and conducted his Post-Doctoral studies in the
Molecular Therapeutics Section, Medical Branch, at the National Institutes of Health. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Kristina Masson,
Ph.D.</I></B>, is our <FONT STYLE="white-space:nowrap">co-founder</FONT> and has served as our President, CEO and Site Head of our subsidiary Acrivon AB and as a member of our board of directors since March 2018. Dr.&nbsp;Masson has also served as
our Executive Vice President, Business Operations since August 2022 and previously served as our Senior Vice President, Operations from March 2018 to August 2022. In November 2016, Dr.&nbsp;Masson founded OncoSignature AB, a biotechnology company,
which she led until its acquisition by Acrivon AB in March 2018. Dr.&nbsp;Masson received an MSc and a Ph.D. from Lund University and conducted her Post-Doctoral Fellowship at the Broad Institute of MIT and Harvard. Our board of directors believes
that Dr.&nbsp;Masson is qualified to serve as a director based on her knowledge of our business as a <FONT STYLE="white-space:nowrap">co-founder</FONT> of the company and OncoSignature AB and her extensive experience in oncology research and
development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Eric Devroe, Ph.D.</I></B>, has served as our Chief Operating Officer since August 2022 and previously
served as our Senior Vice President, Business Operations from October 2020 to August 2022. Dr. Devroe has also served as our Corporate Secretary since January 2021. Previously, Dr.&nbsp;Devroe served as Founder&nbsp;&amp; Chief Executive Officer of
Xione Therapeutics, Inc., an oncology company, from August 2019 to September 2021, Strategic Advisor, Therapeutics Discovery at the MDACC from May 2018 to October 2019, and Founder&nbsp;&amp; Chief Executive Officer of Opsonix, Inc., an infectious
diseases company, from 2015 to May 2018. Dr.&nbsp;Devroe received a B.S. in microbiology from the University of Texas at Austin and a Ph.D. in biological chemistry and molecular pharmacology from Harvard University. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Derek DiRocco, Ph.D.</I></B>, has served on our board of directors since November 2021. Dr.&nbsp;DiRocco has been a
partner at RA Capital Management, LLC, an investment manager, since December 2020 and previously served as principal from December 2017 to December 2020, an analyst from June 2015 to December 2017 and an associate from July 2013 to June 2015.
Dr.&nbsp;DiRocco has served on the board of directors of 89bio, Inc. since April 2018, iTeos Therapeutics, Inc. since March 2020, Connect Biopharma Holdings Limited since August 2020, and Werewolf Therapeutics, Inc. since December 2020. He
previously served on the board of directors of Achilles Therapeutics plc from September 2019 to May 2022. Dr.&nbsp;DiRocco holds a B.A. in biology from College of the Holy Cross and a Ph.D. in pharmacology from the University of Washington, and
conducted his postdoctoral research at Brigham and Women&#146;s Hospital/Harvard Medical School. Our board of directors believes that Dr.&nbsp;DiRocco is qualified to serve as a director because of his experience as an investor in biotechnology
companies and experience as a director of multiple private and public companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Sharon Shacham, Ph.D.,
M.B.A.</I></B>, has served on our board of directors since October 2020. Dr. Shacham co-founded E44 Ventures in June 2022 and serves as Managing Director. Dr.&nbsp;Shacham founded Karyopharm Therapeutics Inc. in 2008, where she served as Chief
Scientific Officer from October 2010 to May 2022, President from October 2013 to May 2021, President of Research and Development from December 2012 to May 2021, Head of Research and Development from October 2010 to December 2012, and President and
Chief Executive Officer from October 2010 to January 2011. Dr.&nbsp;Shacham currently serves on Karyopharm&#146;s Scientific Advisory Board. Dr.&nbsp;Shacham led the scientific and clinical work that led to the discovery, development and regulatory
approval of selinexor (Xpovio). Xpovio is a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class,</FONT></FONT> oral exportin 1 (XPO1) inhibitor and is approved in the United States in multiple oncology indications. Prior
to joining Karyopharm, Dr.&nbsp;Shacham served as Senior Vice President of Drug Development at Epix Pharmaceuticals, Inc., and Director, Algorithm and Software Development at Predix Pharmaceuticals Inc., which merged into Epix Pharmaceuticals in
2006, where </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">166 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
she led the company&#146;s efforts in GPCR modeling, computational chemistry, lead optimization and development of clinical trials. Dr.&nbsp;Shacham holds a B.S. in chemistry, a Ph.D. in
biophysical chemistry, and an M.B.A. from Tel Aviv University. Our board of directors believes that Dr.&nbsp;Shacham is qualified to serve as a director because of her extensive experience as an executive officer in the biopharmaceutical industry.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Michael Tomsicek</I></B><B>, </B><I></I><B><I>M.B.A.</I></B><I></I><B> </B>has served on our board of directors
since October 2022. Mr. Tomsicek has served as a member of the board of directors of Milestone Pharmaceuticals USA, Inc., a Nasdaq-listed biopharmaceutical company, since April 2019. Mr. Tomsicek served as the Chief Financial Officer of CRISPR
Therapeutics AG, a Nasdaq-listed gene editing company, from November 2017 through October 2021. Prior to that, Mr. Tomsicek served as Chief Financial Officer of Abiomed, Inc., a Nasdaq-listed medical device company, from July 2015 to August 2017.
Before that, he was Chief Financial Officer at Cubist Pharmaceuticals, Inc., or Cubist, a Nasdaq-listed biopharmaceutical company. He was at Cubist from August 2010 to January 2015, through the company&#146;s sale to Merck, and held a series of
roles of increasing responsibility leading finance, investor relations and strategic sourcing. Prior to Cubist, Mr. Tomsicek spent nearly eight years at General Electric Healthcare, ultimately as Chief Financial Officer of the global ultrasound
business. Mr. Tomsicek holds an M.B.A. and a B.S. in Engineering, both from the University of Wisconsin. Our board of directors believes that Mr. Tomsicek is qualified to serve as a director because of his management and industry experience,
including his public company management experience. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Composition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our business and affairs are managed under the direction of our board of directors, which currently consists of five members.
Our directors were elected to, and currently serve on, the board pursuant to a voting agreement among us and substantially all of our stockholders and voting rights granted by our current amended and restated certificate of incorporation. The voting
agreement will terminate upon the closing of this offering, after which there will be no further contractual obligations regarding the election of our directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In accordance with our amended and restated certificate of incorporation that will be in effect upon the closing of this
offering, our board of directors will be divided into three classes, each of which will consist, as nearly as possible, of <FONT STYLE="white-space:nowrap">one-third</FONT> of the total number of directors constituting our entire board and which
will serve staggered three-year terms. At each annual meeting of stockholders, the successors to directors whose terms then expire will be elected to serve from the time of election and qualification until the third annual meeting following
election. Our directors will be divided among the three classes as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Class&nbsp;I, which will consist of Mr.&nbsp;Tomsicek, and his term will expire at our first annual meeting of
stockholders to be held after the closing of this offering; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Class&nbsp;II, which will consist of Dr.&nbsp;Masson and Dr.&nbsp;Shacham, and their terms will expire at our
second annual meeting of stockholders to be held after the closing of this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Class&nbsp;III, which will consist of Dr.&nbsp;Blume-Jensen and Dr.&nbsp;DiRocco, and their terms will expire
at our third annual meeting of stockholders to be held after the closing of this offering. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our
amended and restated bylaws, which will become effective upon the closing of this offering, will provide that the authorized number of directors may be changed only by resolution approved by a majority of our board of directors. Any additional
directorships resulting from an increase in the number of directors will be distributed among the three classes so that, as nearly as possible, each class will consist of <FONT STYLE="white-space:nowrap">one-third</FONT> of the directors. The
division of our board of directors into three classes with staggered three-year terms may delay or prevent a change of our management or a change of control. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Independence </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Applicable Nasdaq rules, or the Nasdaq Listing Rules, require a majority of a listed company&#146;s board of directors to be
composed of independent directors within one year of listing. In addition, the Nasdaq Listing Rules require that, subject to specified exceptions, each member of a listed company&#146;s audit, compensation and nominating and corporate governance
committees be independent and that audit committee members also satisfy </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">167 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
independence criteria set forth in Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> under the Exchange Act of 1934, as amended, or the Exchange Act. The Nasdaq independence definition includes
a series of objective tests, such as that the director is not, and has not been for at least three years, one of our employees, that neither the director nor any of his family members has engaged in various types of business dealings with us and
that the director is not associated with the holders of more than 5% of our common stock. In addition, under applicable Nasdaq rules, a director will only qualify as an &#147;independent director&#148; if, in the opinion of the listed company&#146;s
board of directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our board of directors has determined that all of our directors other than Peter Blume-Jensen, M.D., Ph.D., and Kristina
Masson, Ph.D., representing three of our five directors, are &#147;independent directors&#148; as defined under applicable Nasdaq rules. In making such determination, our board of directors considered the current and prior relationships that each
such director has with our company and all other facts and circumstances that our board of directors deemed relevant in determining his or her independence, including the beneficial ownership of our capital stock by each director and the
transactions described in the section titled &#147;Certain Relationships and Related Party Transactions.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There are
no family relationships among any of our directors or executive officers except that Dr. Blume-Jensen and Dr. Masson are married. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Role of the Board in
Risk Oversight </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">One of the key functions of our board of directors is informed oversight of our risk management
process. Our board of directors does not have a standing risk management committee, but rather administers this oversight function directly through the board of directors as a whole, as well as through various standing committees of our board of
directors that address risks inherent in their respective areas of oversight. In particular, our board of directors is responsible for monitoring and assessing strategic risk exposure. Following the completion of this offering, we intend for our
audit committee to have the responsibility to consider and discuss our major financial risk exposures and the steps our management has taken to monitor and control these exposures, including guidelines and policies to govern the process by which
risk assessment and management is undertaken. The audit committee will also monitor compliance with legal and regulatory requirements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board
Committees </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our board of directors has established an audit committee, compensation committee and a nominating and
corporate governance committee, each of which operate pursuant to a committee charter. Our board of directors may establish other committees to facilitate the management of our business. The composition and functions of each committee are described
below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Audit Committee </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the completion of this offering, our audit committee will consist of Mr.&nbsp;Tomsicek, Dr.&nbsp;Shacham and
Dr.&nbsp;DiRocco, with Mr.&nbsp;Tomsicek serving as chair of the audit committee. Our board of directors has determined that each of these individuals meets the independence requirements of Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> under
the Securities Exchange Act of 1934, or the Exchange Act, and the applicable listing standards of Nasdaq. Each member of our audit committee can read and understand fundamental financial statements in accordance with Nasdaq audit committee
requirements. Our board of directors has also determined that Mr.&nbsp;Tomsicek qualifies as an audit committee financial expert within the meaning of SEC regulations and meets the financial sophistication requirements of the Nasdaq Listing Rules.
In arriving at these determinations, the board has examined each audit committee member&#146;s scope of experience and the nature of their prior and/or current employment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The functions of this committee include, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">helping our board of directors oversee our corporate accounting and financial reporting processes;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">168 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">managing the selection, engagement, qualifications, independence and performance of a qualified firm to serve
as the independent registered public accounting firm to audit our financial statements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">discussing the scope and results of the audit with the independent registered public accounting firm, and
reviewing, with management and the independent accountants, our interim and <FONT STYLE="white-space:nowrap">year-end</FONT> operating results; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing procedures for employees to submit concerns anonymously about questionable accounting or audit
matters; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing related person transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">coordinating the oversight and reviewing the adequacy of our internal control over financial reporting;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining and reviewing a report by the independent registered public accounting firm at least annually that
describes our internal quality control procedures, any material issues with such procedures and any steps taken to deal with such issues when required by applicable law; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approving or, as permitted, <FONT STYLE="white-space:nowrap">pre-approving,</FONT> audit and permissible <FONT
STYLE="white-space:nowrap">non-audit</FONT> services to be performed by the independent registered public accounting firm. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe that the composition and functioning of our audit committee will comply with all applicable SEC and Nasdaq rules
and regulations. We intend to comply with future requirements to the extent they become applicable to us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Compensation Committee
</I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the completion of this offering, our compensation committee will consist of Mr.&nbsp;Tomsicek,
Dr.&nbsp;Shacham and Dr.&nbsp;DiRocco, with Mr.&nbsp;Tomsicek serving as chair of the compensation committee. Each of these individuals is a <FONT STYLE="white-space:nowrap">non-employee</FONT> director, as defined in Rule <FONT
STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act and is an &#147;outside director,&#148; as defined pursuant to Section&nbsp;162(m) of the Internal Revenue Code of 1986, as amended, or the Code. Our board of directors has
determined that each of these individuals is &#145;&#145;independent&#146;&#146; as defined under the applicable listing standards of Nasdaq, including the standards specific to members of a compensation committee. The functions of this committee
include, among other things: </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing, modifying and approving (or if it deems appropriate, making recommendations to the full board of
directors regarding) our overall compensation strategy and policies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">making recommendations to the full board of directors regarding the compensation and other terms of employment
of our executive officers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and making recommendations to the full board of directors regarding performance goals and objectives
relevant to the compensation of our executive officers and assessing their performance against these goals and objectives; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving (or if it deems it appropriate, making recommendations to the full board of directors
regarding) the equity incentive plans, compensation plans and similar programs advisable for us, as well as modifying, amending or terminating existing plans and programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluating risks associated with our compensation policies and practices and assessing whether risks arising
from our compensation policies and practices for our employees are reasonably likely to have a material adverse effect on us; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and making recommendations to the full board of directors regarding the type and amount of
compensation to be paid or awarded to our <FONT STYLE="white-space:nowrap">non-employee</FONT> board members; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing policies with respect to votes by our stockholders to approve executive compensation to the
extent required by Section&nbsp;14A of the Exchange Act and, if applicable, determining our recommendations regarding the frequency of advisory votes on executive compensation; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">169 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and assessing the independence of compensation consultants, legal counsel and other advisors as
required by Section&nbsp;10C of the Exchange Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">administering our equity incentive plans; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing policies with respect to equity compensation arrangements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing the competitiveness of our executive compensation programs and evaluating the effectiveness of our
compensation policy and strategy in achieving expected benefits to us; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and making recommendations to the full board of directors regarding the terms of any employment
agreements, severance arrangements, change in control protections and any other compensatory arrangements for our executive officers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing with management and approving our disclosures under the caption &#147;Compensation Discussion and
Analysis&#148; in our periodic reports or proxy statements to be filed with the SEC, to the extent such caption is included in any such report or proxy statement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preparing the report that the SEC requires in our annual proxy statement; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and evaluating on an annual basis the performance of the compensation committee and the compensation
committee charter. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe that the composition and functioning of our compensation committee will
comply with all applicable SEC and Nasdaq rules and regulations. We intend to comply with future requirements to the extent they become applicable to us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Nominating and Corporate Governance Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the completion of this offering, our nominating and corporate governance committee will consist of Dr.&nbsp;DiRocco and
Dr.&nbsp;Shacham, with Dr.&nbsp;DiRocco serving as chair of the nominating and corporate governance committee. Our board of directors has determined that each of these individuals is &#145;&#145;independent&#146;&#146; as defined under the
applicable listing standards of Nasdaq and SEC rules and regulations. The functions of this committee include, among other things: </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identifying, reviewing and evaluating candidates to serve on our board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">determining the minimum qualifications for service on our board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluating director performance on the board and applicable committees of the board and determining whether
continued service on our board is appropriate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluating, nominating and recommending individuals for membership on our board of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluating nominations by stockholders of candidates for election to our board of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">considering and assessing the independence of members of our board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing a set of corporate governance policies and principles and recommending to our board of directors
any changes to such policies and principles; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and making recommendations to the board of directors with respect to management succession planning;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">considering questions of possible conflicts of interest of directors as such questions arise; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and evaluating on an annual basis the performance of the nominating and corporate governance
committee and the nominating and corporate governance committee charter. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe that the
composition and functioning of our nominating and corporate governance committee will comply with all applicable SEC and Nasdaq rules and regulations. We intend to comply with future requirements to the extent they become applicable to us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">170 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Committee Interlocks and Insider Participation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">None of our directors who serve as a member of our compensation committee is, or has at any time during the past year been, one
of our officers or employees. None of our executive officers currently serves, or in the past year has served, as a member of the board of directors or compensation committee of any other entity that has one or more executive officers serving on our
board of directors or compensation committee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of Business Conduct and Ethics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have adopted a Code of Business Conduct and Ethics or the Code of Conduct, effective upon the closing of this offering,
applicable to all of our employees, executive officers and directors. This includes our principal executive officer, principal financial officer and principal accounting officer or controller, or persons performing similar functions. Following the
closing of this offering, the full text of the Code of Conduct will be available on our website at <I>www.acrivon.com</I>. We intend to post on our website all disclosures that are required by law or the listing standards of the Nasdaq Stock Market
concerning any amendments to, or waivers from, any provision of the Code of Conduct. Information contained on, or that can be accessed through, our website is not incorporated by reference into this prospectus, and you should not consider
information on our website to be part of this prospectus. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We did not pay compensation to any of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors during the year ended
December&nbsp;31, 2021. Dr.&nbsp;Blume-Jensen, our Chief Executive Officer and President, and Dr.&nbsp;Masson, our Executive Vice President, Business Operations, are also members of our board of directors, but did not receive any additional
compensation for their service as a director during this period. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Non-Employee Director Compensation Policy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our board of directors adopted a non-employee director compensation policy in October 2022 that will become effective upon the
pricing of this offering and will be applicable to all of our non-employee directors. This compensation policy provides that each such non-employee director will receive the compensation described below for service on our board of directors: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Cash compensation</I>. Under this policy, we will pay each of our non-employee directors cash retainers for service on our
board of directors and committees of our board of directors as follows: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Annual&nbsp;Cash<BR>Retainer ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Annual retainer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional retainer for lead independent director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional retainer for audit committee chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional retainer for audit committee non-chair member</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional retainer for compensation committee chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional retainer for compensation committee non-chair member</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional retainer for nominating and corporate governance committee chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional retainer for nominating and corporate governance committee non-chair member</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We will also reimburse each non-employee director for any ordinary and reasonable
out-of-pocket expenses actually incurred by such director in connection with in-person attendance at and participation in meetings of our board of directors and committees of our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Equity compensation.</I>&nbsp;In addition to cash compensation, each non-employee director will be eligible to receive
options under our 2022 Plan. All options granted under the policy will be nonstatutory stock options, with an exercise price per share equal to 100% of the fair market value of the underlying common stock on the date of grant, and a term of ten
years from the date of grant, subject to earlier termination in connection with a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">171 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
termination of service. Vesting schedules for equity awards will be subject to the non-employee director&#146;s continuous service on each applicable vesting date, provided that each option will
vest in full upon a change in control of the company, as defined in the 2022 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Initial award.</I>&nbsp;Each new
non-employee director elected or appointed to our board of directors after the effective date of the policy will automatically be granted an initial, one-time stock option award having an aggregate grant date fair value of $315,000, provided that
the number of shares underlying such option shall not exceed 32,500 shares. The initial option grant will vest in substantially equal monthly installments over a three-year period such that the option is fully vested on the third anniversary of the
grant date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Annual awards.</I>&nbsp;On the date of each annual meeting of stockholders of our company after the
effective date of the policy, commencing with the 2024 annual meeting of stockholders, each non-employee director that continues to serve on our board of directors will automatically be granted a stock option award having an aggregate grant date
fair value of $210,000, provided that the number of shares underlying such option shall not exceed 20,275 shares. The grant date fair value of the annual option grant shall be prorated for non-employee directors who have served on our board of
directors for less than one year as of such annual meeting. The annual option grant shall vest in substantially equal monthly installments over a one-year period such that the option is fully vested on the first anniversary of the grant date,
provided that such option will in any case become fully vested on the date immediately preceding the date of our next annual stockholder meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Non-</I><I>e</I><I>mployee </I><I>d</I><I>irector </I><I>c</I><I>ompensation </I><I>l</I><I>imit</I>. The cash and equity
compensation that each non-employee director is eligible to receive under the policy will be subject to the director compensation limits set forth in the 2022 Plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Director IPO Option Grants </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On the date of the pricing of this offering, each of our non-employee directors will receive an option to purchase a number of
shares of common stock with an aggregate grant date fair value of $315,000 (which, based on an assumed initial public offering price of $17.00 per share, which is the midpoint of the estimated price range set forth on the cover page of this
prospectus, will be 25,905 shares of common stock), which will have an exercise price equal to the initial public offering price, and will vest in 36 equal monthly installments such that each such option is fully vested on the third anniversary of
the grant date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">172 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc383050_14"></A>EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our named executive officers for the fiscal year ended December&nbsp;31, 2021, consisting of our principal executive officer
and the next two most highly compensated executive officers, were: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Peter Blume-Jensen, M.D., Ph.D., who currently serves as our Chief Executive Officer and President and as a
member of our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Erick Gamelin, M.D., Ph.D., who currently serves as our Chief Medical Officer; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Eric Devroe, Ph.D., who currently serves as our Chief Operating Officer. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary Compensation Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table sets forth information regarding compensation awarded to, earned by and paid to our named executive
officers with respect to the year ended December&nbsp;31, 2021. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and Principal Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards&nbsp;($)<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-equity</FONT><BR>Incentive Plan</B><br><B>Compensation&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Blume-Jensen, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">430,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111,771</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">215,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">756,771</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Executive Officer, President and Director</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Erick Gamelin, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">360,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">120,723</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">538,078</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Medical Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eric Devroe, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87,939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">462,939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Operating Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Option awards in this column are reported at the aggregate grant date fair value in accordance with FASB ASC
Topic 718. Assumptions used in the calculation of these amounts are included in Note 11 to our audited consolidated financial statements included in this registration statement. This amount does not reflect the actual economic value that may be
realized by the named executive officer. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Narrative to the Summary Compensation Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Annual Base Salary </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our named executive officers receive a base salary to compensate them for services rendered to us. The base salary payable to
each named executive officer is intended to provide a fixed component of compensation reflecting the executive&#146;s skill set, experience, role and responsibilities. Dr.&nbsp;Blume-Jensen&#146;s, Dr.&nbsp;Gamelin&#146;s and Dr.&nbsp;Devroe&#146;s
respective annual base salaries were $430,000, $360,000 and $300,000 for the year ended December&nbsp;31, 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I><FONT
STYLE="white-space:nowrap">Non-Equity&nbsp;Incentive</FONT> Plan Compensation </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our named executive officers are
eligible to receive annual incentive compensation based on the satisfaction of individual and corporate performance objectives established by the Board. Each named executive officer has a target annual incentive opportunity, calculated as a
percentage of annual base salary. For 2021, the target annual incentive opportunities as a percentage of base salary for our named executive officers were 50% for Dr.&nbsp;Blume-Jensen, 40% for Dr.&nbsp;Gamelin and 25% for Dr. Devroe. The amounts of
any annual incentives earned are determined after the end of the year, based on the achievement of the designated corporate and individual performance objectives, and may be paid in cash or equity. For 2021, our board of directors determined that
the corporate performance goals had been achieved at a 100% level, which resulted in the aggregate payouts for each named executive officer in the amounts reflected in the column of the Summary Compensation Table above
<FONT STYLE="white-space:nowrap">entitled&nbsp;&#147;Non-Equity&nbsp;Incentive</FONT> Plan Compensation.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">173 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Equity-Based Incentive Awards </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe that equity awards provide our executives with a strong link to our long-term performance, create an ownership
culture and help to align the interests of our executives and our stockholders. To date, we have only used stock option grants for this purpose because we believe they are an effective means by which to align the long-term interests of our executive
officers with those of our stockholders. The use of stock options also can provide tax and other advantages to our executive officers relative to other forms of equity compensation. We believe that our equity awards are an important retention tool
for our executive officers, as well as for our other employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We award stock options broadly to our employees, <FONT
STYLE="white-space:nowrap">including&nbsp;to&nbsp;our&nbsp;non-executive&nbsp;employees.&nbsp;Grants&nbsp;to</FONT> our executives and other employees are made at the discretion of our board of directors and are not made at any specific time period
during a year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prior to this offering, all of the stock options we have granted were made pursuant to our 2019 Plan.
Following this offering, we will grant equity incentive awards under the terms of our 2022 Plan. The terms of our equity plans are described under the section titled &#147;Executive Compensation&#151;Equity Incentive Plans&#148; below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Equity Awards at Fiscal Year End </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table sets forth certain information about outstanding equity awards granted to our named executive officers that
were outstanding as of December&nbsp;31, 2021. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Vesting<BR>Commencement<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options<BR>Exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options<BR>Unexercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Exercise<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Expiration<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Blume-Jensen, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/14/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/5/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89,888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,059</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/13/2031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Executive Officer, President and Director</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Erick Gamelin, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/25/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/1/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81,103</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/24/2031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Medical Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eric Devroe, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/14/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/5/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94,586</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/13/2031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Operating Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">All of the option awards were granted under the 2019 Plan. All of the option awards were granted with a per
share exercise price equal to the fair market value of one share of our common stock on the date of grant. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The unvested shares underlying this option vest in 36 equal monthly installments until October&nbsp;31,
2023, subject to the officer&#146;s continued service through each applicable vesting date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The unvested shares underlying this option vest in 16 equal quarterly installments until March&nbsp;1, 2025,
subject to the officer&#146;s continued service through each applicable vesting date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The unvested shares underlying this option vest in 16 equal monthly installments until October&nbsp;5, 2024,
subject to the officer&#146;s continued service through each applicable vesting date. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In October
2022, our board of directors approved the grant of options to Dr. Blume-Jensen, Dr.&nbsp;Gamelin and Dr.&nbsp;Devroe, effective upon the pricing of this offering, to purchase a number of shares that will be equal to 0.675%, 0.225% and 0.375%,
respectively, of our total outstanding shares as of such date, on a fully diluted basis after giving effect to this offering. These options will have an exercise price equal to the initial public offering price. The shares underlying these options
will vest as to 25% on the one-year anniversary of the grant date, with the remainder vesting in 36 equal monthly installments thereafter, subject to the named executive officer&#146;s continued service through each applicable vesting date. In
addition, our board of directors approved the grant of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">174 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
restricted stock units to Dr.&nbsp;Blume-Jensen, Dr. Gamelin and Dr. Devroe, effective upon the pricing of this offering, for a number of shares equal to 0.225%, 0.075% and 0.125%, respectively,
of our total outstanding shares as of such date, on a fully diluted basis after giving effect to this offering. The shares underlying these restricted stock units will vest as to 25% on the <FONT STYLE="white-space:nowrap">one-year</FONT>
anniversary of the grant date, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the named executive officer&#146;s continued service through each applicable vesting date. Our board of directors also approved an
additional grant of restricted stock units to Dr. Blume-Jensen, effective upon the pricing of this offering, for a number of shares equal to 3.5% plus an additional 1.885% meant to cover estimated tax liability at the time of settlement, for a total
of 5.385% of our total outstanding shares as of the pricing of this offering, on a fully diluted basis after giving effect to this offering. One-third of the shares underlying this restricted stock unit grant will vest on the one-year anniversary of
the grant date, with the remainder vesting in eight equal quarterly installments thereafter, subject to the named executive officer&#146;s continued service through each applicable vesting date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Notwithstanding the foregoing, in the event that, in connection with or during the period ending 12 months following the
consummation of a change in control, we terminate the named executive officer for any reason other than for cause, any portion of the options or restricted stock units described above, as applicable, that is outstanding and unvested as of the date
shall immediately accelerate and vest in full as of the date of such termination (or, if later, the date of such change in control). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">See the section titled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations&#151;Critical Accounting Policies and Significant Judgments and Estimates&#151;Stock-Based Compensation Expense&#148; for additional information on the related stock-based compensation expense associated with the awards granted to our
executives in connection with this offering. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Employment Agreements with Named Executive Officers and Potential Payments and
Benefits Upon Termination or Change in Control </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have entered into employment agreements with our named executive
officers, and in connection with this offering, we expect to enter into amended and restated employment agreements with our named executive officers to supersede their prior employment agreements. The key terms of the current agreements are
described below. For a discussion of the severance pay and other benefits to be provided in connection with a termination of employment or a change in control under the arrangements with our named executive officers, please see the section titled
&#147;Potential Payments Upon Termination of Employment or Change in Control in the Prior Employment Agreements&#148; below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Employment Agreements
with our Named Executive Officers </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Peter Blume-Jensen, M.D., Ph.D. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Dr.&nbsp;Blume-Jensen&#146;s employment agreement originally included a base salary of $430,000 and an annual target bonus of
50% of his base salary. In March 2022, our board of directors approved an increase to <FONT STYLE="white-space:nowrap">Dr.&nbsp;Blume-Jensen&#146;s</FONT> base salary to $520,000, effective retroactively to January 1, 2022. In October 2022, our
board of directors approved an increase to Dr.&nbsp;Blume-Jensen&#146;s base salary to $610,000 and an increase of his annual target bonus to 55% of his base salary, each effective upon the effectiveness of the Registration Statement of which this
prospectus is a part. The annual bonus will be determined by the board of directors based on achievement of targets and milestones for our performance and Dr.&nbsp;Blume-Jensen&#146;s performance for the applicable calendar year. The employment
agreement provides for standard benefits, such as vacation, reimbursement of business expenses, and participation in our employee benefit plans and programs. Upon a termination without cause, we have agreed to provide Dr.&nbsp;Blume-Jensen a minimum
of sixty days&#146; notice of such termination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">175 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Erick Gamelin, M.D., Ph.D. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Dr.&nbsp;Gamelin&#146;s employment agreement originally included a base salary of $360,000 and an annual target bonus of 40% of
his base salary. In March 2022, our board of directors approved an increase to Dr. Gamelin&#146;s base salary to $410,000, effective retroactively to January 1, 2022. In October 2022, our board of directors approved an increase to
Dr.&nbsp;Gamelin&#146;s base salary to $465,000, effective upon the effectiveness of the Registration Statement of which this prospectus is a part. The annual bonus will be determined by the board of directors based on our and
Dr.&nbsp;Gamelin&#146;s performance against corporate goals for the applicable calendar year. The employment agreement provides for standard benefits, such as vacation and participation in our employee benefit plans and programs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Eric Devroe, Ph.D. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Dr.&nbsp;Devroe&#146;s employment agreement originally included a base salary of $300,000 and an annual target bonus of 25% of
his base salary. In March 2022, our board of directors approved an increase to Dr. Devroe&#146;s base salary to $370,000, effective retroactively to January 1, 2022. In October 2022, our board of directors approved an increase to Dr. Devroe&#146;s
base salary to $475,000 and an increase of his annual target bonus to 40% of his base salary, each effective upon the effectiveness of the Registration Statement of which this prospectus is a part. The annual bonus will be determined by the board of
directors based on our and Dr.&nbsp;Devroe&#146;s performance against corporate goals for the applicable calendar year. The employment agreement provides for standard benefits, such as vacation and participation in our employee benefit plans and
programs. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Potential Payments Upon Termination of Employment or Change in Control in the Prior Employment Agreements
</I></B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dr.&nbsp;Blume-Jensen </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the event that Dr.&nbsp;Blume-Jensen&#146;s employment terminates, other than during the three months prior to, or within a
twelve month period following, the consummation of a change of control, by us without &#147;cause&#148; or by Dr.&nbsp;Blume-Jensen for &#147;good reason&#148; (as defined in the employment agreement), and subject to Dr.&nbsp;Blume-Jensen&#146;s
execution of a separation agreement with a general release of claims in our favor, and standard terms relating to <FONT STYLE="white-space:nowrap">non-disparagement,</FONT> confidentiality, cooperation and the like (the &#147;CEO Severance
Conditions&#148;), Dr.&nbsp;Blume-Jensen will receive (i)&nbsp;cash severance in the form of continuation of his base salary for a period of twelve months; (ii)&nbsp;a <FONT STYLE="white-space:nowrap">pro-rata</FONT> portion of his target bonus for
the year in which termination occurs; (iii)&nbsp;continuation of health benefits for a period of up to twelve months; and (iv)&nbsp;continued vesting of all outstanding time-based equity awards that would otherwise have vested had he remained
employment for an additional twelve months after the separation date. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the event that Dr.&nbsp;Blume-Jensen&#146;s
employment terminates without cause or upon Dr.&nbsp;Blume-Jensen&#146;s resignation for good reason within the Change of Control Period, and subject to Dr.&nbsp;Blume-Jensen&#146;s satisfaction of the CEO Severance Conditions, Dr.&nbsp;Blume-Jensen
will receive (i)&nbsp;cash severance in the form of a lump sum payment equal to eighteen months of his base salary; (ii) 100% of his target bonus; (iii)&nbsp;continuation of health benefits for a period of up to eighteen months; and (iv)&nbsp;full
acceleration of all outstanding time-based equity awards held by Dr.&nbsp;Blume-Jensen. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dr. Gamelin </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the event that Dr.&nbsp;Gamelin&#146;s employment terminates, other than during the period ending twelve months after a
change of control, by us without &#147;cause&#148; or by Dr.&nbsp;Gamelin for &#147;good reason&#148; (as defined in the employment agreement), and subject to Dr.&nbsp;Gamelin&#146;s execution of a general release of claims, Dr.&nbsp;Gamelin will
receive cash severance in the form of continuation of his base salary for a period of six months. In the event that Dr.&nbsp;Gamelin&#146;s employment terminates without cause or upon Dr.&nbsp;Gamelin&#146;s resignation for good reason within
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">176 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
the Change of Control Period, and subject to Dr.&nbsp;Gamelin&#146;s execution of a general release of claims in our favor, Dr.&nbsp;Gamelin will receive (i)&nbsp;cash severance in the form of a
lump sum payment equal to six months of his base salary and (ii)&nbsp;full acceleration of all unvested shares and unexercised options held by Dr.&nbsp;Gamelin as of the date of termination. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dr.&nbsp;Devroe </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the event that Dr.&nbsp;Devroe&#146;s employment terminates, other than during the period ending twelve months after a
change of control, by us without &#147;cause&#148; or by Dr.&nbsp;Devroe for &#147;good reason&#148; (as defined in the employment agreement), and subject to Dr.&nbsp;Devroe&#146;s execution of a separation agreement with a general release of claims
in our favor, Dr.&nbsp;Devroe will receive cash severance in the form of continuation of his base salary for a period of six months. In the event that Dr.&nbsp;Devroe&#146;s employment terminates, within the Change of Control Period, by us without
&#147;cause&#148; or by Dr.&nbsp;Devroe for &#147;good reason&#148; (as defined in the employment agreement), and subject to Dr.&nbsp;Devroe&#146;s execution of a separation agreement with a general release of claims in our favor, Dr.&nbsp;Devroe
will receive (i)&nbsp;cash severance in the form of a lump sum payment equal to six months of his base salary in effect at the time of his separation and (ii)&nbsp;full acceleration of all unvested shares and unexercised options held by
Dr.&nbsp;Devroe as of the date of termination. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Retirement Benefits and Other Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our named executive officers are eligible to participate in our employee benefits, including health insurance and group life
insurance benefits, on the same basis as our other employees. In addition, we maintain a 401(k) profit sharing plan pursuant to Section&nbsp;401(k) of the Code covering all eligible employees. We make profit sharing contributions to qualifying
participants pursuant to a discretionary formula. We generally do not provide other perquisites or personal benefits except in limited circumstances, and we did not provide any such perquisites or personal benefits to our named executive officers in
2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Incentive Plans </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2022 Equity
Incentive Plan </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our board of directors adopted the 2022 Plan in October 2022 and our stockholders approved the
2022 Plan in October 2022. The 2022 Plan will become effective on the date of the underwriting agreement related to this offering. Our 2022 Plan will come into existence upon its adoption by our board of directors, but no grants will be made under
our 2022 Plan prior to its effectiveness. Once our 2022 Plan becomes effective, no further grants will be made under our 2019 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Types of Awards</I>. Our 2022 Plan provides for the grant of incentive stock options, or ISOs, nonstatutory stock options,
or NSOs, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance-based awards and other awards, or collectively, awards. ISOs may be granted only to our employees, including our officers, and the employees of
our affiliates. All other awards may be granted to our employees, including our officers, <FONT STYLE="white-space:nowrap">our&nbsp;non-employee&nbsp;directors</FONT> and consultants and the employees and consultants of our affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Authorized Shares</I>. The maximum number of shares of common stock that may be issued under our 2022 Plan is 5,606,723
shares, which is the sum of: (i) 2,555,271 new shares, plus (ii)&nbsp;the number of shares that remain available for issuance under the 2019 Plan at the time our 2022 Plan becomes effective and (iii) up to 2,148,679 shares of our common stock
subject to awards granted under our 2019 Plan that, after the effective date of our 2022 Plan, expire or otherwise terminate without having been exercised in full or are forfeited to or repurchased by us. The number of shares of common stock
reserved for issuance under our 2022 Plan will automatically increase on January&nbsp;1 of each year, beginning on January&nbsp;1, 2023, and continuing through and including January&nbsp;1, 2032, by 5% of the aggregate number of shares of common
stock of all classes issued and outstanding on December&nbsp;31 of the preceding calendar year, or a lesser number of shares determined by our board of directors prior to the applicable January 1. The maximum number of shares that may be issued upon
the exercise of ISOs under our 2022 Plan is 16,820,169&nbsp;shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">177 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In October 2022, pursuant to the 2022 Plan, effective upon the pricing
of this offering, our board of directors approved the grants of options to purchase (i) a number of shares that will equal an aggregate of 2.96% of our total outstanding shares as of such date, on a fully diluted basis after giving effect to this
offering, to our existing employees and consultants (inclusive of the grants to our named executive officers described above), (ii) a number of shares with an aggregate grant date fair value of $945,000 to our non-employee directors as described
above, and (iii) an aggregate of 200,883 shares to our new employees. All such options will have an exercise price equal to the initial public offering price. In addition, pursuant to the 2022 Plan, effective upon the pricing of this offering, our
board of directors approved the grants of restricted stock units (i) for an aggregate of 6.37% of our total outstanding shares as of such date, on a fully diluted basis after giving effect to this offering, to our existing employees and consultants
(inclusive of the grants to our named executive officers described above) and (ii) for 66,962 shares to our new employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Shares issued under our 2022 Plan will be authorized but unissued or reacquired shares of common stock. Shares subject to
awards granted under our 2022 Plan that expire or terminate without being exercised in full, or that are paid out in cash rather than in shares, will not reduce the number of shares available for issuance under our 2022 Plan. Additionally, shares
issued pursuant to awards under our 2022 Plan that we repurchase or that are forfeited, as well as shares used to pay the exercise price of an award or to satisfy the tax withholding obligations to an award, will become available for future grant
under our 2022 Plan. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The maximum number of shares of common stock subject to stock awards granted under the 2022 Plan
or otherwise during any calendar year beginning in 2023 to <FONT STYLE="white-space:nowrap">any&nbsp;non-employee&nbsp;director,</FONT> taken together with any cash fees paid by us to
<FONT STYLE="white-space:nowrap">such&nbsp;non-employee&nbsp;director</FONT> during such calendar year for service on the board of directors, will not exceed $750,000 in total value (calculating the value of any such stock awards based on the grant
date fair value of such stock awards for financial reporting purposes). </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Plan Administration</I>. Our board of
directors, or a duly authorized committee of our board, may administer our 2022 Plan. Our board of directors has delegated concurrent authority to administer our 2022 Plan to the compensation committee under the terms of the compensation
committee&#146;s charter. We sometimes refer to the board of directors, or the applicable committee with the power to administer our equity incentive plans, as the administrator. The administrator may also delegate to one or more of our officers the
authority to (1)&nbsp;designate employees (other than officers) to receive specified awards, and (2)&nbsp;determine the number of shares subject to such awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The administrator has the authority to determine the terms of awards, including recipients, the exercise, purchase or strike
price of awards, if any, the number of shares subject to each award, the fair market value of a share of common stock, the vesting schedule applicable to the awards, together with any vesting acceleration, and the form of consideration, if any,
payable upon exercise or settlement of the award and the terms of the award agreements for use under our 2022 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In
addition, subject to the terms of the 2022 Plan, the administrator also has the power to modify outstanding awards under our 2022 Plan, including the authority to reprice any outstanding option or stock appreciation right, cancel <FONT
STYLE="white-space:nowrap">and&nbsp;re-grant&nbsp;any</FONT> outstanding option or stock appreciation right in exchange for new stock awards, cash or other consideration, or take any other action that is treated as a repricing under generally
accepted accounting principles, with the consent of any materially adversely affected participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Stock Options</I>.
ISOs and NSOs are granted pursuant to stock option agreements adopted by the administrator. The administrator determines the exercise price for a stock option, within the terms and conditions of the 2022 Plan, provided that the exercise price of a
stock option generally cannot be less than 100% of the fair market value of our common stock on the date of grant. Options granted under the 2022 Plan vest at the rate specified in the stock option agreement as specified in the stock option
agreement by the administrator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The administrator determines the term of stock options granted under the 2022 Plan, up to
a maximum of ten years. Unless the terms of an optionholder&#146;s stock option agreement provide otherwise, if an optionholder&#146;s </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">178 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
service relationship with us, or any of our affiliates, ceases for any reason other than disability, death or cause, the optionholder may generally exercise any vested options for a period of
three months following the cessation of service. The option term may be extended in the event that either an exercise of the option or an immediate sale of shares acquired upon exercise of the option following such a termination of service is
prohibited by applicable securities laws or our insider trading policy. If an optionholder&#146;s service relationship with us or any of our affiliates ceases due to disability or death, or an optionholder dies within a certain period following
cessation of service, the optionholder or a beneficiary may generally exercise any vested options for a period of 12 months in the event of disability and 18 months in the event of death. In the event of a termination for cause, options generally
terminate immediately upon the termination of the individual for cause. In no event may an option be exercised beyond the expiration of its term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Acceptable consideration for the purchase of common stock issued upon the exercise of a stock option will be determined by the
administrator and may include (1)&nbsp;cash, check, bank draft or money order, (2)&nbsp;a broker-assisted cashless exercise, (3)&nbsp;the tender of shares of common stock previously owned by the optionholder, (4)&nbsp;a net exercise of the option if
it is an NSO and (5)&nbsp;other legal consideration approved by the administrator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Options may not be transferred to
third-party financial institutions for value. Unless the administrator provides otherwise, options generally are not transferable except by will, the laws of descent and distribution or pursuant to a domestic relations order. An optionholder may
designate a beneficiary, however, who may exercise the option following the optionholder&#146;s death. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Tax Limitations
on ISOs</I>. The aggregate fair market value, determined at the time of grant, of common stock with respect to ISOs that are exercisable for the first time by an option holder during any calendar year under all of our stock plans may not exceed
$100,000. Options or portions thereof that exceed such limit will be treated as NSOs. No ISOs may be granted to any person who, at the time of the grant, owns or is deemed to own stock possessing more than 10% of our total combined voting power or
that of any of our parent or subsidiary corporations, unless (1)&nbsp;the option exercise price is at least 110% of the fair market value of the stock subject to the option on the date of grant and (2)&nbsp;the term of the ISO does not exceed five
years from the date of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Restricted Stock Awards</I>. Restricted stock awards are granted pursuant to restricted
stock award agreements adopted by the administrator. Restricted stock awards may be granted in consideration for cash, check, bank draft or money order, services rendered to us or our affiliates or any other form of legal consideration. Common stock
acquired under a restricted stock award may, but need not, be subject to a share repurchase option in our favor in accordance with a vesting schedule to be determined by the administrator. A restricted stock award may be transferred only upon such
terms and conditions as set by the administrator. Except as otherwise provided in the applicable award agreement, restricted stock awards that have not vested may be forfeited or repurchased by us upon the participant&#146;s cessation of continuous
service for any reason. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Restricted Stock Unit Awards</I>. Restricted stock unit awards are granted pursuant to
restricted stock unit award agreements adopted by the administrator. Restricted stock unit awards may be granted in consideration for any form of legal consideration. A restricted stock unit award may be settled by cash, delivery of stock, a
combination of cash and stock as deemed appropriate by the administrator or in any other form of consideration set forth in the restricted stock unit award agreement. Additionally, dividend equivalents may be credited in respect of shares covered by
a restricted stock unit award. Except as otherwise provided in the applicable award agreement, restricted stock units that have not vested will be forfeited upon the participant&#146;s cessation of continuous service for any reason. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Stock Appreciation Rights</I>. Stock appreciation rights are granted pursuant to stock appreciation right grant agreements
adopted by the administrator. The administrator determines the strike price for a stock appreciation right, which generally cannot be less than 100% of the fair market value of common stock on the date of grant. Upon the exercise of a stock
appreciation right, we will pay the participant an amount equal to the product of (1)&nbsp;the excess of the per share fair market value of common stock on the date of exercise over the strike price, multiplied by (2)&nbsp;the number of shares of
common stock with respect to which the stock appreciation right is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">179 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
exercised. A stock appreciation right granted under the 2022 Plan vests at the rate specified in the stock appreciation right agreement as determined by the administrator. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The administrator determines the term of stock appreciation rights granted under the 2022 Plan, up to a maximum of ten years.
Unless the terms of a participant&#146;s stock appreciation right agreement provide otherwise, if a participant&#146;s service relationship with us or any of our affiliates ceases for any reason other than cause, disability or death, the participant
may generally exercise any vested stock appreciation right for a period of three months following the cessation of service. The stock appreciation right term may be further extended in the event that exercise of the stock appreciation right
following such a termination of service is prohibited by applicable securities laws. If a participant&#146;s service relationship with us, or any of our affiliates, ceases due to disability or death, or a participant dies within a certain period
following cessation of service, the participant or a beneficiary may generally exercise any vested stock appreciation right for a period of 12 months in the event of disability and 18 months in the event of death. In the event of a termination for
cause, stock appreciation rights generally terminate immediately upon the occurrence of the event giving rise to the termination of the individual for cause. In no event may a stock appreciation right be exercised beyond the expiration of its term.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Performance Awards</I>. Our 2022 Plan permits the grant of performance-based stock and cash awards. The compensation
committee can structure such awards so that the stock or cash will be issued or paid pursuant to such award only following the achievement of <FONT STYLE="white-space:nowrap">certain&nbsp;pre-established&nbsp;performance</FONT> goals during a
designated performance period. Performance awards that are settled in cash or other property are not required to be valued in whole or in part by reference to, or otherwise based on, the common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The performance goals may be based on any measure of performance selected by the board of directors. The compensation
committee may establish performance goals on a company-wide basis, with respect to one or more business units, divisions, affiliates or business segments, and in either absolute terms or relative to the performance of one or more comparable
companies or the performance of one or more relevant indices. Unless specified otherwise (i)&nbsp;in the award agreement at the time the award is granted or (ii)&nbsp;in such other document setting forth the performance goals at the time the goals
are established, the compensation committee will appropriately make adjustments in the method of calculating the attainment of the performance goals as follows: (1)&nbsp;to exclude restructuring and/or other nonrecurring charges; (2)&nbsp;to exclude
exchange rate effects; (3)&nbsp;to exclude the effects of changes to generally accepted accounting principles; (4)&nbsp;to exclude the effects of any statutory adjustments to corporate tax rates; (5)&nbsp;to exclude the effects of items that are
&#147;unusual&#148; in nature or occur &#147;infrequently&#148; as determined under generally accepted accounting principles; (6)&nbsp;to exclude the dilutive effects of acquisitions or joint ventures; (7)&nbsp;to assume that any business divested
by us achieved performance objectives at targeted levels during the balance of a performance period following such divestiture; (8)&nbsp;to exclude the effect of any change in the outstanding shares of common stock by reason of any stock dividend or
split, stock repurchase, reorganization, recapitalization, merger, <FONT STYLE="white-space:nowrap">consolidation,&nbsp;spin-off,&nbsp;combination</FONT> or exchange of shares or other similar corporate change, or any distributions to common
stockholders other than regular cash dividends; (9)&nbsp;to exclude the effects of stock-based compensation and the award of bonuses under our bonus plans; (10)&nbsp;to exclude costs incurred in connection with potential acquisitions or divestitures
that are required to be expensed under generally accepted accounting principles and (11)&nbsp;to exclude the goodwill and intangible asset impairment charges that are required to be recorded under generally accepted accounting principles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Other Awards</I>. The administrator may grant other awards based in whole or in part by reference to common stock. The
administrator will set the number of shares under the award and all other terms and conditions of such awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Changes
to Capital Structure</I>. In the event there is a specified type of change in our capital structure, such as a stock split, reverse stock split or recapitalization, appropriate adjustments will be made to (1)&nbsp;the class and maximum number of
shares reserved for issuance under the 2022 Plan; (2)&nbsp;the class and maximum number of shares by which the share reserve may increase automatically each year; (3)&nbsp;the class and maximum number of shares that may be issued upon the exercise
of ISOs and (4)&nbsp;the class and number of shares and exercise price, strike price, or purchase price, if applicable, of all outstanding awards. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">180 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Corporate Transactions</I>. The following applies to stock awards under
the 2022 Plan in the event of a corporate transaction, unless otherwise provided in a participant&#146;s stock award agreement or other written agreement with us or one of our affiliates or unless otherwise expressly provided by the administrator at
the time of grant. Under the 2022 Plan, a corporate transaction is generally the consummation of (1)&nbsp;a sale or other disposition of all or substantially all of our assets, (2)&nbsp;a sale or other disposition of at least 50% of our outstanding
securities, (3)&nbsp;a merger, consolidation or similar transaction following which we are not the surviving corporation or (4)&nbsp;a merger, consolidation or similar transaction following which we are the surviving corporation but the shares of
common stock outstanding immediately prior to such transaction are converted or exchanged into other property by virtue of the transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the event of a corporate transaction, any stock awards outstanding under the 2022 Plan may be assumed, continued or
substituted for by any surviving or acquiring corporation (or its parent company), and any reacquisition or repurchase rights held by us with respect to the stock award may be assigned to the successor (or its parent company). If the surviving or
acquiring corporation (or its parent company) does not assume, continue or substitute for such stock awards, then (i)&nbsp;with respect to any such stock awards that are held by participants whose continuous service has not terminated prior to the
effective time of the corporate transaction, or current participants, the vesting (and exercisability, if applicable) of such stock awards will be accelerated in full to a date prior to the effective time of the corporate transaction (contingent
upon the effectiveness of the corporate transaction), and such stock awards will terminate if not exercised (if applicable) at or prior to the effective time of the corporate transaction, and any reacquisition or repurchase rights held by us with
respect to such stock awards will lapse (contingent upon the effectiveness of the corporate transaction), and (ii)&nbsp;any such stock awards that are held by persons other than current participants will terminate if not exercised (if applicable)
prior to the effective time of the corporate transaction, except that any reacquisition or repurchase rights held by us with respect to such stock awards will not terminate and may continue to be exercised notwithstanding the corporate transaction.
In addition, the plan administrator may also provide, in its sole discretion, that the holder of a stock award that will terminate upon the occurrence of a corporate transaction if not previously exercised will receive a payment, if any, equal to
the excess of the value of the property the participant would have received upon exercise of the stock award over the exercise price otherwise payable in connection with the stock award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Stock options granted under the 2022 Plan become vested and exercisable in full in the event the holder&#146;s service is
terminated without cause in connection with or within 12 months following a change in control, unless otherwise provided in the applicable option agreement. Other stock awards may be subject to additional acceleration of vesting and exercisability
upon or after a change in control as may be provided in an applicable award agreement or other written agreement, but in the absence of such provision, no such acceleration will occur. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Transferability</I>. A participant may not transfer awards under our 2022 Plan other than by will, the laws of descent and
distribution or as otherwise provided under our 2022 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Plan Amendment or Termination</I>. Our board has the
authority to amend, suspend or terminate our 2022 Plan, provided that such action does not materially impair the existing rights of any participant without such participant&#146;s written consent. Certain material amendments also require the
approval of our stockholders. No ISOs may be granted after the tenth anniversary of the date our board adopted our 2022 Plan. No awards may be granted under our 2022 Plan while it is suspended or after it is terminated. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2019 Stock Incentive Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our board of directors adopted, and our stockholders approved, our 2019 Plan in June 2019. No further stock awards will be
granted under our 2019 Plan on or after the effectiveness of our 2022 Plan; however, awards outstanding under our 2019 Plan will continue to be governed by their existing terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Types of Awards</I>. Our 2019 Plan allows us to grant ISOs, NSOs, stock appreciation rights, restricted stock awards,
restricted stock units and other awards to eligible employees, directors, officers, consultants and advisors of ours and any parent or subsidiary of ours. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">181 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Authorized Shares</I>. An aggregate of 3,077,023 shares of our common
stock were reserved for issuance under our 2019 Plan. As of June&nbsp;30, 2022, options to purchase 2,072,851 shares of our common stock remained outstanding under our 2019 Plan. In the event that an outstanding option, restricted stock award or
other award for any reason expires or is canceled, the shares allocable to such award shall be added to the number of shares then available for issuance under our 2022 Plan once adopted by our board of directors and approved by our stockholders.
</P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Plan Administration</I>. Our board of directors or a committee of our board administers our 2019 Plan. Subject to
the provisions of the 2019 Plan, the administrator has the full authority and discretion to take any actions it deems necessary or advisable for the administration of the 2019 Plan. All decisions, interpretations and other actions of the
administrator are final and binding on all participants in the 2019 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Options</I>. Stock options have been granted
under our 2019 Plan. Subject to the provisions of our 2019 Plan, the administrator determines the term of an option, the number of shares subject to an option, and the time period in which an option may be exercised. The term of an option is stated
in the applicable award agreement, but the term of an option may not exceed 10 years from the grant date. The administrator determines the exercise price of options, which may not be less than 100% of the fair market value of our common stock on the
grant date. To the extent that the aggregate fair market value of the shares with respect to which ISOs are exercisable for the first time by an employee during any calendar year (under all our plans and any parent or subsidiary) exceeds $100,000,
such options will be treated as NSOs. The administrator determines how a participant may pay the exercise price of an option, and the permissible methods are generally set forth in the applicable award agreement. If a participant&#146;s employment,
or relationship with us as a director, consultant or advisor, terminates, that participant may exercise the vested portion of his or her option for the period of time stated in the applicable award agreement. Vested options generally will remain
exercisable for 90 days or such longer period of time as set forth in the applicable award agreement if a participant&#146;s service to us terminates for a reason other than death, disability or for &#147;cause.&#148; If a participant&#146;s
continuous service terminates due to disability or death, then vested options generally remain exercisable for one year from the date of termination (or such longer period as set forth in the applicable award agreement). In no event will an option
remain exercisable beyond its original term. If a participant does not exercise his or her option within the time specified in the award agreement, the option will terminate. Except as described above, the administrator has the discretion to
determine the post-termination exercisability periods for an option. In general, stock options granted under the 2019 Plan prior to March 22, 2022 become vested and exercisable in full upon the occurrence of a change in control transaction, provided
that the employee remains employed with us at the time of such change in control. Stock options granted under the 2019 Plan beginning on March 22, 2022 become vested and exercisable in full in the event the holder&#146;s service is terminated
without cause in connection with or within 12 months following a change in control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Certain Adjustments</I>. In the
event of any change that is made in, or other events that occur with respect to, the common stock subject to the 2019 Plan without the receipt of consideration by us through merger, consolidation, reorganization, recapitalization, reincorporation,
stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, reverse stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or any similar equity
restricting transaction (but excluding the conversion of any of our convertible securities), the administrator will appropriately and proportionately adjust: (i)&nbsp;the class(es) and maximum number of securities subject to the 2019 Plan,
(ii)&nbsp;the class(es) and maximum number of securities that may be issued pursuant to the exercise of ISOs and (iii)&nbsp;the class(es) and number of securities and price per share of stock subject to outstanding awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Reorganization Events</I>. The following applies to awards under the 2019 Plan in the event of a reorganization event,
unless otherwise provided in a participant&#146;s stock award agreement or other written agreement with us or one of our affiliates or unless otherwise expressly provided by the administrator at the time of grant. Under the 2019 Plan, a
reorganization event is generally (1)&nbsp;a merger, consolidation or similar transaction following which we are not the surviving corporation, (2)&nbsp;any transfer or disposition of all of the shares of our common stock, or (3)&nbsp;any
liquidation or dissolution. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">182 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the event of a reorganization event, our administrator generally may take
one or more of the following actions, contingent upon the closing or completion of such reorganization event: (i)&nbsp;arrange for the surviving corporation or acquiring corporation (or parent company) to assume or continue the award or substitute a
similar award, (ii)&nbsp;provide for the termination of all unexercised awards immediately prior to the consummation of the reorganization event, (iii)&nbsp;accelerate the vesting, in whole or in part, of the stock award to a date prior to or upon
the effective time of such reorganization event as our administrator determines, (iv)&nbsp;make a payment, in such form as may be determined by our administrator, equal to the excess, if any, of (A)&nbsp;the value of the property the participant
would have received upon exercise of the award immediately prior to the effective time of the reorganization event over (B)&nbsp;any exercise price payable, or (v)&nbsp;in connection with a liquidation or dissolution, provide that awards will
convert into the right to receive liquidation proceeds (net of any applicable exercise or purchase price). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Transferability of Awards</I>. Unless our administrator provides otherwise, our 2019 Plan generally does not allow for the
transfer or assignment of awards, except by will or by the laws of descent and distribution. Shares issued upon exercise or settlement of an award will be subject to such terms and conditions as the administrator may determine, including rights of
first refusal and other transfer restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Amendment; Termination</I>. Our board of directors may amend, suspend
or terminate our 2019 Plan at any time, provided that such action does not materially and adversely affect a participant&#146;s rights under outstanding awards without such participant&#146;s written consent. As noted above, in connection with this
offering, our 2019 Plan will be terminated and no further awards will be granted thereunder. All outstanding awards will continue to be governed by their existing terms. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2022 Employee Stock Purchase Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our board of directors adopted our ESPP in October 2022 and our stockholders approved our ESPP in October 2022. The ESPP will
become effective on the date of the underwriting agreement related to this offering. The purpose of the ESPP is to secure the services of new employees, to retain the services of existing employees, and to provide incentives for such individuals to
exert maximum efforts toward our success and that of our affiliates. The ESPP includes two components. One component is designed to allow eligible U.S. employees to purchase our common stock in a manner that may qualify for favorable tax treatment
under Section 423 of the Code. The other component permits the grant of purchase rights that do not qualify for such favorable tax treatment in order to allow deviations necessary to permit participation by eligible employees who are foreign
nationals or employed outside of the U.S. while complying with applicable foreign laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Share Reserve</I>. Following
this offering, the ESPP authorizes the issuance of shares of our common stock under purchase rights granted to our employees or to employees of any of our designated affiliates. The maximum aggregate number of shares of common stock that may be
issued under our ESPP is 215,000 shares. The number of shares of our common stock reserved for issuance will automatically increase on January&nbsp;1 of each calendar year, beginning on January 1, 2023 (assuming the ESPP becomes effective in 2022)
through January&nbsp;1, 2032, by the lesser of (1)&nbsp;1.0% of the total number of shares of our common stock outstanding on the last day of the fiscal year before the date of the automatic increase; provided that before the date of any such
increase, our board of directors may determine that such increase will be less than 1.0%. As of the date hereof, no shares of our common stock have been purchased under the ESPP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Administration</I>. Our board of directors administers the ESPP and may delegate its authority to administer the ESPP to
our compensation committee. The ESPP is implemented through a series of offerings under which eligible employees are granted purchase rights to purchase shares of our common stock on specified dates during such offerings. Under the ESPP, we may
specify offerings with durations of not more than 27 months, and may specify shorter purchase periods within each offering. Each offering will have one or more purchase dates on which shares of our common stock will be purchased for employees
participating in the offering. An offering under the ESPP may be terminated under certain circumstances. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">183 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Payroll Deductions</I>. Generally, all regular employees, including
executive officers, employed by us or by any of our designated affiliates, may participate in the ESPP and may contribute, normally through payroll deductions, up to the percentage of earnings or maximum dollar amount specified by our board of
directors for the purchase of our common stock under the ESPP. Unless otherwise determined by our board of directors, common stock will be purchased for the accounts of employees participating in the ESPP at a price per share that is at least the
lesser of (1) 85% of the fair market value of a share of our common stock on the first date of an offering, or (2) 85% of the fair market value of a share of our common stock on the date of purchase. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Limitations</I>. Employees may have to satisfy one or more of the following service requirements before participating in
the ESPP, as determined by our board of directors, including: (1) being customarily employed for more than 20 hours per week, (2) being customarily employed for more than five months per calendar year, or (3) continuous employment with us or one of
our affiliates for a period of time (not to exceed two years). No employee may purchase shares under the ESPP at a rate in excess of $25,000 worth of our common stock based on the fair market value per share of our common stock at the beginning of
an offering for each calendar year such a purchase right is outstanding. Finally, no employee will be eligible for the grant of any purchase rights under the ESPP if immediately after such rights are granted, such employee has voting power over 5%
or more of our outstanding capital stock measured by vote or value under Section 424(d) of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Changes to
Capital Structure</I>. In the event that there occurs a change in our capital structure through such actions as a stock split, merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than
cash, large nonrecurring cash dividend, liquidating dividend, combination of shares, exchange of shares, change in corporate structure, or similar transaction, the board of directors will make appropriate adjustments to: (1) the class(es) and
maximum number of shares reserved under the ESPP, (2) the class(es) and maximum number of shares by which the share reserve may increase automatically each year, (3) the class(es) and number of shares subject to and purchase price applicable to
outstanding offerings and purchase rights, and (4) the number of shares that are subject to purchase limits under ongoing offerings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Corporate Transactions</I>. In the event of certain significant corporate transactions, including the consummation of (1) a
sale of all or substantially all of our assets, (2) the sale or disposition of more than 50% of our outstanding securities, (3) a merger or consolidation where we do not survive the transaction, or (4) a merger or consolidation where we do survive
the transaction but the shares of our common stock outstanding immediately before such transaction are converted or exchanged into other property by virtue of the transaction, any then-outstanding rights to purchase our stock under the ESPP may be
assumed, continued or substituted for by any surviving or acquiring entity (or its parent company). If the surviving or acquiring entity (or its parent company) elects not to assume, continue, or substitute for such purchase rights, then the
participants&#146; accumulated payroll contributions will be used to purchase shares of our common stock within ten business days before such corporate transaction, and such purchase rights will terminate immediately. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>ESPP Amendment or Termination</I>. Our board of directors has the authority to amend or terminate our ESPP, provided that
except in certain circumstances such amendment or termination may not materially impair any outstanding purchase rights without the holder&#146;s consent. We will obtain stockholder approval of any amendment to our ESPP as required by applicable law
or listing requirements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations on Liability and Indemnification Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the closing of this offering, our amended and restated certificate of incorporation will contain provisions that limit the
liability of our current and former directors or officers for monetary damages for breach of fiduciary duty to the fullest extent permitted by Delaware law. Delaware law provides that directors of a corporation will not be personally liable for
monetary damages for any breach of fiduciary duties as directors, except liability for: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any breach of the director&#146;s duty of loyalty to the corporation or its stockholders;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">184 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section&nbsp;174 of
the Delaware General Corporation Law; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction from which the director derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These limitations of liability do not apply to liabilities arising under federal securities laws and does not affect the
availability of equitable remedies such as injunctive relief or rescission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated certificate of
incorporation that will be in effect upon the closing of this offering will provide that we are authorized to indemnify our directors and officers to the fullest extent permitted by Delaware law. Our amended and restated bylaws that will be in
effect upon the closing of this offering will provide that we are required to indemnify our directors and executive officers to the fullest permitted by Delaware law, and authorized to indemnify other officers to the same extent. Our amended and
restated bylaws will also provide that, upon satisfaction of certain conditions, we are required to advance expenses incurred by a director or executive officer, and may advance expenses incurred by other officers, in advance of the final
disposition of any action or proceeding, and permit us to secure insurance on behalf of any officer, director, employee or other agent for any liability arising out of his or her actions in that capacity to the fullest extent not prohibited by
applicable law. Our amended and restated bylaws will also permit us to enter into individual contracts with any of our directors, officers, employees and other agents respecting indemnification and advances, to the fullest extent not prohibited by
applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In connection with this offering, we expect to enter into indemnification agreements with each of our
directors and executive officers. With certain exceptions, these agreements will provide for indemnification for related expenses including, among other things, attorneys&#146; fees, judgments, fines and settlement amounts incurred by any of these
individuals in any action or proceeding. We believe that these bylaw provisions and indemnification agreements are necessary to attract and retain qualified persons as directors and executive officers. We maintain directors&#146; and officers&#146;
liability insurance and will obtain customary directors&#146; and officers&#146; liability insurance prior to the closing of this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The limitation of liability and indemnification provisions in our amended and restated certificate of incorporation and
amended and restated bylaws may discourage stockholders from bringing a lawsuit against our directors for breach of their fiduciary duty. They may also reduce the likelihood of derivative litigation against our directors and officers, even though an
action, if successful, might benefit us and other stockholders. Further, a stockholder&#146;s investment may be adversely affected to the extent that we pay the costs of settlement and damage awards against directors and officers as required by
these indemnification provisions. At present, there is no pending litigation or proceeding involving any of our directors, officers or employees for which indemnification is sought and we are not aware of any threatened litigation that may result in
claims for indemnification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Insofar as indemnification for liabilities arising under the Securities Act may be permitted
for our directors, executive officers or persons controlling us, we have been informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">185 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc383050_15"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following is a description of transactions since January&nbsp;1, 2019 to which we have been a participant in which the
amount involved exceeds the lesser of $120,000 or one percent of the average of our total assets at year end for the last two completed fiscal years, and in which any of our directors, executive officers or holders of more than 5% of our voting
securities, or any members of their immediate family, had or will have a direct or indirect material interest, other than compensation arrangements which are described under &#147;Management&#151;Non-Employee Director Compensation&#148; and
&#147;Executive Compensation.&#148; </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Private Placements of Our Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Convertible Promissory Notes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In June and December 2019, we issued and sold convertible promissory notes, or the Convertible Notes, in the aggregate
principal amount of $3.0 million. The Convertible Notes accrued interest at a rate of 8% per annum. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table
sets forth the aggregate principal amount of the Convertible Notes issued to our directors, officers and holders of more than 5% of our capital stock and their affiliates. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate&nbsp;Principal<BR>Amount</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chione Limited<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Marcin Czernik, a former member of our board of directors, is a director of Chione Limited. Chione Limited
holds more than 5% of our capital stock prior to this offering. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred
Stock Financing </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In October 2020, we entered into a Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred
stock purchase agreement, or the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Purchase Agreement, with certain investors, including a beneficial owner of greater than 5% of our capital stock and an affiliate of a member of our board of
directors, pursuant to which we issued and sold to such investors an aggregate of 1,315,789 shares of our Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred stock, par value $0.001 per share, or Series
<FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, at a purchase price of $2.28 per share for aggregate gross proceeds of $3.0&nbsp;million and issued 3,106,561 shares of our Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred
Stock upon conversion of outstanding convertible promissory notes, including the Convertible Notes, to the holders thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Purchase Agreement, Chione was required to purchase up to
$12,000,000 of additional shares of our Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock upon our achievement of certain milestones, provided that a third-party investor mutually acceptable to us and Chione could purchase all or
any portion of such additional shares and the aggregate amount and price per share of such additional shares could be increased upon the mutual agreement of the purchasers of such shares and us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In January 2021, upon the achievement of certain milestones, we issued and sold to such investors an aggregate of 5,482,456
shares of our Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock at a purchase price of $2.28 per share for aggregate gross proceeds of $12.5&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">186 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The table below sets forth the aggregate number of shares of Series <FONT
STYLE="white-space:nowrap">A-1</FONT> Preferred Stock issued to our related parties in this financing: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series <FONT STYLE="white-space:nowrap">A-1</FONT><BR>Preferred<BR>Stock (#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Purchase<BR>Price ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chione Limited<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,497,692</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,005,506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New Enterprise Associates 16, LP<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,187,816</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,166,575</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Marcin Czernik, a former member of our board of directors, is a director of Chione Limited. Chione Limited
holds more than 5% of our capital stock prior to this offering. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">New Enterprise Associates 16, LP became a beneficial owner of more than 5% of our capital stock in
connection with this transaction. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Reimbursement of Expenses Related to Patent License Agreement with Peter Blume-Jensen
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In April 2018, we entered into a patent license agreement, or the Blume-Jensen License, with Peter Blume-Jensen,
our Chief Executive Officer and President, that granted us an exclusive, worldwide, irrevocable, perpetual, royalty-free license under certain licensed patents for any and all purposes and uses, including without limitation and rights to sublicense
through multiple tiers. Under the terms of the Blume-Jensen License, we were obligated to reimburse Dr.&nbsp;Blume-Jensen the sum of $150,000, which represented the parties&#146; agreed upon estimate of unreimbursed past expenses incurred by
Dr.&nbsp;Blume-Jensen with respect to the preparation, filing, prosecution, protection and maintenance of the licensed patents, within 30 days following the closing of an equity financing by us with gross proceeds of at least $2,000,000. Following
the closing of our Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock financing, we paid Dr.&nbsp;Blume-Jensen $150,000 in October 2020 to satisfy this obligation under the Blume-Jensen License. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Series B Preferred Stock Financing </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In November 2021, we entered into a Series B preferred stock purchase agreement, or the Series B Purchase Agreement, with
certain investors, including beneficial owners of greater than 5% of our capital stock and affiliates of certain members of our board of directors, pursuant to which we issued and sold to such investors an aggregate of 17,521,047 shares of our
Series B preferred stock, par value $0.001 per share, or Series B Preferred Stock, at a purchase price of $5.70742 per share for aggregate gross proceeds of $100.0&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The table below sets forth the aggregate number of shares of Series B preferred stock issued to our related parties in this
financing: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series B<BR>Preferred<BR>Stock (#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Purchase<BR>Price ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chione Limited<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">149,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Citadel Multi-Strategy Equities Master Fund Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,190,131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,499,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Perceptive Life Sciences Master Fund, Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,978,578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,999,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with RA Capital
Management<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,504,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,999,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sands Capital Life Sciences Pulse Fund II, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,102,526</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,999,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wellington Biomedical Innovation Master Investors (Cayman) I L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,190,131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,499,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Marcin Czernik, a former member of our board of directors, is a director of Chione Limited. Chione Limited
holds more than 5% of our capital stock prior to this offering. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Derek DiRocco, Ph.D., a member of our board of directors, is a partner at RA Capital Management. Entities
affiliated with RA Capital Management hold more than 5% of our capital stock prior to this offering. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">187 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investors&#146; Rights, Voting, Right of First Refusal and
<FONT STYLE="white-space:nowrap">Co-Sale,</FONT> and Management Rights Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In connection with our convertible
preferred stock financings, we entered into investors&#146; rights, voting, right of first refusal and <FONT STYLE="white-space:nowrap">co-sale</FONT> and management rights agreements containing registration rights, information rights, rights of
first offer, voting rights and rights of first refusal, among other things, with certain holders of our capital stock, including Chione Limited, New Enterprise Associates 16, LP, entities affiliated with RA Capital Management, Citadel Multi-Strategy
Equities Master Fund Ltd., Perceptive Life Sciences Master Fund, Ltd., Entities affiliated with RA Capital Management, Sands Capital Life Sciences Pulse Fund II, L.P., and Wellington Biomedical Innovation Master Investors (Cayman) I L.P. Marcin
Czernik, a former member of our board of directors, is a director of Chione Limited. Derek DiRocco, Ph.D., a member of our board of directors, is a partner at RA Capital Management. Peter Blume-Jensen, M.D., Ph.D., our
<FONT STYLE="white-space:nowrap">co-founder,</FONT> Chief Executive Officer and President and a member of our board of directors, and Kristina Masson, Ph.D., our <FONT STYLE="white-space:nowrap">co-founder</FONT> and Executive Vice President,
Business Operations, are party to certain of these agreements in their capacity as a stockholder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The foregoing
stockholder agreements will terminate upon the closing of this offering, except for the registration rights granted under our investors&#146; rights agreement, as more fully described in the section titled &#147;Description of Capital
Stock&#151;Registration Rights.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employment Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have entered into employment agreements or offer letter agreements with certain of our executive officers. For more
information regarding our employment agreements with our named executive officers, see the section titled &#147;Executive Compensation.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated certificate of incorporation that will be in effect upon the closing of this offering will contain
provisions limiting the liability of directors, and our amended and restated bylaws will provide that we will indemnify each of our directors to the fullest extent permitted under Delaware law. Our amended and restated certificate of incorporation
and amended and restated bylaws will also provide our board of directors with discretion to indemnify our officers, employees and other agents when determined appropriate by the board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, in connection with this offering, we expect to enter into indemnification agreements with each of our directors
and our executive officers prior to the closing of this offering. For more information regarding these agreements, see the section titled &#147;Executive Compensation&#151;Limitations on Liability and Indemnification Matters.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Related Person Transaction Policy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prior to this offering, we have not had a formal policy regarding approval of transactions with related parties. In connection
with this offering, we have adopted a related person transaction policy that sets forth our procedures for the identification, review, consideration and approval or ratification of related person transactions, which policy will become effective
immediately upon the execution of the underwriting agreement for this offering. For purposes of our policy only, a related person transaction will be a transaction, arrangement or relationship, or any series of similar transactions, arrangements or
relationships, in which we and any related person are, were or will be participants in which the amount involved exceeds $120,000. Transactions involving compensation for services provided to us as an employee or director will not be covered by this
policy. A related person will be any executive officer, director or beneficial owner of more than 5% of any class of our voting securities, including any of their immediate family members and any entity owned or controlled by such persons. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the policy, if a transaction has been identified as a related person transaction, including any transaction that was not
a related person transaction when originally consummated or any transaction that was not initially identified as a related person transaction prior to consummation, our management must present </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">188 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
information regarding the related person transaction to our audit committee, or, if audit committee approval would be inappropriate, to another independent body of our board of directors, for
review, consideration and approval or ratification. The presentation must include a description of, among other things, the material facts, the interests, direct and indirect, of the related persons, the benefits to us of the transaction and whether
the transaction is on terms that are comparable to the terms available to or from, as the case may be, an unrelated third party or to or from employees generally. Under the policy, we will collect information that we deem reasonably necessary from
each director, executive officer and, to the extent feasible, significant stockholder to enable us to identify any existing or potential related-person transactions and to effectuate the terms of the policy. In addition, under our Code of Conduct
that we expect to adopt prior to the closing of this offering, our employees and directors will have an affirmative responsibility to disclose any transaction or relationship that reasonably could be expected to give rise to a conflict of interest.
In considering related person transactions, our audit committee, or other independent body of our board of directors, will take into account the relevant available facts and circumstances including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risks, costs and benefits to us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact on a director&#146;s independence in the event that the related person is a director, immediate
family member of a director or an entity with which a director is affiliated; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of other sources for comparable services or products; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms available to or from, as the case may be, unrelated third parties or to or from employees generally.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The policy will require that, in determining whether to approve, ratify or reject a related person
transaction, our audit committee, or other independent body of our board of directors, must consider, in light of known circumstances, whether the transaction is in, or is not inconsistent with, our best interests and those of our stockholders, as
our audit committee, or other independent body of our board of directors, determines in the good faith exercise of its discretion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">All of the transactions described in this section were entered into prior to the adoption of this policy. Although we have not
had a written policy for the review and approval of transactions with related persons, our board of directors has historically reviewed and approved any transaction where a director or officer had a financial interest, including the transactions
described above. Prior to approving such a transaction, the material facts as to a director&#146;s or officer&#146;s relationship or interest in the agreement or transaction were disclosed to our board of directors. Our board of directors took this
information into account when evaluating the transaction and in determining whether such transaction was fair to us and in the best interest of all our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">189 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc383050_16"></A>PRINCIPAL STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table sets forth certain information with respect to the beneficial ownership of our common stock as of
September&nbsp;30, 2022: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our named executive officers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all of our directors and executive officers as a group; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each person, or group of affiliated persons, known by us to beneficially own more than 5% of our common stock.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have determined beneficial ownership in accordance with the rules of the SEC, and therefore it
represents sole or shared voting or investment power with respect to our securities. Unless otherwise indicated below, to our knowledge, the persons and entities named in the table have sole voting and sole investment power with respect to all
shares that they beneficially owned, subject to community property laws where applicable. We have deemed shares of common stock subject to options that are currently exercisable or exercisable within 60 days of September&nbsp;30, 2022, to be
outstanding and to be beneficially owned by the person holding the option for the purpose of computing the percentage ownership of that person but have not treated them as outstanding for the purpose of computing the percentage ownership of any
other person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have based percentage ownership of common stock before this offering on 12,934,862 shares of common
stock outstanding as of September&nbsp;30, 2022, which includes 11,140,262 shares of common stock resulting from the conversion of all outstanding shares of preferred stock immediately upon the closing of this offering, as if this conversion had
occurred as of September&nbsp;30, 2022. Percentage ownership of common stock after this offering assumes the sale of 5,900,000 shares of common stock in this offering and no exercise of the underwriters&#146; option to purchase additional shares of
common stock from us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Unless otherwise indicated, the address for each beneficial owner listed in the table below is c/o
Acrivon Therapeutics, Inc., 480&nbsp;Arsenal Way, Suite&nbsp;100, Watertown, MA 02472. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares<BR>Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage&nbsp;of&nbsp;Shares<BR>Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt"><B>Greater than 5% Stockholders:</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Before<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>After<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chione Limited<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,456,597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with RA Capital
Management<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,421,008</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Perceptive Life Sciences Master Fund,
Ltd.<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,207,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Citadel Multi-Strategy Equities Master Fund
Ltd.<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">888,130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wellington Biomedical Innovation Master Investors (Cayman) I L.P.<SUP
STYLE="font-size:75%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">888,130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sands Capital Life Sciences Pulse Fund II,
L.P.<SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">852,605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Directors and Named Executive Officers:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Blume-Jensen, M.D., Ph.D.<SUP STYLE="font-size:75%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,387,547</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derek DiRocco, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kristina Masson, Ph.D.<SUP STYLE="font-size:75%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,387,547</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sharon Shacham, Ph.D., M.B.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Tomsicek, M.B.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Erick Gamelin, M.D., Ph.D.<SUP STYLE="font-size:75%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eric Devroe, Ph.D.<SUP STYLE="font-size:75%; vertical-align:top">(10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All directors and executive officers as a group (8 persons)<SUP
STYLE="font-size:75%; vertical-align:top">(11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,513,956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE>    <P STYLE="font-family:Times New Roman; font-size:10pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Represents beneficial ownership of less than 1%. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">190 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Consists of (a) 3,445,940 shares of common stock issuable upon conversion of Series <FONT
STYLE="white-space:nowrap">A-1</FONT> Preferred Stock and (b)&nbsp;10,657 shares of our common stock issuable upon conversion of Series B Preferred Stock. Chione Limited&#146;s directors, Mr.&nbsp;Czernik, Andreas Hadjimichael and Anastasios
Nikolaou, and its sole stockholder, Wiaczeslaw Smolokowski, may be deemed to share voting and investment power and beneficial ownership of the shares held directly by Chione Limited. Chione Limited&#146;s address is Simou Menardou&nbsp;5, Kifisia
Court. Office&nbsp;225, 6015 Larnaca, Cyprus. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Consists of (a) 994,706 shares of common stock issuable upon conversion of Series B Preferred Stock held
directly by RA Capital Healthcare Fund, L.P. (&#147;RA Healthcare&#148;) and (b)&nbsp;426,302 shares of common stock issuable upon conversion of Series B Preferred Stock held directly by RA Capital Nexus Fund&nbsp;II, L.P.
(&#147;Nexus&nbsp;II&#148;). Derek DiRocco, Ph.D., a member of our board of directors, is a partner at RA Capital Management, L.P. (&#147;RA Capital&#148;). RA Capital is the investment manager for RA Healthcare and Nexus&nbsp;II. The general
partner of RA Capital is RA Capital Management GP, LLC (&#147;RA Capital GP&#148;), of which Peter Kolchinsky and Rajeev Shah are the managing members. RA Capital, RA Capital GP, Peter Kolchinsky and Rajeev Shah may be deemed to have shared voting
and investment power with respect to the shares held by RA Healthcare and Nexus II. The address of all entities and individuals referenced in this footnote is 200&nbsp;Berkeley Street, 18th Floor, Boston, Massachusetts 02116. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Consists of 1,207,858 shares of common stock issuable upon conversion of Series B Preferred Stock held by
Wellington Biomedical Innovation Master Investors (Cayman) I L.P. (&#147;Wellington Biomedical Fund&#148;). Wellington Management Company LLP, a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the investment
adviser to Wellington Biomedical Fund, and Wellington Alternative Investments LLC is its general partner. Wellington Management Investment, Inc. is the managing member of Wellington Alternative Investments LLC. Wellington Management Company LLP is
an indirect subsidiary of Wellington Management Group LLP. Wellington Management Group LLP and Wellington Management Company LLP may be deemed beneficial owners with shared voting and investment power over the shares held by Wellington Biomedical
Fund. Additional information about Wellington Management Company LLP is available in its Form ADV filed with the SEC. The address of all entities referenced in this footnote is 280&nbsp;Congress Street, Boston, MA 02210. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Consists of 888,130 shares of common stock issuable upon conversion of Series B Preferred Stock held by
Citadel Multi-Strategy Equities Master Fund Ltd (&#147;CEMF&#148;). Citadel Advisors LLC (&#147;Citadel Advisors&#148;) is the portfolio manager for CEMF. Citadel Advisors Holdings LP (&#147;CAH&#148;) is the sole member of Citadel Advisors. Citadel
GP LLC (&#147;CGP&#148;) is the general partner of CAH. Kenneth Griffin is the President and Chief Executive Officer of CGP, and owns a controlling interest in CGP. Mr. Griffin, as the owner of a controlling interest in CGP, may be deemed to have
shared power to vote or direct the vote of, and/or shared power to dispose or direct the disposition of, the shares identified above. The foregoing shall not be construed as an admission that Mr. Griffin or any of the Citadel related entities listed
above is the beneficial owner of any securities referenced herein other than the securities actually owned by such person (if any). The address of Citadel Advisors LLC is 601 Lexington Avenue, New York, NY 10022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Consists of 888,130 shares of common stock issuable upon conversion of Series&nbsp;B Preferred Stock held by
Wellington Biomedical Innovation Master Investors (Cayman) I L.P. (&#147;Wellington Biomedical Fund&#148;). Wellington Management Company LLP, a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the investment
adviser to Wellington Biomedical Fund, and Wellington Alternative Investments LLC is its general partner. Wellington Management Investment, Inc. is the managing member of Wellington Alternative Investments LLC. Wellington Management Company LLP is
an indirect subsidiary of Wellington Management Group LLP. Wellington Management Group LLP and Wellington Management Company LLP may be deemed beneficial owners with shared voting and investment power over the shares held by Wellington Biomedical
Fund. Additional information about Wellington Management Company LLP is available in its Form ADV filed with the SEC. The address of all entities referenced in this footnote is 280&nbsp;Congress Street, Boston, MA 02210. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Consists of 852,605 shares of common stock issuable upon conversion of Series B Preferred Stock. Sands
Capital Life Sciences Pulse Fund <FONT STYLE="white-space:nowrap">II-GP,</FONT> L.P. (&#147;Pulse Fund II GP LP&#148;) is the sole general partner of Sands Capital Life Sciences Pulse Fund II, L.P. (&#147;Pulse Fund II&#148;), and the sole general
partner of Pulse Fund&nbsp;II GP LP is Sands Capital Life Sciences Pulse Fund <FONT STYLE="white-space:nowrap">II-GP,</FONT> LLC (&#147;Pulse Fund II GP LLC&#148;). Frank&nbsp;M. Sands
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">191 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
holds ultimate voting and investment power over the shares held directly by Pulse Fund&nbsp;II, Pulse Fund&nbsp;II GP LP, and Pulse Fund&nbsp;II GP LLC, and may be deemed to have beneficial
ownership with respect to the shares held directly by Pulse Fund&nbsp;II. The address of all entities and the individual referenced in this footnote is 1000&nbsp;Wilson Boulevard, Suite&nbsp;3000, Arlington, VA 22209. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Consists of (a)&nbsp;(i)&nbsp;871,857 shares of common stock and (ii) 147,796 shares of common stock
issuable upon the exercise of options within 60&nbsp;days of September&nbsp;30, 2022 held directly by Dr.&nbsp;Blume-Jensen and (b)&nbsp;(i)&nbsp;293,998 shares of common stock and (ii)&nbsp;73,896 shares of common stock issuable upon the exercise
of options within 60&nbsp;days of September&nbsp;30, 2022 held directly by Dr.&nbsp;Blume-Jensen&#146;s spouse, Dr.&nbsp;Masson. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Consists of (a)&nbsp;(i)&nbsp;293,998 shares of common stock and (ii) 73,896 shares of common stock issuable
upon the exercise of options within 60&nbsp;days of September&nbsp;30, 2022 held directly by Dr.&nbsp;Masson and (b)&nbsp;(i)&nbsp;871,857 shares of common stock and (ii)&nbsp;147,796 shares of common stock issuable upon the exercise of options
within 60&nbsp;days of September&nbsp;30, 2022 held directly by Dr.&nbsp;Masson&#146;s spouse, Dr.&nbsp;Blume-Jensen. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Consists of 45,619 shares of common stock issuable upon the exercise of options within 60&nbsp;days of
September&nbsp;30, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Consists of (a) 20,275 shares of common stock and (b)&nbsp;60,515 shares of common stock issuable upon the
exercise of options within 60&nbsp;days of September&nbsp;30, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Consists of (a)&nbsp;1,186,130 shares of common stock and (b)&nbsp;327,826 shares of common stock issuable
upon the exercise of options within 60&nbsp;days of September&nbsp;30, 2022. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">192 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc383050_17"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>The following description of our capital stock, certain provisions of our amended and restated certificate of incorporation
and amended and restated bylaws, as each will be in effect following the completion of this offering, and certain provisions of Delaware law are summaries. You should also refer to the amended and restated certificate of incorporation and the
amended and restated bylaws, which are filed as exhibits to the registration statement of which this prospectus is part. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the completion of this offering, our amended and restated certificate of incorporation will authorize us to issue up to
500,000,000 shares of common stock, $0.001 par value per share, and 10,000,000 shares of preferred stock, $0.001 par value per share, all of which shares of preferred stock will be undesignated. Our board of directors may establish the rights and
preferences of the preferred stock from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of June&nbsp;30, 2022, we had outstanding 1,769,561 shares of
common stock, held by seven stockholders of record. As of June&nbsp;30, 2022, after giving effect to the conversion of all of the outstanding shares of our convertible preferred stock, including shares of our Series
<FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock and Series B Preferred Stock, into 11,140,262 shares of common stock, there would have been 12,909,823 shares of common stock issued and outstanding, held by 21 stockholders of record. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each holder of our common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders,
including the election of directors. The affirmative vote of holders of at least 66<SUP STYLE="font-size:75%; vertical-align:top">2</SUP>/<SUB STYLE="font-size:75%; vertical-align:bottom">3</SUB>% of the voting power of all of the then-outstanding
shares of capital stock, voting as a single class, will be required to amend certain provisions of our amended and restated certificate of incorporation, including provisions relating to amending our amended and restated bylaws, the classified
board, the size of our board, removal of directors, director liability, vacancies on our board, special meetings, stockholder notices, actions by written consent and exclusive forum. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Subject
to preferences that may be applicable to any then-outstanding preferred stock, holders of common stock are entitled to receive ratably those dividends, if any, as may be declared from time to time by the board of directors out of legally available
funds. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the event of our liquidation, dissolution or winding up, holders of common stock will be entitled to share ratably in the
net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities and the satisfaction of any liquidation preference granted to the holders of any then-outstanding shares of preferred stock.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Rights and Preferences </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Holders of common stock have no preemptive, conversion or subscription rights and there are no redemption or sinking fund
provisions applicable to the common stock. The rights, preferences and privileges of the holders of common stock are subject to, and may be adversely affected by, the right of the holders of shares of any series of preferred stock that we may
designate in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">193 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of June&nbsp;30, 2022, there were 27,471,911 shares of preferred stock outstanding, consisting of 9,904,806 shares of Series
<FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock and 17,567,105 shares of Series B convertible preferred stock. All currently outstanding shares of convertible preferred stock will be converted into an aggregate of 11,140,262
shares of common stock upon the closing of this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Following the closing of this offering, our board of directors
will have the authority under our amended and restated certificate of incorporation, without further action by our stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series, to establish from time to time the number of
shares to be included in each such series, to fix the rights, preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations or restrictions thereon, and to increase or decrease the number of shares of
any such series, but not below the number of shares of such series then outstanding. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our board of directors may
authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of our common stock. The purpose of authorizing our board of directors to issue preferred stock
and determine its rights and preferences is to eliminate delays associated with a stockholder vote on specific issuances. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate
purposes, could, among other things, have the effect of delaying, deferring or preventing a change in control of us and may adversely affect the market price of our common stock and the voting and other rights of the holders of our common stock. It
is not possible to state the actual effect of the issuance of any shares of preferred stock on the rights of holders of common stock until the board of directors determines the specific rights attached to that preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have no present plans to issue any shares of preferred stock following completion of this offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Options </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of
June&nbsp;30, 2022, there were options to purchase 2,072,851 shares of common stock outstanding under our 2019 Plan. For additional information regarding the terms of our 2019 Plan, see the section titled &#147;Executive Compensation&#151;Equity
Incentive Plans.&#148; </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We, the holders of our existing convertible preferred stock and certain holders of our existing common stock have entered into
an amended and restated investors&#146; rights agreement. The registration rights provisions of this agreement provide those holders with demand, piggyback and <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> registration rights with respect to
the shares of common stock currently held by them and issuable to them upon conversion of our convertible preferred stock in connection with our IPO. These shares are collectively referred to herein as registrable securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Demand Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">At any time beginning 180 days following the effective date of the registration statement of which this prospectus is a part,
the holders of a majority of registrable securities then outstanding have the right to demand that we file a registration statement covering registrable securities then outstanding having an aggregate offering price in excess of $15.0&nbsp;million,
net of certain selling expenses. These registration rights are subject to specified conditions and limitations, including the right of the underwriters, if any, to limit the number of shares included in any such registration under specified
circumstances. Upon such a request, we are required to effect the registration as soon as practicable, but in any event no later than 60 days after the receipt of such request. An aggregate of 11,476,837 shares of common stock will be entitled to
these demand registration rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">194 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Piggyback Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If we propose to register any of our securities under the Securities Act either for our own account or for the account of other
stockholders, the holders of registrable securities will each be entitled to notice of the registration and will be entitled to include their shares of common stock in the registration statement. These piggyback registration rights are subject to
specified conditions and limitations, including the right of the underwriters to limit the number of shares included in any such registration under specified circumstances. An aggregate of 11,476,837 shares of common stock will be entitled to these
piggyback registration rights. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">At any time after we become eligible to file&nbsp;a registration statement on
<FONT STYLE="white-space:nowrap">Form&nbsp;S-3,</FONT> the holders of at least 30% of the registrable securities then outstanding will be entitled to request to have such shares registered by us on a
<FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> registration statement. These <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> registration rights are subject to other specified conditions and limitations, including the condition that the
anticipated aggregate offering price, net of certain selling expenses, is at least $5.0&nbsp;million. Upon receipt of this request, the holders of registrable securities will each be entitled to participate in this registration. An aggregate of
11,476,837 shares of common stock will be entitled to these <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> registration rights. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Expenses of Registration </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are required to pay all expenses, including fees and expenses of one counsel to represent the selling stockholders (up to
$50,000 total), relating to any demand, piggyback or <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> registration, other than underwriting discounts and commissions, stock transfer taxes and any additional fees of counsel for the selling
stockholders, subject to specified conditions and limitations. We are not required to pay registration expenses if a demand registration request is withdrawn at the request of a majority of holders of registrable securities to be registered, unless
holders of a majority of the registrable securities agree to forfeit their right to one demand registration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The amended
and restated investors&#146; rights agreement contains customary cross-indemnification provisions, pursuant to which we are obligated to indemnify the selling stockholders in the event of material misstatements or omissions in the applicable
registration statement attributable to us, and the selling stockholders are obligated to indemnify us for material misstatements or omissions in the registration statement attributable to them, subject to certain limitations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Termination of Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The registration rights granted under the investors&#146; rights agreement will terminate with respect to any particular
stockholder upon the earlier of (a)&nbsp;the closing of a deemed liquidation event, as defined in our certificate of incorporation, (b)&nbsp;the fifth anniversary of the closing of this offering and (c)&nbsp;with respect to each stockholder, at such
time such stockholder is able to sell all of its shares without limitation pursuant to Rule 144 or another similar exemption under the Securities Act during a three-month period without registration. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Provisions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;203 of the
Delaware General Corporation Law </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are subject to Section&nbsp;203 of the Delaware General Corporation Law, which
prohibits a Delaware corporation from engaging in any business combination with any interested stockholder for a period of three years after the date that such stockholder became an interested stockholder, with the following exceptions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">before such date, the board of directors of the corporation approved either the business combination or the
transaction that resulted in the stockholder becoming an interested stockholder; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">195 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the
interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes of determining the voting stock outstanding, but not the outstanding voting stock owned by the
interested stockholder, those shares owned (i)&nbsp;by persons who are directors and also officers and (ii)&nbsp;employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the
plan will be tendered in a tender or exchange offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on or after such date, the business combination is approved by the board of directors and authorized at an
annual or special meeting of the stockholders, and not by written consent, by the affirmative vote of at least 66<SUP STYLE="vertical-align:top">2</SUP>&#8260;<SUB STYLE="vertical-align:bottom">3</SUB>% of the outstanding voting stock that is not
owned by the interested stockholder. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In general, Section&nbsp;203 defines a &#147;business
combination&#148; to include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any merger or consolidation involving the corporation or any direct or indirect majority-owned subsidiary of
the corporation and the interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any sale, lease, exchange, mortgage, pledge, transfer or other disposition of 10% or more of the assets of the
corporation or of any direct or indirect majority-owned subsidiary involving the interested stockholder (in one transaction or a series of transactions); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation or
by any direct or indirect majority-owned subsidiary of the corporation of any stock of the corporation or of such subsidiary to the interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction involving the corporation or any direct or indirect majority-owned subsidiary of the
corporation that has the effect of increasing the proportionate share of the stock or any class or series of the corporation or any such subsidiary beneficially owned by the interested stockholder; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other
financial benefits by or through the corporation or any direct or indirect majority-owned subsidiary. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In general, Section&nbsp;203 defines an &#147;interested stockholder&#148; as an entity or person who, together with the
person&#146;s affiliates and associates, beneficially owns, or within three years prior to the time of determination of interested stockholder status did own, 15% or more of the outstanding voting stock of the corporation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated certificate of incorporation to be in effect upon the completion of this offering, or our restated
certificate, will provide for our board of directors to be divided into three classes with staggered three-year terms. Only one class of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for the
remainder of their respective three-year terms. Because our stockholders do not have cumulative voting rights, stockholders holding a majority of the shares of common stock outstanding will be able to elect all of our directors. Our restated
certificate and our amended and restated bylaws to be effective upon the completion of this offering, or our restated bylaws, will also provide that directors may be removed by the stockholders only for cause upon the vote of 66<SUP
STYLE="vertical-align:top">2</SUP>&#8260;<SUB STYLE="vertical-align:bottom">3</SUB>% or more of our outstanding common stock. Furthermore, the authorized number of directors may be changed only by resolution of the board of directors, and vacancies
and newly created directorships on the board of directors may, except as otherwise required by law or determined by the board and subject to the rights of any series of then-outstanding preferred stock, only be filled by a majority vote of the
directors then serving on the board, even though less than a quorum. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under our restated certificate of incorporation and
amended and restated bylaws our stockholders will not have cumulative voting rights. Because of this, the holders of a majority of the shares of common stock entitled to vote in any election of directors can elect all of the directors standing for
election, if they should so choose. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">196 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our restated certificate and restated bylaws will also provide that all
stockholder actions must be effected at a duly called meeting of stockholders and will eliminate the right of stockholders to act by written consent without a meeting. Our restated bylaws will also provide that only our Chairman of the board, Chief
Executive Officer or the board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors may call a special meeting of stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our restated bylaws will also provide that stockholders seeking to present proposals before a meeting of stockholders to
nominate candidates for election as directors at a meeting of stockholders must provide timely advance notice in writing, and will specify requirements as to the form and content of a stockholder&#146;s notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our restated certificate and restated bylaws will provide that the stockholders cannot amend many of the provisions described
above except by a vote of 66<SUP STYLE="vertical-align:top">2</SUP>&#8260;<SUB STYLE="vertical-align:bottom">3</SUB>% or more of our outstanding common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As described in &#147;&#151;Preferred Stock&#148; above, our restated certificate will give our board of directors the
authority, without further action by our stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series, with any rights, preferences and privileges as they may designate, including the right to approve an acquisition or
other change in control. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The combination of these provisions will make it more difficult for our existing
stockholders to replace our board of directors as well as for another party to obtain control of us by replacing our board of directors. Since our board of directors has the power to retain and discharge our officers, these provisions could also
make it more difficult for existing stockholders or another party to effect a change in management. In addition, the authorization of undesignated preferred stock makes it possible for our board of directors to issue preferred stock with voting or
other rights or preferences that could impede the success of any attempt to change our control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These provisions are
intended to enhance the likelihood of continued stability in the composition of our board of directors and its policies and to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to reduce our
vulnerability to hostile takeovers and to discourage certain tactics that may be used in proxy fights. However, such provisions could have the effect of discouraging others from making tender offers for our shares and may have the effect of delaying
changes in our control or management. As a consequence, these provisions may also inhibit fluctuations in the market price of our stock that could result from actual or rumored takeover attempts. We believe that the benefits of these provisions,
including increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure our company, outweigh the disadvantages of discouraging takeover proposals, because
negotiation of takeover proposals could result in an improvement of their terms. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Choice of Forum </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated certificate of incorporation will provide that the Court of Chancery of the state of Delaware will be
the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any derivative action or proceeding brought on our behalf; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any action asserting a breach of fiduciary duty; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our restated
certificate, or our amended and restated bylaws; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any action asserting a claim against us that is governed by the internal affairs doctrine.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The provision would not apply to suits brought to enforce a duty or liability created by the Exchange
Act. Furthermore, Section&nbsp;22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">197 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our amended and restated
certificate of incorporation will also provide that unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a
cause of action arising under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">While the Delaware courts have determined that such choice of forum
provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of
the exclusive forum provisions of our restated certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be
enforced by a court in those other jurisdictions </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These exclusive forum provisions may limit a stockholder&#146;s ability
to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers and other employees. If a court were to find
either exclusive-forum provision in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving the dispute in other
jurisdictions, all of which could seriously harm our business.&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated
certificate of incorporation will further provide that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, subject to and
contingent upon a final adjudication in the State of Delaware of the enforceability of such exclusive forum provision. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The transfer agent and registrar for our common stock is American Stock Transfer &amp; Trust Company, LLC. The
transfer agent&#146;s address is 6201 15th Avenue, Brooklyn, New York 11219. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have applied for listing of our common stock on the Nasdaq Global Market under the trading symbol &#147;ACRV.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">198 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc383050_18"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prior to this offering, no public market existed for our common stock. Future sales of our common stock in the public market,
or the availability of such shares for sale in the public market, could adversely affect market prices prevailing from time to time. As described below, only a limited number of shares will be available for sale shortly after this offering due to
contractual and legal restrictions on resale. Nevertheless, sales of our common stock in the public market after such restrictions lapse, or the perception that those sales may occur, could adversely affect the prevailing market price at such time
and our ability to raise equity capital in the future. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Based on the number of shares outstanding as of June&nbsp;30,
2022, upon the closing of this offering and assuming no exercise of the underwriters&#146; option to purchase additional shares, 18,809,823 shares of common stock will be outstanding, assuming no outstanding options are exercised. All of the shares
of common stock sold in this offering will be freely tradable without restrictions or further registration under the Securities Act, except for any shares sold to our &#147;affiliates,&#148; as that term is defined under Rule 144 under the
Securities Act. The remaining 12,909,823 shares of common stock held by existing stockholders are &#147;restricted securities,&#148; as that term is defined in Rule 144 under the Securities Act. Restricted securities may be sold in the public market
only if registered or if their resale qualifies for exemption from registration described below under Rule 144 promulgated under the Securities Act or another available exemption. We expect that substantially all of these shares held by existing
stockholders will be subject to the lock-up period under the lock-up agreements described below. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 144 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In general, <FONT STYLE="white-space:nowrap">non-affiliate</FONT> persons who have beneficially owned restricted shares of our
common stock for at least six months, and any of our affiliates who owns either restricted or unrestricted shares of our common stock, are entitled to sell their securities without registration with the SEC under an exemption from registration
provided by Rule 144 under the Securities Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Affiliates</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any person who is not deemed to have been one of our affiliates at the time of, or at any time during the three months
preceding, a sale may sell an unlimited number of restricted securities under Rule&nbsp;144 if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the restricted securities have been held for at least six months, including the holding period of any prior
owner other than one of our affiliates (subject to certain exceptions); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we have been subject to the Exchange Act periodic reporting requirements for at least 90 days before the sale;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we are current in our Exchange Act reporting at the time of sale. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any person who is not deemed to have been an affiliate of ours at the time of, or at any time during the three months
preceding, a sale and has held the restricted securities for at least one year, including the holding period of any prior owner other than one of our affiliates, will be entitled to sell an unlimited number of restricted securities without regard to
the length of time we have been subject to Exchange Act periodic reporting or whether we are current in our Exchange Act reporting. <FONT STYLE="white-space:nowrap">Non-affiliate</FONT> resales are not subject to the manner of sale, volume
limitation or notice filing provisions of Rule 144. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Affiliates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Persons seeking to sell restricted securities who are our affiliates at the time of, or any time during the three months
preceding, a sale, would be subject to the restrictions described above. They are also subject to additional restrictions, by which such person would be required to comply with the manner of sale and notice provisions of Rule 144 and would be
entitled to sell within any three-month period only that number of securities that does not exceed the greater of either of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1% of the number of shares of our common stock then outstanding, which will equal approximately 200,000 shares
immediately after the completion of this offering based on the number of shares outstanding as of June&nbsp;30, 2022; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">199 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the average weekly trading volume of our common stock on the stock exchange on which our shares are listed
during the four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, persons who are our affiliates at the time of, or any time during the three months preceding, a sale may sell
unrestricted securities under the requirements of Rule 144 described above, without regard to the <FONT STYLE="white-space:nowrap">six-month</FONT> holding period of Rule 144, which does not apply to sales of unrestricted securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 701 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Rule 701 under
the Securities Act, as in effect on the date of this prospectus, permits resales of shares in reliance upon Rule 144 but without compliance with certain restrictions of Rule 144, including the holding period requirement. Most of our employees,
executive officers or directors who purchased shares under a written compensatory plan or contract may be entitled to rely on the resale provisions of Rule 701, but all holders of Rule 701 shares are required to wait until 90 days after the date of
this prospectus before selling their shares. However, substantially all Rule 701 shares are subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements as described below and in the section titled &#147;Underwriting&#148; and will become
eligible for sale upon the expiration of the restrictions set forth in those agreements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Form <FONT STYLE="white-space:nowrap">S-8</FONT> Registration
Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We intend to file one or more registration statements on Form <FONT STYLE="white-space:nowrap">S-8</FONT>
under the Securities Act to register all shares of common stock subject to outstanding stock options and common stock issued or issuable under our equity plans. We expect to file the registration statement covering shares offered pursuant to our
stock plans as soon as practicable after the closing of this offering, permitting the resale of such shares by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> in the public market without restriction under the Securities Act and the sale by
affiliates in the public market, subject to compliance with the resale provisions of Rule 144 and expiration or release from the terms of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We, our executive officers and directors and substantially all of the holders of our common stock outstanding on the date of
this prospectus have entered into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the underwriters or otherwise agreed, subject to certain exceptions, that we and they will not, directly or indirectly, offer, sell, contract to sell,
pledge, grant any option to purchase, make any short sale, or otherwise dispose of or hedge any of our shares of common stock, any options or warrants to purchase shares of our common stock, or any securities convertible into, or exchangeable for or
that represent the right to receive shares of our common stock, without the prior written consent of Morgan Stanley &amp; Co. LLC, Jefferies LLC and Cowen and Company, LLC for a period of 180 days from the date of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to the restrictions contained in the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above,
we have entered into an agreement with the holders of our preferred stock that contains market <FONT STYLE="white-space:nowrap">stand-off</FONT> provisions imposing restrictions on the ability of such security holders to sell or otherwise transfer
or dispose of any registrable securities for a period of 180 days following the date of this prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the closing of this offering, the holders of 11,476,837 shares of our common stock, including common stock issuable upon
the conversion of our convertible preferred stock, or their transferees, will be entitled to specified rights with respect to the registration of their registrable shares under the Securities Act, subject to certain limitations and the expiration,
waiver or termination of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements. Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act
immediately upon effectiveness of the registration. See the section titled &#147;Description of Capital Stock&#151;Registration Rights&#148; for additional information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">200 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc383050_19"></A>CERTAIN MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following summary describes certain material U.S. federal
income tax consequences to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders (as defined below) of the, ownership and disposition of our common stock acquired in this offering. The summary below is based upon the provisions of the U.S.
Internal Revenue Code of 1986, as amended, or the Code, and Treasury Regulations, rulings and judicial decisions thereunder as of the date hereof, and such authorities may be repealed, revoked or modified, perhaps retroactively, so as to result in
U.S. federal income tax consequences different from those discussed below. We have not requested and will not request a ruling from the U.S. Internal Revenue Service, or the IRS, with respect to the statements made and the conclusions reached in the
following summary, and there can be no assurance that the IRS will agree with such statements and conclusions. This discussion assumes that the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder holds our common stock as a &#147;capital
asset&#148; within the meaning of Section&nbsp;1221 of the Code (generally, property held for investment). This summary is not a complete analysis of all potential U.S. federal income tax consequences relating thereto, and does not address <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> or U.S. state and local consequences that may be relevant to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders in light of their particular circumstances, nor does it address U.S. federal tax
consequences (such as gift and estate taxes) other than income taxes. This summary also does not address the alternative minimum tax, the Medicare contribution tax on net investment income, the special tax accounting rules under Section&nbsp;451(b)
of the Code, or the rules regarding qualified small business stock within the meaning of Section&nbsp;1202 of the Code. Special rules different from those described below may apply to certain <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders
that are subject to special treatment under the Code, such as financial institutions, insurance companies, <FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations, broker-dealers and traders in securities, U.S. expatriates, &#147;controlled
foreign corporations,&#148; &#147;passive foreign investment companies,&#148; corporations that accumulate earnings to avoid U.S. federal income tax, corporations organized outside of the United States, any state thereof and the District of Columbia
that are nonetheless treated as U.S. taxpayers for U.S. federal income tax purposes, persons that hold our common stock as part of a &#147;straddle,&#148; &#147;hedge,&#148; &#147;conversion transaction,&#148; &#147;synthetic security&#148; or
integrated investment or other risk reduction strategy, persons who acquire our common stock through the exercise of an option or otherwise as compensation, persons that hold more than 5% of our outstanding common stock, directly or indirectly
during the applicable testing period (except to the extent specifically set forth below), &#147;qualified foreign pension funds&#148; as defined in Section&nbsp;897(l)(2) of the Code and entities all of the interests of which are held by one or more
qualified foreign pension funds, persons deemed to sell our common stock under the constructive sale provisions of the Code, partnerships and other pass-through entities or arrangements, and investors in such pass-through entities or arrangements. <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holders are urged to consult their tax advisors to determine the U.S. federal, state, local and other tax consequences that may be relevant to them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If an entity or arrangement treated as a partnership for U.S. federal income tax purposes holds our common stock, the tax
treatment of a partner in the partnership (or entity or arrangement treated as partnership for U.S. federal income tax purposes) will depend on the status of the partner, the activities of the partnership and certain determinations made at the
partner level. Accordingly, partnerships holding our common stock and the partners in such partnerships should consult their tax advisors regarding the U.S. federal income tax consequences to them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>THIS DISCUSSION IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT TAX ADVICE. PERSONS CONSIDERING THE PURCHASE OF OUR COMMON
STOCK PURSUANT TO THIS OFFERING SHOULD CONSULT THEIR TAX ADVISORS CONCERNING THE U.S. FEDERAL INCOME, ESTATE AND OTHER TAX CONSEQUENCES OF ACQUIRING, OWNING AND DISPOSING OF OUR COMMON STOCK IN LIGHT OF THEIR PARTICULAR SITUATIONS AS WELL AS ANY
CONSEQUENCES ARISING UNDER THE LAWS OF ANY OTHER TAXING JURISDICTION, INCLUDING ANY STATE, LOCAL OR <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> TAX CONSEQUENCES. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For purposes of this discussion, the term <FONT STYLE="white-space:nowrap">&#147;Non-U.S.</FONT> Holder&#148; means a
beneficial owner of our common stock (other than a partnership or other entity or arrangement treated as a partnership for U.S. federal income tax purposes regardless of its place of organization or formation) that is not, for U.S. federal income
tax purposes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an individual who is a citizen or resident of the United States; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">201 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation, or other entity treated as a corporation for U.S. federal income tax purposes, created or
organized in or under the laws of the United States, any state thereof or the District of Columbia; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an estate the income of which is subject to U.S. federal income taxation regardless of its source; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust if it (1)&nbsp;is subject to the primary supervision of a court within the United States and one or
more U.S. persons have the authority to control all substantial decisions of the trust or (2)&nbsp;has a valid election in effect under applicable Treasury Regulations to be treated as a U.S. person. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Distributions on Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Distributions, if any, made on our common stock to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder to the extent made
out of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles) generally will constitute dividends for U.S. federal income tax purposes. If a distribution exceeds our current and accumulated earnings
and profits, the excess will constitute a <FONT STYLE="white-space:nowrap">tax-free</FONT> return of capital and first be applied against and reduce a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s adjusted tax basis in its common
stock, but not below zero. Any remaining excess will be treated as capital gain and will be treated as described below under &#147;&#151;Sale or Other Taxable Disposition.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Subject to the discussion below on effectively connected income, backup withholding and foreign accounts, dividends paid to a <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will be subject to U.S. federal withholding tax at a rate of 30% of the gross amount of the dividends (or such lower rate specified by an applicable income tax treaty, provided the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder furnishes a properly executed IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> (in the case of individuals) or
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (in the case of entities), or other appropriate form, certifying the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s entitlement to benefits
under such income tax treaty). This certification must be provided to us or our paying agent prior to the payment of dividends and must be updated periodically. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Dividends paid to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that are treated as effectively connected with the
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder maintains a
permanent establishment in the United States to which such dividends are attributable), are generally exempt from the 30% U.S. federal withholding tax described above if the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder delivers to us (or,
if stock is held through a financial institution or other agent, to such agent) a properly executed IRS Form <FONT STYLE="white-space:nowrap">W-8ECI,</FONT> stating that the dividends are effectively connected with the
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In general, such effectively connected dividends will be subject to U.S. federal income tax, on a <FONT
STYLE="white-space:nowrap">net-income</FONT> basis at the regular rates applicable to U.S. persons (as defined in the Code). A corporate <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder receiving effectively connected dividends may also be
subject to an additional &#147;branch profits tax,&#148; which is imposed, under certain circumstances, at a rate of 30% (or such lower rate as may be specified by an applicable income tax treaty) on the corporate
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s effectively connected earnings and profits, subject to certain adjustments. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding any
applicable income tax treaties that may provide for different rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If a
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is eligible for a reduced rate of U.S. federal withholding tax under an income tax treaty and does not timely file the required certification, the
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder may be able to obtain a refund or credit of any excess amounts withheld by timely filing an appropriate claim for a refund with the IRS. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders
should consult their tax advisors regarding their entitlement to benefits under any applicable income tax treaties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">202 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sale or Other Taxable Disposition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Subject to the discussions below regarding backup withholding and foreign accounts, a
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder generally will not be subject to U.S. federal income tax with respect to gain recognized on a sale or other disposition of our common stock unless: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the gain is effectively connected with a trade or business of such
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder in the United States (and, if required by an applicable income tax treaty, is attributable to a permanent establishment or fixed base that such holder maintains in the United States);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is a nonresident alien individual and is treated,
for U.S. federal income tax purposes, as present in the United States for a period or periods aggregating to 183 or more days in the taxable year of the disposition and certain other conditions are met; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we are, or have been at any time during the five-year period preceding such disposition (or the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s holding period, if shorter), a &#147;U.S. real property holding corporation,&#148; unless our common stock is regularly traded on an established securities market (as defined under applicable
Treasury Regulations) and the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder held no more than 5% of our outstanding common stock, directly or indirectly, during the shorter of the five year period ending on the date of the disposition or
the period that the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder held our common stock. If we are determined to be a U.S. real property holding corporation and the foregoing exception does not apply, then the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder generally will be taxed on its net gain derived from the disposition of our common stock generally in the same manner as gain that is effectively connected with the conduct of a trade or business in
the United States, at the U.S. federal income tax rates applicable to U.S. persons (as defined in the Code), except that the branch profits tax generally will not apply. Generally, a corporation is a &#147;United States real property holding
corporation&#148; if the fair market value of its &#147;United States real property interests&#148; equals or exceeds 50% of the sum of the fair market value of its worldwide real property interests plus its other assets used or held for use in a
trade or business. Although there can be no assurance, we believe that we are not currently, and we do not anticipate becoming, a &#147;U.S. real property holding corporation&#148; for U.S. federal income tax purposes. No assurance can be provided
that our common stock will be regularly traded on an established securities market for purposes of the rule described above. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder described in the first bullet point above generally will be subject
to U.S. federal income tax on a net income basis at the regular rates, and corporate <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders described in the first bullet point above may be subject to the additional branch profits tax at a 30% rate
or such lower rate as may be specified by an applicable income tax treaty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Gain described in second bullet point above
will be subject to U.S. federal income tax at a flat 30% rate, which gain may be offset by certain U.S.-source capital losses (even though the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is not considered a resident of the United
States), provided that the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder has timely filed U.S. federal income tax returns with respect to such losses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding any applicable tax
treaties that may provide for different rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information Reporting Requirements and Backup Withholding </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Generally, we must report annually information to the IRS and to each <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder
the gross amount of the distributions we pay on our common stock (even if the payments are exempt from withholding), including the amount of any such distributions, the name and address of the recipient and the amount, if any, of tax withheld. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Dividends paid by us (or our paying agents) to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder may also be subject
to U.S. backup withholding (currently at a rate of 24%). U.S. backup withholding generally will not apply to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">203 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
who provides a properly executed IRS Form <FONT STYLE="white-space:nowrap">W-8BEN,</FONT> IRS Form <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> or IRS
Form <FONT STYLE="white-space:nowrap">W-ECI</FONT> (as applicable), or otherwise establishes an exemption. Notwithstanding the foregoing, backup withholding may apply if the withholding agent has actual knowledge, or reason to know, that the holder
is a U.S. person (as defined in the Code) who is not an exempt recipient. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">U.S. information reporting and backup
withholding requirements generally will apply to the proceeds of a disposition of our common stock by a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder effected by or through a U.S. office of any broker, U.S. or foreign, unless the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder provides a properly executed IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or IRS Form <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> or otherwise
meets documentary evidence requirements for establishing <FONT STYLE="white-space:nowrap">non-U.S.</FONT> person status or otherwise establishes an exemption. Generally, U.S. information reporting and backup withholding requirements will not apply
to a payment of disposition proceeds to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder where the transaction is effected outside the United States through a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> broker. Information reporting and backup withholding requirements may, however, apply to a payment of disposition proceeds if the broker has actual knowledge, or reason to know, that the holder is, in fact,
a U.S. person. For information reporting purposes, certain brokers with substantial U.S. ownership or operations will generally be treated in a manner similar to U.S. brokers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding the application of the
information reporting and backup withholding rules to them. Pursuant to tax treaties or certain other agreements, the IRS may make its reports available to tax authorities of the country in which the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT>
Holder&#146;s resides or is incorporated. Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be refunded or credited against the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s
U.S. federal income tax liability, if any, provided that the required information is timely furnished to the IRS. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Foreign Accounts </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Sections 1471 through 1474 of the Code (commonly referred to as FATCA) impose a U.S. federal withholding tax of 30% on certain
payments, made to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> financial institution (as specifically defined by applicable rules) unless (i)&nbsp;if the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> entity is a &#147;foreign financial
institution,&#148; such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> entity undertakes certain due diligence, reporting, withholding and certification obligations, (ii)&nbsp;if the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> entity is not a
&#147;foreign financial institution,&#148; such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> entity identifies certain of its U.S. investors, if any or (iii)&nbsp;the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> entity is otherwise exempt
under FATCA. FATCA currently applies dividends paid on our common stock. FATCA also applies to gross proceeds from the sale or other disposition of our common stock, but the U.S. Treasury released proposed regulations which, if finalized in their
present form, would eliminate the federal withholding tax of 30% applicable to the gross proceeds of a sale or other disposition of our common stock. In the preamble to such proposed regulations, the U.S. Treasury stated that taxpayers may generally
rely on the proposed regulations until final regulations are issued. Under certain circumstances, a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder may be eligible for refunds or credits of this withholding tax. An intergovernmental
agreement between the United States and an applicable foreign country may modify the requirements described in this paragraph. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding the possible
implications of this legislation on their investment in our common stock and the entities through which they hold our common stock, including, without limitation, the process and deadlines for meeting the applicable requirements to prevent the
imposition of the 30% withholding tax under FATCA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>EACH PROSPECTIVE INVESTOR SHOULD CONSULT ITS TAX ADVISOR REGARDING
THE TAX CONSEQUENCES OF PURCHASING, HOLDING AND DISPOSING OF OUR COMMON STOCK, INCLUDING THE CONSEQUENCES OF ANY RECENT OR PROPOSED CHANGE IN APPLICABLE LAW. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">204 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc383050_20"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the terms and subject to the conditions in an underwriting agreement dated the date of this prospectus, the underwriters
named below, for whom Morgan Stanley&nbsp;&amp; Co. LLC, Jefferies LLC, Cowen and Company, LLC and Piper Sandler&nbsp;&amp; Co. are acting as representatives, have severally agreed to purchase, and we have agreed to sell to them, severally, the
number of shares of common stock indicated below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number&nbsp;of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Morgan Stanley&nbsp;&amp; Co. LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jefferies LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cowen and Company, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Piper Sandler&nbsp;&amp; Co.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,900,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The underwriters and the representatives are collectively referred to as the
&#147;underwriters&#148; and the &#147;representatives,&#148; respectively. The underwriters are offering the shares of common stock subject to their acceptance of the shares from us and subject to prior sale. The underwriting agreement provides
that the obligations of the several underwriters to pay for and accept delivery of the shares of common stock offered by this prospectus are subject to the approval of certain legal matters by their counsel and to certain other conditions. The
underwriters are obligated to take and pay for all of the shares of common stock offered by this prospectus if any such shares are taken. However, the underwriters are not required to take or pay for the shares covered by the underwriters&#146;
option to purchase additional shares described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The underwriters initially propose to offer part of the shares of
common stock directly to the public at the offering price listed on the cover page of this prospectus and part to certain dealers at a price that represents a concession not in excess of $ &nbsp;&nbsp;&nbsp;&nbsp; per share under the public offering
price. After the initial offering of the shares of common stock, the offering price and other selling terms may from time to time be varied by the representatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have granted to the underwriters an option, exercisable for 30 days from the date of this prospectus, to purchase up to
885,000 additional shares of common stock at the public offering price listed on the cover page of this prospectus, less underwriting discounts and commissions. To the extent the option is exercised, each underwriter will become obligated, subject
to certain conditions, to purchase about the same percentage of the additional shares of common stock as the number listed next to the underwriter&#146;s name in the preceding table bears to the total number of shares of common stock listed next to
the names of all underwriters in the preceding table. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table shows the per share and total public offering
price, underwriting discounts and commissions, and proceeds before expenses to us. These amounts are shown assuming both no exercise and full exercise of the underwriters&#146; option to purchase up to an additional 885,000 shares of common stock.
</P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="0%"></TD>
<TD nowrap style="width:10pt"></TD>
<TD></TD>
<TD></TD>
<TD nowrap style="width:10pt"></TD>

<TD VALIGN="bottom" WIDTH="0%"></TD>
<TD nowrap style="width:10pt"></TD>
<TD></TD>
<TD></TD>
<TD nowrap style="width:10pt"></TD>

<TD VALIGN="bottom" WIDTH="0%"></TD>
<TD nowrap style="width:10pt"></TD>
<TD></TD>
<TD></TD>
<TD nowrap style="width:10pt"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="4" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="9" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per<BR>Share</B></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>No&nbsp;Exercise</B></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Full&nbsp;Exercise</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and commissions</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The estimated offering expenses payable by us, exclusive of the underwriting discounts and
commissions, are approximately $2.9 million. We have agreed to reimburse the underwriters for expenses of up to $35,000 relating to the clearance of this offering with the Financial Industry Regulatory Authority, Inc., compliance with state
securities or &#147;blue sky&#148; laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">205 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The underwriters have informed us that they do not intend sales to
discretionary accounts to exceed 5% of the total number of shares of common stock offered by them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have applied to
list our common stock on the Nasdaq Global Market under the trading symbol &#147;ACRV.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We and all of our directors
and officers and the holders of all of our outstanding common stock, stock options and other securities convertible into, exercisable or exchangeable for our common stock outstanding immediately prior to the closing of this offering have agreed
that, without the prior written consent of Morgan Stanley&nbsp;&amp; Co. LLC, Jefferies LLC and Cowen and Company, LLC on behalf of the underwriters, we and they will not, and will not publicly disclose an intention to, during the period ending 180
days after the date of this prospectus, or the restricted period: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or
contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common
stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">file any registration statement with the Securities and Exchange Commission relating to the offering of any
shares of common stock or any securities convertible into or exercisable or exchangeable for common stock; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic
consequences of ownership of the common stock. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">whether any such transaction described above is to be settled by
delivery of common stock or such other securities, in cash or otherwise. In addition, we and each such person agrees that, without the prior written consent of the representatives on behalf of the underwriters, we or such other person will not,
during the restricted period, make any demand for, or exercise any right with respect to, the registration of any shares of common stock or any security convertible into or exercisable or exchangeable for common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The restrictions described in the immediately preceding paragraph to do not apply to our directors, officers and
securityholders with respect to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">transactions relating to shares of our common stock or other securities acquired in this offering or in open
market transactions after the completion of this offering, provided that no filing under Section 16(a) of the Exchange Act reporting a reduction in beneficial ownership of our common stock shall be voluntarily made during the restricted period in
connection with subsequent sales of our common stock or other securities acquired in this offering or in such open market transactions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">transfers or distributions of shares of our common stock or any security convertible into or exercisable or
exchangeable for our common stock (i) as a bona fide gift or charitable contribution, (ii) by will or intestacy or to any immediate family or to a trust for the direct or indirect benefit of the stockholder and/or any immediate family, (iii) to
limited partners, members, stockholders or holders of similar equity interests in the stockholder or (iv) if the stockholder is a corporation, to another corporation, partnership, limited liability company, trust or other business entity that is an
affiliate (as defined in Rule 405 promulgated under the Securities Act) of the stockholder, or to any investment fund or other entity controlled or managed by such stockholder or affiliates of such stockholder; provided that (A) each transferee,
donee or distributee shall sign and deliver a lock up agreement and (B) no filing under Section 16(a) of the Exchange Act, reporting a reduction in beneficial ownership of shares of our common stock, shall be required or shall be voluntarily made
during the restricted period, and provided further that any such transfer shall not involve a disposition for value; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">transfers of our common stock or any security convertible into or exercisable or exchangeable for our common
stock by operation of law pursuant to a qualified domestic order or other court order or in </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">206 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
connection with a divorce settlement; provided that (i) any filing under Section 16(a) of the Exchange Act made during the restricted period shall clearly indicate in the footnotes thereto that
(A) the filing relates to the circumstances described in this clause and (B) no securities were sold by such stockholder, and (ii) such stockholder does not otherwise voluntarily effect any other public filing or report regarding such transfers
during the restricted period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the receipt by such stockholder from us of shares of our common stock upon the transfer or disposition of
shares of our common stock or any securities convertible into our common stock to us upon a vesting or settlement event of our securities or vesting of restricted stock unit awards or upon the exercise of options to purchase our securities on a
&#147;cashless&#148; or &#147;net exercise&#148; basis, in each case pursuant to any equity incentive plan of us described in this prospectus and to the extent permitted by the instruments representing such restricted stock unit awards or options
outstanding as of the date of this prospectus (and solely to cover withholding tax obligations in connection with such transaction and any transfer to us for the payment of taxes as a result of such transaction), provided that (i) the shares
received upon exercise or settlement of the option are subject to the terms of this agreement, (ii) no public disclosure or filing under Section 16(a) of the Exchange Act shall be voluntarily made during the restricted period and (iii) to the extent
a filing under Section 16(a) of the Exchange Act is required during the restricted period as a result of transfers in this clause, it shall clearly indicate that (A) the filing relates to the circumstances described in this clause, including that
the securities remain subject to the terms of this agreement and (B) no securities were sold by such stockholder other than pursuant to this clause; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">transfers to us to the extent required in order to satisfy the exercise price and/or any income, employment
tax withholding and remittance obligations upon the vesting or exercise of an option or other award granted under an equity incentive plan or share purchase plan of us described in this prospectus or the conversion or exercise of a warrant of us
described in this prospectus; provided that (i) any filing under Section 16(a) of the Exchange Act made during the restricted period shall clearly indicate in the footnotes thereto that (A) the filing relates to the circumstances described in this
paragraph and (B) no securities were sold by such stockholder, and (ii) such stockholder does not otherwise voluntarily effect any other public filing or report regarding such transfers during the restricted period; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">transfers to us in connection with the repurchase of our common stock in connection with the termination of
such stockholder&#146;s employment with us pursuant to contractual agreements with us as in effect as of the date of this prospectus, provided that no public disclosure or filing under Section 16(a) of the Exchange Act shall be required or shall be
voluntarily made during the restricted period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the conversion of the outstanding preferred stock of us described in this prospectus into shares of our common
stock of us, provided that such shares of our common stock remain subject to the terms of the lock-up agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">facilitating the establishment of a trading plan on behalf of a stockholder, officer or director of us
pursuant to Rule 10b5-1 under the Exchange Act for the transfer of shares of our common stock, provided that (i) such plan does not provide for the transfer of our common stock during the restricted period and (ii) to the extent a public
announcement or filing under the Exchange Act, if any, is required of or voluntarily made by or on behalf of such stockholder or us regarding the establishment of such plan, such announcement or filing shall include a statement to the effect that no
transfer of our common stock may be made under such plan during the restricted period; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">transfers pursuant to a bona fide third-party tender offer for all outstanding our common stock or securities
convertible into or exchangeable for our common stock of us, merger, consolidation or other similar transaction approved by our board of directors and made to all holders of our securities involving a change of control of us (including, without
limitation, the entering into any lock-up, voting or similar agreement pursuant to which such stockholder may agree to transfer, sell, tender or otherwise dispose of our common stock or other such securities in connection with such transaction, or
vote any our common stock or other such securities in favor of any such transaction); provided that in </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">207 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
the event that such tender offer, merger, consolidation or other such transaction is not completed, such securities held by such stockholder shall remain subject to the provisions of the lock-up
agreement. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The restrictions on transfers or other dispositions by us described above do not apply to:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the shares to be sold in this offering; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the issuance by us of shares of common stock upon the exercise of an option or warrant or the conversion of a
security outstanding on the date hereof as described in this prospectus; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">facilitating the establishment of a trading plan on behalf of one of our stockholders, officers or directors
pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act for the transfer of shares of common stock, provided that (i)&nbsp;such plan does not provide for the transfer of common stock during the restricted period and
(ii)&nbsp;to the extent a public announcement or filing under the Exchange Act, if any, is required of or voluntarily made by us regarding the establishment of such plan, such announcement or filing shall include a statement to the effect that no
transfer of common stock may be made under such plan during the restricted period. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Morgan
Stanley&nbsp;&amp; Co. LLC, Jefferies LLC and Cowen and Company, LLC, in their sole discretion, may release the common stock and other securities subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above in whole or
in part at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In order to facilitate the offering of the common stock, the underwriters may engage in transactions
that stabilize, maintain or otherwise affect the price of the common stock. Specifically, the underwriters may sell more shares than they are obligated to purchase under the underwriting agreement, creating a short position. A short sale is covered
if the short position is no greater than the number of shares available for purchase by the underwriters under the option to purchase additional shares described above. The underwriters can close out a covered short sale by exercising such option or
purchasing shares in the open market. In determining the source of shares to close out a covered short sale, the underwriters will consider, among other things, the open market price of shares compared to the price available under such option. The
underwriters may also sell shares in excess of such option, creating a naked short position. The underwriters must close out any naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the
underwriters are concerned that there may be downward pressure on the price of the common stock in the open market after pricing that could adversely affect investors who purchase in this offering. As an additional means of facilitating this
offering, the underwriters may bid for, and purchase, shares of common stock in the open market to stabilize the price of the common stock. These activities may raise or maintain the market price of the common stock above independent market levels
or prevent or retard a decline in the market price of the common stock. The underwriters are not required to engage in these activities and may end any of these activities at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We and the underwriters have agreed to indemnify each other against certain liabilities, including liabilities under the
Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A prospectus in electronic format may be made available on websites maintained by one or more
underwriters, or selling group members, if any, participating in this offering. The representatives may agree to allocate a number of shares of common stock to underwriters for sale to their online brokerage account holders. Internet distributions
will be allocated by the representatives to underwriters that may make Internet distributions on the same basis as other allocations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The underwriters and their respective affiliates are full service financial institutions engaged in various activities, which
may include securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities. Certain of the underwriters and their respective
affiliates have, from time to time, performed, and may in the future perform, various financial advisory and investment banking services for us, for which they received or will receive customary fees and expenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">208 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, in the ordinary course of their various business activities,
the underwriters and their respective affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account
and for the accounts of their customers and may at any time hold long and short positions in such securities and instruments. Such investment and securities activities may involve our securities and instruments. The underwriters and their respective
affiliates may also make investment recommendations or publish or express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long or short positions in such
securities and instruments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pricing of the Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prior to this offering, there has been no public market for our common stock. The initial public offering price will be
determined by negotiations between us and the representatives. Among the factors to be considered in determining the initial public offering price are our future prospects and those of our industry in general, our results of operations and certain
other financial and operating information in recent periods, and the price-earnings ratios, price-sales ratios, market prices of securities, and certain financial and operating information of companies engaged in activities similar to ours. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Selling Restrictions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Canada </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The shares may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors,
as defined in National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> <I>Prospectus Exemptions</I> or subsection 73.3(1) of the <I>Securities Act</I> (Ontario), and are permitted clients, as defined in National Instrument <FONT
STYLE="white-space:nowrap">31-103</FONT> <I>Registration Requirements, Exemptions and Ongoing Registrant Obligations</I>. Any resale of the shares must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus
requirements of applicable securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Securities legislation in certain provinces or territories of Canada may
provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit
prescribed by the securities legislation of the purchaser&#146;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these
rights or consult with a legal advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to section 3A.3 (or, in the case of securities issued or guaranteed by
the government of a <FONT STYLE="white-space:nowrap">non-Canadian</FONT> jurisdiction, section 3A.4) of National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> <I>Underwriting Conflicts</I> (NI
<FONT STYLE="white-space:nowrap">33-105),</FONT> the underwriters are not required to comply with the disclosure requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of interest in connection with this
offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>European Economic Area </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In relation to each Member State of the European Economic Area and the United Kingdom, each, a Relevant State, no securities
have been offered or will be offered pursuant to the offering to the public in that Relevant State prior to the publication of a prospectus in relation to the securities which has been approved by the competent authority in that Relevant State or,
where appropriate, approved in another Relevant State and notified to the competent authority in that Relevant State, all in accordance with the Prospectus Regulation, except that offers of securities may be made to the public in that Relevant State
at any time under the following exemptions under the Prospectus Regulation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(a)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to any legal entity which is a qualified investor as defined under the Prospectus Regulation;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">209 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(b)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to fewer than 150 natural or legal persons (other than qualified investors as defined under the Prospectus
Regulation), subject to obtaining the prior consent of the representatives; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(c)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in any other circumstances falling within Article 1(4) of the Prospectus Regulation, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">provided that no such offer of shares shall require us or any of our representatives to publish a prospectus pursuant to Article&nbsp;3 of the
Prospectus Regulation or supplement a prospectus pursuant to Article&nbsp;23 of the Prospectus Regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For the
purposes of this provision, the expression an &#147;offer to the public&#148; in relation to any shares in any Relevant State means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to
be offered so as to enable an investor to decide to purchase any shares, and the expression &#147;Prospectus Regulation&#148; means Regulation (EU)&nbsp;2017/1129 (as amended). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>United Kingdom </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each underwriter has represented and agreed that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(a)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it has only communicated or caused to be communicated and will only communicate or cause to be communicated an
invitation or inducement to engage in investment activity (within the meaning of Section&nbsp;21 of the Financial Services and Markets Act 2000, or the FSMA) received by it in connection with the issue or sale of the shares of our common stock in
circumstances in which Section&nbsp;21(1) of the FSMA does not apply to us; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(b)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it has complied and will comply with all applicable provisions of the FSMA with respect to anything done by it
in relation to the shares of our common stock in, from or otherwise involving the United Kingdom. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Japan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">No registration pursuant to Article&nbsp;4, paragraph&nbsp;1 of the Financial Instruments and Exchange Law of Japan (Law
No.&nbsp;25 of 1948, as amended), or the FIEL, has been made or will be made with respect to the solicitation of the application for the acquisition of the shares of common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Accordingly, the shares of common stock have not been, directly or indirectly, offered or sold and will not be, directly or
indirectly, offered or sold in Japan or to, or for the benefit of, any resident of Japan (which term as used herein means any person resident in Japan, including any corporation or other entity organized under the laws of Japan) or to others for <FONT
STYLE="white-space:nowrap">re-offering</FONT> or <FONT STYLE="white-space:nowrap">re-sale,</FONT> directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan except pursuant to an exemption from the registration
requirements, and otherwise in compliance with, the FIEL and the other applicable laws and regulations of Japan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>For Qualified Institutional
Investors, or QII </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Please note that the solicitation for newly-issued or secondary securities (each as described in
Paragraph&nbsp;2, Article&nbsp;4 of the FIEL) in relation to the shares of common stock constitutes either a &#147;QII only private placement&#148; or a &#147;QII only secondary distribution&#148; (each as described in Paragraph&nbsp;1, <FONT
STYLE="white-space:nowrap">Article&nbsp;23-13</FONT> of the FIEL). Disclosure regarding any such solicitation, as is otherwise prescribed in Paragraph&nbsp;1, Article&nbsp;4 of the FIEL, has not been made in relation to the shares of common stock.
The shares of common stock may only be transferred to QIIs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>For <FONT STYLE="white-space:nowrap">Non-QII</FONT> Investors </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Please note that the solicitation for newly-issued or secondary securities (each as described in Paragraph&nbsp;2,
Article&nbsp;4 of the FIEL) in relation to the shares of common stock constitutes either a &#147;small number private </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">210 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
placement&#148; or a &#147;small number private secondary distribution&#148; (each as is described in Paragraph&nbsp;4, <FONT STYLE="white-space:nowrap">Article&nbsp;23-13</FONT> of the FIEL).
Disclosure regarding any such solicitation, as is otherwise prescribed in Paragraph&nbsp;1, Article&nbsp;4 of the FIEL, has not been made in relation to the shares of common stock. The shares of common stock may only be transferred en bloc without
subdivision to a single investor. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Hong Kong </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Shares of our common stock may not be offered or sold by means of any document other than (i)&nbsp;in circumstances which do
not constitute an offer to the public within the meaning of the Companies Ordinance (Cap.32, Laws of Hong Kong), (ii) to &#147;professional investors&#148; within the meaning of the Securities and Futures Ordinance (Cap.571, Laws of Hong Kong) and
any rules made thereunder, or (iii)&nbsp;in other circumstances which do not result in the document being a &#147;prospectus&#148; within the meaning of the Companies Ordinance (Cap.32, Laws of Hong Kong), and no advertisement, invitation, or
document relating to shares of our common stock may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be
accessed or read by, the public in Hong Kong (except if permitted to do so under the laws of Hong Kong) other than with respect to shares of our common stock which are or are intended to be disposed of only to persons outside Hong Kong or only to
&#147;professional investors&#148; within the meaning of the Securities and Futures Ordinance (Cap.571, Laws of Hong Kong) and any rules made thereunder. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Singapore </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This
prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of shares
of our common stock may not be circulated or distributed, nor may the shares of our common stock be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other
than (i)&nbsp;to an institutional investor under Section&nbsp;274 of the Securities and Futures Act, Chapter 289 of Singapore, or the SFA, (ii)&nbsp;to a relevant person, or any person pursuant to Section&nbsp;275(1A), and in accordance with the
conditions, specified in Section&nbsp;275 of the SFA or (iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Where shares of our common stock are subscribed or purchased under Section&nbsp;275 by a relevant person which is: (i)&nbsp;a
corporation (which is not an accredited investor) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or (ii)&nbsp;a trust (where the
trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary is an accredited investor, shares, debentures, and units of shares and debentures of that corporation or the beneficiaries&#146; rights and
interest in that trust shall not be transferable for 6 months after that corporation or that trust has acquired shares of our common stock under Section&nbsp;275 except: (a)&nbsp;to an institutional investor under Section&nbsp;274 of the SFA or to a
relevant person, or any person pursuant to Section&nbsp;275(1A), and in accordance with the conditions, specified in Section&nbsp;275 of the SFA; (b)&nbsp;where no consideration is given for the transfer; or (c)&nbsp;by operation of law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Switzerland </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
shares of common stock may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange, or SIX, or on any other stock exchange or regulated trading facility in Switzerland. This document has been prepared without regard
to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other
stock exchange or regulated trading facility in Switzerland. Neither this document nor any other offering or marketing material relating to the shares or the offering may be publicly distributed or otherwise made publicly available in Switzerland.
Neither this document </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">211 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
nor any other offering or marketing material relating to the offering, us, or the shares have been or will be filed with or approved by any Swiss regulatory authority. In particular, this
document will not be filed with, and the offer of shares will not be supervised by, the Swiss Financial Market Supervisory Authority, or FINMA, and the offer of shares has not been and will not be authorized under the Swiss Federal Act on Collective
Investment Schemes, or CISA. The investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dubai International Financial Centre </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This prospectus relates to an Exempt Offer in accordance with the Offered Securities Rules of the Dubai Financial Services
Authority, or DFSA. This prospectus is intended for distribution only to persons of a type specified in the Offered Securities Rules of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA has no responsibility for
reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus nor taken steps to verify the information set forth herein and has no responsibility for the prospectus. The shares to which this
prospectus relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the shares offered should conduct their own due diligence on the shares. If you do not understand the contents of this prospectus you should
consult an authorized financial advisor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">212 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc383050_21"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The validity of the shares of common stock offered hereby will be passed upon for us by Cooley LLP, New&nbsp;York, New York.
Certain legal matters will be passed upon for the underwriters by Goodwin Procter LLP, New York, New York. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc383050_22"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The financial statements as of December&nbsp;31, 2021 and 2020 and for each of the years then ended, included in this
prospectus have been so included in reliance on the report (which contains an emphasis of matter paragraph regarding the Company&#146;s significant operating losses and negative cash flows from operations since its inception, and management&#146;s
evaluation of the events and conditions and management&#146;s plans to mitigate these matters, as described in Note 1 to the financial statements) of PricewaterhouseCoopers LLP, an independent registered public accounting firm, given on the
authority of said firm as experts in auditing and accounting. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc383050_23"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> under the Securities
Act with respect to the shares of common stock being offered by this prospectus. This prospectus, which constitutes part of the registration statement, does not contain all of the information in the registration statement and its exhibits. For
further information with respect to our company and the common stock offered by this prospectus, we refer you to the registration statement and its exhibits. Statements contained in this prospectus as to the contents of any contract or any other
document referred to are not necessarily complete, and in each instance, we refer you to the copy of the contract or other document filed as an exhibit to the registration statement. Each of these statements is qualified in all respects by this
reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">You can read our SEC filings, including the registration statement, over the internet at the SEC&#146;s
website at <I>www.sec.gov</I>. Upon completion of this offering, we will be subject to the information reporting requirements of the Exchange Act, and we will file reports, proxy statements and other information with the SEC. These reports, proxy
statements and other information will be available at <I>www.sec.gov</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We also maintain a website at
<I>www.acrivon.com</I>, at which you may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. The information contained in, or that can be accessed through, our
website is not part of, and is not incorporated into, this prospectus, and the inclusion of our website address in this prospectus is only as an inactive textual reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">213 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc383050_24"></A>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consolidated Financial Statements for the Years Ended December&nbsp;31, 2021 and 2020: </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="96%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin383050_1">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-2</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin383050_2">Consolidated Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin383050_3">Consolidated Statements of Operations and Comprehensive
Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-4</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin383050_4">Consolidated Statements of Convertible Preferred Stock and Stockholders&#146;
 Deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-5</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin383050_5">Consolidated Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-6</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin383050_6">Notes to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-7</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin383050_1"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To the Board of Directors and Stockholders of Acrivon Therapeutics, Inc. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Opinion on the Financial Statements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have audited the accompanying consolidated<B> </B>balance sheets of Acrivon Therapeutics, Inc. and its subsidiaries (the
&#147;Company&#148;) as of December&nbsp;31, 2021 and 2020, and the related consolidated statements of operations and comprehensive loss, of convertible preferred stock and stockholders&#146; deficit and of cash flows for the years then ended,
including the related notes (collectively referred to as the &#147;consolidated financial statements&#148;). In our opinion, the consolidated<B> </B>financial statements present fairly, in all material respects, the financial position of the Company
as of December&nbsp;31, 2021 and 2020, and the results of its operations and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United&nbsp;States of America. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis for Opinion </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These consolidated financial statements are the responsibility of the Company&#146;s management. Our responsibility is to
express an opinion on the Company&#146;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United&nbsp;States) (PCAOB) and are required to be
independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB. Those
standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial
statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our
audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable
basis for our opinion. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Emphasis of Matter </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As discussed in Note 1 to the consolidated financial statements, the Company has incurred significant operating losses and
negative cash flows from operations since its inception. Management&#146;s evaluation of the events and conditions and management&#146;s plans to mitigate these matters are also described in Note 1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ PricewaterhouseCoopers LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">August&nbsp;12, 2022, except for the effects of the reverse stock split discussed in Note&nbsp;17 to the consolidated financial statements, as to which the
date is November&nbsp;3, 2022 </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have served as the Company&#146;s auditor since 2022. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin383050_2"></A>ACRIVON THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED BALANCE SHEETS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 99,603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">805</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">106,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 2,185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities, convertible preferred stock and stockholders&#146; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 964</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">477</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">664</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities, long-term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,964</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock tranche rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies (Note 14)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock, par value $0.001;
9,904,806 and 9,685,508 shares authorized as of December&nbsp;31, 2021 and 2020, respectively; 9,904,806 and 4,422,350 shares issued and outstanding as of December&nbsp;31, 2021 and 2020, respectively; liquidation preference of $22.6&nbsp;million as
of December&nbsp;31, 2021.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B convertible preferred stock, par value $0.001; 17,567,105 and 0 shares authorized, issued
and outstanding as of December&nbsp;31, 2021 and 2020, respectively; liquidation preference of $100.3&nbsp;million as of December&nbsp;31, 2021.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, par value $0.001; 40,013,683 and 20,000,000 shares authorized as of December 31,
2021 and 2020, respectively; 1,769,561 and 1,432,480 shares issued and outstanding as of December&nbsp;31, 2021 and 2020, respectively.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,865</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,622</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,809</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,413</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities, convertible preferred stock and stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">106,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 2,185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin383050_3"></A>ACRIVON THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 13,718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,466</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,184</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,168</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,099</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of preferred stock tranche rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(71</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of anti-dilution right</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(59</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,138</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,243</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,306</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9.32</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.70</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average common stock outstanding&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,743,382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,432,480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin383050_4"></A>ACRIVON THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#146; DEFICIT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Convertible<BR>Preferred&nbsp;Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-In</FONT><BR>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholders&#146;<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman"><B>Balance at December&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,432,480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,316</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,110</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Issuance of Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock, net
of preferred stock tranche rights and issuance costs of $247 and $169, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,315,789</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Issuance of Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock
related to conversion of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,106,561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,306</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,306</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman"><B>Balance at December&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,422,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 9,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,432,480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,622</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,413</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Issuance of common stock related to license agreement with Eli Lilly</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">336,575</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Exercise of common stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Issuance of Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock, net
of issuance costs of $33</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,321,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Issuance of Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock
related to settlement of preferred stock tranche rights</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">161,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Issuance of Series B convertible preferred stock, net of issuance costs of $247</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,521,047</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Issuance of Series B convertible preferred stock related to settlement of anti-dilution
right</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">497</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">497</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,243</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,243</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman"><B>Balance at December&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,471,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">122,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,769,561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(24,865</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,809</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
<P STYLE="font-size:24pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin383050_5"></A>ACRIVON THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF CASH FLOWS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman"><B>Cash flows from operating activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,243</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,306</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">497</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> lease expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">License agreement paid for with common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Anti-dilution right assumed with license agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Change in fair value of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Change in fair value of preferred stock tranche rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Change in fair value of anti-dilution right</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Gain upon extinguishment of PPP loan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(58</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(764</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(117</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">798</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Accrued expenses and other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(572</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,982</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,803</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman"><B>Cash flows from investing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(238</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(238</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman"><B>Cash flows from financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Proceeds from issuance of Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred stock and
preferred stock tranche obligations in first closing, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,831</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Proceeds from issuance of PPP loan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Proceeds from issuance of Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred stock in
second and third closings, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Proceeds from issuance of Series B preferred stock, net of issuance costs and settlement of
anti-dilution right</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Proceeds from exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112,221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Net increase in cash, cash equivalents, and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash at beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash at end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 99,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman"><B>Supplemental disclosure of <FONT STYLE="white-space:nowrap">non-cash</FONT> investing and
financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Fair value of convertible notes recognized as Series <FONT STYLE="white-space:nowrap">A-1</FONT>
preferred stock upon conversion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 7,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Fair value of preferred stock tranche rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Fair value of preferred stock tranche rights recognized as Series
<FONT STYLE="white-space:nowrap">A-1</FONT> preferred stock upon issuance of milestone shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Fair value of anti-dilution right recognized as Series B preferred stock upon issuance of
anti-dilution shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Purchases of property and equipment included in accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman"><B>Supplemental cash flow information:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT>
assets obtained in exchange for operating lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman"><B>Reconciliation of cash, cash equivalents and restricted cash:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">99,603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Total cash, cash equivalents, and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">99,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin383050_6"></A>ACRIVON THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Nature of the Business </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Acrivon Therapeutics, Inc., (the &#147;Company&#148;) is a clinical stage biopharmaceutical company developing oncology
medicines that the Company matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The Company&#146;s pipeline includes the Phase&nbsp;2
lead program, <FONT STYLE="white-space:nowrap">ACR-368,</FONT> referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation
pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company
was incorporated in March 2018 under the laws of the state of Delaware, and its principal offices are in Watertown, Massachusetts. Also in March 2018, the Company formed Acrivon AB, a wholly-owned subsidiary of the Company, established in Lund,
Sweden. In December 2021, the Company formed Acrivon Securities Corporation, a wholly-owned subsidiary, established in Massachusetts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidity
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company has evaluated whether there are conditions and events, considered in the aggregate, that raise
substantial doubt about the Company&#146;s ability to continue as a going concern within one year after the date the accompanying consolidated financial statements were issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As an emerging growth entity, the Company has devoted substantially all of its resources since inception to organizing and
staffing the Company, business planning, raising capital, establishing its intellectual property portfolio, acquiring or discovering drug candidates, research and development activities for <FONT STYLE="white-space:nowrap">ACR-368</FONT> and other
compounds, establishing arrangements with third parties for the manufacture of its drug candidates and component materials, and providing general and administrative support for these operations. As a result, the Company has incurred significant
operating losses and negative cash flows from operations since its inception and anticipates such losses and negative cash flows will continue for the foreseeable future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Since its inception, the Company has funded its operations primarily with proceeds from the sales of shares of its convertible
preferred stock and the issuance of convertible notes. The Company has incurred recurring losses since its inception, including net losses of $16.2&nbsp;million and $5.3&nbsp;million for the years ended December&nbsp;31, 2021, and 2020,
respectively. As of December&nbsp;31, 2021, the Company had an accumulated deficit of $24.9&nbsp;million. To date the Company has not generated any revenues and expects to continue generating operating losses for the foreseeable future as it
continues to expand its research and development efforts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company expects that its existing cash and cash equivalents
of $99.6&nbsp;million as of December&nbsp;31, 2021 will be sufficient to fund its operating expenses and capital expenditure requirements for at least twelve months from the date these consolidated financial statements were issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company will need additional funding to support its planned operating activities. There can be no assurances, however,
that the current operating plan will be achieved or that additional funding will be available on terms acceptable to the Company, or at all. If the Company is unable to obtain sufficient funding, it could be required to delay its development
efforts, limit activities and reduce research and development costs, which could adversely affect its business prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company is seeking to complete an initial public offering (&#147;IPO&#148;) of its common stock. Immediately prior to the
closing of a qualifying public offering on specified terms, the Company&#146;s outstanding convertible preferred stock will convert into common stock (see Note 9). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the event the Company does not complete an IPO, the Company expects to
seek additional funding through private equity financings, government or private-party grants, debt financings or other capital sources, including collaborations with other companies or other strategic transactions. The Company may not be able to
obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborations or other arrangements. The terms of any financing may adversely affect the holdings or rights of the Company&#146;s stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If the Company is unable to obtain sufficient capital, the Company will be forced to delay, reduce or eliminate some or all of
its research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations. Although management continues to pursue
these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and
classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. Accordingly, the consolidated financial statements have been prepared on a basis that assumes the
Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">COVID-19</FONT> Considerations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In March 2020, the World Health Organization declared the outbreak of the novel coronavirus,
<FONT STYLE="white-space:nowrap">COVID-19,</FONT> a pandemic. The pandemic has resulted in the closing of borders, enhanced health screenings, health care service preparation and delivery, quarantines, cancellations, disruptions to supply chains, as
well as general concern and uncertainty. The Company cannot predict the future progression or full impact of the outbreak and its effects on the Company&#146;s business and operations. Additionally, <FONT STYLE="white-space:nowrap">COVID-19</FONT>
has resulted in substantial market volatility and may result in a significant economic downturn. The Company will continue to actively monitor the current international and domestic impacts of and responses to
<FONT STYLE="white-space:nowrap">COVID-19</FONT> and its related risks. The Company considered the potential effects of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on its financial statements and noted that there is no material
effect on the consolidated financial statements as of December&nbsp;31, 2021 and 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Summary of Significant Accounting Policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation and Consolidation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally
accepted in the United States of America (&#147;U.S. GAAP&#148;) and include the operations of Acrivon Therapeutics, Inc. and its wholly-owned subsidiaries. All intercompany accounts, transactions and balances have been eliminated in consolidation.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The preparation of the Company&#146;s financial statements in conformity with U.S. GAAP requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant
estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual of research and development expenses, and the valuations of common stock, stock-based awards, preferred stock tranche rights,
convertible notes and anti-dilution right. The Company bases its estimates on historical experience when available, known trends and other market specific data, or other relevant factors that it believes to be reasonable under the circumstances. On
an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates and assumptions are reflected in reported results in the period in which they become known. Actual results could
differ from those estimates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Segment Information </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Operating segments are defined as components of an enterprise for which separate and discrete information is available for
evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company has one operating segment. The Company&#146;s focus is the research and development of precision oncology therapies. The
Company&#146;s chief operating decision maker, its chief executive officer, manages the Company&#146;s operations on a consolidated basis for the purpose of allocating resources. As the Company has one reportable segment, all required segment
financial information is presented in the consolidated financial statements. As of December&nbsp;31, 2021, the majority of the Company&#146;s long-lived assets are held in the United States. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash and Cash Equivalents </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company considers all highly liquid investments purchased with original maturities of 90 days or less at acquisition to be
cash equivalents. Cash and cash equivalents include standard checking accounts and amounts held in money market funds. Periodically, the Company maintains deposits in accredited financial institutions in excess of federally insured limits. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restricted Cash </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cash accounts with any type of restriction are classified as restricted cash. The Company has restricted cash deposits with a
bank, which serve as collateral for a letter of credit issued to the landlord of the Company&#146;s leased facility for a security deposit. The Company classified this amount as restricted cash in the accompanying consolidated balance sheets within <FONT
STYLE="white-space:nowrap">non-current</FONT> assets based on the release date of restrictions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Deferred Offering Costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with <FONT
STYLE="white-space:nowrap">in-process</FONT> equity financings as deferred offering costs until such financings are consummated. After consummation of an equity financing, these costs are recorded as a reduction of the proceeds from the offering,
either as a reduction of the carrying value of the preferred stock or in stockholders&#146; deficit as a reduction of additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital generated as a result of the offering. Should the <FONT
STYLE="white-space:nowrap">in-process</FONT> equity financing be abandoned, the deferred offering costs would be expensed immediately as a charge to operating expenses in the statements of operations and comprehensive loss. There were no deferred
offering costs capitalized as of December&nbsp;31, 2021 and 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Concentration of Credit Risk and Significant Suppliers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and
cash equivalents. The Company has not experienced any credit losses on its cash or cash equivalents. The Company maintains its cash and cash equivalents at a high-quality financial institution. Management believes that such funds are not exposed to
any significant credit or concentration risk. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company is dependent on third-party contract research organizations
(&#147;CROs&#148;) and contract manufacturing organizations to supply certain intellectual property and services for research activities in its drug candidates. In particular, the Company relies and expects to continue to rely on a small number of
these organizations to supply it with its requirements for key raw materials related to these programs. These drug candidates could be adversely affected by a significant interruption in the supply of key raw materials. Additionally, the Company
relies on a single companion diagnostic collaborator to perform ACR-368 OncoSignature tests in the Company&#146;s clinical trials (see Note&nbsp;17). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comprehensive Loss </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Comprehensive loss includes net loss as well as other changes in stockholders&#146; deficit that result from transactions and
economic events other than those with stockholders. For the years ended December&nbsp;31, 2021 and 2020, there was no difference between net loss and comprehensive loss. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value Measurements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">ASC Topic 820, <I>Fair Value Measurement</I> (&#147;ASC 820&#148;), establishes a fair value hierarchy for instruments measured
at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#146;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or
liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#146;s assumptions about the inputs that market participants would use in pricing the asset or liability and are
developed based on the best information available in the circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">ASC 820 identifies fair value as the exchange
price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value
measurements, ASC 820 establishes a three-tier fair value hierarchy that distinguishes among the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Level</I><I></I><I>&nbsp;1</I>&#151;Quoted prices in active markets for identical assets or liabilities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Level</I><I></I><I>&nbsp;2</I>&#151;Observable inputs (other than Level&nbsp;1 quoted prices), such as quoted prices in
active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Level</I><I></I><I>&nbsp;3</I>&#151;Unobservable inputs that are supported by little or no market activity and that are
significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the
determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&nbsp;3. A financial instrument&#146;s level within the fair
value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The Company&#146;s convertible notes, preferred stock tranche rights and anti-dilution right were carried at fair value, determined
according to Level&nbsp;3 inputs in the fair value hierarchy described above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Property and Equipment, net </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Property and equipment are stated at cost, less accumulated depreciation. Costs of major additions and betterments are
capitalized. Maintenance and repairs which do not improve or extend the life of the respective assets are charged to expense as incurred. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which
range from five to seven years. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the related asset. The Company had no leasehold improvements as of December&nbsp;31, 2021 and 2020. When an item
is sold or retired, the costs and related accumulated depreciation are eliminated, and the resulting gain or loss, if any, is credited or charged to the consolidated statement of operations and comprehensive loss. Property and equipment to be
disposed of are carried at fair value less costs to sell. The estimated useful lives of the Company&#146;s property and equipment are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated Useful Life (in Years)</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory equipment and computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5&nbsp;years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">5-7</FONT> years</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Lesser&nbsp;of&nbsp;asset&nbsp;useful&nbsp;life&nbsp;or&nbsp;lease&nbsp;term</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Impairment of Long-Lived Assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company recognizes an impairment loss in loss from operations only if the carrying amount of a long-lived asset is not
recoverable based on its undiscounted future cash flows and in such case, measures an impairment loss as the difference between the carrying amount and the fair value of the asset. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company tests long-lived assets to be held and used, including property and equipment and operating lease <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> (&#147;ROU&#148;) assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of assets or asset groups may not be fully
recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover
the carrying amount of the assets, the assets are written down to their fair values. The Company has not recognized any impairment losses during the years ended December&nbsp;31, 2021 and 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Research and development costs include (i)&nbsp;employee-related expenses, including salaries, benefits, and stock-based
compensation expense; (ii)&nbsp;external research and development expenses incurred under arrangements with third parties, such as CRO agreements and consultants; (iii)&nbsp;costs associated with preclinical activities; and (iv)&nbsp;lab supplies,
lab expenses and an allocation of rent, depreciation, and infrastructure. Costs incurred in connection with research and development activities are expensed as incurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company enters into various consulting, research, and other agreements with commercial firms, researchers, universities
and other external parties for the provision of goods and services. Such arrangements are generally cancelable upon reasonable notice and payment of costs incurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Costs are considered incurred based on an evaluation of the progress to completion of specific tasks under each contract using
information and data provided by the Company&#146;s clinical sites and vendors. These costs consist of direct and indirect costs associated with specific projects, as well as fees paid to various entities that perform certain research on behalf of
the Company. Depending upon the timing of payments to the service providers, the Company recognizes prepaid expenses or accrued expenses related to these costs. These accrued or prepaid expenses are based on management&#146;s estimates of the work
performed under service agreements, milestones achieved, and experience with similar contracts. Milestone payments under license agreements are accrued, with a corresponding expense being recognized, in the period in which the milestone is
determined to be probable of achievement and the related amount is reasonably estimable. The Company monitors each of these factors and adjusts estimates accordingly. The Company has not experienced any material differences between accrued costs and
actual costs incurred since its inception. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Asset Acquisitions and Acquired <FONT STYLE="white-space:nowrap">In-Process</FONT> Research and
Development Expenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company accounts for acquisitions of assets or a group of assets that do not meet the
definition of a business as asset acquisitions based on the cost to acquire the asset or group of assets, which include certain transaction costs. In an asset acquisition, the cost to acquire is allocated to the identifiable assets acquired and
liabilities assumed based on their relative fair values as of the acquisition date. No goodwill is recorded in an asset acquisition. Assets that are acquired in an asset acquisition for use in research and development activities that have an
alternative future use are capitalized as in process research and development (&#147;IPR&amp;D&#148;). Acquired IPR&amp;D that has no alternative future use as of the acquisition date is recognized as research and development expense as of the
acquisition date. The Company will recognize additional research and development expenses in the future if and when the Company becomes obligated to make contingent milestone payments under the terms of the agreements by which it acquired the
IPR&amp;D assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Contingent consideration in asset acquisitions is measured and recognized when payment becomes probable
and reasonably estimable. Subsequent changes in the accrued amount of contingent consideration are measured </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
and recognized at the end of each reporting period and upon settlement as an adjustment to the cost basis of the acquired asset or group of assets, or, if related to IPR&amp;D with no alternative
future use, charged to expense. For the year ended December&nbsp;31, 2021, the Company recognized $5.5&nbsp;million of IPR&amp;D expense in connection with the consideration due under the Lilly Agreement (see Note 7), included within research and
development expense. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent Costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">All patent-related costs incurred in connection with filing and prosecuting patent applications such as direct application
fees, and legal and consulting expenses are expensed as incurred due to the uncertainty about the recovery of the expenditure. Patent-related costs are classified as general and administrative expenses within the Company&#146;s consolidated
statements of operations and comprehensive loss. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Foreign Currency Transactions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The functional currency for the Company&#146;s wholly-owned foreign subsidiary, Acrivon AB, is the United States dollar. All
foreign currency transaction gains and losses are recognized in the consolidated statements of operations and comprehensive loss through other income (expense). The Company has not recognized material currency transaction gains or losses during the
years ended December&nbsp;31, 2021 and 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Leases </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prior to January&nbsp;1, 2021, the Company accounted for leases in accordance with Financial Accounting Standards Board
(&#147;FASB&#148;) Accounting Standards Codification (&#147;ASC&#148;) Topic 840, <I>Leases </I>(&#147;ASC 840&#148;). At lease inception, the Company determined if an arrangement was an operating or capital lease. For operating leases, the Company
recognized rent expense, inclusive of rent escalations, on a straight-line basis over the lease term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Effective on
January&nbsp;1, 2021, the Company accounts for leases in accordance with ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-02,</FONT> <I>Leases</I>, as subsequently amended (collectively, &#147;ASC 842&#148;). In accordance with ASC 842, the
Company determines whether an arrangement is or contains a lease at inception. A contract is or contains a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The
Company classifies leases at the lease commencement date, when control of the underlying asset is transferred from the lessor to the lessee, as operating or finance leases and records a ROU asset and a lease liability on the consolidated balance
sheets for all leases with an initial lease term of greater than 12 months. The Company has elected to not recognize leases with a lease term of 12 months or less, but payments are recognized as expense on a straight-line basis over the lease term.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company enters into contracts that contain both lease and <FONT STYLE="white-space:nowrap">non-lease</FONT>
components. <FONT STYLE="white-space:nowrap">Non-lease</FONT> components may include maintenance, utilities, and other operating costs. For leases of real estate, the Company combines the lease and associated
<FONT STYLE="white-space:nowrap">non-lease</FONT> components in its lease arrangements as a single lease component. Variable costs, such as utilities or maintenance costs, are not included in the measurement of <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets and lease liabilities, but rather are expensed when the event determining the amount of variable consideration to be paid occurs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Finance and operating lease assets and liabilities are recognized at the lease commencement date based on the present value of
the lease payments over the lease term using the discount rate implicit in the lease if readily determinable. If the rate implicit is not readily determinable, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at
which the Company could borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. ROU assets are further adjusted for initial direct costs, prepaid rent, or incentives received.
Operating lease payments are expensed using the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
straight-line method as an operating expense over the lease term. The Company&#146;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the
Company will exercise that option. Finance lease assets are amortized to depreciation expense using the straight-line method over the shorter of the useful life of the related asset or the lease term. Finance lease payments are bifurcated into
(i)&nbsp;a portion that is recorded as interest expense using the effective interest method and (ii)&nbsp;a portion that reduces the finance liability associated with the lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, the Company examines other contracts with suppliers, vendors and outside parties to identify whether such
contracts contain an embedded lease and, as applicable, records such embedded leases in accordance with ASC 842. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Convertible Preferred Stock
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s convertible preferred stock is classified as temporary equity in the accompanying consolidated
balance sheets and excluded from stockholders&#146; deficit as the potential redemption of such stock is outside the Company&#146;s control and would require the redemption of the then-outstanding convertible preferred stock. The convertible
preferred stock is not redeemable except for in the event of a liquidation, dissolution, or winding up of the Company (see Note 9). Costs incurred in connection with the issuance of convertible preferred stock, as well as the recognition of the
preferred stock tranche liability, are recorded as a reduction of gross proceeds from issuance. The Company does not accrete the carrying values of the preferred stock to the redemption values since the occurrence of these events was not considered
probable as of December&nbsp;31, 2021 and 2020. Subsequent adjustments of the carrying values to the ultimate redemption values will be made only when it becomes probable that these events will occur. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company accounts for all share-based payment awards granted to employees and
<FONT STYLE="white-space:nowrap">non-employees</FONT> as stock-based compensation expense at fair value, based on the date of the grant, and recognizes compensation expense for those awards over the requisite service period, which is generally the
vesting period of the respective award. The Company&#146;s share-based payments include stock options and grants of common stock. The measurement date for employee awards is the date of grant, and stock-based compensation costs are recognized as
expense over the employees&#146; requisite service period, which is the vesting period, on a straight-line basis. The Company adopted ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-07,</FONT> <I>Compensation&#151;Stock Compensation (Topic 718):
Improvements to Nonemployee Share-Based Payment Accounting </I>(&#147;ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-07&#148;)</FONT> at inception of the 2019 Stock<I> </I>Incentive Plan, prior to the issuance of any stock option grants. The
measurement date for <FONT STYLE="white-space:nowrap">non-employee</FONT> awards<I> </I>is the date of grant, and stock-based compensation costs<I> </I>for <FONT STYLE="white-space:nowrap">non-employees</FONT> are recognized as expense over the
vesting period on a straight-line basis.<I> </I>The Company accounts for forfeitures as they occur. Stock-based compensation expense is classified in the accompanying consolidated statements of operations and comprehensive loss in the same manner in
which the award recipient&#146;s payroll costs are classified or in which the award recipients service payments are classified. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model,
which requires inputs based on certain subjective assumptions. The Company&#146;s board of directors determines the fair value of the Company&#146;s common stock, taking into consideration its most recently available third-party valuations of common
stock and as well as additional factors which may have changed since the date of the most recent contemporaneous valuation through the grant date. The Company has historically been a private company and lacks company-specific historical and implied
volatility information. The Company estimates its expected stock volatility based on the historical volatility of a publicly traded set of representative companies and expects to continue to do so until such time as it has adequate historical data
regarding the volatility of its own traded stock price. The expected term of the Company&#146;s stock options has been determined utilizing the &#147;simplified&#148; method for awards that qualify as &#147;plain-vanilla&#148; options. The risk-free
interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends
in the foreseeable future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Loss per Share </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during
the period. Diluted net loss per share is computed using the weighted-average number of common shares outstanding during the period and, if dilutive, the weighted-average number of potential shares of common stock. Net loss per share attributable to
common stockholders is calculated using the <FONT STYLE="white-space:nowrap">two-class</FONT> method, which is an earnings allocation formula that determines net loss per share for the holders of the Company&#146;s common shares and participating
securities. The Company&#146;s convertible preferred stock contains participation rights in any dividend paid by the Company and is deemed to be a participating security. Net loss attributable to common stockholders and participating preferred
shares are allocated to each share <FONT STYLE="white-space:nowrap">on&nbsp;an&nbsp;as-converted&nbsp;basis&nbsp;as</FONT> if all of the earnings for the period had been distributed. The participating securities do not include a contractual
obligation to share in losses of the Company and are not included in the calculation of net loss per share in the periods in which a net loss is recorded. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Diluted net loss per share is computed using the more dilutive
<FONT STYLE="white-space:nowrap">of&nbsp;(a)&nbsp;the&nbsp;two-class&nbsp;method&nbsp;or</FONT> <FONT STYLE="white-space:nowrap">(b)&nbsp;the&nbsp;if-converted&nbsp;method.</FONT> The Company allocates earnings first to preferred stockholders based
on dividend rights and then to common and preferred stockholders based on ownership interests. The weighted-average number of common shares included in the computation of diluted net loss per share gives effect to all potentially dilutive common
equivalent shares, including outstanding stock options and preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Common stock equivalent shares are excluded
from the computation of diluted net loss per share if their effect is antidilutive. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as
basic net loss per share attributable to common stockholders since dilutive common shares are not assumed to have been issued if their effect is antidilutive. The Company reported a net loss attributable to common stockholders for the years ended
December&nbsp;31, 2021 and 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax
assets and liabilities for the expected future tax consequences of events that have been recognized in the financial statements or the Company&#146;s tax returns. Under this method, deferred tax assets and liabilities are determined based on the
differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are
recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more
likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company accounts for uncertain tax positions recognized in the consolidated financial statements by prescribing a
&#147;more likely than not&#148; threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. There are no unrecognized tax benefits included in the Company&#146;s consolidated
balance sheets as of December&nbsp;31, 2021 and 2020. The Company&#146;s policy is to recognize interest and penalties related to income tax matters in income tax expense. The Company has not recognized interest or penalties in its consolidated
statements of operations and comprehensive loss since inception. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently Adopted Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-02,</FONT> Leases </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In February 2016, the FASB issued ASC 842, which sets out the principles for the recognition, measurement, presentation and
disclosure of leases for both parties to a contract (i.e., lessees and lessors), and replaces the existing guidance in ASC 840. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on
the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine the recognition pattern of lease expense over the term of the lease. In addition, a lessee is required to record
(i)&nbsp;a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset and a lease liability on its balance sheets for all leases with accounting lease terms of more than 12 months regardless of whether it is
an operating or financing lease and (ii)&nbsp;lease expense in its consolidated statements of operations and comprehensive loss for operating leases and amortization and interest expense in its consolidated statements of operations and comprehensive
loss for financing leases. Leases with a term of 12 months or less may be accounted for similar to existing guidance for operating leases under ASC 840. In July 2018, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-11,</FONT>
<I>Leases </I>(Topic 842), which added an optional transition method that allows companies to adopt the standard as of the beginning of the year of adoption as opposed to the earliest comparative period presented. This guidance is effective for the
Company for fiscal years beginning after December&nbsp;15, 2021, and interim periods within fiscal years beginning after December&nbsp;15, 2022. Early application is permitted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company early adopted ASC 842, with an effective date of January&nbsp;1, 2021, using the modified retrospective transition
approach which uses the effective date as the date of initial application. As a result, prior periods are presented in accordance with the previous guidance in ASC 840. The Company has elected to apply the package of practical expedients requiring
no reassessment of whether any expired or existing contracts are or contain leases, the lease classification of any expired or existing leases, or the capitalization of initial direct costs for any existing leases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon its adoption of ASC 842 on January&nbsp;1, 2021, the Company recorded a lease liability and its corresponding ROU asset
based on the present value of lease payments over the remaining lease term. The adoption of ASC 842 resulted in the recognition of operating lease liabilities of $0.4&nbsp;million and ROU assets of $0.4&nbsp;million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2020-06,</FONT> Debt </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On January&nbsp;1, 2021, the Company early adopted ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2020-06,</FONT>
<I>Debt&#151;Debt with Conversion and Other Options (Subtopic <FONT STYLE="white-space:nowrap">470-20)</FONT> and Derivatives and Hedging&#151;Contracts in Entity&#146;s Own Equity (Subtopic <FONT STYLE="white-space:nowrap">815-40):</FONT>
Accounting for Convertible Instruments and Contracts in an Entity&#146;s Own Equity</I> (&#147;ASU <FONT STYLE="white-space:nowrap">2020-06&#148;),</FONT> which simplifies the accounting for certain financial instruments with characteristics of
liabilities and equity, including convertible instruments and contracts on an entity&#146;s own equity. Specifically, ASU <FONT STYLE="white-space:nowrap">2020-06</FONT> simplifies accounting for the issuance of convertible instruments by removing
major separation models required under current U.S. GAAP. In addition, the ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and simplifies the diluted earnings per share
calculation in certain areas. The adoption of this standard did not have a material effect on the Company&#146;s consolidated financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2020-10,</FONT> Codification Improvements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In October 2020, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2020-10,</FONT> <I>Codification
Improvements</I>, which updates various codification topics by clarifying or improving disclosure requirements to align with the SEC&#146;s regulations. The Company adopted this accounting standard as of January&nbsp;1, 2021 with no material impact
on its consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently Issued Accounting Pronouncements Not Yet Adopted </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Emerging Growth Company </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Jumpstart Our Business Startups Act of 2012 permits an &#147;emerging growth company&#148; to take advantage of an extended
transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. The Company has elected not to &#147;opt out&#148; of such extended transition
period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company will adopt the new or revised standard at the time private companies adopt the new or revised standard
and will do so until such time that the Company either (i)&nbsp;irrevocably elects to &#147;opt out&#148; of such extended transition period or (ii)&nbsp;no longer qualifies as an emerging growth company. As a result of this election, the
Company&#146;s financial statements may not be comparable to other public companies that comply with new or revised accounting pronouncements as of public company effective dates. The Company may choose to early adopt any new or revised accounting
standards whenever such early adoption is permitted for private companies<B><I>.</I></B> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>ASU <FONT STYLE="white-space:nowrap">2019-12,</FONT>
Simplifying the Accounting for Income Tax </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In December 2019, the FASB issued ASU
<FONT STYLE="white-space:nowrap">No.&nbsp;2019-12,</FONT> <I>Simplifying the Accounting for Income Tax </I>(&#147;ASU <FONT STYLE="white-space:nowrap">2019-12&#148;).</FONT> The standard contains several provisions that reduce financial statement
complexity including removing the exception to the incremental approach for intra-period tax expense allocation when a company has a loss from continuing operations and income from other items not included in continuing operations. The new guidance
is effective for the year beginning January&nbsp;1, 2022, with optional adoption prior to the effective date. The Company does not expect that the new standard will have a material impact on the Company&#146;s consolidated financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Fair Value Measurement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following tables present information about the Company&#146;s financial assets and liabilities measured at fair value on a
recurring basis (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Value Measurements at<BR>December&nbsp;31, 2021 Using:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">79,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">79,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">79,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">79,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="12"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Value Measurements at<BR>December&nbsp;31, 2020 Using:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock tranche rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December&nbsp;31, 2021, the Company&#146;s cash equivalents consisted of money market
funds, classified as Level&nbsp;1 financial assets, as these assets are valued using quoted market prices in active markets without any valuation adjustment. As of December&nbsp;31, 2020, the Company had Level&nbsp;3 financial liabilities that were
measured at fair value on a recurring basis. The Company&#146;s preferred stock tranche rights, convertible notes and anti-dilution right were carried at fair value determined using Level&nbsp;3 inputs in the fair value hierarchy. As of
December&nbsp;31, 2021, the preferred stock tranche rights, convertible notes and anti-dilution right have been satisfied, and as such, there are no liabilities recorded as of December&nbsp;31, 2021. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">During the years ended December&nbsp;31, 2021 and 2020, there were no
transfers between levels. The Company uses the carrying amounts of its restricted cash, prepaid expenses and other current assets, accounts payable and accrued expenses to approximate their fair value due to the short-term nature of these amounts.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preferred Stock Tranche Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In October 2020, the Company issued Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock
(&#147;Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock&#148;). According to the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock subscription agreement, the Company was obligated to issue second and third
tranches of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock upon the Company&#146;s successful completion of future science-driven milestone events, such as entering into <FONT STYLE="white-space:nowrap">in-licensing</FONT>
agreements, contracting with a CRO to conduct phase 2 clinical trials, and identifying compounds for lead drug candidates. As a result, the Company&#146;s obligation to issue additional Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred
Stock was recognized as a tranche obligation (the &#147;Preferred Stock Tranche Rights&#148;), which was subject to revaluation at each balance sheet date. Changes in fair value were recorded as a component of other income (expense), net in the
consolidated statements of operations and comprehensive loss until the Preferred Stock Tranche Rights were settled (see Note 9). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company determined that the Preferred Stock Tranche Rights are freestanding financial instruments. The freestanding
financial instruments were classified as a liability on the Company&#146;s consolidated balance sheets and initially recorded at fair value. The liability was subsequently remeasured to fair value at each reporting date until settled,&nbsp;and
changes in the fair value of the preferred stock tranche liability were recognized as a component of other income (expense) in the consolidated statements of operations and comprehensive loss. The fair value of the Preferred Stock Tranche Rights was
based on significant inputs not observable in the market, which represents a Level&nbsp;3 measurement within the fair value hierarchy. A change in the assumptions related to the valuation of the Preferred Stock Tranche Rights could have a
significant impact on the value of the obligation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Preferred Stock Tranche Rights were valued as a forward contract.
The value was determined using a probability-weighted present value calculation. In determining the fair value of the tranche rights obligation, estimates and assumptions impacting the fair value included the per share estimated fair value of the
Company&#146;s Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, discount rates, estimated time to tranche closing, and probability of each tranche closing. The Company determined the per share estimated fair value of the Series <FONT
STYLE="white-space:nowrap">A-1</FONT> Preferred Stock by back-solving to the initial proceeds of the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock financing. The Company remeasured the Preferred Stock Tranche Rights at each
reporting period and prior to the settlement of the Preferred Stock Tranche Rights in January 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following
reflects the ranges of significant quantitative inputs used in the valuation of the Preferred Stock Tranche Rights during the years ended December&nbsp;31, 2021 and 2020: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Implied fair value of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$2.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$2.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Discount rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.1%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Time to milestone event (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">0.12&nbsp;-&nbsp;0.40</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Probability of tranche closing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">70%&nbsp;-&nbsp;90%</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following provides a roll forward of the fair value of the Preferred
Stock Tranche Rights measured at fair value on a recurring basis using Level&nbsp;3 significant unobservable inputs (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Preferred Stock Tranche Rights to purchase Series A-1 Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value recognized as Series A-1 Preferred Stock upon settlement of Preferred Stock Tranche
Rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(368</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Convertible Notes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In 2018 and 2019, the Company entered into convertible notes purchase agreements (collectively, the &#147;Notes&#148;) for a
total aggregate borrowing amount of $4.8&nbsp;million (see Note 8). The Notes contained various conversion features including mandatory conversion upon the occurrence of a qualified financing at a 20% or 50% discount. Upon the occurrence of a <FONT
STYLE="white-space:nowrap">non-qualified</FONT> financing, the holders of convertible notes issued in 2019 had the option to convert at the same terms as described above for a qualified financing. The Company elected the fair value option to account
for the Notes. Changes in fair value were recorded as a component of other income (expense), net in the consolidated statements of operations and comprehensive loss until the Notes converted in October 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Notes were classified as a liability on the Company&#146;s consolidated balance sheets and initially recorded at fair
value. The fair value of the Notes was based on significant inputs not observable in the market, which represents a Level&nbsp;3 measurement within the fair value hierarchy. A change in the assumptions related to the valuation of the Notes could
have a significant impact on the value of the obligation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The value of the Notes was determined using a
probability-weighted present value calculation. In determining the fair value of the Notes, estimates and assumptions impacting the fair value primarily included the per share estimated fair value of the Company&#146;s Series <FONT
STYLE="white-space:nowrap">A-1</FONT> Preferred Stock. The Company remeasured the Notes at each reporting period and prior to the conversion of the Notes in October 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Immediately prior to conversion, the Notes were marked to fair value using the Series
<FONT STYLE="white-space:nowrap">A-1</FONT> price of $2.28 per share. No gain or loss was recorded upon extinguishment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following provides a roll forward of the fair value of the Notes measured at fair value on a recurring basis using
Level&nbsp;3 significant unobservable inputs (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 4,984</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value recognized as Series A-1 Preferred Stock upon conversion of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,083</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Anti-dilution Right </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In accordance with a license agreement and stock issuance agreement between Eli Lilly and Company (&#147;Lilly&#148;) and the
Company (collectively, the &#147;Lilly Agreement&#148;) entered into in January 2021, the Company was obligated to issue capital stock in a subsequent financing to Lilly in order to maintain a specified, single-digit percentage ownership of the
Company upon specified conditions (the &#147;Anti-dilution Right&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company determined that the Anti-dilution Right is a freestanding
financial instrument. The freestanding financial instrument was classified as an asset or liability on the Company&#146;s consolidated balance sheets and initially recorded at fair value. The fair value of the Anti-dilution Right was based on
significant inputs not observable in the market, which represents a Level&nbsp;3 measurement within the fair value hierarchy. A change in the assumptions related to the valuation of the Anti-dilution Right could have a significant impact on the
value of the obligation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Anti-dilution Right was valued as a forward contract. The value was determined using a
probability-weighted present value calculation. In determining the fair values of the obligation, estimates and assumptions impacting fair value included the per share estimated fair value of the Company&#146;s Series B convertible preferred stock
(&#147;Series B Preferred Stock&#148;), discount rates, estimated time to share issuance and probability of each share issuance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Anti-dilution Right was subsequently revalued until anti-dilution shares were issued, with changes in fair value for each
reporting period recognized in other income (expense), net in the consolidated statements of operations and comprehensive loss. Upon issuance of the anti-dilution shares, the fair value of the Anti-dilution Right was recognized as Series B Preferred
Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In accordance with the Anti-dilution Right, the Company issued Lilly 46,058 shares of Series B Preferred Stock in
November 2021 in full satisfaction of the obligation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following reflects the ranges of significant quantitative
inputs used in the valuation of the Anti-dilution Right during the year ended December&nbsp;31, 2021: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">0.0%&nbsp;-&nbsp;0.1%</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Discount rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47.5%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Implied issuance price of Series B Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">$0.84&nbsp;-&nbsp;$6.11</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Probability of settlement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">10%&nbsp;-&nbsp;100%</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following provides a roll forward of the fair value of the Anti-dilution Right measured at
fair value on a recurring basis using Level&nbsp;3 significant unobservable inputs (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Anti-dilution Right</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of Anti-dilution Right</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value recognized as Series B Preferred Stock upon settlement of Anti-dilution Right</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(263</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Property and Equipment, net </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Property and equipment, net consisted of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory and computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(56</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Depreciation expense related to property and equipment for the years ended
December&nbsp;31, 2021 and 2020 was $37,000 and $13,000, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Accrued Expenses and Other Current Liabilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Accrued expenses and other current liabilities consisted of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued compensation and benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued legal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred sublease income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PPP loan payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">477</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Leases </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In April 2018, the Company entered into a lease agreement for laboratory and office space located at 700 N. Main Street,
Cambridge, Massachusetts. The lease term, which commenced in April 2018 and was set to expire in April 2020, was extended in March 2020 for an additional <FONT STYLE="white-space:nowrap">one-year</FONT> period. The lease was cancellable with 30
days&#146; notice. The Company elected the short-term lease measurement and recognition exemption under ASC 842 for the <FONT STYLE="white-space:nowrap">one-year</FONT> period extension and therefore did not recognize the lease on the Company&#146;s
consolidated balance sheets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In September 2020, the Company entered into an operating lease agreement, denominated in
Swedish Krona, for office space located in Lund, Sweden. The term of the lease commenced in October 2020 and is scheduled to expire in September 2023, with lease payments being made on a quarterly basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In December 2020, the Company entered into a lease agreement for laboratory and office space located at 480 Arsenal Way,
Watertown, Massachusetts (the &#147;Arsenal Way Lease&#148;). The term of the lease commenced in April 2021. The lease has an initial term from the rent commencement date, which is a month after the lease commencement date, of approximately seven
years, with an option to extend the term for an additional five years at then-market rental rates. In connection with the execution of the lease agreement, the Company delivered a letter of credit of $0.3&nbsp;million to the landlord, which is
included in restricted cash in the accompanying consolidated balance sheets. The landlord contributed an aggregate of $0.7&nbsp;million toward the cost of tenant improvements for the premises. Under the terms of the lease, the base rent is
$1.0&nbsp;million, subject to a 3% annual rent increase, plus an allocation of operating expenses and taxes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In May 2021,
the Company entered into an agreement to sublease 6,330 rentable square feet of its Arsenal Way Lease to a subtenant through March 2023. Sublease income is recognized on a straight-line basis over the term of the sublease agreement. Sublease rent
income was $0.4&nbsp;million for the year ended December&nbsp;31, 2021, which was allocated and recorded as a reduction to general and administrative expenses and research and development expenses. The Company was not relieved of its primary
obligation under the Arsenal Way Lease as a result of the sublease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company recognizes monthly operating lease
expense on a straight-line basis over the term of the lease as research and development or general and administrative expenses in the consolidated statement of operations and comprehensive loss. Variable lease expense relates primarily to office
lease common area maintenance, insurance, and property taxes, is expensed as incurred, and is excluded from the calculation of the lease liabilities and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use-assets.</FONT></FONT></FONT> Variable lease expense for the year ended December&nbsp;31, 2021 was $0.3&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes the presentation of the Company&#146;s
operating leases on its consolidated balance sheet (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Leases</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Balance sheet classification</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total lease assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Operating lease liability, current</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">664</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Noncurrent:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Operating lease liability, long-term</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,964</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,628</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The components of lease cost under ASC 842 included within research and development expenses
and general and administrative expenses in the Company&#146;s consolidated statement of operations and comprehensive loss for the year ended December&nbsp;31, 2021 were as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Lease cost</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Variable lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sublease income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(291</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December&nbsp;31, 2021, the weighted-average remaining lease term for operating leases
was 6.3 years and the weighted-average discount rate was 7.85%. Cash paid for amounts included in the measurement of lease liabilities was $0.9&nbsp;million for the year ended December&nbsp;31, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Future minimum annual lease commitments under the Company&#146;s <FONT STYLE="white-space:nowrap">non-cancellable</FONT>
operating leases as of December&nbsp;31, 2021 were as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Year ended December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,076</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,087</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,533</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Present value of operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,628</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Disclosures under ASC 840 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company recognizes rent expense on a straight-line basis over the respective lease period. During the year ended
December&nbsp;31, 2020, rent expense was $0.4&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Future minimum rental commitments to be paid by the Company at
December&nbsp;31, 2020 is as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Year ending December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Expected future lease payments of $7.7 million related to the Arsenal Way lease are not
included in the table above. This lease agreement was signed in December 2020 and had not commenced as of December 31, 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. License Agreement
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In January 2021, the Company entered into the Lilly Agreement with Lilly, pursuant to which the Company has been
granted an exclusive, royalty-bearing sublicensable license to certain patents owned or controlled by Lilly, to commercially develop, manufacture, use, distribute and sell therapeutic products containing the compound prexasertib. The license from
Lilly comprises three families of patent filings all relating to ACR-368. Additionally, pursuant to the Lilly Agreement, the Company received ACR-368 drug substance and drug product to be used in future research. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As initial consideration for the license, the Company made a <FONT STYLE="white-space:nowrap">one-time,</FONT> <FONT
STYLE="white-space:nowrap">non-creditable,</FONT> <FONT STYLE="white-space:nowrap">non-refundable</FONT> upfront payment of $5.0&nbsp;million. As additional consideration for the license, the Company is required to pay Lilly aggregate development
and commercial milestone payments of up to $168.0 million, of which $5.0 million is due prior to a new drug application. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company is also obligated to pay a tiered percentage royalty on annual net sales ranging from a low single-digit up to a
maximum of 10%, subject to certain specified reductions. Royalties are payable by the Company on a licensed product-by-licensed product and country-by-country basis until the later of the expiration of the last valid claim covering the licensed
product in such country, expiration of all applicable regulatory exclusivities in such country for such licensed product and the tenth anniversary of the first commercial sale of such licensed product in such country, provided, that the
Company&#146;s obligation to pay royalties for a given licensed product in a given country will expire earlier upon achievement of certain sales thresholds by generic products in such country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to the cash consideration described above, the Company issued 336,575 shares of its common stock to Lilly in an
amount equal to 5.0% of the Company&#146;s capital stock on a fully diluted basis as of the date of the Lilly Agreement. The Company agreed to issue its capital stock to Lilly pursuant to the Anti-dilution Right (see Note 3). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In November 2021, the Company completed its Series B Preferred Stock financing. The financing triggered the settlement of the
Anti-dilution Right, resulting in the issuance of 46,058 shares of Series B Preferred Stock to Lilly with a then fair value of $0.3&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company determined that the Lilly Agreement represented an asset acquisition as substantially all of the fair value of the
gross assets acquired was concentrated in the group of IPR&amp;D assets, which all were similarly identifiable assets, with no alternative future use and recognized the aggregate acquisition cost as acquired IPR&amp;D expense in the consolidated
statements of operations and comprehensive loss. For the year ended December&nbsp;31, 2021, the Company recognized $5.5&nbsp;million of research and development expense in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
connection with the consideration due under the Lilly Agreement. The $5.5&nbsp;million consisted of (i) $0.2&nbsp;million initial recognition of the Anti-dilution Right, (ii) $0.3&nbsp;million
fair value for the 336,575 shares of common stock issued to Lilly and (iii)&nbsp;the upfront cash consideration for the license arrangement of $5.0&nbsp;million. To date, no milestones have been achieved and no royalties have been incurred related
to the Lilly Agreement. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Debt </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>PPP Loan
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In April 2020, the Company issued a promissory note to Silicon Valley Bank, pursuant to which it received loan
proceeds of $0.1&nbsp;million (the &#147;PPP Loan&#148;) provided under the Paycheck Protection Program (&#147;PPP&#148;), which was established under the Coronavirus Aid, Relief and Economic Security Act and guaranteed by the Small Business
Administration (&#147;SBA&#148;). The PPP loan was recorded within accrued expenses and other current liabilities on the Company&#146;s consolidated balance sheets. In February 2021, the Company received notice from the SBA that the PPP Loan was
forgiven. Accordingly, the Company was no longer required to repay the $0.1&nbsp;million in principal and immaterial accrued interest borrowed under the PPP Loan. A gain on extinguishment of the PPP Loan of $0.1&nbsp;million was recorded as other
income (expense), net for the year ended December&nbsp;31, 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Convertible Notes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In April 2018, the Company commenced an offering to issue $1.8&nbsp;million of convertible notes (the &#147;2018 Notes&#148;)
to certain investors with a maturity date in April 2020. The 2018 Notes carried an interest rate of 4.0% per annum. The 2018 Notes carried both a voluntary conversion feature and an automatic conversion feature. Under the terms of the 2018 Notes,
the 2018 Notes were automatically converted into shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock at price per share equal to between 50% and 80% of the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock
price of $2.28 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In June 2019, the Company commenced an offering to issue up to $3.0&nbsp;million of convertible
notes (the &#147;2019 Notes&#148;) to certain investors with a maturity date in June 2020, which was subsequently extended to December&nbsp;31, 2020. In June 2019, the Company issued an initial $1.5&nbsp;million of convertible notes. Subsequently,
the Company issued an additional $1.5&nbsp;million of convertible notes in December 2019. The 2019 Notes were secured by specific assets of the Company and carried an interest rate of 8.0% per annum. The 2019 Notes carried both a voluntary
conversion feature and an automatic conversion feature. Under the terms of the 2019 Notes, the 2019 Notes were optionally converted into shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock at price per share equal to 80% of
the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock price of $2.28 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company elected the
fair value option to account for the Notes, whereby the Company recognized the Notes as liabilities at fair value, with subsequent changes in the fair value recognized in other income (expense), net on the consolidated statements of operations and
comprehensive loss. At issuance, the fair value of the 2019 Notes and 2018 Notes was determined to be $1.8&nbsp;million and $3.0&nbsp;million, respectively. The Company incurred an immaterial amount of fees related to the issuance of the Notes,
which was expensed to general and administrative expense on the consolidated statements of operations and comprehensive loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In October 2020, the Company entered into the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock purchase
agreement (the &#147;Series <FONT STYLE="white-space:nowrap">A-1</FONT> Agreement&#148;). As part of the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock issuance, the Company settled the outstanding principal of the 2018 Notes and
2019 Notes of $4.8&nbsp;million plus accrued interest of $0.4&nbsp;million through the issuance of 3,106,561 shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company had no debt outstanding as of December&nbsp;31, 2021. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Convertible Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In October 2020, the Board of Directors (the &#147;Board&#148;) authorized the sale and issuance of Series <FONT
STYLE="white-space:nowrap">A-1</FONT> Preferred Stock in three closings. In October 2020, as part of the first closing of the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, the Company issued 1,315,789 shares of Series <FONT
STYLE="white-space:nowrap">A-1</FONT> Preferred Stock with a par value of $0.001 and a purchase price of $2.28 per share, and an additional 3,106,561 shares of the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock upon conversion of
the Company&#146;s convertible notes (see Note 8). The second and third closings of the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock financing were dependent upon the Company&#146;s successful completion of future
science-driven milestone events, such as entering into <FONT STYLE="white-space:nowrap">in-licensing</FONT> agreements, contracting with a CRO to conduct phase 2 clinical trials, and identifying compounds for lead drug candidates. The obligations to
issue additional shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock in subsequent financings, or Preferred Stock Tranche Rights, were recorded as a liability (see Note 3). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In January 2021, upon effectiveness of the Lilly Agreement, the Company completed the second and third closings and issued an
aggregate of 5,482,456 shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock. Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock issued in the second and third closings had a par value of $0.001 and had a
purchase price of $2.28 per share, which was equal to fair value as estimated by the Company&#146;s management by taking into consideration the results obtained from a third-party valuation, among other factors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company incurred issuance costs of $0.2&nbsp;million in connection with these transactions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Series B Preferred Stock </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In November 2021, the Board authorized the sale and issuance of Series B Preferred Stock. In November 2021, the Company issued
17,521,047 shares of Series B Preferred Stock, with a par value of $0.001 and a purchase price of $5.70742 per share, and an additional 46,058 shares of Series B Preferred Stock to settle the Company&#146;s Anti-dilution Right in connection with the
Lilly Agreement (see Note 3). The Company incurred issuance costs of $0.2&nbsp;million in connection with this transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the issuance of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock and Series B Preferred Stock
(collectively, &#147;Preferred Stock&#148;), the Company assessed the embedded conversion and liquidation features of the shares and determined that such features did not require the Company to separately account for these features. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Preferred Stock consisted of the following as of the dates presented (in thousands, except share amounts): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred<BR>Stock<BR>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred Stock<BR>Issued and<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Liquidation<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock<BR>Issuable Upon<BR>Conversion</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,904,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,904,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,016,545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,567,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,567,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,123,717</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,471,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,471,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">122,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">122,846</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,140,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="20"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred<BR>Stock<BR>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred&nbsp;Stock<BR>Issued and<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Liquidation<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common&nbsp;Stock<BR>Issuable Upon<BR>Conversion</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A-1 Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,685,508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,422,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,793,328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,685,508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,422,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,793,328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The holders of Preferred Stock have the following rights, preferences and
privileges: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Voting </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The holder of each share of Preferred Stock is entitled to one vote for each share of common stock into which it would convert
and to vote with the common stock on all matters. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Conversion </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each share of Preferred Stock is convertible, at the option of the holder, at any time and from time to time, and without the
payment of additional consideration by the holder thereof, into such number of fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of common stock as is determined by dividing the original issue price by the conversion price
for each series of Preferred Stock (as defined below). The conversion price, and the rate at which each series of preferred stock may be converted into common stock, are subject to adjustment from time to time to reflect future share dividends,
splits, combinations, recapitalizations and similar events. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Further, each share of Preferred Stock shall
automatically be converted into shares of common stock at the conversion rate at the time in effect for such series of Preferred Stock immediately upon either of: (i)&nbsp;the closing of the Company&#146;s sale of common stock to the public at a
price per share of at least $28.1489 per share in an IPO (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the applicable class of common stock),
resulting in at least $50.0&nbsp;million of proceeds, net of the underwriting discount and commissions; or (ii)&nbsp;the date and time, or occurrence of an event, specified by vote or written consent of the requisite holders of at a majority of the
combined voting power of the shares of Preferred Stock then outstanding as calculated on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to common stock basis. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Dividends </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The holders of
the Preferred Stock are entitled to receive dividends at the rate of 6% of the applicable original issue price per annum, as potentially adjusted for certain <FONT STYLE="white-space:nowrap">non-dilutive</FONT> transactions. Dividends shall not be
cumulative or compounded and shall be payable only when, as and if declared by the Board and in preference and in priority to any dividends on common stock. There have been no dividends declared by the Board as of December&nbsp;31, 2021. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Liquidation Preference </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the event of any liquidation, dissolution, or winding up of the Company (&#147;Liquidation Event&#148;), the holders of
Preferred Stock (first to the holders of Series B Preferred Stock, then to the holders of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock) are entitled to receive prior and in preference to the holders of common stock, an amount
equal to an amount per share equal to the greater of the original issue price, as potentially adjusted for certain <FONT STYLE="white-space:nowrap">non-dilutive</FONT> transactions, plus all declared and unpaid dividends on the Preferred Stock or
the price per share that would be received if the Preferred Stock were converted to common stock. If the assets and funds available to be distributed to all holders of Preferred Stock are insufficient to permit the payment, in full, of any of the
liquidation preferences, then the entire assets and funds legally available for distribution to holders of the Preferred Stock shall be distributed ratably among the holders of Preferred Stock, acting as a single class, at the time outstanding,
ratably in proportion to the full amounts to which they would otherwise be respectively entitled. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">After the payment of
the full liquidation preference of the Preferred Stock as set forth above, the remaining assets of the Company legally available for distribution in such Liquidation Event shall be distributed ratably to the holders of shares of common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Redemption </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Preferred Stock does not have redemption rights, except for the contingent redemption upon the occurrence of a Liquidation
Event. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December&nbsp;31, 2021 and 2020, the Company&#146;s Amended and Restated Certificate of Incorporation authorized the
Company to issue 40,013,683 and 20,000,000 shares of common stock, respectively, with a par value of $0.001. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The voting,
dividend and liquidation rights of the holders of the Company&#146;s common stock are subject to and qualified by the rights, powers and preferences of the holders of the Preferred Stock as set forth above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The holders of the common stock are entitled to one vote for each share of common stock held at all meetings of stockholders
(and written actions in lieu of meetings), and there are not any cumulative voting rights. The number of authorized shares of common stock may be increased or decreased by the affirmative vote of the holders of shares of capital stock of the
Company; however, the issuance of common stock may be subject to the vote of the holders of one or more series of preferred stock that may be required by terms of the Certificate of Incorporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December&nbsp;31, 2021, and 2020, the Company has reserved the following shares of common stock for the potential
conversion of outstanding preferred stock and exercise of stock options: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred Stock, as converted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,140,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,793,328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">881,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Remaining shares reserved for future issuance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,194,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">899,266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,216,779</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,739,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Stock-Based Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2019 Stock Incentive Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company adopted the 2019 Stock Incentive Plan (the &#147;2019 Plan&#148;) in June 2019 pursuant to which the Company can
issue incentive stock options, <FONT STYLE="white-space:nowrap">non-statutory</FONT> stock options, stock appreciation rights, restricted stock, restricted stock units, and other stock-based awards. Recipients of stock options or stock appreciation
rights shall be eligible to purchase shares of the Company&#146;s common stock at an exercise price equal to the estimated fair market value of such stock on the date of grant. The exercise price may be less than fair market value if the stock award
is granted pursuant to an assumption or substitution for another stock award in the event of a merger or sale of the Company. The maximum term of options granted under the 2019 Plan is ten years, and stock options typically vest over a four-year
period. The Board may assign vesting terms to the stock option grants as deemed appropriate. The Company has the option to repurchase any unvested shares at the original purchase price upon any voluntary or involuntary termination. At the discretion
of the Board, unvested shares held by employees may accelerate vesting in the event of a change of control of the Company unless assumed or substituted by the acquirer or surviving entity. The 2019 Plan provided for the issuance of up to 422,749
shares of common stock, which was subsequently amended in November 2021 to allow for the issuance of up to 3,077,023 shares of common stock as of December&nbsp;31, 2021, of which 2,194,906 shares of common stock remain available for future grant
under the 2019 Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Shares of unused common stock that cover awards that are expired,
terminated, surrendered or canceled under the 2019 Plan without having been fully exercised will be available for future awards. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Options
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company has granted stock options with service-based vesting conditions. Stock options typically vest over
four years and have a maximum term of ten years. The Company typically grants stock options to employees and <FONT STYLE="white-space:nowrap">non-employees</FONT> at exercise prices deemed by the Board to be equal to the fair value of the common
stock at the time of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The assumptions that the Company used in the Black-Scholes option-pricing model to determine
the grant date fair value of stock options granted were as follows. No options were granted in the year ended December&nbsp;31, 2020. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate range</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">0.49%&nbsp;-&nbsp;1.33%</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected life of options (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">5.0&nbsp;-&nbsp;6.2</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility rate range</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">70.77%&nbsp;-&nbsp;79.18%</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of common stock range</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">$1.04&nbsp;-&nbsp;$3.88</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes the Company&#146;s stock option activity under the 2019
Plan: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number<BR>of Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Weighted-Average</FONT><BR>Exercise Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Weighted-Average</FONT><BR>Remaining<BR>Contractual Term<BR>(in years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate&nbsp;Intrinsic<BR>Value<BR>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">859,712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(506</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited or canceled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,228</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">881,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,008</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested and expected to vest as of December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">881,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,008</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested and exercisable as of December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">433,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The aggregate intrinsic value of options is calculated as the difference between the
exercise price of the stock options and the fair value of the Company&#146;s common stock for those stock options that had exercise prices lower than the fair value of the common stock as of the end of the reporting period. There was no aggregate
intrinsic value of options exercised during the years ended December&nbsp;31, 2021 and 2020. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The weighted-average
grant date fair value of the Company&#146;s stock options granted during the year ended December&nbsp;31, 2021 was $1.04 per option. As of December&nbsp;31, 2021, there was $0.4&nbsp;million of unrecognized stock-based compensation expense related
to the share-based compensation arrangements under the 2019 Plan. The Company expects to recognize this amount over a weighted-average period of 2.6 years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The total fair value of options vested during the years ended December&nbsp;31, 2021 and 2020, was $0.5&nbsp;million and an
insignificant amount, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Stock-based compensation expense included in the Company&#146;s consolidated statements of operations and comprehensive loss is
as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">497</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. Income Taxes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For the years ended December&nbsp;31, 2021 and 2020, the Company recorded no income tax benefits for the net operating losses
incurred or for the research and development tax credits generated in each period, due to its uncertainty of realizing a benefit from those items. The Company&#146;s operating losses since inception have been generated in the United States and
Sweden. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Loss before provision for income taxes consisted of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Deferred Tax Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating loss carryforward</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">R&amp;D credit carryovers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capitalized licenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accruals and reserves</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,097</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,588</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,199</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Deferred Tax Liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fixed and intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(73</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT>
asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,436</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,509</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following reconciles the differences between income taxes computed at the federal
statutory rate and the provision for income taxes: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax effected at statutory rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other permanent adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible notes revaluation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9.3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal R&amp;D credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26.9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14.2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company has had no income tax expense due to operating losses incurred
since inception. The Company has evaluated the positive and negative evidence bearing upon the reliability of its deferred tax assets. Based on this, the Company has provided a valuation allowance for the full amount of the net deferred tax assets
as the realization of the deferred tax assets is not determined to be more likely than not. During the years ended December&nbsp;31, 2021 and 2020, the valuation allowance increased by $4.4&nbsp;million and $0.7&nbsp;million, respectively, primarily
due to the increase in the Company&#146;s net operating loss carryovers (&#147;NOLs&#148;) during the period. The changes in the valuation allowance were as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance at beginning of the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increases (decreases) recorded to income tax provision</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance at end of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December&nbsp;31, 2021, the Company had $13.9&nbsp;million and $12.3&nbsp;million of
federal and state operating loss carryforwards, respectively. The federal NOLs are not subject to expiration and the state NOLs begin to expire in 2038. These loss carryforwards are available to reduce future federal taxable income, if any. These
loss carryforwards are subject to review and possible adjustment by the appropriate taxing authorities. The amount of loss carryforwards that may be utilized in any future period may be limited based upon changes in the ownership of the
company&#146;s ultimate parent. The Company has not conducted a Section&nbsp;382 study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception due to the significant complexity and
cost associated with such a study. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On December&nbsp;18, 2015, the Protecting Americans from Tax Hikes (&#147;PATH&#148;)
Act of 2015 was signed into law. The PATH Act has created several R&amp;D credit provisions, including allowing qualified small business to utilize the research credit against the employer portion of payroll tax (i.e., FICA tax) not exceeding
$250,000 per year. This provision is available for credits generated in tax years beginning after 2015. The company qualifies as small business for 2021, and will elect to make a small business election. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company follows the provisions of ASC <FONT STYLE="white-space:nowrap">740-10,</FONT> &#147;Accounting for Uncertainty in
Income Taxes,&#148; which specifies how tax benefits for uncertain tax positions are to be recognized, measured, and recorded in financial statements; requires certain disclosures of uncertain tax matters; specifies how reserves for uncertain tax
positions should be classified on the balance sheet; and provides transition and interim period guidance, among other provisions. As of December&nbsp;31, 2021 and 2020, the Company has not recorded any amounts for uncertain tax positions. As of
December&nbsp;31, 2021 and 2020, the Company had no reserves for uncertain tax positions. For the years ended December&nbsp;31, 2021 and 2020, no estimated interest or penalties were recognized on uncertain tax positions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s tax returns for the years ended December&nbsp;31, 2018 to December&nbsp;31, 2021 remain open and subject to
examination by the Internal Revenue Service, state, and applicable foreign taxing authorities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. Net Loss per Share </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share
and per share amounts): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders - basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,243</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,306</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of common shares used in net loss per share - basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,743,382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,432,480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share - basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9.32</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3.70</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s potentially dilutive securities, which include Preferred Stock and
stock options, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and
diluted net loss per share attributable to common stockholders is the same. The Company excluded the following shares from the computation of diluted net loss per share attributable to common stockholders as of December&nbsp;31, 2021 and 2020
because including them would have had an anti-dilutive effect: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,471,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,422,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">881,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. Commitments and Contingencies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Leases </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
Company&#146;s commitments under its operating leases are described in Note 6. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>License Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company entered into a license agreement under which it is obligated to make fixed and contingent payments (see Note 7).
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Indemnification Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors,
business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has
entered into indemnification agreements with members of its board of directors that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or services as directors. The
maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The
Company is not currently aware of any indemnification claims and had not accrued any liabilities related to such obligations in its financial statements as of December&nbsp;31, 2021 and 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Legal Proceedings </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">From time to time, in the ordinary course of business, the Company is subject to litigation and regulatory examinations as well
as information gathering requests, inquiries and investigations. As of December&nbsp;31, 2021 and 2020, there were no matters which would have a material impact on the Company&#146;s financial results. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Contracts </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company enters into contracts in the normal course of business with various third parties for preclinical research studies,
clinical trials, testing, manufacturing and other services. These contracts generally provide for termination upon notice and are cancelable without significant penalty or payment, and do not contain any minimum purchase commitments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. Employee Benefit Plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Effective January&nbsp;1, 2019, the Company adopted a 401(k) Plan for its employees, which is designed to be qualified under
Section&nbsp;401(k) of the Internal Revenue Code. Eligible employees are permitted to contribute to the 401(k) Plan within statutory and 401(k) Plan limits. Since inception of the 401(k) Plan and through the year ended December&nbsp;31, 2021 the
Company has not made any contributions to the 401(k) Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16. Related Party Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The chief executive officer of the Company received a payment of $0.2&nbsp;million from the Company during the year ended
December&nbsp;31, 2020, which was recorded as a general and administrative expense. The payment was in accordance with a founder patent license agreement, executed in April 2018, that granted an exclusive, worldwide, irrevocable, perpetual,
royalty-free license under certain licensed patents for any and all purposes and uses, including without limitation and rights to sublicense through multiple tiers, for the reimbursement of agreed, estimated unreimbursed expenses incurred by the
chief executive officer prior to the effective date of such agreement with respect to the preparation, filing, prosecution, protection and maintenance of certain licensed patents. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17. Subsequent Events </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For its annual consolidated financial statements as of December&nbsp;31, 2021 and for the year then ended, the Company
evaluated subsequent events through August&nbsp;12, 2022, the date on which those financial statements were issued, and, with respect to the reverse stock split described below, through November 3, 2022. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Option Grants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In March 2022, the Company granted options for the purchase of an aggregate of 710,709 shares of common stock, at an exercise
price of $3.88 per share. The aggregate grant-date fair value of the options granted is $1.8&nbsp;million, which is expected to be recognized as stock-based compensation expense over a weighted-average period of 3.8 years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In June 2022, the Company granted options for the purchase of an aggregate of 486,613 shares of common stock, at an exercise
price of $3.63 per share. The aggregate grant-date fair value of the options granted is $1.3&nbsp;million, which is expected to be recognized as stock-based compensation expense over a weighted-average period of 3.8 years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In August 2022, the Company granted options for the purchase of an aggregate 166,259 shares of common stock, at an exercise
price of $4.07 per share. The aggregate grant-date fair value of the options granted is $0.5&nbsp;million, which is expected to be recognized as stock-based compensation expense over a weighted-average period of 4.0 years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Companion Diagnostic Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In June 2022, the Company entered into a Companion Diagnostic Agreement (the &#147;Akoya Agreement&#148;) with Akoya
Biosciences, Inc. (&#147;Akoya&#148;). Pursuant to the Akoya Agreement, Akoya has agreed to co-develop, validate, and commercialize the Company&#146;s proprietary ACR-368 OncoSignature test, the companion diagnostic that will be used to identify
patients with cancer most likely to respond to ACR-368. Subject to the terms of the Akoya Agreement, the Company paid Akoya a <FONT STYLE="white-space:nowrap">one-time,</FONT> <FONT STYLE="white-space:nowrap">non-refundable,</FONT> <FONT
STYLE="white-space:nowrap">non-creditable</FONT> upfront payment in the amount of $0.6&nbsp;million. The Company is obligated to pay Akoya up to an aggregate of $10.3 million upon the achievement of specified development milestones. To date,
development milestones have been achieved under the Akoya Agreement, resulting in aggregate payments of $2.0&nbsp;million by the Company to Akoya. In addition, the Company will reimburse Akoya for certain pass-through costs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Reverse Stock Split </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On November&nbsp;1, 2022, the Company effected a 1-for-2.466 reverse stock split of its issued and outstanding shares of common
stock and a proportional adjustment to the existing conversion ratios of each series of the Company&#146;s preferred stock (see Note 9). Accordingly, all share and per share amounts for all periods presented in the accompanying consolidated
financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect this stock split and adjustment of the preferred stock conversion ratios. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc1"></A><A NAME="toc1"></A>INDEX TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Unaudited Condensed Consolidated Financial Statements for the Six Months Ended June&nbsp;30, 2022 and 2021: </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin383050_7">Condensed Consolidated Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-34</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin383050_8">Condensed Consolidated Statements of Operations and Comprehensive
Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-35</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin383050_9">Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders&#146;
 Deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-36</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin383050_10">Condensed Consolidated Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-37</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin383050_11">Notes to Condensed Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-38</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ACRIVON THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin383050_7"></A>CONDENSED CONSOLIDATED BALANCE SHEETS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(UNAUDITED) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands,
except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 83,861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 99,603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">805</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,080</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 94,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">106,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities, convertible preferred stock and stockholders&#146; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 964</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">706</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">664</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities, long-term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,964</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies (Note 12)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock, par value $0.001;
9,904,806 shares authorized, issued and outstanding as of June&nbsp;30, 2022 and December&nbsp;31, 2021; liquidation preference of $22.6&nbsp;million as of June&nbsp;30, 2022.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B convertible preferred stock, par value $0.001; 17,567,105 shares authorized, issued and
outstanding as of June&nbsp;30, 2022 and December&nbsp;31, 2021; liquidation preference of $100.3 million as of June&nbsp;30, 2022.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, par value $0.001; 40,013,683 shares authorized as of June&nbsp;30, 2022 and
December&nbsp;31, 2021; 1,769,561 shares issued and outstanding as of June&nbsp;30, 2022 and December&nbsp;31, 2021.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37,905</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,865</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(36,576</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,809</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities, convertible preferred stock and stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 94,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">106,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these condensed consolidated financial statements.
</I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ACRIVON THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin383050_8"></A>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(UNAUDITED) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands,
except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 10,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 8,448</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,137</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,243</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of preferred stock tranche rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of anti-dilution right</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(208</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(217</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,040</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,460</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7.37</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5.50</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average common stock outstanding&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,769,561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,718,569</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these condensed consolidated financial statements.
</I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ACRIVON THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin383050_9"></A>CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#146; DEFICIT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(UNAUDITED) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands,
except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Convertible Preferred<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-In</FONT><BR>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholders&#146;<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at December&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,471,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">122,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,769,561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(24,865</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,809</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,040</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,040</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at June&nbsp;30, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,471,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">122,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,769,561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(37,905</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(36,576</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="8"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="8"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Convertible Preferred<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-In</FONT><BR>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholders&#146;<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at December&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,422,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 9,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,432,480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,622</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,413</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of common stock related to license agreement with Eli Lilly</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">336,575</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock, net of
issuance costs of $33</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,321,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock related
to settlement of preferred stock tranche rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">161,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,460</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,460</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at June&nbsp;30, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,904,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,769,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,082</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,358</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these condensed consolidated financial statements.
</I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ACRIVON THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin383050_10"></A>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(UNAUDITED) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands)
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2022&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from operating activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,040</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,460</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> lease expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">License agreement paid for with common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anti-dilution right assumed with license agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of preferred stock tranche rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of anti-dilution right</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain upon extinguishment of PPP loan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(58</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,496</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(320</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(185</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,242</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,041</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from investing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,489</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(101</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,489</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(101</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred stock in
second and <BR>third closings, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payments of deferred offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash (used in) provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (decrease) increase in cash, cash equivalents, and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,742</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash at beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash at end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 84,249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 6,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosure of <FONT STYLE="white-space:nowrap">non-cash</FONT> investing and
financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of preferred stock tranche rights recognized as Series
<FONT STYLE="white-space:nowrap">A-1</FONT> preferred stock upon issuance of milestone shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment included in accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental cash flow information:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT>
assets obtained in exchange for operating lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred offering costs in accounts payable and accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Reconciliation of cash, cash equivalents, and restricted cash:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">83,861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,908</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cash, cash equivalents, and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 84,249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 6,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these condensed consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ACRIVON THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin383050_11"></A>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(UNAUDITED) </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Nature of the Business
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Acrivon Therapeutics, Inc., (the &#147;Company&#148;) is a clinical stage biopharmaceutical company developing
oncology medicines that the Company matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The Company&#146;s pipeline includes the Phase
2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase,
and PKMYT1, a closely related protein serine/threonine kinase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company was incorporated in March 2018 under the laws
of the state of Delaware, and its principal offices are in Watertown, Massachusetts. Also in March 2018, the Company formed Acrivon AB, a wholly-owned subsidiary of the Company, established in Lund, Sweden. In December 2021, the Company formed
Acrivon Securities Corporation, a wholly-owned subsidiary, established in Massachusetts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt
about the Company&#146;s ability to continue as a going concern within one year after the date the accompanying condensed consolidated financial statements were issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As an emerging growth entity, the Company has devoted substantially all of its resources since inception to organizing and
staffing the Company, business planning, raising capital, establishing its intellectual property portfolio, acquiring or discovering drug candidates, research and development activities for <FONT STYLE="white-space:nowrap">ACR-368</FONT> and other
compounds, establishing arrangements with third parties for the manufacture of its drug candidates and component materials, and providing general and administrative support for these operations. As a result, the Company has incurred significant
operating losses and negative cash flows from operations since its inception and anticipates such losses and negative cash flows will continue for the foreseeable future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Since its inception, the Company has funded its operations primarily with proceeds from the sales of shares of its convertible
preferred stock and the issuance of convertible notes. The Company has incurred recurring losses since its inception, including net losses of $13.0&nbsp;million and $9.5&nbsp;million for the six months ended June&nbsp;30, 2022, and 2021,
respectively. As of June&nbsp;30, 2022, the Company had an accumulated deficit of $37.9&nbsp;million. To date, the Company has not generated any revenues and expects to continue generating operating losses for the foreseeable future as it continues
to expand its research and development efforts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company expects that its existing cash and cash equivalents of
$83.9&nbsp;million as of June&nbsp;30, 2022 will be sufficient to fund its operating expenses and capital expenditure requirements for at least twelve months from the date these condensed consolidated financial statements were issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company will need additional funding to support its planned operating activities. There can be no assurances, however,
that the current operating plan will be achieved or that additional funding will be available on terms acceptable to the Company, or at all. If the Company is unable to obtain sufficient funding, it could be required to delay its development
efforts, limit activities and reduce research and development costs, which could adversely affect its business prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company is seeking to complete an initial public offering (&#147;IPO&#148;) of its common stock. Immediately prior to the
closing of a qualifying public offering on specified terms, the Company&#146;s outstanding convertible preferred stock will convert into common stock (see Note 8). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the event the Company does not complete an IPO, the Company expects to
seek additional funding through private equity financings, government or private-party grants, debt financings or other capital sources, including collaborations with other companies or other strategic transactions. The Company may not be able to
obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborations or other arrangements. The terms of any financing may adversely affect the holdings or rights of the Company&#146;s stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If the Company is unable to obtain sufficient capital, the Company will be forced to delay, reduce or eliminate some or all of
its research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations. Although management continues to pursue
these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The accompanying condensed consolidated financial statements do not include any adjustments relating to the recoverability and
classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. Accordingly, the condensed consolidated financial statements have been prepared on a basis that assumes
the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">COVID-19</FONT> Considerations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In March 2020, the World Health Organization declared the outbreak of the novel coronavirus,
<FONT STYLE="white-space:nowrap">COVID-19,</FONT> a pandemic. The pandemic has resulted in the closing of borders, enhanced health screenings, health care service preparation and delivery, quarantines, cancellations, disruptions to supply chains, as
well as general concern and uncertainty. The Company cannot predict the future progression or full impact of the outbreak and its effects on the Company&#146;s business and operations. Additionally, <FONT STYLE="white-space:nowrap">COVID-19</FONT>
has resulted in substantial market volatility and may result in a significant economic downturn. The Company will continue to actively monitor the current international and domestic impacts of and responses to
<FONT STYLE="white-space:nowrap">COVID-19</FONT> and its related risks. The Company considered the potential effects of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on its financial statements and noted that there is no material
effect on the condensed consolidated financial statements as of June&nbsp;30, 2022 and 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Summary of Significant Accounting Policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s significant accounting policies are disclosed in the audited financial statements for the years ended
December&nbsp;31, 2021 and 2020, included elsewhere in this prospectus. There have been no changes to the Company&#146;s significant accounting policies, except as noted below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation and Consolidation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I></I></B>The accompanying consolidated financial statements have been prepared in conformity with accounting principles
generally accepted in the United States of America (&#147;U.S. GAAP&#148;) and include the operations of Acrivon Therapeutics, Inc. and its wholly-owned subsidiaries. All intercompany accounts, transactions and balances have been eliminated in
consolidation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The condensed consolidated interim financial statements have been prepared on the same basis as the
audited annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary for the fair presentation of the Company&#146;s financial position at June&nbsp;30, 2022 and
the results of its operations and its cash flows for the six months ended June&nbsp;30, 2022 and 2021. The condensed balance sheet as of December&nbsp;31, 2021 was derived from audited annual financial statements but does not include all disclosures
required by U.S. GAAP. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The results for the six months ended June&nbsp;30, 2022 are not necessarily
indicative of results to be expected for the full year or for any other subsequent interim period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently Adopted Accounting Pronouncements
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>ASU <FONT STYLE="white-space:nowrap">2019-12,</FONT> Simplifying the Accounting for Income Tax </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In December 2019, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2019-12,</FONT> <I>Simplifying the Accounting
for Income Tax</I> (&#147;ASU <FONT STYLE="white-space:nowrap">2019-12&#148;).</FONT> The standard contains several provisions that reduce financial statement complexity including removing the exception to the incremental approach for intra-period
tax expense allocation when a company has a loss from continuing operations and income from other items not included in continuing operations. The Company adopted this accounting standard as of January&nbsp;1, 2022, with no material impact on its
condensed consolidated financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Fair Value Measurement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following tables present information about the Company&#146;s financial assets and liabilities measured at fair value on a
recurring basis (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Value Measurements at June&nbsp;30, 2022 Using:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Level&nbsp;1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Level&nbsp;2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Level&nbsp;3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">79,104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">79,104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">79,104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">79,104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="12"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Value Measurements at December&nbsp;31, 2021 Using:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">79,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">79,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">79,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">79,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of June&nbsp;30, 2022 and December&nbsp;31, 2021, the Company&#146;s cash equivalents
consisted of money market funds, classified as Level&nbsp;1 financial assets, as these assets are valued using quoted market prices in active markets without any valuation adjustment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">During the six months ended June&nbsp;30, 2022 and year ended December&nbsp;31, 2021, there were no transfers between levels.
The Company uses the carrying amounts of its restricted cash, prepaid expenses and other current assets, accounts payable and accrued expenses to approximate their fair value due to the short-term nature of these amounts. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preferred Stock Tranche Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In October 2020, the Company issued Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock
(&#147;Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock&#148;). According to the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock subscription agreement, the Company was obligated to issue second and third
tranches of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock upon the Company&#146;s successful completion of future science-driven milestone events, such as entering into <FONT STYLE="white-space:nowrap">in-licensing</FONT>
agreements, contracting with a CRO to conduct phase 2 clinical trials, and identifying compounds for lead drug candidates. As a result, the Company&#146;s obligation to issue additional Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred
Stock was recognized as a tranche obligation (the &#147;Preferred Stock Tranche Rights&#148;), which was subject to revaluation at each balance sheet date. Changes in fair value were recorded as a component of other income (expense), net in the
consolidated statements of operations and comprehensive loss until the Preferred Stock Tranche Rights were settled. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company determined that the Preferred Stock Tranche Rights are
freestanding financial instruments. The freestanding financial instruments were classified as a liability on the Company&#146;s consolidated balance sheets and initially recorded at fair value. The liability was subsequently remeasured to fair value
at each reporting date until settled in January 2021,&nbsp;and changes in the fair value of the preferred stock tranche liability were recognized as a component of other income (expense) in the consolidated statements of operations and comprehensive
loss. The fair value of the Preferred Stock Tranche Rights was based on significant inputs not observable in the market, which represents a Level&nbsp;3 measurement within the fair value hierarchy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Preferred Stock Tranche Rights were valued as a forward contract. The value was determined using a probability-weighted
present value calculation. In determining the fair value of the tranche rights obligation, estimates and assumptions impacting the fair value included the per share estimated fair value of the Company&#146;s Series
<FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, discount rates, estimated time to tranche closing, and probability of each tranche closing. The Company determined the per share estimated fair value of the Series <FONT
STYLE="white-space:nowrap">A-1</FONT> Preferred Stock by back-solving to the initial proceeds of the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock financing. The Company remeasured the Preferred Stock Tranche Rights at each
reporting period and prior to the settlement of the Preferred Stock Tranche Rights in January 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following
reflects the ranges of significant quantitative inputs used in the valuation of the Preferred Stock Tranche Rights during the six months ended June&nbsp;30, 2021, which reflects the inputs used at remeasurement prior to settlement in January 2021:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended<BR>June&nbsp;30, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Implied fair value of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Discount rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Time to milestone event (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Probability of tranche closing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following provides a roll forward of the fair value of the Preferred Stock Tranche Rights
measured at fair value on a recurring basis using Level&nbsp;3 significant unobservable inputs (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value recognized as Series A-1 Preferred Stock upon settlement of Preferred Stock Tranche
Rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(368</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at June&nbsp;30, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Anti-dilution Right </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In accordance with a license agreement and stock issuance agreement between Eli Lilly and Company (&#147;Lilly&#148;) and the
Company (collectively, the &#147;Lilly Agreement&#148;) entered into in January 2021, the Company was obligated to issue capital stock in a subsequent financing to Lilly in order to maintain a specified, single-digit percentage ownership of the
Company upon specified conditions (the &#147;Anti-dilution Right&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company determined that the Anti-dilution
Right is a freestanding financial instrument. The freestanding financial instrument was classified as an asset or liability on the Company&#146;s consolidated balance sheets and initially recorded at fair value. The fair value of the Anti-dilution
Right was based on significant inputs not observable in the market, which represents a Level&nbsp;3 measurement within the fair value hierarchy. A change in the assumptions related to the valuation of the Anti-dilution Right could have a significant
impact on the value of the obligation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Anti-dilution Right was valued as a forward contract. The value was
determined using a probability-weighted present value calculation. In determining the fair values of the obligation, estimates and assumptions impacting fair value included the per share estimated fair value of the Company&#146;s Series B
convertible preferred stock (&#147;Series B Preferred Stock&#148;), discount rates, estimated time to share issuance and probability of each share issuance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Anti-dilution Right was subsequently revalued until anti-dilution shares were issued in November 2021, with changes in
fair value for each reporting period recognized in other income (expense), net in the consolidated statements of operations and comprehensive loss. Upon issuance of the anti-dilution shares, the fair value of the Anti-dilution Right was recognized
as Series B Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In full satisfaction of the Anti-dilution Right, the Company issued Lilly 46,058 shares of
Series B Preferred Stock in November 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following reflects the ranges of significant quantitative inputs used in
the valuation of the Anti-dilution Right during the six months ended June&nbsp;30, 2021: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended<BR>June&nbsp;30, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0%&nbsp;-&nbsp;0.1%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Discount rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47.5%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Implied issuance price of Series B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">0.84&nbsp;-&nbsp;$6.11</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Probability of settlement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">10%&nbsp;-&nbsp;40%</FONT></TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following provides a roll forward of the fair value of the Anti-dilution Right measured at
fair value on a recurring basis using Level&nbsp;3 significant unobservable inputs (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="93%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Anti-dilution Right</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of Anti-dilution Right</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at June&nbsp;30, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Property and Equipment, net </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Property and equipment, net consisted of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2022</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2021</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>


<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory and computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,087</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,259</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(179</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(56</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,080</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Depreciation expense related to property and equipment for the six months ended June&nbsp;30,
2022 and 2021 was $0.1&nbsp;million and $15,000, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Accrued Expenses and Other Current Liabilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Accrued expenses and other current liabilities consisted of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued compensation and benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 881</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued legal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred sublease income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Leases </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In April 2018, the Company entered into a lease agreement for laboratory and office space located at 700 N. Main Street,
Cambridge, Massachusetts. The lease term, which commenced in April 2018 and was set to expire in April 2020, was extended in March 2020 for an additional <FONT STYLE="white-space:nowrap">one-year</FONT> period. The lease was cancellable with 30
days&#146; notice. The Company elected the short-term lease measurement and recognition exemption under ASC 842 for the <FONT STYLE="white-space:nowrap">one-year</FONT> period extension and therefore did not recognize the lease on the Company&#146;s
condensed consolidated balance sheets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In September 2020, the Company entered into an operating lease agreement,
denominated in Swedish Krona, for office space located in Lund, Sweden. The term of the lease commenced in October 2020 and is scheduled to expire in September 2023, with lease payments being made on a quarterly basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In December 2020, the Company entered into a lease agreement for laboratory and office space located at 480 Arsenal Way,
Watertown, Massachusetts (the &#147;Arsenal Way Lease&#148;). The term of the lease commenced in April 2021. The lease has an initial term from the rent commencement date, which is a month after the lease commencement date, of approximately seven
years, with an option to extend the term for an additional five years at then-market rental rates. In connection with the execution of the lease agreement, the Company delivered a letter of credit of $0.3&nbsp;million to the landlord, which is
included in restricted cash in the accompanying condensed consolidated balance sheets. The landlord contributed an aggregate of $0.7&nbsp;million toward the cost of tenant improvements for the premises. Under the terms of the lease, the base rent is
$1.0&nbsp;million, subject to a 3% annual rent increase, plus an allocation of operating expenses and taxes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In May 2021,
the Company entered into an agreement to sublease 6,330 rentable square feet of its Arsenal Way Lease to a subtenant through March 2023. Sublease income is recognized on a straight-line basis over the term of the sublease agreement. Sublease rent
income was $0.4&nbsp;million and an insignificant amount for the six months ended June&nbsp;30, 2022 and 2021, respectively, which was allocated and recorded as a reduction to general and administrative expenses and research and development
expenses. The Company was not relieved of its primary obligation under the Arsenal Way Lease as a result of the sublease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company recognizes monthly operating lease expense on a straight-line basis over the term of the lease as research and
development or general and administrative expenses in the condensed consolidated statement of operations and comprehensive loss. Variable lease expense relates primarily to office lease common area maintenance, insurance, and property taxes, is
expensed as incurred, and is excluded from the calculation of the lease liabilities and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use-assets.</FONT></FONT></FONT> Variable lease
expense for the six months ended June&nbsp;30, 2022 and 2021 was $0.3&nbsp;million and $0.1&nbsp;million, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes the presentation of the Company&#146;s
operating leases on its condensed consolidated balance sheet (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Leases</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Balance sheet classification</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,&nbsp;2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Operating lease <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total lease assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Operating lease liability, current</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 706</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 664</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Noncurrent:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Operating lease liability, long-term</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,964</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,628</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The components of lease cost under ASC 842 included within research and development expenses
and general and administrative expenses in the Company&#146;s condensed consolidated statement of operations and comprehensive loss for the six months ended June&nbsp;30, 2022 were as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Lease cost</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2022&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Variable lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sublease income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(269</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 564</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of June&nbsp;30, 2022 and 2021, the weighted-average remaining lease term for operating
leases was 5.8 years and 6.6 years, respectively, and the weighted-average discount rate was 7.85% and 7.79%, respectively. Cash paid for amounts included in the measurement of lease liabilities was $0.5&nbsp;million and $0.3&nbsp;million for the
six months ended June&nbsp;30, 2022 and 2021, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Future minimum annual lease commitments under the
Company&#146;s <FONT STYLE="white-space:nowrap">non-cancellable</FONT> operating leases as of June&nbsp;30, 2022 were as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Year ended December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022 (remaining 6 months)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,087</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,628</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,320</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Present value of operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 5,308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. License Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In January 2021, the Company entered into a license agreement and stock issuance agreement (collectively, the &#147;Lilly
Agreement&#148;) with Eli Lilly and Company (&#147;Lilly&#148;), pursuant to which the Company has been granted an exclusive, royalty-bearing sublicensable license to certain patents owned or controlled by Lilly, to commercially develop,
manufacture, use, distribute and sell therapeutic products containing the compound prexasertib. The license from Lilly comprises three families of patent filings all relating to ACR-368. Additionally, pursuant to the Lilly Agreement, the Company
received ACR-368 drug substance and drug product to be used in future research. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As initial consideration for the license,
the Company made a <FONT STYLE="white-space:nowrap">one-time,</FONT> <FONT STYLE="white-space:nowrap">non-creditable,</FONT> <FONT STYLE="white-space:nowrap">non-refundable</FONT> upfront payment of $5.0&nbsp;million. As additional consideration for
the license, the Company is required to pay Lilly aggregate development and commercial milestone payments of up to $168.0 million, of which $5.0 million is due prior to a new drug application. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company is also obligated to pay a tiered percentage royalty on annual net sales ranging from single-digit up to a maximum
of 10%, subject to certain specified reductions. Royalties are payable by the Company on a licensed product-by-licensed product and country-by-country basis until the later of the expiration of the last valid claim covering the licensed product in
such country, expiration of all applicable regulatory exclusivities in such country for such licensed product and the tenth anniversary of the first commercial sale of such licensed product in such country, provided, that the Company&#146;s
obligation to pay royalties for a given licensed product in a given country will expire earlier upon achievement of certain sales thresholds by generic products in such country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to the cash consideration described above, the Company issued 336,575 shares of its common stock to Lilly in an
amount equal to 5.0% of the Company&#146;s capital stock on a fully diluted basis as of the date of the Lilly Agreement. The Company agreed to issue its capital stock to Lilly pursuant to the Anti-dilution Right. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In November 2021, the Company completed its Series B Preferred Stock financing. The financing triggered the settlement of the
Anti-dilution Right, resulting in the issuance of 46,058 shares of Series B Preferred Stock to Lilly with a then fair value of $0.3&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company determined that the Lilly Agreement represented an asset acquisition as substantially all of the fair value of the
gross assets acquired was concentrated in the group of IPR&amp;D assets, which all were similarly identifiable assets with no alternative future use and recognized the aggregate acquisition cost as acquired IPR&amp;D expense in the condensed
consolidated statements of operations and comprehensive loss. During the six months ended June&nbsp;30, 2021, the Company recognized $5.5&nbsp;million of research and development expense in connection with the consideration due under the Lilly
Agreement. The $5.5&nbsp;million consisted of (i) $0.2&nbsp;million initial recognition of the Anti-dilution Right, (ii) $0.3&nbsp;million fair value for the 336,575 shares of common stock issued to Lilly and (iii)&nbsp;the upfront cash
consideration for the license arrangement of $5.0&nbsp;million. To date, no milestones have been achieved and no royalties have been incurred related to the Lilly Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Convertible Preferred Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Series <FONT
STYLE="white-space:nowrap">A-1</FONT> Preferred Stock </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In October 2020, the Board of Directors (the &#147;Board&#148;)
authorized the sale and issuance of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock in three closings. In October 2020, as part of the first closing of the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, the
Company issued 1,315,789 shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock with a par value of $0.001 and a purchase price of $2.28 per share, and an additional 3,106,561 shares of the Series
<FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock upon conversion of the Company&#146;s convertible notes. The second and third closings of the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock financing were dependent
upon the Company&#146;s successful completion of future science-driven milestone events, such as entering </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
into <FONT STYLE="white-space:nowrap">in-licensing</FONT> agreements, contracting with a CRO to conduct phase 2 clinical trials, and identifying compounds for lead drug candidates. The
obligations to issue additional shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock in subsequent financings, or Preferred Stock Tranche Rights, were recorded as a liability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In January 2021, upon effectiveness of the Lilly Agreement, the Company completed the second and third closings and issued an
aggregate of 5,482,456 shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock. Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock issued in the second and third closings had a par value of $0.001 and had a
purchase price of $2.28 per share, which was equal to fair value as estimated by the Company&#146;s management by taking into consideration the results obtained from a third-party valuation, among other factors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company incurred issuance costs of $0.2&nbsp;million in connection with these transactions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Series B Preferred Stock </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In November 2021, the Board authorized the sale and issuance of Series B Preferred Stock. In November 2021, the Company issued
17,521,047 shares of Series B Preferred Stock, with a par value of $0.001 and a purchase price of $5.70742 per share, and an additional 46,058 shares of Series B Preferred Stock to settle the Company&#146;s Anti-dilution Right in connection with the
Lilly Agreement. The Company incurred issuance costs of $0.2&nbsp;million in connection with this transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the
issuance of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock and Series B Preferred Stock (collectively, &#147;Preferred Stock&#148;), the Company assessed the embedded conversion and liquidation features of the shares and
determined that such features did not require the Company to separately account for these features. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Preferred Stock
consisted of the following as of June&nbsp;30, 2022 and December&nbsp;31, 2021 (in thousands, except share amounts): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30, 2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred<BR>Stock<BR>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred&nbsp;Stock<BR>Issued&nbsp;and<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Liquidation<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common&nbsp;Stock<BR>Issuable Upon<BR>Conversion</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,904,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,904,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 22,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 22,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,016,545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,567,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,567,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,123,717</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,471,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,471,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">122,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">122,846</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,140,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="20"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December 31, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred<BR>Stock<BR>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred Stock<BR>Issued and<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Liquidation<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock<BR>Issuable Upon<BR>Conversion</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A-1 Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,904,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,904,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,016,545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,567,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,567,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,123,717</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,471,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,471,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">122,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">122,846</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,140,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The holders of Preferred Stock have the following rights, preferences and privileges:
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Voting </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The holder
of each share of Preferred Stock is entitled to one vote for each share of common stock into which it would convert and to vote with the common stock on all matters. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Conversion </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each share of Preferred Stock is convertible, at the option of the holder, at any time and from time to time, and without the
payment of additional consideration by the holder thereof, into such number of fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of common stock as is determined by dividing the original issue price by the conversion price
for each series of Preferred Stock (as defined below). The conversion price, and the rate at which each series of preferred stock may be converted into common stock, are subject to adjustment from time to time to reflect future share dividends,
splits, combinations, recapitalizations and similar events. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Further, each share of Preferred Stock shall
automatically be converted into shares of common stock at the conversion rate at the time in effect for such series of Preferred Stock immediately upon either of: (i)&nbsp;the closing of the Company&#146;s sale of common stock to the public at a
price per share of at least $28.1489 per share in an IPO (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the applicable class of common stock),
resulting in at least $50.0&nbsp;million of proceeds, net of the underwriting discount and commissions; or (ii)&nbsp;the date and time, or occurrence of an event, specified by vote or written consent of the requisite holders of at a majority of the
combined voting power of the shares of Preferred Stock then outstanding as calculated on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to common stock basis. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Dividends </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The holders of
the Preferred Stock are entitled to receive dividends at the rate of 6% of the applicable original issue price per annum, as potentially adjusted for certain <FONT STYLE="white-space:nowrap">non-dilutive</FONT> transactions. Dividends shall not be
cumulative or compounded and shall be payable only when, as and if declared by the Board and in preference and in priority to any dividends on common stock. There have been no dividends declared by the Board as of June&nbsp;30, 2022 and
December&nbsp;31, 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Liquidation Preference </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the event of any liquidation, dissolution, or winding up of the Company (&#147;Liquidation Event&#148;), the holders of
Preferred Stock (first to the holders of Series B Preferred Stock, then to the holders of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock) are entitled to receive prior and in preference to the holders of common stock, an amount
equal to an amount per share equal to the greater of the original issue price, as potentially adjusted for certain <FONT STYLE="white-space:nowrap">non-dilutive</FONT> transactions, plus all declared and unpaid dividends on the Preferred Stock or
the price per share that would be received if the Preferred Stock were converted to common stock. If the assets and funds available to be distributed to all holders of Preferred Stock are insufficient to permit the payment, in full, of any of the
liquidation preferences, then the entire assets and funds legally available for distribution to holders of the Preferred Stock shall be distributed ratably among the holders of Preferred Stock, acting as a single class, at the time outstanding,
ratably in proportion to the full amounts to which they would otherwise be respectively entitled. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">After the payment of
the full liquidation preference of the Preferred Stock as set forth above, the remaining assets of the Company legally available for distribution in such Liquidation Event shall be distributed ratably to the holders of shares of common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Redemption </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Preferred
Stock does not have redemption rights, except for the contingent redemption upon the occurrence of a Liquidation Event. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of June&nbsp;30, 2022 and December&nbsp;31, 2021, the Company&#146;s Amended and Restated Certificate of Incorporation
authorized the Company to issue 40,013,683 shares of common stock, respectively, with a par value of $0.001. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The voting, dividend and liquidation rights of the holders of the
Company&#146;s common stock are subject to and qualified by the rights, powers and preferences of the holders of the Preferred Stock as set forth above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The holders of the common stock are entitled to one vote for each share of common stock held at all meetings of stockholders
(and written actions in lieu of meetings), and there are not any cumulative voting rights. The number of authorized shares of common stock may be increased or decreased by the affirmative vote of the holders of shares of capital stock of the
Company; however, the issuance of common stock may be subject to the vote of the holders of one or more series of preferred stock that may be required by terms of the Certificate of Incorporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of June&nbsp;30, 2022 and December&nbsp;31, 2021, the Company has reserved the following shares of common stock for the
potential conversion of outstanding preferred stock and exercise of stock options: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred Stock, as converted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,140,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,140,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,072,851</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">881,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Remaining shares reserved for future issuance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,003,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,194,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,216,779</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,216,779</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Stock-Based Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2019 Stock Incentive Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company adopted the 2019 Stock Incentive Plan (the &#147;2019 Plan&#148;) in June 2019 pursuant to which the Company can
issue incentive stock options, <FONT STYLE="white-space:nowrap">non-statutory</FONT> stock options, stock appreciation rights, restricted stock, restricted stock units, and other stock-based awards. Recipients of stock options or stock appreciation
rights shall be eligible to purchase shares of the Company&#146;s common stock at an exercise price equal to the estimated fair market value of such stock on the date of grant. The exercise price may be less than fair market value if the stock award
is granted pursuant to an assumption or substitution for another stock award in the event of a merger or sale of the Company. The maximum term of options granted under the 2019 Plan is ten years, and stock options typically vest over a four-year
period. The Board may assign vesting terms to the stock option grants as deemed appropriate. The Company has the option to repurchase any unvested shares at the original purchase price upon any voluntary or involuntary termination. At the discretion
of the Board, unvested shares held by employees may accelerate vesting in the event of a change of control of the Company unless assumed or substituted by the acquirer or surviving entity. The 2019 Plan provided for the issuance of up to 422,749
shares of common stock, which was subsequently amended in November 2021 to allow for the issuance of up to 3,077,023 shares of common stock as of June&nbsp;30, 2022, of which 1,003,666 shares of common stock remain available for future grant under
the 2019 Plan. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Shares of unused common stock that cover awards that are expired, terminated, surrendered or canceled
under the 2019 Plan without having been fully exercised will be available for future awards. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Options </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company has granted stock options with service-based vesting conditions. Stock options typically vest over four years and
have a maximum term of ten years. The Company typically grants stock options to employees and <FONT STYLE="white-space:nowrap">non-employees</FONT> at exercise prices deemed by the Board to be equal to the fair value of the common stock at the time
of grant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes the Company&#146;s stock option activity
under the 2019 Plan: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Weighted-Average</FONT><BR>Exercise&nbsp;Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Weighted-Average</FONT><BR>Remaining<BR>Contractual Term<BR>(in years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Intrinsic&nbsp;Value<BR>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">881,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,008</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,197,322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited or canceled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,082</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of June&nbsp;30, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,072,851</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested and expected to vest as of June&nbsp;30, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,072,851</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested and exercisable as of June&nbsp;30, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">608,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,091</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The aggregate intrinsic value of options is calculated as the difference between the
exercise price of the stock options and the fair value of the Company&#146;s common stock for those stock options that had exercise prices lower than the fair value of the common stock as of the end of the reporting period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The weighted-average grant date fair value of the Company&#146;s stock options granted during the six months ended
June&nbsp;30, 2022 was $2.54 per option. As of June&nbsp;30, 2022, there was $3.1&nbsp;million of unrecognized stock-based compensation expense related to the share-based compensation arrangements under the 2019 Plan. The Company expects to
recognize this amount over a weighted-average period of 3.3 years. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The total fair value of options vested during the
six months ended June&nbsp;30, 2022 and 2021, was $0.2&nbsp;million and $0.1&nbsp;million, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation Expense
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Stock-based compensation expense included in the Company&#146;s condensed consolidated statements of operations
and comprehensive loss is as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2022&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Net Loss per Share </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share
and per share amounts): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,040</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,460</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of common shares used in net loss per share&#151;basic and
diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,769,561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,718,569</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7.37</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5.50</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s potentially dilutive securities, which include Preferred
Stock and stock options, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic
and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following shares from the computation of diluted net loss per share attributable to common stockholders as of June&nbsp;30, 2022 and 2021
because including them would have had an anti-dilutive effect: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,471,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,904,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,072,851</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">705,751</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. Commitments and Contingencies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Leases </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
Company&#146;s commitments under its operating leases are described in Note 6. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>License Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company entered into a license agreement under which it is obligated to make fixed and contingent payments (see Note 7).
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Companion Diagnostic Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In June 2022, the Company entered into a companion diagnostic agreement (the &#147;Akoya Agreement&#148;) with Akoya
Biosciences, Inc. (&#147;Akoya&#148;), pursuant to which the Company has engaged Akoya to co-develop, validate, and commercialize the Company&#146;s proprietary ACR-368 OncoSignature test, the companion diagnostic that will be used to identify
patients with cancer most likely to respond to ACR-368. Subject to the terms of the Akoya Agreement, the Company paid Akoya a one-time, non-refundable, non-creditable upfront payment in the amount of $0.6&nbsp;million. The Company is obligated to
pay Akoya up to an aggregate of $10.3 million upon the achievement of specified development milestones. Through the issuance date of the unaudited condensed consolidated financial statements, milestones under the Akoya Agreement were achieved and
the Company has made aggregate payments of $2.0&nbsp;million to Akoya. Of the $2.0&nbsp;million aggregate milestone payments, $1.6&nbsp;million, which was recorded as research and development expense, was paid through June&nbsp;30, 2022 and the
remaining $0.4&nbsp;million was paid in the third quarter of 2022 when an additional milestone was achieved. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Indemnification Agreements
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors,
lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the
Company has entered into indemnification agreements with members of its board of directors that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or services as
directors. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such
indemnifications. The Company is not currently aware of any indemnification claims and had not accrued any liabilities related to such obligations in its financial statements as of June&nbsp;30, 2022 and December&nbsp;31, 2021. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Legal Proceedings </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">From time to time, in the ordinary course of business, the Company is subject to litigation and regulatory examinations as well
as information gathering requests, inquiries and investigations. As of June&nbsp;30, 2022 and 2021, there were no matters which would have a material impact on the Company&#146;s financial results. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Contracts </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company enters into contracts in the normal course of business with various third parties for preclinical research studies,
clinical trials, testing, manufacturing and other services. These contracts generally provide for termination upon notice and are cancelable without significant penalty or payment, and do not contain any minimum purchase commitments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. Employee Benefit Plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Effective January&nbsp;1, 2019, the Company adopted a 401(k) Plan for its employees, which is designed to be qualified under
Section&nbsp;401(k) of the Internal Revenue Code. Eligible employees are permitted to contribute to the 401(k) Plan within statutory and 401(k) Plan limits. Since inception of the 401(k) Plan and through the six months ended June&nbsp;30, 2022, the
Company has not made any contributions to the 401(k) Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. Subsequent Events </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For its condensed consolidated financial statements as of the six months ended June&nbsp;30, 2022 and for the period then
ended, the Company evaluated subsequent events through August&nbsp;12, 2022, the date on which those financial statements were issued, and through November&nbsp;3, 2022, the date of the filing of the Company&#146;s registration statement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Option Grants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In August 2022, the Company granted options for the purchase of an aggregate 166,259 shares of common stock, at an exercise
price of $4.07 per share. The aggregate grant-date fair value of the options granted is $0.5&nbsp;million, which is expected to be recognized as stock-based compensation expense over a weighted-average period of 4.0 years. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Akoya Milestone Achievement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In September 2022, the Company achieved an additional development milestone under the Akoya Agreement and made a payment of
$0.3 million to Akoya. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amended and Restated Certificate of Incorporation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On October&nbsp;25, 2022, the Board approved the amended and restated certificate of incorporation, which will be filed upon
the closing of the IPO and which, among other things, increases the number of shares of common stock authorized for issuance from 40,013,683 to 500,000,000 shares of common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2022 Equity Incentive Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On October&nbsp;28, 2022, the Board adopted, and on November&nbsp;1, 2022 its stockholders approved, the 2022 Stock Option and
Incentive Plan (the &#147;2022 Plan&#148;), which will become effective on the date of the underwriting agreement related to this offering. The 2022 Plan allows the Company to make equity-based and cash-based incentive awards to its officers,
employees, directors, and consultants. The 2022 Plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock awards, restricted stock units and other stock-based awards. The number
of shares initially reserved for issuance under the 2022 Plan is 5,606,723 shares, which is the sum of: (i) 2,555,271 new shares, plus (ii) the number of shares that remain available for issuance under the 2019 Plan at the time the 2022 Plan becomes
effective and (iii) up to 2,148,679 shares of common stock subject to awards granted under the 2019 Plan that, after the effective date of the 2022 Plan, expire or otherwise terminate without having been exercised in full or are forfeited to or
repurchased. In addition, the number of shares reserved and available for issuance under the 2022 Plan will automatically increase on January&nbsp;1, 2023 and each January&nbsp;1 thereafter, by five percent of the aggregate number of shares of
common stock of all classes issued and outstanding on the immediately preceding December&nbsp;31 or such lesser number of shares as determined by the compensation committee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The shares of common stock underlying any awards under the 2022 Plan and
the 2019 Plan that are forfeited, canceled, held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding, reacquired by the Company prior to vesting, satisfied without the issuance of stock, expire, or are
otherwise terminated (other than by exercise) will be added back to the shares of common stock available for issuance under the 2022 Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2022
Employee Stock Purchase Plan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On October&nbsp;28, 2022, the Board adopted, and on November 1, 2022 its stockholders
approved, the 2022 Employee Stock Purchase Plan (the &#147;2022 ESPP&#148;), which will become effective on the date of the underwriting agreement related to this offering. A total of 215,000 shares of common stock were initially reserved for
issuance under this plan. The number of shares of common stock that may be issued under the 2022 ESPP shall cumulatively increase beginning on January&nbsp;1, 2023 and each January&nbsp;1 thereafter through January&nbsp;1, 2032, by one percent of
the outstanding number of shares of common stock on the immediately preceding December&nbsp;31 or such lesser number of shares as determined by the compensation committee. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Reverse Stock Split </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On November&nbsp;1, 2022, the Company effected a 1-for-2.466 reverse stock split of its issued and outstanding shares of common
stock and a proportional adjustment to the existing conversion ratios of each series of the Company&#146;s preferred stock (see Note&nbsp;8). Accordingly, all share and per share amounts for all periods presented in the accompanying consolidated
financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect this stock split and adjustment of the preferred stock conversion ratios. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><I>5,900,000
Shares </I></P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383050g44x13.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><I>Common Stock </I></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><I>PROSPECTUS </I></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:72pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:72pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:72pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:14pt" ALIGN="center">


<TR>

<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="29%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:14pt">
<TD VALIGN="top"><I>MORGAN&nbsp;STANLEY</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><I>JEFFERIES</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><I>COWEN</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><I>PIPER&nbsp;SANDLER</I></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;13. Other&nbsp;Expenses of Issuance and Distribution. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table indicates the expenses to be incurred in connection with the offering described in this registration
statement, other than underwriting discounts and commissions, all of which will be paid by us. All amounts are estimated except the Securities and Exchange Commission, or SEC, registration fee, the Financial Industry Regulatory Authority, Inc., or
FINRA, filing fee and the Nasdaq Global Market initial listing fee. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,820</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nasdaq listing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accountants&#146; fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">950,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,400,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer agent&#146;s fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing and engraving expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112,971</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,900,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>    <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;14. Indemnification of Directors and Officers. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are incorporated under the laws of the State of Delaware. Section&nbsp;102 of the Delaware General Corporation Law permits a
corporation to eliminate the personal liability of directors of a corporation to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his duty of loyalty, failed to
act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Section&nbsp;145 of the Delaware General Corporation Law provides that a corporation has the power to indemnify a director,
officer, employee or agent of the corporation and certain other persons serving at the request of the corporation in related capacities against expenses (including attorneys&#146; fees), judgments, fines and amounts paid in settlements actually and
reasonably incurred by the person in connection with an action, suit or proceeding to which he is or is threatened to be made a party by reason of such position, if such person acted in good faith and in a manner he reasonably believed to be in or
not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no
indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines
that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As permitted by the Delaware General Corporation Law, our amended and restated certificate of incorporation and bylaws to be
in effect upon the closing of this offering will provide that: (i)&nbsp;we are required to indemnify our directors to the fullest extent permitted by the Delaware General Corporation Law; (ii)&nbsp;we may, in our discretion, indemnify our officers,
employees and other agents as set forth in the Delaware General Corporation Law; (iii)&nbsp;we are required, upon satisfaction of certain conditions, to advance all expenses incurred </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
by our directors in connection with certain legal proceedings; (iv)&nbsp;the rights conferred in the bylaws are not exclusive; and (v)&nbsp;we are authorized to enter into indemnification
agreements with our directors, officers, employees and agents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In connection with this offering, we expect to enter into
indemnification agreements with each of our directors and executive officers that require us to indemnify them against expenses, judgments, fines, settlements and other amounts that any such person becomes legally obligated to pay (including with
respect to a derivative action) in connection with any proceeding, whether actual or threatened, to which such person may be made a party by reason of the fact that such person is or was a director or officer of us or any of our affiliates, provided
such person acted in good faith and in a manner such person reasonably believed to be in, or not opposed to, our best interests. The indemnification agreements will also set forth certain procedures that will apply in the event of a claim for
indemnification thereunder. At present, no litigation or proceeding is pending that involves any of our directors or officers regarding which indemnification is sought, nor are we aware of any threatened litigation that may result in claims for
indemnification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We maintain a directors&#146; and officers&#146; liability insurance policy. The policy insures
directors and officers against unindemnified losses arising from certain wrongful acts in their capacities as directors and officers and reimburses us for those losses for which we have lawfully indemnified the directors and officers. The policy
contains various exclusions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, the underwriting agreement filed as Exhibit 1.1 to this Registration Statement
provides for indemnification by the underwriters of us and our officers and directors for certain liabilities arising under the Securities Act, or otherwise. Our amended and restated investors&#146; rights agreement with certain investors also
provides for cross-indemnification in connection with the registration of our common stock on behalf of such investors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;15. Recent Sales of
Unregistered Securities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following list sets forth information regarding all unregistered securities sold by us
since our inception through the date of the prospectus that forms a part of this registration statement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Issuances of Common Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In April 2018, we issued 871,857 shares of our common stock to one accredited investor as consideration for a license to
certain patent rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In April 2018, we issued an aggregate of 334,549 shares of our common stock to one accredited
investor and one unaccredited investor at a purchase price of $0.003 per share, for aggregate consideration of $825.00. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In July 2018, we issued 185,523 shares of our common stock to one sophisticated unaccredited investor at a purchase price of
$0.003 per share, for aggregate consideration of $457.50. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In August 2018, we issued 278,284 shares of our common stock to
one sophisticated unaccredited investor at a purchase price of $0.003 per share, for aggregate consideration of $686.25, of which 237,733 shares were repurchased in April 2019 in connection with the termination of such investor&#146;s consulting
agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In January 2021, we issued 336,575 shares of our common stock to one accredited investor as partial
consideration for a license to certain patent rights. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Issuances of Preferred Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In October 2020, we issued (a) 1,315,789 shares of our <FONT STYLE="white-space:nowrap">Series&nbsp;A-1</FONT> convertible
preferred stock to one investor at a purchase price of $2.28 per share, for aggregate consideration of $3.0&nbsp;million, (b) 1,918,745 shares </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
of our Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock to one investor upon conversion of outstanding convertible notes in aggregate principal amount of $2,750,000
at a conversion price of $3.87 per share, and (c) 1,187,816 shares of our Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock to one investor upon conversion of outstanding convertible notes in aggregate principal amount
of $2,000,000 at a conversion price of $4.50 per share. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In January 2021, we issued an aggregate of 5,482,456 shares
of our Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock to two investors at a purchase price of $2.28 per share, for aggregate consideration of $12.5&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In November 2021, we issued (a)&nbsp;an aggregate of 17,521,047 shares of our Series B convertible preferred stock to 13
investors at a purchase price of $5.70742 per share, for aggregate consideration of $100.0&nbsp;million, and (b) 46,058 shares of our Series B convertible preferred stock to one accredited investor in satisfaction of a contractual obligation
contained in a license to certain patent rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Issuances Pursuant to our Equity Plans </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">From March&nbsp;13, 2018 (the date of our inception) through the date of this registration statement, we granted options under
our 2019 Stock Incentive Plan to purchase an aggregate of 2,269,926 shares of common stock, at a weighted-average exercise price of $2.92 per share, to our employees, directors and consultants. Of these, 25,545&nbsp;shares have been issued upon the
exercise of options for aggregate consideration of $23,997.50 and options for the purchase of 95,702 shares of common stock have been forfeited, expired or canceled. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">None of the foregoing transactions involved any underwriters, underwriting discounts or commissions, or any public offering.
Unless otherwise specified above, we believe these transactions were exempt from registration under the Securities Act in reliance on Section&nbsp;4(a)(2) of the Securities Act (and Regulation D or Regulation S promulgated thereunder) or Rule 701
promulgated under Section&nbsp;3(b) of the Securities Act as transactions by an issuer not involving any public offering or under benefit plans and contracts relating to compensation as provided under Rule 701. The recipients of the securities in
each of these transactions represented their intentions to acquire the securities for investment only and not with a view to or for sale in connection with any distribution thereof, and appropriate legends were placed on the share certificates
issued in these transactions. All recipients had adequate access, through their relationships with us, to information about us. The sales of these securities were made without any general solicitation or advertising. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;16.</B><B><I> </I></B><B>Exhibits and Financial Statement Schedules</B><B><I>.</I></B><B>
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) Exhibits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The exhibits listed below are filed as part of this registration. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description of Exhibit</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>1.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d383050dex11.htm">Form of Underwriting Agreement </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>3.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1781174/000095012322010286/d383050dex31.htm">Second Amended and Restated Certificate of Incorporation of the Registrant (as amended and currently in effect) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>3.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1781174/000095012322010286/d383050dex32.htm">Bylaws of the Registrant (currently in effect) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>3.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d383050dex33.htm">Form of Amended and Restated Certificate of Incorporation of the Registrant (to be effective upon the closing of this offering) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>3.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d383050dex34.htm">Form of Amended and Restated Bylaws of the Registrant (to be effective upon the closing of this offering) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>3.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d383050dex35.htm">Certificate of Amendment to Second Amended and Restated Certificate of Incorporation </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1781174/000095012322010286/d383050dex41.htm">Amended and Restated Investors&#146; Rights Agreement, by and among the Registrant and certain of its stockholders, dated November&nbsp;
9, 2021 </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>5.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d383050dex51.htm">Opinion of Cooley LLP </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1781174/000095012322010286/d383050dex101.htm">2019 Stock Incentive Plan and Forms of Stock Option Agreement and Notice of Exercise </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d383050dex102.htm">2022 Equity Incentive Plan and Forms of Stock Option Grant Notice, Stock Option Agreement, Notice of Exercise, Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d383050dex103.htm">2022 Employee Stock Purchase Plan </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1781174/000095012322010286/d383050dex104.htm">Form of Indemnification Agreement with Executive Officers and Directors </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5&#134;*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1781174/000095012322010286/d383050dex105.htm">License Agreement, by and between the Registrant and Eli Lilly and Company, dated January&nbsp;27, 2021 </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6&#134;*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1781174/000095012322010286/d383050dex106.htm">OncoSignature Companion Diagnostic Agreement, by and between the Registrant and Akoya Biosciences, Inc., dated June&nbsp;17, 2022
</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.7&#134;#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1781174/000095012322010286/d383050dex107.htm">Patent License Agreement, by and between the Registrant and Peter Blume-Jensen, dated April 12, 2018 </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.8*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1781174/000095012322010286/d383050dex108.htm">Executive Employment Agreement, by and between the Registrant and Peter Blume-Jensen, dated October 5, 2020 </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.9*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1781174/000095012322010286/d383050dex109.htm">Employment Offer Letter Agreement, by and between the Registrant and Erick Gamelin, dated February 26, 2021 </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.10*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1781174/000095012322010286/d383050dex1010.htm">Employment Offer Letter Agreement, dated October 5, 2020, and Letter Amendment to Employment Offer Letter Agreement, dated August 5, 2022, by
 and between the Registrant and Eric Devroe </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d383050dex1011.htm">Non-Employee Director Compensation Policy </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>21.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1781174/000095012322010286/d383050dex211.htm">List of Subsidiaries </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d383050dex231.htm">Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d383050dex51.htm">Consent of Cooley LLP (included in Exhibit 5.1) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1781174/000095012322010286/d383050ds1.htm#sig">Power of Attorney (included on signature page) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>107</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d383050dexfilingfees.htm">Filing Fee Table </A></TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">#</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Certain schedules to this agreement have been omitted in accordance with Item 601(a)(5) of <FONT
STYLE="white-space:nowrap">Regulation&nbsp;S-K.</FONT> A copy of any omitted schedules will be furnished supplementally to the SEC upon request. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Portions of this exhibit (indicated by asterisks) have been redacted in compliance with Regulation <FONT
STYLE="white-space:nowrap">S-K</FONT> Item 601(b)(10)(iv). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Previously filed. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) Financial Statement Schedules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Schedules not listed above have been omitted because the information required to be set forth therein is not applicable or is
shown in the financial statements or notes thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) Filing Fee Table. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The information required to be furnished by paragraph (c)&nbsp;of this Item is incorporated herein by reference to Exhibit
107. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;17. Undertakings</B><B><I>.</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and
controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is,
therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful
defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by
controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The undersigned Registrant hereby undertakes that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(1)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For purposes of determining any liability under the Securities Act, the information omitted from the form of
prospectus filed as part of this Registration Statement in reliance upon Rule 430A and contained in a form of prospectus filed by the Registrant pursuant to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of
this Registration Statement as of the time it was declared effective. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(2)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For the purpose of determining any liability under the Securities Act, each post-effective amendment that
contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="sig"></A>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be
signed on its behalf by the undersigned, thereunto duly authorized in the City of Watertown, Commonwealth of Massachusetts, on this 3rd day of November, 2022. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>ACRIVON THERAPEUTICS, INC.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Peter Blume-Jensen</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Peter Blume-Jensen, M.D., Ph.D.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Chief Executive Officer and President</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>POWER OF ATTORNEY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following
persons in the capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/s/ Peter Blume-Jensen</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Blume-Jensen, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Chief Executive Officer, President and Chairman of the Board <I>(Principal Executive Officer)</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">November&nbsp;3,&nbsp;2022</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/s/ Rasmus Holm-Jorgensen</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rasmus Holm-Jorgensen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Chief Financial Officer<I> (Principal Financial and Accounting Officer)</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">November&nbsp;3,&nbsp;2022</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" align="left">Derek DiRocco, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">November&nbsp;3, 2022</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-bottom:0pt; margin-top:0pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" align="left">Kristina Masson, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Executive Vice President, Business Operations, Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">November&nbsp;3, 2022</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" align="left">Sharon Shacham, Ph.D., M.B.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">November&nbsp;3, 2022</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-bottom:0pt; margin-top:0pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" align="left">Michael Tomsicek, M.B.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">November&nbsp;3, 2022</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">*By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">/s/ Peter Blume-Jensen</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Peter Blume-Jensen</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Attorney-in-Fact</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-6 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d383050dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[&#149;] Shares </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ACRIVON THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMMON STOCK, PAR VALUE $0.001 PER SHARE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNDERWRITING AGREEMENT </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">[&#149;], 2022 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Morgan Stanley&nbsp;&amp; Co. LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jefferies LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cowen and Company, LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Piper Sandler&nbsp;&amp; Co. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Morgan Stanley&nbsp;&amp; Co. LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman">1585
Broadway </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman">New York, New York 10036 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o
Jefferies LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman">520 Madison Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Cowen and Company,
LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman">599 Lexington Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o
Piper&nbsp;Sandler&nbsp;&amp; Co. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman">1251 Avenue of the Americas, 7th&nbsp;Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman">New York, New York 10020 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Acrivon Therapeutics, Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;), proposes to issue and sell to the several
Underwriters named in Schedule I hereto (the &#147;<B>Underwriters</B>&#148;) [&#149;] shares of its common stock, par value $0.001 per share (the &#147;<B>Firm Shares</B>&#148;). The Company also proposes to issue and sell to the several
Underwriters not more than an additional [&#149;] shares of its common stock, par value $0.001 per share (the &#147;<B>Additional Shares</B>&#148;) if and to the extent that Morgan Stanley&nbsp;&amp; Co. LLC (&#147;<B>Morgan Stanley</B>&#148;),
Jefferies LLC (&#147;<B>Jefferies</B>&#148;), Cowen and Company, LLC (&#147;<B>Cowen</B>&#148;) and Piper Sandler&nbsp;&amp; Co. (&#147;<B>Piper</B>&#148;), as representatives of the offering (the &#147;<B>Representatives</B>&#148;), shall have
determined to exercise, on behalf of the Underwriters, the right to purchase such shares of common stock granted to the Underwriters in Section&nbsp;2 hereof. The Firm Shares and the Additional Shares are hereinafter collectively referred to as the
&#147;<B>Shares.</B>&#148; The shares of common stock, par value $0.001 per share of the Company to be outstanding after giving effect to the sales contemplated hereby are hereinafter referred to as the &#147;<B>Common Stock</B>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has filed with the Securities and Exchange Commission (the &#147;<B>Commission</B>&#148;) a registration statement on Form <FONT
STYLE="white-space:nowrap">S-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-267911),</FONT> including a preliminary prospectus, relating to the Shares. The registration statement as amended at the time it becomes effective, including
the information (if any) deemed to be part of the registration statement at the time of effectiveness pursuant to Rule&nbsp;430A under the Securities Act of 1933, as amended (the &#147;<B>Securities Act</B>&#148;), is hereinafter referred to as
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the &#147;<B>Registration Statement</B>&#148;; the prospectus in the form first used to confirm sales of Shares (or in the form first made available to the Underwriters by the Company to meet
requests of purchasers pursuant to Rule 173 under the Securities Act) is hereinafter referred to as the &#147;<B>Prospectus</B>.&#148; If the Company has filed an abbreviated registration statement to register additional shares of Common Stock
pursuant to Rule&nbsp;462(b) under the Securities Act (a &#147;<B>Rule</B><B></B><B>&nbsp;462</B><B> Registration Statement</B>&#148;), then any reference herein to the term &#147;<B>Registration Statement</B>&#148; shall be deemed to include such
Rule&nbsp;462 Registration Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this Agreement, &#147;<B>free writing prospectus</B>&#148; has the meaning set
forth in Rule 405 under the Securities Act, &#147;<B>preliminary prospectus</B>&#148; shall mean each prospectus used prior to the effectiveness of the Registration Statement, and each prospectus that omitted information pursuant to Rule 430A under
the Securities Act that was used after such effectiveness and prior to the execution and delivery of this Agreement, &#147;<B>Time of Sale Prospectus</B>&#148; means the preliminary prospectus contained in the Registration Statement at the time of
its effectiveness together with the documents and pricing information set forth in Schedule II hereto, and &#147;<B>broadly available road show</B>&#148; means a &#147;bona fide electronic road show&#148; as defined in Rule 433(h)(5) under the
Securities Act that has been made available without restriction to any person. As used herein, the terms &#147;Registration Statement,&#148; &#147;preliminary prospectus,&#148; &#147;Time of Sale Prospectus&#148; and &#147;Prospectus&#148; shall
include the documents, if any, incorporated by reference therein as of the date hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <I>Representations and Warranties</I>. The
Company represents and warrants to and agrees with each of the Underwriters that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Registration Statement has
become effective; no stop order suspending the effectiveness of the Registration Statement is in effect, and no proceedings for such purpose or pursuant to Section&nbsp;8A under the Securities Act are pending before or, to the Company&#146;s
knowledge, threatened by the Commission. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;(i) The Registration Statement, when it became effective, did not
contain and, as amended or supplemented, if applicable, will not contain, as of the date of such amendment or supplement, any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the
statements therein not misleading, (ii)&nbsp;the Registration Statement and the Prospectus comply and, as amended or supplemented, if applicable, as of the date of such amendment or supplement, will comply in all material respects with the
Securities Act and the applicable rules and regulations of the Commission thereunder, (iii)&nbsp;the Time of Sale Prospectus does not, and at the time of each sale of the Shares in connection with the offering when the Prospectus is not yet
available to prospective purchasers and at the Closing Date (as defined in Section&nbsp;4), the Time of Sale Prospectus, as then amended or supplemented by the Company, if applicable, as of the date of such amendment or supplement, will not, contain
any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
which they were made, not misleading, (iv)&nbsp;each broadly available road show, if any, when considered together with the Time of Sale Prospectus, does not contain any untrue statement of a
material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading and (v)&nbsp;the Prospectus does not contain and, as amended or supplemented, if
applicable, as of the date of such amendment or supplement, will not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were
made, not misleading, except that the representations and warranties set forth in this paragraph do not apply to statements or omissions in the Registration Statement, the Time of Sale Prospectus or the Prospectus based upon information relating to
any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use therein, it being understood and agreed that the only such information furnished by any Underwriter consists of the Underwriter
Information (as defined in Section&nbsp;9(b) of this Agreement). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The Company is not an &#147;ineligible issuer&#148;
in connection with the offering pursuant to Rules 164, 405 and 433 under the Securities Act. Any free writing prospectus that the Company is required to file pursuant to Rule 433(d) under the Securities Act has been, or will be, filed with the
Commission in accordance with the requirements of the Securities Act and the applicable rules and regulations of the Commission thereunder. Each free writing prospectus that the Company has filed, or is required to file, pursuant to Rule 433(d)
under the Securities Act or that was prepared by or on behalf of or used or referred to by the Company complies or will comply, as of the date of such filing, in all material respects with the applicable requirements of the Securities Act and the
applicable rules and regulations of the Commission thereunder. Except for the free writing prospectuses, if any, identified in Schedule II hereto, and electronic road shows, if any, each furnished to the Representatives before first use, the Company
has not prepared, used or referred to, and will not, without the Representatives&#146; prior consent, prepare, use or refer to, any free writing prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The Company has been duly incorporated, is validly existing as a corporation in good standing under the laws of the
jurisdiction of its incorporation, has the corporate power and authority to own or lease its property and to conduct its business as described in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus and is duly
qualified to transact business and is in good standing in each jurisdiction in which the conduct of its business or its ownership or leasing of property requires such qualification, except to the extent that the failure to be so qualified or be in
good standing would not, singly or in the aggregate, reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Each subsidiary of the Company has been duly incorporated, organized or
formed, is validly existing as a corporation or other business entity in good standing under the laws of the jurisdiction of its incorporation, organization or formation, has the corporate or other business entity power and authority to own or lease
its property and to conduct its business as described in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus and is duly qualified to transact business and is in good standing in each jurisdiction in which the conduct
of its business or its ownership or leasing of property requires such qualification, except to the extent that the failure to be so qualified or be in good standing would not, singly or in the aggregate, reasonably be expected to have a material
adverse effect on the Company and its subsidiaries, taken as a whole; all of the issued shares of capital stock or other equity interests of each subsidiary of the Company have been duly and validly authorized and issued, are fully paid and <FONT
STYLE="white-space:nowrap">non-assessable</FONT> and are owned directly or indirectly by the Company, free and clear of all liens, encumbrances, equities or claims. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) This Agreement has been duly authorized, executed and delivered by the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) The authorized capital stock of the Company conforms as to legal matters, in all material respects, to the description
thereof contained in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) The shares of
Common Stock outstanding prior to the issuance of the Shares have been duly authorized and are validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) The Shares have been duly authorized and, when issued, delivered and paid for in accordance with the terms of this
Agreement, will be validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable,</FONT> and the issuance of the Shares will not be subject to any preemptive or similar rights. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) The execution and delivery by the Company of, and the performance by the Company of its obligations under, this Agreement
will not contravene (i)&nbsp;any provision of applicable law, (ii)&nbsp;the certificate of incorporation or <FONT STYLE="white-space:nowrap">by-laws</FONT> of the Company, (iii)&nbsp;any agreement or other instrument binding upon the Company or any
of its subsidiaries that is material to the Company and its subsidiaries, taken as a whole, or (iv)&nbsp;any judgment, order or decree of any governmental body, agency or court having jurisdiction over the Company or any subsidiary, except in the
cases of clauses (i), (iii) and (iv)&nbsp;where such contravention would not, singly or in the aggregate, reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole, or on the power and ability of
the Company to perform its obligations under this Agreement, and no consent, approval, authorization or order of, or qualification with, any governmental body, agency or court is required for the performance by the Company of its obligations under
this Agreement, except such as have already been obtained or waived or may be required by the securities or Blue Sky laws of the various states or the rules and regulations of the Financial Industry Regulatory Authority (&#147;<B>FINRA</B>&#148;) in
connection with the offer and sale of the Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) There has not occurred any material adverse change, or any development
involving a prospective material adverse change, in the condition, financial or otherwise, or in the earnings, business or operations of the Company and its subsidiaries, taken as a whole, from that set forth in the Time of Sale Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) There are no legal or governmental proceedings pending or, to the Company&#146;s knowledge, threatened to which the Company
or any of its subsidiaries is a party or to which any of the properties of the Company or any of its subsidiaries is subject (i)&nbsp;other than proceedings accurately described in all material respects in each of the Registration Statement, the
Time of Sale Prospectus and the Prospectus and proceedings that would not, singly or in the aggregate, reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole, or on the power or ability of the
Company to perform its obligations under this Agreement or to consummate the transactions contemplated by each of the Registration Statement, the Time of Sale Prospectus and the Prospectus or (ii)&nbsp;that are required to be described in the
Registration Statement, the Time of Sale Prospectus or the Prospectus and are not so described; and there are no statutes, regulations, contracts or other documents that are required to be described in the Registration Statement, the Time of Sale
Prospectus or the Prospectus or to be filed as exhibits to the Registration Statement that are not described in all material respects or filed as required. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) Each preliminary prospectus filed as part of the Registration Statement as originally filed or as part of any amendment
thereto, or filed pursuant to Rule&nbsp;424 under the Securities Act, complied when so filed in all material respects with the applicable requirements of the Securities Act and the applicable rules and regulations of the Commission thereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) The Company is not, and after giving effect to the offering and sale of the Shares and the application of the proceeds
thereof as described in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus will not be, required to register as an &#147;investment company&#148; as such term is defined in the Investment Company Act of 1940, as
amended. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) The Company and each of its subsidiaries (i)&nbsp;are in compliance with any and all applicable foreign,
federal, state and local laws and regulations relating to the protection of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants (&#147;<B>Environmental Laws</B>&#148;), (ii) have received
all permits, licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses and (iii)&nbsp;are in compliance with all terms and conditions of any such permit, license or approval, except where
such noncompliance with Environmental Laws, failure to receive required permits, licenses or other approvals or failure to comply with the terms and conditions of such permits, licenses or approvals would not, singly or in the aggregate, reasonably
be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) There are no costs or liabilities associated with Environmental Laws
(including, without limitation, any capital or operating expenditures required for <FONT STYLE="white-space:nowrap">clean-up,</FONT> closure of properties or compliance with Environmental Laws or any permit, license or approval, any related
constraints on operating activities and any potential liabilities to third parties) which would, singly or in the aggregate, reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) There are no contracts, agreements or understandings between the Company and any person granting such person the right to
require the Company to file a registration statement under the Securities Act with respect to any securities of the Company or to require the Company to include such securities with the Shares registered pursuant to the Registration Statement,
except such contracts, agreements or understandings as have been described in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus, which have been validly waived or complied with in connection with the issuance and
sale of the Shares contemplated hereby. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r)&nbsp;(i) None of the Company or any of its subsidiaries, or any director,
officer, or employee thereof, or, to the Company&#146;s knowledge, any affiliate, agent or representative of the Company or of any of its subsidiaries or affiliates, while acting on behalf of the Company or any of its subsidiaries, has taken or will
take any action in furtherance of an offer, payment, promise to pay, or authorization or approval of the payment, giving or receipt of money, property, gifts or anything else of value, directly or indirectly, to any government official (including
any officer or employee of a government or government-owned or controlled entity or of a public international organization, or any person acting in an official capacity for or on behalf of any of the foregoing, or any political party or party
official or candidate for political office) (&#147;<B>Government Official</B>&#148;) in order to influence official action, or to any person in violation of any applicable anti-corruption laws; (ii)&nbsp;the Company and each of its subsidiaries and,
to the Company&#146;s knowledge, its affiliates have conducted their businesses in compliance with applicable anti-corruption laws and have instituted and maintained and will continue to maintain policies and procedures reasonably designed to
promote and achieve compliance with such laws and with the representations and warranties contained herein; and (iii)&nbsp;neither the Company nor any of its subsidiaries will use, directly or indirectly, the proceeds of the offering in furtherance
of an offer, payment, promise to pay, or authorization of the payment or giving of money, or anything else of value, to any person in violation of any applicable anti-corruption laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s) The operations of the Company and each of its subsidiaries are and have
been conducted at all times in material compliance with all applicable financial recordkeeping and reporting requirements, including those of the Bank Secrecy Act, as amended by Title III of the Uniting and Strengthening America by Providing
Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001 (USA PATRIOT Act), and the applicable anti-money laundering statutes of jurisdictions where the Company and each of its subsidiaries conduct business, the rules and
regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the &#147;<B>Anti-Money Laundering Laws</B>&#148;), and no action, suit or proceeding by
or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Anti-Money Laundering Laws is pending or, to the best knowledge of the Company, threatened. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t)&nbsp;(i) None of the Company, any of its subsidiaries, or any director, officer, or employee thereof, or, to the
Company&#146;s knowledge, any agent, affiliate or representative of the Company or any of its subsidiaries, is an individual or entity (&#147;<B>Person</B>&#148;) that is, or is 50% or more owned or otherwise controlled by one or more Persons that
are: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) the subject of any sanctions administered or enforced by the U.S. Department of the Treasury&#146;s Office of
Foreign Assets Control, the United Nations Security Council, the European Union, Her Majesty&#146;s Treasury, or other relevant sanctions authority (collectively, &#147;<B>Sanctions</B>&#148;), or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) located, organized or resident in a country or territory that is the subject of comprehensive Sanctions (including,
without limitation, the <FONT STYLE="white-space:nowrap">so-called</FONT> Donetsk People&#146;s Republic, the <FONT STYLE="white-space:nowrap">so-called</FONT> Luhansk People&#146;s Republic, Crimea, Cuba, Iran, North Korea and Syria)
(&#147;<B>Sanctioned Countries</B>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) The Company will not, directly or indirectly, use the proceeds of the
offering, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other Person: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) to fund or facilitate any activities or business of or with any Person, or in any country or territory that, at the time
of such funding or facilitation, is the subject of Sanctions or is located, organized or resident in a Sanctioned Country; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) in any other manner that will result in a violation of Sanctions by any Person (including any Person participating in the
offering, whether as underwriter, advisor, investor or otherwise). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) The Company and each of its subsidiaries have not
knowingly engaged in, are not now knowingly engaged in, and will not engage in, any dealings or transactions with any Person, or in any country or territory that at the time of the dealing or transaction is or was the subject of Sanctions, or is
located, organized or resident in a Sanctioned Country. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u) Subsequent to the respective dates as of which information is given in
each of the Registration Statement, the Time of Sale Prospectus and the Prospectus, (i)&nbsp;the Company and its subsidiaries, taken as a whole, have not incurred any material liability or obligation, direct or contingent, nor entered into any
material transaction; (ii)&nbsp;the Company has not purchased any of its outstanding capital stock, nor declared, paid or otherwise made any dividend or distribution of any kind on its capital stock other than ordinary and customary dividends; and
(iii)&nbsp;there has not been any material change in the capital stock, <FONT STYLE="white-space:nowrap">short-term</FONT> debt or <FONT STYLE="white-space:nowrap">long-term</FONT> debt of the Company and its subsidiaries, taken as a whole. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) The Company and each of its subsidiaries have good and marketable title in fee simple to all real property and good and
marketable title to all personal property owned by them which is material to the business of the Company and its subsidiaries, in each case free and clear of all liens, encumbrances and defects except such as do not materially affect the value of
such property and do not interfere with the use made and proposed to be made of such property by the Company and its subsidiaries; and any real property and buildings held under lease by the Company and its subsidiaries are held by them under valid,
subsisting and enforceable leases with such exceptions as are not material and do not interfere with the use made and proposed to be made of such property and buildings by the Company and its subsidiaries. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(w)&nbsp;(i) The Company and its subsidiaries own or have a valid license to all patents, inventions, copyrights, know how
(including trade secrets and other unpatented and/or unpatentable proprietary or confidential information, systems or procedures), trademarks, service marks and trade names (collectively, &#147;<B>Intellectual Property Rights</B>&#148;) used in or
reasonably necessary to the conduct of their businesses as it is currently being conducted; (ii)&nbsp;to the Company&#146;s knowledge, the Intellectual Property Rights owned by the Company and its subsidiaries and the Intellectual Property Rights
licensed to the Company and its subsidiaries are valid, subsisting and enforceable, and there is no pending or, to the Company&#146;s knowledge, threatened action, suit, proceeding or claim by others challenging the validity, scope or enforceability
of any such Intellectual Property Rights; (iii)&nbsp;neither the Company nor any of its subsidiaries has received any notice alleging any infringement, misappropriation or other violation of Intellectual Property Rights which, singly or in the
aggregate, if the subject of an unfavorable decision, ruling or finding, would have a material adverse effect on the Company and its subsidiaries, taken as a whole; (iv)&nbsp;to the Company&#146;s knowledge, no third party is infringing,
misappropriating or otherwise violating, or has infringed, misappropriated or otherwise violated, any Intellectual Property Rights owned by the Company; (v)&nbsp;to the Company&#146;s knowledge, neither the Company nor any of its subsidiaries
infringes, misappropriates or otherwise </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
violates, or has infringed, misappropriated or otherwise violated, any Intellectual Property Rights; (vi)&nbsp;all employees or contractors engaged in the development of Intellectual Property
Rights on behalf of the Company or any subsidiary of the Company have executed an invention assignment agreement whereby such employees or contractors presently assign all of their right, title and interest in and to such Intellectual Property
Rights to the Company or the applicable subsidiary, and to the Company&#146;s knowledge no such agreement has been breached or violated; and (vii)&nbsp;the Company and its subsidiaries use, and have used, commercially reasonable efforts to
appropriately maintain all information intended to be maintained as a trade secret. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x)&nbsp;(i) The Company and its
subsidiaries use and have used any and all software and other materials distributed under a &#147;free,&#148; &#147;open source,&#148; or similar licensing model (including but not limited to the MIT License, Apache License, GNU General Public
License, GNU Lesser General Public License and GNU Affero General Public License) (&#147;<B>Open Source Software</B>&#148;) in compliance with all license terms applicable to such Open Source Software; and (ii)&nbsp;neither the Company nor any of
its subsidiaries uses or distributes or has used or distributed any Open Source Software in any manner that requires or has required (A)&nbsp;the Company or any of its subsidiaries to permit reverse engineering of any software code or other
technology owned by the Company or any of its subsidiaries or (B)&nbsp;any software code or other technology owned by the Company or any of its subsidiaries to be (1)&nbsp;disclosed or distributed in source code form, (2)&nbsp;licensed for the
purpose of making derivative works or (3)&nbsp;redistributed at no charge. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(y)&nbsp;(i) The Company and each of its
subsidiaries have complied in all material respects and are presently in compliance in all material respects with all internal and external privacy policies, contractual obligations, applicable laws, statutes, judgments, orders, rules and
regulations of any court or arbitrator or other governmental or regulatory authority with jurisdiction over the Company and any other legal obligations, in each case, governing the collection, use, transfer, import, export, storage, protection,
disposal and disclosure by the Company or any of its subsidiaries of personal and personally identifiable, household, sensitive, confidential or regulated data (&#147;<B>Data Security Obligations</B>&#148;, and such data, &#147;<B>Data</B>&#148;);
(ii) the Company has not received any written notification of or complaint regarding and is unaware of any other facts that, individually or in the aggregate, would reasonably indicate <FONT STYLE="white-space:nowrap">non-compliance</FONT> with any
Data Security Obligation; and (iii)&nbsp;there is no action, suit or proceeding by or before any court or governmental agency, authority or body pending or, to the Company&#146;s knowledge, threatened alleging
<FONT STYLE="white-space:nowrap">non-compliance</FONT> with any Data Security Obligation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(z) The Company and each of its
subsidiaries have implemented commercially reasonable physical, technical and organizational measures designed to protect the information technology systems and Data used in connection with the operation of the Company&#146;s and its
subsidiaries&#146; businesses. Without limiting the foregoing, the Company and its subsidiaries have used </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
commercially reasonable efforts to establish and maintain, and have established, maintained, implemented and complied with, commercially reasonable information technology, information security,
cyber security and data protection controls, policies and procedures, including oversight, access controls, encryption, technological and physical safeguards and business continuity/disaster recovery and security plans that are designed to protect
against and prevent breach, destruction, loss, unauthorized distribution, use, access, disablement, misappropriation or modification, or other compromise or misuse of or relating to any information technology system or Data used in connection with
the operation of the Company&#146;s and its subsidiaries&#146; businesses (&#147;<B>Breach</B>&#148;). To the Company&#146;s knowledge, there has been no such Breach, and the Company and its subsidiaries have not been notified of and have no
knowledge of any event or condition that would reasonably be expected to result in, any such Breach. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aa) No material
labor dispute with the employees of the Company or any of its subsidiaries exists, or, to the knowledge of the Company, is imminent; and the Company is not aware of any existing, threatened or imminent labor disturbance by the employees of any of
its principal suppliers, manufacturers or contractors that, singly or in the aggregate, would reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bb) The Company and each of its subsidiaries are insured by insurers of recognized financial responsibility against such
losses and risks and in such amounts as, in the Company&#146;s reasonable judgment, are prudent and customary in the businesses in which they are engaged; neither the Company nor any of its subsidiaries has been refused any insurance coverage sought
or applied for; and neither the Company nor any of its subsidiaries has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as
may be necessary to continue its business at a cost that would not, singly or in the aggregate, reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(cc) The Company and each of its subsidiaries possess all certificates, authorizations and permits issued by the appropriate
federal, state or foreign regulatory authorities necessary to conduct their respective businesses, and neither the Company nor any of its subsidiaries has received any notice of proceedings relating to the revocation or modification of any such
certificate, authorization or permit which, singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a
whole. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(dd) The financial statements included in each of the Registration Statement, the Time of Sale Prospectus and the
Prospectus, together with the related schedules and notes thereto, comply as to form in all material respects with the applicable accounting requirements of the Securities Act and present fairly the consolidated financial position of the Company and
its subsidiaries as of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
the dates shown and its results of operations and cash flows for the periods shown, and such financial statements have been prepared in conformity with generally accepted accounting principles in
the United States (&#147;<B>U.S. GAAP</B>&#148;) applied on a consistent basis throughout the periods covered thereby except for any normal <FONT STYLE="white-space:nowrap">year-end</FONT> adjustments in the Company&#146;s quarterly financial
statements. The other financial information included in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus has been derived from the accounting records of the Company and its consolidated subsidiaries and presents
fairly in all material respects the information shown thereby. The statistical, industry-related and market-related data included in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus are based on or derived from
sources which the Company reasonably and in good faith believes are reliable and accurate and such data is consistent with the sources from which they are derived, in each case in all material respects. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ee) PricewaterhouseCoopers LLP, who have certified certain financial statements of the Company and its subsidiaries and
delivered its report with respect to the audited consolidated financial statements filed with the Commission as part of the Registration Statement and included in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus, is
an independent registered public accounting firm with respect to the Company within the meaning of the Securities Act and the applicable rules and regulations thereunder adopted by the Commission and the Public Company Accounting Oversight Board
(United States). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ff) The Company and each of its subsidiaries maintain a system of internal accounting controls
sufficient to provide reasonable assurance that (i)&nbsp;transactions are executed in accordance with management&#146;s general or specific authorizations; (ii)&nbsp;transactions are recorded as necessary to permit preparation of financial
statements in conformity with U.S. GAAP and to maintain asset accountability; (iii)&nbsp;access to assets is permitted only in accordance with management&#146;s general or specific authorization; and (iv)&nbsp;the recorded accountability for assets
is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. Since the end of the Company&#146;s most recent audited fiscal year, there has been (i)&nbsp;no material weakness in the
Company&#146;s internal control over financial reporting (whether or not remediated), except as has been described in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus, and (ii)&nbsp;no change in the Company&#146;s
internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company&#146;s internal control over financial reporting. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(gg) The Company has not sold, issued or distributed any shares of Common Stock during the
<FONT STYLE="white-space:nowrap">six-month</FONT> period preceding the date hereof, including any sales pursuant to Rule&nbsp;144A under, or Regulation&nbsp;D or S of, the Securities Act, other than shares issued pursuant to employee benefit plans,
qualified stock option plans or other employee compensation plans or pursuant to outstanding options, rights or warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(hh) The Company and each of its subsidiaries have filed all federal, state,
local and foreign tax returns required to be filed through the date of this Agreement or have requested extensions thereof (except where the failure to file would not, singly or in the aggregate, reasonably be expected to have a material adverse
effect on the Company and its subsidiaries, taken as a whole) and have paid all taxes required to be paid thereon (except for cases in which the failure to file or pay would not, singly or in the aggregate, reasonably be expected to have a material
adverse effect on the Company and its subsidiaries, taken as a whole, or, except as currently being contested in good faith and for which reserves required by U.S. GAAP have been created in the financial statements of the Company), and no tax
deficiency has been determined adversely to the Company or any of its subsidiaries which, singly or in the aggregate, has had (nor does the Company nor any of its subsidiaries have any notice or knowledge of any tax deficiency which could reasonably
be expected to be determined adversely to the Company or its subsidiaries and which could reasonably be expected to have) a material adverse effect on the Company and its subsidiaries, taken as a whole. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) [Reserved] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(jj) From the time of initial confidential submission of the Registration Statement to the Commission through the date hereof,
the Company has been and is an &#147;emerging growth company,&#148; as defined in Section&nbsp;2(a) of the Securities Act (an &#147;<B>Emerging Growth Company</B>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(kk) The Company (i)&nbsp;has not alone engaged in any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication with any person other than <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT>
Communications with the consent of the Representatives with entities that are reasonably believed to be qualified institutional buyers within the meaning of Rule 144A under the Securities Act or institutions that are reasonably believed to be
accredited investors within the meaning of Rule 501 under the Securities Act and (ii)&nbsp;has not authorized anyone other than the Representatives to engage in
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications. The Company reconfirms that the Representatives have been authorized to act on its behalf in undertaking <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications. The Company has not distributed any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT>
Communication that is a written communication within the meaning of Rule 405 under the Securities Act. &#147;<B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication</B>&#148; means any
communication with potential investors undertaken in reliance on Section&nbsp;5(d) or Rule 163B of the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ll) As of the time of each sale of the Shares in connection with the offering when the Prospectus is not yet available to
prospective purchasers, none of (A)&nbsp;the Time of Sale Prospectus, (B)&nbsp;any free writing prospectus, when considered together with the Time of Sale Prospectus, and (C)&nbsp;any individual <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, when considered together with the Time of Sale Prospectus, included, includes or will include an untrue statement of a material fact or omitted, omits or will omit to state a
material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(mm) The preclinical tests and clinical trials and other studies
(collectively, &#147;<B>Studies</B>&#148;) conducted by or on behalf of the Company or its subsidiaries, or in which the Company&#146;s product candidates have participated, including those that are described in, or the results of which are referred
to in, the Registration Statement, the Time of Sale Prospectus or the Prospectus were and, if still pending, are being conducted in all material respects with applicable laws, including, without limitation, the Federal Food, Drug, and Cosmetic Act
(21 U.S.C. &#167;&#167; 301 et seq.) and the rules and regulations promulgated thereunder and any applicable statutes, rules, regulations and policies of the jurisdictions in which such Studies are being conducted; each description of the results of
such Studies is accurate and complete in all material respects and fairly presents the data derived from such Studies, and the Company and its subsidiaries have no knowledge of any other Studies the results of which are inconsistent with, or
otherwise call into question, the results described or referred to in the Registration Statement, the Time of Sale Prospectus or the Prospectus; the Company and its subsidiaries have made all such filings and obtained all such approvals or
authorizations as may be required by the Food and Drug Administration (the &#147;<B>FDA</B>&#148;) of the U.S. Department of Health and Human Services or from any other U.S. or foreign government or drug or medical device regulatory agency
(collectively, the &#147;<B>Regulatory Agencies</B>&#148;), except where the failure to make such filing or obtain such approval would not reasonably be expected to, individually or in the aggregate, result in a material adverse effect on the
Company and its subsidiaries, taken as a whole; except as described in the Registration Statement, the Time of Sale Prospectus and the Prospectus, neither the Company nor any of its subsidiaries have received any notice of, or correspondence from,
any Regulatory Agency or health care facility Institutional Review Board requiring the termination, suspension or material modification of any clinical trials that are described or referred to in the Registration Statement, the Time of Sale
Prospectus, nor is the Company aware of any reasonable grounds for such notice or correspondence; and the Company and its subsidiaries have operated and currently are in compliance in all material respects with all applicable laws, rules and
regulations of the Regulatory Agencies. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(nn) The Company and its subsidiaries and their respective directors, officers,
employees, contractors, and agents are, and at all times have been, in material compliance with all applicable statutes, rules and regulations applicable to the Health Care Laws, as defined below. For purposes of this Agreement, &#147;<B>Health Care
Laws</B>&#148; means: (i)&nbsp;the Federal Food, Drug, and Cosmetic Act (21 U.S.C. &#167;&#167; 301 et seq.), the Public Health Service Act (42 U.S.C. &#167;&#167; 201 et seq.) and the regulations promulgated thereunder; (ii)&nbsp;all applicable
federal, state, local and all applicable foreign health care related fraud and abuse laws, including, without limitation, the U.S. Anti-Kickback Statute (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7b(b)),</FONT> the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
U.S. False Statements Law (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7b(a)),</FONT> the Civil Monetary Penalties Law (42 U.S.C. &#167;
<FONT STYLE="white-space:nowrap">1320a-7a),&nbsp;the</FONT> U.S. Civil False Claims Act (31 U.S.C. &#167; 3729 et seq.), all criminal laws relating to health care fraud and abuse, including but not limited to 18 U.S.C. &#167;&#167; 286 and 287, and
the health care fraud criminal provisions under the U.S. Health Insurance Portability and Accountability Act of 1996 (&#147;HIPAA&#148;) (42 U.S.C. &#167;&#167; 1320d et seq.), the Physician Payments Sunshine Act (42 U.S.C. &#167; <FONT
STYLE="white-space:nowrap">1320a-7h),</FONT> the exclusions law (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7),</FONT> the statutes, regulations and directives of applicable government funded or sponsored healthcare programs, and the
regulations promulgated pursuant to such statutes, including but not limited to the coverage and payment provisions of Medicare (Title XVIII of the Social Security Act) and Medicaid (Title XIX of the Social Security Act); (iii) the Standards for
Privacy of Individually Identifiable Health Information, the Security Standards, and the Standards for Electronic Transactions and Code Sets promulgated under HIPAA, the Health Information Technology for Economic and Clinical Health Act
(&#147;HITECH Act&#148;) (42 U.S.C. &#167;&#167; 17921 et seq.), and the regulations promulgated thereunder and any state or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> counterpart thereof or other law or regulation the purpose of which is to
protect the privacy of individuals or prescribers; (iv)&nbsp;the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010; (v) licensure, quality, safety and accreditation
requirements under applicable Regulatory Agencies; and (vi)&nbsp;any and all other applicable health care laws and regulations applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing,
advertising, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product candidate manufactured or distributed by the Company.&nbsp;Neither the Company nor its subsidiaries has received written notice of any claim,
action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any court or arbitrator or governmental authority or Regulatory Agency or third party alleging that any product operation or activity is in material
violation of any Health Care Laws, and, to the Company&#146;s knowledge, no such claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action is threatened.&nbsp;Neither the Company nor any of its subsidiaries
has had any manufacturing site (whether Company-owned or subsidiary-owned) subject to a Regulatory Agency shutdown or import or export prohibition. To the Company&#146;s knowledge, the manufacturing facilities and operations of the Company&#146;s
and its subsidiaries&#146; suppliers are operated in compliance in all material respects with all applicable Health Care Laws. Neither the Company, its subsidiaries, nor any of their officers, directors, employees, contractors or agents, is a party
to any corporate integrity agreements, monitoring agreements, consent decrees, settlement orders, or similar agreements with or imposed by any governmental authority or Regulatory Agency.&nbsp;Additionally, neither the Company including any of its
employees, contractors, agents, officers or directors, its subsidiaries including any of the subsidiary&#146;s employees, contractors, agents, officers or directors, nor, to the Company&#146;s knowledge, any of its holders of 5% or more of its
capital stock, has been excluded, suspended or debarred from participation in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
any U.S. federal health care program or human clinical research or, to the knowledge of the Company, is subject to a governmental inquiry, investigation, proceeding, or other similar action that
could reasonably be expected to result in debarment, suspension, or exclusion, or engaged in any conduct that would reasonably be expected to result in debarment, suspension, or exclusion.&nbsp;The Company and its subsidiaries have filed, obtained,
maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by the Health Care Laws, and all such reports, documents, forms, notices, applications,
records, claims, submissions and supplements or amendments were timely, complete, accurate and not misleading on the date filed in all material respects (or were corrected or supplemented by a subsequent submission). The Company and its subsidiaries
possess and are in material compliance with all licenses, certificates, approvals, clearances, exemptions, authorizations, permits and supplements or amendments thereto required by any such Health Care Laws. The Company and its subsidiaries have not
received any FDA Form 483, notice of adverse finding, warning letter, untitled letter or other correspondence or notice from the FDA or any other Regulatory Agency or governmental entity alleging or asserting noncompliance with any Health Care Laws
or any licenses, certificates, approvals, clearances, exemptions, authorizations, permits and supplements or amendments thereto required by any such Health Care Laws. The Company and its subsidiaries have fulfilled and performed all of their
respective material obligations with respect to all licenses, sublicenses, certificates, permits and other authorizations and no event has occurred which allows, or after notice or lapse of time would allow, revocation or termination thereof or
results in any other impairment of the rights of the holder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(oo) Except as would not, singly or in the aggregate,
reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken as a whole: (i)&nbsp;no &#147;prohibited transaction&#148; (as defined in Section&nbsp;406 of the Employee Retirement Income Security Act of 1974, as
amended, including the regulations and published interpretations thereunder (&#147;<B>ERISA</B>&#148;), or Section&nbsp;4975 of the Internal Revenue Code of 1986, as amended from time to time (the &#147;<B>Code</B>&#148;)) or &#147;accumulated
funding deficiency&#148; (as defined in Section&nbsp;302 of ERISA) or any of the events set forth in Section&nbsp;4043(b) of ERISA (other than events with respect to which the <FONT STYLE="white-space:nowrap">thirty&nbsp;(30)-day&nbsp;notice</FONT>
requirement under Section&nbsp;4043 of ERISA has been waived) has occurred or could reasonably be expected to occur with respect to any employee benefit plan of the Company or any of its subsidiaries which could, singularly or in the aggregate, have
a material adverse effect; (ii)&nbsp;each &#147;employee benefit plan&#148; (as defined under ERISA) of the Company or any of its subsidiaries is in compliance with applicable law, including ERISA and the Code; (iii)&nbsp;neither the Company nor any
of its subsidiaries, nor any member of any group of organizations described in Sections&nbsp;414(b), (c), (m) or (o)&nbsp;of the Code of which the Company or any subsidiary is a member, have incurred and could not reasonably be expected to incur
liability under Title IV of ERISA with respect to the termination of, or withdrawal from, any pension plan (as defined in ERISA); and (iv)&nbsp;each pension </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
plan for which the Company or any of its subsidiaries would have any liability that is intended to be qualified under Section&nbsp;401(a) of the Code is so qualified, and nothing has occurred,
whether by action or by failure to act, which could, singularly or in the aggregate, cause the loss of such qualification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.
<I>Agreements to Sell and Purchase. </I>The Company hereby agrees to sell to the several Underwriters, and each Underwriter, upon the basis of the representations and warranties herein contained, but subject to the terms and conditions hereinafter
stated, agrees, severally and not jointly, to purchase from the Company the respective numbers of Firm Shares set forth in Schedule&nbsp;I hereto opposite its name at $[&#149;] a share (the &#147;<B>Purchase Price</B>&#148;), and such dealers may
reallow, a concession, not in excess of $[&#149;] a share, to any Underwriter or to certain other dealers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On the basis of the
representations and warranties contained in this Agreement, and subject to its terms and conditions, the Company agrees to sell to the Underwriters the Additional Shares, and the Underwriters shall have the right to purchase, severally and not
jointly, up to [&#149;] Additional Shares at the Purchase Price, provided, however, that the amount paid by the Underwriters for any Additional Shares shall be reduced by an amount per share equal to any dividends declared by the Company and payable
on the Firm Shares but not payable on such Additional Shares. The Representatives may exercise this right on behalf of the Underwriters in whole or from time to time in part by giving written notice not later than 30 days after the date of this
Agreement. Any exercise notice shall specify the number of Additional Shares to be purchased by the Underwriters and the date on which such shares are to be purchased. Each purchase date must be at least one business day after the written notice is
given and may not be earlier than the closing date for the Firm Shares or later than ten business days after the date of such notice. Additional Shares may be purchased as provided in Section&nbsp;4 hereof solely for the purpose of covering
over-allotments made in connection with the offering of the Firm Shares. On each day, if any, that Additional Shares are to be purchased (an &#147;<B>Option Closing Date</B>&#148;), each Underwriter agrees, severally and not jointly, to purchase the
number of Additional Shares (subject to such adjustments to eliminate fractional shares as the Representatives may determine) that bears the same proportion to the total number of Additional Shares to be purchased on such Option Closing Date as the
number of Firm Shares set forth in Schedule&nbsp;I hereto opposite the name of such Underwriter bears to the total number of Firm Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <I>Terms of Public Offering</I>. The Company is advised by the Representatives that the Underwriters propose to make a public offering of
their respective portions of the Shares as soon after the Registration Statement and this Agreement have become effective as in the Representatives&#146; judgment is advisable. The Company is further advised by the Representatives that the Shares
are to be offered to the public initially at $[&#149;] a share (the &#147;<B>Public Offering Price</B>&#148;) and to certain dealers selected by the Representatives at a price that represents a concession not in excess of $[&#149;] a share under the
Public Offering Price, and that any Underwriter may allow. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <I>Payment and Delivery. </I>Payment for the Firm Shares shall be made to the Company in
Federal or other funds immediately available in New York City against delivery of such Firm Shares for the respective accounts of the several Underwriters at 10:00 a.m., New York City time, on [&#149;], 2022, or at such other time on the same or
such other date, not later than [&#149;], 2022, as shall be designated in writing by Morgan Stanley. The time and date of such payment are hereinafter referred to as the &#147;<B>Closing Date</B>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payment for any Additional Shares shall be made to the Company in Federal or other funds immediately available in New York City against
delivery of such Additional Shares for the respective accounts of the several Underwriters at 10:00 a.m., New York City time, on the date specified in the corresponding notice described in Section&nbsp;2 or at such other time on the same or on such
other date, in any event not later than [&#149;], 2022, as shall be designated in writing by Morgan Stanley. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Firm Shares and
Additional Shares shall be registered in such names and in such denominations as the Representatives shall request not later than one full business day prior to the Closing Date or the applicable Option Closing Date, as the case may be. The Firm
Shares and Additional Shares shall be delivered to the Representatives on the Closing Date or an Option Closing Date, as the case may be, for the respective accounts of the several Underwriters, with any transfer taxes payable in connection with the
transfer of the Shares to the Underwriters duly paid, against payment of the Purchase Price therefor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <I>Conditions to the
Underwriters</I><I>&#146;</I><I> Obligations</I>. The obligations of the Company to sell the Shares to the Underwriters and the several obligations of the Underwriters to purchase and pay for the Shares on the Closing Date are subject to the
condition that the Registration Statement shall have become effective not later than [&#149;][a.m./p.m.] (New York City time) on the date hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The several obligations of the Underwriters are subject to the following further conditions: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Subsequent to the execution and delivery of this Agreement and prior to the Closing Date: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) no order suspending the effectiveness of the Registration Statement shall be in effect, and no proceeding for such purpose
or pursuant to Section&nbsp;8A under the Securities Act shall be pending before or threatened by the Commission; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)
there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded
any of the securities of the Company or any of its subsidiaries by any &#147;nationally recognized statistical rating organization,&#148; as such term is defined in Section&nbsp;3(a)(62) of the Securities Exchange Act of 1934, as amended (the
&#147;<B>Exchange Act</B>&#148;); and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) there shall not have occurred any change, or any development involving
a prospective change, in the condition, financial or otherwise, or in the earnings, business or operations of the Company and its subsidiaries, taken as a whole, from that set forth in the Time of Sale Prospectus that, in the Representatives&#146;
judgment, is material and adverse and that makes it, in the Representatives&#146; judgment, impracticable to market the Shares on the terms and in the manner contemplated in the Time of Sale Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Underwriters shall have received on the Closing Date a certificate, dated the Closing Date and signed by an executive
officer of the Company, to the effect set forth in Sections&nbsp;5(a)(i) and 5(a)(ii) above and to the effect that the representations and warranties of the Company contained in this Agreement are true and correct as of the Closing Date and that the
Company has complied with all of the agreements and satisfied all of the conditions on its part to be performed or satisfied hereunder on or before the Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The officer signing and delivering such certificate may rely upon the best of his or her knowledge as to proceedings threatened. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The Underwriters shall have received on the Closing Date an opinion and negative assurance letter of Cooley LLP, outside
counsel for the Company, dated the Closing Date, in form and substance satisfactory to the Representatives. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The
Underwriters shall have received on the Closing Date an opinion letter of Choate, Hall&nbsp;&amp; Stewart LLP, intellectual property counsel for the Company, dated the Closing Date, in form and substance satisfactory to the Representatives. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) The Underwriters shall have received on the Closing Date an opinion and negative assurance letter of Goodwin Procter LLP,
counsel for the Underwriters, dated the Closing Date, in form and substance satisfactory to the Representatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to the
negative assurance letters to be delivered pursuant to Sections 5(c) and 5(e) above, Cooley LLP and Goodwin Procter LLP may state that their opinions and beliefs are based upon their participation in the preparation of the Registration Statement,
the Time of Sale Prospectus and the Prospectus and any amendments or supplements thereto and review and discussion of the contents thereof, but are without independent check or verification, except as specified. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The opinions of Cooley LLP and Choate, Hall&nbsp;&amp; Stewart LLP described in Sections&nbsp;5(c)<SUP
STYLE="font-size:75%; vertical-align:top"> </SUP>and 5(d) above shall be rendered to the Underwriters at the request of the Company and shall so state therein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) The Underwriters shall have received, on each of the date hereof and the
Closing Date, a letter dated the date hereof or the Closing Date, as the case may be, in form and substance satisfactory to the Underwriters, from PricewaterhouseCoopers LLP, independent public accountants, containing statements and information of
the type ordinarily included in accountants&#146; &#147;comfort letters&#148; to underwriters with respect to the financial statements and certain financial information contained in the Registration Statement, the Time of Sale Prospectus and the
Prospectus; <I>provided</I> that the letter delivered on the Closing Date shall use a <FONT STYLE="white-space:nowrap">&#147;cut-off</FONT> date&#148; not earlier than the date hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) The Underwriters shall have received, on each of the date hereof and the Closing Date, a certificate signed by the Chief
Financial Officer of the Company, in his capacity as such, with respect to certain financial and accounting information in the Registration Statement, the Time of Sale Prospectus and the Prospectus, in form and substance reasonably satisfactory to
the Underwriters. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) The <FONT STYLE="white-space:nowrap">&#147;lock-up&#148;</FONT> agreements, each substantially in
the form of Exhibit A hereto, by certain stockholders, officers and directors of the Company, and addressed to the Representatives, relating to restrictions on sales and certain other dispositions of shares of Common Stock or certain other
securities, delivered to the Representatives on or before the date hereof (the &#147;<B><FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreements</B>&#148;), shall be in full force and effect on the Closing Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) The several obligations of the Underwriters to purchase Additional Shares hereunder are subject to the delivery to the
Representatives on the applicable Option Closing Date of the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) a certificate, dated the Option Closing Date
and signed by an executive officer of the Company, confirming that the certificate delivered on the Closing Date pursuant to Section&nbsp;5(b) hereof remains true and correct as of such Option Closing Date; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) an opinion and negative assurance letter of Cooley LLP, outside counsel for the Company, dated the Option Closing Date,
relating to the Additional Shares to be purchased on such Option Closing Date and otherwise to the same effect as the opinion required by Section&nbsp;5(c) hereof; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) an opinion letter of Choate, Hall&nbsp;&amp; Stewart LLP, intellectual property counsel for the Company, dated the Option
Closing Date, relating to the Additional Shares to be purchased on such Option Closing Date and otherwise to the same effect as the opinion required by Section&nbsp;5(d) hereof; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) an opinion and negative assurance letter of Goodwin Procter LLP, counsel for the Underwriters, dated the Option Closing
Date, relating to the Additional Shares to be purchased on such Option Closing Date and otherwise to the same effect as the opinion required by Section&nbsp;5(e) hereof; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) a letter dated the Option Closing Date, in form and substance
satisfactory to the Underwriters, from PricewaterhouseCoopers LLP, independent public accountants, substantially in the same form and substance as the letter furnished to the Underwriters pursuant to Section&nbsp;5(f) hereof; <I>provided</I> that
the letter delivered on the Option Closing Date shall use a <FONT STYLE="white-space:nowrap">&#147;cut-off</FONT> date&#148; not earlier than two business days prior to such Option Closing Date; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) a certificate, dated the Option Closing Date and signed by the Chief Financial Officer of the Company, substantially in
the same form and substance as the certificate delivered to the Underwriters pursuant to Section&nbsp;5(g) hereof; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) such other documents as the Representatives may reasonably request with respect to the good standing of the Company, the
due authorization and issuance of the Additional Shares to be sold on such Option Closing Date and other matters related to the issuance of such Additional Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <I>Covenants of the Company</I>. The Company covenants with each Underwriter as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) To furnish to the Representatives, upon written request, without charge, five signed copies of the Registration Statement
(including exhibits thereto) and for delivery to each other Underwriter a conformed copy of the Registration Statement (without exhibits thereto) and to furnish to the Representatives in New York City, without charge, prior to 10:00&nbsp;a.m. New
York City time on the business day next succeeding the date of this Agreement and during the period mentioned in Section&nbsp;6(e) or 6(f) below, as many copies of the Time of Sale Prospectus, the Prospectus and any supplements and amendments
thereto or to the Registration Statement as the Representatives may reasonably request. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Before amending or
supplementing the Registration Statement, the Time of Sale Prospectus or the Prospectus, to furnish to the Representatives a copy of each such proposed amendment or supplement and not to file any such proposed amendment or supplement to which the
Representatives reasonably object, and to file with the Commission within the applicable period specified in Rule&nbsp;424(b) under the Securities Act any prospectus required to be filed pursuant to such Rule. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) To furnish to the Representatives a copy of each proposed free writing prospectus to be prepared by or on behalf of, used
by, or referred to by the Company and not to use or refer to any proposed free writing prospectus to which the Representatives reasonably object. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Not to take any action that would result in an Underwriter or the
Company being required to file with the Commission pursuant to Rule 433(d) under the Securities Act a free writing prospectus prepared by or on behalf of the Underwriter that the Underwriter otherwise would not have been required to file thereunder.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) If the Time of Sale Prospectus is being used to solicit offers to buy the Shares at a time when the Prospectus is not
yet available to prospective purchasers and any event shall occur or condition exist as a result of which it is necessary to amend or supplement the Time of Sale Prospectus in order to make the statements therein, in the light of the circumstances,
not misleading, or if any event shall occur or condition exist as a result of which the Time of Sale Prospectus conflicts with the information contained in the Registration Statement then on file, or if, in the opinion of counsel for the
Underwriters, it is necessary to amend or supplement the Time of Sale Prospectus to comply with applicable law, forthwith to prepare, file with the Commission and furnish, at its own expense, to the Underwriters and to any dealer upon request,
either amendments or supplements to the Time of Sale Prospectus so that the statements in the Time of Sale Prospectus as so amended or supplemented will not, in the light of the circumstances when the Time of Sale Prospectus is delivered to a
prospective purchaser, be misleading or so that the Time of Sale Prospectus, as amended or supplemented, will no longer conflict with the Registration Statement, or so that the Time of Sale Prospectus, as amended or supplemented, will comply with
applicable law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) If, during such period after the first date of the public offering of the Shares as in the opinion of
counsel for the Underwriters the Prospectus (or in lieu thereof the notice referred to in Rule 173(a) of the Securities Act) is required by law to be delivered in connection with sales by an Underwriter or dealer, any event shall occur or condition
exist as a result of which it is necessary to amend or supplement the Prospectus in order to make the statements therein, in the light of the circumstances when the Prospectus (or in lieu thereof the notice referred to in Rule 173(a) of the
Securities Act) is delivered to a purchaser, not misleading, or if, in the opinion of counsel for the Underwriters, it is necessary to amend or supplement the Prospectus to comply with applicable law, forthwith to prepare, file with the Commission
and furnish, at its own expense, to the Underwriters and to the dealers (whose names and addresses the Representatives will furnish to the Company) to which Shares may have been sold by the Representatives on behalf of the Underwriters and to any
other dealers upon request, either amendments or supplements to the Prospectus so that the statements in the Prospectus as so amended or supplemented will not, in the light of the circumstances when the Prospectus (or in lieu thereof the notice
referred to in Rule 173(a) of the Securities Act) is delivered to a purchaser, be misleading or so that the Prospectus, as amended or supplemented, will comply with applicable law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) To endeavor to qualify the Shares for offer and sale under the
securities or Blue Sky laws of such jurisdictions as the Representatives shall reasonably request; <I>provided</I>, that the Company shall not be required to (i)&nbsp;qualify as a foreign corporation or other entity or as a dealer in securities in
any such jurisdiction where it would not otherwise be required to so qualify, (ii)&nbsp;file any general consent to service of process in any such jurisdiction or (iii)&nbsp;subject itself to taxation in any such jurisdiction if it is not otherwise
so subject. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) To make generally available (which may be satisfied by filing with the Commission on its Electronic Data
Gathering Analysis and Retrieval System) to the Company&#146;s security holders and to the Representatives as soon as practicable an earnings statement covering a period of at least twelve months beginning with the first fiscal quarter of the
Company occurring after the date of this Agreement which shall satisfy the provisions of Section&nbsp;11(a) of the Securities Act and the rules and regulations of the Commission thereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Whether or not the transactions contemplated in this Agreement are consummated or this Agreement is terminated, to pay or
cause to be paid all expenses incident to the performance of its obligations under this Agreement, including: (i)&nbsp;the fees, disbursements and expenses of the Company&#146;s counsel and the Company&#146;s accountants in connection with the
registration and delivery of the Shares under the Securities Act and all other fees or expenses in connection with the preparation and filing of the Registration Statement, any preliminary prospectus, the Time of Sale Prospectus, the Prospectus, any
free writing prospectus prepared by or on behalf of, used by, or referred to by the Company and amendments and supplements to any of the foregoing, including all printing costs associated therewith, and the mailing and delivering of copies thereof
to the Underwriters and dealers, in the quantities hereinabove specified, (ii)&nbsp;all costs and expenses related to the transfer and delivery of the Shares to the Underwriters, including any transfer taxes payable thereon, (iii)&nbsp;the cost of
printing or producing any Blue Sky or Legal Investment memorandum in connection with the offer and sale of the Shares under state securities laws and all expenses in connection with the qualification of the Shares for offer and sale under state
securities laws as provided in Section&nbsp;6(g) hereof, including filing fees and the reasonable fees and disbursements of counsel for the Underwriters in connection with such qualification and in connection with the Blue Sky or Legal Investment
memorandum(provided such fees and disbursements of counsel payable by the Company shall not exceed $5,000), (iv) all filing fees and the reasonable fees and disbursements of counsel to the Underwriters incurred in connection with the review and
qualification of the offering of the Shares by FINRA (provided such fees and disbursements of counsel payable by the Company shall not exceed $35,000), (v) all fees and expenses in connection with the preparation and filing of the registration
statement on <FONT STYLE="white-space:nowrap">Form&nbsp;8-A</FONT> relating to the Common Stock and all costs and expenses incident to listing the Shares on the Nasdaq Global Market, (vi) the cost of printing certificates representing the Shares,
(vii)&nbsp;the costs and charges of any transfer agent, registrar or depositary, (viii)&nbsp;the costs and expenses of the Company relating to investor presentations on any &#147;road show&#148; undertaken in connection with the marketing of the
offering of the Shares (with the Underwriters agreeing to pay all costs and expenses related to their participation </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
in investor presentations on any &#147;road show&#148; undertaken in connection with the marketing of the offering of the Shares), including, without limitation, expenses associated with the
preparation or dissemination of any electronic road show, expenses associated with the production of road show slides and graphics, fees and expenses of any consultants engaged in connection with the road show presentations with the prior approval
of the Company, travel and lodging expenses of the representatives and officers of the Company and any such consultants, and 50% of the cost of any aircraft chartered in connection with the road show (the remaining 50% of the cost of such aircraft
to be paid by the Underwriters), (ix) the document production charges and expenses associated with printing this Agreement and (x)&nbsp;all other costs and expenses incident to the performance of the obligations of the Company hereunder for which
provision is not otherwise made in this Section. It is understood, however, that except as provided in this Section, Section&nbsp;8 entitled &#147;Indemnity and Contribution&#148; and the last paragraph of Section&nbsp;11 below, the Underwriters
will pay all of their costs and expenses, including fees and disbursements of their counsel, stock transfer taxes payable on resale of any of the Shares by them and any advertising expenses connected with any offers they may make. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) The Company will promptly notify the Representatives if the Company ceases to be an Emerging Growth Company at any time
prior to the later of (i)&nbsp;completion of the distribution of the Shares within the meaning of the Securities Act and (ii)&nbsp;completion of the Restricted Period (as defined in this Section&nbsp;6). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) If at any time following the distribution of any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication that is a written communication within the meaning of Rule 405 under the Securities Act there occurred or occurs an event or development
as a result of which such <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication included or would include an untrue statement of a material fact or omitted or would omit to state a material
fact necessary in order to make the statements therein, in the light of the circumstances existing at that subsequent time, not misleading, the Company will promptly notify the Representatives and will promptly amend or supplement, at its own
expense, such <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication to eliminate or correct such untrue statement or omission. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) The Company will deliver to each Underwriter (or its agent), on the date of execution of this Agreement, a properly
completed and executed Certification Regarding Beneficial Owners of Legal Entity Customers, together with copies of identifying documentation, and the Company undertakes to provide such additional supporting documentation as each Underwriter may
reasonably request in connection with the verification of the foregoing Certification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company also covenants with each Underwriter
that, without the prior written consent of Morgan Stanley, Jefferies and Cowen on behalf of the Underwriters, it will not, and will not publicly disclose an intention to, during the period ending 180 days after the date of the Prospectus (the
&#147;<B>Restricted Period</B>&#148;), (1)&nbsp;offer, pledge, sell, contract </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or
indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock or (2)&nbsp;enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic
consequences of ownership of the Common Stock, whether any such transaction described in clause&nbsp;(1) or (2)&nbsp;above is to be settled by delivery of Common Stock or such other securities, in cash or otherwise or (3)&nbsp;file any registration
statement with the Commission relating to the offering of any shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The restrictions contained in the preceding paragraph shall not apply to (A)&nbsp;the Shares to be sold hereunder, (B)&nbsp;the issuance by
the Company of shares of Common Stock upon the exercise of an option or warrant or the conversion of a security outstanding on the date hereof as described in each of the Time of Sale Prospectus and Prospectus, (C)&nbsp;facilitating the
establishment of a trading plan on behalf of a stockholder, officer or director of the Company pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act for the transfer of shares of Common Stock, <I>provided</I> that
(i)&nbsp;such plan does not provide for the transfer of Common Stock during the Restricted Period and (ii)&nbsp;to the extent a public announcement or filing under the Exchange Act, if any, is required of or voluntarily made by the Company regarding
the establishment of such plan, such announcement or filing shall include a statement to the effect that no transfer of Common Stock may be made under such plan during the Restricted Period, (D)&nbsp;grants of options, restricted stock or other
equity awards and the issuance of Common Stock or securities convertible into or exercisable for Common Stock (whether upon the exercise of stock options or otherwise) to employees, officers, directors, advisors, or consultants of the Company
pursuant to the terms of an employee benefit plan in effect on the date hereof and as described in the Time of Sale Prospectus, provided that the Company shall cause each recipient of such grant to execute and deliver to the Representatives an
agreement substantially in the form of Exhibit A hereto if such recipient has not already delivered one, (E)&nbsp;the filing of a registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> to register Common Stock issuable pursuant
to any employee benefit plans, qualified stock option plans or other employee compensation plans described in the Time of Sale Prospectus, or (F)&nbsp;the issuance by the Company of shares of Common Stock or any securities convertible into, or
exercisable or exchangeable for, Common Stock, or the entrance into an agreement to issue Common Stock or any securities convertible into, or exercisable or exchangeable for, Common Stock, in connection with any merger, joint venture, strategic
alliances, commercial or other collaborative transaction or the acquisition or license of the business, property, technology or other assets of another individual or entity or the assumption of an employee benefit plan in connection with a merger or
acquisition; <I>provided</I>, that the aggregate number of shares of Common Stock or any securities convertible into, or exercisable or exchangeable for, Common Stock that the Company may issue or agree to issue pursuant to this clause
(F)&nbsp;shall not exceed 5% of the total outstanding share capital of the Company immediately following the issuance of the Shares; and provided further, that the recipients thereof provide to the Representatives an agreement substantially in the
form of Exhibit A hereto if such recipient has not already delivered one. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Morgan Stanley, Jefferies and Cowen, in their sole discretion, agree to release or waive
the restrictions on the transfer of Shares set forth in a <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement for an officer or director of the Company and provide the Company with notice of the impending release or waiver at least three
business days before the effective date of the release or waiver, the Company agrees to announce the impending release or waiver by a press release substantially in the form of Exhibit B hereto through a major news service at least two business days
before the effective date of the release or waiver. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <I>Covenants of the Underwriters</I>. Each Underwriter, severally and not jointly,
covenants with the Company not to take any action that would result in the Company being required to file with the Commission under Rule 433(d) a free writing prospectus prepared by or on behalf of such Underwriter that otherwise would not be
required to be filed by the Company thereunder, but for the action of the Underwriter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <I>Indemnity and Contribution.</I> (a)&nbsp;The
Company agrees to indemnify and hold harmless each Underwriter, each person, if any, who controls any Underwriter within the meaning of either Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act and each affiliate of any
Underwriter within the meaning of Rule&nbsp;405 under the Securities Act from and against any and all losses, claims, damages and liabilities (including, without limitation, any legal or other expenses reasonably incurred in connection with
defending or investigating any such action or claim) that arise out of, or are based upon, any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement or any amendment thereof, any preliminary
prospectus, the Time of Sale Prospectus or any amendment or supplement thereto, any issuer free writing prospectus as defined in Rule 433(h) under the Securities Act, any Company information that the Company has filed, or is required to file,
pursuant to Rule 433(d) under the Securities Act, any road show as defined in Rule 433(h) under the Securities Act (a &#147;road show&#148;), the Prospectus or any amendment or supplement thereto, or any <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, or arise out of, or are based upon, any omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements
therein not misleading, except insofar as such losses, claims, damages or liabilities arise out of, or are based upon, any such untrue statement or omission or alleged untrue statement or omission made in reliance upon and in conformity with any
information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use therein, it being understood and agreed that the only such information furnished by the Underwriters
through the Representatives consists of the information described as such in paragraph (b)&nbsp;below. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Each
Underwriter agrees, severally and not jointly, to indemnify and hold harmless the Company, its directors, its officers who sign the Registration Statement and each person, if any, who controls the Company within the meaning of either Section&nbsp;15
of the Securities Act or Section&nbsp;20 of the Exchange Act to the same extent as the foregoing indemnity from the Company to such Underwriter, but only with reference to information relating to such Underwriter furnished to the Company in writing
by such Underwriter through the Representatives expressly for use in the Registration Statement, any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
preliminary prospectus, the Time of Sale Prospectus, any issuer free writing prospectus, road show or the Prospectus or any amendment or supplement thereto. The Company acknowledges that the
following statements set forth under the heading &#147;Underwriting,&#148; (w) the name of the Underwriters, (x)&nbsp;the [third] paragraph concerning the terms of the offering by the Underwriters, (y)&nbsp;the [seventh] paragraph related to the
Underwriter&#146;s intention not to make sales to discretionary accounts, and (z)&nbsp;the [thirteenth] paragraph related to stabilization and syndicate covering transactions, in the Registration Statement, the Time of Sale Prospectus and the
Prospectus constitute the only information furnished in writing by or on behalf of the several Underwriters for inclusion in the documents referred to in the foregoing indemnity (the &#147;<B>Underwriter Information</B>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) In case any proceeding (including any governmental investigation) shall be instituted involving any person in respect of
which indemnity may be sought pursuant to Section&nbsp;8(a) or 8(b), such person (the &#147;<B>indemnified party</B>&#148;) shall promptly notify the person against whom such indemnity may be sought (the &#147;<B>indemnifying party</B>&#148;) in
writing and the indemnifying party, upon request of the indemnified party, shall retain counsel reasonably satisfactory to the indemnified party to represent the indemnified party and any others the indemnifying party may designate in such
proceeding and shall pay the reasonably incurred fees and disbursements of such counsel related to such proceeding. In any such proceeding, any indemnified party shall have the right to retain its own counsel, but the fees and expenses of such
counsel shall be at the expense of such indemnified party unless (i)&nbsp;the indemnifying party and the indemnified party shall have mutually agreed to the retention of such counsel or (ii)&nbsp;the named parties to any such proceeding (including
any impleaded parties) include both the indemnifying party and the indemnified party and representation of both parties by the same counsel would be inappropriate due to actual or potential differing interests between them. It is understood that the
indemnifying party shall not, in respect of the legal expenses of any indemnified party in connection with any proceeding or related proceedings in the same jurisdiction, be liable for the fees and expenses of more than one separate firm (in
addition to any local counsel) for all such indemnified parties and that all such fees and expenses shall be reimbursed as they are incurred. Such firm shall be designated in writing by the Representatives, in the case of parties indemnified
pursuant to Section&nbsp;8(a), and by the Company, in the case of parties indemnified pursuant to Section&nbsp;8(b). The indemnifying party shall not be liable for any settlement of any proceeding effected without its written consent, but if settled
with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party from and against any loss or liability by reason of such settlement or judgment. Notwithstanding the foregoing
sentence, if at any time an indemnified party shall have requested an indemnifying party to reimburse the indemnified party for fees and expenses of counsel as contemplated by the second and third sentences of this paragraph, the indemnifying party
agrees that it shall be liable for any settlement of any proceeding effected without its written consent if (i)&nbsp;such settlement is entered into more than 30 days after receipt by such indemnifying party of the aforesaid request and
(ii)&nbsp;such indemnifying party shall </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
not have reimbursed the indemnified party in accordance with such request prior to the date of such settlement. No indemnifying party shall, without the prior written consent of the indemnified
party, effect any settlement of any pending or threatened proceeding in respect of which any indemnified party is or could have been a party and indemnity could have been sought hereunder by such indemnified party, unless such settlement includes an
unconditional release of such indemnified party from all liability on claims that are the subject matter of such proceeding. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) To the extent the indemnification provided for in Section&nbsp;8(a) or 8(b) is unavailable to an indemnified party or
insufficient in respect of any losses, claims, damages or liabilities referred to therein, then each indemnifying party under such paragraph, in lieu of indemnifying such indemnified party thereunder, shall contribute to the amount paid or payable
by such indemnified party as a result of such losses, claims, damages or liabilities (i)&nbsp;in such proportion as is appropriate to reflect the relative benefits received by the Company on the one hand and the Underwriters on the other hand from
the offering of the Shares or (ii)&nbsp;if the allocation provided by clause&nbsp;8(d)(i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause&nbsp;8(d)(i)
above but also the relative fault of the Company on the one hand and of the Underwriters on the other hand in connection with the statements or omissions that resulted in such losses, claims, damages or liabilities, as well as any other relevant
equitable considerations. The relative benefits received by the Company on the one hand and the Underwriters on the other hand in connection with the offering of the Shares shall be deemed to be in the same respective proportions as the net proceeds
from the offering of the Shares (before deducting expenses) received by the Company and the total underwriting discounts and commissions received by the Underwriters, in each case as set forth in the table on the cover of the Prospectus, bear to the
aggregate Public Offering Price of the Shares. The relative fault of the Company on the one hand and the Underwriters on the other hand shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a
material fact or the omission or alleged omission to state a material fact relates to information supplied by the Company or by the Underwriters and the parties&#146; relative intent, knowledge, access to information and opportunity to correct or
prevent such statement or omission. The Underwriters&#146; respective obligations to contribute pursuant to this Section&nbsp;8 are several in proportion to the respective number of Shares they have purchased hereunder, and not joint. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) The Company and the Underwriters agree that it would not be just or equitable if contribution pursuant to this
Section&nbsp;8 were determined by <I>pro rata</I> allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation that does not take account of the equitable considerations referred to in
Section&nbsp;8(d). The amount paid or payable by an indemnified party as a result of the losses, claims, damages and liabilities referred to in Section&nbsp;8(d) shall be deemed to include, subject to the limitations set forth above, any legal or
other expenses reasonably incurred by such indemnified party </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
in connection with investigating or defending any such action or claim. Notwithstanding the provisions of this Section&nbsp;8, no Underwriter shall be required to contribute any amount in excess
of the amount by which the total price at which the Shares underwritten by it and distributed to the public were offered to the public exceeds the amount of any damages that such Underwriter has otherwise been required to pay by reason of such
untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the Securities Act) shall be entitled to contribution from any person who was not
guilty of such fraudulent misrepresentation. The remedies provided for in this Section&nbsp;8 are not exclusive and shall not limit any rights or remedies which may otherwise be available to any indemnified party at law or in equity. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) The indemnity and contribution provisions contained in this Section&nbsp;8 and the representations, warranties and other
statements of the Company contained in this Agreement shall remain operative and in full force and effect regardless of (i)&nbsp;any termination of this Agreement, (ii)&nbsp;any investigation made by or on behalf of any Underwriter, any person
controlling any Underwriter or any affiliate of any Underwriter or by or on behalf of the Company, its officers or directors or any person controlling the Company and (iii)&nbsp;acceptance of and payment for any of the Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <I>Termination</I>. The Underwriters may terminate this Agreement by notice given by the Representatives to the Company, if after the
execution and delivery of this Agreement and prior to or on the Closing Date or any Option Closing Date, as the case may be, (i)&nbsp;trading generally shall have been suspended or materially limited on, or by, as the case may be, any of the New
York Stock Exchange, the NYSE American, the Nasdaq Global Market, the Chicago Board of Options Exchange, the Chicago Mercantile Exchange or the Chicago Board of Trade, (ii)&nbsp;trading of any securities of the Company shall have been suspended on
any exchange or in any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market, (iii)&nbsp;a material disruption in securities settlement, payment or clearance services in the United States shall have
occurred, (iv)&nbsp;any moratorium on commercial banking activities shall have been declared by Federal or New York State authorities or (v)&nbsp;there shall have occurred any outbreak or escalation of hostilities, or any change in financial
markets, or any calamity or crisis that, in the Representatives&#146; judgment, is material and adverse and which, singly or together with any other event specified in this clause&nbsp;(v), makes it, in the Representatives&#146; judgment,
impracticable or inadvisable to proceed with the offer, sale or delivery of the Shares on the terms and in the manner contemplated in the Time of Sale Prospectus or the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <I>Effectiveness; Defaulting Underwriters</I>. This Agreement shall become effective upon the execution and delivery hereof by the parties
hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If, on the Closing Date or an Option Closing Date, as the case may be, any one or more of the Underwriters shall fail or refuse
to purchase Shares that it has or they have agreed to purchase hereunder on such date, and the aggregate number of Shares which such defaulting Underwriter or Underwriters agreed but failed or refused to purchase is
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
not more than <FONT STYLE="white-space:nowrap">one-tenth</FONT> of the aggregate number of the Shares to be purchased on such date, the other Underwriters shall be obligated severally in the
proportions that the number of Firm Shares set forth opposite their respective names in Schedule&nbsp;I bears to the aggregate number of Firm Shares set forth opposite the names of all such <FONT STYLE="white-space:nowrap">non-defaulting</FONT>
Underwriters, or in such other proportions as the Representatives may specify, to purchase the Shares which such defaulting Underwriter or Underwriters agreed but failed or refused to purchase on such date; <I>provided</I> that in no event shall the
number of Shares that any Underwriter has agreed to purchase pursuant to this Agreement be increased pursuant to this Section&nbsp;11 by an amount in excess of <FONT STYLE="white-space:nowrap">one-ninth</FONT> of such number of Shares without the
written consent of such Underwriter. If, on the Closing Date, any Underwriter or Underwriters shall fail or refuse to purchase Firm Shares and the aggregate number of Firm Shares with respect to which such default occurs is more than <FONT
STYLE="white-space:nowrap">one-tenth</FONT> of the aggregate number of Firm Shares to be purchased on such date, and arrangements satisfactory to the Representatives and the Company for the purchase of such Firm Shares are not made within 36 hours
after such default, this Agreement shall terminate without liability on the part of any <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriter or the Company. In any such case either the Representatives or the Company shall have the
right to postpone the Closing Date, but in no event for longer than seven days, in order that the required changes, if any, in the Registration Statement, in the Time of Sale Prospectus, in the Prospectus or in any other documents or arrangements
may be effected. If, on an Option Closing Date, any Underwriter or Underwriters shall fail or refuse to purchase Additional Shares and the aggregate number of Additional Shares with respect to which such default occurs is more than <FONT
STYLE="white-space:nowrap">one-tenth</FONT> of the aggregate number of Additional Shares to be purchased on such Option Closing Date, the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters shall have the option to (i)&nbsp;terminate
their obligation hereunder to purchase the Additional Shares to be sold on such Option Closing Date or (ii)&nbsp;purchase not less than the number of Additional Shares that such <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters
would have been obligated to purchase in the absence of such default. Any action taken under this paragraph shall not relieve any defaulting Underwriter from liability in respect of any default of such Underwriter under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If this Agreement shall be terminated by the Underwriters, or any of them, because of any failure or refusal on the part of the Company to
comply with the terms or to fulfill any of the conditions of this Agreement, or if for any reason the Company shall be unable to perform its obligations under this Agreement, other than by reason of a default by the Underwriters, the Company will
reimburse the Underwriters or such Underwriters as have so terminated this Agreement with respect to themselves, severally, for all <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses (including the
reasonably incurred fees and disbursements of their counsel) reasonably incurred by such Underwriters in connection with this Agreement or the offering contemplated hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <I>Entire Agreement</I>. (a)&nbsp;This Agreement, together with any contemporaneous written agreements and any prior written agreements
(to the extent not superseded by this Agreement) that relate to the offering of the Shares, represents the entire agreement between the Company and the Underwriters with respect to the preparation of any preliminary prospectus, the Time of Sale
Prospectus, the Prospectus, the conduct of the offering, and the purchase and sale of the Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Company acknowledges that in connection with the offering of the
Shares: (i)&nbsp;the Underwriters have acted at arm&#146;s length, are not agents of, and owe no fiduciary duties to, the Company or any other person, (ii)&nbsp;the Underwriters owe the Company only those duties and obligations set forth in this
Agreement, any contemporaneous written agreements and prior written agreements (to the extent not superseded by this Agreement), if any, (iii)&nbsp;the Underwriters may have interests that differ from those of the Company, and (iv)&nbsp;none of the
activities of the Underwriters in connection with the transactions contemplated herein constitutes a recommendation, investment advice, or solicitation of any action by the Underwriters with respect to any entity or natural person. The Company
waives to the full extent permitted by applicable law any claims it may have against the Underwriters arising from an alleged breach of fiduciary duty in connection with the offering of the Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <I>Recognition of the U.S. Special Resolution Regimes</I>. (a)&nbsp;In the event that any Underwriter that is a Covered Entity becomes
subject to a proceeding under a U.S. Special Resolution Regime, the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective
under the U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) In the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a
proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S.
Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes
of this Section a &#147;<B>BHC Act Affiliate</B>&#148; has the meaning assigned to the term &#147;affiliate&#148; in, and shall be interpreted in accordance with, 12 U.S.C. &#167; 1841(k). &#147;<B>Covered Entity</B>&#148; means any of the
following: (i)&nbsp;a &#147;covered entity&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 252.82(b); (ii) a &#147;covered bank&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R.
&#167; 47.3(b); or (iii)&nbsp;a &#147;covered FSI&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 382.2(b). &#147;<B>Default Right</B>&#148; has the meaning assigned to that term in, and shall be interpreted in
accordance with, 12 C.F.R. &#167;&#167; 252.81, 47.2 or 382.1, as applicable. &#147;<B>U.S. Special Resolution Regime</B>&#148; means each of (i)&nbsp;the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii)&nbsp;Title
II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <I>Counterparts;
Electronic Signature</I>. This Agreement may be signed in two or more counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. Delivery of an executed Agreement by
one party to the other may be made by facsimile, electronic mail or other transmission method as permitted by applicable law, and the parties hereto agree that any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. A party&#146;s electronic signature (complying with the U.S. federal
ESIGN Act of 2000, the New York Electronic Signatures and Records Act (N.Y. State Tech. &#167;&#167; <FONT STYLE="white-space:nowrap">301-309),</FONT> as amended from time to time, or other applicable law) of this Agreement shall have the same
validity and effect as a signature affixed by the party&#146;s hand. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <I>Applicable Law</I>. This Agreement shall be governed by and
construed in accordance with the internal laws of the State of New York. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <I>Headings</I>. The headings of the sections of this
Agreement have been inserted for convenience of reference only and shall not be deemed a part of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><I>Notices</I>. All
communications hereunder shall be in writing and effective only upon receipt and if to the Underwriters shall be delivered, mailed or sent to the Representatives at Morgan Stanley&nbsp;&amp;&nbsp;Co. LLC, 1585&nbsp;Broadway, New York, New
York&nbsp;10036, Attention: Equity Syndicate Desk, with a copy to the Legal Department; Jefferies LLC, 520 Madison Avenue, New York, New York 10022, Attention: General Counsel; Cowen and Company, LLC, 599 Lexington Avenue, New York, New York 10022,
Attention: Head of Equity Capital Markets, with a copy to the General Counsel, Investment Banking; and Piper Sandler&nbsp;&amp; Co., 1251 Avenue of the Americas, 7th Floor, New York, New York 10020, Attention: General Counsel; and if to the Company
shall be delivered, mailed or sent to Acrivon Therapeutics, Inc. at 480 Arsenal Way Suit 100, Watertown, Massachusetts 02472, Attention: Chief Executive Officer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Remainder of page intentionally blank] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Very truly yours, <BR></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Acrivon Therapeutics, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
</TABLE></DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accepted as of the date hereof</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Morgan Stanley&nbsp;&amp; Co. LLC <BR>Jefferies LLC<BR>Cowen and Company, LLC<BR>Piper Sandler&nbsp;&amp; Co.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Acting severally on behalf of themselves and</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the several Underwriters named in</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Schedule I hereto.</P></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Morgan Stanley&nbsp;&amp; Co. LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Jefferies LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Cowen and Company, LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Piper Sandler&nbsp;&amp; Co.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Underwriting Agreement] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>SCHEDULE I </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Underwriter</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Firm&nbsp;Shares&nbsp;To<BR>Be Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Morgan Stanley&nbsp;&amp; Co. LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[&#149;]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jefferies LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[&#149;]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cowen and Company, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[&#149;]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Piper Sandler&nbsp;&amp; Co.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[&#149;]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[&#149;]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">I-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>SCHEDULE II </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Time of Sale Prospectus </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Preliminary Prospectus issued [&#149;] </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[identify all free writing prospectuses filed by the Company under Rule 433(d) of the Securities Act]
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[free writing prospectus containing a description of terms that does not reflect final terms, if the Time of
Sale Prospectus does not include a final term sheet] </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[orally communicated pricing information such as price per share and size of offering if a Rule 134 pricing
term sheet is used at the time of sale instead of a pricing term sheet filed by the Company under Rule 433(d) as a free writing prospectus] </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF <FONT STYLE="white-space:nowrap">LOCK-UP</FONT> AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Morgan Stanley&nbsp;&amp; Co. LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jefferies LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cowen and Company, LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Piper Sandler&nbsp;&amp; Co. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As Representatives of the several Underwriters </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Morgan Stanley&nbsp;&amp; Co. LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">1585
Broadway </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">New York, New York 10036 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o
Jefferies LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">820 Madison Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Cowen and Company,
LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">599 Lexington Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o
Piper&nbsp;Sandler&nbsp;&amp; Co. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">1251 Avenue of the Americas, 7th&nbsp;Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">New York, New York 10020 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned understands that Morgan Stanley&nbsp;&amp; Co. LLC (&#147;<B>Morgan Stanley</B>&#148;), Jefferies LLC
(&#147;<B>Jefferies</B>&#148;), Cowen and Company, LLC (&#147;<B>Cowen</B>&#148;) and Piper Sandler&nbsp;&amp; Co. (collectively, the &#147;<B>Representatives</B>&#148;) propose to enter into an Underwriting Agreement (the &#147;<B>Underwriting
Agreement</B>&#148;) with Acrivon Therapeutics, Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;), providing for the public offering (the &#147;<B>Public Offering</B>&#148;) by the several Underwriters, including the Representatives (the
&#147;<B>Underwriters</B>&#148;), of shares (the &#147;<B>Shares</B>&#148;) of the common stock, par value $0.001 per share of the Company (the &#147;<B>Common Stock</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To induce the Underwriters that may participate in the Public Offering to continue their efforts in connection with the Public Offering, the
undersigned hereby agrees that, without the prior written consent of Morgan Stanley, Jefferies and Cowen on behalf of the Underwriters, it will not, and will not publicly disclose an intention to, during the period commencing on the date hereof and
ending 180 days after the date of the final prospectus (the &#147;<B>Restricted Period</B>&#148;) relating to the Public Offering (the &#147;<B>Prospectus</B>&#148;), (1)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to
purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of Common </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Stock beneficially owned (as such term is used in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> of the Securities Exchange Act of 1934, as amended (the &#147;<B>Exchange Act</B>&#148;)), by
the undersigned or any other securities so owned convertible into or exercisable or exchangeable for Common Stock or (2)&nbsp;enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences
of ownership of the Common Stock, whether any such transaction described in clause&nbsp;(1) or (2)&nbsp;above is to be settled by delivery of Common Stock or such other securities, in cash or otherwise. The foregoing sentence shall not apply to:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">transactions relating to shares of Common Stock or other securities acquired in the Public Offering or in open
market transactions after the completion of the Public Offering, <I>provided</I> that no filing under Section&nbsp;16(a) of the Exchange Act reporting a reduction in beneficial ownership of the Common Stock shall be voluntarily made during the
Restricted Period in connection with subsequent sales of Common Stock or other securities acquired in the Public Offering or in such open market transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">transfers or distributions of shares of Common Stock or any security convertible into or exercisable or
exchangeable for Common Stock (i)&nbsp;as a bona fide gift or charitable contribution, (ii)&nbsp;by will or intestacy or to any immediate family or to a trust for the direct or indirect benefit of the undersigned and/or any immediate family,
(iii)&nbsp;to limited partners, members, stockholders or holders of similar equity interests in the undersigned or (iv)&nbsp;if the undersigned is a corporation, to another corporation, partnership, limited liability company, trust or other business
entity that is an affiliate (as defined in Rule 405 promulgated under the Securities Act of 1933, as amended) of the undersigned, or to any investment fund or other entity controlled or managed by the undersigned or affiliates of the undersigned;
<I>provided</I> that (A)&nbsp;each transferee, donee or distributee shall sign and deliver a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement substantially in the form of this agreement and (B)&nbsp;no filing under Section&nbsp;16(a) of the
Exchange Act, reporting a reduction in beneficial ownership of shares of Common Stock, shall be required or shall be voluntarily made during the Restricted Period, and <I>provided further</I> that any such transfer shall not involve a disposition
for value; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">transfers of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock by
operation of law pursuant to a qualified domestic order or other court order or in connection with a divorce settlement; provided that (i)&nbsp;any filing under Section&nbsp;16(a) of the Exchange Act made during the Restricted Period shall clearly
indicate in the footnotes thereto that (A)&nbsp;the filing relates to the circumstances described in this clause (c)&nbsp;and (B) no securities were sold by the undersigned, and (ii)&nbsp;the undersigned does not otherwise voluntarily effect any
other public filing or report regarding such transfers during the Restricted Period; </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the receipt by the undersigned from the Company of shares of Common Stock upon the transfer or disposition of
shares of Common Stock or any securities convertible into Common Stock to the Company upon a vesting or settlement event of the Company&#146;s securities or vesting of restricted stock unit awards or upon the exercise of options to purchase the
Company&#146;s securities on a &#147;cashless&#148; or &#147;net exercise&#148; basis, in each case pursuant to any equity incentive plan of the Company described in the Prospectus and to the extent permitted by the instruments representing such
restricted stock unit awards or options outstanding as of the date of the Prospectus (and solely to cover withholding tax obligations in connection with such transaction and any transfer to the Company for the payment of taxes as a result of such
transaction), provided that (i)&nbsp;the shares received upon exercise or settlement of the option are subject to the terms of this agreement, (ii)&nbsp;no public disclosure or filing under Section&nbsp;16(a) of the Exchange Act shall be voluntarily
made during the Restricted Period and (iii)&nbsp;to the extent a filing under Section&nbsp;16(a) of the Exchange Act is required during the Restricted Period as a result of transfers in this clause (d), it shall clearly indicate that (A)&nbsp;the
filing relates to the circumstances described in this clause (d), including that the securities remain subject to the terms of this agreement and (B)&nbsp;no securities were sold by the undersigned other than pursuant to this clause (d);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">transfers to the Company to the extent required in order to satisfy the exercise price and/or any income,
employment tax withholding and remittance obligations upon the vesting or exercise of an option or other award granted under an equity incentive plan or share purchase plan of the Company described in the Prospectus or the conversion or exercise of
a warrant of the Company described in the Prospectus; provided that (i)&nbsp;any filing under Section&nbsp;16(a) of the Exchange Act made during the Restricted Period shall clearly indicate in the footnotes thereto that (A)&nbsp;the filing relates
to the circumstances described in this paragraph and (B)&nbsp;no securities were sold by the undersigned, and (ii)&nbsp;the undersigned does not otherwise voluntarily effect any other public filing or report regarding such transfers during the
Restricted Period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">transfers to the Company in connection with the repurchase of Common Stock in connection with the termination
of the undersigned&#146;s employment with the Company pursuant to contractual agreements with the Company as in effect as of the date of the Prospectus, provided that no public disclosure or filing under Section&nbsp;16(a) of the Exchange Act shall
be required or shall be voluntarily made during the Restricted Period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the conversion of the outstanding preferred stock of the Company described in the Prospectus into shares of
Common Stock of the Company, provided that such shares of Common Stock remain subject to the terms of this agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">facilitating the establishment of a trading plan on behalf of a stockholder, officer or director of the Company
pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act for the transfer of shares of Common Stock, <I>provided</I> that (i)&nbsp;such plan does not provide for the transfer of Common Stock during the Restricted Period
and (ii)&nbsp;to the extent a public announcement or filing under the Exchange Act, if any, is required of or voluntarily made by or on behalf of the undersigned or the Company regarding the establishment of such plan, such announcement or filing
shall include a statement to the effect that no transfer of Common Stock may be made under such plan during the Restricted Period; or </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">transfers pursuant to a bona fide third-party tender offer for all outstanding Common Stock or securities
convertible into or exchangeable for Common Stock of the Company, merger, consolidation or other similar transaction approved by the Company&#146;s Board of Directors and made to all holders of the Company&#146;s securities involving a change of
control of the Company (including, without limitation, the entering into any <FONT STYLE="white-space:nowrap">lock-up,</FONT> voting or similar agreement pursuant to which the undersigned may agree to transfer, sell, tender or otherwise dispose of
Common Stock or other such securities in connection with such transaction, or vote any Common Stock or other such securities in favor of any such transaction); provided that in the event that such tender offer, merger, consolidation or other such
transaction is not completed, such securities held by the undersigned shall remain subject to the provisions of this agreement. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the undersigned agrees that, without the prior written consent of Morgan Stanley, Jefferies and Cowen on behalf of the
Underwriters, it will not, during the Restricted Period, make any demand for or exercise any right with respect to, the registration of any shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock. The
undersigned also agrees and consents to the entry of stop transfer instructions with the Company&#146;s transfer agent and registrar against the transfer of the undersigned&#146;s shares of Common Stock except in compliance with the foregoing
restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this agreement, (i) &#147;immediate family&#148; shall mean any relationship by blood, marriage, domestic
partnership or adoption, not more remote than first cousin, and (ii) &#147;change of control&#148; shall mean the consummation of any bona fide third party tender offer, merger, amalgamation, consolidation or other similar transaction the result of
which is that any &#147;person&#148; (as defined in Section&nbsp;13(d)(3) of the Exchange Act), or group of persons, other than the Company, becomes the beneficial owner (as defined in Rules <FONT STYLE="white-space:nowrap">13d-3</FONT> and <FONT
STYLE="white-space:nowrap">13d-5</FONT> of the Exchange Act) of greater than 50% of the total voting power of the voting stock of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the undersigned is an officer or director of the Company, the undersigned further agrees that the foregoing restrictions shall be equally
applicable to any issuer-directed Shares the undersigned may purchase in the Public Offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the undersigned is an officer or
director of the Company, (i)&nbsp;Morgan Stanley, Jefferies and Cowen agree that, at least three business days before the effective date of any release or waiver of the foregoing restrictions in connection with a transfer of shares of Common Stock,
Morgan Stanley, Jefferies and Cowen will notify the Company of the impending release or waiver, and (ii)&nbsp;the Company has agreed or will agree in the Underwriting Agreement to announce the impending release or waiver by press release through a
major news service at least two business days before the effective date of the release or waiver. Any release or waiver granted by Morgan Stanley, Jefferies and Cowen hereunder to any such officer or director shall only be effective two business
days after the publication date of such press release. The provisions of this paragraph will not apply if (a)&nbsp;the release or waiver is effected solely to permit a transfer not for consideration or to an immediate family member and (b)&nbsp;the
transferee has agreed in writing to be bound by the same terms described in this agreement to the extent and for the duration that such terms remain in effect at the time of the transfer. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned understands that the Company and the Underwriters are relying upon this
agreement in proceeding toward consummation of the Public Offering. The undersigned further understands that this agreement is irrevocable and shall be binding upon the undersigned&#146;s heirs, legal representatives, successors and assigns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned acknowledges and agrees that the Underwriters have not provided any recommendation or investment advice nor have the
Underwriters solicited any action from the undersigned with respect to the Public Offering and the undersigned has consulted their own legal, accounting, financial, regulatory and tax advisors to the extent deemed appropriate. The undersigned
further acknowledges and agrees that, although the Underwriters may provide certain Regulation Best Interest and Form CRS disclosures or other related documentation to you in connection with the Public Offering, the Underwriters are not making a
recommendation to&nbsp;you to participate in the Public Offering or sell any Shares at the price determined in the Public Offering, and nothing set forth in such disclosures or documentation is intended to suggest that any Underwriter is making such
a recommendation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whether or not the Public Offering actually occurs depends on a number of factors, including market conditions. Any
Public Offering will only be made pursuant to an Underwriting Agreement, the terms of which are subject to negotiation between the Company and the Underwriters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned understands that, if (i)&nbsp;the Representatives, on the one hand, or the Company, on the other hand, informs the other in
writing, prior to the execution of the Underwriting Agreement, that it has determined not to proceed with the Public Offering, (ii)&nbsp;the Underwriting Agreement (other than the provisions thereof which survive termination) shall terminate or be
terminated prior to payment for and delivery of the securities to be sold thereunder, (iii)&nbsp;the registration statement related to the Public Offering is withdrawn or (iv)&nbsp;the Underwriting Agreement is not executed on or before
March&nbsp;31, 2023, then, in each case, this agreement shall automatically, and without any action on the part of any other party, be of no further force and effect, and the undersigned shall be automatically released from all obligations under
this agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This agreement shall be governed by and construed in accordance with the laws of the State of New York. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Remainder of page intentionally blank] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Very truly yours, </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>IF AN INDIVIDUAL:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>IF AN ENTITY:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(duly
authorized signature)</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>(please print
complete name of entity)</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;By:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>(please print full name)</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>(duly authorized signature)</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name: <I></I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>(please print full name)</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;Title:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>(please print full title)</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">E-mail:</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">E-mail:</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT B </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF WAIVER OF <FONT STYLE="white-space:nowrap">LOCK-UP</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:6.00em; font-size:10pt; font-family:Times New Roman">_____________, 20__</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[Name and Address of </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Officer or
Director </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Requesting Waiver] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Mr./Ms.&nbsp;[Name]: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This letter is being delivered to _________________ in connection with the offering by Acivon Therapeutics, Inc. (the
&#147;<B>Company</B>&#148;) of _____ shares of common stock, $__ par value (the &#147;<B>Common Stock</B>&#148;), of the Company and the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement dated ____, 20__ (the
<FONT STYLE="white-space:nowrap">&#147;Lock-up</FONT> Agreement&#148;), executed by you in connection with such offering, and your request for a [waiver] [release] dated ____, 20__, with respect to ____ shares of Common Stock (the
&#147;<B>Shares</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Morgan Stanley&nbsp;&amp; Co. LLC, Jefferies LLC and Cowen and Company, LLC hereby agree to [waive] [release]
the transfer restrictions set forth in the <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement, but only with respect to the Shares, effective _____, 20__; provided, however, that such [waiver] [release] is conditioned on the Company
announcing the impending [waiver] [release] by press release through a major news service at least two business days before effectiveness of such [waiver] [release]. This letter will serve as notice to the Company of the impending [waiver]
[release]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as expressly [waived] [released] hereby, the <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement shall remain in
full force and effect. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Very truly yours,</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Morgan Stanley&nbsp;&amp; Co. LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Jefferies LLC </P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cowen and Company, LLC</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">cc: Acrivon Therapeutics, Inc. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF PRESS RELEASE </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Acrivon Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[Date] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Acrivon Therapeutics, Inc. (the &#147;<B>Company</B>&#148;) announced today that Morgan Stanley&nbsp;&amp; Co. LLC, Jefferies LLC and Cowen and Company, LLC,
the lead book-running managers in the Company&#146;s recent public sale of _____ shares of its common stock are [waiving][releasing] a <FONT STYLE="white-space:nowrap">lock-up</FONT> restriction with respect to ____ shares of the Company&#146;s
common stock held by [certain officers or directors] [an officer or director] of the Company. The [waiver][release] will take effect on ____, 20__ , and the shares may be sold on or after such date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>This press release is not an offer for sale of the securities in the United States or in any other jurisdiction where such offer is prohibited, and such
securities may not be offered or sold in the United States absent registration or an exemption from registration under the United States Securities Act of 1933, as amended. </B></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.3
<SEQUENCE>3
<FILENAME>d383050dex33.htm
<DESCRIPTION>EX-3.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.3 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF INCORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ACRIVON THERAPEUTICS,
INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Acrivon Therapeutics, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State
of the Delaware (the &#147;<B><I>DGCL</I></B>&#148;), hereby certifies that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>ONE: </B>The name of this corporation is Acrivon
Therapeutics, Inc. and the date of filing of the original Certificate of Incorporation of this corporation with the Secretary of State of the State of Delaware (the &#147;<B><I>Secretary</I></B>&#148;) was March&nbsp;13, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>TWO: </B>The Amended and Restated Certificate of Incorporation, attached hereto as <B><U>Exhibit A</U></B>, is incorporated herein by
reference, and restates, integrates and further amends the provisions of the Amended and Restated Certificate of Incorporation as previously amended or supplemented. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THREE:</B> This Amended and Restated Certificate of Incorporation has been duly approved by the Board of Directors of the Corporation in
accordance with the provisions of Sections 242 and 245 of the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>FOUR:</B> This Amended and Restated Certificate of Incorporation
was approved by the holders of the requisite number of shares of said Corporation in accordance with Section&nbsp;228 of the DGCL. This Amended and Restated Certificate of Incorporation has been duly adopted in accordance with the provisions of
Sections 242 and 245 of the DGCL by the stockholders of the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL>
W<SMALL>HEREOF</SMALL></B><SMALL></SMALL>, the Corporation has caused this Amended and Restated Certificate of Incorporation to be signed by its duly authorized officer this [&#149;]th day of [&#149;], 2022. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B>A<SMALL>CRIVON</SMALL> T<SMALL>HERAPEUTICS</SMALL>, I<SMALL>NC</SMALL>.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Peter Blume-Jensen</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF INCORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ACRIVON THERAPEUTICS,
INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
name of the corporation is<B> A<SMALL>CRIVON</SMALL> T<SMALL>HERAPEUTICS</SMALL>, I<SMALL>NC</SMALL>. </B>(the &#147;<B><I>Corporation</I></B>&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>II. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The address of the
registered office of the Corporation in the State of Delaware is 251 Little Falls Drive, in the City of Wilmington, County of New Castle, Delaware 19808. The name of its registered agent at such address is The Corporation Service Company. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>III. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of the
Corporation is to engage in any lawful act or activity for which a corporation may be organized under the Delaware General Corporation Law (the &#147;<B><I>DGCL</I></B>&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IV. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>A. </B>The
Corporation is authorized to issue two classes of stock to be designated, respectively, &#147;<B><I>Common Stock</I></B>&#148; and &#147;<B><I>Preferred Stock</I></B>.&#148; The total number of shares which the Corporation is authorized to issue is
510,000,000 shares, consisting of 500,000,000 shares of Common Stock, each having a par value of $0.001, and 10,000,000 shares of Preferred Stock, each having a par value of $0.001. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>B. </B>The Preferred Stock may be issued from time to time in one or more series. The board of directors of the Corporation (the
&#147;<B><I>Board of Directors</I></B>&#148;) is hereby expressly authorized to provide for the issue of all or any of the unissued and undesignated shares of the Preferred Stock, in one or more series, and to fix the number of shares of such series
and to determine for each such series, such voting powers, full or limited, or no voting powers, and such designation, preferences, and relative, participating, optional, or other rights and such qualifications, limitations, or restrictions thereof,
as shall set forth in a certificate of designation adopted by the Board of Directors and filed in accordance with the DGCL. The number of authorized shares of Preferred Stock and Common Stock may be increased or decreased (but not below the number
of shares thereof then outstanding plus, if applicable, the number of shares of such class or series reserved for issuance) by the affirmative vote of the holders of a majority of the voting power of all of the outstanding shares of stock of the
Corporation entitled to vote thereon, without a separate vote of the holders of the Preferred Stock or Common Stock, respectively, or of any series thereof irrespective of Section&nbsp;242(b)(2) of the DGCL, unless a vote of any such holders is
required pursuant to the terms of any certificate of designation filed with respect to any series of Preferred Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>C. </B>Each outstanding share of Common Stock shall entitle the holder thereof to one
vote on each matter properly submitted to the stockholders of the Corporation for their vote; <I>provided, however</I>, that, except as otherwise required by applicable law, holders of Common Stock shall not be entitled to vote on any amendment to
this Amended and Restated Certificate of Incorporation (including any certificate of designation filed with respect to any series of Preferred Stock) that relates solely to the terms of one or more outstanding series of Preferred Stock if the
holders of such affected series of Preferred Stock are entitled, either separately or together as a class with the holders of one or more other such series of Preferred Stock, to vote thereon pursuant to applicable law or this Amended and Restated
Certificate of Incorporation (including any certificate of designation filed with respect to any series of Preferred Stock). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>V.
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the management of the business and for the conduct of the affairs of the Corporation, and in further definition, limitation and
regulation of the powers of the Corporation, of its directors and of its stockholders or any class thereof, as the case may be, it is further provided that: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>A. M<SMALL>ANAGEMENT</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> B<SMALL>USINESS</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as provided by the DGCL or this Amended and Restated Certificate of Incorporation, the management of the business and the conduct of
the affairs of the Corporation shall be vested in its Board of Directors. Subject to any rights of the holders of shares of any one or more series of Preferred Stock then outstanding to elect additional directors under specified circumstances, the
number of directors that shall constitute the Board of Directors shall be fixed exclusively by resolutions adopted by the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>B. B<SMALL>OARD</SMALL> <SMALL>OF</SMALL> D<SMALL>IRECTORS</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the rights of the holders of any one or more series of Preferred Stock to elect additional directors under specified circumstances,
the directors shall be divided into three classes designated as Class&nbsp;I, Class&nbsp;II and Class&nbsp;III, respectively. Each class shall consist as nearly as practicable of a number of directors equal to one third of the number of members of
the Board authorized as provided in this Amended and Restated Certificate of Incorporation. The Board of Directors is authorized to assign members of the Board of Directors already in office to such classes at the time the classification becomes
effective. At the first annual meeting of stockholders following the filing of this Amended and Restated Certificate of Incorporation (the &#147;<B><I>Filing Date</I></B>&#148;), the initial term of office of the Class&nbsp;I directors shall expire
and Class&nbsp;I directors shall be elected for a full term of three years. At the second annual meeting of stockholders following the Filing Date, the initial term of office of the Class&nbsp;II directors shall expire and Class&nbsp;II directors
shall be elected for a full term of three years. At the third annual meeting of stockholders following the Filing Date, the initial term of office of the Class&nbsp;III directors shall expire and Class&nbsp;III directors shall be elected for a full
term of three years. At each succeeding annual meeting of stockholders, directors shall be elected for a full term of three years to succeed the directors of the class whose terms expire at such annual meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing provisions of this section, each director shall serve until his or her successor is duly elected and qualified
or until his or her earlier death, resignation or removal. No decrease in the number of directors constituting the Board of Directors shall remove or shorten the term of any incumbent director. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>C. R<SMALL>EMOVAL</SMALL> <SMALL>OF</SMALL> D<SMALL>IRECTORS</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the rights of the holders of any one or more series of Preferred Stock to remove directors elected by such series of Preferred
Stock, the entire Board of Directors or any individual director may be removed from office at any time, but only for cause, and only by the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">sixty-six</FONT> and <FONT
STYLE="white-space:nowrap">two-thirds</FONT> percent (66<SUP STYLE="font-size:75%; vertical-align:top">2</SUP>/<SUB STYLE="font-size:75%; vertical-align:bottom">3</SUB>%) of the voting power of all then outstanding shares of capital stock of the
Corporation entitled to vote generally at an election of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>D. V<SMALL>ACANCIES</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to any limitations imposed by applicable law and subject to the rights of the holders of any one or more series of Preferred Stock to
elect additional directors or fill vacancies in respect of such directors, any vacancies on the Board of Directors resulting from death, resignation, disqualification, removal or other causes and any newly created directorships resulting from any
increase in the number of directors, shall be filled only by the affirmative vote of a majority of the directors then in office, even though less than a quorum of the Board of Directors, or by a sole remaining director, and not by the stockholders.
Any director elected to fill a newly created directorship or vacancy in accordance with the preceding sentence shall hold office until the next annual meeting of stockholders held to elect the class of directors to which such director was elected
and until such director&#146;s successor shall have been elected and qualified or such director&#146;s earlier death, resignation or removal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>E. P<SMALL>REFERRED</SMALL> S<SMALL>TOCKHOLDERS</SMALL> E<SMALL>LECTION</SMALL> R<SMALL>IGHTS</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever the holders of any one or more series of Preferred Stock shall have the right, voting separately as a series or separately as a class
with one or more such other series, to elect directors at an annual or special meeting of stockholders, the election, term of office, removal and other features of such directorships shall be governed by the terms of this Amended and Restated
Certificate of Incorporation (including any certificate of designation relating to any series of Preferred Stock) applicable thereto. The number of directors that may be elected by the holders of any such series of Preferred Stock shall be in
addition to the number fixed pursuant to Section A of Article V hereof, and the total number of directors constituting the whole Board of Directors shall be automatically adjusted accordingly. Except as otherwise provided by the Board of Directors
in the resolution or resolutions establishing such series, whenever the holders of any series of Preferred Stock having such right to elect additional directors are divested of such right pursuant to the provisions of such stock, the terms of office
of all such additional directors elected by the holders of such stock, or elected to fill any vacancies resulting from the death, resignation, disqualification or removal of such additional directors, shall forthwith terminate (in which case each
such director thereupon shall cease to be qualified as, and shall cease to be, a director) and the total authorized number of directors of the Corporation shall automatically be reduced accordingly. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>F. A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> B<SMALL>YLAW</SMALL>
A<SMALL>MENDMENTS</SMALL>. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board of Directors is expressly authorized and empowered to adopt, amend or repeal any provisions of
the Amended and Restated Bylaws of the Corporation (the &#147;<B><I>Bylaws</I></B>&#148;) without the assent or vote of the stockholders in any manner not inconsistent with the laws of the State of Delaware or this Amended and Restated Certificate
of Incorporation.<B> </B>The stockholders shall also have power to adopt, amend or repeal the Bylaws; <I>provided, however, </I>that, in addition to any vote of the holders of any class or series of stock of the Corporation required by applicable
law or by this Amended and Restated Certificate of Incorporation, such action by stockholders shall require the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">sixty-six</FONT> and
<FONT STYLE="white-space:nowrap">two-thirds</FONT> percent (66<SUP STYLE="font-size:75%; vertical-align:top">2</SUP>/<SUB STYLE="font-size:75%; vertical-align:bottom">3</SUB>%) of the voting power of all of the then-outstanding shares of the capital
stock of the Corporation entitled to vote thereon, voting together as a single class. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>G. S<SMALL>TOCKHOLDER</SMALL>
A<SMALL>CTIONS</SMALL>. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>1. </B>The directors of the Corporation need not be elected by written ballot unless the Bylaws so
provide. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2. </B>Subject to the rights of the holders of any shares of any one or more series of Preferred Stock then outstanding,
noaction shall be taken by the stockholders of the Corporation except at an annual or special meeting of stockholders called in accordance with the Bylaws, and no action shall be taken by the stockholders by written consent in lieu of a meeting.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>3. </B>Subject to any rights of the holders of shares of any series of Preferred Stock then outstanding, special meetings of
stockholders of the Corporation may be called only by the Chairperson of the Board of Directors, the Chief Executive Officer or the Board of Directors, but a special meeting may not be called by any other person or persons and any power of
stockholders to call a special meeting of stockholders is specifically denied. Only such business shall be considered at a special meeting of stockholders as shall have been stated in the notice for such meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>4. </B>An annual meeting of stockholders for the purpose of election of directors and for such other business as may properly come before
the meeting, shall be held on such date, time and place, if any, as may be determined from time to time by the Board of Directors. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VI.
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>A. </B>No director or officer of the Corporation shall be liable to the Corporation or its stockholders for monetary damages for
breach of fiduciary duty as a director or officer, except to the extent such exemption from liability or limitation thereof is not permitted under the DGCL, as the same exists or may hereafter be amended. Any amendment, modification or repeal of the
foregoing sentence shall not adversely affect any right or protection of a director or officer of the Corporation hereunder in respect of any act or omission occurring prior to the time of such amendment, modification or repeal. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>B. </B>To the fullest extent permitted by applicable law, the Corporation is authorized
to provide indemnification of (and advancement of expenses to) directors, officers and agents of the Corporation (and any other persons to which applicable law permits the Corporation to provide indemnification) through Bylaw provisions, agreements
with such agents or other persons, vote of stockholders or disinterested directors or otherwise in excess of the indemnification and advancement otherwise permitted by such applicable law. If applicable law is amended after approval by the
stockholders of this Article VI to authorize corporate action further eliminating or limiting the personal liability of directors or officers, then the liability of a director or officer to the Corporation shall be eliminated or limited to the
fullest extent permitted by applicable law as so amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>C. </B>Any repeal or modification of this Article VI shall only be
prospective and shall not affect the rights or protections or increase the liability of any director under this Article VI in effect at the time of the alleged occurrence of any act or omission to act giving rise to liability or indemnification.
</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VII. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>A.
</B>Unless the Corporation consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state
court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) and any appellate court therefrom shall be the sole and exclusive forum
for the following claims or causes of action under Delaware statutory or common law: (i)&nbsp;any derivative claim or cause of action brought on behalf of the Corporation; (ii)&nbsp;any claim or cause of action for breach of a fiduciary duty owed by
any current or former director, officer or other employee or stockholder of the Corporation, to the Corporation or the Corporation&#146;s stockholders; (iii)&nbsp;any claim or cause of action against the Corporation or any current or former
director, officer or other employee of the Corporation, arising out of or pursuant to any provision of the DGCL, this Amended and Restated Certificate of Incorporation or the Bylaws of the Corporation (as each may be amended from time to time); (iv)
any claim or cause of action seeking to interpret, apply, enforce or determine the validity of this Amended and Restated Certificate of Incorporation or the Bylaws of the Corporation (as each may be amended from time to time, including any right,
obligation, or remedy thereunder); (v) any claim or cause of action as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware; and (vi)&nbsp;any claim or cause of action against the Corporation or any current or
former director, officer or other employee of the Corporation, governed by the internal-affairs doctrine or otherwise related to the Corporation&#146;s internal affairs, in all cases to the fullest extent permitted by applicable law and subject to
the court having personal jurisdiction over the indispensable parties named as defendants. This Section A of Article VII shall not apply to claims or causes of action brought to enforce a duty or liability created by the Securities Act of , as
amended (the &#147;<B><I>1933 Act</I></B>&#148;), or the Securities Exchange Act of 1934, as amended, or any other claim for which the federal courts have exclusive jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>B. </B>Unless the Corporation consents in writing to the selection of an alternative forum, to the fullest extent permitted by applicable
law, the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the 1933 Act, including all causes of action asserted against any defendant
named in such complaint. For the avoidance of doubt, this provision is intended to benefit and may be enforced by the Corporation, its officers and directors, the underwriters for any offering giving rise to such complaint, and any other
professional entity whose profession gives authority to a statement made by that person or entity and who has prepared or certified any part of the documents underlying the offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>C. </B>Any person or entity purchasing, holding, owning or otherwise acquiring any
interest in any security of the Corporation shall be deemed to have notice of and consented to the provisions of this Amended and Restated Certificate of Incorporation. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VIII. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>A. </B>The
Corporation reserves the right to amend, alter, change or repeal, at any time and from time to time, any provision contained in this Amended and Restated Certificate of Incorporation, in the manner now or hereafter prescribed by statute, except as
provided in paragraph B. of this Article&nbsp;VIII, and all rights, preferences and privileges of whatsoever nature conferred upon the stockholders, directors or any other persons whomsoever by and pursuant to this Amended and Restated Certificate
of Incorporation are granted subject to this reservation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>B. </B>Notwithstanding any other provisions of this Amended and Restated
Certificate of Incorporation or any provision of applicable law that might otherwise permit a lesser vote or no vote, but in addition to any affirmative vote of the holders of any particular class or series of capital stock of the Corporation
required by applicable law or by this Amended and Restated Certificate of Incorporation or any certificate of designation filed with respect to a series of Preferred Stock, the affirmative vote of the holders of at least <FONT
STYLE="white-space:nowrap">sixty-six</FONT> and <FONT STYLE="white-space:nowrap">two-thirds</FONT> percent (66<SUP STYLE="font-size:75%; vertical-align:top">2</SUP>/<SUB STYLE="font-size:75%; vertical-align:bottom">3</SUB>%) of the voting power of
all of the then outstanding shares of capital stock of the Corporation entitled to vote thereon, voting together as a single class, shall be required to alter, amend or repeal (whether by merger, consolidation, conversion or otherwise), or adopt any
provision inconsistent with, Articles V, VI, VII and VIII. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IX. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any provision or provisions of this Amended and Restated Certificate of Incorporation shall be held to be invalid, illegal or unenforceable
as applied to any circumstance for any reason whatsoever, the validity, legality and enforceability of such provisions in any other circumstance and of the remaining provisions of this Amended and Restated Certificate of Incorporation (including,
without limitation, each portion of any paragraph of this Amended and Restated Certificate of Incorporation containing any such provision held to be invalid, illegal or unenforceable that is not itself held to be invalid, illegal or unenforceable)
shall not, to the fullest extent permitted by applicable law, in any way be affected or impaired thereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * * </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.4
<SEQUENCE>4
<FILENAME>d383050dex34.htm
<DESCRIPTION>EX-3.4
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.4 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED BYLAWS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ACRIVON THERAPEUTICS,
INC. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(A DELAWARE CORPORATION) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 1.
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OFFICES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;1.1 Registered Office.</B> The registered office of Acrivon Therapeutics, Inc. (the &#147;<B>Corporation</B>&#148;) in the State
of Delaware and the name of the Corporation&#146;s registered agent at such address shall be as set forth in the certificate of incorporation of the Corporation (as the same may be amended and/or restated from time to time, the &#147;<B>Certificate
of Incorporation</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;1.2 Other Offices.</B> The Corporation may at any time establish other offices both within and
without the State of Delaware. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 2. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CORPORATE SEAL </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2.1 Corporate Seal.</B> The Board of Directors of the Corporation (the &#147;<B>Board</B>&#148;) may adopt a corporate seal.
Said seal may be used by causing it or a facsimile thereof to be impressed or affixed or reproduced or otherwise. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 3. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STOCKHOLDERS&#146; MEETINGS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.1 Place of Meetings.</B> Meetings of the stockholders of the Corporation may be held at such place, if any, either within or
without the State of Delaware, as may be determined from time to time by the Board. The Board may, in its sole discretion, determine that the meeting shall not be held at any place, but may instead be held solely by means of remote communication as
provided under the General Corporation Law of the State of Delaware (&#147;<B>DGCL</B>&#148;) and Section&nbsp;3.9 below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;3.2 Annual
Meetings. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(a) </B>The annual meeting of the stockholders of the Corporation, for the purpose of election of directors and for such other business
as may properly come before it, shall be held on such date, time and place, if any, as may be determined from time to time by the Board. Any annual meeting of stockholders previously scheduled by the Board may be postponed, rescheduled or cancelled
by the Board or any director or officer of the Corporation to whom the Board delegates such authority. Nominations of persons for election to the Board and proposals of other business to be considered by the stockholders may be made at an annual
meeting of stockholders: (i)&nbsp;solely with respect to the proposal of business other than nominations of persons for election to the Board of Directors, pursuant to the Corporation&#146;s notice of meeting (or any supplement thereto) of
stockholders; (ii)&nbsp;by or at the direction of the Board or a duly authorized committee </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
thereof; (iii)&nbsp;as may be provided in the certificate of designation for any class or series of preferred stock; or (iv)&nbsp;by any stockholder of the Corporation who was a stockholder of
record at the time of giving the stockholder&#146;s notice provided for in Section&nbsp;3.2(b) of these bylaws (as may be amended and/or restated from time to time, the &#147;<B>Bylaws</B>&#148;) and who is a stockholder of record at the time of the
annual meeting of stockholders, who is entitled to vote at the meeting and who complied with the notice procedures set forth in this Section&nbsp;3.2. For the avoidance of doubt, clause (iv)&nbsp;above shall be the exclusive means for a stockholder
to make nominations and submit other business before an annual meeting of stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(b) </B>At an annual meeting of the stockholders, only such
business shall be conducted as is a proper matter for stockholder action under the DGCL, the Certificate of Incorporation and the Bylaws, and only such nominations shall be made and such business shall be conducted as shall have been properly
brought before the meeting in accordance with the procedures below. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>(1)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>For nominations for election to the Board to be properly brought before an annual meeting by a
stockholder pursuant to clause (iv)&nbsp;of Section&nbsp;3.2(a), the stockholder must deliver written notice to the Corporate Secretary at the principal executive offices of the Corporation on a timely basis as set forth in Section&nbsp;3.2(b)(3)
and must update and supplement such written notice on a timely basis as set forth in Section&nbsp;3.2(c). Such stockholder&#146;s notice shall include: (A)&nbsp;as to each nominee such stockholder proposes to nominate at the meeting: (1)&nbsp;the
name, age, business address and residence address of such nominee, (2)&nbsp;the principal occupation or employment of such nominee, (3)&nbsp;the class or series and number of shares of each class or series of capital stock of the Corporation that
are owned of record and beneficially by such nominee, (4)&nbsp;the date or dates on which such shares were acquired and the investment intent of such acquisition, (5)&nbsp;the questionnaire, representation and agreement required by
Section&nbsp;3.2(e), completed and signed by such nominee, and (6)&nbsp;all other information concerning such nominee as would be required to be disclosed in a proxy statement soliciting proxies for the election of such nominee as a director in an
election contest (even if an election contest is not involved and whether or not proxies are being or will be solicited), or that is otherwise required to be provided to the Corporation or disclosed pursuant to Section&nbsp;14 of the Securities
Exchange Act of 1934, as amended (the &#147;<B>1934 Act</B>&#148;) (including such person&#146;s written consent to being named in the Corporation&#146;s proxy statement and associated proxy card as a nominee and to serving as a director if
elected); and (B)&nbsp;all of the information required by Section&nbsp;3.2(b)(4). The Corporation may require any proposed nominee to furnish such other information as it may reasonably require to determine the eligibility of such proposed nominee
to serve as an independent director of the Corporation (as such term is used in any applicable stock exchange listing requirements or applicable law) or on any committee or <FONT STYLE="white-space:nowrap">sub-committee</FONT> of the Board under any
applicable stock exchange listing requirements or applicable law, or that the Board determines, in its sole discretion, could be material to a reasonable stockholder&#146;s understanding of the independence, or lack thereof, of such proposed
nominee. The number of nominees a stockholder may nominate for election at the annual meeting (or in the case of a stockholder giving the notice on behalf of a beneficial owner, the number of nominees a stockholder may nominate for election at the
annual meeting on behalf of such beneficial owner) shall not exceed the number of directors to be elected at such annual meeting. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>(2)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>For business other than nominations for election to the Board to be properly brought before an annual
meeting by a stockholder pursuant to clause (iv)&nbsp;of Section&nbsp;3.2(a), the stockholder must deliver written notice to the Corporate Secretary at the principal executive offices of the Corporation on a timely basis as set forth in
Section&nbsp;3.2(b)(3), and must update and supplement such written notice on a timely basis as set forth in Section&nbsp;3.2(c). Such stockholder&#146;s notice shall include: (A)&nbsp;as to each matter such stockholder proposes to bring before the
meeting, a brief description of the business desired to be brought before the meeting, the text of the proposal or business (including the text of any resolutions proposed for consideration and in the event that such business includes a proposal to
amend the Bylaws, the language of the proposed amendment), the reasons for conducting such business at the </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
meeting, and any material interest (including any anticipated benefit of such business to any Proponent (as defined below) other than solely as a result of its ownership of the Corporation&#146;s
capital stock, that is material to any Proponent individually, or to the Proponents in the aggregate) in such business of any Proponent; and (B)&nbsp;all of the information required by Section&nbsp;3.2(b)(4). </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>(3)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>To be timely, the written notice required by Section&nbsp;3.2(b)(1) or 3.2(b)(2) must be received by the
Corporate Secretary at the principal executive offices of the Corporation not later than the 90th day, nor earlier than the 120th day, prior to the first anniversary of the immediately preceding year&#146;s annual meeting (for purposes of notice
required for action to be taken at the Corporation&#146;s first annual meeting of stockholders after its initial public offering of common stock, the date of the immediately preceding year&#146;s annual meeting shall be deemed to have occurred on
June 15th in such immediately preceding calendar year); provided, however, that, subject to the last sentence of this Section&nbsp;3.2(b)(3), in the event that the date of the annual meeting is advanced more than 30 days prior to or delayed by more
than 70 days after the anniversary of the preceding year&#146;s annual meeting, or if no annual meeting was held (deemed to have been held), notice by the stockholder to be timely must be so received not earlier than the 120th day prior to such
annual meeting and not later than the later of the 90th<B> </B>day prior to such annual meeting or the tenth day following the day on which public announcement of the date of such meeting is first made by the Corporation. In no event shall an
adjournment or postponement of an annual meeting for which notice has been given, or the public announcement thereof has been made, commence a new time period (or extend any time period) for the giving of a stockholder&#146;s notice as described
above. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>(4)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The written notice required by Sections 3.2(b)(1) or 3.2(b)(2) shall also include, as of the date of the
notice and as to the stockholder giving the notice and the beneficial owner, if any, on whose behalf the nomination or proposal is made (each, a &#147;<B>Proponent</B>&#148; and collectively, the &#147;<B>Proponents</B>&#148;): (A) the name and
address of each Proponent, including, if applicable, such name and address as they appear on the Corporation&#146;s books and records; (B)&nbsp;the class, series and number of shares of each class or series of the capital stock of the Corporation
that are, directly or indirectly, owned of record or beneficially (within the meaning of Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the 1934 Act) by each Proponent (provided, that for purposes of this Section&nbsp;3.2(b)(4), such
Proponent shall in all events be deemed to beneficially own all shares of any class or series of capital stock of the Corporation as to which such Proponent has a right to acquire beneficial ownership at any time in the future); (C) a description of
any agreement, arrangement or understanding (whether oral or in writing) with respect to such nomination or proposal (and/or the voting of shares of any class or series of capital stock of the Corporation) between or among any Proponent and any of
its affiliates or associates, and any others (including their names) acting in concert, or otherwise under the agreement, arrangement or understanding, with any of the foregoing, including, in the case of a nominee, the nominee, including any
agreement, arrangement or understanding (whether oral or in writing) relating to any compensation or payments to be paid to any such proposed nominees(s); (D) a representation that the Proponents are holders of record or beneficial owners, as the
case may be, of shares of the Corporation at the time of giving notice, will be entitled to vote at the meeting, and intend to appear in person or by proxy at the meeting to nominate the person or persons specified in the notice (with respect to a
notice under Section&nbsp;3.2(b)(1)) or to propose the business that is specified in the notice (with respect to a notice under Section&nbsp;3.2(b)(2)); (E) a representation as to whether the Proponents (x)&nbsp;intend to solicit proxies from
holders of the required number of the Corporation&#146;s voting shares in support of any proposed nominee in accordance with and as required by Rule <FONT STYLE="white-space:nowrap">14a-19</FONT> promulgated under the 1934 Act (with respect to a
notice under Section&nbsp;3.2(b)(1)) or (y)&nbsp;intend to deliver, or make available, a proxy statement and form of proxy to holders of such number of the Corporation&#146;s voting shares that would be sufficient to carry such proposal or otherwise
solicit proxies or votes from stockholders in support of such proposal (with respect to a notice under Section&nbsp;3.2(b)(2)); (F) to the extent known by any Proponent, the name and address of any other stockholder supporting the proposal on the
date of such </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
stockholder&#146;s notice; and (G)&nbsp;a description of all Derivative Transactions (as defined below) by each Proponent during the previous <FONT STYLE="white-space:nowrap">12-month</FONT>
period, including the date of the transactions and the class, series and number of securities involved in, and the material economic terms of, such Derivative Transactions. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(c) </B>A stockholder providing the written notice required by Section&nbsp;3.2(b)(1) or 3.2(b)(2) shall update and supplement such notice in writing, if
necessary, so that the information provided or required to be provided in such notice is true and correct in all material respects as of (i)&nbsp;the record date for the determination of stockholders entitled to notice of the meeting and
(ii)&nbsp;the date that is five Business Days (as defined below) prior to the meeting and, in the event of any adjournment or postponement thereof, five Business Days prior to such adjourned or postponed meeting. In the case of an update and
supplement pursuant to clause (i)&nbsp;of this Section&nbsp;3.2(c), such update and supplement must be received by the Corporate Secretary at the principal executive offices of the Corporation not later than five Business Days after the later of the
record date for the determination of stockholders entitled to notice of the meeting or the public announcement of such record date. In the case of an update and supplement pursuant to clause (ii)&nbsp;of this Section&nbsp;3.2(c), such update and
supplement shall be received by the Corporate Secretary at the principal executive offices of the Corporation not later than two Business Days prior to the date for the meeting, and, in the event of any adjournment or postponement thereof, two
Business Days prior to such adjourned or postponed meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(d) </B><B></B>Notwithstanding anything in Section&nbsp;3.2(b)(3)<B> </B>to the contrary,
in the event that the number of directors to be elected to the Board at the next annual meeting is increased effective after the time period for which nominations would otherwise be due under Section&nbsp;3.2(b)(3) and there is no public
announcement by the Corporation naming all of the nominees for the new positions created by such increase at least 100 days before the first anniversary of the preceding year&#146;s annual meeting, a stockholder&#146;s notice required by this
Section&nbsp;3.2 and that complies with the requirements in Section&nbsp;3.2(b)(1), other than the timing requirements in Section&nbsp;3.2(b)(3), shall also be considered timely, but only with respect to nominees for the new positions created by
such increase, if it shall be received by the Corporate Secretary at the principal executive offices of the Corporation not later than the close of business on the tenth day following the day on which such public announcement is first made by the
Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(e) </B>To be eligible to be a nominee for election or <FONT STYLE="white-space:nowrap">re-election</FONT> as a director of the
Corporation pursuant to a nomination under clause (iv)&nbsp;of Section&nbsp;3.2(a), each Proponent must deliver (in accordance with the time periods prescribed for delivery of notice under Sections 3.2(b)(3) or 3.2(d), as applicable) to the
Corporate Secretary at the principal executive offices of the Corporation a written questionnaire with respect to the background and qualification of such proposed nominee and a written representation and agreement (in the form provided by the
Corporate Secretary upon written request) that such person (i)&nbsp;is not and will not become a party to (A)&nbsp;any agreement, arrangement or understanding with, and has not given any commitment or assurance to, any person or entity as to how
such person, if elected as a director of the Corporation, will act or vote on any issue or question (a &#147;<B>Voting Commitment</B>&#148;) that has not been disclosed to the Corporation in the questionnaire or (B)&nbsp;any Voting Commitment that
could limit or interfere with such person&#146;s ability to comply, if elected as a director of the Corporation, with such person&#146;s fiduciary duties under applicable law; (ii)&nbsp;is not and will not become a party to any agreement,
arrangement or understanding with any person or entity other than the Corporation with respect to any direct or indirect compensation, reimbursement or indemnification in connection with service or action as a director of the Corporation that has
not been disclosed in such questionnaire; and (iii)<B></B>&nbsp;would be in compliance, if elected as a director of the Corporation, and will comply with, all applicable publicly disclosed corporate governance, conflict of interest, confidentiality
and stock ownership and trading policies and guidelines of the Corporation. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(f) </B>A person shall not be eligible for election or
<FONT STYLE="white-space:nowrap">re-election</FONT> as a director at an annual meeting, unless the person is nominated in accordance with clause (ii), (iii) or (iv)&nbsp;of Section&nbsp;3.2(a) and in accordance with the procedures set forth in
Section&nbsp;3.2(b), Section&nbsp;3.2(c), Section&nbsp;3.2(d), and Section&nbsp;3.2(e), as applicable. Only such business shall be conducted at any annual meeting of the stockholders of the Corporation as shall have been brought before the meeting
in accordance with clauses (i), (ii), (iii) or (iv)&nbsp;of Section&nbsp;3.2(a) and in accordance with the procedures set forth in Section&nbsp;3.2(b) and Section&nbsp;3.2(c), as applicable. Notwithstanding anything to the contrary in the Bylaws,
unless otherwise required by applicable law, if any Proponent (i)&nbsp;provides notice pursuant to Rule <FONT STYLE="white-space:nowrap">14a-19(b)</FONT> promulgated under the 1934 Act with respect to any proposed nominee and (ii)&nbsp;subsequently
fails to comply with the requirements of Rule <FONT STYLE="white-space:nowrap">14a-19</FONT> promulgated under the 1934 Act (or fails to timely provide reasonable evidence sufficient to satisfy the Corporation that such Proponent has met the
requirements of Rule <FONT STYLE="white-space:nowrap">14a-19(a)(3)</FONT> promulgated under the 1934 Act in accordance with the following sentence), then the nomination of each such proposed nominee shall be disregarded, notwithstanding that proxies
or votes in respect of the election of such proposed nominees may have been received by the Corporation (which proxies and votes shall be disregarded). Upon request by the Corporation, if any Proponent provides notice pursuant to Rule <FONT
STYLE="white-space:nowrap">14a-19(b)</FONT> promulgated under the 1934 Act, such Proponent shall deliver to the Corporation, no later than five Business Days prior to the applicable meeting, reasonable evidence that it has met the requirements of
Rule <FONT STYLE="white-space:nowrap">14a-19(a)(3)</FONT> promulgated under the 1934 Act. Except as otherwise required by applicable law, the chairperson of the meeting shall have the power and duty to determine whether a nomination or any business
proposed to be brought before the meeting was made, or proposed, as the case may be, in accordance with the procedures set forth in the Bylaws and, if any proposed nomination or business is not in compliance with the Bylaws, or the Proponent does
not act in accordance with the representations in Sections 3.2(b)(4)(D) and 3.2(b)(4)(E), to declare that such proposal or nomination shall not be presented for stockholder action at the meeting and shall be disregarded, or that such business shall
not be transacted, notwithstanding that proxies in respect of such nomination or such business may have been solicited or received. Notwithstanding the foregoing provisions of this Section&nbsp;3.2, unless otherwise required by applicable law, if
the stockholder (or a qualified representative of the stockholder) does not appear at the annual meeting of stockholders of the Corporation to present a nomination or proposed business, such nomination shall be disregarded and such proposed business
shall not be transacted, notwithstanding that proxies in respect of such vote may have been received by the Corporation. For purposes of this Section&nbsp;3.2, to be considered a qualified representative of the stockholder, a person must be a duly
authorized officer, manager or partner of such stockholder or must be authorized by a writing executed by such stockholder or an electronic transmission delivered by such stockholder to act for such stockholder as proxy at the meeting of
stockholders and such person must produce such writing or electronic transmission, or a reliable reproduction of the writing or electronic transmission, at the meeting of stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(g) </B>For purposes of Sections&nbsp;3.2 and 3.3, </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>(1)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>affiliates</B>&#148; and &#147;<B>associates</B>&#148; shall have the meanings set forth in
Rule 405 under the Securities Act of 1933, as amended (the &#147;<B>1933 Act</B>&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>(2)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Business Day</B>&#148; means any day other than Saturday, Sunday or a day on which banks are
closed in New York City, New York; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>(3)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>close of business</B>&#148; means 6:00 p.m. local time at the principal executive offices of
the Corporation on any calendar day, whether or not the day is a Business Day; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>(4)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;<B>Derivative Transaction</B>&#148; means any agreement, arrangement, interest or understanding
entered into by, or on behalf or for the benefit of, any Proponent or any of its affiliates or associates, whether record or beneficial: (A)&nbsp;the value of which is derived in whole or in part from the value of any class or series of shares or
other securities of the Corporation; (B)&nbsp;that otherwise provides any direct or </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
indirect opportunity to gain or share in any gain derived from a change in the value of securities of the Corporation; (C)&nbsp;the effect or intent of which is to mitigate loss, manage risk or
benefit from changes in value or price with respect to any securities of the Corporation; or (D)&nbsp;that provides the right to vote or increase or decrease the voting power of, such Proponent, or any of its affiliates or associates, directly or
indirectly, with respect to any securities of the Corporation, which agreement, arrangement, interest or understanding may include, without limitation, any option, warrant, debt position, note, bond, convertible security, swap, stock appreciation or
similar right, short position, profit interest, hedge, right to dividends, voting agreement, performance-related fee or arrangement to borrow or lend shares (whether or not subject to payment, settlement, exercise or conversion in any such class or
series), and any proportionate interest of such Proponent in the securities of the Corporation held by any general or limited partnership, or any limited liability company, of which such Proponent is, directly or indirectly, a general partner or
managing member; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>(5)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>For the purposes of the Bylaws, &#147;<B>public announcement</B>&#148; means disclosure in a press
release reported by the Dow Jones News Service, Associated Press, Business Wire, GlobeNewswire or comparable national news service or in a document publicly filed by the Corporation with the Securities and Exchange Commission pursuant to
Section&nbsp;13, 14 or 15(d) of the 1934 Act or by such other means reasonably designed to inform the public or security holders in general of such information, including, without limitation, posting on the Corporation&#146;s investor relations
website. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;3.3 Special Meetings. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(a) </B>Special meetings of the stockholders of the Corporation may only be called in the manner provided in the Certificate of Incorporation. Any special
meeting of stockholders previously scheduled by the Board may be postponed, rescheduled or cancelled by the Board or any director or officer to whom the Board has delegated such authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(b) </B>The Board shall determine the date, time and place, if any, of such special meeting. Upon determination of the date, time and place, if any, of the
meeting, the Corporate Secretary shall cause a notice of meeting to be given to the stockholders entitled to vote, in accordance with the provisions of Section&nbsp;3.4. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(c) </B>Only such business (including the election of specific individuals to fill vacancies or newly created directorships on the Board) shall be
conducted at a special meeting of stockholders as shall have been brought before the meeting pursuant to the Corporation&#146;s notice of meeting. At any time that stockholders are not prohibited from filling vacancies or newly created directorships
on the Board, nominations of persons for election to the Board to fill any vacancy or unfilled newly created directorship may be made at a special meeting of stockholders at which any proposal to fill any vacancy or unfilled newly created
directorship is to be presented to the stockholders (i)&nbsp;by or at the direction of the Board or a duly authorized committee thereof or (ii)&nbsp;by any stockholder of the Corporation who is a stockholder of record at the time of giving notice
provided for in this paragraph, who is entitled to vote at the meeting and who delivers written notice to the Corporate Secretary setting forth the information required by Sections 3.2(b)(1) and 3.2(b)(4). The number of nominees a stockholder may
nominate for election at the special meeting (or in the case of a stockholder giving the notice on behalf of a beneficial owner, the number of nominees a stockholder may nominate for election at the special meeting on behalf of such beneficial
owner) shall not exceed the number of directors to be elected at such special meeting. In the event the Corporation calls a special meeting of stockholders for the purpose of submitting a proposal to stockholders for the election of one or more
directors to fill any vacancy or newly created directorship on the Board, any such stockholder of record may nominate a person or persons (as the case may be), for election to such position(s) as specified in the Corporation&#146;s notice of
meeting, if written notice setting forth the information required by Sections 3.2(b)(1) and 3.2(b)(4) shall be received by the Corporate Secretary at the principal executive offices of the Corporation not earlier than 120 days prior to such special
meeting and not later than the later of the 90<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
day prior to such meeting or the tenth day following the day on which the Corporation first makes a public announcement of the date of the special meeting at which directors are to be elected.
The stockholder shall also update and supplement such information as required under Section&nbsp;3.2(c). In no event shall an adjournment or a postponement of a special meeting for which notice has been given, or the public announcement thereof has
been made, commence a new time period (or extend any time period) for the giving of a stockholder&#146;s notice as described above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(d) </B>A person
shall not be eligible for election as a director at the special meeting unless the person is nominated either in accordance with clause (i)&nbsp;or clause (ii)&nbsp;of Section&nbsp;3.3(c). Except as otherwise required by applicable law, the
chairperson of the meeting shall have the power and duty to determine whether a nomination was made in accordance with the procedures set forth in the Bylaws and, if any proposed nomination or business is not in compliance with the Bylaws, or if the
Proponent does not act in accordance with the representations in Sections 3.2(b)(4)(D) and 3.2(b)(4)(E), to declare that such nomination shall not be presented for stockholder action at the meeting and shall be disregarded, notwithstanding that
proxies in respect of such nomination may have been solicited or received. Notwithstanding the foregoing provisions of this Section&nbsp;3.3, unless otherwise required by applicable law, if the stockholder (or a qualified representative of the
stockholder (meeting the requirements specified in Section&nbsp;3.2(f)) does not appear at the special meeting of stockholders of the Corporation to present a nomination, such nomination shall be disregarded, notwithstanding that proxies in respect
of such vote may have been received by the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(e) </B>Notwithstanding the foregoing provisions of Sections 3.2 and 3.3, a stockholder must
also comply with all applicable requirements of the 1934 Act and the rules and regulations promulgated thereunder with respect to the matters set forth in Sections 3.2 and 3.3; provided, however, that, to the fullest extent not prohibited by
applicable law, any references in the Bylaws to the 1934 Act or the rules and regulations promulgated thereunder are not intended to and shall not limit the requirements applicable to proposals and/or nominations to be considered pursuant to clause
(iv)&nbsp;of Section&nbsp;3.2(a) and Section&nbsp;3.3(c). Nothing in the Bylaws shall be deemed to affect any rights of holders of any class or series of preferred stock to nominate and elect directors pursuant to and to the extent provided in any
applicable provision of the Certificate of Incorporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.4 Notice of Meetings.</B> Except as otherwise provided by
applicable law, the Certificate of Incorporation or the Bylaws, notice, in writing or by electronic transmission, of each meeting of stockholders shall be given not less than ten nor more than 60 days before the date of the meeting to each
stockholder entitled to vote at such meeting. Such notice shall be given in the manner provided in Section&nbsp;232 of the DGCL and shall specify the date, time, place, if any, in the case of special meetings, the purpose or purposes of the meeting,
the record date for determining stockholders entitled to vote at the meeting, if such record date is different from the record date for determining stockholders entitled to notice of the meeting, and the means of remote communications, if any, by
which stockholders and proxyholders may be deemed to be present in person and vote at any such meeting. Notice of the date, time, place, if any, and purpose of any meeting of stockholders (to the extent required) may be waived in writing, signed by
the person entitled to notice thereof, or by electronic transmission by such person, either before or after such meeting, and will be waived by any stockholder by such stockholder&#146;s attendance thereat in person, by remote communication, if
applicable, or by proxy, except when the stockholder attends a meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. Any stockholder
so waiving notice of such meeting shall be bound by the proceedings of any such meeting in all respects as if due notice thereof had been given. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.5 Quorum and Vote Required.</B> At all meetings of stockholders, except where otherwise provided by statute or by the
Certificate of Incorporation, or by the Bylaws, the presence, in person, by remote communication, if applicable, or by proxy, of the holders of a majority of the voting power of the </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
outstanding shares of stock entitled to vote at the meeting shall constitute a quorum for the transaction of business. The stockholders present at a duly called or convened meeting, at which a
quorum is present, may continue to transact business until adjournment, notwithstanding the withdrawal of enough stockholders to leave less than a quorum. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless a different or minimum vote is required by statute or by applicable stock exchange rules, or by the Certificate of Incorporation or the Bylaws, in
which case such different or minimum vote shall be the applicable vote on the matter, in all matters other than the election of directors, the affirmative vote of a majority of the votes case on such matter, voting affirmatively or negatively
(excluding abstentions and broker <FONT STYLE="white-space:nowrap">non-votes)</FONT> shall be the act of the stockholders. Except as otherwise provided by statute, the Certificate of Incorporation or the Bylaws, directors shall be elected by a
plurality of the votes of the shares present in person, by remote communication, if applicable, or represented by proxy at the meeting and entitled to vote in the election of directors. Where a separate vote by a class or classes or series is
required, unless a different or minimum vote is required by statute or by the Certificate of Incorporation or the Bylaws or any applicable stock exchange rules, in which case such different or minimum vote shall be the applicable vote on the matter,
the holders of a majority of the voting power of the outstanding shares of such class or classes or series, present in person, by remote communication, if applicable, or represented by proxy, shall constitute a quorum entitled to take action with
respect to that vote on that matter. Unless a different or minimum vote is required by statute or by the Certificate of Incorporation or the Bylaws or any applicable stock exchange rules, in which case such different or minimum vote shall be the
applicable vote on the matter, the affirmative vote of the holders of a majority (or plurality, in the case of the election of directors) of the votes cast on such matter, voting affirmatively or negatively (excluding abstention and broker <FONT
STYLE="white-space:nowrap">non-votes)</FONT> shall be the act of such class or classes or series. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.6 Adjournment and
Notice of Adjourned Meetings.</B> Any meeting of stockholders, whether annual or special, may be adjourned from time to time either by the chairperson of the meeting or by the vote of the holders of a majority of the voting power of the shares
present in person, by remote communication, if applicable, or represented by proxy at the meeting and entitled to vote thereon. When a meeting is adjourned to another time or place, if any, (including an adjournment taken to address a technical
failure to convene or continue a meeting using remote communication) notice need not be given of the adjourned meeting if the time and place, if any, thereof and the means of remote communication, if any, by which stockholders and proxyholders may
be deemed present in person and may vote at such meeting are announced at the meeting at which the adjournment is taken or are (i)&nbsp;displayed, during the time scheduled for the meeting, on the same electronic network used to enable stockholders
and proxy holders to participate in the meeting by means of remote communication or (ii)&nbsp;set forth in the notice of meeting given in accordance with Section&nbsp;3.4. At the adjourned meeting, the Corporation may transact any business that
might have been transacted at the original meeting. If the adjournment is for more than 30 days or if after the adjournment a new record date is fixed for the adjourned meeting, a notice of the adjourned meeting shall be given to each stockholder of
record entitled to vote at the meeting. If after the adjournment a new record date for determination of stockholders entitled to vote is fixed for the adjourned meeting, the Board shall fix as the record date for determining stockholders entitled to
notice of such adjourned meeting the same or an earlier date as that fixed for determination of stockholders entitled to vote at the adjourned meeting, and shall give notice of the adjourned meeting to each stockholder of record as of the record
date so fixed for notice of such adjourned meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.7 Voting Rights.</B> For the purpose of determining those
stockholders entitled to vote at any meeting of the stockholders or adjournment thereof, except as otherwise provided by applicable law, only persons in whose names shares stand on the stock records of the Corporation on the record date shall be
entitled to vote<B> </B>at any meeting of stockholders. Every person entitled to vote shall have the right to do so either in person, by remote communication, if applicable, or by an agent or agents authorized by a proxy granted in accordance with
Delaware law. An agent so appointed need not be a stockholder. No proxy </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shall be voted after three years from its date of creation unless the proxy provides for a longer period. A proxy shall be irrevocable if it states that it is irrevocable and if, and only as long
as, it is coupled with an interest sufficient in law to support an irrevocable power. A stockholder may revoke any proxy that is not irrevocable by attending the meeting and voting in person or by delivering to the Corporate Secretary a revocation
of the proxy or a new proxy bearing a later date. Voting at meetings of stockholders need not be by written ballot. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.8
List of Stockholders.</B> The Corporation shall prepare, no later than the tenth day before each meeting of stockholders, a complete list of the stockholders entitled to vote at said meeting, arranged in alphabetical order, showing the address of
each stockholder and the number and class of shares registered in the name of each stockholder; provided, however, if the record date for determining the stockholders entitled to vote is less than ten days before the meeting date, the list shall
reflect all of the stockholders entitled to vote as of the tenth day before the meeting date. Such list shall be open to the examination of any stockholder, for any purpose germane to the meeting for a period of ten days ending on the day before the
meeting date: (a)&nbsp;on a reasonably accessible electronic network, provided that the information required to gain access to such list is provided with the notice of the meeting, or (b)&nbsp;during ordinary business hours, at the principal place
of business of the Corporation. In the event that the Corporation determines to make the list available on an electronic network, the Corporation may take reasonable steps to ensure that such information is available only to stockholders of the
Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;3.9 Remote Communication; Delivery to the Corporation. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(a) </B>For the purposes of the Bylaws, if authorized by the Board in its sole discretion, and subject to such guidelines and procedures as the Board may
adopt, stockholders and proxyholders may, by means of remote communication: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>(1)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>participate in a meeting of stockholders; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>(2)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>be deemed present in person and vote at a meeting of stockholders whether such meeting is to be held at
a designated place or solely by means of remote communication, provided that (i)&nbsp;the Corporation shall implement reasonable measures to verify that each person deemed present and permitted to vote at the meeting by means of remote communication
is a stockholder or proxyholder, (ii)&nbsp;the Corporation shall implement reasonable measures to provide such stockholders and proxyholders a reasonable opportunity to participate in the meeting and to vote on matters submitted to the stockholders,
including an opportunity to read or hear the proceedings of the meeting substantially concurrently with such proceedings, and (iii)&nbsp;if any stockholder or proxyholder votes or takes other action at the meeting by means of remote communication, a
record of such vote or other action shall be maintained by the Corporation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(b) </B>Whenever Section&nbsp;3.2 or 3.3 requires one or
more persons (including a record or beneficial owner of capital stock) to deliver a document or information to the Corporation or any officer, employee or agent thereof (including any notice, request, questionnaire, revocation, representation or
other document or agreement), such document or information shall be in writing exclusively (and not in an electronic transmission) and shall be delivered exclusively by hand (including, without limitation, overnight courier service) or by certified
or registered mail, return receipt requested and the Corporation shall not be required to accept delivery of any document not in such written form or so delivered. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;3.10 Organization. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(a) </B>At every meeting of stockholders, the Chairperson of the Board, or if no Chairperson has been appointed, is absent or refuses to act, the Chief
Executive Officer, or if no Chief Executive Officer is then serving or the Chief Executive Officer is absent or refuses to act, the President, or, if the President is absent or refuses to act, a chairperson of the meeting chosen by the holders of a
majority of the voting power of the stockholders entitled to vote, present in person or by proxy, shall act as chairperson of the meeting of stockholders. A person designated by the Board shall act as secretary of the meeting. If no secretary of the
meeting is designated, then the Corporate Secretary, or, in the Corporate Secretary&#146;s absence, an Assistant Secretary or other officer or other person directed to do so by the chairperson of the meeting, shall act as secretary of the meeting.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(b) </B>The Board shall be entitled to make such rules or regulations for the conduct of meetings of stockholders as it shall deem necessary,
appropriate or convenient. Subject to such rules and regulations of the Board, if any, the chairperson of the meeting shall have the right and authority to convene and (for any or no reason) to recess and/or adjourn the meeting, to prescribe such
rules, regulations and procedures and to do all such acts as, in the judgment of such chairperson, are necessary, appropriate or convenient for the proper conduct of the meeting, including, without limitation, establishing an agenda or order of
business for the meeting, rules and procedures for maintaining order at the meeting and the safety of those present, limitations on participation in such meeting to stockholders of record of the Corporation and their duly authorized and constituted
proxies and such other persons as the chairperson shall permit, restrictions on entry to the meeting after the time fixed for the commencement thereof, limitations on the time allotted to questions or comments by participants and regulation of the
opening and closing of the polls for balloting on matters that are to be voted on by ballot. The date and time of the opening and closing of the polls for each matter upon which the stockholders will vote at the meeting shall be announced at the
meeting. Unless and to the extent determined by the Board or the chairperson of the meeting, meetings of stockholders shall not be required to be held in accordance with rules of parliamentary procedure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(c) </B>The Corporation may and shall, if required by applicable law, in advance of any meeting of stockholders, appoint one or more inspectors to act at
the meeting and make a written report thereof. The Corporation may designate one or more persons as alternate inspectors to replace any inspector who fails to act. If no inspector or alternate is able to act at a meeting of stockholders, the
chairperson of the meeting shall appoint one or more inspectors to act at the meeting. Each inspector, before entering upon the discharge of the duties of inspector, shall take and sign an oath faithfully to execute the duties of inspector with
strict impartiality and according to the best of such inspector&#146;s ability. The inspectors shall: (1)&nbsp;ascertain the number of shares outstanding and the voting power of each; (2)&nbsp;determine the shares represented at a meeting and the
validity of proxies and ballots; (3)&nbsp;count all votes and ballots; (4)&nbsp;determine and retain for a reasonable period a record of the disposition of any challenges made to any determination by the inspectors; and (5)&nbsp;certify their
determination of the number of shares represented at the meeting, and their count of all votes and ballots. The inspectors may appoint or retain other persons or entities to assist the inspectors in the performance of the duties of the inspectors.
In determining the validity and counting of proxies and ballots, the inspectors shall be limited to an examination of the proxies, any envelopes submitted with those proxies, any information provided in accordance with Sections 211(e) or 212(c)(2)
of the DGCL, or any information provided pursuant to Sections 211(a)(2)b.(i) or (iii)&nbsp;of the DGCL, ballots and the regular books and records of the Corporation, except that the inspectors may consider other reliable information for the limited
purpose of reconciling proxies and ballots submitted by or on behalf of banks, brokers, their nominees or similar persons which represent more votes than the holder of a proxy is authorized by the record owner to cast or more votes than the
stockholder holds of record. If the inspectors consider other reliable information for the limited purpose permitted herein, the inspectors at the time they make their certification pursuant to Section&nbsp;231(b)(5) of the DGCL shall specify the
precise information considered by them including the person or persons from whom they obtained the information, when the information was obtained, the means by which the information was obtained and the basis for the inspectors&#146; belief that
such information is accurate and reliable. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 4. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DIRECTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.1 Number.</B> The authorized number of directors of the Corporation shall be fixed in accordance with the Certificate of
Incorporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.2 Powers.</B> The business and affairs of the Corporation shall be managed by or under the direction of
the Board, except as may be otherwise provided by the Certificate of Incorporation or the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.3 Terms. </B>The terms of
directors shall be as set forth in the Certificate of Incorporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.4 Vacancies; Newly Created Directorships.</B><B>
</B>Vacancies and newly created directorships on the Board shall be filled as set forth in the Certificate of Incorporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.5 Resignation.</B> Any director may resign at any time by delivering such director&#146;s notice in writing or by electronic
transmission to the Board or the Corporate Secretary. Such resignation shall take effect at the time of delivery of the notice or at any later time specified therein. Acceptance of such resignation shall not be necessary to make it effective. When
one or more directors shall resign from the Board, effective at a future date, a majority of the directors then in office, including those who have so resigned, shall have power to fill such vacancy or vacancies, the vote thereon to take effect when
such resignation or resignations shall become effective, and each director so chosen shall hold office for the unexpired portion of the term of the director whose place shall be vacated and until such director&#146;s successor shall have been duly
elected and qualified or until such director&#146;s earlier death, resignation or removal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.6 </B><B>Removal.</B><B>
</B>Directors shall be removed as set forth in the Certificate of Incorporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;4.7 Meetings. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(a) Regular Meetings.</B> Unless otherwise restricted by the Certificate of Incorporation, regular meetings of the Board may be held at any time or date
and at any place within or without the State of Delaware that has been designated by the Board and publicized among all directors, either orally or in writing, by telephone, including a voice-messaging system or other system designed to record and
communicate messages, or by electronic mail or other electronic means. No further notice shall be required for regular meetings of the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(b)
Special Meetings</B>. Unless otherwise restricted by the Certificate of Incorporation, special meetings of the Board may be held at any time and place within or without the State of Delaware as designated and called by the Chairperson of the Board,
the Chief Executive Officer or a majority of the directors then in office. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(c) Meetings by Electronic Communications Equipment. </B>Any member of the
Board, or of any committee thereof, may participate in a meeting by means of conference telephone or other communications equipment by means of which all persons participating in the meeting can hear each other, and participation in a meeting by
such means shall constitute presence in person at such meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(d) Notice of Special Meetings. </B>Notice of the time and place, if any, of all
special meetings of the Board shall be transmitted orally or in writing, by telephone, including a voice messaging system or other system or technology designed to record and communicate messages, or by electronic mail or other electronic means,
during normal business hours, at least one day before the date and time of the meeting. If notice is sent by U.S. mail, it shall be sent by first class mail, postage prepaid, at least three days before the date of the meeting. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(e) Waiver of Notice. </B>Notice of any meeting of the Board may be waived in writing, or by electronic
transmission, at any time before or after the meeting and will be waived by any director by attendance thereat, except when the director attends the meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of
any business because the meeting is not lawfully called or convened. The transaction of all business at any meeting of the Board, or any committee thereof, however called or noticed, or wherever held, shall be as valid as though it had been
transacted at a meeting duly held after regular call and notice, if a quorum be present and if, either before or after the meeting, each of the directors not present who did not receive notice shall sign a written waiver of notice or shall waive
notice by electronic transmission. All such waivers shall be filed with the corporate records or made a part of the minutes of the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;4.8 Quorum and Voting. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(a) </B>Except
as otherwise provided by the DGCL, the Certificate of Incorporation or the Bylaws, a quorum of the Board shall consist of a majority of the authorized number of directors fixed from time to time by the Board in accordance with the Certificate of
Incorporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(b) </B>At each meeting of the Board at which a quorum is present, all questions and business shall be determined by the affirmative
vote of a majority of the directors present, unless a different vote be required by applicable law, the Certificate of Incorporation or the Bylaws. In the absence of a quorum, a majority of the directors present thereat may adjourn such meeting to
another time and place. Notice of such adjourned meeting need not be given if the time and place of such adjourned meeting are announced at the meeting so adjourned. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.9 Action without Meeting.</B> Unless otherwise restricted by the Certificate of Incorporation or the Bylaws, any action
required or permitted to be taken at any meeting of the Board or of any committee thereof may be taken without a meeting, if all members of the Board or committee, as the case may be, consent thereto in writing or by electronic transmission. After
an action is taken, such consent or consents shall be filed with the minutes of proceedings of the Board or committee. Such filing shall be in paper form if the minutes are maintained in paper form and shall be in electronic form if the minutes are
maintained in electronic form. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.10 </B><B>Fees and Compensation</B>. Unless otherwise restricted by the Certificate of
Incorporation or the Bylaws, the Board, or any duly authorized committee thereof, shall have the authority to fix the compensation, including fees and reimbursement of expenses, of directors for services to the Corporation in any capacity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;4.11 Committees. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(a) Other
Committees.</B> The Board may, from time to time, appoint such committees as may be permitted by applicable law. Such committees appointed by the Board shall consist of one or more members of the Board and to the extent permitted by applicable law
and provided in the resolution of the Board shall have and may exercise all the powers and authority of the Board in the management of the business and affairs of the Corporation, and may authorize the seal of the Corporation to be affixed to all
papers that may require it; but no such committee shall have the power or authority in reference to (i)&nbsp;approving or adopting, or recommending to the stockholders, any action or matter (other than the election or removal of directors) expressly
required by the DGCL to be submitted to stockholders for approval, or (ii)&nbsp;adopting, amending or repealing any Bylaw of the Corporation. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(b) Term.</B> The Board, subject to any requirements of any outstanding series of preferred stock and the
provisions of subsection&nbsp;(a) of this Section&nbsp;4.11, may at any time increase or decrease the number of members of a committee or terminate the existence of a committee. The membership of a committee member shall terminate on the date of
such committee member&#146;s death, such person&#146;s resignation from the committee or on such date that the committee member, for any reason, is no longer a member of the Board. The Board may at any time for any reason remove any individual
committee member and the Board may fill any committee vacancy created by death, resignation, removal or increase in the number of members of the committee. The Board may designate one or more directors as alternate members of any committee, who may
replace any absent or disqualified member at any meeting of the committee, and, in addition, in the absence or disqualification of any member of a committee, the member or members thereof present at any meeting and not disqualified from voting,
whether or not such member or members constitute a quorum, may unanimously appoint another member of the Board to act at the meeting in the place of any such absent or disqualified member. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(c) Meetings.</B> Unless the Board shall otherwise provide, regular meetings of any committee appointed pursuant to this Section&nbsp;4.11 shall be held at
such times and places, if any, as are determined by the Board, or by any such committee, and when notice thereof has been given to each member of such committee, no further notice of such regular meetings need be given thereafter. Special meetings
of any such committee may be held at such place, if any, that has been determined from time to time by such committee, and may be called by any director who is a member of such committee, upon notice to the members of such committee of the time and
place, if any, of such special meeting given in the manner provided for the giving of notice to members of the Board of the time and place, if any, of special meetings of the Board. Notice of any meeting of any committee may be waived in writing or
by electronic transmission at any time before or after the meeting and will be waived by any director by attendance thereat, except when the director attends such meeting for the express purpose of objecting, at the beginning of the meeting, to the
transaction of any business because the meeting is not lawfully called or convened. Unless otherwise provided by the Board in the resolutions authorizing the creation of the committee, the presence of at least a majority of the members of the
committee then serving shall be necessary to constitute a quorum unless the committee shall consist of one or two members, in which event one member shall constitute a quorum; and all matters shall be determined by a majority vote of the members
present at a meeting of the committee at which a quorum is present. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;4.12 Duties of Chairperson of the Board and Lead Independent
Director. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(a) </B>The Board shall elect from its ranks a Chairperson of the Board. The Chairperson of the Board shall perform such other duties
customarily associated with the office and shall also perform such other duties and have such other powers, as the Board shall designate from time to time. The Chairperson of the Board, when present, shall preside at all meetings of the stockholders
and the Board in accordance with Sections 3.10 and 4.13 of the Bylaws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(b) </B>If the Chairperson of the Board is not an independent director, one of
the independent directors, may be designated by the Board of Directors as lead independent director to serve until replaced by the Board of Directors (&#147;<B>Lead Independent Director</B>&#148;). The Lead Independent Director will perform such
other duties as may be established or delegated by the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.13 Organization.</B> At every meeting of the
directors, the Chairperson of the Board shall act as chairperson of the meeting. If a Chairperson has not been appointed or is absent, the Lead Independent Director, or if the Lead Independent Director has not been appointed or is absent, the Chief
Executive Officer (if a director), or, if a Chief Executive Officer is absent, the President (if a director), or, in the absence of any such person, a chairperson of the meeting chosen by a majority of the directors present, shall preside over the
meeting. The Corporate Secretary, or in the Corporate Secretary&#146;s absence, any Assistant Secretary or other officer, director or other person directed to do so by the person presiding over the meeting, shall act as secretary of the meeting.
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 5. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OFFICERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.1 Officers Designated.</B> The officers of the Corporation shall include, if and when designated by the Board, the Chief
Executive Officer, the President, the Corporate Secretary and the Treasurer. The Board may also appoint one or more Assistant Secretaries and Assistant Treasurers and such other officers and agents with such powers and duties as it shall deem
appropriate or necessary. The Board may assign such additional titles to one or more of the officers as it shall deem appropriate. Any one person may hold any number of offices of the Corporation at any one time unless specifically prohibited
therefrom by applicable law, the Certificate of Incorporation or the Bylaws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;5.2 Tenure and Duties of Officers. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(a) General.</B> All officers shall hold office at the pleasure of the Board and until their successors shall have been duly elected and qualified, subject
to such officer&#146;s earlier death, resignation or removal. If the office of any officer becomes vacant for any reason, the vacancy may be filled by the Board or by a committee thereof to which the Board has delegated such responsibility or, if so
authorized by the Board, by the Chief Executive Officer or another officer of the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(b) </B><B>Duties of Chief Executive Officer.</B> The
Chief Executive Officer shall preside at all meetings of the stockholders and, if a director, at all meetings of the Board, unless a Chairperson of the Board or a Lead Independent Director has been appointed and is present. The Chief Executive
Officer shall be the chief executive officer of the Corporation and, subject to the supervision, direction and control of the Board, shall have the general powers and duties of supervision, direction, management and control of the business and
officers of the Corporation as are customarily associated with the position of Chief Executive Officer. To the extent that a Chief Executive Officer has been appointed and no President has been appointed, all references in the Bylaws to the
President shall be deemed references to the Chief Executive Officer. <B></B>The Chief Executive Officer shall perform other duties customarily associated with the office and shall also perform such other duties and have such other powers, as the
Board shall designate from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(c) Duties of President.</B> The President shall preside at all meetings of the stockholders and, if a
director, at all meetings of the Board, unless a Chairperson of the Board, Lead Independent Director or Chief Executive Officer has been appointed and is present. Unless another officer has been appointed Chief Executive Officer of the Corporation,
the President shall be the chief executive officer of the Corporation and, subject to the supervision, direction and control of the Board, shall have the general powers and duties of supervision, direction, management and control of the business and
officers of the Corporation as are customarily associated with the position of President.<B> </B>The President shall perform other duties customarily associated with the office and shall also perform such other duties and have such other powers, as
the Board (or the Chief Executive Officer, if the Chief Executive Officer and President are not the same person and the Board has delegated the designation of the President&#146;s duties to the Chief Executive Officer) shall designate from time to
time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(d) Duties of Corporate Secretary and Assistant Secretary.</B> The Corporate Secretary shall attend all meetings of the stockholders and of the
Board and shall record all acts, votes and proceedings thereof in the minute books of the Corporation. The Corporate Secretary shall give notice in conformity with the Bylaws of all meetings of the stockholders and of all meetings of the Board and
any committee thereof requiring notice. The Corporate Secretary shall perform all other duties provided for in the Bylaws and </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other duties customarily associated with the office and shall also perform such other duties and have such other powers, as the Board or the Chief Executive Officer, or if no Chief Executive
Officer is then serving, the President shall designate from time to time. The Chief Executive Officer, or if no Chief Executive Officer is then serving, the President may direct any Assistant Secretary or other officer to assume and perform the
duties of the Corporate Secretary in the absence or disability of the Corporate Secretary, and each Assistant Secretary shall perform other duties customarily associated with the office and shall also perform such other duties and have such other
powers as the Board or the Chief Executive Officer, or if no Chief Executive Officer is then serving, the President shall designate from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(e) Duties of Treasurer and Assistant Treasurer.</B> The Treasurer shall keep or cause to be kept the books of account of the Corporation in a thorough and
proper manner and shall render statements of the financial affairs of the Corporation in such form and as often as required by the Board, the Chief Executive Officer or the President. The Treasurer, subject to the order of the Board, shall have the
custody of all funds and securities of the Corporation. The Treasurer shall perform other duties customarily associated with the office and shall also perform such other duties and have such other powers as the Board or the Chief Executive Officer,
or if no Chief Executive Officer is then serving, the President shall designate from time to time. The Chief Executive Officer, or if no Chief Executive Officer is then serving, the President may direct any Assistant Treasurer or other officer to
assume and perform the duties of the Treasurer in the absence or disability of the Treasurer, and each Assistant Treasurer shall perform other duties commonly incident to the office and shall also perform such other duties and have such other powers
as the Board or the Chief Executive Officer, or if no Chief Executive Officer is then serving, the President shall designate from time to time. To the extent that a Chief Financial Officer has been appointed and no Treasurer has been appointed, all
references in these Bylaws to the Treasurer shall be deemed references to the Chief Financial Officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.3 Delegation of
Authority.</B> The Board may from time to time delegate the powers or duties of any officer to any other officer or agent, notwithstanding any provision hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.4 Resignations.</B> Any officer may resign at any time by giving notice in writing or by electronic transmission to the Board,
the Chairperson of the Board, the Chief Executive Officer, the President or the Corporate Secretary. Any such resignation shall be effective when received by the person or persons to whom such notice is given, unless a later time is specified
therein, in which event the resignation shall become effective at such later time. Unless otherwise specified in such notice, the acceptance of any such resignation shall not be necessary to make it effective. Any resignation shall be without
prejudice to the rights, if any, of the Corporation under any contract with the resigning officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.5 Removal.</B> Any
officer may be removed from office at any time, either with or without cause, by the Board, or by any duly authorized committee thereof or any superior officer upon whom such power of removal may have been conferred by the Board. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 6. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXECUTION OF
CORPORATE INSTRUMENTS AND VOTING OF SECURITIES OWNED BY </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE CORPORATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;6.1 Execution of Corporate Instruments.</B> The Board may, in its discretion, determine the method and designate the signatory
officer or officers, or other person or persons, to execute, sign or endorse on behalf of the Corporation any corporate instrument or document, or to sign on behalf of the Corporation the corporate name without limitation, or to enter into contracts
on behalf of the Corporation, except where otherwise provided by applicable law or the Bylaws, and such execution or signature shall be binding upon the Corporation. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(a) </B>All checks and drafts drawn on banks or other depositaries on funds to the credit of the
Corporation or in special accounts of the Corporation shall be signed by such person or persons as the Board shall from time to time authorize so to do. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(b) </B>Unless otherwise specifically determined by the Board or otherwise required by applicable law, the execution, signing or endorsement of any
corporate instrument or document by or on behalf of the Corporation may be effected manually, by facsimile or (to the extent not prohibited by applicable law and subject to such policies and procedures as the Corporation may have in effect from time
to time) by electronic signature. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(c) </B>Unless authorized or ratified by the Board or within the agency power of an officer, no officer, agent or
employee shall have any power or authority to bind the Corporation by any contract or engagement or to pledge its credit or to render it liable for any purpose or for any amount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;6.2 Voting of Securities Owned by the Corporation.</B> All stock and other securities of or interests in other corporations or
entities owned or held by the Corporation for itself, or for other parties in any capacity, shall be voted, and all proxies with respect thereto shall be executed, by the person authorized so to do by resolution of the Board, or, in the absence of
such authorization, by the Chairperson of the Board, the Chief Executive Officer, or the President. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 7. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SHARES OF STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7.1 Form and Execution of Certificates.</B> The shares of the Corporation shall be represented by certificates, or shall be
uncertificated if so provided by resolution or resolutions of the Board. Certificates for the shares of stock of the Corporation, if any, shall be in such form<B> </B>as is consistent with the Certificate of Incorporation and applicable law. Every
holder of stock in the Corporation represented by certificates<B> </B>shall be entitled to have a certificate signed by or in the name of the Corporation by any two authorized officers of the Corporation (it being understood that each of the
Chairperson of the Board, the Chief Executive Officer, the President, the Treasurer, any Assistant Treasurer, the Corporate Secretary and any Assistant Secretary shall be an authorized officer for such purpose), certifying the number, and the class
or series, of shares owned by such holder in the Corporation. Any or all of the signatures on the certificate may be facsimiles. In case any officer, transfer agent, or registrar who has signed or whose facsimile signature has been placed upon a
certificate shall have ceased to be such officer, transfer agent, or registrar before such certificate is issued, it may be issued with the same effect as if he were such officer, transfer agent, or registrar at the date of issue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7.2 Lost Certificates.</B> A new certificate or certificates shall be issued in place of any certificate or certificates
theretofore issued by the Corporation alleged to have been lost, stolen, or destroyed, upon the making of an affidavit of that fact by the person claiming the certificate of stock to be lost, stolen, or destroyed. The Corporation may require, as a
condition precedent to the issuance of a new certificate or certificates, the owner of such lost, stolen, or destroyed certificate or certificates, or the owner&#146;s legal representative, to agree to indemnify the Corporation in such manner as it
shall require or to give the Corporation a surety bond in such form and amount as it may direct as indemnity against any claim that may be made against the Corporation with respect to the certificate alleged to have been lost, stolen, or destroyed.
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;7.3 Transfers. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(a) </B>Transfers of record of shares of stock of the Corporation shall be made only upon its books by the holders thereof, in person or by attorney duly
authorized, and, in the case of stock represented by certificate, upon the surrender of a properly endorsed certificate or certificates for a like number of shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(b) </B>The Corporation shall have power to enter into and perform any agreement with any number of stockholders of any one or more classes or series of
stock of the Corporation to restrict the transfer of shares of stock of the Corporation of any one or more classes or series owned by such stockholders in any manner not prohibited by the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;7.4 Fixing Record Dates. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(a) </B>In
order that the Corporation may determine the stockholders entitled to notice of any meeting of stockholders or any adjournment thereof, the Board may fix a record date, which record date shall not precede the date upon which the resolution fixing
the record date is adopted by the Board, and which record date shall, subject to applicable law, not be more than 60 nor less than ten days before the date of such meeting. If the Board so fixes a record date for determining the stockholders
entitled to notice of any meeting of stockholders, such date shall also be the record date for determining the stockholders entitled to vote at such meeting, unless the Board determines, at the time it fixes the record date for determining the
stockholders entitled to notice of such meeting, that a later date on or before the date of the meeting shall be the record date for determining the stockholders entitled to vote at such meeting. If no record date is fixed by the Board, the record
date for determining stockholders entitled to notice of or to vote at a meeting of stockholders shall be at the close of business on the day immediately preceding the day on which notice is given, or if notice is waived, at the close of business on
the day immediately preceding the day on which the meeting is held. A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; provided, however, that the
Board may fix a new record date for the adjourned meeting in accordance with the provisions of this Section&nbsp;7.4(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(b) </B>In order that the
Corporation may determine the stockholders entitled to receive payment of any dividend or other distribution or allotment of any rights or the stockholders entitled to exercise any rights in respect of any change, conversion or exchange of stock, or
for the purpose of any other lawful action, the Board may fix, in advance, a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted, and which record date shall be not more than 60 days
prior to such action. If no record date is fixed, the record date for determining stockholders for any such purpose shall be at 6:00 p.m. local time at the principal executive offices of the Corporation on the day on which the Board adopts the
resolution relating to such action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7.5 Registered Stockholders.</B> The Corporation shall be entitled to recognize the
exclusive right of a person registered on its books as the owner of shares to receive dividends, and to vote as such owner, and shall not be bound to recognize any equitable or other claim to or interest in such share or shares on the part of any
other person whether or not it shall have express or other notice thereof, except as otherwise provided by the laws of Delaware. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7.6 Additional Powers of the Board. </B>In addition to, and without limiting, the powers set forth in the Bylaws, the Board
shall have power and authority to make all such rules and regulations as it shall deem expedient concerning the issue, transfer, and registration of certificates for shares of stock of the Corporation, including the use of uncertificated shares of
stock, subject to the provisions of the DGCL, other applicable law, the Certificate of Incorporation and the Bylaws. The Board may appoint and remove transfer agents and registrars of transfers, and may require all stock certificates to bear the
signature of any such transfer agent and/or any such registrar of transfers. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 8. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OTHER SECURITIES OF THE CORPORATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.1 Execution of Other Securities.</B> All bonds, debentures and other corporate securities of the Corporation, other than stock
certificates (covered in Section&nbsp;7.1), may be signed by the Chairperson of the Board, the Chief Executive Officer, or the President, or such other person as may be authorized by the Board; provided, however, that where any such bond, debenture
or other corporate security shall be authenticated by the manual signature, or where permissible facsimile signature, of a trustee under an indenture pursuant to which such bond, debenture or other corporate security shall be issued, the signatures
of the persons signing and attesting the corporate seal on such bond, debenture or other corporate security may be the imprinted facsimile of the signatures of such persons. Interest coupons appertaining to any such bond, debenture or other
corporate security, authenticated by a trustee as aforesaid, shall be signed by the Treasurer or an Assistant Treasurer of the Corporation or such other person as may be authorized by the Board, or bear imprinted thereon the facsimile signature of
such person. In case any officer who shall have signed or attested any bond, debenture or other corporate security, or whose facsimile signature shall appear thereon or on any such interest coupon, shall have ceased to be such officer before the
bond, debenture or other corporate security so signed or attested shall have been delivered, such bond, debenture or other corporate security nevertheless may be adopted by the Corporation and issued and delivered as though the person who signed the
same or whose facsimile signature shall have been used thereon had not ceased to be such officer of the Corporation. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 9.
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DIVIDENDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;9.1 Declaration of Dividends.</B> Dividends upon the capital stock of the Corporation, subject to the provisions of the
Certificate of Incorporation and applicable law, if any, may be declared by the Board. Dividends may be paid in cash, in property, or in shares of capital stock or other securities of the Corporation, subject to the provisions of the Certificate of
Incorporation and applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;9.2 Dividend Reserve.</B> Before payment of any dividend, there may be set aside out of
any funds of the Corporation available for dividends such sum or sums as the Board from time to time, in its absolute discretion, determines proper as a reserve or reserves to meet contingencies, or for equalizing dividends, or for repairing or
maintaining any property of the Corporation, or for such other purpose or purposes as the Board shall determine to be conducive to the interests of the Corporation, and the Board may modify or abolish any such reserve in the manner in which it was
created. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 10. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FISCAL YEAR </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;10.1 Fiscal Year.</B> The fiscal year of the Corporation shall be fixed by resolution of the Board and may be changed by the
Board. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 11. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEMNIFICATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;11.1
Indemnification of Directors, Executive Officers, Other Officers, Employees and Other Agents. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(a) Directors</B><B> </B><B>and Executive
Officers</B><B>. </B>The Corporation will indemnify each director and executive officer (for the purposes of this Section&nbsp;11.1, &#147;executive officer&#148; has the meaning defined in Rule <FONT STYLE="white-space:nowrap">3b-7</FONT>
promulgated under the 1934 Act) who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or Proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that such
person is or was a director or executive officer of the Corporation, or while serving as a director or executive officer of the Corporation, is or was serving at the request of the Corporation as a director, officer, employee or agent&nbsp;of
another corporation, partnership, joint venture, trust or other enterprise to the fullest extent permitted by the DGCL as the same exists or may hereafter be amended (but, in the case of any such amendment, only to the extent that such amendment
permits the Corporation to provide broader indemnification rights than such law permitted the Corporation to provide prior to such amendment), against all expense, liability and loss (including attorneys&#146; fees, judgments, fines, ERISA excise
taxes or penalties and amounts paid in settlement) reasonably incurred or suffered by such person in connection therewith; provided, however, that the Corporation will not be required to indemnify or advance expenses to any director or executive
officer in connection with any Proceeding (or part thereof) initiated by such person unless (i)&nbsp;the Proceeding was authorized by the Board or (ii)&nbsp;the Proceeding is initiated to enforce rights to indemnification or advancement of expenses
as provided under subsection (d)&nbsp;of this Section&nbsp;11.1 or is a compulsory counterclaim brought by such person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any reference to
an officer of the Corporation in this Section&nbsp;11.1 shall be deemed to refer exclusively to the Chief Executive Officer, President, Chief Financial Officer, Chief Legal Officer and Corporate Secretary appointed pursuant to Section&nbsp;4 of
these Bylaws, and to any Vice President, Assistant Corporate Secretary, Assistant Treasurer or other officer of the Corporation appointed by the Board pursuant to Section&nbsp;5 of these Bylaws, and any reference to an officer of any other
corporation, partnership, joint venture, trust, employee benefit plan or other enterprise shall be deemed to refer exclusively to an officer appointed by the board of directors or equivalent governing body of such other entity pursuant to the
certificate of incorporation and bylaws or equivalent organizational documents of such other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise. The fact that any person who is or was an employee of the
Corporation or an employee of any other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise, but not an officer thereof as described in the preceding sentence, has been given or has used the title of &#147;Vice
President&#148; or any other title that could be construed to suggest or imply that such person is or may be such an officer of the Corporation or of such other corporation, partnership, joint venture, trust, employee benefit plan or other
enterprise shall not result in such person being constituted as, or being deemed to be, such an officer of the Corporation or of such other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise for purposes of
this Section&nbsp;11.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(b) Other Officers, Employees and Other Agents.</B> The Corporation shall have power to indemnify and advance expenses to its
other officers,<B> </B>employees and other agents to the fullest extent of the provisions of this Section&nbsp;11. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(c) Expenses.</B> The Corporation
shall advance to any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or Proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that such
person is or was a director or executive officer of the Corporation, or while serving as a director or executive officer of the Corporation, is or was serving </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
at the request of the Corporation as a director or officer of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise, prior to the final disposition of
the Proceeding, promptly following request therefor, all expenses incurred by any director or executive officer in connection with such Proceeding, or in connection with a Proceeding brought to establish or enforce a right to indemnification or
advancement of expenses under subsection (d)&nbsp;of this Section&nbsp;11.1, provided, however, that, if the DGCL requires, or in the case of an advance made in a Proceeding brought to establish or enforce a right to indemnification or advancement,
an advancement of expenses incurred by a director or executive officer in such director&#146;s or executive officer&#146;s capacity as a director or executive officer (and not in any other capacity in which service was or is rendered by such
indemnitee, including, without limitation, service to an employee benefit plan) will be made only upon delivery to the Corporation of an undertaking, by or on behalf of such indemnitee, to repay all amounts so advanced if it is ultimately determined
by final judicial decision from which there is no further right to appeal that such indemnitee is not entitled to be indemnified or entitled to advancement for such expenses under this Section&nbsp;11.1 or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(d) Enforcement. </B>Without the necessity of entering into an express contract, all rights to indemnification and advances to directors and executive
officers under this Section&nbsp;11.1 will be deemed to be contractual rights and be effective to the same extent and as if provided for in a contract between the Corporation and the director or executive officer. Any right to indemnification or
advancement of expenses granted by this Section&nbsp;11.1 to a director or executive officer will be enforceable by or on behalf of the person holding such right in any court of competent jurisdiction if (i)&nbsp;the claim for indemnification or
advancement of expenses is denied, in whole or in part, (ii)&nbsp;no disposition of a claim for indemnification is made within 60 days of request therefor, or (iii)&nbsp;no disposition of a claim for an advance is made within 30 days of request
therefor. The claimant in such enforcement action, if successful in whole or in part, or in a suit brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking,<B> </B>will be entitled to be paid also the
expense of prosecuting or defending the claim to the fullest extent permitted by the DGCL. In (i)&nbsp;any suit brought to enforce a right to indemnification hereunder (but not in a suit brought to enforce a right to an advancement of expenses) it
shall be a defense that, and (ii)&nbsp;any suit brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the Corporation shall be entitled to recover such expenses upon a final adjudication that, the
indemnitee has not met any applicable standard for indemnification set forth in the DGCL. Neither the failure of the Corporation (including its Board, independent legal counsel or its stockholders) to have made a determination prior to the
commencement of such action that indemnification of the claimant is proper in the circumstances because such person has met the applicable standard of conduct set forth in the DGCL, nor an actual determination by the Corporation (including its
Board, independent legal counsel or its stockholders) that the claimant has not met such applicable standard of conduct, will be a defense to the action or create a presumption that claimant has not met the applicable standard of conduct. In any
suit brought by a director or executive officer to enforce a right to indemnification or to an advancement of expenses hereunder, or brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the burden
of proving that the director or executive officer is not entitled to be indemnified, or to such advancement of expenses, under this Section&nbsp;11.1 or otherwise is on the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(e) <FONT STYLE="white-space:nowrap">Non-Exclusivity</FONT> of Rights. </B>The rights conferred on any person by this Section&nbsp;11.1 are not exclusive
of any other right that such person may have or hereafter acquire under any applicable statute, provision of the Certificate of Incorporation, Bylaws, agreement, vote of stockholders or disinterested directors or otherwise, both as to action in such
person&#146;s official capacity and as to action in another capacity while holding office. The Corporation is specifically authorized to enter into individual contracts with any or all of its directors, officers, employees or agents respecting
indemnification and advances, to the fullest extent not prohibited by the DGCL or any other applicable law. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(f) Survival of Rights. </B>The rights conferred on any person by this Section&nbsp;11.1 will continue as
to a person who has ceased to be a director or executive officer, other officer, employee or other agent and will inure to the benefit of the heirs, executors and administrators of such a person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(g) Insurance. </B>To the fullest extent permitted by the DGCL or any other applicable law, the Corporation, upon approval by the Board, may purchase
insurance on behalf of any person required or permitted to be indemnified pursuant to this Section&nbsp;11.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(h) Amendments. </B>Any repeal or
modification of this Section&nbsp;11.1 is only prospective and does not affect the rights under this Bylaw in effect at the time of the alleged occurrence of any action or omission to act that is the cause of any Proceeding against any agent of the
Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(</B><B>i</B><B>) Saving Clause. </B>If this Section&nbsp;11 or any portion hereof is invalidated on any ground by any court of competent
jurisdiction, then the Corporation will nevertheless indemnify and advance expenses to each director and executive officer to the full extent not prohibited by any applicable portion of this Section&nbsp;11 that has not been invalidated, or by any
other applicable law. If this Section&nbsp;11 is invalid due to the application of the indemnification and advancement provisions of another jurisdiction, then the Corporation will indemnify and advance expenses to each director and executive
officer<B> </B>to the full extent under applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(j) Certain Definitions. </B>For the purposes of this Section&nbsp;11, the following
definitions apply: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>(1)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The term &#147;<B>Proceeding</B>&#148; is to be broadly construed and includes, without limitation, the
investigation, preparation, prosecution, defense, settlement, arbitration and appeal of, and the giving of testimony in, any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>(2)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The term &#147;<B>expenses</B>&#148; is to be broadly construed and includes, without limitation, court
costs, attorneys&#146; fees, witness fees, fines, amounts paid in settlement or judgment and any other costs and expenses of any nature or kind incurred in connection with any proceeding. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>(3)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The term the &#147;<B>Corporation</B>&#148; includes, in addition to the resulting corporation, any
constituent corporation (including any constituent of a constituent) absorbed in a consolidation or merger that, if its separate existence had continued, would have had power and authority to indemnify its directors, officers, and employees or
agents, so that any person who is or was a director, officer, employee or agent of such constituent corporation, or is or was serving at the request of such constituent corporation as a director, officer, employee or agent of another corporation,
partnership, joint venture, trust, employee benefit plan or other enterprise, stands in the same position under the provisions of this Section&nbsp;11 with respect to the resulting or surviving corporation as such person would have with respect to
such constituent corporation if its separate existence had continued. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>(4)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>References to &#147;<B>fines</B>&#148; include any excise taxes assessed on a person with respect to an
employee benefit plan. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 12. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICES </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;12.1 Notices.
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(a) Notice to Stockholders.</B> Notice to stockholders of stockholder meetings shall be given as provided in Section&nbsp;3.4. Without limiting
the manner by which notice may otherwise be given effectively to stockholders under any agreement or contract with such stockholder, and except as otherwise required by applicable law, written notice to stockholders for purposes other than
stockholder meetings may be sent by U.S. mail or nationally recognized overnight courier, or by electronic mail or other electronic means in accordance with Section&nbsp;232 of the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(b) Notice to Directors. </B>Any notice required to be given to any director may be given by the method stated in subsection&nbsp;(a), as otherwise
provided in the Bylaws (including by any of the means specified in Section&nbsp;4.7(d)), or by overnight delivery service. Any notice sent by overnight delivery service or U.S. mail shall be sent to such address as such director shall have filed in
writing with the Secretary, or, in the absence of such filing, to the last known post office address of such director. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(c) Affidavit of Mailing.
</B>An affidavit of mailing, executed by a duly authorized and competent employee of the Corporation or its transfer agent appointed with respect to the class of stock affected, or other agent, specifying the name and address or the names and
addresses of the stockholder or stockholders, or director or directors, to whom any such notice or notices was or were given, and the time and method of giving the same, shall in the absence of fraud, be prima facie evidence of the facts therein
contained. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(d) Methods of Notice. </B>It shall not be necessary that the same method of giving notice be employed in respect of all recipients of
notice, but one permissible method may be employed in respect of any one or more, and any other permissible method or methods may be employed in respect of any other or others. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(e) Notice to Person with Whom Communication is Unlawful. </B>Whenever notice is required to be given, under applicable law or any provision of the
Certificate of Incorporation or Bylaws, to any person with whom communication is unlawful, the giving of such notice to such person shall not be required and there shall be no duty to apply to any governmental authority or agency for a license or
permit to give such notice to such person. Any action or meeting that shall be taken or held without notice to any such person with whom communication is unlawful shall have the same force and effect as if such notice had been duly given. In the
event that the action taken by the Corporation is such as to require the filing of a certificate under any provision of the DGCL, the certificate shall state, if such is the fact and if notice is required, that notice was given to all persons
entitled to receive notice except such persons with whom communication is unlawful. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(f) </B><B>Notice to Stockholders Sharing an Address. </B>Except
as otherwise prohibited under the DGCL, any notice given under the provisions of the DGCL, the Certificate of Incorporation or the Bylaws shall be effective if given by a single written notice to stockholders who share an address if consented to by
the stockholders at that address to whom such notice is given. Such consent shall have been deemed to have been given if such stockholder fails to object in writing to the Corporation within 60 days of having been given notice by the Corporation of
its intention to send the single notice. Any consent shall be revocable by the stockholder by written notice to the Corporation. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 13. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LOANS TO OFFICERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;13.1 </B><B>Loans to Officers. </B>Except as otherwise prohibited by applicable law, the Corporation may lend money to, or
guarantee any obligation of, or otherwise assist any officer or other employee of the Corporation or of its subsidiaries, including any officer or employee who is a director of the Corporation or its subsidiaries, whenever, in the judgment of the
Board, such loan, guarantee or assistance may reasonably be expected to benefit the Corporation. The loan, guarantee or other assistance may be with or without interest and may be unsecured, or secured in such manner as the Board shall approve,
including, without limitation, a pledge of shares of stock of the Corporation. Nothing in these Bylaws shall be deemed to deny, limit or restrict the powers of guaranty or warranty of the Corporation at common law or under any statute. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 14. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENTS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;14.1 Amendments. </B>Subject to the limitations set forth in Section&nbsp;5.6 or the Certificate of Incorporation, the
Board is expressly empowered to adopt, amend or repeal the Bylaws of the Corporation. The stockholders also shall have power to adopt, amend or repeal the Bylaws of the Corporation; provided, however, that, in addition to any vote of the holders of
any class or series of stock of the Corporation required by applicable law or by the Certificate of Incorporation (including any certificate of designation relating to any series of Preferred Stock (as defined in the Certificate of Incorporation),
such action by stockholders shall require the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">66-2/3%</FONT> of the voting power of all of the then-outstanding shares of the capital stock of the Corporation entitled to
vote thereon, voting together as a single class. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.5
<SEQUENCE>5
<FILENAME>d383050dex35.htm
<DESCRIPTION>EX-3.5
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.5 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF AMENDMENT TO </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF ACRIVON THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>A<SMALL>CRIVON</SMALL> T<SMALL>HERAPEUTICS</SMALL>, I<SMALL>NC</SMALL>.</B>, a corporation organized and existing under and by virtue of
the General Corporation Law of the State of Delaware (the &#147;<U>DGCL</U>&#148;), does hereby certify: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>F<SMALL>IRST</SMALL>:</B> The
name of the corporation is Acrivon Therapeutics, Inc. (the &#147;<U>Corporation</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>S<SMALL>ECOND</SMALL>:</B> The date on
which the Certificate of Incorporation of the Corporation was originally filed with the Secretary of State of the State of Delaware is March&nbsp;13, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>T<SMALL>HIRD</SMALL>: </B>The board of directors of the Corporation, acting in accordance with the provisions of Sections&nbsp;141 and 242
of the DGCL, adopted resolutions approving a reverse stock split and amending the Corporation&#146;s Second Amended and Restated Certificate of Incorporation by deleting the first paragraph of Article Fourth and replacing it with the following new
paragraphs:&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;The total number of shares of all classes of stock which the Corporation shall
have authority to issue is (i) 40,013,683 shares of Common Stock, $0.001 par value per share (&#147;<B><I>Common Stock</I></B>&#148;) and (ii) 27,471,911 shares of Preferred Stock, $0.001 par value per share (&#147;<B><I>Preferred
Stock</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective immediately upon this Certificate of Amendment becoming effective under the General
Corporation Law of the State of Delaware, and without any further action by the holders of such shares, every 2.466 outstanding shares of the Corporation&#146;s Common Stock shall be combined into one validly issued, fully paid and <FONT
STYLE="white-space:nowrap">non-assessable</FONT> share of Common Stock (the &#147;<B><I>Reverse Stock Split</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">No fractional shares of Common Stock shall be issued upon combination of the Common Stock in the Reverse Stock Split. All
shares of Common Stock so combined that are held by a stockholder shall be aggregated subsequent to the foregoing Reverse Stock Split. If the Reverse Stock Split would result in the issuance of any fractional share, the Corporation shall, in lieu of
issuing any fractional share, pay cash equal to the product of such fraction multiplied by the fair market value of one share of Common Stock (as determined by the Corporation&#146;s board of directors) on the date that the Reverse Stock Split is
effective, rounded up to the nearest whole cent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">The par value of each share of Common Stock shall not be adjusted in
connection with the Reverse Stock Split. All of the outstanding share amounts, amounts per share and per share numbers for the Common Stock and each series of Preferred Stock set forth in this Amended and Restated Certificate of Incorporation shall
be appropriately adjusted to give effect to the Reverse Stock Split, as applicable. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a statement of the designations and the powers, privileges
and rights, and the qualifications, limitations or restrictions thereof in respect of each class of capital stock of the Corporation.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>F<SMALL>OURTH</SMALL>:</B> Thereafter, pursuant to a&nbsp;resolution of the Corporation&#146;s board of directors, this Certificate of
Amendment was submitted to the stockholders of the Corporation for their approval, and was duly adopted in accordance with the provisions of Sections 228 and&nbsp;242 of the General Corporation Law of the State of Delaware. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> F<SMALL>OLLOWS</SMALL>] </B></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL></B><SMALL></SMALL>,
Acrivon Therapeutics, Inc. has caused this Certificate of Amendment of the Second Amended and Restated Certificate of Incorporation to be executed by its duly authorized officer on this 1st day of November, 2022. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>A<SMALL>CRIVON</SMALL> T<SMALL>HERAPEUTICS</SMALL>, I<SMALL>NC</SMALL>.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Peter Blume-Jensen</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Peter Blume-Jensen</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Chief Executive
Officer</P></TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>6
<FILENAME>d383050dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g165750g1102102718201.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ryan Sansom</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">T +1 617 937 2335</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">rsansom@cooley.com</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>EXHIBIT 5.1</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">November&nbsp;3, 2022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Acrivon
Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">480 Arsenal Way, Suite 100 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Watertown,
Massachusetts 02472 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You have
requested our opinion, as counsel to Acrivon Therapeutics, Inc., a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), in connection with the filing by the Company of a Registration Statement
<FONT STYLE="white-space:nowrap">(No.&nbsp;333-267911)</FONT> on <FONT STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> (the &#147;<B><I>Registration Statement</I></B>&#148;) with the Securities and Exchange Commission, including a related prospectus
included in the Registration Statement (the &#147;<B><I>Prospectus</I></B>&#148;), covering an underwritten public offering of up to 6,785,000 shares (the &#147;<B><I>Shares</I></B>&#148;) of the Company&#146;s common stock, par value $0.001,
including up to 885,000 Shares that may be sold pursuant to the exercise of an option to purchase additional shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with this opinion, we
have (i)&nbsp;examined and relied upon (a)&nbsp;the Registration Statement and the Prospectus, (b)&nbsp;the Company&#146;s Second Amended and Restated Certificate of Incorporation and Bylaws, each as currently in effect, (c)&nbsp;the Company&#146;s
Amended and Restated Certificate of Incorporation, filed as Exhibit&nbsp;3.3 to the Registration Statement, and the Company&#146;s Amended and Restated Bylaws, filed as Exhibit&nbsp;3.4 to the Registration Statement, each of which is to be in effect
immediately following the closing of the offering contemplated by the Registration Statement and (d)&nbsp;originals or copies certified to our satisfaction of such records, documents, certificates, memoranda and other instruments as in our judgment
are necessary or appropriate to enable us to render the opinion expressed below and (ii)&nbsp;assumed that the Shares to be sold to the underwriters by the Company will be sold at a price established by the Board of Directors of the Company or a
duly authorized committee thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the
conformity to originals of all documents submitted to us as copies, the accuracy, completeness and authenticity of certificates of public officials and the due authorization, execution and delivery of all documents by all persons other than the
Company where authorization, execution and delivery are prerequisites to the effectiveness thereof.&nbsp;As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not independently verified such matters.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our opinion is expressed only with respect to the General Corporation Law of the State of Delaware. We express no opinion as to whether the laws of any
particular jurisdiction are applicable to the subject matter hereof.&nbsp;We are not rendering any opinion as to compliance with any federal or state law, rule&nbsp;or regulation relating to securities, or to the sale or issuance thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares, when sold and issued against payment therefor as described in
the Registration Statement and the Prospectus, will be validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Cooley LLP&nbsp;&nbsp;&nbsp;&nbsp;500 Boylston St&nbsp;&nbsp;&nbsp;&nbsp;Boston, MA&nbsp;&nbsp;&nbsp;&nbsp;02116-3736 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">t: (617) <FONT STYLE="white-space:nowrap">937-2300</FONT> f: (617) <FONT STYLE="white-space:nowrap">937-2400</FONT> cooley.com </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g165750g1102102718201.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Acrivon Therapeutics, Inc.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Page 2</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the reference to our firm under the caption &#147;Legal Matters&#148; in the Prospectus included in the
Registration Statement and to the filing of this opinion as an exhibit to the Registration Statement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Sincerely,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Cooley LLP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Ryan Sansom</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Ryan Sansom</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Cooley LLP&nbsp;&nbsp;&nbsp;&nbsp;500 Boylston St&nbsp;&nbsp;&nbsp;&nbsp;Boston,
MA&nbsp;&nbsp;&nbsp;&nbsp;02116-3736 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">t: (617) <FONT STYLE="white-space:nowrap">937-2300</FONT> f: (617)
<FONT STYLE="white-space:nowrap">937-2400</FONT> cooley.com </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>7
<FILENAME>d383050dex102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>CRIVON</SMALL> T<SMALL>HERAPEUTICS</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2022 E<SMALL>QUITY</SMALL> I<SMALL>NCENTIVE</SMALL> P<SMALL>LAN</SMALL> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>DOPTED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL> B<SMALL>OARD</SMALL> <SMALL>OF</SMALL> D<SMALL>IRECTORS</SMALL>:
O<SMALL>CTOBER</SMALL>&nbsp;28, 2022 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>PPROVED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL> S<SMALL>TOCKHOLDERS</SMALL>:
N<SMALL>OVEMBER</SMALL>&nbsp;1, 2022 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>G<SMALL>ENERAL</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) </B><B>Successor to and Continuation of Prior Plan</B>. The Plan is the successor to and continuation of the Prior Plan. As of the
Effective Date, (i)&nbsp;no additional awards may be granted under the Prior Plan; (ii)&nbsp;the Prior Plan&#146;s Available Reserve plus any Returning Shares will become available for issuance pursuant to Awards granted under this Plan; and
(iii)&nbsp;all outstanding awards granted under the Prior Plan will remain subject to the terms of the Prior Plan (except to the extent such outstanding awards result in Returning Shares that become available for issuance pursuant to Awards granted
under this Plan). All Awards granted under this Plan will be subject to the terms of this Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) Plan Purpose.</B> The Company, by
means of the Plan, seeks to secure and retain the services of Employees, Directors and Consultants, to provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and to provide a means by which such
persons may be given an opportunity to benefit from increases in value of the Common Stock through the granting of Awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)
</B><B>Available Awards.</B> The Plan provides for the grant of the following Awards: (i)&nbsp;Incentive Stock Options; (ii)&nbsp;Nonstatutory Stock Options; (iii)&nbsp;SARs; (iv) Restricted Stock Awards; (v)&nbsp;RSU Awards; (vi)&nbsp;Performance
Awards; and (vii)&nbsp;Other Awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d) Adoption Date; Effective Date. </B>The Plan will come into existence on the Adoption Date,
but no Award may be granted prior to the Effective Date. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>S<SMALL>HARES</SMALL> S<SMALL>UBJECT</SMALL> <SMALL>TO</SMALL> <SMALL>THE</SMALL> P<SMALL>LAN</SMALL>.
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) </B><B>Share Reserve. </B>Subject to adjustment in accordance with Section&nbsp;2(c) and any adjustments as
necessary to implement any Capitalization Adjustments, the aggregate number of shares of Common Stock that may be issued pursuant to Awards will not exceed 5,606,723 shares, which is the sum of: (i)&nbsp;2,555,271 new shares, plus (ii)&nbsp;the
Prior Plan&#146;s Available Reserve, plus&nbsp;(iii) up to 2,148,679 Returning Shares, as such shares become available from time to time. In addition, subject to any adjustments as necessary to implement any Capitalization Adjustments, such
aggregate number of shares of Common Stock will automatically increase on January&nbsp;1 of each year for a period of ten years commencing on January&nbsp;1, 2023 and ending on (and including) January&nbsp;1, 2032, in an amount equal to five percent
(5%) of the total number of shares of Common Stock outstanding on December&nbsp;31 of the preceding year; provided, however, that the Board may act prior to January 1st of a given year to provide that the increase for such year will be a lesser
number of shares of Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) Aggregate Incentive Stock Option Limit.</B> Notwithstanding anything to the contrary in
Section&nbsp;2(a) and subject to any adjustments as necessary to implement any Capitalization Adjustments, the aggregate maximum number of shares of Common Stock that may be issued pursuant to the exercise of Incentive Stock Options is 16,820,169.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) Share Reserve Operation.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i) Limit Applies to Common Stock Issued Pursuant to Awards. </B>For clarity, the Share Reserve is a limit on the number of shares of
Common Stock that may be issued pursuant to Awards and does not limit the granting of Awards, except that the Company will keep available at all times the number of shares of Common Stock reasonably required to satisfy its obligations to issue
shares pursuant to such Awards. Shares may be issued in connection with a merger or acquisition as permitted by, as applicable, Nasdaq Listing Rule 5635(c), NYSE Listed Company Manual Section&nbsp;303A.08, NYSE American Company Guide
Section&nbsp;711 or other applicable rule, and such issuance will not reduce the number of shares available for issuance under the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii) Actions that Do Not Constitute Issuance of Common Stock and Do Not Reduce Share Reserve.</B> The following actions do not result in an
issuance of shares under the Plan and accordingly do not reduce the number of shares subject to the Share Reserve and available for issuance under the Plan: (1)&nbsp;the expiration or termination of any portion of an Award without the shares covered
by such portion of the Award having been issued; (2)&nbsp;the settlement of any portion of an Award in cash (<I>i.e.</I>, the Participant receives cash rather than Common Stock); (3) the withholding of shares that would otherwise be issued by the
Company to satisfy the exercise, strike or purchase price of an Award; or (4)&nbsp;the withholding of shares that would otherwise be issued by the Company to satisfy a tax withholding obligation in connection with an Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii) </B><B>Reversion of Previously Issued Shares of Common Stock to Share Reserve.</B> The following shares of Common Stock previously
issued pursuant to an Award and accordingly initially deducted from the Share Reserve will be added back to the Share Reserve and again become available for issuance under the Plan: (1)&nbsp;any shares that are forfeited back to or repurchased by
the Company because of a failure to meet a contingency or condition required for the vesting of such shares; (2)&nbsp;any shares that are reacquired by the Company to satisfy the exercise, strike or purchase price of an Award; and (3)&nbsp;any
shares that are reacquired by the Company to satisfy a tax withholding obligation in connection with an Award. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>E<SMALL>LIGIBILITY</SMALL> <SMALL>AND</SMALL> L<SMALL>IMITATIONS</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) Eligible Award Recipients.</B> Subject to the terms of the Plan, Employees, Directors and Consultants are eligible to receive Awards.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) Specific Award Limitations. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i) Limitations on Incentive Stock Option Recipients.</B> Incentive Stock Options may be granted only to Employees of the Company or a
&#147;parent corporation&#148; or &#147;subsidiary corporation&#148; thereof (as such terms are defined in Sections 424(e) and (f)&nbsp;of the Code). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii) Incentive Stock Option $100,000 Limitation.</B> To the extent that the aggregate Fair Market Value (determined at the time of grant)
of the shares of Common Stock with respect to which Incentive Stock Options are exercisable for the first time by any Optionholder during any calendar year (under all plans of the Company and any &#147;parent corporation&#148; or &#147;subsidiary
corporation&#148; thereof, as such terms are defined in Sections 424(e) and (f)&nbsp;of the Code) exceeds $100,000 (or such other limit established in the Code), or any Incentive Stock Options otherwise do not comply with the rules governing
Incentive Stock Options, the Options or portions thereof that exceed such limit (according to the order in which they were granted) or otherwise do not comply with such rules will be treated as Nonstatutory Stock Options, notwithstanding any
contrary provision of the applicable Option Agreement(s). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii) Limitations on Incentive Stock Options Granted to Ten Percent Stockholders.</B> A
Ten Percent Stockholder may not be granted an Incentive Stock Option unless (1)&nbsp;the exercise price of such Option is at least 110% of the Fair Market Value on the date of grant of such Option and (2)&nbsp;the Option is not exercisable after the
expiration of five years from the date of grant of such Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iv) Limitations on Nonstatutory Stock Options and SARs.</B>
Nonstatutory Stock Options and SARs may not be granted to Employees, Directors and Consultants unless the stock underlying such Awards is treated as &#147;service recipient stock&#148; under Section&nbsp;409A or unless such Awards otherwise comply
with the requirements of Section&nbsp;409A. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) Aggregate Incentive Stock Option Limit.</B> The aggregate maximum number of shares of
Common Stock that may be issued pursuant to the exercise of Incentive Stock Options is the number of shares specified in Section&nbsp;2(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d) <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Limit. </B>The aggregate value of all compensation granted
or paid, as applicable, in each case following the IPO Date, to any individual for service as a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director with respect to any calendar year, including Awards granted and cash fees paid by the
Company to such <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director, for his or her service as a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director, will not exceed $750,000 in total value, calculating the value of any equity
awards based on the grant date fair value of such equity awards for financial reporting purposes.&nbsp;The limitation in this Section&nbsp;3(d) shall apply commencing with the first calendar year that begins following the Effective Date. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>O<SMALL>PTIONS</SMALL> <SMALL>AND</SMALL> S<SMALL>TOCK</SMALL> A<SMALL>PPRECIATION</SMALL>
R<SMALL>IGHTS</SMALL>. </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Option and SAR will have such terms and conditions as determined by the Board. Each
Option will be designated in writing as an Incentive Stock Option or Nonstatutory Stock Option at the time of grant; provided, however, that if an Option is not so designated or if an Option designated as an Incentive Stock Option fails to qualify
as an Incentive Stock Option, then such Option will be a Nonstatutory Stock Option, and the shares purchased upon exercise of each type of Option will be separately accounted for. Each SAR will be denominated in shares of Common Stock equivalents.
The terms and conditions of separate Options and SARs need not be identical; provided, however, that each Option Agreement and SAR Agreement will conform (through incorporation of provisions hereof by reference in the Award Agreement or otherwise)
to the substance of each of the following provisions: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) Term.</B> Subject to Section&nbsp;3(b) regarding Ten Percent Stockholders,
no Option or SAR will be exercisable after the expiration of ten years from the date of grant of such Award or such shorter period specified in the Award Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) Exercise or Strike Price.</B> Subject to Section&nbsp;3(b) regarding Ten Percent Stockholders, the exercise or strike price of each
Option or SAR will not be less than 100% of the Fair Market Value on the date of grant of such Award. Notwithstanding the foregoing, an Option or SAR may be granted with an exercise or strike price lower than 100% of the Fair Market Value on the
date of grant of such Award if such Award is granted pursuant to an assumption of or substitution for another option or stock appreciation right pursuant to a Corporate Transaction and in a manner consistent with the provisions of Sections 409A and,
if applicable, 424(a) of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) </B><B>Exercise Procedure and Payment of Exercise Price for Options.</B> In order to exercise
an Option, the Participant must provide notice of exercise to the Plan Administrator in accordance with the procedures specified in the Option Agreement or otherwise provided by the Company. The Board has the authority to grant Options that do not
permit all of the following methods of payment (or otherwise restrict the ability to use certain methods) and to grant Options that require the consent of the Company to utilize </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
a particular method of payment. The exercise price of an Option may be paid, to the extent permitted by Applicable Law and as determined by the Board, by one or more of the following methods of
payment to the extent set forth in the Option Agreement: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i) </B>by cash or check, bank draft or money order payable to the Company;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii) </B>pursuant to a &#147;cashless exercise&#148; program developed under Regulation T as promulgated by the Federal Reserve Board
that, prior to the issuance of the Common Stock subject to the Option, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the exercise price to the Company from the sales proceeds; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii) </B>by delivery to the Company (either by actual delivery or attestation) of shares of Common Stock that are already owned by the
Participant free and clear of any liens, claims, encumbrances or security interests, with a Fair Market Value on the date of exercise that does not exceed the exercise price, provided that (1)&nbsp;at the time of exercise the Common Stock is
publicly traded, (2)&nbsp;any remaining balance of the exercise price not satisfied by such delivery is paid by the Participant in cash or other permitted form of payment, (3)&nbsp;such delivery would not violate any Applicable Law or agreement
restricting the redemption of the Common Stock, (4)&nbsp;any certificated shares are endorsed or accompanied by an executed assignment separate from certificate, and (5)&nbsp;such shares have been held by the Participant for any minimum period
necessary to avoid adverse accounting treatment as a result of such delivery; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iv) </B>if the Option is a Nonstatutory Stock Option,
by a &#147;net exercise&#148; arrangement pursuant to which the Company will reduce the number of shares of Common Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value on the date of exercise that does not
exceed the exercise price, provided that (1)&nbsp;such shares used to pay the exercise price will not be exercisable thereafter and (2)&nbsp;any remaining balance of the exercise price not satisfied by such net exercise is paid by the Participant in
cash or other permitted form of payment; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(v) </B>in any other form of consideration that may be acceptable to the Board and
permissible under Applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d) </B><B>Exercise Procedure and Payment of Appreciation Distribution for SARs</B><B>.</B> In order
to exercise any SAR, the Participant must provide notice of exercise to the Plan Administrator in accordance with the SAR Agreement. The appreciation distribution payable to a Participant upon the exercise of a SAR will not be greater than an amount
equal to the excess of (i)&nbsp;the aggregate Fair Market Value on the date of exercise of a number of shares of Common Stock equal to the number of Common Stock equivalents that are vested and being exercised under such SAR, over (ii)&nbsp;the
strike price of such SAR. Such appreciation distribution may be paid to the Participant in the form of Common Stock or cash (or any combination of Common Stock and cash) or in any other form of payment, as determined by the Board and specified in
the SAR Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e) Transferability.</B> Options and SARs may not be transferred to third party financial institutions for value.
The Board may impose such additional limitations on the transferability of an Option or SAR as it determines. In the absence of any such determination by the Board, the following restrictions on the transferability of Options and SARs will apply,
provided that except as explicitly provided herein, neither an Option nor a SAR may be transferred for consideration and <I>provided, further</I>, that if an Option is an Incentive Stock Option, such Option may be deemed to be a Nonstatutory Stock
Option as a result of such transfer: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i) Restrictions on Transfer.</B> An Option or SAR will not be transferable, except by
will or by the laws of descent and distribution, and will be exercisable during the lifetime of the Participant only by the Participant; provided, however, that the Board may permit transfer of an Option or SAR in a manner that is not prohibited by
applicable tax and securities laws upon the Participant&#146;s request, including to a trust if the Participant is considered to be the sole beneficial owner of such trust (as determined under Section&nbsp;671 of the Code and applicable state law)
while such Option or SAR is held in such trust, provided that the Participant and the trustee enter into a transfer and other agreements required by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii) Domestic Relations Orders.</B> Notwithstanding the foregoing, subject to the execution of transfer documentation in a format
acceptable to the Company and subject to the approval of the Board or a duly authorized Officer, an Option or SAR may be transferred pursuant to a domestic relations order. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f) </B><B>Vesting.</B> The Board may impose such restrictions on or conditions to the vesting and/or exercisability of an Option or SAR as
determined by the Board. Except as otherwise provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate, vesting of Options and SARs will cease upon termination of the Participant&#146;s
Continuous Service. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g) Termination of Continuous Service for Cause.</B> Except as explicitly otherwise provided in the Award
Agreement or other written agreement between a Participant and the Company or an Affiliate, if a Participant&#146;s Continuous Service is terminated for Cause, the Participant&#146;s Options and SARs will terminate and be forfeited immediately upon
such termination of Continuous Service, and the Participant will be prohibited from exercising any portion (including any vested portion) of such Awards on and after the date of such termination of Continuous Service and the Participant will have no
further right, title or interest in such forfeited Award, the shares of Common Stock subject to the forfeited Award, or any consideration in respect of the forfeited Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h) Post-Termination Exercise Period Following Termination of Continuous Service for Reasons Other than Cause.</B> Subject to
Section&nbsp;4(i), if a Participant&#146;s Continuous Service terminates for any reason other than for Cause, the Participant may exercise his or her Option or SAR to the extent vested, but only within the following period of time or, if applicable,
such other period of time provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate; provided, however, that in no event may such Award be exercised after the expiration of its maximum term (as
set forth in Section&nbsp;4(a)): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i) </B>three months following the date of such termination if such termination is a termination
without Cause (other than any termination due to the Participant&#146;s Disability or death); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii) </B>12 months following the date of
such termination if such termination is due to the Participant&#146;s Disability; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii) </B>18 months following the date of such
termination if such termination is due to the Participant&#146;s death; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iv) </B>18 months following the date of the
Participant&#146;s death if such death occurs following the date of such termination but during the period such Award is otherwise exercisable (as provided in (i)&nbsp;or (ii) above). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the date of such termination, to the extent the Participant does not exercise such Award within the applicable Post-Termination Exercise Period (or,
if earlier, prior to the expiration of the maximum term of such Award), such unexercised portion of the Award will terminate, and the Participant will have no further right, title or interest in the terminated Award, the shares of Common Stock
subject to the terminated Award, or any consideration in respect of the terminated Award. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i) Restrictions on Exercise; Extension of Exercisability. </B>A Participant may not
exercise an Option or SAR at any time that the issuance of shares of Common Stock upon such exercise would violate Applicable Law. Except as otherwise provided in the Award Agreement or other written agreement between a Participant and the Company
or an Affiliate, if a Participant&#146;s Continuous Service terminates for any reason other than for Cause and, at any time during the last thirty days of the applicable Post-Termination Exercise Period: (i)&nbsp;the exercise of the
Participant&#146;s Option or SAR would be prohibited solely because the issuance of shares of Common Stock upon such exercise would violate Applicable Law, or (ii)&nbsp;the immediate sale of any shares of Common Stock issued upon such exercise would
violate the Company&#146;s Trading Policy, then the applicable Post-Termination Exercise Period will be extended to the last day of the calendar month that commences following the date the Award would otherwise expire, with an additional extension
of the exercise period to the last day of the next calendar month to apply if any of the foregoing restrictions apply at any time during such extended exercise period, generally without limitation as to the maximum permitted number of extensions);
provided, however, that in no event may such Award be exercised after the expiration of its maximum term (as set forth in Section&nbsp;4(a)). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j) </B><B><FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Employees</B><B>.</B> No Option or SAR, whether or not vested, granted to an
Employee who is a <FONT STYLE="white-space:nowrap">non-exempt</FONT> employee for purposes of the Fair Labor Standards Act of 1938, as amended, will be first exercisable for any shares of Common Stock until at least six months following the date of
grant of such Award. Notwithstanding the foregoing, in accordance with the provisions of the Worker Economic Opportunity Act, any vested portion of such Award may be exercised earlier than six months following the date of grant of such Award in the
event of (i)&nbsp;such Participant&#146;s death or Disability, (ii)&nbsp;a Corporate Transaction in which such Award is not assumed, continued or substituted, (iii)&nbsp;a Change in Control, or (iv)&nbsp;such Participant&#146;s retirement (as such
term may be defined in the Award Agreement or another applicable agreement or, in the absence of any such definition, in accordance with the Company&#146;s then current employment policies and guidelines). This Section&nbsp;4(j) is intended to
operate so that any income derived by a <FONT STYLE="white-space:nowrap">non-exempt</FONT> employee in connection with the exercise or vesting of an Option or SAR will be exempt from his or her regular rate of pay. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k) Whole Shares.</B> Options and SARs may be exercised only with respect to whole shares of Common Stock or their equivalents. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>A<SMALL>WARDS</SMALL> O<SMALL>THER</SMALL> T<SMALL>HAN</SMALL> O<SMALL>PTIONS</SMALL> <SMALL>AND</SMALL>
S<SMALL>TOCK</SMALL> A<SMALL>PPRECIATION</SMALL> R<SMALL>IGHTS</SMALL>. </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) </B><B>Restricted Stock Awards and
RSU Awards.</B> Each Restricted Stock Award and RSU Award will have such terms and conditions as determined by the Board; provided, however, that each Restricted Stock Award Agreement and RSU Award Agreement will conform (through incorporation of
the provisions hereof by reference in the Award Agreement or otherwise) to the substance of each of the following provisions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i) Form
of Award.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(1) </B>Restricted Stock Awards: To the extent consistent with the Company&#146;s Bylaws, at the Board&#146;s election,
shares of Common Stock subject to a Restricted Stock Award may be (A)&nbsp;held in book entry form subject to the Company&#146;s instructions until such shares become vested or any other restrictions lapse, or (B)&nbsp;evidenced by a certificate,
which certificate will be held in such form and manner as determined by the Board. Unless otherwise determined by the Board, a Participant will have voting and other rights as a stockholder of the Company with respect to any shares subject to a
Restricted Stock Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(2) </B>RSU Awards: An RSU Award represents a Participant&#146;s right to be issued on a future date the
number of shares of Common Stock that is equal to the number of restricted stock units subject to the RSU Award. As a holder of an RSU Award, a Participant is an unsecured creditor of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company with respect to the Company&#146;s unfunded obligation, if any, to issue shares of Common Stock in settlement of such Award and nothing contained in the Plan or any RSU Agreement, and no
action taken pursuant to its provisions, will create or be construed to create a trust of any kind or a fiduciary relationship between a Participant and the Company or an Affiliate or any other person. A Participant will not have voting or any other
rights as a stockholder of the Company with respect to any RSU Award (unless and until shares are actually issued in settlement of a vested RSU Award). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii) Consideration.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(1) </B>Restricted Stock Awards: A Restricted Stock Award may be granted in consideration for (A)&nbsp;cash or check, bank draft or money
order payable to the Company, (B)&nbsp;services to the Company or an Affiliate, or (C)&nbsp;any other form of consideration as the Board may determine and permissible under Applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(2) </B>RSU Awards: Unless otherwise determined by the Board at the time of grant, an RSU Award will be granted in consideration for the
Participant&#146;s services to the Company or an Affiliate, such that the Participant will not be required to make any payment to the Company (other than such services) with respect to the grant or vesting of the RSU Award, or the issuance of any
shares of Common Stock pursuant to the RSU Award. If, at the time of grant, the Board determines that any consideration must be paid by the Participant (in a form other than the Participant&#146;s services to the Company or an Affiliate) upon the
issuance of any shares of Common Stock in settlement of the RSU Award, such consideration may be paid in any form of consideration as the Board may determine and permissible under Applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii) Vesting. </B>The Board may impose such restrictions on or conditions to the vesting of a Restricted Stock Award or RSU Award as
determined by the Board. Except as otherwise provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate, vesting of Restricted Stock Awards and RSU Awards will cease upon termination of the
Participant&#146;s Continuous Service. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iv) Termination of Continuous Service.</B> Except as otherwise provided in the Award Agreement
or other written agreement between a Participant and the Company or an Affiliate, if a Participant&#146;s Continuous Service terminates for any reason, (1)&nbsp;the Company may receive through a forfeiture condition or a repurchase right any or all
of the shares of Common Stock held by the Participant under his or her Restricted Stock Award that have not vested as of the date of such termination as set forth in the Restricted Stock Award Agreement and the Participant will have no further
right, title or interest in the Restricted Stock Award, the shares of Common Stock subject to the Restricted Stock Award, or any consideration in respect of the Restricted Stock Award and (2)&nbsp;any portion of his or her RSU Award that has not
vested will be forfeited upon such termination and the Participant will have no further right, title or interest in the RSU Award, the shares of Common Stock issuable pursuant to the RSU Award, or any consideration in respect of the RSU Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(v) Dividends and Dividend Equivalents. </B>Dividends or dividend equivalents may be paid or credited, as applicable, with respect to any
shares of Common Stock subject to a Restricted Stock Award or RSU Award, as determined by the Board and specified in the Award Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(vi) </B><B>Settlement of RSU Awards</B>. An RSU Award may be settled by the issuance of shares of Common Stock or cash (or any combination
thereof) or in any other form of payment, as determined by the Board and specified in the RSU Award Agreement. At the time of grant, the Board may determine to impose such restrictions or conditions that delay such delivery to a date following the
vesting of the RSU Award. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) </B><B>Performance Awards</B>. With respect to any Performance Award, the length of
any Performance Period, the Performance Goals to be achieved during the Performance Period, the other terms and conditions of such Award, and the measure of whether and to what degree such Performance Goals have been attained will be determined by
the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) </B><B>Other Awards</B>. Other forms of Awards valued in whole or in part by reference to, or otherwise based on,
Common Stock, including the appreciation in value thereof, may be granted either alone or in addition to Awards provided for under Section&nbsp;4 and the preceding provisions of this Section&nbsp;5. Subject to the provisions of the Plan, the Board
will have sole and complete discretion to determine the persons to whom and the time or times at which such Other Awards will be granted, the number of shares of Common Stock (or the cash equivalent thereof) to be granted pursuant to such Other
Awards and all other terms and conditions of such Other Awards. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>A<SMALL>DJUSTMENTS</SMALL> <SMALL>UPON</SMALL> C<SMALL>HANGES</SMALL> <SMALL>IN</SMALL>
C<SMALL>OMMON</SMALL> S<SMALL>TOCK</SMALL>; O<SMALL>THER</SMALL> C<SMALL>ORPORATE</SMALL> E<SMALL>VENTS</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) </B><B>Capitalization Adjustments</B>. In the event of a Capitalization Adjustment, the Board shall appropriately and proportionately
adjust: (i)&nbsp;the class(es) and maximum number of shares of Common Stock subject to the Plan and the maximum number of shares by which the Share Reserve may annually increase pursuant to Section&nbsp;2(a); (ii) the class(es) and maximum number of
shares that may be issued pursuant to the exercise of Incentive Stock Options pursuant to Section&nbsp;2(b); and (iii)&nbsp;the class(es) and number of securities and exercise price, strike price or purchase price of Common Stock subject to
outstanding Awards. The Board shall make such adjustments, and its determination shall be final, binding and conclusive. Notwithstanding the foregoing, no fractional shares or rights for fractional shares of Common Stock shall be created in order to
implement any Capitalization Adjustment. The Board shall determine an appropriate equivalent benefit, if any, for any fractional shares or rights to fractional shares that might be created by the adjustments referred to in the preceding provisions
of this Section. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) Dissolution or Liquidation.</B> Except as otherwise provided in the Award Agreement, in the event of a
dissolution or liquidation of the Company, all outstanding Awards (other than Awards consisting of vested and outstanding shares of Common Stock not subject to a forfeiture condition or the Company&#146;s right of repurchase) will terminate
immediately prior to the completion of such dissolution or liquidation, and the shares of Common Stock subject to the Company&#146;s repurchase rights or subject to a forfeiture condition may be repurchased or reacquired by the Company
notwithstanding the fact that the holder of such Award is providing Continuous Service, provided, however, that the Board may determine to cause some or all Awards to become fully vested, exercisable and/or no longer subject to repurchase or
forfeiture (to the extent such Awards have not previously expired or terminated) before the dissolution or liquidation is completed but contingent on its completion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) Corporate Transaction. </B>The following provisions will apply to Awards in the event of a Corporate Transaction, except as set forth
in Section&nbsp;11, unless otherwise provided in the instrument evidencing the Award or any other written agreement between the Company or any Affiliate and the Participant or unless otherwise expressly provided by the Board at the time of grant of
an Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i) Awards May Be Assumed.</B> In the event of a Corporate Transaction, any surviving corporation or acquiring corporation
(or the surviving or acquiring corporation&#146;s parent company) may assume or continue any or all Awards outstanding under the Plan or may substitute similar awards for Awards outstanding under the Plan (including but not limited to, awards to
acquire the same consideration paid to the stockholders of the Company pursuant to the Corporate Transaction), and any reacquisition or repurchase rights held by the Company in respect of Common Stock issued pursuant to Awards may be assigned by the
Company to the successor of the Company (or the successor&#146;s parent company, if any), in connection with such Corporate Transaction. A surviving corporation or acquiring </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
corporation (or its parent) may choose to assume or continue only a portion of an Award or substitute a similar award for only a portion of an Award, or may choose to assume, continue, or
substitute the Awards held by some, but not all Participants. The terms of any assumption, continuation or substitution will be set by the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii) Awards Held by Current Participants.</B> In the event of a Corporate Transaction in which the surviving corporation or acquiring
corporation (or its parent company) does not assume or continue such outstanding Awards or substitute similar awards for such outstanding Awards, then with respect to Awards that have not been assumed, continued or substituted and that are held by
Participants whose Continuous Service has not terminated prior to the effective time of the Corporate Transaction (referred to as the &#147;<B><I>Current Participants</I></B>&#148;), the vesting of such Awards (and, with respect to Options and Stock
Appreciation Rights, the time when such Awards may be exercised) will<B> </B>be accelerated in full to a date prior to the effective time of such Corporate Transaction (contingent upon the effectiveness of the Corporate Transaction) as the Board
determines (or, if the Board does not determine such a date, to the date that is five days prior to the effective time of the Corporate Transaction), and such Awards will terminate if not exercised (if applicable) at or prior to the effective time
of the Corporate Transaction, and any reacquisition or repurchase rights held by the Company with respect to such Awards will lapse (contingent upon the effectiveness of the Corporate Transaction). With respect to the vesting of Performance Awards
that will accelerate upon the occurrence of a Corporate Transaction pursuant to this subsection (ii)&nbsp;and that have multiple vesting levels depending on the level of performance, unless otherwise provided in the Award Agreement, the vesting of
such Performance Awards will accelerate at 100% of the target level upon the occurrence of the Corporate Transaction in which the Awards are not assumed, continued or substituted in accordance with Section&nbsp;6(c)(i). With respect to the vesting
of Awards that will accelerate upon the occurrence of a Corporate Transaction pursuant to this subsection (ii)&nbsp;and are settled in the form of a cash payment, such cash payment will be made no later than 30 days following the occurrence of the
Corporate Transaction or such later date as required to comply with Section&nbsp;409A of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii) Awards Held by Persons other
than Current Participants.</B> In the event of a Corporate Transaction in which the surviving corporation or acquiring corporation (or its parent company) does not assume or continue such outstanding Awards or substitute similar awards for such
outstanding Awards, then with respect to Awards that have not been assumed, continued or substituted and that are held by persons other than Current Participants, such Awards will terminate if not exercised (if applicable) prior to the occurrence of
the Corporate Transaction; provided, however, that any reacquisition or repurchase rights held by the Company with respect to such Awards will not terminate and may continue to be exercised notwithstanding the Corporate Transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iv) Payment for Awards in Lieu of Exercise.</B> Notwithstanding the foregoing, in the event an Award will terminate if not exercised prior
to the effective time of a Corporate Transaction, the Board may provide, in its sole discretion, that the holder of such Award may not exercise such Award but will receive a payment, in such form as may be determined by the Board, equal in value, at
the effective time, to the excess, if any, of (1)&nbsp;the value of the property the Participant would have received upon the exercise of the Award (including, at the discretion of the Board, any unvested portion of such Award), over (2)&nbsp;any
exercise price payable by such holder in connection with such exercise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d) Appointment of Stockholder Representative.</B> As a
condition to the receipt of an Award under this Plan, a Participant will be deemed to have agreed that the Award will be subject to the terms of any agreement governing a Corporate Transaction involving the Company, including, without limitation, a
provision for the appointment of a stockholder representative that is authorized to act on the Participant&#146;s behalf with respect to any escrow, indemnities and any contingent consideration. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e) No Restriction on Right to Undertake Transactions.</B> The grant of any Award under
the Plan and the issuance of shares pursuant to any Award does not affect or restrict in any way the right or power of the Company or the stockholders of the Company to make or authorize any adjustment, recapitalization, reorganization or other
change in the Company&#146;s capital structure or its business, any merger or consolidation of the Company, any issue of stock or of options, rights or options to purchase stock or of bonds, debentures, preferred or prior preference stocks whose
rights are superior to or affect the Common Stock or the rights thereof or which are convertible into or exchangeable for Common Stock, or the dissolution or liquidation of the Company, or any sale or transfer of all or any part of its assets or
business, or any other corporate act or proceeding, whether of a similar character or otherwise. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>A<SMALL>DMINISTRATION</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) Administration by Board.</B> The Board will administer the Plan unless and until the Board delegates administration of the Plan to a
Committee or Committees, as provided in subsection (c)&nbsp;below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) Powers of Board.</B> The Board will have the power, subject to,
and within the limitations of, the express provisions of the Plan: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i) </B>To determine from time to time (1)&nbsp;which of the persons
eligible under the Plan will be granted Awards; (2)&nbsp;when and how each Award will be granted; (3)&nbsp;what type or combination of types of Award will be granted; (4)&nbsp;the provisions of each Award granted (which need not be identical),
including the time or times when a person will be permitted to receive an issuance of Common Stock or other payment pursuant to an Award; (5)&nbsp;the number of shares of Common Stock or cash equivalent with respect to which an Award will be granted
to each such person; (6)&nbsp;the Fair Market Value applicable to an Award; and (7)&nbsp;the terms of any Performance Award that is not valued in whole or in part by reference to, or otherwise based on, the Common Stock, including the amount of cash
payment or other property that may be earned and the timing of payment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii) </B>To construe and interpret the Plan and Awards granted
under it, and to establish, amend and revoke rules and regulations for its administration. The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan or in any Award Agreement, in a manner and to the
extent it deems necessary or expedient to make the Plan or Award fully effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii) </B>To settle all controversies regarding the
Plan and Awards granted under it. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iv) </B>To accelerate the time at which an Award may first be exercised or the time during which an
Award or any part thereof will vest, notwithstanding the provisions in the Award Agreement stating the time at which it may first be exercised or the time during which it will vest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(v) </B>To prohibit the exercise of any Option, SAR or other exercisable Award during a period of up to 30 days prior to the consummation
of any pending stock dividend, stock split, combination or exchange of shares, merger, consolidation or other distribution (other than normal cash dividends) of Company assets to stockholders, or any other change affecting the shares of Common Stock
or the share price of the Common Stock including (but not limited to) any Corporate Transaction, for reasons of administrative convenience. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(vi) </B>To suspend or terminate the Plan at any time. Suspension or termination of the Plan will not Materially Impair rights and
obligations under any Award granted while the Plan is in effect except with the written consent of the affected Participant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(vii) </B>To amend the Plan in any respect the Board deems necessary or advisable;
provided, however<I>,</I> that stockholder approval will be required for any amendment to the extent required by Applicable Law. Except as provided above, rights under any Award granted before amendment of the Plan will not be Materially Impaired by
any amendment of the Plan unless (1)&nbsp;the Company requests the consent of the affected Participant, and (2)&nbsp;such Participant consents in writing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(viii) </B>To submit any amendment to the Plan for stockholder approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ix) </B>To approve forms of Award Agreements for use under the Plan and to amend the terms of any one or more Awards, including, but not
limited to, amendments to provide terms more favorable to the Participant than previously provided in the Award Agreement, subject to any specified limits in the Plan that are not subject to Board discretion; <I>provided however</I>, that, a
Participant&#146;s rights under any Award will not be Materially Impaired by any such amendment unless (1)&nbsp;the Company requests the consent of the affected Participant, and (2)&nbsp;such Participant consents in writing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(x) </B>Generally, to exercise such powers and to perform such acts as the Board deems necessary or expedient to promote the best interests
of the Company and that are not in conflict with the provisions of the Plan or Awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(xi) </B>To adopt or amend such procedures and <FONT
STYLE="white-space:nowrap">sub-plans</FONT> as are necessary or appropriate to accommodate the specific requirements of local laws, procedures and practices, permit and facilitate participation in the Plan by, or take advantage of specific tax
treatment for Awards granted to, Employees, Directors or Consultants who are foreign nationals or employed outside the United States (provided that Board approval will not be necessary for immaterial modifications to the Plan or any Award Agreement
to ensure or facilitate compliance with the laws of the relevant foreign jurisdiction). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(xii) </B>To effect, at any time and from time
to time, subject to the consent of any Participant whose Award is Materially Impaired by such action, (1)&nbsp;the reduction of the exercise price (or strike price) of any outstanding Option or SAR; (2)&nbsp;the cancellation of any outstanding
Option or SAR and the grant in substitution therefor of (A)&nbsp;a new Option, SAR, Restricted Stock Award, RSU Award or Other Award, under the Plan or another equity plan of the Company, covering the same or a different number of shares of Common
Stock, (B)&nbsp;cash and/or (C)&nbsp;other valuable consideration (as determined by the Board); or (3)&nbsp;any other action that is treated as a repricing under generally accepted accounting principles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) Delegation to Committee.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i) </B><B>General.</B> The Board may delegate some or all of the administration of the Plan to a Committee or Committees. If
administration of the Plan is delegated to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the power to
delegate to another Committee or a subcommittee of the Committee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board will thereafter be to the Committee or subcommittee), subject,
however, to such resolutions, not inconsistent with the provisions of the Plan, as may be adopted from time to time by the Board. Each Committee may retain the authority to concurrently administer the Plan with Committee or subcommittee to which it
has delegated its authority hereunder and may, at any time, revest in such Committee some or all of the powers previously delegated. The Board may retain the authority to concurrently administer the Plan with any Committee and may, at any time,
revest in the Board some or all of the powers previously delegated. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii) </B><B>Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> Compliance.</B> To the
extent an Award is intended to qualify for the exemption from Section&nbsp;16(b) of the Exchange Act that is available under Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> of the Exchange Act, the Award will be granted by the Board or a
Committee that consists solely of two or more <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors, as determined under Rule <FONT STYLE="white-space:nowrap">16b-3(b)(3)</FONT> of the Exchange Act and thereafter any action establishing or
modifying the terms of the Award will be approved by the Board or a Committee meeting such requirements to the extent necessary for such exemption to remain available. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d) </B><B>Effect of Board</B><B>&#146;</B><B>s Decision.</B> All determinations, interpretations and constructions made by the Board or
any Committee in good faith will not be subject to review by any person and will be final, binding and conclusive on all persons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)
</B><B>Delegation to an Officer.</B> The Board or any Committee may delegate to one or more Officers the authority to do one or both of the following (i)&nbsp;designate Employees who are not Officers to be recipients of Options and SARs (and, to the
extent permitted by Applicable Law, other types of Awards) and, to the extent permitted by Applicable Law, the terms thereof, and (ii)&nbsp;determine the number of shares of Common Stock to be subject to such Awards granted to such Employees;
provided, however, that the resolutions or charter adopted by the Board or any Committee evidencing such delegation will specify the total number of shares of Common Stock that may be subject to the Awards granted by such Officer and that such
Officer may not grant an Award to himself or herself. Any such Awards will be granted on the applicable form of Award Agreement most recently approved for use by the Board or the Committee, unless otherwise provided in the resolutions approving the
delegation authority. Notwithstanding anything to the contrary herein, neither the Board nor any Committee may delegate to an Officer who is acting solely in the capacity of an Officer (and not also as a Director) the authority to determine the Fair
Market Value. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>T<SMALL>AX</SMALL> W<SMALL>ITHHOLDING</SMALL> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) Withholding Authorization.</B> As a condition to acceptance of any Award under the Plan, a Participant authorizes withholding from
payroll and any other amounts payable to such Participant, and otherwise agrees to make adequate provision for, any sums required to satisfy any U.S. federal, state, local and/or foreign tax or social insurance contribution withholding obligations
of the Company or an Affiliate, if any, which arise in connection with the grant, vesting, exercise, or settlement of such Award , as applicable. Accordingly, a Participant may not be able to exercise an Award even though the Award is vested, and
the Company shall have no obligation to issue shares of Common Stock subject to an Award, unless and until such obligations are satisfied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) Satisfaction of Withholding Obligation.</B> To the extent permitted by the terms of an Award Agreement, the Company may, in its sole
discretion, satisfy any U.S. federal, state, local and/or foreign tax or social insurance withholding obligation relating to an Award by any of the following means or by a combination of such means: (i)&nbsp;causing the Participant to tender a cash
payment; (ii)&nbsp;withholding shares of Common Stock from the shares of Common Stock issued or otherwise issuable to the Participant in connection with the Award; (iii)&nbsp;withholding cash from an Award settled in cash; (iv)&nbsp;withholding
payment from any amounts otherwise payable to the Participant; (v)&nbsp;by allowing a Participant to effectuate a &#147;cashless exercise&#148; pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board; or
(vi)&nbsp;by such other method as may be set forth in the Award Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) No Obligation to Notify or Minimize Taxes; No Liability
to Claims. </B>Except as required by Applicable Law the Company has no duty or obligation to any Participant to advise such holder as to the time or manner of exercising such Award. Furthermore, the Company has no duty or obligation to warn or
otherwise advise such holder of a pending termination or expiration of an Award or a possible period in which the Award may not be exercised. The Company has no duty or obligation to minimize the tax consequences of an Award to the holder of such
Award and will not be liable to any holder of an Award </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
for any adverse tax consequences to such holder in connection with an Award. As a condition to accepting an Award under the Plan, each Participant (i)&nbsp;agrees to not make any claim against
the Company, or any of its Officers, Directors, Employees or Affiliates related to tax liabilities arising from such Award or other Company compensation and (ii)&nbsp;acknowledges that such Participant was advised to consult with his or her own
personal tax, financial and other legal advisors regarding the tax consequences of the Award and has either done so or knowingly and voluntarily declined to do so. Additionally, each Participant acknowledges any Option or SAR granted under the Plan
is exempt from Section&nbsp;409A only if the exercise or strike price is at least equal to the &#147;fair market value&#148; of the Common Stock on the date of grant as determined by the Internal Revenue Service and there is no other impermissible
deferral of compensation associated with the Award. Additionally, as a condition to accepting an Option or SAR granted under the Plan, each Participant agrees not make any claim against the Company, or any of its Officers, Directors, Employees or
Affiliates in the event that the Internal Revenue Service asserts that such exercise price or strike price is less than the &#147;fair market value&#148; of the Common Stock on the date of grant as subsequently determined by the Internal Revenue
Service. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d) Withholding Indemnification. </B>As a condition to accepting an Award under the Plan, in the event that the amount of the
Company&#146;s and/or its Affiliate&#146;s withholding obligation in connection with such Award was greater than the amount actually withheld by the Company and/or its Affiliates, each Participant agrees to indemnify and hold the Company and/or its
Affiliates harmless from any failure by the Company and/or its Affiliates to withhold the proper amount. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>M<SMALL>ISCELLANEOUS</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) Source of Shares.</B> The stock issuable under the Plan will be shares of authorized but unissued or reacquired Common Stock, including
shares repurchased by the Company on the open market or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) Use of Proceeds from Sales of Common Stock. </B>Proceeds from
the sale of shares of Common Stock pursuant to Awards will constitute general funds of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) Corporate Action Constituting
Grant of Awards.</B> Corporate action constituting a grant by the Company of an Award to any Participant will be deemed completed as of the date of such corporate action, unless otherwise determined by the Board, regardless of when the instrument,
certificate, or letter evidencing the Award is communicated to, or actually received or accepted by, the Participant. In the event that the corporate records (e.g., Board consents, resolutions or minutes) documenting the corporate action approving
the grant contain terms (e.g., exercise price, vesting schedule or number of shares) that are inconsistent with those in the Award Agreement or related grant documents as a result of a clerical error in the Award Agreement or related grant
documents, the corporate records will control and the Participant will have no legally binding right to the incorrect term in the Award Agreement or related grant documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d) Stockholder Rights.</B> No Participant will be deemed to be the holder of, or to have any of the rights of a holder with respect to,
any shares of Common Stock subject to such Award unless and until (i)&nbsp;such Participant has satisfied all requirements for exercise of the Award pursuant to its terms, if applicable, and (ii)&nbsp;the issuance of the Common Stock subject to such
Award is reflected in the records of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e) No Employment or Other Service Rights.</B> Nothing in the Plan, any Award
Agreement or any other instrument executed thereunder or in connection with any Award granted pursuant thereto will confer upon any Participant any right to continue to serve the Company or an Affiliate in the capacity in effect at the time the
Award was granted or affect the right of the Company or an Affiliate to terminate at will and without regard to any future vesting opportunity that a Participant may have with respect to any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Award (i)&nbsp;the employment of an Employee with or without notice and with or without cause, (ii)&nbsp;the service of a Consultant pursuant to the terms of such Consultant&#146;s agreement with
the Company or an Affiliate, or (iii)&nbsp;the service of a Director pursuant to the Bylaws of the Company or an Affiliate, and any applicable provisions of the corporate law of the state or foreign jurisdiction in which the Company or the Affiliate
is incorporated, as the case may be. Further, nothing in the Plan, any Award Agreement or any other instrument executed thereunder or in connection with any Award will constitute any promise or commitment by the Company or an Affiliate regarding the
fact or nature of future positions, future work assignments, future compensation or any other term or condition of employment or service or confer any right or benefit under the Award or the Plan unless such right or benefit has specifically accrued
under the terms of the Award Agreement and/or Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f) Change in Time Commitment.</B> In the event a Participant&#146;s regular level
of time commitment in the performance of his or her services for the Company and any Affiliates is reduced (for example, and without limitation, if the Participant is an Employee of the Company and the Employee has a change in status from a
full-time Employee to a part-time Employee or takes an extended leave of absence) after the date of grant of any Award to the Participant, the Board may determine, to the extent permitted by Applicable Law, to (i)&nbsp;make a corresponding reduction
in the number of shares or cash amount subject to any portion of such Award that is scheduled to vest or become payable after the date of such change in time commitment, and (ii)&nbsp;in lieu of or in combination with such a reduction, extend the
vesting or payment schedule applicable to such Award. In the event of any such reduction, the Participant will have no right with respect to any portion of the Award that is so reduced or extended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g) Execution of Additional Documents.</B> As a condition to accepting an Award under the Plan, the Participant agrees to execute any
additional documents or instruments necessary or desirable, as determined in the Plan Administrator&#146;s sole discretion, to carry out the purposes or intent of the Award, or facilitate compliance with securities and/or other regulatory
requirements, in each case at the Plan Administrator&#146;s request. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h) Electronic Delivery and Participation.</B> Any reference
herein or in an Award Agreement to a &#147;written&#148; agreement or document will include any agreement or document delivered electronically, filed publicly at www.sec.gov (or any successor website thereto) or posted on the Company&#146;s intranet
(or other shared electronic medium controlled by the Company to which the Participant has access). By accepting any Award the Participant consents to receive documents by electronic delivery and to participate in the Plan through any <FONT
STYLE="white-space:nowrap">on-line</FONT> electronic system established and maintained by the Plan Administrator or another third party selected by the Plan Administrator. The form of delivery of any Common Stock (e.g., a stock certificate or
electronic entry evidencing such shares) shall be determined by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i) Clawback/Recovery.</B> All Awards granted under the
Plan will be subject to recoupment in accordance with any clawback policy that the Company is required to adopt pursuant to the listing standards of any national securities exchange or association on which the Company&#146;s securities are listed or
as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other Applicable Law and any clawback policy that the Company otherwise adopts, to the extent applicable and permissible under Applicable Law. In addition,
the Board may impose such other clawback, recovery or recoupment provisions in an Award Agreement as the Board determines necessary or appropriate, including but not limited to a reacquisition right in respect of previously acquired shares of Common
Stock or other cash or property upon the occurrence of Cause. No recovery of compensation under such a clawback policy will be an event giving rise to a Participant&#146;s right to voluntarily terminate employment upon a &#147;resignation for good
reason,&#148; or for a &#147;constructive termination&#148; or any similar term under any plan of or agreement with the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j) Securities Law Compliance. </B>A Participant will not be issued any shares in respect
of an Award unless either (i)&nbsp;the shares are registered under the Securities Act; or (ii)&nbsp;the Company has determined that such issuance would be exempt from the registration requirements of the Securities Act. Each Award also must comply
with other Applicable Law governing the Award, and a Participant will not receive such shares if the Company determines that such receipt would not be in material compliance with Applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k) Transfer or Assignment of Awards; Issued Shares.</B> Except as expressly provided in the Plan or the form of Award Agreement, Awards
granted under the Plan may not be transferred or assigned by the Participant. After the vested shares subject to an Award have been issued, or in the case of Restricted Stock and similar awards, after the issued shares have vested, the holder of
such shares is free to assign, hypothecate, donate, encumber or otherwise dispose of any interest in such shares provided that any such actions are in compliance with the provisions herein, the terms of the Trading Policy and Applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(l) Effect on Other Employee Benefit Plans. </B>The value of any Award granted under the Plan, as determined upon grant, vesting or
settlement, shall not be included as compensation, earnings, salaries, or other similar terms used when calculating any Participant&#146;s benefits under any employee benefit plan sponsored by the Company or any Affiliate, except as such plan
otherwise expressly provides. The Company expressly reserves its rights to amend, modify, or terminate any of the Company&#146;s or any Affiliate&#146;s employee benefit plans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(m) Deferrals.</B> To the extent permitted by Applicable Law, the Board, in its sole discretion, may determine that the delivery of Common
Stock or the payment of cash, upon the exercise, vesting or settlement of all or a portion of any Award may be deferred and may also establish programs and procedures for deferral elections to be made by Participants. Deferrals will be made in
accordance with the requirements of Section&nbsp;409A. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(n) Section</B><B></B><B>&nbsp;409A. </B>Unless otherwise expressly provided
for in an Award Agreement, the Plan and Award Agreements will be interpreted to the greatest extent possible in a manner that makes the Plan and the Awards granted hereunder exempt from Section&nbsp;409A, and, to the extent not so exempt, in
compliance with the requirements of Section&nbsp;409A. If the Board determines that any Award granted hereunder is not exempt from and is therefore subject to Section&nbsp;409A, the Award Agreement evidencing such Award will incorporate the terms
and conditions necessary to avoid the consequences specified in Section&nbsp;409A(a)(1) of the Code, and to the extent an Award Agreement is silent on terms necessary for compliance, such terms are hereby incorporated by reference into the Award
Agreement. Notwithstanding anything to the contrary in this Plan (and unless the Award Agreement specifically provides otherwise), if the shares of Common Stock are publicly traded, and if a Participant holding an Award that constitutes
&#147;deferred compensation&#148; under Section&nbsp;409A is a &#147;specified employee&#148; for purposes of Section&nbsp;409A, no distribution or payment of any amount that is due because of a &#147;separation from service&#148; (as defined in
Section&nbsp;409A without regard to alternative definitions thereunder) will be issued or paid before the date that is six months and one day following the date of such Participant&#146;s &#147;separation from service&#148; or, if earlier, the date
of the Participant&#146;s death, unless such distribution or payment can be made in a manner that complies with Section&nbsp;409A, and any amounts so deferred will be paid in a lump sum on the day after such six month period elapses, with the
balance paid thereafter on the original schedule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(o) </B><B>C<SMALL>HOICE</SMALL> <SMALL>OF</SMALL> L<SMALL>AW</SMALL>. </B>This Plan
and any controversy arising out of or relating to this Plan shall be governed by, and construed in accordance with, the internal laws of the State of Delaware, without regard to conflict of law principles that would result in any application of any
law other than the law of the State of Delaware. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>C<SMALL>OVENANTS</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> C<SMALL>OMPANY</SMALL>.
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company will seek to obtain from each regulatory commission or agency, as may be deemed to be necessary, having
jurisdiction over the Plan such authority as may be required to grant Awards and to issue and sell shares of Common Stock upon exercise or vesting of the Awards; provided, however, that this undertaking will not require the Company to register under
the Securities Act the Plan, any Award or any Common Stock issued or issuable pursuant to any such Award. If, after reasonable efforts and at a reasonable cost, the Company is unable to obtain from any such regulatory commission or agency the
authority that counsel for the Company deems necessary or advisable for the lawful issuance and sale of Common Stock under the Plan, the Company will be relieved from any liability for failure to issue and sell Common Stock upon exercise or vesting
of such Awards unless and until such authority is obtained. A Participant is not eligible for the grant of an Award or the subsequent issuance of Common Stock pursuant to the Award if such grant or issuance would be in violation of any Applicable
Law. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>A<SMALL>DDITIONAL</SMALL> R<SMALL>ULES</SMALL> <SMALL>FOR</SMALL> A<SMALL>WARDS</SMALL>
S<SMALL>UBJECT</SMALL> <SMALL>TO</SMALL> S<SMALL>ECTION</SMALL>&nbsp;409A. </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) Application. </B>Unless the
provisions of this Section of the Plan are expressly superseded by the provisions in the form of Award Agreement, the provisions of this Section shall apply and shall supersede anything to the contrary set forth in the Award Agreement for a <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Awards Subject to <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Severance Arrangements.</B> To the extent a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award is subject to Section&nbsp;409A due to application of a
<FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Severance Arrangement, the following provisions of this subsection (b)&nbsp;apply. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i) </B>If the <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award vests in the ordinary course during the Participant&#146;s
Continuous Service in accordance with the vesting schedule set forth in the Award Agreement, and does not accelerate vesting under the terms of a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Severance Arrangement, in no event will the shares
be issued in respect of such <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award any later than the later of: (i)&nbsp;December 31<SUP STYLE="font-size:75%; vertical-align:top">st</SUP> of the calendar year that includes the applicable vesting
date, or (ii)&nbsp;the 60<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> day that follows the applicable vesting date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)
</B>If vesting of the <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award accelerates under the terms of a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Severance Arrangement in connection with the Participant&#146;s Separation from
Service, and such vesting acceleration provisions were in effect as of the date of grant of the <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award and, therefore, are part of the terms of such <FONT STYLE="white-space:nowrap">Non-Exempt</FONT>
Award as of the date of grant, then the shares will be earlier issued in settlement of such <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award upon the Participant&#146;s Separation from Service in accordance with the terms of the <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Severance Arrangement, but in no event later than the 60<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> day that follows the date of the Participant&#146;s Separation from Service. However, if at
the time the shares would otherwise be issued the Participant is subject to the distribution limitations contained in Section&nbsp;409A applicable to &#147;specified employees,&#148; as defined in Section&nbsp;409A(a)(2)(B)(i) of the Code, such
shares shall not be issued before the date that is six months following the date of such Participant&#146;s Separation from Service, or, if earlier, the date of the Participant&#146;s death that occurs within such six month period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii) </B>If vesting of a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award accelerates under the terms of a <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Severance Arrangement in connection with a Participant&#146;s Separation from Service, and such vesting acceleration provisions were not in effect as of the date of grant of the <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Award and, therefore, are not a part of the terms of such <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award on the date of grant, then such acceleration of vesting of the <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Award shall not accelerate the issuance date of the shares, but the shares shall instead be issued on the same schedule as set forth in the Grant Notice as if they had vested in the ordinary course during
the Participant&#146;s Continuous Service, notwithstanding the vesting acceleration of the <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award. Such issuance schedule is intended to satisfy the requirements of payment on a specified date or
pursuant to a fixed schedule, as provided under Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-3(a)(4).</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) Treatment of <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Awards Upon a
Corporate Transaction for Employees and Consultants.</B> The provisions of this subsection (c)&nbsp;shall apply and shall supersede anything to the contrary set forth in the Plan with respect to the permitted treatment of any <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Award in connection with a Corporate Transaction if the Participant was either an Employee or Consultant upon the applicable date of grant of the <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i) Vested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Awards.</B> The following provisions shall apply to any Vested <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Award in connection with a Corporate Transaction: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(1) </B>If the Corporate Transaction
is also a Section&nbsp;409A Change in Control then the Acquiring Entity may not assume, continue or substitute the Vested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award. Upon the Section&nbsp;409A Change in Control the settlement of the
Vested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award will automatically be accelerated and the shares will be immediately issued in respect of the Vested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award. Alternatively, the Company
may instead provide that the Participant will receive a cash settlement equal to the Fair Market Value of the shares that would otherwise be issued to the Participant upon the Section&nbsp;409A Change in Control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(2) </B>If the Corporate Transaction is not also a Section&nbsp;409A Change in Control, then the Acquiring Entity must either assume,
continue or substitute each Vested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award. The shares to be issued in respect of the Vested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award shall be issued to the Participant by the
Acquiring Entity on the same schedule that the shares would have been issued to the Participant if the Corporate Transaction had not occurred. In the Acquiring Entity&#146;s discretion, in lieu of an issuance of shares, the Acquiring Entity may
instead substitute a cash payment on each applicable issuance date, equal to the Fair Market Value of the shares that would otherwise be issued to the Participant on such issuance dates, with the determination of the Fair Market Value of the shares
made on the date of the Corporate Transaction. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii) Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Awards.</B> The
following provisions shall apply to any Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award unless otherwise determined by the Board pursuant to subsection (e)&nbsp;of this Section. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(1) </B>In the event of a Corporate Transaction, the Acquiring Entity shall assume, continue or substitute any Unvested <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Award. Unless otherwise determined by the Board, any Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award will remain subject to the same vesting and forfeiture restrictions that were
applicable to the Award prior to the Corporate Transaction. The shares to be issued in respect of any Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award shall be issued to the Participant by the Acquiring Entity on the same schedule
that the shares would have been issued to the Participant if the Corporate Transaction had not occurred. In the Acquiring Entity&#146;s discretion, in lieu of an issuance of shares, the Acquiring Entity may instead substitute a cash payment on each
applicable issuance date, equal to the Fair Market Value of the shares that would otherwise be issued to the Participant on such issuance dates, with the determination of Fair Market Value of the shares made on the date of the Corporate Transaction.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(2) </B>If the Acquiring Entity will not assume, substitute or continue any Unvested
<FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award in connection with a Corporate Transaction, then such Award shall automatically terminate and be forfeited upon the Corporate Transaction with no consideration payable to any Participant in
respect of such forfeited Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award. Notwithstanding the foregoing, to the extent permitted and in compliance with the requirements of Section&nbsp;409A, the Board may in its discretion
determine to elect to accelerate the vesting and settlement of the Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
upon the Corporate Transaction, or instead substitute a cash payment equal to the Fair Market Value of such shares that would otherwise be issued to the Participant, as further provided in
subsection (e)(ii) below. In the absence of such discretionary election by the Board, any Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award shall be forfeited without payment of any consideration to the affected Participants if the
Acquiring Entity will not assume, substitute or continue the Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Awards in connection with the Corporate Transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(3) </B>The foregoing treatment shall apply with respect to all Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Awards upon
any Corporate Transaction, and regardless of whether or not such Corporate Transaction is also a Section&nbsp;409A Change in Control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d) Treatment of <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Awards Upon a Corporate Transaction for
<FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors.</B> The following provisions of this subsection (d)&nbsp;shall apply and shall supersede anything to the contrary that may be set forth in the Plan with respect to the permitted
treatment of a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Director Award in connection with a Corporate Transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)
</B>If the Corporate Transaction is also a Section&nbsp;409A Change in Control then the Acquiring Entity may not assume, continue or substitute the <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Director Award. Upon the Section&nbsp;409A Change
in Control the vesting and settlement of any <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Director Award will automatically be accelerated and the shares will be immediately issued to the Participant in respect of the <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Director Award. Alternatively, the Company may provide that the Participant will instead receive a cash settlement equal to the Fair Market Value of the shares that would otherwise be issued to the
Participant upon the Section&nbsp;409A Change in Control pursuant to the preceding provision. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii) </B>If the Corporate Transaction is
not also a Section&nbsp;409A Change in Control, then the Acquiring Entity must either assume, continue or substitute the <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Director Award. Unless otherwise determined by the Board, the <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Director Award will remain subject to the same vesting and forfeiture restrictions that were applicable to the Award prior to the Corporate Transaction. The shares to be issued in respect of the <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Director Award shall be issued to the Participant by the Acquiring Entity on the same schedule that the shares would have been issued to the Participant if the Corporate Transaction had not occurred. In
the Acquiring Entity&#146;s discretion, in lieu of an issuance of shares, the Acquiring Entity may instead substitute a cash payment on each applicable issuance date, equal to the Fair Market Value of the shares that would otherwise be issued to the
Participant on such issuance dates, with the determination of Fair Market Value made on the date of the Corporate Transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)
</B>If the RSU Award is a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award, then the provisions in this Section&nbsp;11(e) shall apply and supersede anything to the contrary that may be set forth in the Plan or the Award Agreement with
respect to the permitted treatment of such <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i) </B>Any exercise by the Board
of discretion to accelerate the vesting of a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award shall not result in any acceleration of the scheduled issuance dates for the shares in respect of the
<FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award unless earlier issuance of the shares upon the applicable vesting dates would be in compliance with the requirements of Section&nbsp;409A. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii) </B>The Company explicitly reserves the right to earlier settle any <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award to the
extent permitted and in compliance with the requirements of Section&nbsp;409A, including pursuant to any of the exemptions available in Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-3(j)(4)(ix).</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii) </B>To the extent the terms of any <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award provide that it will be settled upon a
Change in Control or Corporate Transaction, to the extent it is required for compliance with the requirements of Section&nbsp;409A, the Change in Control or Corporate Transaction event triggering settlement
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
must also constitute a Section&nbsp;409A Change in Control. To the extent the terms of a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award provides that it will be settled upon a
termination of employment or termination of Continuous Service, to the extent it is required for compliance with the requirements of Section&nbsp;409A, the termination event triggering settlement must also constitute a Separation From Service.
However, if at the time the shares would otherwise be issued to a Participant in connection with a &#147;separation from service&#148; such Participant is subject to the distribution limitations contained in Section&nbsp;409A applicable to
&#147;specified employees,&#148; as defined in Section&nbsp;409A(a)(2)(B)(i) of the Code, such shares shall not be issued before the date that is six months following the date of the Participant&#146;s Separation From Service, or, if earlier, the
date of the Participant&#146;s death that occurs within such six month period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iv) </B>The provisions in this subsection (e)&nbsp;for
delivery of the shares in respect of the settlement of an RSU Award that is a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award are intended to comply with the requirements of Section&nbsp;409A so that the delivery of the shares to the
Participant in respect of such <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award will not trigger the additional tax imposed under Section&nbsp;409A, and any ambiguities herein will be so interpreted. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>S<SMALL>EVERABILITY</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If all or any part of the Plan or any Award Agreement is declared by any court or governmental authority to be unlawful or invalid, such
unlawfulness or invalidity shall not invalidate any portion of the Plan or such Award Agreement not declared to be unlawful or invalid. Any Section of the Plan or any Award Agreement (or part of such a Section) so declared to be unlawful or invalid
shall, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>T<SMALL>ERMINATION</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> P<SMALL>LAN</SMALL>.
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board may suspend or terminate the Plan at any time. No Incentive Stock Options may be granted after the tenth
anniversary of the earlier of: (i)&nbsp;the Adoption Date, or (ii)&nbsp;the date the Plan is approved by the Company&#146;s stockholders. No Awards may be granted under the Plan while the Plan is suspended or after it is terminated. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>D<SMALL>EFINITIONS</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in the Plan, the following definitions apply to the capitalized terms indicated below: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>&#147;<B><I>Acquiring Entity</I></B>&#148; means the surviving or acquiring corporation (or its parent company) in connection with a
Corporate Transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>&#147;<B><I>Adoption Date</I></B>&#148; means the date the Plan is first approved by the Board or
Compensation Committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) </B>&#147;<B><I>Affiliate</I></B>&#148; means, at the time of determination, any &#147;parent&#148; or
&#147;subsidiary&#148; of the Company as such terms are defined in Rule 405 promulgated under the Securities Act. The Board may determine the time or times at which &#147;parent&#148; or &#147;subsidiary&#148; status is determined within the
foregoing definition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d) </B>&#147;<B><I>Applicable Law</I></B>&#148; means any applicable securities, federal, state, foreign,
material local or municipal or other law, statute, constitution, principle of common law, resolution, ordinance, code, edict, decree, rule, listing rule, regulation, judicial decision, ruling or requirement issued, enacted, adopted, promulgated,
implemented or otherwise put into effect by or under the authority of any Governmental Body (including under the authority of any applicable self-regulating organization such as the Nasdaq Stock Market, New York Stock Exchange, or the Financial
Industry Regulatory Authority). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e) </B>&#147;<B><I>Award</I></B>&#148; means any right to receive Common Stock, cash or other
property granted under the Plan (including an Incentive Stock Option, a Nonstatutory Stock Option, a Restricted Stock Award, an RSU Award, a SAR, a Performance Award or any Other Award). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f) </B>&#147;<B><I>Award Agreement</I></B>&#148; means a written or electronic agreement between the Company and a Participant evidencing
the terms and conditions of an Award. The Award Agreement generally consists of the Grant Notice and the agreement containing the written summary of the general terms and conditions applicable to the Award and which is provided, including through
electronic means, to a Participant along with the Grant Notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g) </B>&#147;<B><I>Board</I></B>&#148; means the Board of Directors
of the Company (or its designee). Any decision or determination made by the Board shall be a decision or determination that is made in the sole discretion of the Board (or its designee), and such decision or determination shall be final and binding
on all Participants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h) </B><I>&#147;</I><B><I>Capitalization Adjustment</I></B>&#148; means any change that is made in, or other
events that occur with respect to, the Common Stock subject to the Plan or subject to any Award after the date the Plan is adopted by the Board without the receipt of consideration by the Company through merger, consolidation, reorganization,
recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, reverse stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate
structure or any similar equity restructuring transaction, as that term is used in Statement of Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto). Notwithstanding the foregoing, the
conversion of any convertible securities of the Company will not be treated as a Capitalization Adjustment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)
</B>&#147;<B><I>Cause</I></B>&#148;<B><I> </I></B>has the meaning ascribed to such term in any written agreement between a Participant and the Company defining such term and, in the absence of such agreement, such term means, with respect to a
Participant, the occurrence of any of the following events: (i)&nbsp;the Participant&#146;s dishonest statements or acts with respect to the Company or any Affiliate of the Company, or any current or prospective customers, suppliers, vendors or
other third parties with which such entity does business; (ii) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Participant&#146;s commission of (A)&nbsp;a felony or (B)&nbsp;any misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (iii)&nbsp;the Participant&#146;s failure to perform the
Participant&#146;s assigned duties and responsibilities to the reasonable satisfaction of the Company which failure continues, in the reasonable judgment of the Company, after written notice given to the Participant by the Company; (iv)&nbsp;the
Participant&#146;s gross negligence, willful misconduct or insubordination with respect to the Company or any Affiliate of the Company; or (v)&nbsp;the Participant&#146;s material violation of any provision of any agreement(s) between the
Participant and the Company relating to noncompetition, nonsolicitation, nondisclosure and/or assignment of inventions. The determination that a termination of the Participant&#146;s Continuous Service is either for Cause or without Cause will be
made by the Board with respect to Participants who are executive officers of the Company and by the Company&#146;s Chief Executive Officer with respect to Participants who are not executive officers of the Company. Any determination by the Company
that the Continuous Service of a Participant was terminated with or without Cause for the purposes of outstanding Awards held by such Participant will have no effect upon any determination of the rights or obligations of the Company or such
Participant for any other purpose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j) </B>&#147;<B><I>Change in Control</I></B>&#148; or &#147;<B><I>Change of Control</I></B>&#148;
means the occurrence, in a single transaction or in a series of related transactions, of any one or more of the following events: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)
</B>any Exchange Act Person becomes the Owner, directly or indirectly, of securities of the Company representing more than 50% of the combined voting power of the Company&#146;s then outstanding securities other than by virtue of a merger,
consolidation or similar transaction. Notwithstanding the foregoing, a Change in Control shall not be deemed to occur (A)&nbsp;on account of the acquisition of securities of the Company directly from the Company, (B)&nbsp;on account of the
acquisition of securities of the Company by an investor, any affiliate thereof or any other Exchange Act Person that acquires the Company&#146;s securities in a transaction or series of related transactions the primary purpose of which is to obtain
financing for the Company through the issuance of equity securities, or (C)&nbsp;solely because the level of Ownership held by any Exchange Act Person (the &#147;<I>Subject Person</I>&#148;) exceeds the designated percentage threshold of the
outstanding voting securities as a result of a repurchase or other acquisition of voting securities by the Company reducing the number of shares outstanding, provided that if a Change in Control would occur (but for the operation of this sentence)
as a result of the acquisition of voting securities by the Company, and after such share acquisition, the Subject Person becomes the Owner of any additional voting securities that, assuming the repurchase or other acquisition had not occurred,
increases the percentage of the then outstanding voting securities Owned by the Subject Person over the designated percentage threshold, then a Change in Control shall be deemed to occur; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii) </B>there is consummated a merger, consolidation or similar transaction involving (directly or indirectly) the Company and,
immediately after the consummation of such merger, consolidation or similar transaction, the stockholders of the Company immediately prior thereto do not Own, directly or indirectly, either (A)&nbsp;outstanding voting securities representing more
than 50% of the combined outstanding voting power of the Acquiring Entity in such merger, consolidation or similar transaction or (B)&nbsp;more than 50% of the combined outstanding voting power of the parent of the Acquiring Entity in such merger,
consolidation or similar transaction, in each case in substantially the same proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such transaction; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii) </B>there is consummated a sale, lease, exclusive license or other disposition of all or substantially all of the consolidated assets
of the Company and its Subsidiaries, other than a sale, lease, license or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries to an Entity, more than 50% of the combined voting power of the
voting securities of which are Owned by stockholders of the Company in substantially the same proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such sale, lease, license or other disposition; or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iv) </B>individuals who, on the date the Plan is adopted by the Board, are members of
the Board (the &#147;<B><I>Incumbent Board</I></B>&#148;) cease for any reason to constitute at least a majority of the members of the Board; provided, however, that if the appointment or election (or nomination for election) of any new Board member
was approved or recommended by a majority vote of the members of the Incumbent Board then still in office, such new member shall, for purposes of this Plan, be considered as a member of the Incumbent Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing or any other provision of this Plan, (A)&nbsp;the term Change in Control shall not include a sale of assets,
merger or other transaction effected exclusively for the purpose of changing the domicile of the Company, (B)&nbsp;the definition of Change in Control (or any analogous term) in an individual written agreement between the Company or any Affiliate
and the Participant shall supersede the foregoing definition with respect to Awards subject to such agreement; provided, however, that if no definition of Change in Control or any analogous term is set forth in such an individual written agreement,
the foregoing definition shall apply, and (C)&nbsp;with respect to any nonqualified deferred compensation that becomes payable on account of the Change in Control, the transaction or event described in clause (i), (ii), (iii), or (iv)&nbsp;also
constitutes a Section&nbsp;409A Change in Control if required in order for the payment not to violate Section&nbsp;409A of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k) </B>&#147;<B><I>Code</I></B>&#148; means the Internal Revenue Code of 1986, as amended, including any applicable regulations and
guidance thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(l) </B>&#147;<B><I>Committee</I></B>&#148; means the Compensation Committee and any other committee of one or
more Directors to whom authority has been delegated by the Board or Compensation Committee in accordance with the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(m)
</B>&#147;<B><I>Common Stock</I></B>&#148; means the common stock of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(n) </B>&#147;<B><I>Company</I></B>&#148; means
Acrivon Therapeutics, Inc., a Delaware corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(o) </B>&#147;<B><I>Compensation Committee</I></B>&#148; means the Compensation
Committee of the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(p) </B>&#147;<B><I>Consultant</I></B>&#148; means any person, including an advisor, who is (i)&nbsp;engaged
by the Company or an Affiliate to render consulting or advisory services and is compensated for such services, or (ii)&nbsp;serving as a member of the board of directors of an Affiliate and is compensated for such services. However, service solely
as a Director, or payment of a fee for such service, will not cause a Director to be considered a &#147;Consultant&#148; for purposes of the Plan. Notwithstanding the foregoing, a person is treated as a Consultant under this Plan only if a Form <FONT
STYLE="white-space:nowrap">S-8</FONT> Registration Statement under the Securities Act is available to register either the offer or the sale of the Company&#146;s securities to such person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(q) </B>&#147;<B><I>Continuous Service</I></B>&#148; means that the Participant&#146;s service with the Company or an Affiliate, whether as
an Employee, Director or Consultant, is not interrupted or terminated. A change in the capacity in which the Participant renders service to the Company or an Affiliate as an Employee, Director or Consultant or a change in the Entity for which the
Participant renders such service, provided that there is no interruption or termination of the Participant&#146;s service with the Company or an Affiliate, will not terminate a Participant&#146;s Continuous Service; provided, however<I>,</I> that<I>
</I>if the Entity for which a Participant is rendering services ceases to qualify as an Affiliate, as determined by the Board, such Participant&#146;s Continuous Service will be considered to have terminated on the date such Entity ceases to qualify
as an Affiliate. For example, a change in status from an Employee of the Company to a Consultant </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of an Affiliate or to a Director will not constitute an interruption of Continuous Service. To the extent permitted by law, the Board or the chief executive officer of the Company, in that
party&#146;s sole discretion, may determine whether Continuous Service will be considered interrupted in the case of (i)&nbsp;any leave of absence approved by the Board or chief executive officer, including sick leave, military leave or any other
personal leave, or (ii)&nbsp;transfers between the Company, an Affiliate, or their successors. Notwithstanding the foregoing, a leave of absence will be treated as Continuous Service for purposes of vesting in an Award only to such extent as may be
provided in the Company&#146;s leave of absence policy, in the written terms of any leave of absence agreement or policy applicable to the Participant, or as otherwise required by law. In addition, to the extent required for exemption from or
compliance with Section&nbsp;409A, the determination of whether there has been a termination of Continuous Service will be made, and such term will be construed, in a manner that is consistent with the definition of &#147;separation from
service&#148; as defined under Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(h)</FONT> (without regard to any alternative definition thereunder). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(r) </B>&#147;<B><I>Corporate Transaction</I></B>&#148; means the consummation, in a single transaction or in a series of related
transactions, of any one or more of the following events: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i) </B>a sale<B> </B>or other disposition of all or substantially all, as
determined by the Board, of the consolidated assets of the Company and its Subsidiaries; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii) </B>a sale or other disposition of at
least 50% of the outstanding securities of the Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii) </B>a merger, consolidation or similar transaction following which the
Company is not the surviving corporation; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iv) </B>a merger, consolidation or similar transaction following which the Company is
the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the merger, consolidation or similar transaction into other property,
whether in the form of securities, cash or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing or any other provision of this Plan, (A)&nbsp;the
term Corporate Transaction shall not include a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company, (B)&nbsp;the definition of Corporate Transaction (or any analogous term) in an
individual written agreement between the Company or any Affiliate and the Participant shall supersede the foregoing definition with respect to Awards subject to such agreement; provided, however, that if no definition of Corporate Transaction or any
analogous term is set forth in such an individual written agreement, the foregoing definition shall apply, and (C)&nbsp;with respect to any nonqualified deferred compensation that becomes payable on account of the Corporate Transaction, the
transaction or event described in clause (i), (ii), (iii), or (iv)&nbsp;also constitutes a Section&nbsp;409A Change in Control if required in order for the payment not to violate Section&nbsp;409A of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(s) </B>&#147;<B><I>Director</I></B>&#148; means a member of the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(t) </B>&#147;<B><I>determine</I></B>&#148; or &#147;<B><I>determined</I></B>&#148;<B><I> </I></B>means as determined by the Board or the
Committee (or its designee) in its sole discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(u) </B>&#147;<B><I>Disability</I></B>&#148; means, with respect to a Participant,
such Participant is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment which can be expected to result in death or which has lasted or can be expected to last for a continuous
period of not less than 12 months, as provided in Section&nbsp;22(e)(3) of the Code, and will be determined by the Board on the basis of such medical evidence as the Board deems warranted under the circumstances. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(v) </B>&#147;<B><I>Effective Date</I></B>&#148; means immediately prior to the IPO Date,
provided that this Plan is approved by the Company&#146;s stockholders prior to the IPO Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(w)
</B>&#147;<B><I>Employee</I></B>&#148; means any person employed by the Company or an Affiliate. However, service solely as a Director, or payment of a fee for such services, will not cause a Director to be considered an &#147;Employee&#148; for
purposes of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(x) </B>&#147;<B><I>Employer</I></B>&#148; means the Company or the Affiliate of the Company that employs the
Participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(y) </B>&#147;<B><I>Entity</I></B>&#148; means a corporation, partnership, limited liability company or other entity.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(z) </B>&#147;<B><I>Exchange Act</I></B>&#148; means the Securities Exchange Act of 1934, as amended, and the rules and regulations
promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(aa) </B>&#147;<B><I>Exchange Act Person</I></B>&#148;<B><I> </I></B>means any natural person, Entity or
&#147;group&#148; (within the meaning of Section&nbsp;13(d) or 14(d) of the Exchange Act), except that &#147;Exchange Act Person&#148; will not include (i)&nbsp;the Company or any Subsidiary of the Company, (ii)&nbsp;any employee benefit plan of the
Company or any Subsidiary of the Company or any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any Subsidiary of the Company, (iii)&nbsp;an underwriter temporarily holding securities pursuant to a
registered public offering of such securities, (iv)&nbsp;an Entity Owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their Ownership of stock of the Company; or (v)&nbsp;any natural person,
Entity or &#147;group&#148; (within the meaning of Section&nbsp;13(d) or 14(d) of the Exchange Act) that, as of the Effective Date, is the Owner, directly or indirectly, of securities of the Company representing more than 50% of the combined voting
power of the Company&#146;s then outstanding securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(bb) </B>&#147;<B><I>Fair Market Value</I></B>&#148; means, as of any date,
unless otherwise determined by the Board, the value of the Common Stock (as determined on a per share or aggregate basis, as applicable) determined as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i) </B>If the Common Stock is listed on any established stock exchange or traded on any established market, the Fair Market Value will be
the closing sales price for such stock as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the Common Stock) on the date of determination, as reported in a source the Board deems reliable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii) </B>If there is no closing sales price for the Common Stock on the date of determination, then the Fair Market Value will be the
closing selling price on the last preceding date for which such quotation exists. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii) </B>In the absence of such markets for the
Common Stock, or if otherwise determined by the Board, the Fair Market Value will be determined by the Board in good faith and in a manner that complies with Sections 409A and 422 of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(cc) </B>&#147;<B><I>Governmental</I></B><B> </B><B><I>Body</I></B>&#148; means any: (i)&nbsp;nation, state, commonwealth, province,
territory, county, municipality, district or other jurisdiction of any nature; (ii)&nbsp;federal, state, local, municipal, foreign or other government; (iii)&nbsp;governmental or regulatory body, or quasi-governmental body of any nature (including
any governmental division, department, administrative agency or bureau, commission, authority, instrumentality, official, ministry, fund, foundation, center, organization, unit, body or Entity and any court or other tribunal, and for the avoidance
of doubt, any Tax authority) or other body exercising similar powers or authority; or&nbsp;(iv)&nbsp;self-regulatory organization (including the Nasdaq Stock Market, New York Stock Exchange, and the Financial Industry Regulatory Authority). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(dd) </B>&#147;<B><I>Grant Notice</I></B>&#148; means the notice provided to a
Participant that he or she has been granted an Award under the Plan and which includes the name of the Participant, the type of Award, the date of grant of the Award, number of shares of Common Stock subject to the Award or potential cash payment
right, (if any), the vesting schedule for the Award (if any) and other key terms applicable to the Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ee)
</B>&#147;<B><I>Incentive Stock Option</I></B>&#148; means an option granted pursuant to Section&nbsp;4 of the Plan that is intended to be, and qualifies as, an &#147;incentive stock option&#148; within the meaning of Section&nbsp;422 of the Code.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ff) </B>&#147;<B><I>IPO Date</I></B>&#148; means the date of the underwriting agreement between the Company and the underwriter(s)
managing the initial public offering of the Common Stock, pursuant to which the Common Stock is priced for the initial public offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(gg) </B>&#147;<B><I>Materially Impair</I></B>&#148;<B><I> </I></B>means any amendment to the terms of the Award that materially adversely
affects the Participant&#146;s rights under the Award. A Participant&#146;s rights under an Award will not be deemed to have been Materially Impaired by any such amendment if the Board, in its sole discretion, determines that the amendment, taken as
a whole, does not materially impair the Participant&#146;s rights. For example, the following types of amendments to the terms of an Award do not Materially Impair the Participant&#146;s rights under the Award: (i)&nbsp;imposition of reasonable
restrictions on the minimum number of shares subject to an Option or SAR that may be exercised; (ii)&nbsp;to maintain the qualified status of the Award as an Incentive Stock Option under Section&nbsp;422 of the Code; (iii)&nbsp;to change the terms
of an Incentive Stock Option in a manner that disqualifies, impairs or otherwise affects the qualified status of the Award as an Incentive Stock Option under Section&nbsp;422 of the Code; (iv)&nbsp;to clarify the manner of exemption from, or to
bring the Award into compliance with or qualify it for an exemption from, Section&nbsp;409A; or (v)&nbsp;to comply with other Applicable Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(hh) </B>&#147;<B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director</I></B>&#148;<B> </B>means a Director who either
(i)&nbsp;is not a current employee or officer of the Company or an Affiliate, does not receive compensation, either directly or indirectly, from the Company or an Affiliate for services rendered as a consultant or in any capacity other than as a
Director (except for an amount as to which disclosure would not be required under Item 404(a) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> promulgated pursuant to the Securities Act (&#147;<B><I>Regulation
<FONT STYLE="white-space:nowrap">S-K</FONT></I></B>&#148;)), does not possess an interest in any other transaction for which disclosure would be required under Item 404(a) of Regulation <FONT STYLE="white-space:nowrap">S-K,</FONT> and is not engaged
in a business relationship for which disclosure would be required pursuant to Item&nbsp;404(b) of Regulation <FONT STYLE="white-space:nowrap">S-K;</FONT> or (ii)&nbsp;is otherwise considered a
<FONT STYLE="white-space:nowrap">&#147;non-employee</FONT> director&#148; for purposes of Rule <FONT STYLE="white-space:nowrap">16b-3.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii) </B>&#147;<B><I><FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award</I></B>&#148;<B><I> </I></B>means any Award that is subject
to, and not exempt from, Section&nbsp;409A, including as the result of (i)&nbsp;a deferral of the issuance of the shares subject to the Award which is elected by the Participant or imposed by the Company, or (ii)&nbsp;the terms of any <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Severance Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(jj)
</B>&#147;<B><I><FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Director Award</I></B>&#148; means a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award granted to a Participant who was a Director but not an Employee on the applicable grant
date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(kk) </B>&#147;<B><I><FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Severance Arrangement</I></B>&#148; means a severance
arrangement or other agreement between the Participant and the Company that provides for acceleration of vesting of an Award and issuance of the shares in respect of such Award upon the Participant&#146;s termination of employment or separation from
service (as such term is defined in Section&nbsp;409A(a)(2)(A)(i) of the Code (and without regard to any alternative definition thereunder) (&#147;<B><I>Separation from Service</I></B>&#148;) and such severance benefit does not satisfy the
requirements for an exemption from application of Section&nbsp;409A provided under Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(b)(4),</FONT> <FONT STYLE="white-space:nowrap">1.409A-1(b)(9)</FONT> or otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ll) </B>&#147;<B><I>Nonstatutory Stock Option</I></B>&#148; means any option granted
pursuant to Section&nbsp;4 of the Plan that does not qualify as an Incentive Stock Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(mm) </B>&#147;<B><I>Officer</I></B>&#148;
means a person who is an officer of the Company within the meaning of Section&nbsp;16 of the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(nn)
</B>&#147;<B><I>Option</I></B>&#148; means an Incentive Stock Option or a Nonstatutory Stock Option to purchase shares of Common Stock granted pursuant to the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(oo) </B>&#147;<B><I>Option Agreement</I></B>&#148; means a written or electronic agreement between the Company and the Optionholder
evidencing the terms and conditions of the Option grant. The Option Agreement includes the Grant Notice for the Option and the agreement containing the written summary of the general terms and conditions applicable to the Option and which is
provided, including through electronic means, to a Participant along with the Grant Notice. Each Option Agreement will be subject to the terms and conditions of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(pp) </B>&#147;<B><I>Optionholder</I></B>&#148; means a person to whom an Option is granted pursuant to the Plan or, if applicable, such
other person who holds an outstanding Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(qq) </B>&#147;<B><I>Other Award</I></B>&#148; means an award valued in whole or in part
by reference to, or otherwise based on, Common Stock, including the appreciation in value thereof (e.g., options or stock rights with an exercise price or strike price less than 100% of the Fair Market Value at the time of grant) that is not an
Incentive Stock Option, Nonstatutory Stock Option, SAR, Restricted Stock Award, RSU Award or Performance Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(rr)
</B>&#147;<B><I>Other Award Agreement</I></B>&#148;<B><I> </I></B>means a written or electronic agreement between the Company and a holder of an Other Award evidencing the terms and conditions of an Other Award grant. Each Other Award Agreement will
be subject to the terms and conditions of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ss) </B>&#147;<B><I>Own,</I></B>&#148;<B><I>
</I></B>&#147;<B><I>Owned,</I></B>&#148;<B><I> </I></B>&#147;<B><I>Owner,</I></B>&#148;<B><I> </I></B>&#147;<B><I>Ownership</I></B>&#148;<B> </B>means that a person or Entity will be deemed to &#147;Own,&#148; to have &#147;Owned,&#148; to be the
&#147;Owner&#148; of, or to have acquired &#147;Ownership&#148; of securities if such person or Entity, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares voting power, which includes
the power to vote or to direct the voting, with respect to such securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(tt) </B>&#147;<B><I>Participant</I></B>&#148; means an
Employee, Director or Consultant to whom an Award is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(uu) </B>&#147;<B><I>Performance Award</I></B>&#148; means an Award that may vest or may be exercised or a cash award that may vest or
become earned and paid contingent upon the attainment during a Performance Period of certain Performance Goals and which is granted under the terms and conditions of Section&nbsp;5(b) pursuant to such terms as are approved by the Board. In addition,
to the extent permitted by Applicable Law and set forth in the applicable Award Agreement, the Board may determine that cash or other property may be used in payment of Performance Awards. Performance Awards that are settled in cash or other
property are not required to be valued in whole or in part by reference to, or otherwise based on, the Common Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(vv) </B>&#147;<B><I>Performance Criteria</I></B>&#148; means one or more criteria that
the Board will select for purposes of establishing the Performance Goals for a Performance Period. The Performance Criteria that will be used to establish such Performance Goals may be based on any one of, or combination of, the following as
determined by the Board: earnings (including earnings per share and net earnings); earnings before interest, taxes and depreciation; earnings before interest, taxes, depreciation and amortization; total stockholder return; return on equity or
average stockholder&#146;s equity; return on assets, investment, or capital employed; stock price; margin (including gross margin); income (before or after taxes); operating income; operating income after taxes;
<FONT STYLE="white-space:nowrap">pre-tax</FONT> profit; operating cash flow; sales or revenue targets; increases in revenue or product revenue; expenses and cost reduction goals; improvement in or attainment of working capital levels; economic value
added (or an equivalent metric); market share; cash flow; cash flow per share; share price performance; debt reduction; customer satisfaction; stockholders&#146; equity; capital expenditures; debt levels; operating profit or net operating profit;
workforce diversity; growth of net income or operating income; billings; financing; regulatory milestones; stockholder liquidity; corporate governance and compliance; intellectual property; personnel matters; progress of internal research; progress
of partnered programs; partner satisfaction; budget management; partner or collaborator achievements; internal controls, including those related to the Sarbanes-Oxley Act of 2002; investor relations, analysts and communication; implementation or
completion of projects or processes; employee retention; number of users, including unique users; strategic partnerships or transactions (including <FONT STYLE="white-space:nowrap">in-licensing</FONT> and
<FONT STYLE="white-space:nowrap">out-licensing</FONT> of intellectual property); establishing relationships with respect to the marketing, distribution and sale of the Company&#146;s products; supply chain achievements; <FONT
STYLE="white-space:nowrap">co-development,</FONT> <FONT STYLE="white-space:nowrap">co-marketing,</FONT> profit sharing, joint venture or other similar arrangements; individual performance goals; corporate development and planning goals; and other
measures of performance selected by the Board or Committee whether or not listed herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ww) </B>&#147;<B><I>Performance
Goals</I></B>&#148; means, for a Performance Period, one or more goals established by the Board for the Performance Period based upon the Performance Criteria. Performance Goals may be based on a Company-wide basis, with respect to one or more
business units, divisions, Affiliates, or business segments, and in either absolute terms or relative to the performance of one or more comparable companies or the performance of one or more relevant indices. Unless specified otherwise by the Board
(i)&nbsp;in the Award Agreement at the time the Award is granted or (ii)&nbsp;in such other document setting forth the Performance Goals at the time the Performance Goals are established, the Board will appropriately make adjustments in the method
of calculating the attainment of Performance Goals for a Performance Period as follows: (1)&nbsp;to exclude restructuring and/or other nonrecurring charges; (2)&nbsp;to exclude exchange rate effects; (3)&nbsp;to exclude the effects of changes to
generally accepted accounting principles; (4)&nbsp;to exclude the effects of any statutory adjustments to corporate tax rates; (5)&nbsp;to exclude the effects of items that are &#147;unusual&#148; in nature or occur &#147;infrequently&#148; as
determined under generally accepted accounting principles; (6)&nbsp;to exclude the dilutive effects of acquisitions or joint ventures; (7)&nbsp;to assume that any business divested by the Company achieved performance objectives at targeted levels
during the balance of a Performance Period following such divestiture; (8)&nbsp;to exclude the effect of any change in the outstanding shares of common stock of the Company by reason of any stock dividend or split, stock repurchase, reorganization,
recapitalization, merger, consolidation, <FONT STYLE="white-space:nowrap">spin-off,</FONT> combination or exchange of shares or other similar corporate change, or any distributions to common stockholders other than regular cash dividends;
(9)&nbsp;to exclude the effects of stock based compensation and the award of bonuses under the Company&#146;s bonus plans; (10)&nbsp;to exclude costs incurred in connection with potential acquisitions or divestitures that are required to be expensed
under generally accepted accounting principles; and (11)&nbsp;to exclude the goodwill and intangible asset impairment charges that are required to be recorded under generally accepted accounting principles. In addition, the Board may establish or
provide for other adjustment items in the Award Agreement at the time the Award is granted or in such other document setting forth the Performance Goals at the time the Performance Goals are established. In addition, the Board retains the discretion
to reduce or eliminate the compensation or economic benefit due upon attainment of Performance Goals and to define the manner of calculating the Performance Criteria it selects to use for such Performance Period. Partial achievement of the specified
criteria may result in the payment or vesting corresponding to the degree of achievement as specified in the Award Agreement or the written terms of a Performance Cash Award. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(xx) </B>&#147;<B><I>Performance Period</I></B>&#148; means the period of time selected
by the Board over which the attainment of one or more Performance Goals will be measured for the purpose of determining a Participant&#146;s right to vesting or exercise of an Award. Performance Periods may be of varying and overlapping duration, at
the sole discretion of the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(yy) </B>&#147;<B><I>Plan</I></B>&#148; means this Acrivon Therapeutics, Inc. 2022 Equity Incentive
Plan, as amended from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(zz) </B>&#147;<B><I>Plan Administrator</I></B>&#148; means the person, persons, and/or
third-party administrator designated by the Company to administer the day to day operations of the Plan and the Company&#146;s other equity incentive programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(aaa) </B>&#147;<B><I>Post-Termination Exercise Period</I></B>&#148; means the period following termination of a Participant&#146;s
Continuous Service within which an Option or SAR is exercisable, as specified in Section&nbsp;4(h). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(bbb) </B>&#147;<B><I>Prior
Plan</I></B>&#148; means the Acrivon Therapeutics, Inc. 2019 Stock Incentive Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ccc) </B>&#147;<B><I>Prior Plan&#146;s Available
Reserve</I></B>&#148; means the number of shares available for the grant of new awards under the Prior Plan as of the Effective Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ddd) </B>&#147;<B><I>Restricted Stock Award</I></B>&#148; or &#147;<B><I>RSA</I></B>&#148; means an Award of shares of Common Stock which
is granted pursuant to the terms and conditions of Section&nbsp;5(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(eee) </B>&#147;<B><I>Restricted Stock Award
Agreement</I></B>&#148; means a written or electronic agreement between the Company and a holder of a Restricted Stock Award evidencing the terms and conditions of a Restricted Stock Award grant. The Restricted Stock Award Agreement includes the
Grant Notice for the Restricted Stock Award and the agreement containing the written summary of the general terms and conditions applicable to the Restricted Stock Award and which is provided, including by electronic means, to a Participant along
with the Grant Notice. Each Restricted Stock Award Agreement will be subject to the terms and conditions of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(fff)
</B>&#147;<B><I>Returning Shares</I></B>&#148; means shares subject to outstanding stock awards granted under the Prior Plan and that following the Effective Date:&nbsp;(A)&nbsp;are not issued because such stock award or any portion thereof expires
or otherwise terminates without all of the shares covered by such stock award having been issued;&nbsp;(B)&nbsp;are not issued because such stock award or any portion thereof is settled in cash;&nbsp;(C)&nbsp;are forfeited back to or repurchased by
the Company because of the failure to meet a contingency or condition required for the vesting of such shares;&nbsp;(D)&nbsp;are withheld or reacquired to satisfy the exercise, strike or purchase price; or&nbsp;(E)&nbsp;are withheld or reacquired to
satisfy a tax withholding obligation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ggg) </B>&#147;<B><I>RSU Award</I></B>&#148; or &#147;<B><I>RSU</I></B>&#148;<B><I>
</I></B>means an Award of restricted stock units representing the right to receive an issuance of shares of Common Stock which is granted pursuant to the terms and conditions of Section&nbsp;5(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(hhh) </B>&#147;<B><I>RSU Award Agreement</I></B>&#148;<B><I> </I></B>means a written or electronic agreement between the Company and a
holder of an RSU Award evidencing the terms and conditions of an RSU Award grant. The RSU Award Agreement includes the Grant Notice for the RSU Award and the agreement containing the written summary of the general terms and conditions applicable to
the RSU Award and which is provided, including by electronic means, to a Participant along with the Grant Notice. Each RSU Award Agreement will be subject to the terms and conditions of the Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(iii) </B>&#147;<B><I>Rule <FONT STYLE="white-space:nowrap">16b-3</FONT></I></B>&#148;
means Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act or any successor to Rule <FONT STYLE="white-space:nowrap">16b-3,</FONT> as in effect from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(jjj) </B>&#147;<B><I>Rule 405</I></B>&#148; means Rule 405 promulgated under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(kkk) </B>&#147;<B><I>Section</I></B><B><I></I></B><B><I>&nbsp;409A</I></B>&#148; means Section&nbsp;409A of the Code and the regulations
and other guidance thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(lll) </B>&#147;<B><I>Section</I></B><B><I></I></B><B><I>&nbsp;409A Change in Control</I></B>&#148;
means a change in the ownership or effective control of the Company, or in the ownership of a substantial portion of the Company&#146;s assets, as provided in Section&nbsp;409A(a)(2)(A)(v) of the Code and Treasury Regulations <FONT
STYLE="white-space:nowrap">Section&nbsp;1.409A-3(i)(5)</FONT> (without regard to any alternative definition thereunder). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(mmm)
</B>&#147;<B><I>Securities Act</I></B>&#148; means the Securities Act of 1933, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(nnn) </B>&#147;<B><I>Share
Reserve</I></B>&#148; means the number of shares available for issuance under the Plan as set forth in Section&nbsp;2(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ooo)
</B>&#147;<B><I>Stock Appreciation Right</I></B>&#148; or &#147;<B><I>SAR</I></B>&#148;<B><I> </I></B>means a right to receive the appreciation on Common Stock that is granted pursuant to the terms and conditions of Section&nbsp;4. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ppp) </B>&#147;<B><I>SAR Agreement</I></B>&#148; means a written or electronic agreement between the Company and a holder of a SAR
evidencing the terms and conditions of a SAR grant. The SAR Agreement includes the Grant Notice for the SAR and the agreement containing the written summary of the general terms and conditions applicable to the SAR and which is provided, including
by electronic means, to a Participant along with the Grant Notice. Each SAR Agreement will be subject to the terms and conditions of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(qqq) </B>&#147;<B><I>Subsidiary</I></B>&#148; means, with respect to the Company, (i)&nbsp;any corporation of which more than 50% of the
outstanding capital stock having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of whether, at the time, stock of any other class or classes of such corporation will have or might have voting
power by reason of the happening of any contingency) is at the time, directly or indirectly, Owned by the Company, and (ii)&nbsp;any partnership, limited liability company or other entity in which the Company has a direct or indirect interest
(whether in the form of voting or participation in profits or capital contribution) of more than 50%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(rrr) </B>&#147;<B><I>Ten
Percent Stockholder</I></B>&#148; means a person who Owns (or is deemed to Own pursuant to Section&nbsp;424(d) of the Code) stock possessing more than 10% of the total combined voting power of all classes of stock of the Company or any Affiliate.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(sss) </B>&#147;<B><I>Trading Policy</I></B>&#148; means the Company&#146;s policy permitting certain individuals to sell Company
shares only during certain &#147;window&#148; periods and/or otherwise restricts the ability of certain individuals to transfer or encumber Company shares, as in effect from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ttt) </B>&#147;<B><I>Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award</I></B>&#148; means the portion of any <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Award that had not vested in accordance with its terms upon or prior to the date of any Corporate Transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(uuu) </B>&#147;<B><I>Vested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award</I></B>&#148; means the portion of any <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Award that had vested in accordance with its terms upon or prior to the date of a Corporate Transaction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ACRIVON THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STOCK OPTION GRANT NOTICE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(2022 EQUITY INCENTIVE PLAN) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Acrivon
Therapeutics, Inc.</B> (the &#147;<B><I>Company</I></B>&#148;), pursuant to its 2022 Equity Incentive Plan (as amended and/or restated as of the Date of Grant set forth below, the &#147;<B><I>Plan</I></B>&#148;), has granted to Optionholder an
option to purchase the number of shares of the Common Stock set forth below (the &#147;<B><I>Option</I></B>&#148;). The Option is subject to all of the terms and conditions as set forth in this Stock Option Grant Notice (the &#147;<B><I>Grant
Notice</I></B>&#148;) and in the Plan, the Option Agreement, and the Notice of Exercise, all of which are attached to this Grant Notice and incorporated into this Grant Notice in their entirety. Capitalized terms not explicitly defined in this Grant
Notice but defined in the Plan or the Option Agreement shall have the meanings set forth in the Plan or the Option Agreement, as applicable. If the Company uses an electronic capitalization table system (such as E*Trade) and the fields below are
blank or the information is otherwise provided in a different format electronically, the blank fields and other information (such as exercise schedule and type of grant) shall be deemed to come from the electronic capitalization system and is
considered part of this Grant Notice. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="95%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="65%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Optionholder:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date of Grant:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vesting Commencement Date:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of Shares Subject to Option:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise Price (Per Share)<SUP STYLE="font-size:75%; vertical-align:top">1</SUP>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Exercise Price:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expiration Date:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise Schedule:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">[Same as Vesting Schedule] [Early Exercise Permitted]</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Type of Grant<SUP STYLE="font-size:75%; vertical-align:top">2</SUP>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">[Incentive Stock Option] [Nonstatutory Stock Option]</P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Vesting Schedule:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B>[<B>Sample of standard vesting</B>. 12/48ths of the total shares will vest on the <FONT STYLE="white-space:nowrap">one-year</FONT>
anniversary of the Vesting Commencement Date, and 1/48th of the total shares will vest each month thereafter on the same day of the month as the Vesting Commencement Date (or if there is no corresponding day, on the last day of the month), subject
to Optionholder&#146;s Continuous Service as of each such date.]</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Notwithstanding
the foregoing, in the event that, in connection with or during the period ending twelve (12)&nbsp;months following the consummation of a Change in Control (the &#147;<B><I>CIC Period</I></B>&#148;), the Company (or any successor entity) terminates
the Optionholder&#146;s Continuous Service for any reason other than for Cause (a &#147;<B><I>Qualifying CIC Termination</I></B>&#148;), any portion of the Option that is outstanding and unvested as of the date of such Qualifying CIC Termination
(including any equity awards granted by the successor or surviving entity in substitution for the Option in connection with such Change in Control) shall immediately accelerate and vest in full as of the date of such termination (or, if later, the
date of such Change in Control).</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Optionholder Acknowledgements:</B> By Optionholder&#146;s signature below or by electronic acceptance or authentication in
a form authorized by the Company, Optionholder understands and agrees that the Option is governed by this Stock Option Grant Notice, and the provisions of the Plan and the Option Agreement and the Notice of Exercise, all of which are made a part of
this document. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By accepting this Option, Optionholder consents to receive this Grant Notice, the Option Agreement, the Plan, and any other Plan-related
documents by electronic delivery and to participate in the Plan through an <FONT STYLE="white-space:nowrap">on-line</FONT> or electronic system established and maintained by the Company or another third party designated by the Company. Optionholder
represents that he or she has read and is familiar with the provisions of the Plan and the Option Agreement. Optionholder acknowledges and agrees that this Grant Notice and the Option Agreement may not be modified, amended or revised except in
writing signed by Optionholder and a duly authorized officer of the Company. </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The exercise price may be paid by one or a combination of the methods permitted in the Option Agreement.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If this is an Incentive Stock Option, it (plus other outstanding Incentive Stock Options) cannot be first
<I>exercisable</I> for more than $100,000 in value (measured by exercise price) in any calendar year. Any excess over $100,000 is a Nonstatutory Stock Option. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Optionholder further acknowledges that in the event of any conflict between the provisions in this Grant
Notice, the Option Agreement, the Notice of Exercise and the terms of the Plan, the terms of the Plan shall control. Optionholder further acknowledges that the Option Agreement sets forth the entire understanding between Optionholder and the Company
regarding the acquisition of Common Stock and supersedes all prior oral and written agreements, promises and/or representations on that subject with the exception of other equity awards previously granted to Optionholder and any written employment
agreement, offer letter, severance agreement, written severance plan or policy, or other written agreement between the Company and Optionholder in each case that specifies the terms that should govern this Option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Optionholder further acknowledges that this Grant Notice has been prepared on behalf of the Company by Cooley LLP, counsel to the Company and that Cooley LLP
does not represent, and is not acting on behalf of, Optionholder in any capacity. Optionholder has been provided with an opportunity to consult with Optionholder&#146;s own counsel with respect to this Grant Notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Grant Notice may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and
the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other
transmission method and any counterpart so delivered will be deemed to have been duly and validly delivered and be valid and effective for all purposes. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="39%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Acrivon Therapeutics, Inc.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>Optionholder:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">(Signature)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">(Signature)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Attachments</B>: Option Agreement, 2022 Equity Incentive Plan and Notice of Exercise </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ATTACHMENT I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OPTION AGREEMENT </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ACRIVON THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2022 Equity Incentive Plan </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OPTION AGREEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(INCENTIVE STOCK OPTION OR NONSTATUTORY STOCK OPTION) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to your Stock Option Grant Notice (&#147;<B><I>Grant Notice</I></B>&#148;) and this Option Agreement, <B>Acrivon Therapeutics,
Inc.</B> (the &#147;<B><I>Company</I></B>&#148;) has granted you an option under its 2022 Equity Incentive Plan (the &#147;<B><I>Plan</I></B>&#148;) to purchase the number of shares of the Company&#146;s Common Stock indicated in your Grant Notice
at the exercise price indicated in your Grant Notice. The option is granted to you effective as of the date of grant set forth in the Grant Notice (the &#147;<B><I>Date of Grant</I></B>&#148;). If there is any conflict between the terms in this
Option Agreement and the Plan, the terms of the Plan will control. Capitalized terms not explicitly defined in this Option Agreement or in the Grant Notice but defined in the Plan will have the same definitions as in the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The details of your option, in addition to those set forth in the Grant Notice and the Plan, are as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.</B> <B>Vesting</B>. Your option will vest as provided in your Grant Notice. Vesting will cease upon the termination of your Continuous
Service, except as otherwise explicitly provided in your Grant Notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.</B> <B>Number of Shares and Exercise Price</B>. The number
of shares of Common Stock subject to your option and your exercise price per share in your Grant Notice will be adjusted for Capitalization Adjustments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.</B> <B>Exercise Restriction for <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Employees</B>. If you are an Employee eligible for
overtime compensation under the Fair Labor Standards Act of 1938, as amended (that is, a &#147;<B><I><FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Employee</I></B>&#148;), and except as otherwise provided in the Plan, you may not exercise your
option until you have completed at least six months of Continuous Service measured from the Date of Grant, even if you have already been an employee for more than six months. Consistent with the provisions of the Worker Economic Opportunity Act, you
may exercise your option as to any vested portion prior to such six month anniversary in the case of (i)&nbsp;your death or disability, (ii)&nbsp;a Corporate Transaction in which your option is not assumed, continued or substituted, (iii)&nbsp;a
Change in Control or (iv)&nbsp;your termination of Continuous Service on your &#147;retirement&#148; (as defined in the Company&#146;s benefit plans). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.</B> <B>Exercise prior to Vesting (&#147;Early Exercise&#148;)</B>. If permitted in your Grant Notice (<I>i.e.</I>, the &#147;Exercise
Schedule&#148; indicates &#147;Early Exercise Permitted&#148;) and subject to the provisions of your option, you may elect at any time that is both (i)&nbsp;during the period of your Continuous Service and (ii)&nbsp;during the term of your option,
to exercise all or part of your option, including the unvested portion of your option; <I>provided, however,</I> that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> a
partial exercise of your option will be deemed to cover first vested shares of Common Stock and then the earliest vesting installment of unvested shares of Common Stock; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> any shares of Common Stock so purchased from installments that have not vested as of the date of exercise will be subject to the
purchase option in favor of the Company as described in the Company&#146;s form of Early Exercise Stock Purchase Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>
you will enter into the Company&#146;s form of Early Exercise Stock Purchase Agreement with a vesting schedule that will result in the same vesting as if no early exercise had occurred; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> if your option is an Incentive Stock Option, then, to the extent that the aggregate Fair Market Value (determined at the Date of
Grant) of the shares of Common Stock with respect to which your option plus all other Incentive Stock Options you hold are exercisable for the first time by you during any calendar year (under all plans of the Company and its Affiliates) exceeds
$100,000, your option(s) or portions thereof that exceed such limit (according to the order in which they were granted) will be treated as Nonstatutory Stock Options. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.</B> <B>Method of Payment</B>. You must pay the full amount of the exercise price for
the shares you wish to exercise. The permitted methods of payment are as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> by cash, check, bank draft, electronic funds
transfer or money order payable to the Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> subject to Company and/or Board consent at the time of exercise and provided
that at the time of exercise the Common Stock is publicly traded, pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of Common Stock, results in either the receipt of cash (or
check) by the Company or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds. This manner of payment is also known as a &#147;broker-assisted exercise&#148;, &#147;same day sale&#148;,
or &#147;sell to cover&#148;; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> subject to Company and/or Board consent at the time of exercise and provided that at the time of
exercise the Common Stock is publicly traded, by delivery to the Company (either by actual delivery or attestation) of already-owned shares of Common Stock that are owned free and clear of any liens, claims, encumbrances or security interests, and
that are valued at Fair Market Value on the date of exercise. &#147;Delivery&#148; for these purposes, in the sole discretion of the Company at the time you exercise your option, will include delivery to the Company of your attestation of ownership
of such shares of Common Stock in a form approved by the Company. You may not exercise your option by delivery to the Company of Common Stock if doing so would violate the provisions of any law, regulation or agreement restricting the redemption of
the Company&#146;s stock; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> subject to Company and/or Board consent at the time of exercise, and provided that the Option is a
Nonstatutory Stock Option, by a &#147;net exercise&#148; arrangement pursuant to which the Company will reduce the number of shares of Common Stock issued upon exercise of the Option by the largest whole number of shares with a Fair Market Value
that does not exceed the aggregate exercise price plus, to the extent permitted by the Company and/or Board at the time of exercise, the aggregate withholding obligations in respect of the Option exercise; provided, further that you must pay any
remaining balance of the aggregate exercise price not satisfied by the &#147;net exercise&#148; in cash or other permitted form of payment.&nbsp;Shares of Common Stock will no longer be subject to the Option and will not be exercisable thereafter to
the extent that (A)&nbsp;shares issuable upon exercise are used to pay the exercise price pursuant to the &#147;net exercise,&#148; (B) shares are delivered to you as a result of such exercise, and (C)&nbsp;shares are withheld to satisfy tax
withholding obligations; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> subject to the consent of the Company and/or Board at the time of exercise, according to a deferred
payment or similar arrangement with you; <I>provided, however</I>, that interest will compound at least annually and will be charged at the minimum rate of interest necessary to avoid (A)&nbsp;the imputation of interest income to the Company and
compensation income to the Optionholder under any applicable provisions of the Code, and (B)&nbsp;the classification of the Option as a liability for financial accounting purposes; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> in any other form of legal consideration that may be acceptable to the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.</B> <B>Whole Shares</B>. You may exercise your option only for whole shares of Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.</B> <B>Securities Law Compliance</B>. In no event may you exercise your option unless the shares of Common Stock issuable upon exercise
are then registered under the Securities Act or, if not registered, the Company has determined that your exercise and the issuance of the shares would be exempt from the registration requirements of the Securities Act. The exercise of your option
also must comply with all other applicable laws and regulations governing your option, and you may not exercise your option if the Company determines that such exercise would not be in material compliance with such laws and regulations (including
any restrictions on exercise required for compliance with Treas. Reg. <FONT STYLE="white-space:nowrap">1.401(k)-1(d)(3),</FONT> if applicable). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.</B> <B>Term</B>. You may not exercise your option before the Date of Grant or after the expiration of the option&#146;s term. Except as
set forth in your Grant Notice, the term of your option expires, subject to the provisions of Section&nbsp;5(h) of the Plan, upon the earliest of the following: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> immediately upon the termination of your Continuous Service for Cause; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> three months after the termination of your Continuous Service for any reason other than Cause,<B> </B>your Disability or your death
(except as otherwise provided in Section&nbsp;8(d) below); <I>provided, however, </I>that if during any part of such three month period your option is not exercisable solely because of the condition set forth in the section above relating to
&#147;Securities Law Compliance,&#148; your option will not expire until the earlier of the Expiration Date or until it has been exercisable for an aggregate period of three months after the termination of your Continuous Service; <I>provided
further,</I> that if (i)&nbsp;you are a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Employee, (ii)&nbsp;your Continuous Service terminates within six months after the Date of Grant, and (iii)&nbsp;you have vested in a portion of your option
at the time of your termination of Continuous Service, your option will not expire until the earlier of (x)&nbsp;the later of (A)&nbsp;the date that is seven months after the Date of Grant, and (B)&nbsp;the date that is three months after the
termination of your Continuous Service, and (y)&nbsp;the Expiration Date; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> 12 months after the termination of your Continuous
Service due to your Disability (except as otherwise provided in Section&nbsp;8(d)) below; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> 18 months after your death if you
die either during your Continuous Service or within three (3)&nbsp;months after your Continuous Service terminates for any reason other than Cause; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> the Expiration Date indicated in your Grant Notice; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> the day before the 10th anniversary of the Date of Grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If your option is an Incentive Stock Option, note that to obtain the federal income tax advantages associated with an Incentive Stock Option,
the Code requires that at all times beginning on the Date of Grant and ending on the day three months before the date of your option&#146;s exercise, you must be an employee of the Company or an Affiliate, except in the event of your death or
Disability. The Company has provided for extended exercisability of your option under certain circumstances for your benefit but cannot guarantee that your option will necessarily be treated as an Incentive Stock Option if you continue to provide
services to the Company or an Affiliate as a Consultant or Director after your employment terminates or if you otherwise exercise your option more than three months after the date your employment with the Company or an Affiliate terminates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.</B> <B>Exercise</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> You may exercise the vested portion of your option (and the unvested portion of your option if your Grant Notice so permits) during
its term by delivering a Notice of Exercise (in a form designated by the Company) together with the exercise price to the Secretary of the Company, or to such other person as the Company may designate, during regular business hours. If required by
the Company, your exercise may be made contingent on your execution of any additional documents specified by the Company as more fully set forth in Section&nbsp;14 below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> By exercising your option you agree that, as a condition to any exercise of your option, the Company may require you to enter into
an arrangement providing for the payment by you to the Company of any tax withholding obligation of the Company arising by reason of (i)&nbsp;the exercise of your option, (ii)&nbsp;the lapse of any substantial risk of forfeiture to which the shares
of Common Stock are subject at the time of exercise, or (iii)&nbsp;the disposition of shares of Common Stock acquired upon such exercise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> If your option is an Incentive Stock Option, by exercising your option you agree that you will notify the Company in writing within
15 days after the date of any disposition of any of the shares of the Common Stock issued upon exercise of your option that occurs within two years after the Date of Grant or within one year after such shares of Common Stock are transferred upon
exercise of your option. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> By exercising your option you agree that you will not sell, dispose of, transfer,
make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale with respect to any shares of Common Stock or other securities of the Company held by you, for a
period of 180 days following the effective date of a registration statement of the Company filed under the Securities Act or such longer period as the underwriters or the Company will request to facilitate compliance with applicable FINRA rules (the
&#147;<B><I><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period</I></B>&#148;); <I>provided, however</I>, that nothing contained in this section will prevent the exercise of a repurchase option, if any, in favor of the Company during the <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Period. You further agree to execute and deliver such other agreements as may be reasonably requested by the Company or the underwriters that are consistent with the foregoing or that are necessary to give
further effect thereto. In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to your shares of Common Stock until the end of such period. You also agree that any transferee of any shares of
Common Stock (or other securities) of the Company held by you will be bound by this Section&nbsp;9(d). The underwriters of the Company&#146;s stock are intended third party beneficiaries of this Section&nbsp;9(d) and will have the right, power and
authority to enforce the provisions hereof as though they were a party hereto. You further agree that the obligations contained in this Section&nbsp;9(d) shall also, if so determined by the Company&#146;s Board of Directors, apply in the
Company&#146;s initial listing of its Common Stock on a national securities exchange by means of a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> under the Securities Act (or any successor registration form under the
Securities Act subsequently adopted by the Securities and Exchange Commission) filed by the Company with the Securities and Exchange Commission that registers shares of existing capital stock of the Company for resale (a &#147;<B><I>Direct
Listing</I></B>&#148;), provided that all holders of at least 5% of the Company&#146;s outstanding Common Stock (after giving effect to the conversion into Common Stock of any outstanding Preferred Stock of the Company) are subject to substantially
similar obligations with respect to such Direct Listing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.</B> <B>Transferability</B>. Except as otherwise provided in this
Section&nbsp;10, your option is not transferable, except by will or by the laws of descent and distribution, and is exercisable during your life only by you. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Certain Trusts</B>. Upon receiving written permission from the Board or its duly authorized designee, you may transfer your
option to a trust if you are considered to be the sole beneficial owner (determined under Section&nbsp;671 of the Code and applicable state law) while the option is held in the trust. You and the trustee must enter into transfer and other agreements
required by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Domestic Relations Orders</B>. Upon receiving written permission from the Board or its duly
authorized designee, and provided that you and the designated transferee enter into transfer and other agreements required by the Company, you may transfer your option pursuant to the terms of a domestic relations order, official marital settlement
agreement or other divorce or separation instrument as permitted by Treasury Regulation <FONT STYLE="white-space:nowrap">1.421-1(b)(2)</FONT> that contains the information required by the Company to effectuate the transfer. You are encouraged to
discuss the proposed terms of any division of this option with the Company prior to finalizing the domestic relations order or marital settlement agreement to help ensure the required information is contained within the domestic relations order or
marital settlement agreement. If this option is an Incentive Stock Option, this option may be deemed to be a Nonstatutory Stock Option as a result of such transfer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Beneficiary Designation</B>. Upon receiving written permission from the Board or its duly authorized designee, you may, by
delivering written notice to the Company, in a form approved by the Company and any broker designated by the Company to handle option exercises, designate a third party who, on your death, will thereafter be entitled to exercise this option and
receive the Common Stock or other consideration resulting from such exercise. In the absence of such a designation, your executor or administrator of your estate will be entitled to exercise this option and receive, on behalf of your estate, the
Common Stock or other consideration resulting from such exercise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.</B> <B>Option not a Service Contract</B>. Your option is not an
employment or service contract, and nothing in your option will be deemed to create in any way whatsoever any obligation on your part to continue in the employ of the Company or an Affiliate, or of the Company or an Affiliate to continue your
employment. In addition, nothing in your option will obligate the Company or an Affiliate, their respective stockholders, boards of directors, officers or employees to continue any relationship that you might have as a Director or Consultant for the
Company or an Affiliate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.</B> <B>Withholding Obligations</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> At the time you exercise your option, in whole or in part, and at any time thereafter as requested by the Company, you hereby
authorize withholding from payroll and any other amounts payable to you, and otherwise agree to make adequate provision for (including by means of a &#147;same day sale&#148; pursuant to a program developed under Regulation T as promulgated by the
Federal Reserve Board to the extent permitted by the Company), any sums required to satisfy the federal, state, local and foreign tax withholding obligations of the Company or an Affiliate, if any, which arise in connection with the exercise of your
option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> If this option is a Nonstatutory Stock Option, then upon your request and subject to approval by the Company, and
compliance with any applicable legal conditions or restrictions, the Company may withhold from fully vested shares of Common Stock otherwise issuable to you upon the exercise of your option a number of whole shares of Common Stock having a Fair
Market Value, determined by the Company as of the date of exercise, not in excess of the minimum amount of tax required to be withheld by law (or such lower amount as may be necessary to avoid classification of your option as a liability for
financial accounting purposes). If the date of determination of any tax withholding obligation is deferred to a date later than the date of exercise of your option, share withholding pursuant to the preceding sentence will not be permitted unless
you make a proper and timely election under Section&nbsp;83(b) of the Code, covering the aggregate number of shares of Common Stock acquired upon such exercise with respect to which such determination is otherwise deferred, to accelerate the
determination of such tax withholding obligation to the date of exercise of your option. Notwithstanding the filing of such election, shares of Common Stock will be withheld solely from fully vested shares of Common Stock determined as of the date
of exercise of your option that are otherwise issuable to you upon such exercise. Any adverse consequences to you arising in connection with such share withholding procedure will be your sole responsibility. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> You may not exercise your option unless the tax withholding obligations of the Company and/or any Affiliate are satisfied.
Accordingly, you may not be able to exercise your option when desired even though your option is vested, and the Company will have no obligation to issue a certificate for such shares of Common Stock or release such shares of Common Stock from any
escrow provided for herein, if applicable, unless such obligations are satisfied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.</B> <B>Tax Consequences</B>. You hereby agree
that the Company does not have a duty to design or administer the Plan or its other compensation programs in a manner that minimizes your tax liabilities. You will not make any claim against the Company, or any of its Officers, Directors, Employees
or Affiliates related to tax liabilities arising from your option or your other compensation. In particular, you acknowledge that this option is exempt from Section&nbsp;409A of the Code only if the exercise price per share specified in the Grant
Notice is at least equal to the &#147;fair market value&#148; per share of the Common Stock on the Date of Grant and there is no other impermissible deferral of compensation associated with the option. Because the Common Stock is not traded on an
established securities market, the Fair Market Value is determined by the Board, perhaps in consultation with an independent valuation firm retained by the Company. You acknowledge that there is no guarantee that the Internal Revenue Service will
agree with the valuation as determined by the Board, and you will not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates in the event that the Internal Revenue Service asserts that the valuation determined
by the Board is less than the &#147;fair market value&#148; as subsequently determined by the Internal Revenue Service. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.</B>
<B>Imposition of Other Requirements</B>. You agree to execute further documents or instruments necessary or desirable in the sole determination of the Company to carry out the purposes or intent of this option. You further agree to execute, to the
extent requested by the Company, at any time and from time to time, any agreements entered into with holders of capital stock of the Company, including without limitation a right of first refusal and <FONT STYLE="white-space:nowrap">co-sale</FONT>
agreement, stockholders agreement and/or a voting agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15.</B> <B>Notices</B>. Any notices provided for in your option or the Plan will be given
in writing (including electronically) and will be deemed effectively given upon receipt or, in the case of notices delivered by mail by the Company to you, five days after deposit in the United States mail, postage prepaid, addressed to you at the
last address you provided to the Company. The Company may, in its sole discretion, decide to deliver any documents related to participation in the Plan and this option by electronic means or to request your consent to participate in the Plan by
electronic means. By accepting this option, you consent to receive such documents by electronic delivery and to participate in the Plan through an <FONT STYLE="white-space:nowrap">on-line</FONT> or electronic system established and maintained by the
Company or another third party designated by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>16.</B> <B>Governing Plan Document</B>. Your option is subject to all the
provisions of the Plan, the provisions of which are hereby made a part of your option, and is further subject to all interpretations, amendments, rules and regulations, which may from time to time be promulgated and adopted pursuant to the Plan. If
there is any conflict between the provisions of your option and those of the Plan, the provisions of the Plan will control. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ATTACHMENT II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2022 Equity Incentive Plan </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ATTACHMENT III </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF EXERCISE </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ACRIVON THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF EXERCISE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This constitutes
notice to <B>Acrivon Therapeutics, Inc.</B> (the &#147;<B><I>Company</I></B>&#148;) under my stock option that I elect to purchase the below number of shares of Common Stock of the Company (the&nbsp;&#147;<B><I>Shares</I></B>&#148;) for the price
set forth below. Use of certain payment methods is subject to Company and/or Board consent and certain additional requirements set forth in the Option Agreement and the Plan. If the Company uses an electronic capitalization table system (such as
E*Trade) and the fields below are blank, the blank fields shall be deemed to come from the electronic capitalization system and is considered part of this Notice of Exercise. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B><U>Option Information</U></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Type of option (check one):</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">Incentive<B> </B><B></B>&#9744;<B></B><B></B><B>&nbsp;&nbsp; </B>Nonstatutory
&#9744;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Stock option dated:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Number of Shares as to which option is exercised:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Certificates to be issued in name of:<SUP STYLE="font-size:75%; vertical-align:top">3</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B><U>Exercise Information</U></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date of Exercise:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Total exercise price:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Cash:<SUP STYLE="font-size:75%; vertical-align:top">4</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Regulation T Program (cashless exercise):<SUP STYLE="font-size:75%; vertical-align:top">5</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Value of _________ Shares delivered with this notice:<SUP STYLE="font-size:75%; vertical-align:top">6</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Value of _________ Shares pursuant to net exercise:<SUP STYLE="font-size:75%; vertical-align:top">7</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By this exercise, I agree (i)&nbsp;to provide such additional documents as you may require pursuant to the
terms of the 2022 Equity Incentive Plan, (ii)&nbsp;to provide for the payment by me to you (in the manner designated by you) of your withholding obligation, if any, relating to the exercise of this option, (iii)&nbsp;if this exercise relates to an
incentive stock option, to notify you in writing within 15 days after the date of any disposition of any of the Shares issued upon exercise of this option that occurs within two years after the date of grant of this option or within one year after
such Shares are issued upon exercise of this option, and (iv)&nbsp;to execute, if and when requested by the Company, at any time or from time to time, any agreements entered into with holders of capital stock of the Company, including without
limitation a right of first refusal and <FONT STYLE="white-space:nowrap">co-sale</FONT> agreement, stockholders agreement and/or a voting agreement. I further agree that this Notice of Exercise may be delivered via facsimile, electronic mail
(including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other transmission method and will be deemed to have been duly and validly delivered and be
valid and effective for all purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I hereby make the following certifications and representations with respect to the number of Shares
listed above, which are being acquired by me for my own account upon exercise of the option as set forth above: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I acknowledge that the
Shares have not been registered under the Securities Act of 1933, as amended (the &#147;<B><I>Securities Act</I></B>&#148;), and are deemed to constitute &#147;restricted securities&#148; under Rule 701 and Rule 144 promulgated under the Securities
Act. I warrant and represent to the Company that I have no present intention of distributing or selling said Shares, except as permitted under the Securities Act and any applicable state securities laws. </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">3</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If left blank, will be issued in the name of the option holder. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">4</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Cash may be in the form of cash, check, bank draft, electronic funds transfer or money order payment.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">5</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to Company and/or Board consent and must meet the public trading and other requirements set forth in
the Option Agreement. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">6</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to Company and/or Board consent and must meet the public trading and other requirements set forth in
the Option Agreement. Shares must be valued in accordance with the terms of the option being exercised, and must be owned free and clear of any liens, claims, encumbrances or security interests. Certificates must be endorsed or accompanied by an
executed assignment separate from certificate. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">7</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to Company and/or Board consent and must be a Nonstatutory Option.
</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I further acknowledge and agree that, except for such information as required to be
delivered to me by the Company pursuant to the option or the Plan (if any), I will have no right to receive any information from the Company by virtue of the grant of the option or the purchase of shares of Common Stock through exercise of the
option, ownership of such shares of Common Stock, or as a result of my being a holder of record of stock of the Company. Without limiting the foregoing, to the fullest extent permitted by law, I hereby waive all inspection rights under
Section&nbsp;220 of the Delaware General Corporation Law and all such similar information and/or inspection rights that may be provided under the law of any jurisdiction, or any federal, state or foreign regulation, that are, or may become,
applicable to the Company or the Company&#146;s capital stock (the &#147;<B><I>Inspection Rights</I></B>&#148;). I hereby covenant and agree never to directly or indirectly commence, voluntarily aid in any way, prosecute, assign, transfer, or cause
to be commenced any claim, action, cause of action, or other proceeding to pursue or exercise the Inspection Rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I further
acknowledge that I will not be able to resell the Shares for at least 90 days after the stock of the Company becomes publicly traded (<I>i.e.,</I> subject to the reporting requirements of Section&nbsp;13 or 15(d) of the Securities Exchange Act of
1934) under Rule 701 and that more restrictive conditions apply to affiliates of the Company under Rule 144. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I further acknowledge that
all certificates representing any of the Shares subject to the provisions of the option will have endorsed thereon appropriate legends reflecting the foregoing limitations, as well as any legends reflecting restrictions pursuant to the
Company&#146;s Certificate of Incorporation, Bylaws and/or applicable securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I further agree that, if required by the Company
(or a representative of the underwriters) in connection with the first underwritten registration of the offering of any securities of the Company under the Securities Act, I will not sell, dispose of, transfer, make any short sale of, grant any
option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale with respect to any shares of Common Stock or other securities of the Company for a period of 180 days following the effective date
of a registration statement of the Company filed under the Securities Act (or such longer period as the underwriters or the Company will request to facilitate compliance with applicable FINRA rules) (the
&#147;<B><I><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period</I></B>&#148;). I further agree to execute and deliver such other agreements as may be reasonably requested by the Company or the underwriters that are consistent with the foregoing
or that are necessary to give further effect thereto. In order to enforce the foregoing covenant, the Company may impose <FONT STYLE="white-space:nowrap">stop-transfer</FONT> instructions with respect to securities subject to the foregoing
restrictions until the end of such period. I further agree that the obligations contained in this paragraph shall also, if so determined by the Company&#146;s Board of Directors, apply in the Company&#146;s initial listing of its Common Stock on a
national securities exchange by means of a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> under the Securities Act (or any successor registration form under the Securities Act subsequently adopted by the Securities and
Exchange Commission) filed by the Company with the Securities and Exchange Commission that registers shares of existing capital stock of the Company for resale (a &#147;<B><I>Direct Listing</I></B>&#148;), provided that all holders of at least 5% of
the Company&#146;s outstanding Common Stock (after giving effect to the conversion into Common Stock of any outstanding Preferred Stock of the Company) are subject to substantially similar obligations with respect to such Direct Listing. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="63%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Very truly yours,</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Signature)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Name (Please Print)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address&nbsp;of&nbsp;Record:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>CRIVON</SMALL> T<SMALL>HERAPEUTICS</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RSU A<SMALL>WARD</SMALL> G<SMALL>RANT</SMALL> N<SMALL>OTICE </SMALL></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(2022 E<SMALL>QUITY</SMALL> I<SMALL>NCENTIVE</SMALL> P<SMALL>LAN</SMALL>) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Acrivon Therapeutics, Inc. (the <B><I>&#147;Company&#148;</I></B>) has awarded to you (the &#147;<B><I>Participant</I></B>&#148;) the number of restricted
stock units specified and on the terms set forth below in consideration of your services (the <B><I>&#147;RSU Award&#148;</I></B>). Your RSU Award is subject to all of the terms and conditions as set forth herein and in the Company&#146;s 2022
Equity Incentive Plan (the <B><I>&#147;Plan&#148;</I></B>) and the Award Agreement (the &#147;<B><I>Agreement</I></B>&#148;), which are incorporated herein in their entirety. Capitalized terms not explicitly defined herein but defined in the Plan or
the Agreement shall have the meanings set forth in the Plan or the Agreement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="65%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Participant:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date of Grant:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Vesting Commencement Date:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Number of Restricted Stock Units:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Vesting Schedule</B>:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[__________________________________________________________________].<B> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, vesting shall terminate upon the Participant&#146;s termination of Continuous Service.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Issuance Schedule:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">One share of Common Stock will be issued for each restricted stock unit which vests at the time set forth in Section&nbsp;5 of the Agreement.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Participant Acknowledgements:</B> By your signature below or by electronic acceptance or authentication in a form
authorized by the Company, you understand and agree that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The RSU Award is governed by this RSU Award Grant Notice (the &#147;<B><I>Grant Notice</I></B>&#148;), and the
provisions of the Plan and the Agreement, all of which are made a part of this document. Unless otherwise provided in the Plan, this Grant Notice and the Agreement (together, the &#147;<B><I>RSU Award Agreement</I></B>&#148;) may not be modified,
amended or revised except in a writing signed by you and a duly authorized officer of the Company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">You have read and are familiar with the provisions of the Plan, the RSU Award Agreement and the Prospectus. In
the event of any conflict between the provisions in the RSU Award Agreement, or the Prospectus and the terms of the Plan, the terms of the Plan shall control. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The RSU Award Agreement sets forth the entire understanding between you and the Company regarding the acquisition
of Common Stock and supersedes all prior oral and written agreements, promises and/or representations on that subject with the exception of: (i)&nbsp;other equity awards previously granted to you, and (ii)&nbsp;any written employment agreement,
offer letter, severance agreement, written severance plan or policy, or other written agreement between the Company and you in each case that specifies the terms that should govern this RSU Award. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>A<SMALL>CRIVON</SMALL> T<SMALL>HERAPEUTICS</SMALL>, I<SMALL>NC</SMALL>. </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>P<SMALL>ARTICIPANT</SMALL>:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:&nbsp;&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:&nbsp;&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Date:&nbsp;&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Date:&nbsp;&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>CRIVON</SMALL> T<SMALL>HERAPEUTICS</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2022 E<SMALL>QUITY</SMALL> I<SMALL>NCENTIVE</SMALL> P<SMALL>LAN</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>WARD</SMALL> A<SMALL>GREEMENT</SMALL> (RSU A<SMALL>WARD</SMALL>) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As reflected by your Restricted Stock Unit Grant Notice (&#147;<B><I>Grant Notice</I></B>&#148;), Acrivon Therapeutics, Inc. (the
&#147;<B><I>Company</I></B>&#148;) has granted you a RSU Award under its 2022 Equity Incentive Plan (the &#147;<B><I>Plan</I></B>&#148;) for the number of restricted stock units as indicated in your Grant Notice (the &#147;<B><I>RSU
Award</I></B>&#148;). The terms of your RSU Award as specified in this Award Agreement for your RSU Award (the &#147;<B><I>Agreement</I></B>&#148;) and the Grant Notice constitute your &#147;<B><I>RSU Award Agreement</I></B>&#148;. Defined terms not
explicitly defined in this Agreement but defined in the Grant Notice or the Plan shall have the same definitions as in the Grant Notice or Plan, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The general terms applicable to your RSU Award are as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.</B> <B>G<SMALL>OVERNING</SMALL> P<SMALL>LAN</SMALL> D<SMALL>OCUMENT</SMALL>.</B> Your RSU Award is subject to all the provisions of the
Plan. Your RSU Award is further subject to all interpretations, amendments, rules and regulations, which may from time to time be promulgated and adopted pursuant to the Plan. In the event of any conflict between the RSU Award Agreement and the
provisions of the Plan, the provisions of the Plan shall control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.</B> <B>G<SMALL>RANT</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL>
RSU A<SMALL>WARD</SMALL>. </B>This RSU Award represents your right to be issued on a future date the number of shares of Common Stock that is equal to the number of restricted stock units indicated in the Grant Notice subject to your satisfaction of
the vesting conditions set forth therein (the &#147;<B><I>Restricted Stock Units</I></B>&#148;). Any additional Restricted Stock Units that become subject to the RSU Award pursuant to Capitalization Adjustments as set forth in the Plan and the
provisions of Section&nbsp;3 below, if any, shall be subject, in a manner determined by the Board, to the same forfeiture restrictions, restrictions on transferability, and time and manner of delivery as applicable to the other Restricted Stock
Units covered by your RSU Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.</B> <B>D<SMALL>IVIDENDS</SMALL>.</B><B> </B>You shall receive no benefit or adjustment to your RSU
Award with respect to any cash dividend, stock dividend or other distribution that does not result from a Capitalization Adjustment as provided in the Plan; provided, however, that this sentence shall not apply with respect to any shares of Common
Stock that are delivered to you in connection with your RSU Award after such shares have been delivered to you. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.
W<SMALL>ITHHOLDING</SMALL> O<SMALL>BLIGATIONS</SMALL>. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Regardless of any action taken by the Company or, if different, the
Affiliate to which you provide Continuous Service (the &#147;<B><I>Service Recipient</I></B>&#148;) with respect to any income tax, social insurance, payroll tax, fringe benefits tax, payment on account or other
<FONT STYLE="white-space:nowrap">tax-related</FONT> items associated with the grant or vesting of the RSU Award or sale of the underlying Common Stock or other <FONT STYLE="white-space:nowrap">tax-related</FONT> items related to your participation
in the Plan and legally applicable to you (the &#147;<B><I>Tax Liability</I></B>&#148;), you hereby acknowledge and agree that the Tax Liability is your ultimate responsibility and may exceed the amount, if any, actually withheld by the Company or
the Service Recipient. You further acknowledge that the Company and the Service Recipient (i)&nbsp;make no representations or undertakings regarding any Tax Liability in connection with any aspect of this RSU Award, including, but not limited to,
the grant or vesting of the RSU Award, the issuance of Common Stock pursuant to such vesting, the subsequent sale of shares of Common Stock, and the payment of any dividends on the Common Stock; and (ii)&nbsp;do not commit to and are under no
obligation to structure the terms of the grant or any aspect of the RSU Award to reduce or eliminate your Tax Liability or achieve a particular tax result. Further, if you are subject to Tax Liability in more than one jurisdiction, you acknowledge
that the Company and/or the Service Recipient (or former service recipient, as applicable) may be required to withhold or account for Tax Liability in more than one jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Prior to any relevant taxable or tax withholding event, as applicable, you agree to make adequate arrangements satisfactory to the
Company and/or the Service Recipient to satisfy all Tax Liability. As further provided in Section&nbsp;8 of the Plan, you hereby authorize the Company and any applicable Service Recipient to satisfy any applicable withholding obligations with regard
to the Tax Liability by any of the following means or by a combination of such means: (i)&nbsp;causing you to pay any portion of the Tax Liability in cash or cash equivalent in a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
form acceptable to the Company; (ii)&nbsp;withholding from any compensation otherwise payable to you by the Company or the Service Recipient; (iii)&nbsp;withholding shares of Common Stock from
the shares of Common Stock issued or otherwise issuable to you in connection with the Award; <I>provided</I>, however, that to the extent necessary to qualify for an exemption from application of Section&nbsp;16(b) of the Exchange Act, if
applicable, such share withholding procedure will be subject to the express prior approval of the Board or the Company&#146;s Compensation Committee; (iv)&nbsp;permitting or requiring you to enter into a &#147;same day sale&#148; commitment, if
applicable, with a broker-dealer that is a member of the Financial Industry Regulatory Authority (a &#147;<B><I>FINRA Dealer</I></B>&#148;), pursuant to this authorization and without further consent, whereby you irrevocably elect to sell a portion
of the shares of Common Stock to be delivered in connection with your Restricted Stock Units to satisfy the Tax Liability and whereby the FINRA Dealer irrevocably commits to forward the proceeds necessary to satisfy the Tax Liability directly to the
Company or the Service Recipient; and/or (v)&nbsp;any other method determined by the Company to be in compliance with Applicable Law. Furthermore, you agree to pay the Company or the Service Recipient any amount the Company or the Service Recipient
may be required to withhold, collect, or pay as a result of your participation in the Plan or that cannot be satisfied by the means previously described. In the event it is determined that the amount of the Tax Liability was greater than the amount
withheld by the Company and/or the Service Recipient (as applicable), you agree to indemnify and hold the Company and/or the Service Recipient (as applicable) harmless from any failure by the Company or the applicable Service Recipient to withhold
the proper amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> The Company may withhold or account for your Tax Liability by considering statutory withholding amounts or
other withholding rates applicable in your jurisdiction(s), including (i)&nbsp;maximum applicable rates in your jurisdiction(s), in which case you may receive a refund of any over-withheld amount in cash (whether from applicable tax authorities or
the Company) and you will have no entitlement to the equivalent amount in Common Stock or (ii)&nbsp;minimum or such other applicable rates in your jurisdiction(s), in which case you may be solely responsible for paying any additional Tax Liability
to the applicable tax authorities or to the Company and/or the Service Recipient. If the Tax Liability withholding obligation is satisfied by withholding shares of Common Stock, for tax purposes, you are deemed to have been issued the full number of
shares of Common Stock subject to the vested portion of the RSU Award, notwithstanding that a number of the shares of Common Stock is held back solely for the purpose of paying such Tax Liability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> You acknowledge that you may not participate in the Plan and the Company shall have no obligation to deliver shares of Common Stock
until you have fully satisfied the Tax Liability, as determined by the Company. Unless any withholding obligation for the Tax Liability is satisfied, the Company shall have no obligation to deliver to you any Common Stock in respect of the RSU
Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5. D<SMALL>ATE</SMALL> <SMALL>OF</SMALL> I<SMALL>SSUANCE</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The issuance of shares in respect of the Restricted Stock Units is intended to comply with U.S. Treasury Regulations <FONT
STYLE="white-space:nowrap">Section&nbsp;1.409A-1(b)(4)</FONT> and will be construed and administered in such a manner. Subject to the satisfaction of the Tax Liability withholding obligation, if any, in the event one or more Restricted Stock Units
vests, the Company shall issue to you, on the applicable vesting date, one (1)&nbsp;share of Common Stock for each vested Restricted Stock Unit. Each issuance date determined by this paragraph is referred to as an &#147;<B><I>Original Issuance
Date</I></B>.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> If the Original Issuance Date falls on a date that is not a business day, delivery shall instead occur on
the next following business day. In addition, if: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> the Original Issuance Date does not occur (1)&nbsp;during an &#147;open
window period&#148; applicable to you, as determined by the Company in accordance with the Company&#146;s then-effective policy on trading in Company securities, or (2)&nbsp;on a date when you are otherwise permitted to sell shares of Common Stock
on an established stock exchange or stock market (including but not limited to under a previously established written trading plan that meets the requirements of Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act and was
entered into in compliance with the Company&#146;s policies (a &#147;<B><I><FONT STYLE="white-space:nowrap">10b5-1</FONT> Arrangement</I></B>)), <I>and</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> either (1)&nbsp;a Tax Liability withholding obligation does not apply, or
(2)&nbsp;the Company decides, prior to the Original Issuance Date, (A)&nbsp;not to satisfy the Tax Liability withholding obligation by withholding shares of Common Stock from the shares otherwise due, on the Original Issuance Date, to you under this
RSU Award, and (B)&nbsp;not to permit you to enter into a &#147;same day sale&#148; commitment with a broker-dealer (including but not limited to a commitment under a <FONT STYLE="white-space:nowrap">10b5-1</FONT> Arrangement) and (C)&nbsp;not to
permit you to pay your Tax Liability in cash, <U>then</U> the shares that would otherwise be issued to you on the Original Issuance Date will not be delivered on such Original Issuance Date and will instead be delivered on the first business day
when you are not prohibited from selling shares of the Common Stock in the open public market, but in no event later than December&nbsp;31 of the calendar year in which the Original Issuance Date occurs (that is, the last day of your taxable year in
which the Original Issuance Date occurs), or, <U>if and only if</U> permitted in a manner that complies with U.S. Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(b)(4),</FONT> no later than the date that is the 15th day
of the third calendar month of the applicable year following the year in which the shares of Common Stock under this RSU Award are no longer subject to a &#147;substantial risk of forfeiture&#148; within the meaning of U.S. Treasury Regulations <FONT
STYLE="white-space:nowrap">Section&nbsp;1.409A-1(d).</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.</B> <B>T<SMALL>RANSFERABILITY</SMALL>.</B> Except as otherwise provided
in the Plan, your RSU Award is not transferable, except by will or by the applicable laws of descent and distribution </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.</B>
<B>C<SMALL>ORPORATE</SMALL> T<SMALL>RANSACTION</SMALL>.</B> Your RSU Award is subject to the terms of any agreement governing a Corporate Transaction involving the Company, including, without limitation, a provision for the appointment of a
stockholder representative that is authorized to act on your behalf with respect to any escrow, indemnities and any contingent consideration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.</B> <B>N<SMALL>O</SMALL> L<SMALL>IABILITY</SMALL> <SMALL>FOR</SMALL> T<SMALL>AXES</SMALL></B><SMALL></SMALL>. As a condition to
accepting the RSU Award, you hereby (a)&nbsp;agree to not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates related to tax liabilities arising from the RSU Award or other Company compensation and
(b)&nbsp;acknowledge that you were advised to consult with your own personal tax, financial and other legal advisors regarding the tax consequences of the RSU Award and have either done so or knowingly and voluntarily declined to do so. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.</B> <B>S<SMALL>EVERABILITY</SMALL></B><SMALL></SMALL>. If any part of this Agreement or the Plan is declared by any court or
governmental authority to be unlawful or invalid, such unlawfulness or invalidity will not invalidate any portion of this Agreement or the Plan not declared to be unlawful or invalid.&nbsp;Any Section of this Agreement (or part of such a Section) so
declared to be unlawful or invalid will, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.</B> <B>O<SMALL>THER</SMALL> D<SMALL>OCUMENTS</SMALL>.</B>&nbsp;You hereby acknowledge receipt of or the right to receive a document
providing the information required by Rule 428(b)(1) promulgated under the Securities Act, which includes the Prospectus.&nbsp;In addition, you acknowledge receipt of the Company&#146;s Trading Policy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.</B> <B>Q<SMALL>UESTIONS</SMALL>. </B>If you have questions regarding these or any other terms and conditions applicable to your RSU
Award, including a summary of the applicable federal income tax consequences please see the Prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3. </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>8
<FILENAME>d383050dex103.htm
<DESCRIPTION>EX-10.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>CRIVON</SMALL> T<SMALL>HERAPEUTICS</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2022 E<SMALL>MPLOYEE</SMALL> S<SMALL>TOCK</SMALL> P<SMALL>URCHASE</SMALL> P<SMALL>LAN</SMALL> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>DOPTED</SMALL> BY THE B<SMALL>OARD</SMALL> OF D<SMALL>IRECTORS</SMALL>: O<SMALL>CTOBER</SMALL>&nbsp;28, 2022 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>PPROVED</SMALL> BY THE S<SMALL>TOCKHOLDERS</SMALL>: N<SMALL>OVEMBER</SMALL>&nbsp;1, 2022 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. G<SMALL>ENERAL</SMALL>; P<SMALL>URPOSE</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The Plan provides a means by which Eligible Employees of the Company and certain Designated Companies may be given an opportunity
to purchase shares of Common Stock. The Plan permits the Company to grant a series of Purchase Rights to Eligible Employees under an Employee Stock Purchase Plan. In addition, the Plan permits the Company to grant a series of Purchase Rights to
Eligible Employees that do not meet the requirements of an Employee Stock Purchase Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The Plan includes two components: a
423 Component and a <FONT STYLE="white-space:nowrap">Non-423</FONT> Component. The Company intends (but makes no undertaking or representation to maintain) the 423 Component to qualify as an Employee Stock Purchase Plan. The provisions of the 423
Component, accordingly, will be construed in a manner that is consistent with the requirements of Section&nbsp;423 of the Code. In addition, this Plan authorizes grants of Purchase Rights under the <FONT STYLE="white-space:nowrap">Non-423</FONT>
Component that do not meet the requirements of an Employee Stock Purchase Plan. Except as otherwise provided in the Plan or determined by the Board, the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component will operate and be administered in
the same manner as the 423 Component. In addition, the Company may make separate Offerings which vary in terms (provided that such terms are not inconsistent with the provisions of the Plan or the requirements of an Employee Stock Purchase Plan to
the extent the Offering is made under the 423 Component), and the Company will designate which Designated Company is participating in each separate Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> The Company, by means of the Plan, seeks to retain the services of Eligible Employees, to secure and retain the services of new
Employees and to provide incentives for such persons to exert maximum efforts for the success of the Company and its Related Corporations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.
A<SMALL>DMINISTRATION</SMALL>. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The Board will administer the Plan unless and until the Board delegates administration of
the Plan to a Committee or Committees, as provided in Section&nbsp;2(c). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The Board will have the power, subject to, and within
the limitations of, the express provisions of the Plan: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> To determine how and when Purchase Rights will be granted and the
provisions of each Offering (which need not be identical). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> To designate from time to time (A)&nbsp;which Related Corporations
of the Company will be eligible to participate in the Plan as Designated 423 Companies, (B)&nbsp;which Related Corporations or Affiliates will be eligible to participate in the Plan as Designated <FONT STYLE="white-space:nowrap">Non-423</FONT>
Companies, (C)&nbsp;which Affiliates or Related Corporations may be excluded from participation in the Plan, and (D)&nbsp;which Designated Companies will participate in each separate Offering (to the extent that the Company makes separate
Offerings). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> To construe and interpret the Plan and Purchase Rights, and to establish, amend and revoke rules and regulations
for its administration. The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan, in a manner and to the extent it deems necessary or expedient to make the Plan fully effective. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> To settle all controversies regarding the Plan and Purchase Rights granted under
the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> To suspend or terminate the Plan at any time as provided in Section&nbsp;12. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(vi)</B> To amend the Plan at any time as provided in Section&nbsp;12. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(vii)</B> Generally, to exercise such powers and to perform such acts as it deems necessary or expedient to promote the best interests of
the Company and its Related Corporations and to carry out the intent that the Plan be treated as an Employee Stock Purchase Plan with respect to the 423 Component. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(viii)</B> To adopt such rules, procedures and <FONT STYLE="white-space:nowrap">sub-plans</FONT> as are necessary or appropriate to permit
or facilitate participation in the Plan by Employees who are foreign nationals or employed or located outside the United States. Without limiting the generality of, and consistent with, the foregoing, the Board specifically is authorized to adopt
rules, procedures, and <FONT STYLE="white-space:nowrap">sub-plans</FONT> regarding, without limitation, eligibility to participate in the Plan, the definition of eligible &#147;earnings,&#148; handling and making of Contributions, establishment of
bank or trust accounts to hold Contributions, payment of interest, conversion of local currency, obligations to pay payroll tax, determination of beneficiary designation requirements, withholding procedures and handling of share issuances, any of
which may vary according to applicable requirements, and which, if applicable to a Designated <FONT STYLE="white-space:nowrap">Non-423</FONT> Company, do not have to comply with the requirements of Section&nbsp;423 of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> The Board may delegate some or all of the administration of the Plan to a Committee or Committees. If administration is delegated
to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the power to delegate to a subcommittee any of the
administrative powers the Committee is authorized to exercise (and references in this Plan and any applicable Offering Document to the Board will thereafter be to the Committee or subcommittee), subject, however, to such resolutions, not
inconsistent with the provisions of the Plan, as may be adopted from time to time by the Board. Further, to the extent not prohibited by Applicable Law, the Board or Committee may, from time to time, delegate some or all of its authority under the
Plan to one or more officers of the Company or other persons or groups of persons as it deems necessary, appropriate or advisable under conditions or limitations that it may set at or after the time of the delegation. The Board may retain the
authority to concurrently administer the Plan with the Committee and may, at any time, revest in the Board some or all of the powers previously delegated. Whether or not the Board has delegated administration of the Plan to a Committee, the Board
will have the final power to determine all questions of policy and expediency that may arise in the administration of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> All determinations, interpretations and constructions made by the Board in good faith will not be subject to review by any person
and will be final, binding and conclusive on all persons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. S<SMALL>HARES</SMALL> <SMALL>OF</SMALL> C<SMALL>OMMON</SMALL> S<SMALL>TOCK</SMALL>
S<SMALL>UBJECT</SMALL> <SMALL>TO</SMALL> <SMALL>THE</SMALL> P<SMALL>LAN</SMALL>. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Subject to the provisions of
Section&nbsp;11(a) relating to Capitalization Adjustments, the maximum number of shares of Common Stock that may be issued under the Plan will not exceed 215,000 shares of Common Stock, plus the number of shares of Common Stock that are
automatically added on January 1st of each year for a period of up to ten years, commencing on January&nbsp;1,&nbsp;2023 and ending on (and including) January&nbsp;1, 2032, in an amount equal to one percent (1%) of the total number of shares of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Common Stock outstanding on December 31st of the preceding calendar year. Notwithstanding the foregoing, the Board may act prior to the first day of any calendar year to provide that there will
be no January 1<SUP STYLE="font-size:75%; vertical-align:top">st</SUP> increase in the share reserve for such calendar year or that the increase in the share reserve for such calendar year will be a lesser number of shares of Common Stock than would
otherwise occur pursuant to the preceding sentence. For the avoidance of doubt, up to the maximum number of shares of Common Stock reserved under this Section&nbsp;3(a) may be used to satisfy purchases of Common Stock under the 423 Component and any
remaining portion of such maximum number of shares may be used to satisfy purchases of Common Stock under the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> If any Purchase Right granted under the Plan terminates without having been exercised in full, the shares of Common Stock not
purchased under such Purchase Right will again become available for issuance under the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> The stock purchasable under the
Plan will be shares of authorized but unissued or reacquired Common Stock, including shares repurchased by the Company on the open market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.
G<SMALL>RANT</SMALL> <SMALL>OF</SMALL> P<SMALL>URCHASE</SMALL> R<SMALL>IGHTS</SMALL>; O<SMALL>FFERING</SMALL>. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The Board
may from time to time grant or provide for the grant of Purchase Rights to Eligible Employees under an Offering (consisting of one or more Purchase Periods) on an Offering Date or Offering Dates selected by the Board. Each Offering will be in such
form and will contain such terms and conditions as the Board will deem appropriate, and with respect to the 423 Component, will comply with the requirement of Section&nbsp;423(b)(5) of the Code that all Employees granted Purchase Rights will have
the same rights and privileges. The terms and conditions of an Offering shall be incorporated by reference into the Plan and treated as part of the Plan. The provisions of separate Offerings need not be identical, but each Offering will include
(through incorporation of the provisions of this Plan by reference in the document comprising the Offering or otherwise) the period during which the Offering will be effective, which period will not exceed 27 months beginning with the Offering Date,
and the substance of the provisions contained in Sections 5 through 8, inclusive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> If a Participant has more than one Purchase
Right outstanding under the Plan, unless he or she otherwise indicates in forms delivered to the Company or a third party designated by the Company (each, a &#147;<B><I>Company Designee</I></B>&#148;): (i) each form will apply to all of his or her
Purchase Rights under the Plan, and (ii)&nbsp;a Purchase Right with a lower exercise price (or an earlier-granted Purchase Right, if different Purchase Rights have identical exercise prices) will be exercised to the fullest possible extent before a
Purchase Right with a higher exercise price (or a later-granted Purchase Right if different Purchase Rights have identical exercise prices) will be exercised. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> The Board will have the discretion to structure an Offering so that if the Fair Market Value of a share of Common Stock on the
first Trading Day of a new Purchase Period within that Offering is less than or equal to the Fair Market Value of a share of Common Stock on the Offering Date for that Offering, then (i)&nbsp;that Offering will terminate immediately as of that first
Trading Day, and (ii)&nbsp;the Participants in such terminated Offering will be automatically enrolled in a new Offering beginning on the first Trading Day of such new Purchase Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. E<SMALL>LIGIBILITY</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Purchase Rights may be granted only to Employees of the Company or, as the Board may designate in accordance with
Section&nbsp;2(b), to Employees of a Related Corporation or an Affiliate. Except as provided in Section&nbsp;5(b) or as required by Applicable Law, an Employee will not be eligible to be granted Purchase Rights unless, on the Offering Date, the
Employee has been in the employ of the Company, the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Related Corporation or the Affiliate, as the case may be, for such continuous period preceding such Offering Date as the Board may (unless prohibited by Applicable Law) require, but in no event
will the required period of continuous employment be equal to or greater than two years. In addition, the Board may provide that no Employee will be eligible to be granted Purchase Rights under the Plan unless, on the Offering Date, such
Employee&#146;s customary employment with the Company, the Related Corporation or the Affiliate is more than 20 hours per week and more than five months per calendar year or such other criteria as the Board may determine consistent with
Section&nbsp;423 of the Code with respect to the 423 Component. The Board may also exclude from participation in the Plan or any Offering Employees who are &#147;highly compensated employees&#148; (within the meaning of Section&nbsp;423(b)(4)(D) of
the Code) of the Company or a Related Corporation or a subset of such highly compensated employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The Board may provide that
each person who, during the course of an Offering, first becomes an Eligible Employee will, on a date or dates specified in the Offering which coincides with the day on which such person becomes an Eligible Employee or which occurs thereafter,
receive a Purchase Right under that Offering, which Purchase Right will thereafter be deemed to be a part of that Offering. Such Purchase Right will have the same characteristics as any Purchase Rights originally granted under that Offering, as
described herein, except that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> the date on which such Purchase Right is granted will be the &#147;Offering Date&#148; of such
Purchase Right for all purposes, including determination of the exercise price of such Purchase Right; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> the period of the
Offering with respect to such Purchase Right will begin on its Offering Date and end coincident with the end of such Offering; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> the Board may provide that if such person first becomes an Eligible Employee within a specified period of time before the end of
the Offering, he or she will not receive any Purchase Right under that Offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> No Employee will be eligible for the grant of
any Purchase Rights under the 423 Component if, immediately after any such Purchase Rights are granted, such Employee owns stock possessing five percent or more of the total combined voting power or value of all classes of stock of the Company or of
any Related Corporation. For purposes of this Section&nbsp;5(c), the rules of Section&nbsp;424(d) of the Code will apply in determining the stock ownership of any Employee, and stock which such Employee may purchase under all outstanding Purchase
Rights and options will be treated as stock owned by such Employee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> As specified by Section&nbsp;423(b)(8) of the Code, an
Eligible Employee may be granted Purchase Rights under the 423 Component only if such Purchase Rights, together with any other rights granted under all Employee Stock Purchase Plans of the Company and any Related Corporations, do not permit such
Eligible Employee&#146;s rights to purchase stock of the Company or any Related Corporation to accrue at a rate which, when aggregated, exceeds $25,000 of Fair Market Value of such stock (determined at the time such rights are granted, and which,
with respect to the Plan, will be determined as of their respective Offering Dates) for each calendar year in which such rights are outstanding at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> Officers of the Company and any Designated Company, if they are otherwise Eligible Employees, will be eligible to participate in
Offerings under the Plan. Notwithstanding the foregoing, the Board may (unless prohibited by Applicable Law) provide in an Offering that Employees who are highly compensated Employees within the meaning of Section&nbsp;423(b)(4)(D) of the Code will
not be eligible to participate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> Notwithstanding anything in this Section&nbsp;5 to the contrary, in the case of
an Offering under the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component, an Eligible Employee (or group of Eligible Employees) may be excluded from participation in the Plan or an Offering if the Board has determined, in its sole discretion,
that participation of such Eligible Employee(s) is not advisable or practical for any reason. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. P<SMALL>URCHASE</SMALL> R<SMALL>IGHTS</SMALL>;
P<SMALL>URCHASE</SMALL> P<SMALL>RICE</SMALL>. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> On each Offering Date, each Eligible Employee, pursuant to an Offering made
under the Plan, will be granted a Purchase Right to purchase up to that number of shares of Common Stock purchasable either with a percentage of earnings or with a maximum dollar amount, as designated by the Board during the period that begins on
the Offering Date (or such later date as the Board determines for a particular Offering) and ends on the date stated in the Offering, which date will be no later than the end of the Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The Board will establish one or more Purchase Dates during an Offering on which Purchase Rights granted for that Offering will be
exercised and shares of Common Stock will be purchased in accordance with such Offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> In connection with each Offering made
under the Plan, the Board may specify (i)&nbsp;a maximum number of shares of Common Stock that may be purchased by any Participant on any Purchase Date during such Offering, (ii)&nbsp;a maximum aggregate number of shares of Common Stock that may be
purchased by all Participants pursuant to such Offering and/or (iii)&nbsp;a maximum aggregate number of shares of Common Stock that may be purchased by all Participants on any Purchase Date under the Offering. If the aggregate purchase of shares of
Common Stock issuable upon exercise of Purchase Rights granted under the Offering would exceed any such maximum aggregate number, then, in the absence of any Board action otherwise, a pro rata (based on each Participant&#146;s accumulated
Contributions) allocation of the shares of Common Stock (rounded down to the nearest whole share) available will be made in as nearly a uniform manner as will be practicable and equitable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> The purchase price of shares of Common Stock acquired pursuant to Purchase Rights will be specified by the Board prior to
commencement of an Offering and will not be less than the lesser of: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> an amount equal to 85% of the Fair Market Value of the
shares of Common Stock on the Offering Date; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> an amount equal to 85% of the Fair Market Value of the shares of Common Stock
on the applicable Purchase Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. P<SMALL>ARTICIPATION</SMALL>; W<SMALL>ITHDRAWAL</SMALL>; T<SMALL>ERMINATION</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> An Eligible Employee may elect to participate in an Offering and authorize payroll deductions as the means of making Contributions
by completing and delivering to the Company or a Company Designee, within the time specified in the Offering, an enrollment form provided by the Company or Company Designee. The enrollment form will specify the amount of Contributions not to exceed
the maximum amount specified by the Board. Each Participant&#146;s Contributions will be credited to a bookkeeping account for such Participant under the Plan and will be deposited with the general funds of the Company except where Applicable Law
requires that Contributions be deposited with a third party. If permitted in the Offering, a Participant may begin such Contributions with the first payroll occurring on or after the Offering Date (or, in the case of a payroll date that occurs after
the end of the prior Offering but before the Offering Date of the next new Offering, Contributions from such payroll will be included in the new Offering). If permitted in the Offering, a Participant may thereafter reduce (including to zero) or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
increase his or her Contributions. If required under Applicable Law or if specifically provided in the Offering and to the extent permitted by Section&nbsp;423 of the Code with respect to the 423
Component, in addition to or instead of making Contributions by payroll deductions, a Participant may make Contributions through payment by cash, check or wire transfer prior to a Purchase Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> During an Offering, a Participant may cease making Contributions and withdraw from the Offering by delivering to the Company or a
Company Designee a withdrawal form provided by the Company. The Company may impose a deadline before a Purchase Date for withdrawing. Upon such withdrawal, such Participant&#146;s Purchase Right in that Offering will immediately terminate and the
Company will distribute as soon as practicable to such Participant all of his or her accumulated but unused Contributions and such Participant&#146;s Purchase Right in that Offering shall thereupon terminate. A Participant&#146;s withdrawal from
that Offering will have no effect upon his or her eligibility to participate in any other Offerings under the Plan, but such Participant will be required to deliver a new enrollment form to participate in subsequent Offerings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> Unless otherwise required by Applicable Law, Purchase Rights granted pursuant to any Offering under the Plan will terminate
immediately if the Participant either (i)&nbsp;is no longer an Employee for any reason or for no reason (subject to any post-employment participation period required by Applicable Law) or (ii)&nbsp;is otherwise no longer eligible to participate. The
Company will distribute as soon as practicable to such individual all of his or her accumulated but unused Contributions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>
Unless otherwise determined by the Board, a Participant whose employment transfers or whose employment terminates with an immediate rehire (with no break in service) by or between the Company and a Designated Company or between Designated Companies
will not be treated as having terminated employment for purposes of participating in the Plan or an Offering; however, if a Participant transfers from an Offering under the 423 Component to an Offering under the
<FONT STYLE="white-space:nowrap">Non-423</FONT> Component, the exercise of the Participant&#146;s Purchase Right will be qualified under the 423 Component only to the extent such exercise complies with Section&nbsp;423 of the Code. If a Participant
transfers from an Offering under the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component to an Offering under the 423 Component, the exercise of the Purchase Right will remain <FONT STYLE="white-space:nowrap">non-qualified</FONT> under the <FONT
STYLE="white-space:nowrap">Non-423</FONT> Component. The Board may establish different and additional rules governing transfers between separate Offerings within the 423 Component and between Offerings under the 423 Component and Offerings under the
<FONT STYLE="white-space:nowrap">Non-423</FONT> Component. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> During a Participant&#146;s lifetime, Purchase Rights will be
exercisable only by such Participant. Purchase Rights are not transferable by a Participant, except by will, by the laws of descent and distribution, or, if permitted by the Company, by a beneficiary designation as described in Section&nbsp;10. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> Unless otherwise specified in the Offering or as required by Applicable Law, the Company will have no obligation to pay interest on
Contributions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. E<SMALL>XERCISE</SMALL> O<SMALL>F</SMALL> P<SMALL>URCHASE</SMALL> R<SMALL>IGHTS</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> On each Purchase Date, each Participant&#146;s accumulated Contributions will be applied to the purchase of shares of Common Stock,
up to the maximum number of shares of Common Stock permitted by the Plan and the applicable Offering, at the purchase price specified in the Offering. No fractional shares will be issued unless specifically provided for in the Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Unless otherwise provided in the Offering, if any amount of accumulated Contributions remains in a Participant&#146;s account after
the purchase of shares of Common Stock and such remaining amount is less than the amount required to purchase one share of Common Stock on the final Purchase Date of an Offering, then such remaining amount will be held in such Participant&#146;s
account for the purchase of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shares of Common Stock under the next Offering under the Plan, unless such Participant withdraws from or is not eligible to participate in such next Offering, in which case such amount will be
distributed to such Participant after the final Purchase Date without interest (unless the payment of interest is otherwise required by Applicable Law). If the amount of Contributions remaining in a Participant&#146;s account after the purchase of
shares of Common Stock is at least equal to the amount required to purchase one (1)&nbsp;whole share of Common Stock on the final Purchase Date of an Offering, then such remaining amount will be distributed in full to such Participant after the
final Purchase Date of such Offering without interest (unless otherwise required by Applicable Law). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> No Purchase Rights may be
exercised to any extent unless the shares of Common Stock to be issued upon such exercise under the Plan are covered by an effective registration statement pursuant to the Securities Act and the Plan is in material compliance with all applicable
U.S. federal and state, foreign and other securities, exchange control and other laws applicable to the Plan. If on a Purchase Date the shares of Common Stock are not so registered or the Plan is not in such compliance, no Purchase Rights will be
exercised on such Purchase Date, and, subject to Section&nbsp;423 of the Code with respect to the 423 Component, the Purchase Date will be delayed until the shares of Common Stock are subject to such an effective registration statement and the Plan
is in material compliance, except that the Purchase Date will in no event be more than 27 months from the Offering Date. If, on the Purchase Date, as delayed to the maximum extent permissible, the shares of Common Stock are not registered and the
Plan is not in material compliance with all Applicable Laws, as determined by the Company in its sole discretion, no Purchase Rights will be exercised and all accumulated but unused Contributions will be distributed to the Participants without
interest (unless the payment of interest is otherwise required by Applicable Law). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. C<SMALL>OVENANTS</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL>
C<SMALL>OMPANY</SMALL>. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company will seek to obtain from each U.S. federal or state, foreign or other regulatory commission,
agency or other Governmental Body having jurisdiction over the Plan such authority as may be required to grant Purchase Rights and issue and sell shares of Common Stock thereunder unless the Company determines, in its sole discretion, that doing so
is not practical or would cause the Company to incur costs that are unreasonable. If, after commercially reasonable efforts, the Company is unable to obtain the authority that counsel for the Company deems necessary for the grant of Purchase Rights
or the lawful issuance and sale of Common Stock under the Plan, and at a commercially reasonable cost, the Company will be relieved from any liability for failure to grant Purchase Rights and/or to issue and sell Common Stock upon exercise of such
Purchase Rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. D<SMALL>ESIGNATION</SMALL> <SMALL>OF</SMALL> B<SMALL>ENEFICIARY</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The Company may, but is not obligated to, permit a Participant to submit a form designating a beneficiary who will receive any
shares of Common Stock and/or Contributions from the Participant&#146;s account under the Plan if the Participant dies before such shares and/or Contributions are delivered to the Participant. The Company may, but is not obligated to, permit the
Participant to change such designation of beneficiary. Any such designation and/or change must be on a form approved by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> If a Participant dies, and in the absence of a valid beneficiary designation, the Company will deliver any shares of Common Stock
and/or Contributions to the executor or administrator of the estate of the Participant. If no executor or administrator has been appointed (to the knowledge of the Company), the Company, in its sole discretion, may deliver such shares of Common
Stock and/or Contributions, without interest (unless the payment of interest is otherwise required by Applicable Law), to the Participant&#146;s spouse, dependents or relatives, or if no spouse, dependent or relative is known to the Company, then to
such other person as the Company may designate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. A<SMALL>DJUSTMENTS</SMALL> <SMALL>UPON</SMALL> C<SMALL>HANGES</SMALL> <SMALL>IN</SMALL>
C<SMALL>OMMON</SMALL> S<SMALL>TOCK</SMALL>; C<SMALL>ORPORATE</SMALL> T<SMALL>RANSACTIONS</SMALL>. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> In the event of a
Capitalization Adjustment, the Board will appropriately and proportionately adjust: (i)&nbsp;the class(es) and maximum number of securities subject to the Plan pursuant to Section&nbsp;3(a), (ii) the class(es) and maximum number of securities by
which the share reserve is to increase automatically each year pursuant to Section&nbsp;3(a), (iii) the class(es) and number of securities subject to, and the purchase price applicable to outstanding Offerings and Purchase Rights, and (iv)&nbsp;the
class(es) and number of securities that are the subject of the purchase limits under each ongoing Offering. The Board will make these adjustments, and its determination will be final, binding and conclusive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> In the event of a Corporate Transaction, then: (i)&nbsp;any surviving corporation or acquiring corporation (or the surviving or
acquiring corporation&#146;s parent company) may assume or continue outstanding Purchase Rights or may substitute similar rights (including a right to acquire the same consideration paid to the stockholders in the Corporate Transaction) for
outstanding Purchase Rights, or (ii)&nbsp;if any surviving or acquiring corporation (or its parent company)<B> </B>does not assume or continue such Purchase Rights or does not substitute similar rights for such Purchase Rights, then the
Participants&#146; accumulated Contributions will be used to purchase shares of Common Stock (rounded down to the nearest whole share) within ten business days (or such other period specified by the Board) prior to the Corporate Transaction under
the outstanding Purchase Rights, and the Purchase Rights will terminate immediately after such purchase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. A<SMALL>MENDMENT</SMALL>,
T<SMALL>ERMINATION</SMALL> <SMALL>OR</SMALL> S<SMALL>USPENSION</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> P<SMALL>LAN</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The Board may amend the Plan at any time in any respect the Board deems necessary or advisable. However, except as provided in
Section&nbsp;11(a) relating to Capitalization Adjustments, stockholder approval will be required for any amendment of the Plan for which stockholder approval is required by Applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The Board may suspend or terminate the Plan at any time. No Purchase Rights may be granted under the Plan while the Plan is
suspended or after it is terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> Any benefits, privileges, entitlements and obligations under any outstanding Purchase
Rights granted before an amendment, suspension or termination of the Plan will not be materially impaired by any such amendment, suspension or termination except (i)&nbsp;with the consent of the person to whom such Purchase Rights were granted,
(ii)&nbsp;as necessary to facilitate compliance with any laws, listing requirements, or governmental regulations (including, without limitation, the provisions of Section&nbsp;423 of the Code and the regulations and other interpretive guidance
issued thereunder relating to Employee Stock Purchase Plans) including without limitation any such regulations or other guidance that may be issued or amended after the date the Plan is adopted by the Board, or (iii)&nbsp;as necessary to obtain or
maintain favorable tax, listing, or regulatory treatment. To be clear, the Board may amend outstanding Purchase Rights without a Participant&#146;s consent if such amendment is necessary to ensure that the Purchase Right and/or the Plan complies
with the requirements of Section&nbsp;423 of the Code with respect to the 423 Component or with respect to other Applicable Laws. Notwithstanding anything in the Plan or any Offering Document to the contrary, the Board will be entitled to:
(i)&nbsp;establish the exchange ratio applicable to amounts withheld in a currency other than U.S. dollars; (ii)&nbsp;permit Contributions in excess of the amount designated by a Participant in order to adjust for mistakes in the Company&#146;s
processing of properly completed Contribution elections; (iii)&nbsp;establish reasonable waiting and adjustment periods and/or accounting and crediting procedures to ensure that amounts applied toward the purchase of Common Stock for each
Participant properly correspond with amounts withheld from the Participant&#146;s Contributions; (iv)&nbsp;amend any outstanding Purchase Rights or clarify any ambiguities regarding the terms of any Offering to enable the Purchase Rights to qualify
under and/or comply with Section&nbsp;423 of the Code with respect to the 423 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Component; and (v)&nbsp;establish other limitations or procedures as the Board determines in its sole discretion advisable that are consistent with the Plan. The actions of the Board pursuant to
this paragraph will not be considered to alter or impair any Purchase Rights granted under an Offering as they are part of the initial terms of each Offering and the Purchase Rights granted under each Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. T<SMALL>AX</SMALL> Q<SMALL>UALIFICATION</SMALL>; T<SMALL>AX</SMALL> W<SMALL>ITHHOLDING</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Although the Company may endeavor to (i)&nbsp;qualify a Purchase Right for special tax treatment under the laws of the United
States or jurisdictions outside of the United States or (ii)&nbsp;avoid adverse tax treatment, the Company makes no representation to that effect and expressly disavows any covenant to maintain special or to avoid unfavorable tax treatment,
notwithstanding anything to the contrary in this Plan.&nbsp;The Company will be unconstrained in its corporate activities without regard to the potential negative tax impact on Participants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Each Participant will make arrangements, satisfactory to the Company and any applicable Related Corporation, to enable the Company
or the Related Corporation to fulfill any withholding obligation for <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items. Without limitation to the foregoing, in the Company&#146;s sole discretion and subject to Applicable Law, such
withholding obligation may be satisfied in whole or in part by (i)&nbsp;withholding from the Participant&#146;s salary or any other cash payment due to the Participant from the Company or a Related Corporation; (ii)&nbsp;withholding from the
proceeds of the sale of shares of Common Stock acquired under the Plan, either through a voluntary sale or a mandatory sale arranged by the Company; or (iii)&nbsp;any other method deemed acceptable by the Board. The Company shall not be required to
issue any shares of Common Stock under the Plan until such obligations are satisfied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> The 423 Component is exempt from the
application of Section&nbsp;409A of the Code, and any ambiguities herein shall be interpreted to so be exempt from Section&nbsp;409A of the Code. The <FONT STYLE="white-space:nowrap">Non-423</FONT> Component is intended to be exempt from the
application of Section&nbsp;409A of the Code under the short-term deferral exception and any ambiguities shall be construed and interpreted in accordance with such intent. In furtherance of the foregoing and notwithstanding any provision in the Plan
to the contrary, if the Committee determines that an option granted under the Plan may be subject to Section&nbsp;409A of the Code or that any provision in the Plan would cause an option under the Plan to be subject to Section&nbsp;409A, the
Committee may amend the terms of the Plan and/or of an outstanding option granted under the Plan, or take such other action the Committee determines is necessary or appropriate, in each case, without the participant&#146;s consent, to exempt any
outstanding option or future option that may be granted under the Plan from or to allow any such options to comply with Section&nbsp;409A of the Code, but only to the extent any such amendments or action by the Committee would not violate
Section&nbsp;409A of the Code. Notwithstanding the foregoing, the Company shall have no liability to a participant or any other party if the option under the Plan that is intended to be exempt from or compliant with Section&nbsp;409A of the Code is
not so exempt or compliant or for any action taken by the Committee with respect thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. E<SMALL>FFECTIVE</SMALL> D<SMALL>ATE</SMALL>
<SMALL>OF</SMALL> P<SMALL>LAN</SMALL>. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Plan will become effective immediately prior to and contingent upon the IPO Date. No
Purchase Rights will be exercised unless and until the Plan has been approved by the stockholders of the Company, which approval must be within 12 months before or after the date the Plan is adopted (or if required under Section&nbsp;12(a) above,
materially amended) by the Board. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. M<SMALL>ISCELLANEOUS</SMALL> P<SMALL>ROVISIONS</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Proceeds from the sale of shares of Common Stock pursuant to Purchase Rights will constitute general funds of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> A Participant will not be deemed to be the holder of, or to have any of the rights of a holder with respect to, shares of Common
Stock subject to Purchase Rights unless and until the Participant&#146;s shares of Common Stock acquired upon exercise of Purchase Rights are recorded in the books of the Company (or its transfer agent). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> The Plan and Offering do not constitute an employment contract. Nothing in the Plan or in the Offering will in any way alter the at
will nature of a Participant&#146;s employment or amend a Participant&#146;s employment contract, if applicable, or be deemed to create in any way whatsoever any obligation on the part of any Participant to continue in the employ of the Company or a
Related Corporation or an Affiliate, or on the part of the Company, a Related Corporation or an Affiliate to continue the employment of a Participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> The provisions of the Plan will be governed by the laws of the State of Delaware without resort to that state&#146;s conflicts of
laws rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> If any particular provision of the Plan is found to be invalid or otherwise unenforceable, such provision will not
affect the other provisions of the Plan, but the Plan will be construed in all respects as if such invalid provision were omitted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> If any provision of the Plan does not comply with Applicable Law, such provision shall be construed in such a manner as to comply
with Applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16. D<SMALL>EFINITIONS</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in the Plan, the following definitions will apply to the capitalized terms indicated below: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> &#147;<B><I>423 Component</I></B>&#148; means the part of the Plan, which excludes the
<FONT STYLE="white-space:nowrap">Non-423</FONT> Component, pursuant to which Purchase Rights that satisfy the requirements for an Employee Stock Purchase Plan may be granted to Eligible Employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> &#147;<B><I>Affiliate</I></B>&#148; means any entity, other than a Related Corporation, whether now or subsequently established,
which is at the time of determination, a &#147;parent&#148; or &#147;subsidiary&#148; of the Company as such terms are defined in Rule 405 promulgated under the Securities Act. The Board may determine the time or times at which &#147;parent&#148; or
&#147;subsidiary&#148; status is determined within the foregoing definition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> &#147;<B><I>Applicable Law</I></B>&#148; means
shall mean the Code and any applicable securities, federal, state, foreign, material local or municipal or other law, statute, constitution, principle of common law, resolution, ordinance, code, edict, decree, rule, listing rule, regulation,
judicial decision, ruling or requirement issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority of any Governmental Body (or under the authority of the New York Stock Exchange, NASDAQ Stock Market
or the Financial Industry Regulatory Authority). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> &#147;<B><I>Board</I></B>&#148;<I> </I>means the Board of Directors of the
Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> &#147;<B><I>Capitalization Adjustment</I></B>&#148; means any change that is made in, or other events that occur with
respect to, the Common Stock subject to the Plan or subject to any Purchase Right after the date the Plan is adopted by the Board without the receipt of consideration by the Company through merger, consolidation, reorganization, recapitalization,
reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or other similar equity
restructuring transaction, as that term is used in Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto). Notwithstanding the foregoing, the conversion of any convertible securities of the
Company will not be treated as a Capitalization Adjustment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> &#147;<B><I>Code</I></B>&#148;<I> </I>means the U.S. Internal Revenue Code of
1986, as amended, including any applicable regulations and guidance thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> &#147;<B><I>Committee</I></B>&#148;<I>
</I>means a committee of one or more members of the Board to whom authority has been delegated by the Board in accordance with Section&nbsp;2(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> &#147;<B><I>Common Stock</I></B>&#148; means the common stock of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> &#147;<B><I>Company</I></B>&#148; means Acrivon Therapeutics, Inc., a Delaware corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j)</B> <B><I>&#147;Contributions</I></B>&#148; means the payroll deductions and other additional payments specifically provided for in the
Offering that a Participant contributes to fund the exercise of a Purchase Right. A Participant may make additional payments into his or her account if specifically provided for in the Offering, and then only if the Participant has not already had
the maximum permitted amount withheld during the Offering through payroll deductions and, with respect to the 423 Component, to the extent permitted by Section&nbsp;423. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k)</B> &#147;<B><I>Corporate Transaction</I></B>&#148; means the consummation, in a single transaction or in a series of related
transactions, of any one or more of the following events: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> a sale<B> </B>or other disposition of all or substantially all, as
determined by the Board in its sole discretion, of the consolidated assets of the Company and its subsidiaries; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> a sale or
other disposition of more than 50% of the outstanding securities of the Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> a merger, consolidation or similar
transaction following which the Company is not the surviving corporation; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> a merger, consolidation or similar transaction
following which the Company is the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the merger, consolidation or similar
transaction into other property, whether in the form of securities, cash or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(l)</B> &#147;<B><I>Designated 423
Company</I></B>&#148; means any Related Corporation selected by the Board as participating in the 423 Component. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(m)</B>
&#147;<B><I>Designated Company</I></B>&#148;<B> </B>means any Designated <FONT STYLE="white-space:nowrap">Non-423</FONT> Corporation or Designated 423 Company, provided, however, that at any given time, a Related Corporation participating in the 423
Component shall not be a Related Corporation participating in the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(n)</B>
&#147;<B><I>Designated <FONT STYLE="white-space:nowrap">Non-423</FONT> Company</I></B>&#148; means any Related Corporation or Affiliate selected by the Board as participating in the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(o)</B> &#147;<B><I>Director</I></B>&#148;<I> </I>means a member of the Board. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(p)</B> &#147;<B><I>Eligible Employee</I></B>&#148;<I> </I>means an Employee who meets
the requirements set forth in the document(s) governing the Offering for eligibility to participate in the Offering, provided that such Employee also meets the requirements for eligibility to participate set forth in the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(q)</B> &#147;<B><I>Employee</I></B>&#148;<I> </I>means any person, including an Officer or Director, who is &#147;employed&#148; for
purposes of Section&nbsp;423(b)(4) of the Code by the Company or a Related Corporation or solely with respect to the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component, an Affiliate. However, service solely as a Director, or payment of a fee
for such services, will not cause a Director to be considered an &#147;Employee&#148; for purposes of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(r)</B>
&#147;<B><I>Employee Stock Purchase Plan</I></B>&#148;<I> </I>means a plan that grants Purchase Rights intended to be options issued under an &#147;employee stock purchase plan,&#148; as that term is defined in Section&nbsp;423(b) of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(s)</B> &#147;<B><I>Exchange Act</I></B>&#148;<I> </I>means the U.S. Securities Exchange Act of 1934, as amended and the rules and
regulations promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(t)</B> &#147;<B><I>Fair Market Value</I></B>&#148; means, as of any date, the value of the Common
Stock determined as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> If the Common Stock is listed on any established stock exchange or traded on any established
market, the Fair Market Value of a share of Common Stock will be, unless otherwise determined by the Board, the <B><U>closing sales price</U></B> for such stock as quoted on such exchange or market (or the exchange or market with the greatest volume
of trading in the Common Stock) <B><U>on the date of determination</U></B>, as reported in such source as the Board deems reliable. Unless otherwise provided by the Board, if there is no closing sales price for the Common Stock on the date of
determination, then the Fair Market Value will be the closing sales price on the last preceding date for which such quotation exists. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> In the absence of such markets for the Common Stock, the Fair Market Value will be determined by the Board in good faith in
compliance with Applicable Laws and regulations and, to the extent applicable as determined in the sole discretion of the Board, in a manner that complies with Sections 409A of the Code </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> Notwithstanding the foregoing, for any Offering that commences on the IPO Date, the Fair Market Value of the shares of Common
Stock on the Offering Date will be the price per share at which shares are first sold to the public in the Company&#146;s initial public offering as specified in the final prospectus for that initial public offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(u)</B> &#147;<B><I>Governmental</I></B><B> </B><B><I>Body</I></B>&#148; means any: (a)&nbsp;nation, state, commonwealth, province,
territory, county, municipality, district or other jurisdiction of any nature; (b)&nbsp;federal, state, local, municipal, foreign or other government; (c)&nbsp;governmental or regulatory body, or quasi-governmental body of any nature (including any
governmental division, department, administrative agency or bureau, commission, authority, instrumentality, official, ministry, fund, foundation, center, organization, unit, body or entity and any court or other tribunal, and for the avoidance of
doubt, any tax authority) or other body exercising similar powers or authority; or (d)&nbsp;self-regulatory organization (including the New York Stock Exchange, the NASDAQ Stock Market and the Financial Industry Regulatory Authority). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> &#147;<B><I>IPO Date</I></B>&#148; means the date of the underwriting agreement between the Company and the underwriter(s) managing
the initial public offering of the Common Stock, pursuant to which the Common Stock is priced for the initial public offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(w)</B> <FONT STYLE="white-space:nowrap">&#147;Non-423</FONT> Component&#148; means the
part of the Plan, which excludes the 423 Component, pursuant to which Purchase Rights that are not intended to satisfy the requirements for an Employee Stock Purchase Plan may be granted to Eligible Employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(x)</B> &#147;<B><I>Offering</I></B>&#148;<I> </I>means the grant to Eligible Employees of Purchase Rights, with the exercise of those
Purchase Rights automatically occurring at the end of one or more Purchase Periods. The terms and conditions of an Offering will generally be set forth in the &#147;<B><I>Offering Document</I></B>&#148; approved by the Board for that Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(y)</B> &#147;<B><I>Offering Date</I></B>&#148; means a date selected by the Board for an Offering to commence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(z)</B> &#147;<B><I>Officer</I></B>&#148;<B> </B>means<B> </B>a person who is an officer of the Company or a Related Corporation within the
meaning of Section&nbsp;16 of the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(aa)</B> &#147;<B><I>Participant</I></B>&#148;<I> </I>means an Eligible Employee who
holds an outstanding Purchase Right. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(bb)</B> &#147;<B><I>Plan</I></B>&#148;<I> </I>means this Acrivon Therapeutics, Inc. 2022
Employee Stock Purchase Plan, as amended from time to time, including both the 423 Component and the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(cc)</B> &#147;<B><I>Purchase Date</I></B>&#148;<I> </I>means one or more dates during an Offering selected by the Board on which Purchase
Rights will be exercised and on which purchases of shares of Common Stock will be carried out in accordance with such Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(dd)</B> &#147;<B><I>Purchase Period</I></B>&#148; means a period of time specified within an Offering, generally beginning on the Offering
Date or on the first Trading Day following a Purchase Date, and ending on a Purchase Date. An Offering may consist of one or more Purchase Periods. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ee)</B> &#147;<B><I>Purchase Right</I></B>&#148;<I> </I>means an option to purchase shares of Common Stock granted pursuant to the Plan.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ff)</B> &#147;<B><I>Related Corporation</I></B>&#148;<I> </I>means any &#147;parent corporation&#148; or &#147;subsidiary
corporation&#148; of the Company whether now or subsequently established, as those terms are defined in Sections 424(e) and (f), respectively, of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(gg)</B> &#147;<B><I>Securities Act</I></B>&#148;<I> </I>means the U.S. Securities Act of 1933, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(hh)</B> &#147;<B><I><FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items</I></B>&#148; means any income tax, social insurance,
payroll tax, fringe benefit tax, payment on account or other <FONT STYLE="white-space:nowrap">tax-related</FONT> items arising out of or in relation to a Participant&#146;s participation in the Plan, including, but not limited to, the exercise of a
Purchase Right and the receipt of shares of Common Stock or the sale or other disposition of shares of Common Stock acquired under the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> &#147;<B><I>Trading Day</I></B>&#148;<B> </B>means any day on which the exchange(s) or market(s) on which shares of Common Stock
are listed, including but not limited to the New York Stock Exchange, Nasdaq Global Select Market, the Nasdaq Global Market, the Nasdaq Capital Market or any successors thereto, is open for trading. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>9
<FILENAME>d383050dex1011.htm
<DESCRIPTION>EX-10.11
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.11</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.11 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>CRIVON</SMALL> T<SMALL>HERAPEUTICS</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N<SMALL>ON</SMALL><FONT STYLE="white-space:nowrap">-E</FONT><SMALL>MPLOYEE</SMALL> D<SMALL>IRECTOR</SMALL> C<SMALL>OMPENSATION</SMALL>
P<SMALL>OLICY</SMALL> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each member of the Board of Directors (the &#147;<B><I>Board</I></B>&#148;) of Acrivon Therapeutics, Inc. (the
&#147;<B><I>Company</I></B>&#148;) who is a <FONT STYLE="white-space:nowrap">non-employee</FONT> director of the Company (each, a &#147;<B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director</I></B>&#148;) will receive the compensation
described in this <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Policy (this &#147;<B><I>Director</I></B> <B><I>Compensation Policy</I></B>&#148;) for his or her Board service upon and following the effective date of the
execution of the underwriting agreement between the Company and the underwriter(s) managing the initial public offering of the Company&#146;s common stock (such stock, the &#147;<B><I>Common Stock</I></B>&#148; and such date, the &#147;<B><I>IPO
Date</I></B>&#148;), subject to the terms and conditions set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Director Compensation Policy may be amended or modified,
or any provision of it waived, at any time in the sole discretion of the Board. Any <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director may decline all or any portion of his or her cash or equity compensation in any period in such <FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Director&#146;s sole discretion prior to the date cash may be paid or equity awards are to be granted, as the case may be. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Annual Cash Compensation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The annual cash
compensation amounts set forth below will be payable in equal quarterly installments in arrears on or promptly following the end of each fiscal quarter in which the service occurred, prorated for any partial months of service. All annual cash fees
are vested upon payment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Commencing on the IPO Date, each <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director will be eligible
to receive the following annual cash retainers for service on the Board (as applicable): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Annual Board Service Retainer</U>: </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All Eligible Directors: $40,000 </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Lead Independent Director: $20,000 (in addition to the regular Annual Board Service Retainer)
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Annual Committee Chair Service Retainer</U>: </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Chair of the Audit Committee: $15,000 </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Chair of the Compensation Committee: $15,000 </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Chair of the Nominating and Corporate Governance Committee: $10,000 </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Annual Committee Member Service Retainer (not applicable to Committee Chairs)</U>: </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the Audit Committee: $7,500 </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the Compensation Committee: $7,500 </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the Nominating and Corporate Governance Committee: $5,000 </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Expenses </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company will reimburse each
<FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director for any ordinary and reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses actually incurred by such director in connection
with <FONT STYLE="white-space:nowrap">in-person</FONT> attendance at and participation in Board and committee meetings; provided, that such director timely submits to the Company appropriate documentation substantiating such expenses in accordance
with the Company&#146;s travel and expense policy as in effect from time to time. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Commencing on the IPO Date, each eligible <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director will be eligible to receive the equity
compensation set forth below. Equity awards will be granted under the Company&#146;s 2022 Equity Incentive Plan, as the same may be amended from time to time, or any successor plan thereto (the &#147;<B><I>Plan</I></B>&#148;). All stock options
granted under this policy will be nonstatutory stock options, with an exercise price per share equal to 100% of the Fair Market Value (as defined in the Plan) of the underlying Common Stock on the date of grant, and a term of ten years from the date
of grant (subject to earlier termination in connection with a termination of service as provided in the Plan). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;<U>Initial Option Grant</U>. On appointment to the Board, and without any further action of the Board, at the close
of business on the date of such appointment (or, if such date is not a market trading day, the first market trading day thereafter), each individual who becomes a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director after the IPO Date will
automatically be granted a stock option having an aggregate grant date fair value of $315,000 (the &#147;<B><I>Initial Option Grant</I></B>&#148;); <I>provided</I>, however, that the number of shares underlying each Initial Option Grant shall not
exceed 32,500 shares, subject to any adjustments as necessary to implement any Capitalization Adjustments (as defined in the Plan) that occur after the IPO Date. The number of shares subject to each Initial Option Grant shall be determined as set
forth under Section&nbsp;4 below. The shares subject to each Initial Option Grant will vest in substantially equal monthly installments over a three-year period such that the option is fully vested on the third anniversary of the date of grant,
subject to the <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director&#146;s Continuous Service (as defined in the Plan) through each applicable vesting date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;<U>Annual Option Grant</U>. Without any further action of the Board, at the close of business on the date of each
annual meeting of the Company&#146;s stockholders following the IPO Date (each, an &#147;<B><I>Annual Meeting</I></B>&#148;), commencing on the date of the 2024 Annual Meeting, each person who is then a
<FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director will automatically be granted a stock option having an aggregate grant date fair value of $210,000 (the &#147;<B><I>Annual Option Grant</I></B>&#148;); <I>provided</I>, however, that the
number of shares underlying each Annual Option Grant shall not exceed 20,275 shares, subject to any adjustments as necessary to implement any Capitalization Adjustments that occur after the IPO Date. The number of shares subject to each Annual
Option Grant shall be determined as set forth under Section&nbsp;4 below. The grant date fair value of the Annual Option Grant will be prorated for each individual who has been in service with the Company as a
<FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director for less than one year as of such Annual Meeting. The grant date fair value of such prorated Annual Option Grant shall be equal to $210,000 multiplied by a fraction, (i)&nbsp;in the case
of a grant made at the first Annual Meeting, the numerator of which is the number of days between commencement of service as a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director and the date of the Annual Meeting (provided, that for any <FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Director who was a director of the Company at the IPO Date such number shall be 365), and the denominator of which is 365, or (ii)&nbsp;in the case of a grant made after the first Annual Meeting, the
numerator of which is the number of days between commencement of service as a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director and the date of such Annual Meeting, and the denominator of which is 365. Each Annual Option Grant will vest
on the earlier of the first anniversary of the date of grant or the date immediately preceding the date of the following Annual Meeting, subject to the <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director&#146;s Continuous Service through
each applicable vesting date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;<U>Change in Control</U>. Notwithstanding anything herein to the contrary, for
each <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director who remains in Continuous Service with the Company until immediately prior to the occurrence of a Change in Control (as defined in the Plan), each outstanding Initial Option Grant
and Annual Option Grant will become fully vested immediately prior to the occurrence of such Change in Control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&nbsp;&nbsp;&nbsp;&nbsp;<U>Determination of Number of Shares of Common Stock Subject to Grant</U>. The number of shares of Common Stock
subject to any Initial Option Grant and Annual Option Grant made under this Director Compensation Policy will be determined using a Black-Scholes methodology as of the applicable grant date. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&nbsp;&nbsp;&nbsp;&nbsp;<U>Remaining Terms</U>. The remaining terms and conditions of each
Initial Option Grant and Annual Option Grant, including transferability, will be as set forth in the Company&#146;s Stock Option Grant Notice and Agreement pursuant to the Plan, in the form adopted from time to time by the Board or Compensation
Committee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Limit </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything herein to the contrary, the cash compensation and equity compensation that each
<FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director is eligible to receive under this Director Compensation Policy shall be subject to the limits set forth in the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>* * * * * </B></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>10
<FILENAME>d383050dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We hereby consent to the use in this Amendment No. 1 to the Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> of
Acrivon Therapeutics, Inc. of our report dated August&nbsp;12, 2022, except for the effects of the reverse stock split discussed in Note 17 to the consolidated financial statements, as to which the date is November 3, relating to the financial
statements of Acrivon Therapeutics, Inc., which appears in this Registration Statement. We also consent to the reference to us under the heading &#147;Experts&#148; in such Registration Statement. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/s/ PricewaterhouseCoopers LLP</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">November&nbsp;3, 2022</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>11
<FILENAME>d383050dexfilingfees.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<HTML><HEAD>
<TITLE>EX-FILING FEES</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 107 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Calculation of Filing Fee Tables </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT STYLE="white-space:nowrap">S-1</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Form Type) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Acrivon
Therapeutics, Inc. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Exact Name of Registrant as Specified in its Charter) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Table 1: Newly Registered Securities </U></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="99%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" STYLE="BORDER:1px solid #000000; padding-left:8pt">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Security&nbsp;&nbsp;</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Type&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Security</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Class</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Fee&nbsp;&nbsp;</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Calculation&nbsp;&nbsp;</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>or
Carry&nbsp;&nbsp;</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Forward&nbsp;&nbsp;</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Rule&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Amount&nbsp;&nbsp;</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Registered&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Proposed&nbsp;&nbsp;</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Maximum&nbsp;&nbsp;</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Offering&nbsp;&nbsp;</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Price
Per&nbsp;&nbsp;</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Unit&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Maximum&nbsp;&nbsp;</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Aggregate&nbsp;&nbsp;</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Offering&nbsp;&nbsp;</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Price(1)&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Fee&nbsp;&nbsp;</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Rate&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Amount of&nbsp;&nbsp;</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Registration&nbsp;&nbsp;</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Fee(2)&nbsp;&nbsp;</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Fees&nbsp;to&nbsp;Be&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Paid</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Equity&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Common Stock, par value $0.001 per share</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">457(a)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">6,785,000&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">$18.00</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">$122,130,000&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">0.00011020&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">$13,459</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="7" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Total Offering Amounts</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&#151;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">$13,459</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="7" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Total Fees Previously Paid</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&#151;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&#151;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">$11,020</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="7" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Total Fee Offsets</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&#151;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&#151;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&#151;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="7" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Net Fee Due</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&#151;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&#151;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">$2,439</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Estimated solely for the purpose of computing the amount of the registration fee pursuant to Rule 457(a)
under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;). Includes the aggregate offering price of 885,000 additional shares that the underwriters have the option to purchase. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Calculated pursuant to Rule 457(a) under the Securities Act based on an estimate of the proposed maximum
aggregate offering price. </P></TD></TR></TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g165750g1102102718201.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g165750g1102102718201.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  L (@# 2(  A$! Q$!_\0
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M1SCW./I4>G?%.2.]%OKNF&V4GF2,,"GU4\D?0_A2]M"]KFBR;&N'/R?*ZO\
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MK<B^*>@_:M-BUF!?WUK\DN.IC)X/X'^9H7QT#\-FOS+_ ,3)1]DZ\^;CA_\
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MY>6^@4R6&*>)HYHTDC;JKJ"#^!I]%,E.VJ*%OHFDVDHEMM+LH)!T>*W12/Q
MJ_110DD5*<IN\G<A:TMFG\YK>(R@YWE!N_.IJ**!-M[E"?0](NIC-<:7932G
MJ\ENC,?Q(JY'%'#&L<4:QQJ,*JC 'X4^BE9#<Y25FS*\2:RF@Z#=:@V"\:XC
M4_Q.>%'Y_IFN)^%FCNXN_$%UEI)F,43-U/.7;\3Q^!KL/$?ABT\3P007ES=1
MQ0L7"0,H#'IDY4].?S-:6G6$&EZ=;V-L"(8$"+GJ<=S[GK6;7-4N^AZ<:L:&
1 <8_%4>K\ET+-%%%:GE'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g383050g03a33.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383050g03a33.jpg
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MHR9"UU5EECA#5V)G_\0 ' $!  (# 0$!              $" P0%!@<(_\0
M71$  0," P((!A $ P4%!@4% 0(#$0 $!1(A$S$&%!4B05%2T3)587&1D@<7
M,U1B<H&4HJ6QLM+3U>(C-$*A)'3P%C4VP?%38V1UX256<Y7"U$-$@I;$5X2%
MUM?_V@ , P$  A$#$0 _ /Z<>G3I@Z:K+HW5]ALG3SHVP'S52'$S)PWJ6@E3
M!8E,2M^80)DYX"1-GSI3ZUO29<I]U]]U:G'7%K5E6?I&(XOBK5]<MM8GB#33
M;I0AMN]N4-H2D !"$)<"4I2! 2D  "!I7@</PG"W+*V<<PVP<<6TE2W'+*W4
MM:C)*EJ4V5*43J2HDD[S5T^J+TH?>P]//Z%M;?RUS2Y:QGQMB?S^Z_-K<Y&P
M?Q5AOS&U_*IZHO2A][#T\_H6UM_+7'+6,^-L3^?W7YM.1L'\58;\QM?RJ>J+
MTH?>P]//Z%M;?RUQRUC/C;$_G]U^;3D;!_%6&_,;7\JGJB]*'WL/3S^A;6W\
MM<<M8SXVQ/Y_=?FTY&P?Q5AOS&U_*IZHO2A][#T\_H6UM_+7'+6,^-L3^?W7
MYM.1L'\58;\QM?RJ>J+TH?>P]//Z%M;?RUQRUC/C;$_G]U^;3D;!_%6&_,;7
M\JGJB]*'WL/3S^A;6W\M<<M8SXVQ/Y_=?FTY&P?Q5AOS&U_*IZHO2A][#T\_
MH6UM_+7'+6,^-L3^?W7YM.1L'\58;\QM?RJ>J+TH?>P]//Z%M;?RUQRUC/C;
M$_G]U^;3D;!_%6&_,;7\JGJB]*'WL/3S^A;6W\M<<M8SXVQ/Y_=?FTY&P?Q5
MAOS&U_*IZHO2A][#T\_H6UM_+7'+6,^-L3^?W7YM.1L'\58;\QM?RJ>J+TH?
M>P]//Z%M;?RUQRUC/C;$_G]U^;3D;!_%6&_,;7\JGJB]*'WL/3S^A;6W\M<<
MM8SXVQ/Y_=?FTY&P?Q5AOS&U_*IZHO2A][#T\_H6UM_+7'+6,^-L3^?W7YM.
M1L'\58;\QM?RJ>J+TH?>P]//Z%M;?RUQRUC/C;$_G]U^;3D;!_%6&_,;7\JG
MJB]*'WL/3S^A;6W\M<<M8SXVQ/Y_=?FTY&P?Q5AOS&U_*IZHO2A][#T\_H6U
MM_+7'+6,^-L3^?W7YM.1L'\58;\QM?RJ>J+TH?>P]//Z%M;?RUQRUC/C;$_G
M]U^;3D;!_%6&_,;7\JGJB]*'WL/3S^A;6W\M<<M8SXVQ/Y_=?FTY&P?Q5AOS
M&U_*IZHO2A][#T\_H6UM_+7'+6,^-L3^?W7YM.1L'\58;\QM?RJ>J+TH?>P]
M//Z%M;?RUQRUC/C;$_G]U^;3D;!_%6&_,;7\JGJB]*'WL/3S^A;6W\M<<M8S
MXVQ/Y_=?FTY&P?Q5AOS&U_*IZHO2A][#T\_H6UM_+7'+6,^-L3^?W7YM.1L'
M\58;\QM?RJ>J+TH?>P]//Z%M;?RUQRUC/C;$_G]U^;3D;!_%6&_,;7\JGJB]
M*'WL/3S^A;6W\M<<M8SXVQ/Y_=?FTY&P?Q5AOS&U_*IZHO2A][#T\_H6UM_+
M7'+6,^-L3^?W7YM.1L'\58;\QM?RJ>J+TH?>P]//Z%M;?RUQRUC/C;$_G]U^
M;3D;!_%6&_,;7\JGJB]*'WL/3S^A;6W\M<<M8SXVQ/Y_=?FTY&P?Q5AOS&U_
M*IZHO2A][#T\_H6UM_+7'+6,^-L3^?W7YM.1L'\58;\QM?RJ>J+TH?>P]//Z
M%M;?RUQRUC/C;$_G]U^;3D;!_%6&_,;7\JGJB]*'WL/3S^A;6W\M<<M8SXVQ
M/Y_=?FTY&P?Q5AOS&U_*JJA6O/)P'3;59"4;HC,61^6J Q7Q59T00-O3D.9:
M7#:%1(3T]R6AU*FU1T1\O)<QE&485C..;B[GA2VV7G+C'T- 9BZMW$4MA)$A
M16I02 1K),1K6JBSX-N+#;=K@:W"<H;0Q8*65;LH0$E4ST1-9"X:E\GKKTC'
M$7[6?1I1RTN$@E%%W"F:1K)&2.<?D16Y\>$:&PI+T)R3%E1T2FVE,*?C2&DN
M9<9<2FK%[PFN4E=M=X[<(2HH*V'\0=2%@ E)4VM0"@%))23,$&((JSUCP=MU
M!#]G@K*RG,$O6]BVHI)("@E:$DI)!$@1((W@UW!>E.@4Y)K,,+J7I ,2[I$(
MSZ=%%T/2Y"3;((?,C!:;66(@IYT]$%YB2L$9(M,IF%F-(Q)6UEESS:KO^$C8
M=4Y>XVVEA2$OE=S?I#*G(R)=*E@-J7F3D"\I5(B9%63A_!]9;"+'!UEX*4R$
MVUDHNI1.938""5A,',4R$P9B*R!_I^Z&ZK.$B[1I'I0K9,\T5?!CC^MM0!YQ
ME@%%1../"8A$+'D$6@T)QN85<AMO('15HD3%,LJ2O-6\2X0O)6MF_P 9=0V4
M!Q3=U?.)07%96PM27"$EQ7-0%$%2M$R:E>&8$TI"7,/PAM3@64)7:6:%+#8S
M+* IL%00D@K@'*#)@5U6]%]!SM.SL1K3O2,YK]++DA5Y;U[IM=.Q':FJ&NOY
MLR1&0N&6B*%CW'<SO,1-2J*I6'TY;Q)Q#A$'^*F^QH7,@<7-S?;>2G,!LL^T
MDIYP&7P==VM1R=@!9XP+#!RQ!.WXK9;& <I.TR9("N:3FB=-]1(K2O)I@IGH
M\W4NAD//\(/G^!*@=!CYG@2X^*6%3?#2XC+WA"8J;#)CY'F=S-'RXLR,MV-(
M:<7G0_PK<3F;>X0K3F4G,AS$E)S(44+3*5$9D+2I"AO2I)28((K$NUX,MG*N
MWP)"H2K*MG#TG*M(4A4%(,*20I)W*201((-=LOKOR<-?(1A)ZB]$@0I-B#B$
M,:7K.B!I"7 +L-RA,V-#FP69+\0I&>9D#I+3:V9K#K;T9;K:TJS5%SPI=25M
MW&/N(2I25*0[B*TI4@E*TE25$!2""% F4D$$ BI79\&VU!#EK@:%*"5)2MBP
M2HI6)2H!202%#5) A0U$U-[#TW]%-2!RK/:]"=+=9K4%$9R;8;#JW4P4'#1,
MD,1(:Y18D"C0(Z)4N3&BQE.R$8?D2&&6LK<=;2K7:Q3'WW RSB.+O.JG*TU>
M7KCBLH*E0A#A4<J028&@!)T!K.YA6!M(+CN'84TVF,SCEG9H0F2 )4IL)$D@
M"3J2 -371)Z"Z%@M49O9C2O2:)H\B(-GL7(GKC3\"J/03*HZ!$UFQ2@S0AR(
M55,B)&R43%,SE2H^(JW<OM859&)<(7'C;HO\97<!2TEA%U?*>"D25I+0<*PI
M 2K.,LI@S$&JJPW 4-!]=AA"&2$J#RK6S2T4KC(H.%L(A>893,*D1,BNA7=+
M= =O#E[#4]3='UH 5]MUX\<KM$TN;#A&8\=R6^Z7)C14F$-;9B,NRG7)C[*6
MX[3CR\I;0I6+NW_"1A:&WKS'&7'2 VV[<7[:W"3E 0A:PI9*B  D&28&M5;P
M_@^\A;C5E@SK;<E:V[:R6A  DE:DH*4P 29(@"=U9T;TW=%)FO,VT/H3I;+5
M21!>)L68;JW4TZO/#8Z7%2"#)J*"=&N06$LO*>EHDJCM):<RMQ.&U=F)>*8^
MVZ6',1Q=#P4$%E=Y>I="S$)+:G L*,B$Q)D0-:R)PO UMAU&'84IHI*@XFSL
MU-E(F5!8;*2D09,P(.M0>NZ]\F_;S,*N5*C]$5HL))3R1P&NUK1!LR05'C/3
M)"80L9"DSI2F(D>1*>PPPYEJ,P\^O"6FEJ3L.W/"EAM3KUQC[+2(SN.NXBVV
MF2$C,M:@E,J( DB20!J16!NTX-O+2VU:X&ZXJ<K;;-@M:H!4<J4I*C !)@:
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M"3FQ<@--7G6I9M5J<4DB-@I20>97$78W:<15P22DC"[B^3BJ7 2,N& EQVU
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M:Z^!V*,1Q%%HX)2NUQ!P"5)_B,8?=/LF4D'1YMLQ,*\$R"0>=BMTNRLU7""
MI-Q9(,C,"AZ]MV7!!!WM.+$Q*9D$$ BZ6;W69%_):Q;G*S<1-/!WN8-RRYA*
M:S835@KXV<B1G'=.*<*5@M'=92KO&<-LK5CS7T9YSS;/"V1=E/\  6^Y;)7(
MG;--M.K21O',>00=QDC>*VP^V7U6P5_&0RA\IC_\-Q;C:53N\)I8(Z('74PY
M@K-3BE.*4XI3BE.*4XI3BE.*4XI3BE.*5P294:$RN3,D,1([?F]Y(DO-L,M^
M<K"$^>ZZI#:?.6I*4^<K':I6$X[<YQCDI2I1A*2HG<$@DGY!K4$@"20 -Y)@
M>DU1N^MH-4O3>QK/4K4 AV855Y[H*<J4*(^CR;^$1(I%,"2Z[%FNCW9&)C,6
M6T]$?=80W*9>CJ<:7T<-LB_?6K3[#I96ZD.)RN(S($J*<P *0H#*5 @@&008
MK3O;G8VEPXTZA+B6U%"B4JRJ.@5E)A64G, 9!(@@B148S0;#E.4XZU]RX5E.
M<87X'I%SG&>SLPKL]6[S<YQGV^SL\WM^MV>US-QAO_W>L?6QS]5K%Q=SQS>>
MKA7Z=4JT+M1B^:/T]=K79*XJT6[6%$LEC7'F#Q[#ATW6!A$LXS Q)5B$TY/D
M/K;B85G$9*L,XSG",9YAQ*R5;8A?6[#+NQ8N[AIJ4K40VV\M* 51SB$@ JWF
M)-9;&Y#]E:/.N-[1VV8<<@I2"M;25+(3/-!43 Z-U7A'DQIC*),20Q*CNXSE
MM^.ZV^RYC"LISE#K2E(7C"L93G*59[%8SC/MXSSG%*DDA0*2-X(((\X.M;@(
M(D$$'<09!^45S<BIIQ2G%*<4KP1\N CS_5B]KW/JT_6[?=^I-\W/;<#E9>4=
M)GB?]N-5Q,83FXMNTVV_R[+R>2O7WIH]K06IL?\ <H/_ *.>>2O-;I_XY^P5
MV4"$)'DJ\>:U6IQ2G%*<4K5,AU%=/50W<Q4_9QJ& :O%-NQRZV][8]2ASQI3
M4IS757!4X['>F97B5*9V+8)0^+*GP7!BZX;PP,END"4F#V4X7B;^'E[B]ZIN
MW?MV[=@6KRDJ1>MW3SC[9"8A)M6@HI2H+VK<K2$H"N8J_L&KP-;:T2MYEY;S
MQN&@I*K5=NTVRL$S)%PX4@J3EV:X22I13EXI*'*ZLW48FP8;;G3@&E!,N2&W
M%WQHEL8XZ1>KV<92A^/KE@8)>L+D9<S"T;4J[CN(3:65D*%"A@H.52B,5<2Y
M"2.+%%JV$!WJ-T5K#0.6#9O#G$\VP4#BAYR0#AZ%(U!+X5<+S%OK%N$I+A!/
M\TT3&F;FZK9C,#3ZB&7HV9XG9NBK&"$/.X;DVZP4_=^O;B'HPC'8I;AVZS #
M=9#80T_EJ>39DN,.,,/)Y&#)*KX) 5E7:8BTXL"0PT_A]TPNX7T;-A+I=7)$
MI01()%3B9 M<TC,BYL7$()@NN,WMN\AE&_GO%L-HT,*4"1 -; E!@XT-(AB\
M**2$EH,L84'364289 =/CN19L*7'=2II^+*C.NL2&7$J0ZTXM"TY2K..<Q"U
MMK0XVHH6A25H6DD*2M)"DJ21J"D@$$:@B:WE)2M*D* 4E22E22)"DJ$$$'0@
M@D$=(JDNF2=/?TS70Q.;*)S-?G=AZA65G/+DD#+&EMD6W4L(V1D.*4[((FX-
M+C%I[[JLN/RYKSJ\Y4O/.CBZ4B_=<0E*$W3=K?!"0 ELW]JQ>J;0!H$-J?4A
M Z$I %:>&E1LVT*45%A=Q:9U$E2Q9W+MHE:B9)4M+(4HG4J)-7WSF5O4XI3B
ME.*4XI3BE.*4XI3BE.*5KOLY3;&]>F:23[/1#Y3; @3WF<=TC84S7<DD!6C&
M?:Q+S10NT6&5^TKN'Y;25=CRD+ZMG)PW%TH\,(LEKZ^+)N@EP>;C#EH2-T@'
MHK0N=+W#BKP"JZ2G_P".;=2D$>4,(N1/45#IJM"X;8F^MI1K]K*Y1M05K3I?
M8&KXMY17HUQLVU'_ $E %;-K;((S+8K("AUR^4T<,09GCS%O+V^EE, UU6KM
MNS+YMH<M<-LC;7C"KYV_;MKPVQ=+#5D,JEVCQ=;27G;EVV?6O9I4VPABX1M
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M)>:0G."8*0HJT) (!(MKFE6U3BE.*4XI3BE.*4XI3BE.*4XI6J&ZJV9M.^-
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MF!TF02Q.G2A@R+YRWV-E:V[QN!:M/;1X-K:0IQY];F5M+D.%*$9 5K2V2LJ
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MO=Y%LJYYM=38-&,QP\D74C>%:9I$:IRP22)ZE B)D&10-$G0I@E(29,**LP
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MM8  [(D4ZJE MEM"XT4K(D10((I#*%9;3$*&YEYY#:]=Q10@J$2(W@D:J W
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M&1,3,UD!L@XR6;D16&;(E,P%KU^Y6Z&]74QMDZ\U>F;<!O3X0WSS>GHZ 22
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MO7O3UK'69P=:*]'NQ6UBZP<IL:V;"VQM?:]H76K$<#V,L+FV#9]UMY4@RZ7
M"'XCDZ5(?%1X2!PEV",<>AN2$A.Z9@B223J9,DD](J"HF=P!,P  )&@T '1_
MZU=O+56H2>]_Y_ M_P#%S:8\ _&/V"M1[PSYA6%YFK%3BE34![PS^'<_91S4
M>\,^85ML^ /.:S?,59:<4IQ2M8:UT9]-=0$" -?UHU#$ E:@4,@/VN\$F6?J
M#>D?J4H>]*6::N:U5\%B"7&9RY+5A1)RBT(-(;:PW0-H @)TYO2?Z22G>>@D
M^?IFKE:R9)U,] _JW]'3'R=%1:O= ?2A6I6)436I4LEN)614,?<]I[@V""%5
MRF4O<VNZK2P==O=^L8$#K\!2NH3<5>&:]"C8%(C0KI)R@!B0* /"FS1U$[MZ
ME'<%  23  4K3=KNIM%GI'3N2D3)223 $DE*3)UTW[ZZ^.@#IF5BH^-#;7,N
M4.>&G5&58NI;J5LD\(BMW36NPZR)C$#VVR,YRMUFZZBU]9*]5Y,A^O!BP)V<
M/&,231YTHV:=/",&1*UGI! \+<" 0#H")WTVB]?!$[X0D3(()\'>03)WF?-6
M13T(=+W@)XQVB6*7!EL6Z*/8G;;W)-Q3H]UV#K[:Y9K6JY5_=<U;@=LO5=!O
M--7KE=7=U[9ZZP6H3E;E2R*YC9HB(TUZ3I)!TUTU (B(.Z*;1?6.B>:G6 0)
MTYVBB#,R#!FN[$Z'^F6,%L0-Z@%2[5RI6S=?7,Q8]D[3LUNN59W',IL[8[=M
MNQ^ZD;?8S5A7KVDQ&[27-R[0!#5D37ZT8#@8J1O&S1!$3((,E1)!B9),] UF
M:;1>FNX@B D $3$ "!O.D1)DZUMCR]4IQ2G%*P=@]XI_WAO]ASF9CPS\4_:*
MQ/> ?.*A?-JM2G%*S8#W_G\ Y^TCF)[P#YQ69CPS\4_:*FO-2MJG%*I38'3I
MIC:<R_3[_2(MEE;/U;!TO>%RRU@8;,:X%F+%81@1J/!+1(X::,.VLX7'6<$T
M,MD A)BRHAQEX4)5!@I!F1,B#YO]'?OJP4H1!B#(W;]WRZ:$'0]54ZKR?_2V
MI^WRL5"\HEW>4T2.3&][;Y1,:-QMQQ.H.#9*_*QLOOZG:1NZH:=CC;/5W!!Z
M!8Y1-Z*0:C%B4:579HUT.N_G*WYLT[]^83.^9ZS4[1>FHTT'-3NRY8.FHRZ0
M9KM'N@OI>L<+$ G2;6EB3F\-6!P;N;=H6=?!>RC^;3?:SM F'V+!);3IMKL"
MY!0O3-BR[-5I#\XJW@0B.8+,S1;0>@],\Y4D'>"9D@G4@F)H'%CI'1'-28(W
M%.G-(W2(_L(SUDZ+.FJUC/1!?73R82#&R+!&]$W;8("2.-[:V!5MIWLF*F@K
M6.EBY)2_4FK6(?F ]';K3PAF#6&PPMZ7!D"V@[QU[B1O()W$=('HTIG4.GH
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M;:$7 @1K\I)/I,FJDR9,:]0 'H  'R"N6P^\6_\ >6_]-[F9CPS\4_:*PO>
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MTN)N]GZ?>F_J"H(YK2>P7J\^7W)KKJQMU@T&<=L'4948L>P"YO38+]%[$>M
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MW44Y7+,'G>B#AH/*S!*LLD!!<F*(-2AT^5&=@@*$'SB"00>L$5*5%)D=(@R
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M? 'G-9KF*LM1812ZT!LENM@<8@><O;H25;9$9^2B.<(UX6D$,,3!_?>C\G$
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M;;_ ^E^VGLD7\43^6S]'QL/A_1_=3;_ ^E^VGLD7\43^6S]'QL/A_1_=3;_
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M6'8K<9$HBU)1E@KL+%9)0IA:2I2[916";=O/FG,G;(7F1</I<TKW#V<RE@W
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M;VOM-EG#TDD7+.X;C-7-$9F/B6;G)9ALM-Q(T! T5&8:%!0T.! OK@  "WT
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M^L;1AA:V+=MM8R\Y(@P5 &-=9!(U\L:U:FV\*\<&5GM\S,25A/V/.P\WE?\
MZ]BD=O\ Z<]S@T9'^O.CT0J/L->.Q+PVNK*K[1_Z5J;O';5=T/I[96Y+6O&
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MI2,.B<OX0K-L7A"G&&CJ&E*2YAEV>)=6E] F8R:A+6.2G-?X40"C,$X3> J
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MY.[?Y*C.G=.LQ$&9\T3\NZI_6>HS2UMUW=-KB;W!CT+7"S+>P#EB'':<NE*
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MC'Z68'R8!NK6P^()1I6*.(R*@$D$ @D 2.N 3U=,'H(%72K,)T!!((!F"/+
M_MIY:VGY2K5PR/>[_P"!=_85RCGN;GQ%?=-7;]T;^.G[PJ&\Y5=6G%*FC/\
MLFOP:/V<<ZZ=P\P^RN2OPU?&5]IKS!ZN]X;G%;VUKI^J$F*%4,;/Z,C[,B-5
M[_-NF[8EKZD,#=JUJHWBOV<#4:O6-<4VK09>TP1D)>Y]DJ5TD1RX^H@) \P=
MSH2DI*B),.=(A,(YI((DDD\V"((G76,*U$* W"4ZZ\[743(   UW^C6H/!ZW
M>IJI:NTK<]JTO7;MGW[T^TK<%0K55UKM02@#>+.9T)!+:;)>/N5HFF['6 ^P
M[]9R$Q3%4E8"U]J?( PQ]4M,^7(:05* *H2LI,E.J0%G-N$>"!&N\Z[J@+5
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M9BQDR2#6KM%PJ.+LK5>0^4#C_963O.W=7#!JC9"("C!I-E)$I<9(]IW%TIS
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M0:F-X*M0)TW:Z&N<3TP0G+IJ2K-'3NYND@>72K:L/7YHJLA1Y<G&O27RQ+;
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M/J(H+5(2K<3=9#)>Q%<CR7%D03H9G0"9B28 DG*-3)TWU 0D&0.D'>>B8@3
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M>JX  B/A@;]4!7-.NN_-!/1 G2KIF5:$#F[^T1)'5.Z8&^M\^8JO7#(][O\
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MNFUBH36+9IO6\72439=>.5>7[ ;7,>L5+AB0I.S5<E?S%BIJ) 3,'*,ID<R
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M H@003$C7*J#X:2-8RN"-2?!)E1WQSOZAIT#>/)TU[6<UJS5U)_O1_\ P?\
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MU<?V9M^:[=W')%;TX/0!$UPS.1H $P9))).@S!12% +! 5HH<T::%6M5S+U
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M]" 1J -QWA15,YB>G77NK;CIDT9==8WG:ELNI=!=\G0>G32P8JR%!5=NZC]
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M&'*13'7%NNU&L.NNK4XXXX %+<<<6K*EK6M43*EK6K.5*4K.5*5G.<YSG/-
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M5X>^/OJO!OTZGM5< O$/UIC/ZC3UE=U_=I^KE3_@/'MJ\/?'WU7@WZ=3VJN
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M5X>^/OJO!OTZGM5< O$/UIC/ZC3UE=U_=I^KE3_@/'MJ\/?'WU7@WZ=3VJN
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=XKQC_&7[^TXOQG9?S-T]DR;=WP,N;-SLV5,?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g383050g05s67.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383050g05s67.jpg
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M  $% 0$!              $" P0%!@<("?_$ &D1  $# P$"!0T("@X'!@8
M!P$" P0 !1$2!B$'$Q4Q5107(D%187&1DY32T]06,E-45K'5\",D-%)S@9*A
MP=$(&"4S0D-$8W)TE;*SUF)D@H2EM.$F176CI/$U-H.UPL-EHN+C1H6F_]H
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M[OL;8UM29DN#+AWR6-+C4*.\PMM^WM<Z5S74*4W)5@B(A1;'VTHF-]H?L=.
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M+S&5ZJOG'E6U])0//(_K*CE_Q-\-INK\O$)@\VUS;+#MEBA#LB$X4XK#M/\
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MX1E:C.(<9_!BA,41-NC5I)#+U01>1J+10%&2!UDJP0\BW8; G'H2HOD6#?\
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ME&E*-*5ZU\%7_P#37[L)_)#@I_\ \BW6N(O_ /\ ..P/X?:+_P"U(KO]E/\
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MAX@83 =(JN2\B037B"M-F:.\1,+M'U]O"41S5G*S7PI(SD=,J1@0T1!1[D+
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MM<SLO<7FX[J5QN+D1G996%2%H8:96TVL.K:CN)4Z''FT%B,9#S:E@/(;R*5
M[GC9*;A_/N2<NW>I0L[CG$]NR#CFC5"P^J>7N25%XI:)PSV&W/)*.@)&F'QH
MI8I>YL(1ZRN;:S34I#Q<JPA5ZLX5D5K?NL9DS[7$M\9]QJ7.CQ)<F0UQ+<<R
MK+)O#4=*%NHD=6!IN.IU*HZF6T.+0MP/ (%?N;=8A7&5,?:;<BQ'I$9AESC5
MOABZL6QQY2TMJ9ZF+BGDMJ2\'7%(2M*"T2HMS&G<W>('*T)C63K$GC9.5R<U
MQ//QM0E;),-;+ 4+-N6EL'XWR19A1K+NO-JM/9'32AE&,1/S5UC&KUA,2E1:
M1+M)X-Z9M?:H+DQ#R)A1#5.:6^AEM3+LFVP1<ID1G+R75/-1"7 IQIN.LI4A
M#ZEI*:M1=F;C+;BK:7%"Y0B.(96ZL.MQYTPP8TEW#1;#3DD!&$.+>0%)6ME*
M2#6G1^ RXV/BEX:^&V9R'0T&G$JRK-EJ>3*HO+V&N>HN:FK3!2$BRCYB+J<R
M^GXZ5H]K@F=>=,XL)J?8-&T?(J1<JQEUJI.U$=JR7B\-Q)1-G6\R_#?2VR]U
M0VVPZE*EMK?;2TM$EAU3R5+XMI2E*1K0IL0QL^^Y=K9;'),<"YI:=9E,E;C7
M$+6\A2DI6EE:G$KCO-I;4$:W$I"5:5)69O3X!,:9^H,-?.$2SY/KQD<\S/#_
M &:N<5;.M5<R\S&8HO.8/59!V&CM7C=LW85O'=@9VVEO(=_,U:2?0 JS$@Q?
MJND-;[J9EKE.1;^S"=S:V[JR]8U//@-KG1H'$.-25)*BMV6RIB0EQ#;R$N_8
MTJ2 <X;/1;A'0_9W93>+@Y;G6[LEMG*T1)$WCFW&$J "6HS@>84A3C2E-Y6I
M*B1 UOX ,KT:K3=YL5YQ"TI::6,T\>V1.?MJ[;-<SE[%K+,="K6,HTE&]4!)
MJ6H\C'NU_")#X_BXN0?-8N4E&CQ8J>MHQM3!DOMQFHT]4@F89;):8!MS<":J
MWRGIBS)XHM-R4+2.I')2UI2I:$*2,U@/;.S&&5R''X:6!U*(SG&/$3ES(HFQ
MVHJ.(XS6MA22>J$1T)4H(4L$UT+BSN:,)"Y2<U7BFS11*=50+FJAQ4E3;RRK
ML>]XFL)RM BK3P[6C(^1Z@WJ6/9MD.0(]P%[>15DQS-/$6\%7+/)/9'K++4S
M=L7'((?LENDR'_W.E+1(C*=6FSW%N4XS=F8D.07Y;:NI5IZF2XS+;!+KS*$H
MPK8Q-F&VY9:NLZ.RS]O1T*8?#2572"N.AVVNR93 9CK'5"3U04.QEJ ;;=4I
M64TF^Y494FK;$T>BQLG2K*M;\V0\Y%9@GF,G*0L=CC*.*\6P356&Q#6+I(2,
MFO/96KZ<O-5<EIJZD2X/=5G=9J$;)R"1K;B$VPN3*6B2R&+<XVNWM*0AQ<N%
M-FNJ#D]^.A"$M072AMXLO!P",$O2%H23FR4M;R6(Z5,.EZ<A:)CB5K2F-*B1
M$#BX;3ZE++DMO6MH.M%L\>5-,I4H1+-=S0S?$1;&5;7C#UE!\ZJ:B<;4YF^S
M\UZEKOF.[X(K-Z;1#/'(O9BO2N0Z#,L&D;7DI>[NF;J*=M:@N+Q1%OG-;8VU
MQ:D&-<&=*7^S?;BM-\=&M\:YO1BXJ9I;=1$E-J4MTMQDJ2L*D )!5AN;+ST)
M2H/PG=1:[%E<AQSBGYC\!I\($;4MM<B.M(2V%OD%)#))(#G?]RURW#&>1,]E
M7#L/<'F<.&O!M$K[I;(P-[_-<4-$4R#C^6CI$V/2/*XU[QKQRSMA<X2OR+8&
M]G2E$8B1A8B-M%E.VT!S2XU!N#D=-MN]RE.A,35$;LLKJ64A:!**75<8%A*H
M[KJ3EDH*T..+9N*V4F(RAR7"0\J=;(,=LF3B0NZQS(CK2HQ@IH<64DI>;;4,
M.A80IM"78V9]SUS":B263)Z[89I=(AZ4VO<G/6^Z2L6W:Q#_ #!EC!D8T*DC
M5WKEY,RF0L/6-@RC8]%VJ=A)0$DJ9%LO*C#YBMK+>)*(;4:XR9+D@QD-1X[;
MBBXF!!N2U$E](2VB+<&5*6HI 6AU RH-\9CC9R;U.N4Y(@L,(92^MQY]: $*
MF2X"1N942M4F&ZD)2"2E3:N8JT-[-'!!E3ASMF,:SEQ]5$7-^M;2I2L75YIT
M^GZ9.$3J;V7@YYE+0\451XRCKA'=5L%=&RT:3DF\O%Q-HDI& FVC&[;]I8-V
M8G/0$OD1&%/H6^VE+4AL\>EMUI2'%D)4N.O+3W$R4(+;BV4(=:4JU-L4NVO1
M&IBF@9#P96EI94XPX.)*VW$K0CLDI>3AQOC6%+"T)=4IM:4]Q\47<N<24[)D
MUBOASXBJG)W+&Y,ZS>9H++F2*%((T#'&&IBH12>0I^Q8PC7[6HN[ -DDC*8P
MM$2WOD8%<>@9NY>.&D>KS=EVUGR(;<Z[VE]$>8;8U;W8$24DRI=P;?<,1IF8
MM*GTM<4@":RX8R^-3@A(4L;VZ[*PV)2XEMN3*WXPGN36YDF.H1XT);21(<=B
MI4EE3G&+^U'D"0GBSN)*4GF5'N8?$(X94&22L>(187Z$5NC9X>W32#>"QB%$
MOF46F5)51Q4T@E*4]QQCFQ7 0I/JNM$.P6KT=9:S!V&SP$+(;@[:6D*E(+,\
M+BN".4<0T5.3.JHL)4) #YT243);4?[8XAAQ:7ELO.M,.N(U8V6N)3'6'893
M(1QP5QS@#<7J>1+3*62R IE4:,X]ACCG6TEM+K3;CK:%2[D/N7SENPCU,47J
M,GF",+CZU6G)MNL!H;&\%3Y+@PI/%9D6WJ,2T=M=PK,$E8)08%?O,O9GT&6(
MBEJ>K8U'!AP8FV@*U=71EM*+DIEB&PT')CDA&T4FQQ(^HR51B\Z64%T<8&4.
M<8L2 R$BLV3LJ0E/4<A+B0B.Z]*><*(S;"K*S=I#Q2(X?XIL.+T'075-Z$EC
MC,U%58X 4GU"KN0%<R4"](77%W%WD6KU;'SJY1TTYA>&*G7Z4]69).XXW9P[
MZKR5AHZJ3V!<C VY:+DX1%D@V?2,LM5LU_:HHE/11;I48QYMAB//RQ'6V'+S
M(C(ZG+<>6IQ+R&I *71QL<.(=*B4H;#^(UL[JC-R3-CR _$O$EEJ,7TK4BUL
MR%<<%O1DH4TMQ@A39+;VE;8 "E+XJR4[F#GN#<V4DU<<-1<=CX,K,<KSJ]GM
M:T5BFUX2K-,N&2Z-; 945W)R=FK]<O<%()*4*-NE:FE D(R"L4G+,%F&I1MI
M:W R6XUQ6N7U"J"T&6 Y.8N+TB/#DL:Y24(9=>BNI(E+CO-C0MUI"%A50K9:
MX(+FM^"E,?JM,MPNO%$1Z"TR])8>Q'*E.MM/MJ!CI>:7V26W5*3IKC'-.([9
M@;*U[P[>ABCVS'M@=UV96@WPR<*[7; 11%_$OSH-57,=(-5F[UDHX:,W?5W"
M97;-HY*JW2Z&W3V+I!BW"+KXB6TEUL.IT.)!R"EQ.5 +0H%*@%*3D'2I2<$Z
M2=#>M\N1"D:..C.%M9;5J0HC!"D*(22E22%))2DX(RD'($8:S:Q:-*4:4HTI
M1I2C2E&E*-*4:4HTI1I2C2E&E*-*4:4HTI1I2C2E>@/<[^Z$9F[GYF5K=L>G
M<6>B6=S'QN4L1NG:R4)D"$26,1(S8"D<!$W*)*X75JUE;-5G+%RLJQ>(2,)(
MRL2^Y;:S96W[4V]4:4 S*9"UPIZ4@N17",G5O&N.O #S)("@ I)0XA"T]#LY
MM%-V>FI?CY=CNE*)4,J(1(1G T\^A]&26G "03I4%(4I!_2)QI;B7^NQ5Y2K
M]FJB=QKU7LQ*Q=(@\!;Z\6<KL7)!"VB$546/$S\8#GJ<M'F65%H^170!50"
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M]7,!DGG[0WGO5M]\9#Z>>>^5_P#;TXEKX)O\A/ZJ<<[\*Y^6K]=-RVY B*)
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M A[0@)]A#Z^G$M?!-_D)_53C73SN.'_;5^NNF7+]W'8S:/V2YD';>N0QT5P
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MWS*:HD4SV]_B/S8S5O?5CRB;I5-@*)]^K.OF0256$0#H=Q'HT%1  #<1*!
M3G(4RF1]0:O[Y,Q-R=(?FYP)MU=R <PK%0 -Q2VVZ4Y2\V_* ")Q'D Q@4S]
M0"?FJSOLQY>?I5.7DZ3?JKK?DZ$%]^7H.;?HAYN7;FW]9MS^MTID=_\ $"?F
M%(4DZ0<22!43&,*4=* <!35)L(.6Z(["H0H&^6(*AZT1#8H'#UAR&-/:/A'S
M&G;'@/SBHQN7]3J&_E$Z^_SVM]L_]W._U17^)'K1WS[A:_K*?\-^H3UV-<I1
MI2C2E&E*-*4:4HTI1I2C2E."I_LHKW\=1G^>(ZQ)_P!PS/ZL_P#X:JR87W9$
M_K+'^*BNJ&?SXG/X9G_-[37G9YD^#])KOASJ\/Z!7Y,MU_9E;?Y33W\ZN]?<
M,?[G8_ M?W$U\32/NA_\,[_?539U>JS1I2C2E&E*-*4:4KZFOS-+^L^/+^3O
M#M_I'E#7D7"A]V[*?A;S_P M$KUK@R^X]J?P=F_YF57K#Q0T[ DS=K6_R7ZM
MYRR26"B0R[.G42V9 0Q=3V$I?@)E>8BJVPDV*#WK=EFV]9[[LGDTX6K4R[I3
M!RK#V5PP\WD(94M9<UJ46=.$(4OBT@N8=(2#@Y4H)R,G2= .%$>EQUOA* WH
M"4OZAK<0V75D-_8DE922,)&O!"0%I"R-2 8:-PI84=MWB!N*.D-I/(E4L9XJ
M;AD*%!6 :D4S6RS$E0%&-F3;P\0>:@K?;[V->CR5J1?/7SM*,KB,*[%U:ZG:
M.1U2C+B58*0@*T[E$HPK [)*UK*1I))("<'-T270<]3+(;4C*27%#7[T!S*2
M5'"D(0%'4!@942,.I7"F 9>8*TCN)BNQ](A;6WOCRA!)UEM NV$+9;[?5(Z+
M7<3+6+=XS+#9Y1K<X2-CI*$$C" :*R3-ZS?18U%IE1W2$A"5\8492$D!;B\
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M!A'V-<&7'&KN\XT@..)F22E!.D*.MP$$Y&, D\_:KM%(:7:&T/N%II42.%N
M%12-+>"  2<G YNW46>I"B?OM>_:U;\%UNN5+CS=0M^5'SZL5S_45HZ1<\@O
MU=8AJ%"$1'U7O0W_ +F+^U_@NIY4N.,]0M>63\VO-5"+:4C_ .(KP.ZPOT*L
M&I8_#_CB][/+^EBX]O\ B:^3_P#[?3E2Y;OM!O?S?91VO]JJ%1+/DDW)P'\
MOYN+S6$:ECP/+<WWVK<?@FKG*UTZ/:\J/3J@QK+S&YN#(^+N>JK54JF-@#UU
MV?E#??YU.A]OVF6I%UNA_P"[VO+ ?G*Z@L60<]S<W?ZN[ZJM8]9Q@ "!KT_
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M^$"*9.4$USJ!;,1DE15K5K)*M2R2<J:61G<2,LM@9)PD:0<&K@F/)" G0G0
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M@D]@_3!MOL "/>\VPFZ- HCMUWL 52.% #?L*NFGN/0"=55=5%&2W['[?;_
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MSM(Y';VG"0;_ *'$5U/Q_7=]?QTASZ,@#5KS/6X_IFPVV8F#8>F7V$?T6.X
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M=OKFP^7KG[4CHOUW"1O['$%U/K]?KW?Q4Z"3VVZ^VWV'M[WFVW%-<H#MUWR
MJ=NH(;]I45$]PZ<#I*C?W>UNW?G/U%7=#(\V_7F_+S@/+U$=^3IDS"3FZWY1
M1*HES\O8=0JO*()BF=4U;T$IRB'?!MS\FP&[W&V!3H1+S\O7?F>GV5Y.;Y@!
M1Y]QZ4%-_:^;/Z12')$<%DD!7736*:.E!3 B HBF7K#8P 8165Z003,DF([$
MW,F938.DY$Y[1\(^951VQX#\XJ,+E_4ZAOY1.OO\]K?;/_=SO]45_B1ZT=\^
MX6OZRG_#?J$]=C7*4:4HTI1I2C2E&E*-*4:4HTI3@J?[**]_'49_GB.L2?\
M<,S^K/\ ^&JLF%]V1/ZRQ_BHKJAG\^)S^&9_S>TUYV>9/@_2:[X<ZO#^@5^3
M+=?V96W^4T]_.KO7W#'^YV/P+7]Q-?$TC[H?_#._WU4V=7JLT:4HTI1I2C2E
M&E*^KC\R_##A(\<8S_+WH]3_  ^]<YP7$NW?G*_0[@U 5_UQT.W1^SL)O6<V
MO&.%WJC7LSU)GJCC+MQ>-&?WJ%JQK['WFKG_ !;\5[)P2]3Z=I.JL<1Q=JXS
M.K'[[-T^\[+W^GF[?/NS7U?<V&?::_\ 4G_]G7D7_:/^<_\ 2UZWG9__ $/%
M*_51S89]IK_U)_\ V=/^T?\ .?\ I:9V?_T/%*_51S89]IK_ -2?_P!G3_M'
M_.?^EIG9_P#T/%*_51S89]IK_P!2?_V=/^T?\Y_Z6F=G_P#0\4K]5'-AGVFO
M_4G_ /9T_P"T?\Y_Z6F=G_\ 0\4K]5'-AGVFO_4G_P#9T_[1_P Y_P"EIG9_
M_0\4K]5'-AGVFO\ U)__ &=/^T?\Y_Z6F=G_ /0\4K]5'-AGVFO_ %)__9T_
M[1_SG_I:9V?_ -#Q2OU5IR!L1]37ZD#;K71FZ'8DYOS\H\NW2%Y/+M\UV>WV
M:?\ :/\ G/\ TM038,'&C/:W2OTBI7@5FS>L0:RBJ2#4D+%B*JQRII$(+-N!
M1,=42@4!$2@ F$.T0#RCK0N)?7(<2M*ER"ZX'$@:E%W4KC!A ()U:LZ1CN;J
MWC:F4QVE)*4L!ILH*CI2&]*=&2O! QC&K?W=];(SD%[,O$[?5D&?PVJNI)?Q
M:1Y%ST:IZIB_#Q_*M^E5._<#^Z\1[_9?"ZCJ63\7?\BYZ-3U5&^,,>6;]*J=
M^X#]UX?[8,OAM2(LH<T>1O[C3F__ /EIU3%//(8/_P!5OTJ._E?_ '8A_M@R
M^&U/4LSXO)\B[Z-1U3$^'C^5;]*J=_J\'EF88/\ I%C\-J.I)?Q:1Y%ST:=4
M1/AX_E6_2JG?^N_NU"_;%C\-IU)+^+2/(N>C4=4Q/C$;RK7I5:,_6_*,W!_7
M&28?#:=22_BTCR+GHTZIB?&(WE6O2JGJ@K(>6<@@_P"DH_X?4B',YQ%D^$,.
M^C3JJ'\8C>6:]*J>J*KAY9V!#_I./^'U/4<WXK*\@]Z-1U7"^,Q?+->E5/5'
M5OW>K_VTCOA]3U'.^*R_(/>C3JN%\9B^6:]*HX?SM<,#<"S,*(!<VZP@$@Q$
M 0";*H980!;L2!/<XJ?, 3UPCR]NI,*?G(B2_>C>&'N8#!_@<W./'5 E0L$=
M4Q??;AQS7-D<W9<W/^>I"&SU /+8:V'UY:,#_P"HTZBGGFB3#_N[WH5/5=O^
M,P_+,>E5@VFF!Y;%6 ^O+Q0?Y7&G4-P/-#F'_=W_ $*=5V_XS#\LQZ56C:Z2
M'ELM6#Z\S$A_]3J>H+C\2F^;/^A3JRW_ !J'Y=CTJL&WT4/+:*F'UYN'#_*Y
MU/)]R^(SO-G_ $*CJRW?&H7EV/3JI;K1D]^6VU,F^V_+/0Y=]O)OL[#?;?LW
M]OZNG)MR/\@G'_=9!_\ UT$^W#FFPAX)+ ^9='J[H_[\JIZ11'X9IR9<NCIW
MFDCU=.4K=\?A>=,>LJT;]1 \MUJ0?7L<.'_UFIY*NG1L_P SD>KJ.4[;TA!\
M[C^LJ@Y!H0>6[U /KV6&_#=3R3=#S6VX'_<Y'JZ<J6SI&#YW']95HY"H >6\
M4\/KV:%#_P"MTY)NO1EP\RD^KJ.5;7TE \\C^LJWPBX^#RWJFA_[SPGX=IR1
M=3S6RX'_ '*3ZJG*MKZ2@>>1_65HR61L>FCGY2WNFF,9DZ*4H6>$$QC"@H %
M* /MQ$1[  .T1[ U/)%VZ+N/F4GU5.5;7TE \\C^LIHL<A4$D]#J'O%/*F2$
M<)G4-984I"*"+?8ACB] I3CL.Q1$##L.P=@Z<CW;HNX^92?55;%VM61^Z=O]
MX!]VQN?N?OE/CPEXX#RY I/I7!?A^IY&NYYK5<C_ +C*]557*]IZ4MWGL;UM
M4\)N-_.#2/2N!_#].1KOT5<O,97JJ<L6GI2W>>QO6U3PG8V\X5']+('\/TY&
MO'15R\QE>JIRQ:.;E2W9[G5T;UM'A.QKYPJ/Z60'QAIR->.B;EYC*]54<LVC
MI6V^?1?6THQ5WIDZ[*PA+=6)E^<AU",HJ?BI!V9-(.910K9H[66,1,OKCF @
ME(':80#5I^VW&*@NR8$V.T" 7'XK[* 5'"05N-I2"3N SDGFJ\Q<;?)<#4:?
M#D.D%0;8E,.N%*??$(;6I1 [9 P.W3GUA5F4:4HTI1I2C2E(-A_6K3^-(_[^
M&I'/^)7S&J5?P?Z0_32=6_GG8_\ "6?WI?44'OE?[/S4[]*JHTI1I2C2E&E*
M-*4:4HTI1I2C2E-F9^>+3^+9/[XRU/:/A'S*J.V/ ?G344W+^IU#?RB=??Y[
M6^V?^[G?ZHK_ !(]:.^?<+7]93_AOU">NQKE*-*4:4HTI1I2C2E&E*-*4:4I
MP5/]E%>_CJ,_SQ'6)/\ N&9_5G_\-59,+[LB?UEC_%175#/Y\3G\,S_F]IKS
ML\R?!^DUWPYU>'] K\F6Z_LRMO\ *:>_G5WK[AC_ '.Q^!:_N)KXFD?=#_X9
MW^^JFSJ]5FC2E&E*-*4:4HTI7U-?F:7]9\>7\G>';_2/*&O(N%#[MV4_"WG_
M ):)7K7!E]Q[4_@[-_S,JOI>W#R;]OM:X2N^HTI1I2C2E&E*-P'?80'8=A^H
M.P#L/M#L(#]80'V=*4:4HTI1I2NF9;^I0E_)J%^]L-<5'_\ CROZ[*_O/5UT
MK_X$/ZG&^9JN9M=K7$UA/\T/^+_(&E7D>]'X_G-6Z5;7[X_B^85KZR*H5S'P
M'YJU#^0/K_ZATJ:P'^9'_%_E#5S^+^OWU*US_,C_ (O\H:J1[T?C^<TI/5]G
M^^'_ %ZJJR?X7](?_E2<?R!]?_4.LBK"N=7@'SIJ/\FV.?J5 MEAJ=8>72V1
ML,\/5*FQ(H*MBLZZ8M:]$KKI@)8Z.>S"[)&6F7)DF$%%F>3,DX;1[%RX3A:U
MMMN+;07' @Z$#/9K. A)(Y@5$!2CN2G*B0 34-(0X^A#BPVVH ..$@!",Y6K
M?SD)!*4C)4K"0"2!7"U6R!Q&*+5:N9N<YGQTM5HE>#E+9B["L+?5<K7AE/J'
M3E+*%?H68Z]4*Y)X\>4:<.>JHP\"6[SV1JJA<6JF/>HFQ&W9?8(DE]LH&DN,
M1TN%]P+.]>EM]#:%,EI1*-*0XIY'&#BL'.>:B#C%QQ'>+B@H-OR%-<0V4>]0
M%.QUN*2Z'$_9"I7%I966SQN:WL)9 XCR5&[-,[UK)2DN[3+8(&TUNKU1X[I]
M/E*:[<$?$CT*?774Q98ZTPDVP1QE#XURG>()ZK7SRWJW@+/#/#9$9V8$.B4A
MXJ(UH<0AL\6VILD' ;05.!:5#B$LONH.C4'$K23B2V87&-&(MC2.P6VXXX X
MXEP93J+BPE"D*22^I]AI8UA/%K0H5S6^SEQN!6.]SG'U\:RQJ7CD[*T1U&FU
M)$%U\E5TE[M\XBGP[V9FFX?TB3?0<'$P^/5<A0+B$F+G9N&..C)IFA2;/55U
MT%)9="N*9/&!I6K)?;#KJAU&X 5,J*4H2SQR"E;KD$)4D-91B6O7JXYDHXU[
M4VIU." PX66DGJQLX#J4J4I3P97J2TW.)22[+%XL'&7(5&DOJ(M&0=A<<+AK
M#?FEJQZJZ6:Y;>1<6NZ4KC.,ZXBGD*%?I/FT1C^1>O*N^-(.>^17)8MJ#K.<
M7<U-L*9*4.&WE;H<9R1((!.@)R..2=02RHEM1/9>]&<%M%K"W@\"M N 0T6W
M\9C!S"0LJP>)6""I\)#B=(QC4<8UN(?B"3;R+=MPZ3DD\@W$TF[6=(7>..]9
MUNMY1ER= *E ;1<G+7M6@5=&MGJ3ZPP<2^R=$PLX[1F8QE'V?(3-FC4!!6I3
M97G/&IU)0W)6,?8=*EO<0V$<4I:$*D(0LA:0ERT84(Z29J4A801CBE84MV,C
M?]G*DI9XYPN!T(6M,=2T H45-M*X<0/$E()S475L&R]>5"*L964\YKN0YAPT
MM3=&2[PU7JJ^/48MRX3[V$>S%U9C.XR>(RS*,K5GF)(H"XN+G3U%:&H:VSH7
MA9;?60Z,Z&P"P$9!2%*>'&1B%A#;BU<]M,&W@(4[,0L:V\H#C" 6SC6[D/E8
M'980R=$@%"E.-H2=RJPSUGZ4M4G4?%[?12[-VUBFUDF!N3>IR1QLD% NK4UF
M&U.=LR5\Z4A.RJ4,Z=M["U85M!\H5W#V%.7B,I$Z>IXLBWE*DD(#JR\&5=FA
MLNA:62.+[):]!4' EO4<H<UHPG($!+8>Y02H$%2FT<274_8EN!DH+P5QG8MH
M+@26RIPI&%MZ%QTMQ=93)*V6)=8+>Q:M9@I.RO%+.%WJ+0T&G"V"<8V%[+R]
M'-!5NN-#0@PTI*663C"O'A)0T&F]F(I>JFE%WE:W$F I!:;6XKC>/924<6XX
M'%.+8XMII.@H6IQ2=2@OB]2T%JBK1%+;2A."@ZZEL<5Q#R@X7$-J:2VA_C'7
M#QFM*6DJTITZR$+#U==4>>F+33ZY9IZO.*E)V"-2F5:P^5!63@6TEN\CHJ:$
MI"I)3[*-6:(3[5N9=HSF2/FC-V]:HHO%]^PXMUEMUQLLK<2%EI1RML*WI0OM
M!Q*2 X!D)7J"2H $\U(;0R^ZTVX'D-J* ZD82X4]BM:-YRV5A1;)P5(TD@$D
M!?7^8#^]#_(.LH>^'])?S"L5?H__ )4DK^Q_B_UZR$>E_P#C5E7\'^D/TTD+
M^0OUQ_R:R&^W^+]-#_"_HC_\JTS^0/K_ .H=7*M_PD_[/S"D]3YHWUO_ ,>K
MPYD?B_NFJ%<Q\!^:M4_E_P 8_P"0NJJMIYE^#]!K$?YD?\7^4-*M'WR?]KYJ
MUS_,C_B_RAJI'OA^/YC5I7.?"?GIQ4H]M3ME?/1!E N 2C;U/=Y@.,D,D8_*
MB5L4@#S<^YBK$4 6YVXJE= +<50'$N0@*B2Q=.)Y/+"^J^J,!D,A.5%9/-C<
M4D=D%Z='9Z:R[>9J9L4VTO">'D=2]3Y+W'$X2$ <^=X4""DI*@L%!57T0U$]
MW]2M<&XMX,;<:*;#92QCIPG')R?,@"P,_P!"N .'0F746 IRH%>)@@V.HT5!
MRC\FW$01.EBVE\P..7U(9  >+.>QU@'\G/9:,%8"\BOJBWF<844W(,B<64=5
M".260]CLM&1^4 2D+R$$HPJE[I);;]:1W-RCV=\7(!S]$L(!OWK$>45@0((\
MHB"2BRH%$Z)$5L*LO?WO'_TJ[GD^8-VK#EYP 1Z\XYNCZ4H"8"][MN<$!.H!
M.;E%4I4N<"&%8BIW_4_]/#]3NMZ27Y=^J1O/R;\O?%UR])T(#R\W>O?DZQNG
MS\G-T( MT?./0 IO^I_Z5=SR?,(=58<G.( /7G'-T?2J !A+WNVYQ0!)02<W
M*"IE$N<2)E645&_O>/\ Z4@SQY,6C7I&K H]\8\0 CYP<!4YFX\HB:.3V)TI
MG).?83=&D@IT?,NHDVD<_P"(_,:A7:_I#'_6M"O'D0DK#R-V1AZTTY@,\7*
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M,4#=ZP$2 N*J8&Y0$4B)JB0#J&135&_O>/\ Z5=TDIO^M6&VX[#U]QN)>D6
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M1NN%JK:;O+/#*/#ECZZUSK2GA*Z@U5N#F8=.*U*P5?=Q%I<URI4QH#L0I6'
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M:<BV<\]IMI_W"+ZJM"2Q7C D>_.7'%"*<C-T8ABT^O%,4Q4#B4Q3!' )3%$
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M0LQ6%*:;)TAZ0LAJ,QGM<=(6TUG^#KSVJSK+;%WBZPK:@E/5+R4NN)&HLQT
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M"=*G IE.A9 +86X$#*@4L=WW(6.]4\'8H9^G )0DDO(H0\:VIJ3-LNKD)ED
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M3O3&["'4D-A 2[<G9RF371$/+Y!2<KD'_DJG#V=*G&['XJN[UQ_,!^J(\P'
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M_>Z<9N//"Q1$!C+_ +@&_9!P_M[?OC#V=5=;#:/=]FM>_F^V7_#\4[E3UR+
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M>X;E#.(KI[O<322YP5F4J8J&QC=2D3 QSF- 2 %(0I1,8QA%'8"E !$1'L
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MD%5$525V&$BJ1S)J$$6[,!$IR"4Q1$!$-P$.P1#R#K@RE*KL^E20I)ERLI4
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M ;:_70.T?):9P/;_ +?U7R=;_B,/S9CT*QS?;Y@_NS=>8_\ >,OUU:)\EY'
M.S(%V#M_?7._5_M_5Q%MMQ!S A'?\58[W\W5M5^OF2.6;MCN<HS.Y^&K:B\P
MY0A)-A*M;Y:UUV#@CA-"1GI618+B00W1>,7CM9LZ;JE$R:J*J9BF(8=A*8"F
M"'K1;'FEM*@Q4I6DI*FV&FW$YYE(6A 4E0.\$'G&_(R*HB[3[01)#4EN\7%:
MV5A80_,D/LKQSH=9=<4VXA0R%)4#D'=@X(];\89!6O\ 1X&UOH&3@W,JF)%&
M9V;E9!11)1- SY@J0BAS1+LZ@+,UW()&%$%1,*B2!G)_*+I"3;YKT5+R'TMG
M<M)W@'>$. ;DNH&Y:02 >YG ^F-G;NN^6B)<G(CL-;Z3J:<!"5%)P76">R7'
M<.5-+4 2G=V0 6I]=]$.0#]!);"0#[=ZI(#["D1;82"UYP/RJ 42" '!4#H"
M4%DSD+KZW0.>[^,'_P!JN[Y([B'02&X&$OSM?[;@JLB(@8&_+RB9 Y@/ORBD
M=%8!%)=$YU,^'Q&J!)H"&_02/DW[8N1W[2-S^3JV^^SD@"&W8<CA/YMLX*FJ
M<_7!^OU[QJO?)#M^42'9_<R0'Z9\FS8=_P!:J>3?YMM]-MNE5&?#XC6E)2*)
MHZ0+T+\!%DZ#<8U^!0W333W$PM^4 YG)!$1$  A'"@_*VS@R2F?#XOKW?K@T
MT&,@D6?AC"B^$"P+O<"Q[TYAY")*CRD*@)C;E2,4O* \ZIDD2<RJR1#SCP>,
M52-Q']#M9_5]?%3][XH\W+T+_?G!/?O:_P"7<5BH[\W5^7DYC@85!'D!$#+B
M;H2'.6*JSX?%]?KSU9WT0Y>?H)+;DZ3;O5)<VW0]/MR=5Y^?E];T?+S]-\HY
M>F]9I3/A\1J_OBCS<O0O]P,)-^]K_EW!51$1Y@;\HEYDS& X#R"D*:P&%)1,
MYE,^'Q'NX^O>W\U6]]$! !Z"1V$H&[8N1 =A215V$.K;\W*N0HEVY@5*LB(
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ME;!VB+;L[72?E]@CD0[&KD4E"<=W\5($BZ3<R+8")N2<L9(B/6&CEL @95H
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M9P5(U@* TJRDJ2>I4DDT4TT44R)(I$(DDDD0J::2:90*1-,A0 I"$* %(0H
M4I0      US)))))))))).22=Y))WDD[R3SUZ&E*4I"4@)2D!*4I "4I P
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M<X/4-NP=/.0>H]X&-Y'-0IW<WNL2(\JW$T]2-UA1GRJ80P"0>MI<G2M=C8E
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MM^A#C@6I"%JZCPE2TM.%*3@D(41[TTE?)R^ZR=8%KXS+[K0)=.+;P'X"ZP"
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M]FVO2XVK*5I2H8IL+=W1[J\VY.L<3SIOT@&%/IL)</Z72 0PD.).?$Q>8"G
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M^BC3K9;$]"_\0NGMM/=YM9TL?,K=['1\G;[JK[J8_P!QCA\_HHTZV6Q/0O\
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M4\_7=7(SZE]6.-K?;BL\8@N!UIQ#A0F'+_>%]DU9[@R[U"]$:*$$(BN/,1F
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M2$O1W7 V8H.@D;07@.-..V6=(XIVUNH2]U2X$.6^W2(#[K>N*H(?FKD=5%X
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M0[ W#?RAJ.5[2.>Z6X?[[&];3DRY'FM\X_[H_P"KH3X<^(14@*)8(S*J01,
M'3QA=SD$2F$I@ Q8,0$2F 2FV'L, @/: AJ>5K5TG;_/8WK:<FW'XA-\U?\
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MZEG4$E:L;D-I.I:B!E*=2T^W]4JHU.JUVK-IV:D$Z]&M8T)2460?24D1L0I
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M(U/*25'&4AI6E)<*1-!_('U_]0ZS:Y]?OC^+YA7M-2GCAAA"CO&BG0N$,?U
MR2G*0_(88>,*(\BA3D-ZTPAL8HAV^3?;7CTIM#M[F-K&I"ITO(R1G#CI&\$'
MG YC7U3;'7&=D[4ZTK2XBS6PI5@'&8T<'<H$'<2-X_/37]6]H_=0?><?^"ZS
M>H(GP7_F.^G6MY6N'Q@^39]76(;U:OW5'R!_8<?[(!_:FH$"(0/L7:'\8[Z=
M4JN]Q )$D^39[OX.M4;];0YOTV'LY=OT%&^SY?[#U<%NAG3]AY]6?LCO:YOX
M=4*O%R!($D^29[GX.L!\@V\![)<?)](QOU?[3U7R;"^!_P#,=]95I=ZN8.Z4
M>;X)CO\ \U4<9.X@;)C*E3-VDWSY\QA>]O3M(]A"=;5[Y2S&(2Z+K+9%'UBS
M]-13G4+\J(?EYC\I1@VZ"E*E%@X ',X[G>H#X0=VC=XNSKG%HE@*(R"IE@@8
M"E'^)/.$X&[GKG2_\?\ +8SELF.+E%6B,QKBBY0]"MV4&B%-DHZ,L,WC:EY*
M8&7JZ)RVU:'<M+W7ZXD_B8J7=%L;L =1K6!2>3K2GJ.WIUE<96AM00I8==("
MBD+!*0YJP0I*00"=7: WU6FYWIQ+ :GH+S[:G$,F/'!4E+SC)PLL:-0+:EX4
MI(*.8E6$G8+QRVYC5K[8+2PDJ_-45.F*.L>,)O$EKOQG&27"#''\!+1$#-.&
M-5LMFE';*,:)V.48U<RKLC]I;GL*UDY1A<$&WX45Q2"@)R@/+*\K'8)(2]N4
MI6!V1"<[]1&2,9=WO7&,H;N(6ET.?9C$;;9^PY+RTJ5%RMM"05$MI*P!CBPH
MI2JR5XYYBD,E39CG5L32[1BI+R4?(,H2V1L3 G.X1B9R9LM1A96%KS.R/F<C
M!5A&SKP3^SV:)DX&LM)EZ@CUFZ+=;4I!=C%LXR<O/J &_"E*2X4I"L$)"BDJ
M4"E()Y\15ZVA<4!$G&0DJT)*8T1"E+W%2$-NLI6X6P0MPMA8;;4EQPH!.&'*
M]TK@(^8C(HN0;"<CJ5D(R9?JXOFX]M4BQOJQ0=REF3E*.T=1M?92U N$)-V)
M5 (*KR5?EDK-(Q!&+@Y*S LX('4ZN<A1*Y8T8U[U96"$@H6%*]ZDI.HC!JUR
MOM64K4)J1A&IM.BVJ+NKBBE+>&R%.%+[2T-YXQQ+B>+2HD5:W[I%!/&K5UX5
MWS'K3>M+&(XH"[ANS]5+&MR# 7$Q&5*1KJK9BWN-5]4,JQF'D)63V.#+/2<>
M$O'&<WDVVR'&IC&2G.79>!JTD=D'"D@!:-2@2$ZDZB-0SBN7O:])($S('&#<
MU;026E.I5A"V4N9467>+04!;O%KXM*BA0#6;]T-@YA9JDCDF5:INE6]A8+RF
M/WD891J:<<1RMG>1[VJ(S$#4XR90:)2-OLT;#4UL:8A!&8.C*M>DO-VVQKP#
M'.#@@J7+3V&=)4<N!24)( +B@E *DC5V0K$=ONV38)ZN2=*B%A+=L5A>D+#8
M(9*''5)RI#+2G'2$.?8QH-2-1>-2XY.A5;#1,EJ342BX:ME')Z?'Q)RGD(.&
MLT:?J<Y5HYZ9M)5RPP<[&/"MQ:2,3+,)!DNNV<I*FRF+)97D%:(H4,@9XV4.
M=*5C<70<%*DJ!Q@I4""016OF;6[70W.+>N);7I4H#J:VK'8N.-*[)$=:<H=;
M6VM.<I6A25 *!%.97B3S641VNQPV ?\ @"K#[?MP>LI.SMF(WPAS_#R>]_/5
M@*VZVJ&K%U.[./M*W]K_ '2D]7B:S@4!VO!PV$?^+U4'V_;@M5>YRS?$AY>3
MZZK!V]VL /[K'F/\BMWL=:9^)_.@!V7H_E_>[4OJ_P!P=7$[-V0C?!'/\/*[
MW\_5M6WVUH) NY\QMO<_J=;45Q79JCI-@]?V9&;8MW!%'<0[A*\U;R#<!V5;
M*.8Z(:O6_.01Y%FZY#IJ 4X@H4#)GI>V7L[C2T-QBPXI)"'4//J4A7:4$N.K
M0K!YP4D$;MW/2-PC;5LR&77YZ);*%A3D9V)";0\C^$V7&(S;J,CF6A8*58)"
M@"D^FU"R/7\@U&,N$4+ALR?BL@JV=H*@X92#1-0[YDH)""1;J_1*"5R@)D%R
M 42& YA2+YK<(+UNE.17])6C!2I)RE:%;T+';3J&\I5A0.X]T^_V2\Q;];F+
ME$"TMO:D*;<20MIY&YUI1QI5H5N"T$H4,$$'(#P"48B8"]/VB8";=$M\T*J2
M(!OT>WZJND7??;UW,(\I3"&%6W)Q5G?>. HGZQZT""H(]$O\P")UQ';HM^Q(
MAS[;;]G+MS" "I63ODRYN3I_7 ?H]NC5^;Z44.7?H]OU4!+OOM_7;\OKM*C(
M^O?^O/5@2T>)0.#C<HD!0!Z);Y@R*:X#MT>_:DJF?;;?UW+MS ( ID>#P[NY
MW?"*TY.38][I O3^NZF\)MT:OS0$=(B'ZG]$;K%W\GK.;?E,41<],CY^T>UG
M/S?7(IHL)!F$]#'%;UA8-<HCT:O88P,3E#;DW[2KI#OML'-L(@)3 #'YMU4
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M%[M?_3JR[L_=5<T=.[^?8[_\YWZ1'&%<BJ <"0B(\P]GZ;1(?Y7H:N)V@M0
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M*-*4:4I!L/ZU:?QI'_?PU(Y_Q*^8U2K^#_2'Z:3JW\\['_A+/[TOJ*#WRO\
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M8=8+O!79700;A=!D$;E1.WX8O>%4&ULDD\8[O[Z/0IIN>YY8J>&,*]RR"!3
M(""3FN$'ZFQCUY4.SV?6CO\ 4UJW>!79UXY<NEZQOW(<@IY\]M4)7S51R1'W
M?9'MW?1W2?O._3AQWP%87Q_;XRXF=VFW.H<_68Z+M;F%=0R,B0Q3-I%5G'PD
M<9TNR, J-4G*RK4BXD<';J*HHF3R[+P.[*V>Z1[H7+C<G(IXQB/<7(KD1+Z2
M"V^IIF(P7%LD:FTN+4V%X64%2$%-UJV1VEI7E;A3O2%E)3G  ) 2,XQD9W9W
MUVWKUBMC1I2C2E&E*-*5&<A_8W\N&W\_EU)Y_P 2?F%4#F5_3_2*DS4571I2
MC2E&E*-*4:4HTI1I2C2E&E*T93YVR/\ @+O_ #=32E,^/_9#"?Q"Y_[S;2J$
M\X_H#YZ?VE5T:4HTI1I2C2E&E*-*4:4HTI1I2D&P_K5I_&D?]_#4CG_$KYC5
M*OX/](?II.K?SSL?^$L_O2^HH/?*_P!GYJ=^E54:4HTI1I2C2E&E*-*4:4HT
MI1I2FS,_/%I_%LG]\9:GM'PCYE5';'@/SIIDOOV$Q7\</O\ /)C6JO/W,W^&
M;_PG*L.?O2?Z7I4R]<W6/1I2C2E<H<0&*\^7JQP\MAK*,7C5LTJ-PBI!<R2)
M9EU/.JA=24E4CM2J6$30D;D1[0YV<8F523>1,%)-C-'O6!8OKS2VT@AQ!7E2
M2.? &I.K=J3O*=0![I'-SBXE20"%#.\'&-W.,GG&_&0/#48<2?#'>LOY7C+A
M7:?A52#CZ1 0\S)V*PS4';<D#&Y9H>0IS%V0T(W%=H1FL/V.N8^/1N]SRQ24
M:Q#(MNL,G0K.K%QD5(5M.I;04E2\E1(  *4$H4D+02L86"H*R "=( 4,DB4+
M"4XRK.21S$)[$@*&\85DDY[PP0=X@28X$LMOL>Y%Q^C6>'T7MNP!B?#\=D-*
MT2S"=/::5$"C(9'MD+(X#M1K!-5IV[[P8XD%;7ZKH"DUQFWJ]OQY9[.^L5?N
M"0C4E14[V+JUZ< C2H[D@\8-(/.H8*2HG4E82 JKC4Y!RO 458P,;^T.S& >
M<[B"3O! P?7G6%5BC2E&E*5(3Y\Q7\8-/OZ>LB)]U1_PS?\ ?%5M^_3X:EQG
M\^)S^&9_S>TUV)YD^#])K,'.KP_H%>;EPR/W/)I;;2UM%*;.+,VL<VWL3@:A
M8UQ7G49-TG+K"NDJ"2PJR!7!Q53 $U!-SD "B&OGFZ7W@0;N=Q;N-I;7<&Y\
MQ$Y9MD]97,1(<3*45I5I5J?"SJ3V*LY&XBM2X]:PXL+0DK"U!9XM9RH*.HYQ
MOWYW]NFYX3^YJ_O$:^A=G^%U@>Z#@$Z';_LJX>E5''6CX-/DE_JH\)_<U?WB
M-?0NS_"Z>Z#@$Z';_LJX>E3CK1\&GR2_U4>$_N:O[Q&OH79_A=/=!P"=#M_V
M5</2IQUH^#3Y)?ZJ/"?W-7]XC7T+L_PNGN@X!.AV_P"RKAZ5..M'P:?)+_51
MX3^YJ_O$:^A=G^%T]T' )T.W_95P]*G'6CX-/DE_JH\)_<U?WB-?0NS_  NG
MN@X!.AV_[*N'I4XZT?!I\DO]5'A/[FK^\1KZ%V?X73W0< G0[?\ 95P]*G'6
MCX-/DE_JH\)_<U?WB-?0NS_"Z>Z#@$Z';_LJX>E3CK1\&GR2_P!5'A/[FK^\
M1KZ%V?X73W0< G0[?]E7#TJ<=:/@T^27^JCPG]S5_>(U]"[/\+I[H. 3H=O^
MRKAZ5..M'P:?)+_51X3^YJ_O$:^A=G^%T]T' )T.W_95P]*G'6CX-/DE_JH\
M)_<U?WB-?0NS_"Z>Z#@$Z';_ +*N'I4XZT?!I\DO]5'A/[FK^\1KZ%V?X73W
M0< G0[?]E7#TJ<=:/@T^27^JCPG]S5_>(U]"[/\ "Z>Z#@$Z';_LJX>E3CK1
M\&GR2_U4>$_N:O[Q&OH79_A=/=!P"=#M_P!E7#TJ<=:/@T^27^JM-_DSN;YV
MBY6=&:D<F3,"1O4;9B['V'E'F,KL';MVCI[H. 3H9O\ LJX>G\]07K3@X;3G
MM?8E_JKTWQ:X@7>-,>NJJB#>LN*35UZ^@5)1 $856$9'C$@06W51!-F9$H)J
M")R;<I_7 .OH"R.6]ZS6EVTH#5J=ML)RVMA"FPW 7&;5$0&UY6@)8+8T*[).
M,*W@UMV2@M-EO][*$Z, CL=(QN.\;N[OI]ZVE7*-*4:4HTI1I2C2E&E*-*4:
M4HTI49R']C?RX;?S^74GG_$GYA5 YE?T_P!(J3-15=&E*-*4:4HTI1I2C2E&
ME*-*4:4K1E/G;(_X"[_S=32E,^/_ &0PG\0N?^\VTJA/./Z ^>G]I5=&E*-*
M4:4HTI1I2C2E&E*-*4:4I!L/ZU:?QI'_ '\-2.?\2OF-4J_@_P!(?II.K?SS
ML?\ A+/[TOJ*#WRO]GYJ=^E54:4HTI1I2C2E&E*-*4:4HTI1I2FS,_/%I_%L
MG]\9:GM'PCYE5';'@/SII"8GB$ZG'&FDCJMN^$@"92=+N"_?"3$IOE)TS; F
M"H=IN7M\F^PAB3C&2VDRDE3>M 2!J]_H5@]B0?>ZNWC\U6R4! *]XSNY^??^
MC//6GUFA?22__;?PG6KXRS_!J\3WIU1J9^]_,:.LT+Z27_[;^$Z<99_@U>)[
MTZ:F?O?S&CK-"^DE_P#MOX3IQEG^#5XGO3IJ9^]_,:.LT+Z27_[;^$Z<99_@
MU>)[TZ:F?O?S&CK-"^DE_P#MOX3IQEG^#5XGO3IJ9^]_,:.LT+Z27_[;^$Z<
M99_@U>)[TZ:F?O?S&CK-"^DE_P#MOX3IQEG^#5XGO3IJ9^]_,:.LT+Z27_[;
M^$Z<99_@U>)[TZ:F?O?S&CK-"^DE_P#MOX3IQEG^#5XGO3IJ9^]_,:VV#BEF
M?-"M&BQ'0N40;&-US8JXJ%Z(1YG!B[ ?E^:*)?; 0U<97:RZV&FU!PK3H/V7
M<O4-)WKQSXY]W=%2E314 D8.=VX\].1G\^)S^&9_S>TUNSS)\'Z35X<ZO#^@
M5\PV8_ZKN5/_ "CWC_2>4U^=FU7_ ,S[1_\ CUX_^X2*XZ1]T/\ X9W^^JHX
MUH:LT:4HTI3NA*!>;-#RE@KM.L\]!0G2]^)>'@Y*2CHOH&W7%QD'C-LL@T!%
MINZ6%<Y 2; *Y^5(!.&SB66\3XLB;!M=PF0XFKJJ5%AR)$>-H;XU?'NM-K0T
M$-?9%%:DA+8*SA()JM+3BTE:6UJ2G.I24DI3@9.2!@;M^_M5M$QED95R@S3H
MEN4=NI!"):M25Z5.X=2CF%3LC>.;HE:BHN^6KZR,VFU2*=<\4LB_ @ME4U#7
M$[/WU3B&DV>YJ=<>1&;;$&25N2'(B9Z&&T!O4MY<):):6T@K5&4E\)+:@HU<
M0]D)XI9)5I "2<JTA>D8&\Z2% =M.\;JTFM$NSZ)//,ZC9'4(1O,/#RR$)(J
MQP-*\9H6?==<(W% 6\(9^R+++@<4H\SI '9DA4* VF[/=GHQFM6R>Y$#<ITR
M41'U,<5!+8FN<:$%'%Q"ZT)*]6E@N(XTIU)S :=4G4&UE.%'4$J(PGWQSC&$
MY&H]K(!QD4Z&^#<S.TG"[;%60ET6G)UI1*H3IR-15;H.TP<F*Q$$#':N6S@I
M5>0PHKHJ '(H01ST;([5.)6MO9R^+2WCC%)M<U0;*D(=2'"&3H);<0X K!*%
MH5[U0)JZFD'>&'B!SD-K(';WG&!NW[^T0>8TPSU^=27AFJD/)IN;$W:NX! [
M)P5:::OG:T>R<1:8I@=^B[?-G#-NJV!0BSE!5!,3*)F*&G,*8E<5LQ9 <G(;
M<A(++@5+;>=6PTN.DIR\AQYM;2%-A04XA2$DJ20+>A>4C2<K *!@Y4"< I[N
M2"!CMC%51KT\XG#5E"&E%K$1ZYC3P:3%RI+%D&9U4W;(T>5,70.FQT5B+H"E
MTB1DE .4HD-M*8,U<LV]$20N<'7&##2RX9(?:*DN,E@)XP.-E"@M&G4DI4"!
M@T"%%6@))7DC3CLLCG&.?(QS5F9U:RR$2ZGF$!,/81B#T7DLUCG:\:T"."-%
M^+EZDD9NB#()F)%STBA>A"28BIR]91YZFK?/>C.3&8<IV(SQO&R6V'5L-\1Q
M'':W4I*$<5U5&XS4H:.J&=6.,1D$+4DJ"5%(SE0!P-.G.3S;M2<_TAW:T7,3
M*,FT>]=QSYLSE61Y*,=+M5DF\A'IR+N(4?,UCD!-PU)*L'L<9=(QDBO6KAL)
M@62.0++D:0TVRZZP\VU):+\=Q;:TH?8#[L8O-+4 EQH2&'F"M)*0\TXWG6A0
M I4 "4D C4"00"G)3D=[4",\V012?JS5-&E*-*4:4HTI7TRX9G&E:X:L23KY
M-PJTC<1X^773:$34<&(-9AT]DB+*H)F-S' =CK$#8![=]@'[^V5EMP-@MF9C
MR5J:8V8LBUI;"2X1R=%3V(4I"2<D<Z@,=NNMCK#<-A:LX2PV3CG]ZD;N;YZU
MC\2=%3#<T7:_\3"(^/ ^M_\ MJ@[>6<9S'N.[G^PQO:ZH-P9!P4N_DH].DMS
MQ58\:@)E(BY" ?M(Z%$?K=MA+_EUCKX1+(@$F-=#C/,Q%[7AFCN5'*+'WKOY
M*/3IK.^-C%++FZ6"OYN4-QZ.)KP]G:'9S6DGLAK"<X4MGF@2J)>-PR<1X9.-
MW_\ $!W:H-TCC=H>_)1ZRFJ[[H1A=F)@5K>33<OE%.%JXA__ '7,H_\ W:UC
MW#1LJP<+@WX_T8EO/SW052;O&'\!_?\ Z*/6?7'@IPXXXZ<(Y(M\=2VA;95Y
M*7.+>+>6^.A8Z)>R!C%*WBR/8ZPRXHOGHF$C(KM%NW<+%!J1QUM=JW7S+'PO
M;)WRZ,6EL7*W2)781W;FQ$8BNOD@-Q@\Q.E:'GLD,AU"&W%CB@YQJVFW+C5R
MCNK2@!Q!5N27 @))W8&0M6\YW9&#S9S@'LK7J-;"C2E&E*-*4:4J,Y#^QOY<
M-OY_+J3S_B3\PJ@<ROZ?Z14F:BJZ-*4:4HTI1I2C2E&E*-*4:4HTI6C*?.V1
M_P !=_YNII2F?'_LAA/XA<_]YMI5"><?T!\]/[2JZ-*4:4HTI1I2C2E&E*-*
M4:4HTI2#8?UJT_C2/^_AJ1S_ (E?,:I5_!_I#]-)U;^>=C_PEG]Z7U%![Y7^
MS\U._2JJ-*4:4HTI1I2C2E&E*-*4:4HTI39F?GBT_BV3^^,M3VCX1\RJCMCP
M'YTTR7W["8K^.'W^>3&M5>?N9O\ #-_X3E6'/WI/]+TJ9>N;K'KRJA.-CB "
M&?SMDQ3 '@9/-."<05:Q5VO7%TA#2U\GL-A<4\@0QI=R\C8R2J^1Y]2A7=J]
M3K<9::P-?N*)'LI6VUFRRPWG 600VXLA13O"0YITG !(*!J3SD'*>8XO%M.0
M H\RB02-X&<8.,$Y&\;R1O',:=N&.-.U2U >WB[M8G-<:TPE1<FR$CPQ8QN3
MY.LWR=K-JL=FPS.,S7C)C!2TQ3:N('1>+66"/#+2\3&7.'@%9VL/Y^E; "M*
M<H.M20'5I&I(( <!TIW')W $G!TYP<0IL9P.Q[(CLR-X&,$;ASY[0.>U6RMW
M1*$;U%U=%,52QX%"/.1O,L+E 3L!*V,\Z[B(^,B9JNM9A%U#3",>Y=Q\\=!!
MT@Y=1,1-0$/(KRR4'(BDJ"=8R3S%)!"<9)(5C>.8@$]L@D8S/$[\:AX,8..W
MNSSCN=O>02,9:$!W0:QV20A&4?1&2S5?,YJG*2D2W/8RDH%ER7E"H4,K^.86
M=LK3KYZGZ97K%/)3#V2BWM>LL;=:^S<QDNTA&DF, "=1SQ>0"=/9!"5*WE)U
M)R2!@ Z@4D[B:GBA@[SG3GN=E@$\XWC)[0&\$=K-3%B?CBBLHY8I>'!QA8ZI
M;;-6F5RDTIF:BE$H2M3>/6^1H)^V!LB)Y=5./E*_ 65H8(M2*L\PHS@36Z+@
M++,1%"XY0A2]0*4DC<#O4%Z".]OR0<X(&_22D&A3>E)5JS@X&[G(.#V]V_..
M?(':SBF:P[HQ4#+R3B;HBD'7HNN*S#F74O-?=*A*-[)EFLO89NGU5M#2[2)E
M<:PT#+6FMV*=K)+?DNBU^*D9AO.0\S+5=2JQN5DDXQI/-ALY/;!(62$D Z4*
M) P0*N)/WW>YOZ/?W;CG?OP#NW'#9E.Z*.8JYWT%\<+!1:C%U)JV9@X1-:V5
MCF,K9%Q?,26290LGWIQM4V(5RM7L!=0T[),L82*EZD#%)*L8./D1LI3V79$G
M)QV) 0E?8#&5G>4G>!K&D=VG%# WG)SVMV  =W=."1SC?NKK[ '$)$Y\;W):
M.KSJLKT^2@6+N->3<%8G0)6&M1UD8J.Y.I.YFI%=BB^.FLPA+/83,TTT1DUX
M]^NK&-;#C1;TY.=0)S@C>"01A0"NUSE(SG=D;ZH6C1C?G.>T1S'O[_S#Q8-=
M-0GSYBOXP:??T]7(GW5'_#-_WQ1OWZ?#4N,_GQ.?PS/^;VFNQ/,GP?I-9@YU
M>'] KYALQ_U7<J?^4>\?Z3RFOSLVJ_\ F?:/_P >O'_W"17'2/NA_P##._WU
M5'&M#5FC2E&E*G*FYPG*#C61I=7;MV,Y(V]U/^J=>/AI)Q'QK^HNZI(,H<9.
M.>.8:3=-7BZ8S46NT?)LUUVR2I 5,8>OM6U\RRV"1:;<A#,M^YN3>4%L1)"V
M8[UL=MK[,;JB.ZY%D.-NK!EQUM/!I:VTJ 4362W)4TR6T !1<4O60E1 4WQ9
M"=0)2H@GL@0<;JFQ]Q;14K9Z#:7E,DVLAC)W_N7/%3:#0KB,?T%C5IA&90*R
M!%:8)-QS>7B["W!-Z6+ D$_(Z391SEKUKW"7'D7"RW%VU2&W]GG,6XQY:&PN
M._96;=*3*1Q6E<H3&&Y4::@)=$;$)Y+B68[C629Z5+:66U LDZ-*@ 0IH(5J
M&-ZM0U)6,'3V)!P"&^WXM[4]D\1S=I0<R<MC>_3MDDE8T\?"LYVM6&-JL;+5
MI*/9LB-&HS)8:<=3BZB2R$H]LCYRNWZ15;I,%OA+N+TC9F7<DN29-AO4R>^J
M/Q$1J7;YT>VL2;>EEEE+39E"+,<F+4A2)#L]YQ:-2EZJ!.62PI>2IIU2U:=*
M0I"DH2I  &.RPHJ)&"5DXJ'T<IN%8?-3281?RTMETT*LI+N7H*+,W49=65L<
M.'PJ)G4>G=D:F:AR'2Z-0Y5.TA>CURZ-HUJB[6-2D/29.TQB+5*<>RMIR/=F
MKDM;NI)+I=#9;W*1I40K>!BK''DIDA0*E/E)U$[P4N!>_NYYNUBK'N2FSN<P
M[+A%+D)B^!J\,Z0%TF)I<]?MLS95%T#@B -"N4Y0C0A%"K"F=$RIC&*<"%AV
M_(<E[+R1&6!L]#M\5Q'& F485SE3RM!T?8@XF0&P%!92I)4200!!>!7'5I/V
M!*$D9]]H<4O(W;LYQV\<]3FSXHZXTFFTN&.6QE&DN[GT5A+!#(]^7N1K];EG
MZLD>&,\<'4KMNCJLHDX650,C$J&Z+J[@J!.P:X0X+<MN4+$V5-RG9J58A\?U
M4[?KU=%NJD&(77"J#<V;<4K64%,8G3H<"!DB:@*"N)&XZL]B3JXUQS.=.3V"
MTHW]H<V-U883B8JL<U<$4H:K&3E:\A$34Y!)UAH[=/C5K%L3(RA&2\$K&'!]
M,4&5G#LUVIFXKV$YQ*#DB[A>W%V^MS*' JSJ9D28*(LN9#3;VW7'C;]G8LA\
M-+AJCD/2K+)F*:6V4%<XDCC MQ9,Q !^Q$*4C2I:= )5H9258*=.]32E8(QE
M?=R3I*\1U./'2T8UQ:QBHR2=-'ZT)''ABQ;PK'*.0[RC7)$58,S@]?7K]W95
M5<[847J"%?;BR!!LLF@UMJVZM18DQV]G6H\>0XT\N(PJ(([@9VBOEX1 ?U0R
MM<)<&[LVU906W4(@MEH);6$-#+:(4GB $JP=(T:24O.N!)['WI2X$' "L)&\
MT@W#/<!+5^QQ%:HL=%RL\UB8\]IDHNJ/)88U&3R,[E6_1-X!NTCUCQ-UAZM'
M2$6FWD48BK-#'=E.=HA'85SVRA28,^+ LT>-)FMQF%7%^-;79/$(D7UV2@)1
M";:8<5%NT6W,2(Z6WT1;<V>,25-(CVW)25)6$-!*E )UJ2VI6-3I4/> #L7$
MH!2 0E W]SF+7G]8=&E*-*4:4KZ0Z,U=/N$?'31DV</'2^&L>D1;-45'#A8_
MJ>@QY4D4BG44-L CRD*([ ([; .OO"SMN.\&EB;:;6ZXO96R!#;:5+6H]00S
MA*4@J4< G !W5U2 3;VP 22PU@ 9/,GM"N8G%'NIB^MJ%H'R>2ORP^R/M-->
M?JM-U.K%LN';_D4GO_S=:Q;3I.YMP[OO%=T]ZF=*X_OBA#='2;<?M_K*W,F_
M[K(=:YVRW@A6+3<CO/- E'N_S54<2]\$[Y-7ZJAV;Q=DQ45.CQU>U-RCMR5&
MP'W]</DY8\=]:&58+\I*]-DNZNQ/-;9A[0[C-62P_DGB7<9._BU]WP5#<UAS
M+JHJ]'BO)"FX=G)1[.??M]CEBQWUQ\_9C:59.C9Z^+W_ ,&TSU=OO1S5@QI'
M8_8'N;X)?=/^C6#'W"MFK(URC:T:CVNGLG"@+R5GM=:FX6(AX]$Y1<NNFD&C
M,'KP"F K*,:JBZ>+F(7=!L5P[;V[1P=;5WVZ,0.2+C:V7,*?N%Q@2XD:*R@C
MC'-;S;0== .&H[:BXXL@=@V''47FH4AU:4<6ML<ZEK0I(2-*=^\#)W;@-Y/X
MS7T$52GI5BLP5=5G+)/J0L4SC#S<U.2*\M*&:-E6XO7ZR+A%,[E?IU3G,1,N
MQBMC;B=FU42^U;9"-NM\* 94F:8<9F.9<Q8<E2"T@(XY]P :G%XRHXY^<D[S
MU"$:$(1J4K2D#4HY4K QDGMDTX>]K?<#=(_W P&^>LIMN"B*H )>N<HEYD"
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M0I-KL<W-)6$!4?;$69IARRDF41+T)B[F,5V!CGV2*/2'$R@F%4XGYEEA4BH
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M65>3B.P9/'+!P^3ZK(R\R(1<6P;/3G</I!_^A6;1 @I !EG#A5-%,HB "<X
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M!(=*2HC"GDJ)!"DA !<6I*DM(64D"VF1?W$@IF.(U1^J 5)."V%)3J"DLK2
M0I*BLD-MH4E3JVPI))?>Z--:#D%]C";MV04K>VN6-*2T;,ZL5U'RS_)DA58]
MK)QTP5,(P(*G'NE97O\ (R+I@-<3G()N"#Z0L=:8S&:JW;.M/!A=N27.,CM@
M!+I"S(4VG4E7&:=+9=07B2"C6@ %2VPK$3.VA<9$A$\\46GW22MH%(82X2E2
M-&K6X&EAD)!"RE9RD(<4G?4X^(5<&QV?$M3U4WO7S-5TK75CMC)QK)I)O5U'
M("+=!LC'2,6_!TX42;*LI:(=(*J(2L>=SL6K-LLK3F/!()4 >.5C"4A1.>-Q
M@)4E6HG!"D')"TYP7;IM,D*P].& G(XD9RI12 !Q6220I. ,@I4" 4JQ'-@[
MI)%PKJ.:#Q"LW8R!D#.',:^A'3&#8.$K>))>?>=$1O&1Q7E&L,6N*ASNVTBU
M*BX:))&.NGD"T;()4A*HD)15C44N+(0DA["W%!W"4Y8<23DD*&"!G-8AN>UR
MTK*)4M)2.Q"FVPIQ0+64-IXHE2RE]I0& "E60<[CM2/'T^9.W;!7B-ATGS!V
M]8O&??JOF<HNX]9RU?I"B5N90X,7;)^R>*)E.BV?1LFR6.1U&/T6^>BP;'A2
M@N';\I5I4"\O(*20L8X[/8D*2K'O5(6DX4A83KU7S; A*DRI^E20H*XEL I4
M$J2<\4 -25)4G.\I6@C(4DEK'[H=(**JI(\3< !TF*$DJ0]AJZ(I,'+&/DTW
M:G3(DZ-$(^7B'*QS<H-R2T4#CHE))D5?*1L_L2K(,2VY "SF0L804(6%'+XW
M:'$*)[06C.-2<V5WS;,!*NJ;E@J* 1'2<K"U(T[F=ZM;;B0.<EMS&0A6'T7B
MGSRNBDNAE"<417(15%0J47RG24*!TSE$8\!V,42F#R#L/;K:C8O94@*%FBD$
M @ZG\$$9!P7>YWJUJ]KMI4E0Y6D@@;QAG<0K!_BZ>>.^,O+M3M3&2MU@?7:M
M&/U:8@GR;!)4[-4Q>=U&.46K<S>2:\O2-NE.+9<.=NX*4JH+HZZ[<'UAGPG6
M8$5JVS$@KCR6BZ4A:1N;>0I:@IE><*P-:-RD'(*595LV]OD&<T[-E.7"&<)?
MCNAL**"=ZV5I0DI=1C*<DH5O2H *U)]DZ=;H&^5F'MU8>A(0<XT!VQ<\ATCB
M4#G161714 #HN6KE)9JZ1.',DX143$1Y=Q^?;A E6N9(@36^*DQE\6ZC((S@
M*2I*AN4A:%)6A0]\A0.[.*]Z@3HURAL3H;G&QI*-;:\$'<2E25).]*T+2I"T
MG>E:2.U4#4GC P7=IG+4,%G5IXX6D95G=9?(+9.FUE-C#9/R'AEY8(ZS2[E*
M$<P?A,Q5>ZHDNX?-'AGD*FY.Q3CY:&=R&'681CZ]T _IJ2)C.F&H&75@9;)]
M':2[03FEV(V2+65K;4E3G+QWTMPMW*I*A"'JM<F)=&=LYHF'<(MDTD'RCEXR
M0<*8/U\./GK WX@<#.U'Z37-F)'"L7(0T5))HY'IZAV$I8F49)5^.>%),"+=
M[.Q\S$/8=JKRK2;64CUV1%TW:!E%1@]SO_B[M4:Y_P (R,K#P4-E:A6*;GXR
MOST/#5>SQ-HE7U;M,NY@("UIQ]?<R3LM0DIIF[BT+:JB2N%?-UFRLFFJ02Z4
MI6;9DQ"\+7CM,JXW=%MR\DVJ9FUYK"Y;.YAA<%F&]>%*4,$TO%&:N@DDHT7*
MC$6S@'14A14Y53@]P[N?O4A,N(#$LJ%S<0MOC[##T/&%?S#.V.KB:U5Y6A66
M1R;%1TK!R=;"53L2Y7N(KPBYCH0KY\FI'MT2(*N'J")E,$<_U^N:5#9PPL22
M9PQLO8P"7D+<./V,7ZO:KWQ>7L&#B5&EMF02O65K8$8T<R'J>(F:7ZF@JYZI
MT1#'!45@\/6#!9-)(,SXH&.D(6;LC!^&1*@+-]7JTE-+V.>9N0F!1=0T A6[
M$M-2:!U&46E S2CY= D6^%!2HYR?Q>X5Q3X.W4U,2=@@,EUBPWJ$MU$C/5G5
M&5"J\[C>MS5XEI>$<."%K3:8RS16Q'D4E*KN$Y<SMNU49LGJZ"I S]?#^HT[
M,=<2F"LI5*@W&HY2H[J.R7"%G*FP=VF 93[U-*KQESEHM:#6DN^#>?K-;F(Z
M4MD(=$9"M-G*:TNBU2,50RA!'/3Y@,GXUM;V*C:MD.C661GJWZL8./@+; 3+
MV9J'71C/55%-8Z0<KR-;[X@,?W\9IK1G70%IUKIP%/2HIETG/] NA,G&6]4%
M#-B!\1&]IY/@G= &(AG,.%@B[>HM/BV:DJ4M" M(-I9PX;G9D9OVTTUBG[%T
MT25.#X^;O]JEZ+S5B28E&D*PR-3E):4>@P@H]>>CV;JT*FKD?;BKU!)ZNW-;
MHX];E&<N26K02L6=H*YR.S"S>%04P>Y]<XW]S>*;<3Q+X&G+#)5V+RO0WBD:
MRH#D9E"V5Y2L2+W)M@R)5ZA78:QIR9HJ6M<A-8NM[0U:8N%I=(S1MNU,+M(N
ME,'Y_P W/3]E\EXXK\E+0T]D"DPDO Q$?8)R*E[7!1LE#0,M(EAXN;EF+U^B
MZCHB2ESDBX^2>)(LWDB<K%LLHY,"0JBDN(S/AZ?F&==@LL8TF[!(KD:Q\%$7
MNKR4P^<J,I"33;LXQG*K/7*YXZ)E9 B*"!U#,HR0=@44&3E1-2DN5X@,'0R]
MG9O\N8Z+*4U^YB+-!-K?!/['$3C5DRD%*\YKC%\YG#6,[63C#MZ\C'J3+L\E
M'(-6*R[YJFJI@]SZCGI.D>)#!T4^9LWF3*<F@NK;FTE,C88@L#5'U%81$E9X
MR[3"CU-E3Y6+:3L4=Q&6%1@^1,[23702.8H"J<'Z]_F^:E62SIBB%R%&8OFK
MS7(:WSE,+?:^REYB,C4;%6NGEDUW=?<O'B))I1BWA)&3D48X'!F$0B$HY%-D
M8%05'U^OCK;#-V%Q9!)AEW& QHT\<AA(!?JH+(: 5_WJ->0=A+= -/+)_I<-
MFZ3O*#_]!B]ZQ\KTI6NVSABQ_E6%PK%W.!F<C3F.K#E=M7H:4CY1TUHE<EJ!
M#+3THFR=++1K.5=Y*K)ZXL[230GVIY%S&*KI1KDQ5,?FW?7Q4I#F#$@=5WRE
MCH.NV=>DLM[O60ZW<VSIFQ<U%K^F?Z(L[=[(Q[-> 2YY5)T^9MU&A5G*!#J4
MIO\ (V/8N;D:S)WNFQUDB(0MEEJ^_M$(SFXNN'5!N6?D8EP^3?LH0RYBHEE7
M+=)B*H@F"XG$"Z4IO&SGA0L7,38Y@Q=WGKT+ V2>E0O]3&.A:]:@(:KSLL]"
M6ZM'0]E!1,:_)O%464STB?>Y=SSEW4P>Y]1S^*F76^*[AZL5#K61U<JU"I5B
MV552Z0R^0IEC0'CFMM*;%7^7E2,;8O%+N&->J<TPF+%(,@=1T,V.L=Z\2*W7
M,13&_';YJ=TOGG"D' VBSR.6L;HP=+A8.Q6F0"\5@S>"AK2R)(5.0E%0E028
MMK:S517JJSLZ*5A(NW-$G=E63$RIP>X:VXS,V+Y&"IT^K>*S"-KY1/"7665E
MFXNOS#^D)0K*P2-A")E'C=Z6-@XF0:N[ \!(S6$35 TBLW*(&%45:.;\+ BJ
MX'+V+P;H57U=+KC?ZH"*-(Z)BOZL551EN1.J]#)QJWJA.8L1T4@Q4ZYR.T!4
M4ION>)3 S1XI&NLJ4]O+)';G/#+2J1)OO6ZM;>DH6@D,8 DU*.:RNDV!KVFU
M-3DDRN'ZLX2.:.G:*IP>Y]<9\>.USTI6#/V$JE.K5NV96H55ED5()L"=FL\3
M7V;F0LC2U2,1#,)27=,XN1L#B+I5DEUJ\P>.)MA#QY)=^P:QS^.=.U,'N&G1
M.9+QS6 BC62_4N +.VY"@0AIJT0D667O;I%PX:TN,,]?( ^M;A!HZ60KS85)
M95)LN=-H8J1Q*J*V&5_HLG SEIB[G592M5A291L<_&6"*D8:!7KJ9UI]O,23
M-VNTCG$(DF=26;NUDEH\I#"[(EL.E*YXC>-'#UEIN*K?0F.1LCN,R0%EM%.I
M-+Q_//;\A!4:585_(+ZVUV42B!HYJ%9Y1C4K0QMKN'DFUO<)U9BSD)X>]^E2
M1@X.[Z]ZG/C#BGQ9EG)%IQ36PMT?<JJSF)!=E:*E+5Y&48UN2@H6TK1:SY(#
M M6)JS0,1-1TJE%2K=]))E08N44':S=3';_%]?U\U:WC8XG0N,[CV6&VP=YA
MLI5'$K:JR-6D5I>RS]Z0G9&L2]71B.^B<I5WE<JENN+^5,JV5KU,JLW9[(RB
M(E!NY<J8^;/U^O@K9Q3Q689S$^RHRJLZ^8DPZH*MRD[5%N*Q#)P?J@OM3+:V
M4K*"BS4KIK)BW(42=R\58O6IJLZD'K!M#R$'(RBF#X_^GZQ3];9PPJ]B9"?9
MY?Q<[@H@\&G*S3;(%37B8Q2SAS5HDA))2QV;(]A*(&@RN5DC2P=K ' :5&#W
M.?FK?=Y<Q2P"U"^R=CUD%$%D6[B[NE;;!3323Q>.CBVH5I(@5X7\@U<L602_
M4Q=/&Z[9#I%D5"%4ID/^)[ ,=D>*Q0XRU0C7F5=/(WO,C;*^LK%SC="INV-;
MG>22$T-9;$TNU>=U6!?$2D[(V=G7B6[I-(QM*4[ULS8?;@X,XROC5 K2>DJJ
M[,M>JND#6T0RS!O,5MP)Y0H(ST2XE8M"2AU.608K23!)TW2.\;E44P3S"JQV
M9<03"[%K$Y5QM*.92#CK/&-XZ\UAZO(UN8?I14386*+:454=P<I*+HQL=+-R
MJ,'S]9)FV<*N%")BI6W-Y3QU6RL5YZY5^)CI D\="<?2*"%<1&LRC&$G$7]E
M.8(&+<L9J1:1!FLE(M'*TH96/;I*NVSE%)2F?D'/]#H3*BJMD[#D66R@1TZQ
MS6<50Q[S.7*)CXQO-2EDBS1RY(5M48N*>1SE[;YJ8BJR1>8K\2E*K3=EKL;*
M*G'XL<^?KS][GK)1N(G"V0HR%D('(5>:/)N.LTDC5;.]3J%Z8(T><G:O>D9N
MBV88NUPCNCV>KV:N6YO)1+8U?FJ],L)$4%8]P!%""/K]>[6K;N)?!5-HT[D-
M]D^F2]=@<?R>45/4K8X:SR4G0XE15NZL\''0[]TXE83KR1H\)EL!H=)Z!DG4
M@W*DLHDJ*W(WB Q8M'L7=FLK/&;Y\^BH<D!E)RQHLR$_,QZ$HQK[4LT\1C9R
M559.452)UF2FVJQ5"&:NETSD.92MY?/N"FT8::7S1B=*'+!VFSC*'R)4"Q_J
M;HZBB5TGP=]^.@-"U%5%5*SR95!90*J9TY19J<AB@I@]RE5?+^)6L$C:'.4<
M=-ZRYCEY=O8E[M6D8)>);$9*.91&74DRQZL<W3DHY1=Z1P9LD209'45*5T@*
MBE*C/(F/Y"/M4LPO-.?15$<R3.[R;.S0KF/IKN%9A(S#6U/47QVU><Q,>8KZ
M20EU&:K!F8'3HJ2 @?2E:K?*6,G@5PS3(M$=%N,;)351%O;J^N%IAX9 SJ7E
MJX*4@8)R-BFQ3.))_&=::L4"F6=*I)@)@4IAO.)[A]8H@X6R[1U$W$9)3,(#
M*;;2*MQC(:NI6N7=X^0CQ<K9$3BX!=%_(A1T[ =D"R3=R5)VH1 RIP?K^GN?
MCI_K9.QLV<031QD*CH.[0ZBF-9:K6R!2<6)[.I/7$&S@D3R!5)=U,H1LBM%-
MX\KA6128/5&A%B-5S)JC![E:DWEW$]9=V1A9,GX\K[ZFLHV2N#*;NM;BG=4C
MIE9FWB']D;OY-NM!,I5Q(QZ$:ZE"-4'RSYFDU45.Y0*=3![E(:W$#A!"4L40
MKEB@%=4YM/NKJN%HB#Q=("KKU5O-MKO-D=&AJ=(M%+K6A)%V5_%R3M*1%=DU
M<(LWZC52MF8SOA"O*/DI[,>*X56+5K:,FE*Y!J<>K'*W)TV8U%-^DZEDCLS6
MAX\:-:\#@J??E=R@E']8.J0!4P>Y]1ST^*Y:JO<&*\I4K) 6F,;2,C#N)&N3
M$=-L6\O$.E&4M%KNXQPZ;I2,8]25:2+%10KEDZ34;N4DE2&("E+VE*-*4:4H
MTI1I2N>, _/+B#_\X>X?Z*436VNOO+3_ .$L?\Q*K76_W]Q_\1=_P(](7#O&
M+3/!IP\1C=5N@LZX><)E(J[4.DW()*%5%1%10B:IR@)4Q*79,VYA*&P (B&7
M.?3&VGN;RTK6EN[7,E+8!6<R)"1@$I!WD9WC=GP5B,,*D;/PV4J0A3EN@ *<
M)2@$-,*[(@*(SC P#O(K8-BB:$?GU60[-A_3!W[8_P!S];/E^+VX\P'\$WZX
M5J!9) 209,+?G^.7C>,?!4P[SPOPF2F<3&WQI0[9%PDXE8F$-/.GC^$/,(1L
MI%-7,G"K,#14V1HWF'B[-G-,Y!BSE2,)QJV2FHB)?LI5?H+@2ER+,6$$* +3
M9&0" 2GCL$#)("L@'!QD @BSRVR2W,A(*DZ2I+ZPK&02 H,Y3D@9*2"1E).D
MD&%E^YSXE&-EH-BQ8PE<GX)]69^IUK+F7JK39Z#?P[NMJ1\W3ZW88NLRR32L
MN4JM#GD(EPO 5>)K=;A%8^#JE981,<LVP CJ2X)2I&A2$C0A:2DI(4A,H)4
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M6MQ:R5*6M2B2I2B222<DFO9FFFV6T,LH0TTTA+;;;:0A"$( 2E"$I "4I
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M6>?QU$KWN:&*I%U?'[_+F=GTA>7#UTF]D)?&<@XIJ[B7&6CEJ2=YBQ<T(ZK
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M89)RI"<14%<;OD*8K6-X:Z2B%?;\1]N4J4-7[;'(R MXYS/+%LD;'6EM&/\
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MAU$W.HVAG'T2/LF(J1+5.+KR<+*4YRQ?&K,U&#*/144U'\V/%G]9[W>I$O/
M#%Y:R7GF\WS*5_KC+)-\CY^DQ^,'M-A7U=A5,/\ #ACVU*2<W,8YE+*I+VAS
MA&3@I&%]4<M2C4N:;OF\,SN9DI:%4SS=[P]_'-W,UC>]S4Q2^CDH];*N;2!&
MMV9ZTZ;2&+VKJLSS>R</EQ>6IBHWQ6F,G,2UHX;:/+O6]E[^0+925M*$+#1*
M#J%) J9/A\/X_P!?YA2TEW.G#K!M7 @+CDJM2E2/%N*[,PJ>+$%(M]#/^%-_
M'O6\$OBYQ3R@W'A QLR0C"ULL&UCIR[,6D4W0>5HM54*B?KX?UFND\#X/A,
M4V0I%=L]NLT.\M,W9V86Q6N 6NIS75?]R]5BZG6ZI7JY3HGJH#!UN*AFT?$
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MI5SI4D[TJ',>]D5=M]RFVF>S.M[JF9+*AH*=Z7$G 4TXCF<;<'8K;.Y0YL*
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MQQJ&1OE/C> 1VCW:M0&$2;);V7-6A=O@ZM) 5V+#*A@D$<Z1VN:I2\'$ /\
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M^'YNUZ-'BF\,7F Q%Z UOXOTY;O'2<[SEWTJ<DVSH^'YNUZ-'BF\,7F Q%Z
MUOXOTY;O'2<[SEWTJ<DVSH^'YNUZ-'BF\,7F Q%Z UOXOTY;O'2<[SEWTJ<D
MVSH^'YNUZ-'BF\,7F Q%Z UOXOTY;O'2<[SEWTJ<DVSH^'YNUZ-'BF\,7F Q
M%Z UOXOTY;O'2<[SEWTJ<DVSH^'YNUZ-'BF\,7F Q%Z UOXOTY;O'2<[SEWT
MJ<DVSH^'YNUZ-'BF\,7F Q%Z UOXOTY;O'2<[SEWTJ<DVSH^'YNUZ-'BF\,7
MF Q%Z UOXOTY;O'2<[SEWTJ<DVSH^'YNUZ-'BF\,7F Q%Z UOXOTY;O'2<[S
MEWTJ<DVSH^'YNUZ-'BF\,7F Q%Z UOXOTY;O'2<[SEWTJ<DVSH^'YNUZ-'BF
M\,7F Q%Z UOXOTY;O'2<[SEWTJ<DVSH^'YNUZ-'BF\,7F Q%Z UOXOTY;O'2
M<[SEWTJ<DVSH^'YNUZ-'BF\,7F Q%Z UOXOTY;O'2<[SEWTJ<DVSH^'YNUZ-
M'BF\,7F Q%Z UOXOTY;O'2<[SEWTJ<DVSH^'YNUZ-'BF\,7F Q%Z UOXOTY;
MO'2<[SEWTJ<DVSH^'YNUZ-'BF\,7F Q%Z UOXOTY;O'2<[SEWTJ<DVSH^'YN
MUZ-'BF\,7F Q%Z UOXOTY;O'2<[SEWTJ<DVSH^'YNUZ-'BF\,7F Q%Z UOXO
MTY;O'2<[SEWTJ<DVSH^'YNUZ-'BF\,7F Q%Z UOXOTY;O'2<[SEWTJ<DVSH^
M'YNUZ-'BF\,7F Q%Z UOXOTY;O'2<[SEWTJ<DVSH^'YNUZ-'BF\,7F Q%Z U
MOXOTY;O'2<[SEWTJ<DVSH^'YNUZ-'BF\,7F Q%Z UOXOTY;O'2<[SEWTJ<DV
MSH^'YNUZ-'BF\,7F Q%Z UOXOTY;O'2<[SEWTJ<DVSH^'YNUZ-'BF\,7F Q%
MZ UOXOTY;O'2<[SEWTJ<DVSH^'YNUZ-'BF\,7F Q%Z UOXOTY;O'2<[SEWTJ
M<DVSH^'YNUZ-'BF\,7F Q%Z UOXOTY;O'2<[SEWTJ<DVSH^'YNUZ-'BF\,7F
M Q%Z UOXOTY;O'2<[SEWTJ<DVSH^'YNUZ-'BF\,7F Q%Z UOXOTY;O'2<[SE
MWTJ<DVSH^'YNUZ-'BF\,7F Q%Z UOXOTY;O'2<[SEWTJ<DVSH^'YNUZ-'BF\
M,7F Q%Z UOXOTY;O'2<[SEWTJ<DVSH^'YNUZ-'BF\,7F Q%Z UOXOTY;O'2<
M[SEWTJ<DVSH^'YNUZ-'BF\,7F Q%Z UOXOTY;O'2<[SEWTJ<DVSH^'YNUZ-'
MBF\,7F Q%Z UOXOTY;O'2<[SEWTJ<DVSH^'YNUZ-'BF\,7F Q%Z UOXOTY;O
M'2<[SEWTJ<DVSH^'YNUZ-'BF\,7F Q%Z UOXOTY;O'2<[SEWTJ<DVSH^'YNU
MZ-'BF\,7F Q%Z UOXOTY;O'2<[SEWTJ<DVSH^'YNUZ-'BF\,7F Q%Z UOXOT
MY;O'2<[SEWTJ<DVSH^'YNUZ-'BF\,7F Q%Z UOXOTY;O'2<[SEWTJ<DVSH^'
MYNUZ-'BF\,7F Q%Z UOXOTY;O'2<[SEWTJ<DVSH^'YNUZ-'BF\,7F Q%Z UO
MXOTY;O'2<[SEWTJ<DVSH^'YNUZ-'BF\,7F Q%Z UOXOTY;O'2<[SEWTJ<DVS
MH^'YNUZ-'BF\,7F Q%Z UOXOTY;O'2<[SEWTJ<DVSH^'YNUZ-'BF\,7F Q%Z
M UOXOTY;O'2<[SEWTJ<DVSH^'YNUZ-'BF\,7F Q%Z UOXOTY;O'2<[SEWTJ<
MDVSH^'YNUZ-'BF\,7F Q%Z UOXOTY;O'2<[SEWTJ<DVSH^'YNUZ-'BF\,7F
MQ%Z UOXOTY;O'2<[SEWTJ<DVSH^'YNUZ-'BF\,7F Q%Z UOXOTY;O'2<[SEW
MTJ<DVSH^'YNUZ-'BF\,7F Q%Z UOXOTY;O'2<[SEWTJ<DVSH^'YNUZ-'BF\,
M7F Q%Z UOXOTY;O'2<[SEWTJ<DVSH^'YNUZ-'BF\,7F Q%Z UOXOTY;O'2<[
MSEWTJ<DVSH^'YNUZ-'BF\,7F Q%Z UOXOTY;O'2<[SEWTJ<DVSH^'YNUZ-'B
MF\,7F Q%Z UOXOTY;O'2<[SEWTJ<DVSH^'YNUZ-'BF\,7F Q%Z UOXOTY;O'
M2<[SEWTJ<DVSH^'YNUZ-'BF\,7F Q%Z UOXOTY;O'2<[SEWTJ<DVSH^'YNUZ
M-'BF\,7F Q%Z UOXOTY;O'2<[SEWTJ<DVSH^'YNUZ-'BF\,7F Q%Z UOXOTY
M;O'2<[SEWTJ<DVSH^'YNUZ-'BF\,7F Q%Z UOXOTY;O'2<[SEWTJ<DVSH^'Y
MNUZ-'BF\,7F Q%Z UOXOTY;O'2<[SEWTJ<DVSH^'YNUZ-'BF\,7F Q%Z UOX
MOTY;O'2<[SEWTJ<DVSH^'YNUZ-'BF\,7F Q%Z UOXOTY;O'2<[SEWTJ<DVSH
M^'YNUZ-'BF\,7F Q%Z UOXOTY;O'2<[SEWTJ<DVSH^'YNUZ-'BF\,7F Q%Z
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DY.$C<,G K*8CL1D<7'9;8;U%6AI"6TZE>^5I2 ,G R><U__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g383050g06a01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383050g06a01.jpg
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MDR-287%R<W1VD;&RM='2TPH7)#)"@9(SH1@E8H(9)C1$X?"BP</_Q  = 0$
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M^2+_ %];-7G.1,ZWQQC/0?G/P>H?T-5_88.?3'5?)>M_8*?]/'GS4V7RC?\
MVVU]_)E9Y?Y98XQCC&.,9KUZC^4IZ-[=WV,P@V-[EPL?9-SV=G>NMQV%D:"J
MZ_VM]T_[^[>U-/H:38:*08JG'JSR5?>5]0++$.L;2$*E'&EV>]TIL:-:Q9:>
MA8-1*<MNO6GD>S7CO]OLSR1201 B0NHXC9R">>.T%AH>K^$/2[6]3I+4VU(;
M&795Z%R_5@BHVY]3XGMT44\-NP5:)8I&YFCB4A> W<54YK2]D==P S6D^]Q<
M-8/-5#3V,NIHXP8"+T.*PI()BWG(/'-< 3P'543Y&OL YHB1&S0R,>NOBK9+
M!!7G+D.0@AD+$1DK(0O;R1&P*N>.%((;@@YN!V.O5#(UZF(U,:LYLPA%:9!)
M"I8OV@RH0\8)Y="&7D$'*.3W/U.%M[GK<[L3( [G/9RLUMWFCKT *QK,[<-N
MI:^T+85-%''#.-GKDY[/:+.-6A+9%10 3C$33BC=:O':6K.U>65X8IEC9D>5
M#&&12H))!EC7TX9F[%)8,!2;;ZM+LVO>_52[!7CM35WF1'C@F\4QR-W,  RP
M2OQSRL:>(P",K&O2=@8*)L#Y=OD8V%7:YD9\FEIF-(TC6QO=GX'.-1)KM&30
MO6JC5QZ-EC<H_D]JK3%:P>>()CVQ^,>(G\H22!*?B^4?(([S\7D'S\CE<WZ*
M]I:Y4 :;V=2;$([K'D? 7E_.;@@^$.7\Q\7SSLR;3'17)^=EUF:CT%77/M[.
MBDO:MES75,<;99+0^L<4AHE='$]DCS2((QF1N:]TJ-<BK#P)S&LHAE,3OX:2
M>&_AN_IV*_':S\@CM!)^C)C<J"5X#:KB>.,RR0F>(2QQ <F1XRW>L8!!+LH4
M \D\99&9[\Z3V.3K=SG.UL!8Y&X@+*K;]-33B@%C (,\R=DAI8SFQ#Q&@$2N
MD8ST"G@%.\H#19);B777X)FK2T[*3H55HC"Y<%NX*.%4\EBK <<\E6 \U(%G
M6WFGMU8[M?9T9*LRNT<_M,2HZIV][ NR^2AT8D@<*Z,?)U)OT'5Y>S-.K:W2
M4%A8U@0=E9  W%<6;7UUC![S7GG"P$R3B!'C*A 94\<<!4"^U@D?']]RV:&5
M%5VBD5&9D5F1E5G0\.JL0 64^3*"2I\B <O4M5I'>..Q \D:))(B31L\<<B]
MR2.JL65'7XR.P"LOF"1E-9V+U])3CZ&/=8U] 608*+>,T](ZG)*KX"23QA[-
MIRA3$ C!ED&0QSND&@%)EF:R."5S9S5LAS$:\XD4*S1F*3O56("DIV]P#%E"
MDC@E@!R2,IC84#$)Q=J&!F=5F%F'PF:,,SJ)._L+(JLS@'E0K$@ '*)/W-U.
M-L,G@9NQ,@W8;O-F:_'427H#R]'F@K*EIWV]2YDSH"Q2K/058=7[.99;F60K
MYIC-96V;@YQ1NF":R*L_@5Y5@GE\-@L4S)(XC?D<A@D3L_EQ& OB%2\?=1;;
MZM;=6B;]7VN[7>U5A$\9:>NDD,)EC(;M96EGC2/@\RDMX0<1R%),Y:YD<<8Q
MQC'&,K^7^OJ_^'-]FFYD-5\H5OUG^[?,;M_DVU^JGWL>33S>,T''&,<8QQC'
M&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8
MQQC'&,<8QQC'&,<8QQC'&,<8RG7'U3:?HXW[-+RVN_H=O]FG^Z?+FE^F5/VF
M#[U,@CF@9Z/CC&.,9KNKOE%\N;VH5TV7X9?%G0[>KSE9MM&+?XCK&O!RN!M+
MF6CCWFB.3N"9@&5$,&+>>>QD\PPP9,WNK_9HUVT/TM,M(7UVVEDKO*]>)H[%
MMFFLI&)#6B7V$%IF4KVIY E@.1FA1]?5GV;:ANG>J(+L5>*Y82>EKHTJT99C
M"+MA_P :D)65U<NX#,JHQ[3QP<X)>Q.OX!VES;K'0BOM1:)I,NGI(QW79PT)
MH5.V9YR1K:F!DCEBUZ.4L@8B&>*%\4L;W:\*UDGM%><GL,O BD)\-6*M)QV\
M]BL"I?\ -# @GD$9N1OT%7O-VH$\58>XV80OC.H9(>XOQXKJRLL?/>RL" 00
M<J#]=DX[YV5DT^>CT[ G63\X^ZK6WS:YC/6^P=3N)2P:$QGW[BE'2!K/OED1
M/CR3P9C'XPBE\'N[/%\-O#[_ /A[^.WN_P#;SS]&3FW5$YK&S7%D(9#7,T?C
MB,#DN8N[Q @'F6[>T#Y\L3+=^]);7-P:_+]KX"VS!)%T,/=PZJGA G?GIC(K
M=\4Q)<"2#", )-][:BBSU;8[<:::K('+EN9M;?KRF":G9CF C8QF&3O E"E.
M0%/!8L%X]0_*$!P5%E6WFFN5UMUMI1EK,TRK,+,2HQKLZRD%F7E5\-G[Q\5H
MP)5)C97-]U^MREN<^LJM/GK.RCJP[R2OK[JM-.CI+%C9*^X>(,3+.RK/C<UX
M=@Z-!"F.:Z"9[515MFAF10[Q2(A=HPS1LJF1/)T#$ %U/DR\]R_.!E\EJK*Y
MCCLUY)!&LQ1)HW<0N.4E*JQ81N""KD=K \@D93XNQ.OYJF._AW..EHICB*N&
MZBTU+)4RV8D)!)=='9,-4.0X4<0H@@1LRD0PC$2R1M9#(YLYK60YB-><2!0Y
MC,4@<(Q #%.WN"DLH#<<$D 'DC*8OT6B$ZW:AA+M&)A9A,1D4,S1B0/V%U5&
M9E![@%8D  \4(_NGJ6LT.'RAW8V.@T/95>?:X*L6^KWRZNLK9*^ NPI9(YWC
MF"(3;5H@\\<JQFEFCBA*00_V:5%H77BL3+5G,51E2R_A-Q [ARJR<CE6XC=B
M".552S< <Y0?<:N.Q3JOL*BS[&.26C'X\9-J*(H'DA(8JZ!I(U5@>'9PJ=S>
M64+OWO\ ZX\-O6NI[0[)M%AJ<O0VF@6BK2:==7HAJ>*.8\3*T]O;4\=U8PQ2
MLD<-&9$UC'(^66-JHJU-;K;6UMPTZB<R32)%XCA_!B,A[5:9T20QH3Y=Q4^?
MD <H[S>:_I_76=EL).(JT$M@PQM#[5.L0#.M:*66(32 'GM#CR]2,D2NV>7L
MSP:<>^J&Z"PI1=%#FI;2O;HVTY;&/B/EI6%/.:(BR-C>4V)XJ2^;$F<OEYVK
M03*K2&-_"60Q&4(WA>(/51)P%[N//MY[N//C+^.Y6E=(EGB$\D*SK7,D8L>$
MX!#F$,7[?/@L 5Y\N<LC4=VXC.DT 5?/+MS+GLO,]6V F%.SMX5CKW4.L&"V
M&S'EO@9::G =6D)9JQA=Q$JL02G,5)4BN(:$\HE9^*ZQU)KBFRLL8GCA[.Y*
MY$;"21N]>SGMC/\ O2+Y<V=G<TJ[0)&QNO-L:VM=*3UYFJ36>\+);4SH884\
M-O$(#RCR[(G\^/NB[KQ=(9D@:R6?<2ZKLVNZJ(?A3,]>QX[0V-5>6R%[3UWH
M4E/5A14) IR#QV%S$86#%'3S1R3S#HJ$\@F9P*XAJ/='M"RQ^/$CQ)VU_P F
MPD=C*&3DJA56/>. "GW%.%ZJ1%KIL[&/6,:3P3BI/)%-+WW.9D,42"!E?M#S
M!V0")@6*WDF\PSDT"MV>4<F2D2+5*FBIU3,RN<YC8M J&?\ R:1SFN:C++W9
MRN:Y$3S14Y0]GL?DOR$WY<<P_DG_ "P\O.+XOY0>8_,Y]1[\N_;:1\?BW5/L
MIXL_ZQ%_JY].)_C_ )$\^7$G:<JE/?T.B@))S]W47HP1Q56813V0=G )9A.:
MPRN)E"FGC@.$<YK2A)7,('<YJ2QL5419'CDB(62-XV95=0ZLA*,.5<!@"58>
M:L/(CT)RK%/!.&:":*94=HW:*1) LB'AXV*%@KJ?)E/#*?(@95^295S!KQV_
M@#C/YWR?W+8<YZ_"*_PYH?\ .V_H+.= _@\_XCWO^2+_ %];-7G.1,ZWQQC/
M0?G/P>H?T-5_88.?3'5?)>M_8*?]/'GS4V7RC?\ VVU]_)E9Y?Y98XQCC&.,
M9JZ\.?R:77G2_6.T;>9_K_0>(?2P=\ 5_<$ =P5+3UW;=AJ4KH &6JN=43!4
M%X+27)=/7BE&B1&B^W)%*E;-M^UZLM;"Y"8Y;,6KB.N9J):-0[TDA[BY3_:!
MI8VDC$C,%)4\ J./-^G_ (/*&GUMP3049]]8&[2/:JDS&*/:263&J"7GPBD$
MZPS-$BLZAU[F5CS%MU\E6$!U=X3:'"IUN'K^C,J?2=O5LD=UE\[WM>:3KNKQ
M-UKKG7T]1<:6.^HI0K!F2,NL_?(+F+^UR\4-37N&9!>1]8LUS=26?:FAV,ZR
M4'YCGEUL<-M[$4$<$CQPF*4,AG6.6+F:*.<F1P>[&2_!FD>MZ8@I?B]+6FK/
M#M8R)JU?=33T(J<MN6U%%-8$\!C<5GE@FXK3S5@L497M_&E^3-VOGVI7X\_I
M%*WN#PD9'P_6%SJJ?76FWZZU&%ZYVV!J;G"Z8Q+JUL*>]!T5+5ZBSOK%FB,S
MU(@+XRE<.V&$/5D'^IO.NP[Z.[GV:QPR0I7MPV;=:TZ685\-$DB:&1X4C0Q+
M+)W@KY\RV?@ZN?\ Y..I)IO#VO2U71/-9BM27*%FE0N4HIJ5A_&E>*:.Q#%9
MDFD$[P0]A#$CBL=M_);45Y8=8D]9UO7%=F:#I[3=4]B=;V$^BQ5'J+C7QY9+
M_MH739&KMKHO?W3,N'7:NQN:]]UKJX:ME+U%;9@1FNDI=7RQK;%M[3327H;M
M6VHBL2PI7,WA4FAG=$%6/QF>!(W$<#E@L+HY45MI\&L,TFN;6QT(ZT&JLZR_
MKY&L4X;,UOV;Q]HEBK'+*UZ;V9([,DJ>+:C"%K$<B!\_!'R>7<EIXE\OW#H-
MITW;Y#.W'8E3-6Q94^KO+GK+M#I2/JN_JKV""G(EUNN#L9;2^GTF]V&O+T[2
MJX8PJE!IHZLTO4]&/4S4(H+R3RI5D#&97BCN4]BUV*2(EP((&3LC$-:O76$J
MQ42-(9%'H/;R=0UMK/<U$M6O-?C,8K/'--KMEIQK)XYP(6:U;20O,;%VU::P
M&C5FA2$1/\ZF^37T- 'X5:'LX'P\:#.^&O,=]9 X2AQ9\K>RV]EX7!Y+)[G3
M5U_53 R;@.?*%D:$B9Y20BNK8ZRP,DBD]E&[U7%*VYEIMM(I=M+KIU:6PH-0
MU;-F>>M$\3AO9F$RB( +R>\NBCCEJ_@]L5TZ:@V*:&>OT]6W=1UAJ.?QB-C2
MIU:MRS'/$4-Q&K,T[$MPI01NY!RA4WR5-U7=:8W!@;['XFT'\$_9_A?[!V6(
MH31;?5:S;Z?):&IUAOHBJB-#0 ,SYX%H#=6 ]D2%:3B!S#LF?+%4EZR1[<]E
MJ\]A#U!3W%6O9E5HX8:T-B)X%Y+B*5_%1D:-2BL@8@D &A%\&4Z:ZG22]4IR
MIT?L>F[UNG"ZRVK5RQ5GBM/PL33PH('21)G$A20JA )(N''?)K7 Y?4A&OAZ
MH^;L;WUA^W-WE![#9;C,[.+$]2:[K6$@2LUU0#455F8^WS,T%3'1^P!K\R-'
M8:/0$PU[PZ4_5:'VT0&YW3ZRQ1K3,L%>: V+T%LJSP.SNBB.8%S)RSS,5BB!
M?NKU/@\F5]4UH:SPZ>[I[6[55[=RM;%/5V]>"D5N)(HI',U8K&(>$CK*'L3L
ML93N=#_)V;?H[=^&;<Q'=([4CJ; ]B]7;0;39FWFE"H-/X@2NY,IK.L36@/D
M%V60IB7Y&H9;1UP5-'+/)7%O%D498;+JBOL:VWKE=A76[:JW(##+&.^6'6"A
M+#<7NX:":0"=^PNTA [U[N&$^DZ!NZ:]T[=#Z:XVKHW];<6Q6E)2"SO&VU:U
MKG"$K;J0GV6'Q0B1 L8W[3VG;MS2<]4QQC'&,<8ROY?Z^K_X<WV:;F0U7RA6
M_6?[M\QNW^3;7ZJ?>QY-/-XS0<<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8
MQQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC*
M=<?5-I^CC?LTO+:[^AV_V:?[I\N:7Z94_:8/O4R".:!GH^.,8XQFO7N/P<:_
MLKN3Q/=EUVMS==6][>!VZ\*U'7&P6;S:346A>N)BT]J^ =\$E#$W1CMDA#?+
M8*H\RM@5%9Y[/1WL%2AJ*CP2LVNZACW,CJ4[9(46 &% 2#XA\(^;<+YCS]>-
M$VW25O8;?J/8QVJ\<>[Z-EZ9AC=9"\-F1[3"S*54J8 +"\A"9/BGXOIF/W87
MR6-.91] "]=A=;AQ]=]9ZC ]L8LY]]D*#M&^W63QN=U/:$NMS=1<W\FY/^Y%
M@=O9W]+;6.IHBV!E6U.2&PF7)5NL9%DV;66MDVK<-JE87P[$M..O//-#3$,S
MQQBLIG[HTBDC6&5>Y8W#$# W_@TB:'1KKTUZ"AKK-+9TW,]2#93W:M2"SLC:
MKQ33FX_L@262>&62S _8TL3*&/8=\GOW,_Q(=3]OFZ_I>WRG5^ES*QU<^:M0
M=!>823H>+IO=4VD.;46%UN-"=(V4\+0=A;;5D6E3'54I+Z0"KF$LY?\ 2:@-
M3=HK#?2>Y#*"XE1HH[(V1OUY(E[UCKQ+Y*T56O"$D[Y!XCN&2)Z#W!W^LVCV
M]1+6UMFN1&8)4GFI'2#4W8;#^"\MR=SS(D]ZW::6(1PL84B*R\?1_P FG?X5
MOA/S78P_A^U>'\,FK[@-LHJS%'/LNW:?<X2[S.3O-M67E:343[&AMK"L-F:1
M/8"@CU$,E;9SDM'C'FV'5D=C\=2U6V<%C;PT54M84+2>M9CFFB@>)UD$$B*Z
M@@(SER'0 L6CIO@\GICIBOL%T5JETY9VK2".FYDVL-RE-7JSW(YHVB:W!*\;
MD,9$18@T<K,%"T'._)47%+UCU'A*[=8S$WN:\.?BGZ-[+WF'H3!+_7%]Z$TS
M\3;NF;!5F7]5B!:R00JMO;$6;W*1 *8@2)6S03S=9)+;NV7K3V(Y=KIMC4K6
M)%:* :T2>T)QRRQO9+@AXT([AWR!CY&W@^#*:'7ZNE'=J4YJ_3_4FEV-VG"Z
M3VGW+Q&G+SVQM/'32,HT<TBGL/9"5'F*ICODR[X6NZM"U?\ NI4;(=_]%=K[
MBB&/VFQS.YJ.F^N.R\%*L5)JJD.FI;2ZBV6?:+2PT\XPE=FXQ;?4Z!(*AE=)
M/U9&SVVA]LYGUFRI5Y"M>O+7>_;J61^4@=I)$C,$O=(9 6:7E(8NZ3NJU/@Z
MG5-8EK\6%*F\TVSN0*]NW7NQ:K7["B>(;,20PR2BU7[85B94CKA9;,_;$(ZS
MU9\G1M.I]9X8-A7E]'ZTOI,GOC/:.KUF7MB 8<-VOWM/V[DK'KXB$!TM?KNM
MPB"JR@$/'$J ;"P,)K30X72>\R7.J(+L.W@9=A NP&MEB>"9 QLTM:*,Z6@6
M >"VP5Y&4EV5$#JQX[:NLZ N:NUT[;1]-:?4-NX)XK5:5HQ3VFZ.TJO1(C)C
MM:]&:.!'58D=W:-T!/=<_C<\!>^\2FXW>MQMYU/-%V/X<$Z")'[8I+JS-ZT+
M!V=EL1-UUH;4C6#!;.Z=9K57HTP]=/'\UU-I#9FI M5RCT_U'7U->M!/'='L
MNU_&8-*2-%MAJZ5VK6U=E)2/L[XR"P/B2(47GORZZQZ)O=0W+UJI-JR-CT_^
M(V7:0S2/KW2W);2[KWB60+)*9/#G4K&1X<4HD?M\,T2N^3EU0/?^M[.)V]5:
MU6J["&[,JM@W1[:A[,ZYM7]80=9V&?H:^IA2CTE4+5-.&RYEK?5 E/5V<@%G
MF=!&)"DL[=41-K(*8KNCPU33D@\*"6I;07#<661G/B0N9.UIE2-VD= Z31%C
MQ0C^#^S'O+6Q:['+%9O+L8K7M%R#84)3K5UTD$$<0\"Q$L0=:S2S1+%'(8Y*
M\X1>>GUI\GMV/CNNN@^LS5\.E0/T+WWT1V9)O^O\EH<]MNW\YU$?MR+ KLCV
MXLZ/VEM'IX"1&_.]S7Q7!FF/?:P1V40S)[?4U6>ULK:_C20[+6[*H*UJ>*6O
M1EO)755J<$?ZO&8BI/AQL8UA7L)0DRZ[H385*&CUS?B&)=)N]+L3>HUK$%S;
M0:N2VTC[#E2#<F%@,OY69!*UAS*!(%%N]7_)J]HX@;&4TO8&&I,=AO%1U=WE
MELEGGZ&[*R>2Q&#[7S%]04>^T%(-L[*>VN.Q0K7*4.L,OP<./5V$ FDLI+<A
MRU;?5=.P;+^RV)+%K2W-=//+X4:S3V+-*:.62M%(8$"1U62:6!8FLLZEH4$:
M@6^N^#S95%J0F_3AJ4NI=;N:U6 SS-5JTJ6TK3P0W9X5MR-+-L$EK0VGG2FL
M<BI.YE;+!)^2=[.-ZOMNN/\ >)U523T?AR[ \/\ F=3FJ#0UMMVO)NNR:/=-
MWG>"NBE>T^FAHT;#2UQ&K<3I+2QOTOQ(GI6/N5ZSJ+<CM^RW)!)M:NSFAEEB
M>.D*U26M[-KO3E9/%\Y'$ 6*-(O"8_E!8M\&&R?6RZ_V_60F'I^_HJ]FO#82
M7:&]?AN>W;GE>?$A$/E%&UHO8EDF\9 ?#.R'PZ^&=G079_B5T])]RE3@^Y=1
MUC?XS$Y&J6D!R$>,ZJSN#O8YZP802H@(O+BFFMTDJXU2>&:-YKE+]:)JNSVI
MV5/4PR>-)9H0VXK%B=_$:?Q[LUF+AV9I"(XY!'PY\B"%^+QGH/3_ $Z-%L>H
M;$/LL=+;6==/4J58_!2J*FLKT9PT:JL2M--"TH,0/(8%_C<YEOS"YM.8->.W
M\ <9_.^3^Y;#G/7X17^'-#_G;?T%G.@?P>?\1[W_ "1?Z^MFKSG(F=;XXQGH
M/SGX/4/Z&J_L,'/ICJODO6_L%/\ IX\^:FR^4;_[;:^_DRL\O\LL<8QQC.H>
M3*&":7 "59SBB$$PUH3PXS;"6"%\L8(DEB6!7L*+>U(!WG'!!MED8XHL:!'S
M,B "0"RH"0"[=W:H)\V;L5W[5'F>U6;@?%5CP#+(Q1'=4:0JC,(T*!Y"H)"*
M9&1 S$=JEW1 2.YE')&NGH#Y0T+MO/>'NTV'2F]Z])\2Y/;LW6I3K7!7V?.H
M^J\UHMN;8S$U.Q*OQ&24-*VF1+?/4YQ6G:0^.H%HGP6'-IV?3#T9=I'!?K6A
MJ%I"X.RU%*LER:*LJ*'KB)CXLGB?DYI%6'CF0R@IF@:+KQ=K7T4MK3W:#=0G
M:MKF,M*:"2'65Y[CR%HK33H##$(?RL$4C60Q$2PE7RW"?E4NKDR@NVJ.EN\=
M#FH?#[C_ !-ZNPJQ^L8/N)ZJUVKT>2:;<CW'95658W=49FC2BZ3,0WI! <L4
MH<DR1F*-47H^X9VK/?UT4IVD^HA5S</M%V""&?M0QTW"1NLRJ))C&JL#W<<K
MW6[?"9K?9EN1:?<SUQHJG4=J2(:X>QZRW9L5N^99;\3231-6=GAKB9F4@Q]W
M#]M_$_*)==UA.QS][U5V_1=A9_<=&8+,]<6 F!DT78EOXDHKB;I^7.V(&]-R
M=6->CYV]*NFZW19\K+#59#;@>(U8@I+8=,6G6"6*Y1EJRU]C9EM(UH158]48
MQ>$JO569VC,L0C\"*43%QV'MY;+YNO:$;6X)]9M8+\%S2TJVOD6D9[\O4 F.
MJ->2.Z]6-9Q7F:7VJ>!JRQMXJJY"&D&?*3]?-,Q^7H^EN]==VAK-OWQU?+U3
MF*7%66MSW9/AVBRA6_R]N:FXCRDL+JS7UMY3Z*JT5C0&4T<\\QPISAZV>HO2
MMHK/-)?UT%2&OK;@NS26%@EJ;1IEK3(OLQG!#PO')%)"DJR< *R\N*;?"%1[
MZE:'4;JULK5W=ZTZRO%3>U!L-"*S7JTKFX*Q4QVHYH;$<[P/$"6=7*QM7_%!
MXF^S>DN^?#%E\C@-%V#ENQL'XD-5O,!F(\+%LRUZNS_75Q3D5UML=5FJ47YD
M9H+N6P!!O)B+F51@PH3'I$J4M/J*FPUNWFGLQ5IJMG4PUK,QL>SK[;+<20.D
M$$TA\3PHPK-&!&.68KYY5ZDZCV6FW?3=:K1GO5MA1Z@LWJ-<4A;;\6P:^:)H
MY;=FO"G@B>8R(DS&8]J(&\CD:5/RC_79&KTVBKCMQN,=K,9X1).F>M:C YBF
MT-MM_$O8;H#-T8>LM=X- ;<71-+%%HA=6-E<_BHL^1*!>WSCY6MNGZ6M"&*)
MDKUYX+&\%^W):E>)*^H6JTLC0I68K'&)"86A:>6P90'BB[1F/B^$&@UJQ8C>
M[<J6J?2IU&OBHUX9Y;G44EV.O"MJ6ZH>69H0)UM)6@IB E)YS(0+P(^4=QTQ
MV=RN:Z.[KU_9]ML>_>O;OK"G_P!UHN@QVR\-]5D[[L6KN;B\[+J<A8COHME3
MW&;L,SH;V*]#F;#!'%9R,KUHCI:P%EFFV&O@J)7UEI+<GMICGK[:2:*J\<<=
M-["D202),LT,1B9222@+B[;X0*A>O5K:;<6]E+;WE";6Q?BU9ZEOI^*K/L(Y
M99MA%5D7P+<4U=Z\\PG0]H D(CSJTORF_3^PT5-G<#U_V?KB]'T<SO;-Q(G7
MV8M-70RXK0;7[G<1GM?O**_WFF"CSI>:NA<57WX5+J2113SHZB"XNZF,G2=Z
M"*26S9IP+%L?Q;*?]:F2&46(JQEL2P5I8ZT),HFC:PT320JS(A<QQO)%\(VJ
MM3PP4:&QMM8TPW5<?ZC6DLPFG/<]GIP6[D,]ZP@@:O,M..9(;+*DCB)99HL@
M?#1XM.MO%@-L;OJ4+1'8S(+AQ%W)X]9#G;^^V&)J-W89JC>+:&'276$KK^FK
M-N.<$#'5WYJU8LI\@ACX,;MM+;TK0173$MB?VAO9U+&6**"S)62:0%%41V6B
MD>L59B\2][! R@Y[IWJC7]3K;FU:3O3J^QI[8XC$$\]JG%=DKP]LCN9J4<\4
M=Q71!'.YB4N4?MRBYB,V3'&,<8QQC*_E_KZO_AS?9IN9#5?*%;]9_NWS&[?Y
M-M?JI]['DT\WC-!QQC'&,<8QQC'&,M R^-'*(@8P=612O8U7,D5RHU51/-4E
M1%7\ODB?O<93+D$CR\B??_?.M]TA_P";%_5R_P"MQD.\^X?S_OC[I#_S8OZN
M7_6XQWGW#^?]\?=(?^;%_5R_ZW&.\^X?S_OC[I#_ ,V+^KE_UN,=Y]P_G_?'
MW2'_ )L7]7+_ *W&.\^X?S_OC[I#_P V+^KE_P!;C'>?</Y_WQ]TA_YL7]7+
M_K<8[S[A_/\ OC[I#_S8OZN7_6XQWGW#^?\ ?'W2'_FQ?U<O^MQCO/N'\_[X
M^Z0_\V+^KE_UN,=Y]P_G_?'W2'_FQ?U<O^MQCO/N'\_[X^Z0_P#-B_JY?];C
M'>?</Y_WQ]TA_P";%_5R_P"MQCO/N'\_[X^Z0_\ -B_JY?\ 6XQWGW#^?]\?
M=(?^;%_5R_ZW&.\^X?S_ +X^Z0_\V+^KE_UN,=Y]P_G_ 'Q]TA_YL7]7+_K<
M8[S[A_/^^/ND/_-B_JY?];C'>?</Y_WQ]TA_YL7]7+_K<8[S[A_/^^/ND/\
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M'J']#5?V&#GTQU7R7K?V"G_3QY\U-E\HW_VVU]_)E9Y?Y98XQCC&.,9AN-X
MO"D#14F: ZZNZ^ER^KN=CDPZ[M?N&O7'VFCKK.IT5?CR0]] 9D\CH:RYM0;W
M!9XBMQ%P-8%16.?);*O,XW4FY:229[4;R30QP3L]*@PL)$R/"UA6JE9YHGC1
MHK,H>S&44K*.,U)>ANF$AAKIKYHX:UJ:W52/9[6/V26Q')%8CJ,EY7JU9XY9
M$FI5VCIRJ[!X&!.5H+P/^%RNRMQB@^K8H<Q?],U/A\MZO[K]](AG4%%;W-[5
M8]2Y=4\^!@EKH;@M+L8J'23*8L)%Q*/ -%#(W4&X:9+#7"9H[[[-'\&L"MZ2
M..)Y^!"%)9(HU,9!B^+R(^22:R=&]-QUIJ::Q16GU$6BEB]JO'OU4$LTT53N
M-DNH22>5O&5A8/?PTI4*!<.H\)7A[V1FQLM%UZPRUW<?5B7]P/IME5W49723
MK-_55OG+BJT05EC-#BGW%E)5:7'%4-^]Y;WFV1;FQJRE#NMG L"16BJ5O;?"
MC,,#Q]NP""ZDL;Q,EB*P(T#Q6%EB 4!47SRO9Z6T-Q[<EB@'ENC6B>5;-N*4
M-IS(=9+7EBL))4GIF60Q6*C0SDL2\C$#CGQGA3Z"Z^N,%HLI@6U^BZUL.S+C
M*Z G2["XO$O.Y&UK>S]#I+:ZT%B?N-%L4IZSYTT&WGT5PU0XE#-%7U>J$^YV
M5F.S%-9[HK:U(YHEB@CC\.AW^R111QQ(E>*#Q'[(JXBC^,>5/EDU/IC1T):,
M]6B(Y]=)L9JT[6+<LWC[81C93V)9IY'N6+?A1^+/<:>7E 4=3SG:[H\,?2_B
M"L,K;=IYN[MK?%5FQI<Q;9[L'L;KVTJZCL$6H!VM8EAUWK,J68#I0*.MK[06
MPE+AG BG"1C13CXB84-M?UB3QTY8XTL/7DF26K4M(\E5I&KOV6X)U5H6E=D*
M@$,0WF54B;<=.:C>O6EV=>:66G';AK2P7K]"6**\L27(Q)0M5F9+"01I(KE@
M4#)P%=PUKF>"KPP& 6U:O4]8$);YSJG*O;3WFLHYJFHZ.F.(ZE=E"J:_ *Q5
MQA9[(V:ETF0FH]&DLZO*M27,C5E5=]MU9'%UV9);LWY2.&022;$*+WCK)&RV
M$LA%$D5@2Q$#R0>>6S]']-NDL?XKC1):^LJ\0S6H#%%IB[:OV9H9T:I+2:1V
MAL53#8Y8EI6('$';WY.GJC4;SH4NABL<QUEUE+XBK7?T-9O^U:KL#LC3=]5&
M2!L=%;]JT^R#[!M[0LG.3+K3M#JCRM)5E1U!TA-<QXBY&MU1=AK;)9"LMNV-
M6E:5ZU)ZU2'6R3,D4=*2N]5$42CP%B@5874R(%?ALPU[H#5V;VC: 25M=KCO
MY;T$5[9Q7MA9W<55)+$NSAMI>EE=JY]J>>R[6(V$3EH^5R<G^$;IFCML?L\)
MCXJ?;=29,BAZ4$LM=V(;UGU^>/C"\32V0/5S=9]PL!L-(0E58WPF=CU!U:\A
M)+=Q<B$)COQU?D2Q!8G+U[TXEV#)!56W:4V%L2*USP/:2ID'>D32F%7X_)]O
M(S,GI740RU;E*H(KFKJM!J%DM7WUU&1:CTX9$UOM/L0=87\*2=:XLO&6YE+'
MG*KX3/#Q4>%OH;#].UIPUU8TD!]ML=.-70U3=;N]+8$WNOT?N$/FT,<^Z.)9
M5@J^3YLI1ZRJ9(Z$&+REW6TDW&RL7W4QK(52"$N9/ K1*(X(>\^;%(U'>_ [
MY"[D<L<J]+Z&+IK1TM3&ZS20J\MNPL8B%J[8D:>W8[!Y(KS.PB3S\.%8XP>$
M&9'<Q6;!CC&.,8XQE?R_U]7_ ,.;[--S(:KY0K?K/]V^8W;_ ";:_53[V/)I
MYO&:#CC&.,8XQCC&.,9&MG]8&?RB7^TO&4&]3]9^W.CQZY#')NQO=_,?WQCC
ML;W?S']\8X[&]W\Q_?&..QO=_,?WQCCL;W?S']\8X[&]W\Q_?&..QO=_,?WQ
MCCL;W?S']\9;5UM,=FR@0=%J\U0G6<WN]:%<WE96%V,_LY)O8 #&E03F3>QB
MEE]D.R23V<<C_3Z6.5($$ D^0"EB3Y *HY9B3Y=H'J?09%59Y(X4!>65UCBC
M3XSR2.>%2-5Y+NQ/"JH))\@.<Q-T_P H_P"!''3R#7_BLZ8'GB7TR1!:\*Z?
M&[\37I2?./I<OFGI1?)7>IJM14<WS.#&6616C*H)#WJR H2@#*6 #CF1.>PL
M0#R> "1GI>E>HX*JW)M+L(JS<\2O7=1PJ-(S%2 X41JTA<J%$8+\]OGC.?*0
M> [5PPDT_BQZ1]V)D;$.3;;>LS@Q$KF2R)' 1HI*J&5[60RN>V-[EC1CO:(W
MRY1$T32&$.OBB)9RA\F$+<=LA!XX4\C@_/R,U=;M-[5:BERI)>N4FV-:E'9A
M>Y+06:.N;@JHYG6OX\T40E>-49W55))S*7'=B]?=A@,M<!NL=N:N1B2,L<?I
MJ72@O8OEY/:72FFP*WXI]\DGE^[RHK*PY5E8'TX8$_P!Y_EE])!-$>)898CS
MQQ(C)Y^G^\!EY<G[&]W\Q_?*6..QO=_,?WQCCL;W?S']\8X[&]W\Q_?&..QO
M=_,?WQCCL;W?S']\8X[&]W\Q_?&..QO=_,?WQCDOIC'&,DBJ^K@_XEO]:\97
M7T'U#[,J'&1QQC'&,<8QQC*=<?5-I^CC?LTO+:[^AV_V:?[I\N:7Z94_:8/O
M4R".:!GH^.,8XQG7+%@.%)"*C]J*8/,*3%ZGL]I 1&Z*:/UQN9(WUQO<WU,<
MU[?/S:Y'(BI$$J0P/!4@@^X@\@^?EZ^_)7575D8<JZE6')'*L"".001R"?,$
M'W',+*SY.CP>5.9N<>+U0?-0W61S^"4>T[/[=O#*'&Y;65F[HLYB;B[WMC<X
M"J"VM-5:IPV(L,^TR^ %LSO>2HFR)GGZHWDDT<YN@21SRV04J48UDL30O7EF
ML1QUECM.U=WAYLK+VQL43M!S4(^@.DXJ\U5-8Y@FJP4NV38[69X*E:U'=AKT
MYIKLDU&-+<45GMIR0=TZ+(_<R@Y4I/ 'X69J0G,$8G7EYJQW%UV->9PWNWO0
MV@U&OT5M3Z"[LMA3%=DS5NP'L[^@J[TNGTXUM2R7,,]HM?[]86,Y<@ZDW D$
MPL0"9:\=6.5=?K5DAKQ))%'' ZU T!2*5XQ)"4E\,A._M1 M0]#=-&%JS4[;
M5Y+LVPFKON-R\%FW/+%/-);A;8&.TLD\,<[PV%DA,P:7P^^21FO.#P@>'P8_
M<E18FQ2L[)EV1.UQ#]]V-+U9>']A &5NWMY.HY=:_K .[TX=@=':W==D@[6>
M4PLI#&%DSSR4#N]F5K V%[Z@@%>Q[-4%R-:K*]=!>$ N-'"RJ8XWG9% 5>WM
M50+M>E-"LEQA3D\+8&VUNF;M\ZV9[Z/'<E.K-HZY)K*22"69*JRL7=N\.Q8U
MGI;PQ=+^'VPU-OU9F[NIM]K5XZDT]MHNPNQ^PK2TI^OAK@+%5:G]BZW5E!@9
MH&]LZ^K%KY1(8*^6 %6.%  A%DO[>_LUA2Y-'(E=[$D*15:E5$DM-&UA^RI!
M K-,T:,[,&)8%N>YG+5M1TYI]%)9FUM>:*6Y%5ALRSWMA>DDAHK*M2/OOVK+
M(E=)Y$C6,H A5."J(%L GP<>$L:[V6D.PE;%/95W9'S^"=O=JF5R\'=%475]
MHW&:QY&M^Y'K&U["J9CQM)IL92YBXM8)C7R62NF)>^Y7>[HI!$MEB$>IX;+6
MK>-,=>ZO3CFG$'CW$JN%:&&S)-'&0O"  #+%NDNEUFMV'I1@R1WQ/&]ZY[+6
M7;Q-%L9:U1K7LNNEOQ,ZV+%2*M+*&<F3EF)E'K/I7I?"6_W;]94  =D1UWAN
MHFW5=HKN\&EP'5*68.+S;&G75G7.^YQ;"S'?8LB^>C99'MN+ V6"/V5G;V%^
MRG@6Y69!:LW?#:*.,BS=[&L2GMC1ORO8A[.?#4 >&J@GG):[3Z>E+[;KH(TD
M:A2U7C1V)IE-'6>(E.N.^:2,^S^)(ID \9R2)9'('&*_4'R=7467E[,N.VZN
M+M+2;SLGQ):0"0S3]@NRV=QOB)M[YFAI*;$&:=V0S^F/QUZ1D])L<Y15FAM0
M'RCK;*,Y&IF+W5%Z85$I.:<5:IJ86"PU?&EGU21&*22PL/CRPK8B$\4$TKQ(
MW!\/D YK.JZ U59MC-M8QLK-[8=06(R]B\:U>IOII_'AAIO8]E@LO4G:K8MU
MX8YY8R5\3M/&7R+X /"'7UU]DX\+>.37_P"[ZVL&&]T=T':-Q?3,-76=>:2A
MNC^QB-)GKK#!C4U/5Z7-6%9:A5D5=2RGNKD'#Y;MU-NV>*4V8@8/:D3MH:]8
MNV^7>U%)$M00RQV6,DCPS(\;.7D"A^6R]7H7I6..>J*<_P#K?L,K]^WVSV._
M4B..A8@F>^UB":FBQ11V*[QRK&(XB_8%7+R-\%7AM.'-9)A+4>Q.V>>[$=J:
M[LCM&KW@.YRV+K^O*?4TO8-=M!=O07#,95AT5B527]>Z]';//>I9&&FDD6Z[
M[:J5(LH46O+5\%ZM-ZS5IK#6I(9*KUVK21FP[2*)(F\(D"+L55 NWZ/Z>=7!
MI2K(]N"_[3'L-E%=2[6IQT(K,5Z.VMR&84XT@D>&=#,O<TWB.[LW8NO!IX<=
M)7:ZLT>!.T$&]PV5ZWV9-WO^RK:WTF/Q6LL-SG*^UOC]@1=DFAZNUL+DF_=8
M)HK8@I\5Q:GBHR!J/>[2%H&BLK$:UB:U (ZU1$BGL0K7E=(U@$8#0HL:QA/"
MC"@QHA\\FFZ1Z?L1VHYZ+SK>I5M?<::]L));%2G:DN5TEF>V9F=+4LDS3]_C
MRLY$LKK\7+]R/0756#[-WO;^1S]A1[CLYWMMS.)K=D[-7U@L%*++>28*?038
M(+2E"YVF%-TU;F@] :.$D!5E-%.4V>VFV5RQ4K49Y5DKU.17#05_%B7F1A&+
M(B%IH0TLC+"\S1*6)5 0O%]5T>LH[*]MJL$D-W9>=TK:M^SSR<0J9C2:<TDL
M,M>%7LQUUG=4"M(06!F/ECF6QQC,&O';^ .,_G?)_<MASGK\(K_#FA_SMOZ"
MSG0/X//^(][_ )(O]?6S5YSD3.M\<8ST'YS\'J']#5?V&#GTQU7R7K?V"G_3
MQY\U-E\HW_VVU]_)E9Y?Y98XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&
M.,8XQE?R_P!?5_\ #F^S3<R&J^4*WZS_ ';YC=O\FVOU4^]CR:>;QF@XXQCC
M&.,8XQCC&1K9_6!G\HE_M+QE!O4_6?MSH\BOJ/K'VX'K^YOL..5\ACC&.,8X
MQCC&.,9J_P#'-\K3X5_ RKLOI[HGLKN8J,IM9U!@)1CKD4D<-3&KM;ISGU&)
M#6)897Q63R-#((1$;79VQ%5TK:D">T3)"C+W-)%'QW+W S%EB8JS+^3>11%X
MI*Q([IXDB!@3KF\ZJU&ACE]JL+):B6!FI0/&UE1:D,-=YE+J*\,LP\-9I2J=
MQ''.>3SQ*_+N^.CQ#7]SF<9N:WPXXJPF>%44?63)*Z\]B6C(HA;7L6TC74%W
M0\TC199LZ_+U1$[T:X(;VD,+\E3O:.KI]A<FUUO:;""2S"*[F04A5,[UXKHF
MJ]RQJ%:,LS2./$!:-@I0GS_<=>7WTGXTAUVQKPNUUT$*N8)-;6L35VV)OUHW
MF2)$\*214\"5&8, 4'=F.O@'G33^.3H;5:O8ZG>]ACZ36+;V.ML+\JXA:W$W
MYH)-B5:EE/D>^-TP9$;S2997$1>I6M9#,S4'OW]S,C6T$52.Q#6JI6C@AI0S
M7)Y&=&<+SVD1R2*S%F\NXR<(5;S;1[WJ^?X2*=6[)530C:4*]+<:795MS3O3
M3RW8[DNOM^)&UF,30_C""=XT6..K)&@$BF!,6A OGB$>,<BKKBK*@D/*<38C
MO9)[*'W(2:23W>=4#BD",+@A=+(20..QTK?=D5TNM;#:U^E[34.U]A7TN[[%
M\&$O'9A\-980EA;$<=^>&2:2%GB6)(I%BECD9@3G:?XSWWPD[3I+I*OU)W7I
MI-V=]?TFS$&HV.EZ<V?ATJ'5E2"[6J],V]?11K6SN,MUMAK9:\VN62X^NK1V
MOI\065UK?BO-G?<XDZ[%@048U\4U5 HY1$<9$SFO"F#&MQBI891(8T'"G<^1
MGH(='D5VZ;*]8VE-4KZ_9A$-=WBBL);D/L\=CPTEE259VKEG\*1UCFFE!*IX
M??Y;LI9/@^^%F_T?=CZ6LST-W4I]068;*:W;2/MZ]6#6;&#76=-3L[C72[?5
M;6E<M6+D<]>[:IU*D$\8JPR868O?;KKBY9H<#L=1A-0!,UPM_DM!:9NW#F;(
M[TJ)9TI0A8SV^2JJQ2M6155$<K?2B1!X)9?BN#QW \$<GYB.2/0\@'WGW<=,
M2QI,D(E43URK.L97N#$HI8LK*%8^8X+?FCR9>>X'>3X0/]HE^4!\.TU>!VG=
M"^*?K %T$1M5VBU1-S "BHR1*;M"M$^?)#O)$1A&M$U\2*[TJ.U%1Z74-VS'
M\;EI4'D0X/O] WF1S[_,#TS!WNG=-8>.$%*%N3R'@.&4>0(:2%F*^2GGA#&>
M!SW<_F^R/P _*Y>$/Y0L&.HZQU1&*[?% :;>=(]A*)4;8=C(_467FY8YY:K;
M4X[D>Z0[/%3F!CI'-=55.LT<2Y>O<BL @<HX +(Q!(!]Q'D?/W>?T9I&UT5S
M5-W2!9J[2-'%9B/*.5\^"IX="1YCN7@@'M)X.;0>7?KF%QQC'&,<8QQC'&,<
MH-ZGZS]N,<AC)(JOJX/^);_6O&5U]!]0^S*AQD<<8QQC'&,<8RG7'U3:?HXW
M[-+RVN_H=O\ 9I_NGRYI?IE3]I@^]3((YH&>CXXQCC&.,8XQFD[Q)=P>-1_9
M7C(ZNZYLNS;2N'Z+WVCZ6-ZPZR($K</9Y_,9(F'/W%CJ.H:Z]N>Q-883HF8W
M3]>]O;>IM&F>Z4^.H=%2>]U^_:FCH/9-%<M+31CLJT.P6Y;!>PDDTX,J+#>:
M..I75838AM4:SIV\R3RQ2]K>.]1;;J\[#JW6:^392QKI;UC4/KM<5BIR05JK
M"":2SJHYI;]IWL"I8H[6Y%*&[8JD,\)=+XZAVWBL[ [9ZLR&/[M[&9T92>&?
M%]JZ[;;SPU5U1K]WNZKNC7T.IZN%BT6(P3*$^QQU8%1*<E?-:I3@5>JJ!#B[
M^733VUV#35J-V:?7U?QE)M[%*"O6VQ>"M6;7UY(;A\*Q:\5%G=I I8)WN\,C
M*L0AR]U-WJ:]M-;4J;C8#30].4]G:N7NGHXK=R[%M[4%G6J+%.EX+R5(XX>_
MPS*(DBLQ([SFPV'=SXFO'/V+U5XDJ<0WQ$UB)A>C>P^NK,CP_%4'9592D]PK
ME.]\VU,SU%G*($^IQJ/OI,J%8=C7U:&$4!6[W430Z%@.=34].U;NI=EU3CVC
M95;:#9K+4DD%#Q];*3+>ED9'L<1"=EIQNS*[UH08N[4YNH^L]CK.H(4??1CV
M+2WZ$C:-H-A%$^V-;=5Q[/JH(5>*H#.:R27YXT1DCNV6$P2I=\8OM7NZ[[8H
M*YN_U.#U_</R9(YN_/\ #G2Y?0=RXPVXV<6ZL>Q:>QZNH4T%%AI_F:\L*2]H
M8Z#-#BC!6U6-06Q@9LFMLTM>E*9C6BLP4.KNVLNUDFBH6%CA-9:DB7)?"EL@
M21*\4OBS%BR,944K5WE39[B;9P1^W6:5K;?!VCWGT$-:?;5'FMB[)?BDUT(G
M@I$1320S0""NJJDL:P2NCW[@NP?$'U36X#K\.LU7A<Z%+[<\8*V^VZ:\)P^S
M/@LL]V^<-U#B?]WU!UOI0,QF];EIRKH/6QXH@K8N%& J;D-RN+Y;6*VLNM9M
M,\.XV0HZ(I7O[HUU*2T5-^Q[3+;A>:6"8+&T!L 5^XM)&P';EY0O[W61T:"Q
MV>FM(VTZK\6YJ>F%MR+)7VC+JJ?L,.OL)7KVJS/.MOV-FM]JI%,O/?EV:7Q,
M^,2V\0O:_7^)9W8/A[;)^*K'8Q;[H)HSLWVEU[3 ']1W&0L*WJQH<%#IW%RP
MYVZVW9>Y'UL$3KRVSF!81359]&'5:)-72M6#KS8CGTL\YBV?=XU.U(RWHYT:
MYW&6+@&6.M4K&!CX<<UGMD=;JQU'U9+O=G0I_CA:4M7J:I4,^D"FOLJ,,;ZJ
M:I)'K0BPV2S"":WL;JV@/&EKT0T,<D697L;Q54^.ZAWG66>["[T[?R7@)[:@
MDNNV>@2\_M,[V_5$]$1E]8#WMC@LAI=0E)*S3G5HBV-L9V==TQ<<]QISQIY8
M[N:KII+%ZM;EJZVC-U)1(CI;)9:\M!QLB+AC2S8BA\13"C-V1K3BD4^'"I'.
M-J[#J6*KJKNN@O[G:U.A]HOC;31M7MU]K$VE#:U9Y*-6>R(B++HOB2-L986Y
MEL.C,)C&[U\:UV=#F,'KNS-#UW:>)[PO]?YWO[5^'>HS>UL,+V'A-@=W_$9B
MCNO<Q0#Y_K?4@9F"MVL^*K8*DZRFH+>YT,M:=(19'7Z"-/&L05([2:C<69M;
M!M'FKK9JVJZZSML+:FE,MN%YB\ L.9%02QQQ=Z@9==UUA,XK4K6QFH2=1].4
M(-Y:T,->X]._2MOO%:F]"M *^OLI7$5QJ:+&\A@EFG,4A;8+X,=GW!M^D8SN
M\_G.?L&B[%[:QA%Q<Y6#%VFFS^.[(TN>R.H-SX5?4U8TU]F *H_WFFK :>P;
M*T^O'8.2WSUK?04:^P*Z[L%62K2G$<<QL)#+/4AEGA65G=R(YF=>)':1".QR
M2N;UTC<VMW3]^Z\1KT.PVE0S2UEIR6:]386(*EEX$CBB4SUDBD[H8TBD!\2-
M0K#,K>8;-GQQC'&,P:\=OX XS^=\G]RV'.>OPBO\.:'_ #MOZ"SG0/X//^(]
M[_DB_P!?6S5YSD3.M\<8ST'YS\'J']#5?V&#GTQU7R7K?V"G_3QY\U-E\HW_
M -MM??R96>7^66.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&?%5$^E43X^7Q7R
M^*_0GQ_'QCD#U/&?E\D<3?5*]D;?4UOJ>YK&^I[D8QOFY43U/>Y&M3S\W.5&
MHBJJ)Q_Y_P!?L\\@2!ZD#YO,\>9]!^_/WQD<<8ROY?Z^K_X<WV:;F0U7RA6_
M6?[M\QNW^3;7ZJ?>QY-/-XS0<<8QQC'&,<8QQC(UL_K S^42_P!I>,H-ZGZS
M]N='D5]1]8^W ]?W-]AQROD,<8QQC'&,^.<UC7/>Y&M:BN<YRHUK6M3S5SE7
MR1$1$55551$1/->,9Y=OE5?EN8,H?M?#7X-ME5_=120%U?9G=M:Z6P2AFB,C
MK[S.=8EC(X"2^J8E+BM=4LTSZ\MJ#9B&6QB^=PK.Q.H:!(Y45VDL"4.610(4
M)$*R ]QLV)>(HD1&*,"\A5"I;Q[X0.N=O0DUNGZ9HV9I=OL9-1^.D6 P0WA5
M>:.E465F,LT\WAUGMK#+6J,T@FD@<++'X_KG<$6VVM77T1UG-9_-YUG'HW?.
M-A).X<<J6PL3#_>)8KFPLY$GLSB)&2DC*Z"4PACF^TO*^NL;C7:VB$KB8$1U
M]B;+%(WFM%D@E\&!HH4:H[V7CEG1GL!I+%A9A'7SQJOTY=VVEH7&V*V[DE_:
MB+=U]@ZA[ER]*LD3/"7$E*O7E>Q";2^!'L6>V52THA%IB1U+932QB&I7H2MW
M7OD:\&42"9S)!)@ YX8VLDBDEKHY(@D>^Q8+&D#(_1"D-RE2J(Y+56O<BKUC
MLZSEH!/8M7)&2*I!8HR-.L=!*LD?AL\TI@GN'NNO*55\Y!/(L= W*,TK4U;7
MVN1%:;;S1F)9M=?5)"(:MFHUE?:+#L-?/<=Y+-@&*%\\OD]"2;KQQ]$%A$/L
M8!-"3(::R-4@.6MQ5M%)/[3W>&22&5H@[PXS8TD?*J/*9YK(]<7!V/7K1S:Z
M&JM5+2H.91+Q9E6.2S.7=1XL<@81*O*I^44*8D BW/HW4Z72QUK.SH5M5?W.
MRW$/2^I\/Q+U"&[;M.[W")IZT,U=3+7,E605DC:5*S.DD4,..-L6[4'@6P+)
MZ Y!70%OJXW10EU\4;)F,'60UK*Z6-QB/3VHRC/A"'E$+$F2>(FU;1(FV&GI
MUS=1%ISTIMK/6IU_&<F5FL>&";,5A8G@1GDKOSVQ,/$,"#T7I+X(-O!INIM4
MM723:1-EHK6FV?5T&T2VN^A,5'8ZBN=32,&QU74)<FW>NNFQDN-/'.J0FB$Z
M61D$?7ZK+RN/2QN)+GT6;BT!8=&955K1AK&P+&]4<I4CE!6")\XYL;"H/1Y%
MCO=4V5:>I'8/XJ,<KP5U?A>:T<]?:67DLU83*LW>.8F6N8R8HI':P%Y/=@NK
M*3Z:E>ZNZDZ&]MV^JJ= 5JE1(H-S6T8L=2;S=;3>4=5';>\LDD4>MLZ^3P(7
MJ+-%)9F1HY8%CFBZ'#]WT-SM#6PV ?SQ9UM( \5S[M@*'.C\RB$<$-![6ME6
M,='/G-]N'^QQ1E(]<)<=JL,5WPA/'+>@@E@C+-.HL"K+$HB2&?DVHK:- W/A
MKX%GQ?CIVY[!I.OKW476?27173^DOSTMUJX+NSW%BQ7H/H:$73L?5,ZHEN2K
M5NW=EJ[<,,$J;,+0N4MG2,%W9PUZ$M=-Q7NX@CZ^4:;WYH;1:DA(ARW1GMFF
M9[%ZJT>:,09P;3Y7>[,B():Q$]2/8S*B\M6M--L_9JT42NT,L9D:&ZD:0%UJ
M Q+*TR-,R21/&@!0^$\P5FS9:72MJ_JM5<BWFNM;F_:CU]C63"3361N$6R-C
MKZ,6RG,M^35V:\,%JQ"W@//L:<%=YI0Q>RB,3M<%KL'N,"18TES\^5Y%);Y"
MU6ALJJ["G(+%* M9'@2T=@R *:84YR0Q,GB]4<JD#$Q-PBVX-C!+L*,<]9(G
MDJL\\?AP+8,33* R.4D(1&+K'('X'Q1R03L_2B;?9[_<]"W-=;V4^FV-%+DZ
MO#[--%8DLF""'93L:M:S8CJRVHJ>S]FO1U7@L6:25+5:27VW?);_ "X%3W;>
M8'P_>*12\UM-Z J=,]QW@<=14=FS0%-!@RFJ]C#!6 ;>171L!O*]L&?TI#V
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M$TGX7>D-7T;U4E#3^*FON:VOL8H993,U=I9[5>2)9&^.T7=6\2/Q&=P'X+,
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M&G/!_P ,'PD]/=>^S1:S13Q6=;-+'7WEJ<)-)39^9(4I1$HT4[HDJ-8D:2(
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M/4#NW&?_ "P+8!69,Y%;;6E]!Z)K0VP1ZF6E#HAKX!# _:E00V#X X==HQ%
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M3%Y>0J/7\LLDC_/]]%=Z?_;FI&5S_O']P _F!S_/-S%>(?[I/UDY48A!8/\
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M1QD0=A^F+0Y$EODDD1D3'+^-6%S.KD3][R/E1/WW<Q&Z7NHS^7HJ-_RRJ?\
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MB*58Y(VKB- U?X9>DK4\/3&^U*U-1K6FV$FXBN[6S9UG5LTPJ-5K[<V7C_\
MR$6WK2KVR5J$$S3^ ER:91$WI0_V;SJ8[5=]=N=YV<(\H>&ZU I0I_9)(1#>
M=B'Q0"Q%RO8V..S%S^0N/>9JY&B$QW#F,\HFL8VKH6<3RP*K&"O$[>*R_&::
MS.>>)  TD96N!X<A?PF4,H4.QSC;2;"YMM9TFT/3T'2NETNGW&OKT*$,<&HW
M4\MS5U3U)J2FTN6FCO2Z2_!L:>VABL5K]1;$*(MKOE]D/-JS8<<8QQC'*#>I
M^L_;C'(8R2*KZN#_ (EO]:\977T'U#[,J'&1SR[?[0;\F<G9V1-\<_2N?]IV
M'U_30P]]T%4-YD;'KRH'; %V'%! SUD7_7X4;!=#*YDDAN%AA+DG@BQD<!WM
M'P5]8^Q6%Z:V,O%2W(3JY7;XM>W(26J$GR$5MSW1#R"V25 )L$KY9\(?3'M4
M+;VC'S9KH!L(T'G-60<+8 'K)77RD/JT !) A ;S=?)I>/78_)^^)&B[0KEL
M+CK/2>Z9;NG#"RIZ-1AYRD>\X$:62,5=7DIY'WF5*D>.Y2F&4DQ@]3?6Z2^N
M]8]+U^JM1+2?LCN0]T^NLL/]C9"_F.0"W@3@"*=0#Y=L@4R11\>:=,=03=/;
M..TO<]67B&] #_M8"W)91Z>-"?RD1\N3W1E@DC\_TG^O]]CNU,/D^R.OK^OU
M.(W-!5ZC*Z*KE64&WI+@2(T R%7(R2-9()6I,//'$2+.V08J&$B&6)G(5JK8
MI69ZEJ)X+-:5X9XG'#1R1L5=3]1'D1R&'!!((.=,5[$-N"&S7D66">-)8I%/
M*O&X#*P]W(/F#P0>00"",N_EOE;*=<?5-I^CC?LTO+:[^AV_V:?[I\N:7Z94
M_:8/O4R".:!GH^.,HO\ G']WV#'&2YKO^5+J@+'P;[PDUB.GI;[#VE8_[Q%C
M.=JJVI<Y%<U7?? 6IT2I&K7^F1WWWI]376&R -23GU!4K]?=Q_,$CCY^>/3/
M4?@<FDAZ]U2Q\A;$&P@E]QB]BFF(/NXDBC;GYN!]!&D7Q!X>UI/!IX&KHP%H
MXAD'=KI)$5/:?_F/;A7]2]_E\$:;5(XJ!?7ZO0U?-C53R7%3H15I$^A\0<\$
MCAG!7D_^Y>3Y^1]1]'O_ $ML8INOOA*ABD[GC_$A53Y &G1EJS <\?[*=A&W
M'O\ +D9ZJ\I7@U&7S=560H/6UE!3U]>.U$1L (5<,,)"U&JYJ)$/%&Q$1RHB
M-^"JGQYL2CA5 ] H'\!G&]N62:U9FE/=++8FED8^K222,SD^GJQ)],K_ ";+
M?'&,<977T'U#[,<9''&,<8S0G)E(S?EBYQJ@2+V EH_36C'(WV3%EZ3;/8$J
MC$5/5/8GQJ[U(CG$D_?+ZG>:]3>WF/\ !U5K$C=\L0HUSY\GMZF(B3D_,D,+
M ?,$3R\AG)3:\2_A*NM9!VQ,;UCD+V@OTN!*_ Y_.EG3DG@F1_/@$9S?).9H
M>F[\\2HUF-['1YBK@S:,18E8)"[9VL5V.GQ27S]]I*QK5C9[)6PKZU:JQ(Z'
MP\W7L]*]%-"_?3NRO=Y/=R[C75C6?T[?]E9F)Y/=RWD".XB?\'NBE;JWKU9T
M"W:*QT>!VD1K^,K@LH/][@RU81R!V\)YD'@'?-SEK.LL<8QQC,&O';^ .,_G
M?)_<MASGK\(K_#FA_P [;^@LYT#^#S_B/>_Y(O\ 7ULU><Y$SK?'&,]!^<_!
MZA_0U7]A@Y],=5\EZW]@I_T\>?-39?*-_P#;;7W\F5GE_EECC&<^%7V9.O%\
MU5(]#"4U%_:FT51(JI_]/M62M3]UJ\WC1-W:]!\Z/*I_>Y8?R(^SYN3H&^0K
ML92?]]8V'U=@'/\ $'^&2#S,9ALXIXTF@FA=Y*V6*2-R+]'D]CFKY_N>2\@?
M,$>\'&87Y7KS%N[QK-^3GJUVE2G'S_S\Z%OOKV/FMCQ@/:_]<*3!M+= OFQ)
MHXB/2DOG(N*"Q?C.-NQ/&-1B7[!W]HE10.[CO"^;<#D#D>8.9UK^P_$3Z_VN
MS^+AL$F%/Q7]F\=H7[I/"Y[/$XX^,5Y\^0><S5YELP6.,9"F]D]YV.;":OP2
M8%7)^1PKCK=?RIYJP%B_B\T3R3X^7,/NG[:,_P!(B3][2+Z?N]>?W9F-(I;8
M5^/F9V/T!8V_Z\?Q_=EQ\T?/0,<8QQC'&,<8QQC'&,<8ROY?Z^K_ .'-]FFY
MD-5\H5OUG^[?,;M_DVU^JGWL>33S>,T''&,\MW^T'_)G-['R9_CKZ5H$=O<%
M30Q>("@JQD]MKNOZ<9L(?9$<,#?5/>X$&*,/2RN9(\S#00'RSC18WV9_M/P5
M=8^QSKTUL9>*MJ0G5RNWE!;D/+5"3Z16F/=".0%LDH QL<KY7\(G3'M4+;ZC
M'S8KQ@;"-1YS5D'"V0!ZR5U'$OD2T #<@0\-YR/DS/'OK_D_/$C2=EA+86_5
MVI]SRO=>($E\VZ3$RE>OYTKQ99(QG:S'SRR7F7)D? ^29I]#*:+5:"U5_K?6
M72]?JK424V[([L'=/KK+#_8V0O\ LW8 MX%@#PIAP0!VRA6>)./-NE^H)NGM
MFEE>YZDO;%>@4_[6 G\]02!XT))DB/(Y/=&6"2/G])S![K(]G8K*=BX*^ U&
M*W&?JM3E=#5RK*!<T5V%#85IXSG-9(UA L\;W13,CG@>KH"(HIXY(V\A6JT]
M*Q/4M1/#9K2O#/$XX>.6-BKHP].0P(Y!((\P2"#G2]>>&U!#9KR++!/&DL4B
MGE7CD4,K#Y_,$>1X(]" 1QEV<H96R-;/ZP,_E$O]I>,H-ZGZS]N='D5]1]8^
MW ]?W-]AQROD,<8QQC-"'^T(^&$SN+P<IW/EJM#-CX=K.:_LI8(U4U_5^CEK
MP=TD?LT]I-%52A4E\4QRI$/55]N2[XL5K[*U42Q+6E9@IK2,_FO/<I'IS\W#
M!6^H'Z\UG?=-5=Y?Z>V%F81?Z/;([$HT2RI:C$$@%=RS+X06T*UKQ>U^/9V3
MM'B]R^" RL AK4-@OP!:\X.4Z*,A24-D,8-ZE'D1(F/7V#UC$] KXV.'GC>Y
MXWK3E!MM?OQP:ZV;TT$5BL8(85!"(A$$4L3R.J*YJ^)#7)'80"I'"AAXU<W.
MYWC/H[?3UNQQ?A>C:JPND#U;ESB'9+):LF((U6.6&D95%558B&)A$ARMU%P,
M-A[:(Z8RPM;*6:N4D5KHX?=YA(Q 0VF1Q3-F5LDD3(Y71R.?,A KWO46& G'
M0ZUVV=)6\.C3G#V(Y;K+V"K#:FCEDF!:,.R-6F1DB*]Y7B,!F'&B6-//_I-K
M@Z1:NFDLEN/VU_$>*.K:L)9>6)7C$L:"*1+**8^?!C,43FR77JC#UM9 E3+5
M2/M1ZNU&LIV%,=3!G3^^^ZNC<UDTGOD\S(T01BQL>KZ^%[DD;&-%DQV[&^UB
M,A*1M5DJU'8+>L5HO!@^(74]@]E+RI:99&@D61PS 2RYDYK<^UL^VPVHX-,V
MXU<FOA(E79V*%5((;(1V*4PHK2B5K%M2Z>!:,3,GC/-:AA,5D2/#3U\*-)D2
M,*MJF%2S$RH6;$V/V)$<R2>_F#$O=*/+#.WS8D@Z^B)RYPUY]&\4GMJR6ZT[
MU9!=F\6#726$IO8G\52$2$0W((A(@G\416'98694'H<>JET^IN;6UN;$U[27
MH6GL;FU72O2GV=6I+?MF2J[<10PW:RQS^)8285I2!&\D\29U_)E@58WC9Z2C
M=%./8R;#1*0(7[5CPG18G1J(&]2%]K.GO?N_N9#W0.]4*1S"JKHY78>Q,Z1Z
MV,^RO%)!&ZM560%Y5FDCEF;Q8XU3F$>&ZPF6)F25DD'+\3=,W;9W^GA$E:PL
MJ:^KJ[U**6:"Y(;;I:V,5J4Q^REJ-6S!*(HIE/<5AFB,<T>0>S*4\\V*6YLH
MK.*W:];>,!E>/#6H-,6 ,Z">:O\ 9$!JRH'D(CA:0=,LA12QAS.1T^&CW>P@
MUNRT&LU]:2XSG?48;-0&2:NE9;EN$E&CL/XU"$HD9E*2H.R%>Z;NDZ:^"O76
MGZKZ]Z-ZVI7(_@\Z3ZFGZ?H]3UME9O169]EKJ/5EQ(ZVPAOVHJ-(;*ZDUPTX
M:<T4M>OK9+<]ATCH14YLXM21<SG,#$1T-1"(/9$6![IRA26R(!/,P">NC8ZN
MAFG?. 241/"/(1)%,Z)<%3LV(9K]*N8)8FD+W('9$DB@K&::9$LS(9DD4QR,
M./&"+\7L?M531W_2VB^#WJR 5M-U%TIH.K-/-?7J+4:OIV:/6;#330.)*AV*
MT-G5OT]3W;&$:^>6=^5M5X?:D?)#CMB;B[I+*<CV</\ P] UY%7$/''2FP'A
M0$R#$LE*6N)C)'+:'".<8+"QK!8W5JS^[RSZ&C7UUN[421XGL6+<M/7-:GMP
M11-";D#WQ'!5B)@$RQR6(H$>5I?C$QNF>@VYM= O0D?PE_""G4NMU&RT@Z3O
M;K5RF[O-+9OUK.MW_5,33RMM*&FU\8:'9/3>R8_"_3;8"V_M*#+"^2B;=5YX
MUZ?/JCI9![F-+$ !5H)KT4(\2CC=;70JD#ASN(>HIT$A?S<@L]:5/0N)J'BL
M;/15Y9K.J[83794GKQQWI)IJD,,PD:<C6@U$F$L*I)9=Q#.[^1],LV=C\'+T
M!U#U1>ZNZ5WMV[=:AK>G[MNR(KNQIZROU->FXUT$-"GJS=I1[2XQ6*4S;C:2
MQO+4DGN>*LKZPP6I@^<AQ9J>_P#.K(:9-J*RRM21;%\ RVP@BQQBR'T9D%A
M]TI\)K3!R94:^&# 5X;-^HVSFK/-))-'6AV,7*:VVU:+PI5\2(D-<0,[RQF0
MJA!0Q*0&.J;[8]&_ +0KU/A O6HNC>IZ/46OV5<:V";9=';;;=-:780Z/8T;
M1D385/8M/1AU6ZUT#T9O&9KT\RLDT5K75=/C*J:X'+)T13J9&G25EW8EU5(6
M B2Q6MD(*(QIDYLGHK073UC :<L_WR>5\#6227-&Q$-E$L\7LFOCV"P3U)5A
MCGVNO:2'VFM%>8/' DR([M(6DDGB0(T/Q>UJ?2G4NNZKTFZFZ0H=7[+H+?=
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MH;X?+;J78J/1;2F?-H>INQ&A,*/Q&QBA1(GR-\O;%YN]9%'6:BH:]&F@+&7
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MV$4Q#6)++'#ZW^R8][FQ^IWH1/4OF,DA18R[F-"S)&68HK-QW,J$]JEN!W$
M$\#GTP(HQ(THC02N%5Y H#LJ\]H9N.XA>3P">!R>/7.UR3)\<8QQC,&O';^
M.,_G?)_<MASGK\(K_#FA_P [;^@LYT#^#S_B/>_Y(O\ 7ULU><Y$SK?'&,]!
M^<_!ZA_0U7]A@Y],=5\EZW]@I_T\>?-39?*-_P#;;7W\F5GE_EECC&.,8XQC
MC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&5_+_7U?_#F^S3<R&J^4*WZS_=O
MF-V_R;:_53[V/)IYO&:#E*L**CMI(Y;6FJK.6)BQQ26%<(;)$Q5]2LC>3#(Y
MC%=]\K6JB*OQ5//DZ2R1@A)'0'S(1V4$^\\$<Y(T<;\=Z(_'IW*K<?5R#QG$
M%FLY6D-+KJ"D *8CVL)"J@12&->U6/:V:"".1J/8JM>B.1'-56KYHJIR+33.
M.UY9'4^JL[,/+T\B2/+(+%$AY6.-3[U10?X@ Y6N4\J8XQCC&1K9_6!G\HE_
MM+QE!O4_6?MSH\BOJ/K'VX'K^YOL..5\ACC&.,8XQCC&88^-KP)]$>._JPOK
MGN&C?#;"#EOQ'8U"D 6WP=H1[*3WBFM5B>^:I,(%$^?LV;[:GO1QXXRQT)@"
M,$I2PQ3#\J@;A)%!(4LG>I4NA8$*Z@DJ2" QYXYX(Q>UTVNW4 @V%:.;P_$:
MO.40SU)9(WB,]9W5@DJJY*\@J6"]RL!QG@#\7_R>'B0\%NFU-7K*%-;U,-92
MU%?V-EJMY-+4>1KA(GZBNG<05ERBFS1J888KPS)$1]7H#W2N'=->T5M:4,U=
MY+<< 68RR604:N!S$@A9U>!HY96X2/F)5EE\8]JAAYIU?\'M_3:BEMA+:VLF
MMAMCVY;-P1R:MS+/"5CCD1JEJ@\LAJ4&>2C-.\_*LS0E=<[3#9B)+(,48NKK
MHXX[:"0=P9L11GJC+@E0$F*5B^2*C;%DD,BO]HR:5'K)Z;.6N\<]AHV<V8VD
MFJ(9(K58TTLBDBQ+*MA.Q2R+"JF91% &0#L5AKNAKU+6WHZ7;[?8:^L]FV^N
MN5^-P(-=6$T<=JK4L5[ >.62%+ K=DZ**Z2M%*L43/G5\G$3-8>.7PW^YC/8
M%37U@-Y%SQD2+%)G]681[-$B8R&$4BP>BROB;&/ D+&ME8YTDFRQQ%M7=D6K
M---+WW"(TFDCJT_"K4.;A)<JRF-P7>:538E*,L;+VO[1T=IH]6T]D[#V]]SL
MZ5V:5XFJ\R05J5!1(EFQ;<6/!I*;1E<'Q4<-$H4HL8C?=*VIO+^B0+YGGL8K
M"PJ9UAMBJUUC&+[G/9V%A30RD1S6U=6V$_S2]L$HK38XX0_>F10>51+K0-10
M>*Y6>O(TUBU$7K4MHW%E:YUZ032L)/!M6=>XG<Q)*Z*X<1F23V/X1]UTAT=U
M/U!4L]76!-\.O2W6.LFULT^P?J&9])8>QJ8*N^DH4=3IKM*WNIJT-ZLE26_J
M-;6IV)O&HB62SK6/W;ROJ6RF?KBZM63K&3),.,TJ>8>8=]9.))$9Z:YL\(Z^
MA%%DE&+\D8+)Z,SWTYX;$LGAZ>&A;DKT U61S:EA26RAGG0SQ07)I>.V)I71
MH()@LI#11/X=JNE=ILK$6HV^LACT?0\^HO\ 4L9U.LJV;NQCD>]IY.F]I6VL
MMC:6YX3H;^QE2%^^RFUISQM4%8S=T6R/>:>80*-#:PG1F+8/,E)5XZ!SW%?(
M76-(:.#%\8I)Y)Q9"F>MT*/A)K3YIM;EK5+E>2&U843+&TU=4CK11-,5CCLI
M,X0O*_8"T"]XA=E#L&]H*C;>F>MJM.5=EKEEFZ4WVQ@U>IWE2,],]5:2MIYM
M9H]GK8HNF)([M]]A8.LLTY*T,DNVV&BEDU]V7VUX:U,]W$><XR,LFL@*@;.<
MYXIC)C[T09J60:EQN&?7+)+[5P<Q$,0\@P\44D:R)*Y-SBGZH6K9EH02V5?8
M0_\ Y>O=2&O4@E=8GLI7B0$QV/$\">+B:)%/B*HB <^T;2J-GJMPFEZDV.CA
MZKT^NOZ?JG:F.]JKW5<=?733:RI2AC-[7ZO:V9++M:LAJDTQGA@A#0Q^)M$\
M!_R3?C'\;]H";:UA?4_AIEE#>7V#LH)A:XL>")0O?.MLN/(,7J]*E043 )<,
M=%G1BFOANKWWR)X4DK=*ZRDM;8T0]+=R06*]B<2N;59A-+7LUK$)KU^(IX@)
M8'B95E3L/:A;Q&QNB^%?9U-0=#OXK6QJZRE#K/8BMC703;G40-J(=O5KO!2]
ME/XO><5-M#6%B:.12T13M7/<IX1_!WT?X*NJZ[JGI/.N!"BB%DT6KMWPG[/<
M6P\"0?/6LNV00/.*]/K042"(:KJXI'CU@(D+GM=DJ]>.NG:G)9F>21SYL\DC
MM+(Q/F?C2.[=O) [B!\Y/F%^_/L+,UB=B3+/8G6/N9DB-F5II G<2?-W)9VY
M=S\9V)XXREY7RRQQC'&,<8QQC'*#>I^L_;C'(8R2*KZN#_B6_P!:\977T'U#
M[,J'&1R@$93+%SRDE9J@))GD=+.0135TT\TKU\WR2RR#.DDD<JJKGO<KG*OF
MJJO*HGG4!5FE  X $C@ #T  /  ]PRF88223%&23R244DGWDD<DYWZ^HJJAD
MD=565]9',Y'S,KPA@F2O:GI:^1HT437N:U51'.151%\D7RY*\CR$%W=R/(%V
M+$#W#DGC)E1$!"(J ^9"J%!/O/ &5#DF38XQE.N/JFT_1QOV:7EM=_0[?[-/
M]T^7-+],J?M,'WJ9!'- ST?'&,Q<\6G;6EZCP.0+QYA-=HMOVQ@L )8@=>Z7
MM>SKJRU-*N-8?5]=Y" G2:JQ#QM!H21*^K&(FCDB0V6)PXLRIE]+2BNV9Q.H
M:*M2LVF5K4-)&9%$<"O:L$0P(UB6(,[D \]O(+#-:ZHVEC54:CU':.Q<VE&B
MLB4+&SD2.5WEM/%0JJUBS(E2"=E2-201WD=JG(:S_CG'R>-K1^\NO]M3]CU(
M&)K=HM319S*95=SV!'\Y8S)#R[WL&MBS6IT&0]6XN<]?W;J_KNJ'L!-CJ@IX
MZJ2YOY>GC-.YU]FN]5WL-7[Y)9IO9JQ*SSD5JK>-#%/_ *M'+%&'M2%6KP,"
MXCQ,'6BU:D:[FC<BV$4=..YX4->K6]MO+XE2JINWHQ7LV*O-R6">8QT(UD6W
M90B)I:EM?&U1FU."(ZMS^J/BT.RZ8&V6KMJ6D'S775)L)JS?:C*Z:,_45UJ5
MNYNG M#9C"8VOUH6>?89^^O#1JBPJY[&G#H9%>T+DL2&*#8&"&-Y&EM25P]:
M&:$K"\8K"^8D8SO TH66*)3(CA)[G6,,D5%M9!:<3W-0MNU+#"M>A#:,=ZS6
ML"2RDC73J4GE5*D=I(.^&:9UBDC:3E3QL+_NM%W6<Z?[)[642/K#,W&CS8>
MZ^QAO:O8Y^&H!<-6#;OM*;30V4.CW=35V"5 FVSV?ME,S1^S-N*BT6%^(?\
M7&KS7JE+DW)HXI6LV9UIU4L2FPS5Z8B*&&L[KXAKRRQA9EKK'(G,PZP__&)=
M@U6PV94:ZM+8KI2H4WV>PDIP+2C6[LFLB1;%R*)Q$MR"";NKO;>6*0BY0/'1
MTU9W>QSP &T-M,K:E9L$:N!S5P1L]@!OZ[JP_'YH&FU=A9 W<'8%J)0#3;<+
M'4=T(RPU^=N;?!TUSJ0*3]/7TB@E9H DT:S,6:5!7@:L]Q9YFDA1&0U4:4BL
MUB2,]L$L:69(X7N$ZTU$LUN"-+DDM:1JZ+&E>5K=M+T>M>I72*R[I,+TJP(;
MBU(9D$EJ":6E%+924O#GV5I^V\'=[;44DV:DE[4[@RU-G365"6U+1]==EZ;K
MD8&[GS]YI*$ZW][RAQ!9]+=V545[>.2O+($]E/)9[2K#2LI7AD$P%.C,\J]_
M9)):J0VRT8ECAD5.V=0%DC5U((<!N0,GT_L;.UI37+,+5R=GM:T,#B'Q88:&
MPL4%29H)K$#R]]5V9XII(V[@8W9.&,]<QV9O'&,QB\6?;&CZBZQI;7'E3@:;
M5]I]68&O/$PFA[./KZW2[.K;L;&LZ_RD!.BUEI78,34G5M35#SD2'#P3.ADA
MAE8N6TU**];D28!H8*=VTZM9BJ*S0UW,"O:G*PP(UEH5=Y"%[21R"01KG5&T
ML:K6PRU69+%G9:VDCI2GV4B1V+<?M<D5"J&L6I4I)9>.*)6;O4,5*J085S?C
MACR.*A;WM@]O5;W/U>279%U68I\AF?GGLC56M'U31R#;K=@S9/8;FA#K];=9
M:]M) .L@SR6[S3TP0*GR7\O3QFG/XOLUY*\CSB -,\\OAU(4DNR@UZS">O6E
M9H(YXXPUQE!JPR%NT8>OUF*E,?CJC=CNUXJIMO'6AJ5_%V%F6'60E;MV,U;=
MR!([4U::0IKD=O;;$*)WFI:OQKTUS2863J7.:D\S2[SH^EUF@N*K/1YCK*IW
MG8=2/J*;6$3:T:6RUCNN:[9V=3#U]#NZ\!?N=T]F7#D[NFM[.2+0O')9%V6%
M%AK;&2"-'E\:V]:K(T$D \ A(/:VKHYM^S,W,L**9XI8TGM=8Q30TOQ57M2/
M8NZ:*U/+% *VNBNWXELQ6F-H&2T=?';EB6B+J)^0LR,*TL4LGXA\<,4_4+>Q
M\MU%V5VPE?GNNVW%WG ,)U[D7=B=D XLBBZ_CAW?:$^ABNO>=[G0KA,X+OJ;
M.V1)-$9HR[VM.!BC_H^1=-6:[4I%I;12.5K-J;V6HU@26N:U,1F/MK2O'XQK
M22H!((EB=7)>L@VJ&PK:K8;,I!0$TU=*5"I[?L$IM#1 N[)IUF[KU=)1 MZ*
M"1F@:=YHW077'XZ>FI-/LLB@&TDN,<4=1.A!!S5S)H-S5[?*=96/75(#1:NT
MMX-;!V-LJC&"+I:W.YN^LX+T_-:*YSN;OKJOHGIZ^(:\_= $G59.6:6,15WK
MS6UM2-+"D9A-2![#>"\LL:&-98HY98XWNAUIJ/:;=7LMF:H[P%42O*9[L=RM
MKI*$*0VI)5LK?M15%-B.O7FD69X)Y8()IDE'P[=F:CMO):_8::A)RS(>V^TL
M;09RQ;2+=4U1UQKK#KTP"^)S=_I\^=<0ZC,:-"RZ:\L*]R+%".1(R'VC[/9U
M(:4\,$,HF)I4YY95\01N]N!+2M&LT4,JH89H>%DC5N>21YYDM!L;.UJVK=B!
MJP&TV52""3P?&ABU]J2BZ3M7GLP/*MFM8[VBFD3T56/;R9\YCLSF8->.W\ <
M9_.^3^Y;#G/7X17^'-#_ )VW]!9SH'\'G_$>]_R1?Z^MFKSG(F=;XXQGH/SG
MX/4/Z&J_L,'/ICJODO6_L%/^GCSYJ;+Y1O\ [;:^_DRL\O\ ++*?;SV U59D
MU 4=E:CUYL]973$M"A/L(AI9 @I3'M>P2,HEL4$A+F/; V197-<C%19D"EU#
ML40LH=@.XJO([F"C\XJ.2!\_'&4YFD2*5HD$DJQNT<9;L#R!240N>0H9@%+$
M?%!Y^;-.7A/\=_<MW==DUGBB.93=GXOK^ZVNC\+$7A_M^I>Q<V@>RIZ,"\Z_
M['V_;!?7_8_6;*\XE;?0W9F8DKW2 WI5J)G0[$N;>=UT[0BCJ/IU,E.Q:CKP
M[D[..]5E[H))&BM5*U%;52WWJ/#BC$P<!HPC3,JCR;ICK;;S3;&/J1_!V5.A
M-<L=-#1RZN_7[+<4*34K]S9O1V&O[';Q;$S5NPE)FD2!)&.1N:^4FZBV]-UJ
M9A.M>Z-QH^T]OW%USG,-E:_K"TO8]=T=40WVU"*O$[4BZ]+KI:B>(^@T6?VU
MYG;<9R2LM(6.8KL7+TK>KO;%FW0K14Z]&W+8G:XD9@V#F.NZQ^Q&TK=X[98I
M:\<L9\BAX.;!7^$+57(=>]+7;>Y8V5S;:^O2K1ZZ2<6M-$)[B/-^,A1:,Q,'
MAL07)J\J^8E X)IU7\J#T-99.+=2XCNRHQ]MT3V!X@<;>W&1S0<&]R?5*5\?
M8]'F1$VTME%J\F;8Q $#Z4+.T%O+%(9G-%<U$H5D7,_2.R2<UO:->\Z;&KK)
MXTGF8UI[I?V629O9PAAF5"X,+32H#VRQ1R!D6G'\)&DDJBZU+<15)-+>WM2>
M6K71;M76>&-A#73VPR"S5DD6-EL)!!*P+UYY8BLC6UM_E"4MB>N\[UWCM?UY
MN"O$UX2.O=WDNXLW1Q6A74'B3O3(:O7YB7)['2TTD5[4UME%7E/MUM:"S!G%
MOJ ,GV4$E:MTR4%J6U/!9KKJ=W:K3T)I"@O:F-2\$PF@AD!C=T+J$[)4=6BE
M8<D6]SKOQ6H5Z%2U0N-U%TM1NU=M7A$KZGJ&=UBMUS5M6(2)HHY!&QE\6"1"
MLT*MP#-/A\^4 \/_ (E^PC.N>MC;F6S6KUE[F[.P(QDU?KZ3%:,;+W]D#6Y[
M8Z#791&6!HA=17]G9C!7&EHYEOLY76M2,84-8;/IK9ZFL+5M8P@>".5%$X>"
M2Q$TT2,TL$4$WQ599&IS64AD'AS-&[(&R^BZZT?45]Z&O>8R&*U-7DD:H4MP
MT["U[$B1P6Y[5;AW1XH]C7I2V(6\>O')$KLOXG\>O5@?;I_5!^'[;!&J^]J3
MPV6':$]!E9.LQ>X=305F@R>7E,$VI6P:S2P6X(%=:KC$JQ[2>$6V+K6$BSSA
MTY<:BMU;%%B^NEVRTQ+,+9H02R13S!6KK7_(F-W=/:.\H"T:N0P6#=;ZQ-J^
MKDI;1%BW4/3TFR:"J=<FVLP1SU:Q=;C6_P#65E1(Y?9!$LA"RO'W*6L+$_*9
M]3=B9G#Z?(=/^(NR@[5T53D.H 2L3CJ.?M;5&,UTU[2XRSONQ*S,2IA!L7<$
M;>[N=!39BG1X(T%V>>4T1MQ8Z3NU9;,,U[5J:43SWF6Q/(*4*^ (WL)%5>4>
MTFQ&*\<<<LS_ !RT2*O<;*I\(FKOUZ=BKJ=_(NSL15-4CTZL)VEEQ:::&G)/
M>CK'V)*<S7)IIXJ\7,:K,\CA!=6:^4+ZDWUEU[G>KL#W-V?M-UG=/K;/#Y++
MYF#1]9YS%[LKK/4V?9"ZK:9FDJVU.ZK[//-#H+G26%L373D40EH#,"491FZ9
MNUDM2V[-"I7K2PP+8GFF,5N6Q66Y"E3P*\TCEZSI+W2QPH@<"5T8,JW-?KS5
MWI*,&MH[?96[E>S:EIU:U<6-=7IW6UUF2_[3;KPQ^%=CDKA();#RM&S0K(A1
MFM]GRG_ADDV78^-@GUQQ'7(_<"RV%2+DKQVJLNBZ<^\[%I\UDJ796'9 TX5?
M4W$E'<;'$9/*:M:BR7-:&TB&]J^K_HCMQ!5G(@46C0X1VGC\%-E(D=62:>2!
M*A#-)'XD<%F>>'O3Q84)X% ?"1TX;>PJ*;;G7KM>9(EJS>TR:6)YK\4%6&V^
MP1D2*4PRVZ=6M:\*0UYY O)[%!\I-TGHC.AJX'+[EIOB'+MH,/[30=%2U,(]
M/>T6>+F*U07=)>0O;1#= +)]PV O]IV5! +9L,Q8IH$H:RR]+;")=D[2URNK
M"&SQ'L1(2\4LH"P-KUL1IVQ$&Q:BK4R63MLE6#9-!\(6GL/I8TJW>_>M**?,
M^E,06&>&N[-93;O5GD[YU/L5&>WL J2!JBNC+D7Y/Y3;%4/78-KM,SVQVE?Q
M8;OON+07/7?6N.R]=2=5=,=[:CJG0V]I1WW<9RA.S#*P59/=+RV+T8(OSF&(
M/<6<6:BO9NDK$EED@EI4XC9UE")+5N>9I+NPUL-V*-)(J*]WC%VX[HT6)CV%
MFC0S'&U?A&IP4$EN5]GLYQ3WFVGEU^NJ5HX=9J-U8U=B66&?;/V^S>&O)6:5
M["+XB(LL@KB;+/Y0GIT7MG-]24N0[3UYVD[!ZRZPCUN?J<6/DZS8=L8:'LS,
MAV4.GWN<V<@0^ E747-O48^UJPAH9:V$LN_]G428].F;K4IKLD].!8:MNX8)
M7L&=X*5DTY60PUI8.XVAX,<<DZ.Q(<J(N9!F)>N]2NSKZN&KL[;V+VNUHLUX
MJ8K16]G278UTD%F]7ME!1;VF66*K+$B@QJ[3\1'._FNYNV.,8XQE?R_U]7_P
MYOLTW,AJOE"M^L_W;YC=O\FVOU4^]CR:>;QF@XXQCC&.,8XQCC&1K9_6!G\H
ME_M+QE!O4_6?MSH\BOJ/K'VX'K^YOL..5\ACC&.,9]1%5?)$557Z$1%55_[<
MAR!ZD#]^,Y?=R/S$WZI_^7CD>\?Q&1X/N/\  X]A.BHGL9?-?/R18W^:_#X^
M2>GX^2?']SZ>.1[Q]/F,<'W'^&8?^(OJR(\Z'3MJT)$O!_FF^$E#28<B:.!T
M4+R(9(WQRQF@M<).R1OLGM&8UZ.6947/ZFX CUF(^)\:(]P'Q6_.7W\*[<@?
M22![MHTMX^"]20!@O)0..08W/QX^#R&7GSXX\PQ!\@.='OB$^1K\+G>;K"UI
M<Q=]+ZPY(7K==7>RJZAQ0\C)(""L84.3F?4Q6^3UJ@ZB<AKG).0]5\^4K>CU
M=N3Q^PUIPTA,E9@@D$JLDBO'VF(JP/=R(U<..\."S\V<W2NA>6>U6UE*G<L3
MR33VDHTYY)A8J6Z-R BS#*T<%ZO=G%I:S5GDD$,XE6>))5PGZ+^1+[H\//BI
MZP[FJ.U,SV)A\AHB["VAL:J[RVQE!*I[L%_LZU@][1&$/D, A<K;ZN;[O C%
MC6-GIY/%0-:@U.&T /%=P%C>-61D':G+SS$(L@>1HV#))):G?XI"YC=;TO-I
MJ=FK1EJB-K4UFE!#%+7AHHQ45ZU9)IK<@2,#Q)7GLR23SO--*Y:5N,)S?DG?
ME :MEG7D=/3ZZ.U>)7S3P[_KY*Z.G@EK5E:+*3J1+<1'-%F>.V$1CX)%;*R"
M)S?9S8#J[03[-X9*4IN-V]S<BK5BAE?QQV+ &I0B*$F&5#'$6F>2P9W'*JVY
M]0;K<[3;:+;W*'^D%7I&_I-O0T5W;7$3:NVFZBZ=ZAIO:EF[(9XJFSU]W5RR
MPK!))%8CE\!(HJ\E$!^22^4(-OXV_P"XV,"!J4WNVCM>Q.MXX*V<0 D"X*]S
M$T9%H41:0S-5DS X_8E1L*>.]KGC+A*O2^R0QK8KUW@-N&26#VE((IZT#1GP
MIEAEMRH\BJ_QDE9E+D"0'NRXLU>F9[<MS6Z?8=.Q5XND*&GCT6WET%^E0U$-
M=-JUA=?%<K7Y;#*Z)+)L*UYH8(HC<C6:3C-WPZ_[._XA.PK7WOM+M_+8$5-!
M8VEH;DZ^\VY$0EJ'+))%)%8PY*)VB2TD>X,@6].A&!D>LCFO5JON-KH[=B6(
M/+J-=KX8V6#7U*KSRLWML\Z-9E9Z\<XCAE]F5WC8I''$BJ$3A<7&NAUM6A9%
M?;:[8:OJK7;W6:;3[..'ICV#26;5K5UY=;)2::O>CL2J\]NM82-8WF@J11L(
MW7?KX6OD/O!#X9T"M3L);=Z[08F*P?I>YY(='5MLH)730%@X$80+#0/$E<YX
M,Y]);60CE62.R65SY'7=>NM<JRSS<K$(%59GCA6+M*M&($<1E'[F9ED$GQG8
MKVC@#%S]1[R=]EQ?M05MHU<ST())12C%66Q/"E:.1Y)($6>W:EX64_&L21KV
MP=D2;=H0'#0Q#CA+ /!&R&""$=8H88HFHR.**)C&LCCC8UK&,8U&L:U&M1$1
M$Y=<K[Q_$9@N#[CY>7IG+[N1^8F_5/\ \O'(]X_B,<'W'^!Q[N1^8F_5/_R\
M<CWC^(QP?<?X'.)45%\E147\BIY+QR/>/XY#/G(XQQC'&,<H-ZGZS]N,<AC)
M(JOJX/\ B6_UKQE=?0?4/LRH<9''&,<8QQC'&,IUQ]4VGZ.-^S2\MKOZ';_9
MI_NGRYI?IE3]I@^]3((YH&>CXXQEH:7$9C6W.#NK\)QMGUMJBMOCW(:6/'7Z
M,K':S!2V,PH\\4%BC<SMM(%"/81%"P$&Q6,4++ ((D>M%8EA2S'&W:EN%:\X
M[5)>);$%H*"02GY:M"Q*%20I0DHS*;2Q2K6IJ,TZ%Y-=9:Y4^.RB.P]2U2,A
M56"R<5[EA L@959Q( '1&6R-+T'UOJ/NIG-!N0+76[_/]I':&BTU_2:*OWF7
MR&>P5)?9^WK["$JB<-DLQ74A%=7.@J;((BYBM #67]TAUQ%L;4/@A71DAK2T
MUCDBBDC:M-/-9DBE1D*R@SS/(K."Z,(RC*8H^VSL:/7V/:6=)DEM7H-D]B&Q
M-#8CNUJM>E#-!*CAH.VK6CA:./B*1&F$B.)YN^R[[PC],Z6X6YMQ-F5,0&L-
MP))V/NIJ_26;>L+CIN'6Z04F^G2XW$'7%X;G$V93W:,F*&J,/L2["CI2@*\6
MZOPQ^'&T"@-RA%6L&B3VR.^8(B(AX=8VXUE]G4>"I+JJ*DDBM9S]+:BQ*)95
MML2G$JF_<*6)1KI=4MJPK3-XMQ:$SP>UL?'8"-W=I(86C^F>$GI\D715HK-W
M24NCN\WJI,_G^RMS39ZFV&4T>5UM/L<S1A7D=;GM+'HL7GK4BRK!H%*,@L9Y
M8EFO]#):%W5Y3$Q->1XHY81)+4K22O!-%- \$LC1%Y8O"L2HJ.Q"J5 \HH1'
M%NEM4RSQK[=##/-7LF"#8W(H(;=6>M9BMUX4F$<%CQZD$C21J.YQ(Q',\YE[
M\GA<ZG?77U*B;F"IN]/]VX56-V9O1@LCLONO=OY]3A1X="QN3N2-I+/H"2JE
M(4DE-L:ST-HK2QJBI?QO=#Q2$US)'#[,7:I5+SP> *PAL$PGQT%<"(*_/ 57
M_P!JB.LQZ:U?ASP_ZZL4UGVQ(EV-U4JV_:O;C9I*LX]FF-LF=FCX!+/&1X,D
MD;2MU[@<[UCD*G$Y6,YE+4.LIH7V=B7;V99MS;'WMQ8V-F=),6<?:7-F?8FD
MSR*Z4DJ5R(UOI:VSLV9;<[V)BID<(#V(L:!8T6.-41 %54C1450  %&92A1@
MUM2*G6#B&+Q"#)(TLCO-*\TLDDCDL\DLLCR.Q/)9B<O3E#+S/GFB>:JJ(C?I
M7S3X?#S^/Y/A\?C^+X\8RTM/ALULCL59:$%YQ77VM9N<LYIA@T06EBSFCRL)
MQ$ L\,-C'#3ZNY9$'8,)#C+E&L60(< $1!6AL2P).D3]JVH?9YOBJQ:'QHIR
MH+ E>9((R60ABH*\]K,#:V:5:X].2="[4;0NUB'90E@5[%8.P4@2 16I@$<,
M@8K(!WHC+9>GZ(ZXUK-DZSKK4>PW&MR&[M;RGT5[3WP.OP5;0561O,];5Y\!
M>?GIA,U6,:-5O'KSO79LM SH;JXB.N(MC:A,'8Z%:\$]9(WBC>-H++RO/'*C
M*5E$C3/RS@NOQ.QE,<96SLZ37VO:S)'*LEVU5NRS16)HITM4HX(JLT$L;JT!
MB2O'PL9$;\R>(CB:4/9=SX3.GK^Z&OK2';EFL'"9:LG[)W1 FGLJS*7>)JM+
MJ!2KV>.ZUU9F]!8UPFH(\KM8F52$&3MH*%M;7CW-Z*,QH:ZKW,4(J5@T2O.E
MAXH2(AX<#S1J[0C\GR7X4>))WV<O2^IGF6>076<*@EYV%QELR1U9J<5FRKS,
M)K4=>>2-++?EN!'W.W@PA.O/X0^FG5]_3 0[FBH- 5CK>?.9_LG<U&=K=1@K
M?$7N6V=#2"7C*ZDUE=:]=8\YUN /"\PFL*G-B(FO=!):Q&[O]T3L:\LD2SH)
M9:E:25X;*6(YH)9&C+20NEJ=>QB0JN A41Q!)6Z4U)2:)!=A@G>I*:\.PN15
MX[-&6G-6MPPK,(XK22T*KF5%!=HV+@F:<RU6?PM]4$!::L>W=-J=-?MV#ZB'
MLS?CUE!M_NQ [#FW&3#'T,<6;UY>]K8-@5?5B0FR7I%P2U[(]'HH;60;>X&A
M<&OXD,7@"0U*K/+7\!JPKSLT1,L K.:XC?E?"$:D$PPF.JW36K9+$9]M\*Q/
M[68AL;JQP7/:H[S7:J+.!7MO=C6TT\?:YF:5N0+$XEE+KOK_ #G5V3!QF7;8
M)4AV&AMG36]F7<6MA<ZS1VVNTEM9VA\DI9UC<Z.\MK8V>5ZJX@R7T-9&C&-L
M[5F6W,9YBG>RQ1@(BQHJ0Q)!#&B( JK'%&B* /11ZGDYDJ%&OK*J4ZW?X223
MR]TLC2RR36K$MJQ+)(Y+/)-8FEE<GU9SP . +WY0R]S!KQV_@#C/YWR?W+8<
MYZ_"*_PYH?\ .V_H+.= _@\_XCWO^2+_ %];-7G.1,ZWQQC/0?G/P>H?T-5_
M88.?3'5?)>M_8*?]/'GS4V7RC?\ VVU]_)E9Y?Y99UC0QK$,NO-A:0&<-.&7
M ]7(V<8J)\$\+E8K7(V2)[V.5KFN1'+Z51?)>15BK!E/!4A@?<0>0?W')719
M$>-QW(ZLCJ>>&5@58'C@^8)'D><P8_\ PV/"3+7Z^NM,=M=(S88\'K^0S7]Q
M]N["US&'K-/4[2MRN%M=/M;6PQE,%J:*HN8AJ$@-99P8ARGD OG$EV'_ $JW
M0:!TL01&"=K0$%"C DUEX9*[SV4AK(EB1H99(R958 ,64!P&&E__ -/.EBEI
M)*ERQ[552B7M[;:VY:U..S%;CJTI;-R5ZD*V88I>V!DY*!6+(2IO_K[P3^'S
MK+94.^RV?UBZK-;KLCLJFLM!V9V-K?==IVYGTS78=X\;4:BW%)+T];ZW64A4
M,SYSWK92.<<R&>.VM;_9W():TTL/@35:E.1(JE2#FM1E,M6(-##&P6%_S ".
M%^)^;R#?4>CM%KK<-VM#:-FO=V&PBDGV-^UVV]I![-?F*V+$JLUB,DR%@>7/
MB?G@$1?VU\GWU'?^'TKJ3JNFAR>@RG0O=71W3=O>Z/6655D:GNH8=VD;<,D.
MLB;H<FS KB7EV ]I9 PP/BK71-EDC?=TNI;L>S6]<D,\<VSU^QOI'% CSOKV
M;PNSA46,A'<!4*(Q(+\\<YC-KT)JY]$^KUD0JV*VDV^FU,L]BS)%5BW 4V/&
M!:1IE:5(V+NLDB!>(R 2#=N#\!W0N5IL^MQ1Z+4;*OU_2W9%MLM'V-V'JKX_
M<]#CJG6SF7FET1]K]R>0*(L'4>1?*R@; <0TRLG?/,KJ-CJ+9322=DD4,#07
MZB015*D$:UMD?];'APPHGC3@)XDX'B\JO:X &7='HG1U8H/%AGLW$M:C82V[
M%^_9G>[I%_\ Q_$UBQ)+[+58R&&J3X/#MWQL2<E;JGPT=5])VA1O6T&SS]3(
M1H"JW"KV5V#9=9YHC56K[O0R97KBSTA>,S_SA;2DG1,KJ:&*I>=8PT3*L6R/
M@)L[NUN;!0+9@ED B#V/9*R6Y1"@CB\:TD2V)>V,*I+R$OVH9.]D4C*:SIW6
M:>5GUXMP1%IWCI?C"])KJ[6I#-.:U"2PU2#Q)2S@1Q 1%Y!"(U=PV/G7G@2R
ME?WGV]W7VB65L2]'XC!^^>K<V'L]W!B\M:5F"RV3HK[0]>_.0.'MM_0'5=V5
M3Z.>GM"@!3P5A/\ >*\%H&2L]0S-KZ-"HJP+%JVUMR5J]8V)D>U-/)'%:[&L
MI6E5XEDA$B*S(W*<,Q; T.BJT>ZVNXV3M;>QU N[UM=+EY:E:2.C6JPS6*/B
M)3ENPO',T4[12LBR)P_*($F!/!ST)#U/UETS7YFZILCTS=,T?51M%MMC3;/!
MW[);B1;;/[JMO!M8.3-'?W 9C)K:<4^O/F .')$]$3++\>;(W;=]YHY)[\?@
MW%DKP2068OR?Q):S1F @&*-E(C#*RAE(;DG+?Z)Z0:O7:A*\T5743>T:QX;E
MN&Y2GYE/BP78YELJY$\J-S(RO&[1NK)Y9;\'@1\-E8SKUV7R^MP5EUI37>:S
M^CZ\[5[1PNM/S6GT<FPT]!K]9F-?6:+;UFBUDT^EMF:RRMYY[PDNRC(A),*D
MFJGJ+:N;7C3064MR1RRQ6J5*S LT,0@AE@@FKO%6>* "%/ 2,"(!""JJ!;CH
MGIZ,4/9JUJC)KH9JT%BAL]C2M25[$YM68;=JO:CGN1V+1:Q+[5)*S3,T@8,S
M$W55>$OI_/W.TM\RO963AWMGL-!?9W(=S=LY7(1ZK? F ZW7TF6S^RKJ7/:>
MU:>6>VVI1 9:V]E325+0-#'':,H/NKTL=>.;V28UE@CBEGH49I_!K,K00232
MUWDEA3M5?#D9@\8\&3NB)0W4?2VI@EN2UCL:JW9+<\U>IM]I5J"S>C>.U:AK
M06XX8+,HD:02PJACG/M$79.!(+#$^3_\,XE/FL_]S^Y+HL[V'+VO/2V';O:1
MU1KNQI="#JVZ_?59&N?7[6Z'OJP T4J_&,=!&,E>Q/FN6<*6Y/4NV,DLOBUU
MDEJBD)%HTED@JB)H/ K2+ 'KQM$[*RQ,O)/>?R@#"R7H;IU8J\'@76A@OG9M
M"^TV+Q6KYL):%J]&;)2W,L\:.K3*Q4+X8_)$H:D!X$/#)64]O0AX6PCK+SJC
MMGI.R@78Z^1T_7/=V^-[-[(I6S27;IH9[O96)=G!;12,MJB*1*^I,# 8P9LC
M]1;=WCD:RO=%=H[%#X%<<6]=66I4D(\+@B.NH0H?B.?C.K.>[)TZ(Z<CBE@6
MG((Y]9M-/(OM=H]U#<WGV.PAY,O<&FMNTBR@B6('PXG2,=N8WQ^!+MNE\7M;
MX@,?V=EJ+,U=WUI55Z/"FL=!7]&=?Y&#-D]+1YZXSML(1/H7OMWE=E#[RIN(
M&6ZD?,$Y0439<K_I%2DT;:R>G-)*Z6W;XP2)MA9G,J[ RQRQL!$!&%J-6DC)
MCX\8!B1@!T5M(>JH][5V-:&O%-KHH^4,D\>FHU5KMJ!!+7D0M.3*6V"W8Y5$
MO/@,R#NVH\T_/2\<8QQC*_E_KZO_ (<WV:;F0U7RA6_6?[M\QNW^3;7ZJ?>Q
MY-/-XS0<<8QQC'&,<8QQC(UL_K S^42_VEXR@WJ?K/VYT>17U'UC[<#U_<WV
M''*^0QQC*W4U*G*LLJN8,UWI\V_!TCD^/I8OQ\D3_J<J?D1$5?BVFS'G@>7'
MU'G_ ,_Z_1DZKSYGT_Z^6<6@W&;Q185::)8NF+AE(:^NK9BXX!X7LBDG+G:B
M(U$<[S5C'33(B)^Q^J2%LM6&K+85W0H I />X4L3R0%'S_8"?=R19V]E7HO'
M%*LS,ZL_Y*)Y%1%(!9V X Y/IR6^8 DJ&J^7U]3KHRY:R(QB!*.V="QO9>EY
M,2R)&CV.EB6:%S9(B(4D62*1GJ5JPRCS32S5Y("H?M^-SQVL#R ?7CR/!\B#
MQP0?7D$"K4NPW YB$@[.SN[U[0"PY[>02I92"K+SW*1Y@*5+7"Q$DG>]4^\A
M\XF)Y>2*]?)TCD\O^;R3TL1?Q*DB>7DO*1\@/_=Y_N!('_4_5P<N1YL3SY+\
M4?7Y%C]B^_\ .],Z-[4#7E2;6$-;Z"87-:Y4_P#3F:J/@E1$^E8I6LD1/Q^G
MTK\%7D8W,;K(OJIY^?T/D1^\>1^@GYN<KQ2&*19!ZJ?X@^1'[P3F*UA55]9/
M*,7*QA$+W1R0Q^<\L;V.]*HYD*/5OFJ+Y*]$14^*+Y<SL;R2*&525/'!/"@\
MCYNX#G]W)S->TH1R#Z^?OX X_N/?Y^7D?+*+(\!JJD8A<GQ^#O*!C53\OW\O
MK1/WV>?+@1RG@LR+]'F2/X)Q_/)?:%X_WN?<"0/Y@_-__/.#VH_G]6S(GXU2
M6'S7]U4_+^YY^7)O#?G_ &@Y_5;[>WC(^U?7Y>GG_<'Z/=E<I*P6X,8*T8L9
MB_?3D/BBDB@B141TBI#(][E_Z6,1OF]ZHWX)YJE&8RQJ6[E<_P"Z.[@D_,/C
M* ![SSP,DDNI&A<EBWH 3SR?7@#CD#Y_F\C[\RCST%'6@05M3)"R*)OFD;E1
MA$LCOOI)YHY&LE=)(Y55SE9Y)_RM1K$:U,#,)F=GE#<D^O'*@?, 1Y<#W<YB
M))C,Y=FY)]!SZ#Y@ ?0#W?O^?+B\FK]"(O\ V3E'),^+Z$^GTI^_Y)_7QC/O
MDW\B?T)QC'DGY$_HXQG6("%*:K9X6/\ -/+U>2(]/R>3T\G)Y?O^7[G'H>?G
M&0(!\B/IRQ[6L=7R(K55\#_/V;_+XHJ+_P C_P#ZD1?@J?!R)YHB?%$JHW/D
M3Y_-E)EX^K_S_P _CY92>3Y+CC&.4&]3]9^W&.0QDD57U<'_ !+?ZUXRNOH/
MJ'V94.,CCC&.,8XQCC&4ZX^J;3]'&_9I>6UW]#M_LT_W3Y<TOTRI^TP?>ID$
M<T#/1\<8S41W5U]J-3XRB^WS,U4.P?7':WA&ZPLMH/C; SMO)"44EYV<#8=<
M:U2D&JNO=3O.W,Q@.](Q*PEIG7UIH7GV PE$9[MNM&U##H?85ED]JM4MW<2
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M>M.LX[%,KDK9*_L+L#4#;&WN-%2ZC1!9P\6A'S4^ *=7C9<=DMS,>D#J^O\
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M+L7/)YX'/ Y/ !^CTYRN3S001K(1)%'&B*JNE5J(GE^3U?C_ '$^*_B^GE(
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MHJ>:HU$^#43\B?2GXU^/GE:E9 !P!YD$_.3]?[N?+W'CSR21B.?<!_'GC_\
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MM O;W?'DFC1B1QY?DC(.1Y@$<'XQS%;%RR*H) [CP.>%=E Y!)X':%9CZ_G
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M9POB,G+$E&8KP%[0"OG)+;O24TUSW+;4(YFL1T6L3&FD[ AITK%_!65@>UI
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MJ,O';W0($+*^,(.QNSHW(' 1!%.P6+XM<<2KVN]G#$OG[-JJBRR)Z6HK6O\
M+>=93,Q:Q/(\-*#_ &CJQ4R-\T,7F.YFX /'YOD?7C-'V=U8 M>%%EN3?[-2
MH(C7YYI/(@*OS _G'Z.<QS3Q)%X7N_I+I/*VMG:Z_:[W&UV@K0"IYA*O+S68
MKKXVT"8Z6'UD4\9\C620^L8=)3G/A2!LK&ZZ0I7^ENINH+E.K!7U^LO34[$D
M,23O<6-A42*;M5^1.T2GA_CL1&0W<5R35=37*?4.@TU:W8FL7MA4BL5TDD>*
M.J9%-F22+DH!X*R,.5!107\@O.;FN<L9TECC&.,8XQCC&4'0GEBB1!UBM^>+
M:9 *QSVH]@TCVN>39S1N^\>/5"-F.?$]S&E20P@MD;,7#YO+Y_3]_P##R].?
MY>OH#DCD@ +^<QX'T>\_N'GY\?7D+]X=;EW'7]4[)BSEW.!/BO:^NC1"+#0@
M,'('OJGVKU24JPL(2%NQXW2QNMM'55D1),+2)28\SH-DNKV,<\O/@2*\%CCY
MHI>.7 \_]FZJ_'_"& ^89;7(#+!VJ.60]P'O\B&'S^9!)')X[N.3QFOP!M(?
M1VSCXK".D6UDF>1='%B*Z0<A37S1$HY2&C0DI*.\:1D$L!4#AIHO>73>CW-9
MY)'JS59()FFKIV&JB..QT9.&! 4OQP>0/0]WDHXS#$L'3L92_80%1!SQ^;VL
MAY"N "6Y)^<$ #SJ=C$$D]=H#+MPU<#7,A=$\V-*$]AZO4,Y?A(Z2:5SO:1H
MZ'S1\43_ &C6Q(Z>6+Q2DM2.L'EDD[@PC/CQF/CQ$'D.%''!X;YR."2>V"EC
MW1A>XLY//!\5>WCN7S^*.!Y'D\>H]W$V>&OKTB^W\&O<3:'YG$VMP>/:64R2
M,L=A9!STD--5R1J^$^JS58=;DVDJ(V(:\*IH Y5*#N!A-!ZVW<<L<.KA6))/
MR)M"'D!5B/<B2#YI7?L=UY)58U##E@<NZT1D[IB@1(HG50!QW-VL.3[^/,-\
MP( Y)'EL*YYGF;ROY?Z^K_X<WV:;F0U7RA6_6?[M\QNW^3;7ZJ?>QY-/-XS0
M<<8QQC'&,<8QQC(UL_K S^42_P!I>,H-ZGZS]N=<>+VY$$/GY>UECC\_R>MZ
M-\_Q_EXPOJ.?G\OX^62@QC8V-C8B-8QJ-:U/H1K4\D1/WD3C*^?7*J-5417*
MB>?DGTK^XG&,Q]JJG2;;L^/3Z.IL:S-92*U#I*:S"]WCBO![0L$:[AF(;,ZS
MELJA[S4. 97B5\#@*^(JY=,<\;2ZM>]M^H!L;U>>O0UB68J56>(QK[8EF2&.
MXID#&R;%0F43P+!'"G@0![1:8Q^@6[6LT?2QU6MM06MGN7J3["[6G\0MKY:D
M5B77R)$4%1:EP+ :]IK$UF46;+14A'766>941\D,#?BQO[)*GFJ_>1JGLVK]
M*^;I$1R>:IYI&]J^:*J<W4>0)_</W^I]>?(?7YD<YYVWFRK\WYS>[@$\>7TM
MYGW\?7G:^CD,J9\5$<BHY$5%^E%3S1?W%3\:+]"I^-/AQC*9)2U<GGYA1-\U
M\U]DKX/-?Q^?L71_3^/\OX^5!-*OHY]WG\;[><E[%/S#_P _\^WWG.)<_4KY
M?\,]/+\A1:?_ /?DWM$W_'__ &K_ -N0*+](_?\ WYS\+G:I?/\ 894_>*+_
M -?^KR3\?EQ[1-_Q_P#]J?\ ;D>Q?K_?_;C/P_-U[O\ D4B+S\OBV=S_ "\O
MA\$F25/+R_+Y^7_NDPLRCU[3]8_L1D/#7Z?W'C[!G2ERZ>2^[FO3]PB%DO\
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M,@V#U>1,T!4@-DZ>02/_ (CW <20PUC'P!M>2Z*.2O7CBEF2.640(QX,A7N
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MD\(B-1&M1$1$\D1$1$1$^A$1/@B)^1.8#,Z !Y <#W#/O&,_<?\ ZD?\-O\
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M41515'HJJ % ^@  #-79F=F=B69V+,Q]2S$DD_2223G[Y-DN.,8XQF#7CM_
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MF( )) ] 22!]0]!^[(<#DG@<GU/SGCTY^K/W[*+\W'_ZGM?^1O\ ZOYSZ/\
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MKJFGJ1)C[*R/*F<V(8($*"8HJ>5S8X88GR/5&M5>152S*J@LS$*J@<EF8\*
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M_IC0!RODDQI;8R,%H/FQ\<)\!.;&,L.N-N(.R>&NL[K+EF6M/"9%#6:>ALI
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MI*/0,"Q521]#A6]X'/IGJ#YYQGI6.,9@UX[?P!QG\[Y/[EL.<]?A%?X<T/\
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MA2>&">7F2['@*H'FQ)^90?FY\B,F,T2E0S@=REQSS^8!R6/E\4<?.W&4"O\
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M'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8RG7'U3:?HXW[-+RVN_H=O\
M9I_NGRYI?IE3]I@^]3((YH&>CXXQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQ
MCC&.,8XQF#7CM_ '&?SOD_N6PYSU^$5_AS0_YVW]!9SH'\'G_$>]_P D7^OK
)9J\YR)G6^?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g383050g07a02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383050g07a02.jpg
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MH;&RM+7!Q2DX1&)H=(2%L[CP-$-'4EAR@K?$PO_$ !X!  $$ P$! 0
M       $!08' @,( 0D*_\0 9!$  @(! P," P('"0H'#0(/ 0(#! 4&$1(
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M:Q1*Q01O+(0MJ,L0D:LQ 'DD#P/)ZG?IQ8@JZJJ369H:\*UKP:2>5(8P6K2
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M^E>I1HK_ ,*\#_TA%_H;J[?G?_LX<R_^%;D3_P [[CU\(=6_^%6IO_O!F?\
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M/_I+3_\ /;?]G]'][5=;G\]_1E_G/Y5_L,]'[J^"_16H_P"85/[0Z/W*<_\
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M@)D0A!I(@SHTF#/B%]N5!G1Y$.6$,D!1,US035I6AGB>&5" T<BE77< C<$
M[$$$'V((()!!ZW5K->W"EBK-'8@D!*2Q.'1MB5.S D;JP*LIV*L"K $$=?FX
MY1X\XUJ/K^[V%%F*=-1E\4^?9S6# +6;6TJ*;*T!_;]QX+&[L;ZG## 9C%4=
MC%E%4<0GOH1033-PBC9V[;R[*//;C5F=_P#R5"-N?O4CW&W1-9KUTYSS1QIW
M8H>3, !+,R)%&?N9VD0 ';PP8[+YZ7GK5UOZ\),J-#%[\N0"*#W !]Z288!>
M[)..-&%[A7-9[DB284<#._D4Y1B&CB/:U38GV&_N?X@-R?XAY/ZNO"0/)( \
M#<G;R3L!_&2 /O/CI'<D<E83B#%7G(W)NHJ\7ALT.&:^TUT5X*RK'864.HA/
ME%8PCF-DV=A"A#5&.[FDC:O9%54VPPRV)%AAC:25]PB*-V;8%CL/U*"3^H=:
MK%F"I"]BS*L,$8!DD<[*H9@B[D ^[,H_:>L[<[C)<:8[2\@;R^@9?%XZFG:'
M4:.T(X5;24E8!TF?93B,81XXT4#'E*YK'*UC55&KZ\BBDGD2&)#)+(P1$7RS
M,QV"@?>3X'7LTT5>*2>>18H84:261SLJ(HW9F/T  W/6OLN3N.Z7CMW+=WM<
MS1<8CS438FWEY;PJ;+1LM/A@GPKV7<698D.)728DJ,8)Y)1(]#B8B>X]K%]$
M,S3?#K&[3\S&(E4M(9 2"@5=R6!!W W]CUBUFNE?XMYHTK=L3&=W5(A$RAA(
MSN0JJ5(.Y(]QU&K,_$3Z']ED=SN\OU.<4W66XTCUTW>V,*_\BY6LMKB#GZZZ
MMJQX&6P*&5=V=?6#OT@OIDES "?.:I$]+),1DXI(HI*-A))R1"I0_E&52Y56
M_-+A5+%-^6P]NF^//X6:*>>+)57BK!6G99 3$K.L:NZ[<PA=E0/QX<B!RWZ?
M\_-?$L?E#/\ "IN0\JSE?5XZ3R%F\%]6C.T5WB8DHL,^EK837.655)(CRFCD
M#<OOLAS3 :0,*40*45K!@>T(9/AXY!$\O$\%E(!",?HVQ'@^VXW\D=+C<JBR
ME,V(A:DA-B.#F.X\()4R*ON4W!&X]^+$>%)&9QGRSQOS+0S]1Q;L*?<9RLTE
M[D9EW0F)*K&Z+,S%K[ZL#,48PS"5DYKXD@\-YXOS RB&=[Q$1ODT$U9Q'/&T
M3E$D"N-FX..2,1[CDOD ['8@[>>O:UJO;1I*TR3QK(\3/&=U[D9XNH;V;BW@
ME21N"-]P>G$]:>E'1Z.CIV^$O^O^%_WNM_\ YA+ZDFE/^.(__1[7_J6ZA>O_
M /P;G_\ 2J7_ +0G32>HWU-.CT='1Z.CJ*O*'7#TC<*<AMXIY;Z@>-^.^0%!
M32GYO6W;::1&BZ!>U/+FS)8F5L")._2*5-FQX[6HKBD&U%5%T&,R%F'OUZD\
MT.[#G&A8$I^< !Y)'U !/399S6*IV!5MWZU>P0A[<L@0@/\ F%BVRJ#][$#Z
MD@=2H8]A&-(-S7L>UKV/8Y',>QR(YKFN:JHYKD5%:Y%5%145%[+Z0].?2%?R
MCQXS;9GCA=A1.W&SR5SN\IG!36&GW^.S\JEA7&BK/9\P2:R%)T5*-TAANQ4G
MC)'0HAF>+;V)NV\W;?M1R+%(^QV21PY5&^YB(W\'VVV.Q(WT?$U^]'7[T?>F
MB>>*,,"TD*%%>1=O!0&1!N#YY#;<;[+SUJZW]>#I45DD,)\D#)D@,B3'B.,-
MLD\>(^,.6<(%<A2ABDF0QR"L8Y@7RHS2.:XXD=[L=B=CL" 3MX!.Y )]MR =
MA]=C]QZ\W&X&XW() W\D#8$@>Y ) )^FXW]QTQ&QZJ.G3C[EG*<%;;F3!YGE
MW;OJ@Y?!VUV"+>6LF_/*BYZ&T;D6/$GZ*5"E1<] G2(LV^D@?'J 3#=F*JCH
MW)J\EJ*O*]>+D9)57=5" %S]Y5 078 A 1R(Z12Y/'P6XJ,UR".W-P$4#N [
M&0L(UV/@-(5(C5B&D(V0,=ATO=KRMQUQS;8*BW.NJ,S;\H:L.&X^K[,SQ2-7
MKI$.1/#05+6#>AIY(<23(:-ZC;[87KY]T[+IB@FF65HHV=8(S+,5VVCC! +M
MY_-W(&_WD#Z];YK5>NT"3RI$]F400*QV,LI!81I][$ G;[AT@-UU4]._&<[D
M2MWW+>1RT_B6NPUMR3%M9AA%QU;R7;@H<',N49'(@0ZBYE1ZZJ<Q2*625C7H
M-%[INBHW)A"T5>206&E6$J-Q(T"EY0OGWC0%FWVV WZT39.A7:PL]N&)JBP-
M8#ML85LN$@+C;P)7(5-M]R=NDQS;UO=)'3AI(&.YQZ@N,^.-;910SH^9OM '
MZ^.ODN<V+93ZB"V9/JJV4K"?*V-H"'"D^R90'(@2JS.MC,A<1I*M2>:-2071
M#PY#W4,=@S#QNJDGR/'D;ZKN:Q6.D6*[?K5Y6 8122#N!3^:S(N[*K?X+, K
M;'8G8].;C^>.&^0=6S$8?D?*ZS4FX\S'+4>JH+,=F^7QIM%1,GMX<J*A(,S.
MZ%'-?56$6284L3F%$JB>UZZ9*MB&/NRPR1Q]Z2N6=>.TT7]\B(/D.G^$I (^
MO2F*[4GE[,%B*60UXK06-P^]:;^]3J5W5HY/=&!(8>1XZW7&?*O'?,F7;M>+
MM=4;;*NM[RA;>4AGG@K<9JTDTE]7H0@Q.^8J[6'*@RF^'9AP/:BN1.ZX3P35
MG[<\;12<5?BPV/%U#(W[&4@@_4'K.M9KVXN]6E2:(LZ<T.Z\XV*.O[5=2I'W
MCIP/6KK?T>CHZ5F7_P#L[_\ !O\ _8].%#_QO_X/_P#/Z9\M_P#J_P#^%_\
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M/YT)T[P.;M=P9TR<C\!;[I_)R)QG5;3BK3ZCEC1;NJYAXRO]#<3.,+S0GIK
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MFKHMMH69I(9E9)9E1"%(*B$DD\7/T:?1\"]>UOU(<A0LS@N:,-P3J<QU9\,
M9 ZF)MKB"YZYQ]?!Z:.2HL*[ZCITC(1J^T9*0--QGPKQOH>.Z]15$R1R/+GV
M]M!WI:Q2TH2\M:6W&^/LG>DJR\TE)NP%EI 2;KL>4]F99B"0( $1DLE'./D;
M C@N0498LK3'')EX>W)"JXVRJOD280K@[)5I5Y:R[(QLEG<)?#],WQ",YPUQ
M;CN$L]S;P1IL7T-<K\3W8^4>HVHWE([J.2OX+JZ.^QD0/,?)D/,YN\AY7=0.
M)/ID&CHN-$;\X.AP\:RCMFYR7<0]F>2R]:TDN4K6%[%)HF^#WM,Z2$UH"[J9
M(C8Y%GGWVYRE3MK@QN>BIUH:4=VC)#@[-5Q9R*3I]I!:*I)"HN65BC=8IUJ\
M5CCK>2(X%8 N'A>FKK=OR<'9S3Z#JGH.+G]0E)?\O4%MS6["Z/.<;IPEM:#8
M5=;N<QUB<\\K:K&WO(3<C-+#)R-'M86DFV>@QV8SU4HY\+5+=QB?%ND=!Y_A
M&2LZU>ZCS?$QO&S1/C:E>.5(>X >R5:,*DLCMNI40X[-2?!1RR91*WQZ26T:
M[V)(Z_P,T<J+8BR]ZU+"\XB8CX@,LK-)#'&NS#"X$Z7NK_.\U]$'*O41D.?^
M1YF(X9Y.X@W=C1=3((MIQ]JDZH(&NXUVG*@XG-6<B<F8"?PS25'X\4M:[D>5
MN9%-0P-YC[^\J*<,;VW>QSULG!3DJ0B6U!9B#T=UFC^",<T4!-5S!*++L8F(
M@$09S%*BLQ.-#&Y:.YA;60BOV&AIV:D[1Y'9J\OVFDM::UM=C%F!JB)WT7XD
MS&.,3PR.B<91]<V6Y^Y&YQZ9,IBNE/2<L<!\?\IY'GWE799S>\)Y"??<@8.1
M)!Q9FVQ]SN:72/SV-M"-VNTDAH)<F^B5U'DZ(JQY-ZK4.,DJ0U;LDE]*]N6"
M2I!&\-J15AF ,[[PQ,G.11VH@7 0LTC^0G3EFXK]B[C8H<9+:HU[4-^S-'/3
MA9[$!(JQ[33I)VX6VFF(0F0+'$A(,@Z;?J^Z2^LWGK2]+,:\Y'K+V!A.K^-R
M#+Y"X$H*+A_8<*\2)CM+5-N/<Y,V?(,/8:NOGSH(63J7/2WE4CRIDG!1Y!;L
M??QU5+Q6%E,N-:$16W>S'9LF6)N.T$4)CC(5CLSCVV,N^V^C+XK+WI<8&L*Z
MP986#8HHE2:G4[4BA_[IFL+-*K$#DD9WW/Y';J'G4=\-SJPFN^(;2XM_*/4,
M'FK$=$U=Q9R!RYR'PZNUVUEQ;S/1:_D.GE2("\=UM1#Q=##DF@OO,]1ML8P4
MB5<R[GN8Q[C3S-!1AVE[%0UILFUB*O#9[4:V*DD4+@'OLQD<@'B[\3Y8(.FF
M_I[*$Y](39OBY%A15L6[%/O3-5N)+80E?AD00QJ2O../D!LI=B-WXY,X-ZX^
MGSESKLU'3IPBG+N@ZO[W.[3B[J*RVKX+C[KB.PJ:2LJOW+>1,=S][=/<\?17
MUTB!6R*5MW%AYRP.=L6/?O@LITL-K%W*^*CNV?ADQRO%/4DCM-%85G+=^&2H
M.:S$,"P;B2X'DH&Y+;-+-T+>;EQ]/XN7+-'-5R,4M%9ZC1HJBK8BOD(]=2FR
M%.X%C).PDX\??C?H2ZL=EU25/)O+?*'*_ OM]"G3UQIKN2^FW4<)9@&LYHRD
MN4;>X[\6Y.)U4>OS-5(DOL*Q:+#9G-HK8\>FFNBA;!;Y/E*$=%H*T%>U_P!U
M;D\<-V.U(8ZT@ ADYB6,EV V;G*[^Y8;G?KVOA,I-DULVK5JC_W$Q]:6SCI:
M48EN1$FQ%VV@F"QH267MP11^P1MOEZF7\+;@;E+IMZ2ZKBOF*EG46UK^4>:+
MLL>TN\UH;*?2Z;DS1WF>NY]GDIT^D),O*>;$M)(HY %CFDO#)@P3L?%$WYRW
M!=OF>LP:(UZR?*DB*KQP(CHJR /LC J"=P0-PS#R7;3-&SCL4E6VC),MFXY#
M/'(S))9D>-V:)F3DZ$,0-B"=BJGP+$_3/U(.CT='2LR__P!G?_@W_P#L>G"A
M_P"-_P#P?_Y_3/EO_P!7_P#PO_\ #ZGS^,E%_*D3_*?^KU<?VC1_A47^-_\
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M5U0R+\-/RD=8T'*/=W=@J(HW\LS$!0/))V'6BQA5J0O8M9"K7@C!9YIB8XD
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M#&U\8[?<+WKW4VGJNHZ$]W%V*\C6:K0SO&!+'9A#!]E=1OW8]CV^7)?F)(W
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MS]'(9=UL4&66>W3JH24C8PA88V;BJ[)"$?=V!7V+(/3C5&B9*ER7/X2Q'ES
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MFVQ,;,FLG8\JRGQ:Z.=L(RL#\Q[DD3P(-T=Q&,9$8G@0(7G"C5;*L]NQ3S6
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M#,"1OL.M%U%6UG0%N@"+I(L71ZI$!K0P O-*E261R&#7V ;9LHA9;F2Q.*4
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MM46M+-%+CM..2,D6?&-V$KG#\V/5",(-K$:KT60@-^HR-4L05I8):CS@,@L
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M<YGYKSD\G9RB:>IX_(Y#)8ZE6L65ISO7DAPMJR\<F0B25$&]5YW0H7#"5?E
MW)ZZGUM#^#?KCT.@UEH/X/3_ *L:>;"XZQAL;DKSKE^,D&.REFY6F%F@\%F&
M"?(RSU.VW=';FD,D_'J#FW3):ZI/;1P S$K-K&BQZ>.7YV=*JSMCO,89'-C-
M(Z U[9:R'.>Z0AB(B#:Q&I)L95X0+#=L"%JKQ?%&<=NS::Q:,86M"Q+$UXD8
MO$8OE +.^S+U4>.LX+):3H+9EAHY; 004;@@@!DU##<L6%FNJI9(X9J4RKS1
MGF<K+VP%1%XM/ KZY+/V9VP?#B.GRXYI[(DII;"E,20AYXA*@3HI_;8J09K!
MO8Z1YKV5CV+(< 'OWO@/M.+"U8J=I1D)?+(D@024F6%D[PD5B2HF[95) IW^
M5D$-/'MC<=9R,DD3FQ7+8V.-9;"TY.Z)K$%A6,.\#1"$Q/N"T@D0LO/KJ2_!
M>/:<7KK=&,]H5+TT-&A/N5S&)U (PI%1417O:J(Y41/NU?T?H1J1WBW0.6XG
MRT7)8R?()53L0#MN ?(&P.QWZ;)V032"'N&'N2=MI&4R%"Y*"0@@%PG$,0 "
M=]AUW(^JYZM+H]'1T>CHZ/1T='HZ.CT='1Z.CH]'1U_/7_"49A*_XN,"P!6"
MNRUW!W3U/6IDL<Z)/9$KIQODY"B\2M!(5OM&<A&*C']FN15]35D5\.J/*81+
MCTC$JG9H@T 4N-_!*[\AX]Q^WJIL]$LXR\+6#4[K784L)_?(6D>5>Y&"""R!
MN2[@@,!X(W'6'46W4'S)LLSH=)P%)P&5@96!/RT&9I&GP5J[Y?WT'?5SHTZ6
MLJ:X@CPPP10)K(@S(_YC\\JP7"YF?T^TME*^+R=J=]17):C9P59Z^1@'%XY(
ML=<C[2;\6V<EF7D22-OE'&F931FGZ%V#':FKW[\EP07Q4IRG)PJ&8.:LK6(T
MC1UY]\22-'+(00-]MI)Z'BO:<O\ &7(ZWES!PUWR]1 XY(RNV,B]QE+$JD"R
M*"CSDK/ULJ$2]L8X(\E$)8OC0#R"K8QTD&:_'3^G,]?,&*&F[\_XIB;/KE,A
MC%@NVWL;V)%ENLP:601.'5R.)&X50/)B%;5F)P.:PV0QXBM4*MQ9WAGKQT[A
MX,CE9?A[%EC!5XI+"^R)R&SQ[,6ZYGV3^4.G+D'29DI;G-V,*3.H-)5&=)@
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M\<=OLN1BA&KFM5.R.[,_.LS'PM'25;,S"Q%$G%0#(DVZE9.4A8,&3Y67Y2&
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M'-1&$\"-5KA)W?<1=TE5P.6:>I934*R59</.DDBF%T^2<AD9$5>0\K(LA9&
M!!!ZE.6PQS%7X*Q)RJ2<V/R\)$8<2A5QN1Q((/MN#L?)\24C?$*YI%G$RU$#
M,P@2"0O>DV='#O;5TV(IF4UK6V%@ OTNVSS9,E:.QB##.@K)>\1GE:-S*EO8
M*&_E),G9OY!C,00BW)1&B@$R(P+,SQ.W(E68A =E(\]0*EZ1:;I3RW)'NSMN
MSF..8PP+L"3&Z ;N)2=I!OLP\?*&.^JY8O)EA@ODP6%;6GM&>,V+%--ABG"K
MALFF'81#L>&5<F,^(%9PW#)-2,TQ1^XI'DO+):)Q<6D]/IC;]2"**I?S$J-8
MDE%F=88)-E9R&YLLG&(#DG$(/!4;OM'&U?MFG=%7MO5IR!BW;<EC\BNC*693
ML6Y*RJJ@[#8@[3FZ;,EJJ+A"%E[#6RL>&P%&OHZ#+D8]A7@2).M?K,>SMI+9
ML>-8QSC@19D-XS090)#'JY6H-&GTGP-),CE=72+#;1JK8^=H)9)9X(IG4-7%
M/Y8Y))5B4L'5CN 5(W!ZH76.9HVM;29&/$19<5G:CQ?XUZ\SDK6$+Q0*$,L3
M RO%(>+KQ8^=CU ;K'K4761KZMM9=VDJI VV<LH5Q'I97MN#'@EN8'E62R2(
M,44L90$<\@9+%)^<GWA.;FQ8U+EJV,I1T*JV"T$!A-6=BQ#NTE=B67BQWW'@
M@@[[L>KG]-I66A9BE@2CO;<UX0C5V>)?SN,$A,BHLA*$$<=U)&_D%CNE)47J
MDZ;/T?\ 9^X=_1_'^Z'G/M]_O]OXOX/O_!Z3]6@OCE[>Z^V^WD_3?]O^XZZT
M_C2;#C2OZT>5:CD^E^N5LKD6(V ,RQ9LB/8UW'^0)%^2CGCQA"CE#9G:6. \
MV<5X&D*B#0;&5GD=4YK)97-X"8UWQ&#, K&"%HK,)FC263O3)*QEW+,"W!"H
MXKRV!VZS]-?5;2F)CTWH'UAKC)Z(@TC/G,$*58$U[5S+9"%JV1^=VF=>U.\,
MBB,*DI4J?\*L/C>XKM/3[&CX\X_T.DERCF^:?(*E7)H16!Y$.*\NG]XTMHEK
MX@IL:'#@BFQV>,04PS1H=SCHS#9C,6+%"G3J+C&EXODB^TM82(I'))?D<M\W
MR*YV(/+;J;>F6H6SF)UKI;T]]+<%=]/VOW8ZNJ\F8_CXZM\.Q2>(%'LS0ABM
M?MD%4"!P>.Q@7S3Q6UEIJ:3.R[4UC(!*DWK(]])A4$&?5/1ZQI<"0A6&<"/V
M&)LF44Y#D)(-(]QI&.M*]H.'$WJ=*EF<?=>G!)+<-B!%LIR)\12(=QOX^A78
M<?;8CF_.^C;8_,/4P5R&Y'3CMM/'<B03UG"]QHTFWW2,D\5# [* "QX[]15X
M]W_*/%5K:AX[V]SD)$X;1V1(,YL6%/\ D2?-A#(]QBQ9+126C*#WD4;3H,J*
MUXVO1BO:?QF:L"O8JU[X@$DG*55)C &TA#AOE''<%R1X_;MU4>:P].URI9.%
M+8K."T1>1U1U'EU"<1L/H1[^-O&W2[R_4/S%66$R<ZX@RC22B/;DEYNFL"G2
M,QHQ22JD)6((/=BB(CFL1[D7^#LK?/I2/-+\.D-RVM&)U01V;4T=2N/#$;22
M+&AWV)^4 ;>=AOTA72N#OQP-9GLUX(F41&*W8#1\#R79#)L0K#PI(^[8#?=)
M[$=%'J*Z2:UKM+<7P7VQ/9D3(B9EZ2'(ZN6"X0H!GR6=GO<%2()OB/R:]BHC
MCCXJU,<(HU>2#97$I+(>WMN"?=F;;8_,=B=O<^;BS5'!8_"XV&+*0:@R%RFD
MQL);F27#HAV6FT#*(G+_ #%R22-O VVW;FNT-UFY_P!1R]Q8T<Y[/!7U<N1%
M,T7FCFHA /:YX?-K7>/FJ>36JB(YOV<++UYC\3445^3$/73D!&?;96)+;MMO
MY/W?<.H=C<ME\-9:;$Y&S2G*\#+4L20.4W#<&:)D+KNH(4GCN!XV'2IEZ#::
MZILY=S?S)\%LMMA.;-F&(>9-(P0O?5)!'>^9&@%W5R.>J,1RJ[[KZ\KX:"9;
M.=LS1"1-H9FD;>VX(/!5Y;\_)V/S#VVVV  W6H<CGK5K4%YY+=N)4DL6[+EY
M'  0#D_S.R@#W)^_;JP7BB!,P?&>6I:*.#)Z._M93[S4S1N8#49>YI*@XS23
MF8\9Z6OGDMZHJ-&T858%Q!K(,WM3]R1<]J"2![L;0JJ0PK,RA,?9@DG4JP!!
M5Y$6*?\ .W92VQ 4CJ$Z4]/Z?J7KRG2SN3CIXBTA%62Q*(HJER&SV@V^_%97
M8H0YW/NHX@>5%QWE%XVY1278S4T=5?:"%7W<ZH$Z1340ID26TI+>1!:5(4.+
M.M:<XYG=$&,)I;AM=%'V,M6GEA%6.#OBC"=R#P^+E7M,T4;,2#SC2;8D\""/
M)#>;TSOH=:T9K/%S)B)]=:2TG8HY'/B@JV8Q5Y1RSI,P(1F6,,_$A1MNIV4]
M37W<76WF;M"\-K%M,?-C2JNTSEBU_P!"V6IM QHJ64V-*D,2/69^NSMDRI82
M,23.NBQYI6! 9R!9A0IY&R<DU%\?*IK(DI")/24([-$NP(4V&)C=EVYA6 #
M*3T/ZU?@N8S\("SI/U"]/,/0TY+=QE20585@HV15H0M)5=GJ%UYS$=E@5#!"
M$+@+X:Z(6SJ>)5XIAU>SK["TI;@102JV#IM*2X+FY^QG4@*BK)%DQ8Y9!PU0
MYK&6I8C7K(?$CL5D>.X6<=/1Q?VR]G#M4R&6B@91*8C# #!")6#$!]G@D>0R
M%=MPH<D*>HA6]1?4?T1_!HSV S>*TW+'8U7=PLKVK?PLM.C.T-*UNLH[=B59
M(9&[A8%5)/G;<.AT\7D2PQEEFZ;&V$[1129:XU^<K)D>DUM7HZ+.R(==D"44
M^H'.D0[2EE639$@48C7H$TV'>07Q9,=(;F9I<;D:F02_'19QD:T-J2,6*5FG
M8E53:BD$H6.:&2-2H;=S),H"N-NJ)?U]S^F=.X#)^E-O[,UFU2UI>U0@P!R>
M.O8>W,0F::_6/&&:L[ ++(0WY0GB0-NHQ]5_) I>;U-O>\<SZJXU\^78L+L(
M8Z4F2K/H8LZS-0(E7*;]5L(*?+0*>'!^6K8]<1YSUPS@]J+(M&S02QPXBI9@
MG-*VMEK5)FEDLR<ED$\CR(3#&W&265F=CR8H.9?F7',Y#,:1]*L5Z?ZIQ&$N
MZLSFH)M4975"21WLC/);5I2TK@AZLG&3\URP159 #R\5[:3-V-WAXUI>9.DR
M=C1Y6L?66T2 2I6_!&EN&K3-_,#,NG0I"+(DL:J/'7B8Y72GJ0D\JWA!DRE:
M_8M16+<@EB:43&%V4,"K>7CA$B^%/D<R3LNPZH]&BP^3CAJY0Y+XUS/+!'86
MR*7>0R!7*ENT 4([8W*<SX ! CY46385M#FF(HQ1# .\;@^\V26(_P!P()+%
M5449G#0;W*CD1CD<YCD1$]2[OW8X)8H)9$,\9Y\)-B0"=B1['B?.Q\;CJ8T\
ME/5NT;D(BD:I;KRNC /'(D4B/M)%_P",0<02IW!V(^N_72%\.'F/C/3==?P_
M;K&Z:._:77.V S&NSZU 8"2Q3#&8>:P2A"CW0"C: <\'NN<Y$:JL[KZEDZ8A
ML'%9K7&;)Q)7K6ZY<!IC*I:666, *6B(!#KR!'$$@GSUSZI^IFFLSH.&QAK]
M27+9B@V)RM"+'+3/%H^#V$0JNX@D7@)T+[@'?CN=Z1^OEBNZZ.LY41?MU5=0
M?V1._?\ Z+&M_C_C_P#H_P"QZBI;SMX/G;?VV_E!]OO_ %>WW\6$[$[;>^_M
MOY_CW\CS]WU_5T@N-\UK]UC;O.\=\<R+[39ZT;L;G5TRR9&ECT;8H:NOH8<9
MI$:&(R:6PGE9!":?92)0O-/:K HC#D+%6E<AL9#(+#5GA-.*I*$%9I^;2RV9
M'*\F<H(XP781Q*K$?-*QZC.9R6,Q%ZI:S68AIU;T9QE2E:(2K+:=C-)/(^Q5
MG,:Q1J92J0JK -O,=YD4?(L&[J;>JP$ZKQ1+6HK$K)5=7C#:YB?$#7Q+VON*
MMI5F-.X@IC"6,89'F"3WD?Y+]V*W0H5%Q]JT+5V023KDZTS;0R_-(U6>E84*
MLD+Q&-FB?9XY4*-NK!A6$F"EKY*E9U!7LYJ*G:MR3P6)^=3)0RM/+2DKSGC$
M53E PKR-$JE'C.PV)=]-G60N,:6#H-95[.W97SXDB1)@VK*N5.=-/(=&GJ>'
M[BQX\ K8#T=')+EC 10HQWD4;&]25\G(M2E/7666(P0J0TP0JJJR;-Y+/\XV
M8*I8?.1MU&K..:[JO(W\5A9M-XU[,$L56"S7::O"*ZQAJI,[DRRV(VG0]TQ1
M,X5^0XJWU1:O/\?8%]GA(F1]NQ)&EW@8%.L>I<U46&[S)) MGYKV:(9E.A2-
M<A4:OGV;[8IW[V22E;6X]Q'->*)WD-@.266,)SX;DMN$/C<^WG?I-;Q60U%G
M%KY9LLYB5X,:9[:M:9^0D  A/8.QY.T:Q%4*\-R0-X9;?>:WBF_C7]/51Z>J
MT\P<R3"%81[C,WT08P>3QQFM"6+W<;Q/Y*AE(UI&E<K/))%1Q];(1/6GD=IJ
MJ-&.4;0V*[\W!5R2RN 5(523Q^92!OU;6.Q.,U'1:G;G>S:QZ&!9WADJY&E.
M0XW[A/S,54$$+Q8'R@#;%];GEJ5H^/ZTTZ%%JJ4U&:PD-RY%J)U-+G%=!A_,
MDNC%&2)(:(CBPXA%66![5>)X'N>-CCH=F^\:,9)4G,:"13(DH3=B!V1N'7?\
M[8<3N ZL #$:6E8L=FK(AEGM7/BHX4DRH%R&W!"BSS&):B(RR(S!%FG [3H0
M#R"!HEZ.QIN5(V&RL2I"/<)>R:29HXJLC0R4K7L'3#? 81D(3&N.K2&:T:M:
M%%555[O4MKK8QK7KDDSO5,0L"&5B\AL.-YF:5P7+;KML2=RPW\@GJQ:=>Q@)
M<K?EML<1\)':AH,G<>*V.;VV2;BTS\PH*Q[MN2P   Z9O:X6WQ5M],G#=(5Z
M>(R!8KO(K5<A =F*_N0;FN:]K>_96K^E/NKK0R$-^$RH0NQV=6.Q \;$CVV8
M'W\#Z>>I-C<G7R-?OQ'8;;G?Q\IV*OY .S@@CQY!'U.W2]XFS5&.;.MMA\]'
MBQ(J&!$AB&MB9JM\$&)Y7=H2RE*T8Y3F/(-KE<-K55"!UW([UZ6G0QD:R27+
M254D<D0B5C\O)M_F6,*SNOD;+\VX^5FS.3WYA!4Q*Q26;,O:1IF;L[@CD2J#
M>7L@L[1;@'P';8A3(3BGCM-#J+F#5@EQ<VV)1F+>WX@.!4,^0"=M*5PV-5]B
MCWE<JL5OYC/=/XJJ.<UZKR61!@K92U%8M8L38R.*LS!.W6?L++$%"#M\8U!+
M#FS;\BS<MH;JW-2XFG7^-?EE(;-N!:%/DLUHQ6)(GF5) &6N JGDR\CN-@23
MTX<:DL..N63X[1R*MIYMO364&X:9ZQOG'5Q$'7RB!]M_NI'F1I2B9_B2 E&Y
MSWJQOJ+F1+N-CLUP_P"166.2([ENV9=^ZH(\ NI4G[B#X'GIEDN5]0:8&6I1
MVGB2I;BDJ<460HLX#2HKAU YQ2QAB#NC*0!YZ4'+W'*CC0R!EQ(<6SDR8LYR
M/&6!93X?S,HEBK)"C;[XHPD:SS<0YV'"UB,5RJ[10N=I]RC.\:@IY9716(7B
M"/926'MLH9?))WZ0:3U"+,D\;1S225DBE@4H4FJUY5BB6ORB!)5I"2VP1$X,
M6)4#:"&3XJVFTT&PAXZB99-R>;N-7<,DRAPPQJ:'"DRR2VH4@W'=\JU\B*#Q
M>XJM1%:K.[5GUG+5:=6JUJRT27+$->,*.7*=I$15;;< \SQ8^PY>-B-Q;>1U
M#B\56QKY*T8#DKU?'52D;2/);E<((SP#!%WW61VV5!N"P/4E>F &'UU(Z!R!
M3X[\6<18)9SY>@8.-$ER)EA'/#!/.!K;"2ACM'5/$THPF 40I#V &7LW94K7
M:_'%%FK&6R52&+#C&V$CCK31R#XJ6S6>M.UI&K+(88X7@:*;>7DY 4P+U!ER
M^+G6Q@ILDV2RT7PM>.D3*\2QQ,)6BBD#0*%A,DX(VD25>:\VV4^W+\>%8:^?
M"FU^5Q#+5MD,D6@AU=-DG3ZP;$@SJ^!6"@A""TJVP!(4C'O<1&RWO>5\A&LV
M.,D4"RQM:NFNT?%YWEL7.U(S<T=Y&D?>*3DQ /L2HV7@!NTI/,N*BE6Q>RTD
M/9?N7'GFR CL'>:*66=I"[5['?/!>"HH,"J%1"UEGX.;00ZKXL/"!T<!KI'&
MG4$>(9CC'^H+^Y%MHQ1-D(U(RH%@7R5<%Y&*(@T:]RN[,M"UA[5*CCLBTC-5
MR-&*W&LM>Q596<SQ2PQ]Z%8YGADC4L8Y&'9DCD^I'5JXU4M5KLT]DPSUUA$-
M3LOO*TTH5EY$@1]N(F0D@\B%0 $DAC[^62V44*/9GIUOIIZU9G@YU7&GP*P3
MFUUH1&N,QEBD5),*0K?S>SE1KT</U0L!4[//"'6-Q(T!XLSQF9M]O9&"KL"-
MP?G&X.S;48]"K@\C=LU9Z^8APTL$L:1_$TLC=KV)I"^0QT<R*L;U))I*]R(E
M9$?@57B"PC_9TMGO,82%82W>=3;18MH< U*B1(3V,*XWB@3F(%[F@,]&*]1"
M4J,>HT:Z54K-"IGVGJR38S'RFVE662,6IJ=:W'+%")$4_E L4@24H2W L4#-
ML.III:]IW%:WQKY[G!A<@\EN;<2RR[.9)5553?D)BB[E=OGD9MB#MTDL-E*6
M%<QHS[FK%.B0H]_[,J/(<$$NJ))/&<)&#5Y$EG'[$%2M !Y)9/?5/ 3E>M1Y
M5\?@3B\)<LY3%69H)\G82EVA;RPYPQTH9;"+/\'1K3+.781MNT[!6!$;6E<L
M:0U3DK>(3+8[2V"OX*Y+;R^0I6YY&R5*JTS8W'<$B,-R^L4<$;@+&QG[;2<B
M6;>;'6P[*Q@R-E,;56ZO84<_Z3/+6S3,(YKFQ)-8!6*@&/$R0!_LG$)SFO5K
MW^7J)TEFC9Y*#EVA&SK#/''8B#*"O)3('4ML2C>Q(\>W59:8TSJ3'5X;6E:^
M5@JV99J=2]!8EIN"$1;$8M.44\A(#)VY73YU)'';J4-)B4QMQG*C9HRGC:"&
M\\!QI!!QHK3$]ITJ(<!U+" TZC::)*<J*)[")[K&N\8X;278A:2"P $6U6:Q
M"T(LQ,6"RP\]A/&2KA95!3D#Q.^QZ>/67T8]8_1:C1;5N$BQ<NJZUHTHJ>2Q
M65M7:N.> SPW8Z;VEBF830O$VT<KJTBE4W;K=7/3TW)[N+=3IK(ZT<VKF54V
MJ*KAADV1%B?.%=':IUCC@G)9$"UXF$CADK(*@8[E:AL:@ H2_"PR3-:BE_(E
M"H<UQWF21F^506B"#_#9F5$V+;F+^C=BOZE93#:8S6=Q^F\3ELG1T[G\QGE2
M9<1C<G=KTA;J59W2)[%>:QL)Y=JU-P+$K*-V'KI]#=YNROK8LPIZ_'TZ7OSH
M6FD MDH[H"'",!2D5LBQ"^5\M[)"_+M*4ST5C'/<NQ2292OCHDJNEG)O%72J
M%_*)+90JB;!>6Q?@ #L?* '<@=1?7&B-.:8UYJ?1>%SE+5=.CK#-:7QN?K-$
MJ9*HIL5ZV41X&D@:)D$3S*DDL,K_ "Q2/NC&.NWZAJC$TO-]+3^Y;T.]C-/B
MK-6O<1I;F?.G3HMFIBM*]0 LYPG^TBR&2FN]U57L9SH-,7LOD\+-:7A/CY(Z
MMZ,(L1A7'Q0PPB)8H]C*1#PD[@)=6YD\@=NT_0SU>M^GWI%ZC:/RFG7KY376
ME</I!;M""M%5AR> AM8Z]:MM)P#?$8;)JR"!)F6=*[<$20E:ZZ*'$N;B]M9=
ME#?]$J#ZB."P&(0K.=!-7R/I+@$\D(TONR!(%/L08O)$8WR1MP4K*XJ[C)OA
MA;6&Y5;M?G0.L3&<K-R\=IA%VY#L22Q'DGS$\#IW'9#[>1<BM:/$Z=LY:H]@
M)"UNU5-0_!K'(7YR$RRA "&E$?<V')@J,$99K[,TEP@EEN+-&)H%4)B.D^X^
M/'[(J@[->Y&_9W=K4&O9'=TSNV'N7)[;JJ/8L33R+&0B(TS-(P"[_F\CLHW.
MWC8G;IEH&(QVH7E1'$2M&LD9?O,KJ3%&^S-%(R]QN0!$@4(0 VX6N J; 6I!
MX1)L8@J@MHC'!)&.2$:#[C#@]Q$50$0HBQRHUS##\'HCE<GDTYGC%4,;<E[I
MKC\LFVQD*."5/NC*>2$>"A# ['<-&=04XHC9@D1)_AI$2='A$D<Q$D;IN-VC
MD0$K(OAUV8'8]6$:SB:^IN!:_258/DW7'XL6<4L>=(>A*^:AVV5C9A<Q5B-$
MEC6QI4=K%;_@XBM5[''>^N]/7JV7U19QLEVK&T4EB'G?XU:Z20AE$:6""K*\
MD+B*1@ &)!91Q*N>NM!YW3W[CN<SND*ND-/:]TWE&Q^HI\[%E*NHK%>S6M5[
M]B!99Y,):&/M12BD5C1J\B.D?Q"S(C1IE63(1MD/6ORTMU37S)T>2V46 $;8
MIXA2P01F$3PFEKC-5B*Y"?GC>B"D=EL/"97%X>#(X_,X>GFA)8EH5(4,<EEV
MCF4S2&RLY%18EE1ZUA(>Y8DW6&95CE;JFILA+4MOA1BH\K"ENS"L\,D22&4R
MJZ_ES(K-VEE0APK J5*%B& P)EG8U+(\W&1X\@5E7PV?50'F+/B'@0 DC3G5
MY&CC1QL8^:6*&..41IX#XXW- T@SS:PN>RP;!:DEMY^&;!197"XV.2M% G;4
M) MZXT=.?(6,/5=H)-Y)-VF)1G+M(DW@TYD;%F"C;GM6[HQZY.C#!M4AL1V"
M5L5N[($L698#RKS*>'+F9%WY )E,Y3FQ%EYM=)^.\R8W,6=9<715G'=;UXG
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M"XVG?R5@7H)K*SV(KO?Q%IA-7BFAL.84W[:NHDA4.H8.(T<-&PV(:E- Z?\
M6?2V,Q6K-+^IQ;)9"QJ3$R:&O%+^!PYHW+$':A9B)E,4D0>,J".'$ [;'K40
MKVATO(=F6ITZ5UQ5P:B#&EKH((;:QM9F8KZ^G!H(\?Y6RL 3JJM-:DMY,0U6
M]T>N@Q88K!75L9VQN%M3UZ6"NR]J6>Y-::6U'WL?4BC/=D%>52P#\).!A5S*
MH)920>H#5TO5];<$OHYJF<5?5'*9[,9S.:GR=F48%8H;LD\BX^)'[:%T<1I
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M #$E?<:=7:8DCR<^9.2QDEC#-!6EB[@?'V(!%'.*\4M8R&':"17/;#D-N&
MWZ6.KQ,O+3.')\FJTN@?#O)=5>@N1K8:"RES(,2)2SH4".,Y'P8:G]J*-#OD
M,(C!L]QXQ/75:S,>8LYFTT=''&S7KF**J/AZ<4=5461"S-L))5A#R.=N3EB=
MMR.F3%99<G'JFK6L8ZD):D5F@V/Y0X^JBRRFS#+-(P FE:/>0A!&4)8D;L.D
M5?,TS^4;K"T$@\KZ*"=&9679I0B5TB8=U@!>UH01P3*^6\=?/8]&&4 #!>)8
MWN^#ACYL%^+LLN1KL;4\\<]"[32)C*(Q'$]:9PX45GB669&1&WE=6!!5>3O5
M-.+3M?+78/AK%AX));=01E9%A7X>:-XZ_.-H9XN5F!T5R)C'LP)&[1:"RW>(
MTGXUDKK/'6A,=8Y2Q)0RA9UTD+ZTL48B#(,L>=#DUKT![0QE6PBA<K2MG!)(
M]/=F# "ND&.NU<S5MR0V(H<A6LSSXZ?O1-(LPC:OPD60.T,_-XTY\I$;<;V'
MHNAI74$60Q^6A_&+'5X[>9J(V0KUYH+D![]>Q%-;CF$TM2\O=DIP*9F0LD1C
M0JJG#5[71[T-::LER\Q996+7;-"GK<ZV#95CGS V=?.(DT,QT5R@(4DV.7YE
MDHB'C>#!.;*=;6UH?BMFL*EBEEL'5HUC))C8O@WRT"\Y8$$?*.VL\,BRM).P
MDE5A\H4[=-&JZTTE6&Q3LK5R=.VLV-<UY;:R!B(WKRPJ48+(ON5<,A12&_/4
M^75)K*&ZUF>KLC62H64RV=KJ"OF3ID>R)>R*MY2VT[ZC%:D.:ULV86&U\5$
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M.Z-&$')!\^P"],^:Q=?':HMXY9*EV[3GEMT3'!##=3XUEE:.68MO:FA7B4
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M7%"Y/;)YIZG/I7GL;J3&7_0ZUC5QC_#W+5W(1M"1?IV[9E6=2VSB4<^)#?,
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ML -E5F7ELS>&(!:<5 :^2L6:$"6X6C669XI.YV"R<F=)&7F?RJNP5]]@PW
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MK$!*D#8YYXT&>G3T_<..R,-FV\-:*.M/%*0LD+,8P;_<XPQ(WD-,>V-P0HV
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M;W.YW_C_ &_Q]1T@;G<_?MMM[G?P?X_O_P WCJ)#AN1RHGCXHO\ "YRKV_\
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MF_BJ8&1,.X(W*#=TAAA&OB5"%DN8P0Q(U5>]S6HK>Z.1+;DDC[95"_.1 54
MD NN[>XX@*2=]_&WL>D5J26$Q2)&[AW1"%7D=G=5+$';8*I))]E )._MUTZ_
M&/R68J/B0\B:JJU<RJV]MKAS4KVMFV-8D6%@LK'.60&RDPJ:!*<00VQV5*6$
MT[B/+.9&$P:F3:-AQ^I?4==-5$$5H=ULE<DKK*5D6NDU>.)20SG@%/(D*H)
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MOU_T>?/CQU^_FHJ_;LO?MW[(O=._;^'[_P#B7^#]'V]&Y]M_ _D_D/1_OO\
MLV^_W'ZMAMN-]^K6NC7D"CY2XBV/3ERER#A<71T]<>7QK<Z1&5UY53K.T^J6
M08%S($VK)5.LD&:?739 YTA9BI!>P0Y)15EJJM-@\U2U/C,;?R$TLB)DZU8=
MZO/'%%VXVEKAN8E$>X26-2J\#W Q**:9UEC[FG-7Z?UU@\+-F9H[H?.4&X2T
M+M:*J:O:FB[5B5;,M9C'7G^'E@@DB24J)#^4^NH748'C_=\2UT;DRCY;K:+.
MCS-WH,Y*\;F%-H+1/JL>=($KV28%D"8YM9-;82AO$LP8T 0(C(\:)I'4[Y^.
M]C&TVV5[S8D9!6^$JSV3'-4GV1DX-$(GK2QO"!&90Y5@=NE_IYBXK575\^3P
MEG%/DWR.2Q6+!X4?C;]1DQ2[RP!1!5G5);G:K1O+&L84H[\5>GF+6\(ZO)X_
M?8>YQC--5BL(6\L*^KG5+R8\M4/\7J_259Q073]'536Q@U,L99IOE02AEL%C
MNB!;%$P>I<%F<EA\S3OP1L(I*<%F6.93;:5N]8H2H\F]*S%N[[<(RYC=$Y"1
MNJ\TS0U3C)+>!SE+)!7L++B(F>.5DM+,AM21VT62)*EA>])(-MR)0"@91M59
MK^5(/N6];DDN!UEG(59A[*6!Y)0QM<P:#BQXXFPF-5Y%0:2#N:U_97IW=Y6'
M2PS*();1B,D"_DUC1@%)/DNQ8\V\#W51N#MOMN+WQ^%F*P2Y(U38AC'!8$D"
MQ%B"099')E]E!)1 2-^/MQ<KCK;A=QXD&!\_96T.U*+Y8Y%?)K(LET8IR5[O
M:*QX'QV27/0@U1CB&<K%5 O7U,91MZFKKFG6IC+$9[L\'Y+=TC94Y[[[,9>!
M;;\]0-OF)'3;=Q(DST+3M'6J3QQ1EXNU"EB3\HD'Q,DS*L125XB9&.W!020.
M8$JG<%V)N-KGE^)4AD7^FK"QR5!S(L"965PXTEUO853'.)#FRI,>&Z0(4QR>
M+3N"/WE*U6"74"U[RZ9DMM-AZ.3699XT7XCB))HU6O88;$=J24K\I\N WRD
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MKV6#35ULK,T13MAE(58> ^=>V&)+CY2YX[L?F-$^:UIM+R=G[JTI*V6>9JX
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M'M]=AX\==)9_5N4MX#!Z7O9G*Y3"5"B4L+<F,N,Q]B6U),R4J[%DB3NR&9B
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MZ'<]S6O)([$5IWHSM^^M]-WV/INA/'%5IXQ4E1(8):T*QK(J@E8DV5=@H!(
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MKTHLXZUC]%W'CU R1145J7K*2D5[-J&L;#+8CBJUF!BM-\,W]SD*4D"Q$/\
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M/R9O8MN?)^4;DD[@&?>C?IOB=<39"OE\^<:U2M+)3BAB[MB>ZR2.BJ/'R%D
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M?#6/(<,Z5?KG+#2>4PLE:))\5+(9[])U9UL0PF,F+N!TDB,D?<"D2*7=@O(
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MR%>&S+*]N:!WCLWHU?N3%9)MW?D_%?F*MLWF&X34V:T="U]*6-K57F;$R-)
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M1)O&0R-Q<(6+HX12S^ -Q7>O8+%8XO44*-+7QTSU\Q6 >1)<5<*I/*T2$!Q
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M.XNXMR=!P_G5M:"UN<:AY1]&KX)2VU]#@D@L<9]C"A3)-B2]4HI4=DEAAN;
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M5=_:D'JAZ!ZWDG-2>4^)H43,:*HJ''DXH!VR@:FHKR,ACM8<H?=@[RR*BO\
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MZ?, 6S?'C-:TA%8U27TAI;RL]^3O]Z.=1(TD=<1.)N^&#("H= B)Q#B$%@2
M3?7X1_X1OI3K['^EN7T!IR6#4.G;U/,9&B^,6C2QB54+V,6+<(CGECDLJ)CQ
M8H2>Y'-&RB,G,7%&:F\:3+C= ?H+W-V0Y;*.',)46F=G ;&@P*KYZV ,WR$X
MC6FG&<V3%!$<U!R2K$9)*LTKDKF%GDKT["UZMOEW+7:,U>U$^_*=H8FE#30
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M=#R%9%?(96T4S,DJX4KY2MGK(FN(TFU\YDH<^:-UXL=4DN1P8]9L?-+#D86
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MY J..[$EN7L89JOTJN7);]K3EN*(6Y8+8Q\@,<33QL_B.Q%*KQHG-G14X@,
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M'(S*9MP[*!R+%>G9OMWB.G/9ULG"1S;$&2'+@R;B5)/8UUU-O6QBSH(Y;O\
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M/VE/#D2(;W29#FF8)Q9<QYO)&M\FJB^7JB$B6+(2THX4"3H[J\A#(7Y<74,
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M(DU&3NGYY2TFS#.=TD\(FVE)O9]5J[>USVCKMK55EWR3R%<8^/N:H* @;?\
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MC^K<#;<DA0H'\G6Z]F\KZ8/AL#J#2ZR7JMAI%K31![5U;J-%$K&%9"5/,NO
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MMMN?>RZ%>O%7A6&$Q*T8<!V,DHY;'9Y'9W9E/RD\C_)YZ1G=/^U[?I5/M_\
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MEY-7JRD!EB,NX 67BL8C8\"6\'DQ;I%;6)X95*MOP) 0CDWZQN1L0=CY/O\
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M-*&-VN%F,:KLF\>RHPD=D8K(T:GF2 !MNIZUYO44UO'22XG"G/XY(IWR++*
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M5IG/,6YK5A<\V4Q>1?42')V'I104)?C&)BLSV:E69Q#WV1>(FBAG[T5H/W
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M[3CFEKDG,RB-R#^441S>5Y@CQ!Y-!BC)6K.*-M+#V8*]J9Q6@DDF62>*0O\
M.TS+)N0_)N\%"LZA5XH"=R^2^F9WD25#F/E1;=<S6,F6LZOJUIS^90V6BJ60
MGLMI$5YO9\JY0$(5 A.=Q%\F^'&O2%G%DUSSB6V[0I%8F#JO(15K"L6B1E)9
MU8[ #?MCCMT^U-*1P07<)!*JP25A?LF.K7GM?&QA4DKT+1F!JQR+'W-K!D1
M7=$ !V;3::"79WTG#PM!/UC)G)E--GTUF]?*&)CAL@TM7[SB0_EE.CXCS,:
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M+0R(SF.1/?(D-TGW(J"?'K+.:;RMZG9SPD)J5HH)+U=2)9X)'J2-.G#N1B9
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MJ8:#F6TCPG,.I) XO=8SWQU?[?N>6N7/5$F7[5$LLL<-B&+LH'D=)5)83/\
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M1#7LTC8M*SR*W.6X[3*A21+4E$3+8<*.7;L2_#CD'[2@%@HI_3!?8*.>/;:
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MV%AXNVKK+9?/P](1] &2R0&@CR(C9#(LC16[WCLI,.##(H8L"/'+$"I&E?\
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M\G-3[(J=O%J_;[^79>Z>ISS5CQ##< ?X2G;?8@>YV/MX/[>J/5DD(7G&TB[
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M=7IG$%DB::RC@JD='N"$S,5^2Q#M$R/YD8$[V08?C7*8.@@RLOIN-N=-P:Z
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MD#55<O@-7K+#X;!2#&K+-?S4-Z"S2R-:"M'1DQ&2HI8M?$2QEII9Q-'6BBB
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M?9UK[H?YS7_^+T?:]+[Y_P":V?\ X71^+5I_%"_K.O\ ]9]'V=:^Z'^<U_\
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MBHLIT9IGTXQ6.R=G4F;FOZER%F*26Y1HY.O#)!&S!8U1J[JKHA!W;B/=5W
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MI#>"IW'RD'<$;>#M^O??Q^SK8K-L2N\+C8HX^9E((/G8G<[>S>X\?=U,&D^
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M5\J,.]>LV$$[VM"=Z#/[/97B(UR'?8XUEASFXL-W1+\1W#2F".L<AC)[D1)
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M)".5YJSJ?!W3Z;;[;;'J;0'X'>L_4/T SGK#1UC0.-JXO*Y>KC9Y,DN4L0X
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M6.F@*^+<TJ;QRNR+!W2JQA(F"'Y QD._D'8L'H^HSJ>I9-I%LNH/G9'QW,#
MD1>7=X(*N3V2M>]K;Y_N"?$>CF-0OE^>Q7/>C'-5UK6FG2O-"[;/OS[G)VV
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M$4I+;KSA/)MBZI(I"A6'-:Z/J;YPY<IZU*WDSD_-@G9J'/+ H^4.2!W,VQK
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M"=S51X?08"_ERJ_3U$/327J]\M]>,<>S9]*EL$P;OWL[*X<TT<'YL.0,@&/
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MVE6,2!I%M03&%O(,:,D3KW(]Y >*;<6<C!LAE)$B*YS/9EN>3][>K5>G=KB
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M;^'U4]B-&::-"9('>5%)5>3Q\FVYJ-QN4/D E=MQY]^EKJDB-'*%(=&5U(Y
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M^$#C@EB:882/8]5/8KZ?QT1HPB6"*,7GBE++.DG.)&DEF+;1CBQXI\A+)XY
MGJD,M-+ZS^L\&!UKE:=7X:I=KUIL)66R7EJR2258HS&$:2.:1W"'<-L-]PJD
MA);/@<E)CI&R=:5)(@9RP9,=RS8%O#53*-)18#'NA$<B(Q[PQQM1P2>Z-'JU
M>R_%:U^.RJ8N.*WLT9:-RRRUW&PW&X/- /(Y$L2R[';< K];?@^WM*:5FU71
MU#6L5J=WMS8VS&T%Y(RXC.X)=6<#@X"D?)Y7EYV;YE+)HJNCF&D5%S!TA%C
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M)4/SA38,/'R@L2 -A',=K#+Z0KIB<SB[5^CCZT"19*J6FD2LJ!5%@%2H:,$
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MQWCV7[=NR4@I7<@%& )VV8D^#L2/;8'V]CX.X/GJ[:=V.W5@M1@&*S!%,@8
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M>8"LX8[=<]9'05B]JZ.&RD\V,F6O+;N;/,:L4EV2"0S(J\7^'AFELNH\(M<
MNA<CID,[U$ QFFF:*VM=3+F[>6VZN8#8%3/C5(EF*R//$L\$8R6P48-5E 6-
M-50L<)XS]O&<T_33.:OKG[+J5;]7 M/0ISO9,2,L1#M7KEW(6M)WUD2%N,),
MA)#$'JU5QNJ$TQF-':4OQ8[!"M)C+<^.R-_%2:FK;0.U'*QU)PMW%2O!#/%2
MO?$58Y-W"?,_)4Z#=<$J*JT<O,,F.V-UI4==1,\$TFK)'6O841R.LW&KRQY4
MV%+M7EB2;"4$SI+P-:C'/5KI[7EXW< ]B[;K:/HQ6Y<)=N2UA#&ZR"Q)4JL&
M[T4,@D5)(2L;1*O%E$R@0'!XK6L4E_'RVK*QX3'5]L:V4DB0L[2NM@1B%5=7
MCCF^'C1A"CIQ9FV(ZQ]BQ(]7 M,RX,.'1Q8T">6KERH;:RT@QQ#MU:\C!$*A
M4(K16!8I%<Y5B(%[6=U68"G2I8:]C\QIK*6=0YV%<CI_XA(8:-[#&.65+41D
M5I2\9@EE@-9AWU)YR$A8W<,77BFLQ4\M/>2[DUFM0+9@6REJI=DE;&J$*[J'
M*I"T:.Z!A\1&_ D"^;\'=U=;O5ZP[Y\*62R:3I_KK&8_L25/6*'F8D:5+.Q@
MQE,0,COY(4Q5:J/(C&/"XJFIAJV+CC7'6[5U;->"Q8$E5:U:M8)E1Z]4&>62
M58^/&29HX4<A1&&XMQN_ XM--T1AK>1/<K-W8\?$DD4=&M: FB>))>&T5IC*
M8V4#D(=R .)/6QZB75[]'HZ.CT='4"N&>O\ P/,>GQF;B\<<DY9O)%5R%;8.
M\N?Q,L*J]%Q>^8/7!EASFMN+K-OC%@R P#:.HK8EF9K!Q)#U/%4\3QVKJF1G
MKPBE=@^+CN2599/AGCE% L+((AL220E2I"&:.-7.P4^5WZ'UQ^#GJ+1&*SF4
MEU1I?+MIBYINEJ&A1^W*US'OJP0MAGA?)X:E1R:RK8C>PF,N6IZL99YHE$<W
M;0K_ (K'3 WA(7,"2=(ZS+?+FTXE2/4_NELGM\9#ICZU;9*Q,^E2YELFB2T6
MI<,C*QLE;U75;4OX^X/[+&1WFYF7L_9^T?QO/WY%.YVQ%VR).[W.V0> ;N_)
MU(!^"%ZL'7;Z*,6+%1,=]J?CD9;GXK-6.\8A6T*?Q9R1N TSC/A!<#*;1B^S
M]KALL$]"C&5$5$(QCT1?THCVHY$7MW3NB+]^R^IJ#N ?O /\O7+3*59E/DJQ
M4D>VX.W7WZ]ZQZ/1T=<JWQNDIMCU2FQ^BRU=H*?-\8\2Z D-I:6?:7DN36RU
M97!JK,WD$X(@I)V$;%D%)%0CH[5(Y/&T= Z-@GU/4U3EYZ0PTN!>@ZWF*QU9
MH*;=NP-RJ/\ E7# %RW)  AWW' WK/-=QGJ59NT;QQTUVA\(;C_$Q101"2R.
M<D\(<,@E*@!0G&1MW/'SUST5G3AQ)R7S_P A3HN:I*+.4^MJ4!AYQK6I$3%@
MI_.PNZ 3'.228TF+(G6$%&O ,;O:@.8/Q7UMT3AH<S<R^"N69+<HBMVL9EJI
M:!)S%<F(BC7CL8FB[:QOL6*$D>1OTWW?43.X31.#B6_9GR%K%3[Y&!(;31Y4
MV@L%>YR/)%[;JD<AW8D@LON _.>J3X-FB@8^D#!S![6FILG](>SV!1);+ 1Y
MQ'B'^^QI,,\APVRD]HA C(JO:+U=6@\!Z7PZA.-FQLUO)78[=>]+D9'GI&1'
M(6(EGV5G)(0!4(VWY?00S[0HYV?#2:@NV9;R5[L^;DL$H#+&$$$407=XWBD
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M1SI#V/' +!BJ1H&-!$0C9KFL>KY;FJTCF=FI8.7QU^R2N=%?'U=-V(L=0KM
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M,!P@P+/PE.++DVBE)^_FCHK4C $$;D>]3-57J]72/'8.?)XN2];N'X3&[2U
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MNUJ<333RK&B+OY(\_<%4;LV^^^R^P^GOTCR&3I8VI-<N6(X8(4Y.[,"/)XJ
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MI+DQKXZA8Q@Q$E7DIH212PSI)+#'.]CA*B.L-CS)%&0> 9N+%./3F'B:)7C
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M*F;YZ@DFC@BOX^K64,DL\?*7:S'%'.BS/S06MMU#LROMRKT_5.SW=M($I\?
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MDQBO&X3FL5AB(_MYHX:O:YCT?XNC<]B:)8I"4E[<T<SQNNT7&%N1!\>2 #L
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ML\P,T\E!OBIXU>7>"&,1%NRW<F4R/R6, 2$(2>*%1P+=1YY=Y'_&?70;ELN
M\<:0RJWT&XU#*Z'G0K(6?$G18)S?(6BN>4CQFD$DV$96+&$)H%15<<5C8*M:
M:N68%$YX\Q5A+\6X9(V0R*RF+=03NJLC$ L.74UTUA+%'%S0/#:$MH/<Q%FI
MCC8L77,?9FBGG5&LP ;*&1.U _+N,S,=Q%WFPV'M1[XM[D9YIL>LI38[D*1-
MEH6TD'&B546H"U 1V0!A]]I (IY"O$0DSVW(,,::XW'/!B,;DJ^:KM/9R$E:
MW@5B D@A5)7FLS.S;L5$<?(]L(HLP!)"[.#8NCTR]8X6.GE:RQ+/=BS& 2O&
M#65"QL6+,I+L\S2]L!P8TV=1%R'<8YU9B:K,Y2NLI')UON;&*.O+ P$C>U\.
MEK)-@Y!R!VU<VU#8''"&XA"0X\J&IBH-LA[(Z2/36EB.[;[4U6OCJSB4S7UI
MR/*PAC:1%B=8Y%5II L:N8W"\BQ&WLJJ95\IJ04K.&@TQC+,\T&0U0FF[.3O
M&I&#RGI)\-V9)I H$+2<@IWX.K\'#>\XZ/!66=@Z2BV=S$Y#D6!H<^FSYB2H
MR*Y/;]J19$*A?E8\9D:''AJ>:YS6*Y[W^X3Q4XBM:2U) ]6.:@%+I+:4J>'(
M\7CC*CB[^6+<4^FX&W3KIC'Y2IEKN.DQE>;3<*AZ&1OQ15K<T:/O%*U.,RQ1
MSRLS3SNK(D<C%$9@JN7LXXY9I>8+C,0+'#659+I**OH+,5571PT6O2MK5BO&
M>* L$,"Z,=S'*V,+Y>0Q1=F1'B_?]<T4.&PV6HR1T[<U^W'<HY&23>_BU64R
M2Q+(\<AEI3Q[?*622.13M(\;LHA.HM+W],0Y"[4S<,T-B[/>A-V>5K6+^(GY
MJ\;MWS/75-@>YLZ%25[G,A4QR[QMM68P-OCN/C<6W$"3(D3(9[-B6C\^!IY(
M[:%91  C18\ISBF,CG"EL(.4_P!Y(A$1-&%R&/COJU^PN5KJNR[)RB[[<4[<
MD3NQ<Q^P !!^0;<ATY::U#BWRKT,GGTU)6M1PI#*E7A6%QRJ/3EA=VDD< H$
MVWA9#&G'N@EHI%YMWGU7-1;SDN\,2KFTL-IH<V;.JJF#"'#KYMFZ(9RQ;2V6
M%%9[TPHI!9JB4CI#U4362=L50E6U/7QL40F$\G;:...61W+R11(5/*&(,Q(C
M!41[@!0.1ZL--*8=:]Y:N I+%/':E"RQ1QV+$\[23I!W54R05^ZY"(K1K$-@
MJ  [S/%PWF>3Y&<YXXPN7RY-?R-%A6QPB,T2GE2GSY"VTEHF$AVB@*DY"3B!
M'8A>]HD)]T2&G*SXX6,'>3@9J+2Q12%2X2,+&&A0DAH5;Y"(^7;8#<J?>L&U
M/E<!#?TKJ/'B*J^#D^%D.S)^3@,<44(W,<L+%.TJ1(9(63DPX@D23Y-P%5QS
MPO,RLJ3<6<Y20IE%#%%,24;0-D1[AH)L(,5 2AFIB6 YD24QHO"O&93NF%<0
M31B,UD#>L-C[4M*"_#)3R?8LO!'<H%N+0S&.11)"+,%>0*0R,QW,8506B=/6
MF6USKV#/V8\?46+&5<9:["Q5JL.&QU"'$U0C!U97CEKU2LPY2R3RLT@91LU6
M?,7$TK-:C)VJ&D9W/[.='@S/=JY4)M+.+&@BMW.K /E&+$>&8IHZQD>27'88
M0F&035?9>F,E:L22U:$;7LE$LL-9(G+/>CE[B+7#,$)#[F%XW(&S[.!N1U?V
MDM5RY/'7:43/:MXU)9H8(KB3K9$AE2N1*W;B2PZ0+',6"=MN =E4_*WMCQ)*
M#I[JA?<TYZ:#HZ.G/H(15'"?^,4X88DL(SAC.8-T=[Y;VG'&:)@2"*HR,\7/
M"B>*K=GO4+M"Y3K2.U&>!XY8K$3;M7G5MV0%48*?\)BC+S!\V1CZN6LZ(S.J
M'IM6K8F&*2S2N.HR MR<UCK11QF82N[PRAG5F0]H[,20#.#FOII''X#C3\_K
MAZH_%\=Y+S,W,ND+?9JHO!Q7!L:DM$LIC*>4J1I"5DPS'(-331M:TA%+$:&1
MR%"U%)?PIK4=4NLF+SD<4YKW7QTDT5FJK3,H25)&(EWB64\(@3PV!Y]TAZ@L
M^H9JF2P:XV+55@?9>6@KW4AO6<8TJSUI'NK"C3*2\<LT 9A(L<+C8J>H^XKC
M_.T>&-I*[:P#U=I7S)$&B=8"A6LS1@I9L2<)1%+%86-7$D#*X+9"&,!TG\PX
M0.<:=:;U%$LF;P=W"FS=OU.U2LF.-ZU26%S+7M6I7#RQPUXC/:5H$)>U# "I
MV'">16<MG=1KIV#"%[\G)#<E6(4:V/CE^-:PUN=@L3RU:M@Q@<0ME*ZJW<F5
M!<5^#FZH6@^+5T[OEQ&1;>/Q+S!1R+%_S,J?I"P.+=E(-,MYCW^VVR@A2+#B
M(C/SJH31G>0[!/5RE?[6KVLKFLXU_.]^&Q4BY23'X0<\9)5LO*[R1S0Q0P6H
MM^,<B/*5 )XBYM4V*%N+35?'8"KAHL'B4Q]JW O&;,729IY[5S@J5VG1K9A'
M!1,(8HA,\K#N&,_4/B&TG.7->BNBDD@I^;>5;FK*QC_=&YVNNBS([1C[-*WV
M%[C1%12$:J*Y?:1JTI-9F$]N"%@B6',$R _+*J3<HR?K_?%#>^PV\#KF6QG%
MOY&]BJ "36FFI7 Y0)XL2K%)SW)4<E'/=20K+X'+<*[CV;G]UGK2NK*XVCVV
MG@NC8\BM."O@,?#18UC(L@C(RK=%G1O(DH[2%]QL2)&1?FCC6*9(6Z^2CGG=
MX<=5BY.(G0.;/-DD22-B3(G98% @#<@Y+  'KH3TDUC^#GZ8>BWJQ#ZFZ1^W
M_5'*3VL1I];M$6ZE3$7*-45[=&>6S'#6LT<E\3>LF*);DT:58H7,)G,;:\\Y
MO1Y"9GH6'KKZ$'0PH,,V6W,OW9Y=28LIQH\ 46+!BMCDE1HSJ@I&%^HJUSW%
M%YC8RP]#XO":DQ.?.3S=6EF\7%+DZ<H AQ-C%50IL1&<M8G.2?N@)"$5%X;<
MFW8CE71N0PV4&1M9:U1Y8]WFAR..B18VH+%&NTTK/))WC%(QDC3CV1NIY'YN
MFDZ<[(<8O(*ZZ'>3^5,Y=Q?=J99BQTC9\YCK=BK(/FL ,T?9T4)5 A(RF0T-
M[7=B";\M&G/&M&L?V5+'R8P'YY&1D!4RD"0<D).P;\X[,-P09YF7P-75>@+F
M3CBR/IG8R.-M:C@J\8K&5IU[5:62DUM)(YPMJDLJ!TL1AF #R*-B9F\:]/>'
MZA-'RUL=9*N,KDN,Z&&S(,^?#%L:KZW*M;R1;6IG"EI&=5UD"(H0D<LD8))'
M(9ZC&7U%\KKF]HZ6KCL'6@M'4DMFC8?(5*]R8T.*1""!IT<13SO,09XN,J&.
M/YU+-OH]5]3::Q&H=33>B]:2EHC-YR];Q>'R,,MII<;42K5JT]I9IK#(UA[+
M*W=FD7BD0DD=)"<TT<61LAP<[)C:_P!ZN$2@LZR')E)HQJ!21G1AP5[M;(8P
MDCYPGOQ0M:\K58-R'8GDL235XII(A64R\+B69XX!5C 8N[LX(+)X7MJ SL>)
M^NT=]%_2NQZ[:FS&CHK]G!ZG.%S>1T[A(\?8R)RVH,9VISI]F0B2DMBC\;(+
M;(4@^''Q"E"2'%XQY0JI^DI8C-=1P=/<P+^ ^MEO2/-/#=6F5?&&YBN?,BR(
M\*3\LHQ]W.*C$_-=W0Y.@'INPK335HY*LZ/$>2AQ*I&[@^%=&D4L2?E'[.J1
MU)I;,X5<LMK#WTKXZ9(++-$66"PLY@L0RLW%HU ::)G/S1NJ%RK>>JDNJK<2
M)V_U<DT8#VGT,^=)G!$%"6=N&P)$C3_?$)1M<0<5TB8-BHKU.1CF(Y?O=N@J
M]6GAK.0>XHM5ZBX>CC9)7+&I9A F4Q*W,UX4F8(7(C$D:A=V/R]-Z PT":=Q
MQ6Y(+;58N-5A*1'!/76>SW#*=V51,T,1;_"CW;DNPZA=$GQR_47R*TMA(.Q4
M8=%5K0%*16H\B(SP[/=_BJO@K>WV[*JHCJA[:LH*KS3@OGRH#*Q*CR6\*$*_
M4$DGP-[NQE[&XZM8BMTEL321%*T@DX=HKY)*$$OL/._AQMN-MP>EWB,W@WP+
MJWVLFW#%#\M%!(J'B4PSG>JJ( "E:V1*+&&=1-/_ (.K&D1ZC:PAA;K6/RRB
MLM62@MB538CJ6GVDEB7VD8<"%CC<J)-F4[-MR!^5F^.2G+0S4KY-ZF:AK5WP
M..6 2QY.9IT6X+UC\ZI5CI\@DD88M:**Q*AHW1-_6L 8AZ/YJ=22SO+'E_*-
MBRU (BHWYJ,$A@B*!.ZO4)'#57>;%1CU:F36Y9KIER$=>K:#1&Q#3*B ?*N_
MPH\ +(H#(#M\QV.VV_37!9#2,)MHIXR%[32!@I8<E(DV4/R&QW"C;;;IS..B
M2&V%J7(SY,2QG9RR C9 W$.A8S8DUJ,*%%:[YPX#-:C4>1K&*Q[/;5%77J:'
M%Y+)T8,15N35;=O&Q)7G938DNV2:TL8(+E@TK(4&X4M)Q4@^[5FQ'*T"Y*/N
MPI>KN7Y!BW=Y1D\?))CY@D_4D<?/5CG"/"%/8X=W+$^<.#>VDNGD3<Z0P(QV
M6;I,H$F<,,J.5T6M?/(CVOE#*OO$(,7BV('O5.H<Q9QUZ7%313,F*2]!W6CW
M>)*PXM6?;;\M'&C(54 Q@'E\S'JN\GJ+.:JUQI7TAPAQL:7\M7TMBLU8:Q#1
MD^V[=6G5FR%A&XAH4FC-F2)4D$"DLDAD,?3J\ZV.XL=3QV71:>U!<OM)5.PU
M8C$=+AP##-&>@ @'(L(T>0=A9:21_OM>A2.\G.:$4;P+XZ2C)-0JHM>5'D*-
ML3'*6[<JGB[1J=XR%V;CN 0!Y)SS_I1DO1_5OJQZ8ZB;"6<CH?X26Y*9[5BC
M?ELPP"O)C;5J&.6![M"Y'+6[L-=D<&*7@T0Z9KD7@C2P9D3EBBM<Q:9*'+C'
MNH%,:,,ZV)!%JG,1DL;H$@-G)8OM$"BCCSRN+%$Q7!<*X=+^IBC X[0F36T:
M<5BSPN/*\4LM6>03K#9* F2.ISVCA<HG:$8D796+/&@-9X[/:GHZ!U%BK&#F
MR-JJD9DD:I7%*)ULLL5Z:=C5::,.BO/*T>[!.>P"JRLK3UDB7G16-::P@/<6
M':5X:J/-=8:ZKAA; J%:6,8CX$*0YPIWR;(<R6$SAI(,00CB7ZFP6I),/=U7
M#.E'%3VH*D3M=!AL0O8DLW6[-2<+&RH*\L*6%[:,5E2,(6WZ/U=]D^H.MLNE
MFCFY(,?I$8;3%C2XC:[;RD&-+P!BL<@N5&S,AC8JDT\M%(9D8<@3TZ_@YYPV
M4;K"D6I:ZKG,E<"QOD!S'@G1X<07,D6&*QKY3/&&^(T)*V.^.5XI((".<P11
MD\TM"ZC0QUJ%G(2UJ\,3=J>0RU(9IS(\IH.#R[<_%)I0P7C(P"C;SU3%6_EL
M1+-@8,=E<:<2D462JY &=SGVDL19>PA:-9J[6#7JO/2EW^%GYHAXMN>M/U$^
MKZZ/1T='HZ.CT='1Z.CH]'1T>CHZ/1T=<=?Q>GWFJ^*-R1Q[3 ]B9*Z<N YD
M&^F2/8JJTA*BQ:^/,*@B$&.01K'^V)S%*]K55'*B=I)5QN2N9S2HQ;3-/,]-
M)(8)'B<PJ(A)([HP*H$)5F(.P\ $^.N+_P ( T<9-7S=MU*1W+<$E>- UF9>
M<A#Q#D.31>?)WX!O!\GKGYZP^$M!D<];WVE)(T$RBNH,1M]''*<TDVZ :4>!
M*3LZ,&#&''"D%[S>^WS1BM:A/!EG^IK8'#:DQ.GL'D*4\CX^2UEH(9Q++7M\
MEYB4\F8S,Q]F)/$<B &.S1Z5:JQN9R$<>*A2A5L4W8U'=6?^YV$?<#-Q=Y)'
MY/( H5?.WMOU7QQHZ&^9.:.N,^\C/CVU;9H9XPU\>N53SAR1M7Q(.0!JB\E_
M.8]S>W\/95IO%XO4&)SV(M4&DR<E-K5/(*6"4XJR,7#)N 0Y]B=_._W &^<M
M$6INC/M&T$BML Q=BA*@$^-P1[?4??\ 3H<!EL-7].M7J1T*'??1JAD.PSU]
M&J[9DXA_>LFGD."4-!7G:+P<R,$,XT=6(60\SF.]1'TLU93FU#7]/9+=C%RY
M99H;>19RE0A^8[0CD=8^^>';#;?,6^8^P/"H?,6-:B*7(QU: MVH9(K:"=8T
M4<(G:NFTDKKRWC:3\GR\@=O<FB_JXRM=F>5SRJT7L#T]3%TY(*E=(;#+/E3X
MQ0!DO:U\N.1\!9$8Q5(1XSHYQ3N12ND^M=,4](9ZQA*-Z3(PPPPS&U((T)>P
MG<>+C&SJ>!8;D$GR =B-NNQ_3ZY)8P8K/8BN#'V9**6HE*I,L$<;EF0DA67N
M\&"_+R1N(VVZLTZ1MFM[TT_C5*8+\8>+C+19HTQPY@AO&8,U93Q(B&BJ**91
MQ#-1[B22L<]JQ@D:^ :1DRJZZ_$VI4-W!:KF@L:CKQ\HF..B81VF,RJ2JF)I
M%<@J4&Q#;MMUSYZH8?X774=1)IEJZA"6+L==3$\AW,94/NJRA60R,N^VRDL0
MVQ%:'51QV/-;Z1?0ICYT':GEW;1^XP[ZRSEE^9LX!R@" +R#+)8=K$8Q1 E
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M-S*'\UQOMU79)F/D->4C_,Q'>3WN=YO=]T[JJN<JJCNZ]T[(O?[]U[]TCP
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MYOLS+NH9 %X['CR))BV8S/V1J!((\9<L2P12H##$D,;PRQ[2RQ[V)&9#QV+
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MHB^82J&,8D'&K72[-\+D8?*.-DGM-'G8--!VIS]F#MCS%'2V,@)A"$J2AVK
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M_P P("H!WE$1Y&N8<RL8UJH[LCE_,V9&W<CA:1*DJ<E9XY70\8H_&[[-L0S
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M\-^":99(P&"*PV^7D3L2-RI!(*[^QV]STT0:$P\%[XV-6W=4#(Y+#='9PPY
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MHCG/6IZ5?$XRI9PV0BM8O.U8J]M$<2![-(JS3';PN[?-[^Y.QV;8U/!)WSS
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MWK/DC[N4+6.<B]E_,\E>C'HUJJGDJ=T1?T>IE:N)#7+H!(\@VB0[#F3M[^Y
M!()(]AOOMU<]N\D, =%YM,/R,9W 9B!L3[[#VW(]O8D=2RX&=K^F[E[$<D:
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M+^)L2I%E!*!DY8WA>*:+\K9D7A*"%B65-@K2-Y57)/GIKNO0P;2DHRQ:MQ;
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MK'/6AH22D1UK%.-S%'#+Q$BUX7#.U5B1)#$4'%5VZ10V,GI;,P9+.7JL>/U
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M)X\>R12=UI:3INU:H=P#&CD]^0*0@ 13NQWGW+FRGB>)\^!]0?J=O)_4?O\
M/W=7+?&AXKRVW^(_UPFBPR6_)LWF/$U&6K8,4LF'.!)XMPZRPV#@@8^,> K5
MDSY12_X,+Y+Q5\>2BNY^RV2R5+4,161(\-'6DEO,\JK,C@CMM C?G*_E /8O
MR/AAOU;=%?1^IZ-ZRS6H\Y+C?4''96H,53>PI-G'RQGS7JEP3&2DQ=^)(9$
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M*^Q8!N.Y(0$#V4;#QU8U\%E0TWQ!.A6QCRX4L]QU,8FALJF1#:67 *LLI!6
MI/N(X"$"X?LHX*JX@WN85>SF(VV8'LYJ.*99XVJ".W%,LK+'*JL 8F0#9P#N
M#N?&XW W&\\PFM+^)ASVFOLZG/3R]!XS:L1JTT#2 ISK,1NDJD<MU;VX^/.Y
M@EUS?_7M=8BK_#U3=079/OW[?NM:[]"?PI_"O\*??[)Z?=]CN1^KP//U/Z]Q
M]^WMM[=,W46T7LO?LJ]NR_;^%/M_'V1%_P!A5_@]>GSN//D?Z?OWV\_J_5UX
M1N"/O&W4B> .=+GANZL$8!+?*:-M6W39HZ 6+9NI+(=I4RD]X96 G5TP;GQ9
MC$:<+#G8QWME>UT<SN$@RT<3-QCMU#*:MG9N40GC[4J_*5)1T(Y*=U+*I()
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MF60:.=E14(81I()!7SYX),J*(%A73%\7R02HLIK_ )AJE8]5152(4=(Y/)9
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M#Z/L"M^_3_RQ_P!3H_&:W_!Z_P#^,_K]'[GU;_W;._\ )_\ 0^C[ K?OT_\
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M\? KJ]Q2>X@8 Y?#TV2$ 5[-"TDLSV-:B.(Y>[E1HI6,1EW< ;<I"&<^WNP
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M!2/DVP,L$_!)/AA*B?\ /YU?*G;[+^ZKQHO=/\R?W[^F7IXXC[O\Y_U]?O\
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ME28!06_PV5D<,P\['P"&8,&! #38PM:S-#.]B\KP%F0):<(69>/)D8,K$ D
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MZ.CT='1Z.CH]'1T>CHZ/1T='HZ.CT='1Z.CH]'1T>CHZ/1T=-5L.<>),!?\
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MR+_6Z]^V,9_#8?Y3_JZ/RH. /YT\S_E9G^J>C[%RO\"F_D7^MT?;&,_AL/\
M*?\ 5T?E0< ?SIYG_*S/]4]'V+E?X%-_(O\ 6Z/MC&?PV'^4_P"KH_*@X _G
M3S/^5F?ZIZ/L7*_P*;^1?ZW1]L8S^&P_RG_5T?E0< ?SIYG_ "LS_5/1]BY7
M^!3?R+_6Z/MC&?PV'^4_ZNC\J#@#^=/,_P"5F?ZIZ/L7*_P*;^1?ZW1]L8S^
M&P_RG_5UM*+J'X2TM[49FCY*S$^^OY9(%)5LED#*M9PH4NQ?#@MD!"V1*2!
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M^!N?'TZ=,'-G#4J+O9\;EOC&1!XKE$A<GS ;W*EB\<31(52Q-[(':N#CY0D
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MP@WQ'3__ 'A8_P"F]2__ +QY7J<:L'++5 /^;.B__P!S<"?IOUC].W7YP)U
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MU_E)J+^U.C\;,I_!=-?Y&:/_ +"Z/W,<W_*7(7^=SE;_ ):>C[ H_O\ FO\
M*347]J='XV93^"Z:_P C-'_V%T?N8YO^4N0O\[G*W_+3T?8%']_S7^4FHO[4
MZ/QLRG\%TU_D9H_^PNC]S'-_RER%_G<Y6_Y:>C[ H_O^:_RDU%_:G1^-F4_@
MNFO\C-'_ -A='[F.;_E+D+_.YRM_RT]'V!1_?\U_E)J+^U.C\;,I_!=-?Y&:
M/_L+H_<QS?\ *7(7^=SE;_EIZ/L"C^_YK_*347]J='XV93^"Z:_R,T?_ &%T
M?N8YO^4N0O\ .YRM_P M/1]@4?W_ #7^4FHO[4Z/QLRG\%TU_D9H_P#L+H_<
MQS?\I<A?YW.5O^6GH^P*/[_FO\I-1?VIT?C9E/X+IK_(S1_]A=81N'<!+,LB
MRK[N[.HAA870[7;Z)X!">5[1Q77FBL%B,<\Q'%2+[*'7P4WN>T+PU/IC#2OS
MG@M6WXJ@:[E<M=9%4L0L9MWINV"6)81\>1VY;\5VWIK;4<*"*K9H4(^;2%,9
M@L#C%D=PBEIAC\96[Q"QJ$,W/MCEV^/-^3G^G_J)]'HZ.CT='1Z.CH]'1T>C
MHZ/1T='HZ.DMI367O9V!663ZI]K=&AR98HL269(P:"\LO;&.:$X&J^1 CHYZ
MB<Y!H]K5:KNZ'1UY?0='^O%I_4^;_97HZ.CZ#H_UXM/ZGS?[*]'1T?0='^O%
MI_4^;_97HZ.CZ#H_UXM/ZGS?[*]'1T?0='^O%I_4^;_97HZ.CZ#H_P!>+3^I
M\W^RO1T='T'1_KQ:?U/F_P!E>CHZ/H.C_7BT_J?-_LKT='1]!T?Z\6G]3YO]
ME>CHZ/H.C_7BT_J?-_LKT='1]!T?Z\6G]3YO]E>CHZ/H.C_7BT_J?-_LKT='
M1]!T?Z\6G]3YO]E>CHZ/H.C_ %XM/ZGS?[*]'1T?0='^O%I_4^;_ &5Z.CH^
M@Z/]>+3^I\W^RO1T='T'1_KQ:?U/F_V5Z.CH^@Z/]>+3^I\W^RO1T='T'1_K
MQ:?U/F_V5Z.CH^@Z/]>+3^I\W^RO1T='T'1_KQ:?U/F_V5Z.CH^@Z/\ 7BT_
MJ?-_LKT='1]!T?Z\6G]3YO\ 97HZ.CZ#H_UXM/ZGS?[*]'1T?0='^O%I_4^;
M_97HZ.CZ#H_UXM/ZGS?[*]'1T?0='^O%I_4^;_97HZ.CZ#H_UXM/ZGS?[*]'
M1T?0='^O%I_4^;_97HZ.CZ#H_P!>+3^I\W^RO1T='T'1_KQ:?U/F_P!E>CHZ
M/H.C_7BT_J?-_LKT='1]!T?Z\6G]3YO]E>CHZ/H.C_7BT_J?-_LKT='1]!T?
MZ\6G]3YO]E>CHZ/H.C_7BT_J?-_LKT='1]!T?Z\6G]3YO]E>CHZ/H.C_ %XM
M/ZGS?[*]'1T?0='^O%I_4^;_ &5Z.CH^@Z/]>+3^I\W^RO1T='T'1_KQ:?U/
MF_V5Z.CH^@Z/]>+3^I\W^RO1T='T'1_KQ:?U/F_V5Z.CH^@Z/]>+3^I\W^RO
M1T='T'1_KQ:?U/F_V5Z.CH^@Z/\ 7BT_J?-_LKT='1]!T?Z\6G]3YO\ 97HZ
M.CZ#H_UXM/ZGS?[*]'1T?0='^O%I_4^;_97HZ.CZ#H_UXM/ZGS?[*]'1T?0=
M'^O%I_4^;_97HZ.CZ#H_UXM/ZGS?[*]'1T?0='^O%I_4^;_97HZ.CZ#H_P!>
M+3^I\W^RO1T='T'1_KQ:?U/F_P!E>CHZ/H.C_7BT_J?-_LKT='1]!T?Z\6G]
M3YO]E>CHZ/H.C_7BT_J?-_LKT='1]!T?Z\6G]3YO]E>CHZ/H.C_7BT_J?-_L
MKT='1]!T?Z\6G]3YO]E>CHZ/H.C_ %XM/ZGS?[*]'1T?0='^O%I_4^;_ &5Z
M.CH^@Z/]>+3^I\W^RO1T='T'1_KQ:?U/F_V5Z.CH^@Z/]>+3^I\W^RO1T=-+
MREI-MA/H7TW5EF?5?J?O?/4M(OM_(_3_ &_:^7A [>?SA//S\_\ %9X^/YW<
MZ.I$>CHZ/1T='HZ.CT='1Z.CH]'1T>CHZ/1T=)B^_P"J^*_]\<W_ ,T-3Z.C
MI3^CHZ/1T=,-U2[^7Q7TU<_<D5TQ]?;8GASD?1TDP3D88%]69*VD4+@/7NC#
MK<,A, Y45$*YB]E]-.>MM0PF7NHQ22KC;LT3 [$3)7D:(@_?W NWZ^K%](--
MPZP]5O3?2UJ!;-//ZYTMBK\#KR23'7,U2BR(D7<<HQ1:PT@W&Z!AOU1MA>IO
MJ5X!SG*\7FC8\[5]Y-Z'\'R7CLMR'N^,]]KM/REJ=Y0\=3N3N,M15YG64> S
MD2YU=/"KN/-[%O;D\JP9+F5Q6UQ%%5U7.9O$0WUR5C+)*VEZEZM!<M4;=B>]
M8MQ4GO49XX+$5.%99XU2G<6:4LX9XSP/7T'U%Z3>E7J5E=&S:#PGIU9Q]?\
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MG^L*M@;L])DD_;YF45C6M3PX##&+L_9\':./7%</G"_9ZRF85?#?WKNDN?\
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M>OY%M^.N/ZB++:"+RSS-:RI')_)MS-E3#-DSY=*[Z+GJX & K%T&OGO(\EE
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MU[Q2%?KAU-FX(*=>.Z.WCY(9*1>K3FFKFO+WX5CLRUWL=F*7YT@,I@! VCV
M'6V;3.$GGN6)*1[F0CFCNA+5R*&P+$78F:2M%82OW98OD><1"9@3O)N2>E-'
MZ->F^#RK6\U5G'A:7D2LAY*$ME0[7D&@H[IF#I69W%2M?AZ;5P<+N+7*40@5
M-!=;+-WUO5P8L./#G"9"BH'2<_EFI/CGM"2H[3MPEKU99(_B9.[86"S) UFL
MD\N[RQUYHHW8L64EFWVK@<4MU,@E4QVD6!><5BU%')\-&(J[3UHYUK67AB C
MBDL0R2(JJ%8!1LTE?\+_ *%ZJ'KJV!P6$%7ML/J>-+NI_=%Y:+41^/\ ::^I
MWNFQN8JC[TE=A\[9:VEK[?Z7BHV?BPWMEPZ\<6OLK*)+7/K'4DC0.^2)>O9@
MN1O\)1$AM5X'K0V)G%8/9E2"1DYV#*6^5F+.B,J)-'Z<19T7&@)8K3TY$^*N
MF,5;,Z69J\2&R4KQ//&DG"NL04AE7BKNK2VY+XKP_+N!M^,=U63YV+NQU8I]
M=1Z748JP:VDLX%S5.KM)B;G.Z:F-!LJN!* >GN(!VK':-2*%Q!O8ZEVS1M)<
MK.JV(RY5Y(8;"_E$:-^<-B.6&0,CLI$D;#SOMOL0]VZ5:]5>G91FKR! RQS3
M5W';=70I-7DBFC*NBD-'(K#;;?;<=1SKOAY=&=1-X[GUG!6?A%XLXKTO"..!
M'N]DRM'Q3L1Z1FFQ6EJ$TGTG>5=N38ZJ=)?O(6EG-MM!;7(98K::::YV?5.?
M=;2ODI6%V[#D9R8Z_,W:YA,-B%^SSK/&*\*K\,T*]N)(RIC4+TU)I? 1M59,
M;$II4IL=7"R3A!2G$HFKRIW>%E',\S'XE9F#RR2!@[%CK,A\-WHPPT*37YWA
MTK(TR?P_8R?K/)7+>ID$+P%>R=)P_$2;J=Y<S64V%N)3SU5 .0RB/&#!K+*N
MG5=;7PXN4^K-066#RW_F5;Z#MU*,  R<8BOMQ@K1J9+,:@/*1W02SHZN[LV$
M&E,!74K%0\,U%SW+5V8DXV0S45Y369&[=:1B8XM^WL%1D9$50M?R(.EQ0U /
MW*XWA0V_/-_5._&O=(>+=]3E=:5/.5LLE-1\Q(L-U6W5I"++DE,;/@FE9E7T
M7YBM3_C%F=Y#\:WY6/&Q2?D:VS1X=D?'1[=G8)6>-&"@ 2E09A)TH_%[#;1C
MX)?R4F2E3::P"LF71TR+[][<M921U+,28PQ[/;\=89NA#I.D9N_R!N(8#\WJ
M,-P7QI>52Z?<H";A.FJQ!;<*9EI&Z=)$2NQ=C&#*[031C:-[/'6FOAO>QV0U
M)FQ-%.+SB:&SDKD;]FONMG+H8\A-_>=B]A"5^8$0C^\"(@'K$Z;PIBE@-%>U
M-6QM.1.]8V:MB7#X^'?O;JE=P&^4@RG^_F4=1*Z;^@;GOA;K"VG41:\Y49<C
MO]CS+K>2<MG$U)P\LNY!GR)&'A6./TKIM%Q@7CH24SWV>-O[>1IRT$>--%%B
M3I+1OF6U-C,A@J^*3&R">K7Q\%.:7L*:(JJ!999X0LMSXLF0<+$:+")69=V4
M=,F*TUD\?G;&5?(QF"S/?GMPQ=\B\;3$UE>"8M%3-0",\Z\CF8Q ,%5CM(S3
M]%F0W7.W4KL]S&J]1P[U6\"\4\5\L\?'GZ&HM[/0<37N[^F60+C/RZN6"CN,
MAMFU$\,.VA6 9=$!S'2(MB=L9IAU!/6QN(KUB\.0PN3NW:-H+$\:17HJW-#'
M*K@RQSUNXA9&4K(1X9!NZS:?@L9++V+ 2:CFL;2I7JI:1'>6C)9X.'C*,(Y(
M+/;8*ZL&C!\ACM\8WX;/17@EU9<WPNC+'9X"[XLN;^[Y#Y6UFJC\?:6 >KO\
MMF==K-U=Z?$UMO6R9$&=^)EM02#Q3/"\ZL=V]>SZLU!9[ ER'R5[4=V.*.K2
M@A-J%@\4\T$%:.&P\; ,OQ"2@$ @;]>0:3T_6[YBQX#V*LE*262U=FF%652D
ML,,\UF2:NCH2K?#O$2I()VZ<+0]%G3!J*?CC/V_$]6M/Q)Q5O^$..X-9=ZR@
M'F^+.4,/ XXW60$^@OZPUA$O,;60*E)UL2?;59(S+6FL*^Y5]BY+%J#,026Y
M8[K]R]=JY&TSQP2F6[2LM;K3D2Q.$:.P[/Q0+&X8I(CQ_)TJET_AYHZD3T4[
M=&E:QU54DGB[5*Y72K9@!BE0LLL"*G)RSH1S1ED)8K#7]-?".\X)A],VKP<2
MUX,@9[#Y.)Q_]7T4& +.<;S,_/Q=1]4K;B'H"1*63EJ)WB6V>^Q# ^5M7SHL
MF8&1H@R^1JY)LO!99,DTMF=K7")F,MM94L2<'C:(-(LTOL@X%N2<652%$^)Q
MUG&KB)JROCEBKP+5YRJHBJ-$]=.:2++QC:&/W?=PNSE@S I#@_I]F\?\L=1?
M/.VMJV^Y/Y_UU&)Q*ADI*?'<1<9UA\WQ/@:I\X09)Y,>#*N=?K[#Y>**PV>N
MN Q@DJZNJ._?D<HMJCBL971XJ>,@E.S\>Y8O7'$MVU(%)4 LL<$"[L4KP1DG
MF[CK1CL6U6]E<E8=);F3GB&Z \*]&FABI54Y ,2%:2>=M@'L3R!1P2,]2B],
MW3QT>CHZC/U%?^X__P"$'_TC]'1U)CT='1Z.CH]'1T>CHZ/1T='HZ.CT='1Z
M.CI,7W_5?%?^^.;_ .:&I]'1TI_1T='HZ.CT='1Z.CH]'1T>CHZ/1T='HZ.C
MT='1Z.CH]'1T>CHZ/1T='HZ.CT='1Z.CH]'1T>CHZ/1T='HZ.CT='1Z.CH]'
M1T>CHZK[^(;RIU4<"<-7?-_3WM^ J>HPP,Y'TF.YCX.Y"Y-L=+8ZO>YC'P9=
M)J<7U%\-QLO#JH^@),E0)V7U9[0T9@PV-6Q[O$ZR7;?8@G<@>"!M_*#O_FZ4
MF%ZJJ/#Y>54]0G+V)V_(E)SWI^GF\T/%7!W(W%>07D>EXEL.>?Q8B8[2\B\V
M6XEKN*ZV7;3-0N\G4%K8#2NA-@61!UBG_7UX1]P(&V_D@_7;[A]?U=)*G^*%
MTG7/TH@I_,E?"MJKB+5,MKWIUYSHJ2NX\YWMG9OB?E2^N;; Q*VAXSVFJ#.S
M-5K[>3#KB651=RGJRCI;2WBG1Q/UV^OU'N/)'[?_ *>Y +E"Z\>F@V\G\?MU
MFJ'+B:+?8J#L9/%?*4/B73<@<6UV@M.0^.L;S)+QX.+M?OLE%R6K'9Y3/:RP
MMG6.4UE+"!+N<KHZ^K.@@C_,?I['V.WOTM>'>JKA_G#C2XYCQ\O95'%U/GJ[
M9)N^1>-][Q?FKK$6F2B[:-N,M:[_ #V>BZC&MH9#SGTM$2=4B=$DJZ3[#HIY
M)T$$'8^_3$#^)MTLFIJVS 7FF1:7FHP>8S>$C].O.!N4-0SE')<D;KCC3YKC
M-F$7;7>,V66X@Y,LJC20*0L%AL3H:FQ6!=5LJN&='$_J^_W'W@??]Y'\O6AU
MWQ-> \HP&O@V&@Y$XWM\MP3,H(7&G&7*VEY6=J.<.HK7=-E;77N))D8*T+*G
MD7-ER5OF;0T+D>FVU5=XVRR#-1+R])=G7O$_=L?.^^P]AR_T;G?V]NOSA[XA
MN.TW+O+/%W*L#08'Z;U#2.).)-%9\3<GY7)2:]O3!QKU$1LUR5NM%!/DLWRR
MM=;<ESIF;L9V8E5U-F*^KM*.OO9->[1G7A&P!^\;^X_Y1'6%;?$?XZVK^(XW
M QI]C/W'.73KEK:'RCQCR5@SW?"'/EOJJRAY8XXCZF'CC:"BT+LE;LS&GBMM
MZR,>$[ZU3(V=6-E'7O'WW^@)\$>XV\'^7IR.,.OCA'6<41-_H]= ;,K,/T[;
M+9%RF:WTC.Q(W5!M[;CGB611+H,U4Z";"T6PH[* 44NJCV5#'"V=H8M=$*([
MS_?^7KP@@D;>Q(^GT]_Y/_ITG++XG_2K6OLFJ3F^P9!@<MVL.32=-G/%W!TE
M3P#L28;G.WR<^KP$J%I*CB:];&'L;:KD'KH[+*L!6RK*QFB@*='$_J^GU'U\
MCZ]2MT?/'%N5A\.VEQIABHN>=12X[C/1QX,^9G;F^TV0O=OEP3;F-&)"H8NF
MI<[.#065X6!7VEY(I\Y&DOO;VGKYIT;$[_J&Y_9TS?#'77T]=06YK<#Q'9[S
M76%GBL_R"V_B<5<C Q%?F-E NKK#6%WM)>;#G:,6[SE#.TF,/;3HD/15!:Q:
MZ46=<5<&6=&Q'O\ LVW&_C]7O_FZ^>3.NC@GBO5<W8V[9R?>WG3QQE(Y4Y97
M$<0\B;&FRU(S'V6^@5,[2TF?DYN-H[O)U4NVIX,VUB0Y3&_+%L8\QI8XSHV/
MC]?MY'2:J_B)=/,T^.K[.%S1E[S6<>Y7EF;1Z7@3EVMF\?<9:[6[;$5_(?*A
M5R!('&^$B7^ T#[;8ZZ759VKSRUFQF6(LE9QKIQT<3[^-MR-]QYVV/CS^L=>
M(?B2]*3\Y<Z:7H.3Z6)5 XKLZ^JT_3]SOE=7MLSS5R?E>&^--EQCC=)QU5ZK
MD[)Z3D;;9;.-M\'47[:R5>5+[@4 =K5NFG1Q.^W[?J/H"3OY\> ??[NOO-?$
M;Z:=19K30W<S0+5J\KUJU]ST[\XULLVYX2JK;0<E<45D<V#4VAY:H\Y16^AB
M<?YMEQ?Z.I@FD9F/<$5@7G1L?U?3ZCZ^WU]O/O[??U(G@_G; ]0>2LM=@?QH
MB!H-9?834Y[<8W38#9Y'99HD=MSF]-DM=65-W56,8,R!/"I8KHL^LL:^RKY,
MJ%, =YT$$>_3R>CKSH]'1T>CHZ/1T='HZ.CT='1Z.CJI7A7KGVD;<\_&ZI.0
MN-^/V\7:FPSUGTO1.$.0\QS=QS4:3G>JXFX(Y(@<@6W).BH^?>*N3Z6YI[*T
MY"PG'='F*S27\"N%95A*NYHQG61'MM]V^^X(]MR/U$?<3O\ J\]+KFGXAV>X
MSZ@\'QOG<SNN0LI#M>HK#\RUG'?$'(/(_(M/ON(N/NGWDZG%F:O*!D/-FP8_
MFIEEH;@E580I<EU?1U<P5^@JRS/^KH \?R;>0!Y)'G?]G_7[=._2=?G3=K+V
M)78J\V6XS'X@Y?DS2<L9+C;<W/#7'N0V_';>6<?/Y&Y+#1MS6./?\;F@;%D"
MUECF5%%=9Z=I TH='1.L#KP@CW&V^^W\7OTR-K\2'$;N5PY!X(2S^IZSGGA[
M%[:AY7XYVN)T+>(>9<)S)J,1R+EZB^3.S%K-C.XIM8N?N)0I?RIJ'34UY15]
MS#>"*=&W@G^3]H(!_P!/^CI3=,WQ \#R1TQ\)\I\JV8:KD;2\;=!TOE2MRV6
MT \W4\I==%=QQ5\<56;#)-;R5S]KN>0J^ I26MHN9JRH>]LGMBR)3O!Y /W@
M=!'D@?3?_-UB].OQ <]M<OP17<Q4NKHM]S;IM=D:C4YKBCD$?"#=5$WW*M#C
M<6;D8\>XS5=K[_.\:3)BU)]!(>.<L1+!U0_29N#/]Z]*GSM[ GZC?P?N]_K]
MWW_<>I*].W5+QEU14\[2\4U_)!<G'K:.UK=?KN+]QALGK(EV>[AK^)6AU-+6
M5>M-26&?L:_1AHY,Q]))6"LQ&QK2MD2CKPC;WV^OC<$^/OV]O_KU$/A_XG'%
MK^"N+MOSM+O(VZM^**WESF,_%'$/*FUP'#&(N=%JJ&IW')UUF*?90.,LA/=D
M;^2&=K;UA656<TVE.T.9H;>U@'7I4^=O;<@>1N=ON'N?I[?>/OZD2;K>X@-I
MN1LWF,WSCR('B^78T6DUO&7!'*._PDK<U3:A;#CG.:_,YNPI])LX9;RNAS8E
M0>34UUFZ?465Q#M::[AUQUYL?&^PW]O(_E(]P.HS;[XD%4*_X\T/')Z6)Q+I
M>GGJOY T\KDS$<@4NPR?*O3AU/\ 2]TXV6+T.=AM%HJ5^=TG*W)F=UM.N;G3
M#:.CHYM?:@HXLHML=>\3[?7QMY&Q!!._\FQZ?-OQ N(R[GD[C.+QMU.SM]Q-
M0Y[2:7)P>F_E.9<2ZG8:^?BL?*H(P*%_U:/JK6FT4^FG,<*M+FLOIM3*FQ:"
MCL+ !UYMX!W'G]?\?^__ -.F_P!'\3?@\]9+7CNMY)O5F])FPZL:GD&RX@Y&
M3BK+XV@JMC(BMY*L(M2'19^4"UQ-Y67U,VJ2SAV<-N:$Y=/.C5J'1Q/^?;W&
MY]O8;^?<'?V_7T[$?KRZ?![.GP-A>ZPEA*TV"XXN]Y5\6\FS.%,WRWR36YR?
MCN,-!S S+$P.?V>C?K<O!K:2XT$<\>ZU&8R]J6#J=#3T\XZ-C[_Q_3?8>YV]
M_&QZVW ?6YP7U(::+D^.2[Z/97&&M^2LE(VO&NTPU5O,1FM7"PVMT.(L]+45
M\70P<GK;6DI;LD9[?$E]23Z]+"HLXMB\Z""/XO'T/GWV\?[^#]QZESZ.O.CT
M='1Z.CJ,_45_[C__ (0?_2/T='4F/1T='HZ.CT='1Z.CH]'1T>CHZ/1T='HZ
M.DQ??]5\5_[XYO\ YH:GT='2G]'1T>CHZ/1T='HZ.CT='1Z.CH]'1T>CHZ/1
MT='HZ.CT='1Z.CH]'1T>CHZ/1T='HZ.CT='1Z.CH]'1T>CHZ/1T='HZ.CT='
M1Z.CIE^H7A#.=1W$&LX:UEK=4E!KR9LL^SSKX([B,[,:RBU\-(C[*%8PD0\^
M@BQI/O0S*L0QT$HC*,PSH'@@_=U%W9?#RR&RY3O.0#<R\MU65ON;;#J*E<1U
MX.-78L?+MUT\VO33=:$-U.X_E\B-KYN$L6V8<ZNS6FB:M)MHD8T67&KJXZ]W
M\;;#VVW\[^^_W[?YNL^5\//BR5C[+&/V6_;7VG3)TM]+)I39&=^<'B^E#:[;
M<XB_&Y:!0?C/H;+=6435%>%U46%$@MJ*RJ.V0<YT;G^0D_QG;_4.M4SX=6,=
M? C3.:>9;#A>AY*Y1YHP/3W(=QN/ 87E;EUG(!=+I*_10^/HW*5W3U-UREN]
M1CL9I]Y<9K.Z"^0B0IM3196HH#HW/\HV)^I'C[_V?3;J4N9X&P]#TZ9_I@L6
M3]3QK3<*5/ TX=T=@[31X>NPL?CV4RVDU0JX8Y]O0!>V>>M!!8V1(*2&*,U!
ML8=&_G?Z[[]5?Z+X9F[XSC],5#P)S%MI*X?J=P&LN^0G\;=(N7TO%?%_'W3K
MU08"MO2ASW"^'C\MWUK?<HYG+Z29MH6^T$P%@.]HZW/R0Z>_DG608?-N!Y'L
M-_?D#]Y]MNGY_N7O$T3+VM+3<H\O5FCLJ/B\CN0RRL+9ZIW*?%O5YK>N2!S1
M/C3\03+6.OU'43LK?3Z^D)G!86;5%7/4^7HZY6-&=><C^K_/[<>.WO[;>/O^
M\GIPP= O'LV$H-OON0.0IMEU(0.I[86F@'C*TVUW@NFR!TRW-=<0,GE,]30,
MYI<I#+H[2OSM;2DC:6?)2G/6T;(U. Z\W_B\;?Y]_P#3TVW$/PON,^(:_#4<
M#E+=7V?XOWW$6TX^KI."Z><K8UD3A>;92LI0Z?7<<<,8O9\C.E1YX*Z\T&]T
M%]>3H]5$G!E1+Z=H;F[.O>7DG8>=]_?Z_P ?6KC?"KXZJ,_ELAF><^;,SD*S
M =,_'VUSD$?%DZ-R; Z2^5;CEOB&QT-A=\;VEW0SPWNBNJ_4?B/9Y@&AJ5JH
M[QQ'UQB6!T%B=SL-R6/U_P +W^O\G3ST_05QG2UV4K8^NW10Y'%]9V'@D,?/
MJ616];?)=1RAR)*EJRB8U9N6N:>/ Q;@M" -80S;P%U*5DEAUYN?]'^8;#I:
M<M='7%_-/20O1UM)^I=@ X#"X>KU%19AJ=[13>-$S\G#[BCNX<08:O8YZ]S%
M+HH-C#AB"*SB)X1FQGN IT;D'?Z^?V>?<;?<?;I.AZ),/#ZEN)NHNKV>HHQ<
M(X.7QWQQQ=09[C"BRU-DI>*?AOQ.FZVIP4/E;1<<1(JBU==QMI=[;Y.LY$@U
M6QKX4634UT2,=&YV(^\[_7W^_P!]M_U[;^3UHN8>@?"\Y\YVW-&\Y'Y!<&UX
M>Y(X4=B<_5\89N,/%<JX&5Q]JZ.9O*GCV/REI<L@)TS;4F*V.UT68H>33#V5
M; "^#6UT(Z =OY=_K_KV_D\]9^$Z',K2Q]X+E#D[D'G<O)O3+F^DW;%W$+!9
ML=MQ+E[GEJ?!A,B<98[$1XEI)J^7[V@L+$+/?DPX%=,:X5BLJ28Z]+>W@#8D
MC;Z$[?>3X\#IN@_#;S=R6CG\J=0_._,U[AV\&4G&5]MF\3U<[!83@KJ*X<ZE
MZ_)Q0X+C''0-%,Y!W/!'&T#DK8:F);Z:YH<["!23,Y.^;G3#HY;>P ]_O^H(
M^_Z G;]9^O2KWWP^>/MU47%<+D_EW%V%IR]U'<TP]3A[RCHM5F]?U*<*\B<(
M:0V;N/Q?D%J_Q2H^1[/0XN8QC[*!IJRIE6$RRA"DP9)]WZO]1'_7T<O;P#L
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M *%;?MOT='1^4-M/Y+R_]"MOVWZ.CH_*&VG\EY?^A6W[;]'1T?E#;3^2\O\
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<^7S/T_W/<]ZRD=^WR[/#Q\.W=W?R[IXG1U__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g383050g08k08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383050g08k08.jpg
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M 0$! 0$!_\  $0@ [P)= P$1  (1 0,1 ?_$ !\  0 !! (# 0
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M1'.6HL+AXC0U-G*"@X2%H[*UPR5T=;3Q-T5CQ$:&MO_:  P# 0 "$0,1 #\
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M]!.INXU&G&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FK*@ @9
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M_7C67L08<>)A[+9*O^'EWR[;?B>'XB^YW^WN=]?=[.]GMG<D'<D]X\?B.HV
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M.--.--.--.--.--.--.--6\_^^L7][Q[\Y5SD^8_&/D;4><?$?E76&_I)/\
M]SO:/\=H'_S#JW.7>S/_ /IKQ)_W/_Z_BM=]_P &#_\ 7/@?_P#V7_\ X_B#
M75XY\'Z_733C33C33C33C33C33C33C33C34CZBOL35VR:CL.76XUM]CRJ3L$
M%-FK'PY!F"R\Z"E29"(LQ>611G$$LJ,EG&9GD<1,O1TO9?;S7#N6CP.;QV8D
MI)D?:V<6XJDLIAC>S$K-5DD=8Y"5KV>E8*!1U>ETRR!BPU?C3AV;BWA;-<,P
MY27"^W=,XZQD((%LSQ4;$B+D(8HFF@4/<H]HIB4R?4.T=8)(8Q&V3T?K?-RQ
MXV':M7TDXIMG9%;/I'/$:W!LNN-L>5(W2HRH\)4B;")2K=$;MP^U1"B9 \H[
M+3@8^B9)6[O2>RE:DA@CR&!Q=LJN:I6Q"\U**[A<^$FR6.D2/GECG?(QC(PW
MX[ :&=I!T'$CD\EE]@''PV;4^'XMSV.5GX6RF--F.KE;&*XHX-ZM7 YJ&6P(
MZ\]6'"S-A+.'FIF.S42$]KC:")4M2H]40_4CUTDZ*UU*UC-M=8!@V"KE_*6D
MN-(![C M+A=^3.#0HD]F=$@YKKH>./%Q%#I#ZYCDYQQU+MACN/(>'FR;\*X5
M\'+D*56JMALO/?L0S5LC#>-AWEK11S)+'$:;5DAKQF&1S(TI9@V9S7L26N,X
M\'%[(?$\/%D&'RV0R$E->&ZF'I6JU[!V<0M*.*O?L3UI*\]CVS2]+9N3"U%&
ML*5U5"E LG4*)M.PYMKFZS$"*]/OTK9;@ZJS! '8<.U3(4AQUP9N--2EVR,(
MCV64[8QP&3'G"H#K<2(W&6N%&FHM+O&5>_F)<A+@JU>G+EGS9AH25ZF9BOR1
M,6:#B08^3()62Z[78:DB2P0D1QA"8DE&1Q7L:7,1PS!AX.*[MW)U^'(>%%M9
MB&]D>&9\/!/$J+;X'.:@PTMV3%0IB[61BDKW+*M/,TJK/+7:3)'6Z7D"-TBD
M:\%P&MMG[P?:CB["1@AA<G8%)AT0W[2@VX2HE]=CCX+1T4^16+Q"N+\ZP+9D
M>9Q!:S;^RC8>OQ-7&&KQ#B&YE;BI!<FAK5WR^+BQ-H7JJQ&/+%(8EMUWF-?I
M9%Y;9#"3I+JL7L!4H[W EQN)KEE^#,;P_C7DN8RK8O6XN&\]/Q#C_:K(/.)N
M'4DLV'QUR.LMLV,''7QH>/H]H>-=\=2<G>%<IM?D5%FOIJDN1.:>4=>-L0/,
MUFJ5C-=I<)T8/Q3**RU4V"S%4;?,);-$)\WUEE+B64X3BSC:3BFEC:;XY:8Q
M\CRJQM-:2+GHX^CV/&1-!",;BE6@MA* :R%LS2R"?8A1M/L=^Q9%P!D\YDH\
MT^2.9ACKL@QZ4)+'2RV9RWMGGITMV3G>(7?,RTY<RT=$O1K5H.R J7.,7-%U
MUG3C33C33C33C33C33C33C33C34P:H_X?_\ [5__ +'F\<&?_N7_ &/_ /M:
MY?[)/_[+_P!X_P#]#7<0Y^A&OQ?TXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXT
MTXTTXTTXTTXTTXTTXTTXTTXTTXTU;X7]W6G[X&_Z.U_DGP7XOUG4#Q;X_P!0
MU<'(U.G&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&F
MG&FG&FG&FG&FG&FG&FG&FG&FK>?_ 'UB_O>/?G*N<GS'XQ\C:CSCXC\JZU8>
MG2.&ZWZ+[J.-5TP5 &84W3'DRP4A+%$XGF=[ZTB2/+3X+S$ICQXK[\9[PG4>
M+'>=97WFW%I5M_ -&ED>+<32R%.K?IS=OZU2[7BM5I>GC+DL?4@G22*3IRHD
MB<R'ED1'79E!&J<<9'(8KA;*7\7>N8V_7[%T+M"S/3MP]7(U(9>E9KO'-'U(
M9)(I.1UYXI'C;=&8'I%0]1==4Z]TG6\:\WY=LV%T^L=3U6@YW1.0Q-T])UR6
MVJR>>G*LN(D(@JEA")#(&4ZT73):0/S$Q,=;95W=L3['"UK%L\+\-]"KE#AI
MF'#6/W6^MM*1B"]BYF46)%3JJ#'L>?FY03KBB\2>RDUFO5'&?%O6M8L9B%?=
M9E=FH&K)<$I;M^RMT(W;I$B3<!>7F.VL:$[9Z@U9[J=E[D5GMCX[$W*[9SVR
MXJYT7'9@EV]LF$TY,CX^V]%;7(;[S*%+QE_<9P3]ZG"OG/\ Q%B/!6Y6/_!?
MYK$*?0W<>_NUB/=_[(7W[<9^;_\ R3-_SE++_CO\Y06'I4$CN[]?LG:_4)"0
M^Y,V5N6(W&=B,25R;C=V$1WY\?,N"R^ITBA+3LV*E4F(VYE*Y$=.7F<+;QE7
M X-X(;;EX4X5;<,1M@L0=PIY6(VJ]X5O)8CP/<=CJ6X_]D-=RW&O&:A2H8MQ
M)G!REAS*#O=&Q9064'O(&XW&N1G9O4=B8\.SL'=N"$?#.7X.;7>\3&<26E2(
M^7HWG_';P^PE3S.5H3XK25.([R,95R/<=P/RAO<MPIRG?9O:/$<IV.QV/9=C
ML>X['N/<>_4^[WV1.8K[M.-.8;;K[H\YS#<;C<=LW&X[QN.\=X[M43Z^6Z_X
M8-I?S@6S];\J>XG@S[T>&/T!BOW35/\ A#X_^_GC#_.;-?ONGU\MU_PP;2_G
M MGZWX]Q/!GWH\,?H#%?NFG\(?'_ -_/&'^<V:_?=/KY;K_A@VE_.!;/UOQ[
MB>#/O1X8_0&*_=-/X0^/_OYXP_SFS7[[I]?+=?\ #!M+^<"V?K?CW$\&?>CP
MQ^@,5^Z:?PA\?_?SQA_G-FOWW3Z^6Z_X8-I?S@6S];\>XG@S[T>&/T!BOW33
M^$/C_P"_GC#_ #FS7[[I]?+=?\,&TOYP+9^M^/<3P9]Z/#'Z Q7[II_"'Q_]
M_/&'^<V:_?=/KY;K_A@VE_.!;/UOQ[B>#/O1X8_0&*_=-/X0^/\ [^>,/\YL
MU^^Z?7RW7_#!M+^<"V?K?CW$\&?>CPQ^@,5^Z:?PA\?_ '\\8?YS9K]]T^OE
MNO\ A@VE_.!;/UOQ[B>#/O1X8_0&*_=-/X0^/_OYXP_SFS7[[I]?+=?\,&TO
MYP+9^M^/<3P9]Z/#'Z Q7[II_"'Q_P#?SQA_G-FOWW3Z^6Z_X8-I?S@6S];\
M>XG@S[T>&/T!BOW33^$/C_[^>,/\YLU^^Z?7RW7_  P;2_G MGZWX]Q/!GWH
M\,?H#%?NFG\(?'_W\\8?YS9K]]T^OENO^&#:7\X%L_6_'N)X,^]'AC] 8K]T
MT_A#X_\ OYXP_P YLU^^Z?7RW7_#!M+^<"V?K?CW$\&?>CPQ^@,5^Z:?PA\?
M_?SQA_G-FOWW3Z^6Z_X8-I?S@6S];\>XG@S[T>&/T!BOW33^$/C_ ._GC#_.
M;-?ONGU\MU_PP;2_G MGZWX]Q/!GWH\,?H#%?NFG\(?'_P!_/&'^<V:_?=/K
MY;K_ (8-I?S@6S];\>XG@S[T>&/T!BOW33^$/C_[^>,/\YLU^^Z?7RW7_#!M
M+^<"V?K?CW$\&?>CPQ^@,5^Z:?PA\?\ W\\8?YS9K]]T^OENO^&#:7\X%L_6
M_'N)X,^]'AC] 8K]TT_A#X_^_GC#_.;-?ONGU\MU_P ,&TOYP+9^M^/<3P9]
MZ/#'Z Q7[II_"'Q_]_/&'^<V:_?=9=]*NX-M$/;OS^T=BSO!]E_"\Y=K+)\+
MQ/:+Q/#\8FON=_N([_=[.]W$][M[N.S YOA'A2OV7H<,</0\_7Y^EA<;'S<O
M2Y>;DK+S<O,=M]]MSMXG6<PW''&EKM/:>+^*+/3Z/)U\_EIN3FZO-R=2VW+S
M<J\VVV_*-]]AKZ:?/ES7TIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQ
MIIQIIQIIQIIQIIQIIQIIQIJWPO[NM/WP-_T=K_)/@OQ?K.H'BWQ_J&K@Y&IT
MXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTT
MXTTXTTXTTXTTXTTXTU;S_P"^L7][Q[\Y5SD^8_&/D;4><?$?E76IOT]G_DJ^
MI?\ CND?_G_J[F\^QK_RVPO_ 'E_Z3?UI'LD?\B\S_W=_P"K4==30!Z8/9P"
M;JT%'K1;.GM?]%@[I2*:M39@28UEL(_1QK42-H8L*Z*Z7&-J)$!]KQ4T+E)2
MD9@1DVO$E<Y'<). Z<BW9#,G;[7$+YM+O1EWAB?)1W^Q]'M(C<A%:#K^2?+Z
MG3&P0\2CXZN1&G$L+]AK</KA7I]:/EFE7'R4A<ZO9BZ>6R3= $CR.3J=Y;5:
MJWI9JM45T@^)T+:6KT)*].YVWF,;?'MA21/IWZ1=E])P%5/$L:R9*59!@?>(
M%ZF/$K#9I$4F-E!XJDL/QR+-.?@B:P+$4F3A-9TRL<$?8&,BIE<[4S<O:'-P
MI,8VKM64)%"K(ZR'O!0U8>-H8#!*F-F%E'Q<D\G;U".^+P=O"Q&!!3#P]1;"
MV6+2RE70HO<0XL>#Z56R$:V!J.R:OLC80"%I3IXUG88LS>ED&33]ST=U,UW>
M9#;D8TR&DE0=ZM5+K[6IQ]F@R5VZJP4P"\2S3HXN("3<MP5"DLL]2:I5F;(Y
M:Y"RXV%UBKY+$38U:!C,BI)6@L2F\T3 03/S1M"ID:75LO&<SQ106X;=J)<?
MBJDJMD94:6QCLO#D6O"01L\=F:O$*2S*>O"O+(LS!%CU,=F],O'=LHNUT'4>
MR*:<BCNF:LEBJM[><*&Z=TW;]V!MV("G%8&O!!F8JYUF\JH)N6:*&5+'CH;I
M-!WN3<E,?#P 1$\-J]4L1%\Q-''[6E4CL9?&5:+2*CVY(U[/-6[5&L:1[,[!
M#'Y/)?S<> RI-6HVZ\@3$0O)[9<SR08G)6KJQLZU4D;KPV.S2-)))NJ*7$FS
M<^EW8]JC7K8=\N\(2V AW&YVBU1 33S<AH+&L)R<78$MOM1H;3[8UJ8B&AYN
M'%;<2SA:(S"58:1T&I :U6M69S*U>O# TI!!D,4:QER"6(+E>;8LQ&^VY\=:
M#;F6S:LV%C$2V+$TRQ @B-99&D$8("@A W*"%4';< >&K,Y<:M].--.--.--
M9U>C^Z6*;U:[5V-2[W93M8!:_P!![,W,J37S-$K<HG*U^D*ZT$DV;9A$/1*R
M/(MDGDRK!:# D*)PVB83)0H#4F0C6^*,U8P=*I8K0Q326LG3Q^TL=F546UU
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M7>+)>%+?#M7)KEN6:.A9@EE.8%4"PR- ,;"!UM;,^;7KY7TXTU= S][IW_\
M%&_VT\R%?_@5S_J_EUAKG_&F.^*3Y#JU^8_69TXTUK$WEZ1Z-I/J+-:+F:R
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M0CLBQG*>%;AG-%[=VSJ*QV*1)-V,3'D R!#4!^P#X0=9:S^HYD1Y8!2HI7,
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MC0Y$&8+% A MN8[,'Q7)4=+9"DR8;3LF:)6@XIF?A]$57;F#+PG.$/N+SM^
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ML.OU)@=^5@@D5E0D%"%WW<CE&[ @ $!@P/B-M>ZQP[YJ*<0JER!S%M$1(LA
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MQ']37$\_.^&R_E+WS^1UI??9/QV^?53L%'[2J?FT/[&H7JW453+63MX^*5L
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M8J-BQM&"N\^=OQ)%E32CQD\X;K!8(FZ@164A9D:PSSJ[+U@DBH[#D $D[:L
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MU.C:1%$/4Y5WP++'!#OR0P5R@41\@*A.4(@5D"E(@ /)() )&ZJ!M>FC6SI
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M\D9E<#F94W(4,1OL"0"3MW;:S<,20Q)%&"$C4*H)+$ > W/>=O-OW[:S_?\
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MCHW*EF!]J-:)JL]2TNP:-;"1<MU)$Y9&1)H' /DV"SHJ[DM92;3;)UT#D(,
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MK=]YM= .Q@ES)6?9("/(]:CQC4< %*.#I%JKJX5@;)M'A=H'H$LG0A\2'D1
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MJ4J1,4YN.)SN;H<+UX<75C[%Q"7SM?+Q+RWS5K2R17(I^FP/97DB+206E*L
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MG?6DUQ]R@_\ &3/TGD^X_AK[DP?E+'TVH_A1X_\ OHR'JK?0:?6DUQ]R@_\
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MP.F@SOS9FLH.FC@7?-OTN6UW9;9-*NUN2#ZBW-$#(]@L%.JMM2NTNK<A/D(
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MZ?R-3K4I U7U=#M=G-05;59*G%0'5_U<[S [7=O>K9-;LM.W)U ]3&TZ*D'
MCV,C<@IYL;MJF2IJ3%;#N#9XXI'Q+SAIOS4 ;>LGUG?4G8^H ?& -_P=Q]8[
MO1:=DT/Z18.W7Q-8V;L$K4X=F<(NNL[)@6'8T"RFM&].3$*X.E[1L2A03FOZ
MAN\#U(3S&NK,:MM7?9O8+(S45OJ <!7:_.I!7NW'Q_V_*-OP]^X.K]ZPNE3>
MFV^K?4&S:$/=D4$9]BVW87(EJIP>M.+T7U5HWO9_KS@[&'(7HZ)%U^(-):+;
MT>7K196T<&H.X'B^O)H^/ : C8CX_3Z-N[S=_G)[]O#OUMGXUYTXTTXTTXTT
MXTUK%D?NA_\ XYW_ &U<Z^O@/B'R:YB_U[?\YOE.O3R=>=8RU[0Q\9O8ON'%
MY550$J077G6&O&#8JLWAXF/S S8]M1CEA.5JP6AEW#1: 8I-,U[88TV-&AGK
M3;Q*'H;]LM=A.9NIR+N?J488+(2-BTP9F1FWV8-''$X(V9Y%[C=-84UUAZ?.
MP ^JRE6>/8[A82JJZIMNI61Y5()*HC=^L+)W2;NU-#T=4FJP!*$&M(5#3UF,
MOV46RO2ANO;HHNSIM_"X=2XZ>3+&UQ3S#=:6HKFYTO7[+S+8F5.L%:L>R3B.
MNG*I(@CA8\P^H,D\<QD7?Z[N3N"]_4CC_FDNE\+D'5GDYV [0\Z+R,>N&ADB
M$9[QR[%]B6[N1Y/$@*VVWF7UA].--.--.--.--.--:S^O3HQLG5WM;H_=BD"
M];I6I[+NNR6N^56S(KEWUW8R^K7XFHKK3LI>:E$#-<V@/KAAN,TEZ)E,'N%F
M'A;TII>,R%)[DM+8LB0O.[R(_+)$QA(A>/SEEFY& [QW>5W=QRF/NK3AN@@-
M),L"I&Z\T<BK+O,C^8*T18=_?W]W>!K6M_X+?K0V%#"B=IW.GA;A+ZA^O;9-
MRVW36J20$D6=[:,HU+U]9VZ';@EDC,B[Q<*Y/9M=<A#&+#50\Z4\!)@"+8@Q
M#Q?M3>D"B:2-9#9R$KS((RI[17CCC?INC#E=U(= H9%)*LIY6&2]M:419H4=
MD[/CXTA?G!!KSN\J<Z,AW1&'(Q8HY #!AN#O4Z2Z;9M<],.@==W*GPJ#:=?:
MEHM%.5 98,VH8$(4^O0:X\P+L*II)XH,?]6XF#GY<^5.3"DL,SWES6Y&>9^H
MC15:\3H(WCACC9 W.%,:!-E;<DKW;J22=MM^_?6!N.DMJQ(CF1))I)%<KR%@
M[%N]=@%(WV(  W'=W;:R%Y<:M].--.--<AC_ "_^3_VN8^__ $7_ %G^IJ\J
M?TG_ $/];6SCG+]=$TXTTXTU &_^H4+H(;35/438VUKAL2S3ZM1-8ZF'U<C>
MK1."U&R7ZR2H+=TMM&JT0;7*;43QHC+,6@;YIZ/ KP1LM:CU?!%&I W_ %D^
M U)NN;_4]L:^HNTJ&5;.T;9-.K-^IIMIIYAHQ5;@%A6&O%&V9"&I#*)XDC$E
M):?;;>:P[A#K:'$J3AJ/#5Y<::<::<::<::<::<::<::<::<::<::<::<::<
M::<::<::<::M\+^[K3]\#?\ 1VO\D^"_%^LZ@>+?'^H:N#D:G3C33C33C33C
M34/[WTK6NH+6TW65K,6BO#9%IUM=H-@I1" +M *U:EV54=M4<R'F%11P8A\7
M=*0 G.,D!!"',C,/0Y$9;3ZNQJ0=O[?[>[47:9Z-M4:1V!(VM7RE_LNRRXK8
M ^VW6]6G!\S=INRS6N#%DL%C2T/'CDET-ZGH@,.R!@ P0>OA6QT(*WXBWN--
M]QM\7]F_SG?5R+Z7]6IUI<-6KS8$5.Y[E-;Y.J48;203>3>ZVM_$%QIN8?<C
M!<7UE*FH"F7%-!,*'9DJ5GS6&F_R;?V;:BB?T$Z-?K]>#"CVPZQ-KP:BAJ5:
M@5H$)L5?DZZW%.W]4C8=1>O%@<\Q!N\F7)?;,!# <@!2L;-$2&$N.J:;]^_Q
M_P!OCKAUWT>NAJ=8RUG'EKXW!F;,%;E17I1:K(!AKV,V^$WT4,QB3%0BVV5!
ML6S 39\L&L%J,@Q,6<4#TZ!50TAN$PTW)&Q\WQ_%Z=O[/C\^J58O1K]/UKD)
M48+[+>&LTC=E$AAF+" BQX0KJ!-6T[LEU@S'J:+<ZT2FW(B[&K4RR2J$S/'5
MRQO5&5;:X(L,5XZGF/P>(/XO</[^/>=<:X]!H"P[(U$MLGDWI:F]45QZRS]+
MNTV(9E -TR<WBP5N!JR.Q4H\L563^U]K6_;=YG6"X$"4,K6JY3Z]#<II\F-"
M-1OX_%M^#_\  V_OWS%U!]*&L=^$XYNVVB]4HA-JRM=V211[&)"M7ZA>T$.X
M-TBUQ#X.PP9HZ&<&N$QL\3&$VD2F:<8&'H<(N48DM-_-XCT'?Q_!MJ)K1Z.7
MIRM$Y3=H+7^6(F4OJ/HJ*JY: HZ&X(ZJR.Q']Q88,P*Y"O>6#3FVC<>+746W
M-*CD8=*L<BKS;I4:U8X+3F/R?@(\#MX;ZEN'TB:^]F;]7[):MC7F;L^Z:FV!
M>K;:30+VG/6C3$JB2J;.<<KU8KX.$UW]<UILK#&@H<26PU+:CLP\2,9::;_K
M'X#O\YU$P?T<.F@;$!V%?MV*L-3GUV1J>WRK=6Y1S2@NLVXO=85;US#=I6:M
MD+.+G23)]=WK=T-6$8N".,&)C 0%@:U/,?@\^_P[C;?X_B])])US@7H^M%5=
MD#$%6K:$>MU49T]PBE:E7 1."V,ATM[@B;XU%8[@^0KDDTZ="VA+T<NY ,AQ
ME@K920P9&2IS8PM :CF/?\._^D-CZQ_LU[:IZ/?1%3FT;ML.T[&SJM.O(.E
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MQL#OS=.0^3NX++K?OTB5:T47I;Z?*)=:5/UU;*-J"@TJPTDG:!=UEU\K4:Y
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M0[H[!]6](.3=RZ_#AZULB:"E4NW#,' \2-ZI';DBZVN."=GUC$G1VA V/AX
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(;^&R#TZ__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g383050g09m65.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383050g09m65.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X6I\:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z>&UP1TEM9STB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(^"B @(" @(" @(#QX
M;7 Z0W)E871E1&%T93XR,#(R+3 X+3$R5#(S.C T.C,W*S U.C,P/"]X;7 Z
M0W)E871E1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y!9&]B92!)
M;&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]X;7 Z0W)E871O<E1O;VP^"B @
M(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#(R+3 X+3$R5#(S.C T.C,W*S U
M.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I-971A9&%T841A
M=&4^,C R,BTP."TQ,E0R,SHP-#HS-RLP-3HS,#PO>&UP.DUE=&%D871A1&%T
M93X*(" @(" @(" @/'AM<#I4:'5M8FYA:6QS/@H@(" @(" @(" @(" \<F1F
M.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.G=I9'1H/C(U
M-CPO>&UP1TEM9SIW:61T:#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z
M:&5I9VAT/C$V.#PO>&UP1TEM9SIH96EG:'0^"B @(" @(" @(" @(" @(" @
M(#QX;7!'26UG.F9O<FUA=#Y*4$5'/"]X;7!'26UG.F9O<FUA=#X*(" @(" @
M(" @(" @(" @(" @/'AM<$=);6<Z:6UA9V4^+SEJ+S1!05%3:UI*4F=!0D%G
M14%304))04%$+S=107-51VAV9$<Y>F%'.7=)1$UU34%!-%%K;$Y!*S!!04%!
M04%"04%304%!04%%028C>$$[05%"24%!04%!44%"+RLT041K1FMB,DIL04=4
M04%!04%!9B]B04E104)G445"055%0F=51D)G:T="45E*0W=G1T)G9TQ$06]+
M0W=O2R8C>$$[1$)!341!=TU$07=11$$T4$5!.$]$0DU41D)15$5X=V)'>'-C
M2'@X9DAX.&9(>#AF2'=%2$)W8TY$03!914)!64=H55)&4F]F2'@X9B8C>$$[
M2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(
M>#AF2'@X9DAX.&9(>#AF+SA!04519T%Q045!07=%4B8C>$$[04%)4D%135)!
M9B]%06%)04%!04A!445"05%%04%!04%!04%!04%11D%W24=!44%(0T%K2T-W
M14%!9TE$05%%0D%114%!04%!04%!028C>$$[05%!0T%W449"9V-)0U%O3$5!
M04-!44U$06=10T)G8T1"04E'06Y-0D%G35)"04%&25))>%%614=%,D5I8UE%
M54UP1VA">%=X46E00B8C>$$[571(:$UX6FDX0U)Y9W9%;%%Z4E1K<4MY63-0
M0TY546YK-D]Z3FAD55I(5$0P=4E)2F]-2D-H9UIH2E)&4G%3,%9T3E9+0G)Y
M-"]0128C>$$[,4]4,%I85T9L85<Q>&18;#E76C)H<&%M='-B5S5V63-2,61N
M9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;RM#:S535FQP95EM6B8C>$$[
M<6)N2C)E;C5+:G!+5VUP-FEP<7%U<W)A-G9O4D%!24-!44E$0E%514)1645#
M04U$8E%%04%H141"0T53355%1E523FA)9UIX9UI%>28C>$$[;V)(=T9-2%(T
M4TY#1E9*:6-V17I*1%)$9VAA4U5Y5VE9-TQ#0C-04TYE2D5G>&15:W=G2D-H
M9UI*:EI&1VED:V1&53,X<4]Z=WEG<"8C>$$[,"M0>FA*4VMT3515-5!2;&19
M5U9P8EA&,658,5)L6FUD;V%7<')B1S%U8C)2,61N9#1E6' W9D@Q*V8S3T5H
M66%(:4EM2VDT>4YJ;R8C>$$[*T1L2E=7;#5I6FUP=6-N6C9F:W%/:W!A86YQ
M2VUQ<39Y=')Q*W8O84%!=T1!44%#15%-4D%$.$$W5'!7:69M;$1R,6IC6&YM
M5S)V9"8C>$$[3U=E-&QV.$%4>$=I35EM8W!(2$=W:G%F5$%"<6%B,5AB<5-R
M1B]Z6G-F34TO;7=V<"]M1S(P=40V=D5$8E1A:W1M>&(T<70V6F1D:B8C>$$[
M-#5Q9%A'4FYS9G1$,B]S.6QW># Y5'A3>4AI3S1X.%AD,7!H;C9*.#5F.$%5
M-5=0+V-B5"]Q<&U.=U0W>"]P:"MT,W8U:E,O.&\X+R8C>$$[*U9*+U4W.44K
M8W8K<'ES9BLT,FXO5E1(9VXS:B]41#EA+VU.3"]Y:GHO-55N.51V,%0U>2]W
M0W!Y<V8K-#)N+T%&57@T2CDT+W="328C>$$[4#%R*UDP=B]!0VIZ+W=#5DHO
M53<Y12MC=BMP>7-F.$%U3G O,55X-$HY-"\P=R]7=C5J4R]W1$M04#A!-55N
M.51V,%0U>2\V;DMX+R8C>$$[-VIA9CE6365#9F50.4U0,7(K63!V+TM04"]L
M4V8Q3R]24&Y,+W%C<D@O=4YP+S%5>#1*.30O,'<O5W8U:E,O.&\X+RM62B]5
M:#<O5"8C>$$[9D]S8T-S=FY',$I-,$LO0G)3:S!A5E904U1P43<K,D51;#-J
M+U1$.6)$2FXP,6)A969-9C5%.2]U4D@V2C@U9CE4;%DO=T1C8E0O<28C>$$[
M<&<T2CDT+S!W+U=Z+TUA6"]L2&XO=T%Q5"MP,S9*.#5F.51L62\X06-B5"]!
M2W%9.$4K.&8V669R6#AX<&8X06Q(;B]!37%4*W S-B8C>$$[2C@U9CE4;%DO
M=T1C8E0O<7!J=U0W>"]P:"MT9GI';"\U4C4O.'%4*W S-DHX-68Y5&Q9+SEX
M=% K<6U00E!V2"MM2#8Q+TUA6"]L2"8C>$$[;B]Y<% V;F9O;GIL+W="5&Q9
M+SEX=% K<6U00E!V2"MM2#8Q+TUA6"]L2&XO=T%Q5"MP,S9*.#5F.51L62\X
M06-B5"]!2W%9.$4K."8C>$$[9C999G)8.'AP9CA!;$AN+T%-<50K<#,V2C@U
M9CE4;%DO=T1C8E0O<7!J=U0W>"]P:"MT9GI';"\U4C4O.'%4*W S-DHX-68Y
M5&Q9+R8C>$$[.7AT4"MQ;5!"4'9(*VU(-C$O36%8+VQ(;B]Y<% V:WDP+WE*
M*V%U;W=F5TY0,3%B>3,U1F97=#E4859/439J:VI%5C-Y8V-'5UA,9B8C>$$[
M-&HY8FI:=3%U>G-2-%HT=44Y>'@Q.3124"]+<V9Z;B]!3W)L2B\P;GEF,7<O
M;',S-$Q6+TQN6F8X=V8V44\O-59J*V,O=T0Q8W!0*R8C>$$[:RM4*W50-6).
M*T-V.'5D;"]W07=F-E%065!)3VPV,7!F;$]X<V1A;$TR<'<K<CE9:V%1>6LX
M<&Y:4&I/-2M":&TP,#A41T%%=6)X6"8C>$$[83)F1FPQ37 T:%=-,5<Q9G=J
M<#<R45IC-C4R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6-'0U571F>6Y4>GAA
M4'!U=#-S*W)36&,V5R8C>$$[,7)*1GA1>E<U;60Q16YO2WEP+W!,,4%C03DY
M:'AW<6A0>FIT4$HP=FY%=')';S-L<F0O5F]G27)E,E-:3T97;V544TIV,3)P
M;6XQ;R8C>$$[:C1M-5!Y+V%(=F9:<DIQ:'!J-%5)4VIX2&Y):G4X:7=F.4AF
M;' O,65T4R\V46\O*W$R66Q2-WHX:"]X5#!0:F$O.$$Q4$@O04MC+R8C>$$[
M.%,W.4AF;' O=T)8<E5V*VM+4"]!2W)9,4AV4'E(+T9,-#)V+W="5'@O-F,O
M=T1%=2]2,S5A9CE8<E5V*VM+4"]Q=&I593@O268X028C>$$[1DPT,G8O,5!(
M+W!Z+W=!4S<Y2&9L<"\Q9713+S91;R\K<3).4C=Z.&@O>%,K3G(O05!5.&8K
M;E O174O4C,U868Y6')5=CA!<$-J+R8C>$$[04]Q,DY2-WHX:"]X4RM.<B]W
M1%4X9CA!<'HO>$QV,&0K5VXO049E=%,O-E%O+SA!<71J564X+TEF.%5V:F$O
M+T%&4$@O<'HO04U3:"8C>$$[9%(P-SAT+W$V8TY9,49J-C!&46)+26)E<VQ4
M=E R1RM'26HS;C5F.&5A<W586$5B-#AF369X;G9(.49&9F\W.'10.$%Q.6%L
M+W="228C>$$[568X03%7=U9(=E!Y2"]&3G9J82\O53AF*VY0+T%"3'8P9"M7
M;B]6-C%,+W!#:B\V<EDQ2'90>4@O1DPT,G8X03E4>"\V8R\X4S<Y2"8C>$$[
M9FQP+S%E=%,O=T-K2U X039R63%(=E!Y2"]&3#0R=B]!3E1X+W=#;E O174O
M4C,U868X058V,4PO<$-J+W=#<3).4C=Z.&@O>%,K3B8C>$$[<B\X054X9BMN
M4#A!>$LV3%-F>3)L;%-*3F$Q3&Q)=U9A,E5F56UG+S-D:E5/."])9CA5>&QQ
M3F-"6G@T+W=$5&XO:5AO,R]1=4=N+R8C>$$[05!6.&PO-45,+WI8;68X07EC
M9C4S,F9T95HO,&%4+S%-9C9B.6IV*VAC3E O=T-R-4PO>4E8+VUV2"M4:B]/
M*WHY<2\V3DHO-FU0.28C>$$[3BMX,R]1=4=N+SA!5CAL+S5%3"]!33$T+W=!
M;D@K9#EN-U8O,&%4+T%.5$@K;2]9.4,X:654;W9+5VE(4V]R<')T5$TX,W%S
M9U$O1R8C>$$[1D9+070O3&U:<#A(:'AQ-S-E8C=6-U-/<WDK25DX3S%D-TES
M=F1A-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T98;5=H*R8C>$$[
M6DIR,WI086%F3C5&*W!X5SAR2D1F1T9X-E%-,#='5TYJ07-A<41'<DXX86US
M;FHX2DMS6"]/5%=03#EN-7A-5B]W0U@T9%1N3G1%=R8C>$$[=5I,:35H255L
M<4QX:616,CAA6G%.6DU#9DE(-2]R92LY;61.;6YP:5E:5$%C4C(T66YU-W=W
M6"]!0DPU3R\V:RLR+S948C<O04MQ-28C>$$[:2M)4#5O*S,Y8C!0-4A69CAP
M178Y2D0O04EL,RM*9DHS+U5N,C,O4V)F9CE68V9%2#@P9F(K=&9Y3W$O-5-*
M9C932"]!0DQV.%,K5"8C>$$[=BMP4'1V.$%P3G9V*W%U4&E$*V%0="]7=C5(
M5F8X<$5V.4I$+VE89C1L.&YF.5-F8F8X05-B9F8Y5F-F14@X,&9B*W1F>4]Q
M+W=#528C>$$[:5@K:V@O>$QV.%,K5'8X07%4-V(O<$YV=BMQ=5!I1"MA4'0O
M5W8U2%9F.$%+4DPO045K4"M*9"]I6'ED+W="4V9B9CE*=#DO,59X."8C>$$[
M469Z4CEV-C$O239R+VQ);"]P268X4VAT4CAX*U57=#!#954W94DK=$%3=W9B
M>F-#6D-6*TM2:#A1*TAX,S)O9#A)>40K85!T+U<Q-28C>$$[3D9Q45 W*UA-
M9G=1-W@O4E)0.$%I6'ED+W="4V9B9CE*=#DO,59W94E0-6\K,SEB6BM2,5@O
M2U),+U-1+W=#2F0O:5AY9"\Q2CET+R8C>$$[,&TS,R]66$AX0B].2#(O<E@X
M:G%V*U5I6"MK:"]W05,W+T5V:S<O<50W8B]!2U1B-R]Q<FHT9R]M:C=F,7(K
M4C%8+TM23"]342\T;"8C>$$[,RM*9DHS+U5N,C,O045M,S,O5EA(>$(O3D@R
M+W)8.&IQ=CA!;$EL+W!)9CA3>7HX<S102DAM:GI,*VHU9DQ%3F]);U=U1FQJ
M=3=X:B8C>$$[>6I:44)2<&%F=%IF<'A#8W5%>$@R+W)D4C(S4%8V5$)X:DU:
M5V%R9V@Q=BMI*V<X,TPU=3=&6%EQ-T9867$W1EA9<3=&6%EQ-T98628C>$$[
M<3=&6%EQ-T9867$W1EA9<3=&5T)A6'%(-7<O<'EX1W V9' T,&%A968V-#!"
M+V9246-I<U R<&%&='52-#$K13EZ=&A6269Z3E@X>B8C>$$[:C5N4"M'65IP
M3D\Y0U!K,&-53&HQ9"M7.&EK.4M:<3E736Y(<T18=65W-T-/9SA$.2M12CA2
M-FMB8F1Z12M(-3AF.$%,3&,O.4DY="8C>$$[+W=!,%IJ8T]8=5!Y9'IF6D@X
M-E K;6PK=#-$."M0.$%L;'5F*VME,B]W0V%-94A,,T@U3&9:2#@V4#A!<'!F
M<F1W+U!J+VQL=68X028C>$$[<$AT=BMA365(3#-(-4QF6D@X-E K;6PK=#-$
M."M0.$%L;'5F*VME,B]W0V%-94A,,T@U3&9:2#@V4#A!<'!F<F1W+U!J+VQL
M=68X028C>$$[<$AT=BMA365(3#-(-4QF6D@X-E K;6PK=#-$."M0.$%L;'5F
M*VME,B]W0V%-94A,,T@U3&9:2#@V4#A!<'!F<E%M<5(O;FUB6E!6="8C>$$[
M<FM,.5ET<451440T=EA4:CEH2R]A<#=E3S%C35DU930O2FAK4%I.8E-J>D@X
M574O,V]V:"MF2"]!0WDS4"]34&)F.$%.1T1H>3EX*R8C>$$[5$\K>5 U,&8Y
M3DPY8E!0>7%T+U!-;'AQ4"M,-UIX1T5I*W K=D1#;S568FY49V\Y<WDY2D-2
M2C1H.'<X+W="=GHP9VI$.'-D.3=O;B8C>$$[>7)M.44K;S)0+TQ01B]W0R]W
M0DUZ=D1J,T(U<GA:.34K8G9Q3FHO>7IX9CA!=CA!5$AW-#EW6'A:.34K82M/
M,G1O,C52>$EJ9$MQ;R8C>$$[0B]$0TEG8V=G>FME6DMP:VU$<U9D:7)S5F1I
M<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-695=A1F]&:$8U<# V
M5S,O328C>$$[1U<O=31P-VEE6%-P3&XQ175$2S=Q55=-4S=+:7AN:5!I,U5N
M8V1#<50O;3-O8T8W-71->BM:8E131T9V178Q5V0U;&,P-69(4D9);R8C>$$[
M835P.6)!2$IZ2#(O<64U.6YD56-E;F]96EI0561W0C5B8G-,+W=!2U=N+U4X
M-F8O04UJ8FXO;6I-5'=H,W@K,R]I6&4O;C5F.&\R5"8C>$$[-5(O5S<O0VQP
M+S%03VXO.&IB;B]!2F]X.$ED.&9T+S1L9GHX=BM58DHX;R]R9"]H4S O-FYN
M5"]!4&MB8R\X04Y'4&A$=FHY=B]%<B8C>$$[*V9L+WEJ6E!L2#EB=CA+5VXO
M53@V9CA!.&IB;B]M:DAW:#-X*S,O:58O4'DO=T-58DHX;R]R9"]H4S O-FYN
M5"]W1&MB8R\X,%DK128C>$$[3RM0,B]W1$5R*V9L+W=!;S)4-5(O5S<O04%P
M868Y5'IP+SA!>4YU9BMA369#2&9(-V8X06E6+U!Y+S52<VYY:BMT0S9L-5=T
M0F)O9B8C>$$[.&)71"]V-V-C5FMU0V0U,$9F<VI:97 O:FMO-&@S>"LS+VE7
M=DQR<$5F-'10;4]K93AE8DED1B]+:E=D8VEK;#!N>E1A6&MC3$):5R8C>$$[
M:FMU0T99:6]"<754>#91>BMK>"LS.51J-G(R9WA90T)K=U-I5#-I4#8S<V8U
M92M79%$X="M813!Z54QL8G$T5U=347I)5TE)8S%!*R8C>$$[34$W6G1.3&A/
M3TY(=F5*-UDQ,$Y6;CA30319,$YM4S5K=7)D:7)S5F1I<G-69&ER<U9D:7)S
M5F1I<G-69&ER<U9D:7)S5F1I<G-69"8C>$$[:7)S5F1I<G-694]E5F16+TLR
M5'IT1D)P=6M8<T]Q4&-F8FMM3%(K=C9L,%DS35!R='EP>&QB:T5)2$E-979,
M0W%7+VY,+V=Z+T=8*R8C>$$[-6XY2F97+W$P5E!Q9F]E;G=Q,5 W>C1Q.6,P
M*W,T95!E,W8O04=:+TYF;&HT6&@X4$5F<31R-F1Z0F8K45EF.7)V.$$V9$UX
M9E(U=B8C>$$[42\T9B]T4"MZ9"]Y1$0O=&0O.$%4<&HV4$YF.% O,FXO6G4O
M-4)H+S)U+RMN5$@P96$O-&8O=% K>F0O>41$+T%,6&8O5'!J-E!.9B8C>$$[
M.% X03EP+S)B=CA!:T=(+T%'=2\K;E1(,&5A+S1F.$$W5"]S,V8X04E-4"LQ
M,R\P-EDK:GI8+T0O=T1A9CEM<3)7:V9L=G)';S)/;"8C>$$[=U-A=D9.93-D
M=$1(2DPY531!=D]G,S8O4FQM2TU:4T$S,V-,=$1583-$:&QK:TU216%0.%AE
M2#!*-4<X:#9D-5!T3'$R<V)I8313-B8C>$$[:U=2>E!X<4-O-#=C475B6$)P
M>&IU:GIE0C=6-U=N<EI2;$U!8TER6FLR6D1Q;EEQ-T9867$W1E9+-W9,4WIT
M,W5B=65/,G0T-D=3828C>$$[5FQ21G%A0W)-44)U8T5P04-Z<WIX-#54;'=X
M0FQ).4)U=FEL:6QI4U=*,6MI:U5.2$EP1$MY<TMG9VI99VI%1SEW>&Q%9S!D
M:49+,B8C>$$[=C='-FIK:W1R;4ME3TII:W)X=7)H5UAC<7A5;6A'0TTT;F-&
M;E!$3T)!:T-#93A,-6)I,VA-66UL4TUY=4DT9S="951K16A6<C%.028C>$$[
M9&AH36=/8D=-1$LV1C!P,F5O-F9F23<R5GI&9$I'>&IK848Q:T-U3W%S5DIO
M4C1927I%=5)T;&QW>GAM<&=X=G9&26I*3F%X-31%;"8C>$$[:FEE4E9L;'(V
M55I)1$YX1E<T:G%A1')G36AD36A!:T5G8D)F:%EU>%8R2W5X5C)+=7A6,DMU
M>%8R2W5X5C4O<%AN:GID4'(Q:F$S9B8C>$$[:S)A>7-B>64T:6)595IF,&]6
M8VA*2D9%9%8Y4G@P86Y:=&AH5F@O-7=A,#EN-79-2RM8<DA60CE7:6(V>F11
M>GE30W!B-&558W-A,"8C>$$[2'EZ5#9Z24)08T0W9C%V9"MZ96U%.4YF:7IX
M*V\W4DU13VYF17-)+WA03"]!3E-:<% X03!I,V8O5F9-6'A9+WI9+V(K=#9$
M.&E0*R8C>$$[56I,+T%+84@O174O>%!,+T%.4UIP4#A!,&DS9B]69DAX62]Z
M62]B*W1F>4DO=T-5:DPO<&]F.$%%=2]X4$PO,4IM:R\Y270S+W="5B8C>$$[
M.&9&:B].:CEV-C$O26HO;$EY+S9A2"]%=2]X4$PO,4IM:R\Y270S+T%.5CAF
M1FHO0419+V(K=&9Y22\U4TUV*VUH+WA,=CA!13AV+R8C>$$[049*;6LO.$%3
M3&0O.58X9D9J+TYJ.78V,2]):B]L27DO=T-M:"]X3'8X5'DO=T15;6%4+T%.
M270S+S%8>#A74#@R4#(O<E@X:5 X028C>$$[;$EY+S9A2"]!0DQ-4'DU;G,Y
M5G8U2C=R>359-F1.650R36QR4&)25%%V>FMV231Z=DLP-$]Z9$MF4T]O>3E%
M67IN>4<S=CA!,79/928C>$$[,&=L:'=G4GI4;4IM:4-9;C=G2'4K8EHT9#)+
M=7A6,DMU>%8R2V]$6'1&=&1A,'545&)P;E-#5F]N9&]Y1F8X0613<DM!0U%A
M5DM5>28C>$$[=DQJ130X2F-N4V%M5T1)2GAQ>&90>D)(-E=,86XK6#-L3WEH
M13@R<%0V5&)+.'%Q=W569VI66FLT3$5P8EE"2V9!4&,Q<FU(4%(T>"8C>$$[
M=51W+T8R,D1T9E5Z3D-!>5,R+VAS-T<W*U!8-$ID6651+TI&=7,K;5)E66YL
M96%A5TTR<EA.=7A7869I4VEX8V9H87-F44-P-DA)1"8C>$$[4S1U6$@Y;V-N
M3#)T<356:T]+<4$S-%IC:#%V=3-40F9)+VQN4TQQ,C%7-S%Q9%DW0S9E-$)U
M-VE)4D-75%E+4WEQ1BM1<%A*:E,T-"8C>$$[15--=5(W,T=086UF3D4T-#0T
M,T].96U*=6=O,B]W0U=V;&,S1#(Q;G)&,',T5C5P8F5'-&HU,'5%.5 Q1U96
M-55+9V-E,S,U16%,2"8C>$$[9$-2*WAN4'1V56-01DQ(1W56;4HO:$XQ*W15
M<R]W07%R9$5C6$]R6'I(-G@V<UAP4VAF,V%/-U)Q,59.6&\Y1V(V0E%963EN
M:G%4>B8C>$$[635/,S5%*VY(1#9A,TA7:&98;'1S1DM4.'%V3#1L:70U3EIV
M4D]9=E1T,&%A4#%+2U-Z1D%5-6)M<&5N6'9G3V=H9&-2=&U/,S@Q1R8C>$$[
M47AW<3=/>'(T-R]*4'1&.&M71VM8.&0W0F0S8W-Q0V--<S!V3E@K<U-E;U-W
M239R,$)(8G)M4FDP<UE3-&=3-B]69'%4>E%-1$=)2"8C>$$[<#5$*V%+*S%K
M16MK8UDU4T]%2%-R14%6*VY-<#%I>C8U868W+VHO-$IF-C1Q-S8U868W+T%)
M+RM#6"MU2W4K=5=N*R\T+SA!9VPO<B8C>$$[:7)V<FQP+W8K4#A!-$IF-C1Q
M-S8U868W+VHO-$IF-C1Q-S8U868W+T%)+RM#6"MU2W4K=5=N*R\T+SA!9VPO
M<FER=G)L<"]V*U X028C>$$[-$IF-C1Q=U13=$4O3DM(6')'-'90371T939C
M<SEX3&8V94DP4FI%>FQ)-#0R1614-EE!3E1497$W9%-64T@X,$DO>DAB>E%4
M-61V;28C>$$[=#=$,$DK56$S='9B1#%.*U(T4WEX=#!P=E1.6'$K4&HR3D0K
M=%@V6'-U=U1O9D$O9GAU9D5F-$I3,C(V9T9I4&\O;EHO=T)85U0O=28C>$$[
M2U=F+T%&6'I'+V5F>G8X05IF=&0Q>&1L9GI"+WER;B]!35,W,&9Z<R]W0W)R
M2B\S1DQ0+T%+<C0O=E U,RMY+V%V1C)6+TU(+TMU9B8C>$$[+T5U.4@X-U K
M<G)*+W=">%-Z+S9R-"]V4#4S*WDO879&,E8O34@O2W5F.$%X2W!$6F9N;E!+
M26].4FUL;&%V1TY.5'1'63!&5%%#928C>$$[=E1#2353845V.6PK,6I,3#)4
M15=9040O04E84"]I550O:#<O04IY1R]W0BLS=CA!,&Y7+R]68DHK1'%04"]4
M9G1A=GIN679D1"]34R8C>$$[+W=#2E9B8GDY+WIK0TQM27I3,VYP0C$Y4W0Y
M8FXT83<Y2F9$2'=D4C4O-F(Y<D-E<S='-%11:&8Y4U@O04),,FY8>E-X:3)*
M+W="328C>$$[<W1H>C<S8U@K*SDO-&9Z9D183G<K97!J:7)S5F1I<G-69&ER
M<U9A9$]A36A*2$E%5D=X1F9$05)A46%.<TMT=GEM,$M+2EE:-WDX=28C>$$[
M-V-.13!K13!I;$@Y2E%+3E)184AE=CA!<DAX>D)(6CA/.'4Y;C=16FEB15E2
M3RLT2$LO:BM+0TM8.'1D0U,Y:'9)6EHT2F]B-E,O+R8C>$$[04AB26],4U!Z
M.4PW3E9J0C)O=$MJ<EAA:R]Y54]+>#,R,&YT=DU91TI%4T1!43-V;TMV;G5F
M9CA%53-K3'DY.58Q5S)H4U-"9%IL5R8C>$$[8E5'4GE3-5=4,4-">C5"43%3
M1%%D1&MZ<%E54B]/-711-U=Z8U5*16<K14MJ='DR<F]P,U!K2%,W:34Q3SAK
M=4QJ-C=Q;'5,5V4U528C>$$[>&\V;T<U07!X4E)7:6]V5&]O=TA34DI*2DYY
M6E$W5WE2:D-)165(2$QI03,O6#=Z-WE5=F8X<3E,84PP:'%M;V]G85)L5EIL
M05@Q228C>$$[,6I016-.=G-$.%(P>7(K5#0Q5FQY0C(Y:T)V9W@Y3VYC4V4O
M>E=T*U5U:6TV4S8O4T8X<S!20FED6DEW>4%44$M!<F-+9T0Q3T\S8B8C>$$[
M2"M4-#-D;&PO;VAY.%!$=W=O*U(W9T\O>78S<W(P8E,T=$LP=3(P-DM34V%/
M,E1G<W-P0F1T-C%99T1X>DQX62M#26E/:G Y5&Y/8B8C>$$[25IK06-88W V
M-R]V26XO1U%F.$%%5&QJ46ME1D1S5F1I<G-69&ER5#@O5&)H5&Y4-&584W1.
M<3!X5C5V6#@P9%5L1558;4133%=72R8C>$$[>6ML5F)!1U)P3&E8:W-)8U-I
M4VM984IQ3U!F66YO<%I,-5ET+TUT=G%..41Q,G%1-FQB:4LS3G1W0W!):D97
M16I-:6I:6%EF0U-X-B8C>$$[66]D-60X;"]L>&%E8F],>7<X>&979%1%:E-W
M5U!R,GI%=7(S1WDX545V1W-S=%96=FDT+WEI;4M73B]N3'!8;'4V.#5E<G%7
M=2]O-B8C>$$[-"MR4DM,9C9R3% X24Q58FUH03,X33 K<VE/4&TY+S=--FI0
M1%1%47@X631J=GA!9#-E=U@O1"]!2D@O04]P<R]W0S5F8V8X,5II."8C>$$[
M364Y-D@X-7$O=T154"ML:UAF-&8X:B\Y5%HO,TPW:B]!2G%X-%DY-B]N3E@O
M<4@O045S:3<O1"]!2D@O04]P<R]W0S5F8V8X,5DX328C>$$[93EF>FUR+S%$
M+W!:1C9:*U8S-59X5V5Q85@U=',Y6E<Y<U9%>E)2+U8S:5IW.&-K4#=41VQ#
M,65M6C)K,"LT;41T*T$X<C(W,CA:-"8C>$$[-39A5U!H;G0O1F954S=N<V5B
M3C1L,DMP9G)T9G%-5D8U;C8S6F)50C(K='A63S58<#$O<C!X5DU-5F1I<G-6
M9&ER<U9D:7)S5F1I<B8C>$$[<U9D:7)S5F1I<G-69&ER1W90=7$V:G K;5=P
M,#=4;3%3-G5,:U)*8DQ*-E)O25I:4S-)<2]14CE-<'I:5$%70F)S3WIT2$10
M36EC+R8C>$$[1&I'3C-6.5%/.&0W0C5V3FYN1TE84#A!>G%P:V$Q35EL:FEV
M56MF.3AN<4M65EEI5RM$8S V9E%C>'9Z<W8U;DQZ9'1(<U!41W8X028C>$$[
M0TLT<C5W235'=C4S97!R-7DX-G1B9E="-4UU94AQ;4%Q6GE(-3AE6#)$0T=P
M-S!P,G@O3WEQ*T$O:C1-:C)$<%),:"]->#58.4\S>B8C>$$[-&UR8GIR-75N
M;&IJ+W=!2E-W=$Q,2$)'6C=N,&=Z>6AI;D5V0TLW265M1#@Y3"M:*U!K;699
M1VUI0V9Z04Y!;F%&.'9D2DEP+W=!-R8C>$$[6EE*-4E*9$0T>7A-56M8-C)$
M4FQ.0TMI26IR:V8U4B]O+V(K>'HT97AG:T%2;3)0.40O:GEZ+VQE;B]A:R\V
M978K=D]0.&\O,&9T+R8C>$$[67DO,$9F-V(O<U K4$YN.#=W.$1L=$4R<49)
M*W1D47=0+T90=&<O;$PK:CEV-T5F-D,Y-CA8+UEF.&59:F%2955T9$QA9D8U
M8F0W>"8C>$$[;VPT6$0V;C94:C9R17E21F5C87AC,%$O1#A06&9$+TM0.4@W
M5W)0-TEX>%(T<%IT=BM&,SDP;6(V3$9Q2&PV+VUM,'IY:C9,6#-Q228C>$$[
M15A5565+<T-I5B]40E$P-6,Q<"M(97-V>C!V-78R=4-/=SE-4F9J.'$O>5HV
M;78U>6$K5F16+TLR5'IT1D)P=6M8<T]Q4&-F8FMM3"8C>$$[4BMV-FPP63--
M4')T>7!X;&)K14E(24UE=DQ.:3AY;'8U>6%L-59T=D]*:C%44EIT475F<3!2
M13AD-F)C8U-7;W9!4E-D3CDV-7%.628C>$$[63AE-%!Z+UDY.3=--&123%1%
M-#AG:$AI3S-">&0S6&E$0F8P,RM8+T%0,4LY>B\S13(O-THX>&)H,T@U+W-E
M:"]+-GHO5F\O.'$O*R8C>$$[4'4O5&8U9B]!4%5R,U X03-%,B\W2CAB:#-(
M-2]S6#AR<E Y5VHO>7(O-"MJ=$1U9GDO,517=% P>B]$9'I$.65U66)B,78P
M:WIC4"8C>$$[5VM#8W50;TQ7;DMT2S5+06A+449(9GHO04=.1W%H<DU72V54
M>&]N9VE46&@Y=W8K8RMK.40P5W@P5%-R9E,W14U,4S%5<D5(4$IQ1B8C>$$[
M:3(U*UIZ9%ES66A(:$0U9G%T5%!0:T]39C%34C)73T\W1E5T.'=-1G-):E5$
M+U1,15901VTY-45+9D=#4#0K1SE-5E1,1EA9<3=&6"8C>$$[67$W1EA9<3=&
M6%EQ-T9867$W1EA9<3=&6%EQ."]W1'IQ:G9*9DQ.:D9B-G5U:'$Y*V=N=C-9
M<4%O=#5I<2]$.%(U4T)/;GHW6E!(:28C>$$[:$TQ35=09E1/1V9,:4XT:4),
M>FE*8F4V44EE339X65@S,2]516LX*W)09E)"5$1C4VYN2$U'<U=E-$)L:6%A
M;D=0;$-+5C5K:%(Q,B8C>$$[=$=J,#4S34]F.4M8=3<O=T<T9'$V-D$T67I!
M2%0Y,6IR*V0O33<Y+V5M16UM*V1V,&,W>F9M5%IM8UA"4F]&=D,V3D@V4B]E
M.&@X4B8C>$$[23A/2'97=4@X=G!U6$1+=C8P=BM+85)R3EE.*TM&+SA+>"\X
M46=B-C(X,DI"0S)P*V4T6F]J4$%Q3&)4*W4P871(2U1)>45X.&94<"8C>$$[
M>&]01VYH:BM5,'@R-%0X6E,O5WEH,FAR64AA569H:G@O=T1%368X05!':2]O
M<3,P,BMT9DU55W98=7!20S0Q15%Q:D='5U%"<4TQ5R8C>$$[6G%N;#%52&)C
M0V]W-'1"<%I%,T-V.#0O<F(U*S!886U/245-:#EW>'<R+S),179R;7%F-5@O
M040K;5AF>5AP3S1F-EDO<F%F.4988B8C>$$[2#@K6"]+=4@O14MG=DY5.4)X
M5G9T3"MW4$)V8D(O2F5K=FM0.4UF,7 O,%5D<C%F2$PO;%A$+VE&8E1T8CAX
M5TXR<SEL8U-7,#E#9R8C>$$[;591<$-U3TQB,#9%2&9$+T%#6G!/-R]:2#EB
M5FPY;RLQ8V\T6GE*2&YJ:"]X1#!+-G,Y9F=V9E10;G1,;4HR,41L4$)+<#0X
M645:5R8C>$$[4$HQ,FY,8T14<%1V,GAX;SE-9C10.6Q,<GHV='8X<&$T2#9O
M,2]W=D@P-69W=EID2W5V>F-'=E=*,4A3.4]84TIP-V=8<VQV+V9X5R8C>$$[
M-6-I26)Y54Q%:FTS1W5X-VYB2T=H:G8U<#-F;F5(>E56,%124#!H6BMH1U10
M*VI6=E!J,W%V<6U.*V=P=%A.5G$T>DTY:&8K840K:"8C>$$[-U1S1$AP2F%F
M.3=K-$IC4C(X5&@W=6QH:"\V4R].5"]!2VQB+W532B]W0E5C>'5$2B].+S))
M+U4W=G=E>B\X059V.$%P8V8K2V0K:R8C>$$[=GI5+S9L8B]!3&MI9CE58V5$
M2B].+S))+U5V9SEN+S9T+S!U4"]&32LO2V%0>D)F,W0X+VUB46\W33)W:&5X
M:VLP-4Q1."M41FEJ928C>$$[;6A*1D(P-EIL-E1'94DX568Y:4(K:#4W,F=/
M2$A#23 K57DT<C1V,VAL=#AY.55Z6E!)=7A6,DMP9G)P:T9L15EY43,Q=7E"
M;U-P-"8C>$$[;3=I1&)G3BMZ6&)V-V1C5E1$1EA9<3=&6%EQ-T9867$W1EA9
M<3=&6%EQ-T9867$W1EA9<7=8.#1,-WDS6F58<DM8>D1B=F,R0G96528C>$$[
M4GAQ>G0V:'0U:7!O<DHT2'9L5UA44WI$:&E,-B]J:S4O6BMV+TMZ32M,9TI&
M6%8Y465G4&,X2G5T8B]+=5-85D).0F514VU+26%D.28C>$$[6%%X24IW2D))
M6&IK955Q:#52-U9*<40Y:T=M630W1WI59E0W='@K<W91>#ES65(T0C1O-6YI
M-&]Y=71Q;VE),S4Y,U!Q=2]32#5-<"8C>$$[8TI(2DYQ<GA#2W-S,%%3:&TT
M>#!#0FQ"-%8U,4HS=VIS6$XQ:69N2&UG*S)O;S%02&0O>EHX="]T-4EM-3%N
M.&HU<C)6:$AQ=')!."8C>$$[:D5*148K0F5W54]84#-N>#ES2C='>6LO4V$Y
M.%=Q2'1K67A!.%=":T(Q:% Y15%L,G(V,RM856QP<4YV<$YR8W)/-S)P,'5E
M5DA,:"8C>$$[63155UI806%L6D@U=C!0>3A)>3=(>F1).3-59DAQ-65M.7(X
M4$A!-4UT:C%C445:9%-41W94,$9$.&)X539J6D%K1U=H2%5C5R]P:R8C>$$[
M4#5',5 X,S=1-U0O045B9&TO>GHO<%IF<5AR<61J.5AC97(K,FXW3&5$93)$
M*U)D5&8P+V%%9C9.97IR=FI0*VQL*W!-4$QM<V57628C>$$[=%1$87506'-J
M2$E'45)Y365243A306I22'(S<G0Q=VIS8E5D62]A4#%U3G)08E!24VA73$E2
M3W@O0V9J+T-7551E6E!Y:F%65T=M6"8C>$$[4W%R6%A.47-G-4%X2TEQ07E(
M:GAA<F1F:#DX;B])*V(K8CEO*TA8.&5B<30K,6=!<GAV-78X175H=5@X2&0K
M03EL.'5F;&YR,FHV<"8C>$$[<'0S2C5Q=G(V1S%H:5<W:75(;&8Q<%4Y6#%/
M24UV<')(2C9Q:VAK62]!3C9M;WI8;$5P+TUN.'9V4$=V*UI49F%*97!B,EEH
M:FE-8B8C>$$[6$5K4C5R56LX54)(4FAM=3%7;6Y/9&@V-W-0=&93869"=UI9
M,TQI2BMK2&)::78O04-P>C@Q9BMR<$@O04Y*:S,O3D]9,S5,23=J+R8C>$$[
M04539&YF>D0O<$DO<F5U9FPW;V5S84HU5W1T3S%I550S.&)Y=$I)<G1)0TAC
M<W9X34%E:'I:86)'65%O=D<Y<V%R1FXQ0FYI1E%.9"8C>$$[2S9-:WI)9%<W
M1EA9<3=&578Q,DXU3$M*57%#3'5Y63!$13!7-VE9+UE+;F]0;#0Q1TMS13%B
M>D(K9#%Z<49X8F%0-6-S.5!T<F0U=B8C>$$[4W9,=61B:&)H1F])<4MJ4G1'
M>D9V96Q#97=6,55D1C5G+TY7,W5.3VAM.'5W,S!C.3=D=V%H8U)Z2F)I,W19
M-4EH8E1Q1V51>6,P828C>$$[5&%G3E%0<SDQ5U$K54QV>E1C869C2'I,87@R
M=#AL,4MS26AP=V4S<GEH8EHS,S1M:F1.>#E*5E1Z1EA9<3=&6%EQ-T9867$W
M1EA9<28C>$$[-T9867$W1E5Q.'AA3F-A<F)14E<Y>71R2D1+6F54>'1+<D%X
M4$AX2W)*0V8Y,E8V.75M5&A+:T57=W54.&XS:U1656TQ0S!U4G%K328C>$$[
M54)E-7-7=4I)4D-*1E8T<$IB;#,U:U1S3U1%;6Q!2T%$3"]Z4$QB;#4O<V%4
M:'4O3E9J+T%#9W-O<FE/4D)P5'=X44=!47IA56HX:28C>$$[5FI8,5A95$M7
M:TAP8D@S3S)0-6LK9GI4-$DX=FMI<FHX=$1D6#AT-V1V<%8Q3$Y+.'-W;3!S
M3TA,+WI&<F=S858X9D1W>4EZ,$M&+R8C>$$[3FMC9#@V*U,S5"]Y,C%05#EF
M8E=R6%9B4DI#,&),82]O."MG;F\R9W-K.4U#-$1*4TEF<W0S4&)B1U=C1TY%
M9F(U,S-):FEO,RM/5B8C>$$[34\Q8B]N1V5(5DY4=612=5!-5$QC6&-J5%1"
M3%%"4S=M<D5!>D=L5'9436E/=C125D].4%%I4G-L0VHO04IX6',K0E@O16-L
M0U%F.28C>$$[-48W5B]W0TQF9D0O04-I935J+THX835O>E(O*V-A-#E+=E=U
M-V9Z0UAK84,U=&ES;&U#=D<V=#-T,TY"34YW:W!).3A%.61X0W%:428C>$$[
M,$EI8D):9&0O;'1Q=#%/:SAU<C(S3TDS0FHT,DQ!5G5956=A=BMK+T9267@Q
M-C<X<3%Z2$=C1' Y=C=(2TU#;3)N9FU8-4\Q2%9&,"8C>$$[>3!V5V4V9'I%
M05E:;%%38S550TTU44MR33%V2E%%.79(361S670U*R].2'E6-5<X>'DV8G$X
M3W)Y6&IX<$U7<UHS4TAI-$%&1D9Z028C>$$[068S9EIF,6Y-<D1P6EI"67!X
M<S)Q:FI.1S),-FPO>FM,*UAO=$I:3&$R,3EB;&9I:4IN2W)Y.50Q3B\Y2VM7
M;&5X46EN=S T-UI99"8C>$$[0DUD4BM09S%$6'=042]J-&]J+V]92#AS*V%V
M.54X=S%504%F5TAP<T-.>#ED;V9T9"]B=T=0.$%*."LX9FHT22]L0TAC9G@X
M5W8X028C>$$[;UE$.'-Q3B]O=FU(-&=19CE)9F]Y.$14+U1D=&AT5&]D*W4K
M4#AN>C=X*U!G=CA!2T5/-"]J-')V*VAH4'DP-7,O,51Z0E9I4U(V>B8C>$$[
M53-93G-V,3)G,UAT,G%/:$]0.$%*."LX9FHT3"]+14\T+VHT=$PO>FM$*U=A
M:VM7;FU'<D=P<F-/96I&='$S=3(W9F1T,$%X+VLK9B8C>$$[95!X.$8O;$-(
M8V9X.%=H+WIK0BM745%)3%AZ1%%5,TYW-5!W<55'-79A.4<S.%1V,4%X+VLK
M9F50>#A&+VQ#2&-F>#A79"M43E,X<28C>$$[*V5T06953$=0559S;'5$15DW
M>39N16=L:45B:#$T6$5T3TI#<W!$5D1B:6@S3TYM>$A'84QL67-O;D=W>5IT
M0W-7<%=7-S).9'(R-R8C>$$[1R])3C)L.%(Y,C-42VTQ<CE!5U!W+W9B>C11
M05 Y3G4K>$HS+V4W+T%'=2]S3W=X5G@P0WA+<79Q,VQ%04$O,#(W<G-N1&,K
M<E4W928C>$$[4&9F<G9I<FXP0WAD:51,959)23)V8G-$96Y94VHK6#EF:6-6
M8B]15FPV;E Q8G9L>34P*W4S9$LX*V8R9E9P4W9B<%0T96TR2W1*;R8C>$$[
M1FEJ06E7.'%!0G9E,UI',65X;% X,S9V05EQ-&%"66A76#%B>6IG9R]W0VTS
M9&0P-&)(,6%J8G<W-SED.%9D*V=,2#1V,W0U.%%)4"8C>$$[*VTS9F-G-V9V
M9'9S.79C9'II<F$V1EER5VMT,W5A-S-T,F0K4F)V3#1N-W1U;4MT9F]#>#1+
M;G$S;$9O069R=#-86E-U-V5R53=.,R8C>$$[-S!0541&6%!O1FDV;%1,94%%
M16)8=#)P,U%*,45O4%)F=G%E<$IX5GIA0EES451,9595,49,,C=(5F<R.4ID
M.3$K-V)O5&EQ-SE",B8C>$$[6$Y8.5,W<7!"02MU6%9.;4QB<C9T1'4S9G11
M9$%-5E=F-&9S2TPK.790:$%!+S V.#9+=D%6+V4W-TAE=E4W.60X5E1,1EA9
M<3=&6"8C>$$[67$W1EA9<3=&6%EQ-T98;&9L=E8T-69/54U9.&=,<#!V<4UH
M,5%137)Q0SEW=G%Q-6=63TMQ9T)Q-% W>6<O;'=Q=U@X.2]-5VLV9B8C>$$[
M-3AA,W5V3'1J<6MV,5=&=G).>3DP<VQ$>2M':TTP4S!(>7I:-E!'5$1A4D<W
M<F18;&I'9$=)3WIZ83@X-2M8>F%Y06549$Q5,#)):R8C>$$[,4-V-%A.8WE4
M:6Q8,4@W2$=J;FAF,$)7+W=!6BM8=BMP33!R+VM:9B]W1%I4:W9";"]/4#))
M+TU1+VU"32]+*W8K5TY8.'DV5'!5+R8C>$$[:R]4231D479B93%L9$I,-VMQ
M>E-R1WA7='=254)T<VAK>'EJ16YI3W<X;5=03D-59T]!8FPY0R\X<5$O2WHO
M<7=X+SAJ<FHO04MQ6B8C>$$[<2]Z951V9&XK5W@Y=V0O>7!$.')0*W)$2"]Y
M3W50.$%Q<&HK8GED-B]L<V9C2&8X<5$O2WHO<7=X+SA!238T+S9Q62]M.&YE
M=C5B2"8C>$$[,T)K=FPS>7AO6&QY=T]N-DQA0WIS,FM->&E6;EEC,D%"87)L
M:C!56E9025I'>3)W9TEI9VUM45I/>%8R2W5X5C)+=7A6,DMU>%8R2R8C>$$[
M=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMS0C!44U!Z86DX
M>'AZ87!Q.71.;WEY179%=D=P:4QZ17%514-K<U$X428C>$$[5FA)2T)4-#AC
M2W-4+TYI-B]/5U!Z838K54)E;E-F46E**W)2;S9E<G9Z,UI383!P;61P:&DT
M9EA6=49Q4$<T=E)Y*T1!.5-V4"MC:R8C>$$[;7-*;&Y456UI2R]'1VAI27 W
M+T--=DDP+VLP039M.2\P27(V.2]Z:W@O3'%N+TEM3"]M;D17;CAK6'%F>%1/
M+WED=69Z9FPX>EA3*R8C>$$[8WAE1%-X6D]99G)-84EN,6HQ675.0V]"<G<U
M-6IA;UEU2#!C-V-J5&5.>&5V;%AK.6AZ0F,Q,DMU>%8R2W5X5C)+=7A6,DMU
M>%94=28C>$$[8FE',G0U8FED=45-2TY*2SE#84MG<7AO3BMG=V=7<5-A5#4K
M.&TV=%HO5S=,5C=D;TLP+V5T-D1J96TV5&5M-$)043 S>6-S36]M:28C>$$[
M1T5C9TES2VMF;EAY<$IQ1GIP-C9N04QM>G%,;FM3<V%%1D%637)!4CAQ>DE+
M0G$Q3D]O3U!H4W$V5'AH,3$U,SAO,C)M>6%N3'$Y<28C>$$[8DM*5EHU635&
M;&](<G@K1U!K>$IO9&=-4FEK5%9+6F=#-U=.-3@X;W!R375I>6%N2$AQ541M
M3V%"=S8X1T5*;E!*,E5)0C93;'$Q<"8C>$$[,C8T*T1+<G):2&E2=7(S4F1X
M-6\X=7=75C-E='%-1#(Q:$8Y679(:6-3;4]+;DQK>7@X,F]2,#(S=T1(26UQ
M-7!-9T)A:G S;DQY<B8C>$$[<4YN1&57;7%7-U%4,#E)=31I8S%::T%-8VY"
M=U-Y14%%9'-:67!!,%%O;4-,5B\X5&584%1%;C96<R]42SAW+S%I2VY(;C9F
M2W9,<"8C>$$[>BM(-3=93T-88VYI0VMV;D1Y=6(R87DO4VQS3&DS5TXU9UI&
M0V=48RM!-6XT0W@Y3FIX0G)T:#A/5EA33TU84T]S=%0P,BLU+U5R=28C>$$[
M1S8Y3VYQ96I):VY'=&%C=4I.2S!Y2FE2>E1A2G=*9&ER<U9D:7)S5F1I<G-6
M9&ER>6IY<G Y=3-M>3)U65!Z0VHQ4EAC>7<V86LW328C>$$[-V]8;F8P=W8Q
M:&M:6$5L9#!*<$=+9$]71E=%9FYV-60P;E504&I81C$U:7-D3&PK<7=R.5=U
M575M:V]/6'A6:&AL5V@K96)04C5#228C>$$[8E)*,V1B<3A56E1S>4$R96%8
M,VLW445T2E=8>FAP5'-&,E5*96=N-EAT=W8S-6Q(3$MV<% R3TY(0D<O<D0S
M5"]N2')Y6"MH-#E4,28C>$$[:3,Q5S Q5W=V9VM%571Q2FQO.$Q%<T=%,&-2
M+V)'64=T>3A60W%)8S=2-&5!16<R0SEL>D%C,3)+=7A6,DMU>%8R2W5X5C)+
M=7A6,B8C>$$[2W%D>F)1,TYT3&)4<GIH;E)O-55Q4E982$9H55504311859I
M;'HK53-K0V4R1G9.<&$K:6M-1G5!2&M3:V1Q5UI.,5EB:WE.>E!6=28C>$$[
M*UA$550W,F\T63DS-$1(8C-Y+RM33VEW:E8U2C1K:FEN-7)08EA-.#534UEG
M:6DR-U--<6M18V5N4W570V575WI%>&A(9$%1-D@K428C>$$[5C=F3'!52$M3
M-VUM4WEJ4E=V.$$T<%EL84E+:V@K2&E&4$5K2&HP>5)N;4%V.51%4GAN8CEA
M8V$Y;R\U3UAK*W%A,7%-:U4X.7!/=R8C>$$[,4]E0U=:,VEL;&I&=5$V=T9M
M1D9H.$M,46YX>45*6E)11$EX>#=N.&1Z8652+WEE:G9T43!O,CAA6$U.;7!U
M:$Y*4'AI=#59,6A%:28C>$$[4WEN9T1W;T]3=%56.3AF1GDP1#5R-%5.=S O
M-65F:SAY1S5H93%I859M.4,T4SE*5EI)+S-V-W5S:%@T07EN:C T9V)5>#AB
M3"M!;B8C>$$[=V]*9%HK4F9Y471:9$\P;6$U9W5T5&UI:4-30S9K<F-.13--
M3S-P=C993$UH03EV:$=43V)-8E!29TU736)D53AT9GED+TQ#-&=I;B8C>$$[
M='))5#(U15IG:VIU<&Y3:UA-1&=W:U W5'-443EC<D]P>41Q>D=#2&-Y8E%0
M2UAL+U%(=5@P;3%&<S$R<TM4.%=9:&AB>"MN2'-3428C>$$[2TPQ23-09DM:
M-4I3-71K64%C:S-Y1$HR2W5X5C)+=7A6,DMU>%8R2W9'=DI7<B]L;%!R=6A2
M860U8W9T36YK=#=B.4=M66E/3FLO,"8C>$$[:S(X>E)#671.5&I.5U5O,4-A
M:S!O=TMS6"]095AY2W9N>&AR9')Q:S$W.59H*T]Y=4QE2TQH.%A%8UI96E=R
M,7(X5V)04CAF0C9A<28C>$$[,U=A>G<K4#%89&1+96%8,7@K5G8Q4U@P8DA8
M4DQX*T5T95=L2R]283%Z2TEY,7IJ.78V,T9J-$XO=T%8,E!P:CAJ13!-95%)
M2DY&:B8C>$$[=5ER1U<T;EE*97E2>7EH9S-&=FEI4TIA9D1T.$]A<E8X6$AV
M>F1R<&5(=WAW.&YO1UEZ:T]X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,B8C>$$[
M2W):63!L:F5.>%9(0E9H,'%#2TAP:7)$<DPX;B]W079R3C1N:#!Y=F]T1S9R
M2DQ,27!-455,>59M2W0Y9U9"1D1L-3%->C%A;S19:B8C>$$[:T5D3"M82&LV
M5S=J=3-S4#E):G9N,5 Q0DI+=D\V:V8Q0S<P64)W1S-65'-/,U4Q:C0X-G$K
M;$HX2U V5F4X.&IE5C=Q>3%#>D9K="8C>$$[=$AQ:VEZ6#<R<&$S:VQD2#E1
M33=X;%-F:4IW1$Q)14<K4U1J2'I56B]W079F3&1W,F]'-5<U=4)Q8T%T8G1:
M<G4T:T120U%Y<4)Z8R8C>$$[:V-82DLK1E0T;D--,&A8:W!X9S,U<&)**U1(
M-6132U9F5$=)6754*R]N,S5O15 W9BM1<"M9>68U<69E>$]'2C9.=BM49C5E
M=DHV:B8C>$$[-F%X8FM74"MK5#!Q6E=M+VXO;F,O4F<O37HW,3A'4&0K3V)+
M3D8P9E0Y1S!U,C!V5#1Z1EHR<3A)67EZ3U%+:R]A66LY5&Q5<$=2<R8C>$$[
M=&M104M#3GE+6%EQ-T9867$W1EA9<3=&6%EQ-T98;FYL=GHW-7-V.5<P>3(Q
M2'EF3'!Q6#!%56YR8S-D;V]P9E9.5W!#15%2*VEV2B8C>$$[2&17*TID<2]$
M:%8U-2ME3W(V:F%E95=I="],=&QQ8V8Q5T4O5V)I>F$T97 U9D1Z0D=W.$TR
M5VMI1$1E4D<O938W5GEK2F)2171U-B8C>$$[,VTY.7(K<WE7:W%F-$\P,653
M,#5,<'-O669):&=C>51!5CE2*V)J>&Y++V](*VQF579L>2]W1$QF;"]Y6'!S
M.7DQ<&]L<S%V0DYC4B8C>$$[5E=#2DIR;%9::'A9+T1Y9#@P*U5K>4XW=3)G
M04%+,E105&9.,VQF531M;3 O5G)3-FE2:U9N:FU29T=L0F%-5G(Q9%)69D5:
M5WI86"8C>$$[9FUN>3-A4WE26%=Q5W--<TUI47I).'E+>5-3:$=25T)0=VQH
M2VA&97A'2W!P:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:28C>$$[
M<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-6968K6$Y!+TYQ>C%4
M5%I.63$K1R]S;&AI3W!*=VI197 K.3EA3D972&LY4R8C>$$[,%A&*V%5;S(Q
M4&A+<D9F>EHX=&9M.7%0;3%R;GEP9%@P1VQ',VE8:&)8<C(V97%+.&IW1'!V
M,#-P;69P<VU)4G%1,SEZ9S9N1FQL2R8C>$$[-&UH-S K+TQZ4G9/,7 U1#%0
M5'9.<EA6-7$P.3%),75*-41E3UE$1D5&54Y)>%=N3E@K17--<#%-;U-L8T]6
M3C)M:$]-86MB3G U<B8C>$$[4#5A95%.83$U9&4Q5%-J9#9M<VM5=G%Y0UEQ
M5$-O5D$P9CA!9'-O0R]:2S!Z1V-H6D8K5TAK0TQ3-61+:C R4DY/;5<S4U,Q
M0G5!:"8C>$$[1F]J2DAS1#%)9'5B9%A*<3%4:7)C+S5:95%:>7I3-F$W4T])
M9S!T8F=/9E%I9VAI*TE'=C=T8E-0:C1%16IC;7%R3%)C4F=5;R\X028C>$$[
M=T0O,'A6,S%M4'=F+VM7+SE-5F0Y6FHX2"\U1G8O5$989E=9+T(O*U)B+S!X
M5C,Q;5!W9B]K5R\Y359D.5IJ.$@O-49V+U1&6&97628C>$$[+T(O*U)B+S!X
M5C,Q;5!W9B]K5R\Y359D.5IJ.$@O-49V+U1&6&9762]"+RM28B\P>%8S,6U0
M=V8O:U<O.4U69#E::CA(+S5&=B]41B8C>$$[6&9762]"+RM28B\P>%8S,6U0
M=V8O:U<O.4U69#E::CA(+S5&=B]41EAF5UDO0B\K4F(O,'A6,S%M4'=F+VM7
M+SE-5E9%8T]+:7108R8C>$$[14@W:E1&5SA69&ER<U9D:7)S5F1I<G-69&ER
M<U938E),<GI,3G$R=%(V<F%X=V%D0D]I-E!-:$A+5TEX9W57*TIU:F5Y.7A4
M87!65"8C>$$[;D9867$X*W5T6B]/0F1C,"M',S!7>F936DI13E%U1V-"-#0O
M<F-I5E%E<G8O;S12:G-A9&1Z.$E696<T<3=&6&TO;6989GIK=#E9=28C>$$[
M-%!,=6DR.3=P.&-H.4ME-%99=C-24D-#:"MS5FM93GDV<71F655W<3E':DQM
M3E1)07)K1&U!86=';3E$9U9D:7)"9D]E<2]M<F%A;"8C>$$[2VYL6%-R82]S
M=W1V-EIU4W-D5UE4970X9G)!,%AJ2"MX,W!4.7)&5U=A2$QQ:S)J5TUU<E),
M0G%B=U)T95%P.6Q:4V],9U5,9"\X028C>$$[2U!Z3TMO-T9722MF=%0O35-Y
M5S!(:R]3<F953V9-,V-K.&="4VQ/059#.&1D=5(K,3%O3SE1<6UN;$,V.#!8
M5VHK<C5M=$ER3%905R8C>$$[;55W44YY45)Q-45:1%9A=G<Y1#-'.4)79U94
M<D973V5E<C=Z;%HV6F)Y955R2TLO,45Z,&QG;DMQ;G!E;$IU5TQX.&8S;D1F
M9F%O<"8C>$$[=E5+<E!)="\U-79,4S9B>F)945=&=VMI0S%306=H:TU3;&EA
M4$IV>DHK4G%U-$A)<7-M>%9+=DY.-7(Y;F].,V,V0EI*<4]R>&A0<28C>$$[
M=&Y)-&I6-GE+2'%X24$T;U=B-DU64V)Y:'%8-6@S5W!Z4BM:3DYG<S=%44TP
M8VM21F981C%)<6]+4U-66#!!<')19&HK,%965FPR2R8C>$$[<4=O3F-R65A,
M5V]R9$Q%-6=!54]F54-N:CA*6D%D*WA99DU9<7<S>71Q6#5R4'$Y<F)E671/
M=$DW14-:8C(V9V]"5DE)5$<P9C<Q:B8C>$$[.&-Z4T-N2'!8*U5&:7)/8T-U
M>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6-7):
M*V%F>FII93)H;CAP>"8C>$$[,S1U6FQ35S5-.%9K3&1344I'9$$Y>5A22S%6
M:%)M,RM%54A*5G%X.#<O;D9-:GE4*U%69TY1<V1U8BM+;U!">5AA459"2$I2
M<T8Y="8C>$$[>5)I<7)Q,VY(.# T8G$R+U(S;$E82R]6-#=I*W17;E)7:F1R
M3C5$17-X4$)J.6%):G%O3D%H,BM-14MP<#54.# K8SE6,5-"3E<P1"8C>$$[
M.49713%Q,7=S;G%'56MN,&UJ<E99>6@O94UP4FPU5DAS8U9:;&ER<U9D:7)S
M5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5B8C>$$[9&ER<U9F+UH\
M+WAM<$=);6<Z:6UA9V4^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO>&UP.E1H=6UB;F%I;',^
M"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T
M:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIP9&8](FAT=' Z
M+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B/@H@(" @(" @(" \<&1F.E!R;V1U
M8V5R/D%D;V)E(%!$1B!L:6)R87)Y(#$P+C Q/"]P9&8Z4')O9'5C97(^"B @
M(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N
M(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SID8STB:'1T<#HO+W!U
M<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B/@H@(" @(" @(" \9&,Z9F]R;6%T
M/F%P<&QI8V%T:6]N+W!O<W1S8W)I<'0\+V1C.F9O<FUA=#X*(" @(" @(" @
M/&1C.F-R96%T;W(^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @
M(" @(" \<F1F.FQI/DUA:&5S:"!4:&%N87!P86X\+W)D9CIL:3X*(" @(" @
M(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+V1C.F-R96%T;W(^"B @(" @
M(" @(#QD8SIT:71L93X*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M9&5F875L="(^<F5P;&%C;65N
M=',\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \
M+V1C.G1I=&QE/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D
M9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z
M>&UP5%!G/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O="]P9R\B"B @
M(" @(" @(" @('AM;&YS.G-T1&EM/2)H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C O<U1Y<&4O1&EM96YS:6]N<R,B"B @(" @(" @(" @('AM;&YS.G-T
M1FYT/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O1F]N=",B
M"B @(" @(" @(" @('AM;&YS.GAM<$<](FAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]G+R(^"B @(" @(" @(#QX;7!44&<Z3E!A9V5S/C$\+WAM<%10
M9SI.4&%G97,^"B @(" @(" @(#QX;7!44&<Z2&%S5FES:6)L951R86YS<&%R
M96YC>3Y&86QS93PO>&UP5%!G.DAA<U9I<VEB;&54<F%N<W!A<F5N8WD^"B @
M(" @(" @(#QX;7!44&<Z2&%S5FES:6)L94]V97)P<FEN=#Y4<G5E/"]X;7!4
M4&<Z2&%S5FES:6)L94]V97)P<FEN=#X*(" @(" @(" @/'AM<%109SI-87A0
M86=E4VEZ92!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(#QS=$1I;3IW/CDV,"XP,# P,# \+W-T1&EM.G<^"B @(" @(" @(" @(#QS
M=$1I;3IH/C4T,"XP,# P,# \+W-T1&EM.F@^"B @(" @(" @(" @(#QS=$1I
M;3IU;FET/E!O:6YT<SPO<W1$:6TZ=6YI=#X*(" @(" @(" @/"]X;7!44&<Z
M36%X4&%G95-I>F4^"B @(" @(" @(#QX;7!44&<Z1F]N=',^"B @(" @(" @
M(" @(#QR9&8Z0F%G/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O
M;G1.86UE/D=I;&Q386YS350\+W-T1FYT.F9O;G1.86UE/@H@(" @(" @(" @
M(" @(" @(" \<W1&;G0Z9F]N=$9A;6EL>3Y':6QL(%-A;G,@350\+W-T1FYT
M.F9O;G1&86UI;'D^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%C
M93Y296=U;&%R/"]S=$9N=#IF;VYT1F%C93X*(" @(" @(" @(" @(" @(" @
M/'-T1FYT.F9O;G14>7!E/D]P96X@5'EP93PO<W1&;G0Z9F]N=%1Y<&4^"B @
M(" @(" @(" @(" @(" @(#QS=$9N=#IV97)S:6]N4W1R:6YG/E9E<G-I;VX@
M,2XV-3PO<W1&;G0Z=F5R<VEO;E-T<FEN9SX*(" @(" @(" @(" @(" @(" @
M/'-T1FYT.F-O;7!O<VET93Y&86QS93PO<W1&;G0Z8V]M<&]S:71E/@H@(" @
M(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9I;&5.86UE/D=)3%]?7U]?+E14
M1CPO<W1&;G0Z9F]N=$9I;&5.86UE/@H@(" @(" @(" @(" @(" \+W)D9CIL
M:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT3F%M93Y':6QL
M4V%N<TU4+4)O;&0\+W-T1FYT.F9O;G1.86UE/@H@(" @(" @(" @(" @(" @
M(" \<W1&;G0Z9F]N=$9A;6EL>3Y':6QL(%-A;G,@350\+W-T1FYT.F9O;G1&
M86UI;'D^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%C93Y";VQD
M/"]S=$9N=#IF;VYT1F%C93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O
M;G14>7!E/D]P96X@5'EP93PO<W1&;G0Z9F]N=%1Y<&4^"B @(" @(" @(" @
M(" @(" @(#QS=$9N=#IV97)S:6]N4W1R:6YG/E9E<G-I;VX@,2XV-3PO<W1&
M;G0Z=F5R<VEO;E-T<FEN9SX*(" @(" @(" @(" @(" @(" @/'-T1FYT.F-O
M;7!O<VET93Y&86QS93PO<W1&;G0Z8V]M<&]S:71E/@H@(" @(" @(" @(" @
M(" @(" \<W1&;G0Z9F]N=$9I;&5.86UE/D=)3$)?7U]?+E141CPO<W1&;G0Z
M9F]N=$9I;&5.86UE/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @/"]R9&8Z0F%G/@H@(" @(" @(" \+WAM<%109SI&;VYT<SX*(" @
M(" @(" @/'AM<%109SI0;&%T94YA;65S/@H@(" @(" @(" @(" \<F1F.E-E
M<3X*(" @(" @(" @(" @(" @/')D9CIL:3Y#>6%N/"]R9&8Z;&D^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D^36%G96YT83PO<F1F.FQI/@H@(" @(" @(" @
M(" @(" \<F1F.FQI/EEE;&QO=SPO<F1F.FQI/@H@(" @(" @(" @(" @(" \
M<F1F.FQI/D)L86-K/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*
M(" @(" @(" @/"]X;7!44&<Z4&QA=&5.86UE<SX*(" @(" @(" @/'AM<%10
M9SI3=V%T8VA'<F]U<',^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @
M(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @(" @(" @/'AM<$<Z9W)O=7!.86UE/D1E9F%U;'0@4W=A=&-H
M($=R;W5P/"]X;7!'.F=R;W5P3F%M93X*(" @(" @(" @(" @(" @(" @/'AM
M<$<Z9W)O=7!4>7!E/C \+WAM<$<Z9W)O=7!4>7!E/@H@(" @(" @(" @(" @
M(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \
M+WAM<%109SI3=V%T8VA'<F]U<',^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N
M/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @
M(" @("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP
M+VUM+R(*(" @(" @(" @(" @>&UL;G,Z<W12968](FAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B"B @(" @(" @(" @
M('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y
M<&4O4F5S;W5R8V5%=F5N=",B/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)
M1#YX;7 N9&ED.C$P-# T-3@R-C,Q045$,3%!,$0Q0S=#03%&,#,X-T$X/"]X
M;7!-33I$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX
M;7 N:6ED.C$P-# T-3@R-C,Q045$,3%!,$0Q0S=#03%&,#,X-T$X/"]X;7!-
M33I);G-T86YC94E$/@H@(" @(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N
M=$E$/GAM<"YD:60Z,$8T,#0U.#(V,S%!140Q,4$P1#%#-T-!,48P,S@W03@\
M+WAM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.E)E
M;F1I=&EO;D-L87-S/F1E9F%U;'0\+WAM<$U-.E)E;F1I=&EO;D-L87-S/@H@
M(" @(" @(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YU=6ED.C=D
M8C$P83(W+3=E,S$M-#AD-BTX.6-D+3 Y93=B-S,Q9# R-3PO<W12968Z:6YS
M=&%N8V5)1#X*(" @(" @(" @(" @/'-T4F5F.F1O8W5M96YT240^>&UP+F1I
M9#HP1C0P-#4X,C8S,4%%1#$Q03!$,4,W0T$Q1C S.#=!.#PO<W12968Z9&]C
M=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)
M1#YX;7 N9&ED.C!&-# T-3@R-C,Q045$,3%!,$0Q0S=#03%&,#,X-T$X/"]S
M=%)E9CIO<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(" @(#QS=%)E9CIR
M96YD:71I;VY#;&%S<SYD969A=6QT/"]S=%)E9CIR96YD:71I;VY#;&%S<SX*
M(" @(" @(" @/"]X;7!-33I$97)I=F5D1G)O;3X*(" @(" @(" @/'AM<$U-
M.DAI<W1O<GD^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C!&
M-# T-3@R-C,Q045$,3%!,$0Q0S=#03%&,#,X-T$X/"]S=$5V=#II;G-T86YC
M94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(R+3 X+3$R
M5#(R.C4S.C4R*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B!#4S8@
M*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HQ,#0P-#4X,C8S,4%%1#$Q
M03!$,4,W0T$Q1C S.#=!.#PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @
M(" @(" @(" @/'-T179T.G=H96X^,C R,BTP."TQ,E0R,SHP-#HS-RLP-3HS
M,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W
M87)E06=E;G0^061O8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO<W1%
M=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H
M86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(
M:7-T;W)Y/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&
M/@H\+W@Z>&UP;65T83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K
M970@96YD/2)W(C\^_]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$!_\  $0@!BP)= P$1  (1 0,1 ?_$ !\  0 " P$
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M8K[GTX3+QYR:Z/@>SAV!FYA\!*AYY7A[[#UTO$2]\Z)V4Q7W/IPF7CSDUT?
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MF>$O@'B+]%;7O\/9Z]G??1 _Z1(/<FG!!7><J3^],]E#MF>$O@'B+]%;7O\
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M25H9:;90IYU:DM-H;(R0A)%33TUMR>MKLUV\RGWKK5.N>Y?"&N=+3_:!Z*X
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M-)_0AOZT]"SWJ X%ZVSC^'&;W@JRX):3X1._0QO7C9^V38B^)>E=*UWW:'J
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M % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0
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M+2P_VEGB>6>5I)VYF<_88D6L&.MA0 H 4 * % "@!0 H 4 * ,SCC_NAL/\
MTS:__P"\(U<PO^&1/\I8_P"]0,#=7\V+C_S#6/\ _/D#_2MKVN/RFA0 H 4
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MCN'H* X"^)I_N[]DO]-B?^JS?KRAB!_/"M_X]C_4XP_1EN,O^3)A-_F>K?\
MB:N"B=:</3P4 * % "@!0 H 4 * % "@!0 H 4 * % $=2+;E#9GT1_?_J_;
M=_\ &!?P0[<G3/I9_P!-N5]V_P#-ZW^7^65G*'L.K;:V7]A*A_Q*69[2:V57
M_P#"_IY]XM4.28MEFUAUW.%2LL5;//\ ^*JM%I.1U#NL/]I:6)Y?]4D[<SW_
M +#$BU@QUL* % "@!0 H 4 * % "@!0!WG\)W_>]-:/]&'1__17C7J[#[^9U
M$_Q,G_7I0_.9NS/^4UBO_G>D_P#ABAC8C6Y#S$% "@!0 H 4 * % "@!0 H
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MK\P4GR%CT [)3= >.3$;SKJ_M(>K]T@ZJ,#=FK8^7TZT;7Y@I/D+'H!V2FZ
M\<F(WG75_:195DL=G1LUDAD,!LHC.9Z ",71&TW4\LE(J4 8-F#PX1!/*8!%
MRP8QPT9-"8A88VR''%$O:^6>5[YJ+%C0F&XL-AJ-&9(R:890EMILE*4M1(0D
MB2DC4I2CR+:9F??'*:_<%<NJL3;@N2K3ZY6ZDXAVH56J279D^8XTRW';7)DO
M*6ZZI##+3236HS)MM"2V)(AE57 PX4 * % "@!0 H 4 * % "@!0 H 4 * %
M "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H
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M'@9_T<O[-_[J9'R'\QAF7*7SD(YD;#+FV7^(P;\L@-NUO.!:]@^7E.<GD?\
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MW[(':Q+C\<=*\T9_X@#VB1B=5)Q]J2/W%IPQ1.8'O+V_9 [6)<?CCI7FC/\
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M5D:#4JZU;..!A0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 *
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M@#XY<-?/&A^V!Z!&[75/V"[*'G\HIUI7/X/U?R"3ZL.R0P!\<N&OGC0_; ]
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M "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H
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M@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4
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M?C0I\>1%72(]:?4R;L=E:.Y*N]CXYA0 H 4 * % "@!0 H 4 * % "@!0 H
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M$:[92K;J[]7DRJ5,@4BI,LR*\E]-9=I3M1I\J30UU+?,A4M5$>I^M<?==/\
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M"JP8E-J%SS$3I4&FF^<*.XW$C1"0R<EQU\VS1&2M6L<4K34>1D61%M0K*#0
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M-+BM%'@QF6U+TK75GQQL* ,5?/\ M.<W_P %4/\ \?.HIXR^4OZQ*O\ -/\
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MZQBD(<3/0?8]ZHD<0MM/%+W?;G+'336:@"N:15IV!)H8HRCBTR;D(HV;H,$
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MSX\\C(LSX_B$ :UZ#;^N/6GACZ:2UK2T8!0M&]E&/L4^]DEF;HY?;A5B4>R
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M % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0
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MUAVKD_'D7U:'_P"8 >T:VZG-_P!H2WW(4X9O\&_],?[K#M7)^/(OJT/_ ,P
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M4UE#I+;2B:39QR3JSD1%FZ@^Y-8\[+M,V6* \Z4Q)SID"-5"4T;;<=-5-#\
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M+4R%'Q=_QVTVQ+V@#;*1BYF(07VVUQ'.SY334T1ZJ8IK<.;D489^XA-1I K
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M0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 *
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M$\RF,[2L(G8Z#0:6'+)J*V4FT9*;-+2KF-!&VHB4@R26@9$:<C(AES.?<[O
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M69)R]65T[9."E-/1YCBQ>C115L#XB2 \6BL(F*IBE&_%ZM9-'."AEC^:2?\
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M7-4PTZI3CAI4K1(VEI(]%"5*/:9%L2?'R"WT(3Y!S9A&.U=UR4.@K\50/LO
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MG3=G6L;O9$I?>#3@;D<_L]'+]L#MH-&\3=3\]HOX8%J=*>#"X=2MEH[G\_L
MC/@JQ0W@&(V"D='D$PI7=+&<K.PO@JC/%5#*]"$7\3^?A$!^?P*Y%[<UD+88
M//VQAJ];U;AU==7;E)BE)(V$PE-&O7Q7HY9.')<).B;NG^8>>CH[,\RX]CYN
M[Z;C3A3<^&T?#6=;[UPKH:DU=ZZ(]2;B]1[AI5<42H:*%#4]KTTTXQ926]6I
MXG3TR0;:M]-=7'SE"@!0 H 4 * % "@!0 H 4 * *-;RB<V2U3_E&E!?P]U8
M&PY=U@.?)C>%DZ?R&KWY,3FMR!.3_$</^)S>6+F_*8\OTA,GO_G?FG^;_M_5
MY1^3<^$9>FM18"?'J](B(VDB/]B<7!>/)F=\.'!G^LL!.)PJ.>.LIX-!56,4
MUY F#A&QDP<24@WA8ZI!!@9WRS"!&6>W^K/+:7+\68I9GI!M$XI2@$!<?DRH
M<?,V:V-,#D?9>=\7?(;-7570V>HEF(TS5B1E=_*B6E..:72SD@ZUT$A="!*N
M1PK[42DHD*IJQ<)LRR/+OEEQ%_?D9?86W/,2"PN',D1J\MJ@TEL/Q7A54BV/
MF!%D&WG!438_GI#1('5F.\6M,18T<6#"F9=:\I'4E7=;U ,FQA%4PO\ @G<,
M,LL@@9YDDL^7/9Q;=F7_ *"6X,CS:E-U3V:CUPX2@WEDZ5DA!U'198DUDN^?
M66S5"'T).:J*_P"7H^<J\@JRLD2[F\<V*[#[X<CS)L.[0,/EWG7.64!2P0/+
MO9<6W+/(SY=O_H6?$60P2!-=]KF;,S"DM\N>33^(TV/XI(A!>GUSNYG7@,[J
MTAI32+$XX4'RJ,DL= V)0RZ@&:0FT [RXYE45#)RR$K*&9A_!B)F1\1<N6PB
MVZ1GM/Y/E[W(,1D;3.=#&WLC;7(&"R[49O[1:_RBT($//9OI<?2HT4'75GPD
M^'X&4Z4F&$:8XL-J#I<L;^6J\ SUPVU $D^AEQEQ">S<!F7$?)EGR'F9_-WC
M[_)GQ'N0H)0H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@
M!0 H 4 * //5DA)7TP^B+J8G+2,J%1B*FDJQ(LHIBB2,87#,$SY X$,5.%1P
M\KAC%S 0@0N%[XYX98WO:IT.+:6EQM:VW$*)2%H4:%H41YDI*DF2DJ(]I&1D
M9'Q"5:$.H4VXA+C:TFE:%I):%I461I4E1&E23+89&1D9;#(1+Z-FNGN"A7LL
M8WR*KWJM5><ZAY;)]8+'J32N;*?Y%&]6'HV:Z>X*%>RQC?(J=5JKSG4/+9/K
M ZDTKFRG^11O5AZ-FNGN"A7LL8WR*G5:J\YU#RV3ZP.I-*YLI_D4;U8_:-K[
M I@D331X1B$=.3A38R>GC1JS!"1$8_<"Y\4F5S1<@"HIVY4M<V( 'AD9N7 N
M-?/F0_!E*J5,E*651G$M1))2BER"4HDYZ)*5K,S).DK1(S/+,\LLS$QTRFFE
M*#IT$T(-1H0<2.:4FO+2-*3;R2:M%.D9$6>19YY$/Q>C9KI[@H5[+&-\BJ;J
MM5><ZAY;)]8)>I-*YLI_D4;U8>C9KI[@H5[+&-\BIU6JO.=0\MD^L#J32N;*
M?Y%&]6'HV:Z>X*%>RQC?(J=5JKSG4/+9/K ZDTKFRG^11O5AZ-FNGN"A7LL8
MWR*G5:J\YU#RV3ZP.I-*YLI_D4;U8>C9KI[@H5[+&-\BIU6JO.=0\MD^L#J3
M2N;*?Y%&]6'HV:Z>X*%>RQC?(J=5JKSG4/+9/K ZDTKFRG^11O5AZ-FNGN"A
M7LL8WR*G5:J\YU#RV3ZP.I-*YLI_D4;U8>C9KI[@H5[+&-\BIU6JO.=0\MD^
ML#J32N;*?Y%&]6'HV:Z>X*%>RQC?(J=5JKSG4/+9/K ZDTKFRG^11O5AZ-FN
MON"A7LL8WR*G5:J\YU#RV3ZP.I-*YLI_D4;U8>C9KI[@H5[+&-\BIU6JO.=0
M\MD^L#J32N;*?Y%&]6'HV:Z>X*%>RQC?(J=5JKSG4/+9/K ZDTKFRG^11O5A
MZ-FNGN"A7LL8WR*G5:J\YU#RV3ZP.I-*YLI_D4;U8>C9KI[@H5[+&-\BIU6J
MO.=0\MD^L#J32N;*?Y%&]6'HV:Z>X*%>RQC?(J=5JKSG4/+9/K ZDTKFRG^1
M1O5AZ-FNGN"A7LL8WR*G5:J\YU#RV3ZP.I-*YLI_D4;U8FJL>,@% "@"@$3;
MS-%WI4$ERT$[4(^4[2S+\8I CBA10206$H1NJ*HYYT2L)FK"V9#&<M@[ALIR
M&+&PG"+GA@$7 OERVB>WYB^PB("2:2R,RV%GL,CXSXBY3+/:7>VCVV/O>SWW
MYC>AP)M>@^?B39,BY'\JX0443R!4(PZ3T]U2QSBN-Y#L1T]&OY"N8STP%R\Z
M!S)<OSEN2 B999[2V$1[#+;GR?'REW@8V][0??F,Z' >V"!Y^9,DR+T?RLA!
M10_(%0B_I/C!TRSSBN-Y#L1T]&R\A7,8Z8"Y>= YHN7YSZ 9<>TMA$?&7?[Q
M<I\N68,;>]H/SS%]#@/;! \_,F29&"/Y60@HH?D H1?TGQ@Z99YQ7&\AV*ZN
MC9>0CE,],!<O.@<R7+\Y] ,N/:6PL^,OF+E/Y 8V][/?GF*Z' FUZ!Y^I*DV
M,4?RLA!10_( _%_2?&#HEKG%<;R&8SJZ-EY".4QTP%R\Z!S)<OSEN0&7'M+8
M1'QEW^\7*?*1?&#&WO9[\\Q70X$VO0//W)4FQDC^5D(**'Y 'XNZ3XP=$M<X
MKC>0S&=71K^0CD,],!<W.@<R7+\Y] ,N/:6S+OEMSY.7+O\ (#%WO9[]\Q/0
MX$VO;_G[DF3HR1_*V$%%#\WY^+ND^,'/+?.*XWD,QW5T;+R#<AGI@+FYT#F0
M"_.6Y 9<>TMA$?&7?RXN4]NW+BV@Q=[V@_?,1T. ]L&_Y_)(DZ-$;RMA!10_
M-^?BWI/C!SRWSBN-Y"LAU=&R\@W&9Z8"YN= YD OSGT RRSVEL(CXR/C[Q<I
M\I=X&+O>SW[>"+$X$VO;_G]D>3XU1O*V$%%#\WQ^+.D^,'/+G.*XWD*R'7T;
M+R"<9GI@3FYT#F0"_.?0 RRSVEL(CV&6W/D^/E+O Q-\&>_O,/T.!-KV_P"?
MZ1I/C5&\K8044+S?'XLZ3XP<TN<XKC>0K)=?1LO()Q&>F!.?G0.9 +\Y] ,N
M/:6PB/C+OY<7*>W;EQ;08F][/?WF'Z' FU[?\_TBRA&R-Y70@HH7F^/Q9TGQ
M@Y9=YQ7&\A&4Z^BY>03B,]-!<_.@<R 7YVW(#+CVEL(CXR[_ 'BY3Y2+XP8>
M][/?_F&Z% FU[?\ /_(LH1NC>5T(**%YO3T5]*\8N67>=5QO(1E.OHN7D$X3
M/3 G/SP',@%^<^@&7'M+81'QEMSY.4R[Y P][V@__,+T.!-L&_Z0$B2A'"-Y
M70>I(7F]/17TKQBY9>YQ7&\A&6[.BY>0+A,]-"<_.@<R 6YSZ 9<>TMA$?'Q
MY\G*9=\N\##WO9[_ /,+T.!-KV]Z0$ARC'*+Y70>HH7F]/15TGQBY)>YU7&\
M@V8[.BY>0+A,],"<_.@<T 6YSZ 9<>TMF1\?'GR?)WRXR!A[WL]_^83H4";7
MM[T@9"E&.D7RNA!10O-X>BKI7C%R2_SBN-Y!LQV=%R\@' 9Z:$Z.>+\R 7YW
MZ &66>TMF1[#X\\N+EX]I<?'R&#"WO9\@>8/H4";7M[T@I!E*.T7ROA!10?-
MX>BGI7C%QR_SBN-Y!LUV]%R\@' 9Z:$Z.>+\R 7YWZ &66>TMA$>P\\\^3X^
M4N,&%O>SY \P?0H#VP;WI!2!*4>(OE?!ZB@^;L[%/2?&+CF#G5<;R"9SMZ+E
MY +YGIH3HYT#F0"_.?0 RRSVELR[_'GR<N7?Y!6*8-G3VR1;0P*-=5%H^)(V
MZ/2E/'<751RKQ:%VIK[DY;O&3T_ @KC7A66U2PI;T<)76.FI!G(\I\X"6Z>'
MR!$BRTMO>[RN//B^4B/+,ON%G6#O>SY!O -B4";7M[TA']*D?(OEA""B@^;L
M[$_2O&+BF'G5<;R!9[MZ+EYOUXSTT)T\\7YD$MSMN0(&66>TMF1[#+;GR?)W
MRXR!@[WL^0?,!T*!-KV[Z0K]E2/T7RPA!10?-T=B?I7C%PS%SJN/Y M!W=%R
M\WR\9Z:$Z>>+\R"6YVW( RRSVELRXC+;GEQ<O'MY-N8,#?!H2%Z/_0H#VP;O
MI#/R5& B^6$(*"#YN3L3]*\8N"8N<6!_(%HN[HN7F^73/30G3SI?F02W.VY
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MZ3R],B @>7,(*+;\UHT+=,\:J$Z<ZKF/-JD/;H>7FR/'.GXO'GRW,8%>>MR
M,LL]I;,N(R///DY<N_R!&F][0D[T9_%\![8-?TGUV94%O^7,'J+;\UHT+=,\
M:J$Z\\KF/-JDO?H6?FR/'.GXO'GRW,8%.>MR ,LL]I;,N(R///DY<N_R"<M<
M9X1]E8C;TP(3!EB,DQQ'G*0 9LVL<S'4CIN;8<JJV3!A9:1LX>'3RBH821%1
M#'R,YV4D,XGJ6%@\#5@\0&61Y9D?R'F0G*@@% "@!0 H 4 * % "@!0 H 4
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MF>61=\3#5@+\* % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0
MH 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * %
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M_P#I2M<VQ6_FB[_E\+_]UCHV%G\[&?\ (9O_ .B1_H'5Y@'IH* % "@!0 H
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M@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4
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MSR&?U:BZ"@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * %
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M1&:3(E%FDS(R)1<699\99]\M@@2DF9D1D9I/)1$9&9'QY'EQ'EWC'U 4"!G
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M%7W#^P;D;Z5(#Y@R,&]%$KQP455-@MJP8.RCAEQU-#,JD*29*(TE1S%JFVU
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MAR<F>&-\;\EKU@KBO>SY%.)O?YU#*7$7O>$])B/EH/H5KM:;*<VV<M-QO/\
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MRF-Y$5XOCM51FCS_ ))I"DRFT>3&QTD/FC/D\0-)@I5%Z0%>X0_BT(MSH=_
M$\+'Z*J(G36UNN-S)2''\M>XB0\E;VB>9:U1+)3F1[2TS/(]I"FN#"<0TVN'
M%6VQGJ&UQV5(9S+(]4DT&EO,C,CT"+,CR!9B&)W&4;2>X8OCM>(,L,$)G$5E
ME-I4*-,(N& $7";18\F#@H08 18L$#@EX%<0@RX&&%L<0@[8FYTYI3RFIDIM
M4@S-]3<AY"GS,S,S>-*R-TS,S,S6:LS,\^,P<@PG4LH=AQ7$1R(HZ7([*TL$
M1$1$RE2#)HB(B(M DY$1$7$0R8LU6P3,KYPFW$$H<==P;NDV61T\ RY+EB?B
MXO=?'"+X"K%RZ?\ R &ZCF9N$3_DH?@@?B52-]Y1-)4\ZI+&>I2;BS)G25IG
MJB,\F\U]T>AEFKNCV[16)EE*G5):;2I[+7*)M)*=T4Z"=:9%FYDCN"T\\D]R
M6S8/P,Y@L2/$XPD,!E-)C))LZ*I&DQG-Q';*<941\<,!CY@DBDR188Z-@&'@
M*:$"R'$Q#PQS$O;#&UIGY4F4HERI#\E:4DA*WW7'E)07$@E.*49)+,\DD>19
M["$C$:-%0;<:.Q'0I1K-##3;*#6>6:C2VE)&H\BS499GD69C+:H"N% "@!0
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ML7!3:/\ 13_+5^@-?X5+L_I('D2?3#VB_B3?G##O92G_ #.G!3:/]%/\M7Z
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M9+U,./#E(?=)J2^MPT)(\R0E41"35MV$:DE\9#LAK@8[N% "@!0 H 4 * %
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M@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4
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M0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 *
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M % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0
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M$)B"9Y9Y97H)#XS_ -O'^T2W0 H 4 * % "@!0 H 4 * % "@!0 H 4 * %
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M0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 *
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MWV_F!C'!I&B--/+K<;B<X'LCNR16@]5I-/J;E L 2BYJR*X<"J8L&3"(!S)
M-2")%G_![?DR(0$O\2V"6JNR*0<34EM+;#,QF @SI&R;;:.LV=7K ;V1HREJ
M-(;#37D==JF^VQ)JZ2C\DFO5JL9->#C++EV2KN-';BZK)X1T3V;2VY'EMS(C
MXC/9EEEMXSV&68LY <[HD^MAR+!%I/2.7.Q'RMQI),92*"UPWQ'C[0B:2L#M
M]P"L=TOAEG[GVTXFR[$55:CP<:&JMMRHJ@54LLC(I< (&67Q\AEGD9?%GE\G
MR[!.5! * % "@#XO>UK7O>]K6M:][WO?DM:UOIO>][_1:UK?SWH US&>)U R
MH@K*U%+1EV>S*;*\D1:EM^)6\U#*R\2\/1TV9/D^3F>*]WNQT%9BUL-MV(H9
M!QV6P#S\55)$)QJC/$-T-0RMA-H\ID6S/;_5L(]OQ=[OY9&,S8W$%A&2)39\
M?LM'D%<9S^641EL^?RZ0W<(37I2<4'E=D4:*2:D,Z@W[9V'84. O,-5&CX)@
MV,\XR\GI9_A"-7$(9'_Z=_CR_KV<OQ"\]! * % "@!0!659V<2TK8Q1UT*Q=
M)BX9:\7,V7Y&ED@?A],BJ,F:_E.6D9KF'5Y62TVY/4S)U1AAVES=F'&+S)(^
M)A$,+!T@6/CC$PCELSS+C,LMN>S+XLN_RBMR%Q/XI<J4F8HD+;$&I!?&<6GX
M/ALRWHQ29(V!9$T($F.^-Y*C;!8E@@S$IG++-AB6'8K RL\8U=[+1V&JV>[4
M;JD?;R<LA'1R,]I;,\SVY;/V9]\N(LMO'EF+PP[*[0G2+F++S"'/C-*06XGN
M1&P5B J4M$0CH?(92%U*&OD,DKZ(>P-(Z\E#99"IJN1.D1,\LP,LKA*99;#$
ME4 * % "@".9<E=CP='#KE61E05(9[/(!G5,<H0/*ZH<,'#I5*14) 0TL TK
M.%SN9=/IK=:S<2"AM8<3B5$Q$22AI0/E@! $6>PA6>0=[8_C!SLAJNZ,9F)'
M5AG1"^Y8.!(S$,)^L;<G=[&8TB\U.XH<A\^6$<,A);D:Y@.+2THX(.+0=;H<
M J8R4<1S"A$BSSVEW\N/;EM/+9R<N0]Z!]THWV!D!68+::<D-BXK=<[XC%VO
M5*;)%ISO'+)??FT>$A14,ANYPKN;:;[R,(I$P&_D%B+Q]+=;0<Z,BJ;9<1!6
MS :3+Y\C^(SVEG\I<0N!00"@!0 H 4 :\Y&XB37A^3WA&DIZX[*,K!L,219)
M2GT.6@%SM%^-%A.]KQ^EG6FG,/8!V2,3/2J]GPS6O$R(^6"S%IT+#@Q*G2")
M=#=>2 $Q)S(C(R/,\LMN9;#/OEEWMN1GWN4>"O<3^)6R@FSBQ#VP0+Q9MI<4
MIUBHHWXT5']KDRX)"8IZ5)#E7Q7*IQGJ+3;R%)\=NA*"B9W2<ZGRW':146"V
M7/=/7@$@&CMXR^(]N1Y\1%LSY>,BRRVY#9$4-%CQ4L>)& 39,X7!-%#1<3 8
MN9+& \1@#  H=\L!01@L\! A,,KX9X98Y8WO:]KT$H_10 H 4 * % "@!0 H
M 4 * % "@!0 H 4 * % "@!0 H 4 0[L-#B3L/ TS0,NJAU"2)DB]]1D?7DT
M(,=2007JVE)O>/4\ ;/  P>1LS^*F3+F,K%QS!4,(?E!SSM<(D>1D?(9'\PB
M[6:#I,CE?F>4YO>;+><P3@OLDTXA8V;2RU&&AMR-F(E,=K)"*F.%=<2V.</#
MEG"[UL^>4O!"4'5D@D0,DY!*'U !_P ?.8MG00"@!0 H 4 5ZVOA50V+UTEN
M$$I=)ME1DAJ#-THO*!0<^23!13A0S8R9)EA01QP[6+7PO@$+AERYVOR\EKVN
M$2/(R/D/,55FS0MQS!,;S.C2&VR.N\S2= <W32Q3#95AY(/R+KBFHQ!H$V6\
M %\NA)#5=(K$B8XY<%-N'U1-LQEDHEC&K/>YEK!$CR[VTB,B^0__ ',OCSV\
M6W--/=2I'@9P&'5+DEM21EYN0#".JT=#LYHJ;1+AQ+ YM\'TAV/$!4<"_<Y)
M;^/O?(P[@4?,DU4C!NI0#>*VL;41! @9Y][+:9_/E]FS_P!1?N@@% "@!0 H
M U(J>DVTST>\T20^Y-@09^N:6H@F&('4GM*13YQGAZZ2$1<T,0DY21QSD$\W
M$99L'Y(3788;H*2Z#[ZE-X2*2&!%,$V\3";,BRRSRRR/BXS+:9?^Q;"R//:,
M.)<+^328[SM::F,(4VD.-Q3W3M=@+N)A;--S:B7=I,"L$7\K\@6F34//>]X7
M%$>6#D,EF:1:CPM<TZ4Q2)+(#47)Q<6W+O$6W(MO%R_%Q#<_02A0 H 4 * *
M-;R:Q2#M@TF-&C=7(H;+23WNWWRM.]X-!T.&4XY=K-<*&LLZ1X%5T1UH"4VI
M#0"8+H3D]272AP$L:7")_G#"<15FZX0B1Y;=OW\I'LXC(56>_#"?;\&7&NH3
M4U4R-&&\]BYAUD ),)6-.]HS+L-.B7L6&JRF;,.T%*=[-BI_EUY(;;>;I=M*
M+K:#D#++:VF*K>+J"H$=+XN,B(]O>(LOM^SO<>R^6L,)O"(4R7'%);E;;HE6
M?)D5YKD@VRDA30V2FK(S&C^*VXW6F06U)66<DMOQS%;(2C*DJ'>EKBV65ERY
M-+"40DLF$#/BRXB++^/VG^SBV\8LY00"@!0 H PR16 UY683QC-[%E,ZSGZW
M%=I.DDCN-R-%3/("\2&3E8B4<S/5D%SHN9PB8'+9'D-935 ,,7.P!H*^5[T
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M@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4
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M0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 *
M% "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H
M 4 * % "@!_/_/0!\8XXX8XX88VQQQM;'''&UL<<<<;<EL<;6Y+6M:UK6M:U
MK6M:W):@#^?, \E\>9"\&^6.5[<WAR7RPSYS#*]N3DOE@)^4QO\ SXY_CVY,
MOIH ^]\,,LL,\L,<L@[WN'E?&U\L+Y8WQROA>]N7&^6-[XWO:]N7&][7^B]
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g383050g13p30.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383050g13p30.jpg
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M 0$! 0$! 0$! 0'_P  1" #2 EX# 1$  A$! Q$!_\0 'P !  (" @,! 0
M          <(!08$"0(#"P$*_\0 6Q   0,# @ (!PH("@@%! , !0,$!@$"
M!P ("1$5%E63TM02$Q135%:4&2%8DI66E]'3UA<8,34Y>+2U(C0V071UF+.W
MU1HD,CA7<G/7(R8W478E,Y'P87'!_\0 ' $!  (# 0$!              $"
M P0%" 8'_\0 3Q$  0," P0$!@X(!@(" P$! 0(#!  1!1(A!A,Q44&1H=$4
M(E)A<9(5%A<R-E-55G6!E)73U"-"L;*TP=+P0U1R@I.S)#-BX0>B\24T_]H
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ME_F]@OW9#_!I[;-I_G!C'WC*_%I[I!P@7PU]TOTZ9(^\6GM3V7^;V"_=D/\
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MDV!96P=(<.YNQ@/Q-*GF.9KDC&2<?E..,MY.#8L%3R'Y3:G%(D_9"9"459$
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M+9A*@S&9VX,E#:XYD24*:<CI6Z'T2"A(0O>9,I(P,;2[F7*@8[$;P>1&@#%
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M="0,U%F H;$P&.$H\35",(V(%W(#!OC6UE7*:]UMO6]NDQMUPQ(<>#%3@<S
ML/B17)"$X>Q-<0ZY);?4XM]V874!Q;SBP5KL38@5RCL;#<:;$J7(FR58W#QR
M?+DML+5/?AMK:;C.,I;0PU$#2RVEEMNR$>+J#6/$<%-AELZQ2#DLF)SK#V&,
MC[E)A <+RR.@B<1#P_<C$U8X1Q2DHOXQ>V)P)^Z?R*%.;4J%F#]U99<Z_P!3
M9KHV<VXQ!0G.LLHC3\1AX/'E8@P\ZA]R1A#X>1.-K ORDI2U)%\BD)X74J]6
M]BL.28+3KJY,##I>+OQ</?::<CMQ\78+*H0N"=Q%4I;L8VSI4H J\5)&XSW8
M[(''!]/-F\9R>3F<AAHF.+8HF^0TDD7-[_%^1 ^3<5QF7+"J*6+ QCF,@8.[
M)-6?E-D8;V.J,5WR%:+:\7:5H;5IVA>A(CM2''A.C1"2G)-B.0ISS <U#JTO
M.R4H4K*7R4Y@DZ;$G9QT[+JP!F:Y(=CMLF%)E@9BJ%+;FP67RCBTA3#492TI
MS!A(5E4H:R6\VHP[*VXW!^\?(L48QS(^,,7$! 2!N $,>&XY.)<BE:3*2K(H
M!<BXF2T+%+DHW$@R1!Y% ;XD;E 910B21<-]-..2(.$8GL_$?4]#FS4..R@[
M(2V]&CDY$,1'0@1Q)6$/2'"E+[J$-L. (0I*MQ6"1YN+8;C\IA+4N%#6VU&4
MU'4XU(D 9UO2VBM3YCH*V6&PM3#:UNO-DK6"G4<2[%K\9%\^S)UFV3',D;AQ
M4 B4MF8"#P+%U!4+@BA5"U&/@<="@0QK.S8F12%HZR*O1R6'/G0PD%8L+0Z3
M%QGG;3>&-X7'3AK+</"5RGX\=V3*FE<B5D)+KLM;JU1FW&FE)B#*VI*5I<4L
MN%0P0=G/ W,3D*Q%]R7BJ(K#\AJ/&A9(\7. &FHC;:$R7$/.I5+.9Q"E(6TE
M ;"3)VW?:=&]N,NRG(HK+#Q$-D5VSJ,A[ELQ8@X@*'R.9R(:.:V,;;:EE@C>
M9T@T=(.TT% N,8=C^$MT;VT8L>O-/%L=>Q>/!9?8:0Y$2K/(!4IV0M;4=I:U
M%7_K#AC^$O(22'9LB5)40I[*G<PO!6L*?FNLONK;EJ241R$I:CH2[(=0A(3[
M\MB1X,TM5BW#CQ(X!# 4JWE/S??_ $Q+^X6UPJ[GZG^[^55<W.[8XENE!XHC
MDT(JM0F+\\XSSG>+J)&&QLN7QP[(.;8;(!Y:Q5HK'I$B179%Z526ON:UN3HD
MI8I?;7LX+C+^".SGHZ IR;ADS#0O>+;6P)B4#PAI2+*#K)0%-ZCQM;BU<;&,
M'8QEN$S(64MP\3AXEDR(<0^8BE*\'=2L%):>"BES0DITL;FH'RWP<N)LCY<%
M94!NQL);IX]C6+S^/TH%%CT%=QB'R\M-8X\C(%VDR81.2C2QXOQ/+FIR/.+5
MVKIS%E23.U\KTX&UTZ' 7!<2N23*?F-2C*?:E)>D1VXSR7G4E2GVEMM-Z7;>
M3924OA"B@<V=LI!ESD36RB./!683T41F'8RF(\AR0RIEM02EAY#CKGC97&E7
M2I3!6D*/@^X.N"78RI"P$[.QF7BMW$BWG1')3&.1=V4#99-38[+F:)H&19N1
M<NCPMD=5C'D12Y)TZ%L12]CQF]&LU4)3M;*\-\)=C-/,+P%K9V1#4\^E#D%N
M,VPHMN(4%L.K4V'\R+I2XI8RJ2M0)>RL8P_!VI+K+Z,=>V@8EI:94MN<Y)=D
M)#C:TJ0^TA+I9RKLHH2V0I*D)(XY+@\@9_.#?/<HR:YE4S-IX>=9,LD&/8D^
M&RB281+*$X7*8BQK5-GCTHG95LQ<VIM9(V1M'L"PI(9)45#BTHVL=:PTX6Q"
M2Q';]D$PRU*?2MEG$F\DAE]>JI2"<RDG,RHYU-N%;)#0JO99MW$AB;\LOR'!
M ,P.Q6%(>>PYPKCOL)X15ZA)L'0 E*V\CPWITF_@J<8N<;M,9OLES180UVVY
MYVX5>MAH-H_4%YUS )S*^E?'XM="TM&SP=LQ8LKDE&1!C>M<\K:M?X5-GV\3
M!,5-$*.'%8QA>,92MTI#F&8>YAR&.(.[=:<4M2KA2%@9=!:M<[%PU1$PURY!
M;&$8IA)4E#25%O$Y[<];W!0WC+K24H38I4DDJUUJPF=-IIC<+ME'8 R!F8Y?
M)&4A@TI6RX)AL7'E')K'\W834"O9#[+;XTW036%#QBC:MJ]BK5O59Q5PX66O
MOY.&8ZWA.,KQ2)A[>Y4S)8$!R0^M ;E1E1W09&CRB0M:PK0A1L+ "NIB6"+Q
M7"$X9*Q!TO)=C/F<AAE#BG8LE$EM6XL60+H2@IL04BYN2288-\&P&GC;*<AR
M]GG)&5<RY7;X9 D\K'04&!TB\!PGER-YCC\!A,'B ,!&P@0S*([8O(7#BA$B
M^=.U"5KE-U1:CGHM;8.13!9@89#@X?!.(NH@M.R7=_*Q*"]A[LJ3)D.NO..M
MLNV9 RH0E.3*4D6Y[FR3<D379V)S)L^<,.:7-=;C-[F-ALYG$&HL:/'::9;:
M<?:NZ2%K4I17FS7OJ<GX*:#2DQDLXXRU*PRDRS-#,[QB,1N.APV-HGD6'%YL
M_ND1/'J3M4'(S,M%SHG'IL5&4A[B0,V8TJI1O)D+SBNPQMS*8;AM)@,."/AT
MG#'GWG7')C\20W&1N42BG>LM,+BH=CMKWZ6U*6C5@[H8'MBHSSDQTSGVS(Q"
M/B;++33:(C$N.Y)67EQ0=V\Y(1*6U)<1X.IU*4.>*^-Z?9,^"\:RI#%[(?N#
MF,1"8K>1.31Z&QV&1MICYCD.+9S-9RNG(>$6.DPC H;*G%X^8<DTCQYZ)9,5
M',B<.',CYPQ'VU4R9BEX5'?<FI?9=D.R'E2E1'\,;PSP5R24EQ2&D-AUL(+3
M2'%*"60E+(:F3L<E\0DIQ20PU"4P\U'9CLIBIEL8DYB1DMQP0VE;JW"TX5AU
MQ3:$DNE2GB[Q"W!008NZFI&_+LI&.#>;HCGN'QL)&PXK%T-G$72R"P(/U,9(
M/:@G[N=ALCEQD\?Q]:%J&;Q<?*M$A9A@X?/I;VYDMB.CP!A8;PU_"Y#SCKBY
MLB*\8BT($PIWJ4Q7(;:XJ'1)#8<=;45MJ2E,.;$QG%25^'/(+N),8I'9;:0B
M%'DLB6E2_ PK=+5*;F.(E+:,?>E#3B0VXDJ5:60;+,6S3:8ZVAR]1U=!7C)2
MM"\*9#($4!2"V9J9!%2>'MA+=PPCY*/2^K<L'\<F6JM>TLMD*I]1V46(<1K:
M*='QT8^P$^%)5JW(4N2VZT8XBN,2"M06ZAZ/=MRQ1;,2T&LJ CLO;/PI."*P
M)_-X,I/OXR415M.^$&4AZ.&P4LK:D6<;N'/>@.ETJ65Q07V*9%R)CJ5XZSQO
M,S'F-@_1A*T&7?0C#\02@\@QY.HWD*+2YZRBL,9UGDA2.Q,0U*+2MVX9$@JI
M=I1BU?$^5&V^WM-$B2V)>%[/8?AZTF2)(3)Q"09+4N,]$>82I^2KP5G=/N*0
MEA(4EP-JS%* @Z*]FY<J(_$Q/:"?B"5>#*C*5&@1_!GHDEJ6P^I+$9/A+H=8
M;"R\HH6WO$Y$J7G3PA/!OQ-O,+<CG<I2D_/RTKW*SF;&*@00P5()/N3Q5%\0
M%U!(!K6]&,B8C%(>%H#86.RKU^\M>+FB[VYU_P"'9S:]]4?P-J"PU%;8P>-&
M;#KJUM,X/.?GH#CJM7W)#\AS>J*6TI3E#;:<NL-[)L)?\*<F/.RG'\7E2'-T
MVAMU[%H3,!PH:%PRVPQ';#: I:E*"BXXHJK55^"_!HPB:8X YSF86&Y.VE8A
MVIY*&7Q.)DW$D88/@\@@L!G+ DZ3M>QXHV8R1\_*!F*BK F_3;44<)-;+VZF
M<;:.F3&ENX9'<D0L=GXY#7OWT!E>)269,J,M"3E>;*F4H0XH!:$E5@56(P'8
MYH1I,1K$9#;$W X&"3$;EA9=1AL9Z-%DI4H9FG AY:EMI)0M83<A(*3O.<>#
MF@.8BIU49.S^-HYD'!L+VXY7BT7CT7<,I3BJ RE>4Q]C%W!!E?= #Z:C\H%<
M%QZ!1C>$>(V(!&Q0>R*I:N&;6RL/0T%Q6ICT3$Y&+P7GG7TJ8G2F$L.J>2A0
M\*:.1#@;6I"MXDDN*0M2#M8CLK%GN.E,EV(S+PV/A$YEEMDI>@QGE/-(9*T'
MP5T9UMEQ 6G=*L&TN)0X)=CFT6,QK$NZ3$;25FU1.Z*8YPEYLDJT:5>Q)7-T
M<2CA(>'LNOOL?H &R-JX]<C?5=VK6M'=:TXZUT7L?>>GX)/4PV',$CX;';0%
M*RR!AKQ>0MPV!075&RP@62/>UNM8&RU"QF"E]PHQE_$7W%E*<S!Q%D,K2V+V
M4&@+I*M5'WU5E"\%O&<?@R 7"6<<@83I)MON$\)SY7'XL2#LG4AP<8 O N8"
MU!#@2^93F4Q\42A4T7$$F*QB-R,KX!%J6NM)U[#FVKTIU#F(X9$Q'<XKB6(Q
M1*6XX8K6)MNI<@-[P.(5&8=6B1'#B%AMUEOQ"W=%<=K8UF(TIO#L1E8=OL+P
M[#I1BH;;$EW#7&E-SW,A0I,E]I"XTE3:T%QEY?C!RRZR6+>#28XD?XF(QG.\
MN\=BV1;@*>(<0R(>1R3&.Y"91Z<S[&[M)-.U84K8: WT#3(4X1+CVI9\@BVM
MHB-JQI-VQ7/1.0]AC%IK.%7(D/YFIF#QW8T68DWLN[;HWD=8+:U-I).JPJ\+
M9%$%<%;.)/\ _A/8KXI88RNP\7D,RI4-5A=!#K7Z.0V0XA*U) T04RKM"V*0
M_:$O?;&95?*V@Z&IX[C#PK$(\,ES6%-3=38T7*):.I5S)G N^U-LT58L8P,5
MMJY?$ SXLXH_2TL?VFD8^!OF PI4@RWDMR'5L*DJ;W;CC+"]&0YJI04MY8T0
MAQ+8R'>P+9N/@6C+V^2A@1&%+8:0^F,EPN(;>?1XSQ1HE)2EE!U4IM3ASCL/
MC/\ '%_Z-7^]2U\Q7TR.)]'\Q7S)^$@_2!;U_P!:7.G^)$BU[(V3^"^SWT+A
MG\&S7D/:KX3;0?3.)?Q;M8/'F]/-.)L)0?"N-GPV&IXZW.*[KXCD0+840R"+
MR.ICT3C?DZCR\JI'G$3Y#$(JKB7,=57?KNGS4D^>!W2@S625L]A\[$9.(RTK
MD&7@XP1^(YD,5<02G)>?+D#H?WCA <#H" E*D)2XD+K'%V@Q"%A\?#XBD1Q%
MQ<XTQ*;SB4B68J(F3-G+18W;8)06B5E2DK4IM114P95X53>MD;,F0<V1G+\F
MP3(<H(0BV: <$R.6P6)%WT#AHF#B"RPJZ1%'%S]42(24<7*OU44W#AQ8R2:-
M*I-4M"%L7L]$@1<.>@,XDU#,GP=W$F6)+[:9,AR2ML+W2 $!;A LD$@ J*E7
M)WYNV>T$N?*Q!F<]AKLP1_"&L->?C,+5&CMQT+*-ZLE10V"25$ DA(2FP%<,
M$[FLBX&W!B=RPFT7-LD#GL\*.UI]4N69'RV18O)XM)"IU0<6$%GI!=&6%"EK
MFTHC>H6HBX=>4H^/;K=;$L'B8GA;F$.9X\1:8R$B+NVU-(BO,O-(:"VW&TI!
M80C+D("+A-C8CE8;B\O#<41BZ,DB6A4E:C)SK2ZN6R\R\MPH6VM2B'UKOG'C
MV*KBX,S8SX03+6+MMY;;>)B.,RXU2.YJAD/R,>$2)?(F.85N,& !&;8Q%5F,
MH'Q)=I.&,;')U?R6)GC *Y8BH#(LKW+>K+0F;+P9F+(Q=;\QM8=P^0_$;<:$
M27(PE;KF'//!3*WPJ,IY?BLOM-NV1O$*RG-O1-IYT/"5X2AB&X@M8A'8EN-N
MF5%CXJAMO$&62EY#!3(2TD9GF'7&B5EM:;IRQ1F'=1D;,F(MON#3%K(/C;;G
M%RX2( ACPZ\J9/20I>2D<WDKHZ6*K.SQ!*P<%'M&56("-1X0P#1P0,:U>4=[
ML#!8F'SL4Q)O,Y+Q9YMQ]U:6D[MMI&1J.R&VT!+225N+*LSKSKBG'7%G+ETI
MV,RY\'#,.<RMQ,*9<;8:0IQ6=QU96[(=+BUE3J_%;2E.5IEI"6V6T)S9LGE/
M=UD3+Q#;>YE@*&+BMLN)L58?BD1JQ-/8;+X[B0N8+!GN08\5//VALH=Y;=C9
M14?R./(B;;&;9@QI56]2D+ HD!&+)8<D!>,3IN(/OYFTOL/3D(0XF*ZAI*FT
M-;M*F<^\6A=U*6K0"\S&Y4U>%*?;CE&$0H4%A@I<5'?:A...-JE-+=4EQ;F\
M4A[+NTK;\4)3J3;^6<+KE*:E!:T@P#@)W'&>/,[X?)0ZKC.= YK$VX$ZUDLJ
M@'E7X:.6(V$ EV+&^$VPPA'%8D-8,(Z#N91IBU#I<)C86%'0L-8GBB752\-G
MH?MAN\;FX6T66)-O8_=O.N-J5X29"'0^M:WG IY2G#W']MYDA:"[AF&*:$3$
MH"V+XCD<A8HZ'GHV;V0WC+;2TI\'\'4R6$I2TV4LI2V-7B7"N9ZAHGFJ%B4(
M#PFN&<485YMQ&39OQX\;AL)2[(,PQT?'3N 9=C>2!YX:XR9* A5-&7U!2&.N
M$6A<,Y(MT"J>9_8K#)#@?<?DN2!/G8AOGV<-E)4YB+$6/*;7&E0'8BFUIALN
M(.X#C3H*D+"%%LXF-M,281N6V(R(_@$+#]RP]B,50;PY^4_$<3)C3FI:'4&8
M\VNS^[=:(2MLJ 6(^?\ ",YF)@'$?>1B N$76#-R& W!![=/S)IQ%]SV7#69
M9T=>FY#/#!@M+A<E.NV4?-FWY-1478FI*$Y*:4=&'.RC9/#T.AU+TH%.)83B
M@0GP5ML/8/!;P^,TEMJ,VVAA;+:5.MMI0 NX9++82V-56U4]3:FU,QE!6&XM
MABEJ\)<<+.,3G9\EU3CLE;BWT/.J2TXXI=T %X/.%2S* OA7<H!\ISC-;+"&
M%$LDY/QJ(Q[DPI:6SY9&LC7AXI2%H'IUC:S-MN-)11<$BQ\HBI:(N(;84'H%
MV0-F]<$5'NHO8F$Y"C8>O$<1,2'+<E0T9,+WL7>/F06X\LX:9C)#A59]$A,@
MH44*<4D)"=U&VLQ$V3B*<.P\2YD1N++7GQ/<RBVQX.'9$08@(;P+83=A;!8"
MTA:6TJ*LW5?K[.OC*^E3P:/Z/G9M^KYCS]T6:\>[9_"O:#Z4E?\ 8:]:[(?!
M; /HR-^Z:N_KYFOHZ:4II2FE*P$LBT>G,6DL)EHIJ>BDP &(M)@;ZV^YD9C\
M@'.1)D4[M3O3ON:D!SMRT7I9?9?5):^EM]MW%=3*P^]&?9DQW%-/QW6WF74&
MRFW6EA;:TGH4A:0H><5B?9:DLO1WT)=9?:<9>;5JEQIU!0XA0TNE:%%)\Q-4
M+@O!SQ>'1E[B\GN1W33[ 5\!F>,!. YGD",.8$*@LWB!>#O(XL2#P4-/#PN.
M1XRNU@[0]+WZ$749BG;>QR\%,'"'U$G:YZ0\B:C!\$BXJ)4>:YBD>*\F4Y)C
M2&Y*7@AR2Y%:6\ZV#)4TPDOA3B24I<6%?-1ME&8[*H2\6QJ5A9BR(3>&2)3"
MHJ(LB.N,IDK;BMRG4--.%,9+LA89RH("E(2H>L'P:^+6!>+R>1Y/S!.YA#Y;
MMK/ I3(WF/VC]M'=J1 J2Q7 5&,6Q_'@JT?4>&B3J6DKQG.L^Z=7*VR >FDV
M00.[835MO,LPL/BQY#&,-.,,IEJ07<<0A$Z5F?ENN![*VA+" O<-!-MRHE1,
M-[)0DK9>>F3Y+[#^$.-//*BI4EK!%N+A1BEF*TV6BIU:GUE&_=4JX=0 D##D
M>"[P\L,+CP.3LR1!>71'/N,L@E0;_'SE_.,3;D,I%<N9!QX2MD./3C$0R;28
MR0;1B0QEF&E@D0[<M7)LBNI8[2RIVUQ +;6["P^0([^%S(B'4RPF-/PB$B#%
MEHW4MI3BE,MH+[3RG&''$I(;0D%)HO8W#RAQ#4O$&#(8Q6'*6VN*5R86+S5S
MI<5>]BN);2EYQ89=92W(;;4I*G5DA0EUIL0PFR@NZ+'#565MXINN""8W-VJ!
M$98]C((#B"/X7"#H63O#J/$$A4:CC0DSNDBDENM/.'SI;QS-U>PUH*VGQ)4G
M!)B@P7\"=6]&44+RONNSW<1<7)0' DE;SRD*#(9_1!*192<];R=FL.3'QF(G
M?AC&VT,R4A:,S+3<!K#FT1EELJ2$,,I6G?%XATJ424G)62RAL^"YIVEO]I>3
M\LY0DX8JUBK4CE&B>.@V2%[89/ <\CM4TP< 'P%"@YQ'1 &SP(151R#:^$_5
M>'%W)I>D+:!W#L>3CT*#"9<0I]2(1,MR&/"8SD5ZY<E+E'.'7'3_ .38.J\0
M):"6Q>9@3>(8(K!)LZ:\VM+*5S;1&YA\'DMR6K!N*F*,A:;:_P#^:ZFT^.5.
ME3AB(UP96')\*S!^&S)6;L[SG,V/P.+C64,D2&%\[(G!HO,1N0P,>@ F(0&*
MP"/#6<]"AI>Z:.8860-FAJ5QU,DP7>,'&\WMEB$5S#_8Z'AN&1<.E.S6X4-J
M1N'Y+\=<1UZ4Y(E/RG5JBN.1TJ3(;+3:SNLBPE8T'-C\/E(G^R,O$<3D8A%:
MA.3)CT??L1F9");;45$>*Q%:0F4VW(4DQEAQQ WH6DJ2K@E^##Q"<C^.(^YF
MA\+9CO*U^7VY. 8KVPXN,OY36F/[++V)C'.!HR6ABE[?'0I@2,0=]'I'(190
MN*DADN/9Q!M%+M[9SVW9CJ8[3GA<$8>42IV-36T,?^4;*1+Q1Y$@7EK4AN2E
MUEI:&ULMMJ4^7X<V/@.-1&C(=;\$G>'I7%A8-#<4_P#^+JER+AC+D<VB(2MR
M,IIYUM;C;SCB$QPQGD^#G@"4!D6&K<O9C4P45R8+RO'L.N?P6.XS!Y*RS8(S
MT^; CCC&*D\(@2LS&.V:HB4RP^W;1^0G&;>MK]0:4&8CM=*,IG$/8_#QB:(2
MX#V(#PY+TEE6'.88DNM":(J'41UI4'&&&BIUIM2KI"T+R#92*(KV'^'8@<-7
M,1.:@'P)3,9Y.(MXHI+3IAF4MI<A"DEMY]T!IUU(.8H6WJF[#8R<R;D!CEK$
MDLD(+(,SW ;-Y;/"2CZ(4:PB$;9C4]=)2>!CI#%3(]]*D&\^?OE!4H;R006=
ML1R%HM%M:\0>9\#VE:AQ509\=IV+'PK:!B*@)D9I,G&6XH+,I;+[:T,$Q4)#
MC*F7&TJ62LDI*<.-;..3)29T%]YJ5(Q/ 7Y2\S%H\;!W)2@[&0ZPXE3UI2U%
M#P>;64I 0 %!6U1O@YL>PTOCN417+F9 LUB2V:KIO+[%L:$">9VNX6<"<B99
M8SUB6QN_!"T9#)PK*K5QCL5""(035P/%/FRUZ#YO@>VNER&Y;#\##W(T@8=X
M-'(F)1AZL)BKAP5Q5-RT.++3+BLPEKDH<<"5K20"DYF=E(L=R(^S.Q!N2PK$
M3)D9H:EX@,5DHESTRDN0UM(#S[:"%1&XRVT70VI)*5)U5IP5N#A\;%P=AD#+
M[.!O,?;?,;93B29.#J,<T@-L!BXYB969$G$$6/ B+)W=<TD#C')6%)'Q/$Q6
M;MU*5=5SJVWQ);SDE42 J4F5BLR$^42@K#G<9;#4[P="90:=2I(S,B6B26G/
M&!(\6L*=B\-0RB,B3/3&5$PJ'-8"XQ3B#6#.%V"9"S%+K:TJ)2Z8BXP=;\0@
M>^J:L>['L8XWGF-<@AI-/'A?%TYW23X&T)OH^J.?%=V4C:R:?-2R;6.-'*H\
M"]:)HQ!-FZ9.6C6Z^TTZ.*UM6MYLO:2;,BS(CC,5+<V-@D5Q2$NA:48$RIF*
MI!4\I(6ZE1,@J2H*58MI:&AZ$79V'$DQ)3;LI2X<G&93:5K:*%.8X\'Y25A+
M*24-* $<)4E24_\ L4Z=:N=KYZN_32E-*4TI32E<UQ_%&'_(X_:+]*5PM*4T
MI32E4>W+[H,CX_RYB+;5M_QI&,DYWS"!F,U;+9$F+Z"8R@&/X+<.;&)5+"X>
M/RB1EEGI0HS$"(_&@KE\JK5R]>.&B#9!)]])@V"PY4"?C&*S'H>&8>['C*$2
M.F5,E2I6<MLL-N.LLMA*&U+<=><2D"R4A2B<OSN+XS+BSH&$87#9F8E/:D2
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MF@^#I)'C9DX,<8U0-10A<NP24/EQ:H;(E\_$+@'JP-5E<.NJA78]N&*>&'$
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M(:=W\/P/!FG5MA:3_P"/AT-B2A(4E*LR%MN(O:Q4FZ218GMO;9FQEC3??O\
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MP"T72H FUP2#T::U9_D GYFSKDNUKB5V<AYCM[J<@$_,V=<EVM*9#S';W4Y
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MJON"CLA-9MB,J@KXYN(DF;("[DSE'!Z>+)DBS'LW!*/8U:#W"U\8(MY"_P#
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MQA,C)W9'FTT?S6<M]OF>1)['I]KG]CBG;9A]K.7[R70C,>*7^*Y9=+X[+,1
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M *5E_P#8:]:;'_!? OHV-^X*C[>K@N>YSGNW@/$ , )"&B&=Q<O,Y4QXXR=
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MR5EZM+:6W*5<(74MIQ75]_P;;J__ -4KK"\I*@+$&QJZ 03<$:<O.*^?5O\
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M'P TPQ7N-ETQ!PPXBBR>'X-MPETQ;LAQ0X ,,G"(F3#+7($D;BQ-!)=!J_>
MW7@J,KY62D7Y)6=#I<))'$:B_,?556TA1(Z"4 $C6Q6!T'D=;'ZZU*:;]IS
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M8%(3AX,(:G78F9.#,0&1  N(0C)@@M'0KC I7B$E9"BMQ*25E.N=03<@ZA(
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MV*-7K6]5LX3O15OLKG=;#K3C14M <0MLJ;66W$A:2DJ;<392%@&Z5I(4E5E
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MGD4>/'L:2E_)'N(P(.2QN-LA($HRQAL@) R@!+8(OHI20K->Z5 @DI(N"3E
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M\*GXK>YKX.F=OHBR!]WM/9G!_E7#?MT7\6GL-C'R5B7V&5^%7]SVT6$S,3M
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M '?3.CRD^L.^ECR/4:<V)+ZO'/DE_P!WTSH\I/K#OI8\CU&G-B2^KQSY)?\
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M '?3.CRD^L.^ECR/4:<V)+ZO'/DE_P!WTSH\I/K#OI8\CU&G-B2^KQSY)?\
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M2R"LA0 U2+9C;37@;C06XFY&E$H!23P)N4:Z^+Q %[JOJ!8$W'GJX^>]S8_
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M)/)<5#F+5;;O.<XE99'0[?'\U?47(,( 9<CHT9;B+T%E&(%\Z'V/GA^.Y,Q
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MR%'V4;!EG4C=)K-P:K A*EY5$6%@G-QL>)'HMSY5"4W U-RJP%KCG>][\+Z
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#J__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g383050g14s30.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383050g14s30.jpg
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M 0$! 0$! ?_  !$( 2 "70,!$0 "$0$#$0'_Q  ?  $  00# 0$!
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M<A$[BJQK[U\G:0\GG(W0=TJWK9:XJS6W2."U*[B)(^7#1(TTXC$C3MQVR$-
MD X 491%U5I'<C-@*[YDC!5M>8!-I-/O"3'BNU'E2DX8">!(1H=VJJW5$_<6
M53(H '%(P(U,,9=\T?=(@K5/%*I8D,<WB!8T\6#\R3M,DA!\F<QQ,I/8X6V$
M!::GA299.WDHH*]I+$*_QB?K:>?N"LZGCN'/;MATL#2LQ**KID%@LT?$#*,9
M5Y&/8XRZA1*HW(S]9Z94H*)';J?$B)B98W($Q,7MMW):A7!DC]:LB+QHYI(G
MC^+R B$>*60N0&Y6,J)".%)"KY":3M5_"C+]C(&5N%;@DGXO#=H\O-@Q \^
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M.ESJ^.+7)"\QJ%8D%4<A^UBI>,^\=H<, A<$D<\'CJ8D-K.U#(1/(SHH8-)
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M6R/32N9-94D+R.SK*SO*%61I#/*96=5EF56,G?R!*_!Y!X/*CBT"+$H( X*
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M4\_M(=M<D)%%PHVLB+9THURR-.[3/,0.9G62U&!Q';>.9IHFE4>:>%XD\2+
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M2+IBKY^<552.CSUU:4\4I#'9-#1QFXMTA)M1WKL7@>%;LQ^JK,M;LGD7U=;
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MV]9M3O)W#P?5Q)%8ED#RABY>?PRI:7-9;73+% B:MH4[)TL*E,PI.O@5XE0
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M153,)%2'+U =,Y#"5-0A@YE$2D. ^@HAT=%;V716X/FKJ#P001Y$>\, ?UB
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M3VE=(^'4-,L8)8@*=$4\ZMU+J+:R$!_&1%HE'$2R8JO7#9FQ8O9)W&>=VSD
M0,5JW>BBLX*1F;PJ+E YU! Y290?1+3N7^L*4=Z<UX9J5K915O"[HKSTF]9M
MP4PLZBNZO&&[&YCE7D=X9T8>P=9C8ZO7;.G!<-^"^(0L5N-)9JUF>!ZBK5LH
MI=8(Q-&/#DAD\..(=OFS\W5+QLP_D(!S7499]9W$O#/(%XDLNX)#GK[*/DU)
M0CU(#)^-3EEF23)$QRK'=K H0""@J5.R[E9*N]7P_$DMV+DDB\ENR*$2EU<(
MK$)W#M51SR6) ^*3E"Z?MQ;A[%F2M*4\"OK/"G>8TJ>N@T\(W4A/L5GD>0R0
M.Q3O8@]ZHZ$+]Y; RIV+(ZPB*QVC8RHC[8JF1(*@C_E$XB(_Y<]F'N'/O^7/
MAJ0*)'"_%#L%_:@GC_)GKQG3&,8QC&,8QC&,8QC&,8QC&,94V/N9_H_[(9M0
M?$/[8_R#&09+?)63_E![_M*N6*'\RB_<T_FC(.;\UE_='_G'*?F3,>,8QC&,
M8QC&,8QC&,8QC&,8QC&,8QC&,8QC&9(97\L&,8QC&,8S#.?X#.'RPOMJJ+H[
M/C*[NIMLLNQ]<5[=.U(#5%@E]P5>:J&QK2KK&+MC:EI66SQ-@E73V02ABI%L
MK@MR1:IV]NWG$I^+J7:1+2X--YM>U,U+<NOI2WHHZ$T<]2 7'@-@PPO$BJAD
MY\%?5RWJY,1AI-#KY&M\BTL=T6?6:T=VU'4D>W&\5F4U4E$(EE21BS!./$/C
M "8"06S9?)M<*EL)=T)RK6MVRV ^G7T[&GV#;E(YJ>T;)G=OV E;9KRBR55-
M);*L]AN)'U>".EHJ;DP>P<C%K1D(:,SP]7;N UFCF@5JJQK$XJP!V\&I%0B,
MS! 9^RG#%7[9>^-XT[9$</)WXI>F]5-XXDBE86&=I%]8F[09+,ER3PP6(B+6
M99)NZ/M=7?E&7MC[+A/P!<,ZEKA+FM59QS-UJ\;%OE>%_;[!*,(.2VS?&>T=
M@QL1&RCUZSC(2P;&9$N0-&"3=U#S#F1" >Q3&3?LG&(=4;@02UQ-$L<U>I6E
M[:\*-(M&LU*J\CHJL\D51C7+.662,+XJNR*PR'0:PS).8I#)'/9L1EII&5'M
MSBU85%8L%22R/'X #(Y;PV5&9378W@CX=XEOIEJPJ<F@AH.N4:JZS(%GGQ"(
MAM=7* OU61>B+X1F%VMGK42_=NY/Q+B1*DLW>J+(.5R'Q/U%M9#L&>="=G+9
MGN?68OKDENO)5G*^S];#0RNJJG"IR"H! (R+I-<HIA86 H1P15OKLGL)6FCL
M1!O:]LB6)&);DMYAB03D.Z2\GY%Z"XCD-PT#83-EKF*U[#:UKVIW6O(R3F8J
MMU^@4VD138=J3$Y)V S@BU0;S$I*L(J+FK&V+!5J?D9"%JL2F._L>J'V>I-"
MU59K;VGMRWEM.D<DLMJQ9<FE'$D7;Q.8XXV=XX6\2:)5DGD.:=+I]*&R%RO8
M5:R5TK1U#75G2..O# @]:>1Y.?K(=W5%>0".*1F2)1FQ;*IEBQC&:P.)#@(N
M6Y.+FG\5M0V/7JC/T"J:<K539R=>1E5F;FF3O$0M:YU5Z6."92<M8_=,#-52
M(B[#&UZQ3M07@]C1<U6I%OX&X:GJ:"AHY]+/4EGBM37Y9V24H&%B/5>!&$+^
M&07U\L<[O&\L4<XEJ/',A[JCM>FY[V[@W,%J*"2M#0AA5X@Y4UY-H9Y"W9WA
M@M^*2!$E2*62 QVDDA<!;<2X.^,=_'T*(LO$D6Q1D*G7CW%G<[E8[['2K^O;
M%I=U-(0D6>A5'O24J:O2R[>3OLA>%*<A(M*S56S5-DWL[;*=]H5>U)%J?">3
MQA :\$59D66K8KA9']9GX1/%0%*R5O'*--,Q+&%L0T>\9:R2[7Q4C\,SK//+
M91VBM06.Z-/5X>6?PG(:RUDP!EBA"A1*M-2X.>-IO%SBH\2WG6U3>OF5"93<
MMN#>J#JL QVU8+6ZM:2U>\QPL[>K!2)]K%N+ WJ%2@H"4J4-#1]*D*?(R#!#
MN=]T\S1CX(\.&.T]IHXZ&M*S=]**$0$2B22*M%8B9Q$9YY)4GDD:PDZ(YZ?
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MBT/B.5/!Y4KVD@$GD#G;6?I1R17Z3%F3CDQV]9K[$07D<N([CUH@X/ #"0N
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MK",_//'U)NJ_[F?QQ_Q?'U5^E?FV?\33\8Q^F1/)S_.]^_:PC/SSQ]2;JO\
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M]C$RO)G'ES@ZRYE(;9,@B8P)G<4"/5./-N00W==8]5NUYR2$60"3CWF)P4E
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M.1QR.1Y<^[GYN?DY]^?U1VU1(NHLY;I)M0 SDZBR9"-RB4#@9<QC "("00,
MJ"4!*(&]H>> "2  23[@ 23\GE\_GY>6"0.>2!Q[^2/+]GYOX<["+)*"!2*I
MG,*9%0 ARF$4E.?;4  $1[9^DW0?XTW2/2(\AQP1[P1YD?PCWC]D?+CD'W$'
MR!_@/N/[!^3.M!VU<B8&SENX$G+K!!9-42=7/IZNV8W3SY#RY\N?(>7M#@@C
MW@C]D$?RX!!]Q!_8(/\ )GHSC.<8QC&,R0ROY8,8QD;[5_:Q%_3(TW]]ZC8Q
MDD8QC&,@'1<<67T!7(DZID"2D)98XRQ2@<R)7LQ.-C*E((E YDP5$X%$Q0,(
M<A$ 'GD]O)##OK$H'<8IJT@4G@$I# W!/R<\<<YKUQS70?.K#[9;/[ T):U:
MHGJ-+6)['OC6RU)HVFJ(F@I".E(.^O9*%F8E%V[FC,W3!_',712JNW0'51,)
M3I@<H)\3WEJ[6"[%722,5:I-6TWCQR13T(XIH9F1(>])(Y)$)")P&'D>//JL
M1>!XF<J>]QWQ^RP*R<JR\EN"" ?>?,9@+L_7,I$UZ)K-OVQMA78#ES<W\D6Z
M;SGJQ0NQ79=:*AY:HH[#D*Q%3R4B28KAW(1UJ<N:XREE3*I2:XI,G-\UFPBE
ML2VJFJU0H*M..,TM)!9O=UB(2S16SKX[,M<Q^#8"^)55;#Q  Q*#(L3/5/:$
M>S;,I,A*R6Y%BX0D*T8E*!P>Y.>UR4#'WGRS&6MQC%ON?A?<HVB3D7)N(.B=
M<4]VVUN@HBI&V$5"JQ+,SAHLJV-ZAG;1VY;I' 3H+K)&*H:S697;3]3*:L<:
M_ %[B5-4]/NXDK\$2OPX##S[&16/N95((S26!8[-!A)*3ZY%[+V/%'FDG/*@
M<$CYP2!\G/OSZ$<\ RVY;-RZ_8S*]LJAC]I'I*DH=)0?U4ASZ5$R'.40#F/,
MI1$0 0] "(A1_22"W1&_ %XDUZ_ UKS1W?LZK]CO79)E;]-V,#X?>#[)(S;H
M?9</YG\8_FO!C^(WQ^X$<?LCWYCMS??.)'^L7_Y+GQKX,GZ3K[^.;K\;RT\C
M])J_N8?]S/$:)D#&,;Q4F7J$3=(+&$"\QY](":-$P@'M<Q$1'EZ1$<J,W2NP
MEEEE%K=J))'D"R/<,@#L6 D+:F5BXYX<M)(Q;DEW/M&26Y7"J##5)  ) /!(
M'R=MI5X_84#Y@!Y9U'C&B8\I"0E2N.7/D59( Z.8@7GW%&)N?,!_Z$0Y<O7,
M/,"ZDO3VI@81[C>]1U+? (B@@HRIX))[&[[TVMGY+!P1ZMV#@=LCGN"Y%MRD
M<UZE-X^?>R.Q[OE /;8\O=Y>)[^?9'O/ 8]L/R/>KJ*_WX2#D"I@G^^06X2)
MA/U=(<C)IEZ1'U^?(HXCI-2!SJNH=G+-S]=&W2M7A$7GYQ-K7VDK2]W;[,D,
M<?9W'Q>X!&[>LN3_ %U6BB3]":T)9RWEY,'-4=O')Y#L>>/9\^1;-R:R#:J6
M%P5ZU;F1B7J@+HO7@*I"5$P]Q,2Q29NLOMEZ5"&Y^T8!ST?T/ZF6/TH]!.^T
MJ6D7J?5%JZRW)&F LIS&$EU4,;%O=P\L:GY7 \\J'I L0#HGJDPM/#*-)?*2
M^ (_#;P&X?Q$N2.G;[^Y4<CWA3F'/GB7_C8^^OY?\5GZZ>K0_P!CT_BT'^_G
MP)Z[>_LW-_&[G]'G:%WDD !$9=XJ*0=L5//$@7N"3U>OI,L40ZN75R$I1#GZ
M0 ?1G4ZE7]L54 ;V@/5AY ^8'D"/=\Q(^;RSL.H+47UOX0D;L]DL;]@=Q7R)
MX,JD<GSX*@CW$9<T+/S$HW562=6-<$UA2$T=//R) ($(?I.'FV2YJ<C<^?>3
M]42_$_[XVG9K0U'6-X*0++WCQZK=W!)'EQ<JCM\OTC'GGVOD$G2V5V[&TB6M
MHX5RA-38RB/GM5N&[J5[V_:Y/$B>R5]C]$UQLK2ZKRIGTJE,.6QTQ;%3GUE9
MYD"RABJ%,1F\8PZ1' $24 C@'1SD3%5,$#@J8Z>E-42Z@A@6O$X82%J2R5I2
MJ@@@R"W<Y3E@63PAR0I[QV\-*5=O+K)#8N>O68F0Q"/9R#85P[$,&6"2IKU6
M4!&"R>.2J%U$;=Y9+OK.U8I[9*^S)'Q)#NYN*;$.2MLDCE,N_;I%,14LL<R9
MBB<!*H4AQ(( 8"F$.0QEW16(Z=N0R6R(ZT[D-:D*D+$[$,#  1Y>8) (\B1E
M@U'6%&?:ZR!:=%6FV%*)6760(RF2S$@97%YBC GD,%)4^8!XXS9GGF6?2N81
M\7G[IOD^?Y[B?_"+Q;98M%]A]4_O=/\ MW1Y7MY]E],?OA'^P]WF;F5W+#GY
M5O&+_==<4_\ ..WA]\VSY]I:#\XM+_@G7?ZG#GQKO_S]W7^%MC_KDV8XY+9$
MXQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC/UJM:?N<:__P"Q-4_W$PSX
M?M_9=K^^)O\ 2-GVQ4^Q*O\ >\/^C7+VS7S8S@I[FI] ;[D<ZO\ $;]JW\AQ
ME"S1QC&,8QFF7REW$':T;K3^&^JE4&G/HF/M^[4&YSH+6^N2$HX;,-:+/B"F
MLR@Y5C%OWEM1;'*>:CI"*B57)(M6:82/I/0W3T-V&SM+ #.C/7H!E#+',J O
M:[3RKO&718>X$(X=^"PC9:IU#M'K20TXB0&"RV."06C+$+"&'M /VL7 \V!4
M<]O<#9U>XR7E?@&=3@*LR@ZVFDFR+ 1D0PBX1DR*F)00)#L&P,>R  5(J)4B
MI<N8<N7(0M)Z/$DGB32EY2>?&9V=N?+N;N8ER??Y\GR\_/Y(^/>HB",((T[?
M)5C4(%^4!1[)_7X]_'F,M+A@XF[%0>*V-J;"*2@-&;NG6M>=4MJW(WAJWL26
M(9M#7*L1C<I6D M9YT6<39HR-*UC909(9]ZW5EVI%5(WJCIF)M,]P'Q+^O1I
M3/Y]T]-&]N*9C[4AACYDBD8EU5?"Y[67,FJW)^$17X"U;+!%C  6.<_%=%'D
MHD;V74< D]_'<&&;^/\ [^7^'_[_ *,\?R[X]/\ ]A__ +C&,8QC&,8QC&,8
MQC&,8RIL?<S_ $?]D,VH/B']L?Y!C(,EODK)_P H/?\ :5<L4/YE%^YI_-&0
M<WYK+^Z/_..4_,F8\8QFF_?G"3O>>XBMB[&KNF=([L?W[8^E+)K7<.WG<)/.
M] T"DQE=BKEKN+J-F8GDZIU2T;-WZN6W5+M:5DYZ<$EB8%71%T:\Z[=Z^+55
M:DE_8:]:U7816Z-(21KLK-AY7KVGFA8)-PCQUI8;B]B1Q$Q-PW&4G8Z;82;.
MS:BHT+YL6:$U6[=:.1M=7KK$D]9(95[X>71[,4U1BS2OQ*O([C/;CAQV;(V+
M>\?(Q#)6E[>XTZONMP=M:4HIZOKW7W#EJ].K.2O&15Y*(E5]_:DJ\:)&S=62
MC8KN6)-%1%!,BL;\*5%BUS([">EH)=>.Z'O46;.TN&8=K<*Z#6WIF\R%=_K1
M(Y)$A\&6VFV"LBF"[O(KY(E",:U;65?!(9?;1SL:<*^0+(G,O!  ,:\%'"=N
MS2>FN(_4RL=7-.L;7 -JSHNW-&6ME]P1+WV#SD&>T;/M6H8*KU[8;RL3K^+=
MU&XR\:UV'-MVTDO;Q3<G8%)M[_<Z_87]7=[I;S0R&78P,]L49%]8CD$-2&])
M-+56:)76>"-C50E! ..[G6T6GOT*6TI]D5)98Q%KY@M4W4;P)$,UN:E'%'9:
M*1D:&>1!:D 8S\'M&8ZV+@;V7-<*%ATQ7>"W3^LMI$CM#Q]QV96MAZ[LLGOQ
M_KK=&N;E<I.44M%/ ;(A88RMV*TE=[J,_>&E7B%<D(288R$BODG%U#5CW45^
M7>WKE/NV304Y:UJ%-<MK7VZ]=(Q#/Q"8GFBA*T.Q>Q3*CHRJN1DF@M2:>6C'
MHJ52WV:])K45FM*VQ:M?JSSL_BP?71(D4LP:_P!S=[")HW5W.3_I+26]]&;G
MU[?*]P]H.:;^AM)I>:@HRR\/NOG=.G3<0NP-B/)=6LZPA*5K==BX@K$SE3$I
M%;8*.W3Q7SD1S8#RCMQ&[#8:_8T;->79$6#M3?21XME96>/X,JU5036Y+%L,
M)(F3FQ*W:JCLXB[%$C0H;"A>K6(M:#!\%^HO&LNMK&&0[*S:9_"J1P52ICE#
M\01*69CW]TA=C./!+1-Z:MTDEH78NNC4!>K);/<0FS6%SJ-KCY5]<ME6ZT0Z
MC&O1KD\JS7CXZS-W:@2R:38[B/5;&-\63YZ&_LZ^YL#LJMGU@3&FKU&@FA=5
M@J0PR=TK#L(9X2H["3PX;CR.;^AK["I0&NM5O5C%ZVT=I9X9E=I[<TR=L2DN
MI5903WCCE2/E&8]\./ ^S:T&9TOQ <(.JVDQ+ZKL=!VOQ306PHJQ7G>\T_FX
M23-;579ZZVV4:8LD[%-MAA)W.8:/*!:8B+2K)7@)-W+*2VO4#-92_K-W=:-+
ML5FEIY*SQ5]=&L<J" *)34$<43FKV5T9;,,CF;M\PT=J]"HK24=CI::N]26M
M<V\=E);&PD:2-_&+&+UKODD06>^>16K3(@A# *5L6.X$]L0>E.%AQ=-:5KB+
MMU>M]WV?QBZ9V)?V"Z&^]I7RMIPL5?)BS3[25IMTDM5+M&S:KUFW($K/L>5*
M@P<,Y&(CU5=E^HJ4E_<"O;FU<$L%>IH[]6LX;6U*TID>M'%$R3UTN=Q:::$F
M;Q02P99' UDZ?N1T-09ZD6SFBFGM[NC9L(WPC;L1>''8>64/!8:F55889^(O
M"X"E6C0Y/FI=6;GU%Q&H[ K'"]7*IJ^Y\/NFM2K4ZC[/I*<3IUW3MK;DLDPB
MBT=,X#SS&,8#8$1)%95B*(S1> _A(<SQ!HV=+QEV[1NZKU67;2S6X-G?O>/8
MJ3]]Y9Z="*,E@TO8[2U9%+3/W%>V1^TLRB1IT[U/:"S%J8H:D^MHTS!!;@"4
MFAN797 4K'WHL=A&[8D[0>Z-.X*":'Y+?A8V+PM4"9J^S=:QE0M#JOU1A)6*
M,9Z!,A8WL._M"RQ4[!JVGP.QK(FBG+H* [V[8;8^;F'HA7+/O28.LG5^XK;B
MTDM2T\\*RSLD;MLN8ED6$#F*Y/+5AY*$=M**!2/S0-PG;TZ2U%G45GAM54@F
M,<*O*BZ[B5D:8GB2I!'9E [P>Z[),P_0%>7YVKY3\MV,8QC&9(97\L&,8R-]
MJ_M8B_ID:;^^]1L8R2,8QC&11I"+2@]9P,(BX<NT8=[:(M)V]%N+QTE'VV=:
M)N'8M&[1H+E8J(*+BV:-6XJF/V6Z*?2F65W4IGV4\S*J-,E64JG=V*9*D#E4
M[V=NT$\+W.S< <LQY)Q0+VQ*H)/:64$\<GAV')X '/S\ #];(-D>)>OZQ-<H
MIS1-BV<8._7%F_D*W$Q Q0RCV4E[&G#,W\U.PZ#V6)#*M'/@$#"NZ<2,;&1Q
M7TJ]08FFX^F[&S]4E6]KJPGH4WC2S-,)?"2**L9GCA@F9(O&5U\0^RBQR2RF
M.)"^:QM)%X@,<K]LC@E%4CDDL%!9UY;C@\#WDA1RQ R ]M<3=-V HS:2'#MQ
M@Q5LJZ,B:%GZWIII8G$$:Q1XMET7S%=S8*](-G9$6;\8V69*+)N&$;)L%&#U
MNS?)SNIZ;N4 [Q]0](RU+1C\:"SN'KK.*\G<#'(J5[$;*2\?B1. 5DDBD$B,
MZ'6GN12$*:U\2("59*O>5[QQY^;H0> 2I'/D#Y'@Y 3C8L/9=I<,D2STWNZE
M.1XB]?+#8+[J79U-@0!!A8^MNI,VG:UNATW;KG^IFPPIEUS%.5!PW$HB:>77
MS5M9U+*^XTEQ?R/;!17H;76W+'M25^&$-754YBB<>TWC!5\BRMSY:4DRO/14
M068SZ["0TM:>)?)9/(N\SKR1[AV^9]Q&;PL\4RR9:UU(=2KRQ"+IM3&11 %U
MC 5-,?%H#S,)BG  $/5#F4>8B ?Y<HOI+UEW<=#]0:W76H:5VW6KI7M6&[88
M66]5D9G8PS\ HC*/K+^TP\OE&W1GBJVX9YU+11LQ=1[R"C* /:3Y2/T0_P#E
MF-_@GG\8HS_OD?R3/C'ZE/7W]MNC_C"_\$RS_DBU'ZFD^Z/XUEK*HCW5.J3
MP]P_,Q12$IAZAYB4?&DY@(^D!Z"<P]/27V@\FM](;V*U9BD;<2R1V)HY)8*R
M-#(Z2,K20MXT?=$[ M&WAQ\H0>Q?BBQQ;?6F.,AJ2@HA"M/$&4=H\F!B8AA[
MB"S$'GDGWYVHQ39P3N+2C,IN8EY+N2I'Y!RY#T%%R %YB/(>X B//U0]L=FK
MZ.]K?B\=Y;,9#&/MN1O'-[/!![8ZUI2A[O9/B\\\@JO'GT??TXF*H]7M/!]B
M6(CDCCW_ %OS\OD7C]?GGCN"'13'J;RS7J'T&\,L+@_3[?K%(T5$I>8!ZW2
M<^0<^8@ [L?H\V% EWVL-(2#L$DU+:7E<CVNP1T=':D0^7=WNBIP"O=W$ X7
MWM>8!4ABLD'DJLT"]H\QW$M9A'R\<=Q/G[O+D6Q=VAFM0LKA63%1)&&?J*$.
MF<I3$(W.)BF,HP3(4!#VQ,<I0]L1#/4?0STK<A]*WH^E&_J6RG56H85HM'U%
M#).1:3B-)9^G*T,;,?(-)8A4'WR+[\I'I%VT Z$ZM,E%(4&AV)>4V:I$:^KO
MRY!O2 A1YGV&_8.80>?(KYZV_P"^9_@S]B_@K9?J6?\ Q5G/SL^&-3^J:_\
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MD(S!XW"MQX1APAVMJT5.,B\T261P:X13@R8B)2KK0:97I>[T\C*I)212&/U
M04RB %NR>D"X$XDUU%Y>/S0>,BDCW%HUE(Y^<*R@GW!?("O-TM3+<K:MK'SY
MI]:8\'GD!RO\X'W_ "Y!$1P^[2X9^(R)V;ON[FV):7[-POJ^T13,L%0ZPT5
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M^^$?[#W>9N97<L.?E6\8O]UUQ3_SCMX??-L^?:6@_.+2_P""==_J<.?&N_\
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MN<:__P"Q-4_W$PSXDM_9=K^^)O\ 2-GVG4^Q*O\ >\/^C7+VS7S8S@I[FI]
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M!_$C%RO902\*5Y15?L+>UQR,B&[[0LK>H61>F6-@[M:,.^4KS4-2WED*\J1
MQF:0.S0*Y6XG5 H J9)0">V)!ST7T*[C?[?TM>CO5[\ZJ32WNK-/6V:#J!;!
M>G+:19E$!WDXE)7D=AAE[O=V-[LJGI>T^EU7HOZ]V5'2[6&Y2Z7V]FK,]_1%
M(YXJDCQ.PCHUW*JX!/;/"W'ND3WC"7X.G'9_!FWV+W'\R,_9WZGWHH_4&O\
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M!'<.QC'JL'$=\DL;J#L]FV2S$V%XE)8\OYG.?A/9$NQV%TM)4&O<^M3\O1
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M X'<G(\^<^@/)?/:,8QC&,8QC&,J;'W,_P!'_9#-J#XA_;'^08R#);Y*R?\
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MO_Q'/<%QB$0!$M344*D )%46A+$JL<J8=('55*R*514P!U**%*4IS")@  $
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M,>QZ ]XX?^K&7XC'C2_2R?=M^''AQ_1I]ROX,JX !0 I0 "@         <@
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MO-7SCY)?)#_K?[&_ZEC&!3G?3R=1/R0ZPYL'GR*]/Q ?UR],A[7ZK#DV]O\
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M_P#;^4XW M:!,88)60"$$PC#@ZX;A5<A%"/./!PJ66*55<&G9[R@%*!U.HP
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M!K0*5=(+GQ(5A3Q\[>-_S[ .B L_Q(8_8VFJ/6S*J<^2:QYTCU+D86K5P(G
MK&?J"8QD1;YKTG:]27.OPUG"FR<DR8I-+,+2/?A%'2F(YP=46DJ4T>MWDD5&
MO2Y 2E[_ %DY*%((26HV4.HV-78V*<5^&JSM)4GN2T(I@\3Q!7N05K<L 5G#
MADK2EBH0@!BRUSJ[7OM.G-I0CM+2>S#&JVGA%A82MB&3N,+6:8DY"%>#9BX+
M<\GCM;5G^AJVO_C7I?87K7\5E^^JAHO[2M/_ .-]S_[7SY_^IQ>_MNJ?>&#_
M -TYZRZ8WBB4$26ZLR!$@!(K]2!9$4?%3#H*\.1NL5N0[D !8Q4 !$ICB"0
M0"AF8=2^C.8"6;H6Z991XDICI068S(_M.8[$E2.2="Q/;,Z(\J\.R*S$"%?H
MSTDH[K!U!KF@5F6$F9XR8@2(R8Q-($Y0*>P22!?BAWX[C2WG#OOB66\62^Q3
M O05/L,]9ZCG$>9.?,_C;CK"YS'6;JY&1\\ T3Y *#1 QE#JZ-GT@>C/6R"L
MO3G6E$%1)X.JM]>ZZJ>XD=YK]+;77:OQ6[>'D]7-E@JB:1@L868H]#==2P=U
MR/I':S!V7UK8TNG;M@(."L7C;;3["UX:<DJ@G\)2S%(U)8M<-1X;]J,WKH]I
ML;NTLSM>ENSB*GKZBKMW/=3'Q*LAK;5=6E'B7:!1+P;]XXC^M0J_AA<IHJIP
MNS](&EV$,<?1;;/2WDD[[<_6S=8;BA+4[67P:D'6>RV=&*WXQC?Q:L4=OP5D
M3Q/!:13/:SH38)+(>HM+KY*IC^L#I Z_2W1/W#SM3],:_4VY:OA]_P!9L32U
M_%\-_"\54=;_ #:,FHTHR PMA5!F N!2?6>R),U 2];H<J! J"1(W+D<P)G$
M 'T%$?1GG'7?6O5='HWJ6Y+U'TG)'6T]V9TH:.E'=98XF8K5>EZK;28@>PU:
MS!,#YI(K<'+YTET5TXG4VC:;2]3UXEV54R3WMQM]E4B42#F2S0V=R37VXE'F
M\%R-Z\@]F12O(SS^Q65_B=%_9U:?S0SX<^K;M_[*[#^)]4?^Z,^KOR*=#?34
MO_"G1G]%GD/#WQ,QDVU5; W((E0 LG'N2@D7T)@5P\K9':Y0*  "KDI7"@<C
M+ "@F#+95_JC]77K006=#US;LPPQQSVJW4E"I7L3(H62>"K<Z>V%NO%*X+QP
MV;UR>)6"2VIW#2-Q^164>5'TGZK7TO\ X6@WH_$C4Z__ $58R5.KJE5S G$9
M>O5K0-V]T4$2%47QKTY_*&!:RZ\0DG:9>T@L,I7DNAL B<$^E:E/C#R5,H;J
M!0@#U '1S 3&J_47]4)ZY:@DUFLWM*%:X22/<[MKD[2B21B\4FMKZ6%8>QE7
ML>O+)WJ[&8J51)?7Z,UH72UZ28[LC2%UDI=)0:^-$*H C16=OMG=^5)[UGC7
MM*J(@5+O2I#6,:\0*D33Z+TP*E/VBV^%AA* %.'<\4PI+%8X!U=/8,L*9^KK
M,F8R9#%KS>GK<@?6)MA0?Y9JENW-(5^6,I9MRQA&/:Q8*&!50& )!EJ^JTAD
M(VO60N5NTE8K73:3QB;D=KA*%RI-WA>]0QE,8#,&0L5*^JGZH9LK=5GA=+$C
MS-+'".BOPV:5X+$4)-JJ#SPGF-/Q7AA)WO#]Q/O]':ZR=74$QTUZ;^H-CU'T
M_KY=WO9(KV[U5.2.4Q^'(EJ_7@=).'Y[&5RK_P#9)SKM=7T0FKV3UM[0DL)0
MN-!&O2FSA9YEKR&)%F?=2)$S.%42M'(L9/>R, 5.WS/T!SYRR -T_MUX8_I\
MNOO%[LRG]4?GGT+^^Y__ "IU1GH_0GYQ^E?_ +NH_P#U!Z"R?\N&><8QC&,8
MQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC."GN:GT!ON1SJ_Q&_:
MM_(<90LT<8QC&,8QC-*7$MO^V..(2UA,Q#.;U9JE0:Q7:C*-F[J*=6Y))B^F
M+N^CWI%&$C-,E2/8R%6D ,C#1**KN-!H^?R"SBFW-G8EW)J1*CPP=L2QR#F/
MQF*@SN.UNY@[") 5;M')4!G)SR7J#J.VW4,M&)%>I2X@6*0<QFPWAL]B12"K
MNK-X,0(;L )0*SMS%UNW[=;2VC[5K^OQU,V!6%XV7AK:QAFT5+-V::YU5(=V
M=NU;#-5V;00.TE8"0.O&.FBQ3N&A':;91#6V>SM590(_5N])#X=BO)%*>(R.
M^*01'GM(/8T;^RQ#% >%80][J:_7F26!:\<T4H*6(?";A4([XI3%QW1N#X;Q
MR$JWFR@<*XW5:GEX786NJAL,*S%1+V_5N'L\VT38-.OSM*1L<I)).5^R"CXR
M+AF@V(Z<"95=!@R,?EV4BIW.M,+52"4#A)HEE\,^:@R .PX/D3W^9/'F0"?/
M/9]?<%ZE4O*"OK5:"?CD\J7B!"<^\^'W,@/R#GCR.7.- H@Q(0 TJI#!%4*L
M6%&MPPQ)5BJ+*E5"-%EX,%"JN7"I3@CU HNL<!ZE3B;9))XY)/'/')YXYXYX
M^;G@<\>_@9MCR)(\B?>1Y$^1'GQ[_(D>?R$CY3EV  % "E "E*  4H     '
M(   ]   >@ #T &<$DDDGDGS)/O)^<X]WNS^XQC&,8QC&,8QC&,J;'W,_P!'
M_9#-J#XA_;'^08R/7O[,=_Z2O_K3Y6['V1/^[2_SVRU5_L>#]QB_F+GFS#F;
M&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC)8RX93\8QC&,8QC&,TT<4Z>J]
M0\1VWKEM:!<2&MMQ4W3#:WP3>P6YJWND^]A]K:F35E$*N>0F&C.+KY(SOI1$
M4N=-E&/).-BW<XJH=TQFKKB3XF=;:Z\0PUIPD2EUFG4?<GX$LVOJK??,\Q-6
MMTY(^F;1%:XJ%M=2L2HG+I)PVR;9/V%!@FQ0G6<6JX3D7;&: I3BPJ,I*RTL
MKP6=I:7EI2872#4_!"^(DXEG[B1<)(N9A])29VZ:[E0C8KQ^[52;E31[QBIE
MQC,BN!K=]=OO'YP(U^,X<O@8NC\4=)=A:/@><+E:[9&T%;!.Q\YZE_\ 6XOC
M.L ["?ZWK=OD^]4J>,9^B?C&0;Q*6%O5='W^P.C'(A&Q\<JH9.33ASAW9V*;
MEZ9)51)-IS.L4!.90H' 12 1$X ,_P!+I!)OM<EJU!3@:63Q+-F-98(@*\I#
M21L55@6 4 D>TP/(XRF^D%[,?1V\>G6L7+*UX3%6JS/7L3-ZY7Y6.:-6>,A>
MYB54\J&4\ DYIH_1*5_^$O?MK1O_ #'/;?4.G?[;.G_O=7_I\^2O7^J_[4NH
M_O[=_%\\_P"B-X;!]+Y[L@'H^EX"&K=T2B .A_9 (R;'5;QE(I=[K[;]F[=-
M79.3ANY714(J;5;5=:=Q]5TR6*O)]6L)N.C8DGK\_69DCEZHCEC66/M=4EC2
M1 P5T5@5$VM;I9E5K5\06F4-9@DEV3R0V" 9HI&^!6[GCD+(S=S<L">X\\GL
M)O6HO0[^OJUNZ=@.?09]&:,V.[;>/+R\2CW9JKU]YW$R"@)R P%$H&*)%U!$
MY2=EU^S0=NX;IC66_>*VWZQTE*WX/Z"00Z^QM:_A.>_L?UH.S*X:). 7U+"1
M12=NE;96Z94$RTM6]Z'QB2'4S6?@Z0. $+(*Y505(D8L0M)F>(1:$0275UYN
M]4JRO: )'74Y14@'H,?FG(2O@D7BG(HAX--0ZG3S7Z.E(Q@DM;HX=A+)')N>
MDH!''WAJ&_K[^0GN5>UZT,$9A3SY\<DCN CXY?(^S;V55%<5-O)W-V\3UCIE
M'D3RL\,UII3Y<>$44<$OW<J :KK7B;1DK]4&"VN]F-TGD]'MU%W[P09)$47*
M4RCH2K2)@0* \U!!B[]7G\04^-&L^E/5T^E_1SUKU$W4$+#3=.[/8D:>M#%M
M2*U=I#\'R68I($M\#ZRTL;H'X[E(\LLWH[FV.XZYZ4U;Z^4)?W=&LQN;:Q+5
M DF4'QXV2%7C_3*TJ CWL,V/?!4@OXM/OK]Q^8>?E]^6'UG]G/2W_&>F/^$Y
M^@GU*I?U%TU_C1_Q'*FGLL#)D,A1+,JB8A1242]D!TE"=(=)TSI:],D<A@Y&
M(9,PD$H@)!$O+/7-5Z0^B[^MH79^FNN;TUNG7LRW9_1YM=C/;DFB61[,U^E<
M@IW99F8R26JL$->=F,D,2(RJ//;_ $OU55NVZU9NFTKU[$T,*?5&Z=H=L<;L
MB+ZE/#+/4X  ]7FEDDA^([LP)-,?[9*T5(12I+LQ,F!@3FG4VV7,'48.M(JU
M:BC&1'ET]0(*!UE,'>$0$A/&?2GUI5?<Z\].]';(U1K%$_PQTOO]%8]8]:LD
M^'7\>?QH?#*<3=X]OO3M'9R;MTETU8>A8.\W.KH6?6V$45/J33=0(\'@P\2-
M:JS5$A<R&1?5V1G 42=Y$@4=+;;17:@I)5DBI@()Q+'/Y0Z_(!* B8#Q1P[0
M"8 ,/+GU"3T_O^<5^J+UIS'9T%?5QA2XLR?DBH*S A1%XT>MVK$L&+>'ZLH;
ML+&9>T))9WZ;JH.ZKNDOR<\&&!]6[A//F0K-MZZ=JGA2?$[@6'"D<D5^(V$L
MZEHML-5ED <2+) 5CNGPD1!9RDF*IP-$IE$J?5UF QR ( /,Y0](6;IO;"3J
M+01\TO;W6J3V=KU'(WM7H%]E)ND8(G/GY)+/#&Q\GEC4EQI7-)+'4M2%IN(Z
M\[GE-(!PD3,>3'U#+)QP//LBD?\ 2QNW"G-?/OS/+L@#=/[=>&/Z?+K[Q>[,
MI_5'YY]"_ON?_P J=49Z/T)^<?I7_P"[J/\ ]0>@LG_+AGG&,8QC&,8QC&,8
MQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8S@I[FI] ;[D<ZO\1OVK?R'&4+
M-'&,8QC&,8S1AO'8&JH'B?VIKK9B+9FQ>S4=882U.DO_ %)?OI6+:KO*S(S*
MQ1C&5PB')%%W$9('2*[:ND1CEG;UK-LXRG[K56:]CX2K!BEZ0PA8V^O>/%#X
MDPCB!\22,1HLLKQJRQ,ZB4IXD7?Y]U!TM.EF;>159YJ5R<)+) &,D=Q(%\51
M&O+R1^&$E=XU=86E43!!)%W1O>MMZ A4"--?JMMH[$G(]P%-UOKA\WM=IL[I
M R9^47$PQGJR3<SI=J9](J)@U3,9'J%9RH@W7@XZ<MFQ#'*IKBW*L7K$\;1Q
MCO/;Y%NU7X/LHB'N=RD2>VZC*Y7Z=786%AK5;$?>8UFL31.D->-O/QG[E7N(
M0=RQQDM)P J^9(SYX1>+&KR5+IVL;FDUKEOK=:AH]XU;$."!54TR,S]A$!5,
M^:@^ S,K^/%9-9X"Z3=%TU9N)0]QF3:]-OZO<@.UTJ1O)4VVJJSO8BI0\ RV
M]='X\MNO73@6[VM,MFD.)MUI]/6:.W/ZLU2STS#KZ.UK)5HRK%3TV\K3>MZ#
M<=B]D<4&Q,<)I[1@H\73[2&EL!,72O%;2-I<V+-7;5\W1=LG"#MHX3*J@Y;*
MD7062.',JB2R1C)J$,'I Q3" _*')6O9KW((K52>&S6G020V*\B30RQMYJ\<
ML;,CH?D96(/SYO9Z,S8SSO'C2/:.G[]TV8L&+9=X]>O%TFS1FT;)&6<NG3E8
MQ$6[9NB0ZJZZIR)))$,HH8I"B(<$A068@* 222   .223Y  >9)\@,Y +$*H
M)8D   DDD\  #S))\@!YDY'2>Z]-*KS;5+;6LE'-:0=.K&W3OE5.O -F+-E(
MO7$VB65%2*09Q\C'OG2SXJ";=F_9.EC$0=('4[ $N(P"7+F,( 2YD$\-8QA1
MYEQ9L5ZY7CN$\\,1'B2HK=6(1/%<A8O#,OB-[*>$(9;!D[SPOAB"":<OSVB&
M&63GLC=A)N<9SC&,8QC&,J;'W,_T?]D,VH/B']L?Y!C(]>_LQW_I*_\ K3Y6
M['V1/^[2_P ]LM5?['@_<8OYBYYLPYFQC&,8QC&,8QC&,8QC&,8QC&,8QC&,
M8QC&,8R6,N&4_&,8QC&,8QC-;/&%IB/V/O+1D?:9!F[H^TQDM9S=>+!(*S+%
M>)I^T7:-DC9Z1>R,0"R2-U6.Q8.Z@Z.PF(F/ER22I2FC\8S#.>B=Y5IUM.);
M7GA?"ZT2'H.MXS6'%6UI<M(I0]4U;[*S2M96@DWT.K%;5MM\5404D'57:QZK
M.9&4]1-K!UIC-)&[GW%R\DHYP'&%Y./5Q).*;H)5Z#U%LK34X>"A).4)6I)T
M.H[?%5.6:/D7CX2.ZS;K9#=!"-64]-QY4'"+&4#AC)OL.-7@6'8G%OPQ[EKG
MZ*_7W72]52>\7=M5>>9+=X6222O^Q++7_ ,!ZS/3&C#/"E43\,NB(G$S&?>1
MC&07Q+-X]WHW8+>53!6/4CH\'*9@0$#$"=BC% 0<MW2/NA2>Z(*!^\ &Y&+9
M>CVG3J75-6)$XFE,9'F>?5IN?\WG*/Z26@3HCJ!K*]T K0>(IDDBY7UVJ!]<
MB99$X/!Y5@?+CG@G-+_L:UI[VH_40/YNY]#>M=0_IW^Y7\.?&?K73OT"_?39
M?C&2NUNMC:-6S5E7XXS-L@BW:&,_M93&;(IE30$Q6RB3<IA2*01*W231 >8)
M)D3Z2A29];0DFF>;K"_#*\LCRPJ_2P6*1G)>-1+3:4!&)4>(S2<#VV+<G+)'
MU#?2-$AZ?IO"B*L3LW4I9HU4!&8I:["64 DK[))]GRXRC2<FM,N0>2T>DU=@
MF5'M-_.;I,4B"82'[LD91QU")S )>KMAR 2@ B;GOTVBI0^#7W7K\?>S^/9M
M:N.7N8 %.VA'#!VKP."4\0DGN)';Q%WIUV$PL7=<E6;L6,10P;&1.Q2Q5@]V
M228DEF!'<$''L@'DFWI)] QJ2:TBRAUDE%.VF6;9LU$ 4Z1-S1"0BI5,%NDH
MAS313/T=0=SI$2FE*J6]@[15+3R.B]["I;[G"\A>6]7M56"\D#VG9>2/9YX(
MTC8H:\>*T0C#_6^9*2."?C< 6*]E0>%)Y55;_M<<@U2AW*BL;G67BR=#B$FT
MPR64D^S76'@2)J@87/C?8HU\-V@#J[WB$>CES[A?;RC^EVGM==Z,.O+TYMR0
MU>F-M/)':GM/7=4JN2LRG9R]T9]S#PGY'Z$^[+SZ,KL&X](/1VKU\4D]V_O]
M=5JPT=95:Y+-+.JHE98M:DIE8GA C*W/N(S.;X-6K?\ "I1/LRK_ .+S\DOR
M9Q_V/TG^+L_[N?I5]3'K3^USKC[R6_Z#/$>_ZK=&,Y]GM35[YC*]TFRA2(IW
M!$W61)!8J"93<^92(E*D4! I  H!G/P_TO+]<L2=4Q3R>W-'0ZXO4J*2MYNE
M2F-9(*M96)$-<.XAC"QAF[>3N+TSZ3:ZK7BZ=O>% HAC]:Z0LR6>R,!%\>3A
M>^7M \1^!W-RW'GE+>VW4SA0IU+70G0@0"@=]<V$FH4.HP])%GY%U4R<Q$>T
M0P)@83'Z>HQA&E]2V>E[MR"2.MN[@2L$,FRZFM;.53XLC=D<TFCE,<?![O"!
M #%GX]KDR%32^DB.-EFU&]KL7)"Z_IS958F! '<\<%J!6DY!!<J6*A1W<* .
MMM9-0&4$#W6BQ0= CXF-LT6DX,/,OQ$QFK8%!2-Z3&*(] F(01](%R-UNETF
M[L&G4K["E*L33F6&[=L.R(R(8S'!TW(X4F16+<!04 )Y(![6JO6U&,2WM7O9
MH6<1A=EJ+T=<2$,RL&N7)8O%"HP4!0_:7X8#N!N2"G=3*3D,FRV;"O'JDK'$
M:-$[2DLHZ='>(E;MB(@B JG75$B14@$!4,8"@/IR]=+= UJW4W3MD6]NQK[W
M43A7^%^QC%L*\@#]_34*=I*\-WS1+QSW2(.6$)?L[XT;HDTOAQFI9$DGJ$:]
MB&%PS]PDY7M7ENX>8XY^3,_L_1C/&L@#=/[=>&/Z?+K[Q>[,I_5'YY]"_ON?
M_P J=49Z/T)^<?I7_P"[J/\ ]0>@LG_+AGG&?/ULORF/$?4MC[ JL4VUR,76
M;M:Z_&BZJ\@LZ%A#3K^.9BY5)8$BJKBW;)BLH5),IU.HP)D 0*'QWO/3KUMK
MMWN-?7CTA@H[384X#)0G:0PU;<T$9=A=4,_8B]S!5!;D@ >6?H_TK_4J^C#<
M]+]-[BY+U.+>UT.GV5H0[:LD0L7M=7M3B)#K7*1^+*W8I=BJ\ LQ')LGX:CQ
M/?P767V)R7YR9%_E@>O/HM#][['X]D]^5#]$_P!-U7]^*O\ PO'PU'B>_@NL
MOL3DOSDQ^6!Z\^BT/WOL?CV/RH?HG^FZK^_%7_A>/AJ/$]_!=9?8G)?G)C\L
M#UY]%H?O?8_'L?E0_1/]-U7]^*O_  O'PU'B>_@NLOL3DOSDQ^6!Z\^BT/WO
ML?CV/RH?HG^FZK^_%7_A>/AJ/$]_!=9?8G)?G)C\L#UY]%H?O?8_'L?E0_1/
M]-U7]^*O_"\?#4>)[^"ZR^Q.2_.3'Y8'KSZ+0_>^Q^/8_*A^B?Z;JO[\5?\
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M)+O*]"/TG3V7618.F,T:\07E0'%.)3M2--3;5VE":VBW5-FJ1+[GI]<B8M]
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M^NF]GY_(^7R'W8ZGZOT\_3?4,$>RZK=YM'MHD2?1PQ0L\E"PBK-(-]*8XF+
M2.(Y"B$L$?CM.]7/U6S\_<@#=/[=>&/Z?+K[Q>[,I_5'YY]"_ON?_P J=49Z
M/T)^<?I7_P"[J/\ ]0>@LG_+AGG&?'CO+]VO</TTM@_^+)?/S6ZK_P"=/4O^
M']Q_M&SG[9>C_P#YA]$_O1Z;_P!C4LBW(#+=C&,8QC&,8QC&,8QC&,8QC&,8
MQC&,8QC&,8QC&,^T&J?M6K7\@0_^[FV?I[0^P:7]Z5O]"F?AAN/SVVG^$;O^
MLRY7\V\CLX*>YJ?0&^Y'.K_$;]JW\AQE"S1QC&,CS:6RJ_J:E2UTL1CJ(,2
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M1[>0?C!O,<@>7\/R9=U0D+#[)X/NR,H*?G% 3_KZH(](&YCR#NFYB'[W2/\
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MB* $"@ #%_=#-2#V!H"4;$Z75TUE&0@'Y>A-C4I495_T@  (\RWYOU!Z0Z
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M5HX::=LM>4)X]QIWSAY=\(K*AOYF*))Q:UDL98Q)&TM]IN=QOK\U;0ME.V;
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M)5W3&<>/TE9M/+F+L-:KJVDH=02[F]0AMW:VFT.YW,6L,K456E+:U.HN0^/
M=7%5NDO"DDU>::/FO:C?/GD[[0G5U+VRN044V3W9];!9VU.!VTZV-A!2OS&>
M,EVV4MW:7Z0('&M?5V@&\;L$I,N+/>U@BF%LKKJJRE8FD"/V)(,]?=OVK-<
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M+P*O\'//ZWORJ5VG69"P02ZSJ8%%&9C%5049N2IBFF]0.<#F$>12"4! PCZ
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M!X\+U^QTD#@\+("0Z2Q-S'-&WM12JZ,JLA&7BIHV#@9K5U$>6EG)WW8FT*E
M0AR+(MEWEEE)ADDR!GUD#PS=L"'C':XI&\.BBX7!,Y@21/*Z/OV74NKE@"UX
M-98CV#$A9(X*]&479"PD!1W>2-8HHVY6662*+@]V4OTJ[G2CHSJ&IN66O0W&
MGV6F2NS(9YH]A4GKV4@5^5:05II77D=H*HAY:1%;Z,*KP&:YKD.PA7>Q=NST
M<T2^*QSF<J\5&.'2RAW#YT5&OT^*?HB]>*K.E2#)JG[BIA,L<XF.;U2YU%MK
ML\LTEIE,DC.%4+R@)Y5!(096"+PH+.6/'+$MYY^>9OK%8>;7Z_4ZI"L4,$6M
MU.MI^K5*L:5Z5..6O5CF,%*K%#6KJTA\.&)$' 4 6)5^%72.K]ROJ"[JDF--
MO[%Y<=?JC<KR@$9-HNFJ=YKIW#&Q-Q% TU(M+$AYT5.5VM=B0T&V180+I(M)
MLW[NLWT-IKMD4.HBM&ZK32F--U6A)UMIN7[$-^C#-K9Y'Y,DU/2UH@&<]W=M
MOMI%(;9WV7N+%#<LE23P">TR%?/W'R'('GS\EH<;.J-&:LJ5*V$77=(!"BVJ
M/N<BT>P<;,REB)69".D6D4JO,D>/7:3]R0J"QW"_:.?LI+JB*A"'ZR736ZKH
M5D\:S:WO3F]I0T:["2U<M:JSJ]U598F=0(Z].ON2UF5HZ\'C$23(95#9*%E?
M W$5F<(L^KED#RR< 24)H=D>"W/=(T%2Q'$B\N[2=D:L[ 9PF[G.;HDW>LM$
MT*"9PRB)2RA(-BQK]8B(I\GR2D+1.,H]/PB3M Y#LD6[1U*N16.Z@X!](U.>
M8*SD>@CB*7.LC7V-P%)*O2=24SZ372(RO'-N+#*@W]^-@'"31+IJ[JOJ^OO2
M"ON! 1T;=P)8W'KFFUO*O#J(W-7J/;)Y%&V+\&3IG62+PQKCCJ6RC*"FD7B6
M75'OSR>.\]8V6IZ-IDS7]Y1VP'S9Y"H.'3:E6&#.B^4>OVJ7G5*7CUFD)&HN
M5B/1D4Y<T,DJX  <D,J7U3IOTNSU[5ZEL=?ZT^HIZZ7UNO*86(VLNPBJ4G1@
MZS-##J[$KN\B.L?JWC"9YS(9B*)Q#:V,(BKPP2PUT@7Q&3Q+2S-%!'WN\ACC
MAKS,6ED=B(U#NSOW-G5PC^38V77-IP6W-\K5:NMJM,(V>(HE3>>=G<Q:&I"E
MCY6S3"2#9F5&/4 '2;)F#D7#Q,BJJY"BJFI'=4^D"WOZOP=5@:CKSVB56F,T
M]A4;N6-W[$6.$,%?PE#$L!W2,JA1H<D\=S=W'DH_0J//G@>\?/Y?/\G'&;P\
M\\SC&,94V/N9_H_[(9M0?$/[8_R#&1Z]_9CO_25_]:?*W8^R)_W:7^>V6JO]
MCP?N,7\Q<\V8<S8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,9+&7#*?C&,8
MQC&,8QC&,U?[KT+!6?A/WWPXEF'RL-=-[ZTUY'24ZZ13>MB6FZ:/08%47@6D
M,=5*%\:0J!FJ!)%5A'D.[<O'HN7B[&8^[OJ8[GL.[:+(U/5FK[\OQ RU*G-Q
M6Q*JS%-2>M.#>C7JG46%V$_5J^T8@H2DY4[*]DF%';1Z/A9J#:*21W#@'3&:
M^X72]VJ._.!JY3;EJYAG/&=K!)@X@-1*1=3D(]ZQO(P<K!;2<[3?.YV,E(LC
M618+N-6UY650=$.HTAS$%$6,^L;&,B+?)TB:DNAEC*D2!BRZS(#R5 /.\> =
M ]1>0\Q !](>CG_FR9Z?#'<40H4L9'X#>:D^#)[_ -;*AUZ47I'=%RZJ((.3
M'\<?UY7X[?,>?/'\'.:L?%Q/\*E_^\-^.SUKP['T=;[G_P#9GRMX]3Z6]]O_
M /RR36UFA"-FY!O,NB)$$BBEX%\;M=*90[?4"G(W1RZ>H/0/+F'H'(9Z,Q=S
M\&5VY9CW>*!W<D^?'/ES[^/DRUP[:BL,2_DBNQ\1H/#]7E/9PH'9SW<'M]W/
MR\<Y1)6;@7#D%#/4IP>T0OC9"%17<!R$WQ#K>*=X$T^?44OQ@"<PE](CFU!!
M9B3M6)JP[B?#BLNJ<GCVN%/')X\S[_+(ZY>UTLW>;*[ ]JCUBS15Y/+GV.9&
M[NU>?(>[S/'RY1UI.N&* *$*V#GS T;$-6RIAY#ZJAD7K4QD^7IZ1.8.H 'I
MYAS#86*XW/:Q8CY)9WD7CYP&20 _K\ \<^>:,EK6<#E0GG[ZM..-SY'R8K/$
M2OZW)\^#QY<Y6JE(5\;+" S7DS.O."'ARJM@(D*O5Z@*'"66$I.?QP@D<>7/
MU1SS7TS#95_11Z0IT6$O%TIN'4<L?:6I(1Y+"K'S^16!/R$'+7Z/[&LDZVZ7
M16M]S;JB%[H@%Y,PX[CZX_ Y]Y[6_8.91^-??_E_5'_#GXV_#_4/T<?W%K_?
MS[U\&K_VO\S\.=Y7,H( )0+R$/1\64#T?YNZ'+_-R#_-F\FWZH**5BC[64$?
MUU*GD1R/8,X*^_XI (]Q'.<>%4^8G_["'_+\N=*LE)H& HF5*(AU<DE7(@(<
MQ#T] G#GZ/EB \OE9K6-_P!0P,JS-:B++R%J["TB$<D<L$E<%N?+D\'@#Y.,
MR)6K."5[1Y\>U'"#_G,IX\_V/?GE6D91P3H(J\ 0,!O5,[.(@ "'+D;H#EZ>
M?/GS]'M9HV-WU#=010S;,L&$AYOVY/9 *GV6< >;#S_@^7,T=:HC%G$;#C@#
MB%?/D>?*L2?+GRXX^7Y,[XA26&6BP45?"09%D!P,1QTB07*74!N:@AT\N?/F
M ARY\P$,FNC)NICUATF)I=@83U+HA*&L3,IC.TJ]_<I?@KV\\@^\<C,=U*(I
M6RL<085;':04Y#>$_!_@.9K9^K^>39 &Z?VZ\,?T^77WB]V93^J/SSZ%_?<_
M_E3JC/1^A/SC]*__ '=1_P#J#T%D_P"7#/.,^>?9WDW>)FU;)V%:(F-IAXJR
M7BV3\89Q;6R"YH^8GG\BR,LB+4PHJBV<)BHD(B*9Q,01'ESSXSWWH1ZZV&\W
M-^O!K#7O;78W("^QC1S#9N331%E*$JQ1U[EY\CR/DS]*ND_ZJ'T5:?I;IK4W
M;6\%S5]/Z;76Q'II9(Q9HZZM6G$;B4!T$L3A7  9>#P.<L?X5]Q4^]='^S)K
M^29%?4%]('ZGU7WSC_H\G_RV7HA_5>_^\<O]-CX5]Q4^]='^S)K^28^H+Z0/
MU/JOOG'_ $>/RV7HA_5>_P#O'+_38^%?<5/O71_LR:_DF/J"^D#]3ZK[YQ_T
M>/RV7HA_5>_^\<O]-CX5]Q4^]='^S)K^28^H+Z0/U/JOOG'_ $>/RV7HA_5>
M_P#O'+_38^%?<5/O71_LR:_DF/J"^D#]3ZK[YQ_T>/RV7HA_5>_^\<O]-CX5
M]Q4^]='^S)K^28^H+Z0/U/JOOG'_ $>/RV7HA_5>_P#O'+_38^%?<5/O71_L
MR:_DF/J"^D#]3ZK[YQ_T>/RV7HA_5>_^\<O]-CX5]Q4^]='^S)K^28^H+Z0/
MU/JOOG'_ $>/RV7HA_5>_P#O'+_38^%?<5/O71_LR:_DF/J"^D#]3ZK[YQ_T
M>/RV7HA_5>_^\<O]-CX5]Q4^]='^S)K^28^H+Z0/U/JOOG'_ $>/RV7HA_5>
M_P#O'+_38^%?<5/O71_LR:_DF/J"^D#]3ZK[YQ_T>/RV7HA_5>_^\<O]-CX5
M]Q4^]='^S)K^28^H+Z0/U/JOOG'_ $>/RV7HA_5>_P#O'+_38^%?<5/O71_L
MR:_DF/J"^D#]3ZK[YQ_T>/RV7HA_5>_^\<O]-CX5]Q4^]='^S)K^28^H+Z0/
MU/JOOG'_ $>/RV7HA_5>_P#O'+_38^%?<5/O71_LR:_DF/J"^D#]3ZK[YQ_T
M>/RV7HA_5>_^\<O]-CX5]Q4^]='^S)K^28^H+Z0/U/JOOG'_ $>/RV7HA_5>
M_P#O'+_39]'<"S6CX.&8. *#AC%1S-<"&ZR LV9HHJ@4P<@,4#D-TFY>D.0_
M+S[9J1M#5K1/P'BKPQN >1W)&JMP?E'(/!^7/S"V$R6;]ZQ%R8[%RS-&6'#=
MDLSR)R/D/:PY'R'RRJYL9IYP4]S4^@-]R.=7^(W[5OY#C*%FCC&,9B7Q$4*:
M9N(?;M ,1E<ZC(MI(INVN9L\52249]B31:@99U%3+!=Q79I B2SLS!^(1"L3
M(+*S"$2DD>FV3R32"+2=0V*T&R9CQ#J]]VQT]3O68^4-6ZH@T>[?XBQ'4[&7
MLBU=EY(';PRUI8=[2B>:S1C:*[6B4M)?U#'Q+$*(OYK;IL/7=>I#.TBV*<9C
M&PE?)XUKL"%VA2X>XPI3HH22*B,A&.%$E7D),LSF:S$$_.@8[=5U%OTUVIG+
M8ZK%^D1*1C7#J-=M'2TS+$\,DD,R%)(G>*2-APRNA*NC ^XJP((/N((.3,$\
M-F&&S7E2:O8BCF@FC8-'+#*@>.1&'DR.C*RD>\$',/N-?A^HEEUH>T,V!(*Q
ML=@:;%M(1G4T$BKO;U+BRN$3-Q(HR=-$95\=DNV$"-%G;MTDV\<L5TG2]W0E
MTFAZ@GT<RU*@T^YLV-%.AGT5B7X/LN9H*H9)-/;:0!I+.HEJI8+.;U:XQ1HY
M:ML9X8C4D"6J3,7-.P&>(/\ *\+*RRUI6 "M+6DBD90$<LG*G3Q=M"E_1.W-
M*]O;M&0$.>)A[':]52C* >S"#5FC*S5I?09TE:K-24>O+O(20DA18SI4*TEY
M]DYV<=J=$EL;6DK]$K<V-%=7MY+NHU5&ILGBED2.%_6=O)J[]9DBV:)H*NTV
M-:%4@O$U(EFU\#"5%LU/J;?Z&/55NB]YL=?+N=G>M3ZR2Q$S#6:/6!;YKQR*
M*ER27:;G1H)!5AN21Q21Q0N%D.9W<'/!_P .MQL%_P!F1:4A?(UNQ>4:-GKC
M,*V"PLI*9;-7TJW(UD$4T:^M%0J[)JH@VBV+>81GW+69CS.HQ9$LM+T^*_2U
M'5["!]7O-@XW=QJ?$%W1V9'=Z%&&;AU,^K@,5&XLJRP6[%:\+$,U._+7>NV.
MH=]U#!/N^H=C=V5K<SM'JA>E=S4Z<UTTD,4T,1]B ;[:)9O@1!$?6T]-*J_7
M7+YY56ZV;3T\PUMMN27EJM(N48_7>U7ZJJISG65(W85.^/W!U#^<#J*MV%>M
MCU8ZTLX4;U^UN%+,M"678<1K=K8%H:;=)'!ME1WK6(D:.CNZT0!>WK^YG,4\
M2E3?UCR//29N^-[-)X;<D9QR.1_"/F_R >?S#^#YA%W&-MVN1E)[M7=MG]^H
M4NVNU8>INT4&;>4AFSPCZ+*[4$S<XS\ YFH,SY8JL?"BZ7L?)TXK#A!OVDI6
MNM*=VAIS'!J@KI8ZNL'C74+M2025WT8Y4[S;:^_%7E!KR1:NE9B$=W9);04)
MM+UJ2:X=;K:YV&Q1%FLPI+'#6UE5SP+VXO3?UOKJK<_65D+W+K Q:ZI<E#(,
M3;%2=A\5.FK!MBTO'#+7;^$;R\5'N"F3M%R.LDW6C")12Y>Y5HI7QR74,P@G
M)%2?2D:S@S0RD!.-<6LMZW64^GKM&L1NJG56HH]4[>[(;.TM[&Y--TCL^ZRR
M1/#KXHM_;N:JK7AITH:,M:>E2I^,[R3W3E:IKMW0LS67VFSFG%239RQM7HZR
MK=YJSP:'6=[+6[8I6,FWNM/N+)'=')K8.*4>R;A7CZ[&\/NJF]<CF,:D2HQ3
M>:*R2 IW=KCFY(FV/Y%P83N9&7=6&/D3R<D^6</WKP%5W;A94QCC9I XD</S
MWAF#=Q)/<">>2?,^?/[.:$RR++(LO(D61UD[B2W>&(;DGS)Y!Y/RY#.OQ'97
M%S=+2IS6AM65KM1Z*OKHA8+.9Q UZR1BP<P!-U4V-TAG: " =X15.7J%,PP^
M@]O5S[$_&Z@W.QVR,/BOKZK1Z#3LGRF*QK]/'LX?T)&R9U +MS*7/ZWU6LJ^
MY[)L;.;]K(_J=6-OEYC2I-.O/EV701SR3F<^2N0^,8QC&5-C[F?Z/^R&;4'Q
M#^V/\@QD>O?V8[_TE?\ UI\K=C[(G_=I?Y[9:J_V/!^XQ?S%SS9AS-C&,8QC
M&,8QC&,8QC&,8QC&,8QC&,8QC&,8QDL9<,I^,8QC&,8QC&,8S6)ONR516ZT"
MK*3U>6M+'RA6EYHU;/*1I[ T8^PZO$)*C#F7&10:B#DA"/A;D1$'!2@KR5 #
M,9CCLG9NTMC7"ULZ9:]E:DE-AQT#M20I57UXHM(KT>PUQ6A5.TL+M.;<BF4A
M,NHRF0BTK+T6F^9890&,.$VC8@?+J,9JJUOK*PU/B6X$9-WQ%WS9<0GQ;ZG;
M-JK-T5&M0ADE8*W@U>HN$-I6Q)#P292^$:)0@)]!^@B[8I  S.3Q\QY^7D__
M "XS['L9QD1[X*0^I;F11N9V0S)B!FY510,K^N\=Z 6*102<AY&Y@0WH#ERY
M#S":Z>/;N:!#!.)']HKW<?69?/M+*#\W'</X?=E0Z^ /2&[!C,P,$/,8<QEO
MZ[K^7>$<KQ[_ (IYXX\N>1JU\&R_BRX_KM7_ )?GKOC-^JQ_%5_I\^4_#C_L
M8_\ 'G_%<EYGJ#Q;1JZ+'G(5RW0< 09]GS*"R15 */5%B;F4#<AZA$?1Z1YY
M 2;WL=T[P>UV7GU>?S[21SY2<>?'/EY?-EX@Z+::&&98&42Q1R!?7H/(.@8#
MVJO/D#QY^?S^>4*6I1H)T#$( SKFD1?N^<@7]T$P=/<;BR)Z.CGT]D3!S])S
M ( 78AV/K*>)ZPL?F5[3'V>[Y>).]O/GW\\>7D/GCKNA>A-X!H/+["OWBR'^
M,2..Z,P+Y=ON[.?G)!''@3KSU41!I5#'. <S!XHIN1?:Y\G!9 H>GD',J9#>
MGX_ES*.0VXP/KEP ?(5!!Y^;F-HC_ 6(_6Y (UDUD[$B'4,[ >?+J_ _8D%D
M#SX]RJ?^UQY&ZJ;69@EJ@#+5<&J02;45'!U61B(E[@<U#%&+1 2E]L0%5,.7
MMF#V\I?I%-6_T)U92-U6%K1;" B2,RQD20,I#QV+0@=>#YK*0A_1$#+3T;K[
MU?JK03MJ#$L6TJ.9.8E[ L@/=RE-7''O]@AOTOGF7OF(?WF'U$=_YL_/'\@M
M#]4:W[TZ#\?S[ ^$)_HV_P =:_H,YA#M0  ,S,8P>@QDQ< 0P_+$@).RI 41
M])>V4I.7+I "\@S&>D]4A*'43SE3VF:&#8)%*1Y&2-*NY6LB.?:5:ZK"H($8
M" #,@M3$ F0+R.>WO0]O/GP2\'>2/<2WM']%Y\Y;\O&HIKI@1(R "B B4R+I
M43#UG#GU&<*" <@  +S .?,>7IRA=5Z"C7NUUBHRU5:J&*24=A,6/BRCO#2W
MK) X ':'4>7/;R>3(5+#E&Y8N>[Y)8E ' ^3PT'G^P?=^QE*!HS)Z70NQ3]H
M/!MSIJ]?RN9EDG1>CD!N8 F!N?2(&  $!B=70Z9J66EZAJ[>:B8F2--/2:"T
M+)9#&S/:@NQF 1K,'40ARYC(=0&#9I)K94"J*_B<^?K<G?'V<'G@0R0MW\]O
M!+%>WNY4D@CW1J4*$BP%,)ON ]:B3N%2!/K[Z?3W!"-(($Y\NKD<H]//UB^V
M%ZZ;;T7?DBT'J>NZW2W\-:OU5[ I>KI9]>@\!I^W31MX*R]IE[70]@;AU/F-
M.S)N?5Y^\:GL\&7O[!/W]G8W=V<W".[CGMY!'/'((\LRQS[[RBY &Z?VZ\,?
MT^77WB]V93^J/SSZ%_?<_P#Y4ZHST?H3\X_2O_W=1_\ J#T%D_Y<,\XQC&,8
MQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&<%/<U/H#?<CG5_B-^
MU;^0XRA9HXQC&=+ELW>-W#1TBFX:ND56[E!4H'2607(9-9)0@\P,FHF8Q#E'
MT"41 ?;S%8@AM035;,23U[,4D$\,JAXYH9D:.6*1&Y#)(C,CJ00RD@^1QF"P
M.''##MQR\>+*!J38[E +$NH8?#U^4YD:1=Y7./,J1(YN1.%O#M8HD+7DHV?D
M)&)B*I$1#[7U,\\L4NEO2R3[;254DK6I6+S;OII)(ZM2_+(WM3;/3/)7U.[8
MEI9P^KVL@[]E/X=;K?\ (FR&O/EJMM/--JS[DH[*0/8MZK_LP7.V:_KA\2.0
M7JG<B>H0M*?%[*LHC2$E(2#@C:/:W/5LD^=&^,;L8/9=4L+QP80YCT(-8A58
MPE 1Z"&Y9&=6!CTMU*J@EFT&X10/,DOK["@ >?))/  \R?=YY91R3Y>?_P"W
MR_\ W^3Y\UXT-27LC&47/'E=6[9-ID9!Q770CWXRSV^7.Y<,$7"7-PA!><)=
M1T$LB55**41;.WB8, 5-DMO=%!U%U!T1T]L$@FZ?Z0U\W7_4]:9%E2U>L2R:
M_HVA*C#M9FN5.H[<\3$&6KJWKD$6ER'V\3;;J9.GXII(!!J*&EMVHSVR:VE)
M7/5G6&RBX/*S+K=OIM/4D//_ "S'KH7!([3D_9N%Z.TO#QERU-?'U"M4)&$;
MO7R!FZ(V9R4RTE*%<1ZB+B(D&LB_7EI92'EX]U!,'LD\GGJ3E2-8"TT-QN]G
MK++6K!FZDJ7K(AI:7AI>J4FD_,JF@N1QO+N^R-.?@_<QO,(UEL/OJ-6%URY6
M]]1E21MO6KPZVK"L=6:%HJDVHH5HUBK5TL.!%/3IUHXH5AN*W$<8$,]4EF;$
MO9/&3?[RBGIC8VN&B1IHRT0YL,6P!6ERA#JN8]U)6IO*N'"U3B4$TY'SLF[?
M/(@(V*G4)ES'*2L&VS*>G=3U7#8EWMVT];7BO93I&F&UF_U5YUE\"[U)/WM<
M@:!AS335L-':8N6V?45%FK-HR:.Y>B2_4N2P=/>''9FGBJ-%U':KN4>)$U=U
M'&DJ3C@/NK\5R,Q,OP=5LO-'9@FG2.GH;A]LM=L>[)AELZI3R<6ZUELH\LK9
MJ;KAZYZ'C-D^DGB(#/L^KP?F#:$]R<QH-TI 6T::1L-C6YCZAV1L5>G]YX4+
M1Q^#I;%6)*VMVE>K$W$,5>(+'2VE6LA:;6\>$\"R6=5W5(;577:ZM%#5%&C7
MAH4%FDL^J5P1XMF7DRW+L[EI]A=DYXDNW)9K+CA ZQA(UR4-'FUYL'8&L.DI
M:GN"(L5\U\ \@:Q]K.<BEN@RAZ0();-),K @LLJ7Q);=&PL6U3:5U<P5/JJK
M+6.R:L.(NI=?-1)_05>IZ=2230WS[E5KJP1T))&/M6:.F@0%YF)QJQ5@RGAE
M(((^0@\@Y:?#/<V]4X>MBQRCH$2ZKNMYKJ3U4>0*/I8S.U*/#]7/I;A9;?((
M]1C&!-!J81-TDY!;.H]F\VIGV>J)-G>5*,ND''QKW4RUH](A^8-<V5-';CA0
M68C@<9-;>!K&\G2!>YMC/!:KH/?QM4BMP)Q\X6RB^[S]_ ]V7KP:5Y5GK.;N
MKY S>2V5>+'8S(*^N9A'1SKV-,XYFX'TK0AWD/*S\*)?B(M+ *Z0 #@PC*FM
M7HI7UU3[#U=2IJZ?Z]36UHJ59C_VFA@1F/RL2?/GG,&YECEV-A86#5ZQCI5F
M'N>O2B2I#)[S[4L<*ROQY=[L?E).7.=<B\8QC&,J;'W,_P!'_9#-J#XA_;'^
M08R/7O[,=_Z2O_K3Y6['V1/^[2_SVRU5_L>#]QB_F+GFS#F;&,8QC&,8QC&,
M8QC&,8QC&,8QC&,8QC&,8QC)8RX93\8QC&,8QC&,8QF%O&S?ZUK6L:;LMMUS
M+[7AE]X1=9)0H>NM;0XL4_<M;;.JM.BSQ;]%>/Y2-QEX&.:N7R?AT)-XP'F5
M4R0XQGSMW+B707C:EKC9FAMNW&>TTWD*8UL3_9%\8.UV: -&8-CU>4T;;H*K
M)"SC8DYXFM*(,"*-4#(KNFI&QL9SP?UOMC\.6EKW:5,MO%-P.1$'I*[T-\;B
M_P!8. GYZWR,W'E20A[B*C,S)SI"@I=USU!VEAGRF3$@]+-SU>HQQQ\WVP?Y
M#GV1XSC(OW0T=/M8VQJR XNEF;,$0(Z09'ZBRC$X]+ITY:()#TE-Z5'"0&#U
M $3& II?1-&FVI-*RJ@=^YG1Y% \&0 E(TD=O/CR"-P?,\ $BK=:Q33]+[>*
MN&,SPPA LT4#$BU 3Q--+#$GL@\EY4!'*@\D ZX?8?;OF'GV6UW\Y\]0]:U_
MZIK?Q"Y^)9\V_ ^[^CG^_6J_XMDGM6%[3:MDRO-@E*1!$A00+&K( 4J92@"*
MQ7:A54@ .2:A5#E.3D8#F 0$8IFUA9B9=1R6)/<EM6]_Z)37!!^<$#@^7 RS
M1Q=1K'&H?J<!410(_4G0 *  CBRP=!Q[+!F##@ACSSG?YOM)N8NT9YVK[7=E
M^V1WT<O5)TMY!,G:*/,2")>H1$W,1#EF%Y*2GB.6KV\?_#=XCYY//YI"&[O=
MSY<<<<9L)6W+CNFCV,K^[NO,BS\#W#B&TJ=@_0^7/OY^3*+-P+QZW1)*-YIN
MB1;K3-'-'K]4RG08.DZ321.<B?2)A[A@ H& I>?,P9E@LI&S&%H'8C@B5D10
M.0>07C YY'N!YXY^;-._KK$T:+<BO1H'Y1JL4]ARW:1PRPVBRKP2>3Y<@#W\
M9U5.NL(RRPD@4;2H+*1;.0(\AY=HU/VC@?I<.7#PR*"0\N1E52F(0/28!#T9
M5/2-NVU_0?5MV:*A-%5T.PGDB-JM"'6.!F*^*Z%(^0/C-Y#Y<D.CM+".J= 4
M?;AOA2IVF6C>2,'Q!QWLUAE5>?>2I ^49E/[*6G\ 1_K1'_S9^=GU6-5_8;7
M?^(=5_1Y]>_!$OTTW^+GSL":JZ@ =9JX*L< ,J":R1R H/I/TG\27J+U<^1N
MD.8>GD&6.OZ1/19)!#)=H3I<>)'M+%JNFKD2V&4&81VY+L;V4$A;LG>-&E7A
MRH)XS0?5;8.XC=2@9@A:W>C8KR>.4$9"'C]""0/</+*6_E($RI!:H"!.WR,"
MZR('ZNHWM /B/5Y<N7K%]//U?EC2^J>KN@KMRO)J:,7@+5"2>MIIM8_BB61O
M9AJ"XDB=C+]<:17YY7LX4,9&E3V,,;K*Y#%^1V-8LCCM \WE564\\^R!Q\H/
M)/'2U?QJB@E31:=0$$?BRZ0$Y=10'XQ-,>KT^CF;ERY^CGRY1NGW?3=BTT<=
M;10MX+L7V%R&2#@/&" M6F)/$)([23V!0_/F5S8ECN*H/=._F!Q'#[7N/F?$
M(7CRX\O/DCY.<K#-PT%XT $HP!%R@ "1?U@$52<NGUOCN?QO^7EE[T%S2-O=
M*L?Y#?$;;:X1^!+8,_>;D(7P0:P!E[N/#!('?V\D#-.?UOP)NY+G;X4G/=#"
M%X[#SR>[R''O/R#,CL^U<IN0!NG]NO#']/EU]XO=F4_JC\\^A?WW/_Y4ZHST
M?H3\X_2O_P!W4?\ Z@]!9/\ EPSSC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&
M,8QC&,8QC&,8QC&,9P4]S4^@-]R.=7^(W[5OY#C*%FCC&,8QC(WVO3X.Z4B;
MCIX[%LV:L7<@60D3HHLV'A&ZBRR[QPX*=%NR[)#BZ75(<C0I2OR%!PS043CK
M]6U*U2[K#&FYU=CUO5/*&:&69HW@GUUQ4!>76[:I+-K=A" S&O8:6("S#7DC
MTMC2@V%*>I9+)%(H82QOX<M>6)A+7MP2?]%8J3I'9KRCSBFB1Q\7-4#NV;"X
MB.&AQJ>KS&MV54;V%)C4MB;$NLY'2UIU[79))!!@%7A:7;7947#,DE68JP3U
MA;S"D4SB9Z1:S,BNY>/[=;Z<:Y4D21+FKDV%)6-&2M!?GU<ERLKR4[4D=V&M
M8GI/(T+O6ED@F:(R*ZAPJQ6JW-B6O7:S%4L20L8[,R6FK17? E:,VJT:UK#P
M1VXHQ8$4G!K&0Q!I519GH=(FTX<]XIRNP8/5NVZVWKJL?.++R%P21KPJK'"T
M5,\*YK[V?(HR8DIQC*K5V2%K894D]#&?IUV/L&NVAVT&RWVQBA6<=2;.#9V+
M;L8*U;7Z;2:[7:W4SM*P\/MV,5JX888;4(@FLSRGFQ8;-S0SP6+V]D\.>YU+
MU)M-C-8@I1M)%K]+/LIMGW&XZQ5Z]-5MB&S;LS48XAI]+'XD4B0QODC3]+;8
MV*O6]B5K;=G)7BR-GD? SNP-KS$#8&=FLFQY)EYE5M#IXK(0M<@IW7S*O.SQ
M(PKPU87<0#AJ4Z4JXT(4AJ7%F'$IC\& 3@ S>J1W);$L1<^;^LQ&&"9>]1(4
M#R/)'"D4L[92+O 9()'B3D%%#1"X*]2,3PE@%4168[-B&3PFX#@1)$\BSP9)
M:DX:8BGZH:T/8DJZV5/2",>]L]@G'3J56/-$@8**?H1$C+ K+*08NX0KYLSE
M5G"0JN%2>#:L/#1;2+V&NJ[%JD\OC0WZ"L*6VJ3RU-M5D<DR207X&6POBGM%
MB*1Y(+4:B&W%/!S$>8[=F*RUR*Q-%9,C2":.5UE5F)Y*N&#+R#PP4@,">02S
M%H3MG#QL352$RYT_)%LE(ES.5[%K*Q)+2T%)@X%1=RX",,Z079S*RYW"QY^"
M?1LK(2CYNZG'Q("#0B58F^\SU)*'551]MKG[&7J'3U7CV=62)P\%G9Z77A9!
M/6E6*:/<]+HEB&=5F&B@$3W!*"U0V/(O(M"X?,;&K%_6\K_/=HQ *G/EW3T%
M0@ EZ5J5RXQ6E=\#5:J6F6:-L$(I29J)LVI&SWNR\M4K<W!Y',*'7IINS3/9
M*5>VB\[0X)1Q%M+#2#R!;1'5UUK5FS=:]BK$WB:J36[JZFPUNRA<Z#K#5^%8
MJ[)X'$M9B]16KU.I-;9CAL"$+%!;EK^LUX:TD=S74<$NHNQ/$HC66.?O,%J%
MTEISHGM,Z3KRBE$(:2-RDT/DDL22'MRYW\-NZ.I>VEH2L4TL=L%*K/V]0^"%
M$C9T%H=G94[(G(QA6*E76<6<DRQ2$C.\.#1X1:/:._5[:8=M/\(5]5T17VR5
M'GZ7CKM=CI65D]<EU=#85=+X,4HB54IV'U-UN^P["6@44.65Q+131);H6F$I
MLT*!A5Q$_A/=KQV$UT_<2)%CKGU/NYBY/J[\#VAQEI$5EQ?*5J.R\/UYDGNO
MJWJH*2>.:WJVU(9L\'9M:LBQ;J*9G!I!6PE'B-IU5U-OH]G8ZU89R)=IKM)&
M)BY>OV^K9AMJMJ!Q/6F6/CM8J?9>3N'##NC=)"AE3A))!&]=VC[BRP#QBN98
M;$96PCDQD@$#NCD')\RLB%_"9>0Z <NH8=R/5Z5J?B*C7LA/VC<*[EVYMVM%
MVM:8O'KV,-2X,] ]F$;-2$VF^CE)!RVC;L@W<TJIT!U8'<J#^R/W:;MFQK^Y
M$55(%EXED$<GK4@4*LECU>_&LD2 +X<<L\U6QX*E(ZX@CB1'[)7L:JE?$F)7
MMB)E%=>2SQ1L(6AC=BW$CP]CQ/-)XLDOB23=R%HXX<P\QYUQC&5-C[F?Z/\
MLAFU!\0_MC_(,9'KW]F._P#25_\ 6GRMV/LB?]VE_GMEJK_8\'[C%_,7/-F'
M,V,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&2QEPRGXQC&,8QC&,8QC+'V'
M0HK8]=2KTLZ?,"-+'3K;&R<6G$*2498*);(:Z5U^S"<BIJ,[B$U!,15!S&N
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MM^GV\TXK5.NQ=>GE)*E?;I22#@D'XKRL.?+W\<_K^><LLQ'MVFXY^24#S_\
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MS%(8PD@5U8H3VLIX(QR;N22-XS4K .C(2/$Y 92I(Y<CD<\CD>_)/SWK(3(
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MV^#\Q^T<P8Z#_,F^I'\&.#\Q^T<8Z#_,F^I'\&.#\Q^T<94F0""9^8"'K_+
M0^4'[^;,/DIY\O:/\@QD>/?V8[_TE?\ UI\K=C[(G_=I?Y[9:J_V/!^XQ?S%
BSS9AS-C&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QG__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g383050g14s40.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383050g14s40.jpg
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M 0$! 0$! 0$! 0$!_\  $0@!G0)= P$1  (1 0,1 ?_$ !\  0 " 04! 0$
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M8EL41V]J]5.A3C.L7HZ=_JAR4NRR+KT,?7K88LL):Y./WW^)LXF8%F_=.O\
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MW+_8SM3_ (6SL_Y,.8_Z!7_ZA1_OU\S?E-X?_K"?_D+G]RG^$!],'_/+<O\
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M3\FG(1\Z?#-_VLI"/L^:GY1\ ?2#,N^D8N8C_P!6_P!B_1Z\G#,GQ<4'E@T
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M^KW'ZW'^U.AG^2W]4?V+ZBR9F*8AFC4Q#E$IR"W2$IRF 0,4Q1)V,40$0$!
M0$!$!^&6GY0+7=VD$$'N""-$$'L01V(/8A7-^2YKF_)<TAS7-[.:X'8<TC1!
M! ((.P>X4 MG<4[+K>SO-W\/EH^G7CN#FW:B<@FCK3:#)$QU5618HRB#& FE
M"F5*S5;'8L065%1FX@':KN1=<BS?!,A@KTO*/#>6/&90_G,EQUQZ,'GHVDN=
M'[/U,BJ6R"X1.8Z*+J=N-]21TDTGTAQ7Q=PW+,37X#XX03Y[  &+"<V8#+RS
MB,\@:QL_MA9+8R-!I:QT[)6V+!C9TSQ9*%D-6+.7'GD32=_0T@BA%*T[8]46
M-';!UA8$2M[+4I9!06[D#(+H-EWT2=R4R;63(V1[&[-G[=B_*HT)*^'<VH<N
MK3-8R7'9K'N\G,8.V2R[C[#3T/VQ[6.EKEX+8YPQO?Y$K(I08QSWQ,\*\QX<
M7JSY)J^;XOF&"UQKEF-#9,5F:<C!+$6R1OECKW!"0^6HZ5_;<M>6Q6+9W2-]
M*V_R=#_4I_[N3/9^)^\KF&A\!]P3TK;_ "=#_4I_[N-GXG[RFA\!]P49>:&O
MMF;*XF\B*!H]X2'VU;]1W6 H;Q!TE$.CSTA"N4$(]G,&.W+#/IA(RT0QF3.6
MI8EX^1D3.FP-A73W''[5.GG,5:R+?,HP7J\MEI:9&B)DC27NC )D;&=2.CZ7
M>8UI9TNZNDZC/U;=O"Y2MCG>7>GHV(JS@X,/FOC< ULG;RW/&V-DV.AS@_J;
MK8\:'1BX/<YJ1U#-:7*7TOM[3=,U@\L_[7K-?Z=8Z77'E9<UZ6C'5.36GF3!
ME<'=BDEXQ*/C8D98K8X-+7V1:124DCWWQ Y'QNSQ6W7CR%#(6+C8?8(:MB*Q
M,V82L>+!$3G.KB%@>7/D\O?RH.[GEAX-P'CO(JW**EB3'WJ%>F9O;IK5>6O$
MZ%T3V& &5K6SNE>6=#8^O7R9NS6!X]Y/I6W^3H?ZE/\ W<^:MGXG[ROI#0^
M^X)Z5M_DZ'^I3_W<;/Q/WE-#X#[@GI6W^3H?ZE/_ '<;/Q/WE-#X#[@L!\H[
MSKK5_'W;EKV-:JC1*VE0;7&#/6R6BJ_%C*2T!(L8F,2>R:S9!:3E'RR3.,8(
MG.\?NU4VS1%98Y2#M,+6MW,K1AJ03V9O:H'^7!&^5_1'*QTCRU@)#&-!<]Q
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M'EX_D#1U9+&//9IGD +[-8G7F%X>\ZW*V;3'P\]R/&+V%LRYSAKFP3N=YE_
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MBN3")A$PB81,(H%\D],W.G7%MRNX[,BCM&LM/*V/1FX*$8[BHZ!4A?Q[IJW
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M,Y:YE>Q*QDDAL3SO=,YH:'EKF,/2.F-IWO4\;?8FP>-M6K<]RQ=I5;DLM@0
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MG1.Z'O=&^1C8VA\C9(R7%W)=$SFMJ?DQP_UGJ2NV!=3;?&O6E#U]LFL24&,
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M%$SE Y#D. E.0Y3 )3%,41*8I@$# (@(" Y4$@@@D$$$$'1!'<$$=P0?0JA
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M\Q0 $ZGA+^\;L)%K!)@_!F^!-F]!, <Q[P"(N0(5=,/"X9N.Q_""R1@[*H'
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MA&<Y)0'M$KE<L3%)O2]& :WUM!/Q&R._T['?UWZ_>5.SI1J;)'A'K]GM1;8
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M?'X0/X1*4!#Q@0@'[=O%X"]^_A#L1?4             [  !\   #X  !\
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MX$HO<>E_A"K_ "")^DR*J1)[CTO\(5?Y!$_281/<>E_A"K_((GZ3")[CTO\
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MB81,(F$3")A$PB81,(F$6%>0U!NVTM16[7=!LT;4)FX,BP;R?DT'CDC2 >'
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MDUXH@=DVY3WBFN8\5[-#N785GH"3'G*L8'IO3_:VL^&IY)-: K,])6:#YF:
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MYO%]G_)SZ5;/@[_9\6X?'X?;\,T%CA_*ZN_/XYFV >KQC+CXQ_\ W(X7Q_\
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MP[?#[,\ZV1R%(@T[]VH1Z&M:G@(]_;RI&:[]UZ6*-*UOVJG5L[['VBO#-L?
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M!VBL4JR3A)4JR:Q2K$.4X (;%_B9A9(W0R<);) ]AC?$_DN3=&^-S2TQN:Z
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M!_\ 4X\IGZ7Z[_WD3V6T_-?,'_U./*9^E^N_]Y$]EM/S7S!_]3CRF?I?KO\
MWD3V6T_-?,'_ -3CRF?I?KO_ 'D3V6T_-?,'_P!3CRF?I?KO_>1/9;3\U\P?
M_4X\IGZ7Z[_WD3V6T_-?,'_U./*9^E^N_P#>1/9;3\U\P?\ U./*9^E^N_\
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M_>1/9;3\U\P?_4X\IGZ7Z[_WD3V6T_-?,'_U./*9^E^N_P#>1/9;3\U\P?\
MU./*9^E^N_\ >1/9;3\U\P?_ %./*9^E^N_]Y$]EM/S7S!_]3CRF?I?KO_>1
M/9;3\U\P?_4X\IGZ7Z[_ -Y$]EM/S7S!_P#4X\IGZ7Z[_P!Y$]EM/S7S!_\
M4X\IGZ7Z[_WD3V6T_-?,'_U./*9^E^N_]Y$]EM/S7S!_]3CRF?I?KO\ WD3V
M6T_-?,'_ -3CRF?I?KO_ 'D6Y0;)-@,"7F]C" CYBZZX]P^ =A744$H?'X@4
M0 ?X@.7-:&[UOO\ %SG?^HG7V(OOER)A$PB81,(F$3")A$PB81,(F$3"+!7(
MS=3;1&M#VU..2GK38KAK_5>M*PNY.R0M&U-N76#USKN%?/4DG"\?!GM%CCWU
MJET&KQ6"J;&=G2LW81HMU"J!O^D_4L'[.YF,M-;,Y5UR]5U)2B<5^$="YA6*
MRPZZWMR=;3L]R:86BMLX9R)FC<D=%<?4'D,J:066=O;"NT<B1-FDLL0#>M>\
MZ_H_M6!*[S^V]29.?KG*'46OM?6.DJ<4+]>"ZYO4]<X2(T1S%N%RU#3+*A)3
MU7JKE6T:CW54W$%MINHP)#+T)L[OE=<E751K215T/<2=[UVUW&C\2=$'MZ=^
MRM@PK4PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"*N+E;SP=Z%1Y!*TRGU
MZUH<<JIHH^QI^W6)_5Z=4[CR0V=$4VIOK=.QL1/.X/76H:&:6W/O2>)"OG<1
M1)"KK0B2YU)Y:)*X-V1WUO>O>?NV.Y/8?$^\+J_&#J$2FXBZ@5O%=UP-9VUN
M[>?&FJ[=TY<Y&\:>V%M34E<DM@URQZNM,G%1/O)K/8]'IVUX]"8$@^[^R=92
M%/8O[@UG&4VS(1ZZWV )!&B 3KOW^.OKV#H*T7"M3")A$PB81,(F$3")A$PB
M81,(F$3")A$PB81,(H][4WO':_VGI?4+5..5LNTT-C767>R[L6<73=-Z9B(9
M_LJ^/C@) 7%K.W#7-*CVZKAH@WD+VC/NE7#"OO8YZ5?X^T^BA=J[J=T_;/'"
M\<N*PCK*1TM2-L5MM*QU<VI#W'9M<XYV*4B*R3;6U:O!H"AJ2WM_:+W</[,I
MQY*39-/1/HY,8F_/',-#E4MT0.Y/U>I[]A\1[@?>?H5JN%:F$3")A$PB81,(
MF$3")A$PB81,(F$3")A$PB818+Y&;J:Z%U@YN81J<]9IJU4'6&MZNJZ.Q2M>
MUMN7:!UKK6O.WR2+I:.B'MPL\2>R3"+-Z> K"$U/"S=)QBB)RJ!O]I^P#9_8
MHT6_F\_5Y8P'$'4=-87>UN=:;FF+-LZ6>.HG6,%N#6U7I$_#Z=2<,QD)"0GE
M&U^KD_L,69W(:_KT]6&RIY:>FW#&()KML_$?60=]Q]RE=H/<M:Y#:7UINRH-
MWS&!V54HJSMXB5*B69KSQVCX)BKSA&ZBK=.>JTTE(5V<2;K+-TI:,>)H++)%
M(H8A&B1\%EW"HF$3")A$PB81,(F$3")A$PB811"YJZHLVS]74R8I,<M.W/1F
M^-'<BZ_5FYT4W-R3T[L.&LMLID<9RHBU"?M5!+;(2I'>.&S%*WO(%:0<H,4W
M*I2J/7["/O!"^=\X@TK;&R.1]XNTW(R51Y0<1*1Q(N=$2C/9B[*FUV<Y"RTO
M.-9U=PJY+)V*.Y!R43[.<0B PBE>;O!</5'ZC5B3?I]!W_1_8H97_@#LUYKJ
M\U&Z[:E^0>V>2TGQ1T/;=JGH<7KF#UMQ?XW7J3V4Z*\@XZ=L15+7*14EM51[
M94)%).X;<V+546M:J55C@0B:?T]A_'WE5WW[#6M^_?<]O[/L'UJX[*JU,(F$
M3")A$PB81,(F$3")A$PB81,(F$3")A$PBJKW'PAF=L[=Y55]>9D*O5>1<AQ.
MY&4G8J-=B[M U7>G$Z=K<<I3]AT:;6;P]KI4TQHVGIIO5Y)TV2N4>MLMFV?U
MV2KD=,JE<':T?>-CW@Z(^(^L_P!A[KB:=P5M=(O?'NMO;1[\)0_+W9W4 WML
M>'HT;JZ@J[!6TO8=(TK6>M=>QTQ825%A-2%VC;L[8%GK4Z5)KZZS-LL03M_C
M#2!-^OU=(]_;W]_V?;V]%;5A6IA$PB81,(F$3")A$PB81,(F$3")A$PB81,(
MF$4'.0>@WETY):*VV$0_L-,=:=Y)<2MPQ<8J8DA%:\Y&$U?:F-U;E((.O3PU
MQTE"U&35C2*NV#/8?O$[33A:Y*/615![$?2#]VQ_7[_@H+6CI?6ZL:-VKJI/
M98;;LV^-$:;X"U^6K^IJUJ&)UUQEK%BG%['==D>[\U,-KOL>$H$_<'HW$P5>
M(FK(QK=4J5)JCJUR"STKNH;';0#B[6]]SKMW'IL?3V]=Z"O,     /L .P?Z
M PK$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"*(?-;4]FVEJ:K2-'CE9R
M[:3WEHKD96:NBJ@BO<SZ2V;7KK8Z0Q4=*H-$YNXTIC9ZY5UWKEK'M;5)0;N1
M<HL$')P*K3K?T@C[QV/V'2Q);. W&2K<@:)S>U[H77D%L;4T%ONYR\'KO2=-
MCMA[FO6U(J#>IS[ZP$0A)8=A,7,386\8[F$W3]](WR:(]DHD'#]5V39UK?;Z
M=]OX_J"SIPKTA.\=.+FGM0VMVQ>W*NUY[+7I:*5.XAR7Z\V"8OU[:0CA5-%5
MS!,+=:)IC".54&ZKB);,UE6[=0YD4R'U[>GNWZZ]V_7^/12CPJ)A$PB81,(F
M$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB
M81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"
M)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,
M(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB814H=?S9&U=
M6]/E[8]-7S9FN[N]WWH"LMYO4>PYW5EX>QEDV QBY2NQEVKTI#/H<D^U6&-7
M54?I,0*L4[TID$S!A7,UU=]>CCW&QV:3Z>]0XU;N3J.=-K6=KN6]=<[,VO7N
M1_._C1Q]XH\<N0W+*)W[O2@P>THVQPET>3O(EBC/P\H2T6IE7@HU=E9=Q'U<
MJ<D,JLW(JM(2Q7::XC1 (:2XAN@=;/H->[UTI 3'5@Y:53>MVX]S'"EC<-C\
M<JMI6Q\F(+3LYMS9)'J>Z965?HN=-6*)TZ%:;PM)UDR;7.2E]P2-%:V>Q^V-
M?PZC%:#=60[_ +?]_N5.D:!WV.];T/3XC9]?HWKU7<*EU8=BS?-C>/">;U?H
MVOV+C-![KV9M;:,EOMA'Z]FM34FGU"TZZ"F%4B7<XQV,]-;T4MZP%C8DB=%P
MT4ZL"\K<"/HZ.5(6_)#AL@Z&M=P?0[^C8.OC]&BL2T'K*<B;]2^6ZM*XFP6Z
M+]H6K<9-D:W1TG([J>0.U-7<C9";1<7: JFRM-Z\VY;XBA05>D;=$O*;2'9-
MOUX6TG3D8V%<(S:Q"P?)^5K>P=Z[$ >I!([['KKI]_HO@?K;;,N<OK2J<=..
M4+R2LTEQ?/R@N@:R#?<@QMD87;MNU,77&KH\-&J6>L6=M)TB<:V:R;DA:I4*
M?=O)H;]Z^%)U9$RJ6:[DZ'5KN1V[ [/?N-'W?7\ <R,^I9RVV/?.:D;I?BOK
M!76'#0;8%KV#M3;L]4YB26'C87<U#BV=&K])M#YY.$M"K2"V R-)1C.(AI&)
M5@Y.6?.I4]?*G2--))^4/0#9[.T?V=Q\2H'V[F_RLN.A.GY?]R3J5=V9R-X-
M=0O;58M?''>=_J%>.2I<$*WLRO6[;.MFE0K$,_V5'VJ2D7E7AHN6>1.I)IHW
MGJI9I6376*V*N@"X#T#@.X&_G$=COT^/Q^ 4Y.E=SDWG>U>+G$[D;7*Q.7"Z
M=,S1/,*B[IJ^T;;LBS7&H*I4O7,W^WA.ZU>$F8O;-CFY=I;7LJSE;-"2CMU/
ML/;TE(QJD@_?P%1S1W(] XM(^'J1KN>VOZ/7NN=X:[_GE>J/UF->[3W7+J4/
M75IX0(:CH]_V.\-4:*VLN@K%,7-'7-:L4R,-6$)^8!C*V=.LLF*<K)>D?2I5
MW7DJX1P'1&>VSU;^)T[MM<!"=7>^2>S*G*K:$JW\F^^=1FS=,ZMNV.PY5QR%
M;[8@&\ZBWV?-Z^7J#6HM-?R,[7'S)]7C6]*S5R"=QMH?NG":JD24G2->O?IZ
MOHT==A\3W[^[U'NVN7X ]3[D#S:Y LJ(ZXY4BA:H)JN_[!OD^PMFT9VYZ3N5
M5V<[UA%:"VF$[J:G4MENI\[:.;%*5F)G7B3&OQ4\Y1<N CV:DF0M 'J=[&O3
M1!]".^]?3KWA5S:[Y%;^MG1CZ6:EJY";FBG_ "JZ@E<X\<B^0@;2L[7<##2]
MDY,\BV4F1ON63DW5JJCIZA2J;K]E:2S"*\- N48-JX19*(ML*NAU.[#LTD#0
MUL >H].WK]8[^]3_ ."_+W9M,Z1_(;D;>['8MZON*CGG"CKB]W27<6*R;DUY
MQPM.Q0UQ*V>V%,5>SN7D?7&]7D[;YIW<FE$*RC]VYDA>/%BH6_*#1V)Z=_ %
MP&_L[JM3?EWZB->?=!^.XP<C[K8N2?);4O+#E'LZ&OFP+,;5'(;8(:6U7R.D
M-5W6JDEVU2]Q#,GMEU7J.,%E%06KX^5BI*L+5-RW7FD"O ;J38[ M UZ@;(V
M/B?3?Q[_ %+L?'NU]1KD)SIYL:WY=[=V'H"U;-Z:Z?(73^C=8[2ML76.(,ZO
MMN(;Z?%!O&R$?!R6T*PG6F4ILJPKQAC6SVY8:39$7%6</:V0J.#0T=/?3B"2
M/7L/3X#OV^]>@3IQ<D[%R_X,<8>2%PCT(VX[2U9"RUQ0:-P9L%K?%K.ZW:9*
M,9A\&<3,S\+(R\2S R@-(U\U;@JL"?FG+S<-.(]=$A38PJ)A$PB81,(F$3")
MA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(
MF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(L=;0U%J[
M=E93IFWM?U'9=22FH6R)5NZP4?8H5.?KCY.3@)DD?)H.&Q9*'D$DGL<[!/SF
MCE,BR)R'*!@)_'W^JW=[UAKK:"540V-2*Q=T:+>:SLVF)6>&8S)*OL2ENE'M
M2NT$5\BL$;9JV\55<PTPU\M['KJ'4;+)F,(X39'H=>[[/@L7[2XB<6]W7:"V
M3N#CWI_9=^K3!")A[?=:!6[#8&\.T?\ M5G".)*2CUW$C!LI432;*%DCNXMG
M)'5?-FB3I514Q5V1Z$C[5L_Y&G$T0C0-QPTNH:(M6Q;Q'K*Z[K"SA&W[?CCQ
M&U[&=TK''<.)?9D0<T3?GCE596WQ8$CI\7[---$I-GXGW>_X>GW>[X+%[+ID
M]/*.CY>+8<*^-+-E/5B)ILP1MJ&FHK2%:@9QE98:+<NR10/#IQD]%Q,HS7!<
M':+N'ACD< $/&E:E7J=_E.^\_P!J[?8N _"6VU[753LG%#C_ #%9U'#O*[K2
M#>ZKIZD93*W).%'DM6X-J$45-K7)I\LL_G( 0/$3<@LL^EF;QVJHL8J=3N_<
M]_7N>_U_%9NJ6F]3T)S>W=*UO2:JXVA)(3&QE("M1,6%WE&L$SK#9]:"-&J2
M<RX0KD>Q@DCOB+>"):-V!0!LD1,"IL_'T]/H6#*AP!X1:_8-(NC\3] U..CU
M]EN6+* U?4XMLR5W)4V-"VIZ5%I&)D;IWZD1<;3[.@D!$).LQ[&#73&,:(-D
MRJ7./J2?3WGW>G\?'NNYZ/XB\6^,[ZPR?'KCWI[2TE;&<5'620UIK^M4][-1
MT(0Q(F.?NH6/:++1S QU7"# 3@T*]<.GXHB]=.7"I"2?4D^_N2>_Q6.]H=.K
M@;NV]S^T-O\ #_CMLO8UJ48K66\7;4]/L=HG58R+8PD<I*S,G%.'ST[*(C8^
M,;&76.*+)DV;$\*2)"@50YP&@YP'P!("[J?AQQ@1V=+;R@]%:JK&]I1K)D)N
MF!U]4&VR(N6E80:ZXM,;8'$*Z,E;/8X)1I[ L@O(O(QNC$R"[R)*+$Q4V?39
MU\-G7KO7W]_K4 > _26DN$&WF6S$^2LK=HN/H=VJ#^HUNG7FA-MJSUXM,=:I
M#:.^_>;>^VJM>=D,G[1^K'S-#I&I&"3R=EG2D4H@N1BF5SG]0]-=P?N!&@-=
MA]I^M6+K<4N-#G1:G&-QH;4Z_'A1)XD.E5J-7U-:D!_8W5P=*(U([$T.W<GM
MKQU9R.T&J;I"P+&F&ZR4@!7 %;L[WL[^/O\ O7;HK26HH'4)M!5_6].KNE34
MV4UZ75]>@6$%2DJ5-L'D9+UQO!1*+-BVC9)E(/DGJ3=)(SDSQRNJ<RZZBIB;
M.]^_>]_2H]<;.$FO=$T/C_4K:>!W99.)+2\T[B_MBYTB,;[/U/J2U,_=J-H[
M:RB_E3N9:,UTWB-=3UL@D*HE<J] Q0R5;:.2.CNBJ7$[]1U=W#?8GU]/K[Z[
MZ7:.0/%.K;?@MO25%5K&G=\;DU(IH6>Y(1= B['M"+U)*215IZMQ$DK(P;KU
M*<>YEU:<XD9%]#U.W.8VUN*]821:D'(E0'6M]P#O6^V_X]?B.VPLS:=U-1=#
M:IUUI;6,,2OZ]U73*[0Z;#D4,N=E7ZQ%MHF-(Y=*?SSY\H@V*O(R+@3NI%^J
MY?.U%'+A50Q"=DD^\[^]9(PJ)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F
5$3")A$PB81,(F$3")A$PB81,(O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g383050g17s56.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383050g17s56.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X7BS:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z>&UP1TEM9STB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(^"B @(" @(" @(#QX
M;7 Z0W)E871E1&%T93XR,#(R+3 X+3$Q5#$Q.C(S.C4R*S U.C,P/"]X;7 Z
M0W)E871E1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y!9&]B92!)
M;&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]X;7 Z0W)E871O<E1O;VP^"B @
M(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#(R+3 X+3$Q5#$Q.C(S.C4S*S U
M.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I-971A9&%T841A
M=&4^,C R,BTP."TQ,50Q,3HR,SHU,RLP-3HS,#PO>&UP.DUE=&%D871A1&%T
M93X*(" @(" @(" @/'AM<#I4:'5M8FYA:6QS/@H@(" @(" @(" @(" \<F1F
M.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.G=I9'1H/C(U
M-CPO>&UP1TEM9SIW:61T:#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z
M:&5I9VAT/C$X,#PO>&UP1TEM9SIH96EG:'0^"B @(" @(" @(" @(" @(" @
M(#QX;7!'26UG.F9O<FUA=#Y*4$5'/"]X;7!'26UG.F9O<FUA=#X*(" @(" @
M(" @(" @(" @(" @/'AM<$=);6<Z:6UA9V4^+SEJ+S1!05%3:UI*4F=!0D%G
M14%304))04%$+S=107-51VAV9$<Y>F%'.7=)1$UU34%!-%%K;$Y!*S!!04%!
M04%"04%304%!04%%028C>$$[05%"24%!04%!44%"+RLT041K1FMB,DIL04=4
M04%!04%!9B]B04E104)G445"055%0F=51D)G:T="45E*0W=G1T)G9TQ$06]+
M0W=O2R8C>$$[1$)!341!=TU$07=11$$T4$5!.$]$0DU41D)15$5X=V)'>'-C
M2'@X9DAX.&9(>#AF2'=%2$)W8TY$03!914)!64=H55)&4F]F2'@X9B8C>$$[
M2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(
M>#AF2'@X9DAX.&9(>#AF+SA!04519T%T045!07=%4B8C>$$[04%)4D%135)!
M9B]%06%)04%!04A!445"05%%04%!04%!04%!04%11D%W24=!44%(0T%K2T-W
M14%!9TE$05%%0D%114%!04%!04%!028C>$$[05%!0T%W449"9V-)0U%O3$5!
M04-!44U$06=10T)G8T1"04E'06Y-0D%G35)"04%&25))>%%614=%,D5I8UE%
M54UP1VA">%=X46E00B8C>$$[571(:$UX6FDX0U)Y9W9%;%%Z4E1K<4MY63-0
M0TY546YK-D]Z3FAD55I(5$0P=4E)2F]-2D-H9UIH2E)&4G%3,%9T3E9+0G)Y
M-"]0128C>$$[,4]4,%I85T9L85<Q>&18;#E76C)H<&%M='-B5S5V63-2,61N
M9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;RM#:S535FQP95EM6B8C>$$[
M<6)N2C)E;C5+:G!+5VUP-FEP<7%U<W)A-G9O4D%!24-!44E$0E%514)1645#
M04U$8E%%04%H141"0T53355%1E523FA)9UIX9UI%>28C>$$[;V)(=T9-2%(T
M4TY#1E9*:6-V17I*1%)$9VAA4U5Y5VE9-TQ#0C-04TYE2D5G>&15:W=G2D-H
M9UI*:EI&1VED:V1&53,X<4]Z=WEG<"8C>$$[,"M0>FA*4VMT3515-5!2;&19
M5U9P8EA&,658,5)L6FUD;V%7<')B1S%U8C)2,61N9#1E6' W9D@Q*V8S3T5H
M66%(:4EM2VDT>4YJ;R8C>$$[*T1L2E=7;#5I6FUP=6-N6C9F:W%/:W!A86YQ
M2VUQ<39Y=')Q*W8O84%!=T1!44%#15%-4D%$.$$Y039X<&-8;7E)=F\O;6DW
M<TEB828C>$$[57=81#943D-F,S!"6EAJ6FU754%G=CA!1W98665'2W!N-6PP
M:3@Q6'DW93986C,P;&AD6$U*:6EV,')Z4G1V:2M%<#$Y:FER1%@O3"8C>$$[
M+W=$36MW5VM59FYP,%=Z-6U%9E4T-CAV<3=14C@S1&=Y0E,S2VHW13<P<4)H
M5FU.:'!L.6%A;F0V:&5A:3%Z1%!A5VM(;W-/0U)Y5R8C>$$[>&U-<W=(26]V
M<F5Q2S!!<'@W-$986$]T,C1V9$EI=')I1U=,535*5E1J.&9.2318;#5X=7)C
M84%Q2S=(<FEQ85EQ;$=T=EHS-TYO128C>$$[97)N5'17;FI7-6E7,VM28F]1
M>'E,>61587 T12]!>' S>%9V>7IO3GAO;&A*87HV=&4V>3=Z3DU,<E5(4C56
M1$%$,'=9,&I8:4].428C>$$[2V0X5EEX8RM2=E!+-C5Q;6]A6C5W:W,T3E%L
M.5-/,6MT;'56:552;$924%99.%%P3F1U=FAI<79P2&MV>F9A851A,D8Y-6UE
M+V$Q=28C>$$[-T=E3V1O,VIC45=Q;TIO:393:'!06%I46#%#=V]E;&5I<DYS
M5F1I<5%E93EF=5!,+VQ7+S%I0V$R=#)S,5=2-7)X6EI)5E1M03%59R8C>$$[
M+V5-84=I9V0X5E$R="M59%4Q=&],9V5:3E(P;'A$14I9=$UD26]M:U%L;5E#
M5DI706)L46EV440S<7%Y2SEG:W5,3V5#3U5W4U-X=28C>$$[:51R6&MJ37!!
M8U5),UAR,7A6-7IP+S59*V0W5T-Y=&XX-EA$>%<W,G-L>$IW;6%755<P.7A+
M62M45&M"6D9U44<K12\S84-L34MS;"8C>$$[.&QE5DY9,$)(6%5T8VXQ;W1B
M45%"<"M65F5'5S1K6GAY9"]T3$]I94Y%1E-E=U9K*TMU>%9H,7)F-G U:3%(
M>DQO4C%32S!/;'IW4B8C>$$[>'DV86MQ6%503VLV<DQ*3E=.*V-81W9"86)K
M67%N,F=A3E!P3G).0DYQ9#-Q<E-Z3DUS,3AY4$EI<T9!:55X<$=/0SAA:6]R
M=C%X5B8C>$$[:FYM,WE0-6PQ9GI*0G$K;"M9-61,9V=G=#1Z64%3=$9).$9Y
M6C):9VMS9CDT=$5B8F]/+UI62S$O3$1Z:W1X951T-3%V2F9R46PY3R8C>$$[
M,UE3<DA#6DQH2F%X.$IL649656=E+SA!:S%5;%AP5T)615AC0G9'<W=38FA)
M,6U:94QC46IS>7(X9$].4U5/,6$T<7)9<3=&6%EQ="8C>$$[36M9<E9G2T5!
M-VI9=#!(,#%X5GEY>$U&2W5P1&MH4T-#0U)7;T@S2$97=WET5VA"<#%P.'$T
M<3-I<GEB>51C*V,P,&96;3AO-F9:4R8C>$$[4GEA-7%,3RMQ6$5Q.&@V>E9K
M57=X9$@K16]/3DM6,S995F5S2GDT:FY14%%C9TYX6'9407)E2W!686$X=#%,
M<4U&=D=S.#EJ8TYB8R8C>$$[24I/86QH1VMN-W@K2W)',S=Y:%4Q27 S>%9F
M-69S8G$Q,&UY4RM#:2M3,FAI;E=.:39)>4E!55)I1DQ+1"LQ458V,$A12W!L
M:7)"<"8C>$$[-')6=GIR=$I23D]B<%!,.'ET8FE*9G$T5#8R:$1'6&M'-7-4
M<W9%:6<R23-Q<7IN1EA9<6=.6#%Z5&1+1G%,>5@P-4PK9&)3>&IO5"8C>$$[
M-G1W-G-Y4D%G14%S15!88F)&5EA3<F$Y=')#2T<K=3)V-W!E4FQU;5))>3-*
M:7=(1TU+;T-G.%)T,C,S>%9&67%W-S@T26\U9GDQ,28C>$$[-4I,86$X47=$
M;&%7-4MY4R]V1BM"4T9C-RMW>%9&-GHU4G9D6&=T9E,X=S9N<$II:6E6=G%-
M:U-C>DA5,6)L1W=Q,TPT<4%6;T]G<B8C>$$[5E9K,DMU>%92:W4T23=Q1S%9
M;C$U,60T,4-S4GAJ-#AI5T%+<E1M3W S>%9*3D\X-394<4QW,E5&,V%N5DQP
M<F=7.71$34IW63=76B8C>$$[;UI*86=*5E9+,7 Y1TMP=G!M;G!P.6A$6G!.
M4&-,0TM#839L865:<6MM<GE/4WI(9D9716589$IA-3@R969);UAV3D]E83AS
M:6(Q6"8C>$$[2#<Q;'0T,S525FI7:6=,-E(S3S%E*RM&5UAE6#E&;C!I,&QT
M-714=3E685-:<&QN=FU2-456;%5#3E1':UDT3'AQ2VEU+UA!<5HT<28C>$$[
M-T95;SAW83)D3G1R;W%"1DQ&6GHS:V1Z349.=5!1-&=Q+WAO.5-:0C=E*TMO
M9E0U-VEF>E9D4T,V:BMQ=G Q<5DT1E%C-4<Y868X028C>$$[9G%X63!496=8
M:69'=4MP9&(K47174G R:S@U83(O<7ET26=6-U%"5F)O=G@R.&Y4+TIO4%E:
M96-W+VUX*S,Y8E0T4B]N2#=0,4MD."8C>$$[13AN4U=E<&%L<C)S87!B,TYZ
M1EER8E1M,&5)4&-%<7)U<V-%36Q&<"MY4V9B27EY06EQ02](=EI29U(Q2BM8
M-FM.4"ME2#5D>#)S="8C>$$[>$AF4WHK:6E33D=L=DU'2WE7-UA3,#5Q;R]U
M:THO1')L5%EW+U1,,SAQ.6,X,4A563E:,4)D6#%E*VEL5S%U645L9V1Y2DEB
M8C1(9R8C>$$[;&E596TW;VI-95$T.61T>7%684I$*U4X,F<O;U=85718,#8S
M:'5#16=U15)P3U1X43)G;5)O-'!E4$YR<$="<5!L>%59<7EF>5(U>28C>$$[
M+TM,>7):5$IP=7585GA&<6QZ035E-FAM9'A,8TE6445R0VY8,&E35#DK2W O
M6F9N9"M8=#%:9E=X951);W%8:DYT3S=O=E989C P8R8C>$$[0E-P0G)79W(X
M5DXX0W!6-4DX>C9*-6(X;UAC,7-U;S8S8F9P<3ET,F5Y<S-N;$5H8W5A>'AY
M5&M2<5!H1$5J='--2W946DQM0TLS*R8C>$$[<U1U<TU)04Q02U%G54@K8FQ3
M;4)5=3%#-C%I5S=S-'1*14PR<&Q),4\T:TIR2$9W2DAO52M&<$]60E$W06)N
M=TMQ6E%W47=P=VE1228C>$$[<$I9,#9L:C%::C%*4&-N1E8K2W5X5F=U<S)/
M;#9L*UDW859E>FAV<FUJ5DYR1TE)<&Q72S9$:50Q,6U7-F]7<%)22'<R3E<W
M67%Y5"8C>$$[>7HU5S!F>3%94U=/:W!+;'1,33%W-&UN;75'.5)W07@U>DY)
M+W=#>4YQ-'%R86YR*VLV6F,R5G1E>FU/-#%#47<R8U-P2DDP:FAE4B8C>$$[
M04-+,4YH,4]+<DY-5S9V-V5#.3%E=T9N94M363=*,VIN.4%G;%%W9$MQ6%EB
M,4A11VYJ5E9-.%9D:7)%=GI8:G,U9DE/<4IE;4YB3B8C>$$[:$-,:#5585)6
M47IP>6)I<51';S=F06%9<6E.9CAG95=036XQ96)5-#4S355C85(K:&,S1G5/
M2T5S;%9H94U':%DY4BMO559:3&EQ;B8C>$$[3&17,%5S555S>5)Y>FMR0D=Z
M0E=C9U9)44AD<41F8D9737=00C5I,2LP,4LS37IA9G!:=C=#9%DU:T54,T%K
M:E(Q;E)(65-)4%-0128C>$$[2&\S541&53@P8E,T.4US0EIX*VU),6ML:U99
M62]3465T2S!P0V]#,4%#-7A62%EQ=T11.4DP1RLQ:GHQ85A24E=M=DQD=%)%
M2'%7>"8C>$$[5E5I5U-&,FM#4F9&4599:5)U+U1P:%9K,VQ84V9,,FU753A7
M:%,K=&%Y,T145$XY6F4W<$UY<4=!95(U0W9W:&9H0F]01$%Q8S1Q:R8C>$$[
M9FUF>D9*;SA%-5-.2&Q&:F0S8T%*3$\P;'%Q:U)R0T]*:S5'461(1TMP5G$K
M:#-/=&LS='I:>E1R8S904&)F55IM5EE&:VYA2FM74R8C>$$[,FMK2VE7;TI9
M:T5,44-P27%3<DPT;%99:U95.4I654)9.6AX04@R84QT=#=91EA9<3!Y<3%/
M44)O86EV:4U68455439);RMG9&A4.28C>$$[5S)+=$Q$0W1/2TMT04%+04-G
M1F%F9%A&5W!B5S)M4F\U;VMK4F=66DA534-P<%5%2'1S359A:71,5TM+3TM+
M1D5I:%95:5)604-Q9R8C>$$[;V=59&=O-EEQ=5='1E)X5D9#,'!104%5>%9+
M=$,P<&1",#8U1C%C=TUR>7E853EW:T56;VQ704UK:V=4-%,W148U2%!6:51S
M2T%+<B8C>$$[3F$P9E9D670W*W=L=D5T=$YU55=/13(T;%<T2TUO.5%027-K
M6D94,#1%8F0X;41(<6<R;4AP86I%63%I84)O5C)E4&<V1VQ.=4Q";B8C>$$[
M-RLR4' X,3-B5V4K:E8R=4QC1E%352MR='I0169Z0F=H<B]Q,7AO9$-I>75H
M=C=757AR>3E/5U5C:V=L0FIL27!5+T$Q1S(W-$1!:"8C>$$[26M%4FM5<%<S
M;'I4,CAY<C5I675B.4Q5,F%!;%-I>',T9'%F1'I&4T)58W%E,60X5E4U9%1V
M3#8V14]H>E=J=S)T>DIA-C%,2UI$2B8C>$$[07EW:#%72D98:3<X;E-V2F=!
M<')U9'-)<G%H8G!&=61%<W)E>6Y-.35*,&4K2FMU6DA.4V%Z3S-+5&%T0E5N
M8C=S;%%02D9K8S!A=28C>$$[<S9C56IC>4UI4W1W4C-J:U%&=#EI5U55-F0X
M9D1+.%%82G$K;'E#37!D4G0V>F-)-DU#4S(K,S19;DA)9$8T9VDV:GAY1$IJ
M9C5I828C>$$[3F,V-351=CE(=#=B-C Q*T5H94UM9T-&,4Q/9C-K3E%O2%%/
M35969DY0;%1Y-7)U;7=2-CEZ5S%S:4I6:U,T;'1!<$%'-TY%.&4R,R8C>$$[
M4FI41E=R;GI.<418;C%7=S!E-VM%9#DY4W4W<31J94=*22]237!U669H67IO
M1TMO2V-15%@T='-G6F=D+W=!;7E/36MC>#AW;&QV-28C>$$[5VEK,6E++S%)
M86AQ3GI"<49Z8S)H;DU:9V=%,75),FI62&0V43!R=S0O=$A)*TMB<FA0,F9R
M6FY#2W9I:GDX+S%*.7!K8T9G<E<Y;B8C>$$[<&LX154P.#AZ:VU-<C9J3U=D
M>E=6:E-2:5-V.$U2:U X,"]:*W1"=V=$-F\Y3R]R.$]N5D92-G!B1U)9<'<Q
M<D\T9&QH;6]#5E)G<"8C>$$[25I3>4AQ1',R27EI-D]X.#%/0U974%5/.&5F
M,F]I1V%'94I:65I&;&EF9%I%25I34%EJ8DQ)>4)&:')L17A.15573F579DPX
M,79R6"8C>$$[;6DO=DQ2654Q<391:4YQ4#9K8T58,6-->#E34W9.5415-$I1
M1VQ#86Y#>%).=CA!;UA11VDP-U%D2$A#.75:4F-,<'-54U%1,T%H.28C>$$[
M4G!,;V=O27EY<7$Q;U-34F=*<&Q'3G!B9'8X06U295<K;6=146%D23A&=TY8
M4S-D3&=,23!$0T@P;F-W=#A-=$-/;G9K3TTO>E0Y:B8C>$$[6C1C8E!Q2#(O
M<5@V9F]O9R]1.#)U:C9Z8S)M;7DR=#=D,W-3>F-M:U=%5&QP+U5D63%F,#DQ
M<#A1<E4T*TQ8358Y>2M$9#A*170O:28C>$$[9F-'4D15.4AH4E5&,6)X;VMF
M3E8Y4D954DQ18W5T06]X3V%(95!M;S K43AO;G4U9%9E3S=T6EI$1DA.1SAO
M6&U55F=7-&LP-55"-B8C>$$[6DE4:5113$$T-4%746%68VMW9&ER<U9D:7)S
M5F1I<G-656(R>71,-C!M<S=Y1DQM,'5%84]E0U91-D]J0VI+>6UO24EX5E)S
M<F$K:28C>$$[;75Z8WIX>E<W>6<R34M20TUW=VE.1CE.:E9U9GAH;7)19&%D
M<U963&E#-&5A,F%'9C!9;W!#,7I(=U9V5E%X<V]3<"MZ4C)6<6IW<"8C>$$[
M,WA62DY..#<K5W1D=6)J4W1),4)F,'5K5'8V2FEF;D="5E9L6E=!0EAL-S<Y
M3W5.2VY';E=T,T99,GEA:DY(95@X4T%4,U-20T98928C>$$[;$=:62M4.$%F
M1&MC5F%T<F95:S%#-VQM=6QK<UI/4#%3,4595F\V26]A<VQF:7%W63E/*TMO
M>D953&,R1%18;'!C<&-Y=TQB3S=Y428C>$$[4FQ22%!Z:DU95UE&4U-&<4=7
M:$<T1TMR-VDP.6%A,FPY85-0-G1)6D]%8F-6:W)',&9'469T2T]F2VYI0FER
M2%!.;FUR>3%P=6\R;"8C>$$[;G%M<U1A5DY'63=V.3)'0U-*-FA!:FM9230T
M=5DR0D<R,S!9<6YU;V%D2F5Y5VMI6&LY<4QA5EI74T)G;VQ#:T@P-4%187%A
M8C1Q<"8C>$$[-GAP13)O=&%'3%5,;7<K<7IP32\Q5FQ8,6Q29WAI:S5+,55A
M;$0S<&EQ631Q;U@Q:EI8.7!,6C-S161Z851Q56UT-59$;S9N<WET528C>$$[
M2$9534Q45BM/<&AR,DUT3WA/;4519V96;$U3<4$Y5V(Q85-H;G)T<V%9<6LS
M;7)8-V916DY':S%(6$ED3G0K56I8<&QT*UEU:VAI-28C>$$[3W%S1"LV22LS
M,S)"-T$T<6MS,S5K*UAL:G9B<B]%,$UD;G%-45A26C-T2$5D=DM#-E9::5 S
M;V1I=$LK2'9J4W-G,%IT53%44CE&=B8C>$$[-U17;W)M2FM75S=U;S=54G!D
M<5=5+T1'-4Q29D-'2%AV:7%:5U9L<3!/<E@P,#$W2$IP37%W:7<P.5E64F]'
M4E-*4UI19FI%:&]A128C>$$[8EEG56MM,'AX46QX,' T3#9+8E1J1%HR.',X
M;'AQ,$MW<5=U;F5(,#%B;4-V1G=Y;U,Q1%5#;4MQ97!T9#)6:G)&-TQE<D9B
M<$$X="8C>$$[<7=G-6TR16-*3$]60G),.%$U8V9O>%9H.&8U:#9*3EHR.6Y(
M-6YG=713,#=H3')443)4;%HT,6M+4WAH1%521G5$2CEQ;U S63!T,"8C>$$[
M;5!L<GI*82M:3E(Q-61).'<R=6]79V=H*V\R561Q56MS=E9J6F55<G8O93@S
M47-&2VEG1T-G;7EN32ML*UEJ63)35RMQ>'@S.$YY:B8C>$$[,W0T,7-J979A
M<3=-,$A!1E%H6D-&-4$W9&-.0F)+9#1O9&ER<U9D:7)S5F1I<G-64TQZ4#5U
M=%!,<7A.8U=';UAX;58R4F10=%I,<"8C>$$[=C-:545%4CE#964S,"M'2V]M
M-SAY85I:95A$-6AV:DIA865L=70Q3#8P8G),1VIQ1T%E34%S<D1L47(R3TMP
M5V9Z4#AG:4<Q;6)83"8C>$$[44QE16E-97%P6F%1;61V54%*35E61C-,54%.
M0C%/2W!N6C9P;T4K='E73G%%8E5O3%9,9W5S4D%.=&-/4W!36&IX6E=D2R]#
M,UA&528C>$$[,7A6,DMQ3C=D2F%78SDP-E!);'9'.')*1W9.,D-+5TE24C%9
M,#)'2W!F;TAM3S,Q<%IM:',W>3%%4$5(-C5B=F(X=5)99D)Z*S!0:"8C>$$[
M-FHR.&-645$O35AY54Y4=CE-;3%A,W1R=E18.4LV4S5C44%0>$QK2UI/4$MI
M<G52:7%Y4'IR-40Q5%0W5SA&.6)85G9E>E<Q<$-R3"8C>$$[>F-Z,V9&-V5*
M;WE#-G,S24Y29TMD93)+<VUX5C)+=7A625!-4&XS>68U8VU%3W0V<$99>6M2
M:TQ,>3-%<%E*,$(K,%DR*S0T<6YD>B8C>$$[8U$R,79,8U1.=VAH4G!*1V]4
M4E9&5TY"53E":7)%-%!Z5"],-CES;TQO6#1A,G589VEH37--;T109%-44E),
M4FLW=&%3,3=!3%AP5"8C>$$[1E56-64X>2M39DUQ1S$P;C W<48T4')*:DYU
M>5)T1DQ--G5F,VE+<').13-)9GI$1E=3<7%Q;U911E9244%B04%9<3-I<4$Q
M=EAD2B8C>$$[,%!4-4Y2,6$U5S!S678W>61W4W$Q.&5)3TMR4$PO;5!1+TU7
M;7)Q96DS85@Q9S=-:7IX,31L:TY'2'A!2%DT<6=.8C@K*U9.2#%Q2"8C>$$[
M43E4=6I&<49Z2$1*1D0V56IH:W5:+W$P9GA+<DPX56TS-CA64V<O;6HK5G)8
M;#%',F\R-75R5EI5=6E96#5!97-S8DIY-&9&-FMH5R8C>$$[9T@R=75+<W<Y
M3W=S635:=4U6<D=36&YK;W-A:VLW<S4R-VYQ8U9204E)0D)Q1'5#359D:7)S
M5F1I<G-69&ER<U9D:7)(=DI8;7%4>B8C>$$[2EDS.3 Y<4Q4-FYQ1C%92V]C
M>4(Q=&XT0U-P5E!T.6%F:6-65'4Y<V)/+W1*8D\Y9U,U=%HQ-%114W%(4FQ0
M67%D<U936B]Y+W=$228C>$$[>B]B,$14,DY'1E1B4D4O1VY"<6YJ6&14431Q
M;71V<%=M5S%Y.3%B,G-53GA,1VM5:S!A2W)'3TE5:E%K1#=+,3)'2V]06$IB
M2T\X,"8C>$$[6#8P.&%E<&9E;D0V<%5C<$1B5$9&6&PQ87$Q04AH:7%B67%X
M-EAZ5DEN;C)$>7-,54=/8E18,49R>C%$5E-K=VE%9G X4TXV,7%7*R8C>$$[
M438T<7E(1E5M=79*9FQ#-W5:<G$V,%=Y;G5*,DQZ4WEW4G5Z35)X3$AK1'52
M<V9(1E93,#AP958W3T515W5K,FM%46QH=4%K8TUA9R8C>$$[4S)W55%Y8D0W
M569!8U0R>%9.8U95:&17<'57=%)-:'5K45-004=(<4)'2D%9<E=T0U(Q>%9I
M2#5Y>#)S;C5A-C,Y6F533D9I4FME1R8C>$$[251Y0GA+<%1J0WIX3$EE6%ET
M5$966%8Y8C%B5&MT271$.'%3-CE:;3)G.4<U9VYT66M%6G%/4#<Q:#EL5D1B
M5G)8-31Q>3)33T]73B8C>$$[;S5&1'AU0W)O=T)6;$EO45%E;T]+<$I$-4,X
M:W=Y47EX8499<$IB8U1!-'0T-F]58W5P6&)9:&U*0C8W;D959'!U9V%(<&)&
M=$XP*R8C>$$[,W-M6D9I67=22D=3:45L5BM%1%E&:6-64E4Y>F%X3DA&3DUK
M5#-"2U%Q>FA79'%6;VTT2DY01$952C5E-69O2%1I>G9)-U<P5'9*228C>$$[
M-U-/>DUG66QM8W-X,U!C-'%W3'DO<4AL4%-03C-N<35V<FM2;V)Y1#%44$-&
M4F8Y2$UZ.$A$4TY)=E!M4WI+=$0X239$0W)09$,Q=B8C>$$[4G1:<U!R96M4
M<F-787E343@P57%"2D=X5C$T<T9/>F4R0E905E!+=FQR5G)K6%=P-EAA,W1Y
M15=)5%1X23=H16-U9T1-0U)X66MJ=R8C>$$[<FEQ;6YK-WEK;E!J;S%K1$MR
M<DMF<3A8>$Q)=V1G,W<W,6119"LK2W%8;FXT=DMM<%%#9#=:-VE#4TI:;S)#
M3W162EEQ>$)!4$5(1B8C>$$[53E"0D%)3E%D=U)I<G-69&ER<U9D:7)S5F1I
M<G-6958K4G9/:392-5IV.$%53#8S,5!61&4V>'%C:4Q:,C Q,C9C6G@K-F]+
M:T)E6"8C>$$[1F5X;U0P=W$Y3G-,=$PR>'0W>$DU26MU66MM5TM:1$A+;VM5
M349D1'5R0W4T4%$T1E8X5F-304-384%B:VY&5T\V5&%R<58O9C-..28C>$$[
M6GDO5C=454]E;$,Y<$E#>7=)=C%M,T1.2GA4:WII36II9#(R,T=+<VEX5F<K
M;S)6>G%(-6]M,FUU0TY,8GDO3D1,84I-1EIN=4QG3"8C>$$[-FY!4'I"0TM1
M1T,O5&EQ9BM7=DM7:2M7-$AG,'1*;%-52TI$4&-46$1(9U=)*TM:-40K,F5M
M2W!Z:7)S5E%L,7%55G9D=S)Z>'5Z5"8C>$$[4GE32S8X94E%6E931%9G>$I-
M:6=!031Q,6$V9&)R9%!Q36M%63%+94Y9<&)G2W9Q0TI35U-(;E1K55)M2G P
M<5-E*TMS6B]/1U<W:B8C>$$[+TQ86%1A6$@Q4S5-2W)(8V@O5#1%>4M#,TQK
M=$YV9C<X5E(R=398-3!V23=C-D)R<T=L;TDT=E5%,6],=FM62DQK179(.7-&
M4C=5.28C>$$[.6Q74UEQ-T960U,X4DPR0S T37IZ<$I)1TA(:7%X1E%3,5-$
M=5I!0E%(1E=,>F591#9M:5%O6F11=7!T575R9%HT;WA):V%O='I':B8C>$$[
M>FU)2W%!24(T5G!H5D]02CEO8E1Y<G!.=5HU8FMP87AF=C=H9SAJ8VM$9D51
M1D<Q841B<&=6:"MJ87-B3'I(-2MV9%%%=7!78TXU828C>$$[9E8W2T)F<DUK
M87!A:$-&:D1-1C5/<#(K*V@R0E9M9FQV5S=F5W1+4RMT-T\V<TEM9#!&=F5W
M3F)3:F=X0E!P='9X4%5(07%A67$W1B8C>$$[56<K<39H4#4S:G9L:E$V5F)7
M171U6G5+8WID3DY',4$S3&M1<4)H.6UG4$QF1E4O>%8R2W5X5C)+=7A6,DMU
M>%8R2W-.+TLR86544B8C>$$[=%0Y6F):3T=Q,UEJ5WII14U8<'-Y=D=W06IH
M-3@Q64U(;V5126)K=TYC5EIL:7)(-R]Z;%I26&-&<%E24'%%>C9G3DUU=E1$
M2VQV3"8C>$$[-E)L2FMC<GAO;S1G,%!6:&AP5D-$>3EP53DT6G18,4IT575)
M=%-A.'-O6DIU2U=S+W!C0D)':4UV24MH8C1(<C%R5$=I:3)4339,5"8C>$$[
M:W=(23!7<'!5*T%W2F)X5FAK;'I,+WET-D-"3%I04T]I=5IR<T-(,4]1=48T
M4G172#$K4#)I3TTS0W1A:71-5E13>&TQ3%))5VLX>B8C>$$[87I$9$IC4WAW
M,G)R8B]6;%(S3%56:4=E=DQB8S!',W9H<3%D965A:6UR,D9H63)B6#!.,G,U
M;G9%8TMK2FE#;$MR4FYK16Y,<6=.328C>$$[:TU:<3)0149+3S(X,% U;6UV
M<$HU63E):W,T-&\W1TE23GAU1FM9=$E(:V9U;D5F,V5':%A.8DYQ<S)J*W1R
M*VYA;3%M,#EX6E(S0R8C>$$[4C-6>$M"-F)4:$%E0V]76#1L56<P55EG0W5A
M-S)M<TYT9$,K:W5P6G%O.&%O='-V27%H5FE3=TIA:$I"02MY3VU22D95:T%S
M92].3R8C>$$[96$R.&<V=F-W44YC>G=*2$Q&07-A>DUZ2DMH045B<DER9DER
M:U5P8BM9=&PK5R]O,D]O961B=#=%4VA)3&1L=6)M,U9N43@Q5VQU>28C>$$[
M9VQ3-4\O.$%$6E9N=4MS9G8O3DA(5TY0,"]4;S)U:DYD5%=T+W=!66E20S!6
M=3 T1'E-.%EJ-55(13A7-6(P-EEQ:S)I439H4')6;28C>$$[,#DY0F)10V)7
M9V)/>F]F5U0V,TAW5C57-'5(44%.*S=P<U!$0W%A85!P2S)D:'!L=%E78E<Y
M<&(S.35-23%54F5N1DLQ>49B:$IX8B8C>$$[8WI"=6U+<#=P,6MT:EE7.6US
M:GI*8GAR16MK;DAM5E552$QG<4PP.$)G5FE8;#=5<#=B>D(U-5IR2UIR97AU
M25IO56EH45-4;')26"8C>$$[9C!Q3$=:0U<R2$IJ=C-W<7E8471A:C%I=RMU
M4C)T>F%,-FMK6'!8:U)H:R]D<U8U0E17<713<6YU34-P:&EQ4659<')Z55EB
M-WDO<"8C>$$[,$UI6$XS67HX3E5:5DYR0DEA4G%J365F-S)R.#%89U)116YW
M2W%C5TYT.5=S;TQF<5E9,5%N8F-Q2T4W0E)V.&AI<79I<G-69&ER<R8C>$$[
M5F1I<G-69&ER<U91,%9P839F85-R<#EN2$=0:FQ&=D%Q4D(U1'5E;D9E5$AU
M8U931V)Y.7 R=3-D;'%D-&)M>3%31T\R;G5T3FEU1B8C>$$[+V1S03=#3UI5
M<41U-TM72%AJ<V%:351)1DU4149-8F92=$)3-&MI=# T,T55:3--<V-C-VAL
M9#!+2S=+2#(U24-":#A76#1P94%,,"8C>$$[,#-1;75':6EI:E<V:&M&=S9X
M4'AL5C)5<4=B9W=95EAX,G=E3$IE04]T9$\P2T\V;5<S:FIA-U=B-GA/3V9/
M4EI7569%,5=,0W%K628C>$$[;DI)<4EH1W@S='!*8WDR<512=&-W9T=A04]P
M:U%-2W%754=O<C)R:T=3=&EQ5U-Z=WI8<VM'<%=58V1T8GI13G Q,4\P5$Q.
M3WEL9R8C>$$[66Q0>$LX8F)$=C195E1+<#A$*T="5D]A-F=G-&5T27-8<75)
M-"MB2W9*,BMY<3%/-TAS35962VYW4#19<7-M=6)E2# O6&M73#%8128C>$$[
M8V9.;%AK-V9:5F%N9&HR1TMO6%=T13!V5S=".5 Q3T0V>%IY14=317-Y:'5*
M<E)U2D92-&IO8U9B,5=383(P>6%A,7-4<44X0U9G<R8C>$$[5EI%85%J;W%T
M25%O*VY&56UU=$\Q>31U-7!N.'E,1EHR9"\Y6FMT-$E9-'=L<4QE:'1,:50Q
M0S,R;CE8;CA*-F)D.&EE3&]Z0FHQ0B8C>$$[*V8W2%=':&%B<&PR2D9N<R]5
M,4,Y;'9O1$Q%:&ME5U=&56(P6$UL4S-"05=95DQ$<FMA;C-J-69T6CA73W52
M*V8W15)"8S9O='DO<B8C>$$[-G!A1TMZ85HW*U T87AX4'9">C-8:'A65%=T
M4'!Y26IK=FU0;#AM57!9<3)"=F)R."MI>$QN5791,#!3-GAA8W)I4C9Y2UEX
M-C9-4R8C>$$[15=,*UEJ:W8R869J9T5C;3(O,DI-.%9M;VYY,U1,4UI);V]V
M,&,Y.'0W9C)A<CEB4$EE<5!5<7ET26Y*,EAK3VQC=&A%9U548E1K:R8C>$$[
M2E-*06]D>3-3+TPR:F%68S,Q,5E7<7=83W!Z1S1V-6=35VQL2DHU35-4,#55
M2&=.<VMW54@Q3%=:565/2S-G<V)T<$QQ2S!I=DI!>"8C>$$[;$5.4D1/:7A'
M<%)V=$UU>D%E1U%L>&1+8DEC1DAI=3!R;G1V33$Y8DI$<6UO865,84LP;&<Q
M*S-T:$I%:E1Y47AM=DUU,'-586=S,28C>$$[3V%T>%EB.3A"32MG1$E$2#%*
M*U$U9DY-<D]T;'!T:D):,U9N1F%F5C%H<W%H;59N;W%X8T=-=%A5+U!K9DA"
M5U1V2'DV+TY)3TQU;"8C>$$[>C=X>2M83E=L=35N835H:C%+,FIE,6DO,')I
M:6PT1UEC;&MC3DM1<3A15%)H:5EZ4%5F3#EQ>&QJ2$]*3R]F,"M32T]R85E)
M25HR=28C>$$[-%)"8U-#1S-M36EC2DI'2D%21W)2;4I"1D)L<E%I<U9D:7)S
M5F1I<G-69&ER<U9D:7%H2%DR558S4&52=U)P9#-+;VQX8TMO1'E,1B8C>$$[
M>3E-3W<S8FIZ86QE;&-65D5G9U-74UI),5=76&E*6D%!1UE,<W14,4Y+-UEQ
M>&)38DQZ9$0U='5R=3DP+U-X63-2;%)T4V=$0SEA,R8C>$$[:60O<7-5:$Y/
M5D9:5#-&95A487%R2EET4'-98G%E-VEG4DQQ-7 V.#150C,T<49(2G5P;W%G
M67%P=S92<&-';S-'<'<R:U5E;S-A;R8C>$$[;#%D<6EI5U)9>%)&6C9C:48W
M1$956&EQ:F,R5FYD96PY6F=38C!*1FYG.5)1,T-64'-U=&5J0W5X>%97>%9J
M4&Y!961H3EIZ95AB4"8C>$$[5#<V2T1L2DY"9DUY4#9L449A2F=#07=6;7!8
M1E=3<'HT3'I)3#!(27%+0W9E9TYC5E5,,U1R0RM%2S-T=$9C<F)Y<&-10U9&
M8TI.1R8C>$$[87!)=DE':DPR2399<6E-5F1I<4984W1-55AG5S%I56%G4S$O
M4D9(<DU515)-;$(X4C1+1C,W67%K=FUR5$YA:R]2<S)H-F1P;#-.<"8C>$$[
M-6ME1F111$HV3"MN>&E-1$ER.&0O:&)P46)J<%%Q<$)0<"\U:VUZ;G5";W5H
M>3-L+T<P5W)7:$QQ<S9,27EQ=G%B."\S8G-Y.'%D5"8C>$$[5VAW<7ER4DY$
M:&HP8E,T9%(P*WEH=3='3F5-1FUN*VIW4T%H=C-!65950FQ"*V5"569$<&5M
M=U@Y>G%-3G)&2&8S:6]L,61+:6E74B8C>$$[66=21TAE;%-&0C)R:7%+>%92
M;'-R3V$U9W5P645E-71U9C%A6FQ"95 Q0GAF9W@S6&M.:E1&54QQ5VUQ,FYA
M;W1L8C(U=DPK2U1K2B8C>$$[:T)I;6Q-4'!*-C1'-W)X5E90.$%K-UEQ=W4S
M,'HX>D5T<F5X9E-F3#!.=EE146Y4>F)I57AX5%)/;UI9,&-,-EDT-W@P0C9B
M;G!5<28C>$$[;3-L5%-D96)5=&%U+TU7:F%485,V9W-556PS66-M;75X1T=J
M4')L>%AG131H0518<EA!<69Z84)O:SER0F%Z5T5%;'1A>DQC,CA$4B8C>$$[
M<55J;5)I-GE+<$9!=UII82M/2V\O1EA9<3=&6%EQ-T9867$W1E5M.'DK84QB
M>2]B<$Y063,Q-DA6,D-A9F)09% X0E55-'!V53@Y=B8C>$$[644Y06-683%F
M>E9:85HU5&PX>E1W5"]627):8G1R67!W=4%R9T5),&)L94QJ;%%G.4U667,O
M-3AF;#E(1F%S.7I-2DHK6')W*VA,>28C>$$[9T5D=5HS3#%55C0P-"]$53%0
M:%4T<7EN5%!.;6TV;')T,7!&<7-H:W1B5S-V1$]10D<X9#!'2V-D*U9A3'95
M1$95-GA6,DMO6%4Y428C>$$[:C K>6MU-4EP6FMJ2VAO-$5-:VYX349Q1DA9
M8W%N=T<K2V]0>7HU:W0O349H2F5W5V0W67!(33!":#%#,V4Q;$I103AH2$I2
M=4HU8B8C>$$[2$973C-0-7DK5$Q,5V14,')5-5IR1UA46E1#6EI);F1*5U9$
M2351>$-46E%/*TMQ;6TO;3DU4C%(5$Q/+W1M;E Q=3AS.5!-0FEB;B8C>$$[
M1E!F;TI)9SE+<E%+9'EP3TMS,GA6,DMQ1CEQ1FAP.7$Y,V8S359P87@P.5,T
M;F19-#%Q841K-VM+2VLP>%9)9DU0;C-49$5L:%)R1"8C>$$[56125V5/3V%+
M8E1B4U,X:DM337EG.&]Q9U4T,5!S4C0T<6XY-V12,F1N4&1Y06U/,VIE5G=T
M0WA61DQ';%-..7-6964R4#4X955,=28C>$$[,W,U4D)D4GE8,&QT1$)B1EEJ
M2U=U<')I24AG<VA.12MQ37IE>DPS3DU65'IY5BM:1VIE8C5:23E0=#=M07@R
M.&1Y>'5%5E!H:VMK:B8C>$$[;T],3C!-4BM9,WA6;&U+=7A62V(S>E)O,79$
M94Y$3W0O4%E-:5AD;EIS:S%X1S!J:$)Z:D165VA.5'EP=%A&5B]L+U@T3F)T
M2F)M1R8C>$$[,'4W3EE:;6=A3RMT,W1P0WEQ<D9L4U%!<VYX8DU.:FEQ465A
M=GI4,$1Y>C5J=#E#,4-'8WI8159V371W9VHY2E9U8FLR>3AM9#%P>"8C>$$[
M2VQM.7-64V<O;C$U3T9X95).839G0EIC+U9L.4%&1'=U171W54E9:V=T240P
M,C<W-UEA5C949U8R2W5X5C)+=7A6,DMU>%8R2W5X5B8C>$$[:79L9GHW639T
M<#DY939I64Y+4S!V-W5X:CE79&5-:5=J:%!61$]).6I7=G0T-'%Y9$AH=4E6
M9$=75T-6459914UJ27=Q0T-.:4--5B8C>$$[82MR5R]%3#938U%+06-24VA&
M4#%';4MQ;$)5;6TU,DHW,$=+<DEP-$IU9G!33$HV8D=/5&=W8FDT-G$Q3VA&
M96U+<CA64U-8>D1/;B8C>$$[;D]$>3DV15AO5%=$,S,Q:WIQ2G534W)(=U<S
M<'E+,&%P971/,DMP,VEQ>C!)96)0-F$X,G!Y86=Q861+;D97,6EJ455206\R
M,D%!1R8C>$$[=T%(,T%$1E5G.#%A:44P5'I(1F-1>&U#,# Q-VYK>B]!075J
M>'DX=5E+,%AI66HT-'%N='%53G1%54-+:%)E2WA(;$="5%E)44)69B8C>$$[
M1&)&5TMF;3,K:T(K6&5S='!S26XQ1DEL87I1=W!0.$%V4%57:F-*07EB9&%K
M8F1C5E)7<"MD3$Q2-%535%1D4G5E1G1"4'AS-U(U9B8C>$$[:&UF,'=O4E%P
M-4PQ6F50=VI&5U,T<7!R8E<V:T99:U5Q3TE)54-G0C55*R]F1E8V;VDO6E5$
M641953)(45EQ,VEQ1S!U-VMV9$]T<B8C>$$[>5--4DYC4G),-F%S6$-H>'E!
M-495<G-F1$971&%(<DYX<%AM8GIV8U@Y;$XY46AV3%%7471R4#0R:FQJ55-.
M*S913DHK+VM:>5-3828C>$$[5F)P:%9M96HV>$9Q<T5S,%9V8U<V>$])>71Z
M1UEI>$UA4U97=&53+W9+5DAC161S0V]X-$E:0U,X87533TI,04AA=&%B.7-6
M8D5C628C>$$[<%)12U9P<TYQ;7 O2$97,V1%4FYD9W%+0WI->&]!0G534V-6
M4U!49%EU<B]!37AY:3%0,6IY*S%J1DQB6#AB0F]8=41+-GE+:DQ(4B8C>$$[
M-DE&3E),+W-E*TMP-VER<U9D:7)S5F1I<G-69&ER>F(X=CA!>79:83,U9C%%
M*V%93%184%8Q:2]N='A/<V0P:U-3>4M7:4):-7@X3"8C>$$[<E-M,4M$86]R
M:%8V3&$R='1A5S!.<F%X3$)B5S9,1D)$1T%Q26E$:7%Q;S)!049!34-Q;4MP
M5D)Q=#=D-G1E5T5.;SA6<F)*17EA;R8C>$$[,CA5<&LU8S!I1E!I85!H=G91
M5DAY>%9%85IO,FYA64QK5U5):4XU3S$Q9'15:WE4>4%"-4=*2C-)55EQ:F-6
M96$V,V\R;F%Z*V-Q,B8C>$$[;#1J96XO:'AL;$UF3TYM2#$U2%0Y.&Y%<G=:
M5%)A-S%0875+<S X<RM6=$@X=%=%;&IP2U-P8E-Z3F-/2G U<FAV56-!365C
M>E-0*R8C>$$[>4YQ-'%M<G5K84TW<T5205=:;4Y!04YY4U1I<4<O4V1J-G--
M66Q$1S1J96%*,$)A37AX,#5.-FEG;T%/439N1E=04C).,W$K=C8S1"8C>$$[
M<4-P3&]L>&)7<T56=GA95FIP3C9Q>3%!-49U9%%0,E9/+WA5<$U#=#)04%IL
M355A4E)P1D=/36%+1E)2,D%&04UG>5EH*V-&=CE:+R8C>$$[3&I7-V)I6#EE
M2DEU0W59,F)N2V=O<D-/8C1J,BM!-'%J9&4X-3)N;#5)27)J5&13=D=A3TEJ
M.4@R:W0P0GI*6&-O3G501#1Q.4MJ>"8C>$$[1TMS:WA6,DMU>%9#5#,W439H
M1F)-:6E&-%I:,VU,,$MI16]#3U!(+T%)<TAF1E5(-5)U;75V2RML5'1B>3)R
M4&%X9G5*=V]K6&EG1R8C>$$[-%9N1SE+:F9P:7)&=DQL=W5L*UI04&UQ=F)4
M5%)36'1P+W9/5VY:>7-#46M)=G!X0F5',TUC;7!V53166F1O5W5W-GIB>GI2
M5W0S828C>$$[9E8U,G0S:G995W0S3$E&2EI!,S)K4$Q:>'-E,D)5>7A6,DMS
M8W4Y5G1D43AW=S9*8C-F<G<S;6Y4>C--2T%.1C90<7!%2D9L0S=S,28C>$$[
M6%-N4&)R5&)D5D]D3#!V5#E+,"LS,#=4;T9T<D<Q45(R.$-6-&]G-D%6>%9&
M67$W1EA9<3=&6%EQ-T9867$X,CAK=V59.5$X;S9T2"8C>$$[;S$W1F\Q-C)R
M6%)T3&QR93)U26A!4W),4TM#2WA7<D)Q;FU/87154'5#;TMS,G0Y5&AT64EB
M2SEV63=Z5TE966AD2D%!2DI*0W4W:28C>$$[0E-X4EI'56M6,DAJ:4%3:3!*
M<&QX-6=V6DPW.4Q746AT:W576%0T;VU!.5<R-'%5830U:TAL56M&5BM(-35)
M>$$V;T)2.$UE<D<X;28C>$$[16I*1%HX145+;U$U0DA,;GAQ:54R-#EA-&YH
M<&0P5F(R,%9U<D-/=GAS6&-S>%EL:C%/-4]237)30E-R9U-W;3AL=D0K87DR
M.75B828C>$$[2EID1&Q!=5)#1W56;$4T-$)P9E-0=TQY-4-0,5)8<G@W-'%Y
M1'EZ62M:3$]W:VDX=V%P1G$Q-C!Z4$AC=S)W=$9726=C62]41'EF6B8C>$$[
M3F0V-'%L,6PU<FTQ-DA78EA2;WEL-7 Q,6-A8TQO,&MI5U=*1G!*=496:4=C
M9D(W9F9)4C<P5V]A6C55,357,$)R+U9#53!Q>F4R=B8C>$$[24DQ44,U85))
M:%9Q2V]523!.4E1$-E%J9&QQ26E+1E%5561!36=3>6)X5FE0-713,U50-65A
M>E!A96XY86=J:FQG.5@P94A.2FM98R8C>$$[=G)!84MM,S=1>%9-.60Q9EAD
M3S K0V)3.4=B5S53;SE71TME2T)H=6=Q=G$P53=-5S9J<&EQ9#1Q-T973W U
M-#!I5%8W5%19;41Y,R8C>$$[3#-S4E936DI&:W-(5DI&-%%I6#EP:CET;#99
M<6Q8;#E.53%$5TY-=G!P3&DQ<V\P,55(4S=S0U=C=$AF26E.2DQZ:S0X84QX
M54U2<R8C>$$[4&]66DPU86Q35'DY<')*5V=T;VQ.459.5E%+9&I1.5)G0D(S
M0UI23512,DQ'=DLQ>G%%9FUJ>C)I>%)Z2F)85G4Y;F)2;3-74C)E>B8C>$$[
M5U)G-TE!=TQT,#E5*R]1-%5-;#!(54Y6=C=2-713,'0Y2FY$9TQB4U-X>DU6
M36%0>35217)S>D9#2SE6.$U65$Q&56=S4$]';F%T2B8C>$$[075L8S5B4S5I
M;6M45DA54C(T3G9-24I%06M+4TTO33=55&IS9FDW14=12$US:$%K5T%L=FQ+
M,VAS8DA4;S=9,W0K8EA4,U9B;&HV:R8C>$$[16AA4F5233!Q4GET269454)E
M9U5503)Y<UIH3#914T<V5VU-9G%):6)Q=7%E-EAC-G9C,TEN=6]'=&)74S-1
M<F)S5EER35=B;4-A2R8C>$$[*WDP-U5X>'EM5%I&0VM:630T:6]N:4XX+TI.
M371A2%EQ-T9867$W1EA9<3=&5FMZ>4I$23AC6FQK5E-5:4)!3$5#;U5&<4%6
M.3A6428C>$$[96U4451Q3&@W6DQ45DHT64I,*S)R1S X6EI35FIL6D0X6$$X
M;$(V9&%98E9(5E!G9G=W2W-3-6=E85-"2%9P;V=P;&E$2U=54%AI5R8C>$$[
M5W12>6]A67%V<69!+VAI<7A,;3-E6C1&:U%Z>$%'4TE-0S9H=6A:46%I=4MR
M9G%6;#EC*W4O5C0O<FY$,'9R4$)F5CE/=DQH>G!Y-"8C>$$[,3-P6$95<VMT
M-TQ7-W-02TPR0F1)=7!);F=*;'0T3&MT0T%E8UE)5S1H<$PX3F%R>4AT:$)P
M1DIT1DA$16Y#2D)'9S9+<3A2-&1!328C>$$[0DYP<&1592\S2$985DAV.7AX
M5G5O>%9#87!P5FIQ;'-,83E2;FA$<$E!<G9'955B8VQ02D-P-BLK2W0V<&,S
M9'!P,#EX6C)J,SEZ128C>$$[:&%+>E(P4C534#)1.&A#:C94:7%4>G U:W5B
M;31:.6%T8D-X<V(S;7=T26MK;$YM<T%0;S--;'=Z<$<O3BM:2W Y:TPT;DE%
M1FU$128C>$$[9$5*4&]%-S9P<#%X9F5A3&E:4')5,#%P875L:D=:56MG-$Q"
M2$I(1DA,4E!T,5)Q;G8R>#14,VQE361W5$,P,')Y=%I34VTR2U%V628C>$$[
M=$Q.8TMT=W=%2G5J>FMA4F5D1C5L82]&-%E00TAN.'EZ.&58;#AH,"M#<&$R
M,VQ3,%,Q34LR;SEC=#E3:V0P9#5056%R0TXS6FUA<B8C>$$[3C!">&IH9T]1
M5U=O>5,U>5 Y:5DR.7I91V%7>70U2797=%%V<E<P8DQZ:D1I<6-K53%8;#%&
M975407)K,45K;7ES,"]38D=W831A,28C>$$[4FM.,4LX.#%89'=:2D=,<U%'
M2D,Q6FIS34M%=6XQ2'I$2F9X45%7.719=R]7-5E(93AK-7E4=TIB*V]K=')(
M17=Q5$EA37)S<$-Q5"8C>$$[-%E$9E))<G%L<T]I-GIC86XY9#%Z>D-*261.
M;'5J3' Q:T)B5W)7,#1":$8R<&0R-5))2S%,57E(06(U='!Y4G)A22](-#EY
M93)Z-B8C>$$[1&%25SAS1%<X85A"-%<P=V10,VAL8FQX4GEF:35.,D)W=WAX
M:GE$1V5A8R]Q3G$P5C5P8UAR,CA5<TUF,4IE5GI#:DE04E9G5W$V9R8C>$$[
M+T%#3CDX:T%W2G1S-G1P9V=H;F$W:$5&>$E)8F59>4IW:VM9:T)%871'66M%
M54=&0TMX5C)+=7A6,DMU>%8R2W5X5C)+<45D:EI26"8C>$$[8SDU2$)';#-C
M<6E81G=Q9U!)<UA,,'<W1&1U4$YQ5C96>%98>%9J1VQ,-31J.'E80G9R6%1V
M,%)02DU295%&>&1E:VI-3%I*061I928C>$$[0EAX+V$V8E966E!I<4AJ,#-4
M;W(K8E5)-V%*3"LT4DDU-W1555-U:V1E0W,Y3U)686UG>%9%67%H8G)43%,U
M=DQ/-VQ$1V5W9#5,628C>$$[<3=Q;V%33F]M-4MP0W8X04,U*S!$5'%-5E)%
M,%-44E!%-'%K:6Q'2%1::%$T<7AN5W19,3=16DQE>C!F>35*<6UL=U<X87$X
M17EO-B8C>$$[14U9=V=6-FLX1E94.5!S8U94>3$P:7ET=%)V3E-I5GAD-F=)
M:&1%>5--:#E&4W%C55DX1C)/+T926'9I<E=O-E!986A,85,S4W-Z,B8C>$$[
M57%Z,C56,E-J<5%26&E2>4913FIT:7%.>%8R2V]69$LP>%)E0F)72E)Q0DQ8
M.45597-X45)%>55(>$AG;UAF=&EQ4RMA=$TQ<50Y1R8C>$$[>F%(<#)M6&,R
M;FU2-%8Q04UN;W8V9D=)=TUI=G@S*T9U;$)U3VQ#<6M%*VXO;5-B3V4T1VDV
M2$QE6#AB4F%T845U<7IO<VI+<2MP=B8C>$$[>B]D=7I,>7 Q3F%(0W)+=$4P
M3T=04G1,:#%(5#=+1S=S63$T=U=A9C900DE#1R]C0FA644=52#4T1E(X3VPV
M8D)F,T]O=S)S560O928C>$$[2VE85C!Q2TI:1FE"15ED-E9)54AA=4MO<D96
M0V5X<W W:3-U6F])-4QI,%IN=%IN548T;61$1WA2:G5V2D=+;6YB1E5.<65M
M<2MN-B8C>$$[;4Q/,W0R=F(V1C%B,3!":FQK.4EP1THV8G-N445E1TMS3FHP
M:GHO>$9G,FDV0D)P=&=N4%(O441S235O6F%X;%5924EY4GAD84$P228C>$$[
M3E0P<5944'EN<%!M0G11,6TW.'EA3G!.<$YQ0U)24S-E;CAM;'4O5%9O,CEC
M=4LX06Y%24-A.6$T1EI"3F]':50R<T9R3EE14U<Q<B8C>$$[371Z8G=.1W!3
M3UI'3'))<6M51$)M2G(T-'%J.%9D:7)S5F1I<G-69&ER<U938GI,<E=S85A#
M:C9:;VLK='EU<D@P64I9;VE'5FM!5B8C>$$[;6Q+<4MQ>DY7=C=.3RM+<DY4
M.'HO;VYY:DHU:3%7>&UT:F(R>3-&,7 V;$I*;S))1EDK4W1W67%44V]/2W-9
M9C@K4'DK:FET5V4U;28C>$$[16LO3#$T9E%L-5%#3S---VPV<4LX86-F:'%A
M;G=Q8U9:8G!N;5,Q,4A6<G)4-V%'47!A,CET9&981'A%5')D:'EI<G9Z1$%2
M,4E:4B8C>$$[<U(T:D95,GA6,DMO3%=B-CES9$]K=6)+>&95<FA#9U<P:F15
M9&=Z:%=)6B]H*T5(;#E'2V]B>7IQ,G-A;EE36$=R84Y,;V1Y:WI2<"8C>$$[
M851447IS,%E!2WEC;U=:4&EQ4E-V8D973C-0-7DK5$Q,5V14,')5-5IR1UA4
M6E1#6EI);F1*5U9$2351>$-46E%/*TMU<W9Z:SAP,R8C>$$[,6IP=#-A<&-Y
M+W!#.71.3V%%4FA79VYV6796:CE5<WEQ5D,Y4VAB1E=D67$W1E5"<FUU85AO
M96UY86QQ:S,Q97EI2V@U06IY1W)S1B8C>$$[54))=S='<%!967%K*W4O;4)P
M=6IY46\R;F%P9D-E2TME3C='>&UU1C13:V=C=4DK16IJ5F<Q2V)E3TMS:'9B
M<4]Z<S4W=5%%>#(X8B8C>$$[>75&;U=+;W!9,'%2=G1I<GHR>"]0:GEH9#(Y
M;DM)3'%/4RMK=&]93%ER15I3,3%.8U)!.$9K2F]N,5)M8C):935P:7))4$I8
M-6=A9"8C>$$[-75%:C9F6C--14UC154U;'5"1V]0<7E3>#A+2S=(:T1!>#9F
M6DE08UEQ>6I&6%EQ:T5N;F9143)O4C(W5#-C*VQ3>'<S,$U&=DMZ228C>$$[
M,&MN<$-H6E96=T=R>4MK,&]C5E)N;"]8-$YB=$IB;4<P=3=.65IM9V%/*W0S
M='!#>7%R1FQ344%S;GAB34YJ:7%196%V>E0P1'EZ-28C>$$[:G0Y0S%#1V-Z
M6$56=DUT=V=J.4I6=6)K,GDX;60Q<'A+;&TY<U935V(X+R]!0VA(8UA-2#%,
M54=.<7IR231I:D-.=VY70W%&<$8U5B8C>$$[3#$Y=2M';&5M649D:7)S5F1I
M<G-69&ER<U9D:7)S5EE8*U9D>&-4-EAR4G5,.71195!7.5)J16IT32]P<6LQ
M0D-P;4-T4U!P=#A0:"8C>$$[:7)-,E9757%W1$MW;U%D=U%C5E=F5G)F:48Y
M2D])1D%/27!1:6XV:E1&5E1&5D153"LP,"MW=6(K.6Q%3FY:>%!08WI.5VE2
M4DM89"8C>$$[:E-P;T9"3TMQ:TTP53A-8S!40C1P5D1X=4]H5FA52#=S5EEF
M8WI802].*WEH*W9S='4R:'I0.$%O>FY,>%HQ=6M";3E-1#!F:$1"828C>$$[
M:SAV:T]Q<DTX5E=E:$1Z6B]46&TQ3U151E14<%4T<3)S55-I:6]Q:EDP04$V
M0V<O05EQ=7A62V)O4VYZ4G!X4S!-,%,R=#!*-W-&2R8C>$$[44UZ=RMK1T1%
M3V95-'5">$(V1W5+<$XK8FMF<69L>')S6FAG=4$X055X6&-J47=%1C$S:VM6
M-%=64C$R65EQ:61A.'AE6DY0:'1V,"8C>$$[6#59;C%C4U)2331H=4QE2#!Y
M,65A;C%(<"LW04A1;71D=6A/2W-M>%945S)T,4E+>$EP56-146]&041Y<#DK
M*TMQ9T%504%503)!2"8C>$$[4VU+<U1L,2]63F%/:S-8;#)13'!R,VLX3V]Y
M<VEZ:5-/2#%)>4DS9UHP2#<R3VY,;5 X06E60W%B*U9,4%9,3'DW65=U<7IV
M9&%J1"8C>$$[149U<FE8-V)V53%*;SAV+T%"3"MM0E=)-DQB-G9.-6XX.5)A
M5CE6,#(K:W9,2C!V9V9R4EE,0D=$.5EI37)C5V%.5'A#<6]!25!7=28C>$$[
M1E=984):-CEA,G-Y83%Q35=P6$1433A%,%9U3%E*0U%O5TUO2&LU145%.'$W
M,3991E1"-$E:0U,X87533TI,04AA=&%B.7-68CE+4"8C>$$[8C1&,C9B1&)E
M=C9X6$97,EE+<%DQ;T)5,$)*,CA!3GII<5@R3W!.95AZ:49L87@K<E$S14Q&
M2%8R.5IP0416:5!H<$8O3#-X5DUC5B8C>$$[9&ER<U9D:7)S5F1I<G-695DK
M4V1%.#1,-51V8EA3=%1T9$PQ239R9DY035DT<C5F:6Y$07-)-5-054MG.'=7
M0G$Q5#!W<3E&,'E++R8C>$$[:# K,FDQ0S17-W9O-#%7-755:CE*6DI!2TTT
M:G$S144W,')G5D4T<6\S1C5:,C-$-GI02$(V:F-)+U5D535.46UI.&E+;6=X
M5FE':B8C>$$[>2M99&,Q4U!72DQ#3S!T-&)A-'0Q4S9I93)U5VTK<R]U=E58
M;$MF4S123$E&-C%A=&%D6F=$<7A*3$Y%-3A&-3 U,$A+;E-V96QC9R8C>$$[
M5U1!3EDP=EA*+WI4834P*S5G<W!$;U!O,FQZ2TEP;D0O6%9E44-%>4Q,=TM,
M46YH>'%2=E55>%9L6&QM>#AY5V1H2D8U9S%33%9R,28C>$$[<&UE3S5H=&AA
M2W-2031X*VU(:RMY83<Q>%9.<U9D:7%J9EAK1FI:6$8W8T5R0F%X4$Y-44MK
M2D=P6G%$-41&54)O;7$R=6]7.$8Y028C>$$[2&1D4VI&>$A*=U!&26EO84Y(
M4#=,8U=Q5G(Y<FQK:D4P:3!K+TXR=VPQ1#AU.5ES26]P6C-U:VII5T="4S!J
M1G!K2$925F1Z.#AI;"8C>$$[1C8O3"M915 Q9%!,3G!P<SA!:FHY539J3DY%
M-G-#95E!:5)W9FAP5#-R.4MR2F-68U-!2VY91$974&YZ1F,S<V-F-E!T1$A&
M2F9.628C>$$[>7HS57-C0C1)>DLX,75"-G!L2D,Q:E4X86<Q.7-&:%!#5BMK
M,T]M85A9,C%L8C@K171X4$A':FU!37-H95-2=U)'5D9/46%N14A)2"8C>$$[
M3D9T1VYL=G1Y5%143'<S=6XR.3)9+U---D-4,'IY,D1B9V9%<4@X36Q#6$5!
M5T=32$))>#=N;C%J<#ET0G%8;BLK,4MY=G!,2SAV<B8C>$$[3FU%16(X,TU%
M8V%+6492:3="3TMS>#9%93-W:6)":V9K0TQ1-'1,=3 P87DQ0WAT+W)K;G%X
M86U,:%I43'=4:S!F,6QN9C!Y2V-E4"8C>$$[=SEA649:4&ER<U99-4PU>'1*
M9%E44G)*:TXQ9&%A*W!7,')K<GAJ5U%20C5);4-S<V17<GDW,$Y-1C<P;71R
M4W9Y1EIT.5IT8C8W=28C>$$[,G4Y4D]I5TYV2DI#1U<Q-&\X<FM+9W%G66-H
M=51Y-CEU9S1W5%A6:V-C9TQ02FTK4UE/>%8R2W5X5C)+=7A6,DMS62],+WDK
M,F@V5B8C>$$[95%.87I76G5R-F4X34YX8TID34=N-',O0C!!<$=(<7%!+T9X
M04QB:S1Q;3@K<E-X86XY4514<G5F.7E*+W)C87AI,S-C<#9F3C5%+R8C>$$[
M94-L94Y/;45"1G!0<48S-3AV:$QB86)94C911TTP85@Y>DQ&37DX47!I;%=.
M4%5(>"]%3TQ$8DHQ1D<V-E1Y3F$S=#5B6"MS6'0Q9B8C>$$[,U9T3D)D>%).
M2GAT;W)M0TYO>$I"16](<#$U;71$6$AJ<F]&-&9.4#='=W1,0S)7,G1)>$9!
M<%IG9W%D,EES>'%A;F-N27EK4V)+428C>$$[2U8X:6QJ3"M8,F(X>%DO34@Q
M85E#4%1'<W9R675&.4)G,'=K-$YB534X=U(Y<71+93E-5E1,>D9R3C%P3FES
M.7!P9#%Q.7I+>&IH="8C>$$[8E%*6&XV8GE+6DAK6D920U4T.'0V16IB0T)A
M0U5$3G)F;6U93$1A84,Y=DQ,6E!-='ID5%%T1D9D9D-%:&%/2U1K*S=%;C1L
M,DA82B8C>$$[8TDW,%<U<DAZ;&9K5S$Y95=T;G!T>%IV2&1Y5TMY>#-Y,TPX
M441"2WIY4GAQ1C4W,%IG85509D)S13=Q,%AL1WE34WAD-WDO=45S;R8C>$$[
M;6AA1S1U-7!O<FIK14A/-6ID:7-J:FA58E5Q5'1J>$9A5'1%4TY&4D9#;V]#
M<7%I9T%'=T%!>4M72"]M.#=$.'4Y66IJ94Y,:5=.128C>$$[=&I+<D]P;#E2
M4V\T;W-J13=B04Q7=4MP<#5G,"]W03%8=&AA3#5F,6E,4V)H0T=N;&YT4F1#
M4DM$-%%P95!G9F9&5G5T*V-,3WAT3"8C>$$[<#E-:4]U6#%N36QV8V%B64US
M:S9337E!<31&46I+<V=E:C!.36I+64A.;DA(2UA*3'!03'9M4%=O2E4X=WE1
M*VY"<7E8=6TR.$1K0B8C>$$[8F5#5DI):$MY<4]B1&EW2VMC5%AE=5%K2E,X
M;7E*:$4O=T$W8CAD>6-*;W1X>&<Y5U%U67)Y5S1).59L0FIK36@T+T-Q9R\S
M;39K8B8C>$$[.4LP>5!G.3504'9:2%5C-D%(<')L*W1&,BMJ,E5-54U91$US
M16IZ4C<X04AK-6-Q<DAW52]B3WA'5U)X9T-G,5-Y>6MB2C5O<4='1R8C>$$[
M1TY9;U572TI.;&I10E9!.6=.<VM"5$%M,D0K5%IR:6)Z5C4X;717:FMR9'=*
M82]U-4DP.5-+,CE.=S=S:4(V4V]14VAB-3%Y4T=1828C>$$[4G%E<C(Y<U(U
M<F94-T<X;&YD3$Y,861I:VM3;T="<DUS8F,Y;4Q+06%!9&-I4T%K06YK9V)B
M.'E03&PY<4U&:G!)=61686%A-G1N=28C>$$[3%-";6=H;G-G<&QJ;&QF9W%T
M.%E#.5(X<VHT9W5G>CA),5HR44]K-FPK64=S-G)9,T5L;3)J-D=5=30W*T]9
M271Z-G-C>%-":VID6"8C>$$[86IO=&582VQ.-EE!2FYN<WEL-%DU5U5D-5<O
M3'I2=DPX3FE)=C,P=&Q:=EDQ2V=*27-K;VQ:,D0K;S5A<6=#<FUG>$=+4'91
M8S!I928C>$$[-S--;FEH:6AI4TM&1FII44)5:E%"5E5$;T%"<T)K=T%"46$U
M4TUJ6DYL9&A1-T9867$W1EA9<3=&6%EQ,#9H,4MT,%E%1VA),E!U328C>$$[
M5E,S4S=#-3 V4TA48F%.1C!+,'1);W)6,FQL:W5F5E%S<%8K9DQK9VI#+T57
M-59R:7%V1TY61G1D1U0P5&-C-69Q4W%80V-0.3%E<28C>$$[4U-A+WIC8U93
M5TQZ1&983FQ&85=L>G!C;FUA371(9E=!=5AA2DI54BMA<'-S<$-Y3%-P5&]$
M:E-P<&5.-6='<E=+,F-6<RMK='DO4R8C>$$[36MR>4Q/=G=T=SE&5D)6<71X
M<GEP=%A&5CEU,G5F<&DV4V5/,T=J:4Y$6GEQ>FTT85$O,V=K56IG1DA99R]2
M-'%O+T95<FHP-C1S8B8C>$$[.5<P-DY$83,Y,4IC-G4X,'-R4TM40451=TME
M4S=V1V=+,4%!<5)V:7%-=4)E*W1B9E8O5#E(,40Y8SE4;'DY3# R<#9D1%1L
M-FY$<B8C>$$[,G)I<5=A,W(P5FIE,G1P2&5734TW<VHS158W3UEN*W)L*TQ.
M1T\W559U3F5P2'IX<%5B<4(Q8U-7;C9/4T(T;6Q8-C9:,F-%43%(228C>$$[
M>#AA,6%L858R>%94,6AV34-.869O94LR;$)N45@S,7 U131W1FAZ85!G1W$T
M5W1!9'$T<6U205!81E5,<6QL2F9A9F-78V0Q3EI03R8C>$$[:%)B=3)+<DY'
M5"LP:%E/2R]2:7%&:&@Q5TEA=3!D=&%24U-31U14:D=72')(,$5!939O<3!B
M,49+-U8K141'9VMK=#-482MS,FU,8B8C>$$[2F%T1S<O-VQV565137%C3W1V
M44AK968X,V)&0VTX,VU)4S9M:4Q:=%-)3F]Y97!*>6510F<T=5!"43-$9&9%
M-'%T:6)Z66)F5$1,1B8C>$$[6DIC3E0Y3&]R>7-I+T5T4D%X0VLO1'DK,'98
M1E5484YR,S99=C%U;S=984]&:"]2<VMB3V)H;DMN,6A-<$A!04Y4:GA0>GA6
M34%!3R8C>$$[;4MP2$IO;'=U<E=T>59I,4=(-C5.9$Y.9E5A87E6-V(P,5=X
M-' X24QR4G%M=$=B8S1K2D)+2TUE<%%*<5@Q94<Q:E5!=G R-TE':R8C>$$[
M36173GA18D0Q3S8W,'=!0E-354]:=DY#861P.&MS9&I(93@T>G$V*W)+655I
M3$0Q5$-X0VMK3%=N255R:%%V4B].2G8Y5U=30WI7=R8C>$$[4D4O46MI>5-M
M5U-1>&MV.5I19TMQ:5198U<V67%S;F)Z975N,E)T-')&.5).,&<Q0EAE5EE2
M86,R-71%4GEB,4](1V=B875+<#%I<B8C>$$[<U9D:7)S5F1I<G-69&ER<U9D
M:7)S5EEV62\X04MU+SA74#A!569Q6"M*9C,S<2MJ5#$V.&HV=E!J,S5C=74O
M,G%F=%EQ>6I&6%EQ-R8C>$$[1EA9<3=&5TLK8U K5F-E<U X5F959G)(<'!X
M*W15.50P+U500VXW5D]F3' O;&1Q-'%Y<D9867$W1EA9<3=&5TAF;4XO9VXV
M=F%F-"8C>$$[;BMS.4QJ-G Y52MT97!4,"]W0CDO=DQV.6UL3U@W6$AJ.%A(
M1E=$,T@O2VU0,$)B9CAD4# V>695+U,K="]7*U@Q9S K>CA69D0Q4"8C>$$[
M,E!T-S154%4O2U@V1B]W,7!V-D4U9F]N,$8K<&5P-FY,,"LQ9E8K4#<X0U4R
M>%8R2W5X5D$V-RMJ=C!*<4@V5"]W0T]B.5=M*W4Y9B8C>$$[-VHP>C9N5&8W
M1F5M2W9+-U@O;%10-E<Q2#!F<B]R9E8U9G)0<2]84%0T975E4'!E=G8X06$U
M8T](=SAE=3-(0VAK4#57+S1!*W1A="8C>$$[+VA8-C=Z<$0Y62MU9E=F5#E(
M;$HV2&]E=CA01#=F,F0O=T-B06PV1&ER<U9D:7)S5F1I<G-69&ER<U9F+SEK
M/3PO>&UP1TEM9SII;6%G93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]X;7 Z5&AU;6)N86EL
M<SX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I
M<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!D9CTB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(^"B @(" @(" @(#QP9&8Z4')O
M9'5C97(^36EC<F]S;V9TPJX@4&]W97)0;VEN=,*N(#(P,38\+W!D9CI0<F]D
M=6-E<CX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H
M='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @(#QD
M8SIC<F5A=&]R/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @
M(" @/')D9CIL:3Y286IE;F1R86X@0F%W86YS:')I/"]R9&8Z;&D^"B @(" @
M(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]D8SIC<F5A=&]R/@H@(" @
M(" @(" \9&,Z9F]R;6%T/F%P<&QI8V%T:6]N+W!O<W1S8W)I<'0\+V1C.F9O
M<FUA=#X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<%10
M9STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W0O<&<O(@H@(" @(" @
M(" @("!X;6QN<SIS=$1I;3TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP
M+W-4>7!E+T1I;65N<VEO;G,C(@H@(" @(" @(" @("!X;6QN<SIS=$9N=#TB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+T9O;G0C(@H@(" @
M(" @(" @("!X;6QN<SIX;7!'/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O9R\B/@H@(" @(" @(" \>&UP5%!G.DUA>%!A9V53:7IE(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T1&EM.G<^.38P+C P
M,# P,#PO<W1$:6TZ=SX*(" @(" @(" @(" @/'-T1&EM.F@^-30P+C P,# P
M,#PO<W1$:6TZ:#X*(" @(" @(" @(" @/'-T1&EM.G5N:70^4&]I;G1S/"]S
M=$1I;3IU;FET/@H@(" @(" @(" \+WAM<%109SI-87A086=E4VEZ93X*(" @
M(" @(" @/'AM<%109SI.4&%G97,^,3PO>&UP5%!G.DY086=E<SX*(" @(" @
M(" @/'AM<%109SI(87-6:7-I8FQE5')A;G-P87)E;F-Y/D9A;'-E/"]X;7!4
M4&<Z2&%S5FES:6)L951R86YS<&%R96YC>3X*(" @(" @(" @/'AM<%109SI(
M87-6:7-I8FQE3W9E<G!R:6YT/E1R=64\+WAM<%109SI(87-6:7-I8FQE3W9E
M<G!R:6YT/@H@(" @(" @(" \>&UP5%!G.D9O;G1S/@H@(" @(" @(" @(" \
M<F1F.D)A9SX*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT3F%M
M93Y':6QL4V%N<TU4+4)O;&0\+W-T1FYT.F9O;G1.86UE/@H@(" @(" @(" @
M(" @(" @(" \<W1&;G0Z9F]N=$9A;6EL>3Y':6QL(%-A;G,@350\+W-T1FYT
M.F9O;G1&86UI;'D^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%C
M93Y";VQD/"]S=$9N=#IF;VYT1F%C93X*(" @(" @(" @(" @(" @(" @/'-T
M1FYT.F9O;G14>7!E/D]P96X@5'EP93PO<W1&;G0Z9F]N=%1Y<&4^"B @(" @
M(" @(" @(" @(" @(#QS=$9N=#IV97)S:6]N4W1R:6YG/E9E<G-I;VX@,2XV
M-3PO<W1&;G0Z=F5R<VEO;E-T<FEN9SX*(" @(" @(" @(" @(" @(" @/'-T
M1FYT.F-O;7!O<VET93Y&86QS93PO<W1&;G0Z8V]M<&]S:71E/@H@(" @(" @
M(" @(" @(" @(" \<W1&;G0Z9F]N=$9I;&5.86UE/D=)3$)?7U]?+E141CPO
M<W1&;G0Z9F]N=$9I;&5.86UE/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT3F%M93Y':6QL4V%N
M<TU4/"]S=$9N=#IF;VYT3F%M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT
M.F9O;G1&86UI;'D^1VEL;"!386YS($U4/"]S=$9N=#IF;VYT1F%M:6QY/@H@
M(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A8V4^4F5G=6QA<CPO<W1&
M;G0Z9F]N=$9A8V4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT5'EP
M93Y/<&5N(%1Y<&4\+W-T1FYT.F9O;G14>7!E/@H@(" @(" @(" @(" @(" @
M(" \<W1&;G0Z=F5R<VEO;E-T<FEN9SY697)S:6]N(#$N-C4\+W-T1FYT.G9E
M<G-I;VY3=')I;F<^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IC;VUP;W-I
M=&4^1F%L<V4\+W-T1FYT.F-O;7!O<VET93X*(" @(" @(" @(" @(" @(" @
M/'-T1FYT.F9O;G1&:6QE3F%M93Y'24Q?7U]?7RY45$8\+W-T1FYT.F9O;G1&
M:6QE3F%M93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(#PO<F1F.D)A9SX*(" @(" @(" @/"]X;7!44&<Z1F]N=',^"B @(" @(" @
M(#QX;7!44&<Z4&QA=&5.86UE<SX*(" @(" @(" @(" @/')D9CI397$^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D^0WEA;CPO<F1F.FQI/@H@(" @(" @(" @
M(" @(" \<F1F.FQI/DUA9V5N=&$\+W)D9CIL:3X*(" @(" @(" @(" @(" @
M/')D9CIL:3Y996QL;W<\+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL
M:3Y";&%C:SPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @
M(" @(#PO>&UP5%!G.E!L871E3F%M97,^"B @(" @(" @(#QX;7!44&<Z4W=A
M=&-H1W)O=7!S/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(#QX;7!'.F=R;W5P3F%M93Y$969A=6QT(%-W871C:"!'<F]U
M<#PO>&UP1SIG<F]U<$YA;64^"B @(" @(" @(" @(" @(" @(#QX;7!'.F=R
M;W5P5'EP93XP/"]X;7!'.F=R;W5P5'EP93X*(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!4
M4&<Z4W=A=&-H1W)O=7!S/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @
M(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @
M>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B
M"B @(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(@H@(" @(" @(" @("!X;6QN
M<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E
M<V]U<F-E179E;G0C(CX*(" @(" @(" @/'AM<$U-.D1E<FEV961&<F]M(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T4F5F.FEN
M<W1A;F-E240^>&UP+FEI9#HS,S(R,C1&-S,Y,3E%1#$Q.4(R-40X1#9&-S@T
M-CE#03PO<W12968Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @/'-T4F5F.F1O
M8W5M96YT240^>&UP+F1I9#HS,S(R,C1&-S,Y,3E%1#$Q.4(R-40X1#9&-S@T
M-CE#03PO<W12968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.F]R
M:6=I;F%L1&]C=6UE;G1)1#YX;7 N9&ED.C,S,C(R-$8W,SDQ.45$,3$Y0C(U
M1#A$-D8W.#0V.4-!/"]S=%)E9CIO<FEG:6YA;$1O8W5M96YT240^"B @(" @
M(" @(" @(#QS=%)E9CIR96YD:71I;VY#;&%S<SYD969A=6QT/"]S=%)E9CIR
M96YD:71I;VY#;&%S<SX*(" @(" @(" @/"]X;7!-33I$97)I=F5D1G)O;3X*
M(" @(" @(" @/'AM<$U-.D1O8W5M96YT240^>&UP+F1I9#HS-#(R,C1&-S,Y
M,3E%1#$Q.4(R-40X1#9&-S@T-CE#03PO>&UP34TZ1&]C=6UE;G1)1#X*(" @
M(" @(" @/'AM<$U-.DEN<W1A;F-E240^>&UP+FEI9#HS-#(R,C1&-S,Y,3E%
M1#$Q.4(R-40X1#9&-S@T-CE#03PO>&UP34TZ26YS=&%N8V5)1#X*(" @(" @
M(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YX;7 N9&ED.C,S,C(R-$8W
M,SDQ.45$,3$Y0C(U1#A$-D8W.#0V.4-!/"]X;7!-33I/<FEG:6YA;$1O8W5M
M96YT240^"B @(" @(" @(#QX;7!-33I(:7-T;W)Y/@H@(" @(" @(" @(" \
M<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^
M<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.FEN<W1A;F-E240^>&UP+FEI9#HS,S(R,C1&-S,Y,3E%1#$Q.4(R-40X1#9&
M-S@T-CE#03PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @
M/'-T179T.G=H96X^,C R,BTP."TQ,50Q,3HR,SHT-BLP-3HS,#PO<W1%=G0Z
M=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^
M061O8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A
M<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO
M<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA
M8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM
M<"YI:60Z,S0R,C(T1C<S.3$Y140Q,3E",C5$.$0V1C<X-#8Y0T$\+W-T179T
M.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P
M,C(M,#@M,3%4,3$Z,C,Z-3,K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E($EL;'5S=')A
M=&]R($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^
M"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI3
M97$^"B @(" @(" @(#PO>&UP34TZ2&ES=&]R>3X*(" @(" @(" @/'AM<$U-
M.E)E;F1I=&EO;D-L87-S/F1E9F%U;'0\+WAM<$U-.E)E;F1I=&EO;D-L87-S
M/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z
M>&UP;65T83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD
M/2)W(C\^_]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$!_\  $0@!I@)= P$1  (1 0,1 ?_$ !X  0 " P$! 0$!
M       ("04&!P0# @$*_\0 61   @(# 0$   8! 0(&"P$A! 4#!@$"!P (
M"1$2$Q05%B$7,2)!4515E!@C)"4R4Y*3E=+4U1DS<7B1N-'3-U=88626H:36
M\ HF*#0V0G>!-3A2L;.TM__$ !L! 0$!  ,! 0             ! @0%!@,'
M_\0 2A$  0,# 04%!04%!@0$!P$  0 " P0%$2$&$C%!41-A<9'P%(&AL=$'
M%2)2P2,RDN'Q%D)3D]+3,U15E"1#8J(E-'*"@Z/BLO_:  P# 0 "$0,1 #\
M_P!_'B*"/0[/]G9K]5UH-!:S6B"I1@WK]@KCPBN&UDLZ(R,;5[2TV7;%@("K
M95L3)P-3Z_7(K!"46V8MX 5X)A48YY]9_ER*[SP [NA]8LDO?DZQ+:M+HPC2
M"IYTA*[>M925^;:1:0E8'[3HXK7-:@JJ2^T66XJHAH"K8J#L$Q^-R''+UZY\
M->&B[KXHO\T7XD7T3]%H?Q1%' J+VOKE%Y/%\&T?KN]0YI]*_,OS!'+T%E]
M]6IIUE-N/TK0+PDL.Y%<4JUDE911BM=L "-(]]1 &&LY?08#,X;G>(R03H -
M-/%25??B^V>B]0O".Q_.0+3BE#^C?IKY?AO]7Z\58NJVFX?.'RX;]19L 7+M
MN6**]LGN-94DUH?2'I<S&&Q,!)H 2 !]\EED-R..N,_^X-X^)Z*+O.?Q<>]X
M[+?KM<:;SMRDZ_S7\,E'P+C50[W+9N0<VM_VC>>R+A+AUOL6W&TS*G3!* ZZ
M/T8913;J'&P0I%]8+,WLD<H9:+1@ '4&3)Q^4 X ^7CKCE<_\@?51/U;QB_7
MPNF#T*T\UZ]W#@]L 26?:\4MC<>(V]M2G-GYQ=YD%6GMU$>E+M6")N7649FF
MVY2LQ?J2NEFF+!&#[@?<1GO6@?A0=7Z)W/\ #F^1>N=:M3&[](OO)5KZWVQM
MJ+HR>MYF32&4XS4(<03$V\4$6F<0#0Q_EIC\M,9_/.2KAAS@. <1\585XLIX
MB>(GB)XB>(OQ)^K]&_Z,_EO^C;]&<8QMG&WY9_3G].VVNNWY9_+/Y;;:XS_N
MSMC'^OB*N.Q6W[X)JU._Q#G3X-U 0V"N6EASP+>R_P!(186901\VPO0=*,7?
M%U*FI8J>6K%[4%E:\=-Q80%@0E,@W*X'7EQUX]^F?ATX<I3_ #Z=W<^L6:7Z
M"3*DEKTN[*)&*EG2DK)*ME-7YM95I"9BPWG21VB6T!UDA_HLMI56$2$VI2$\
MF-UV(<<O7K^FB[QXHO\ -[^*O]!=TI7X@WS]QFD=IZ!SKF=D^3^A=#?5NG_4
M7'?DL1M<DO4DJ%8Y+Z5VJDWBL'$#*3R@]:J,NA;-(]L'B%1#IS=)R^C0-PG&
M3O <"=,'@,CX_1=UW_%3Z%0.N:\R-X:ENG':/])<&^0FO3U_:Y[AU^V6WL/R
M<O\ H9#=%%44<O"I-L#'DTE0MV -[7_Y00R#=5]</!O()J4W1C.<$M+L8Z.(
MQDGNYJ&%9_&7[67UG3OCFJ4 SF71_A_YNN?+N"T[NY%BHU(N?T3]A[\@K%Q^
MB+]/R];GE]HJ:E^ !U.%6AM02<-1"M!DE8&9_C%2T8(SJ"03CD&DZ:ZYQIPY
M*YSYO^G&_P!?<+^F]7A(WS[;N,]9[G\R6SI_.;:GN524O^=I5NY/:.47"]4X
M!(>F5AV41G!BZ4TI=7K8A>H'X;P)*00>6" ".8(!U&/=Q^(*XA^#]VMCV_CG
M=K#I],'?3'/!/IOI ? [!=;A2;?V5'P42!,EJ'^UB6G@IBU9ENM".]7.CKKB
M@56O'/'5:F/CUBD@ 6E7#&-"-->/'W^[(Y%6W^+*>(GB)XB>(GB+F^.Q\AVZ
M!GDVO5.;YZIB#).>:8O%8ST# V!?YV2,TW#3_(\08"S@S,N5O[>!<_R,[?M?
M\/Q,'CC3JL?V#JJ[D*.LOVN$FP3_ *+0Z%)JYLPU9DT_S>PB(/YJC8L$R!RP
M4:E[.B4TDRN/=$N<LIVP(ZR7?8G'UZ]:*$UA_$GJB8BZ1B<[D9"5*\&4F%EM
M>5(:]Q_W;N,%:(BOZ@F$2JJ(Q9-.E,MY)Y.>-+#SE9,,\_SF,M06MWA@C49^
MO#/H'HK)5QNK)>"QT'+%T/#%-U%/@V%.&U*@TGU',&VSG8<N'$F(R(-LYVAF
MUWCSG.=?S\65[/$7^7;\<'ZA^H./?4="H/">[VWDJR7X<[KUP)>H[KR+@]=G
MZE2[>M%J5CL;3L5:L*"^"+H")8"N6J]TUCNP>VXBAXIV&(,TA]<->[7^7BOH
MP#!)&?Q-' GCO: #K@+MOQ5^)$/>?K38KNOTPGJW)+O^&I\7=DJ2SLK.E\55
MM>IWV>W_ .T2W*JLV<Z+U;FQY &+-4(WCM2&OP%_5&&+,BG$U0MP- <A[P>?
M#=QP]ZKLZQ^)']LT:P?7]JY[W>RVWH6*E^)M#>>&$ TQ\C^-J[\P=^Y/S/Y^
MZA6ZH%7='E>*UYO;K)8&+&Y%N4712]8K(6$=$##M&6PUN!D<V8(XNWFG(_B[
MLA3%0?67>%ORY;M*?])W/K=;YK^-)\_?+/+/H@YU5K!9>M_.MFZ3P/>SIGEQ
MJZ9=7KN+D^^WBAFV98!%J<N7Z+,38+5328+(:,ZC_P MSL:Z'!QQ]Q7^FKQ?
M-/$3Q$\1/$3Q%SF^=AY'RR=(-T[J?.><DV4C82N#WR[UFH3OR]-XH]Q4D5@9
MKI&I&F\\&FT(.L\FN\T6N=<9DTQDK@G@"5C^P=3 Y'40;@?HE)!*MM+J^8FU
MD'K>"-[E9%U;$T4&$@G!GN=RF<&5RPV90L+V_7(TL*%9 6U%(!GX_#U_50S>
M_B-5)99SZZOI$#(2*^6.C+;9/?E(%1(U4GRK0[6R>:)SQ5=2%R)O8KZT@RTV
MH-#LO-+=- \@Z &"M*[O>-./EG'CQT[CT5@E5?Q6NKUNT0KV:F&R(4[^)6Z%
M_A.%L3A>.QC7M@_UR?Q&8>A.!SQ?U[_QRHY8OU[?H_/)96>\14K?CD=PZ[PW
M@?RTPX_TFU<P8]%^\>$\HN;FG]#J7)6K;GENJW5)[%7-^F7M0^J%$$83J%A$
MELL2HU.@F!':,1Y@A9X9"VP DY&?PD\,ZCN59?R'^)/V9H__  T5O<OJ$P=
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MD6S+>=<^2TK/-D]%IJGG651J+-!6UA(!2LI&6L^C%/FJB@Q(OZIAH45J:O\
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M_9+#(AGB_7IIO^B37]6NNWYXP465\1/$3Q$\1/$3Q$\1/$48OK[_ .8K'_\
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M,:8*$EQ)/$KN/BB>(GB)XB>(J]M'E*W^^C*AC@WSS_F,5?2OHNR:3<@D[?\
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MS]]<=K4'/0OI'F'S':B^>\AIC&[6_CW.5G0)^M?<-%K*?@G7+$<)W:U,^5)
MT--Y5T0"F5--;V--Y1$P,V>I2?@SRX$XUQDXPTZC@,ZYXXR3P7;?Q!.9_4OT
M_P#@T+:!8ZNUZQ]&6JZ?/&+,&HXU:!"[$#6_INE$&W)]Q>PUREV ,3:B*([?
M=ZXVJ5('U'PYQ+7*FLWU5KBC2 _/ 8=SQ_=(&O+7@>7>H-<@YK^(E\-TKK_$
M.1\XOM"!,_$5O5L[-UG@G"=1^9&<'O?%AB^06[Y1XNBX3](@TRC%6VNJ$79Z
M?0N2]NLU">"Z+R&RX&P9:(2T<..21^Z, G7.=<DEN2-<9(R",$XP>B_1WUK^
M*UQ))UJ].;'T4BNUOX!L/0HKC5/G&#F_)N1=PI7#]79=TNL?</G1S%>2NB]
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M=F7M%G3,NV?=Q0;0W^UTTE';KC4T-/)(^5S*6ID@=VDC86R/;+'&V6-SVT\
M>6/;O")F<X765EEM%PG94UU!3U<S&-C:ZHB;*-QAE+&NC>3&\,,TI;OL=NF1
MV,97(>I?*YCJC.:_Q.]7GASPZ9)D.6I]6Z$-510P'RMBQ!#JF2"E%=U8*Q#5
MNA-3"23:;E1Y-PP7QSK2>ZM.UTL%P@J;[:[5?8(Q/V@JZ"A?6/?)3RQQ2/J_
M9&35/9RO9*6UDDX(:[L^SE+96]9<=G&2T<L%IKJ^T3/,)8::MK&TS6LFC?(Q
ME-V[HH-^-KXPZF9$07#?WV L/=^2U:YT3G55J5J=Z7%^D D%960YX^8%,I-S
M"B(LRGOHVCHS^*--"%H4S8%FSQC:23S;;[9QCS]XK8J^YU=924<-%33R!\5,
MSLXVQ ,8UV(Z>GB@CWW-=(611LC:7D-& NXMM++1T--35%2^JFB86R3O,DCI
M"7N<,OGEDF?NM<&!TCW/<&@N.2ND1[G9WUQ,,)I'G\_U;1FS2[X_TS^7Z8]@
M(==OSS^6,_G)K^6,YS_KG'Y9ZX%^=6M YD/)/D6#/F%SM.I\OYKU^THGB)XB
M>(N,<5I_2::NO0_2[=';S7?2']AK14;5LUPLJARY(,&NS_;AA[)\DM@G3_%8
M68*0U75WK7D9YBQ:--L3UZ]=ZZD//NPB_EKFH!0<DDVL4PT6A<.<PS202QX(
MA,S')O!-')!+^G\LZ31[Z;:Z[Z[:XP1)DX>T#D-S./?OC/DKIT/F/HOO^TP_
MYZ/_ -1V_P#;/3=E_P 1O^7_ /VFG0^8^BX]9^1\9MEZ#=7&H\ML?0\K<[!3
MV.KH6MBE5#CFKLS1"L9IRB!!QCC@<$_L2:0PD3CXDUUVVT]VM->[]14KJ&CO
M-;2TCG%YIZ>>:&/>+V2$XCF;C+XV/." 7-#CJ,KKI[3:JJH%74VZDJ*D-#1-
M-!%*_=#7L R^-V<,D>T9R0US@-#A:"Z^*/F>PW%;>F_'* 4\5##B#!Z)C!*A
M-$+&UB'W:<]#;CT!V3#HY8?MFN:R>9KMN-)B?]Q>OV%[6#;7;"FHI:"':&L9
M!*YSW/(:^M:7F(N$5Q?O7"!KC!'ED%5&S1PW<22!_ EV5V<GJHZR6T4KIHVM
M:UF'-I2&B0-,E"TMHI7 2OP^6G>_):=[+&%N*Z1\4\(O-7EK<2!9S/29FF-%
M<\U6)ZJP".7-1308Q!"16=:D_DE0Q#;0&(#/UZRYU%UA)_9FC^MMVWVGMU6V
MK?</O,B.:)T-U;/512,FB?$[?D94PU0(#RYKHZEAW@-[>;EIQ7;*6.MIS3MI
M!0_CCD;+;Q#3O8Z*1LC=UAADIR"6X(? \8)QAV'#4[#\.U\_CHG)J/V'J];#
M6"596,P<7V]WE*1%3W:HW<=I2C+LMK44)W]/( 8KJT%35A232?PEXT4&H>>;
M1[=5S+VZ\W&V66M,DE;))%36J@MU0U]9!/%O17!E-/4E\+I@]LM7[9*\,W9)
M'.<9!Q*G9*F?:FVRCN-TI1&RE8R2:OK*V)S::6*3$M&^HB@W)&Q;CHZ84L;=
M[+&- W#O7/\ YBL=(I=:J.WT9V4[%?5#K?Y )=?5A2_LXS^>0P2E#H\,7'Y_
MI'%)=LY1XL:QY,E_3^O/ N6T[:^OJJUE@L,3:F9\HCEIJF>1H=RDE95TT<C^
M;GLIX0XDGLV\%S*&P/HZ.GI77F[2&")L9<R6")CBWB6,?3S2,9R:UT\I:,#?
M/%8OYV^<B>07/H]R'[5+TR+H3!R?%HQ5_K9BX*MSEM/LU<P6QB$^*6%&3)(R
M@DE?B'_BD09$TVVP,-]-H]J&WZWVJBBMD%M=;8H8WOAD;)!*8J2&F/84_L\4
ME,R0Q=J]DE35DN<!ODM+G8LNS[[167"J?<):X5LDKVMEC<R5@DJ)9_VTQGD9
M4/8)!&U[(*<!K3^##L-EU^TP_P">C_\ 4=O_ &SWCMV7_$;_ )?_ /:]+IT/
MF/HL>4W!4RYU<V%*%C0(EE)$9*,ODPO%D'')/SDD[\] A23 XB"LZ9@BE)'B
MDDTWGBQM6AX/XGM(Z!F#Y[Q^2:=#Y_R6>]M1/$3Q$\1<D[I;KQ1.6V:T\XK6
MUMN*V6OQJT>J)[9\S0,K,F5.#O\ 'JS,._<X2HS63O9>JFB+)U79CTWQC.WB
M#UKCXE8[J_">,_2%+KU=^B.&\UZZF5L5MP"H_4JA5.B)J]<(59@&K%>-9%YZ
MJ-RM#<-U43@6**780PV*&76 N33>'0<">X8S\2!\502.!QG3.O#IHNJ$ZX-Q
M#J8B_EZC$P&#X)_K)\0&#;_N#%0XE(WQ$2/)C&\$^GZ98M_^%'OKM_K[YO8R
M7=$D D#'ME8'MC?N2,.62-WG'=>PZM>,.:=005]8IIH#(8)Y(3+%)!*8I)(S
M)#*W=EAD+,;\4C?PR1NRQ[=' A>G^45_T83_ .?!_P#:O;WC^1WFS_4OE@=1
M\?HOY@DG&,8PK(QC&,8QC$P&,8QC_3&,8P5^6,8Q_IC&/]WF2.#'?^S_ %(=
M227 DZDG>R3U.B_O\HK_ *,)_P#/@_\ M7F\?R.\V?ZDP.H^/T3^45_T83_Y
M\'_VKS>/Y'>;/]28'4?'Z)_**_Z,)_\ /@_^U>;Q_([S9_J3 ZCX_1/Y16?]
MZPG_ ,^#_P"U>;Q_([S9_J3 ZCX_11\+^;^<[7T[I")1<*-9V*?909OSZXE4
MM45^X=JP(9EI4+$16>S+GTB_G2,!BA3MH("2PYCHM"]?(2;$V,W:6]4D=PM5
M=-3&FD=:+A-;('YF[9\TE+2RQT\L\CPWM731R,E+6ODC=*T2#]*A^U;:T;.T
M^RUQDM&T%II:T5L#=I+/1WVLAW:8TL=+#7W&*>KIZ6"-S_9VTTL,U.))(H9H
MZ=[H3^;!S/LOZ$^M*[Q?ET8ED0L&@=NKO*[,.97@&,1+9(*:MK5:>PRLA=-H
M,F,&S3?.F=H=OT:S9FBE98MHL4PMFU]UA$==233QW&ALE:R2CBF:^HI8Y8*&
MBJFNFC!9VDU1.2,M) <7"VW:_8S>KC?OLRL%2Z:U7&FI)[+=]J;5)!<ZBF?%
M15\T%7>;K;WLI9B).PIJ.D;O8D&\6;CY'0222:[9E'D'SC/Y8UDWAWSMC\O]
M^,PR28QC_B_+;.,__2_+WL02>((\<?H2OS0^(/G^H"^WJHGB)XBYMUW%_P!N
M?N\<QV,TN/\ (0?P]E?^,?W>%&+(HS;,5S_-M)*=_E&:EAYBK_Y5IFN_Y#E;
M_<_DN_D9P3U]%F52EDWIM<#Z(NK3>SZ)D1%E'A"P;6_\M&"&D9DJ8&$4LNH,
M+?!,JJ2;3!44&(=L[:RXSG&7-#A@M:[4. <,C>:0YIP<ZM< X'BT@$:@+37N
M8XN8YS"0]N6N+7%DC7,>TD<GL<YCQP<USFD$$@[%C#+&/RQ@'&,?Z8QC]_\
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M:LL'PDO0YH=S/4WL%GHNP[U_>/3DUPO*[*DF]W#GGCKO 9^7)3=XK\?G?/\
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MGZ#XXXZ\,\PZ]\>=R^ON:W7F'U=] @5[FE_KYU?=<7^9JG/3ZX>M9:?HG6]
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MT_KXZVNI9B]R&-!7F+3%,\"FU;%!R[.%@*C?G4=,"54-'"LOUNC#+0('+/\
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MYUV#ZI;?3/3DQ7 >F#T@9$=O7!;U9=Z[2E[(!RHCDG@MT%<>U-S_ '03K&X
M57;OR ($1N8()],,YX;<K-LG#LO:IV;0VM]>^>,5+Z"E%1721203$-=1NJ8*
MN#L)(,2OJX:=LCJAF\YI[%KOG0W3:.6_W"%UEKVT;87&!M9/V%+&]DL0WA4M
MIYJ:7M6RDL93S3EC87EH(WR/Q]2\V^P>O%\L)KO,N##15)\T;%#2V1)T[?\
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M/%<:FMH:JFNIDVKKG4D5+'5,FA%->=H[H^3V@SQDM95P4)$1-7;ZV9M)-1;
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M*01Y7#[;:)1-+LLR5AL9&=()N=%F&(C0>(G@MX\1/$3Q%'[O-M[M5DKB?AU
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M%3+M<2]8Z%*5R)/6^K,N[5M%\_F;O\D\81H.TMS^GK55*D7AZ6J;20B(A9!
MMC*[[M->'<.F,GKIIK^IS,WYW^>.9?+W,%_)N4 NAZX*[M-J:-+39'5RN-NN
M=YL+&V76ZW2WV,P]Y9K5:K(V8-W#9B7))).1B ;08$<42 H22<G^0'( <@%W
M#Q1/$3Q$\1/$3Q$\1/$3Q$\1/$3Q$\1/$3Q$\1/$3Q$\1/$3Q%&:?M%VG^E8
M>+J:I2YJBK6+FEMLC&_#+KI )8*M:6R(FLT.<'0VPBC/ZONFL9,!.H@ CI0P
M6EMYQ;:!4R>O7P4F?$3Q$\1/$3Q$\1/$3Q$\1/$3Q$\1/$3Q%P:M]F>67N%Z
MY.)RZQ156@1ZAMNM;N:\16I[216*!;Q*K H#,(=B,,)+S&2;_<PK)=-(5I"D
M5T$Q9%UXKRSGGP_5=Y\43Q$\1/$3Q$\1/$3Q%QICWOG*KL27@QF;]KTFPI65
MC3BC\=[ =4"T2;"C#AKMU$&B$\N%"4SOT2]G,9<A]0&[E6F+_::GBARE<'&=
M,>(SY9SRZ+D'X@%O44OXS^D&#D6S%#L>.]&1CZU:DW.]%Q&LZ8]T&G8+Z0@L
M)ZI/'F/;^?8F@P=?58S'LT9AZS19W(T9(\1S Y]ZE;7W85E1J; NA;C .EXK
M,,>P5]]4WD(QD.L\,;:LVE:FLB%AIIOC4I2]4KFH,V-QS0QY]-XM2BR_B)XB
M>(JUJ_ G(_$CO9@^RZ)J#5E()T9R?E;5T7MOS-$5#*FLK6C!]EK2.$0J&.6L
M5JZMJ&2TPV=RX&;O;*J%*ZX'P[^OD0._AT"L1<6*OUW5;M8'J=%JY<+Z\GV<
M,PEFK9^VDVB5(UN39X,'.&<NF\:]8+F4TR37;0:"3;7.,%%J977^2A8/R;U'
MG0F%4KJ!IDJ[5H?"V>MG@JK%"?F5GI_#E0,V:U:ZC(_;W5'L 0SM8""X(Y"8
M/3T>'FNB?[_]WB)XB>(GB)XB>(GB)XB>(N(=Q[7OQ!/6G>_+>D=-%LMNK5'B
MBYT1S"$E78+I8DM2J [37I72^<19@L%D?+U0Q2N9G"OWVE,>;*5L63<E?>!X
MY_0%=KADVEABEWAE&WDBCDW'FS#M-!MOKC;:&78>6<?:6+.<Z29@GFASOKG,
M4LFGZ=]BB^GB*M;[S@3F]$^6PV&RZ$[_ "*Z'+R7:?E=G4Z1B,N:1&0:5[KM
M&M2&-Z1N6'A3:*ZWKEZ0"QM@D.&8#]Y(K*C@?H?=P[^NGDK$75BK]:@#*L;U
M,@&8-%R, ATS"50'.FY.H:E.',=/!&2T:%[Z"KE\.VY9I.^L T,LNV-<E%@'
M/3.;UPLD"P]!I"$X*$\@P)S:T*LL0=6,K,9SDC''P300K@WB4H^6733009PK
MG(VCB8";S$6ZZ;Z2::R1[:[Z;ZZ[Z;Z;8VTWTVQC;7;7;7.<;:[8SC.NV,YQ
MG&<9QG\L^(OUXB>(GB)XB>(GB)XB>(J=/QK/JRN?(WS?RB]-$G<[4\L_TQQV
MG):M\]];Z!RN^-TD;[_->B!R[<[MU4;V)/8J#3GO.\#3[,(5=AOM=/'U!/\
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MO/2A-('=K4IGG-&JRNME91%A95:9$.!_1%6VP0Q?O@2+ UA7/KUQ]^> 4R@
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MJ^X\RQ4]8OH)BBGN2JZ61TPOUT=\Y=PBM&^%=BM1S6RT>BK;1E@A H:4H6C
MS #;)0 OY/\ 7AE>_P!W#']?FIG^*)XB>(GB)XB>(GB)XB>(HX.^F]67?35(
MX^'5.>D<ZMO.;[T2:VDVRR074 7GK?FM<9K8JO%49T9)![GIRN4";>T01ZK%
MK"0C70J0<?8KC0GP^.?HH)]_^KPTWW_#\N\&<H7GUS>_G);7J^C> ,)ZURM6
MPM[.W..O] SMJ *WKM)IPI%@ J"EKJYO5DEKE+A(1C/&-E0%<?ASR#B#XD#
M^'?CBI!7_B]4X+\_\LH-6G:-Y,?5/RY8K=<[(3&PN?1[]9/J#F+2Y=%O+:*
M;5K;+<ZF(9M)X1Q5X>NXZ=&O55]8J5 E"<^N'<%/GQ1/$4,/HUYP'GW3>.VC
MN-2UL^+BZCJ%%9V=RPLE8JO25[!852=*QRYX:33@[Q8-FCW<>^H$XMX'C1CJ
M]C3ETL&BLKR^/#7SZ*9_BB>(GB)XB>(GB)XB>(O\\?VET.Z]O_$T^5.5_,O'
M^>W 9&%?>?==^SX.8H[]8?G.TKCE[=\JI5ELP>:@RZ/R53_$:J1?W[6'RN]W
MT8ZU5<TS!U79%L8#23U&&ZC/'CW<^6<8!!U4^JDGX!\__6_SUPZAO*\E8 <
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M=QS734%+$"'8P989& _O,<,@Z)\[_-%L"YE2E7U'82NKV:F1_P!2@JK*9/\
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MRJX"8?7J\5R^NVI=1V+>^7_<B;IE50/$*&E!5:V/-+_3WKUZ_ELMW0"2#G4
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MMREJ,;U"H=BZ/0ZB9:+:U_25:>96+2L_.$$(P6HBNTUUXU;L;U8SC6KX857
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M>TTUBN<]QI8VS5=+%2R.?10N;OBHKG@=E0TP80^2IJY(8(V9>]X:"5#7Y!^
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MTLRJO;J8JA4KA971<(!RVLJ,U4NJ<OY)_-"(:K6N)"9X=WKUWDGFO#V#\/\
M7=1*,OKKI-@N_78%5WT!9W1=3DM<=S6#G^]!1U)I+1J:KL57H:]678(&.E2,
MCL+/>YV!FU8N35=,CK1,]WCU/S[OTYY[I\^_*50^=[%<;+6;)97C&^U/F-?M
M4E@PHG)>O.<I#U)5_<-(5T;EK<[R4R,>6]B:QEA8.")S,#8FES)@A.?7OPI2
M^*)XB>(GB)XB>(GB)XB>(GB+G'7.;KNN\ZLW.6Q<8*ZSC!C%$S(*U9XM- V8
M+3&DB2VJ7:,K2?<'2#:64'# '$F6"-@G>BK6X)%!R/\ #*YK E8UN#K'68DS
MW_-)+03C_9_O:KBPNX5AU9V*XVS>C[,;+;,-[?9G$MB:Z$&M?WDBAUA@F1:!
M&%<GT3Y<?Z8&,+<>1_"52YB]ZK/HVSA'=^<6GG2(5' &BB5;=0N%RO76+A'5
M$ZI31T;Q\2^HU&3"JDAF%E$XU1@I69$<Q"L$A.?7< /+'Q*PUQ_#YK=RC2N[
M9T6T]'N59&YH"NWN"GG:I&VK7'#7+2D<\,Q7.>Z%I:LT(M%X575D)$V=V)'T
M.T!-/[05=20*J3)X<!KIX^O63GI7S+\=UWYQ8Q6@2X6.T7%ORZJTB_M&^\!F
MMTM:IFRLMDZ&R8LHC[+(\LML?6)Q+I([S%C1W.$R_M1U56CKA"<_'X^OAXYF
M1XHGB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(G
MB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB
M>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB
M)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(HE=D^D77+[)<*
MVMIZVRF)ZO1'"#35A:8R#6-MM1B9E R&4TMYO(%6:TKL-[=8KN7C!57:YF=J
M*%K8E,L14>7%:AQ+ZKZ;U/HFM.LWSS9><+-G399EFZGL>YL HE=9O=V!&A-,
M6H<ZU5HM!H=V_@V%@##;[A5]:XS=K=R"=B8TSG7IY?7YZYT4Y/%%7CW_ /$8
MI/"?I0;Y17?/OTSW;K<O$$WT&6'PZL\J:IE/.GE[L_.1"63'H?8>;3ZLX[+5
MBXB0Q 3(M!3ED\94N\I4(9:#21G( SC4XUX_JID*^O\ *W%HQ10.CT,B^X_L
MM9Z%#<JR1= YTD A#X4NLBM9VT1*&(X/9U%_&V_K<%#[E;1Z3P[[E,'H5P>F
M_=/S7?.L]KY/7.AU\O\ V <]YWTGHW3-;12)N0KDW27=[0*UVEY#M18X[Y(Q
MY\YCM(+@)3 IP6IUC,,F*GA$)@@ XXD@==,?4+M=KZRF3\F;]@I"2P=S2!5_
M>Q($?$<UVZ6*_BXWUTB&H62+$EK;TPK\]MALR60$*76*3_NW7.N,9*?!<9^-
M?L2F_:_.KCTFC\V[!S!;1^LWGC#A'VA!4Z]9)KCSB<)=<<KA:?=KVM*4I[ 0
M;6)CMFT,FS]$\#U&S$%H3.5(QTX Z=#J/@I<^*)XB>(GB)XB>(OQ)MMKIOMK
MC3.VNFVVN)-\QZ9VQC.<8WDQKOG33.<?\+?&F^=<?GMC7;\ORR15R6+[@O@-
M6ISRJ\2_S4AZ2W ?[IV-[F5U[0:P,@0;+/@#F31X&D$K(]<MUK56!,DL:"+H
M%82:AFLPWN BN.IQCUY]WCJ I3?/O6[3V*L69];>;-^7')+NRK B!WN?(P(
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MZA?.C[7ZN84]FY9_3/R8[C'7H]I(COV%\#/&=Y/[/34,MM?AN[^+B3EKMWB
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M63?6+6C?0 <72OW>PZ7AUA7RFW25HKFBX[G*G?>15.S=,XLO!-_AIS).O/&
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M+@WT\U[?T7HE1_V6-ZC6:>0]UK]P:$VB&>U *['A,M8SU^P\^JFJ.*R+9(;
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M%V]-D[%9L.G\(880(FJQ.[4.C7KQ1$4<%M>:G*3]M5&ZDKD_#'N]!3' !$6
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M1NWS@[[6Q[HX![P25<9S+YYXAQRLUNH\VY=3JPFJ4A)*/(Z<8YQ"T/(V-;6
MZR-=3K&YM+UCO*UL5K<M6%CL3><AL[:'LB9RI.$YSG$N<2YSB2YSB223J22=
M22=23J5]@            .  &@ Y :!=88+E[8,A<T!#9+RM/VR@6 T)@9,>
M-M=\:$"D:203:8WUUV_3)IMK^K77;\OSQC/HJOZ" "K#'7K A%P D>(A001H
M1 QHL9SG$0XP^D<,,>,YSG&D>FNN,YSG&/\ 7Q%Z_$3Q$\1/$5:@#!!M^)<\
M%>$TS6WZ<]%"I<&TU Q=9*?_ (2 S91Z1"*A[UN!K897D_Z6K([]N'&\@\L:
M>04(8KR]:<=/$X&O=XJROQ10BN/P;R^[LK4T;WCJT,UKO6G19106E'T6)+*&
M>\9II*XK*H!8"M>G.MUY/RM_CSB65Q>++8[U':[+,M<K2T'$<,<"//CWY^BF
MBN &5+P586F\8:T,4 2.266??08.#0>#3>>?>2:;?6*/37:6:3>63.,[R;[;
MYSMDLK4NG]%J_(.;WWJ]X*)"IG-:=9+W;#0@B&18E<JB@MXZ)%7!Z2%GD0+@
M2)8@Q8Y"2=]-88(]Y=]=<E0,D#J<*E[KOXCD'W?\B=-!_#E2] <M.FU&]T>@
M?05SFN' :U6K^"NFA'VYJ+'6[!VOK704+3(Y@*+F_,&U*T+#E6= Z!31MYM)
MNIN][H++3]K5O?),]LGLEOI6&HN5QEC87^S6ZB8>VJJAP& U@W69WY7QQ!TC
M?2[.;*7?::M%-01114L,D!N=WKY11V2RTTT@C-=>KI*/9;=1LR2Z2=XDDQV=
M-%/,YD3O[^&?\.?1:?A?&;M]B7RRW/Z*0A6$C7J73+M:.UWZJ MGSK51KQRO
M]01 5+A+(ZF3J@[/<9ZG;NK6>2=D VL"U3"F7KNDI*J_[2TT%5%'/LI:ZF)D
MC6U4,4NTTK' $AU/()[?9P[^Z9!=*E\9#C%0RXW?47.AV.V'KZN@FEH_M!OM
M#,^%SJ"IJ*?82GE8>+:R!U+>MIBW0/;"ZP4$4["UL]VIM[?LNY9\]U.HWCH[
MQIRJL2[V-Z,V572PM\7^X'Z"*52Z7=FRL89C@<MHS@;OR-]&4FF)#]8-\9VC
MCQ#P[#LA;[?=+S5U%@H7.K*ID\%SK*@7:XS".G@A<9YZR*2H9)/,RHJWD3D!
MTP80=T;O9;7_ &E7F]6#9>WTFV%V8VUVZ6CK+%;:([.62F=-6UE4QM)2VN>"
MBEAI*22CML;74C';M,9&G#W%_5><UFR5UST0MRBJ"<"W6H>S+]:P\/9S:[15
M:M57<9B.53ZU#'OM%68F."8"#,YD8R YBQJ%J:;WUFHJVCJ;Q)4TMNIH;A7L
MK810U<T[P6T%%0%DS)+=1-:2VA;/OM?)^*9T1;B(2R^0VGNMJN=!LQ!0W"]U
MU39;/+::DW:WTU)&0^\76\-EI98;W=9'M#[L^E,4D4&&TK*@/)J#3T_N95VV
M$],KEL%*KNE=25NRUV<(B-EET1I:&%19%E131[8!TW$FJ T0\>^FV)8CI]I-
MM-X8\;_6>CN#[Y17".2C%'2T5=1OB>V?VIXKYK=/)(US3V0,;K=&UC2#O-E>
M7$%K<\:EN=GBV4NEFEAN3KG7W6TW..>-]**&-UHIKU20PO8X>T.$\=[F?(]K
M@6/IXPT.:]Q;TCW=+RZ>(GB)XB>(JU/Q F* *U?,&ES)I@M2ST!N;K);YJ!!
MG6ZA'4G2H;I][@J-;88:0%V'.O\ C9H.OZLPZLXBY]D\@14<_+S![N[KPR.&
M597XHJ^+O??N,.W-E]/YH*93A^FVE9'8]0*DS-)Y7^PH(#LZ-*QNM3(&L-?T
M(F75U.SE?:WMR,]:'Y1)_P"E51E1CGZ/?IP\^(XZJ=-5GL157K95O!!5VPE"
MGGM"Q7/L4L76*9>/(Z!7%;;R;$@B,MB1Q)]I)-IAXXY,[[9V_5DHL]XBP=FL
MM>IE>=VVVNEE;J]:5'/+#8'1D"Y.D3+!I#&35HP*WC&!7@"12DF%D21P#P1R
M32[Z1Z;;8^<LL<$3YI7!D<;2][SDAK1Q) !.G<"5]J>GFJYXJ:GC,L\[VQQ1
MMP"][CAK07$ 9/,D <RN1H_J+YTM-077VJ=KYM;JBZ(8"(751M:JU06(M3/(
M*S#K<-?(8EV$P J&88L1*.<1!/#-#)'K)%)KKU%1M'8Z6-DD]SIHS(YS(82Y
MQJZA[1DLIJ)K75=2\ YW(()'$:@$ KTE'L1M;7S2PTEAKYA3L9)55(C:RW44
M3R0V6ONDCV6V@B)!':UE5!&#H7 D*LJ/\6;EA/TUUKA?.G][ZU>:J+I&LY3I
M5I"WH+3^0'AD&)1.;<HL78YBA=V*^)=BTP*T*95&W9])LU4%C&;Q>4H+QM17
M7JZ?=]MNLMI#(A03;1"CLEN:][Y/:'10PV9]_D?3N8(H*>K;&[=$OMCXWO@E
M7Z+=]F-@K3LML_\ ?5[V?IMH725)N]-L4ZY;57I[(HHG4+:BJJMIX=CX(JV.
M5T]766Y\S!(8!;89XXZN!5Y_AS<W[=]@_8/W*N^@O\DX%PNM7[,X7&>9=<FP
M][BD<N3Y]JQU5Y7_ *![ ZJ],KP$->GNU4YDX0UNW7.RV6ELK9.KK5NI!W=V
MG9^*CKIK@^>4U-6WMJBGI:&BMMNCJ (V2"-U-14]RJ8G2-?+'#<:^O9OODG<
M#(8GM\OM%ME-<;/36:"FIS1V][J6DK;C=KK?+W+1DS/A,C*ZZ5EDH9V0.BIY
MZJRVBT2[D4-)&X0-GB=?4Z^2!!>Q<#O'+X. <WYOPA ;7$_-8?G34YM_6-BP
MMCAZI<D/4*8DI,"M>L"CIH\'.G45:<3-G!&KN%C$K"[S[JMG:MG^[J#MV.8]
MDQI*<S-?'(^:-S93'OAS)I))6.#LMED?("'O<3Y$;17\4TM&+Y>!2S,ECEI1
M<ZQM-)%-!%331/IQ,(GQS4T,-/*PM+'P0PQ.!CC8T=T8<+Y<UZJH[8?6YR.G
M(5Q:A/9O\CM47]>J81 1,5PZ:%W'7\ LOZI3,R%V5;0L#%*HXS2<U:"1!SUT
MRZWXB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XBT4_I5+
M67Q/S,UQO#='J[5HL5_U3F468:6"Q%"13O(5\B %BQ#J%M.4J#V@S5N#5;(:
ML"+%1-)A2*,K[X3^<+#]'OOIV[(8+=>K**K@,0W171'M,UD15I35E)HP#2H2
MO]B%@"F(H&,FR% A-33V P<,T^G[7K8=M[S1V**P4<D5##$-UM?2RUM/<G1>
MV5=:83,RM$ C,U;,'&.F9(^/=C>]P!WO.2[*VNINTMWJ625<DI#G4E1'2S4(
MD%-34HD$;Z4S%XCI8BT/G<QL@+VL!(Q+U?JA4B0+U>JA: -IK$,$OP$&(/'K
MC&NL< PW[<,6FNN,:ZZ1Z:ZXQC&,8QC&/>3DG,KW22S&61YWGR22%[WN/$N<
MXESCWDDKT3(FQL:R.,1L:,-8Q@:QH' -:T  #H  M$J/+.*<_LMNN=#YQRVD
MW#H!LK*^6NHU"I5NRW9C.<6SG/MSU,N":60V9D><PE*<E&SR'&EE[R9()FDW
MQOL_,W^(?5:P[H?(KH_\\'_GHG_68?\ U_-]GYF_Q#ZI@]#Y%/YX/_/1/^LP
M_P#K^;[/S-_B'U3!Z'R*?SP?^>B?]9A_]?S?9^9O\0^J8/0^13^>#_ST3_K,
M/_K^;[/S-_B'U3!Z'R*?SP?^>B?]9A_]?S?9^9O\0^J8/0^13^>#_P ]$_ZS
M#_Z_F^S\S?XA]4P>A\BOWH8)+MC2,H:3?;\_TZ:3Q;[;?EC.<_EKKMG.?RQC
M.<_EC_=C.? YI. YI/0$$I@]#Y+T>THGB)XB>(N=5*^<_P"PI[9#6&'^1IE#
MQQ0;/'.J=*H<LH5H)1X46&X"V1FL.3NUQZYXI_EI'*MD*P3LS1)XY\DQ\=5#
M*D?A:_AW\NHI?,^>_.=%I%6*N$MY+&1/;6&ZDLTJ'%9GGWM$EFEM6H$J?2,>
M6OX<:H-B8(&6RO\ LQX3-.\LFU-[V<=,;/<Y*1L[2V:$B&>G>=^)_:&FJ630
M"8&&,"<1B9K Z,/$;WM=U-VL-KOHC^]*)E2Z(@Q2YDAG: V1NX)X'1S&(]J\
MF$O,1>0\L+VM<V9-6YSR6DAA@5*FT2O#@"P!C?U29()/K /%I!%B4J*#4HB3
M]O37$DY$TL\VWZI)I))-MML\&KO-QKGODK+G5U+I'.>_MJN1[2YQ+G887[C1
MDZ-:T-:,!H  "Y5-;:&D8QE+0TT#8VM8WLX(VD-:  "X-WG' &7.)<3J23JO
M32*-RWF@):SG51HE#6L"M#3@*<C0UH(PR,>(2,HH9,,'#//&+!"-'++IMOI!
M%'#KG$>FNN,UUVK[I(R6Y7*KN$L3#'')6U<M4^-A<7EC'3R/<UI>YSB 0"XE
MQU)*U26^BH&.CH:*FHHWN#WLI:>*G8]X:&!SFQ,8'.#6M:"02&@#@ MPC)5P
M_J_9(7Q?KVSOO^W*-'^O?/\ OVV_3MC]6V?^/;/YY_\ I^X1D#OWI <:#+P<
M#IJ5R@W'!N,\<#&?@OK_ #P?^>B?]9A_]?TWV?F;_$/JK@]#Y%/YX/\ ST3_
M *S#_P"OYOL_,W^(?5,'H?(I_/!_YZ)_UF'_ -?S?9^9O\0^J8/0^13^>#_S
MT3_K,/\ Z_F^S\S?XA]4P>A\BG\\'_GHG_68?_7\WV?F;_$/JF#T/D5^XRQ)
M=\:1%#R;[?G^6D<T>^^?RQG.?RUUVSG/Y8QG.?RQ_IC&<_[L>!S2<!S2>@()
M3!Z'R7H]I1/$4+>34+N+GI8W1NVU"K:2)'_28*RS@[IU9H8N2ZO[?7J&Z@X5
M&B%X<CL;#G; 5:QLBHV6SQK&S*,IF46R:C2%?Y>O/^BFEXHG^[_?XBKS_$CO
M'XAU"XY2&OX;?*>9==[&;UA"GNB#J<X,")7S ]!9]&+\3)W0^;:9.#MFM0'G
MWB<FR#*2V1>ZW(PY!P/SED[)H=N2/R]C V-CGD&1X8US@T$MC:7 R/P6QLWG
MOPQKB.130MGD<QTL<0;#-,72R,B!$,;I7,:7D-=*]K'-AB!WYI2R&,.D>UIT
M/7\/_H'<-LM_N/MXG=BRL;2?[.%E.7:\.JLTFN?UP5#EELC<\Y8Z"[Y_6EM/
M3N?=$ZU7Y=II$_4!,2QQ#><=0[2W $5MWI;/"]I:ZGL-/[15M#AAP%WND;XW
M \ ^*R4DS-7,E:\M+/;LO&PME>Q]IV;K]I:J)P<VMVNK?8[;(6D%KSLUL_-'
M.QP(!=%4;57"EE'[.:FDCWQ)*WY=^0>!?'M"&H'#>?5NH@:REDLVJVOU]0X=
MEG%;%D3,9D*I2+^W^YG36$,44<2+6+23]G<G:<B;[V'9RAL, ;'+5W&N='V=
M3>;M.ZNO%8P/+V1U%=*.U=!#G=@IVEL,30-UF^7O=PMK]N+MMA5N?/!;K+:6
M2F:AV8V=I&VG9JV2.C;'+-16F!WL[*JHW=^JK9!)5U#SB28QMCCCDW[T"\:G
MB)XB>(GB)XB>(GB)XBA=UFA=RZ7U)TAGJ%6L/"P%U(G5Z.>Z=6Y+,T/89?0=
M#4-*URA$P#Z7795\2/2>N=--WKANQ!*[17N"8RGD*\.''/\ 3]?@IH^*)_N_
MW^(H&_B)?7?6?BOA"GKG&ODGIGV?;&/1Z_2".3<IGLH]D6I7".TMC+L1)5><
M=19?U"<I  I*UWK<(F2GX/[K463$(YA:8T.."X-TSD^[34A:=TOI7XC'1^2W
MJ'D'R;R[EK]WSNSQULKK_P!.@Q]%76!A6CM4T2>E4?C71N=SOHV4HV@>+?U5
M(A%.Q%L\SD#4N/7B5+9Y(9F"-CF.BD#F->YTLK2P@Q1_M*1L<D@.ZR0U+&L<
M02YH_&WL:!])!54TKIY62,J(7,E?&QE/3/;(US:F;$-RDGAA< ^2!M#(^5@<
M&M>[$;X/_'_PK]Z=T^2^D\N_%1[9TJ-Q;K!=*^3Q/F]PY;5*'<J.ZKR(<-A;
MNE<@2&]/9+BB9G"R6I"76LJ,1BFPO:U8E9BO>+KK=1NI*":*BIZRCD,LDD<5
MTJVU;GRN##ONGBJK@]L#L"/<$P<P,.Y$T$.?W=]N<5QO%+47&MMMS@%/#%/4
M[/VV2VMC@8Z1O91TE1;K)$ZK9ETYE-.Z.5TS>UGD(=''*_Y5_!U^!_G#E"/G
M9OR?\\=#:IRS3)+CT?F53ZQ:BYS]XB"=_P#+>CUUO9H1=C<3SB*OY\H:J*74
M,+? T46FG,MT-;'31_>;J2:O#&,GJ:2-T;*@L8UO:EKVAS"]P+NS!+(P0UI(
M"ZR^U=MJ*^<V,7*GL[I9):2AN,[99*-LDCWB!KHGN9(V)CFL$S@V64ATD@#G
M$+K?SO\ AK_+/RO]$];^FN(U4ZE7WM"::O7!&G_QU1SX=-LU4M@E]<IZ&MJ
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#1?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g383050g19a20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383050g19a20.jpg
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M(E&G&B-!<20E)C0X5&%H=+*SYC(S17-V=[;_Q  = 0$  00# 0
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MS$:YY[PYS)(X@O?K6O?SZ>!0?FD-J'7N#PN+\YB-<\]X<YDD<07OUK7OY]/
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M73CBXYB-@/HF;:V1\ '.;$701V>_=-8'Z4YU%L'IMC73CBXYB-@/HF;:V1\
M'.;$701V>_=-8'Z4YU%L'IMC73CBXYB-@/HF;:V1\ '.;$701V>_=-8'Z4YU
M%L'IMC73CBXYB-@/HF;:V1\ '.;$701V>_=-8'Z4YU%L'IMC73CBXYB-@/HF
M;:V1\ '.;$701V>_=-8'Z4YU%L'IMC73CBXYB-@/HF;:V1\ '.;$701V>_=-
M8'Z4YU%L'IMC73CBXYB-@/HF;:V1\ '.;$701V>_=-8'Z4YU%L'IMC73CBXY
MB-@/HF;:V1\ '.;$701V>_=-8'Z4YU%L'IMC73CBXYB-@/HF;:V1\ '.;$70
M1V>_=-8'Z4YU%L'IMC73CBXYB-@/HF;:V1\ '.;$701V>_=-8'Z4YU%L'IMC
M73CBXYB-@/HF;:V1\ '.;$701V>_=-8'Z4YU%L'IMC73CBXYB-@/HF;:V1\
M'.;$701V>_=-8'Z4YU%L'IMC73CBXYB-@/HF;:V1\ '.;$701V>_=-8'Z4YU
M%L'IMC73CBXYB-@/HF;:V1\ '.;$701V>_=-8'Z4YU%L'IMC73CBXYB-@/HF
M;:V1\ '.;$701V>_=-8'Z4YU%L'IMC73CBXYB-@/HF;:V1\ '.;$701V>_=-
M8'Z4YU%L'IMC73CBXYB-@/HF;:V1\ '.;$701V>_=-8'Z4YU%L'IMC73CBXY
MB-@/HF;:V1\ '.;$701V>_=-8'Z4YU%L'IMC73CBXYB-@/HF;:V1\ '.;$70
M1V>_=-8'Z4YU%L'IMC73CBXYB-@/HF;:V1\ '.;$701V>_=-8'Z4YU%L'IMC
M73CBXYB-@/HF;:V1\ '.;$701V>_=-8'Z4YU%L'IMC73CBXYB-@/HF;:V1\
M'.;$701V>_=-8'Z4YU%L'IMC73CBXYB-@/HF;:V1\ '.;$701V>_=-8'Z4YU
M%L'IMC73CBXYB-@/HF;:V1\ '.;$701V>_=-8'Z4YU%L'IMC73CBXYB-@/HF
M;:V1\ '.;$701V>_=-8'Z4YU%L'IMC73CBXYB-@/HF;:V1\ '.;$701V>_=-
M8'Z4YU%L'IMC73CBXYB-@/HF;:V1\ '.;$701V>_=-8'Z4YU%L'IMC73CBXY
MB-@/HF;:V1\ '.;$701V>_=-8'Z4YU%L'IMC73CBXYB-@/HF;:V1\ '.;$70
M1V>_=-8'Z4YU%L'IMC73CBXYB-@/HF;:V1\ '.;$701V>_=-8'Z4YU%L'IMC
M73CBXYB-@/HF;:V1\ '.;$701V>_=-8'Z4YU%L'IMC73CBXYB-@/HF;:V1\
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MA$GGJF*BO?0KG;=/\5'.=L+S]A]AU/P0;C^IK[@HW:A$GGJF*BO?0KG;=/\
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M% * 4 H!0"@% * 4 H!0"@% * 4 H#GYVZG_ )OIK_\ WI3_ /D85:3MS_\
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MRV@'7C3I\IZ<^O\ A/\ (_K@_9F3;/N7:^)^71N [+#WEM .O&G3Y3TY]?\
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ME'VD?U<<LO\ RRD[_P##:]__ -$;'_"UZV_8ZJ).YG>MW_T4W_VN$-1VP?\
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M;N7DM7+<MUQOQ6VB.8H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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MK2%TKM*?7E[_ "WI@'":0*!VI-.##&],-#ML79Z0_- W6D+I7:4^O+W^6],
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M-/&5N1J>2I8'G>* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M $B$J8E1#8N> 8&(F>5K7 O2@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M85[#O&'K-][#2+E.D:IIGEN* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% :HZ[GK)4;Z*-6T@PY@;RE5DZ<)G=,?")X5S"@4=B''R^HHJBG%<<<
MLCBBEG2X2B0)88"9G3A4$K@&)D-;#(51$541>A51%^J\YH7WHL?LSS3L>P-(
MCX>,0JL<;,U=EN'=1B E**LS"\WC@LY]$!I76L""@G+B7-BFONCG+35(8=1=
M1)WN-0'(K60AI./#EY2(C?*2^]NY4Z%1,N5.JZ[(2%[#\'48JN/:;OC4S"JW
M!,NR'J]#6W$SS194+M_-P%8Q;Z,N*3!<"@6N7<3+.K)$R<;BZEFEL@(EFB=P
ME96MC8Z9%C=R<FY;TY/3_P#Y-+E^DO70KITVC,<:AT!TZCUZ9#\6ED!TEE,L
M\]H>2U%(62F<2!@$;(>, -&\,B*0^![(.Y92L^R-D<7T';DE+U.2Y TK*ID1
M$6__ %;OQY;7\OM,-:V;:9CNUMT7HA>$7.TY)9\N->>)IU6,+3S)3G<KQ>@K
M#+0K!6G W+C,9*T7(,]6(+:.\94R<RZF1VUV<TT@$R8#7' L9DA5GE<EI47)
MT77IT=*K<J_5==])HELP8!4U/6++25.$+NI,CY]Z=]H,R-1C8>,4.M@8PDE2
M9J\.NY+:4^SBY$0BW=5K@D-C9BKL>.U,,D,FFQ_;7 3U0F1$6P!5I?W?IO9N
M5+LJ(S=D1/[MWE3K7H2XGIV-;_DV3]F)H\>DO'U=7>JC&1I/^G5_V^2VY&>V
MG>YFQ&CI5AS5\C1U0=$;(S2<!I2-9BF5092R41QAQ368V8L;N1IJ[HOZKOKR
M>3+Y"36A:* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% 1"[4%IL
M9W.2!B+]E),BA,+(<LFRBTJ-9TNL%0/8GXN!P2PR34)'CI<7,N,8-V-& \"N
M.!3('+/VPP6.6F;;)?*IC3LL=3:?.) Y8G3IX[B7\!'1[+YZD#'LHX1W .WK
MQAI6&FWG+;91A$=JS?RFF463W<L3FH9+6<^B*<I"+K&*>TQ$.7T!"3B429N&
MAUFLH;:BVHB<OX>'>L,O';IRKETVT^57[+:,\AAM4B\YDM.'3,:'8S,WEVHS
M8+T9I*EW9NH]T)V8?6I:"YUV[H7B8YDM.'3,:'8S,WEVF"]&:2I=V;J/=!A]
M:EH+G7;NA>)CF2TX=,QH=C,S>7:8+T9I*EW9NH]T&'UJ6@N==NZ%XF.9+3AT
MS&AV,S-Y=I@O1FDJ7=FZCW08?6I:"YUV[H7B8YDM.'3,:'8S,WEVF"]&:2I=
MV;J/=!A]:EH+G7;NA>)CF2TX=,QH=C,S>7:8+T9I*EW9NH]T&'UJ6@N==NZ%
MXF.9+3ATS&AV,S-Y=I@O1FDJ7=FZCW08?6I:"YUV[H7B9_ D+:; 0\Q1=:#-
M""#PR$$$$AN9, P\,+7RSSSSR;UL<,,<;7RRRRO:V-K7O>]K6JJ4M1K2HRS:
M3+U:541$2FJD5555N1$1(2]55<B(F55*I7MJ:K<EA4[55Z$2NZ%55^SQF>!,
MBO2PM!9CHVN&/E8 (2X0HR9$\N'P@Q;?ZAYB%4(7# 2W_;AEE;*W_"N1]2%)
MP[2,O[0X-PTTE[++ZEJF=-*G6B-P3*JGTID+FZZM5=K<W81/6%5+T1NN:&95
M4Z[EF29"I<R6G#IF-#L9F;R[7%@O1FDJ7=FZCW0LP^M2T%SKMW0O$QS):<.F
M8T.QF9O+M,%Z,TE2[LW4>Z##ZU+07.NW="\3',EIPZ9C0[&9F\NTP7HS25+N
MS=1[H,/K4M!<Z[=T+Q,<R6G#IF-#L9F;R[3!>C-)4N[-U'N@P^M2T%SKMW0O
M$QS):<.F8T.QF9O+M,%Z,TE2[LW4>Z##ZU+07.NW="\3,E15HTC2;'1DS(QU
M5M!S.7!,-K.2;:+I+1[V32(A8$T8L;7T]+(W]D(;+X^QL9N/G82^086>. E\
M>[D%FLDJ>/662.OI='1J.'D2KCQ%.H?^Q=-,,O&^^13IPZ_=5XPG)Y?*6^]&
M51%NQ:L+<ZLH*4I/:LL=G4IE346Y@4BEJ^E8Y/"HAAZVY==YEL1&1"<MER]7
MEJZ1VSR;FFV5:91=C_L?'UQI:?558\2K-.;E-<YI?[!$_'-7<]J09ASC;,%N
MAEF"MF$[HBEY@26?E=N+)-F. LMCI91N*98R>P+AC8\G!,#*&80.6=Q+?]9G
MAG;&UKW]7*_HM?(*4L,F-.U%*)V]J""B7<LC&(IMP[@G[#;U&$:3D,MM/E99
M555,JHJ)U*8;:%W64FK6BJDI2'HZ9P+Z>RUY .XQ]-(1\ZAVGC;#7?&W3$*R
MVVB(PO[K+3*JJ]*$Q=20(0B@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M 4 H!0'\"!X"X9A"X8"!"89!B!B8VSP$PSM?'/#/#*U\<L,L;WQRQRM>V5KW
MM>U[7H#$,6QU#NG5DI,41J42&"QT914!FXS<W&>,)Z#F\' I+-D1ME' K'QD
M1 $65 \7:S12,BC=0"5@6\U$E,1R!)-+!TF.]6FL"'M&<!/[4=*PR^KL&-EA
MIH#G)QZGD72Z0%AYN]NLE&3@$;-53 [G+++I2<SA8P>+#@$1<S-@Q+V#"%%4
M16EN3I6_\$O,<:=MH7"6H>6EW3_9J3A!<]H;.#D4.&M2<3."(7RXX\S4<$<1
M\,X!5R.HCL;I-7$Q3% =#6CAM/.>O@<)@X C9ABJLJB7Y%3HO147+U+Y4,BZ
MKM8D-:/-.[^U.R><6EV-(W4VNC..T<$D]VN'%4=KW;L?II FF_2R<6&-@N%S
MI>"@7%4"XQ0K<<:X>8@>((@HB*TMR=*W_@EYB6'-3>G+:/-/4E )IGS(T52/
MK(\;ZCH*F%M/*#Y3;R'*#<,+3>+K0*&MDU8LW9#:X"G<F.BN3')71,#Y<\'@
MG'\,#HJK*LW+DN7*BHJ*BW?Y>6\S5ITU'Z5YF2U!DZ;9,C5PA1)EDQ%F-6B9
M*(CAC#!I"6;@+<6HT- )+F91%*Y#@FI992;R80S*  62[BD_8YW%%14Z47+E
M^OZ47RF'E/:1:;$>$-1<_*0[[+LK3-J$>^EQYIP32S4'@Z9J9+U0XZLTHX;:
M8H'33K'=CS<B*AM 2XB=<^*=Y4I!I! N;-@"J,JJHGE5+_LNO_"Y?\#-6F/5
M)&&J^*S$L1S@Z$%/17<]8]?+1D9 $9K_ (SD..5DR@OAB2$VS1@S9 <K:42N
M5E MB>.%>3#%CA<X.5,!BY"BHJ+<O5>GTHO0IG&[I;-@C0UW$A6!)#$"YP6Z
MNGV"*&%7$'-+ -"<H]0N,I8&2^1 (6^&9S$<'(OB)87"^0H>T962BR@323"F
MGEU11#,"IZ:,<+!*!\(IC;,T(3)B"8F309;"]LS&8 >>(.-[9"7QM?TT!\<%
M]"$-9D<%I)S.AAG1A">"B3R-!A)HH8"B+F7L-<7 ,@,*$"=SRPMB5%$##'N'
MGGC:X&JAO79ILQ>NF=FHCY+O$+5D>E\E$ST:0B:K,$;&$&*KR&]U%?<N2D6"
M3$B[>1#^:&JEBZ@26!L0!2XN*:8!4,Q6Y<J]5U_V_K*;0JKK;B*!8=16"05Q
M4Q06"A0$3EJFIIR63R/GS",DDK&%1:N 4Q]M[%))G# EL@\00A,Q0\<A0URT
MPZSX*U>A/D6%5E<5\8^6<DE>R56\?2P?9"J[@1TH^"<O8P0+CJV;94C^315S
M27(S:3!4@V^66U/IY$#4!545.G]?K_,R3%\X-:3F5=\9I#NC0IBXGLWKH<OH
MF,?NFWU'>JJQC*[=%4S@@EFTX#Z9@JM-8N+[%;;ZNB*6& %U$,OB"I<OD7ZC
M,E"@H!0"@% * 4 H!0"@% * 4 H!0"@(;MJS'C\D==@%)C]F.=[*9))EE0.)
M[50U)>.E2&!R,2V1TP63"YD8$KB8,EP+CB88AV%'"#OEZPF-KZ1MUDTVG5-R
MJ'E$MCIF_=3QT^>.8"%?13UVZ2 F#"O6V'##;3+M&VV&>6J(SRFF4OO5"5?<
ME5-3M+UO4$94D]E,AA']*Q$,XB9O,(67.'T0U-Y,]9<.WL4]=,-O5=NGKQ';
M+2M<AVVU=<RJI$UNL:EN ,Q=G+L\*J+6 5;YHU'L:/\ @'H!C>LJTCT1VGD^
M^#=8U+< 9B[.79X53 *M\T:CV-'_  !C>LJTCT1VGD^^#=8U+< 9B[.79X53
M *M\T:CV-'_ &-ZRK2/1':>3[X-UC4MP!F+LY=GA5, JWS1J/8T?\ 8WK*M(
M]$=IY/O@W6-2W &8NSEV>%4P"K?-&H]C1_P!C>LJTCT1VGD^^#=8U+< 9B[.
M79X53 *M\T:CV-'_  !C>LJTCT1VGD^^#=8U+< 9B[.79X53 *M\T:CV-'_
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M4!R*\I9'1!D:YU1L3QP-#B!!8V.F+9A88">O:^5\<9A69O96W14F=2:+B(^
MA&(F$=1<3"^!/GS3F*?=]::AN^ON]HCQIIEE.^MWLHC5^6Y/-.W=Q/W=J=3Q
M%32V#E$WF#R!F#^70,P2:PT,[B)="(X98CD<0O?U:<L,-MJL.Z5EMIIGDW(B
MKM16>&H10"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
M H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"
M@% * B&VH$0R/,CD@9!C1K&W6KIJ'+2N>)$S2:4$+IH9^+B69K+-3.D0<L,3
M1TJ%ZF F0E[BVO;"^..>6.FK;*<G524]+(21P#R81#B=.HAZZ=O'#MIARD#'
MNE>*K]ZZ95$;>NV;D55O:3)=>J2=[EFMJ6H:LY[,:KF[F3P453$1!0[]\YBW
MS+R*:FLH?LN49A(>(;1I74.^;O:91FYA4Y5ZHBQ>[BFK+@TM_&6GY@J,V*FT
M'-J*]IE^^$[.<-8UGS >P3KAHW%-67!I;^,M/S!3%3:#FU%>TR_?!SAK&L^8
M#V"=<-&XIJRX-+?QEI^8*8J;0<VHKVF7[X.<-8UGS >P3KAHW%-67!I;^,M/
MS!3%3:#FU%>TR_?!SAK&L^8#V"=<-&XIJRX-+?QEI^8*8J;0<VHKVF7[X.<-
M8UGS >P3KAHW%-67!I;^,M/S!3%3:#FU%>TR_?!SAK&L^8#V"=<-&XIJRX-+
M?QEI^8*8J;0<VHKVF7[X.<-8UGS >P3KAHW%-67!I;^,M/S!3%3:#FU%>TR_
M?!SAK&L^8#V"=<-)\M!4<O6*]-C69T@()AMN4FMNPV92C0Y(R,$74%\X:)BY
M"IYDV6O8<N)@+A;$;+*V.5O6MC?^E2ULGDTSD%$R^6S>$;@HYU$S!X\AWC;I
MMIEA]&/7CII6G+;QBYMAI&DN:5;E2]$/.?NB:GD-86ISB>4W,74UE3^ DSES
M&.7;]TPV]AI;#N7[",1+IR]17;UEIA55VB*J+<JIE-R:V2:.% * 4 H!0"@%
M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H"#W;&_^>Z>/_A97
M_P#K1Q4?^Z'54I63W+=_]8'/_=TR)C]Q;_S@5+_\'1/_ 'W(B%&H@7KUKZU/
M2D4O7K7UJ!2]>M?6H%+UZU]:@4O7K7UJ!2]>M?6H%+UZU]:@4O7K7UJ#JXT'
MWO?2/"7IO>__ )-J-OZ_U_I9S+EK6_[K6M:UO^%K>BI^V4_\WM+_ /N+W_MD
M4>._=#_\]%>_]*0WXRJ7WFW%;"-+B@% * 4 H!0"@% * 4 H!0"@% * 4 H!
M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M^^Y$0HU#\]*10"@% * 4 H!0'5OH._\ 1'A+_P#CBE__ *==J?UE/_-[2_\
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M H!0$&&V;B_3[*AK3JC:B6Q(CJ:R>!*RFC$HX>:8R58NX,!(Y*A&CJ@J-MS
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M+'>F)@T^2^'>HTKM&+F>5RV>INMFD:A0"@% * 4 H!0"@% * 4 H!0"@% *
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MJ/XK0#EQKW,I?BH_BM .7&O<RE^*C^*T Y<:]S*7XJ/XK0#EQKW,I?BH_BM
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MD74,$FT?9R$T<7O=4$!Q,!IMFI=7LO74!"^>(^!/D'*,P<L1<0[X7ME<#*E
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MTWOZ/^RUK?UO?_A;_MH")+9_E[KVJW71+#79SJ2HCD!!TRI3 <+DTV/S2ER
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MG*9L07-=/3]66^Y$Z,J>3Z/)<2^4+10"@([CD-$95VAB5(A^*R3=9.E&/!7
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M"@% ?E[VM>UKWM:]_P"EK7O_ %O?T>GT6_X_TM>__=;TT!^T H!0"@% * 4
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
MI:XB)#F1%AN.!.**Z"X$M01%M)/A8CD51(52@Q!23C@&?IP&*'29@8L8"RM?
M$0$7/#+^F5Z CJTG;/%I03%<;P=*8+4FYD:49G<<@:*'8OE5/*0(P:"L:/+#
M81G/F+?%/.O".!W OM!'=2::%*+[/+((QM%15$ T7$%RM*JJO0JI<O4O7Z^F
M[K^PV(<>BK2H[F;.$>N6#&*LLK4H]2DC3NVSI QFFR@^""DAK!-S.@+$UCF:
M4RZFVD$Z&*#F!A89+*Y>I>V%[9"EZY%O6],B?1]744>3=!.C29I/ F64]-\5
MOF2\+MRYUSK[< -"N+)G"8B-+-YIELPT5\B-;(,+%NB/%-71$0,$ %-R+!
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M9997]-[BTN2@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M-I0:&J\(ZBK8BU'X0[+4UYS:?R^+;!;JN+RUQ**3@?7/JO\ 2I,^*JS=DO\
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M8%(+,=I*!'E:&W2R"UE!D)!8F2'SS#$+$FDK*3?P -V, B)ITP -@);.]ZS
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M44E6,E6V2^EE0T[@DH\?1[7S+FR!,.2MU]R]"JOT7+<M_P"'K/#$6T)A]Z1
MAS#*B@TX/156-(+?ADHO2$C+YDJK3N7=0S;990B4))CD45?,5JG $6_U:*&G
M=?$\(AI@F",I^P!4NO\ K5/490-ZY=(9'ZUV,:A(S]HR(L&FMS  +X9HT0C
MLV6^\C#K"*E<!C"D6 :KM::\,02@CJN$FNML&!$_'%PH_+ N7J7+T9.G*J?S
M14^M%/&A:W=.JVEN=Z9R<Q4>*6['L52#C)*X\$5(3SI267I*+!;Z<,@J0Q1P
M))HTZ8O4T%!R4"0=WBX#!E ;(2@J(JB!B%R]2WY<ERWY.G]>L]ZQKCT?("$S
MW.K:D8@*-Q_)3@7&BN7>B2,EK2*T5Y/:[Q5@3I8<8 NG,IPJI%'>IP[F6+L\
M\(("Y1$O(J:]@%R]7Z_71UFU-"@H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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MG+U;Y>KZU[>F_H]/H]-_]:%IZ: 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0
+"@% * 4 H!0'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g383050g20a23.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383050g20a23.jpg
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M3 /O4%)G:-<?A&!+KYZ, 'O$+%")(5F+,KY,4Q%DRO5>:FC)$'V5[)1B7)Q
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M$S%;LMO0U (9?:Q<6GQ6KBFK;N,:^5FV%@FFBPV9E:S+GL[>!XYYF(FL(OI
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MS(D,P0S,3$YC:IJ&M0];$O2PU.2T"6U35E(,6Q9Q!@P#&1,"B"$HD2B)B8S
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M(]H)IG06D$%L.YRF1RUUO5'7QU%LK[#J'8[)W1/6=_K"I?TBZB>E^HJ-%K-
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M(UZWG8FN5-MI7+=L%=C2G7!$?/AE7K6(2^3K^,9SA"'2;4A?QQTYQM_0V_\
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M2YGU',W'3]&;CJ6VP-V@N;?=P,[IGPWKF=J70]7E]4'NNA4-"1+JA>W3JQ)
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MDJ+CB?I",QQQ[^I_)M5K;6C\HVIN)2]?[O=UNJ,. 3]+MM%:UFP1<KR0R2K
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MS1,UI:P%1$L,%F8K@IF!DR&)@(F8F(DICF8GC.A-6! !L #9,PL2,1(YCWF
M&9B2F(]Y@8GC/B]:ZO'9@2'[( 8CE8C,\6^\8'-LDH$F1!BQYL!U<E*)D1^4
M4&1F9,=3C+L@C!90M3DN.ESF*[YDQA#IE92)Q"SF0*((I$X@>1*! RF)XF(
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MQFQ=3UZU;Y'_ )&F)/R/5L.L>F5J*2*[<<>]+=OLSPL$R*1V+[=HN1(B?_"
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M?,0<,H(J5X$0EAMEA<RR1[9%A,,A$6%F]CM#ZE^1[KKSKGS:'JGI;J)]F87
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M72IXD,$))8Q@@P2$A*)"2B1*)B>)C.$T+UAC55Z5M[43,.6FLYK$R,R,PT
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M,&,+Y'N'Z0]T1S'O'MF.&];.Q9D:4,A]!;J*AP9$R(-%ANK+S.&ARU=E/0;
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M)+(P63(X@Q$O2LP!TZ7Y7L\20XWB#>:5D,D-QJSA0>1LAL*A0M?<(>1DPZ8
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M5O5C8MY!0.RMTV\-;K-+KMFLYJRDVK2,C!:H1O$>%'UF+!QY.;@1(71EO(3
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MR1-,Q6$2,V/3-1>L52U>UZ-O6-VK90RQN_0U;59SRN2X-O.X:R&1"@D6R/\
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MQO0?7>[[=0HP3K_UVZS7/3W96ME!:D:NVX'UYD-MC1FW2S*G6%4NS,#H.?\
MCJF)E'O,2&_,<R-*/+&4=KICJ-.HZHMZZO:)FTVVXK7].T#_ *;09:AE'9T
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M .MQFD?-DRCQQC/=I_)E_P#\ FR?_P UVP?_ *5Z2Y\S_+'_ .=%/_ZCJ_\
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M7D]$;V7IW?VN^O5ML&8:2\=-PUI9P@P%:)<#,F&B?*/5&;3[B9&>T04,E3!
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MJ&Q?K%5_$7'[?]'??U/\G_HX_8WJ?[GM?FK]3'Y)7TC7[J&Q?K%5_$7'[?\
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MHM9L;/[.4G6/E$K=%%96S;V];N:S>9]3I K5FW*EJ[',:_YY%%+M43K;TBT
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M+OE-Z,1J:6\G96G:F\AMH+M32[RZJM6KV2IV'[*:FN<6K!%H#KL^<8K%#08
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M.<*U]O>OE+FJ%G+P0<,?#FP*VT#K]!V/<#TPUJMVKM[#A#@50J)PN3S4V[B
MGEGQ\*3%;$2)QMI]T0$.3AW:OT]M[(]ZJH0OQ5'2UUNG64*KT/\ 1D;;%A2P
M]1-=HK@R$I9 KF(8Q0GU=NM:@NQE@I/R650M5>T]A,IRGU0BM"6&7AAZR.1&
M8@))G,@MA!(ZIV1TU=]A$-75JV2YUO'R;1 2B14;L*K1HI1I[(N\!:E?"]<@
M42['J22>P/N0*GV0X8JLUJ5%/0A[T*8AC#8TNRJTPO/KB%<Q0?,6*S'+7:"6
M56V*JW':K*LA'?7;82I;QD941P0\Y4[2B^R513B)XRX?=+P4PJY0%@$V#4->
MPQ!SVO6AK#24%#!&1*(H?L!WAI6K(^YZY589\KL?2;>KY]J;-ZWV/C7L4=L"
MW5<4\W[]00T:M22T2N'E%88YD^B1.E*;9&,EW1AZ$/M-3TQ9O%K7/)(4]E-X
M$>*[3]9)U*[V#/I39+A63E0!'*I@1YDY7!J(Z_8[]%2+RE"P[-#TA.\E6UZ8
M1LN4$_T@0A4F*F28C#(DIX@(.08(V<[W#T U7$V3-GM;F%78MKG-3C:AW)+V
MFW= 0%BUF@3VFXM >VU'>%5.7!M9"4_2FX$2K$!MC>EH"D8,Z1"CIW;R[P^!
M$?T9=SSEL-<-&:S6RA38V)6XH3#'B2 &+,F3Q-,#Y (8ESN];XH;YG3R\ZWA
MBE=*W#UKAS%S2BO-P9!)"XIE$"*B%LS $)38YW=^JJYJN%NPI=!G\UY456S0
M6UC6IYR/8(5R>&Q:@W6QP2&1,V,E:IA@2/K84&.(&3A(E!'#($J=)9CKAJU=
M]]\M8NL?KEL<ME<Y!4J*M!E8EQM(%)! K8;FM,%K ",S$8F<E,OU%5!O&\/2
M&"C!PP3(8+Y 40H5B1M-Q, 5+6)&PS$ &2F(S4NB]]*B5FWLQ?) :AZ]J=IW
MZRW/ME;VU1]@-TO25=TX9EEY>M[)0%&4DVY&S)<8^+/.TNP-Y36F*M5+.^1)
M9&[!:Z4L+"JNK#;5QZ-3,A7=K[52;.S?LE0L;J;<+\?%$22:HLJGETO>@0#O
MIJ_4*3*P=B5UZRF['@G*N(L^GH*HLDYJMK^3OYM3# 9*&1_"%26R1=MW6#N%
MH&J JW8;+9;:"AV<993L:"5U!N6%90%:IA1H+;;=L"G/T!%MU=2ZV3?8C&[G
MLD)5*L-Q(8?E%VHS[3RZM73NV>URDHKM)!H41KV.M-+7V0\E>O4L1;FO>LN"
M))5:FU[SXF!7,Q,1/9N]<I:F-:Y8N!S!$Z5X6K4@X!SK*)K0ZHA13$,?:6E0
M\Q,G$3$Y]2';_KR()[$$F;W+"R-6U6TW>URC5&V((#/52D$QP2X&Z;8"-3C
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MN6'Y"7+8-RTK8?,=:.B71N'86=<E2ZT]8E0KQ<6=PS8T)V$?QC5!M9V#V0R
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M5"W,KB.BR,4S%QEDH/<:0EB9B9,<Q,3SQ,3'M,Q/O]DQ,3$_9,3$Q\8GG-:
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M.O,'_1>(!BW#)U^]H9 Z@2U5-B:-]QWUV6UDHF@XC75A),/RKO%6B)%T2/\
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M;93KBYQ 1N(136GGTRH,:Q=T/MD-4EKJ8$9VU/-D7E*J/IT+&R<IK641%_\
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M6K%J8-EI(B#*P;"[<:L,F!L "EHQE^50J7!I&QR6Q3$MF#-K0W6UPG(%$([
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M\:9*5.5+/_E"R)"R27/<!B M4#!Z6NGJ-LW&9V0*P5DFRM@1!>J&H+8&&*9
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M-MM6S)&"@KP9>\FVVV7N*/\ VHA P4_'AO$3[SGM'Y\_9[1E.D_]HSO\4_\
MYBN,9P>,9I)V;[37O2%B/A:7K"KWJ-3.N6S.RUMFV/89.EOXJFJBP2*;K==A
MCJ%<&R=D,02CJP[A.8$%,RF4XGS$-9_I[-I-%5V:4MLWGU9L[FEI4"FH%F//
M>6PEN<1VJ\@E9!$,@!8<C/T1F?A0[7;V->UBT5$V(1J[>U<3;)HGPTS6+%*$
M:SX-IB<R'>2PB8^D7&519^^%_J$^51CFEP?\Z9B_:IJU%&5NV[ O-3E@MMZT
MV3M,6:L<JHZ;)WYHM7@>H[N.)@*OKNR)(%D 5Q2D,.0*E0%@GI6I8"+2MD[T
M"JM]UHW5ZE6P+=?=I436F+&Q"I*W-V%8P:^VGL7Y>Y9,  ;#;U#904UV45^K
M98IJKBIUFPDEW*EJV+&RFB5F#4NE8$U*K-[B\<P< 1DNP];]I=S[;NH.CU;0
M@:J&*[2J/>MY0ML7NVT4M5AMWV#L:BCX6N@#^I9=AN#LB'JJV7,20N8C6<:>
M%F5"!,8$DSI9-8AW=%K=?6;:?M66%.LVJNL*A5KVEN.M3IVB*XV+XIKQ!WT5
MF!69<D6!9,98"@\TFKM[UVPNNK7 DU(18V W+#JYI%]FU7 :RIIDQ\S%-SP)
MX58)9)&8 V'XM=-%=M]OTK6--$7X%1C>;C4.QUTUWL6^[MLL9V<[J;?P&ESQ
M^U)<_7!F77(+H_9@C-3;JTK8)63&K3=;C"DDC N'$N-IT_KK5ZRRJZTKT]C3
M5KE2KK$S Q?U3;('0$+BQ<<'29YY?%1<$Z7$SL69%64-S=KU$!8779YD;-]:
MS9OM'NFGL5H(;9%6.5#(VP\,*FR90J%"'>8#$YA=]-I6.OU/-1T=3I-TET;N
M+;KJ*M.S+C4 H5[IQMBG:LL@\ [/TV]:YZ[W+M'MX5BUU&E%*VA+<:P#LRH\
MICD8^E*"&V)L;2S%8;73U>L:*5>PUD=14+%Y!M@-C" BJ*.ULHL60?SRHXB8
MG,X]17&K1X=>B7E7W;W@ZT] !\R7$5&BN2HRXIL2[N7#D5S5\&CS$QF/.]Y;
M: A[$OU1US+/T^/>].HL![8EX-0:#J.E; ZOTG;K%G/8U_J6]VBH5?)<T.K!
M\L^*M-? &C$Z]6.P@*RA8R-V5TO7:5.I8N"JS-78^%5.JHK>PLU-W:U\H5ZN
M_518?XU&]2X8ASE+"JE37<&7#.H'+BS835EB(L48:RS8,:].O9U->[#F>FIV
M'(5WL%+#D'*4PRL-:M7T(G4ON-N$A>HU9INFM:%0-B[&77K#3K"8W.?&R)EV
MJVJS^WVK8;&B]1'8L&E2:S4K##3\%&#1F08^"FFXK ^6\1CQ1Z<UP52?9V-X
M&IT];=V4KUJ3@:S[ZM?*%&S8*(K(N>DOXBUKA<LF2DQ@"D3N[IV(2BC5-;=G
M8U26'>8,R]--EWS,$:9B*)4EL?0-C)/LB!@2DXS<#T@VLHFE,;,N=9NX>W0-
M0W?:AVC5^F7VS5]C&ND6QBSA!VX,TT3K#+KA2EFHH9RQ6"LSI,98V61%"\SV
MF.8CZ1O%LO15W5F5SV%6BJTZS42V?6>GE#3U\667>(7943(2IPB7>(,/MF<[
MQU)5"AZIZ;"W#2L7&5UHL.7'I?-#0&[X J>YH. EK%%,2,D 241E"=J.QW8U
M5'+:3):\INL-JVP]U>G0R6O^PUQF#96J-P]F*-IBU!V]BA-1U2Y4:ZJ)GH-2
M(% 0"0S$JUF,WBC6@G8ZJFLOVVBTVFBTO9+N6+U%"]X!!;U%<6#?UVEM;)#9
MIMOOK6:WC43P6UL3+TKK6D E_GBNV^TVGISH%614MN9J2@ZVR>0S3O;6O1<$
M65TDOKO[F"DC6N8A33?7<;$^*;PVQW+!ZNUF5EZ9 8N\S5:S%>.U[<#N^]<G
MC+%!J1HW,&4$E9--W:V[CL<D95B+\RTP62=<'#(A"Z7.Z,PDI=(UE#IQMZZ$
M;)OI1O\ C<IVNC57%+FW86H66@3L:]?7)$WA US);C,@K5J\E[!87-VNI5.:
M*O4%4DU,5=G8U6'%9)L(*Q-HO==;()*2<,&H @K#WP,<E+*WV:VCLZU;!1J7
M5E$GZ_U4-K$>WF]@;2-5*VS;=<M+UC=(@=7*J!UG=8CU>&!KW2AQ>P%CPQV9
M,G6+X#%SLUE#9N.[24*2*<["_;"W?-TUU5**GH&O7V3M<9N>V[6*',96LFM2
MU' B*?*8^;E>96UN6W68ITZY5J8J%[+-MB7$]]%-X!4E=5XRH L($VFP9(B9
MXP+Q?3UVK_>/8HJH:3VGM>@CDG-E]1T;C"TO6NQY$BC&BU]V)UDI- C'&;9K
MX00K!J?8MQQF"9?-A/ ==5O!S+CEZ7)03'V[NF*;+&RHT+1^*EU!.N99N4XB
MTM=6GNK5J537ML%ZP3KBD%^)3;CO%Q%3B5G6+W]H$T+=RL'DM:;UP(JVIFN9
MV+.JKUX9#JP$HR;>B#9Y&+K*\G/J)F""T3O<?;]8N</2IW26O&-YS-BZEJ30
M\7ND\7U8JK[GJ&[;'5[;[\.:=%VIHD*GZ*MH<_4)FNHDG#2A98<6E02T52(*
MNG=<^L6R5LKDZL:>PL29ZU2[WGUMC6I?7]-\X&B0,-I78JP-PHYABS6)!/,M
MF[NJ?%!E"M&P*S33 C>8=3Q7D7FJ=ZCT0M@P*@X&H*M!1$@8F0F,Y*K/V5*F
MNB&W^Q$BO$:I9*90-](,U^H7!A$T=;-,'[S0[$FHW@I4)C;3$BPTHA+K5@)T
M=]UF%(@RYU=4^AV%S C2K5U5K]/#@L)L6]5*VV*\R!U]DFK:3ZBJ%@9F839
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M[Y@%]4.N:I%"F(U'4XT[63.8U)(0H\J 2$Q%'W+6[!D$84N/--CY%I>D665
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M\@H1<(19*'6)6)DAMUM33BD<QMN6G68N,>TK4$HXL=TBT22("HA,>)$EBL(
MHXD>V)B>8YS(%9"T36!017F&#*>V)7(MDB8,B7,2)R9=T3S$]TQ,<>V594^J
M772C"B(6J:AIX<>6.42Q$&V83STB23U?9(-OUQZT^7(D3T#J)9AL,S4PC4I
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M-Q&@!4H$1'P+)38C\J>HMW-B;4[%_FE)HDHA<"2F,%Q@2H"%%W. '$4A)2T
M;SW@)1'^9-5X?3^A3XH:+H'Z<E#0 EB<,DO)$BLS7$0<1"S-?'81#.6-]5NO
M%B16DE]3520NGE;89K<IF/*@3Q<V]VB5=KHVT1'RHL]X9:;;,D6 \$E27PI,
MHI$F7 =6RSY?16^W"?/X]A8B+ (6X9(3!@U4#6K3(&)!#$5Q%*FB,- (X$XY
MGG(S4:UOB[Z:9E)N-11$B0%8=+WQ!C,%(.<4L8N9E9GQ,C/$<2':6@M.[K5
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M!Z^/VFH&1VG:TFPL 1-+Y9C-1'JA&$DF$/0BSH4\0'X"J9:;EF(L5\-Y@:!
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M2WR5UA,164I-6RJ8EHFZZH1>L[&RNW9LS7D[B2HNIVX2S7\0NF?J#$:T&U<
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M"*L165D5+GT9%J;,E4Y#QSZ:9JS*.5_PY\79]#Z/]7VSK'1'60P\108C:_\
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M=!,&E!S#0,P;$EPP3(3Y@IB<C.ENOVKA+6W6)&5S"F;D37$J(35, 5J1B5F
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L8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g383050g22j00.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383050g22j00.jpg
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & 8]+I,VPJ*2>9/.E
M&V>)1YZDSKI&4$]7MM86U2ZKM)2!&%!.4;2I#?(*$:6$PWP@V8#6]BT"XM+O
M*93KM%>.]<2=KCTN'-FY"OK!%:BZ6 CZ)4PL#2ZU=9ES,S(YMZ9Z-F:U^=:Z
MI^PWM.9&HD_QI,J8@,#G(T$B=F9J<!.']>/R^UKZ?264INX6*Z(RZ/S2Q2J(
M.L;E#S"9G!IRA;6Z90F6L>DJA6Q2%,R.\A8Q*#VIR9W]N5LK\\M;BQO;4XHU
MYI:KP@!K'Y$M8(& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MJJAX-X;2=7J'5Z[J\5)T]WK>KI;_ ,3.>KCSQC@67RT%W& , 8 P!@# & ,
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M^C)XA_5TX_C:59R_M]Y8:[ZW'W>B=,[!^2.A^JS]XKFS/,0,N& , 8 P!@#
M& , 8 P!@# & , 8 P#H)UQ_^;\<?KPM/_<\E^#TO^P^:/\ $CNK\S_F><K_
M +-5Z_E=*<'GCS7I7VG4Y]QP?LIV@7](>-'W;>>#[5^<?0_M-BWNJ;Z*Q=]H
M>GOZF6X*:/QUZ&1)P=Y?(N"_N8>M>1W5)B)5%JSO!CK%,H\L>W"UIIR1MR*U
MZ2%*/6]KDZ"2.J-]>$Q81#U'VAW4B\!2<TP 2CO56N^7'T=IUD^QW[0CB/PA
M8>7"[E30UY<@)3RJA@JC<ET*;8FY-@*E>R'L=DLSFZRF5,KBK<; >'- -[V
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MG\C8+@^4N;]+^TNG@@8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M9QK4_M*G_/+^)G8E/^SI_P#)'^%')Y05C & , 8 P!@# & , 8 P!@# & ,
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MD7"<-D?:G60*H@](H^YGLC>J7,^W;IEA24'%+BI*2[>QKYGA_.N!LWP4C &
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MCE+7A**]WHSB_&'&/U!84?KF A8)_*4?'&2(:;4AL=["R3-ODZE$_7Z^WO\
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MT92KY?4ZQRX*TE+:(JU,Z!KZMS#4,GBLR:69R=)^!(:C4+Y G3&(5$=41IN
M>(]L4%EB)YSQ4D\?[SWGS?;A</,;G,% P!@&D7W0M]&/9WUA5!^.FW-B=%OE
MA9^JW_NTS7O2AY(W?K5C[Q Z0,C^9'3GVJ.2GY2<4,Z+I>4-_P"QM)]^UHYZ
MJ^3UA[9U;W'13RY1?J7&3[*M:??\YRG1?C:Q[;O?N[<:Q\72/8UG]Y<%JG/Z
M7/D']I3F)_7W!ED7D)I?L?0/X; O4O+C4_:^O?Q7Y>'W,7\_&VOLF3C\WJ-S
M'NF'R:L?;=M[CJ)D'1%Y2WGL2Z]^TT[U><W'1HP!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MXZ-& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M::333364UQ33Y-/M3//()& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MY"O!;95>[N"9BHLJ]]V;NVRJEVBC^DX9?JZA"MTL.Y]J?&14JQ-ZD)4''&
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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MWS4X<:WO6^6G&;6]?!O6[XJSOUO_ ,-__=6!A]S^ADB32]:0K=JCC[8=R55
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MI0:60048:,(=AA]S^AF13OD=QZJU]U%[-OBF:ZDNT2=RU'9W:$(B+[MN5B-
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MO.JV-D]0V?;L[5NKK%SUK=O1;J9T'6YOK'N>/F<5-[V?&2ES29:M*O[Y:?M
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MAM5UO$GLLDY,6\1F#QAA=0)U =!4)P.#4UI%823PZT$XH)VBS0ZUH81:UK6
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M+DNSEH(G9EAV40]!AJT2M8KL&+5C%U36:EVLT24F;2:R1JTZ@!@C3S75268
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M2M%4V-VFE.ZM(W4J<;:2G;N=:O25"M&5%.-5*BJCBTO$J0?)Y?QJ:I4AN?\
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MM.4F\KEPPG%-)8Y8YMK@^"9VN\D^0P!@# & , 8 P!@# & , 8 P!@# & ,
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MR/\ 68\7?G4X\.+WIRX]V%V&3?\ 9E\9??7+N7R9[[9ER@F7A%[6!]+]8(4
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M(& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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MHU0%, PP!&C1CT2$8PE^'0A:V!]. , 8 P!@# & , 8 P!@# & , 8 P!@#
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MTO5=IM8O["ZC3K45<6ES>UJM"LJ5Q3I5Z:J4Y1DH5:5.I'.)1B^!,V9*8,,
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g383050g23a01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383050g23a01.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X5[!:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z>&UP1TEM9STB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(^"B @(" @(" @(#QX
M;7 Z0W)E871E1&%T93XR,#(R+3 X+3$Q5#$Q.C,U.C,X*S U.C,P/"]X;7 Z
M0W)E871E1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y!9&]B92!)
M;&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]X;7 Z0W)E871O<E1O;VP^"B @
M(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#(R+3 X+3$Q5#$Q.C,U.C,Y*S U
M.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I-971A9&%T841A
M=&4^,C R,BTP."TQ,50Q,3HS-3HS.2LP-3HS,#PO>&UP.DUE=&%D871A1&%T
M93X*(" @(" @(" @/'AM<#I4:'5M8FYA:6QS/@H@(" @(" @(" @(" \<F1F
M.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.G=I9'1H/C(U
M-CPO>&UP1TEM9SIW:61T:#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z
M:&5I9VAT/C$R,#PO>&UP1TEM9SIH96EG:'0^"B @(" @(" @(" @(" @(" @
M(#QX;7!'26UG.F9O<FUA=#Y*4$5'/"]X;7!'26UG.F9O<FUA=#X*(" @(" @
M(" @(" @(" @(" @/'AM<$=);6<Z:6UA9V4^+SEJ+S1!05%3:UI*4F=!0D%G
M14%304))04%$+S=107-51VAV9$<Y>F%'.7=)1$UU34%!-%%K;$Y!*S!!04%!
M04%"04%304%!04%%028C>$$[05%"24%!04%!44%"+RLT041K1FMB,DIL04=4
M04%!04%!9B]B04E104)G445"055%0F=51D)G:T="45E*0W=G1T)G9TQ$06]+
M0W=O2R8C>$$[1$)!341!=TU$07=11$$T4$5!.$]$0DU41D)15$5X=V)'>'-C
M2'@X9DAX.&9(>#AF2'=%2$)W8TY$03!914)!64=H55)&4F]F2'@X9B8C>$$[
M2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(
M>#AF2'@X9DAX.&9(>#AF+SA!04519T%E045!07=%4B8C>$$[04%)4D%135)!
M9B]%06%)04%!04A!445"05%%04%!04%!04%!04%11D%W24=!44%(0T%K2T-W
M14%!9TE$05%%0D%114%!04%!04%!028C>$$[05%!0T%W449"9V-)0U%O3$5!
M04-!44U$06=10T)G8T1"04E'06Y-0D%G35)"04%&25))>%%614=%,D5I8UE%
M54UP1VA">%=X46E00B8C>$$[571(:$UX6FDX0U)Y9W9%;%%Z4E1K<4MY63-0
M0TY546YK-D]Z3FAD55I(5$0P=4E)2F]-2D-H9UIH2E)&4G%3,%9T3E9+0G)Y
M-"]0128C>$$[,4]4,%I85T9L85<Q>&18;#E76C)H<&%M='-B5S5V63-2,61N
M9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;RM#:S535FQP95EM6B8C>$$[
M<6)N2C)E;C5+:G!+5VUP-FEP<7%U<W)A-G9O4D%!24-!44E$0E%514)1645#
M04U$8E%%04%H141"0T53355%1E523FA)9UIX9UI%>28C>$$[;V)(=T9-2%(T
M4TY#1E9*:6-V17I*1%)$9VAA4U5Y5VE9-TQ#0C-04TYE2D5G>&15:W=G2D-H
M9UI*:EI&1VED:V1&53,X<4]Z=WEG<"8C>$$[,"M0>FA*4VMT3515-5!2;&19
M5U9P8EA&,658,5)L6FUD;V%7<')B1S%U8C)2,61N9#1E6' W9D@Q*V8S3T5H
M66%(:4EM2VDT>4YJ;R8C>$$[*T1L2E=7;#5I6FUP=6-N6C9F:W%/:W!A86YQ
M2VUQ<39Y=')Q*W8O84%!=T1!44%#15%-4D%$.$$Y531Q-T9867$W1EA9<3=&
M6%EQ-R8C>$$[1EA9<3=&6%EQ*THO>DPO.&U&-6LO=T,R;&1F.&Y7>F]D4#A!
M,V-F8S984#E:63%L>E4W1E=3,D5F:S0K6$Q1-F<O2%5Z<6-9=691.28C>$$[
M67HO;R]I9E=*1$0V=E5(:G=P.%A7=55Y-"M),7ER-U<V4$)W:2MD+UEY2S P
M,SAP<'1D33$O<55.<G X371T=W1,3F(V4T=A1G!7.28C>$$[6&Y*3V=M5B]3
M-#AU3D%+,54Y:%5:6F5(66(O0G1%8U8W;C<P2&1A1BM5.&1V3E!&-6EU<'!&
M0F5+,E-";%II62MF<#%D0711,48U128C>$$[-RM!<'9)5'DY>41$1C-L0F5:
M.4DO3#8S=$=M,$176F)U86I&8F%:2$).2&E64&E-36$Q6D=K66EU>$9.*SAS
M8W-H4'%$2$I$1T(V4R8C>$$[>$A,,TAD:7)++WEQ+W=$2FHK6&8K639,+VE7
M539N*S=L-VTW5"]72#)L;E!/-61I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D
M:7)S5B8C>$$[9&ER<U9D:7)S5F1I<G-69&ER<U9D:7(T,#@T:E,R+TYJ5U)Q
M:D9D4$]R6$@Q;&QR<VYR3C$T9W14>#1I=$]M*V(O1F9H0W5D3V]Y5B8C>$$[
M-'!V;&%9439D*U5D,6-2<G%/<%-A8DYX275V,&5,:5=X1'-S:%%W1V5+931O
M:%9!-&5T4W@T:T)D-#A756-H9G8U+W%:8T],<6$Y,R8C>$$[2E=/;69K:$I#
M<B]P5RMH83,U;UEL36AE-$-T4'AK-6TP6D5,+W5A1&I13'-2>7$R1&EZ9'<O
M2'A8:'<Y-2](=U5.2S S.'$T9$YU-R8C>$$[9E=T4T0S560X,V]45W=U:E!*
M6G1(15EJ2$U&93)4:7AF,4$X1$UE9TLP1T=5<W1I:# X=68S+V%S631X64I6
M-W)3+WE36%0T1VDQ828C>$$[.&4U:6A*;E=)>D(U6E!5<6\O95=F<'%746M%
M:'%2,$905G%49T5S,3AH*U!J*U!*5$A$,R]J-4LP96MF:TE,96-N5W12831-
M<G=X2B8C>$$[2GI65FE6-DQC0FMT1W%84F5147(K,7A.2V,X2$9N-V@K4&EK
M4G<Y-2](=U%&,7!V-5986&PK*VXP>2]K=$YB15 K:#).-CAZ<%=*628C>$$[
M<%AB,55G:E%Y=45L44$P56QL;V\V-4E3>6E1<V)F:GI9>6II23)/-F%85VYF
M:U1D5SEK1C%74WAL*W%L<G0W5TLY6G9R0VU/:49:,"8C>$$[;59I>6PY,5I6
M-4%D0G1K0DQ/3#)V-4UY34HV,3@Q,'5L9FM"3$%Y;E=,=3)L145B2S%U3&U9
M*W5K458P<DQA>$%Q-R]!0CAU235(;R8C>$$[26Q!56]L;C=V>#@O>#5R=S1A
M-2]J-4UF+TPW.4<O.$%+,3E&1VUI4F)!86I'3&(Q;D5K:%%.449M0U%G,38O
M64=7-3<X23-Z<')W,28C>$$[-&=R:RMY33!$=#-9<3=&6%EQ-T9867$W1EA9
M<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ:$I.6#!M2U)O
M-4PR0B8C>$$[2D5.1U)P54)"2%EG;DMZ;6=$4FM0;3-$5#5#3$5:9DER9C U
M;W8X03%C3&(O:V1(+UA"-"M0.$%N1#5P+TLU9C5S=FM89G!Z4F8X028C>$$[
M<317,R])-E K=5!J-"\U=RMA+VQC=CA!3FPX:3<Y3V%,+S%C3&(O:V1(+UA(
M>#AF.#1F3F9Y=5@K8DPU1D%A+W)':WEA1'%58V0W8B8C>$$[=DDY<DUQ27-Q
M16MM3F=!041U5&MO86I(>$0Q1#5H0C!U5W9P;#AI<C9F<E=J<EE7>71F,C9S
M<U-!9WEO0T-&2'9G;&YX,SE1*V%F>28C>$$[=5@K8DPU1D5F<'I29BMR:&)F
M.$%)-E K=41X.&8X-&9.9GEU6"MB3#5&,S9C,%@O04MU1G0O>4]J+W)J-"M0
M*V-0;78U6$PO041:9B8C>$$[274O5&UI+SE80S(O-4A2+S%X.&9(+T](>E@X
M<FPO;7DK4EAX871P53!I>'A8<T5K:D=I;VMQ37A0<T%C27I12F]%9DY%=%!K
M07-X:R8C>$$[0C=I:7-S85A9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ;%,V:G)%.#%W3%-Y=#-H9VQA15!,8W9'>$LP<65+=R8C>$$[
M4T%D9C5S>'AL;DEM9TM"<FXK>'EZ:'A2031P4W-I.6]G+S<T35<X,V52+TU8
M;5!6<D16179:9$EU9$]J;&EH3VXV9UEW4DY4:U<U,B8C>$$[5#$V665,3#-2
M+S!X+W=#2EDX1T0K9% O045G+S1T2U8O2S=Z:$YO,7AP,3ER.3(W,S!A0RMN
M=#E194PQ2FM9:WI+2DQ39#1Y+W=!228C>$$[258V55=G;TYS94Q,,U(O,'@O
M-&QE1$(O3VXO<$(O>&%,8CAT=DU%*VPS3VY8*W%896]X>E1X6$YV3F1A;'IL
M=&YH-6-F4F8V:4M6-28C>$$[-S%Q9'-E3$PS4B\P>"\T;%!$9R]N5"\P9R\T
M=$TO2VYL4'I*-69U<C(U839F5E=V06EO="]Q1$]S0TE88FA&=W,P,DIK,S56
M+UA5."8C>$$[5UAU:B]P:B]!35-J9W=F>G O-E%F.%=Y5#9X-6LO-5EB4#A!
M-E1*9BMY8DAI>3DP9CE-9BM*6&=W9GIP+W=#;$@O1G9&4$Y*;%!M4"8C>$$[
M551-<7!+8F@K86]X6E$Q9'='255K93E";DUA;2]%;&9E.7AO83A'1F-U14I6
M;$QL2G8U95A1,FUM+U-H569#=F]I57EI3#=1-3%-228C>$$[3#AU2#)E,65U
M6#1/0WIX9G O431M<D]7:#1F>'%R.'5E,U!M:G!T3CAL3D=:2616;%5K35)#
M.&)%.58T-VA+8D%N8G94<4US3U!$5R8C>$$[,&DP4GIA<39-0C@O,F]P8DAY
M17-,4DQE*W)+2D<T5$]*9U=":4I#;6=J44%39"\T6E!G=U96+V8S9G)A:FPQ
M6DXX3D-U5S-F.%1Y8B8C>$$[=E!,;FLR>G9$8C-'<G5H1%99<4)*.$A!2')'
M<D-P63=E,V)E=4=E;G=X3D=3365S,4TT.%%X+V\V*UI1-F%6-4A+<U@Q959E
M15%*0R8C>$$[;W@U>6-6*WI7355Q,TQB-5I!67-0.#=P*T]J66,K<2]M1&XS
M.4XO4#-*4G)&=F\P3'=(4S=P-VQ*27<P=VM8:7E/97$Y0EA+37-90R8C>$$[
M=44R-6UN;FMK1#1G-&0Y=DY,<W%C:$]F2GAM2&UB5'I!:79+2F9G4C)+2U11
M.5=#=5(O=TIZ23!L*TQ'=3EW*S!A.$-6.'$O2&,Y;B8C>$$[*W-E6E K5T=Z
M+S942F8X07-M>G!E3$PS4B\P>"]W0TIE2C1-2#@V9BML2"]!0F%5*UHY1S$O
M>D)P3&%B3$9"86\P<TUP;&=V2$16:"8C>$$[:U=52V56;W<T:W!V:GA:9390
M.$%P:B]X2SA'1"MD4"]!16\O-'1I;&HK5UAN<3(Q:4LO9GI29E12,G-,5SEP
M03$K3FML1EI05DQ75"8C>$$[2DE3=U%R.$,P-&=B-$],3#-2+S!X+S1L4$)G
M+VY4+S!G+S1T1658+T%-=&9-,FI815)'=#,Y.5EX*W1Y,#(X,4U3,C=I9%=$
M0G@Y428C>$$[1$U!6#5$9G)J>%IE-E X07!J+WA+3T1"+T]N+T%+468X5S=1
M4'EY,792<B]!174T:3%#-75,8E-I>E)A9DYQ5&96-4-9;6E4,593>28C>$$[
M570V87533CEZ=6%M=%AI>60P9CE-9CA!:58T34@X-F8K:T@O04)B3GIQ3W-1
M,TYR2&0R9'5K5GI,-E!/2S5E4FQ00FY"-'1"1T0Y:B8C>$$[*V)!8VMW44-"
M=6$U+W-$3'=C8V]K>&Q+-&DY-&=F-S1P<&U1-&IS5F1I<G-69&ER=U%F.#55
M8VY#2C573$]4>%9293%*2C)!02MR-28C>$$[<R\U3R]P9EHK,7=0>C,Y2#=7
M6F8X<DPX.6-:>69*4VAR6B]4:U$V;D=0:312=E%-64](*S=L2#)U=&8U5W!J
M+T%*94@X-S=0,G52-"8C>$$[:R\U=C(O<U-855!Z-S$S5&UV179F2TAO>5=&
M=$9D,U-(555,2DA.2VM+9$E$.%A/44%J=#-Y,D]I:6%Q6%!Y+V$Q>3%-:'IJ
M.7%+:R8C>$$[+T]F>F-!9E$X:GE86FI:-#4P=&(T5$Y&3D=&85-'4E9T>5))
M9V-%:BLS22]L269Z+W,O87E/868X,S=7<E0X-G9.9'EP66536&E8:28C>$$[
M>DE:3#A,-F=34EEN368X06\O>&A78U9),G!4>$95-E-!+VDK>CEQ:DY-+W<O
M86A.3R].8GIV85!0>#AI,VQY3#)8-GI%9G)9;T5M228C>$$[5F5*5S,S56MB
M36-Q>#9#16(O96-Z9DPY<F1M,6,U.%!O<6A84&XU<30O3S-Z9U96;#AG,T1"
M,5)X>'9!,4),1C9Y5G!!845X+T91-R8C>$$[-60K56@O4"MZ.7)2-#@O-78R
M<71T*V10;74T:G976'E5>51A9DMK1GAA>5@T4V(Q2D%'54MJ5S1R.$HU9DQ!
M9$I%5C9U9FPK,4EZ5"8C>$$[3BMN;#5U:"]/:GIB2D=(8GE02D15:T9:<C12
M=4%(1613<E<T8C=B0F5M2C!K4#4O,F9T55IP;BM(-U5V,68X035Y1#AW84UI
M>6%R-28C>$$[2'5,3D=C>$LX,3)60F111TLQ3G8T1W53:F]9>354*WHY<D-E
M<6Q(;D@W5U-F;&(K8C0X*UAT+V%J4V8P9#E3:5-8;CE9.69L>EER4R8C>$$[
M;G!X539:5G%D3#110G4W8DU'9GA,,G!03F(X=656:T8W<6PY62MP-F%Y6$9W
M>4-6,TE51FTT;VA*63=B0E)V;6UN<$U5<$5K8FPS928C>$$[4'1$4$=)06QS
M4&-X1G1E+TII3C=.2G!B94HW-59A14\P9V]8;%=%2WA$14LS3B](;T-E9W)G
M+TDT=C5R3"M632]W1% K-48O5W9Y;"8C>$$[93!L=7)9=UAK8U9U.3)286U7
M6FI&1VE/>DM%2C9#5F$K1F0K*U U2$8O3E@K5DTO."\W;$-,5U!Y66MU:F%I
M-7-X3T9::6AL879+328C>$$[3S!K9$]8.35'27E76'%.=D59+VMC6#@Q9C55
M>B]W02\W;#,V5B]*9TYC23$S6F\Q<R]P>DLX:VEK3GE62T%%,4Y88FE+9%17
M;E$T+R8C>$$[:V-8.#%F-55Z+WHO04QK8DEN-55X,WDR1'DR679(:VAH5T@Q
M5TQ'4S5!34LW3C%K<4]0:F<O231V-7$O>7!N+T%*+S-*8EHV-2M43B8C>$$[
M>F)#9'!R83%"17!#6$QV12]'1EAD,C1L=6=73FIH+TDT=C5Q+W=!<5HO-2\S
M3B]P:CAP:71T26M!93-U8F<R;C%H4DHV8U4T6D8Y3R8C>$$[5FEW-$4K<6A(
M:4=&3W50-4A&+TY8*U9-+W=$3RLU5U164'E76EIM1CE9570V;6%S>D%O07).
M5F=7,D9),C-X+TDT=C5Q+WEP;B]N+R8C>$$[04A-<#!F>3$U6%-7,3%#=W1%
M0DE75S-M578P659"04HX1&MS96MX>&M#0G5W>3EO6G!X35I3<T9)4'I3+TXX
M95$W,G=T5'!0-E(K=28C>$$[>%!,>BMS96AX-$U&<%0P-6$Y8S-';3!V:6=M
M-G P=690-&1B5VPR:"]N2#5R,74P=&)Y>#AM,71R=WE#,VQB54%!,W!-1D]W
M='E25B8C>$$[<6=F-G)E1U-N<%EX3D=8,F9T4D1.2U%S4BLS.6EY-2]/;GI0
M86UZ3C,U4%<S:G8U631,4U8Y5&HT=3AQ;#%P>&=9,#)P,#8W9&-),"8C>$$[
M:U1D4S5E6#=63V%1-7@K,5%G+U!8>D)003!K6&Q!4$E*1VI7,EA5:TUR*VY+
M<TQS:4-$-&Q75G=P22]66$-D2$5F>&9:*S%!>GE)*R8C>$$[;C=6>69N9#5T
M37AI9GE*4$1W9$EP6DIR,%)P1WIY1TIF561R8T)2>4(S4&)F<&HK56@O4"MZ
M.7%J4% K8CEQ;G%V-7!E9$QI-'16:B8C>$$[.&Q81F)7-D1!=S-G64\V0U)$
M1#A6=5!I;T-30G5";$]447=L4C0V;S-Y+V$U1TQ6>FAX1&=V:49C,55F;F(U
M=TU#>FIY1&-'3G%&5"8C>$$[.6-&4T-%3E%V;V-Q9G95,W S>3<X<$0K9CEN
M-UA(.&5F.#,W5W@K9&9M+S8O1%E395$U-&)Q-%=:-$5L=E)'2$9U:&552WI1
M0E-6028C>$$[-E8V-%!Y:TMV:BMZ.7$K4$\V-&9T8FXO041P.#1W>4]J95%B
M:'5%8GI--C-D5C120E1)95@Q96YW8W=$-S=9:E-1+VXO6BLQ2GI42"8C>$$[
M.% R<7-N-7=E94DW3U<V9GE"3T5H;UI%1C9$249,4TQZ2T-!<T9$471U9C%9
M4'ES3')J*WHY<2M.3W9P*S%)9%$O-7E:=F1/=G!,1R8C>$$[+W=$2T5L<F51
M:TQ,0DQE.%A5:T%I;TYV,T)R;'-E>G=266PY;C=7<5=S24Y'4#)V;G%/85=#
M-%=A1GI(3D4T94]25%)L6E15145D=R8C>$$[8S)P1G5U0G!-9CA!1F9M:C!L
M:2]3.34V84LX87 V.&Q!<W!$3W8R=6I&450X<V@T564T3FYI>3=Y:$<Q5%5N
M4C0R=7!74U=*3&524R8C>$$[-T5.1$=W9$EY2R]:5FM"03A2:W5%365-.3=.
M9DQ-;#%Q3VQX6$YZ-3-L,&DY1%A6=$)A>5-Y9V5L8E=O:VI*9%A(0E=-:DHX
M43,V3"8C>$$[53=::EI+0C)J9CA!835'36U1,VQ365-A2')W4U5J.'<W36TR
M.5%,1V(V44=J,6M004%N<7EF2%1P-SDT.&-F-6@K5%E94R]N<'!Q="8C>$$[
M;G)Z,U9Q3%0X>')*1W0W4U-*<$DW:$Q11DQE8FA'04QD:4A,>&A7*TDX='9#
M;5%I63%V07-P0U)R,6]D4$LS;3-6=$AJ:VHX+W=!5B8C>$$[-UIV4$AA4C(O
M=T)B;F5J>E-.1$=P4W!98S%R>%=L5'9153-W*TI'2BMH2&AY22MT-3=Q5W1A
M-4)R3C!W,6EE-VUH=6UC6'EY>4@Q6B8C>$$[27%X3$]P63$S5&]4=E1B37%-
M26MC;D5L3U%L>C9R1#5T.#!S;U4V=F5%2T-!1%!*,$QI42]T9#-(3#4T9D-J
M,T)F1FXS;$0S,G5A>B8C>$$[9GA*1&98,7AD4DDS3D5M;&510G5)4V\U13<X
M5D%W:4%(24U:5&ME6F5X+S@T<R\X9'98=BM984@O:S1C=T\P9G!$;39(;5AV
M=#-"1"8C>$$[8TI.0D]I>7=40F\U63-!2W-J0VI+465O27I32&TW66-M3WIF
M;'0U0VUA2C(P1WE6-%I)<%EN4T9%6E=H9$I%,U5$87-3,4A1:EDW128C>$$[
M-#)M9WAZ>GAA-EHU5G1.4"]19FLR,C%23'0R<S=M0T-!9W!B<VE+,SDS1RMX
M5TIE;R]:1T5)2U)0-6DX;')R5C5P<"],:59B:3%:6"8C>$$[;6TK<%)+9U<V
M;64P37AB:4]-4E@Q3U1N8EDY44LT;U)R,R]L<U@R;79B*U)):6163FA/-6MT
M,#EA1F11;F0O5VU%8V,R.%)T,%DK1"8C>$$[;F-Q05=X5EAT3F%T=G$P=7(S
M;FMC>3-Y43908WE7.7!A:S-A>GI2:'=H.6%/24UB4U)%,T1F1#-O5GA605AF
M;3-2-W5/,G0U=GDR=B8C>$$[:7%34U%33&-72TUK8V%"3&1Y<%5.5E1&8TAT
M=6]/>'A7,E5E56]03%!M9E-,=&)J>7A$63)W;6E:-T<U=&M1.#5,5S-K+V52
M;&1P228C>$$[>'A1+S9I+TE!<$-D2'E(-4IB;GDP1W=0<41J2E<R:2M*94QP
M4G9H,TA'5F@Y2GAT3DHO1B]E3#@X63@P4S50;C<O;DMB+VIT-D0O>B8C>$$[
M1%1F.&Y";3<W3RMK=7 Q,TU024EF36YM2T-"64E.574T;T9#0EEK;FM644EY
M4V=!1%5(16YB330T-&YO-%EY4TA5<&PU674Y478X028C>$$[5T%,:E=:-U)O
M9V)U2U0Q9VIV4$%N1TY9,VQD23%K-"]#<DUE;7=R<TUH:T%!-4YM2U)L3&-S
M;7-F3$8O-E1#2'HQ6C)59'A*2% V1"8C>$$[6&A".6%D,G%:1$=X5&MV<&IM
M>6MJ;#=52G%/469Z0V9G,T1'9C4Y26TK,')55&)02D@K645C:E-7-'9#:W0V
M87-62WE,1S1$="LX.28C>$$[85%S3W4R+W1K4DEF>E!S6E-I9C4V67DV5')L
M<' X=&UN-6E71'EV8W@S2FY&>D=75BM%>D5I9FLP-'!X56UM=S5(<EAE4$9%
M;2M!<"8C>$$[-%I!5GAP9F%'-E,W4WHQ2'HU8U-'5F)54C-&<F4X;VQ3930K
M<D]R*V\T,V@T*V\R+W=";6AY4C572699>$<R>&U512]L=E5,;&]Z8R8C>$$[
M969,2C1N3G=Q33$S235(,7E623515G)T-B]R;'!.-E5Q5#-Y6&E!9G=(*WAJ
M-%I0.&%0,5!4+T](;')2.5%U;R]/3G9E>$QB:$=H5B8C>$$[,G5784LT:T-)
M66DT:T5F4&E'4F=19FA*2#)A-4=-;U1)2$-Y:TIW0E!%=T\T.#9E8C=L1U,T
M,74K;%)W5F17=4I30T-'56=J;#!)9"8C>$$[=G9/6DEX44A13TMC,'HQ2UA8
M;"]E,SDV.35F5'E85C%+45I:-6U,=7A!04A*;7%4<TUM26=#9W=-:51:9EHO
M*T%F278O575A6"\P:"8C>$$[5R\X07I2;E K3E K8V9M-VYW;SEW*U1V.$$K
M4F8K<&,P=CA!-E%R9B]M:DAX<"]Z:C@Q.$M08U!K=U1Z0TY.,&YZ3#E59R],
M4S(Q2"8C>$$[46\U631,:E5,87=I95AL2D5R,6EI.4PY-$$P:7%454%53R]8
M:2M04"MC9FUV:%$W:#AL9E$U+TM/<5@Q;F%39FQO.6E,=59O:F-4-B8C>$$[
M6F)R1D=&:DUG9#)+:6=904%D+V)(>#4O>FHX,3A+2&-%4$TR:DIP*VPS15@U
M93)5.#$O2F5*2D9(<'9);W-%:E(R-W-'9U1G2F=O8B8C>$$[-#9C86=5,S5+
M*U!0*V-F;79H43=H.&M.2'(O;$IR1F)L=GEQ=55K36MK4G1Z<$528V5M<45-
M44DO<W-Z.&$K4# P9DAN+T]0>EAW;R8C>$$[9'=4;E5B9GDS83-&>D9B*U$W
M5U@P.4]3.6<O,TA+2UA,2S570U9K:&119FAO>%1L>#<Y9&YX<#DU*V$K1DAU
M1$@R.# K5$Q3071Q=B8C>$$[-6%I>FM5:5 Q2F1/:&=H85(W:$QE3E$X.&-9
M<31K.5-G3%559&1J4CAE9C@T+TYF0V@S1#5--CAU95=V2D]S-DYB-FQ*-4YT
M3DUE9B8C>$$[;E=Y=DQ#,E-D3T1L4&I52V%6-#%(=&HT,"\U>"MA*T9(=4AY
M5$PO05!K6"]!2VQZ4R\X07!#="\K84UF1VXO3U!Z6'=O.7<K4UDV4"8C>$$[
M-60X=C942DI*<&5M5VQG.&]#>5!A=U)W;&=$54)I:7)8251Y4VQZ2DQ+34%/
M451!=TE34V$Q3U9C3&%*1C,Q95 S>#11;FI,=G$X9B8C>$$[=FIW:&5-=$<Q
M:$YA:71242LT>#11=D=89E9O<3$S<C0T.$E8:DQF,650,W@T479'6&96-"]F
M2&A#.%IA1G1%3VQ26')J=VAE370O5B8C>$$[-"]F2&A#.%IB5T)&24ER55EI
M2T1)<&1R2&PS>2]Q,&MC;7%A6F%8-WA!<D<Y,4)(359"3E-&3'$Q371H:VQ(
M:U-'<55!95E3-R]!4"8C>$$[:U@O<5A.3"]!3VM+,R\U;WEF:E0O;D@U<V9#
M:C-$-4\O=T%!*U)F*W!C,'8O<$-T+W=$;6I(>' O=T$T+TYF0VHS1#5/+W=$
M-48O-B8C>$$[;'I3+RMK2S,O=T-A369';B]/4'I8=V\Y=RM4>G4Y=3E/<TYE
M=6)E9CAR;V)J4D5E-6ET8BLQ,"M/4U(S=#)+<51&-EAW>'9W66@V-R8C>$$[
M:6Q!4E%S*U!0*V-F;79H43=H.&LR,$PO04%F<6PK,7!,*UA",#A*8E!C3F-8
M3VU7-GAC:U9#66=1;%=E<VQ0:$(V9F,K4% K8V9M=B8C>$$[:%$W:#AL2'EX
M0F\R<C)Z+T%&>CAU-U14<G1*-TM%<DQ94D--<E!'<C-*1$Y%1"LT;RLY2V9:
M1F0X9DAN+T]0>EAW;V1W*U-F95=F3"8C>$$[2&Q(5F1.839U+TM7;3)J:31N
M:%-.<D=.955C57)):VY'5TM.=TA695%Q369';B]/4'I8=V]D=RM38B\T1#AJ
M57 O:#-42V5(,4\S-R8C>$$[9C=$2'AP+WIJ.#$X3U!C1W8X02M29CA!<5A.
M3"]W0VM+,R\U;W@X868X-"].9D-J,T0U3R]W04$K4F8K<&,P=B]P0W0O=T1M
M:DAX<"8C>$$[+W=!-"].9D-J,T0U36HY3F-P='1P,W!R:F$P-S Q>'1A9#9A
M-#)T3SE.8V)7;F5M=4YR5'946$<Q<&]W>&M527%+9S<K23-'3G)49B8C>$$[
M<')J83 W,#%X=&%B5E%/;4MT-'$W1EA9<3=&6%EQ-T9867$W1EA9<3=&5VU5
M2')I<EAP<FIA,#<P,7AT860V830R=$\Y3F-B5VYE;28C>$$[=4YR5'946$<Q
M<#-P<FIA,#<P,7AT860V830R=$\Y3F-B5VPR2W9L:B]N24Q5.5-T+W=!>6)Q
M3S-U-6]9>&(R-4-2>4UQ,4ME04]B<B8C>$$[4E)">'5T,6,U0V5X-E!.=C S
M<E@O3&9C+W=$2394*W5:9D%/-7AF1FPS;&,R<C8X;W$Q-V1+3G5S<V<V-VIV
M:G=X-VLK2E!V3$LO3"8C>$$[9C9#=3E&;&LQ-WI,9C96<68Q:&QH;UIP67I#
M3&-U0U9!-FU39RLQ.4AF2TUN140V66=H=GAM-"MQ4D)41'I(;VYL+U-B3S%U
M<E1Z,R8C>$$[3G%8,6E337!"2'I6;6=A5FMK66Q:2D1'>4EO86IR=EAP:V-C
M-5-.1T9-<&=205!'5T<V<'$Q.49Q3C!T:G%6,4I93$Y)='!+,'-L6"8C>$$[
M:59Y15DQ-#=L861S>4EX1F)J9'@U6DI8<U131B]45W0P<CEF=6%(=C9S;CEC
M4$%/-6HT<RLX=&9P=E=V*U<K-2]W0U(P;CEC94%D>28C>$$[*TQ,=DPV-R]!
M0UEM;&TO3$Q1<%IN85-2;W!3>G53>D@Y+THQ2GI287-F=D,W:D-B9U!C>EA-
M9'-D:7)S5F1I<G-69&ER<U9D:7)S5B8C>$$[9&ER<U9D:7)#=GIN;6QH+TQ,
M6%I96&%/4EEO:7)O4W)$.2](,$EZ23!G+V5"<GI';T@S4&M4.4XV,2]Y,S-0
M+T%#3VLO<FTY-$(S3R8C>$$[;CA76&589G!V5W8K5RLU+S5(4V8Q>#1",TPT
M<W4X<#,U53%3>6QV<FXO15=P86E,4DQA4C=E3WIM8C%P3&=&4D=G-6-L-VLW
M-5AL:28C>$$[83E)1&)I>45N,45S=3%04G9Y*T8R>E=0-6M84U=J>4%,1DQB
M,V)3;W)V1T(X6'="=TDR9&DQ0C!',UA+27IY5G9$-VTV46IF,6Q*028C>$$[
M9$)0;$<W=6XX>5@P9FU+,S1T8C)X335J;7).27!7;D5C2WAE;3E3+SEL;G$T
M=T]%8TQ'+U)F16(K3$5F,#-R6"],9F,O=T1)-E0K=28C>$$[6#A!-VY'.%=8
M95AF<'97=BM7*S4O=T-2,&XY8V5!9'DK3$QV3#!N+T%*>#DQ4%5R:CAY8E=/
M-'4U<&]Z8C-"2U-337DQ0V5"3UEM="8C>$$[:4)J8W)35&M:-VYO*W X,')S
M;EEQ.$LO3G(X;69.,VUR>FY0<D=M4&%,85-1=WAQ2C584C9X<%$W2VIF<GI:
M86)646A#:F)H86I4>28C>$$[;DMW>$<S+S5X>2]-2T<T:6TU-F)*-F)Q+W!V
M3DE68FEA,%EE;#!09DQZ<G-:-S)K85-94%)N,G,K5F9Z:#%#1S1T:W0Y0VIT
M<&5A;R8C>$$[6F55,'%X=4-/2F1O=#)&4U$Q05)V4VQA6FI2>5EH=C9N2VM-
M:"]M<DEF2D@U;'9C-F%D4C W4F(V>C P<S8R:S Y>$MS<V=S=G%C4B8C>$$[
M;#E:2F%H84)Z='5F03<T;DQJ;S!:0R\Q,FIG;G1D8F4O=5,Y=GEY+TU5+V\P
M1%)F2S92-F5R2S9,1S,K:TUB8U<V=D]42'E:;$%,0R8C>$$[:$$U1W!";TUN
M*UEX-S=Y,UDK1E!B84M:;GEF*UI,5V=T2#AU*U5N:%5K=W$P8W!%6EI&4B]4
M2$=I.'941$@S>4AI-#=V:6UY-%HY,"8C>$$[56LX>2]L3"M9*W9A5&$R371R
M;S%Q.71)6#E3,60T:TDT:V)2<D925V)L.%I(,G%,='1V6FHQ3T]*=C%-36U'
M8WA7>D=0*VAB9GI#+R8C>$$[,SEP+R])-E0O<6QL,S4O2#5T2#5/9F5(,$8K
M5R]L*R\X=F539$PP82]+1S=S,&1:5$53>59A5C-&0U%V6G9$3EAN;4I42D1S
M8V-E1R8C>$$[241*8W!:=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5FI8
M-6ME6#<O>D0U2C%44G)!;TQU.%)&:4UP2W!66E5C,4E$9&PX375W5"8C>$$[
M15IG;&AK:GA2269-*W0O:W@U9S!383)T.54Q4%1,835V968Q3S--,'I3>F5N
M>#5I2TY)5V1Y3UDR07IA9FXX9FTV-SAL4'9#6&8X028C>$$[2W5*=E%G;B]!
M12]O-&EU5$MS1$=E66-J0DES36]!34YF:&MD4FHK9G@K82]K<#DT5#=Y,6]6
M,S5),4-0>D9.<D=I36E2;UE(;'5:;"8C>$$[54Y.1VQX0U%6:'(X84935D<U
M4FE.<3%Y<DQQ.&,T,74R-'103T)V6FM8;5!2+T]M<&5G3E1V=DMC83(W=T0P
M1TM+,U V=4QD0DEP:B8C>$$[-6=&1'DT;EIE;V]&,FI$4&EJ>31M8W-E4UA0
M:%<S;' U:#%+,3%45#=J561!2W)&8C)C:DQE5&-&;'59;V)E07,W;WEY8VA#
M1U5+9"8C>$$[;F]E,4U%8RM-1457>6Q#6D)'>D)7+TQ'*U<U*W%N5W1,*W-L
M,&E715,S0EIN:S-65D%G*TDP24IP.6M%13!">DDO4#0O3GAF>54K."8C>$$[
M275$.&Y.6FUK;&I45W1'1'=&;&Q6-W1K;U9(2G9T>')7:2]&561Q2&]2:BMF
M>"MA+VMP.31E;&9L2BM46&TW>7(U>G0Y63%+4S!E,"8C>$$[4T=A3G91;%HS
M<DEL0G-Y3'0Y3UDK<#%52G=O5S,V9E1Y:$MY.3%Z5W5A-T952'%K3C5.6EA-
M5FQ-3&$W:VED3&4U6E!55T]2;$E2>28C>$$[;%8U8U1V4W5%24Q!3% X04PS
M.'<W94\S3"MD-7!R;4)*-&YL:W0S2U1,3$=%:F%33#$K265+;7A7;%0X4BM)
M;D97-TQY4#A!;6Q:4B8C>$$[5$-,>GHV.#=R1VMC=#%90UE+<5-3<W@T97-O
M-7-R>'%7+WEE;4MQ,3<U52].<35T6C15.#8R.74P<6-5;&DP=$$V365P0DUR
M94\S8R8C>$$[9E!F1E=P9DQ8-7AI,U))=D]&:3!O9$%Z;E-W;%DO<W,R.'-V
M>&)L<54K26=$-&1Z:7$K-CAP9FU49G=O<S-M:U=-=VAG5U-7,6@U9B8C>$$[
M=E5U1VMM;W8W<&%.0U)(6'8Q;W1.,59+6'EN*V)%5G):5VQP-71G94))26)A
M*V5A,$EN66=5;755;4QY:W5X-DE10B]L3&EQ8657+R8C>$$[3&9N97DQ:U@K
M=2M9=C!T15E(:&MT-#1"87<X=6%T17EW9WE!34)Z-4YY,RM%549$5E9M4V9:
M1T),94MU>%8R2W5X5C)+=7A6,DMU>"8C>$$[5C)+=7A6,DMU>%9P+W-N1E5M
M,6)Y=#5D,6E72V)69$QT<C9A0VYO>5A%2U--;$LO6EIG4W8R:C!W<U5#+W=#
M6%AK3C0P:6)Y-7!P:B8C>$$[:EAG:4<P:&]&4$@T44]05#1&*S=&2U<K85!+
M;FPK=S!A5C=(>5I"<C=Y>5%Q,FU)<T-F0VM8;TMY97933D9J:2M%2W1/<#A4
M:7)%="8C>$$[6#!A85A8;759+WEK:75I<7IR3&1'-'-O:W5#=S1G3V]B-#%+
M<B]U>4YQ13=5<'E+<6$K5GAQ86%J6F%F2BM84S9*6E1M2F)M-#4R,"8C>$$[
M;'5I,G=K=4DK155,3TDK1G<S2D14<69(9D975U)F;#DU26EF;DAO3FER*W1(
M8V-H8G@Q.6%),6IK-F9A6'-C5E%W+TLS.'5U1$EF3"8C>$$[5VY/2$I:>3ET
M1S=->$)7<%IG4U11;F9&5U923'A)049!0E%$17%&6$%L,DMU>%9,.5@P4S(Q
M4TU,3%!D,C=+0T5K=$QQ93)95C<P:28C>$$[9$9B+T%'44]3:D]K15=W8E=F
M>6XX>51C;3!F>C5R5FUE3S!D>D\Q=W9,+U=6;U-".2M:34Y42')#3%1,0U1Y
M:U=#-G@K6% O041K2B8C>$$[6D=T:C5K;C%21%=G:'8U66XR.%)/63$K-6IM
M5$A09U!/3F9";VQI>D1K8E-05&9,=B]/4CDO2WE*8S9T8FA$4G!,;3A-2R]2
M>FM"8B8C>$$[+UEG-5I+96Y(9#AM<U%Z;&Y':F9L3BMB:W!$87HU*W5R5F%!
M;4\Q;75*,G(T1FYA140U-S5J>C%/3'!"=FIH>61:334P9CA!3'1B3"8C>$$[
M:3$W-6@Q=E9*05!I.6952F\P2CA1<T)I4#!&:FU.3%!F25)(=V(T-#8V:W-T
M4D%I2V=Q46]!0EEL:G0T:S%**VY+1WAV1EA9<3=&6"8C>$$[67$W1EA9<3=&
M6%EQ-T9867$W1EA9<3=&6%EQ,#9",%I$54)G45-P2VYF=TEO4CE'2W-3,6HX
M=3%V43=76&U,5SE,:TDK15%A:$Y)9R8C>$$[8GA+>FU5+U%'1UAX>C%Z150X
M1W573RMP1$)D6B]+8C@S66E7,&)Z-V184U5Q175P<FE"<2M&56%92#4W6FMW
M,4],<D)O;&AY9$I-228C>$$[,4QY.2]W035(,D5Q>'9C-G1C0GI26DQA.$UY
M+U1W:TI8+UI!6FM2;G!Z,V9*;TU--%1Z4B]W075F*V-H3# Q=G9-:RML;TM6
M13$O3"8C>$$[2RLO9TE$278S<TUR;&YW1&Q'+V<R4GA::GI.338P8CAP+TUK
M4$9T63@K83%E2&IV2&)4=&)R>2\Q;6%9:V9D;4Y057@V46DS>'=K8R8C>$$[
M-49N3VMA2F)A6$=6:6YU-VAM041Y6&0Q4&-S860V4W4V<B]S44UX<%1T=4%P
M34UI;#)+=7A6.&]F.#5$=38O;5ID0E=)2#%A,S9(+R8C>$$[04ER>F0V2"LW
M9%IR2D54*T1Z5#%:9C4R*S@U;54T=D=E.6-X=59&5TQQ3G5T4C$S1T1:94M8
M;7ER>3%P6&MY.#!34U189%IN,'95=B8C>$$[<D1,0E-.-5DR:%<S3&=L4795
M>55(,BLO5'9L3U-5=V933$1F:C142#%%9W!L-6<X;2M3=$MT-T\U=&9.>6%N
M.5IL:4M7-F]9>3!$5"8C>$$[36MJ339'6F]3:4M'*TI+-S=!.4UH1$Q/5F=X
M<&Y/15)2-&U(-C1T;$)R1CE&<&,X:RML<&-3<%EZ=516-%9C:$=*;VTU5VYB
M3#17428C>$$[3#5U4$]613!D:T0V:S%+.&UO93E4:S)0164Y,W%Y+WIT.35X
M<&5-.3<W1"]!0U1*4#5884-4=693;"\U4'E:;V18+V5&,T=(-D(W;28C>$$[
M8C5J3G)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U994BMD:$DO2S=8:4YJ
M-E58+THK4$UN4V8S9V%S,S!(,U!M6'E41#5%;E,U+R8C>$$[>%IE6&1U-75,
M4TMZ*W%T44-+4C,K<WEY5E-8-%DP5F5M*R]4=4YV;4UX.4%(5C%U1U54.5)+
M86%L-5(O3#)',&YM<U!00G9*631N828C>$$[1T0V:F-+6&M65TM)5%5H9E59
M2V]*.&-H2$QK=F5(,G1H:$=T<'(Y2C!,.'1B;UA59#5R5GAA>2MH<"\Q85-0
M,4QH56YM-4,W-40P;R8C>$$[:3-P2&IT.'=/6%E3;FM(260O-T5X:D$Y5#!2
M9'HU2R]+-C)9,C!V;FQH355T<#0W:$QA4U)/13EE8UI60V%-:3A72DQD-D9A
M:D%-=28C>$$[43<X0U1#03(T:T=V;%@X<W!,848P.#=Z3$Y,1S!J>%!9>3AK
M64%5:5E+>F9&,7%186):3'A-;"]4.7)%46@O4$Q6=#5B+TQH3'%/2R8C>$$[
M.3AZ6$AO6%9O2C1P>$92;UA--&I#=6M:;C5(,#%D*TY624)8,V]N2FMR84M2
M1T8W>4M,9SAN9FQD26PR<V9N85-A4DQC6$5*3G$X2B8C>$$[6&=*2DI526M9
M2S=C27=Q9TU0:5ED96U23UA*+TY546AV-FPS+T]01',S-6TR;TQ%:C9V8U5R
M+WAJ>#$S.3)J4GE*;CA(,69M:V1M-R8C>$$[1EAI6#5Q9FMH-6\X,V5C2CEA
M,"LX<UEB85-+2TY5=4AM16Q9,6]A:$EN2#0U<V1.<DEW:%)"8U10<&I/5C)X
M5S,O-7AL.#AW,T55,R8C>$$[,2]3<%!49%@Y3C-U0W)C5%=J1#!E:#<U8V4P
M24AO5VMA26<X=WHW5U!*2#5S86A$8U=Y4#5E:G1P96%O6E9M;6Q73G=2>$QT
M0G5W<28C>$$[4T=O0TXV57)436%/8D5.+U4U56]Z4&-U4&M8.'E,<6939C!R
M8BM83'5Y,&=Y4$1:1#9Y<U1U,6XY5FHU;S!,<'A19U!X0VHR<&<X8B8C>$$[
M1TQR:3,O6&$K2$DQ9&)F<5-P=GEL."M(.4=G5U!L4DDY4%9L9$9G;2]W0DE9
M,C1T,65C;4AK>DM!5T9#0GE.4T116EHK6FAV=E!D:"8C>$$[-$UT=G!432M1
M=GI"83!&;RMK950S:%5K=W$P1GE21U=2568P>#9D1C5E;4=0=FM01W@S9'I:
M.$5U-DM2*UIF>5@X+S8Y<$YR67ET;R8C>$$[5G$Y=$E8.5,Q33A3155),FI7
M0VES,TPT>5!T55AB8F5Z2'$T4DXK<CAF1G)Y64I41F)-6B]W0VA8+U!0+U9X
M,'HO:UIC9CA!5D1,=B8C>$$[-5)H,T9O+TEN=F4X+VPU-6-V9DQF:S-43D5V
M6DDU8G%Y4C%L:VA,1TUL<%=C8U-Y;V5J94=A>E!K135M439U9FIJ=WA!6D9L
M5$XR2R8C>$$[=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W-C+TU4>3=E*UDO
M2FUP-DI:4U)X6%8V:4Q(2DU715DT>7$U-4968SE&.$UT=U1%2F=L:"8C>$$[
M:VIX4DEE0V8Y0WEE9"\X07$T-EHO=T%J3&HO<6AM,"]L0TAC6$$O2DAV6F@U
M3"]+>CAY4$M6:&17.6A,;W,X,7I+:G9*8TYC3VA25R8C>$$[4FEJ<#9)-6)X
M:FEA+T16=35"1U!L,4=/6C,T;2]&:&Q!54M23F@U02].87IU6EIX3F],3DI(
M87=K26)U16-,4V8V=VQF4VI4;7I0<R8C>$$[>E!5:V)D>F=L;7A(*V0Y:DU1
M;F92>F9L;C4P*W%7,%,V9#58:W551'1D6&LV5'EY>5136&8Q:W1Y.45F1%%"
M3TQ6,G)V=F<O35%V;B8C>$$[3#A"2&AN*VDQ;U@U8V9M1F\X54EI<W9+<S%X
M14MF6$I)8F=3<U,W=7A*4TI+8VA)5DE!*WIT:&YN>'DV>E=/3U$O;6]U,3AI
M969O3"8C>$$[<4=34%1F2VQT16Q"24Q72V5+56='3VA76#!76E=(<$=H+WEJ
M54AB26Y.06IN3FM)4T(V34%U4"MC869/.#%X3$XY93!Q4#%(6B]44B8C>$$[
M-V=+=DDQ;V\Y2&]/,EI1,3A",$QI;E)K;FUY>CAQ=GE4.'HK579/14=S-FAE
M5U4Q=$A&3$=Y5S=Z1U-S:3!&03A31#AC;S%/<FI/1B8C>$$[049T=V%C=VQD
M=F)S,7IM3WA6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R
M2W5X5C)+=7A6,DMU>%8R2W10.6LT<28C>$$[.#(Q9CAL9$\Q6%5R,BMU=&0Q
M8R]8<F<S5'=#5T@P-'!+:FE)2WA&;VQ!5D%E2BM)2V]A=3E3:%8O=T-647=$
M5FLQ46599%EA-%,T3B8C>$$[,W=E5TEX=$M14E5Q26PR,UA:840T4FEQ;F)F
M:S-B45AC3C5(<BMR4C-5151X4G1(2D=%475T>6]E3D=J9FE5*W5(:%5K:FET
M4V0V<28C>$$[<6EF;%AQ8G,S,7IZ:')5-G$V:3-D6D936#!#9T5S17IC5VIK
M5U(Q-45R1VID<3=9<6EX*U=%0S981%I1-GAQ5G1,8F\X8U4X37A+<28C>$$[
M2'9293%%53-R25-R3#9A;'$O0G0T14MO5%)F>6=G,&9I8E!8.59745%X,B]Q
M8S1E6'!P3W,W2W)E;'E54V-E3&-4=E5N<5-C5E4W-R8C>$$[.&QT379T46)5
M8FY7=%=K=3)T63=4;3 T22]D=TQB*W)4:'9)53E1;&U**TIY96]7:7)+=DIV
M;&%(>7IP0V%:1F181C9Q=3!J6$8P428C>$$[,&A:<4$O6D-Q2S!Q841C,5!5
M-'%N*T),+SEK/3PO>&UP1TEM9SII;6%G93X*(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]X;7 Z
M5&AU;6)N86EL<SX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR
M9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS
M.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(^"B @(" @(" @
M(#QP9&8Z4')O9'5C97(^061O8F4@4$1&(&QI8G)A<GD@,3 N,#$\+W!D9CI0
M<F]D=6-E<CX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C
M/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @
M(#QD8SIF;W)M870^87!P;&EC871I;VXO<&]S='-C<FEP=#PO9&,Z9F]R;6%T
M/@H@(" @(" @(" \9&,Z8W)E871O<CX*(" @(" @(" @(" @/')D9CI397$^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D^4F%J96YD<F%N($)A=V%N<VAR:3PO
M<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO9&,Z
M8W)E871O<CX*(" @(" @(" @/&1C.G1I=&QE/@H@(" @(" @(" @(" \<F1F
M.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UD969A
M=6QT(CYG,C-A,#$\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@
M(" @(" @(" \+V1C.G1I=&QE/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*
M(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @
M(" @>&UL;G,Z>&UP5%!G/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O
M="]P9R\B"B @(" @(" @(" @('AM;&YS.G-T1&EM/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O<U1Y<&4O1&EM96YS:6]N<R,B"B @(" @(" @(" @
M('AM;&YS.G-T1FYT/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y
M<&4O1F]N=",B"B @(" @(" @(" @('AM;&YS.GAM<$<](FAT=' Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]G+R(^"B @(" @(" @(#QX;7!44&<Z3E!A9V5S
M/C$\+WAM<%109SI.4&%G97,^"B @(" @(" @(#QX;7!44&<Z2&%S5FES:6)L
M951R86YS<&%R96YC>3Y&86QS93PO>&UP5%!G.DAA<U9I<VEB;&54<F%N<W!A
M<F5N8WD^"B @(" @(" @(#QX;7!44&<Z2&%S5FES:6)L94]V97)P<FEN=#Y4
M<G5E/"]X;7!44&<Z2&%S5FES:6)L94]V97)P<FEN=#X*(" @(" @(" @/'AM
M<%109SI-87A086=E4VEZ92!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @
M(" @(" @(" @(#QS=$1I;3IW/CDV,"XP,# P,# \+W-T1&EM.G<^"B @(" @
M(" @(" @(#QS=$1I;3IH/C4T,"XP,# P,# \+W-T1&EM.F@^"B @(" @(" @
M(" @(#QS=$1I;3IU;FET/E!O:6YT<SPO<W1$:6TZ=6YI=#X*(" @(" @(" @
M/"]X;7!44&<Z36%X4&%G95-I>F4^"B @(" @(" @(#QX;7!44&<Z1F]N=',^
M"B @(" @(" @(" @(#QR9&8Z0F%G/@H@(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M/'-T1FYT.F9O;G1.86UE/D=I;&Q386YS350M0F]L9#PO<W1&;G0Z9F]N=$YA
M;64^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%M:6QY/D=I;&P@
M4V%N<R!-5#PO<W1&;G0Z9F]N=$9A;6EL>3X*(" @(" @(" @(" @(" @(" @
M/'-T1FYT.F9O;G1&86-E/D)O;&0\+W-T1FYT.F9O;G1&86-E/@H@(" @(" @
M(" @(" @(" @(" \<W1&;G0Z9F]N=%1Y<&4^3W!E;B!4>7!E/"]S=$9N=#IF
M;VYT5'EP93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.G9E<G-I;VY3=')I
M;F<^5F5R<VEO;B Q+C8U/"]S=$9N=#IV97)S:6]N4W1R:6YG/@H@(" @(" @
M(" @(" @(" @(" \<W1&;G0Z8V]M<&]S:71E/D9A;'-E/"]S=$9N=#IC;VUP
M;W-I=&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1FEL94YA;64^
M1TE,0E]?7U\N5%1&/"]S=$9N=#IF;VYT1FEL94YA;64^"B @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O
M;G1.86UE/D=I;&Q386YS350M0F]L9$ET86QI8SPO<W1&;G0Z9F]N=$YA;64^
M"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%M:6QY/D=I;&P@4V%N
M<R!-5#PO<W1&;G0Z9F]N=$9A;6EL>3X*(" @(" @(" @(" @(" @(" @/'-T
M1FYT.F9O;G1&86-E/D)O;&0@271A;&EC/"]S=$9N=#IF;VYT1F%C93X*(" @
M(" @(" @(" @(" @(" @/'-T1FYT.F9O;G14>7!E/D]P96X@5'EP93PO<W1&
M;G0Z9F]N=%1Y<&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IV97)S:6]N
M4W1R:6YG/E9E<G-I;VX@,2XV-3PO<W1&;G0Z=F5R<VEO;E-T<FEN9SX*(" @
M(" @(" @(" @(" @(" @/'-T1FYT.F-O;7!O<VET93Y&86QS93PO<W1&;G0Z
M8V]M<&]S:71E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9I;&5.
M86UE/D=)3$))7U]?+E141CPO<W1&;G0Z9F]N=$9I;&5.86UE/@H@(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$9N
M=#IF;VYT3F%M93Y':6QL4V%N<TU4/"]S=$9N=#IF;VYT3F%M93X*(" @(" @
M(" @(" @(" @(" @/'-T1FYT.F9O;G1&86UI;'D^1VEL;"!386YS($U4/"]S
M=$9N=#IF;VYT1F%M:6QY/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N
M=$9A8V4^4F5G=6QA<CPO<W1&;G0Z9F]N=$9A8V4^"B @(" @(" @(" @(" @
M(" @(#QS=$9N=#IF;VYT5'EP93Y/<&5N(%1Y<&4\+W-T1FYT.F9O;G14>7!E
M/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z=F5R<VEO;E-T<FEN9SY697)S
M:6]N(#$N-C4\+W-T1FYT.G9E<G-I;VY3=')I;F<^"B @(" @(" @(" @(" @
M(" @(#QS=$9N=#IC;VUP;W-I=&4^1F%L<V4\+W-T1FYT.F-O;7!O<VET93X*
M(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&:6QE3F%M93Y'24Q?7U]?
M7RY45$8\+W-T1FYT.F9O;G1&:6QE3F%M93X*(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D)A9SX*(" @(" @(" @/"]X;7!4
M4&<Z1F]N=',^"B @(" @(" @(#QX;7!44&<Z4&QA=&5.86UE<SX*(" @(" @
M(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D^0WEA;CPO
M<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI/DUA9V5N=&$\+W)D9CIL
M:3X*(" @(" @(" @(" @(" @/')D9CIL:3Y996QL;W<\+W)D9CIL:3X*(" @
M(" @(" @(" @(" @/')D9CIL:3Y";&%C:SPO<F1F.FQI/@H@(" @(" @(" @
M(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP5%!G.E!L871E3F%M97,^"B @
M(" @(" @(#QX;7!44&<Z4W=A=&-H1W)O=7!S/@H@(" @(" @(" @(" \<F1F
M.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'.F=R;W5P3F%M93Y$
M969A=6QT(%-W871C:"!'<F]U<#PO>&UP1SIG<F]U<$YA;64^"B @(" @(" @
M(" @(" @(" @(#QX;7!'.F=R;W5P5'EP93XP/"]X;7!'.F=R;W5P5'EP93X*
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E
M<3X*(" @(" @(" @/"]X;7!44&<Z4W=A=&-H1W)O=7!S/@H@(" @(" \+W)D
M9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"]M;2\B"B @(" @(" @(" @('AM;&YS.G-T4F5F/2)H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C
M(@H@(" @(" @(" @("!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(CX*(" @(" @(" @/'AM
M<$U-.D1O8W5M96YT240^>&UP+F1I9#I#0S5!030U0S-",3E%1#$Q0D(S14(R
M1$4S.$9".48T.#PO>&UP34TZ1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-
M.DEN<W1A;F-E240^>&UP+FEI9#I#0S5!030U0S-",3E%1#$Q0D(S14(R1$4S
M.$9".48T.#PO>&UP34TZ26YS=&%N8V5)1#X*(" @(" @(" @/'AM<$U-.D]R
M:6=I;F%L1&]C=6UE;G1)1#YX;7 N9&ED.C@W,3%&,C<R,S@Q.45$,3%"0C-%
M0C)$13,X1D(Y1C0X/"]X;7!-33I/<FEG:6YA;$1O8W5M96YT240^"B @(" @
M(" @(#QX;7!-33I296YD:71I;VY#;&%S<SYD969A=6QT/"]X;7!-33I296YD
M:71I;VY#;&%S<SX*(" @(" @(" @/'AM<$U-.D1E<FEV961&<F]M(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T4F5F.FEN<W1A
M;F-E240^>&UP+FEI9#I#0C5!030U0S-",3E%1#$Q0D(S14(R1$4S.$9".48T
M.#PO<W12968Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @/'-T4F5F.F1O8W5M
M96YT240^>&UP+F1I9#I#0C5!030U0S-",3E%1#$Q0D(S14(R1$4S.$9".48T
M.#PO<W12968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.F]R:6=I
M;F%L1&]C=6UE;G1)1#YX;7 N9&ED.C@W,3%&,C<R,S@Q.45$,3%"0C-%0C)$
M13,X1D(Y1C0X/"]S=%)E9CIO<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @
M(" @(#QS=%)E9CIR96YD:71I;VY#;&%S<SYD969A=6QT/"]S=%)E9CIR96YD
M:71I;VY#;&%S<SX*(" @(" @(" @/"]X;7!-33I$97)I=F5D1G)O;3X*(" @
M(" @(" @/'AM<$U-.DAI<W1O<GD^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@
M(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%
M=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)
M1#YX;7 N:6ED.C@W,3%&,C<R,S@Q.45$,3%"0C-%0C)$13,X1D(Y1C0X/"]S
M=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE
M;CXR,#(R+3 X+3$Q5#$Q.C(Q.C0Y*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU
M<W1R871O<B!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N
M9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @
M(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#I#0S5!
M030U0S-",3E%1#$Q0D(S14(R1$4S.$9".48T.#PO<W1%=G0Z:6YS=&%N8V5)
M1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,BTP."TQ,50Q
M,3HS-3HS.2LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@26QL=7-T<F%T;W(@0U,V("A7
M:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @
M(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @
M(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @
M(" @/"]X;7!-33I(:7-T;W)Y/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*
M(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @( H\/WAP86-K970@96YD/2)W(C\^_]L 0P ! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@!"@(] P$1  (1 0,1
M ?_$ !\  0 " 00# 0             &!P@$!0D* 0(#"__$ &<0  $$ @(
M 04'#080"P8%!04#! 8' 0( " D1$A,4%18:5UB6E]4*%Q@9(5)55I*4TM;7
M(C&5F+'4,C,T-T%1<7)S=7=XLK:WT2,E-38X.72SM+7%)"="18*#)F&$PL0H
M1F)GD?_$ !T! 0 !!0$! 0             ! @,$!08'" G_Q !F$0 ! P,!
M! (*"PD,!P<!!P4! @,$  41$@83(3$400<5%R)15971T]46(S)24U9A<9.4
ML1A4@9&2H:+2U#,U-D)7<G-T=;*T\"1#8F6"EK,()31$P<+#M2=%8W:%H^$W
M1X3B\?_:  P# 0 "$0,1 #\ [_'%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%
M*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2M.[^XU<YQ^_P"KK?\ =[<E/,?./MJ%
M<C\Q^ROR2=\YSOOG.?+G.VV<YS^_G/ES]W//O \S\Y^VOB"O7D4IQ2G%*<4I
MQ2G%*R_DG2BU 76Y/M,*E5.3^M&*D'0G3*N;1CTMFU3N[':X<PYA9\49;:/8
MN0*JYR-W8>D>NQY9-R-)(LW+-YHWT#.T<%V\&R.,7"),4)1BJF07F(TY,-6F
M0J$^H%+R$#OPO"4K;(6@J"D:MZ[L]-;M(O*'H$J(DQA)3$F-/R(*I8S'3,83
MA3*UGO-.5*0L%"PDI4!MO6#IA>G;=S,EJM%QL;#JW'-2UE6C8LL#5_5]?#R&
MZR0Y643&0.$&39<@HW7PS'L]'Q)9)NY=X9X9-'3E&N];16RPICB:MY<B8M3<
M.##8<E39:T %88CM J4$ C4M12@$I3JU*2DTV;9^Y7PR#"0TAB(A*Y<R4^W%
MAQ4KR$;Y]TA(*R#I0D*60"K3I2I0C_9#K'-NL<AC8262VI9Z/F )211>94M9
MD:M*$F1[<@X%N]6YV.N%,-WC-ZVW2<,B#9FXQKLDLGHHBIJIR[:+S&O+3SC#
M$^*N.Z&7XUQAO0I+:RA*TDM/ 92I*@4J0I0R"#@BK-VL\BSNM-OOP92'VBZS
M(M\QF;'<0%E"L.-$X4E22"E:4GB",@U':ZH&P+1K2\[8BR8?>)=>8]$9-8FY
M EAF13&3:6-88$R%9>@5]J+[&G:.'2/I6_J[7SE_.W\WS,WI=TB0IEL@/EP/
MW9V0S$THU(*XS"I+N\5D:!NTG2<'*N'#G5J);)4R'<IS(;W%K:8>E%2]*PB0
M^([>[3@ZSO%#4,C XU2G-C6OIQ2I)((?*8FWC+N31\J!;S.-H3"*J%6:S+V]
M%G90L%:2 ;JOKINX%/"8(LV:/-=<(NO4E%F^RB&R:N]EJ0P^7DLNMNF.\8[X
M;4%;I]*&W%-+QG2XE#K:E)/%.H X.15YV.^P&2\TMH2&1(8*TE.]84M;:749
MP2A2VUA*N2M)(R,$QOEZK-.*4XI3BE.*4XI3BE=DCZF.SG[,>\L>7/DSUF+Y
MSC^QG.+3K#R9\G]O'ESY/[7ES_;YY!V9OX/6S^V6_P#!3:]9[$'[_7+^R%_X
MV'7=XY\W5]#TXI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4
MXI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3B
ME.*4XI3BE.*4XI3BE.*5IW?]2.O^SK?]WMR4\Q\X^VH5R/S'[*_))W_H]O[[
M;^7//O!7,_.?MKX@KUY%*<4IQ2G%*<4IQ2N7=Y;O5^ ^%W8?6YG>;6X+4LZP
MZ9MN"0N)5)8=:%J@F0YNABU6EO3<RFPBMK!&@9<E%(0Q&O9.T'%L:RH>BP]I
MYT \&F!>I6VL2\*MAM\&'$N,"5)D7")-1<(ZU'H*K?&;*GX#BG0B1)4XAA2V
M\L**]&7>Y5.L\;8Z5:4W(3YDR5;YT:.Q!E1%P)"1_IJ9TEP)8FMI;*F8Z4*>
M2ES#R G5[7M/3:_^MAGJ#?\ T0[-6'*J#C]I63$+F@]\1F%%K&$B97%V+ 6Y
MBUBPJ-J)R<S&7386Q=B-0^KCU4HL\?N-FBK)EAY5M#:KPW?[5M/98C%T>A0W
M[=)M;\AN&MQAY2W _$DO99;>2I:DN;S&4!*0%!2M-%@NEH<L5TV;O$EZV-3)
M;%PC7-F.N6A#[*4(+$J.T0\XR4H2IO=YPLK42DI3JG77N8='.I-HV4-KGM,0
ML"43[K-8D,KSMD1H2=PV+T'>)PJ,WC9N.Q19G++7:M]XXR)B'UD1Z+.I5'W1
M;7($!NT<$5DL>[1]I;]"AKF61$5F+>8DB78D76+(>NEM:;6'FWGP8\%1#RT.
M(AO/I8>2V=\Z%)0%9-J?V;L<R8B+>ERGI-GE,1+VNV26&;9<7%H++C3!2_-2
M-TE2%2VF%/-%?M39!61D?-?$=HJ*1OLL0I^T-U.P)_IIU(J9"[V%;'!V>P79
M&L+-7.6C;C%O((EH[$/]8H\9Z#)I9 B*2LB2C[<NT;M#K<6KS3QMD+F^]9T7
M"%BU-;0W^>;:N8VOM59YL,-P8"BT^4K27TJ*XT-Q]A"'BVI2FRX*VTC:RVL,
MW=<&:3=';!8X0N*8CJ#<[M#F*<F3DAUD*0H,*3HD2T,/K6T' E+H0:F4N[Z=
M3I%9_9X]2E\".M5AVK:75:QT>R6M0V+ZM.()"ZDB@B]*HU&0RO3,UCY S9;0
M[)R+1U%AL.L]ZJNRD9O06]P^5QX^R]\9AV5NXVMR\Q(,*^1#9^V$0&-*D3Y#
MELG:Y,MJ,ZAN$IMA"DOKD0DZ5,M[Q&@7W]I;&[,O#MON:+1*F3;++%VZ#+Q)
MC1X++=RA:(\5R0TMR6EQY84RB/,5D/.:5!1IFZ/$NIZ+4AV!;=+- U3S^S/$
M$L"S(J!?52*=%0'7F64!$(,=. '!J.&H/$%IY- AA-Z %/=90&"F2 QJW8B"
M#Q1QL;=L=<'KE:CM$7)\2'LI$AONHG.);=NS%UD2FVG4MO-2I BQG&]+KB=P
MXXVAQ2EN(2!@3]KH#%NN8V?#<*5,VHE2V&EP4*<:M3]KCQG7&E.-.1F#)D-N
M!32%;Y#;BTI2A"B3:V/$7K,W+NA-DX[1PE0/4O7F 5A:-!VW6%[MA,+MN,5/
M.X/,;783.J(&77!$C:9EJ+@4QJ]60R2-/"S<LZC;%H.>I:8/L1F-,;4P^TLD
M+GW:7-@W2!-M9<DV]^?%DQX"X\Z4@.(:+:ERH\X-,O);+:7E*6DUF^RN&X_L
MU+[<Q]W!M46',MDZ'<@B/.9A28S\U,B#&66UN!P(BR(9=>94M*U,I2A0&"W>
M>\Z3L2-7J)I'LM(I]#)-VQB%@1FLK"J1\0L&1CF5 B(L;MQQV)D( '+'4?%2
M=$E 04!E3-A*38E ;.I(T4//"[M?IMF;9<8CUL7<K,S$DL6*1$>FQ)Z$Q&EJ
MNJWFX";0R\['2ZXP42W)3"E,-N%<5E0:2VD<WM'<;=*9N3=NN[LJ.]>V)3,.
M5!4J4ZE-L;9<G*NKK3;ZFD/!<9J,\E#SB F2ZG>*<4>)SG<UQ-.*4XI3BE.*
M4XI79'^ICO\ ID7E_FS&/]J=7\\@[,W\'K9_;+?^!FUZSV(/W^N7]D+_ ,;#
MKN\\^;J^AZ<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4
MIQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G
M%*<4IQ2G%*<4IQ2G%*T[O^I'7_9UO^[VY*>8^<?;4*Y'YC]E?DD[_P!'M_?;
M?RYY]X*YGYS]M?$%6S3=&V9?<E?Q>LP34FY"@WLIE!DV?CT.AT,B@U5N@1E4
MVF\P* XE$8ZS7>,VJA:0&1[51\\9#FVZY!ZT:KX%PN4.ULI>F.J0EQQ+++;;
M3TB1(?6%%#$:-';=D2'E!*B&VFUJ"4J60$)4H9T"W3+FZMF&T%EMM3SSCCK3
M#$=A! 6](D/K;88:25)25NN)!4I*$Y6I*3([DZSVK1HN-2:6M8F>@LR<DF$3
MLJL; A%KUN>*A=&VYD$VFM>'I&":R,1H[;*D8T4=,#[5LX;O5!N&3ANY5LV^
M\P;DMYEA3[4J.$*?AS8LF#,:0[G=NF-+:9=4RYI(0\VE;14"D+U I%V?:)MN
M0R\^EAV-(4M+$N'*C3HCBV\;QL2(CKS0=1J!6RM270"%%&D@F@>;2M96_P 9
MBYV8F4(_&V&21=PU*/46>KAHUSNV"BGILFKZ9ZNV;:X:BQSQUG39;7=7".4D
M-55]TDM[3SS4=LNO*T-A3:2K"E=\ZXEI PD*/?+6E/+ SDX )%UEEV0X&F4Z
MW%)6H)RE.4MH4XLY40D:4(4KB>.,#)P*V#EVK5.*5DN;ZGVE&JHC]Q2,O4 &
M-2R%H6%%P!F\ZA&V9(HBY-$H^U+A*I>3)&Q":3DL'*M6Z3.-K+K9'/=TT]DV
MRVVFG;OL%Z<[;V43W7F)!B/NMVRX+ALR VAU3;DY,8Q$%+;C945/ #6D$Y(S
MMW+),9A-3W7(+3+\<2F6G+E!1,=84XMH.-PE2!*6"MM8 2R2="B!@&L:.;BM
M14WF-=2V!,8$2E Y-@SLR$-K%ARB;YB]R3B3N1R6*($54V;A=0>IN<B)YIEB
M_P!6S[71IHYV;X;.6RJN-'EL2E2D,+*U0Y*HD@%*DZ'TM,OE *@ L!M]I6I&
M4Y40#E) R)$1^,F,MY 2F9&$N.0I*M;"G7F LA))2=XPZG2K"N]SC2I),(YD
MUCTXI7MG3?&FJF=-L)[;;Z:[YUSC3;=/&FV^FNWD\W.VFJB>=]<9SG7"FF<X
MQC;7RO\ /X\X_'@_B-,'&<<.(SU9&,C\&1GYQ6^HQ<ZXBY&:(L,[QD2>#1@@
M3]8::ZMSL@'G2H=AEKLOJ^5R\81DXXPX1;*-4,,<IN5T5G#5->T7F@\B.5X>
M<:<>0C"LEIE;2'%YQI&E;[0P2%'5E(("B+H9=+*Y 3[2AUME:\IX.NH=6VG3
MG4=2&7#D)*1IP2"4@[RTKF7/:U/6XV');P2-3B)5R8+9?,=%FTMFX&:26-CM
M1F[C4DX2?!Z^E3E1\W:J,6FX]-N[<(KO62:]M4MA,QJ"I9$IZ,_+;;TK(4Q&
M=C,O+UA.@%#DM@:5*"E!9*00E1%:8CZHCLX(!C,R6(CB]2<A^0U(>:1HSK(4
MW%>)4$E*=("B"I(-P4EU'N?L'&RTJKAK O9 N9QRN4E)O;=75@L>G\N'%BD8
MA<62LB71;W2R8ZR!E%!H@/L[=NMFBB2:>5/)KG7W*_6ZU/-L3%2MXN.],(C0
M)TT-1(ZVT/R7S#CO[EAI3J MQS2E(5D\*S[=8[A=&5OQ$QMVB0U$!DSH<,N2
MGT.+9CLB6^SO7G4MK*$(*E'21C-5G-J?L2N8_&I+-8ZO'QTK.SV,B4GSAIJ4
MU/5D79 9L+)"-5]B8AV$+$&S)9,FU:Y65RKAMZ;""V=,V-<(DMUYF,\'5L-Q
M7G"@**-U,;4[&6AS&AQ+K:2H%M2L#&K&1G$D0)41IEZ0T6D/N26FPHIU[R&X
M&I"%H!UH4VXH)(6!DYQG!QM5=5U+;6EC.$0<<F5DCX;)2[9DL^8C4U&$1C)B
M8'ELNR+AJTTRT  2;S1+=;55SNAJU;:*NED45*Y<MB"PJ3)66V4K9;4H)4LA
M;[S<=H:4!2CJ==0G.,)SJ40D$BB)$?G/IC1D!;RT/+2DJ2@%+#+C[IU+*4C2
MTTM0!.21I&20#Y UU+9+#)[/PXY-S%JSUB^TQ(;/F+=09K,2Z@*/Y29.'";T
MAZX33W0WPP0<Y:ZX],Z]"CG&^3LMAF1%BN+*7YF^Z.C2LA?1VPZ[E024HTH(
M/?E.KDG)X5#41]Z/)E-H!9A[G?JU)!1TAPMM822%*U+&#I!T\S@<:@_,FL>G
M%*[(_P!3'?\ 3(O+_-F,?[4ZOYY!V9OX/6S^V6_\#-KUGL0?O]<O[(7_ (V'
M7=YY\W5]#TXI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI
M3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.
M*4XI3BE.*4XI3BE.*5IW?]2.O^SK?]WMR4\Q\X^VH5R/S'[*_))W_H]O[[;^
M7//O!7,_.?MKX@K-;J[-:W>51V4ZX6'/V5/[7RRJDM$;3.#)"5AHR45')S)M
MI#+"2B(H]*!\+FK>1.%53PD">U!RF-Q1^2$*"TW;\=S=ZC3$SK/=XD55P[5K
MG(D06ELMR%L3V&VE28AD.-,+DQBT &G'6MZP\^A#@<*4KZ&SR(BH5WM,J4F!
MVS3"<8F.(=7'2]!><<3'E!A#CR8\@.DEQ#3N[>986I!0%*3D) K:HWJ'6@&H
MBTV@7:]2?=BX#9MQ@84(D9:K(?4L3K^TJQDD:CIRPXK$U2UK6%'+B..,'H\"
M6$0S,3BCMN>>GT]$@NJE0+E?ICL]N-*L0BVB5#M[LEQE$Z1/D2X,UEYUN(_(
M#<&(];V@6GG Y(W[Z2TEKBYM(TZVV*&W!7(C7LRKK%F7!J.VZY"8@L1IL-YE
MIR6RP5S9;,]P[UIHHC[EDAQ3H ;R&JZU.F0ZR[&A3.QJK8=>X4PBW7F+,9Q5
M44:&+GA;.NK*8'K[D$M(5#/I=MO(KA)YDC>*1XA #P=M,XL:*RAJ/K08W;ZJ
M;!VA7#AR5Q)R[M(6_=GU19SZF[=)5+A*;M3+";A%CX9MZ-SOWDRVG#&?:;94
MN8M1VL.9L^F7+C)EPDVN.EFUL)D0F0Y<(Z8DQ+MS>?7 DO>VSU[T,-+C.($A
MEQ;P3#; H<!V'ID;..N=>.5Z;WI0#UGSI:+[2H8FY>$+V84I<,<9/C,L?P;>
M?O2?NC/1MFCHW(IA-G7LLFX:8?H.R&-F[:;BN+=Y21<.V3MY)A)-P?2E%L7<
MK>\I+;")0B)1N6GE$J07=.M 5I*$#6M72WHDVJ(3;^U[5HQ,6(+!4NYIMT]I
M*UOKC=**RZZRD +#95H6I.L*55^1VUNHPB-=<7<ILJB9X;K T[>+KO:DBH['
MN3EW4TRU1BI*#AJ1"L7@F)78U'Q]V/L"2647*2 >I/GY)CB:;-W&J>@WYQZ[
MB/"N<5N:@)2$W!]?^D1[ZT2^B2Y<W5)7(MQ4\E<1F&VAE8BH2KHV1LV9MC0S
M:5/3+;)<ANE9*H3*/:'[(M.X5&;MS:5-L7!*6E(E/2W''4&2I:>D85@;?&8A
M>]5UU<PV:U:,LBN.O$3:WE'F,;1@QR=V*6[*W/#PB <7&(F)A9.5@*<VJHL;
MU378O'L.::DF_M5V#D.&'46L/VN;+MRXTU<.7=GS;'5/&4U&B(LUMD.EQQ^0
MY(0P[<>G-MG"DIDJ+:MV'&=7,W/H]RAQ9Z)$-$N):F!<6DLB,Y)EN7>>PV&T
M,L-QUO-0#"6Y@I4I@!0UJ;=T90R>RZ?E]"]3D-)IT[>8K.D:]B-ACY]&;'=]
MC1)<!=$TE)L!$B#2(/(8H*VCQH>LW0=ELHKZ$#Z"N^/3)XSI6(=PCW2^DQK^
MGIMRER(BXKT--H<;=MT9AMU]"I"9 6'6U@E+>04-$#@:W+TN"_;+*!(L"NB6
MZ*Q*1):E&[(<;N$AYQMA:6"QHW3B" IS!"G4GGBI$0[&=6Y;8KL]*W-)MW<7
M[-=VAU)'LTF!;PJ&5S+JJ;MNK$KFT.B%>82F=:1&X?5I,D*-QN6FABF3A9['
M#*;L@)+V46F]QXB6V$W%27[+LXNY-=LG3)D3(\XF]L1I$B9F-,D6_4R7&WF&
MUX:;0\T4(<;NJNMF?EJ=?5;TJ9O&T*;<[VO;$>/%?A 69^1'8BXD1&)X2\$.
M,ON()=<4TX%+0Y));=]7R5J#'-K\ZO..SH#KM2,0#7?.*N0E-)LTP5N]D)'<
M,*CXPI2)F/1N='0TPITNUE#FL&S=Z%#3:.MC38Q)%435J/;9K!<6;7>TV9R[
M7.0Y;8LTL7)1=@VAFWR'EMW)MYZ,TY'N"%,)FE277(SRFU-LC=WG[C#>#21<
M[,;PU:K<PW<9,,/VY.[G79V?':0NW.-,R7&Y$!:7C#2E3;<AI+B5NX<^03LC
MT[C%@1$?#TJ32K>4=LIXK<VI*C@+D*;J0IUYH>.'RD>&2J#D)!#:DEUS#;8D
MD%@H? 5]&V*PK"\?"N!S!%L=M&T#\20M\W'IK-CBBW:+FX'6IR+M<WFD/.,R
M4-2)\>W+@,R93F\2\L.$/.!:R8;NUA9E,)CBWB(]?))GZ[<TIMR"NU6UEQ;2
M'XRG6(+]P1.=C1D!M3*2C4VVI*,1BF^P/7"2"81)K +5''>R13J^:B7NZ?P>
M(06)@+# ]H)238,C>@FAK/@T<EYOKOJ&C\>FJ-4%=-8^U;1%X> .R29!G?N%
MJN[*Y+,1$]ZSIO;<@Q427Y+[L1VRL(4ILKND*4]':N^\>>BF<C+RE2$M.I;T
M*LP+I:7FXSTIR"U=EV=Q@R5QF([#4IJ\O+0ES1;)L=I]VU[MIJ0(2P&DICJ=
M:*PH3F.]ANOYE]1PI[.>K\*JJM?$9*6?<M8L*[>$@TKI^:2_JN2:$JS)%:("
MES,+#DHA<3R4"GC>![:0U@PC&L=>Q9.$1O&,]:;HVFYK3&O4F=,V01"MTU<M
M*'&)\>/?$*;F(;NCK;<EQ$BW)86E4K,A:WB\E_I+U9#5UMCB[:A4FSQH43:M
M<NX0TQ5+:?@/R+*M*XBU6UM3D="V)ZGD*$;$="6MTID1VJQYI&_JWGH%TI;4
MRIFLK %W]6&T#D"=#UFFU"U3$:/[;I9&(#F=:%8PFU=3V5UC$F\NEP*4/XL2
M?0>9$F!YG7+!(?MKE:YD5W$"/<)L1RU31):-TFE3LZ1=+"=X5JFMO%0B,37R
MQ'=80^A$F.A3:I:RO66ZYQ)+*NFR+?$E(ND/HSHML0);@L6V^#0$)AN,A)DO
MPV$O/MOJ84J.^I+J8B0BRKP(]?[V0G]/U3;U/1)U>5U=$[!0);M#(2#AC$-Z
M:W/&+YD,G7C]71 6(U0NHVLI(RPV#1P)NZF+>2[" (7)C0%AVU%UMAB3YT"X
M2!;+=M/%4@*:=E.-R-H;<_:VF [.?6X3;6P&6URGG=,<L[QUP-ES)N*K9<NE
M0(4Z P;C<-FY07A;<9MR/8)[-S=>4U#80C%Q<)=<1':;*GP]NVF]8;@G1*ZH
M77_7F;1Q:==68O9+#M%3=M1UCVKBM@2J(X 0N!66,?22.-(!$Y023E(<Z=!I
MM-TM6C[#%T1R/5P[]#MC(VFMTF5=XSPBWM^&NR7" \NQOQ6)&]DRH:TLNJE/
MLHW#C33I5G4G4E&L%.16/LW<(\6UR&C)LS,M%Y@3FDWIF4^QNH\:6A3S28S+
MR]^VZZV$GO2$J7I(.#61;/L'U(WF@4C!;I$#89"9OVDE0IC;D+:3&0S&.6%V
M ILNT%.Y%9U66^M&W4BA;::3/!9>*%[!E4;C;RNR3\6>F[]?;4*M-^Z.\B5;
MEKD28]D86JWR51V8[L2TW!M3B684VWA]+,DQHV[#[<1AYY,QM"VHJ!6V3=+'
MTAI<:X(1'C2+P\VF='2^Z^U)NL%Q+:G9D*>62['#[^M3#DEYEI45:D.R%D[;
M7=S]:*VDTJ;U1;=!5[!P\U[O:V*+=P$FXE]J1^P(Q-A775:L9FYJXR[2B(,&
M8!11I%&<IA>T>.,I&97'/64B;E75R7;KQ,885.@767)<C[-]$6);88@O17HS
MEV$V.)S8,AUQMU]4A3$G?-J9;"TK9*$TQ+A:(CSPA3K9%C-R=HNEH5%67YC4
MEF0BU&'(,):@PVVXVPEA+T?=.)=<*%(="S\P_8;JJ/@^HV136I"W64I(NBRK
M3K?%:]=!;6%1^MI1$278P;8+G6O0B\P+%'#67$RIM:QI2C-MWR3L>]:>G:M!
MDN6F]KE%;,>>W>4L[3!5X?EI<@N.S&9"+0N(GI;@CMH"HZ&VA#8,8)*5H5I4
MI=#=TLJ(^AV1!79W'MG%)M3,4MSD-1'F%W5$L]$:5(6LA];CAEO)D%04A:<I
M"(U9G8*B8ZZLN1C#76*96&QZ[6,)JZ7QF(#9IL4ES_L#UYD%=Z%8V1ZN4A78
M8[&(8,M!["$E8L;.@P.I&-2PFV&M8L#<W8=JN;PA,K;O4>(J[Q7)T=Z0N/HC
MIM-W:EZ'D7NYRW&GY*X29)#[;3KI0\PA2U/NIM3+I;6E2WD.6>1*3:I;<-]E
MA$C6^JYVMR+K:59K=%0ZRPB8N."RXZVT%-/K" RV>%J32$E+I&?E9G [!>2F
MB9\K@0&#QP5@B7>KD'OLV/QYB+ @V'K+A3U02%&CQ0Y#T;0>R;-4DD=/166D
M,--,-Z]VRVAI&\<<><T-I"$ZW7EN.NKP!J<=6MQ9RI:E*))\_>=6^\Z^YHWC
MSBW5[MMMI&MQ14K0TTE#3:<DZ4-H2A([U*0D 5V*_J8[_ID7E_FS&/\ :G5_
M/).S-_!ZV?VRW_@9M>J]B#]_KE_9"_\ &PZ[O//FZOH>G%*<4IQ2G%*<4IQ2
MG%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<
M4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2OFJGZ5)5
M+R^;Z1/=/SO)Y?)Y^N=?+Y/+CR^3R^7R>7'E_M\D'!!\!S4$9!'A&*ZD&WU+
M,KG;;..\Z>,9SG/D^QHVSY/+GR^3R_7_ ,>7^[Y,?W,<]X/9M!)/L9/'_? ]
M5UX?W&C\8QY(/K.O'O657X\Z?\6?;]O_ !W;1\6CY8'JNG<:/QC'D@^LZ>]9
M5?CSI_Q9]OV_\=VT?%H^6!ZKIW&C\8QY(/K.GO657X\Z?\6?;]O_ !W;1\6C
MY8'JNG<:/QC'D@^LZ>]95?CSI_Q9]OV_\=VT?%H^6!ZKIW&C\8QY(/K.GO65
M7X\Z?\6?;]O_ !W;1\6CY8'JNG<:/QC'D@^LZ>]95?CSI_Q9]OV_\=VT?%H^
M6!ZKIW&C\8QY(/K.GO657X\Z?\6?;]O_ !W;1\6CY8'JNG<:/QC'D@^LZ>]9
M5?CSI_Q9]OV_\=VT?%H^6!ZKIW&C\8QY(/K.GO657X\Z?\6?;]O_ !W;1\6C
MY8'JNG<:/QC'D@^LZQ8[;_4_JG5F#0":9[9Z3GW=7I4%+>S<45M&?9>;6EC>
M+^Z7US-Q2#UW 'UCU[V/ZJT]J>9ZM[4'^=Z?&ZL795%ZDRHXL1C=&MEPN.OM
MGOM?08ZG]SI[7M:=[IT;S4=&=6A>-)T6T'8T-BBQ)/;H2>E72WVW1VN+.CI[
MX8WVKI[NK=9U[O"=>-.M&=0RG]ZRJ_'G3_BS[?M_YI>[:/BT?+ ]5UO>XT?C
M&/)!]9T]ZRJ_'G3_ (L^W[?^.[:/BT?+ ]5T[C1^,8\D'UG3WK*K\>=/^+/M
M^W_CNVCXM'RP/5=.XT?C&/)!]9T]ZRJ_'G3_ (L^W[?^.[:/BT?+ ]5T[C1^
M,8\D'UG3WK*K\>=/^+/M^W_CNVCXM'RP/5=.XT?C&/)!]9T]ZRJ_'G3_ (L^
MW[?^.[:/BT?+ ]5T[C1^,8\D'UG3WK*K\>=/^+/M^W_CNVCXM'RP/5=.XT?C
M&/)!]9T]ZRJ_'G3_ (L^W[?^.[:/BT?+ ]5T[C1^,8\D'UG3WK*K\>=/^+/M
M^W_CNVCXM'RP/5=.XT?C&/)!]9T]ZRJ_'G3_ (L^W[?^.[:/BT?+ ]5T[C1^
M,8\D'UG7)-X8O@V[^')<DZMK;L7K<7NTK)W76 &M29K[V;ZW*8Q)<F,E,V9-
MO7/,]S>&6&'LYKYWKGK'KNOJ_H%N/VS[(0VNM\: +0;?T>:F7O3/Z5KTL/,[
MO=]#C:<[[5KUJQIQI.K(ZW8_8([*3Y,XW7I_2(AB[H0>BZ-3S+V\U]+D:L;K
M3IT)]UG5PP>;[GFU>B4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4X
MI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE
M.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE<6'B
MW_UC: _SZ>H'^U@=SM=A?WSNG_Y:O_\ @'*X7L@?O7:?_P T;/?X]%<I_.*K
MNJ<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4
MIQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G
M%*<4IQ2G%*<4JO9I;=4UN6A8"Q+-KV!';).Z1>NPLTFD;BQ:?2515H@G'86-
M.$F+R4G5%G[%'02#1?/]E7K1/5OG=RCC=3!\%3(46%GA@\T#)#S(8LS;D!98
M4\;$1A)@[2U7:OA[]FHLU>,W*.^BS=RW54162WU43WVTVQG*E:8?(X\6*G@8
ML\&)&XJX8-).''E&+PK''14<@8&-CP]NNH[#N"0ETU*,$2"+=1X.<H/6^JC9
M9-792M 4G$*!R>*P@U+XN(F<Z1/N(1$2D@$CY/,4(HU:/I2O%0#MVB5D*,:8
MOV+P^H(:/- [5ZT<$=FR+A'?=2I1Q2J1L'LSUOJ67AJ]M3L%2-9SZ1M!Q"/0
M>P;7@<,EYY@8)O HEZ&C4C/#311H4,#WXD<Y8LET7I-B\8-MU7399+14@$@D
M D#F0#@?/5OI%A:Y-Z%0)#UC(UF.(D1*3QNH3'CRZI%N)?/6&BF735F47#ET
M1SI=)-!ZJ+(IMMU=V+G5)45I0DCCTF1?N8X>#2!N+,F(X37"%&)5$=(8\_6%
M'P+]5@NXT9F091LX&F!;C9-\,?MUF;U!!PENGJI6\\4IQ2G%*XBB'BP@F#]\
MQS29=7+)XY:95Q.F>F%,MUMT<[XT]R^WFXW\SSO-\[;S?+Y/.SY/+SYS>_[0
MD5EYUH[+2%;IQ;>KMLV-6A13G':\XSC.,G'AK[4C?]C>XR8T>0-OH2-^PT]H
M]CSZM.];2O3J[;C.G5C.!G&<#E6C^VU@?@/+_+QE^JO+?W1$3XJR/*[?J^K_
M -QA<?Y0(7_+K_KBGVVL#\!Y?Y>,OU5X^Z(B?%61Y7;]7T^XPN/\H$+_ )=?
M]<4^VU@?@/+_ "\9?JKQ]T1$^*LCRNWZOI]QA<?Y0(7_ "Z_ZXI]MK _ >7^
M7C+]5>/NB(GQ5D>5V_5]/N,+C_*!"_Y=?]<4^VU@?@/+_+QE^JO'W1$3XJR/
M*[?J^GW&%Q_E A?\NO\ KBGVVL#\!Y?Y>,OU5X^Z(B?%61Y7;]7T^XPN/\H$
M+_EU_P!<4^VU@?@/+_+QE^JO'W1$3XJR/*[?J^GW&%Q_E A?\NO^N*?;:P/P
M'E_EXR_57C[HB)\59'E=OU?3[C"X_P H$+_EU_UQ3[;6!^ \O\O&7ZJ\?=$1
M/BK(\KM^KZ?<87'^4"%_RZ_ZXK$_N#W6&]HX'7D,95Z^ABD&ONFKH5(.I&W-
MZ$F]52YM)UX_HV2#C-FJQK1OEFD1V67T8[;87W9NL8]%G>6#_M/PK+*ER%;'
M2I DVNXVX(3>VFRA4Z.I@.DFV+R&RK448!5C 4GG6@VB_P"PM<[Y$AQD]DB!
M&,6ZVZY%:MF9#H6F!(#Y9"1>T:2Z!I"\D)YE*N598?;:P/P'E_EXR_57FC^Z
M(B?%61Y7;]7UO_N,+C_*!"_Y=?\ 7%/MM8'X#R_R\9?JKQ]T1$^*LCRNWZOI
M]QA<?Y0(7_+K_KBGVVL#\!Y?Y>,OU5X^Z(B?%61Y7;]7T^XPN/\ *!"_Y=?]
M<4^VU@?@/+_+QE^JO'W1$3XJR/*[?J^GW&%Q_E A?\NO^N*?;:P/P'E_EXR_
M57C[HB)\59'E=OU?3[C"X_R@0O\ EU_UQ3[;6!^ \O\ +QE^JO'W1$3XJR/*
M[?J^GW&%Q_E A?\ +K_KBGVVL#\!Y?Y>,OU5X^Z(B?%61Y7;]7T^XPN/\H$+
M_EU_UQ3[;6!^ \O\O&7ZJ\?=$1/BK(\KM^KZ?<87'^4"%_RZ_P"N*?;:P/P'
ME_EXR_57C[HB)\59'E=OU?3[C"X_R@0O^77_ %Q3[;6!^ \O\O&7ZJ\?=$1/
MBK(\KM^KZ?<87'^4"%_RZ_ZXK*CJOW-'=GI!*@+* /8=O%PS,ONY=2) UJ\U
M>/<LL(:))"!N4-D\X])E3.ZN-L?N?,QG[O._V [)C.W<RX1&K.[;3 C-22MR
M:F4'0ZZ6M 2F,QH(QG)*L\L#G7D'9?[!4KL2VRSW)_:1B^)NTY^$EIFV.0"P
M68^_+A6N;*#@4.]TA*"#QU'E6;//4:\#IQ2G%*T[QXT'M'3]^Z;L6+%NN\>O
M7BZ39HS:-DMEG+ITY6VT1;MVZ.FZJZZN^B226FRBFVNFN<X4JOJYN:G[A&(&
MZDM:MK2#.D73AL7KF=1>;C'+=B_4%/5T'\9*$VJR+,HBL-=*IJ[:-WZ2C-;;
M1QILGA4D$'!!!\!X&I@:D<>C:8Y61'@P!(P9%QP0H:*,12920FW.K,*!';OE
MT-7QDN\VU:BQ;;*KY^YVU0:(*JYQKE45K2)$>('OBQ9\S%BA;-T1)DR+I!D/
M'#V2&[EZ^?/7.Z39HS:-DE'#ITX430;H)[JJ[Z)Z;;84K;XQ)XU-HX F,-D(
M.6Q&5AADCB\JC!9@>CDDCQIFB1#'0!P4X=C# 8L/<MWXPH.=.6+]FNBZ:KJH
M*Z;[*5H9M.H36D6,3FQYC%:_A,>02='YA-I"(BD6!MEW*#)%P8D!UXP$C$%G
MCILT26>NT$U'+A!#3;*JJ>FRG/E45@EZTC:417L"LKCJNQ8&U-IQES-H)841
MET1;R1588W2CZ\DCY<@&1-JN#09!,2H]U?[K%AB6K?.[]KJJJ2".!!!\!&*G
M9"1QX24 @RAX*--RIP_9Q<.0*,6922.Q0YP8)M0(]RNF[,.!PAHZ*/T!Z+A5
MF.;.'SC5-LBHKJJ*WGBE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE
M.*4XI3BE.*4XI3BE.*4XI3BE1B736(0$/M()O)@<3!Z.4&>2L@)-!3#UMSG;
M#=MAR\523V<+>9OE-'7;*FVJ:FV-?-TWSC!N-TMUHC&9=)T6WQ0M#9D3'VX[
M.\7G0C>.J2G6K!TISD@$@8!K;66PWK:.<+;8+5<+S<%-./"';8CTR3N6@"ZZ
M6F$+6&V]2=2R E)4D$Y4 :K^RFZW?#E5WRS!_P \YH/9[L5\:[!Y4B>EKK^Y
M%V4OY/MK_(-Q]!3[*;K=\.57?+,'_/./9[L5\:[!Y4B>EIW(NRE_)]M?Y!N/
MH*P'[2Y@]S7?0-P53VVZ^U29IG!MJYEZA\H_FQB)R-^++S.K'XYI,6\!E-=V
M$0B< =/$91&ESL!D,0'S>&E-CJ;1!H]GNQ7QKL'E2)Z6I'8B[*/'/8]VO.?]
MPW']G^7J_#PKCCLRH[3I>GU7]*=]75SSUG"J_J]&!#NSTUA 0G'XT4Z* T2B
M^Q>UD!D4;I07K3>Z<R.0$6E9DJ)]EI2OJ1=*Y(.]WL]V)^-=@\J1/2U6.Q'V
M4#P/8\VN',_O!</]H_>X',@ <A@>"IY3O79T&*5!8RGB0FJN7<G:ZL:V*\6[
M #97/E9!&:)ZC5PR'V59*"IR+7G)PCOK]/14OU+A](%+=;>ECX'@8$<$ ,A@
M;>[%?&NP<?\ >D3A_P#NU![$?91XCN>[79\(L%QQS5R]HX#!X8QR'RU-+5Z]
M.K"MX%?"WBD0&1VE5X:0PNG)-,!U9!B(:*2FC;_K\V8-+U6+@(T=,WTYOOVP
MZ5A(&/""47J2IM#3<K+XUI(N3[/=BOC78/*D3TM1W(^RCQ'<\VNP>H6&Y>$'
MAE@GJZ\GB<$9KS(.LT>W.E'4,\4>61\*CC9I$VI#MI?YU^+9Z0FAA[=V86)7
M0[;GRWUR8I>=C+JDTG;93:=PB,[);QR)9&YCV>[$_&NP>58GIO\ /#P"G<C[
M*7\GNUV?[ N'A.>4?AU#_P#FL]KQE%-6A;]/6E'.TE.1O>G:W[(" 3)W)&#E
MSFS+@C$,B4(F"3EL31T080T0/FZ9%MC39Z^VD3/#)9OJW<^EGV>[%?&NP>5(
MGI:@=B+LI8([GNU_''_W#<>K_P#Q_P#/@KC>F?5=1Q%LQ*O_ !3L@V#^*P6)
M'21WL;=[^8OW,8J\P%=3W>PFUPZ3AT;:VO,I_8@&$/#F]=8W.QU$B%41@<=&
MZ/9[L5\:[!Y4A^EJ>Y)V4LY/8\VN_!L_< /Q='(_-^'GGE.ZS6!U]HBL'L*,
M=CJCDITU;78"VCQQC*!3)N\+7K>]C70Z;IH.2*R^- V)XF 1V44SC9 4EE+5
M)#T2*;V>[%?&NP>5(GI:@]B+LI'_ /M[M?R _>&X]0 ^ ZZR ^RFZW?#E5WR
MS!_SSCV>[%?&NP>5(GI:CN1=E+^3[:_R#<?04^RFZW?#E5WRS!_SSCV>[%?&
MNP>5(GI:=R+LI?R?;7^0;CZ"GV4W6[X<JN^68/\ GG'L]V*^-=@\J1/2T[D7
M92_D^VO\@W'T%=5XXJFN;,+([ZJHK%""J2FFV-M%$U':V^F^FV/+C;7?7.-M
M=L9\F<9QG'/@26I*Y4E22%)5(>4E0.0I)<400>L$$$'P5^O]N0INWP6UI4A:
M(<9"T*!2I*DLH2I*@>(4D@@@\01@UM?,>LRG%*<4IQ2LDJAHV/RZ"RRWK-G2
ME>U9$3+"+[$1P)632*2RPBWT>)1X"*T=LD=%&[%5%\^?/''HFZ*R6=4%$L.W
M#+MMG-E(=QM5PVCOMU-FL%NDLP"\S$5.FS;@\E+B8<2,'&D@H:4EUUUU82A*
MDD(4D.*:\LVV[(5RLNT-FV)V3V>3M-MA>H,B[)C2K@FU6NU6:,XIA=SN,Q3+
MZU(=D-N1V([#>MQQ"P7$++#4B033J\[78UW*:(//;BAUH/S@./>:"VCLK&R:
M.,W1(M'305R\<(ZN$QC%Z0:/&SO*+ULR=*:HI)>IK/LRY[!NK:LL_9*6[M);
M;\]*BPL13#N#$Z$VX_(A2HJW5IUI8:=>;=;<TNH:<4$)3NE.ZRP]EQEN1M/:
M.R);H^P][V1C6^X7,FX"Z6>5:;H^S%AW.!/98;66E2Y$>,\PZSK8=?:2IQ2]
M^W'JUQU_NAK)(U$5JVE'NCF#-P0C8I)AZ=<HS9;;Z$5D]T-U$$/9.Z>^IE-T
ML@J&VUS@IHTSY/+H5['[3MS8-N79)XFW)I;T*.&2I3[;1(>4"DE".CD$20XI
M"HW_ )@-Y%=>UV2M@WK7=;TC:JT=J[&^U&NDQ4C=MQ'WP%14*2XE#KG3 H&"
MIE#B)P.8BGJ^K3KW<[X^<C#2OS*QB-IBU#B>%!^K$;@YC7V*FN8W>ZALKF,[
M8U%-DW^[@BIJHFS26424UUJ;V.VF=F2H#=GDJDPDL*E)U,AID2L=%"I)=$8K
MDDXCH2\5OD*2TE92H"A[LF["1[;;[L]M+!1"NJY:+>HIE&1*-OST]3<%,<SM
MW! S,=5&2U%24J?6VE22;SJ/J1B85Y.I_.7EABG$(FZD#*0.!5_[L)X'?-AS
M9^_.2 "\,A'C(,QRZU;*HMD'+W=1%TIYJ23?;;/5[.=COME9KM>+J[>8Z[5=
M%6E^TVFS]LKM&>0RAYV5,AN28KK49DN!M2$(6Z5(</>I037GNVO9I-DVFV>V
M;V>8V9F-7^P(VBB;1;1[2=I-G9T=V2[&CV^VW%B#/8?G2-R74..N-1TI<91W
MZW0!4Q"D'#\)&G==:S6=DY78\[A<>T2A2@M@?&135HNP+#<;%7I%$B[8*+D3
M(=ZT3P ;Z;X=O?1M=W#GGGME5O183EE%UNS]PO=VM<,)M9CLRV+>&U,R& 9#
MKZ7W&E+>DQG6DB&@*#KN&RMSLXW9 ;C7"ZL;3FP[.Q+-LML]?KFI=^1,DVZ7
M>"\B3#E%,1B*Y%8D);BP9K#RC<75)++&I]+37Q5ZP7XBY2:;5C(-G"X;>1))
MHY'.,;@4WC5@H9\]N^53U&)NGK?11[MOAOIIMNONIA!!=1.A6PFUR5I;-BF%
M:HJIJ0DLK!AI<;:5)U(=4D,)6X@*=)" "5$A"5J3<1V6^QPMI;PVLMH;;G)M
MBU."4T4W%3+TA,'2Y'0LRU-1W5)8"2XI24MA)<<;0K0,.N=W$I,=AS.N#^\D
MC2@Q(T-5U9MMFBQMNJ["(:NG3M%D[7,M$%G(A%DY<JDVZ*JS'1=-/?;6TSL7
MM2_.EVUNRS#-@J83)84&FRVN4VIV*@+<<2TXN2TA3D=#2UJ?0E2V@M*21D2.
MRAL!$M-NOC^U-M3:[JF6N!*07W@^W;W4,3W%,LLN/L-P7G$,S5R&FD1'5H;D
M%M:D@ZUGULN!]7[FQT8FZU!MI0_B>[5SNDS+X(",K(&5=ASO=!;1N,))ZB''
MG8PXV)[+-DD-\LW6R5UK8C:1VS+O:;<X(C<]ZWJ;64MR=]'U)DJ+#A2L(8>2
M(R\X67RI"4'=N%.._P!E78B/M*SLLY>63/>M$>\I>:2MZ"8TW0Y!0)3*7&U.
MRXJE3F\>UIB!#JW$[]D+C>*2M?+]^,Q!S67XN:B:Z(-?,;^D:S<[OMH(CBO_
M  _FX(/]]-M4-<;92SG'[I77[G,'V+;0[UUCM5*WS%TCV5YO"-3=UEY$>$KO
M\;Y[!T $I\*A6U.W^QHCQI9V@@=&EV&9M/&>U.Z'K!;P#-NB/:\]&C!0+A("
MQG@@UO\ MUJO=)TW9N*RDC-9R+<FM-R"34>U3%-26!&[YV^?.F[)@@L2VT:L
M=GKAODENJAL/PZ371WWRSL1M8EQ#2[%-:4MA<D%Y+;+:8[;XC%UQYUQ#32%/
MD-M%U:-^5(+.\2M).N'96[':V79#6UEK?;:F-0%",IZ2\N8]%,U,=F/'9<D2
M'$10IZ0([3HBI0X)):4VM*:@-!2\<+$0)X:]#FA#Q<>4%DFRK1^P>M5-DG#5
MTV6UT51624USKOIOKC.,X\O[V<9YSDJ+)A2'HDQAV-*C.+9D1WT*:>9=02E;
M;C:P%(4D@@@@&NV@3X5TA1;C;I4>= FL-R8DR*ZA^/)CNI"VWF76RI#C:TD%
M*DDC\-;9RQ673BE.*4XI7)?X:-D0"MYU9CZ?S*-PUF2B8EH/=2,NS$H/7*1C
M995!LH\52U6532_X3?33.=M=/W6<8QSW'L'7NT62ZWUV[W.%;&G[?&;9<G26
MHR'7$R2I2$*=4D*4$]\4@DXX\J^4_P#M6;+;2;4[/;*1]F['=;X_%O,QZ2S:
MH4B:XPTN#H2XZF.A9;0I?>I4H %7 <:YAOLINMWPY5=\LP?\\Y])>SW8KXUV
M#RI$]+7Q!W(NRE_)]M?Y!N/H*?93=;OARJ[Y9@_YYQ[/=BOC78/*D3TM.Y%V
M4OY/MK_(-Q]!3[*;K=\.57?+,'_/./9[L5\:[!Y4B>EIW(NRE_)]M?Y!N/H*
MKNWKTZZV+5=CU^WN:@R6TYA$GB"HR=2-(K#"K22!G@=\*E(\#(@)MT")LGCA
M@3T%&![_ %:.%=VKC"NFNNSV>[%?&NP>5(GI:#L1=E($'N?;7\/]PW']GKA[
M'=:"GN/$1@IXH$3;:!X:-AXS6*VW8L7?B $=3[I$8?%%9R"L45/9:,CA6Z^K
M@!])I,:6E,WB/6I?27*O7<G:-Q;V>[$_&NP>5(GI:J[D?91S_P#T\VN\@7#Y
M,G!CD=1X<ADXJF:^K.U[9M6Y,W!W#*5DTAMA)O*0MZ8=EQ5K#"XB/P;LM"(-
M,HM32<Y) 8;8D<G$DHRX<2%5V@R,Q0$/B3]F+GR,V>NGL]V)^-=@\J1/2U)[
M$791 &.Q[M<<CB!8;C\G#_P^?#^'CG@*RQQ3#DIUN^Q]D?BM[E 4W8[1"W0T
MLE=;6H/?04Y/]I'/](S/)A#VENO#<NA&B]8IBY/,7,$#1F1F_119XZ9CE]WL
M]V*^-=@\J1/2U'<C[*.<]SS:[GG]X;EX.7[AC&>/+/RU#81UACL9@X6'OO$H
M%ZIQ!"KX)#VT%O2T*LBXZFZSF$]F2L>VAM=6=&8VUEDW<%*] 265CQJ)5K$H
MD_C(8@T"%W ]9[/=BOC78/*D/TM.Y'V4>/\ ]GNU_+KL%Q/$\,\8^?EP<\?Q
MC+?KDG$J0H*Z:LDG?>-6Q-; 9,,0J=V%;,CG#F'ED>M%35,7>J/9Q,9$?]3D
M5OPJ;W,^#"R;(0/=6 \&!F#'"&VRCV>[%?&NP>5(GI:@]B/LHG![GNUP\.+!
M<0"<D\@QX,#\%4PZH^K=!E4QZ/=]XW%8S3%3] JC@4;C]LRH1#A@CJ;:#V?6
MT9(UV)G(^!2DW>(-E"H#EW*019P$B\9V':NL-2+M%9[/=BOC78/*D3TM3W(^
MRE_)[M=DDDGM!<>L</\ R_#!R?PUH^H]2A*:M:!VE>_B!5]>#^%-;%<80,6G
M-Y6LYELSJ3KK6^TM&NK,GDJ4C6YHY +UG$BCD?\ 9\9&N;:#Q^*C1P6->B6>
MSW8KXUV#RI$]+0]B/LHGEV/=KQ_^@W#PD]4<<<$#//AX#BN6O[*;K=\.57?+
M,'_/./9[L5\:[!Y4B>EJGN1=E+^3[:_R#<?05J679KKP1>-1[&ZZR=/7SE!F
MS;(S$'LJX=.5=46Z"6OKGEV465WT3TUQ]W;;;&,?=SRMO;G8UYQMIK:BQ..N
MK0VVA-SB%2W%J"4(2-[Q4I1  ZR<5:?[%'9,C,O29&P6UK+$=IQ]YU=BN*4-
M--(+CCBU%C 2A"5*4>H FKRYU5>?TXI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*
M4XI3BE.*4XI3BE.*4XI3BE.*4XI6(7<ALV>Q6F6;QN@[:.^S-)MG35RDFNV<
MMEY"LDNW<(*Z[I+(+);[)JI*:[)J)[;:;ZYUSG&?..R6A#EOV9;<0EQMS;G9
M=#C:TA:%H5,6E2%I4"E25))"DD$$$@@@U[7V#W76+OMV^PXXR\SV*-OG67FE
MJ;=:=;M:%MN-N((6AQ"P%(6DA25 *200#60GUL*T^#R#?)(!]'\['M!8O$MI
M\G0_0UYI[+-JOC-M!Y9N/[33ZV%:?!Y!ODD ^C^.T%B\2VGR=#]#3V6;5?&;
M:#RS<?VFGUL*T^#R#?)(!]'\=H+%XEM/DZ'Z&GLLVJ^,VT'EFX_M-/K85I\'
MD&^20#Z/X[06+Q+:?)T/T-/99M5\9MH/+-Q_::?6PK3X/(-\D@'T?QV@L7B6
MT^3H?H:>RS:KXS;0>6;C^TT^MA6GP>0;Y) /H_CM!8O$MI\G0_0T]EFU7QFV
M@\LW']II];"M/@\@WR2 ?1_':"Q>);3Y.A^AI[+-JOC-M!Y9N/[33ZV%:?!Y
M!ODD ^C^.T%B\2VGR=#]#3V6;5?&;:#RS<?VFGUL*T^#R#?)(!]'\=H+%XEM
M/DZ'Z&GLLVJ^,VT'EFX_M-/K85I\'D&^20#Z/X[06+Q+:?)T/T-/99M5\9MH
M/+-Q_::?6PK3X/(-\D@'T?QV@L7B6T^3H?H:>RS:KXS;0>6;C^TT^MA6GP>0
M;Y) /H_CM!8O$MI\G0_0T]EFU7QFV@\LW']II];"M/@\@WR2 ?1_':"Q>);3
MY.A^AI[+-JOC-M!Y9N/[374>/ZZZ'36FFNNFFA8EKIIKC&NNNNKQ;&NNNN,8
MQKKKC&,8QC&,8QCR8QY.?G;, $N4   )#X  P  ZK  '  =0K]H[:2JW6]2B
M2HPHI)))))8;)))XDD\23Q)K:>8]9M.*4XI3BE9(5#>@2'0>5U)9,$Q8]5RX
MPQDRHAH><1@_'I6.13:(2$ :;M7NNJRS)%%F^9.FNR3M%!%/TZ*&SQ![VVSF
MUD6V6JX;.WNTB]V"XR6IRH[<M<&9#N#* VF9#E(;= 4II*6W6G&REQ*$@+0D
MNH=\MVV['EPOFT%FVTV5VB.R^V%D@R+4B:];F[M;;G9Y+BWG+9<H#CS!+:'W
M''H[[+H6RXXM>[6XEAQBW0G<8'#I;3Z<$JW:,U-3Q"6&V$+]U2Q.0R:1RR.F
M #R0GI4\&9U]:0T+;[M&J S*+5#9RTT541V9ZL>CB=DJ+;+CLVFTV P=GMFW
MKC*9MAN"GYDZ;<84F&Y,ESW(Y&\0))4VVA@I;05M!126]UQ,_L'7"^6;;=>T
M6UZ;MMGMQ&LT"1?>TZ(ELM-KLUT@W)FV6ZSLR\[EPPDI>><EA;S@:>4A+@?5
M(C]>]L6L*B590M[!ES8>*P6[:YF&Z<CR,(R&.W/(&)QXX /DQ;E2.%PN6"*:
M+I34GAYY5M<89^F](GAV;LA(M=NL5L=M2I4:WVG:BRW(B;N'ID+::8U*<5#=
M$=:H,B*64I2X0_O,K #>K(V6TW89>OUZVLOS&T+<";>-H=@-J+&E=KZ7%MES
MV$MDBWLM7*.J6TFZ0IXDK4ME"HA8P@DO[O2N/QZ[:L QF6U?BOYVXJTY*HE.
M1FN9\$1G;.21=LJV7P1.(0=$,^#F4EMTO44 31</G71TV>/''G9SAP]J;!$@
M7*PBSW9=AEW"W75@&[Q479J; 0I"@]*1:DQG8TE*BG=(B-+C'#B'75ULKGL!
MMA<;M9=KCM+LZUM=;[/>MGY9]CD]>SK]JN[J76^BV]S:!<Z/-@+0%](<N#[<
MX%3+K##>*L.,]PHXVM:67+)*^E[6;'9II*6KJO+2?Q%@Y",AP<>+@,N$J@B8
M^2 D=1.R[U_Z!B\?K$R/I6WH=FR+?<P>R3"1M!<-I9UGN3=TEW--P;79K^];
M67(K+,5F/:+C'5$?9FQ$B,5//:&G'E/O:FRDH2CF;MV$+H[L=9MAK5M+9'K!
M;K$JT/,[3;(1[U)9N$B5.E3-H[+-1<(LFUW!PS0VQ&#C[$=N)&T/:PZMR<U9
MV?$V!9T!3E&@2MFPRU+CM(X2<EAC>/G6-@@U4'5>8R<;,PXW)ENFL$7.R HT
M8+;D5'JRPYSA+?FUV?V\CWB^VA,],2R-L;0;27^4^N0PB'+:O$1:5V8=+;;C
M,F4D*BKE3)#;*R\IQ2F7-)//;8=B2;LULGM&NT&?M4[+V/V(V/M\5J%+=N5O
M?V;N+;C6TQ%O=?G21 =*)[=OML-^0VF,EA")+6M-:.[;@C,):G(_'BXR5,[#
MHG2LF,2CY6$*LJ79CYJH8:C%3->OI-%I3DFGHZ(*ZM36Q1/+_P A5UKMZ%JG
M;VIVD@6MN7#A2&+@W>MDTV)JW0Y%K4ULPTS<U26V#)LSL^!/WX#CY"):I WW
M^D.#O&Q?V!V(NU^>M]RN<*5:']F.R&=K)-ZN</:!$C;M^38407I:(.TT>U7B
MT=$46HZ5.P$PU]'_ -#9(WCRHZ&[B0AG,])V4I]8A(Q@VFF4>+:2 &J1%XJY
MJ@T+-D%SL-.MQ[67:H)Y=/@K0;(FC750<V-I:.=G2.#&[)-K;N:;K(V;4],8
M8V99AR!,BJ?CBPMH;D(0N5;92&F[B$)WCD9MB8VV%,HE)"RXG:3>P=M ]8E;
M/1-MVXUKERMN7[G#5;;@B+,]ESKCT-UQ%OOEO=DNV93BMU'G/2K6^\4RG8"U
M-!E<-DO9:$22/RD,M7<E06VNZ07E 7FLV&[:BY%)6[+5^,E:&(?I[:#(/VJI
M!H@*4"/<(K-QBQ%3+18B0UT[;BU385PBJLTY*SM5,VKM#@NC!#$R:AH.L7!/
M:T=*C(=;4\VB.8KNA2&%/DMJ?=WEJ[%.T%KN5GGHVGM+B!L!;>Q]M&R;!*!F
M6RU.OF/+L[G;L] G.1741GG):9[&\0[+1%2'FXT:<E.Y<-W-.SH.K9"Q>G;[
MKV^9)[3G+$DBL4ARF57T>#IMXB-RP'/<YVPR=.]R+I#?=95QZ9/9!JVVDCLF
M6U4I<N+8)C3LK:ZS;6S=_=FGTKD6W)=AQDHMS&Y8=/!IQPON()4I>L%+:.?A
M]@N^I@,VZX;76R0Q;^QUM-V.[7T39^1%6W$O@"8]RFJ=O4KI,I@ &0RR(S+B
M4H0UNU!QYV!0SM<X#&[WWD@0N8 7F=;GW>[4J&7DD7?"I$3.A/4%Y3&Y-'RC
M1%(FJ+>L7X+1/=%-LX'+#5VJ>-M1;>R J-*VM,Z)(DQ-JY:)CA;D1ESH#L>8
M_+BAI=P@SH<AM*7U,.M/1 "@(6RIA2$UT=][#;<ZW]CM-JGP85R['UN<MK*7
MH<YNU7>/,MD2WS^DMVBZVJY1'EKB(EL2(]P4I*UNM242D.J*<=[.FRUBSH_,
ME]C&ZAE5EG*D@(CRII71@,9"TE2) 2$C@UPY529:*;^I!!Z"6-L(Z([83]*I
MQM]NBKU=IES49),I31S,>9D22EEAIA*GWH\6$RMPI:!):BLH&=(1@9/IVR5@
M1LOL];K$V(*4P42!IML63#@(5)ER):T18TR?=)332%R%)3OY\EQ>"M2QJT)@
M7-171TXI3BE.*5RE^%K'(](I_::$@!!CJ+:'AU6Z)D6Q*)(*[FLZ;*(IO4%]
M$E-M/W.V^F-=LZ_N<YSC[G/>^P)!A3;O?TS8<66ENVQE(3*CM2$H491!4@.H
M6$DC@2 "1P-?(?\ VO+G<K9LUL@Y;;A.M[CM\FH=7!ER(BW$"!J"'%1W&U+2
M%<0E1(!X@9KFL^MA6GP>0;Y) /H_GT_V@L7B6T^3H?H:^"_99M5\9MH/+-Q_
M::?6PK3X/(-\D@'T?QV@L7B6T^3H?H:>RS:KXS;0>6;C^TT^MA6GP>0;Y) /
MH_CM!8O$MI\G0_0T]EFU7QFV@\LW']II];"M/@\@WR2 ?1_':"Q>);3Y.A^A
MI[+-JOC-M!Y9N/[33ZV%:?!Y!ODD ^C^.T%B\2VGR=#]#3V6;5?&;:#RS<?V
MFGUL*T^#R#?)(!]'\=H+%XEM/DZ'Z&GLLVJ^,VT'EFX_M-/K85I\'D&^20#Z
M/X[06+Q+:?)T/T-/99M5\9MH/+-Q_::?6PK3X/(-\D@'T?QV@L7B6T^3H?H:
M>RS:KXS;0>6;C^TT^MA6GP>0;Y) /H_CM!8O$MI\G0_0T]EFU7QFV@\LW']I
MI];"M/@\@WR2 ?1_':"Q>);3Y.A^AI[+-JOC-M!Y9N/[33ZV%:?!Y!ODD ^C
M^.T%B\2VGR=#]#3V6;5?&;:#RS<?VFGUL*T^#R#?)(!]'\=H+%XEM/DZ'Z&G
MLLVJ^,VT'EFX_M-8L=QH-"0E+9(A8?%A!!&PZIU2?BX^)8/$M5;$CB2NJ;IH
MT27TU53VV34QKOC&^FVVFV,ZYSC/ ]DFTVJ)LQOXMLM\9Y-YV?"7H\.,RZD*
MO,)*@'&VTK 4DD* /$$@\*]?[!VT%^G[=]%G7N[S8R]F-L2N/+N4V2PLHV9N
M:T%33SRVU%"P%))22E0"A@@&LX.>J5X!3BE.*4XI3BE.*4XI3BE.*4XI3BE.
M*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE8.]X2\G%@J3V!0U[+&VM_UD34U&.]
M$GJ9@.:U=A@^S=1!1/T,EVV<L$2BBR* U^BT1<).,$T]F_E?94D3F(FRYB6U
MVX(&U]C?(CN .B3'E!R-&*%)(TSB7&DOJ4E#+R6D+2O?I*/H#L 0K1,N&WPN
M-\CV5U78VVLB),ME2V%09T LSIP<0XE6\M0#4E<1*%N2XSC[C:VC$4'<VVN7
M.S9OL\T12>;((Y=)ME-UFZ;G*>N5]$%E$D5%4=%?.U24412WWTQKMNDGMG.F
M/46RLH07 E+A0DN)0HJ0E>!K"%*2E2DA60E12DD8)2"<#P-T-!UP,*<6R'%A
ME3J$MNJ:"CNU.(0MQ*'"C!6A+BTI42 M0 4?ORNK=.*4XI3BE.*4XI3BE.*4
MXI3BE.*4XI7$,1\-VH'A!\[4FEDZJ.GCESOKH]C&--=UU]U=M=,;1?;;&N-M
MLXU\NV<^3R>7.<_=Y\WO]A79UQYYPW.] N.N+(#D' *EE1 S!)QD\,DU]K1O
M^U)MLQ&CL(L6RI2RPTTDJCW<J*6VTH!5B[@9( )P ,\@.5:/[6K3OXZV7^>Q
M;]5N6NXELYXTO?TL#]AJ_P#=4[<>(=E/J]W]<4^UJT[^.ME_GL6_5;CN);.>
M-+W]+ _8:?=4[<>(=E/J]W]<4^UJT[^.ME_GL6_5;CN);.>-+W]+ _8:?=4[
M<>(=E/J]W]<4^UJT[^.ME_GL6_5;CN);.>-+W]+ _8:?=4[<>(=E/J]W]<4^
MUJT[^.ME_GL6_5;CN);.>-+W]+ _8:?=4[<>(=E/J]W]<4^UJT[^.ME_GL6_
M5;CN);.>-+W]+ _8:?=4[<>(=E/J]W]<4^UJT[^.ME_GL6_5;CN);.>-+W]+
M _8:?=4[<>(=E/J]W]<4^UJT[^.ME_GL6_5;CN);.>-+W]+ _8:?=4[<>(=E
M/J]W]<4^UJT[^.ME_GL6_5;CN);.>-+W]+ _8:?=4[<>(=E/J]W]<4^UJT[^
M.ME_GL6_5;CN);.>-+W]+ _8:?=4[<>(=E/J]W]<4^UJT[^.ME_GL6_5;CN)
M;.>-+W]+ _8:?=4[<>(=E/J]W]<4^UJT[^.ME_GL6_5;CN);.>-+W]+ _8:?
M=4[<>(=E/J]W]<4^UJT[^.ME_GL6_5;CN);.>-+W]+ _8:?=4[<>(=E/J]W]
M<4^UJT[^.ME_GL6_5;CN);.>-+W]+ _8:?=4[<>(=E/J]W]<4^UJT[^.ME_G
ML6_5;CN);.>-+W]+ _8:?=4[<>(=E/J]W]<4^UJT[^.ME_GL6_5;CN);.>-+
MW]+ _8:?=4[<>(=E/J]W]<4^UJT[^.ME_GL6_5;CN);.>-+W]+ _8:?=4[<>
M(=E/J]W]<4^UJT[^.ME_GL6_5;CN);.>-+W]+ _8:?=4[<>(=E/J]W]<4^UJ
MT[^.ME_GL6_5;CN);.>-+W]+ _8:?=4[<>(=E/J]W]<4^UJT[^.ME_GL6_5;
MCN);.>-+W]+ _8:?=4[<>(=E/J]W]<5E5U6ZKPCK[()69BAZ5%W$A#,ACM.0
MN!"R**+9[EUINWP-$#5,*[*9\W;*BBFGF?<QIC/[KGH/8^V"M>R$RXR8$N?)
M7,C-,.)F+CJ2E+;I<!0&8[)"B>!U%0QR&>->/]F#LP;0=DJV6>#>+=9X35MG
M/RV5VQJ:VXMQV/N5)=,J=*24!/$!"4*U<U$<*S;YZI7@5.*4XI3BE.*4XI3B
ME.*4XI3BE.*4XI6$W?8D?'4FRP'B[V2M'5AUYJ1]EJ^4@.6:3$*1%;:LLH[:
MNFY9ZSP!UVU7361*DQ&NJ*Z*[C=OY=V6WY;.R[71H#LYM=YLV^W"LO,J:N45
MZ/AK2=XB0ZWT0$*"DR'XX"5)6LH][_[.D6VR=O9'3;O'M3S6S.TW1NEHQ&DH
M?L<^-,"GPL%EV&P]VQ*2VI#D.)-)<;<;:2[F2*6(.18YP69(C2CADU7(CF[K
MU] >^51T4=,4GWH6_KJ;1;;=OJ\PW;X=83]/ANAA3"6GI<=3RV&5R&DL/K:;
M4\RAS?)9=4@%QI+VE&]2VLE ="$!P)UA"<Z1X;,1&:ER6X3ZY41N0\W%E.,]
M'<DQT.*2S(7'UN&.IYL)=4P7'2R5;LN.%.M6X<O5C4XI3BE.*4XI3BE.*4XI
M3BE.*4XI7Y8A'M)V83(/M-.PUW:Z:/'6FFN+4G&,:ZZK[XUUQCVY]S&,8QC'
M_P"7/MU-FL^!_P!U6WD/_(Q?!_15\:.7F[[Q?_>MR'?JX"=* ]T>K>\*T?V4
M_9KXP]W_ #J3CZ<Y/::S^*K;]1B^BJCMS>/&MR^O2O2UF6 K?Q&9)U!DG=H;
M>MFYIR,2!Z%<L5KLGZ<\)#11F-1LU- D8U=[Z$H4"DDL% 39I,EKN,(^M>M,
M]&K?+K;GG9VR;-_9V;7;8?;!YI+@4+;$Z*A;C;[S<=U\I&B2ZS'6ZTWH(6G2
M$J*CI&_:B;5O6)[:%%RF] 9=4VI)N4L25H0XRRY(;9U'7';>>0TXX%]XO5E.
ME)55FM.M7B-DJ0&W<([9*EDBU &NS[*K6O9.PV]O+TG&72S233-"+$T6 QVV
MC^[=?8@U92%R[V]%E%BB\=J(ME<-5ZV31<EVURQALHNK5E5-59X9@"Y/I"F(
MY?05K2701H4II*1G*RE.2,Q-HVK7;D7%N^*<#EL<O"82;Q+$\V]DD/2 PO2A
M26L'4$NJ5PPD*40#O;'IGXNIB9];H@ L6X)"V[25T%M&O9P'N:Q', "Q4H%'
M2$BI8$CW71]R1"+AS ET=8N&;G=PH3'L8UM(2+QNT4MKVCV$;CWB0[%M[2K)
M,=@RXKENAIEN/MN+:0(C.D](0^XVXEI:5 #0M3^Y0DJJXG9_;ER1:6&ID]U-
MYBMS(LENXS#%;96VAU9E.E0+"F6W$*<24DDK2EG>K4$UB9&RG=R4]G6?4P9V
M/LO6T'UR.:-1=.KFL1*)XF;65KPY590MHY5?:@\EFZF^C[ C9SEGG5;+#"F<
MHXWKR=G6+,J^KM$/H2+>+F4IMT,O]'+ D8#92$[W=D=[O,:N&K'&M(RK:)^\
M)LB+M-Z8J>JW!2KC,#'2$O%@DK"BK=ZTDZMWJT\=.>%1.+3[O#.KC'T+!KFO
M67V>9FZU>A8^$MB:[^UI(@36%;IMG;TZR;MQ^BS=9RX*$=V+)@.26(D5F;1!
MPJE??C[.1K>NZ2;?;(\)N,);KKL"-[6R4!S*DI:4HKP0 A 4I2R$("E$ V&)
M.T4F>BVQKA<WYCD@Q6VFY\DZW0LH.%*=2 @$%16O2E* 5K*4@D94V]1OB 53
M7DXLL3W(&7>$J<H+#7.,H'M=)[(DU.OC)+8(.S/P2+P8Z;,%CVNX+8N!R?$(
M%4EV[A\EJW743T<"Z[+SI<:&YL^NVN3FUN6YRZV)B&Q<4MH#J^B.J2M*EAHA
MT-N[IPMD$))4 =U/MNT\*+)F-[0)N+<%:&[@BV7R1+>@*<7NT=*;"D$)+N6M
M;6]0%@@J&DD84$[R[F!=QR9BVNRHE0P[<L!"9.;6:PW*OV3G1D\9#M'1)+9\
M[:/%4VCELVPJL@Y4T05TT5WUTST:+=L^[KW<&SN;M*5N:(T)>A"DE25KTH.E
M*D@J2I6 4@D$@9KGEW&_MZ Y/O""XHI0%RIJ=:DD)4E&I8U*2HA) R02 1FM
M7FX^[6"Q0!FSNT&#H1CL3-!<RZT_:P@;HGHKN1*#O7_7&#'1)5-39V[12;ZI
MJ:;Y4QKOKG-/0=G=VAWH=EW3J]VVYT>#NW%Y(T(7HTK7D$:4DG((QP-5=.VB
MWBVNF7K>MI*W&^D3MXA &2M:->I*0.)4H  <<UE4'K;O2[ZY1;LY)>Y*=:P>
MPV-A$:L 63V8G<9FEHMJP<O!\KTAK#RO .Y#0JP=B0X<_) )B0$=$D0S![H[
M9*.=(N;LV+N_9F-GS,DQ%1$SG8=EBO1H1FI2M@R%X2[I*%I<<<:9=;:0275I
MTJT[IN'M&JTLWA[:#H<:4F4J$U+O,IF1,$-2D/\ 1TY4UJ"TE"&W7FG'58#:
M5:DDT%-YAW-C4MUA3*_;@LPBE%X/-E7%:V99\Q&LFDQC8:7#$'*J:C=PV,!-
M2S<6:3V:82&R)D]9-G;K#9-RKL6HNS<J,'W[1;(S8E/-)3/@0&5;Z%)6T'$I
M6E2<%QG?1UA6K06W,(5P&O=F;20Y!98O%S?<5%;6M<"X3W$[B;&2I;*U(4E7
M%MXL2&R-&K>-$K3G,(?7CW-&#EBY*V>RP\2V]5]8*/IM9K0<W]>7=-6/IGJY
M%-LEZXY8O6[7SU=?6%V;I%'SU&ZVNF8FW6!:PVB#9UN*U:6TQ82EG2$J5A(0
M5'2%H*L#@%))P%#.&JXW]""XN=>$MITZEJE34H&LJ"<J*PD:BA03D\2E0&2#
MB61N;]_)?*AL'CLY[3DI<8!%)0+CVLQLQL3?1H(*?&RT@;H/"C?.X4>)&OG[
MDIC/J2:#57;*WEQC&;#S&S##"Y+L:R(8;=0PMTQX10EYQ:6FVE%+9PXMQ:4)
M1[HE0&*OM2-IWWD1VI-[6^XTMY#729H6IEM"G%N@*<&6TMH4LK]S@'C41<7G
MW+:;J)N[;[*-E$6A9^LFXF]F([I,0#E5F=>J:*$M=M&@5V@NU+.=L81'.454
M'FZ*J>^NM\6ZP* *8-G4"IM((C0B"IU(4TD$(XJ=2I*FQS6E0*000:L&XW].
M<S[P,)6HYE31A+1*7%'*^"6R"%GD@@A1!K5IW)W:5>L1J5G=H%2)-VX8#6"<
MNM/=Z0?-&+4FZ9L6NK_*[MVV&O69!PW034618NVKM335NX24WI,'9T)4LP[*
M$(2E:U&/!"4(4M2$J4K1A*5+2I"5$@%:5)!R"*J$[:(J2@3+T5K44H2)$XJ6
MI*0M24IUY4H(4E1 !(2H*(P0:LCK@<[N=H;VA'7>N^Q-IC;!GI$T*#^[&X;%
M"AFCT" ,2(@D7=M711ZRSHQ!ODM==1JZGKGHD%-$]=MU$\2[HV=LMLDW:7:H
M*XD5#;CG1[?#<<4EUUMI!;24H2K*G$GW8&G)!/(Y5I<VAO%RCVJ+=IR)4E;B
M&^D7"8VVE3;;CJ@XI*EJ3WK:A[@G5@''$BQ;QAGB 4BC5173L=/;DB-V@99(
M*OG5#7?8MD1>5M8$:UC\Y;,]VZ@XV@]B)95NS.IO C9%JJXTT3<+;I.M6^);
M96R]R,YLVF+;Y%M=8:FQ;I;(D-]A4IO>Q5*"@MHID-@J:*7%%0&2D I*LNXQ
M]I[<(2Q=I5P8N+3[L.3;+E,ELOIC.;J2$D%#@4PLA+NIL!)/ G!QC[#[?[CS
M4@*;CKSOED((RL%#7<O*V/9;>&QTQ("3,6SQ)C[=Z[;"4$EGR"SK"FJCK1MY
MRB+5??S$]]K(@V",E97;;8IQ+#LA,=$.$9#S;*%+5N6BA*G#A) QA.K@5#G6
MK8G7Z0I 3<KHEM3[<=3[DR:F.TXZM*$[YT+4EL J!5G*@,D)/*KD8B^_;N81
MJ/KWU;0F(2^WY72L?NHM;5G-:8(2:%2 5&Y$8TF&FZSK2(,GYP5G0]N%UT=:
M.56[9LJ1'E&++7+=V83'>=%L@+D,6]BY.VY$""JXI8D-./--F/@)Z0I#2\M;
MSO<!2E!"T+5GH1M,J0RT;I/;8?G/V]JX.3YJ;>IZ,ZAIUSI ).X2IQ'MI;P=
M1 !4E:4T.0O/N(-</T%[H[$;:CF:11PZ2G]E9:>QG3G#1@=U6W))X]B$EMT]
M!Q-35-J\RLEJBIMNIKKG:)MUA6$D6^T]^HMI!B0M6\2"I36 @^V( )6@94G!
MR, UK5W&_(*@;C=L(2%E0ES=.[4=*7,E8]K6<:%G 5D8K0'.PW;F,/\ 85);
MK[#QXIJB@XV&G+"L42_U;N4\*ME]F;\LW<81<)9PH@KE/&BJ><;I[;:YQGE3
M5KL3R-XS;K2\@D@+:B0W$$I."-2&R,@\",Y!X&J7;I?&5:'KC=FEX!T.RYC:
ML*&4G2IP'!'$'&".(K9_LI^S7QA[O^=2<?3G+G::S^*K;]1B^BJWVYO'C6Y?
M7I7I:[,'U-?;=J63;/9UM8EE3V=MAE=P=<:WF,O/R5 >NO)2::ZS)$R0>)M5
MED]=4U54-=-U--==-MLZXQCGCG9A@PHEOLJHL.+&4N9*"U1X[3)6 P@@*+:$
ME0!X@'(!KUWL23ILN;>4RI<J2$18I0)$AUX(*GG 2D.+5I)  .,9Q7;GYX)7
MN-4FM_35?\)O_I9YR*_=J_G*^TUWR/<)_FI^P5BAV_[!G>MM:@9P&!1=VV,V
M" ALBFMA&9!'JKJ*/F!QU\O9=J'HQ&I67#0IH1$#(HJ5]F-Q(X]+@+V2FX_&
MD"YIC6RV'%%))X))"4@%:R"!I0"0"KCG&<D XXXJAYPM)"@ 05!)4HD(0"#W
MRR HA.0$YQC*AD@9-;PW[-5\QC"69/)X>A83)6$Q.1QR*%3LJBZ%JSFLV]GA
M(C&YBI& V)&%+Q];),!*]PXIL0"[-GC]F(?K[BD8W:L\ 2GOE D '0E6DJ(R
M<'/ CCQX#--\D).2G4-((!)&M2-82%8&01Q!\'@/"J7I/Q!J@N6 TG)&A05'
M)38C2LE9[$)BG.8&\@>UCTU/K98$P>9C A>\XBCK2M9@/CDW:X$U_)QT:E14
M5,UW<<7#/+BXZT*6.:4ZM*DZ5!6E:4\<*.D]\,@Y4"0"..10B0A26SD J"=2
M3J24Y0I>1E.5)[Q0"AWIP<*X8JPD.]75YU&TI0TL T\;/) 'C0@ SJNWW=@R
M8A(8V1F4>=PZK6T"5LJ9QP_#@QJ7 Y?%(F9B9B+!#4B'&W(<02>MJ-P[G&D<
MB22I 2,$ @JU:4D$@$$@Y(&,D54)#1&0HGB !H7J.1J!"=.H@I!(4 4D G/"
MK'J;L75UVR.SHM7CV4D25125O$IDX+U[/HH$T-N! XUAH#D4IC8<%)%$&A-M
MZXD#(/G#/&Z#IR@D.("7I"E;:T!*E8PL9&%))QDCB 21RZP/Q@XJ0ZAPK2DD
ME!PK*5 9P#P) !QGCCEU\",XK4%WU8S:NCEE7<S@M=8Q,0L"%517Q"T;7[ Q
M"RB ^1&3=(VC3 NIV$X96O% (/$@<LX8(E(\Y'TI)*A6ND&CC:7R&ZXP4J"4
M:E$@J*E!*$%.0 M*RLITDG&21@X',X%IN1J25N!*>( 0G4MQ*L$E"T!.=:0,
MG2"",D=Z,F<"N^=,*%K!<FCB.8*(,UDPJ^1PD/,[+-VJ/L2E1MV9+@85 XO(
M)2X8A8NY)%BCL<*?LA$;$/) ><BF2#G9""PO"<#OB%%040D)TK*,$J(&21PX
MY). #50D([XD]Z"@)*0I17J0%Y"4@G@,]7  DXJ33#O;U@A@FP3KJ?DI$%J^
MO-[/FAV!U_8L^BHB+^XP;8C1)6<1"*&(-B2DX*:"S$9#U)(G*'<5+C9-H)P!
M=IDLTAATE(T@%2M "E)22<Z?<DA6,@C5C&01G(Q4J?:2%'42$)U**4J4 ,!7
MN@"G.D@XSG!!QCC7UQW2I-EM(W,B/.@C <>A\<C@GW'VH[M&2%I; \V$B+S3
M&];L['9&FD=;E#2X8<%/O6D8%/9(<U!M&SM%JW*^&!DX43Q2$@!6G.O5I()(
M&<@9X#--^WWQ)P 4@#"RLE0SC1IU9QDX )P"3C!QNS+NEUD*2>(1$1:3(T3G
M3&NR,<( XY,S415;6VY,L*O]KSX5''<&C#F?E8\9!Q)C)Y$'>G9"P5CP]NN;
MV28*-R[A1T8"=0()2"- !5WI.HZ003@' X\JD/-$I 5DJ"2#A6#KSI[[&D:B
M"!DC)[WGPJ5VKV:HRDC0V/6A8#&+%2 KW0K);BY 6;1V+9(X$8F<Z) 1!0;7
M4&R5](-Q.)Z[CD2R^;O&N#/IF3O1&E+2U@E*<@'',#) S@9(*CCC@9/R5*W6
MVR M6"1GD2 ,XRH@$)&>&5$#Y:^4,[/4?8%DEZCB<S<$9V%=3P>Y'.(C-PXE
MZ3J^0#XO8H@!+C<;'0Z4F82:+"6\F#QD^6)B&Y482>-$A9!H\6%M:4A9 TG3
M_&23WPRDE()4 1R) Y$<P:)=;4HH"LJ!4,:5 90<* ) 22DXR 21D'D16([+
MQ!Q([L3V1KBQCE$UU676L](6,H>F9W,G5QD8Q&:&@UUEY^R@8^!.0'N7'(S!
MV/>9UE2I'5G&BSY%FLMZNT4O=')0VI(6I3H! "1HR5J0$ZM7,E.0-/6!\M6>
MDX=<0HMI0V3G*E;P@-A94$A)&!G!.KJ/#E623#N;UR(2&-Q9.<E6AJ4O!S!@
MB8K>T@#,:Y/RTU XCK+BQR%#A$"2L&91TU&ZP<SE]'6UHEF"K6O5I-ONCZ2W
MN7,$Z<@<>"DDGO0HX )*M*2"K .D>ZQ5W?-Y U$$XQE*QC)*1DE("0H@A)5@
M*_BYJF3OB.T0/)5!(!;Z1%Z5LZ'W-+7%G)UE<FBHX=50>J9,UD(B*8KG>0R&
MNCD2LK:6[V@Q8;0)M%Q?NB0D#H+NZ?-*A'6=8( 6DH&G6C^,5#!.K 4"G 3G
M42>7+-LR4 MD9+:TN**]"^ 0$'(&G)20K)5C3@9SC-2;L_?78"J#5..*?A-'
M3R#W#/X#5HDO-+&FT<+M)7.L2-XV+8:QBO):)>0] 4(8+I/VY;8FZ</%]=!V
M&Z*+A>&FT+"]2EI*$J60E*5 A.!C)4..3X,8ZZEUQQ!04);4E:DH!4I0.I6<
M$@)(TX'/)/R5+F/<FD1$#A,EGUA1UJ9D\6C1I1I"0UARP<2(GK" TYHVAK9*
M&(2L^V?VY(1D*C[96.,Y 3=/V*VP9!)53=*-RLJ4$I) )&5%*<=Z5<>^P.]!
M)XD#'.J@\@)25*&2 >]"E DJ".][W)RLA(X9.1PH [T=5Y(Q/$V-J)L!T:BI
M:9E'LHAM@PIMD+'92Q@DI1%JS&)@=#\BAT^*"J^FT- 9)S"%V 6%0:4@A$L)
ML0[@6'00-.23@84E7$@J&=). 4@J23@*2"02!F@?:.3KQ@$G*5)X Z3S R0H
MA*@,E*N](!X5]]^[G670:%(8L,@JY/'I+%F$8;5U:+NP49+#F,?+RH 8K-K"
MUK#CQB/Q^51Z5%AL@C QVRAI1"9+):Q;58NDW+G'O1@ $G4G3@YP=6K2<X(X
M$\>]Y\*G?M<.^XDD :5:LC&04Z=0(!!.0,#CRR:RMY:J[4QAW]4O/\ G_P!Y
MGFUM7[H[_,3_ 'JT=\_<F/Z17]VI_P W=<W7Y?\ <79WLBQMVTV3/L!=+5FS
ML><-6K5O:$V1;MFS>3%$D&Z"*9O5-)%%+35-)/3773337777&-<8QS[3M]GM
M*H$)2K7;BHQ(Q),&,2264$DDM9))XDGB37QY/O%V3/FI3=+BE*9<D)2)LD
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ME*FY#+B5QUJ<2EP:N(TG'3SK/M=;[Q;K*_>'C)N:D(BOM72:Y$WBGEQUMK>
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MI@:C,F>IF"UD@I3)M2[4>=!FP1'1ZJ_I5)*R=2$E*@0I)4X0<D*R,K)1@I&
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ME 2E*,)  SWH25*X$DDY4LDY)\ P*E#"4K#A4M:\J45*T]\5)2CDE( "4I
M2!QR3DDYR_Y9J_4QAW]4O/\  )_]YGFUM7[H[_,3_>K1WS]R8_I%?W:G_-W7
M-U^4;=G]>:W/\IT]_P!:BW/N2W?O?!_J<7_H(KXKN/[X3OZY*_ZZZM3IC=<
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MXVJ4DA6I#JBI2%DFH],O$UKZ65:7BKFLK-W)SR$=/ZXED,:6*Q 5E78+JF;
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M(8[:M4T\ \Z#D+5G&./'K*N1R,A2BH'F"200:@L-$8*!C.1C(P=(1P(((!2
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M_P"DYTL/$N(XY*CWQ4.%%;(=D%3R)"KA$+S<B7*0YTI.I,B>T&);HQ%QJ?9
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M:GLH9^#V7YJC^AQT>/\  ,_1(_5ITN7]\R/IG/UJ>RAGX/9?FJ/Z''1X_P
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M_6I[*&?@]E^:H_H<='C_  #/T2/U:=+E_?,CZ9S]:GLH9^#V7YJC^AQT>/\
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M-&XMC'V#79JN2G3UY. .6."<X\/'CQ.?Q5+CFO& 0 I:N*M1*ED%1S@8' 8
M'#B22235LQOK%8==]+$NL54WKB#VMK BP#/8[:N]3+QO8,S*OI!8UKC:ZWFP
M])J?D$C/RF2 A[J:D4(V<*,7;YW)T1B[8H"2$Z0>..>.L\SCY^./MJ"L%>LI
MR,YTYZAP2DG'(  ' !(Y8YC>^D/6DKU ZS5MUV+3\79RE<-"@YK,A->M*S3+
M,WQ=\6T<D8XUDDN4<R%TN^</I/)B,B)EY;(G921E%M7I)9/0D:4@9SCKQC/'
MP?:>OF>-0M6M15C&>K.>K'/_ #CE66/*JIIQ2G%*<4IQ2G%*<4K4(?\ Q_\
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M[F0VWH3[6CW*?XJ? /DKX^N-ZO*;A.2F[7-*4S)02D3Y0  ?6   [@ #@ .
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M]]"5BX6Y(6$.K4D*"5*2% 9 4H9P37?,Y\O5[Y3BE.*4XI3BE5)?W]8BZ_\
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M\Z--I:+!XC\P'R=!5N5::Z+L',CB-_WA U1KRB[-J;M^EME3C%O:F--PM[T
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M*DO,-M34:6$K::<RI+J5-K5,E>LO6Q--Q&H7"76]?6%X:$B[!O;8D<]A=@*
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MW)E]<N.\E<IJ,EK2SK*DE3,MY040<CO,'&"179[$;"R-E[E+GNW*--2_;EQ
MTRR^VI)7*B/;PET!)2 P4D#CE8/(&NSWSQ>O3*<4IQ2G%*<4KYK?TI7_  >_
M^CGE*_<*_FJ^PU*>8^<?;5=\V5:ZL7Y[W(Z\U?;DAI:?3QO&)=#Z#DW9:7O"
M;)XE%8M4T2*HBC!8Y)M4MAK(KKC=T5;1WTFYER"&$"Z;3U--%1>"H X)XX*C
M\@'7500H@* R"H('AU$9 QSXU2\V\2[KW6<1%SJR(QV"@,9--Y6:&.IA0=C
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MX]Z,#. <ZE'YN X9.">&0*QILGJIVBF87M#&WE330W?EGV/8+*&=NG5^"5(
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M-71,+#HO#(VG3S&>-@,^+M)>-*RB2;0@"G,BDN,D71D= 1C3QXC!)\.!@ >
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M/C5B1&C2VRU*CL26CS;D--O-GYT.)4D_BKC4N'P4/#:N/UIR\ZZAZ[,.?/\
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MQRD:D"5K71:Q#)&!:G+QD8(]M:U02>CI<%$O)I;<H-5?$%H5,#RP>'UF4BX
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MQE4/XIU9G=!4' J]UDTBCGNGLF]%K<^N%,I!9,ME9IL:JXK(91,X428[+O\
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M,>.I5K;+R[4ZZO5*;;NI>21+1,=6RAI+;90LOC$:_7?2)?L74\&JZ(8B77H
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M=6;/U+='<YSG[,\U]W__ $4Q_:MSVT]FQPDGV-HX_P"]E>KJ\A[C]F\:W/\
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MPR?.HL2,&D(FL#'&2C)W.D> =?YSJ^WB/ 2<<S4:U^^/\7EP]RG2.7^SP^7
MSG J!&O#LZ<25D492>GL2CVY-<STZ1D]@6C(Y =,;QMW#5!!N3FIL^D1BOUH
M@_?11Q51$HYK!Q&GCD$O$%!:RC3:"A)YC/'/$D_^O+_9Y?)4AQ8((.,# P
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M)RX^&LE[*QQR4F#<A*MWA<T5>/!0DC&,  C )' \P<$9_#_ZT#BP2=7$G/$
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/2>' 5)^7:M4XI3BE?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g383050g23n00.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383050g23n00.jpg
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M-#@Y0G)SDIBRL]1XH=?P)RA(4K?!1UEB9H2%E+C&V/'_Q  > 0 !! ,! 0$
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M#&!%2!KJ&%D+:$"8<))<0.,P\2^I#+2U)9'9=?=SC"&FUN*2G.+Y6ZBL[6I
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MD+397+W5FI+/JFF7C9@\?:-V6")K6M(4$4V<,L9TW( 1<84G$(">W'PI,A*
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MD@ZRW[4!51K5$)8ITLAB'*ES"R/-8)@A2(*/C81LGW7N'_[)]!I3;N<>7BR
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MFQT='1TNZ)_X8?\ \&;_ /F]/^ _M]C_ )I?^V.HYJ/^T5O^=?\ ['6/N?\
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M2:W)F[,+IBACHY/A@S=@2K"O:6+OENU*A^0D#(T#>8X6T?$QWXL>;J!^YZ3
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MG?G2'L+PYG##;68)*LEXPVKN)GL_]4XPC.58QTTLS(I:6&>)59D9I(G55*D
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M&X-(/@U7)=U(_A5A$PF=V-CN,A$951W86G6L^QW-$-8-0LS83IC]I<;"V_%
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MMHJ82<,,>XV(HA^*9K3U^'U/L89KD5?$QWC8DRC1)'')49&:%8XH/R8GD=&
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MV<E<,4DEA[$VT-PIYF\0A_#*UWI:7YC:.U1LR2TA?:4EV8V978FP4:Q6,BX
MQ4L0"N3'D!"XEZ2#EF4IPT1V;:<:5A2D*ZZ-J12Q5Z:R1,&CK5 Z,-B"D,89
M6!\@@@@@^QZ^,FHKM2[F=2RU;D+Q6\[J&6M9B</&\=C*WG@GC==PR,CI(C*=
MF4@@^>D7-<@^)1?&G:>G&=G< $L[*N:)JKZ]$Y!Z]*I&BX:?J<#K6Y$ZX?EJ
M<R")<FX6+N.QZQ-BUP$838.S2FY 4P4*9+EUHY<U;>3Y1Y;;RY#%@&^;?;?9
M=M_S5&WG;J,,BFK- $J$2R<DC$@,==618I.URB #\1)*K!0!+,=P=F+2;T]S
M-X95WD9O+<$YRBXDT^ V)1=2U..C8G>FNIR6DYBBR6Q).5GY F(KM1)6@UFZ
MAM$%7&5O-E*F69-$?+0U;%CQ)+6RL41 &)4L=R-M@P7P-V/ML?8*/;P3N0K@
M>-;5B=FAC66.% %=6+-&96+'C&A\]P;ER[EN0!"!=Z\=M<O.+DUR^Y66N(Y
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MMK>&3A&Q[:RUI!N5=3'/#,OET;R6'@-RP),'87*LCN$N2ASH*G4Y0Z2\4_\
MIJVVQ\^9Y2\Y7W4XE/;"U?VV%9ZD$..R_P!GC,1A6K3RO1#,T;/-(RAG BY=
MTA@?,@0C?<%@VVY%):NW7*"2Q;ML2H56:5IYV8D$@$$L_(@J 2-SOXZR0TR$
M  =&%1XDHJ7P&X:^^PIJ2AS8PY;N?A9*%8PG)(GG')0IM3*TD=\H\[*%])H\
MC*L-R":O%O*\91N*ATL1C\E8!VY+PW96B7<2 [MLVVSG%>ITJTM:Q6CN_'F
MWGEC=+>.FJ627BHR[D*MB+Y)B592)/&Q0'IY*IM]W1>ZZEM_3:3H)J)<BI3$
M41*#2&#&2&$-6""-('2GUHV3:]T,^T2PV2PE["U-)=996IIUEI=LYC9Z.>CH
MV(LU45A)4*&)9''Y.9$4LT5F"0!W0A6612!LIZ;?4[&:/U,]JMIFK<QV'MTZ
MKUZ]Z:.Y<Q^2[6[S064"]V..PO./E&"T?.&52C,&W^?LYV^Z_P FSN46X8V
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ML*(PTT\ZI6%/>=7F[;;%*K7FLOCK,T^+>4V(*\CE^SW=V< G8A>14;GQL-E
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M.R9E+<7%@J2_@AR6)VW'3) &@;O0*%9-U8M\VR$$;E"?F&W+8D?I]]NO5/\
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MTZ[Z6Q-]J=9[5^]+!#:6><M8N7JT;.L1M*525RT>\6Z%710J,/9*998^UIJ
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M'N"#YZTK+AJ^APL:(Y&P##1LE-1$*P9)S=L?C8]4H:V-DPUABQ@NOMH3E3;
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ML6!+'L^0H4N=E'R^-Q[],1SF;%::09K*&6&3@",QF#%8)CC>-(E&0Y!I'E2
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MR7?^T;WQ*QK/\1(95B96C#<V&R</EV^4G=?!)WW.Y/6-V22:U/-*%$DCDR!
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MP8/Z[;["VV1G,+93E.<Y<=/X#7.4Q<]B# "*W4J!;>,AFBKSPM*S'Y78E]C
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M<D0M;C;)B#1$$MN8:\RDYPN,Z@M4M*Y3&I-BY,CJ"U%(D66>'M<>\QBC!["
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M6Z]+XF,03Q12QA76H;QJZ==*HYQKQ;=KV'9GOT;AS'YG:U1:_P#!?;*U=@K
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M:S#QDLSU*\5JU8W$=8*QYK$OE-Q=A:J',VRJ"0@04&\-7Y"7A2%QT'.6>NC
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MYE;SX#(SC*0Y:-<=0XRII["/,2EYUI*E*<<B>3KFQ8E2&R5G!K2=B)XHI&"
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M&\V&V5$/J>*0Z[V=Q6<FF(Z-VUDJ54-?L*@BK9!W2")>X#.8CL.SW4VW9@Q
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MC+SC[;D>IK).%K:CV5J<4IA+CV5UWGM7T,!8*W<?]JWKN/:OC*I9E-EH&8/
MKA6 1NXORC;?P -QL>E?P;_3C*ZKSN<U-*E+'Z4P]6M1S>K;R169=/\ Q)L3
MPVX:TLJLB1R01,]D*JP*>;,J*=G\VI"[5NMLJ,%"[@_"!!@!.Q0<I$Q+T>&;
M+%H&;?K!YT3AP,B3E1\BD#X>><92#YGB7FF&'GE5CIR_I_%U,CDK."BPMR65
MK$U:>43/%""_"Y#%+\XBA<O&W!0W<4*%W95ZNWUIL^LV8U!H#$:,UK8]9\'9
MN_B_'D]+UJV&H0W+<BK/B<SD:]E\;,TU-$D>:2X%$2$M%R+=+^CZ:?E;I;*Z
MQ-1^L4Q%="8N4'(GUV9E'0<Q4S8I?$0 F568@$T9#K/OF<.#I,/<]?R*0G.<
MCGT^R5NRJV9CDM//C;B06(8XWCEBKQ-+S@$)D@:3EVF._%.2EB#MSE^$;ZEY
M3\'?7?XDZ&T.<3F];X;&XW4M+LQS5UR63=:< I7Z)MUU>>O:=7CY++([JRCE
MP/21"TS8[ 4;#-!II%@'<SL!F!/L!RLFBQT9'-,FNG8#D5N'&RQ)KBG(YY&
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M-'CE!9A")%0V,.B&-NCX<:3EOW1+CJLJ=9<A=I34IWDMV<5R6"P]F2K8=+7
M@RR.LAL*BON&C;<[_P!R !U5V=;4>C+N$&6HYBOI^:**O<3*01):@L2H.S;E
MYM':6LSG9P8)%#,"-E4+TYJ:O(UZI09\I8 /P1!+$AY)2&R3,%6EM"'69&2C
M8F0DBV2G1B\)$(P1%-K;';;(2V(4A#N%S5./S-QHH*#T]65*T:4;D(*LE.-F
M$H6:Q'%&Z@H2$6-RK$@;\2>NO[C^J2^@6'UK2H=C15>Y2CJXG36H:C][+4+I
MA:SJ:"PRRU%N8]9(NU!%SB26NW'Z]1GV;O2QW'8D>96 A%M5N+8J=:CP0,D
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M%7M^QI],S%7J#>K%DO)J]F4AN<A#)(6,C"ZY'A#1L+3SA5M S_Q!Q]T)_)6
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MI,0H*;*"Q+$#;<DGW)Z;Z@?+9&R-Q0FPZ_586OA_A.#PV[IJ@QK>J"ZS?=@
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M'FU,[YK%=^K/4JO3G"JTE)K:I+-$6')IG5"[OR"<2I-CVH^+M4T:%6[_  3
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MZW*"LJSV6H)+S258PV[YUM95W;;1V8M7:/-ZI7LQOCX[]NJST[@$%J>HN[
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MA2P"6(%GBAJT3*D51454/:>*Q-7V=AM')LI7Y3T].Q][[XV-8'+$BL.10\=
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M3,LD->W(%BE[;)O(D;LZ L&(8C;%[SA37*A1R\( >6>=9%?$4%1@Z2U%RZI
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MKYMPI]8"/6053\P^#86QLVQH9NSO2AKF1S@2 P\^T9;9RVI@@/#V<N-.J2Y
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M4E&*26(T;BZ%74[$[,K!E/D$$=:C5JV+MZ" $<C]Z<D3Y*3EHV%CAS.3>\
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M4/GJ!@,]8JX+*:;R4D+9&M'.JU78P\)Y.)[IC#_+RCWDD&_#;CQ.[$3CT?\
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M'_AZ$_\ 9/\ _HW1^--3^]K'[\?^GT?BY8_OB'^"_P#-T?H=;'_AZ$_]D_\
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M3(13;:FA"08Z*#>#4P"G"XG<TA3G.8<!9Y,S#!%)+;9VFJFLCI#+5G13*K1
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M(\H3BJN1Q_E;E!5";9X_\7Z].4B0NMAFBW*!R(X_S-<CK%+>R,/AQ7JE(_#
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MY()VV=J?JIBZE^WD$P.8EFLPP51&]K"QPU:M=Y9(J\*U8*[NBF9N+W)+4R*
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MO=43\D:__5_1]BX;]B<9_$*O^JZ/QNU7_A/J'^6LE_2>C\%NLOWNJ)^2-?\
MZOZ/L7#?L3C/XA5_U71^-VJ_\)]0_P M9+^D]'X+=9?O=43\D:__ %?T?8N&
M_8G&?Q"K_JNC\;M5_P"$^H?Y:R7])Z/P6ZR_>ZHGY(U_^K^C[%PW[$XS^(5?
M]5T?C=JO_"?4/\M9+^D]'X+=9?O=43\D:_\ U?T?8N&_8G&?Q"K_ *KH_&[5
M?^$^H?Y:R7])Z/P6ZR_>ZHGY(U_^K^C[%PW[$XS^(5?]5T?C=JO_  GU#_+6
M2_I/1^"W67[W5$_)&O\ ]7]'V+AOV)QG\0J_ZKH_&[5?^$^H?Y:R7])Z/P6Z
MR_>ZHGY(U_\ J_H^Q<-^Q.,_B%7_ %71^-VJ_P#"?4/\M9+^D]'X+=9?O=43
M\D:__5_1]BX;]B<9_$*O^JZ/QNU7_A/J'^6LE_2>C\%NLOWNJ)^2-?\ ZOZ/
ML7#?L3C/XA5_U71^-VJ_\)]0_P M9+^D]'X+=9?O=43\D:__ %?T?8N&_8G&
M?Q"K_JNC\;M5_P"$^H?Y:R7])Z/P6ZR_>ZHGY(U_^K^C[%PW[$XS^(5?]5T?
MC=JO_"?4/\M9+^D]0>Y,\SO#DX>7J%UIR+G:1K^[V&G9V#$P3&B;S=G2*:F4
ME(5R?>-U]K.UQH(;,E#20Y"9 P4@=(V2'V6QG6'G5,.F<?84O#A,8ZAN!/P=
M%?FV!V^=%).Q'MTFFUUJ.NP2;5>H48KS ^U\LWR[D;[I.P'D$>3O^^.I0:J<
MXV;QUY4]LZDBM4W[7-YBT3-4MU>K5?*BIB/4\\,XME:HQMY@D0P<D"1 ,9'D
M(R2$+C9$44X4@=O3)@<3$[1R8?&HZ$AE-"J""/\ [%^Z"/!&Q!((ZW1ZRU1*
MBR1ZIU Z,-PPS62V/T_OG<$'P0?(/@].#^"W67[W5$_)&O\ ]7]8?8N&_8G&
M?Q"K_JNL_P ;M5_X3ZA_EK)?TGIH=EV?BSI^RZEI^QH>@5NQ[TO'X-]51J]<
M9E%6NZXBC)SX(@J%K$D%$*^%QYA7OY\F*B^S.6O>^NMMI>Q,!BI%D9,/C"L2
M\Y#\#3'%=P-_,8)\D#8;G]'6N36>IXB@?5.H5,C<$'VSDSR;8G;Q8('@>YV'
MTWWZY](3W&/D;K*O;BTW7Z-;]<VMZ>8@;"O6V:ZHYVLV.6J<VG,/:JS!SHOL
MI^#E ,*-C!TDX&]T)E\)\<AWR3 8F%VCDP^,1UVY+\#3;;<!AY6-E.X(/@GW
M\^?'1%K/5$R"2/5.H61M]C]LY,;[$@^&L ^""/(Z<A-"T\N4=@TTO6JII@ >
M5?ATUVKYE&8LL@D,62=C\!Y+; )+",%',6S@=X@0EAMQ3K#J48?8F'VW^R,9
MMOMO\!5VW^[?M>_D=9_C?JK?;\:-0;[;[?;>2WV]M]OB=]MP1OUW_P %NLOW
MNJ)^2-?_ *OZ/L7#?L3C/XA5_P!5U[^-VJ_\)]0_RUDOZ3TT,=9^+,MO"R<;
MX^'H!&Z:CKZ$VI8:3C7&6W8ZA6.8*@(:?5.O5ENL$I-EPB1,1P<T1+L9:]<H
M!D9;;R]AP&*$0F.'QG;9S&&^!I^74!B-NWR\ @[D;?IZUC6>IS*T(U3J'N*@
M=E^V<GX4G8'?XCB=S] =_P!'43]V>(3X6O'/;=LT9NB]:]H^S:)FK?.<(3H?
M8,M&5A%TAHFP5A^:N%>U=+TL 64B)R++06_84"C>ZRP:\,4P2RSOBTM1FC66
M/!XQD?EQ/P=$%N)(8!60,2""-@-S]-^M$NO-0PR-%)JS4*NO'D#E\L0.0##=
MA.5&X(/O]?/4_(>BZ<L41%6" IFM9J"G(T&8A9F*KE8D(N6B9,5HV.DXT\4)
MT4T \-]DH,L9UQ@D=UMYEQ;:TJRE.$PX)!Q&-!!((-"J""/!!!BW!!]QTJ&K
M]5, RZHU 00"",UDB""-P0?B?((\CK)?@MUE^]U1/R1K_P#5_7GV+AOV)QG\
M0J_ZKKW\;M5_X3ZA_EK)?TGH_!;K+][JB?DC7_ZOZ/L7#?L3C/XA5_U71^-V
MJ_\ "?4/\M9+^D]'X+=9?O=43\D:_P#U?T?8N&_8G&?Q"K_JNC\;M5_X3ZA_
MEK)?TGH_!;K+][JB?DC7_P"K^C[%PW[$XS^(5?\ 5='XW:K_ ,)]0_RUDOZ3
MTT,%9^+5EW/?./4)#T [<.LJI5+O>*=C7&6'(*KWA9K=6E%39598K<@F57'F
M)2)%3!QXGH]SQ1<+:RO8<!BEC28X?&"-V95;X&GY9-N0V[?(;;CW 'W=:QK/
M4[2/"-4ZA,B*K,OVSD_"M^:=_B.)W^X$D?4#IWOP6ZR_>ZHGY(U_^K^M?V+A
MOV)QG\0J_P"JZV?C=JO_  GU#_+62_I/1^"W67[W5$_)&O\ ]7]'V+AOV)QG
M\0J_ZKH_&[5?^$^H?Y:R7])Z/P6ZR_>ZHGY(U_\ J_H^Q<-^Q.,_B%7_ %71
M^-VJ_P#"?4/\M9+^D]'X+=9?O=43\D:__5_1]BX;]B<9_$*O^JZ/QNU7_A/J
M'^6LE_2>C\%NLOWNJ)^2-?\ ZOZ/L7#?L3C/XA5_U71^-VJ_\)]0_P M9+^D
M]'X+=9?O=43\D:__ %?T?8N&_8G&?Q"K_JNC\;M5_P"$^H?Y:R7])Z/P6ZR_
M>ZHGY(U_^K^C[%PW[$XS^(5?]5T?C=JO_"?4/\M9+^D]'X+=9?O=43\D:_\
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MY"4;5TM)4Z#*LDZBM2>M"[C8[#%L(A;22XZ-7)$ZS;;FP/ZIO/[_ .@GW_\
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M;ECF[E<:B)8+--Q-'&(Q<(.D#U"IQE;CU(U^=)O /QCE96SJ<CMH-T+;MOQ
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M.*!400+WD*W90(R;C'?6&>\B#0FL$,^D6*I\,@<AW*2-HG:-]N2'9MF5AO\
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MQ\L-]A]!Y/T'6J5*D(4R0Q .ZQKM"AW=]^(\+XWV]_8?7I[?T)O%C_<T<?\
M^1K77YN=:^]+^NR?PV_GZV_#U_UB'_JD_P!'H_0F\6/]S1Q__D:UU^;G1WI?
MUV3^&W\_1\/7_6(?^J3_ $>C]";Q8_W-''_^1K77YN='>E_79/X;?S]'P]?]
M8A_ZI/\ 1ZPT7QPX<SA=ACX;0?&J6.J<RW7;0'':IU@8379]V$A;,W"S;(\
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MP.Z5V*CB5;;YML)6GXV)#WZZ_"1(C."I:164,J@L-G?RGN'(.X'D;S?\%UN
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MW2.K,B\!\W..SQ4B!C-I:8<RGX=S]G3*R'@Q>RC H&[<<:F1QLH=$4L >/@
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M]PL(PB'+):I61EBC#WB[#/O24NMIXAQ B3$AC8;%'9:0TS2=V623B$#L2%4
M*J_W*@  ;*-AX WVWZ>((^S%''R+%5 9F.[,VWS,3]Y.Y_1[>PZ>SK7UMZ.C
MHZ.CHZ.CHZ.CHZ.CHZ.CHZ.CHZ.CHZZM7_VYJO\ \F.S?\ZM/];\-_ZS5/\
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MD+,_T'H^RG_932_^.6DOZZZ/FAK]S6R/Y*=F?FGT=^3]C\U_(69_H/1]E/\
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MUU94R[=>^4&BQ(%LV)AL,Q6EMSW":E96Q2@D'#0D'4:A*S]ILTO+29XP0</
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MP]!$VN]@[V#)"U&RE5C:WL ,++2"> ((B(58%G)YJX_'/CGI/:^L&;3;:+.
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M'6(\270W):M\".6\_.\[]KW2'A]%WR1D:G*:8XQQ,=8118AYUV*-DJ[J.+G
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M@#E[#?8?M=<=V]1YO"7+^)JWO[%QE^_2A,E6HTABK7)XE9SV/+L%Y-MXW)
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MB<=9 "&#HU5HUOB([:DP$1=Y=%4AE2!U[N?T?7ZKOL=_K[_7Z[^?WNI%U.Z
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MV<P$N9D)HNQCF2Y&;.^R4JLQ=/B2WF2)8^*-DI'U 4\E1WABB5ZJ\'DD+&W
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M[-"BB":MD'+E4!9^^ 3[(/K$NWQ&QQJ^:JQW^E244^[' JCDZ?D#73SI&3#
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M8^.S<M^YRW7;AQ/+UX>N?.K(Z.CHZ.CHZ.CHZ.CHZ.CHZ.CHZ;V^_P!I%_\
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M=$ 9>7%LR,XVW[KR)D7<-8<=4X3-KFOC&2 PQUI42,L_)I4<.5=EXJ(R0H/
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M )[?6^K_ +YK_P#/P_\ >+TGM_[TM?\ 1YO^[;I^^K!ZK?HZ.CHZ.CK 6O\
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M*4CC0^ZHBG;VW50#M^Z.N4LI9CN9/(VX>7:M7[=F+F K]N>Q)*G( D!N+#D
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MERL:UR4"JGQD#6K%*5=V<L9JJ64EE;CR;L[1JFW&GN@R8A4D'Q_.;@  ]BD
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M5X&0/+%)LW'XAMMC2"Z;SFG\Q9?[*CL-#''5.7=[$-7'B.U'V9Q'+7:LQ:I
MB-N[;<MS+R/S5[[ZY%S]]A8'6$,(Y7==TE]YP2#]PR2_(SZQPPI*8D3F0P5.
MK>R U[4#+7HQS:?2PM][U2'$-BU>SF2_&'-RU[64EI5J<1@KBK6KT*ZE8((:
MZNX5BK%I)>1,C;MX'RB]=(:(IX2S;SMN3[1S>7<-/<,?;6& CE'7K1<G6-
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MP"0N6W,*YSUJM-;HE7JQ-YT5"1\Q/6F00$PB6FB./$HU$PX 23I:5,Q%R9.
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MP-?#4+54%3A[?PQB:QL4[KI\0&?=&0E6"DL-@5>1U#/B=-8SFUF7(VV@Q<]
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M]>\9RN(,'M0:GNV$Z2KS(^R#J^2T]9AK6T\P:XW(OH4ZJ)!C9<(=O+38S:'
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M!^Z"/IN?WAUMK,L5B"1CNL<T4C ;[D(ZL0-]AOL/ )&Y^O4-=EZIY<7^"CP
MN#'+&LSD#9("W5N?9/X?RR8V<KQR"QU%Q)?*MD>3CS1E%Q<@&I\5Y81SZPS
MCFQC&(1#IW(Q,234=61HW0S2KR5QL=F$.X(.S*=B-P-P1N#U=D?6W1=^!(TC
MU%6G@L06Z\XQM"7MS5Y Z\XGR862-UY12)R1C'(W!XW"NK&,\2MY/1^FI5CA
M5R^((X_? 8?7]E8O_%X85BO4R(9@%5VS 0G,J,K4ZLR?C&Y*T%O1PC\@^ Q
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M.<7-1)&2'5HHT*]:P)%S>$F#QSUWAY9@&2*U!)6E567$%E<QRMVV"MQ?B2K
M%3S5JV2]<@8N%%U%M@QH 9+>3'U:Q]8UYQ2GR3',,[&0RA99+KI"FV$(8;R[
MY&4(:2A.,L=E;>/I5J<>D]4RK!&%,KG37.9V)>29@NH0@:61GD*H BEMD 4
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M1_[1Y#8 R_TFD3\=<8,$;AQL-:>M?;WE>%A(]>&PRKVTA2TS3&-B) %!#$J
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M+0>#K:MT^5%;EQDM 1L600^E@Z .?4HDICV9HK"FAD>DRAE2LJ2@="%.+XK
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M*AWFL+[KPC/>5::U1)B<_?U;HNM-D-,M<NUC(L$HK6:\;'XB,3<5:(0'D8W
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M92I*L*2I&>RT*QG"L+PKMYL?7[L85]^._P!.HN -B"H.ZL#M[;?<!MN=_?\
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M%>+@['8[#[SN>K3B)958J-V\G?P1OY\C;P1]WW^X]^O92Z:^MO1T='1T='6
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MM>E1%6N9D7*6"(M4\5'F'E1U]BKW78/7)V^W'Q #[D, 0=@HV)+!B#S<%E!
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MM\'WTB[4<W;C;DG*NS(P!X,0J$+N0:C.;E >@KT%>E@ 1+E[P>7+1<."Z)#
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MC+OGRXXE"\9SFM]0Z-N:.;%1M)$L>4AGNT($M/8M5H8)V54LR-'&>X(^!#J
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M:]:/M6E CDM1VG6S/RB?>M!\*1,J\&/=4B5-MF<_X%G]TVQOY5=E_G9U)/\
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MCNKO]$Y\O;[L]LJ3CZ]^^._T:T9XWC6&41R2,(@ID,:,TC!%#OR 4,3Y+$
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MJZ]<I?U-GL#@(]082/%8W$)FX;="I'+(D$+QP.)WCDC-BK*B1\:XY/( 7*L
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M/MN)I[HUHY 7S80-DE8:K"41&H.-<HJURDW(,CA1F0[728RMJ9:4E<D6[,R
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M@C CB"J"$1=SMN3Y/39<P]?TZMSZ;P$DOV?!VYT-HI/,9+423R$R,OMRD(4
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M#I7$Z=P4M:7+O3O9S4E"T%@LY;4=EXH*D>TW&*:.OLTE6I&Q#_*?!YD\T9/
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MA[2+ECF=AU2"T769&X0!E@.<EBZL<O(=EO1YME.O?'WM[_J!ON//GY_IN?\
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MO#:;-L4K&+Q.5:Y/CX,MC%BPSUC)5:1:EE1(8JR1QR/:M[LWQ,Y9.PH8%RS
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M<$^4$39]P72!KFIZ]G=6ZYB7MUMK%NV "-K.3#K,O#4:L3@$!?9N#L%@M/L
MSWCH(W'NN^_W^/V@-O;]T_Y3UU_$FYL5:W<!^7%8'X_<S()^=T5?8UJ9MO%#
M<-8K,:LJ'>;29.V&5KS$;#QK.<^<J0.>:&';QEQU:4XSGK; =IX3L3M+&=@-
MR=G!V 'DD_0?4]8,ORL.2^5(_.V^GU_1]_5&VR^0=;NL)&#PE.WU 6"O6BO6
MZ!DI3CELB?B$24 >@CV\M"C9@"9 $T-98:DC3,>0*^^Q(,O*<$2R[TY=MR68
MD6+'YJ*:*>&Q$[X2]+&'B<-QDB7M,Z,O)3QE1E)#@GCL:?JUU@D8R6\=)')%
M)#(J9*O&Y61=MT<\PI! /E&! *D>=PP_Q:LY HM>P-R$9K54JVJJ7)X"XS[-
M"L\K":8G86X4@J(L \HEFKSR[;'G$3\B-$'CG0A@49& PQT6B9*:OAY.-6(5
MLX(8(*%9PN"OK-)%C98[%5HY0^T$IG1C*XC<-&RHB1M&)"N[J\IY!-C.[++:
MF3EDZS1(]R-H9@\93>6,1%1&I==I 78LK< [6DMK:UTA4Y*FP=)Y*R<.1;+#
M8HQ$CHS9#KT4%-$-NCPZ7R BG24@MM)PX8M;:SBG"#7&6G2'$]+\8Z8NN]:+
M'9]XS8FF3GB+Q*+*P(CW*,6X@>6\<F)8@$GI)=1[TJ3/;Q2N(8XW*WZX#L@(
M+[ @ L3[?0;#?8=3VXD[DA;=P!J>I931',63AKMKC9=*D+)1.-&TI^.7&7&<
MND66=7YX"!)CBWQ1)5STWFE.ML'LK9<QE;*TXY2RU>9\OD)T4 &_8D59#P<?
MEF(#HVS*P/AE(!!W!ZZXP&<Q<6F<=CK#V XQ:5I6AKRR*.<11FCD12K#9MU8
M$CVZR$K);;D=4[5H"*7R7:G-WV(*9V;/X\.?D*S"248JOU77]EJT#6PMBB'U
MV'M>L*1 54\H>T$3@,G(VRSP\J ;)0HU=1"M(&1NV-D!"#OIN#N6!)*$$AV+
M $;'P"" =U;9RDU>S#\;('MNKSO]E6^!7A'#)&D8L!HTDKPI&2)"ZLTLBL"R
M!)&T/<BJO<=AWZ>T%S/L-HOJ*7$MO@\,=S0<?6J91JX@.'ID2&Z),NKBV;A,
M;#NS;Y!:BDEWLR.<4Z/&".JUFI.0J@( O(_VQ3N6/DGV\\0J_=\N^PW/2Z'4
MF)CEFF>6R\DPB7<4;"+'%$FRQ*-F/$2M-*-SN#,5\A0>M?7F?LHRU<VN2%A"
MU%OR/:D']1H5$3VFKO"V.-6%IVF"93,P1\:T?%J+PU@P#!32,F1[PYK/F8?;
M6KJKT'S4&$TWE:]FIE+#R9<RAL?CK-Z)5^%A7B\E=&5'\;\">7$AMMB.N5O6
MZN,[JJ"[3LTXH?LV&,"]9BI2LR,P8K%.5<J"-N0'$GV/OU%BV'3UBALQXNM=
MS@&,RD!- E/Z@N!HS9]<GHVP@I+$;9#<($>*BV6"VFBQGLCN.98?9>PVXFXL
MIJ:CD*GP\=+4,$J6:%R&5].9&:-9L?>K7X1+$HA:2)Y:R)*JRQN8V8I(CA6%
M34</8J6.Z]O#RQM#:KRHN8IQN8K=::K(4<F0)(J3,R,49>0')2NX/)53IBM5
MZ*@\ZSW6:X -Y'S/P26T9)13KBR"WVAO:O\ M6'2GGEL"^N_[9E3;'K.^GZB
MLL9J;'XZA6I? ZCF,$?%YOQ>R$8DD9F>5UCX/VD:1V*1<W[:%4YMQY'R[AK-
MNU-8%O#1B5]TC^UZ;E$4!(U9^2\V5%4,_%>;;MQ7?85]>(/*FRB]29+J=VK/
MHIO>&_G"J2]9R;ZF:=Y_A^)0=GWOMO(CW?H>;V_KC>IV]=OO27K=FZV6.F>Q
M5R5?L#,\OC\?8H\^[]E<>U\0J=WCVSW.&_#DG+;FN]D>FV.EH+F1)/2F[IQY
M'PEN"SQX"[OW.TQX;\OEY;<MFVWXG;U(N1O]TJO_ ,!DO^T"]5MI7^T6_P#G
M8_\ L-T]ZC_MM7_FY/\ M+U&WJ5]1OHZ.CHZ.CHZ.CHZ.CHZ.CJC?[2#J_9>
MTN-O!**UX;(C,A[ V\[9FH\DX?+D>2S71QWW$"(R@M0SN7$,"NN(6\Z1A+.%
M9RM3=4:KCK-E+$MKX)4A,6TEV:O&L9ECJ1%D6=@[[<@TG8221(U9N)'@Y:CU
M/@=+X3$VLW"DK3_&QX\M#'+M9C(D*<I#O"LFR*\BJW%1N?8 T-6$X>M:R-;C
MD$2K:*4-6)QX,S$A+L7%445$UY<G'OOFN1]=!C7<F/IEB4):DW\DM-+;:,%+
MC%K56=QEO%X"GJ..M#HR]-D-.-C8:ZX^YCKBO:NWS/,1'9S$C3FNBQP$+"\@
M6,.03RQC9;%[-TY)C\,),S8R%*!XVKU15DN)8N25)84@,MR214B22)2_:0)W
M!QC9&/Y0.%63C7",GU] T[3JI&7=,W$Q+R$15H3/(AI7S22774H$+C&XT<?+
M;JG<E)$>>]-)"6VMF!IU<U1SVKL[J.U/J2WJ$4*]?(R6)_M'%BG'*8(W;>$.
MEFQ+)P;81J@C791\T_\ 3F,5M<Y%Z-J2SC;%Z:A:AM3K+)9HRQ&2M(\3JDC-
M#*S,P=2 #*HW!9CU==\R-4R.GH=JZVR7K4['0L- 6*$AX[,G)E/0TFU(ILL>
M*:0##G$S;J&T2BG'VY+R-MH4I]EE'3;B,3FL;E/M/$Q8Q[F ^T<EC6S!C:I<
MAOQM6EIJCI,PLU1)W(!&H!7D204(*;/^DFI(-7VSBL?5O8V]:L6ZEV61(XZ\
M=F!H6HRE%,ZI45F:M\O;))92'^41\I =EYF\@GI<R+.#TO6'Y2='J :C6FBZ
MM3V7Y1FI04>+@MDJR2D?A02,#^D/[@E?JD!C^3R++-6[B<%=U+>JV+TCW8!F
M<N6BBC2SD909>4\H7MJ&;G&H#,B ;+X)-EWX,?Z::,-2K8KG4EJ*.N<E.K.3
MDK^P:6Q<2O+)7@5D+1O."JK&.08[DO\ ;+JMOWWRCDZEK^-=I%6@ZRU*[!>G
M(UJYR*VH@>2,(]:$B&SFY6;B8B5&AA:_!..# -AA#+6A8KSF+K?U&L48H[/I
M;7AS&'RR8[O8R?"1TL54R\M3X)XK<S1QI#7E<B=II2P:5@RLXVWCFE=0U]&Z
M!2_DI?MG)Y.__P"CZ]53CXN]/VXSQED9>U6EEKRVI+<JP]\=R41+S(Z>#3/'
MS9&E"[SJD0Z,O46.U=L8J4U+@H9V*17B6I.K2-:AD/29M<(ABU-,6>..2PP+
M,-/((#*^'J*9JW6,%(: TAZA4,-G-(ZOHY1:^H<U"5KT:D62>6-)$<V8_B(7
MA,*1S5:IC,<S1L^YC'33GM7XC45C"Y>E!=Q&7:S4IW\E!2D-.E5L-(+=7)/9
MA2O>1UA$]8/&>$2+(SQN"@B'S?U739NF5';K$1":SVK+)/C[=1F&)(-N?37&
MQ@2;!GW>$QP<PAUM:"WQ<)38?50^Z.))8>^(:OL&_IK)38[[;AU+0:C2R-C*
M1Y.M;FJW,D&G:O&8XHYY:YWW0REI(R2DGD#:Q="YV_7O?8Q+97 +5@CI9F.P
MEGNW%YFPY C5OA[')2D:D"H\;1@2(P85P5+8\K6!WHQ]AB=@"D%9>K\HLC,3
M[HD93"3L-LO,KP2/YL/,JSG",*0C*D+\N,=:[>,AMLLG-H+2E2MJ(@2\ >3(
M>0( /G?]!/W[&T;V)AO2),KM6M+P(MP\!8,:.)#"S,K#M/L5<#8\6;8[GIOR
M7,.O..X0E"''%*PVG.?*C"LJ5A*/[Z4XSVQG[^V/]_IR52H7<\^(XD[?H]S]
M_OOTY?,H7DW/@.)._G<>/)_3_M]YX<9QG/U^GW8QV3C./U_KGO\ _7^O69!'
MD#?[]MQ[?M'SO^[^UUXS<OT;;_IW_P G7YC'UQV[Y^N/+CM],_7^_P#K?K?W
M_P#F_7R/D'V'CSYW(\?H]_\ )UCU]X2I7UPG&?KV[Y[?_7Q].WW??VQW_P!_
M[_-P1^<1MY.W^7SY\>1X'M^YX.OCRY_O9[_K]\=L?\V>_P!?_M_W^@ML-_&Q
MVV]_YCUDJ[G;VVZ[X0),F6* $P02:6\R*.,.TX^^2^\I++(X[#>%+====RAM
M"$8SE2\XQC&>^,=:FD1%+R/VD57D>60[(B(.1\^W$#R6)'@>=NLG=8DDFDD"
M+$A>25R%6-$!)8L2 H51N=SL -SXZMOJ7$?C[Q>I-?VIS5L<C(7:5CTSU7XX
M0+6$2<FC*<N B6Z19=P2(AU24>]'P]&#B+SEA94BMLD3%6G5F1U@F7HZ,<UQ
M7M048\_,HDK-NVUN:M&PXR"% 1$^[%G9&50-B*9R6L=3ZES#X+1%)$IQDQ6\
M[8+#MJ0/RT;,3'64CD8]H;-J5#SCAA!#]>E5H6V"V7PJM,WJOU\6 "G_  _-
M>VN$JPKF5A0HLIQTB)>-@!G4X'RH6.:?9CF5IPQG+3*58PUGMY;$HU[%/'4Z
MO>DL6ZM*O7^("DRSV(($C[P5>3&225>X%7<EFV&YVZM:M2:IA8,?9G,[UL7%
M2GLGD3,T-18)9R7:5R9"K2?.TC'?YF<[D^;GS%I#%@TW!WB <FE+UID&::+E
MA1AWQA;20"%- *R&RACVT?,BQ+$*PG#2@F$%(RDG)6".K*U+<S&IM)X35NH=
M.087,0Y";3&2, ,+75J0"6E;GJSB.PK,).'#9^T259BI7;FWTUU,_P"-LV%M
MU:$(S*3X\_ E^W:;%UR]:Q(K[/W9*QF::1B>Z7!)4KP$7%<Y;B)1X>MTVE5F
MJ6H<0>-+N,2)G)K[#"BW628J/4G(41+.EGOFD28C2C'"$L/#J'6SYEPN;+:@
MMZ?_ !8OYRW:PGQEBR(YI9!-/#.AC;&W)>6]BA$2[)!(I5&8;>%'5@GT=Q4V
M7GR&5R^3R>*:<V8L-9E!J0S$1AEFF.\T]=8HDBCK2.(E4$$,I.ZKT=HJZO%J
MY+[7E0H: HSXM@=?GB&966FYO+3I,+YHIQLYTPC)R17<BE#..//8;:+0TSZS
MS2[$T-&8R9:.NK5W&4I:ZSU,+1K.,AEH7<[QPMNJUZS;$2RNT?Y)F56!8'IM
MU3K?#&9?3_3M.U<MY0?!.F.58*U2B2([BI:/;BBV@[B*Z_*H)=.1 ![FEM(;
M$Y,7[<^TH"-E2X5C,MG,G*3(T'(O2%A7(XC'LYR*D&6<1[539<<.M+BGW6FA
MFB2%H:7(--Y[3^E,QE9\=I[4<VG+6.R\>%CQR"62A7#!8A>,CB.:!1O&Y,DB
MQ;@OS*[,X9W6FG/3K$X# VRHG,"K%1AC%@15:\<:R"21R!&@#!5=^7,@^/(Z
MF_JG6G+.N1M)589ROB5J1:C!C((>0]>Q7%F.=(E(QS)TE$N-MR)L6 40 .;(
M-K,%][[539 S[2<:N&J>I5[3-6QH/(4=*Z-:Q4S60P\ZUJ%OXJ,R36:D#,@G
MD65U:_+56>3MNP[B\DZH[4NHO2S*OD6H8K)+:J\WEMQ1.*M 3O%7L2?#]_C&
MJSS1JSQQ.O(1%E,;*X:?GYPAAZ10Y#<T&.- R0L^(R8(TJ.0-;X2;:).8E&!
M(ISVP$Z E"<G-,"C#%#Y<=0Z04PI\VJ8M38_(YFU7H8ZQBXH;^1QGV3.)#)0
MFQLYAYB21562%T 5@C2!9!N'V.YFGI'ZBYALK5TQF&-JC<HQ3XVXTQGEKR]I
M76NSL\DC5I8RO#NOSA<JI*HRJM0+NQ+H[56Z2]8I1VKCDMD-0ZRLY%0ME:W6
MD([_ *=@=EYY\AH7S^U;?==?;:P\XI2I#N1&D9,IA$C2"(R$UQ)(O%I%B\J)
M&]FDVY'[]CYZ3^RL<+S9%*D*6VC[9L<#NH8#GL-Q'S9?E:0 R,/!8@;=(\PX
MPYS#A9+A"\8QC"G%>;/;'W8[X[=^V/HG']JG';'E[X[]:0H0%438?0C_ .0/
M;[Q]^_GSTMCBBB'&)551OL%&P'W[#])W/W[D_?UC<]^^>_T_W^MW6LG<D_>=
M^OG/W9_WO_M^_HZ.OKM]>W;./K],9^G^3.?^O/Z_?HZ]]SX'N?;_ ,M^OO",
M9^_&<?XL9QG/_-],=8EMOH3]3^@?[;_O=9A!]=Q^Z#_Y=2=XV\7-A<D9V1'K
MR$0=-K+")&[W^59=^7ZM&I0X[A3Z\83[^3*;;<1'10ZTNDO8QEY8XB7BV=#3
MQ0STX'F2%[MRK36:8NM6LUJ>.ND]R9598*\<DJ%W<'P=E4MU#M8ZYQ6CZ:O:
M)LY"R&..Q4#H+=Z1%)\;[F&!?[N5QMM\JAI"J&6;6]-;:%A&M:<.(>?+V;.Q
M^8786[YHD9N5EPGFGVYB%@!D-J9K,&LA A2CPC&G66Q?2<-.6A!_5D5]/X4Y
M6QIVAC:'J'+;F59[>0J]O%U1&8Y%6E&S<%ABE4R6K]E@75>*@1D;0FGIG4NJ
M,M/F=>6Z28*%?_0^FJ*S=B/<EELVI-XY)YI(W,1257#*Q(5%8Q]0NMFS)Z2B
MR(&4DEFRP9;P7Q"*<:;#?';*P8IYPQ&%$&N+([8;6C++.&FT.94\K/=$DSVO
MK\F)FT[+.K9*C+\##:PQ2O06I!,LJ\)D)DEXNHC41]M%2-2 3U:M>C#"%,,0
MBB"H$B8<>"J@1%">%5%4 !0%VWVV&W6VI]CA=6YO#F[ESS*4K5FJ5J<7V4XX
MM5NL^5J4YG&%KSG.<=^^>W?OGRXSG.<U!)))([F20R.SL[LQW9I)#R9BQ)+;
MG<[DD[DG?R>G*/;SL-O;_(#_ +?Y/IU*_P ?!D>5YN!Q$B)*/^[XZ4>)CF!#
M&6HZ2C[!9=C1EH"/"6,L@XMR+>6*"H=UY8C9I;K0F7LX<S87IZ=5SV+^"3$U
M[NAM1U;5;*W,C&R5*63K5))*\M6YOPAL1[PNY96"[1."&'7-_K7:M4<UBI:Q
M@$34X+-AY8G[M>QC;-BQC[,%H,JP=N=N4@8@,$16)5MAIO0FWK3Q)V#LW70<
M%5[:Q'6&2B,-6,-Y[ )<5(*4.6&2 0&<VGUAV'2H[W?LRU#M)*:6I*L8K[&7
M\KB,C'E,/E;6.LPK;I3&K*):]J&0-#,DB_-$_A%>&PH+(0&C.W@SBWIBAZFX
M#3V<GN9+%V+%"M:[N.E6-IH[-;C+!*CB6)E*32*LH3F"S%' X[<]1JF]>9-U
M958)YIF,*)8$S)RN?AT+%L-N..^6*CV6TLM,LH6M;KC+;37J.>8A_#[JLJU0
M8^*O6LZAO&TF.KS@Y7-,&N6$YM&) 6.\L]CBX,< W+!=E'C;K#+9C1GI-B##
MCJ/*8!F%6#:2Y8E<(O<MV'DY%F8 CN.?'A51!L'+V)0C]L[*U#QFU64=.!4E
M;58:FW6R!ZTTX4<*Q)R P[327_8I/P<6?,I9;(D5*4I+7IC,+S)LA9T3/\'9
M]/=-Y.>Q05K69R=I^U?SJHT)BEL1Q.XJQI^8I*Q&))47M[KN6K"YVGIK 9[7
MVHJRTK68WN/7$PEOS@ FC7D0L(H)1 T4*5D8K$7W9PTC+U,*N<2^0E,LEO5K
M^\PU*@5CUN68+C#):SNH-:B4%Y^72$H9^-8*0&4.M8HYF7'F% ,Y==PTEZ49
M[/9K5MS4NF,1Z<]MLY#6QV1K9:S!%D,#!22!39R&461TAHV+$G<JQ2ROW .?
M %N'599[U6T'G(J*9K2\N4ORL\4<<XKU9D1IEC3XER\9A"NZLQD=8HN09F&Y
M(D#<.($1N/38AFRY2(>DHZORP35^;E8_)C$F)&#V.+L<*,N)"D7@)'WA@<K7
M%%O+;RV2IL!)[2R$UCKZ;&Z+RN)TEC-,'%O5P5;(7,G6E&2>WE6)CR=6];BE
M=!5YF(5!(D9C4]Q%",PZA."UY=TUF)KVFD^%QS9>**]I^U+\\J&-(IX?[>(I
M2A'*I9JH[\EVD=HB$;7*3-6O7<K8(F#L$C$N+45#R:X:3*%9DQ<*6WEM[([C
M6"1G6U9_%=0I*D+SA2/KG'6N&8R5TD#2Q+-&0P!,9=''E)0I)9?)4J=PWG<G
M?SW (,;FZU.W8IQ6%,4=B!;$*%XF8\]_R@;@X(4, ?/$>YZ1+QI+C7I+)==;
MPM:L-K6M2$K7GNO*4*5Y$JSGZJRE..^<=\_7.>L@$^@]P#[?3;_-X\#?P![=
M.)158,L:H>(3D-BW$> -QMX'N!X'@?N]+.>__G*S_O\ _P#W/67G]S]O_P M
MO_/KPGQ[D_<#[?Y_N_1U\YSGMV[_ -[Z9SGMV_\ M^[HZ\W/WGKZ[*\N,]LX
M3GZ=^_TSG_ZV/\7^+HZR\[>-]MMCY.VY_> ]Q_Y[]?:,?=WSCMG/U^O?^]_>
MSV_W_P#%].O"VWTW/OMY]NLU7Q[K[DG<^/VB0=AN/!/OL=NI'<<>,^Q>2MSS
M5Z,"EJ+BV6I*XVXYM[$!3X7U4>M*2KC*%.+RVWAQ3 3'J%F*;<PPWAMMUUM+
M<M"G5L6!#9L"",S3)7B:;MPJZHTTG!6[=="P[DC#QN-@6*CJ)ZOUGAM&8^.Y
ME) +,[R18ZC$1\3D)U1G$4*^0JJ 3).RA(]P/F=D1I<+VGK?CJ-(:MXL5N1G
M=UJE#8J?W\:8M,VVR(<EHL*I" N*CX.&+9%7@L@=[+J!W7/<29Z486U9F/Q>
M,BR-2EIB!=:Y/)THUM_:F-7['IP6X(VGKU*TZJW<CDW:;)6>';@+Q*H5R>JU
MK::U+KZY0S^N;T-72T4<=VAI.J)HH)II80T<F2D>19K$]5I"8V*@/(-TBA3=
M6AU:]D61P>9KDU/.64I3K[>#0S7,Q_FD/([(J<>4C!4FM+R<--.N.^@I>'G%
M9?2O&5/^8UK>H8Z_I.2Q7R(JH<?3;$L(,36@GC1)8(0@62;X3B(H55E@4J3\
MP][AJ4*L"0?#01UH8XT18E14XI$O&-%1>*JH4   #8>/&WA]?#;^$N\]^'C5
MA*($"<Y,:1=:(&#P<0[)M;)KCD>SG*EIRRT^8EML@CZ^DVM:\MJRG'EK7%P8
MRY9M-F+=R!4HW9HGAC:9Y<DL;-5@F.SE(II-N[*1N%]RFY95T@8%#$ [=Q 0
MS% $+#F?;RP7?;[SX/CKV/>FGI5U2%]H7_\ )F;&_P"4?47^>8?5C^E/_KE3
M_P"B7_\ PS=0;U%_]5[/_2:?_?KU<-K/_:WU]_Q(JG\P@=0&[_ORW_TF?_O7
MZF57_>U?_F(O^[7KEDIJ'L=!E)ZO2T9.P<M59(^*F88\64BI,$B,(<'-CY$%
MU\,T1]O.%LD#/.LNHSA2%J3G&>M,D<D3O%*CQ2(Q5XY%9'1AX*NC ,K ^""
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M)J)W3K!2[) 1(&;=;=CSZ K2OTK-<;W:3ZP0)(860Q7-85618P(Y.2+"S8[
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M-)5D484=G9IO7D6!GGDL6+V7KS9"'("C;TAE!562MN*RNK4YGD[&_*,EU42
M2%.0!ZKRI^#MD3J2?5F;R6F<WFF!CJ3/JC2M6OCX/E"Q5:PS]A 410JR.S./
M+CYV9BPS/V9O4,75):K5SFKM.'S84J1/3KG Z[GS9[#B4Y=$:)5L@9L$-;F%
MJP.,RGLA?IJ6O.,N*L;_ '=<14PN0P^%P%O%/EA*,EDOL?.6;U@3C\LBM]DU
MXX8V)8)&B<8U( !8,[38^EF>>:.:2[IU^T-HX_QRTJ(U/GYN(R^Y;;QN2=OI
MM[=-1_J4C3F.W;GMN?"OKYE?H#;Q^-]?I]/PG_3M]WZ_?^]U6JZQQ"N7(RYW
MW)'V!FQY(]]_@3_FZ6_[G.?V(^(TS[;;_CCI7?\ =_\ 2_G_ .EU<GX/WA?:
MN\)FX;IML9OK:>\W-Q5JJUQX4[BEL+7;D BL2DG)I(04/-W1,FDQ4EEK(ZA
M5,99PY[E_"_31O.ML*8%A^'R083-*9QI_.]Y@RJHB8FF4[:D%EXHK<F.Y(V
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MQXX')![J!LY"M8*=P02F,+SYA&*\/(Y;[;;#8[GZ ;G8>>@VJX?MF:,2<N'
ML W+]3L?KY _;('N>HW\JO%'T/Q_V=IK1M)MNL]N;NV'RKT=QSO&JXS9  -N
MUG$;>FGX>1N\G&1\=//$G5%Q46LNJDIC"7,RP:#SXI+S#CVV"E+-'+*RO'''
M7EF60QDJYC7D$!)78-Y^;S['8'K3/>BB>.)&225IXXG0-\R*Y(+'8'RIV^7]
M/G;J6T'RUXQ6;:\[HNO;ZU5-;@K3DT/-Z[C;I"%V<$VLBI-LT6J.9+6M^:K
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M;SELD9U&<ISM@&\\(\C>6,;@D'RZCP1L0?N(.X]QU@[GBWA?S6_N$^X_H_\
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MB0G?/F:5D112]LE9B!& 06.[!5^7W^8GP!OX'([ ]8"]7,LL1D"F+\YB#Q\
ME]FVV^3;8[D;G?;?;I807B*\*;'0;KLZ*Y!5!5+UQ;ZC0[[)2 5FA3ZA:[\:
M/'4J+L%=FH&/LL9BU&$MM01Y4.W&26$D.BF.,B%.,^&G95U0PMR=69 -B&5
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M@,H^.:W9K-PX(6146B/)+$1)Y(&8/6 <D-YYM#92@BTL*7D9["'3_P#.<TH
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MR&:M"IE^=*/-/L$Z"5&IJ%=ADU@U3]IQJU=DB<&N+*KLT:CC.#QV5(U4%#Q
M V 53N68\@E^S)B)E:6,B?X<L-I">4)\[N[LQ# MN3Y).XX@<3\^,C3+6-R
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MP[2(SQ"5&#=Q49))&?<&-E=6'+8^2#MY'3WL^$A- _AP9@[UK"K1>U/#$G.
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MNG=^RN1,G)VT!S0CT8_.:[M%LA=:4>$'G"P"J>[:[B18821.$HW3K^+.I/\
M!_-_R5?_ -1U!SF<21M]J8[Q_P#AU;Z#8?\ RW_Z6Y/UVZP%!\0[A;2".!%9
M)Y#:DL5(XI:DJ\!;["FB<H8&[G[4KNFI?2 -AK4>GC!-#6*E0M-N.RVXZNS-
MKJ#Y\K?6YDEP!VJLASY^+.H_\'\W_)5__4='VSB//_I3'^=S_OZM[_3_ .6_
MO_\ R.J/OM/_ #4XS<NG^$:N/.R_PA)U^SR03;L_)NP*G\(S:EZ'S X_V<56
MM9/]_BN3/]S/>^U]G_9OM_<">NAN8S)8[M_:&/NT>]S[/QE2>KW>WQ[G;[\:
M<^'-.?'?CS7EMR&ZRI=IV@_PMNM9[9'/L3Q3<.0/'GVW;CRXMQWVWXMMOL>O
M0AZ1=:^CHZ.CHZ.CHZ.CHZ.CHZ.CHZ.F6V31[A/6NIVBINUI2X.O6^ ."L1<
MH$EU-CDJ;(CE"/QL;)YRH;-7=:>9>:;PK!;:T.=VU)S%<_ALC?O8Z]CWI U*
MF1JRQ7'GC#"[-C9DDC>"*8[H:+*RLHW[@(;Y2#.]+:@PN.P^9Q.93**N0R6%
MR->?&0U+!0XNKG*TD,T5JU4 $HRZ.DB2.0865D^8,$Q\F;C_ &KK/\H;3^:G
M35]A:C_XD_C5_P#H/3O]O:(_7M5?R7B/ZZZ/DS<?[5UG^4-I_-3H^PM1_P#$
MG\:O_P!!Z/M[1'Z]JK^2\1_771\F;C_:NL_RAM/YJ='V%J/_ (D_C5_^@]'V
M]HC]>U5_)>(_KKH^3-Q_M76?Y0VG\U.C["U'_P 2?QJ__0>C[>T1^O:J_DO$
M?UUT?)FX_P!JZS_*&T_FIT?86H_^)/XU?_H/1]O:(_7M5?R7B/ZZZ/DS<?[5
MUG^4-I_-3H^PM1_\2?QJ_P#T'H^WM$?KVJOY+Q']=='R9N/]JZS_ "AM/YJ=
M'V%J/_B3^-7_ .@]'V]HC]>U5_)>(_KKH^3-Q_M76?Y0VG\U.C["U'_Q)_&K
M_P#0>C[>T1^O:J_DO$?UUT?)FX_VKK/\H;3^:G1]A:C_ .)/XU?_ *#T?;VB
M/U[57\EXC^NNCY,W'^U=9_E#:?S4Z/L+4?\ Q)_&K_\ 0>C[>T1^O:J_DO$?
MUUT?)FX_VKK/\H;3^:G1]A:C_P")/XU?_H/1]O:(_7M5?R7B/ZZZ/DS<?[5U
MG^4-I_-3H^PM1_\ $G\:O_T'H^WM$?KVJOY+Q']=='R9N/\ :NL_RAM/YJ='
MV%J/_B3^-7_Z#T?;VB/U[57\EXC^NNCY,W'^U=9_E#:?S4Z/L+4?_$G\:O\
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M?S4Z/L+4?_$G\:O_ -!Z/M[1'Z]JK^2\1_771\F;C_:NL_RAM/YJ='V%J/\
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M^3-Q_M76?Y0VG\U.C["U'_Q)_&K_ /0>C[>T1^O:J_DO$?UUT?)FX_VKK/\
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;I%_>C_>5_P!>.M<GT_=_\NMD?U_<_P#/K__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g383050g23s23.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383050g23s23.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
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M<&#!P8,'!@P<&#!P8,'!@P<&#!P8,2]H-_JKVK_Z<_YMUCBOS7^\'_\ LO\
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M=+-)-28?,':-I5ER!;>IUHV[/ID"]:<U BRWZK!H:I=8?BLQ'WY$"0MFHU*
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M.=F;;,BWUK.K"+(ME#+-[2K;5\B.7^U4DW?\KX49XHR[;2<484)*>9KT5/\
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M5P:A5^LN:5V=5W(I1WILVS'Q&$:4@^N4*GZ<U1UM$R-VS<?1RBMS^KK.,LW
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MDZN2JE)ER+BKCU0M:3+:;)^(?HU?R]MRG>S7*G3F;O:O+76$Y<RO^R"XM04
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M> Y8HX>#!P8,'!@Q<===>67'G''7"$@K=6IQ9"0$I!4LE6$I 2D9P  !@#A
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M#[, )!D&"+@C<'K@4I2U*6M2EK6HJ6M1*E*4HY*E*))4HDDDDDD[G@  $
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M+V@W^JO:O_IS_FW6.*_-?[P?_P"R_P#&;QN9?_?;/_:?^$O$G\^'^OBYS/\
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MB7-&G,O;;2XX*9YUU]5.NK4X:5%/V2UI5VZ'U);4G_&2&W+3),R^N<TX2IJ
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M1X\+01]Z0>8@3O'.V\;]8WPBM5IU@3!)D $QS//R\,9)[ .[:#ML2A.<;XV
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MISP_VM<"XCN\0K;NW[HYXH=DM,-.R'EI;89;6ZXXHX"&VTE:UJ.X[*4A1/D
M?'8ER=*8*C  ) N??WG#W( 0#) M:)($E6WEX8X-K]S5/5&6_5JS+F-VLJ0\
MFWK:8D/18A@M/*1'J563'6VJ;-F)0'DH=6IEIE:4!"@LI1<MM"G2$I +D#M%
ME()"B)*4DB $S'7:YMC?!2P A&G7^VLQ),<I)D B_4WQI?N8MU.PHU/('3\
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MU>VM1M82K<6Y'K,VZ]#@1;].B/MS**N3;]3CGM1JG19+L*2PL8P2AM?<R$;
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M6D2=AI\H 0H!:0/53?4.5B%7&P @]QQ%QTIJ^<??:M,>PT6-D8/0D5S&?/\
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M35FTQCRHL;'T_P"'C^YWX.V9%_1G?Y<^8TX ^CFTL^%OB3A?O55?_&U:0_\
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M*3)5:=IL0(._M]N#M@[=KXD_MXB%3>)CKRF=H3YX9) (*C?:YM!'XE?".O+
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MA5Y31N2VIB*9576$A#4]IQD/T^JMMI^:T)T97:<:3LV\VX"$$E"-*H:#*DE
M46UIU)YJ!GU@>4 [;^-\:E4@(*5(5ZJQ(U""F+%.T;]+0<=,ZRK'WX-5AG_P
ME7UN/(715??[ ??Q594 ,LRXP/[PH_/T=OVQX<]^_=XDD\0Y]N?[=9I:]O[.
M?W\[&\^[$;=L?V9S]8 ^OC?[YL>7+V<_?BEB>1\2DCX$CW# 7-B!GZ>F/W^W
MAB)$F!?\]L'K<N700?@%8I[S;PZ>>.O3Z/J]H.W#MMJ]6;[[<SM&#23>"2?;
MW>,_+GR7O!MG&<]/9^^PX2@D&U[;V-[\XP &.8'@;S^74WY6PH<'AG?RQO\
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M\":L\/YEG*' 5Y6T*BJ8+D)6T+NMTRQ(=J&D?:*!4@*$);!4I(/$GWI[J/\
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M'COIRF962VIJJUSL+2 MBF1W# @.I+B%U"1+<26GZ:TM?&<49D4-IRYHC4X
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M\L2+H8RX]4+VK[85\G3)5+I41U(/=RGZ3&>$YYM0&%H:>DB.EQ.4K["NR2D
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MG/AMM\!G]?!V)DF?.#/L@^\88< ,Q/B ?SP!\9 R<>1Q@8'M'[_J.R,&>M@
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M,WF8Z;#ER$<[S88.U!Y$=PV'LG]&^ NA0SVADY'MQG; QG/ETW]_ 6O$#F)
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M;.D%:H*B5+4HDDDXE>UK=>K,Z)2HP4EI* Y*?QGN6$D=\\I2ANM9(2C.ZW%
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M$) (4GM2.\&9(()2DD@.S_,7ZJ?_ *4VC?\ ZK-?_G&.-89]1#;)<P_[T_\
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M %2.UIGE=7ZGQ@>,77O1[/TA]G"B><=_Z_7MQ#UMR#[9VW\;;VPO;]GUC[.
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M!J'($%4\[C^KWX/N?H&1_@J+CQ_![_1OC@U*OZT>P>ZQ]^ 5#DB2J.>WGO\
MKI@^Y^@_[DQ!X;M@_3^,=_I'T<&I1_:CEL.?LY>8Y3<89J'.14-^8^1]@Y\R
M,'R!0O\ <J'[@T,_K ^L$;^S@U*_%^MNGMO\;87I#O/5X2!%O(WY&X\I/D"A
M8_[%1?<6Q^KM$9\OUCAZE?B]D>XV]OQPB^YJ"O6M:)'?@^Y^A'<TJ+]*-_\
MZ;]O3X<+4K?5[(CVS&_M]^#TAZ;%0'*Z9\?'\N_ BBPXCJ9='<ET.HM$+CSZ
M7*?C.M.#<%2$NEEY!/X[3K:DJ&0.R<*"F?O7$W!O;NZ'ITP=NM7JN#M$'=*@
MDB]I$7![Q![XG'2FE]Z3;HI4V)6>Z-?H$M,"I+: ;;FMN,I?@U)MH;-B9'/:
M6V  AU#FPSV4XEM@*E*O55<"\C>183O<GPDG%76,AM04V"&W1J0%"2+^LDQ/
MW2(!.X\\=&:Y/I&M>L QC&J6H .2 3B[*N.AWZCBNR9 .4942=\MH??3->.-
M_B58'$6?B#;.LU_XZHQ%@?Z=#G;? &?>/W]G%CV:KQ<#Q]]HQ2A8,;W,1%A.
MU]7Y8#(P>R0,^PYZ],>' $2.A[]OATP%8!@@QU%SMTM\<4F1[1]) Z>S!X8;
M',W]WPG#UI_SOY(_I87OU;9 QX_OMTX.SYB>>X/Q&T>'C.#4G?UH_P!$?TL'
MK )ZCRP,=?C]7""" =B?#WS$_KOD+6GD%$VB8'LL2?SP=\ ?G9QY9QGIOU&/
M:,'KPPV.L?KN!P!P09!GN-O?^K;XJ]8!&PSY>'QW/"".I\OWC 5VL//;W'"%
MXG(QCR(Z_P!'U\/0.IP%8BTSW@1[C^6%#^^Z=O?_ $?'<\&@3S]L?+]>S#UI
M[Y\!_2/P&$[_ !OC;R) ^O<\&@<X/F#[C'NP=HGH?&+_ /[T8/6 =@,9\0<^
M?LQX'A]F+G^KY]3O\L&L;P2._GOT/<>?+!WX&,_LR?K_ &<+LQO/E\C)]NWP
MP:QO$=WZ)/Y8/6,_B@$>_P ?HX.S&]X_7=@"Q!,*]@!'M,X"^?+S^)Z>)_?S
MZ<'9CJ?U^A^MEK3T/=M[>?Z]N$$@9.XQG;IL/+K]?C[.#LQUG?;W;C#*TP(D
MF\_EO&%+Y\!^_P!?!V8[_,?+ %CHKV $^4C )'A@'W'?Z=OV</LQWGP@_ 86
MNY 23^NZ?B?'"]^!U!]N2/Z/'']O$2@[#KSW\-I]_LYX-8Z'O[L=><H'+^]K
M=?0J=;BN?>\M!Z/-N%Q2%AFLS@I+L&V6G0M'SI:0J34EM=LL4YHMK++LZ(OB
MAS[-!EM-V:"GTNH!0R-RA,*[1\BPA/JH;!W7) ,&.RX,X>.?9B''D*^KJ,I7
M4J*5 /.2%-TJ%A28[0!2G5)U%*$Q*5*0<>C_ #$Z7T.Y-3M&[FJ,>'(H]E4R
MXG9-#'8")\F+,H#MJ4^3$3\U-&1)54I<M*6^Q):IQI7X-$XO,<;EU>[3T68,
MH4I+E2MH)=DDH2I+J*A:=B7%H4E()/JF%7-CZ?Q#D[%5F^2U;R$+I\O:J=3'
M);B54QHFEI&S!<+BW$I1ZR6BVDH2HJ$^T!@6U1*Q?]WO$3C!D526Z_LY%@--
M*>[M*3@)?D)2AM#"$CL),>*TA/94%52CJ4EEI-K)$&03ON8)OS,\^6.A9EEM
MVOJU N%*W7%&)0V-HN )D)2E(2!*0-]1?7*Y;5PZRUY&MU[Q50;/M^5)BZ76
MJOM&.JH)[;,VZ9@6A*)TB&A2X<*6I!;,]4M<1$40$%_EN*<Q12-JRJE7JJ'0
ME5>]S2B913B(*2H +6F1"=*3]]03V7 F65&<OCB',&NSH*9:DY/2*"H+R90N
MM7*4APM K;:7!2IQ2E(".Q25]WW=>%MV)0YEQW34X])I,)&7)#ZOG.N8):BQ
M64Y=E2WR"EB,PA;KA"B$]E"E)XFEI*BM?13TS:G75S"18 "ZEK482A"1=2E$
M) W./4LPS&CRNE<K*Y]%/3MCUEK-U*@D(;0)6XXJ#I;0E2U7@0"1Y*:Z\RMR
M:M29%#HZI5OV(T[^"I270B;6@VL*;EUMYDJ"DJ(2XS3&G50XZDI4LRI#:)"/
M5<CX<I\J2E]W345T:E.Q+;/+0P% 'G=TA*U D )$@_/_ !5QM69\5TU,5TF5
MZ@$L3#U1I,ZZI25$7,$,I);1:2LPK$@\K_+:J\I$6_KXB%-I1G ]1*/)00JY
M)#2_FR9*" ?D..M..R1BHN)[L=J*A\.U_$W$?H@<H*)<U2P4ONI4"*9!CU$J
M$$OF]R3V:2G]K:XX'X,5F2V\WS5O3E[:@JFI%)(-:M!LXX# ]%2H;! #Y$26
MM05ZG--I:;0VA"$(0E*$(;2$H0E("4I2E( 2E*0$I      QQYEU))))))))
M)),DDFY)-R3CW0         "  +  "P %@!MBO@P\-N\J5)KMH771(7=B96;
M;KM*B%U12T)-0I<J(QWB@"4M]Z\CMJ )"<D G;C+3K#;[#BMFWFEGP0M*C[A
MMSQB?07&'FQNMIQ O$:D%,SRWQ\O%.B>JVY08;\=V#5K>AHLNYJ9(1W4NEW+
M:B4TFH1)K! 6RZM,=#[7> %YE:'D_-7@>]4+O:%]&K4A2_26%@DZV*A2G$J2
M1:+Q&XB#??Y^S2G[-;#F@I5H%-4)(CLZBF1H6E0(%R F_0 \R3JYL+UVNV8Q
MCM=JZ*85#&1V0XEQ61N2.RV>T0-@">-RH6&Z6J43$,.D$_Z"N?MY^V<53;?:
MUV6M@#2:YGQ@.(*^AB HGI'GUR2"$@> W^KCSY1%ATD'O/7VX]+Q3Q'!C75>
MH-TFGR9KV/P+9[M!(RXZKYK38]JED ^2<GH.-NEIUOO(: @J5)5OI3S5(-H]
MMR-M\:]54HI&''UQ"$G2#L5FS:1SE2B!M  )[\<ZR93DF0])?65O/.+=<5C<
MJ<)4?HWP 3@# Z<=TVVEM"6T@!* $@"UAW<I.^_OQYN^\IY2W%DEQ:E+5))N
MI6J)V(B!R$6C$H4_Y/9Y3^>-:GHC52J.D%N18C+KS+<N<B%<,R6ZW$:<6EV0
M6&BMU;;27%)2.V4@'>IJDK5Q%PF0%=FG,GU+4$DH;*V4I"E$ A()C> 8Q8CL
MOX)<<$%/;.9*PVV"1VC@14.+"4 D*7IDD@3$]+8WGH[;FMJG<O'+:[$J&GMU
MMVCK9K#<NK=?OR^+6MJM\JU-J5IUJC4>Z;)I]8GTU3\6XZ8J/57957@751U5
M>HS6&8#$H&;2=/C.GJ%YUG84W64YJ,KRUC+F:.DJ*AGB!:*EIUQBJ6VAS2IE
M>IO2VNG<#:$J+A3ZCI]'-53-\.<,J0YEU8*3.\YJ<WJ*^OI:9_A1EVD?99JZ
M)MYQO4FI:TNE;K54RIYU:0A*AK9\I^5:#H'5^>.SZ9K7<,.X-#I&I-X(DW)>
M#Z(5)N5#<>XG+%J5X/O".RQ2[@N-NWGJZ)H9IZF9C[-5[FFKF+;] X@.<-\*
MU"\KIEL9J*&FTLTP*W&"2P*M%,!J)<:8+P9TRY*4EN7 D'R?A3^#[_'5&UG=
M4BHR-69U@54UI2AFJ 34FA<K%*"$AJIJ13E_4$MPM0="6BN.[8&G&M%V<SU(
MINK5I<G6D[=.M'6FO:;+M?3WE^O&+<=$MQ^T7XU.M:RH-R0*!<]S*A28B=+I
M.KK\1J)#EW?5AW\BDSFH7)KK<LILB<7ESW$V8%=3E;-<:BMSBF4RZ\*@*<J*
MI;"GJ=C6E1S!.6A1*TTS?JI=05]\UEV=U?%#+6;TG!N4!JCSNHRST3+N'ZU-
M2Q2JHBEJEHFZI%/4U0;6CZJ5FY0$(76/0I3+@1T5<UC:%TO6^!JH_I]H'(H5
MP>C9O:YJG0JK'T=GT"IZ_6O-@2IRZC:EF3C;D>[41Y$&F3:K9\6%!F.&;"MV
MJN+8D%JD8J<W<RI67BKS=+S/&]-3H=;.9H>;RBH2I* BHJD=NJGU!:T-U*EK
M2-"GFP"F>BJ:'(FL];S567\/JIZGZ-:VI>IW1DRZ=WB"F<;4X7*2B<-.*P)4
MVTX[1I0VLE:*=TD&(JTZC\K^I-R\@^I.K]NZ"TJ\+^T=UY;K](%%M"Q=,KBU
M4LRX*93=)(>I5L6['IEN4Z-)ARJIW+<^!$9K,MNETY34N.B%3^+&M^OZ)CB^
MARYW-W*>CS+*2TYVM35U[&7U3*W,Q50U#ZG'UJ2I*)*5J+:2XY*5:UXJLN'"
MV95/ &99Q3Y W69EDV?A]KL*2ARNIS6B?9;REO,Z6F#5.TE3:W=(<;2'EAIL
MA0[-O&AT9MI<S7;4%/-GISR]6KK6C0>Y'^7FT;-IG+I#M^N7(S79"$3!1XE0
MJ.E=5U!B1E+8T_:U)2XJ;3FES);,N+ C36<N9O%.4T?\'JS.:C*SFS(SFHJ5
MYTMYI@LI)3VBD(S!NB4H UBJ$IT.'0E25+4@Z^2L*<S[,!Q;EO#M)G8R"I5P
M[1T;?#B*>HJDU"M*^R0Z[E3N8H22C+TYD"5M)*UI6AM+@WM 9T$I^H^OETW]
MH'I_1ZK;_(C>%QUNPKWEZ- 7CJ7;-Q1VX5RQK:TNF2:%IE=]WTR,(DRF6M&M
MFN*82]7J/3((K"9DK$]];KH<GIZ3-JMQM[BRF8:K*5&9S34+["BMA3]>@.U]
M-3+5J2X^JH9!AEQQ?9%"<]/]0-YEQ!5YCD&7L/4W =94OT%:YDQ]-S.EJ0$5
M2:;*UJ8RNMK6D%*VJ5--4%(54,M-]KK7Y+??Q9OOF2LK5ZY[*TGLRGM7AIZ_
M6+5M"Q:=1-,XM-MUVBT^?*<L]7KT)YN;%@O56L-2S+9F37Y)+(B%N&WZ(G*3
M29)5Y:S4YC4K--6)9J:FK<=KE+>#JT)%3ZBP4*4&VB-)2@)@ZI4?(OX0)K^)
M:'.*FCRFB:%9EQ>I*.@;8RQ+5,6&W%JHSVB"%H077@LK2MPKD:80/:C5EXWY
MS[2M+M5K T5NG0SFEI6H6G6D5_V-:^C]S7S&>N&TK3E4;51RN6>)M[+J%LUY
MB##IM>NZ1"$:E2[CETU^1!ITQQOR_+T^B<(IK\OJ\UI\VR!RCKLSHZM_,F*1
M09J*A+M &:G32A%0RI:G&:8**G$LI6E*EIGVW-UFOX_5E6:Y?DE7D7%;.89;
MD^84-+D]37)-11TBVLU+]'KKBY25 0AI^L4C2RNI4TI2&UD::S:5I==.I?.=
MI_H1I!HQ=+7+#R[6CIEI-,O"Q=-IT6ZM2;.K;M.N._Z_.NR(U1*K<5;N9,Z
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M0[JLV\Z52;M?CQ;FT_H%"M>TZH50X;T@TRWK8)MVDNQ)+KT"JQ*&$4E%8BU
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MDDW))N2=SCW]"$MH2A"4H0A(2A"0 E*4B$I2!8    "P&+W"Q+!P8,(2!U(
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MGLUH$BK;)[>9[(*T!2%)#BT]H$E+4ZG+@)2"J\1CI[_,=WWX<UFC/_JM'_\
MSSXX?Z]IC?ZCKS//MB9]IIR?,D]^/3?J%_\ ZXHO^Z3_ ,W%M[D^OYMEUQ'-
M3HRXM#:U(0;8CH"E)22$E1O%?9!(QGLG'7!QCAC.Z51 .25X!(!/:FP-I_O<
M;;XBO(JE*%*3F]"I24J*4J;2 I0$@$]J2!R/CW8YGJV@&H$]AB+4N9C2KNS,
M>4W_ -;4<%3SP4M#>1=.Z&@'$L@_BI/9"B<8[>F>I&%+<9R^J2HMA!)<2J
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M9,NCB0IS&FJG:9MLUGI*J13!+RD!+].$DJ;2E:7NT40G)2<3T#&9!JKKT5%
MC*6,I>9/"!5E571M53CR* 4B:PU,4Z%J73U)*$I<4ILL%I*5*EJ;6^7>J<F5
M6O2!J!J;RX:('TF\Z\["D4FWJI>MZ.4^F:3P9]-MN1&BW=#J%$5,:ASJG1IT
MRI7 FWY4"BPYL26E*I\?20WG">)&Z8T=%G.:?P)32U04ZW34R5N5ZDN/!2J=
M2'(*DH=2E#/;!;JD+3]PV3JLD5PHY5"MS'(,H/TA+K:(H8<JZPH;RU"FJ=2$
MU2'&BL(6ZRM3C_HY0TE25 :DPAJISR<O?,]1.9_36ZJI?/+[0]6.8VS-<+,O
MNA6=]V4JJT6T+%M:P%6O>E H5?ILV'49QM5B^Z;ZC,JM-9NJJ2TRI+*XB*A/
MLZ'A?-\C=R2MIVZ3-G:#)JG+*FE>J?14H<J:I^K#[#SK2DK0GT@TC@4$.*IV
MTA (5H139CQED7$37$.7U;M=DC&99]1YO1U;%,:M3C%-14]"::J89>2MM;GH
MXK6]"G&A4NKUJ24:W*==/2*:-ZGVOS_1+=I>H5JUO7Z!RQVOINMUI$*NW71]
M'ZNN-=U8O2I4N4IBA3JY;[CS*X2GZDFH4MYJCR7%@/H4\KX,S.BJ.%"Z[1/M
M92K.JBL2/7:IG,Q;"J=NG;< +R&WH(7#>AQ)<2)@XR9MQWD^8,<:(:8S"G>S
MI'#]-1R-#]2UE;I34NU2VU:6%NLDI*25AQI0;5(D%WW-Z0SEXO\ N+7*RZC6
M;VLVT=<^6#0W3->L+5FS+CN"V+\TN34GJY2JU:Z*Y2*E7+0NQFI+I=6FTJI,
MS)J([*'F3'D*E4_79X+SBE9RVJ2FF?J,LSK,ZWZO])33M.TM:4=DXR_V3B6J
MA@H#B$N-E"9,*D0K?<X_R&JJ,TI%*J*>ES3(<LH3F:J9RI>9K*%*@\R_2=LT
MMVF?2LMJ6TXEQ:A)!2H+1Q'SVZ\Z*ZX7%RZ'3.J7_6*-H[RQZ8Z.3[DJ]LL6
MW-FU^R9]R=_*51IE:K*F1(C3X,SO&KAJJ$/2'HHE33%,R1TW"N59OE=/G*:Q
M.7AS,\ZK<P33I?+P#=4AF(=;;0+*0I.DLM$!(7Z@.C'*\79YD></9*JB5F?9
M99D5#EA?53)9':4JWP=3+KKA'JN)(6*AS=2"5Z2LR]Z/:@TNH6_JG<]8U*O*
MV:/<-=H=.H_=TBJ2(E:308#@GRG44R0TWF--D)CLK5VT+#?>(([2>,N;"L:<
MIDM9'05I0APJ4JHIT+:4M4@ U#;BH4B9@#<#K/#UU1E3Q53U'$E=ERM*5%*:
M*H>2^@D%(<33.H2%)*0I-X &Q-\?-SS#URF4_F%UUCO5>#!FQ=8]4(TAAVH1
MXTJ,^W>M=9D1WFUO(=9=;4%M/-+2E:%!;:T@@CCI\KK:+ZLRX*JZ610T8(+[
M5B*=NQ!7N#Y''4YE0UWUEF!31U<&MJR"*=ZX+[EP0C8CS&(8^Z"@_P"[=(_Y
M2A?]-QO^G47^64O_ +PU_3QH^@5W^15?_NSW]#"BX:$DA2:Y20H$$$5.&""#
MD$$/Y!!W!&X/!Z=1?Y92_P#O#/\ 3P>@5_\ D57_ .[/?T,9$B[:;+D&7+N:
M#*EJ*"94BLQWI!+8"6R7G)*G"4!*0@E64A("< #A"LH -(JJ0)O8/L@7WL%1
M?GAFAS!1*E4=8I1W4:=\D^)*)P/W;39+K[TFYH,AZ2I*Y+S]9CNNR%HW0M]Q
MR2I;JDD I4X5%.-B. 5E   *JC 3]T!]D 3O "K3W8#0Y@HDJHZPD[DT[Y)\
M247]N+?W3T?O>_\ NAIO?]KM=]\K1>][6,=KO/6.WVL;9SG'!Z;0Q'I=)'3M
MV8\M>#T&OF?0ZR=Y]'>F>LZ,4IN2BH67$5^EH60H%::K$2LA8*5@J#X)"P2%
M;_.!(.03P_3:&(]+I(Z>D,Q;;]O"%!7C:BJQX4[W]#%QBZJ7&#Z8UR4^.F2R
MJ/)2Q6([0D1U$*4P^&Y"0ZRI24E33G:02D$I) X1K:$Q-72&#(E]DP>HE=CW
MC#%#F F*.L$B#%.^)!W!A%Q86-K85%V4QM@Q47+ 1&+Z)1CHK,=+!DMI[")!
M9$D-]^A)*4.]GO$IV"@-N UE 3)JJ0F(DOLS!W$ZI@]-L'H.8 :11UD3JCT=
M^-0$!4:(D"T[Q;%1NZG%D1S<\(QQ),P,&M,=R)9'9,H->L]@22GYI?[/>XV[
M6.%Z903/I5',:9[=F=/X9U;=VV#T+,(CT2LB=4>COQJVU1HB8Y[XI3==,0W)
M:1<L!+4PH,MI-9CI;E%M?>MF2@20E\H<_"(+H5V5_/3A6_#],H)!]*I)3]T]
MNS*9$&/7M(M;E;!Z#F%QZ'60K[P]'?\ 6@R)]2\&]^=\4?=/2,8^Z&FX+08(
M^5HN"R#V@SCUC_0@KYP;_$!WQG@]-H?\KI-Y_N[._7[^_?O@]!K_ /(ZS:/[
MW>VZ?<V[L+'NBDQ'FY,6XJ=&D,J"V9$>KQF7FECHMMUN0E;:AX*2H$>!X#6T
M*@0JKI"#8@OLD$=""N#@%#F"2"FCK 1<$4[P(/4$(D80W/2"XZZ;AII=?[SO
MG#5HI<>[TDN]ZLR.TYWA)+G;)[9)*LG@]-H8 ]+I($0.W9@1M UVCETPO0*^
M2?0ZR3,GT=Z3-S/J7DW/7%UF[:=&>;DQ[GA,2&4%IE]FM,-/--E"FRVVZB2E
M:$%M2D%"5!/84I..R2. UE 1!JJ0@F2"^R03,S!5O-YZX8H<P!!%'6 C8BG?
M!'*Q")%K8H3=5*0P]%1<=/1&D+;<?CIK$9+#[C/:[IQYD2 VXMKMK[M:TJ4C
MM*[)':.3TVA)"C5TFH @'MV9 .X!UR 8$]8P>@Y@ 4BCK-)()'H[\$C8D:()
M$F.DXJ:NVFL.A]BYH++Z6E,!YJM,-NAA;996R'$20L-*:4II38/84VHH(*21
MP&LH"(-52$3,%]DB9F8U;S>=YO@%%F ,BDK00(!%.^#$1$A$Q%HZ6QWIR[>E
M$UPY8=/K<T[TTKFE_P GV1=5W7O8%9K<)]ZMV9=-\4JGT>X*K';I%S46WKM6
M]%I<-4.)J50+X@4QQHII\6/&4J.>9S7(.',XJG:NKK!KJ&&*>J;;K:8-U#-,
MM:VD*+B7'6(*U!2J-VF4L?>43?'2Y7GG$>44K5)242M%.^]44SCE%4EQAZH0
ME#JQV:FVGR0A.D5;50E$>H +8YQU<YI+AUCM31>RKJKMF4ZS] =/5Z>:?6_;
MGJM(I4.#-KM2NBY;EJ3"JC*$V\+QK]4D56ZZX"Q\IR&883%C,1&6DVU"SE&7
MO9A4LUC*G\SJO2ZMUZK96LJ2TAEII"I3HIZ=I 0PW?0"KUB5$XJJUS.,P9R^
MF=H7TLY;2^B4K3-&^A(2IU;KKJDZ5:ZBH=65O."-:@F$@ #'*5<U?M:E]MJ
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M2TVDTEQWL)2H.B"NL)#2%@Y0/7G"I.%!6%=D7M+F2JJE9JTT[82\@K2@N.$
M<@7.S 4JQD!L!-KJF1Q%?GU)EU=4T3K-613.J;4]I;DZ0"5!C7,'58J?DB\
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M.IT'H)C#4N#T>6G,&<W18_.K9LBZ41U'O&--;J>L],C_ .!.W937)]-2XI6
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MR;.**C2\*DTJC7"E%1H#9?#51K;[<-DH[1$+T**20#B/QZ/*Z4N(*M5*>T@
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M%3394^X@6_OEU<%,@3!/<:Y[LUQENN5BXYD5I* AM4V9/4$I.$MM)ERE-,I
M ""E)"#@=A0&#M%#;:5*I6:5"S]Y1:0V!)W/9HD7B=@>>Y..;35NU2D)KZS,
M'VTV 54K>43R2D/.!*1:P$D;@'&WC5;3B.%(E6]?$E24X[QNO4M*UJ"<A(9>
MI#;;22H %16\M(SE+F<<85(S54%-9ES8G;T9U8 O)E#RU$]!$#OO%PP]PVF
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MU"I6+@72T-_!G<1%R>=S8X\NN:?_ %SO,;_Y>-7O_:#</%GE'^"<L_U=1?\
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M,<59/4YG54#-92.,TM%35;F8HK:5=%KJ:MRC12EU+A2FH#J4C0I0)+J$ :E
M'*]P[F;% Q6.4M2AVHJGZ9%$NDJ$56EBG34KJ.S4@*+/9J)UA, (6HD)23B#
M4<LO,BXY=K*.7S6];U@T:G7'?32-*+\4Y9=O5BFBLTFNW:@4 JMRC52CD56G
M52L"'!FTTB=&?=BD.\69SG* &"<URT"J<6S3$UU*!4.MK[-;3![7[5Q#GJ+0
MWJ4E?JD!5L5_U7F?VP^KJ^:="77QZ)4?8-K3K0X]]G]FA:/72M>E*D^L"1?&
MOA\O>OE0MZR[MI^A^K\ZU-2*VS;.G=SP]-+SDV]?MR21+,>W[+K3-%73;IK;
MXI\\LTFAR9T]T0I91'4(SW8FK-LK0[4,+S++TOT;9>JV55E.EVE9&D%VH;+@
M6PV"I,K="4C4F3<3%.79@IMAY-!6*:J5AJF=32OENH<,PVPL(*75G2J$-E2C
M!@6.-BSRQ\R<BOWM:L?E[UP?NC32#&J>H]MLZ3WZ[7]/Z;-A"I0ZA>U'10%5
M&U(,NG$3XTNNQX$=^$1*:<6Q^$X@<YR<-4SYS7+0Q6***1XUU*&JI:5:%(IG
M"[H?4E?JE+140KU2)MB8RK,RX^T,NKR[2I"JEL4=07*=*DZ@I] ;U-)*?6!<
M"04W!C$I\NW)'K;S%6OJ7J#1;8N>V=+]-M'M7M6)6J=;LB[7=.:T]H_;$JYZ
MM8M,O*)3%6]]UM5CPY$6#"<J7;9?:<5):2AM93HYOQ)EN4/4=*X\R]6UF84%
M"*%NI8%6V*]Y+**E=.I?:]@V5!2E!$$$0;C&UEN15V9-5-0VTZU2TU'659JW
M&'C3+-&T75L)?2CL^V6$E*4E5B#(MCCSCH,4V#@P8.#!AO5JU+=N%)%7I,26
MX1V1)[!9F) & $3&"W) &!A'>]@X 4DC;C0K,KH*X$55*TXH_P",TZ'1X.HT
MN =VJ#S&-RFKZRC/]CU#C8WT3J;/BVO4@GOTST.(<KFAC:NV];E64V=RF%54
M]M&>N$3HR M"1T2ER(ZH[=M[8D\I6\&INN@JBDW(:J;CK"7FTR.@U-J/57/'
M14O%!$)K:<*&Q<8L?:TLP9YD.)&\)Y8?%D<Q7,YH,&8B:Q4*[;$4H0*/=27;
MGH"6$8[#42I)?^4Z.R$!7=QH-5I[0))=BJ*>R*U-5Q)D/JNI=<ITVAX&IIM(
MVTNI45-#F$AQN-RG'/9W]'OT?<9ZW5T;5#F+@)-9E93EU:5JW4ZSV9IJI1,:
MEO4SRR  EP SCO/2_P!(MIG= CT_46EU+3RK+"$*J#?>5^UW7<!/;,J''15:
M?WKF%!N12WXT9"OP]34$*</14/%]!4%**Q"J)9@%1';4Y/\ II2'$3T+92G<
MKW./"^)?H#XDRSM'\@JJ?/Z4$J#!"*',TIW@-.N&F?*4VU-U2''"/4IP5:1W
M%0[RMVZJ8Q6;9KE*N"DR0>YJ%&J$6IPW%A()0),-QYL.)[20MLJ"VR>RXE*L
MCCK6G&*AL.T[C+S:ONN-+0M)M-BF18;SMSYX\6K<LK<LJ7*+,J.KH*MJ-;%8
MP[3O)!V);=2E1"H.E>G2K<$C&V2\\^?FCL(_*(V._0#&YZ>P'QZ\9@E(%P";
M#81/6TR/#K;><:92$W!G81S-^^ 3W0!SW&*'Z@F.DI9!<=Z%SJ$;> &W:\=N
MAZDGAI;U[A(%X ,<[Q( C?H08,'DPA420;& FY(F=X! MO'.((QOTK,FFQ\]
MI3R6@H%1W7MVE)VP?G=#L<*'D=LJ5)20D)V[A&T]Y_7B3JJ;*5K5J(U$2 !,
MV MM_7UPVW)!2%%'3'3?(.?:1D'.,8SU)Z[3+4D$CR(V/CTOSW\SM(<(E,B\
M0HWGS(F9L .NQQB&6YG WSXA*>I^D'/T</LTP#R V4+^$^X>[#A7?%K@)"8]
MD1TMC7N5 H>R204D()R,@#J21Y9)ZGH<;$<0_:("04GO$&W0#?D!$@QAW&T@
M[38G?Q/?YVOB_P"L+6<$[8SV@=R<X.3@[>6_3'MS. D&P-X$\@1/ZZ7&V"%7
MU$$6&UYOOY?GO.,=;O94=P.O4!1/MQC ]GGOL.!(229^,#V;'NZ=]QAA,R0!
M//K?Q_5O#%/?'\H?H#^;Q+2WW>?[\2T*Z>\?/%2978/XPWZ@@ $>[LX)Z^'M
MWP!PBD<@(BYGGWWL-IB_(1)PM!YI'C(Z$7OT//&>R^$9)S\X9V*<CR V.#ON
M<9P3OUX2DA0Y @01$?>WDR+6MY3?$(TDV.U]I'<!'@9/B9YU.R0L*0KM XV.
M.A\/G #PVZ#X@<8]"8$Q[ 9&_7QZX+]_.-C[Q_0WZ\\0!QU264X*U'YBL=DI
M)P/G*&_8(&<G<=<#IQKD03 O?P_+<CEW3RPR@%,@ ];008/(#NOM$@P#&,>H
M%R$2VM04%C!4,!(&X(4#N%=0$D;C<''$3)W!@\C&UY[R2.1MN#87V*=!"TK2
M2E22%)(W*DJ"@00+%*@#/46.&^HI_@D=G)P!X';;89/4;]>-5:-%XA/@0 >A
MGGSWQZ%E.8)JVPVY":A"05D;.)%@X$S8W@I!,':1)Q;#B5 *R3^O8D=>G@?[
M=N(?E[K?OQ<F#,$D^X>-YVO[<5!7EU!Z9&1@[^/AU^'GP2!N8Q&4 &20;]/9
MWGV?$8VL*>2&H9&REX0L*P>V2HM)[)1MAQ:TA05CLO'("4#B*%A#DE0 !),?
MYT2"=@! YGG;D>>SG*FZEJJJ@07PTR4I'WO[&+Q5_+:7H((@E(4HVG%4U]28
MR05?Z,Z=C^,$M)W! 2/FE3HZ[$I(.X.,SRM2D#< %7B2;'<V@B,5W"U.4NU5
M0H60A+2%1((=E2HF-DI2186*>N-/VAX;_ ?K(XQ_K]?KECLR4_YT<K3X[;8O
M1I!:D-.X)#:TJ5DC=(/SDG(4,*&0=CU)QMQ%8E,3!F4^/=?>8]V,;Z&W6'F%
M24O-.-D&/VTD6M^K<XQFU-]!<:90M*T-(4>VA86E2G59!)2<9+2&@?$'90&
M UGM5E1F( TFW0D1M$DQW1.*3A^C714BPX-#SCRBH?M:&P4)$[F2-0  M&QL
M-85I3OGX?OMY?T9X)$Q-QL/?;%\%)M"CJ'*XM[0(\+_'"%U(&>T!GQ)(Z^9
M/[_1PYN!UGW?UX9]4[F2),>^\S[ORE2X, DY!\<GQ]_U^/3;@P"#,DS^K\Y!
MZ[]Q,@!4!\<?3C.^>FV_NWX, @DCGRVBW6>7[Q@[8\#^L9]F?MX (\)M'(>[
MG.$(!N3'=O$<NOZ&$[8S@Y]XW'Q&0/=D\ L!W <N?OPY3NF?]H#]>["]M/G^
M_M\?JX,+&7 = E-'.,=L?BY_V-74>/T[^/#2$A8$ D@D\^7?X\ORQ%P)""20
M9(M<QOR(^%O=CA7FF.>9SF-/GKQJ\?\ ^(-P\:V4",IRP=,NHA_^S-8^@ZTS
M659ZU3Y__57CMVW><GE2U>Y=]#=#^=?0_6.Z*]RR4RO6QI+JCR_:D6M9E;KE
M@URK&N-6'J#0[VM.YJ,Y$HTW\!3[AHJ&ZJ:>6FDL1I:*A-K',/</9Y09MF>9
M<.9EE[+6<K:>KJ+-:1^H;:JFF^R-32NT[[+@+B;J:<);"I,E.A+?1MYUE%9E
MM!09Y05KKF5I<:I*K+JEIA;E.M?:"GJ&WVG4$(58.(A>F( 5J*YDY:/25\M.
MB"]%ES= =685.Y:N9/7C6/1:V+6U)MVJT]NR]<+0A6H+3OFNW/;2*Q6ZS9;-
M-C.Q:I36J2S<:G'%RQ2NZ[J17YQP?G&9?6.G-*%2\XR?+,OS%Y^C>0HU&6OJ
M>+],TR\6VFZDK(*%E99 ]7M)D;N6<3970^A:LNK$HRS,Z^MH6FJEM:>QK64M
M!JH<=;"UN,:00I 0'#.K3$%DVCZ4J?:^J?H\ZZW#U,1I%R;:3:;V7?&E,"[6
MH=%U(O*RZW=]2J-WQ*8T\W1W%3HE5M>-3E7 Q*ET]RWN\9+)6E2MA_@E+U#Q
M8T541K^(*^LJ:6N4P5.4E/4-L)13J607!I4A\K[(A*@]!F(Q@9XK4S5\.N15
M>AY+1TS#](EX)14OLK>4MX)!T'4%M!/: J26Y$3@T#]*76[4MC6RV-:GM0+P
MK.HVK-C:RV7JTBGZ:ZJ7G9%>T_J=RU&BVLJU]<:!<]J+M>+*N>76K7?H#MOS
MK N3UVI4)B6Q6)T(&:<$MOO9:]EHI*=NDH:G+ZBA*JRBIZEJJ0RAQ_MLM=8?
M[=264M/!T.IJF=*7"DMI),OXK6RU7-5QJ'UU-8Q6L5>FFJWV%TZW5(:+5<VZ
MSV0+JG&NS+9IW=2T!06I.'?1?2P46#(T8^4+,U%G4W3ZV_2&4R\*8JX+6B0[
MQK'.E<]^W%;E7>I%MT2UK02]9RKNB)N!NGVG0:7)D07ON9H=&@"%3XVN[P,Z
MI.8A%12)75N\*+IU]D^I5.WP\S2M/(#CSC]014=@KLM;[JTA0[9UQ6I1SHXN
M;'H(4Q4E-.UQ&A]/:- /+SMY]UI90TAEF6.V':!++:"4GLFVTZ4C&IWI--*$
MM:-W?5[$UIEZEZ?<C5Q<EUR4LWK;<S3&IQU:3WCIM;VI5(@2J>U7V[DJ$BXJ
M?5+E1.E%$:'#F4^$JI.2&9;$U\'5W]L:=NIRY-'5\2M<0LN>CO)K4'T^GK'J
M-Q25%KL4!E:&2A/K*4E:M !28IXHI(HGET]<:FGR%S)'4=NT:57]AO4K=4A)
M3VG:J+B5NZC9(4A.HD*&G]('S6N7/RH\E?+)#NVQ[SO6'I-8NJ?,Q?-@U6EU
MS[IKPIE!FV1H585ZU^DSZ@FJ7GH[HXU&I-XQY4R2&[EK2B^W&JD"2VB?"N1]
MAGG$6<J8J:>F57U5%DU-5(6WV-.XZFIS.JIVG$(T4]?7DKIRE(EENQ4A228<
M19L7<IR3*P\P\^FCIZO,WZ=25]J\EHL4##[B%*"WJ.C 0\"H_:KN$J2<,'2C
MG'Y4KFY8=#N6GG*T,U=OJG<L%[:C79HY<^B6H]O69)K%'U5K\.[+QL+42F7-
M;U70]2*A<,%EXU^WIT.OM4_U>%3E4MR)*E5;:KN'\\9SG,LXX?S.@IEYU34C
M&8,YC2.U ;<HFE,4]52.,NMD.):41V3J5-:I4OM I*6]>CSK*'<KH,LSJ@K*
MA.5/U+U$[0U+;)6BK<2\]3U"76URA3J9+C:DN!,!.D@E<VW7Z867?E\7KJ)6
M=/[EM:M7QS^\MG-C4*59UV(;IK>EO+W9<2R(.E<R:MJFR*W6:E3:);<QZJ2H
M,6B2ZO3G*DY2X9]58CUS'  I::GI&ZIE]NFX7SG(TN5#)*S79M4*J%5J4RL-
M-H6XZD(2I3B6UA 6KUB=Y[C(OU#]2NF=96_Q!EF;*0R\ GT3+F$L)I%*A)6M
M:6VE%12&RM.K0+ ;>A>D\Y9*?8G,1;S^A>K$*X>8ZV^<.T+UK5.NFTZJI5)Y
MA=4ZCJ)IZ[1)-S1*F_9,.Q*?.70JU:%F1Z3;%?K<F=?=99N2MJ@QX.)W@O.E
M5.4NC,Z!364/9 _3-K9?0->542*2J#B65(%2JI4GM&WZA3CS3:44S99;UE4F
MN*<K139DT:&L2[F;><LON)=96=&8U2JBG*%.A18#"5=FMED(:<65/N!US2$[
MJXO2_:8R*AJ)J;0M']2I6JFJ^I'(UJI<UF7;>=NU'1*UJQR<UZGU)VUM/($6
MCMW!2+6O:+ 5W2IC4E^C29##341;5-0]-@SP#6I12T3M?1IHJ&DXEHF:ABG=
M1F+S?$#:D!^K4I9:<?IU*$Z2 X 252J$S=XQI%+J*MNCJC5U=5D56ZP\\VNA
M97DRTDM4R0CM$-/!,@JU%"B!IA$JSJ!Z7+1?3NZK,N'3_3[7VK+M[7GFRU]F
M5#4F\K,N"NLW!S+Z(UC3:%1*-(C4]J-\CV3<-2CU1)JC4IZK08TJ2ZEF54?D
MZ)![@/,:QBH:JZK*D!W*\CRI**.GJ6FBUD^8MU:G' I15VE0R@H]0I"%*2D2
ME&M4V^,*&F=9<IZ?,%]GF&;9B553S#K@<S.A73);00D#LV'%A?KR5A)) *]*
M8-Y;/2H573;1PV%JJ_J5<&I=O:_HY@[1UTA0=*-5K[J%:-AT6P/N>K[W,':-
M]_(\RD4>WX,>U;_H4B55J)3),J@O4&I4="(KMGG'!+=9F'I5$*-JC=RHY549
M8I==0TJ6_2G*KM6AE3]-VB5N.J+]*Z AQ8#H=0X2H:.6<6+IJ(T]6:IRI;S
M9BS7I325=0ISL$4_9N',&G]!0AM(9J$%2T));+:D  N6W/2@Z=4:P.62 ]:F
MJ?WX=!+LMZ52]:H--T1B7=9&F]%L^_+=>THMI,6RH= U.L61+O1T4JW]4K;
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M"_\ 7&5_[V;_ .?@^3.9\]+ O<__ &@R_P#)?!]9<7_Y+5?[N'_)P>D\"_\
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MXQ.U)5?[M_\ )P?6_P!''_UCR/\ WY3_ /Q.*E6SS8)25*TQU"2D DJ5IU4
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MME)F.H@F>?2/"#/Y3%:1I)(@&), S)]G2??SP_.8%W&O6MQZ_P">]J3T\/\
MKSK1SYXWV(VVVXT\GCZIRK8$Y;1"#T]':M',CQ!/.^UOQ H?7^=?ZWS-/2YK
M7C>;XB+O\8/PP3X>>4@XWVP#X]>+.#W=Q \[7]M[]V^*N=_Z_'GSZW_/"=_U
MV)'B,GJ?'H,CPW&<XZYX.=X)^'Y\_?A2"8G8>)'L[^=[3WXJ[\8&,Y\LXQOY
M]/W]_#/LCG/ZZQ@)O%S'4'^KWXMEY63LG&^.OMQOG?/U\+K!F.5H'06CXX,5
MEX;8Q[<@_5OGZCP;<R?9\A^O/"'.Y]H\=K _'YH7]CD;XV\03OOGRS_;PH(V
MMS(M!/E.T^Z.> ]Q/N_/YC\\4=^OR3\#]O %2(/WH-H/Y]W?@F.DR(&Y(M)C
MGS\L*'U; XQY ' Z],J_7_3P@J\$&>8$1MX]([O;&'-IOWV,GV;^["]^K8 ;
MG;)/4;[8R/UGIP$WM!.T&U^IO!(B!'F8PIN(/LY_,&WS[MU1*-5KCFH@TB&Y
M)?64A:L89923_HCSI^8TA(R2222 <)5V<<"EA(DF+2)Z6/Y?&#C7JJVGHVPX
M^YIF2E,2M9$ !*9D] 8WL.<=:V-I[2K.:1+?":A7E-E+T]25=W&"@.TQ!;Q^
M#0.SV5R%A3SQ))+:%!I%:\XITD"R)L.MQ=4DE1'+:+]0,<7F&:NUJBC^YTH"
M2EK42I1'[2R(.J_W;#J-L/NH5EJ!%=EOE24-C!P#E;A_%:3D;K4>@&=@5$]G
M.,#+"EO:$BR@2DF2;3!/6\^4$3O5*$IU3,'<F(DR))!L;VV D[XA&M.UVO2?
M6Q#EJ0I2^Z[##ZVVF0/FMH4&^R>O:4K8J62M0R=N@;IDM-I2E!@;J-U*4)!,
M[]1 MS@2<:R'F4D]HIL$1 *QJ@GN,^!B=]\:15&J;8*Y$6>0 ,CU:5V<9\>[
M:63L/,'S/AQDT@ 2GP]62?SZ;]9$WQ-+S:[!2#/5T"P\5;VF#R.'90+(>J<?
MUN3+-.8<([ILL)]9<0"H*4I+SB5LI) [!6DK4,GL=DI4K*EHG>1SV$_SK=\?
MU8TZC, RK0A"7%B29<.@7M"@#JB!,;$V,B^^=TUMQ3874*G5'V4#Y[9EQHD8
MX.2%J;BI>4#N"GOP-LD$G:1ITF/O'Q(O/6 (Y6%X/4$8U!FU4)#+5*E1N%:%
MN*N 8':'0!?I/,V  U;E$TZIN1$H#=2>3D]Y*?FOLA0R,J]8?<0L9&"$,!*L
MG!'&9%"#I)2$#>3/F;D6M(-@!YP5F>9N @U!!FX;"$&TV"DI29-[B\@0<:*?
M6J) )"(E*@  XBTZ!&:<3^:M3+?>D>&'5@ Y.V^-@-L-@RE"E 2>9W_9 %QT
MWN3A);KZ@C[1]05<K6\Z +\P52?]':^PPT9MZO$*1!9#:<8#CJ05GVI0D]E)
MP!U[>Y(P-P%VD_=  ',Q(B!81I.Q&T\QC;;RQ )+I4X1<)];3>9 ,DQL=Q><
M-.35ILPE3[ZW3DX[2CA/F$H'90D8." GI[=^,2B3ZQ))'2 )CI^5]]L6#3#;
M8TH;2@<H$*M F;F_.^_LQB&0Z<@J(&!OL.GN]GU> X@"F/6$DD_=,&_7QG:?
MW9NSF!$B!R%QMR L>NT]UC94ZK;*B<9_?.1CX''ZY:T]"/;,^%A'MP%E-H2D
M]?5-CWW@>'+&BN!+DB"XO)*V,.CQ/83D+'4;=E94<@C*4[ \07ZZ3I!$01._
M?>!!$38])[MVA'9U"0I(TK!203(U[(]NH\_=B/#)(_A'IGHK?/OSC<^>!@#?
MIQ@*5&UXV,G:.X;VC;GSQT"*<$DJ"#>Q$@]X/K&? "XZ#%I4K)W6/ISGW9]Y
MVZ9^/$@V2.9'A?N@].HN![1B?8)U1I&GD4Q//K87W^/6V9(QV>THX\=]_P!_
MV<2#1F8L>5OS/Y#XS)-.V-P3XQ/F+8ZYLYTJM6@ +Z4U@[DG<@^S8CC;920T
MC83J.V\*(D0;;?U8\VS5A*LQK"I*3]NJ))VTIN-)$GOO\<.;O%?E#P/\(_5Q
MD*5"Q OU4-CX 0,5X9;,PE,<S*_S.(UOGL)D1EMG)<0I;Z1D94G#3:R=QE0[
M8.V^/-1XR0=,*$">I4 (L([Y(^.+C+$)!(3'W=*"3),F57-N=[&PY;XC_MC\
MDX]JB?Z/JSPM*3-[\_5,VZ^6+?LU@R D3MZQ]Q!'CBA;;2T[I3G?^#G.? DC
M/T@@^WIQC*0?9M%L94!:=Q(Z3SGJ2?AC#=>+2%-D]DA/S,DD;=#D%).1GV^>
M-QQ!+0)N))GGO?IRZ[XV!<#3 ,3U.UQL!,\YVFT'&(S+4'$=MS8D@A1Z#&^-
MQ[-]QP%I %DW]I^,_EWXBH B(()ZFYZFXZQYXVJWE((RH=DXP<;9\L^W(QM]
M)XCV?.$Q$\OU^6(AE47"MIG8>\?G[,5(=/9[94GLC<>&0/'._CX< ;!W'D/S
M ,&8D;[X@4$$  F1/(_#;;GBLRQ_!4!D=1XY]VP^&.F/+@+:;0DR>IL//SO[
M.YAA=H1O-P(V/,Q,'V7\,6N]3^7]9XE"^4CN!_?B?8N_@3Y8.]3^7]9X(7W^
M?[\'9._@3Y8M./%([3:T]H#\4G (Q]&=@!CV^/$%,J5>+C>(]D^&XO:,9FDK
M'J+1ZID@\D^<W)_1VQ6B8TZCKL=EH.3@]"",$8./I'&$R#<;6_41-CW=^)!-
M[#O! @P#'LO-^GGAL.J73I#CC"NU&6<.LC)4T,_CMY*MAUV\-CV@?FX7&-:=
M28! MMRF9Z@WZ$=\SBTHJOL5A"I&J-23LKD"!-E38$$ SL,;-$CMX.06U#M)
M4,_.!P01D^W?;;C1$ZBD\N?M_KY<N['1A6H @R%"1^X=W3EA>^()Z8WQ@[XS
MX_.\O#KGW8X0DD@BTVD6_K_*< W-S[1\# _/YH'R,Y'N[)]_7??Z,<,#>0(!
MM,0!W=-KX =YD0!:.=YN8[KB?G7WQR<JR,9RG;&?9VE9Q\/VN01?G[Y@<P.9
M_4X>HGF3MN3<';SP%X'H"?:2!^LYX-K? '\A P2.9@[ 6^8W/OPG?XW"?Y2?
MV9_5P$BQF/9<]T&_NP$@<[;7C]^$[\'P.>IWS^_O/D>"Q&^XY=#^O/!8\_AW
M]_ZOTPI?&!@DX&XZ#Z,^&?#KT]O!&PDB/E'Z_4$Q:_=ORY^/CBWWZ_)/U_SM
MO?QC)5,;;"-_ 7G];]RD;6'=L>X0?U[L+W[AV^;[\;_$G;B7K[P//\M48-4[
MD^T'XD?GA \O.#V>NY_I!QPM2B8V,&PC>)&\X<SMBL/[#*3G'AL/;CV>'$@#
M%R9-CL-I^=B.[V@CON(-N6XWB=[_ +L9M/?!EM=K8#O#U)_V-?@0!\"?V\$'
M>0>0MUC>_=R&^(.JA)))(D >?CW8D/F$<2G7S6X;Y&KVI8W\ONSK7D#Y>.^W
M&CDR0<HRN 3_ &NHIO$$TS?7K8VYXL\_6D9[G95O]<9IO/\ EKPM MMW>.^(
M@[U'7QZ=//QR1MC?;V\6>@]".Z09]O+RQ4!Q'4S<7DD;7F)$7L <+W@[/:ST
M/MR?#P  W]^P\]PH@Q%^FY,CN'+>=_B)A8TSN =R3?Q) C?GY;'%)=2? 9\]
M_P!@!\O'@*"H621MN>AZ6/OQ N),[ ];GW@87O4$9)4#G?J?IWR,'X\/2;2+
M\X($]]R?+WX?:(C[RIYQ/Y_+W;A>3X9/GMO]'AY^7#*=H2>^2+^\_# 746V5
MON#;;J,!>1[P??GX8Q]?PX6C_-/\H?#\IP%U!(N8Y[[=XB_RWPO>(P2-A[L;
M_1]&_$=(F(O:#;RY[S:_CW2U)@J L!90$?(C]1RD"TX[6?9V23G.,[DG'3?.
M,>W/#T@;S/2/SN/U&(ZTZ=6J!,1*ID=Y/2^W=AUV];4BNK;()2RMPH"4 EQ?
M8([:NT04-H0<A2U @8W23@*B0D J,)'4[DQ('638VCJ,5U;F*:;4V$!3I2""
M3"4IZK,:E$$?=$3O( ,]-VU$I]JP1&AL-%U21W[Q"NTM1QE(R3V4'LC/Y9 4
MK.R1H+6IPVLG8"=Y$3;?D;[]T8Y1]3E6Z777"HD;<@F3I"0#I $3 D2-N>-Y
M(KW<M]\\V&V^[4Z5K4I(["<E2\E.>R,'.-A]..&EF3]V]@!O/*X$^=NO>-<,
MHO"Y(O<#>?"XD#R\!B&[BOMR6^IU#*O5(YPPCOBE2SD)4^K*%96L' 2K'900
MG915FR;IDM)U #6?O$6-C9(D[3(Y$SN<3;ITNJ*%.  \])(,;V L!,R#'(3!
M..@Z$MUFC4Y,C")*X;3TA*R"I#SS8=<;) '^A*4ILD?D^&PXLTH]5,FT#UO"
MYV$R2/;'6^.-J5MBH<@(4@NK2DZ4DZ4E22)4 2)3(U$2E5I%A8GUUII7<)<2
M7% ?-;!<=6=QAMI.5D'&.T4D;G< Y.VU36U+!(%_6MOS-N5MX(%H!Q@)4N=(
M "IGU /5L+DC29YWZ1>1AIUFX6:2T52GH\5]204L+6E;X!R>VZA"B&_-#22Z
MXOHI*!OQF*DV";"/OG[H-[ $7_=C*S3]J3I0M>T>J0G>"FT@0#*;F8B!SB^I
MWZEQ6&U/2R-D=X5,QTG.?F-A/:4G.,CL(4<DE61OA(3,C>+V-_?;RZ3/*U9H
M%Q"R$#:$ :K3&]CR!F\7%\,V9<M1F9"I/=-K^:6V.TTGLGP4H$N'R/:7CS Q
MQC)<7"282-A\/$_K>,6#=(TT1ZH*C^TH2;[QO$]/@,:0RE9)R-]SD$Y/B3OD
M[[[GC&6@HQ*A?NBP_.3^AC92G;U;<Y$=YM:1.T@Q[,4JDK(PDI _\7?Z#N?K
M!_5P@QR)'.3?V;$S[O#&71:=(BUS'LW_ #Q:,E0V*]_?G;W=?I.?@>'V*1:)
M[R3'L@S/CWXD$JY >Z+6\/9Y;8ME\GHXD'WC]61CV\'9GKX75^N[OYS@A7X?
MYH/O@_+I;%"I(2=UC)Z9(!VQT\?IQX?3Q(M6!TJ*O\TBYOO>#$;;QOC(&PD2
MHCP$&U[SX]/C;%A<AM:'$J6DI6E25#=64J!"LGP&#]? EI1,ZE <P#8\HZ21
M&_N@8DE-Q%HN%09!%P! F?;/CB)9A4P^ZR5X+2U('7) .RL[#*DD*Z>.P&PX
MP%(2HI(V)WDGRB#SY_#'2L_:-(<$>LD$@6@\Q!B(,]VY$S)P^^4/X9Z9^CIG
MXGA^J+0)VB!C+I5O'O$V[IGPZ\L7$%YS\3MK_P#%25'X 'AZ0=DR>@3)\@#B
M"B$_>(2.I( ]A.^.L+3J,>-;%#:??2VMNG,I<00YVTJ Q@I )SN-C@[[X/&X
MVV2A%CL(V&Y4;BUP.@@'>V/.LR1KKJQ6H@*J' E42($"W78\_=!QN%5^(,]E
M2W, X[.0"=O%12<^0P!YGC(&5"\B9Y\N_>/CC3[ J!/K!(W&G<<[GNGIB/*[
M6T2YL@!L=E*4M#M+R1V4A1V[(W[94>NY^L(,$2-R+R3WGI,QL;1X1?T-"E+3
M:E+TDRL@)N >7,':=R+VWPP'ZG+0XILEM!2HC(0<$8!!^<O!R/)(_;Q$( ZG
MQ_JQ<H;00""8'40/$@D&Y]_=B_$J"UMK+BTJ4'".UD@8QD#"4G8;_;YO0"9G
MS@CIS(^/AA*;&H[$<K2)O/2+=\7WY8Q)D]2G%MJ[)1V04D!7:2<;D*.,@[9"
MA@[;#J H VY>_E)@[]X.]\'9 IM &X)[B9@B(,F+QYXPEJ=:4A2CA!PI*AG"
MDD@YZ#< [@]#GA% BVXY_/IAA#:Y@ ;Q @WVBPY\Y\L;83 2D*65)!22D@;C
M;. >N0/=XG'$(._N@^5A$^WRQC2IPD@@$ PJP^[)VM!,=#)-ID3A7I3O:!0L
M=C;L]G.0,8Z!8[1V^@ 8P.H4Q-R.1,'^C$3UQ$J5K^S)2!,&#,\[Q?;?RQ1Z
MR]^6K]'_ /Z\*!^(>_Y8?:5'XU_R5?T<'K+WY:O@/^EX('4>_P"6#M*C\:_Y
M*OZ.#UE[\M7P'_2\$#J/?\L':5'XU_R5?T<'K+WY:OT1_P!+PH_SH]A_-)P=
MI4'=:_Y*OZ.,=3ZVEAT=/X8QLH';. I0!&,YZ''3;>*FTD[@\SM'LD"_G@;"
MB5:IL)!((DF;1 /+D.>^^+$EX*6%I4DA:0=A@9\1T)SU)VQ^OC$4$1$QM '=
M^KB1C(A!)U&Y2;P#('*]]C?H>NV,9J2F/A*BE+*EJ'164..$!)20<=A2B00I
M([!(.0"<:E0P(*P"#L4@1-M^0\KDXN:.I4I78K[RDGPN/'G)Z$D[$[/O$@#8
M>61L<CKT&1^WPXU(D :=H_:VMT.UN4;8L]:0 8 F1J3:2(DV'?[R.N#OD^WX
MJ^SAZ9$:/YWZW_JP^U0.<^U7YC]<\+WJ-\YR??X=/=] ]O $"/ND1,>L#OWD
MS;\KS@#C?6^W[1\+D6]F%#B",GIXYR?U[GKY<1TWBX)D\C;E[?+$@M!$V@2)
M,G:_,3%^G=A \@>&/</?N?W/7AZ)-TGN@BWF;XCVC<W '0P?>(^?YX7OD'.Y
M&.@(.^WL!QO].W!H'X2-^:=M^G,\O;@[1N#>(V@$3O'+G.$[Y._U=?,^_P ,
M'Z3Y< 21^S/+?PO._=[#O.$'DB;?ON=]^4>9P=\CQ^K/V#]? 4R22G?H1N-O
MZ^6XOA]J@S-MKB9MM>.[G^\'?)_?/V<&G_-/F/E@#J=I]I)^6#O4D@>/O)'U
M;?KQ[<8X40)TFW4CX$8>L$@ B>4%1\;:8VG?Y84N ;D?6??C&#T\_'X<%B8T
MWOL8MOM$>TB<"E0"2".\$CG;E^4XS:>X/6V3L<AS P1OW2SC/NSX#IQ)"4ZM
M]@>1MM[#TGRQ!TPT57/W=]7/QL?$ >_$C\PASKYK?[-7]2Q_^^E;XK,F)&4Y
M5'/+J'?_ /#-C];8M\_0%Y]GDD@C.,SV[ZUXCVQOXXB#BR*U3N!%K#YXJ0PG
MJ3^N[!P0HIF29Y>V/W[8 V H"#'XAMSM<GPVY^W!P@2.9'O]QQ(LI(YSUM^O
M,X/W]W!J4;2?98^["#21U/ZYS(Y=V#A@JDB;]Y'NG\L!;08@$\Y$1\4WP<,E
M8W\X%O*WGA!E)YCV$F?'!Q'4K>?UX;8.Q'L[C!]DR//%^+'=ER8\5A/;>DO-
M1VD^;CRTMI!/@GM*':/@G)Z<&HF23L"8VF+\HOSQ%P(:;4XH>JV"3J N!>Y!
M'@.?LQU#1:=$H4%N(PKMK2TA+K_XI<4!G"0 "A (*@CKC*EY4=L"B5QZL "P
MW!O(-]R>E^[''OK6\XMPB2HS:""DDQ$@;6&\D&\S=UPHRG"EZ5D(V4AK."OQ
M!7G)"<XPGJ=LD#=44IG81)BPG\O9/7;J--9B4Q<&\=P]@FT<P+1W1IJ+=C3H
M13XSH2PPI9D/)6$I<[("2RC&W=H4!MT6M! "TXS94S 0E+B[J4%$)/)),BUI
M(B-B=C-I,J5LN.*.DJ D"?Q]!-MC$V &Y!Q$$"8AZKTV14G1$I#4MAZ09+J6
M2^RRX'5A*%'M*[SLA(R.QV5;$GILQJ5Z^E+84"29DV,F "38[;R/'&^\E+=.
M\FG0IZI4TI"4MI#@05)TF2FUI_%,B3%L3Y,U*AS4O(A*FS&T)*NQ28RPPX0#
M\U^L31&C-M#;MK8("1DA:NR<;R7*='W4K=4!(( "4GD2"9@Q>0?"3CD49.ZG
M2JH"*8D@ U#B=<$!(4&6RIPJ.X2/O2;Z3 C%>H-S2G'4Q/4Z%"[2@#!_OB;*
M.Z25U&0%N% W_#1FV%.$Y:66R%\06^Z[$D!-R$)$GE&H[CI"=(/AM;_567MI
MDAVK=*4R7 $-((@V:0#ZRMP%JE(N1,@-U^>[(<6\^^MUU9*ENN+4XZLG<E2U
M$J42?,^SIQ'[0[ [<X,#XV%KXRHIRF$H;"1:P2  !8S$<@ /9SMC#7)2G)*L
M ] <[_\ %&<]?#IX^&)I20+R3-Q-QM'G?V]<;/HX !5;JG4#Y<_'V<C.+"IB
M1G!\=B4G!\P#D 8\"3\1Q(I)^\8B^X)M<#GS\)@WPPT@^J; 7B;G;>2-[C\[
M8LJFX/S749'@0",^(V/EMC!W\=\\/2!U(&^_YCVW4#!Z[Y%(; ,08'W;P>Z9
MV\SRG%M4PJ()6!X82E0R? #/G]&_OX4B3I3,Q$\NMOSG& J.R6P +VO;F;R?
M<9]E]BF&Z4H4Z2 ZD@* R6G",M%U/BE>0DCJ@D92>)>L(MN=A;K [KWY]^P&
M(I=,D:9TG5-HTWF.IO.PCK&^FD27([BF5[+0<$'M8]BAN1@[XP3XC8C'#A4V
MMWD 'OV'Z]YF0ZJ[21>]]"3!\9/]?EAF0I1RIXGKX*\>O\']9X4*M(GG8@#I
M!$7M;>(M@0R[ZW:)U;:=*TB(GJ/"+VC"%X$C\)MXC"OZ<_$<2),[&.=T_G.,
M@;4!9+G6[B)]WS'LWQKGZ? DOJD/I4MQ0 5A;J4DI& 5!*TG. !GR &V_$2V
ME1*BE1)',CI'*![L;**BI;;[-"0$C[H.B=Y,JD^S?V<KK42G- =F.R"/$ME9
MV_.6"?;C/ &T@60";V,<SY=_NQ!3U:LDJ62D_L!83'M2 #[9F=L9(6E)/84E
M \DI*1CW!(' 0HW@CP*1[XG&(H4=T*D[_:(^)3,3RP]X-5A(B1FERFDK2TE*
MDJ5V<*&<_CXW\\>S?IQLH-@#N +[W)-I CITZ6C%4]3OEQ<,J4@F1:;DF?VD
MW-KF9.UM]B*A%7GLR6#_ .*XWG?Q&5>WZN'J3UY3/ZO/=&-9;;X("F'$#G F
MW<9-_#J,-6= E=XX^PZ)25J4LA!3WB2HDX[.2%8\.R2>@(Z\0@&=H)F1&]ID
M6,7)/G Q;4U4A:4I6T65 Z84#I)%OOQ[8( V,VPV)O:4"LJ/>-G"DD84!N#V
MA@*!3U]@SGAJ00)L/$VY1!!5SWD^[%BTG4J($&]B"(@<Q>QW]N]\8<>04%0)
M"@<$^PC;/7H!]/$4@DVZ=2/A?&=U@ITRG4+\R!W0;;3XDF\[X$K#LA2E$!(R
M3Y$ #"<CSP/;V=^O5A"E*($6%S)WM:_E\8PE)*$),#UA"!N )]^W.9(M'+/5
M(;4D)4K('3IL,8VW\O#V#B9:68D)F\P=YWGK^HC&L$*D$ F]X,F_B /,^-IQ
MCNK[.,_.R/FJ2,[#!((&0D[[XP,#V<1T*!@C?S%_9)]D=V,R1(!*0//SVN;\
MOR&,AM]!;/:7A6, =,#SW(W/\(=!C;KQ I,F$\[Q/E(G:WF9Z8@4 *F#ON)Y
M]/E[+XQB\,[$$>>"/JR>%H !,"QOMS_*;>[EC-!YA4CO(Y=ZOSWP=\/9\#PH
M'0>0P>Q7\K_YL'?#V? \$#H/(8/8K^5_\V#OA[/@>"!T'D,'L5_*_P#FPH>&
MV3M[ 21[L\$#I^OS[NF"!?U3?O$^>J<8SRAD*0K8DY3^22 20-SOM@;XS\<;
MB-,+ D'<#ERVD#>+=Y(N3C,@["(FTBQ41%C%^D7)D<Y.,1PH=:6VLY2M*@?,
M9!Q@==C@CR/LZ8%&1(F)[K_GOR]OAG2E:52.6WPW[Q,SR[][5(K':<-/F+_#
MH44-N$[+"3@(45;]H?P22>T,#KMQH/,J'KHL+D@=YN3ON1>;8LD%*K$22! &
MW<),F1)VF>N'/QJ:U=?</EC+V(\/"3\3^7=%I)Q*5P=XOT!V_+N\\1#:)'WI
MD;@1\>=^H[C@XA)ZG^K#+:=02-0D<M,7F?ATY8.'J5-B9_7+$NQ1$7\;3[8
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M#2381:/V0(]XC] \\;RD,=\H2G$CNFSA SLMP'.<X *4>.V"O !^:1PNS V
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M">O_ .H?EA?7%>+8'_')_4H\04SIB9O/ZN._"*4CJ?!9/Y8S(*)$]WNVFPE
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M#?GX\R;SWX@&000D3OL#S %YB>MC[ ,7N\5C&3V01U).#U'B-]O(<02X%'4
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M&]QUV/+E>Z:R$(:2VM=.LD2N7M,J4 5"PF4V"2#8=X&')2=1(T]7=/T^IGL
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MKXD%3L)GH01[3RQH$*2=*DE)!((4"DCP"@"=]]NDXO;=D;;[[YW&_E^_C[^
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MEC&4B!H*M,_>5,FWG<WW'*W,W-_ X.<Y&//V@CZN):!U/ZZV/[^F$$CG"O\
M2O\ H=WQQCRU.=PHH5D)(*QL>TGQ&? #91 Z@$>/"6"0!>#;Q/+V[\L-M"4F
M0E(MR2!8=;QML3YWQHB\2<DI_?Z>,(2!U\S^48V;\E$=P/ZO^["=[[4_'^GA
MP._S/SP2K\:O,?+!WOM3\?Z>"!W^9^>"5?C5YCY8V$1A;A[QP!+>-@#\Y8\/
M<G(&3U.^#MQ(-R 1>_,GSN8QC6M4$ J)Y:H@=^Q]DC8XW"5=D=E(  \,>P=,
M8VV_?QF$S8@B.\&9W^ QJEG4HJ4;G<B\]-]H\/A@[6P3@8QCI[>OAO[^)Z1
M!O B_P"OZL2#8$";#NQ20#NH9/F<=/I!X6E/,3[OA&'HZ'S .#"/R?U?S>#2
MGI[S\\&@]1_)&#"1T3CZ1_-X-*>GO/SP:#U'\D8,)_)^L?S>#2.0]Y'SP:#U
M'\D8QGTJ*2<E2?$#JD^S&//J>@ZYX@4D1>?9WCJ>_;KROC,V$_="0";6&_LY
M;==]L:*1'.5*22M)!SO\])P-MQ@CIG<;;G(R>(B+S,D6C;V\[']'$RG8".0'
M6#8CD),[Q!/+8XP%(4,[=-R"1GIX8.#X>77V<*"!8==S'C^NML,-B85 @;]?
M8#OY_D+0<(/0C((S]/U>?7/CC?AP8F0#TY^5IM[L3[/U8!ZF >4;[]"#!V]F
M*P>T/F_./7 W4<>S.?@-^IX5_$_$^\_'$.RC<3OSGRC?O.PZXMEP^(.1M@DY
M&V?$?J\O=PXB-KCER[CC*&4KD:T@IZ__ /8OMOBH.#&ZB#Y#)^O[,\*W(@^'
MPQ%2%"-B#SU#?IX[QM/G!W@_*/U\&#0KI[Q\\)WJ?R_K/!@T*Z>\?/!WJ?R_
MK/!@T*Z>\?/%*U-.)4AQ601L=R0? CW?OU/ 0#OB(04JU7%^X@SN(D?'&F?0
M6%]G\9)&4JW&WB#[1MG'3(XPJ3I[Q^OUYXWD*U)!Y\QOW"XYF#:+8MLRELNI
M=1V3V>J5 *2H'JE8.00?'/3J,$ C&I"5@@W'YBT^S\HQD2#( D$$;6('A:>5
MOW$2%39+B4-S*1,>@N$94EAPED.@?.0]&5^"4 =\=A!4"/G!)!XKU2TI0!(O
MUL1(V$=VUML1=2AT::AM#B>6M(U@7L%1J!-]O8+F7U2KU<04L5UI#7:(2BHQ
MTJ,8DX $AHDJ8))_'&6LX2.R#D94OA4)7J'0[@DG?EX=Q'(8I:C*=UTBE+%U
M%AS[X&WV9F%&UDF+1%[8D-MQ+B4N-+2M"TA2%H4%)4DC((4"00001CW\9KF+
M$[Q;SQ4:2@D*]50LI)M!F8@W'.VW3"G/@,_O^XX8 _:)'LGQZ;815T@V)^6W
M61^K@W\1\#^O8?MX('(S/.(BXZ_,;8B#)_9)ZB1UO!B8'[L+PC:P/7GR,;QX
M=?"US(7-]P!RB+]?/N/G@X6&3W$^ )_=A2?$DD^.WV?9P84A(DB!RW)\H/?S
M.+\3_3#9!(_'/B/X"QOQG9!*Q,QI/6-NX'X>W&)Q0*;0;\]KB9OMW@Q?OWE+
MF&.-?]<A@'_/AU-.^?\ ?K6AYX\/'R/MXT<C3.393)4/[5Y>" >M,W[X(GIB
MWX@(&?Y[J%SG&91W$UCYZ^!YVOMB'B2>I^CPXM4I2-@!RF(F/W]<5&J(,S'?
MTW G;:_RPH40,>'LV/GU_HXBIM))4 -1ZR1[0(^.^ *M8Z1WG\QY6^>#(\1]
M)R2?K'  H"!!BT Q\08\#A$\]^_KWR8P=YX#&WQV^GB/8@DDE4FYN-SN-N77
M8\AB:5S:0!%B>?O$VZ8VM.@HF(E2YDMFG4JFM>L5*H/G\&PR3A"$-Y[3\F0I
M*FXT=&"ZL$%2$!2A$H"-9(E"0"2J)B#.G8$S%K^&(+6HK0VA!==<44M-)W<(
MN9W 0D"5*-@-XF<:F9/56DM,ICJ@6]'6'(-(6?PTQU([*:G6U ($F4Z!VFHZ
M@8\5M7=H0DA21IK45WA4=P,@6L01N+]+\L7=+2BE3,)<J5)4EY\&R18]E3I_
MQ:$V 4FZX)F#&-=49"0E+22E*0DN.KS\U"$;)!P"1DY*<9). E.>,S*9,@&?
MN@'>;FWLY>W&54CN)NHFT ==[DP(*23%L,R5+#ZCV3A*=FPK':(S^,K&W:5G
M.-^R,)!."3O)2$C3'K6_JCP_JOC2<45*.I*RD;) ,'H20!<[F]ON]^,%Q]+2
M%N.* 2VE2UG.,)2DJ)._D,XVST\>')V),1M[+6\ORQC;0M;@2$J&HPD$&+F
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M;SZ<2"5'9)\CSQB(9'^-![@4SO\ J-Y.-]3+>G5!:2ZGU6,2,N+ +BAL3W:
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MQ:0MPBX2F2=]MZ>ERC,\S>J4Y9E]77>C(545":5AQ\L,@_W5SLTJT-#FM6D
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M <J6I/:& K@0M:5.K:)$0WK2HRF(),BY$VGO ,S>ISI\-L)I4I!4Y*G9 5I
MNGU2/VB;*Y01S!$]RI3\QT.RGE/.A"&PM:LGLMY"!ML<9.Y!*B25$DDD6ZZX
M=:U%1 B2.0Y2-NIB+WQRC:0@ (2$I!)( M)W,<CX?.;!.VYP,@GI^, !VO?C
MZ#D[;\0U&;"]]IFY)(W_ %XXRE0CU;GD(/ZVP9)W*BK/B<'Z\<$D':#W2/<3
MM[,1*U>'L^>,N$I0E-G)/X^V 0,H5T 'T>[B;?K* (BQN+$VY]<0<6=!GNY3
M-^E_AB5^8C_7 :Y_^6+4W_GK6^*G)_\  ^4?ZLH?^&;Q>Y];/<Z_UOF7_&/8
MAT_O^^#Q8C]?J1BJQ*>FT'\+*J;C>0PCN&>T.KKV>\4E0Z%+2 ,CP<() )!Z
M#*FH07.\QN-]K'>QZG?GBHSEW0TVP%?W0]HNY$ >J#W#:.NJ=CA]W6GUBBR@
ME!)26G5'(PGNG$@[@$Y[)4 #T.20.O'14Q^T!) Y<KE1F>Z('0]Y (Q0H5ZZ
M!"A*KFP'W8BU[R-S,SM)!X2O=MR3)J3H2I;T*HR'4K[7:4IE#JVU( Q\T=QV
M<]!\T>.W%)F[17VK@.I;3JE@09*9A0VV $QSZ3;'I&2K0TW3ID!+S*$J$$ J
M*9DF+**R!,\S<"^(7J[B3+!&X+2""#D>/3?IC'LXXFO7]N#$ZFTGH=SRWV@"
M;V\NPIDJ[.(N%*Z<^7N.-7VQY'ZOMXTNT[O?^[&7&="IU1J/>?)].GS^Z[(=
M]3B/R@WV\]GO"PA?8[795V>UC.#CH>(J>0G[Q2F=M2@)\XQ-+:USH0M<;Z4E
M43M, Q.+II-5$Z/3#2ZB*E+6TW%IWJ,DSY+CRNPRB/##1D/+>7\QI+3:E.+^
M:@%6W$2^G27.T0&P"2K4G2 -RI1,"-S,0,,-.ZPCLUZU$!*-)"E3L$@B23R@
M'&/5*=6*14G:/4Z34Z5565H:>IM2@R851:<=2DMMNPI+34EMQQ*TJ;0MH+4%
M(4D$*!XQ>D)<0%MN(6V02%H*5).X,*%B-YN1Y8:FW&E=FMM;;T@%"T*2L3L-
M"@#)MN)O:>6WM^TKEJ%5<0Q;M=E(I:&IM:+5+G.)I<!:L"94EAD(@15I2L)D
M2E,,J[*@%G!'&>A>0:QA)6V5.**6TE;:2XH0=#>I22I4&=*9)YC;$'TO(IJM
MSLW/L&"I9[)PE"2(2I>D )$@0I>YVDXG:(9T^8Q3X-$K,Z=)<#,2)3:>NI29
M+IR0VQ&IZI,AY:NH0VTI>,D)Z\=D]5(8;+K[;J$-@J6Z4IT) &ZBEPA !&ZO
MAMP;="Z^X&Z=UI:W#"&B5!:B3 2D%LEPF=DD'?QQ8<>]0JQMV53:O!KCDUN%
M\ARZ-5&*NNH2EI;:A?)KD1$PRWG'$-M1NZ[U:UMH0@Y3G4&;4!;+QJ-+125A
M:FW WI&ZPX $:  25"0())@6VE95F)=".QU.C2V6TJ3VFN8"=!45!9D )(U$
MD 74,25KIROWMRSZL6=IIS 1YMBOUNCZ>WC=2H%-G5FIV+;%_.,RA&J<(1XS
M+]VT6DO%V?;T>4XINIA%&5),Q+R&Z6AXLRC.J"JK<HJ6J@LNUE/3!Y::=-6_
M2R IM2I*:9YR VZH))0.UT!,3V;W"^:Y+74=)G-.Y3E]BB>JBTA3RJ1FJ .A
MQ*0 JH:;(4ME)4-?V845 XR>=*Q^6#2K7>JV;RG:O7-K#I%&MZVIT*[[UI2J
M-6C7:A #U<I@#UN6@:E#A2>PIBH(MRF(0M]VF%,QRG.5&7K\*9QFF992W4<1
M4U#EN9EY]"J2EJ4.(+*%PRX!Z14Z%+$R@O.2$A8TA80G:XHRK*LMS5RFR"LK
M,QRT,L+;J:IA27.T6B7FY[&FUI0O[JNQ1&KL_7*"M7-]5H=?H+4)^N42K4=F
MIM=_3G:K39=.:GL82KOX3DMEA,IGLJ2>\84X@A0.<$'CHVJJE?*@P^P\4&%A
MM]MPH/100J4GQC%"Y2U+027F7V4K!*%.T[C86!%T%<!0N+IF>6*I= N.#2X-
M<FT&L0J+4R4TVKRZ9-C4NH$!2B(-0>8$260E*CAAU9PE1_@G$T/,.+6VAUE3
MC8E;:'4J6@6NM"2M21<?> W\HKIWD(0XI#J$+^ZX65!"_P#04J$JF_W2=N[#
MTT5LF+J;K%I/IS5'Y\.E7_J78EE5.?3$M&?!IUU732J%-EPE2&7XPF1HT]UZ
M,9##[ >;07FG&^TA6KFM4K+\MS&M;0E;E'05=6A+FK0I=/3N/)2K3H44J4@!
M4&8F"#C8RNE:K<RR^A=>*$5E=24JU)TI<2BH?;:4I&HJ3J 62DJ21JB01;'8
MWI(^2B)R<\T%^:,:5C4"_;!LVW[%JKUXW/$I[K\:9=EN0:R_'JM2HE+I5&C(
M:D2E,PT*C,NJ:" M3R\J/+\#<5O\3Y!29G6M4E/6U3]8VFFIW%(;4FF?4V%-
MM//+>7ZJ9605 &;18=)QMPU3<,9[5Y;2OU-11TK-(XM]]HN.)54,I=4'%T[*
M64 :H1J"21$DV)X0A6M5I\N/3*32ZC6:K)2%-0*7"DU&2\>P5.)CQ(;3LAT-
MA)[2TH40$E1[(/'<K4U3-=L^MMM  "E+6$($V$J60$WB),XX/6_5NEJG0ZX2
M);2V@J6H).^E"2HF!J,6@W $1;=H\^!-?AU:'*ILN(XIJ3 G1GX<QIQL94V_
M'?2V\PM.Q*74I6 <X P>,:5H=^T0M*VU %)2I*DJ3/[*@2#SB%$'?<V' M@E
MI:%(>$I6%I*5I4024J20"(M,B>HC&5<%#K]$5!-:H-9H<>:R)%,-5IDZG(GQ
ML()DPC,893*8(6G#K'>((6D]K"AQC;J67UJ##K3I0H)4&W$+T+'[*]).DV-B
M1$$&,9'*5YAM/;M.MJ> 4@N(6C6DW)25 :A<&1;:^,0T"NIHXN(4.KFW_6/5
M!7C39HHQE=KL^K"I=QZD9 4.SW/?ASM;=G.W&5=>T'C3AUKMP-1:"TEW3$ZN
MSD*TWLJ(CGSQ!-"\6P_V3@8U!/:E*NS*MB.T"=$S,B9Z#K11:37*W.1!M^EU
M2LU(MN/(@TB!*J4M33*>TZXF)#:>>+32?G.+#?80/G*(Z\:SM4AD%UYUME (
M!4XM+:)-@"I9 D[ $WZ'&PBD+Q+;32W5D$Z6TJ6N!<D!()@;DQ;'J%S8<C6G
MNA')%R7\S%(NJ\ZA>W,G G2+LMVO?(R;?MV5#HS-1+%!;ATF'560'W%,NHJD
MZ<I*4A.RP2>)X=XOJ\]XJXIR!^FI&Z7(U(32OL]MV[X4Z42\5NJ;/JB4]FA,
MGECL^(N#Z3(>%N%\_IZJK<JL[2M56P]V/8,Z6@L!E*6D.#UB >T6O;D8QY;M
M0JI(<?1$A2Y?JR.]>,6.Z^EIK?\ "N=VVONVSV5'MKP-B2>.[<6EL@+6A&HP
MF3]X\@#(DD$6WY8XEI <!* M12)6 %$)GF0!83^UL?;B]4:57Z.W!>JU'JE+
M:JD5,ZF.U&!(A-U&$K'9F05R6&DRXJLCLR(Y<:.1A9SQC14,N%8;>:<+:M+@
M00LH5^%82HZ5=RH/=C,MA;827&G&PM.I!6E:0M)V4DJ U)/42._%<>BW)+D1
M(D6AU>3*GM.OP8T>FRGI$QAADR7WHC#<=3DEIF."^ZXRE:&V075J2@%7 JH9
M2E2E/M)2@@*4I0"4J)T@*)5"256 -R; 3AIIW%J2E++BE*!*4I0LJ4$C4HI
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MZ<1:"D(!).I14HD]3$V%@.47VQQM<]V]2XM*B4CU&S)^ZF1)'.=Y(O,1:[D
MP!]&??CB1W,;<O#]=<:N^%X6% F8O^A@_?W^S@Q+3()F+ SXF.AZ'D?SQEP
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M'FJ=;22EQ*7"WJQVO%Y7Q1PSG5=EN:YK04;+5*G-L@S3+TTZ&$,.LN)%(I;
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M<M]FP34-O.K0\J5!+06VML,@%DC7Q7I Y7^6;T6?-7JYZ/ZR[FMW7!SF]O\
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M04H<5]X%6X"C)2"#S ..@H7Q4-I;4H=HR#,QJ6@0$D[ D) !CRZMQ.",#!
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MR % E*@>UG*5#;?L@C I<[>;>?85)![(@@Q(.LVM(VMO,WB)Q>T5,[3(<2L
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M/7]\<&"!L#!_TC;K:?'%8<_%R!\T$9R1G/7.Q]OAGR.0."-^_P#JPBE7*_\
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M?O'LP@5MT3[-B3Y^X>/3ZO P0=B"3O(5&UMMMHWN9\C()/XN ,],9./CU/\
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MR'&)JG89_N++3=R90A*229))($DF3))QHU%755<&IJ'WXB ZXI0$"+"=(MT
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MU;XK,E_P-E/^K*#_ (5K%QGO^'L[_P!;9E_QU1B'.+/%7@X,&#@P8.#! Z8
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M)!()428 'K$D0!OCK6U;4AVS#"$)0]47DI]>G%.%/$X46F@HGNXR-@A P7%
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MM(&2 >Z7VVCCH4'8$X&DL:5$&TW$VF>@F=_ZSCT+*GTU=$TZHDN)!:<@6UH
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M1_8R=I_&X9[OO^Z_<Y*],RXW%#ARV XXH*"?G*![*<Y\$G.,[]H$#KQ;E5R
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M8^OA3M8W,7WY_+"!!)',8R8G^F&_^/\ _2*XDBY%N9'E.,;WW#XC$K\Q(_\
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M4LI0E()4IP)0D!/XV5*P!CJ<D8 .>$IX)!4I8 2)4?5A(B94=@(YFV))0I1
M2"2; 09)Z <SW8C&X+WIT9QYJ!B?(![ <0OLQD%([()=!)<QU[+?S3NDN#&_
M%YIQ)2TZW44Q%2Z#]Y*@EE*H.[F[@-B= ,&TR;=AEN15+K;*J@!AO3.A9AP@
MDF0F(1&WKF=K; Q'4:U5*NX537UJ2#E+"/P<=OK^*VD@%0R1VEE;A'XRB.G#
MUF95F8*"JA]2DS*&AZK2.X("HU1,J.HFYD8Z=BCIZ)L]DVF2(4XHZG5'F9@6
M-K  3&,$+^;V>U@#;KC/0G/OZ$>SS'&J2; Q81:_=YQ[NXWS R#TVCRW'C^6
M*,)\T_$_SN(DD;K4/$CY8F%*Y>X#Y8>=EVA/NJJLQ(;(4DDJ[UP.".VEL$K=
MD.(2YV&4$=D'LY6ZI#20I1P<E.Q45CX88.I1!*BH^HE(23J60/5$@ 6,F!SD
M:.8U[5!3./5"X2F $"-:R2(2E,C4;S$CU9/+';EJ6E M.!ZO% >F/)"ILY3:
M4NR7$X(2D#/=QT'/<L]H]DY6LK62KCN:"A9R]E*$'M'5077ONJ6;6C<)%P!L
M!'08\LS+,ZC,WM;OJ-))#+()*6TSOL I:MRHW!V !(+JVR#OD>..O48\\^&^
M^V#G(XWI)29[H'.)^'C?KN,5FW6!^@!\.5XWF34<8W..G7S&_!)1)$$1O!C8
M[0>\^6 P003'CR._ZZC;%(&,;G;KL<>)\-ML]<GZ,;@65)N$WVG3;VS/38Q[
MY0$#PWFW>;#?QD^Z,+XY&^V-AMC/7/L\OIV'!J(!,$V,$D"38$1]ZT1,7B=C
M.&>L208,6W@_+]V *R0-O'(SN,<2M<DJ M!!,7]GR_+#OU'/];\N?7NP9Z;9
M)QGW>>VQQD#VCW<8U+F+?N%I)/.+?'"F([XD387N1OS/ZC"''@$^[ WSTWR/
MZ1TX:8,F5$B\:R9Y_+KOAD](/MVL3W[\MO?8'3P &%92!CQ\P?+<C??;'$IE
M5QIA(,GG)VOT[K^&V$>\;0?;>TGPN>_EA22-O Y.1X'))S]']'L J5Z;WG94
M Q^A-P/?@'J@#WP>9VCK?^N\4D[8V)(.3T.,$@X ]NWVYPIDV5$:@3.T'G)N
M3^H@2BKD-R><6L((WML?83X94$_WTV"D8_" #&VR%YQL,^9SCI]'$Q$V,S,W
M]H\A;I'38XW%2V9!Y1?H>_<QO)CP, RSS%$IY@M=>F^LFI_7/^_>N$?KZ_1X
M;TN3'^U.53_U90?\.V/S']5\7>?6SW.Y_P"M\R_XY^/CO\CB&LYR23DG&-L
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MM2=ZO:,=A) 7)G3'%=DX_!(6E S_ .,I &!G.,^8'7Y2K^U[9MZRW#T,A1!
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MNHJ%^H?50D74M>P2E)B3S)F$CUE6!&.\K5M2DVE3TPJ8R XI+?K<E0[3\M:
M0%+5CM);05+[EE)[MOMDD%:W%J[JCHV:!HMLB5DA3JC)4XH1,\PD7"! "09B
M2<>1YEFE5F;_ &KZK(*@TRD>JVA1)T[25&VI=]1 /W8 <W;QX>8\?#W[^7AO
MGPQQMA4S(BYY;;0/?T$\N^O"B=^_D?9WR=]KSUM@"M^H'7Z,D#.X Z9/Q)ZX
MX HR9$"-[CG;>/UY! F;V%^H&XZ@#]Y)M,809W.!@CH!@>&<YV\_/X<34JP2
MD IB#;H181 \QRO@YV%@"(Y;B8F!\+S.#*B1DD9WZXZYQC ./WS[( G?G8P3
MZMY ]AZ;DC )-Y,V,3 @R!R-CYR,+V@D)R!TWP-\>'Q\>'J4H#:!?G%R9O?N
MW]N&-@3XGPCD>>PF23[L(5^7T>?V;]/B#Q$*E6^\VW&W(^^^T1&V$% F/&/F
M/$'GM!!WPO:'N\.I. ?( CZL8^K@F=MYC<FQYB"('?RVZP \AX6)(\8!$#OM
M%N^*2<=!C&?'Q \QC?W==LYX:2 ".L3-_#D!TO?>QVEB!;8[>WR VBXWMO::
MDDX_@]1G?&VP) ^OWYXF2G<**NI,>'0=//;:,$B)!G;>!W3RZ?D,(59)!Z>[
M<>&V>GM\O9GB(@W)&Y,&8$;;7'*?':^ $&9ZGV08D<QR)Z3-IPF^#U&!N#Y'
MKUZXQC..GEL X22=2B"9/*3,"XTQ!Y=_LPA>02=CTF#$\K]T"1$&+#&7!4!)
M:/CE?T_@G/?OU)^WB28U"#/WO=(Z#S'D.>-X@-D]X\3>/#>3R$8ECF+_ -<%
MKI_Y9-3_  (/_;M6^OT8WP/(].*G)KY/E>_^#*';<_V.WW=WO/CB[S\?V\SN
M9']MLSL+'^_7MQUMOS!]N(:XL9@0$J%QR\)]V*B8$!*A<<O"?=A<[ #RW]^?
MZ!^^>$J38 P9)L>MO<!^_$3)FQ@S-N^WN _KP'J22.ISC/Q'3Z-^ "\B9D\H
M'/J#'O\ #I( 3-YD\K<_9X7.#)QCP_IS^SB1 N/6OT!Y$GIU,_NPS!D>M$\@
M?'IUO\+83)_7]?7@)%R9V DB_O%^I@>S 2(O/(3$'X>TC;NY87/NZ8ZGRQY]
M<8S[NG$1L9!@@"UX@0?.QYSWQB(VN#! %KQ:\])MMX&X.$_?]_W^/#).WK;B
M\$&.>P_(>W#DW'K;B\$&.>P^7MV)P D6O$GD?NQ;EU]N $BUXD\C]V+<NOMP
MH]^/?G'PWX<".?+E/F(/PWGJ9<".?+E/F(/PWGJ9,^WZO9CX;X'ZAMPKFUQ8
MBX,1;K$;D>'(6 5S:XL1<<K;3$>SER$  R=]^O7@@?YUQ>RA/L'PV'+! _SK
MB]E"?8/AL.6#)Z?OOC[!PYN=XM'JGVC;!-S,Q:+'VC:8G?!X>SW#]?7@,;D&
M^Q O/QGIX89C<@WV(%Y^,]/#!TZ=?U=?[<_#B$2>8!,[&>>T"/T+X@!)FX!O
ML9Y[&".A\H,C!D]??]?7]?#B=IY]+;VB!>^QCNPXWWO,FPZP(@7@\X[C@SG.
M<=<[YZGKTXB03%B=_P!F-S/?A03RG?=*AN9/W9_6W/!DGQ/EU/&0P>NT<P/;
M;SFW=B1@R?6V(V4!\/W=V [X^&/$?4."9VD7)VG;<=WL^,@.9B)%SR)L-P>G
M=$_EA 2#D<,D'KY*'P&'([[=Q^6%!.1[5 GWY_IXB8]7?[PY'>>9(\>>(F+;
M_>'(BY/>/' >ISY[_OG]O#)-C'4&!.QY=Q@^[;<,W D3UL#$;CGO^XQ,A1G?
M!/MZ[_ ']GZ^(P!^(&!,3>?UW<\1M_G P"8DS-_/RYX3;&XR3N#GS_7^XX?J
MD$7CP,']\[D^_#L1%XC<20>??>=YO.^$XE(Z'^2>6W+$I'0_R3RVY84$CX8^
MC]?7[.(D=-1O>0?W<P(O[L1/+[QWY&8/L!W Y^["Y'9&P)^GIOXC'Z^ ':4F
M8 F+1[??A@P!8S8;&P\3[\("0<^/[CA@I.V]N5^6]H_+"!2=MX%P+^VT?ECF
M_F%M(SJ1"NR&C,BE 0JCV!A2X+Z^U'>.$_\ O:2M;94K<B0G)[* !SO$E%V]
M.*IL'M*?[YC[S1)D&+G25$@WW,CIW_ V:=B^[ECJH14@O4Y,P'T!.M(GDXBY
MYZDR-SCC@]H=21])XX/'JF*VWG&UI6A:D*2<A220H'J""-QOY;?7Q)"UMJ"T
M**5)V4FQ&(E*52% *!Y*N/8.5[^.)&H3RI8@EU67'7TH4H@#M?A"$DXZ9 .3
MMGJ=SCCM,K>6^W3*<.I:UPH]=+A3L !LF_7OWQ15P2VFI*82$-.D$^M?L2H"
M\SZ][SR$'$Q=M)ZK&/ =O^S'NX['4._R5\L<2D _>-N0)_?;P[\8TQM+\22R
M"E1<8< !5MV@,I\?R@/?Q!V%M.(OZZ2-CO!B)'C<"WN.9EQ++K;@CU5I4;\@
MH2-^:9_?B*@1G (R#CVY!QT/MXY74KK[A\L=>$C<:9!@0+S[1[]L2.*O&MJV
MX[TLE;H2X&(X("WGUK6X6T@;A"">TXL I0D$D$J2E76^FL91E32WE:G8);:V
M4MU1*M(@?=3,J5!"0;R2 >672KS3,W4L@A!4$K=TRE+;:0C63<RH)A(W)(]7
M2#B&9<Z=69CDZ2OM+=4,J4"&VT ?-;:22<)0G8)2#@Y[2B25'SJJJGJU]RHJ
M%DK69.Y"1?2A(O9,D"Y, DD[XZE-,Q1M!EI8THV2 023^TH@$%1DDWD3$VQ>
M0VTV00<JZ]HYR?, '*4[9QC!\^A/&).@<Y,;F9^ $\K#&$D'<F)'LDQMMN>4
MF.D8;+BRMQP@')6HG<#JI6.N0?/(/CDXXTU&2>XD>1Q<H;4E*;G[HYQR',3,
M=.7NQ1E0W(.V_5/V< ,&?U[<24"00;VZC^B#[QC?VY;U1NJKPJ+2T),F<X&^
M\=)0Q'3A2G'GE@$I0VTA2\)"EN=GL-A2BD':8IW*Q:6F0"I1 *C9"!!,J,VY
MZ8)U$0)VQHUM73Y;3.53TAMI.I20)6LF$A"$J4)))C>$S),8] ;-LZDV31VZ
M52TJ6M1#LZ:X$A^?*QA3[N,]E/@RRDA+#>$ K5VW'.XHJ1F@9"&KKMVCI!UK
M4-]5XTCD)CN)QXOFN:U&:U*JFH,!)4AEI,EMEO5(0D$W/-2S"E*GD2"[-P?$
M'C<[R+G<Q?W3\<5P@7B_.!?W3\<)G]_W_?SSQ#G,&\S:_=R,7Z$]3B//8WF3
M&W2T&+P;$[2<&#U_?Q^P\2WL9! $GQCGWQ[CB438R" ),^'Q(]Q]I]..$0.\
MBW(S-]Y&T=/SPH'.2/ S-][;>'/QPN<'S/F/=CQQT \O'KMLKBPF)')0,6&X
M Y#X\XPK@P)B1R,Q !Z<A:W.=P,)^S[2?UGB4V,3SBQW/LZXE-C$\XL=S[.N
M%)R3N2,[;G]O (_SO:%&/R[L @?B/B%'\L)PDVG[VY@08CRPDVG[VY@08CRP
MI.?K./+)_<\*)/,'D0#S/4WMN8B9/M5R>8W@@&TD<SM$7B+2+<P$[X\00?=X
M\'JR1?:.<[DG;??I@$ D7VC:^Y)V\;6P @ ^?@<]/W_;U'  !R5W&\CJ1:+V
M[XF>0P  6A7C>1[H$QY3)&V%S@;'?H?#ZL?7DG]C ONJ38VY"8O \]_#DP+[
MJDV-N0F+P//?PY9,''K3(/3*R>O^U. =![?V^'$V_O\ M5$V-P">G/NZ8Q/$
M=FH';5S!G<'QW.)=YB03S ZZ[D?Y\>IW4#/_ &ZUOKL/V[<5F3 '*,JF#_:V
MAW&W]C-_KV3SQ?YZ <]SN0LCZVS(1 M_9K]MO#Y=8<[!\Q^B.+/%7 Z+\A@[
M!\Q^B.#!I3^%?D,+V3T[6WEV1P8(!$$+(Z0(\L)V#YC]$<&#2GHOR&#L'S'Z
M(X,&E/X5^0P=D^8_1'!@@=%^0P=@^8_1'!@@=%^0P=@^8_1'!@@=%^0P=DCH
MH#_BC@@=!@"4@R$K!Z@ 'SPN%?E?R1P0#N)P$ [AP^.$[!\Q^B.#! Z+\A@[
M!\Q^B.#! Z+\A@[)\Q^B." =Q.#2D[I6?8,'8/F/T1P8-*?PK\A@[)\Q^B.#
M  !L%CP& I.V3[OF X^S@P$IM.OND8.P?,?HC@P0.B_(8.R>G:&/+LC@P0+6
M7;:PMX=,'8/F/T1P8('1?D,'9(\1^B.#!I3^%?D,'9/F/T1P8('1?D,+A7Y7
M\D<&"!T7Y#"=D^8_1'!@TIZ+\A@[!\Q^B.#! Z+\A@[!\Q^B.#! Z+\A@[)'
M10'_ !1P8('1?D/E@[!WW&_FD']?!@TIZ+QAU"GQ:G!ETZ:VE^+-CNQGVU-I
M(4VZ@H5U0L!2<]I!P>RM*5#<#B#B$.)*'#ZBTJ2H2-E6/+I\!B;3BZ=YM]DK
M0XRM+B"18*29DP)CD0#<$@B#?S3O&W9-JW)5*)).T*0I+"U)['?Q5Y7&>3U!
M"VE()[*B K(R<'CRW,*8T-4ZP0=(45-$ ^LVKU@1.\202>EL>\957(S.@IZQ
M! 4ZV@N(FZ' !VB5 $B9DB;@%/3#9R/,?'C1"P>H\?Z\6)!-@8[_ ->?@#B1
MK//;<@IP24*><V.V&^\.^< 8!/N/':9"0INE .Q=5'. 5J(O^IF,4&=0BDJ2
M?O%*4=YU%*?."09Z^&)2[XG?<9]@/'7]H1;2JW35'LA0'EC@H_S3Y$^\*OA0
M]]/O ^T<+63R5[X]YP:9_95/(1 GODD^\8CEY<:#4);\M11&A.J?4 1EPG*F
M&FTD_.6X>R,#(QN2 ">.>6XW3/NN/>JVPHN$&Q69EM";B25:01T..V05/T+)
M9!4\^VVE*A>#ITN+5>P0$JGF#R)C&CE37JXZ)\M1[O"D1HQ.6F&@M6$C/52C
MDK7XJ/XN  **KKW<P<[=PPD2EI$^JVW)A/23N5;J,<@ -A#(HD&G9@& 77/V
MUK(DF=AO Z#J2J4&  ,C;IA0 'N!0HCX_#IQK:^BD@<@1,>9[SC%I)W@^)'P
M*3^@.@@4H $]?+"@2/H[ \,CQZ\+5,@J3L=@ ; G<3\-\,($@:4W(Z<CSA(_
M.\>.&6I[YQ(4K).Y!V/ETQ^^>*\ND*.\3[N5HZ>?7%U*0 (7( D@ C;E<8V5
M&IM0KU0C4NFM/29DMU#++2"3E2SC*CN$I R5$[  DX SQLTS3]8XEEI*BI1(
MDB  /O$P";#^OGC%4U=/2L.5%0L-MM)*B3 F.4:C))MRO;ICO:RM,*79\*E%
MC#E5CNID56:I2E"6ZIAQ"VFT%10TW'6X$L=A*2I*5%TK6K([^CH&:)EMI%UR
MEQQ1!*EJ @;S %X38 &>=O'\UX@J<S=J@M %,I*FJ=I(DMH"PJ5*!A:EQ),3
M&D6C$J=GR.WM2#O](&>+  =!X[V\3W?+'/A">:53X?.2>?LP=D^8_1'#@3,"
M>O/!I3,Z5SU@3@[!\Q^B.##@=%^0P=D^8_1'!@TIZ+\A@[)'10'_ !1P8('1
M?D,'9/F/T1P8(!W"S[,'8/F/T1P8('1?D,'8/F/T1P8('1?D,'8/F/T1P8('
M1?D,'8/F/T1P8('1?D,+A7Y7\D<&#2GHOR&$[!\Q^B.#! Z+\AA>R?ROY(X,
M$"(AR.G+&1$3B0V2<[KZ #_8U]?'^G'$D"_2!/Y8Q.I2$&RXD3;<^R/C\C+G
M,4 >8'73(_\ #'J=_P ]JWQ59-_@C*A_]V4'_#-_+%[GPG/<[N1_;C,A8_\
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MRQB>;4IUPA*E>L-A_FIGD1._/YXRN_/[I1]G$]:>K?D?EC'V2OP.>0Q2M_\
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MCYN.TD)/;'GTS@C/SL=<G HC3M<&=@.D;1S_ $<9&TR;@FTWY\XM:XQMX[R
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M1PK&T[>?3Q&_=@P<1F"((,S/O(&^YDB^^#"'Q&>HQ[=\_O\ 0?H<GF('C/\
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M[OE@R?S_ (#[.#!!ZGW?+!D_G_ ?9P8(/4^[Y8,G\_X#[.#!!ZGW?+!D_G_
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M5?A/FG^E@[1/XT^1^>#NG_R'?XE?\W@TJ_"?-/\ 2P=HG\:?(_/!W3_Y#O\
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M/FG^E@[1/XT^1^>#NG_R'?XE?\W@TJ_"?-/]+!VB?QI\C\\'=/\ Y#O\2O\
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0@P8.#!@X,&#@P8.#!C__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g383050g24m45.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383050g24m45.jpg
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MDL2N6.1&N5J21J]K'JQZ)S,5[&.Y53F:U=T3]A4T
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M5GVJ-:Q9I)<<K[#:=B2-98$>]RO3E<JQOV=$K'-:K=^W3N/CR'QE Z[5L/\
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M=>&.%BR/=+(K(F-8U9)'JY\CU:U.9[U5SW;N<JJJJ5(/B?8
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M3$<]RN<C(HFLCC9NJ\L<;&L8FS6-:U$1/V%30
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M:L5JJ]62*K^:.-O9NDR4"T2[
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M9CZN%@CR-^ED)Y8K\\]>*O)0LMA[1R]BLW83Q[21,6%)D=+$R3D:DDB8FCX
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M=:2Y7M8[+U6V+S+5!74:MN?XNXC:
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MJ;M9S.Y&?6,YG<K4YEWO<...1
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M/&(Y,;#?<^=R7/BY'O2A)8226FCG>C/BYEW^24<C<^O9SH_M-0UC&[ ,@2Z
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MR3J4YY*'8O(JG?UZ]_BB>'FO3_;W$H@*
M
M                                   !%/L!NE+G7<'(B2"X'!P*O:DU
MBTFE;EC]'28IC23YI.>E3_*)(I2HI!7R9!J:=/*Z2&;NT_CNJR-M9!RM:7ID
M53O\.Y>_JG<ODB]?+R7J2L H
M
M                           $(N]OBI]RBN/CAGG[#=_*6YV]1_E'XFN8
M;[>^Z<R>Q,17$$SJZXMC+AZ'[EV7'.8YB7>S\R#&6WTV *MWWZ;[[+W=_<O]
MU^;N)N@4
M                                 -3_ +W\?KI+D[KR[N>(935'R.,5
MA(FMG:'N3DSW9^<"%\687XPURV:I@W-^3=%+L<3IZJB3Z>@+*\[7)GG[[9LT
MQPQQ&<P6.RMB_D89KD4CY(X5K=DU63RQ(C.>N]^RI&BKS.5=U7KL86U+Q,RV
M%SF1Q=>ACI8:<K(V23)9[5R.ACD57\D[&[[O5$V:G1$\>I)#PB_&3O3Q"^DI
MG2UFU?4T*88U2DCLQ(ZP0N8:.Y[LS3>NXP0@49D$G>D66XU',5R@[!:4M3ZR
ME29T4:%8.+-XK7.@<;I;$5\A3N7K$LV1AIN996NL:,DK6YE<G90QNYT=7:B;
MN5-G.W3?94Y71&O,CJC+3X^W3I5XHL?-<1]9)^T5\=BK"C5[6:1O(K;#E79N
M^[6[+MNB[& Q094                                 "*G7R^3MU>0@
MZ)K[A;UYMZ4JE6G4G3\>NN3&LBF>M13RE?XS)4JM$P5ZI0[&DSVPDA>CM XY
MLLD36>2L1EF8%4[^NR]%[^G@OE_=258%
M                                                         #FO
M>,_^,]ZY_3F._5S#!+;A]ZG8/\GF]\LD3M>^M^<_*8_=8">7P8WW];6_5,G?
MUN4:+;XP>K%+Z<J^X9(N3A%ZRW/H2U[]C3>O$;21H
M              0^[62%K:S@)1L?)DFI?0=#J,(C^AOY->J7<BQ6<S5VUFGD
MS\:S&O.OK>E2?_>GL7B(>7_M "J=%_0OAOX+X?WV[R8(%
M
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MK%+Z<J^X9(N3A%ZRW/H2U[]C3>O$;21H
M     0M[I<(PVU;79\K<:F;$!O1_/B1$?<5+2*](X<]*K+926=&QQ:-(7!;'
M9XK6[%$PBQU9);17S_LDDKJI3(T1AVHJG?\ H7Q1/#S7]7CW$T@*
M
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MB0FQ'VAHP[:N.2<X%4[_  \>_?;N^;K][Y_F)1 4
M
M     .:]XS_XSWKG].8[]7,,$MN'WJ=@_P GF]\LD3M>^M^<_*8_=8">7P8W
MW];6_5,G?UN4:+;XP>K%+Z<J^X9(N3A%ZRW/H2U[]C3>O$;21H
M                       0I[N;XNY5771$M;Z;<F\KI+GI4B)N^V))3T8*
M>TMF,IS,KC\BBZI(N?;$2KM2C8# UAF[--Y)JB8'<DY$K-TR*M[_ !ZHO<FZ
M]R^'EY_-U)K 4
M                                      .:]XS_ .,]ZY_3F._5S#!+
M;A]ZG8/\GF]\LD3M>^M^<_*8_=8">7P8WW];6_5,G?UN4:+;XP>K%+Z<J^X9
M(N3A%ZRW/H2U[]C3>O$;21H                                 1 [4
M5GHJT@1A$A5QK<SH*B$^RU%SP1TL8K+/L1G+,:3(4HVTTBB=TUSE(?;FN<FU
M669F8%Z[;-V,9%4ZKW;]%\43P[]U\N_;Q[B7X%
M
M   #FO>,_P#C/>N?TYCOU<PP2VX?>IV#_)YO?+)$[7OK?G/RF/W6 GE\&-]_
M6UOU3)W];E&BV^,'JQ2^G*ON&2+DX1>LMSZ$M>_8TWKQ&TD:
M                     $3^Q&^2N-=08F+-]JN*XJ^*15+":AO"/T'(2F9-
M/VDUW5ODLD:Q"BDD%2HM33IK6:4TQUL9AU5Q=L3J%:XLO(JG?X=R]Z;^"^'Z
MO)>I+ "@
M                                !S7O&?\ QGO7/Z<QWZN88);</O4[
M!_D\WOEDB=KWUOSGY3'[K 3R^#&^_K:WZID[^MRC1;?&#U8I?3E7W#)%R<(O
M66Y]"6O?L:;UXC:2-                                 "$7>QD4*JF
MM]I@9S\6W9Z7YUT0[='H9JX0W+]M9[)ADTBI,%-)=2[8W</0ZU>J<=MHVFEV
M6\V0E[MFI^N15-]^F^^R]W?W+_9Y_-N3= H
M
M<U[QG_QGO7/Z<QWZN88);</O4[!_D\WOEDB=KWUOSGY3'[K 3R^#&^_K:WZI
MD[^MRC1;?&#U8I?3E7W#)%R<(O66Y]"6O?L:;UXC:2-
M                "*_7:^4MU>PDZ)+KH0.!MY4LE7&T75<;MV4FL:J>-13T
MED4>E!1R%DKA2@V-*L&<H]=7F%QK9:_-)FBQ*7M@53]'<O?_ /A47?R_V$J
M*
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M/+UB!F,ZN&0*IW_H7P1?!?!>G^SO)A@4
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M[^MRC1;?&#U8I?3E7W#)%R<(O66Y]"6O?L:;UXC:2-
M               "&'<SC&FVKJ\.E+G6#4@.Z-Y^2(U%L47(.@6 YY564RDM
M")EB4<;719&9LL6[%D0ZSU9!+36[YLEE+HL2)$)A^@JG?X]R[[+MTV7?K_J\
M>XF>!0
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MVP*IW]=O'OWV[OFZ_>^?OZ$H0*
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MT6WQ@]6*7TY5]PR1<G"+UEN?0EKW[&F]>(VDC0
M           A-WBWQ5RJJN2)>@I-P;BND^>%:(F^++D]614I\2V:R',JJ./L
M3.)<'FR4R_4HVO(8MVV9)?)]4+(\%[H5)NN15._;KU1>Y-U[O+I^GR[_  )L
M@4
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M,9O+T^<&-^ *I_J7Q1/[5_5XDO *
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M33'6R6753%6Q,H5KRR]A5._P[E[TW\%\/]?AWDL@*
M                                                     8P?%/GC
M/7-9\X2(KGJ<]-6MMU[5[7SW6,&G$:K7*^XG2&V<D3YE\YF3>[15A@KU7N]A
M0N2:OK8K1/!4K(8?*@.="G5O&IJ;[]4:FW55W[MTZ;)OOUV+?^#SS[-:"JBY
MT4_Y5M_E)\EUKHG5NB-R=90WKEX7P]D@D8BT-;8K,(4WMR.)U_7[$SIH'#H<
M[:.#XVL[(GPI>%Z'#=HF%7KNJ=47IWHWE\5[^B=?$R_ :  +95C==-W6B?W&
MF[9K6V6^*2!9$Y0NK6<QB<HXY*&_&FRZ./JF,.CH2TOJ/4PO=2U+]TZXG0S3
M<PC77?7.0V5.]-CX:RO^B;K7S%KIRZ*HMASKQW]@3YNK:PXE.%T)?/2JR,,\
MM21EW<SXZY9/0+R-43L6D4;'(5I6I>3$JC4L55%3;=%3?JFZ=Z>:%VP*  <U
M[QG_ ,9[US^G,=^KF&"6W#[U.P?Y/-[Y9(G:]];\Y^4Q^ZP$\O@QOOZVM^J9
M._K<HT6WQ@]6*7TY5]PR1<G"+UEN?0EKW[&F]>(VDC0
M                A#WNJB:.J*W,F)W/Y#=OTQSH0AVZ.89O(8;L_'6>QEL9
M<51P(].[)K7,<,DZU@Z..^T:;);EO5R(HUL+/TR*M[^F^^R[<O?W+_9Y_-N3
M> H
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MF"'/MR)Q?*YY9?\ 3TQ(%4[^NW<O1=T\/F_NO<2G H
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M2/H%7S@C3+$]CLQJ5T23)&849*G9M.UU5M=3F;93V@K++B)^FY;AG7(JG?\
MH7P1?!?!>GZ?#O\  F,!0
M                                "&'?;+9*_F*P7"E53#';61J8 E;+
M!=8I7\N75Y!7"T(4EN&9L;39A6T.7O<6J,V<2)B;7\S1L7/C8W$GZ[[[%ZY%
M6[;IOU3RZ]?+NZ]_D0M\&'>_S(%TU_*$L*2VA)D=[MK(BF3HLHPN*/&T;JB
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M9!N=J*IW_H7Q1/#?O7I_M[B9@%
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MHEAP1,)I;B:3O@53O\/'OW\OFW_1\Y*$"@
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M1+20HKEG;(YJL[*65-D2)W-S<O>FV_7;(R+3+J
M      "$O>;=%'.J:Y(F".BUS<5TKSNL0E= SZ65U$2WY)9S(<R*(R\0[.'%
MTL].X:E&5M%5W_8,FE6J!I>_^SSS0*IW[=>J+W)NO=Y=/T^7?X$V@*
M
M      8O/&$B=>/_ !%+7ZT);<L(A\!LWG^6.LGI2SG2KWR.)R[ZK9JWF<@<
MTS7(F==$ZX]I:V0]8?8N^:LA$1Q)6/V3(F=K>D U-WYNFW5%3JF_>BIMWIU7
MN3J4QX6&_/FBWLIMYZM&Q>DF1DOV'M<GZQL6_=>CUU\2'[@-4..-$%@H65H8
M"DU7-SBDKK+ P*9 C0Z,Z=:>^85N1S&Q@Y57;?IT[D3;;JOA_;X=YEJ T@
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M'^^_<2Y H
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MNVZ+8_\ R?W&?^[S /\ W5P_Z@.+_DEIS_%%7V2?[YD#_K&<;_\ U'S_ /\
M53_Y0EP6@1%%Z%%I$VA9>FI>FN"2_)KIIKC777'EU\ODQKC&,?\ Z"X41$1$
M3HB)LB>2(86<YSW.>Y55SG*YRKWJYR[JJ_.JKN0 [)\.:L.TI)"Y--K$M2!J
MH2QN+$A25NZ1YK1+R'%?HX&*'(MVCKR8:J*,TP43N2:3IJ5G.NVFVW\X6CJ3
M1U/4T]:>U>R-1U6)\3&TI8HV/1[T>KGI)#(JN14V145$V\"27 OX3>I^ V*S
MV)P.DM%:CAS^0JY&Q-JJAD+EBM)5K.K-BJ.I9*BUD+VNYWM>R1RO1%1R)T(\
M5)X+%&5!:%?6HSW;T(]NU=S"/S)N9Y!(H>I8G1;'7-,Z)T#NG2PQ(I/;E1J;
M4E840J3F[D;[ZEG%[9QMCA\?PUQF.OT[\65S,LE.S#99'-/76*1T,C9&LD1M
M9KE8Y6[.1'-56JJ(J=YD[6OP[=>:WTCJ;1]WAUPNQU/4^#R6"M7L9B,S%D:E
M?*5):DMBE+-G)HH[43)7/@?)#*QLB-5T;T16KF)]42?DR?\ 8E_PC(Y!TTF/
M&C>'9N\0.TTK>Z.*%+I&*OVT3(URE*GTVWKZ/[[YU)(-T+USOOG.VV<:XSMM
MG.V?+G.<B,7$N:9FK[[62R-:D%#9K9'-1-Z<*KLB*B=5ZJ=^OP#<5B[7P:M(
MS6L;0LS.R^KD=+/3KS2N1NI<BC4622-SE1J(B(BKT1$1.A[/@D.[LX][0Y*X
M.CBO3;0"RMMDRU:I5$;;:1[?;3;8D\TPO.VFWW]<YUSG7/W\9QD?7AA-,_5E
M=KY9'M]#N_)<]SDZ0].BJJ=#8_#]Q6,J_!RS<U7'4*TR:ETJB2UZ=>&1$=DT
M1R(^.-KD1R=%1%V5.BFZ=ZHD_)D_[$O^$28.A@YZG94@?D_7W51!#V[D$$=(
M7@2222Y+2RB22K-D^A111>AVNA99>FNNFFFFN-=-<8UUQC&,8$/]2SSIJ+/H
MDTJ(F:RJ(B2/1$1+TZ(B(CMD1$Z(B=QZ9N!.%P\O!#@Y++B<;)))PKX?/DDD
MH57O>]^DL0YSWO=$KG.<Y55SG*JJJJJJJJ9H?@\J]<[3GI_1T6JW+4F)UCL3
MJX*3EFI6V[Q,<;[%84;F8+SOC77&V=<8SMC7&,^7R8&2^#TLDEK.I)(]Z)7H
M[<[W.VWDL[[;JNQ _P"J;8^A2T_PC6G2J5%DS&KDD6M6A@5Z-I8)6H]8F,5R
M-555$=OMNNW>ILO3U,FT@TSWT3D:[:Q.1;:[:E%Z[:[:LZS.-M<XUQG&<9QC
M.,XSC.,X\N!FVWTJV53O]'F_9N.J'3J([4&"14147,8Q%14W146[ BHJ+T5%
M3HJ+WG-N^,TC_P!H'OZ57_\ ,"%OI%C_ ,>;_*O_ -X]4?Q%A/\ $V*_S=4_
MX)MZ^ &>>Z<=66H<SC7$_3I>8$Z'KS-UAVA.M6TWOJ5J8HV,WU+UW,,WQIC;
M&N-M]]L8\NVV<R(X2/?)INZKWN>J9NRB*]RN5$] QJ[;JJKMNJKM\ZG25]4E
MJ5:?'+2D5.M7JQ.X48.1T=:&.!CGKJ_735>K(FM:KU:UK5<J;JC6HJ[(FTV?
M$YQA%P5TTJ1XPD4DU_KL2H38P0>5M\8&37SBSBO,,+V\F<X\NNV,^3.<>7R9
MR+GUPYS=)YQS7*UR4^CFJJ*G\]%W*FRH8#^"5#%8^$=PFAGBCFADU*YLD4K&
MR1O;\69!=GL>CFN3=$79R*FZ&AC\9I'_ +0/?TJO_P"8$4/2+'_CS?Y5_P#O
M'HQ^(L)_B;%?YNJ?\$WM/"GQA=X??-BI;CUQ4=&9/L<I5?Z0H-VUL.8:8R8<
M;YYF^<::ZZXSMMG.-=<:X^]C&!*G0#G/TAA7.<KG+#8W<Y555_[;93JJ[JO3
MH>=WX8T,-?X2O%6&O%%!#'EL2C(H8VQ1L1=,X151D;$:UJ*JJJHB)U55[U(A
M>/T>>U\=5PH;#C6X_?I.'D[GH#-T9VY.U96_OL5L8GV+WV+VW++WSIG;.N=M
M--LX\NNN<6_Q;>^/3=-6/<Q5S59%5CE:JIZ%D5VW147;=$7;YD,U_4W*E6YQ
MSU1%;K5[43>%.=D2.S#'/&CTU;H=J/1DK7-1Z-<YJ.1-T1SD1=E7?4(^,TC_
M -H'OZ57_P#,".WI%C_QYO\ *O\ ]X[M_B+"?XFQ7^;JG_!.CS4*=.94U7F&
M$$[[[UW"M]]]RM-M]]]HTV;;;;;;:YSMMMG.<[;9SG.<YSG.?*)G8_K0HJO5
M?0ZW[%AY:];-:W6>KFM1&M;J?/M:UJ(C6M3*VT1$1.B(B=$1.B)T0UN_A#2]
M<TS?E_5K6JVW4Z*VAL=JWJ3D>INVCO#,:;&X3[EX,SIC;;&N=\9SKC;.,>3R
MY&%^,,DD=G!=G(]F\%_?D>YN^TE7;?E5-]MUVW\SM.^IDX^A=P/%U;E*I;6/
M+Z02-;-:&=6(ZEGU<C%E8]6HY4151NV^R;]R&$3E60OY_4'-Y)SX\'$G7W3Y
M1I1KFM,*-*,L*.Z&%F%[GYTW+WTSG7?3;&==M<YUVQG&<X&+\!8G7.X5%FE5
M%RV-1461ZHJ+<A145%=LJ*G>A/\ XQ87#1\(N*<D>)QD<D?#C7#V/90JM>Q[
M=,Y1S7L<V)'-<UR(K7(J*BHBHJ*AT0_5$GY,G_8E_P (F(>8LTN/&]=W5M[R
MDR5N<W! FUKBM]]4Z):I2D8WW:#L[[8)(-++QMOG[^VV-?+MG[^<Y$:>*,TK
M-5S-9+(QOH-)=FO<U-U8[==D5$.^/ZG]B\9;^#IBIK6.HV95U5JEJRV*E>:1
M6MNQ<K5?)&YVR>";[)X%"^#@\O#AXB-$)%[JY+4IJ*V/2IE:Y4I3F>CIN?&:
M>D).-W+W\PS30S3SM<^;OKKMCR;:XSC:<-YIGZQQ37RR.:K,ANUTCG(NV.MJ
MFZ*JIT7J7%\.;%8NK\&+B)/6QM"O,RQHQ&S04Z\,K4=KG3;7(V2.-KV\S55K
MME3=JJB]%4W@?5$GY,G_ &)?\(E">?HY^O>3\^I>U>JTR9Z=DZ<B_+1*(((<
M5A)))6DN=-="RBBSM="R]-<8UUTTUQKKC&,8QC&!$75D\[=39]&S2HB9:^B(
MDCT1$2Q)LB(B[(B>2'I4^#GAL1-P$X.2S8K&RRR<-](/DDDHU7R2/=A*:N>]
M[HE<YSE555SE557JJF4GX/JXN#KT#>93HO6N11=.(C"REZH]8669\=F/7TFF
MB@PS73?S<YU\[7&-O-SG'E\F<X%]\(999,QE$?)(]$QK51'O<Y$7TJ%-]E54
MWV54W^=2(/U2W'8^EPUX>/IT:=1[]<6&O?6JP0.<WX@OKRN=$QBN;NB+LJJF
M_7;<VM')(EPW+\X3)\9PB59QG!)?EQGT&_W_ /NC/K_K'?@N_4ITX5NMFNB]
MW;Q?M&G-/^,TC_V@>_I5?_S A/Z18_\ 'F_RK_\ >/5I\183_$V*_P W5/\
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M]Y*4"@              !H_^-?\ C"[5_1>K/J\CPB]Q-]<,A^(H>YPGH$^
M+]S-H_Z8UA_$V2/9\#SW_8;\WUF?NYN/KPN];:WY'>_8FQ^J"_<VYS\YM)_O
M-#=G$G#H).=KVA[X?5_ZREZ?6?*!#K4WK'J#Z;ROO]@]/' 7[1O!G^JGAY_"
M.(,UOP=;^G?4?Z)5?_C$R&3>#G]+SOY/0_:62!'U3_U>X0?3.K_<<";.$_\
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M<']_UJLZ=RJJJO5>O7K_ /T92@-(
M         '*7ZG]YWHWY^+>^L&0B:V&^P^*^C:/NL1#',_9C*_25[WJ4V:/@
MK7X5[C_]/YR_O-XC#_&GZS3GX66_5C3+G!KZ_47X.)_7DC< &"3.1#;N!>SM
MU85\<]O$)94IO1- I4ZF>4*[=$-2AQ560S$H&]NA[.D6*(O)5ZG;1-';4/+T
M05FY[D2M<>2G0;F8%4[_ -"^*)X+XKT_1X]WB3) H
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MYT0A%_DT>#/]URK/HI7_ ,\+8_D3I/\ Q%0_R;O]\S__ -:[X1G_ *O:P_\
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M+#@S+IA"C5*\I?5TYIF@;+Y?/^CS+M@
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MCCL@5;W^/<O<FZ]R^'EY_-N3= H
M&'KQLJ7M>].5H%$J>@$GL>3-]_1:1+F2*-ASJXI6-)7MHMJEU.3D8SOHB(7N
MS:D,.S_-U/6I],_?,U&.>)V-OY3 5:^.J3W9V9>O,Z*O&Z1[8FU+['2*UNZ\
MJ/D8U5\%<GF3?^ -KS1O#SC'J+-ZXU)B=+8FSPVS.+KY#,VF4ZLV0GU-H^U#
M39+)T=/)6I6YFQIU6.O*[N:IJZ_Y.CNG_=6N?_X.7_\ \#!/\C]4_P"(,I_[
M27_=.WC_ *T/P>?_ %AT)_GRO_M-]6KF]:TUG7;4Y)3D3BVP6(MZ]&HTR6H2
M+4<?;TRI*>7G[^AR<\LPHW3/W]=]-M<_?P)946.CI4XWM5KV5:['M5-E:YL3
M&N:J>"HJ*BIYH><G5UFO=U9J>Y5E98JV]0YJS6GB=S1S5Y\E9EAEC<G1S)(W
MM>QR=[7(IK/?"*OZ<<M?HI:7^+PH82XR?TG _B,A^TJ':_\ 4O\ [ <8/IC1
M_N6H#!QRA[TO-?S_ %.?6)'!BW3_ -GL)]+XWWV$[!^,OVG^*W]6VN?X7RAT
M8A,D\O!I0>.3[_,G^;:M?\'.$9>*?K9-^0TO]!QWX_4]ON<,5^=>JO?8B@_!
ME_&,T)^96U]3%@#:<-?7+%?@9#]VVRX_AV_<N\1ORC1?\=Z:-YL2E//6<]?O
MGWV^L/U@+4_?!U$0-6^L^H/I>_[S(>F;X-_V@>#/]6NCOW'3,J7P>;WA;V^9
ME%^^[$+\X/\ V9ROT8WWJ$AW]4V^UGPZ_/JQ_#^0-LER_!R_\R5?V!@D"_ZQ
MWX+OU*=,E7^DU_Q\/[1IS+!"$]9)MT?!Z_=BNCY^%/U?0D2%X/\ V#R?TJON
ME8Z4OJF?VVM!_P!747\2Y\R1^(Y[BG5'S.2S^ZZB]=9^JN>^C;'^B16^"Y]T
M/P>_/K"_MSGZ"(IZ5C>O\'C\7)SE_P "T_KLL@2IX<>IF%^]D/WI>/.]\.'[
MJ3BG^-TA_ .E2R7CP>XMCYYJ]_N,I'%\5_55/I.G^SL&0/J=7W0R_F)J;WC#
MFEZ(U'?"='?FWW=J#^9:K/W&8A,W"_8;$_1E#W6(\M?%/[9_$?\ /S5_\0Y$
MP"?",OP?R%^>7O\ V%/C$G&7ZS3OX66_5C3LE^I=_P!)XV_B.'?[36YKP\^?
MU]TA\[U:_OFRC#V'^RV+^D:7O,1V<\2_M<<0/S)U7^XKYT@A,\\LI@+LCP/>
M=>N^]>U>DNV:A0V1"[(_DX)^>%;-;%D1%W;D4*II#"[1+D#1 )-%2RME,D96
M;V5LZ[NAAJ--N>CW2:'*"S1]$D<UJ(U=N_?HB]Z_.ADRXUX,Y;X"A,JKOE2N
ME5;Q&:RG$TDC8JFLYF^Z^1ZM*!CPOU7SR1R5P1ZX;&Q$G]41*DZ/RE9.]7].
M889N-+G*Y=W+NNVW<B=/T$P@-)@G\0UJM"T+4[GKN,MDA?ET1\*M@65'$HYJ
MI-?945;]TVXDZ;:8>0DVT4K)5)X-3%60TE ASESV,<6E&FWTR_EZ'#6W9.5?
M)W7IW=VW7[^_L[E+D<76Q0Y'2/5=D5&:@B_,EX.G-%;4CEB@D@BD1L&]JUH^
MSY-<AL*CI<=;O2'M%5LE<19\<RVM*DV>ZV<(;LI-D,>,:RQ1>Y/--U^=$54V
MW_3OT7KUW[E0Q]2Z6QV3Q3QH;]IA^CDUA[+S=SI/>>;;JNJ'JH(?#[3H!WO2
MPJ7H_P"+;@C*VG5W55.RH*]R>P$"S=8N13:$PQ;&(3NQI6 X:O\ X$7?;==T
M^951%5%3P5/#[Z[KN; 5C0_IF5N!SK6=UQ"IVM?1LRCB>+O=2I;!4L=[/GL\
MZ$V<:]FRMDV<HW!<:."1SKS*4E/+,J"CC)"V>KXU,&A-O%-^J>.W3Q3N\?/P
M\BEEE:=C&J7XQ%U#7Z5*L<.>CX^09SZB4[LK="D^VG1B%4=F>%^U3KR49U/B
M2O;1-FH],9*3%2K&?.P'3R7Q\?/N\/#O7S^8^Q!7/7),E;5Z_I>!K8P19]Z/
M[I'RJ&1I5J^K)>PK$="UX0]8G!NZ-[IM_-1/4GFV$9QMH)4IC6H9HUJHRI+#
MIY+W)X^/CX=R^7AYE)**F[IWB9S:FZ_K0B7;\_LL,)DV_,S><@*Z&2S4]U>[
MNV8<V-IH9%':$;D1)-4^5VJ9M<B=I)K*5!AGL_4-TW[EVWWVW\/+?;^W]16Z
M^O.KSI4L<6_H^#HHF;>%<RU'&S:,1JER6B6.+8;[*I\Q]S-2MU$FGDK\LC9[
M-RB+40]#GV&5&W;3'KH#=/+PV[_'?O\ 9TV_3\Q3Z.K^T2FUC(6]5UXJ<DD=
MZ!0OJ\OG9"G)>))-%AIO/#\F1XGYF&Q'2*+8E++&?4U3K;)A6RE2KBV3,E:A
MNGEY>/DG7VKU^;NZGSKZL[9.C[JB;^L:Z12)17]#,K0]F\XH%:1ML2'NZ)3?
M\W/:<V"5JN:;H9REK7%HGE4055BA66X)W23[)L)S W3R7Q\?!4Z>'@O55VZ^
M2%5HJ^ZL*ER=R6]&0A7#]+^E,R4Q@NCDB9P/Y[<8BG;(I2>D@Q-#-R95')CH
MHE"ZU\(-U+XWG:1_>+HM"O7]PZ>7AY^._?W>73;].Y0J"I^Z28HC;G#KZM%L
MN*H>:P];)2N9T"1 JOYUEV'*#W.6PXL8W1/%HC#\9C#E5F%QB>2N&<2 R3MV
M^/4<ANGEXIX^'BGZ?/PZ]/*IEM;=@FO+VJ1=.P%(RJYC0+HQM1E HE*AHA<,
M:$R;H6*J7',Z+V<G"['C12Z121;$)S*H(/T;TR"4:D^GW#IY>?C[/#P_M^8-
M];=@DN[(I<.G8"M9TDNOUS?&PJ@4210[PZ9-1R;GN+IG#$Z-V;7"E'?8ASE4
M@U(4;VL05N@4H(OJ;Z?0.GEX)X^/BOZ?[-_$II?4_<YT26MK?U[6J*8&T3"(
M@ADYO,[>K0)+\:9=NY3JYC6#-C%:*8O+X?G2,-E6Y7%IXROUR_ER9QWV]1P&
MZ>2[;KX^'@F^WAY[=?(KI;7W51LL/<471<(21'>_XO,T\:,I!(I7D<\M\//;
M)52.[]F9E[G2N13+<B4HK8RAT4LC>3M'M(LLT-ROU#IY+W>?COW]W=MTV_3O
MX%*(:M[8)CS0B7]85TLD::O;Y97A\*YR0)DCI8LQ>5RKG^<IVC%@F:M[32[*
M<@:I3$M51Y5J*$9KBH=8QLJRG+#IY+X>/S=?#Q7K\WSG[KZO[1.0/A+?U77B
M)P5Q^@$3$M-YV0JBFB10Q669T,]J4N9^5AS27:CU,311IV-3ZU.9OA0F52G.
MGH\AT\O/Q\TZ>'@O5?/NZ'OH*\ZP)EB)Q7](0=;$2KOLB6KHT51:-*O5T4^Q
MC#?6=0%/V)J9NFDL!E7ED3Q9N$)BB9(L^Q#8XT:?Z: Z>7AY^/3K^GKT^<H=
M/4W=6D5*;E/7]:'RS7GYXA9LDTYE;R4)G1"J:E.K-=^K%BQ]]"XFU0?4Z(J*
ME]>V3.+D9K)=I4G,+]G;!NF_<O?OMOX>7=W_ #_V%7+:XZZ-DKFO0],0-'&%
M%H49(&N/FT*B4K6^JXBQ(T=\UT>]9G!>ZU[N-_*6O48F^49)U7I59;4G99+J
MFPJ-#IY+W+X^/@O=X>7CYH?"CK/LDHYAV6]25\J)1K>A39 47SVB3[/2&;)M
M2^<D:4S$],RUF48JQLHEJG753FW--L$J2XKC'GY#IY>7C[?;^C8\A?5/<)T4
M<6YOZXK=%+3Z;JF+MLE-YK0*D"&Z8[)2%]M6L<Q9L0K17';*C&A\?8JZRM*(
M@BP[5Z)D#WN5A'L&Z;]WBO3?P\$[O#S\2MMZ_P"J<RS9RTZ*A.D1ST$GFFL9
MS2"/9?CG;2';-:BC\OV9GY^98?-,ZRK6VO4<*2F[&8[B+;:9]H8#IY+W>?CO
MW]W=MTV_3N48@JKMXF+-K>X=:UNME9%27+&W.1E<VH$J%?;\HD*Q;2MG$L>+
M#,T1L%41PU$Q2* 86G$6,K2F.Y[[']E&4A8;IY+WIX^'BG=X^?AY'J+*R[)-
MV?LH^I*^2ZK,\\_%_!G/:%1EFQ"==\='859S/2_:OW=-LEYB6=L)?N1>9G"7
MXU^?]X.GDOCX^SP\/'S^8]%#7/6Y,H;W!?TM!%D5(MNYY*XQTJAT:5<NI^4Q
M]2BI.L"7O$W-W2/]3R$Q,]R.?X1&G6.D3[M)[%'M3O6M Z>7AY^._5>[[Z;>
M'FOC1^]3=U9BNS=IU_6FDLSSZGA>LDSS,W[(<=$Z379U47AEB^Z-C3,3/@^=
M8CI4OKV$Q+EC,EQ*MC,^S\!NGEX[]_AY=W]O]A:_J1AZ9CC6B>U=\[+8F]=8
M<PGQB-P/C5GNJ21NM23FQAL"$O:->^/!92>7S0SXVJ;SRUMJREX[@[*1*?E%
MAWU!-N[;KLO55VZ]^_7IT3IMXK]_8O2CK#L\I,Q%K>J:]5JD;=T(0_J"^=T*
M;1Y<IJ9Y>=%Z4G$^,PUDT<7_ #)8CUV4XMO;^>I.BO\ W0'3R7P\?+O\/'O3
MR^<^-PJOMPZ,N:!OZTKA%*%%8T;'VJ0&\WH%:)NM*(OJ!9?%B'LN;"*T7,MQ
M,!+@S1B$Y6$DU@J6E.B=YDFR7"4T.GEXKX^'@G<G=XKTWW\"L4U?]4ERPIR4
M]%0E1$=>@GB:&QG2D$A*\SG95#BFMEH_5^Q,]]])8U334Z5*+:]1V4N+<;K'
M=HJGT+]H;!T\O#S\=^_V=-OT_,4,WU1W*3$T#:X]=ULNEY-(V-$W"3%<TMZ1
M MO-\E.SC6UO%,.+%-T2QJ!Q3.L<>*SPN-3S!=K[<-D;3OG*(!NGEXIX^'BG
M=X^"[=/G*A6UKV$:XO9Z+I^ )&U7(.?5K&A,H!$I.:(["T.I/1+(J5YG9>7)
M7=Z_&RR)NVQ2?:I2ML)4R64XU])D-T\O/Q\^[V?V_,?J@K?KPE_:5CATU UL
M>33^^GEX9"J#1)5;G7LQ9%:3GZ$IW7$Y-V0.M+/IB1XE,LU2GF6HF3&-BEKC
M&JC*DL.GDO<GCX^*]WCX>7SE*K:F[I-B2IM0]?5HDEYE!1>&I9,9S,WJ6]/T
M(WS(YTE5V;L&;&+T/BLBA>Q$50U1E?HF9'$K:1:2A;N9[/U#=-^Y=M^[?P\M
M]N_Y_P"PKE?7O5ITM5N3?T;"$40,OF#S!'&3:-1JG!+0#3%#FZ=TN8_YFA>Z
MB4S"7;$25LM/*$M3&$!6S"7&7+0SU[4.GEX>?COW]WETV_M*805=VL2SLZ5?
MU?7:UZ2PZ_&MY=2N<T"5.Z3.9.*@_GR5)V[%@&ZM[?2C;NF0RJ.X4*"[6.(W
M6*5\7R=DG0-T\E\/'R[_  \?#R^<_P!75=VJ<S/"5!U=72-Z50Z@VME=3><T
M*I.U3.&N*<_H.5*&[-@%:N+?=;;HI016.[*$Y=4G'Z+$R^49)P5N&Z>2^/CY
M]WAX?IW^8J9!7O5I,M2.2_HV#K8@5?$YF"R,%4:C2KU5 N\3);8'3!;_ (FA
MNZ>40Z7:'R9SM/"$Q3)T!NK"9&6W0O"[8.GEX>?COW]WETV_M*&15-W25$TS
M:MZ^K17+RZ!E$-528OF9 F0*.A'"9IW2*W9HP8L<S0F*1R$Z*(FNJC"[=,^.
M)^DCWE"(PK#?N*[M_P#A7O3Q\/%.[O7S\/(JI?6_7AT@=EJ#IJ!HH\IG]"O+
M0R&T(B5*VRO8<R)$G0,)4.V9R5NO=KI?2U;O%I9LE),JI,I+;$S7)]4_K)@I
MT\E\?'V>'AX^?S'XHJU[#*<&0Y=T_ %;<DD'02U]0E\_HDQSO'IHAV)YW9$R
MO$[,RVJZ07YU62QVU*4[6T5KE*I2Q;&?28#=/)?#Q\N_P\?[/G*?<*H[E.B:
M]M;NNZV0R\ZD:YB;?)C>:6]6@17HQRG5PLJWS6'-B%:*HU/(IC:.,]9Y7%)X
M>NV]N%R-WWQA$ W3R\5\?!>Y.[P\_'R*X45]U3O+#7)-T5"2(CMT$SS0J,[T
M@D.7E\[)8<<V/5'[/V9GIOO+'69[$RI/;7J.JEN;BMH[K%5&AGM#4.GEX>?C
MOW]W@GAY]=_ H]OJOMPF,-C>X]:5PNE*>K[UC[I(2N;D"1$X6I+WYQ64)8I+
M)BPS=$3)3; >VLLHA&JPXFT52 YU4/4:V692DANGEY>/EWIW+W^'E\Y]JRL.
MSS4KZ6BZIKU(J6-O/9# H,YW0J-&9RA1GG=%KU1.9\7AT)O$O^9$D>VZ;%29
M_GIC95_W0&Z>7GX]^_=X>"^WR0]I#7?69,J0.*_I*#+(F3<ML2A?&RJ*1I5R
MVE9'&S$-1U04^XFQNZ615I)=BW]^L;"(T^>(R]F8Z/,>F_K>H=/+P\_'?O\
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MII^SA_CS!(N,L<R91$>[XP79SY[L/Q:Y$]'^2E#NF;N[TSO582=_&?!<3/\
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M)]6STI*=:Z,+84Y86-.5[8N KX
M       1([,0NSA6\$*9V:7/BDJ_:-5'I87?K3SHY)T":P6@U<XKYB\GITTH
MC[>GUW4OM5$;[+[.;M#HDA*-4.&FF15._P#0OAOX>6R^WP[R6X%
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MB.SGB7]KCB!^9.J_W%?.D$)GGEE
M                   A%WLX1%MJBMSIFLHA"VG=+\ZI$!O0L*F$ZB!C^JL]
MD)8T\8:X5OHYMMI*'#8DJM)(X9S'X]*]D#F^Z[-Y)N *IW]-^Y>Y=E[EWZ]?
M#O\ -.A-T"@
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M7^XKYT@A,\\LH
M    $7.M5\M;J_A1T-47\G<C;OIE*OWYSB<0F,QV8%,Z:RGPJ4MTT.(;4%4F
MM^QVEGOR#?:0,<2RX.#$68XE$Z9%4[_#N7OWV[E\NN_E\_?T)1@4
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MD:7O,1V<\2_M<<0/S)U7^XKYT@A,\\LH
M                       $,^XT#(X5?7I+^SP1Z2%=%T J3);!OEVYX:"'
M--9+,:W.#9+V=:@42>4(%6NBF-U8>:8@LQUT(BBY,H3K]RMA5._]"^"+X+X+
MT_3X=_@3, H
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M91A[#_9;%_2-+WF([.>)?VN.('YDZK_<5\Z00F>>64
M                                 "&_;RYM05A7YKH]1=B(,Z(H),2J
MEM!+^BV]2L46.S%)&U%#FY,J.BSVXG;:I6:UC2]$E8KC"I:J.)*;]M\"J=_M
M\43P\UZ?[>[Q)D 4
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MMKOIOKC;3?7.-M=M=L>77;7;&<XVUVQG&<9QG.,XSY<9\@&D_H
M                             $7.M6^6N5?PHF&H[V6N1-WTRK7%<^3R
M)UY+BV!+.FLY\429XF)9C<Z5>0WZG&63%D.N'Z317"YI8]M7!03M@53O\/'O
MW\OFW_1\Y*,"@
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MKO+<-Z&0;Z-II^V!5N^_3??9=MN_N7^S;O\ F)N@4
M                                                UF_A&7X/Y"_/
M+W_L*?&$>,OUFG?PLM^K&G;#]2[_ *3QM_$<._VFMS7AY\_K[I#YWJU_?-E&
M'L/]EL7](TO>8CLYXE_:XX@?F3JO]Q7SI!"9YY90
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M='(US'L<YCV/:K7L>U5:YKFN1%:YJHJ.:J(J*BHJ;H?V*FD
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M01Z&1%,7N:X:ZY%4[_#N7O3?P\O]?AWDN *
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M]6O[YLHP]A_LMB_I&E[S$=G/$O[7'$#\R=5_N*^=((3//+*
M                                      !"7O-SB3555<'S)=1S>VG=
M*\[HD!U_5Y*K*B1K^LLYD(8TL:98AC9Q:;-4N&Q)5<2Y=Y&*+2G9 [O6<($Y
MH%6]_CT15Z+LO<OCY>?S$V@*
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MJ-5[47=-AP9A.L@
M      "+O6BR6H8!"S88=T"2Y&7=32=?MSA'X?(YELP*)TUEOI<J138XAL2U
M.8W;':V@ZM^VTA:XCEP5L)9CB63KD53O\.Y>_?;N7RZ[^7S[$H@*
M
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M\UMLEZT315Q2JDR_<G85;W^/<N^R;]-E\/\ 7X=_@3/ H
M
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MN.,TT;\[8%4[_P!"^*)X+XKT_P!O<3& H
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MMG1S@B(YM+-.<D4K;6EW93B%*%V;T:],>E+%>1VV_3O5.JM3=4[]D5=U_09
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MQ2388(ZPK4^_MAR<M2$[>1L2>HWT+/)R8*HU7)NFVV^W543JOWU0M18WC-<
M5>^-[7(;.FCFSK:KK:[U<^A-*W!/ZXCE26WYF(%/IA,H;"GMJB3 ];&ED^GD
M&Z Y&JWU1+""%N-D^H(QR^'BJ;*J(NZ=Z;*J*JIOX(90&UQ;WAN0.[4M2N36
MZ(DKBVN*$\M4B7MZX@M2C6HU).VY*A*J3FEGISRM]BS2C-#--MM=L9R-)]H
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MTT>;4Z!P?+,):"CU*G4W5M4%IG).*\S45KMU54:B(FVR;HFW5=_/KT0VAVQ
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M8/HK^AT7^=2LOWL;P!?P
;                                !__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g383050g28m28.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383050g28m28.jpg
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M=R1"5EAAL[2VMS<X0[$9-$1B8X&1E;7!\/_$ !T! 0  !P$!
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M^28QL;0UH])[2>\_?ARY*R<XN))YG[X7[R=07L9O7$2Z,\:E,LDJ)?:#$HE
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MU5"#O]3\;O.&#I/]L1:3D>4ZKRLSP(*.8>2Z]2N8QY*1S_7=I=G*>TFGOJ6
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M*G+VO+&X.ZUK@-YV\3D$\P!R. !V#"W"N 6\(3M^GFD#I.FG>'NE\TU4(X;
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M#VX'G/F7S<,]T+PXF$3")A$PB81,(F$3")A$PB81,(MW/U/5_*<:P_P^V_\
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M/=Z2K$W=ABO=7;5DW+$;^D=(&V%/9_4:HTACZ]K%?3M(C8:=JBP:==K/=+J
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MQS],$U:*2'3MG9ZHBEDC,4VI6HJU=\,@:Y[NCC@KRQODW#&YEIVXYQ#@,6.
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MM!XN)FL1-('$ EW)I5O-:A@EJPR.(DNS/@K@-)#I(ZT]MP<1P:!#6E=EV 2
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M^ V30;@;U*D7+6U@-;W[QX]O+[\.7F5:#.\>[=^O(Q^M71RR5TF$5F#?"/\
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M$EUB( F"J@&IV=G-!N1UH;6D4)H:;'1U(75H^BK,>0Y[88F@,C#B 7!C1O$
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M#,P89*>,C7+BI\AMXI2U<G4]JW8DQ4+;6[[6)()UX#N"N=.KT!4ZM9HU;O\
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MT9WF/:?46N!!:]C@'L<"U[6N! \S6ZEFC8FJ6X9*]F!Y9+#*W=>QPX\1R+7
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M>Q#Q_4[QS-W?;J99&;=\B@JX@[55IF)L5?E$BG9R\+),9)BLNT=(JG(XY/\
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M1(=0LKG-8"7' ^_(=JB 7' &2IA!U\[90DC)^&H^* ^5;$'OMXTIRB0YB'$
M\P_4(8R:SONE*BD8S5F4J9W2[['RS&3AR:.0[_.?1V*ZCC#.)XN/J'H[?2I9
ME%54PB81,(F$71,D/J:#GZZ?OG2>P.+ )N7CE=,#["V8!P(LL=0H& -,F #
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DPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g383050g28s66.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383050g28s66.jpg
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M 1$  A$! Q$!_\0 'P   @(" P$! 0          !@<%" D*  ,$ @$+_\0
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M8H*6U?$)&"9#1**VUN)%8V1WMU>$EZ,9.&6#A:2EPN-&IL37Y.7_V@ , P$
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M-S>[[Q_'P*:9,YE'T49WGUYD6[M0 +:YQ,23D>C??:TRKUUW ?4?D#QXTOW
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M6QA:2M%/;+3V5020QKPRYR Y'#KC_--AO[*;_)['\UPK_H.>(7[21?YUQ/\
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MJJ*4;/VU]@ZDJTK>><VSA-I(!EZB4DBSN=CB[71&:$RQG-$SNEU- !7PZ;4
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MR.:,K96FTEV(\APVA#CVH+6IM;>1Y(I#+"J59:[2M#">/U77[SH597]"Z.'
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MOV)U-O4V+OV%BF_0;MI;UBN[7:6]8C37OQ@_U'\N'DM_/A:_T(PGQW[X _\
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M[,4U,4\7HD=7EI4K-6EEK/ 8SRS"T#Q/"R2UWC1ZT@>!QOC8\;7'AHGIX?\
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MK#?X)G,/\\/D3\:'\:/T7EW^YY3_ $J''K?_ .2__J'QI_=?('\#SCQ@;V%
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MCI97O<YZ\N9KFJZG,>5HQT,40N:NU4DF7(;B!>EB5Y2F01=3V9RB*NNNU0-
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M-:UC&!:1K&L:B(UK6ML$1K6HB(U$1$1$1$3T^'(5>8P !-@P   !7O  #L
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MY+__ !.)E_0[J?\ .?G3_/W_ /J<<_9Y:_W7.Q_XY1?]4?!\LR_V%C?\E_\
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MS70 IW8:FNR9GCDI@=#Q:TI]7E+Y+BLAK,I:71=93BAHYP8-M3Q59(DU@X:
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M0I8X*\/)^-LFG3%WDJS:E2*)>C7]+MV+#A4Z]B60O*R??#,S-$D_2ES+3V3
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MU T\CKQ!W+#[4:^?L)U(&H7M]KK^R/8::$:D<)K?]PZY4:F\%R>9:?EHI/\
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M55_557^/XD<]BP)IM)YOT63_ -:_[,_]+C3-#&8WT&E_2^C_ %)6_P#9*_\
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MIM@@^P,#D04W?K=X4-^MU'"6]D9,:\D=WG'F&!HX^J=<3@V5XP 6:%TY49+
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MB<H?C,W6&7W1>B=*8#^:=DRITE/XY0B5@?/,9?:NXN:J8_QNT43M1'6AS5U
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MZ&N;GYJOB7*Z]_/2]:5S"&J*!3]@0$%'>VXEIE;2=P!(544#CQEK]-;STX4
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M_K</(#^9+JW]!+[XQU_ZH@_NT7^FO"G*_I7DOW!<_B\G =E?]K&<_P#4-/\
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M*.&U57Z'$UO>K2$/7:T]J3(Y2&<K!:FH*&ZV81-_7WK%OM*.E*3JKLT7$?\
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MZ:H)65LB\9N;Z+XI8(>7ZK_*U]J_0Y4Y6C^3[<=^IB9;\30X3;#9G5*I>?=
MI6O!4%J2?T**:U%SX1A<JZ/X_P"ES7=NMR7$_6CJD8BRJ^1$Q@-+X]UF>8L<
M=G,889270B/#1IC"1FPESR) A+!IX,./Q6,I-:GKTPLBU67UI[+@JT\&H(:8
M^W0ZC0]O/0GA5SGXD\^<VU<1B,US )J;9J.P!#B<17D6:#&90QNKQT@3V9U*
ML&4AB=NX*0Q?)'.7>.S-69J.B:OI\->FLVK*C2Y#Q_06JK^=XG0:J_O*F2SX
M=?P.T\=.*354 3!P%.(MI82KJHK$/,8YU"LCL$BCAUZ<>Y'M:LTLJ(BL%LJ=
MA8AF/?0+J%8Z#C7.;-BO!&UB[-?">D6A%8JX?;&E.K-/-+&9,5,.N(E:.%0J
M;C(0TL:;V$)T#EY&$V.A0,W0:.[N>7:_52WM7R_QUDO-3#!K*.LT^=N!ZW@=
MMH":4HGHKM!>F,BNRS(I])-%F;<Z1L=E=%*)(U!"(JSQIM::WM0['*.I-H)N
M BV*/5 .P;U'<8KE>2I9F*M+-++1L6#-'C\*9K %B-)X953$23&-FO&:9M)6
M8-.PAD<D.QN18;1Z'D-2?ENP;O#T08VGSPV0J,)P^LI*2;(WMWE;(&E#9Q7/
M/BI%LZ4R6H?)1414]9**034594LH4&&=T2=E>"*1B4<NTE@LW457!8^D.-VC
M#=ZSC=KHS#N5N-2U+CHFKY*U4A19X5K1T\5'%$:TTM=UB08N'2'?$QB/2B9H
MRK&.-B5&P=X:?IX@>*:>JKZ>-G#/U7T]5_[V&7_5?1$3U7_T(B?VD3XVSQQ$
M_P!LW]L?PGC&_P"6]CQ#'^8'<^@=BX?5=K6N\9?$6FI #XK!T]*$);?B5]/T
MYD$M;2W\\,<]'RXJ#YQ0(M&*:X _4W^6RP=UI*HX-/5']LWX$T^^?J[^S@GG
M#\"VE7.;'\4<N_<B=.M^24]6743"96SV$7=@^&9X0S9QC%MKFV9=O3[*Z0*B
MNYL]FI+-D$5[: A!6YQ33O\ <!^L:_E_)Q 6;/#@.A%M!_"7'O/M.?8#H=(!
M86E0 '95NJYGWSJ6@%6U&BLT"FS=/XX] I:T@D)HFFT<M GS:3,V<FG$.#3X
MZ=R/+OVT^/Q]I[>_@KNLWX2TVDES!GB1BZPN+J<V&DL+NONG4PF3$PG(MT5T
M&X,QV;VT^>#F%[1CJX&OOPZVN'*(EFU>ER8\!C@S@T_!]?GY?5^7;5Z\<\6?
M%KIF=O;JZ\5N29N6EW6PQ$#J(\W64=W)B+:7-7MK4VMCG\;9J(+K*[0YQS#\
MZ"LQ5 185\A],;6V)9Q3Z.,4O/\ Q6\=B-[Y1"S\AQD@]/Y6=DIJR)U<Y6!5
M8)]6T,&!/G?P1QT>](V?K[4<OZ_$#S]FQ%DG2.5T411':IT&I7OQT=X;8S'V
M^5J\UFI#-*;=Q2[IJQ59=%&ON [#CP=9Y1XS<N^T(OCYC[YY==H=+:-C:VN6
MNR&0?2,TUB$LD9?W>]'70U?V?.)]#]Y5Q:+:@?2HLS9!/;FW?GJ10"J#VZN^
M[8#Y;5.P[F[[>VBG7M+KU'#T^G_2JO+N269] %VP0&/K,O9M\@ZJ=.+U>IZW
MKKIW!>S5/B5Q&#IA&J\?\@V+ Y3%:6J=*73US=I+L5Z-*^MK9#3&PUKZ0'F6
MBL#)+*1A9L A+*RN*G8!%:9(&NV.ELM2?./(K:!CTQ'TNYT'?<95 T[#4:D#
M71-D(\'CA;,V*KZ5H:\R=XUZ_7]+)52Q 3IK3F9MYW,%(12=H>S47B?XT31Q
MS0\>PTL,K&2Q2Q ?,CECD:CF21O;.K7L>U4<Q[55KFJBHJHJ+\)/3;8\YY/K
M_P"'#P,)AR 10JD$:@A 00?(@Z]P>-:SLG(>9@>0_DA5AXJC'KZKM6D KA(Q
M52$,.*IS[XQX6J]?;$Q\LCFM]5]%>OQWGX%XG&Y'P\QUJ]3@LV'N7U:65=SD
M+* H)U'8#RX\]?&VU8H>(V=JTIGK5XC6Z<,1VHFL"DZ#V:DDGX\)?69;F^6A
M@E7 U!_N'L[$IK&H.L%32BH7:$0JYLJ%',B?&@5?_4?K)'.:I0[(W2?&S<EC
M<#CE1OD6K-JEB>4 !"E6I'U;,B:ANI,J%1%!ZG58D&2-5+#6=.WD[98?*,T>
MC11(22VZ:=RD2MIIL0D$O)WV :[6)TX&KH;G-5H)<[!S2G,+DFM!*Z5Y#!("
M2Z*CIM%;L+<X>90(&5EU E?.B%..-'('FA!@<*82@MQ8*O=:@G+]664O8C@9
MG$2224Z=7(6A*3&_005K:>COI(9ID='6"/9,ZJ!LG-66RV4G1 L3RJ%+LB6)
MYZT)0!AU"98&ZB^KTXV5@9#O1&2#S;FM@$&?!CJEL)PHYD+91/9*V(F%DT:2
M,^8[V2(QZ(]OJOM=ZIZKZ>OP_0X# 3PQ3)BJH2:-)4#1;6"R*'7<-3HVA&H]
MA[<-DF3RD4CQM=FW1NR-H^HW(Q4Z'3N-1V/NX#^<9NF!)Z,$"-*"&+T>UB'%
M".L QX6+19N16LA&*BC3U?(]RN]ON57?JJ^B>D<Q/)?*5^QGI;W+F&N2QYRQ
M"DMJA7GD6%*=!DC#RHS;%9W*KKH"QT\^'NYS5S+0AQD-'/96I"V-AE:*M>L0
MQF1YK 9]D;JNY@J[CIJ=!KQ/:NPKLO"/*H=F=[X+*P):W06HZP55,*A=F1"K
MB94)-9$^-H5?_4?K)7JUQ([&.D3+D^3^1,:B.>2^7YM4L3R 8VG'LJU(NK9D
M0F!Q),J%1#!ZG68Z&2, L*4N:^<KC,/S5YR/1HHE/RC<?=-._3B5@)EVQD@F
M23UMBC4(Q('$!;ZP&NT,N;'I[(PQQ)8 $LFIM QR#ZZHSU\>PIZR3J"*VKT8
MK@RD0IY1@Q0LHXD:B$E(K7+?(L%]L?'R-R]+,7EA@9J-**.2>O5HW9UE;T5^
MA$*V0B,4NDADFCEB>.(=*253!S'SC+56TW-^<1-J22*+UQV6.6:U7B* 6%ZC
MF:JXD3U D;HX9SU$0_K ZNUK:^T'^Z,'L@1#X&S6UNR9L)D$9$396)8.1DB,
MD:CVHYR-<BHCE]/7X>Z_(?(5FO!9CY0P 2Q#%.@?$TPX25%D4,.F=& 8!AJ=
M#J-3PVS<Y\YPRRPMS1G"T4CQL5RELJ6C8J2#U>X)!T/M'&V3_J?B",?P\ZY%
M%[_8WRPZ/Z+)++/(OKSOD"^KY9GR2O7^QZO>Y41$:B^B(B<E>(E"EC.=,]0Q
MU6"E2KV*ZP5:T20P0J]"I*XCC0!4#22.Y  !9B?;QN?EJY;R&"QMR]9GMVYX
M9&FLV97FFE9;$R*7DD+.Q5%51J3HJA1V '%__,'& ] T_AQDK*^V&9"M/*&[
M?/>8+7WF#U0+:_Q#\KK-JUFKS9M?<U39WAM&/4,R%#*V8L GWB%3QOA?#Z/;
M]'P/M'OX];/#G#2$3",[QY=O*'CAFG&9Y==O<1!"2Z9@\LT*;)9(XYWC$-A>
M]K6RN@F:Q7+$]&G!J?A]0_%QUQ>'^!F;(^'OOEO*V)KWRNB\ONVR-C9%-./*
M^16[148V,@8B![G*B,F'GB<J/BD:TX-3\/J'XN.Q/#G#*](T[SY=K(LSADC3
MRZ[?[U(;"I#H$;^<O<LS1T6=T7I[TA195:C/X7P<&I^'U#\7'Q%X>X*9[(X>
M^>7$LDL7SHHXO+WMTCY(?56_-8UFS5SXO<UR?,:BM]45/7U1?@X-3\/J'XN/
M5^Y?C_[N'F%_QM>Y_P"F/P<&I^'U#\7&L_\ BV^,6+J?,ZKI2=OW'310^,7)
MK2$_9=NZ1J[F&2QZKY$B3AQV]U?E'LK(VU,$PM:DWT@I9%@5!$R8\I\FH_%"
M98I,+NJTK.Y,AH;=2&T4T-/]#,R-L#:^MMTW:+KY#CT)^P8QTV0J>)9BS?,>
M'Z5CE(,,!G<CA!8WQ<QZ&V,?-"+)BVGHF4,8A)*$TZC:XV'>-_/6)[GV_16M
M]43U=TW9M3U<Y&M3U6W1/5SE1J)_&KE1$_54^-4"W&?+&88_1BJ?\UQWP>7[
M*C5N=O$0#4#4\]\P@:D@ :F[YDD >\D =^/EWCESIB^C[GH;%]ON]'=.V35]
MJN1B.]%N$7V^]R-]?XO<J-]?543XKZ6A\L7A_=^E-/S]WZ%Q0X"PIT;G?Q#4
MZ:Z'GOF '34+KWN^6X@:^\@>9X[/W;>?_P#G7H_^4O:?];_%/3(_VLPW^:J?
M\UQ=^9VW_P ]/$7_ +=<Q?[[Q8WQI\-N/ZKD@-W;'=0^NGW'80Y%"ZSO0!UB
MJ.Q;VG$<@PEW%"DSA ('%3(SYA12S%SN?/-(]TQE]'<56;'XTEL=BV.M"J=-
M<=5(4:Q]E4:*BCLJ@*- !QR]%;Y@I6\]4J\Y<[0P0<W<Z1HD?-694$CFW-;Y
M7TM#?-.Y::Q*VKS3R232$N[$O=?!CA:/;&MCUE)'M>YC%[/T1'O:Q6H]S6KH
M/<YK%>Q'JB*C5>U%5/<GKBVUOVNQG^;ZO\U\#QF^5N9]0/S<<\:G4@?FMS.I
M TU('I??34:^[4<?+?!KA+T16V?5W(Y[XFJWM'1%19(U>DD:*F@7U?&L<B/8
MG\)BQO1R(K7>AMK?M=C/?^E]7R/D?T+VZC@&7YG/ESSSP>Y';FW,GN-=1_5?
MF-#J/9H>%/Y >%O&L[P?MF@KCNIK847(^D7("&=<WYHBF5F-NC14*")O)!BQ
MUG@9\\4B-\!$7NBE8Z-[FJMQJUAD:!6ACE87:I#)1K*ZGKQZ,K+&"K ]U8$$
M$ @Z\1[F_)<QR<I\T1S\Y<YV(9.7<VDU>QS1EYJ\\38VRLD,\,EDI+#*A*2Q
M."DB,RL""1PV_P!W'*?[NNX?Y;.C?]??"#Y0;^Q,=_D%?_8XDWYFT_;WFW_M
M3FO][X^$\=,BJO1-[VU5B5$D1.W=$58U5J/1'I]__@*K'->B.]%]KD=_$J+\
M'I[=OSGCN_E^<*_?V=O4]_;BGYG8NX^7^;-5^V_]*LUZO;7O^?.W;OW]G?RX
MXSQUR#U<C-]VUZM1JN1G;NB.5J/;[F*Y$OU5$>W^$U5_\)OZIZI\'I[?V'CO
M\@K_ .QP#EV(Z@9[FPD::@<U9HZ:]QK^?/:.X]_%D?"CD='AO.7Q%N:[3=(N
M")>A=1 476]&UNKJVQS^+/D',Z:.LO+0P-AC'#,9$6V))XHI)XV/:R:1'3+D
M>T9LO,A@J1:4)FW05HH7[3UAH7C4$J==2I.A(!\P..>_LEL0M#D''3+D\[<+
M<U8^/I9/-9'(UP#B\TV]8+<\L:RC8%655#JC.@(5V!V;.R?R0]5_FWW/]&+3
MXVOQPPOF/I'X>,:'CC@^;:/FF)S4?FGY54%]D,%RFEOJH_J%9EJ@6[N\+D+
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M3])UDHKZ>%9/F3?3"DD?+:[Y,$TGMC==C9<.<C0"9_'NYNU0B+5S89V,\85
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MPDT$;QL5/9@&.A['A-;5^:UL(4+-/4BM@;8CR_5#2&HR&S$420ZO1LXWTEV
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MU<?52<MZ4PKKG<CQGX#8L(!L>S]&/KS8'9VQ;*(>"5HI!C R8U="4(1') 1
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M?<>XO/A8[OAG9OV#=+Y_!:,SEE?STVRT71-':R[@W""&6.3U=I*?2&7&EU%
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M;2* ^TR4I/10J_5UH-ET*NA9'[N4;V^T-;;GU,F.Q%#/J-$4&KXZMQP:??\
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MWX\S_'7GD;2GOZ!WIC 4]37/\H^^M:&GRFS^I3EZ6B#I\A[)O656?U)S9/\
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M6#A_*G*E5Q==]U$E892V])*R<+ZP'YCH8K=YHCU(1(#Q1)W1RMC=&[46-O\
MR?.9NF\FJHND<W0D4QV(+*E9.G+H&: 1R#8=T3R*"I(8>@O.?*WYK<5'C1;@
MJ=.:S(6M4/E*K*EO$93#2I-3]*I]1HHLH]NJYG AO5JLS)(L;1M ZGFR:F5Y
MA%H-!81A@! E,JR$^5$+=LMBE/>+<A'V/UK:_/L1JV(J"'4D9X_I&7."BJCF
M#241I"[1&2625#.GK%ZS01](25Y8H>GUK9UZ3F2.R8V[QK)PQ<R^'@YDE>W-
MD:T%^.G0IT;*XVPO2CK9A,I9-QZN6IWKWIB4<$@'I]85;F'2[!I%:FI<,H6)
MXXP\$DSR9(8(8GD2,CC?.^.-K'3/9"QD3'RN:KW,B8R-JN5&,:U$1&=V#.[!
M0@9F8("2%!)(4%B6(4'0$DDZ:DD\;$K1/!6KP23-8>&"*)YW5$>=XXU1IG2)
M4C1I"I=EC544L0BA0 "[B?\ M"7_ '\]9_SK[7XE5W]$K?O7AO\ 5%'C27*_
M]1YG^_CQ(_\ KA<S\2EUA2+/;56S%M0Q9JH46*$4NF>>]"0J[:UX\D)L=J \
M<6=NU(DLA&PN>:M77L84,U)%7)!>6*G+3:)W65F)990@VO)3D8%#%(&=?0U$
M3DZ)U9"5;MPFR/+,MSF2CS%#>KPRT8((XX)\>UIA-6J<QU8GCL)>JM%!*.8Y
M7NP+&6L^@U%6>$!CP'9KBLM!9Y&SFV=F?^3KFPL:\!:\9H4T%GDY<T>A$AT]
MG:+;6)$GWBPM&V2#+(\D&MJ:P<A7L66<R)XK<0IQIZ9#''))U&WAH[0LQE0B
MQQ=*)?F8X^GN("O++(R@<1_#>'+XN[@;LG,5RU^9_(6KE6KZ) M:6*[@7PUH
M2O9DNW?3;<S#(VKBW!#U&FK4Z-.&4E2_L?\ )%U3^;C<?T8M/A-A?TYQ/[YT
M/XU%PZ^)W_)MXA?WC\V?ZAR'&:?XDO',_%> ^&FUY72IA]'0SP]%=/&1"=D;
M)2!Q9MCO]K%];85>UJ2[&Q!/WQ%?6V<#JR0&JIJJ*"%"6/)5Q-Y66N#'(#7T
M(*RKH2(8(#M5HF"J5@#LIW;G=M3IVXCD>!>)\HRV:[#)DAEDI2[E0W<E> DD
MBOPO++')DGCBE4PF.*")54,"YF.4<==S*TL[)UZ#:K8X?FN*=&#G747S&<YK
M[D&"V,1;NV&<59I<S/<'5"4]<'['.4<LDB4GXLMW/241=C)MFLS$EP_>PRMM
M'J(=%V@;G+L?> -.,V(PGR5+++Z1',9<?BJ!"5C7U&+BGC69_P \3)NEZY)C
MAC@CCT)VR.[/Q;'Q^_KP?#S^=KI'_-.\DOB2<C_IO/\ O?-_&*O&G_LC?U"X
M_P#OGH?ZMS'&>;LG\D/5?YM]S_1BT^-K<<2KYCZ1^'C#[Q#;^/&:Q&'U^,_$
M(\9<3>;N/C>DZ)2G]3Y'6DLS><P7+ZZ?,3%TNIHM19: 5F0N*6!-G;W592"Z
MZY96U=;'$=671Q70^14]M?8?/WGX_B'NXB[BF\8K 2ZBL//KPSWUAI>?AXK3
MZ'IW8\=J]9>);TG":;:RMU-WTJ^LZQXA7(-3K.;G(E@[#:GKER72UU='FH4T
M9P#</8?/7VZ>W74?'R^CB1LA/%TVPLIF><G@E\BWT6BO"[*7HO/XM.EL23N#
MZ/<R7H721[1VUMBMP*/U8BDLLP3T:FYQ@\Z3H*S,+>T)YP:']B?J/UZ>1]OU
MD\-;QVW/B?PV[Y^5)YJ>&MG69'G/6<8>0)VOF(^DLI.C]E;U6F$E.'T5;5E5
M&+A0RJ$<RJJV&F7=O8A5%%!*H$IP$$D]CYZ^1]OG^7WSQ=C]]WPO_ON_&#_+
M[RG_ $L^#BFA]Q^H\:]W"/)7QSK^3Y ,_OW% 2X1[-)A3.J848F%77EG(U)8
M)KYDL:N8]KVH]J*K'-<GJBHJZORE2T^1NLM:PRM9F*LL,C*P+G0@A2"#["#I
MQVCR7FL-7Y2Y=AGRV,AFBQ%))8I;]6.6-UA4,DD;RJZ,I[%6 (/8CB'U'2O'
M^X[#F.IUWE!XY0IG*VN%A!L>D8H@V.2OJNI5!0H9X^M@^16Z%G3 [&XB2-J_
M78'.I)$?\^(BDP)#:6!X32MG>Q.HAD [M"P)!C[LG1*K\)7\M-'<;%_"RY.#
M()G\&.A'&H1[]0N"D>0C95<61I'/Z>KRC3[>G!J'U!B&,/L^!Y;4Y?33^1/B
M>.37:3HUW>IG.AXRH'F&VM74UP=?FZQE^@5$(*VDJUM!46;[P4 R[LB3] 98
M61%\D5IT=/1;QU2)5WQ2-^ALQ)<[=6)W$*>VT':-$ 4)ZMO#P6:]ALWRXICG
MNRS="]5C4K:CC14@C$P2%5$4?44:]5DZTC/,[R%@=_\ )7QSL>$=KKZ_OW%#
MSS^2=(#!!#ZIA2C##"L=<P#"BC07SYB"2)GLA@@A8^6:5[8XV.>Y$7'5IVQ:
MK$U;  GA))@E  $BDDDKH !W)/EPLS.>P;X?+(F9Q3N^-O*B+D:;,S-5E"JJ
MB8EF8D   DD@ :\8OZ;M''64]4Q_6>:,>RM!:]C]WEFN:YHL2.:YJVJ*US51
M45%1%145%3U^-=2XO)F60C'7R#(Y!%.QH1N/?]#X[IH<^\BK1I*W.G*:LM2L
M&4\QX<$$0H""#<U!![$'N#PKK2\Y+8:G87K^S\?("UE!=4! )&THX"G@7M+C
M:><">Q#T,<S1*]<D6;7.@1LD1&KMW11BRPNGL5\<.22O6A&+R:M7FBF#K5F*
M[X9;4H<1M 06?TE4?=V*UXM2P.U(?<R')=G,9S(GGSD:6OF<;?QLM>7/X^.9
MJV2H8*C+6DM09-76"L<)-8JM&-R2YF\46%XS):D,?H^,9ZVK;RPZ_P ;+LJG
M,F9P">NT6)JYH1;.]DM"12"!;&)3QJ^N S5-4R20P3M2NMK AKI[R>."RU!E
M)XY(DQF36.2PL[B2"W("T<(C5E5D.QG=YY) "P]>-%(6$%E."RG(>+N5,A:Y
MWY$FMTL1/BJ\E7*<O4WCAMY%[DL,LL-F,V8JM6OBJ-)FCB<"M=LR+U,A(D9I
M>]GX\\SG[F=7YJ]HW;. GD.;NLNYHX-=V_GQ]@9,J6JI$("",0:81)[811()
MB9WLAB>]N;!XW(QY*%GH7440W06>K.J@M1LJH),8&I8@#OW) '<\-_BISKR;
M;Y'R=>IS;RQ:G?(<M,L-?/8J:9EBYHPTLK+'';9V6.)'ED(4A(T=VT521EM_
M>:\;O[X/B'^5?!_]?_$E]!N_V':_R>7_ &..?/S2<N_M_A?\Z4?Y_BK3M'Q0
M,;KT=;Y,^*YK^GD%(L6AUF&M0F13[K>[*"SMP"].776E]7!;N#,5\Y]?8@QB
MXG,&$BE!I]@ 7=.T37W4;XZ '=(Y58Z111;581AE0F+>=I5M99 "#ZYC7I.&
M1<J$YDY8?Y29^UBU2E0!KUZXLDL;VFCEGC2\M9#(CH%I5G9&3\[HR^;]$\6,
M!;::\&[QX]#V&AK,50I]KZ9A87QT6+HG# CVUC/H'GZ.W?H+?5V,VBM'K9&5
MUC55Y:R/J6D389H+\JHIJ7"$:5_6@E^WE?5BJA $78L8V+ZH*DCL= XX_(\L
M49;,ZYS +)8CIP?-Y*D"(*<&V-99&L%[$OI$UN0V)#U'CECC?4Q;FII^*/V_
MBVP\?\?69+KW+]190=BSYT]?G=_E+LV$*+%=!'D,E$K+8J>,6.<H:!Y#XTA9
M,1!&YZ/EC:YVY>JV8KLK25YXU-5P&>&1 3UH#H"R@:Z G3ST!/LX@GBSFL/<
MY<I15,MC+4BYNM(T=>_5G<(*.24N4BE9@@9E4L1H"R@G4C7/YM=)HLQTW3U%
MQT'F5%A]Q=>>1]P3N^-Q[:'(<>Q>SY<O::8J6.^D*V0NTDN<W<&9I]/5ASUN
M9F#F,*G'"'.V1QQT!J/(^8'8Z>>NFO8_1[/P\1]A=93$#$24?:<PG3,S5ZCF
MM3G"?$74Y;JC;3M1FIM;S)F:S2]. NJ2QW=MQ4JQN=7<7T;@X1,M=SW,(FIS
M$UT<'8^P_P"$/8/=I[!Y?4. >RHKW-YS,$7 O.3:@+G7:N2#THW$:+3GU#^"
MZCHG&-+C8ZBWZ]!'+SP:YL;GG6.ZK:2USZ,+L%'EDK,W3[/0" '!V)\CKY^8
M]O\ U?CJ?<->"P<O79$<':7>@IJ5.5\*\T-*497\,JM+70P^/_:*[!=^P555
MR]W'*W=QT;>GLV?YFUV=KEVTR9V_T)B:MI N<.#MY=^^A\Q[NVO;MY_1\>W'
MJY8W9-[!RJ+';+G.8T)@+L$=IL9PXRKI,/=:>_\ *"Z;A+/(V'0L586SP=;R
M?L#-I%?XZKLL9NM13"QU!\BZ*TR1Q4Z=^QT[>T>S33OM/O\ 8?+C6TIZKH0.
M!K+$SH]*VK#R 9I4+N<Q%*T >FCGGB<U=0U"50=CV*U6)\[^)6I[O3XYMS$]
M(\P9.$4)'G;,7(Q(+[1AI6N2*' %=NF"YU #';[SIKQ[-^'M3F2'PHY'NMS1
M2@QL7AYRU:-9^6([;0T8^6Z4I@9SE8_26C@'39C&G6()*+NVA(K7:"#"V<\4
M=;##3W@=#=48N(-(&#$O<OFM,ZQM[*BT=D5/1C9<^AK[=TP)00$ CZ+UDSP<
M9,JOK0-=C0B1C- \\4SW K.\%JQ6Z<4<T"*)FLQSO%HZNY;K=IW*AB]$R<?+
MEJ5/14CHY&OCK^/AY?L2PP09'#8G+FU>MX[)VYY,?%A[.-JWNI6G@KQP-CB7
MQD"2N7\[;=6>YVM1F=1FJPZFBC?/9BX(>04P:R/(E)DKAV:I 11;,^%UI,^A
MD+'.GD:3?N!O$4)$N0>&*E3EL59Y$F)"QM=<,C1Q@*'8UB[-'&>F!,%9 -L(
M>'U^'WE9<A;YBY@I8C,XFG9H(C26X>6X'AL0VK,KRM5B7,"O!!;M(;<AQK30
MV9&6;)FOD/F [N8^+&D[3O\ I=C=]>6I-HJGGP*/K,!7NA+'*;K2(_?"3H)%
MBD@>V5%>R5R2ME;ZM8L?JZBX[$93'4Y9JEE!'8NHB1W?+M5+$LU8ZZ]M!H--
M/;KV27N>O$/D7G#/4<;G,':-W$\NVK$USEIR25DS4421QQ9J,($"L6)9RY8=
MEV^MUC^$%'8]@M\@_I%LPV,TG/3:QV#S_M+T]/D<%T$BN6MCT'SXQI<MH\T^
M*\5_S#2J$FF/&@%KJ::P6CE_&I1C -_HJ.HL'IRD+')):@!#&H==)#9(B^U0
MSO*GKRRD13^C/SQ/S-;=X>4/E"5A5FRGYEYP\UJM4PV2*-$O,0*EZ<>)1[>G
M5LIC*]*SK7I4E*FK?%#(BV]=6PZN^!LL[M2Z.UD#RM,QN=@9:\9R[;&!)[T"
MQL61OZ9AQY* NO!'BH\W=OI9+2I%R7YL6R\OTI8YC)+=ECL0*6#VHR)=!?GT
M/YS95<LMN0S(2[33AI&65IFBCM/QEYII6J'H>.Y4J6,1DIEBEJX&_":(8\LX
M[<A_-+#+- M>3!U$QTT8JQ8W%BM41Z4%&.S=O(^'&IY3V_QXU&;[>Z>[?U"Z
MJP);3FU80$$XSC/6I)RI0X-**\Q5$&(%CA4J!K'E-)5[E'2*3%@,/B:%JQ8K
M5[0D%-T/4N!U*M/7U&@KKH=0"#J?(C3OVN\7/$WQ YMY>QF'S>2P34WY@J3C
MT' 2U9UF@Q^4*-U),Q95DVLZLG3!)8,'&W0W$\FZ[HN;RU43O=SD>D" )L-:
ME._B]:-]!0XC":.^VUBV0OH[(CW%9*.SS;<U([Z+5OT#:&[<-G#+FP"E]7I.
MY$:21%C&F[TCS:21%C&@AU&C[7W>:;=RZN%!YNS"V884-JQ#;5?2)^GZ @VQ
M5ZTLMA]6M -K 'BZ1]6;J]*32)I&7S[?.:K ]"+L-=T;.PNKN4;_ &+-<7R$
M.PJ#JA=GG)M7D:_-S]>G<5<7VGU5"9"(33CQ7%J^I!K92B0Q(0Q&22,!(W.L
MT:;!-HP8(VQRWHXT"JC#4,=HW$Z#76EB*:K:9Y[40*4K,XG:DK(R>D1-/ D)
MO'622:>-@#& [E%0DJH4\XW2=;TO#L/H<9U;%8_+7.($LJK) \6I)1\Z.4$^
M::E9/3](GJY9*\ETXL\P,DH\A$<LC'/]55;)S"EB1'BD=UD(+F<^L0?MM#"#
MW&A[Z'3A30CNS8ZO+!<KUX9*X=($H1D1!E),8,=HH2IU!*Z@G4]^,[OAIZIX
M?^*2*OJO[MG#/5?XO5?V89?]?1/T3U^-H\<A/]LW]L?PGBDGD!BN[;SRU\AJ
M3Q^TD^5UT?C;X@V%C:P7EAG_ /8 S?Q2&9L60VJOL\>K2.GS\];#Z%656&6T
M:VTV:UF5KKS-6IQ7]:-?V3_@3X'\O;PSS\UYNK'IA%GMCL:?U33&-SH6IR5?
MO)^36'>P]L0+0;B/2UUC3:JPY%-?<\RP<&JSU;EH"JZ(2SSQ5=67E0<6ZCW>
M[\'?M]/?\(X"[["^:\M']F&9ULZ1W+>.B6YP/5L#3EE=!J>5=^JKYV8NH-U6
MVX;ZCIN@\>-#O[.QCK1-Q^2]PHT&MHB1<SICBO;X>9[Z>0[:=M-/?V_ >#+7
M8+R]N[[0,S>BZ1G&#>0E+<9RTL+C$'9<O DY;B@M[?1#4O7**YKLGG]%ENN.
MS_/=#E]8#>5NX@ETN )NT#N\\< T^\?K[_#Z._L]_LXL1XIY7LF0YU:5?:KZ
MYO[I^I?-G)=+-&1IA<W!E<I6%NT#X>@]7@B-O=O7;/8# "]%U 534:2MJ 'T
M0( V5H3BAT]GY?@_ .-;C>_UQOF%_A6=9_\ E]1\;9Y0_26+^[V/]/A)/]N/
M[4?A/"0ZM5[^R7/MQ,EDUL3K))75=P-3J!?R.K5S5[>_4'@+<9*I;'<I?Y^%
M+26T4L!$HK)(%49[MI8?I= N-"VNQPFU_5Z<DFK+OA31^I&-Q?5?FVT[6QE!
MKNT]FFHU[=]0- =#Y$'MY>?"HVM!W"WT.@MZ&'7! /BG.J*1-37#UEA*ZDP"
MYNA-%I^BYPRE@J+H/H*:VSI+@4@Y]K62C2ZZMC@KJQ)/'?>21XQ,%[LB=50K
M'97Z4;!+,31A'%CK,C@MN0@S+HJW@Q@ :J?($E>_FVI!*M[-N@(]X.FFO%M&
M>]6-61&M>K6^]K'*]B/]$]R-<YK%<U%]4:Y6,54]%5K57T1W&NG?S]NGEKQ@
MX#?&'_Q#M/\ A!=#_P#F3.?$$L_U;?\ W7)_HIQ-<1_4,7TM_)P9=EJ>BVP=
M'%@)+5D[)+A'/J+L6C?7:":M5F1T%Z\FPK_N^.H[/YT^DSL*6LUO%,(W[!<1
MP20,2RAR $UU[Z$$#1M/49M2-4!^V4!B>WJD:\+Y QTVZ^WR.FAT]4G4]U!^
MV'?7MZIX3F]HO(NTU%Y;90;1 T)DGSY:4C3UK4,J9:3G+Z&CI0*CHN:=27%'
MIJ_>NU]G7ZG-.M*JW<@%]IX_M=77X9%L%F*;@I_6EAW!6/:%"R)H582%SO75
M6[,WJJ+&$I)*@@>XD=P0N@4!UT*G=N.X:@]BPT N$!]7]"%]PCAB/^D&^MB&
MFE('C+^2SZF,<B=D<\\+)O>V*:9C)96(U\C&O<J(K&NG?S]NGEKQF&N@U\]!
MK[>_T\8^,E_M]\A_Y]K[^AF#^-E<E_I5/^^%C^#@XU7S5^G$W]RA_P!'B+ZG
M6[FR%J(\7)8LF8^T1SZRV'J' W4M>YF9NKAQ!H26>8J+#YD][1Q)8R6<<@S?
MLMI'"^!K]D$M.L8JEP=9.\<BQ[)2A%>64ETZE>.34S0C>9 5^:D *\,<#1 M
MU0"/5\U)U77UU70':[+]JWJZ$?;+YA;[&DZ_;V6Y)IX=;7"6M$?!FF":*KC;
M7G$5?.DH$@K0]]G8Q3Z2ZK^B$VQC+0<<V&YKF$/U $<5,"ALQ9*22VT8L(DD
M+K7"S(-CM'1Z&B+<@"O#,EYI6$BAUDC!,Z 1+FC:NJQ!C&2KJ7U1CN :;?J3
M"^JNIA"C;J"I/J'5C9<7ZA11E+:UA2P0_4L9+\YC"/EM^<UDWR1_FM;)[D;+
M]/!\Q$1_R8O7V-?5UVKNT#:#=H=1KIWT.@U&OMT&ON'EPC.FIT\M3IKYZ>S7
MN?PGZ>,Z'X*'];]Y ?X7.^_S5\5^.<.=/U49C^[0?Q*MQ,L=_4-;^T;^%DXM
MQYBXRBZ#H_#O)Z:UUM'16/D]>S6%KANA[CE.G"BJO$+ROMV2U^^YQH\EL:")
M908V6+ZG05[+"L<95V2DU1IPD\7X7 Z:GX>T ^T>P]N/1#X7\0(,+KH.G^6\
M]@!&-,<##^(1YO2F!PF.(8)*6,SR)=,/&4X0MHSYF,;.X8AL2N6&1&G%=Q]R
M_P" G^SQX6>(/C_(IB1]?\J9%KQ)3ST9^(EYKN4$&$DP*8PQ&^1JJ,)$97GB
M2D3>R&,D$R!STE&F8PX-Q]R_X"?[/'TWP^X"XIH3>N^5;C'6,].T1OXB'FPI
M3K88+[D35M'3R,^:MB/7*A\X*,4F(+_94D38/ZI\'!N/N7_ 3_9XY7^'W ;9
M\$55UWRKLI"@5M!HZ_\ $1\V#'DUB$N#6Q@8-Y&2.F!0MKA5+C1PZ$M= LGS
M45J'!N/N7_ 3_9XF/W'N0?W0?,/_ (_WG+_[D-\'!N/N7_ 3_9XPF>:W@[P:
MX\Q[ZET)'=-6+4^,_"+2N)V/E5Y0:^Y%(O.I^4 EA!'H-+U^TO5K'1Y^ND%I
MG6+JFN+6P-KPA3+BVG-@7.L4$CX[K5:=G1;6WTJG5M[-37UZ?I,,O3W:#=LV
M[MJ[M=HTZE^QPR&6IP<W_)N<YAPPDEP?6&!Y@S.!%C8F6Z9M##WJ0M&+<_1-
M@2&$22B(H)9-U=2O #Q2!A4@VFZ(&.U\4;IRO([R"'A22>5D$$:RR]48Q'S3
MR1PQ-5WNDED9&Q'/>U%A JTB=!B\23[AA\83[_[$]W'3#9_FA!N?GKG]5U W
M-X@\Y*-6(51J<Z!J6( 'M) '<\>,WP1\0JU9VV(FX 46*"<E#?)CO@JCPE2O
M@%FG2?J\:Q1$S120P22>UDTL;XXU<]CD2HJ5&TVXK%'74#3#8TZD=R!I3[Z#
MN?=Q:_,?,D>[J<^\^IM"LV_Q#YQ7:K$JK-NSHT#,"JD]B00-2.))OX>_BT]K
M7LS_ $I['M1S'M\B?(9S7-<B*US7)U)4<UR*BHJ*J*BHJ+Z?%OHU+]K,1_F?
M&?[IQD&>YI(U'/'B"0>X(\0.<]"/?^GG'7X[> /C-?\ -S+"RH^H.)BZOY U
M#%#\B_(BK@0'/=]Z905;/I*SJ88JS1UE8)&48L*EV)39K&QG*L2BBIG>>"IN
MBUH8P_G6D!NQF/8@"G  H)K$A5 "HH]5$"HH"J -;4<]S/&+ZQ<X<ZQ+\N<Q
ML5CYSYHC#229_)R2RN$RPWS3RL\UB9M99YY))YG>61W9TO\ P\_$N,J &2LZ
MC&:5%/,,&_RB\DV%$0BK$A,L [NOI+-$.L\"3R1L<V)9HDD5JR,]</H]30GY
M.Q>@TU/R5CM!KY:GT7VZ'3Z.%AYCYI#!3SMSP&()"GG?FG<0NFI ^5]2!J-2
M!H-1KYCCK=^'SXBME&@<#TULYI!(@<+O*7R124LH)LSS!AHU[![YR!&CSN)A
MB1\D#8)EE:Q(WJVOH]7O_2[&=@"?Z58[L#IH3^=>P.HT]^HXH>9>9P5!YWYW
M!<LJ@\\<TZLRZ[E4?+&I*Z'<!J1H==-#PGO)CP$\:,OXX>0.FIJ;J4-OG>(]
M6O:J4OR,\BK06*RJ,)?6 ,A-9:=3,K+$=A0\3I@+$,L N-'#F#3CR21/44X:
MJW*C+0QJL+,!5DQE!'4B5"&5UK!E8'NK*0RD @@@'AJY@SO,L^ S<,_-W.=B
M";$9**:"QSCS-/7GBDI3))#/!-E7BFAD0LDL4J/'(C,CJRL061^ZGR__ '0=
M^_XU?D[_ -KGPB]);^L4?\VX_P#W7B4_(=;^S^8_^UG,_P#WOQX)/&CC<3+"
M279=OBCJ?1;1\GEOY*L96HL#"D6P<[L"-#]1I(R$^I6/^H/9+_[S<URUZ\GJ
M_G>EZWVO]+*'K=]/5_.O?OV[>WMQ8</2 <G)\P 1?HA/-W,P$?JAO7)S'J>J
M0WK:>J0?(Z\=L7C#R*>>86#6=TF*'B'F(&B\LO)>2>"$M)%%FFA9U]9(HB4B
ME4>1[6LF2*18U=['>AZ0X )KTM#KH?DW'Z'3ST/HO?34:^[7BHPU1F*C)<PE
ME"EE'-W,Q90^NTD#,:@-M.TGL=#IKH>''XQ\1Q?.?,SP^OL]:]1-.GZGTNL?
M#L^W=EZ+4H,1XH>1Q$DD5#O]WI:2$YL@D38;*&O98CPN('@*C@+*CFDO*DQD
MR,JF.LGYSD.L-2K WZ-7[%X(8W*]^ZEBI(!(U (TYXY8Z*GRA2ECM9:8MS!3
MC*7\YF<E" :&4;<L&0OV8%D!4 2K&)54NBN%=PVPCV3^2'JO\V^Y_HQ:?&PN
M.3E\Q](_#QCLX-W"DR6 P%-T/C](-EYA.+<MYG>#9;,B_F:Z.Y_RY]@DUJ7I
M[$ZZM"BMF08+7?E#*O@K,M>S@$ZID1IE4<&GX._W_P"0?CXG-;Y.U]9B]IJ
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M>%:<\,>X9;8L^D!-4T92Y+DJ2V]BWDJ( 226?7=JY+((P2IRXK#_ "7)8*6
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MREZ\,\$TR!=T44T4CA4D1CX.@Y+H\6"V\I/2JPD>/(:62<9N!&'<1"RF-=+
MV=-'(L+I6(Z-)4C>L:N1Z,<K?:N7%6,*<IC0F(L(YOTPCG*LX1O2(]K%/0EW
M!3H2NX;M--1KKP@YYQOB(O)/.+6.?,3/ O*W,+30IR1'"\T(Q%PR1+-^:&3I
M-(@9%EZ;],D-L;3:<F-#X%;(FCIB&^1#HFSU-=,V+]DU0_Y:2APO2/WKKD5_
ML1WM]RHBN]/543U]/B5RX'E\RR$TKA)=R?Z8^TL=?_9>.?:?BWXKI4JHO,'+
M85*T"J#RDY.U8E U(SPU.@&IT&I[Z#RX\C_#$F*SLJ27RQH8[FFKI+BWJ9.>
M9=EE55,48\LMI8@NW"% UT418DLII,40T<90SWR-;/$KP<N8,JKC&WRCL$5A
M>;:SG4!5;T30L2" H)/8]NQXH?&GQ.$LL!YJY2$\$1FFA/+ $L4("DRRQGF'
M?'& Z$NP"@.I)T9=?BG\-)M%.P;/^6F?O"9*R"ZC'J.?9:RG?3$E$!#6S80]
MQ-(M:0:&6)"<C?II2A21V2NE@E8VK\MX2,:OC<@@W%-7O,HW@ E=34 W $$K
MY@$'30\$/C5XFV6"5^:^49W,2SA8>6%E8PN[1I-M3F%CTF='19--A='4$LI
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MH/EK_P!B7Q=Z#/\ LZ?^<<?_ +SQ@_-/C/['S_\ V3YI_P"YN$(W=<G"9O\
M[%H_+>A(W[C83#0/#WR40RJK+#9[C=E5U46_QY4H977?1]?!#9LG9;AUAE?&
M"<-95<-K(J,4YZ6Y<>PBT(!R-+1F$440+#TS0^K#&2I!5F#:@JVT,POXM/3C
M#-S5"]XN'=.4^8@\4<ERY==(F^0-RDS9"THD#"5(WC".LL2RF:Y?TKAW*3M&
M50C>3<P>A0/THY?#[RD#HJB2"QO+<J:KKJW@HD<4II^@,C]973(%4!TM*$V
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MW9 Q:0VIN^JG0@SRPUD,=)1U5=&-"6I%H]6+6C5VVN# RMZLNW4JL*>KZAV
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M@F_@F.'UYVM*@KJV]!^I?+FH\Y65,<UAL[OV5M:WZHSVFPV,WL+6EJY:;.B
M5(N>3)%Z[5Q&0IA6$%FC;327JLY"P)ZS]E]4J-1U&#RLSL@K<K)#DH\F]I6F
M7(2WY!%%:CWEJ(I0UPTN0L:0P@R2 2K,P$GHT!K4XXJZ%7D7_6^=V_F;Z?\
MT)O/C'BOTTQO[OI_QB/C+SM^HSF[^]C/_P"JK?&7SXD/&CN*LF>-Q$]?VJJB
MUE%(%V*DT>?(CM\)):NJ -!J>K;5LA?LUP$-\=5Z+K%J@$\L-=#%35%37L%C
M.0NX)6"T-8"8VU@9&&V334HD,?;U#M5EA4D#4[F8ZZ:*&1L0Q3(H)XBN0CFB
M;J53)L26>]9&[2P@D:.6\^PD(!'&B;0VLA9//^9'XO4[33E:$4_\Z#9IQU/4
MU=U4U#+VE#*#LM'])<Z_6QPGW4,@0SX*5E&%$'6"-/@M[!'6?QBEF$B(@4CI
MEM&9E9MK::)JL:'1="?6W'4G30=N%E2DU:>Q,TJMZ0L.^.-)(X^K&I5YMLEB
M?1Y 54B/IJ%0;@[ZOPT,O_7.^&/\^>__ .:%Y0_#YRO^F$O[DD_A8.-=>+_Z
MEZO[]5?XGD.,KO9/Y(>J_P V^Y_HQ:?$]XYL7S'TC\/&+WDWS+[CW%#S_P -
MCRUM31:#E^__ #)G.O>(^;9HM+68[#PAVQ;A/.K.6MIG#&Y/-FID=( RB(6L
M!DM<S&8R>)*:GW'[WX^*_0P]H\CY?4=/N<,0X"2PKC*>7\-GSB'I[#EF:XH=
M45OD=XPU%47R_)0V(U'DR*RK_$-# D'A%M[80RR</][MA;,X>VLS8B96N-3[
MC][\?!]T>>OD?Q<01F'S%D;(=:_A6>6MPL\YCB +KLOB%<4954=JZW=29 K/
M6?GX51$\\'V517Z:MYM/728*IMX'E5><#4HM)S4^X_>_'P?]8??^CW?'@UQ!
MA7-[VKT.'_#$\M\X;1P;D>D! ZOX8?ERE;TK6S[G<RU&2G\\)LM6%:'3$R'$
MF!4\!0XZ150,PM1#" PU/N/WOQ\'PW#[_P!'NX=G[RW;?_Q>OEQ_CUX%_P#N
M:_P:GW'[WX^*:#WC[_XN-)^DZ)L6B%(W@W5)$6]TSU<RZX>B-=)H[5[HE^9V
M.-WOA<Y895:CHUD8]89)8E9*_G#F6E6?F#,.V7QT+-?L%HI(LL9(R7.JN8<7
M+$6'D3'(Z^YB._'LGX,\RYJMX4>'M>#P^YMR$,/*>&CCO4[W(:5;:)4C"SUT
MO\ZT;JQ2#UD6U3K3@$"2&-M5$?86UG:7@NC+\>.PK<A00CC&#;'D8*,8-%<0
M#.<.#W0862<:#0WD$!,L#R(H;4V)DB,F<WX;(XHXH6KIGL1T78LR-4RKZEC$
MS#<^$9@K-!"S*&"DQ(2-1Q-;5ZY<R,.5G\*^?#?KQQQ13Q9WD6OM6%+\<1,5
M?Q(BA:2*/*9&..5HVE2.[817"R$<1E.Q] 56EU/CEV42:IG))!1-WRZ4>.0F
MFK\\YLP<_>Y1#((*2IK:T$8R @>N&"@:!$,YJN7)*>NDB2Y_$,LH59/SEDPQ
M"S23@AUP8=29I9)'9&5G9VWE@=.$= -C)JD]'PHY^@DHR2RU@.9.3'B1IL?5
MQ9$D$GB8\%B./'4JE2M#8CEBJ15XQ52%AN/[T_H.OGYIT."7A?4 HIL-K8I3
M";GBCQA(Y*"P8\HA@?7BRW0#M<LLK112271L<D \TJMC<8VA57(T&&:QKD7:
MI"+%F-S$3H0J[\2B;F\AN=5U(W,HU(.<>:,[)RCS3&_AOSE723ES.(\\U_P]
M:*!7QEI6FE6#GN><QQ@EW$,,TI52(XI'T0F5-RKR*?3U+XO''H,L;ZT%T<C=
MKP!K9&.%B5CVMD[.R1K7M5'(DC&/1%]',:[U1,<O*TG5E_IOB!\X_8C+ZCUC
MYZ8DC7Z"1[B>'&C]D/BHJ52(^'WB"QCJUT+*>0MK%(D4E=W/:MM.FHW*IT\P
M#VXC5\>^X?>2M WQFZ;%;&,>P@J#IG%!VO22"J&F5HT'>(Q(GD04=/$2^*!C
MR&5HB3.?\IOQF^0KG02L<UA3"A!5&@R+$:-,ZZNV%+D*UB=E!8A3*^W37AL/
MC/RE\JV,TOAMXEQY*TK)-8AR?*4*L)(L=!*5KQ>)"5HVFAQ&+CG>.%6F2A6$
MI?ICCZ \?>X5AM>>#XQ='A(JJ1,Y6-7HO#I10*9/H/4,4&;ND@4/O^UU_P R
M=@Z$R?3,^9,[W2>^DF"N2I+')F\.RS6/2I?FLF'DG^=^<>1<*)&TZTNBEM@W
MG11H-*T_&?E''VZ5VIX9^(L4V-Q(P6/'IO)LE>GBOSGK5KU)?$5ZD6_Y/I;Y
MEA%A_1UWRG=)O]EAA^\Y6WYQI+GQUZ(/74O;^ 6,WR]AP,B<J0;M_/GB5HD4
M/9GHIUL8D%8"\EPU=$89!+:'UU:PH\9?@>77JY2"=LKBY%CBNDI&,IO(:C94
MD=3&1IHN[<VK@[0=H9M%,6\5_'"AS%R)E\+6Y&YXJ3WKG+R16+K<DBLKQ<RX
M>P%D-3G2W.#+T>C&5KNHED0RM'%OE3,S^VWI_P#>?>0O^-?B=_[DY\2ST6O^
MV-3_ !5__<N.9_E;(_\ -?-_Y3RW_P#*#A0&BNL!M<&1X3^4#!=W*1)JQPNQ
M\)K8[:(N]N],77O2M\P!%%IS+W3:2Q,I 5&J"GZ"ZA("D%LS()E (!C(R=+6
M( 1DUK3;=$5 ?6QYU8(B*&.K (NAU /#6ZEULJW*?,(6X2;*IE</&) TTUAD
M/3YG7;$TUB=VA3;$QFE5D*R,I+,MKM5C;#1VE%X<^3S3]857FWQ%OU7QXTKC
M"JNNAJ09HF:3RVMHJ]T5<..(]*U@C"(AQ_J6RN@B<S')'%*$#Y*EI&&"A:]Q
M- S%CKLH+NU8D^MJ1J=-!PJKVK-5YY(>5N8-]ED>9I<C@Y]S1QB)"!/S+*$T
MC55(C"A@J[@2 10G\4OIVYT7C]CPKGQT[!@Q8NQY\J.XU5_X_FUY,[,5T*%M
M;#%B.X;&V:9-'/*5'(1605R0!D-E/B)>(.4\\O00I=E*7:\Q]%<;42VI ZL)
MW$RUHUT&@&@8G4CMIJ1 ?%'(7)^7Z:38/)TE&8KL);,V%=&84L@!&!3RUJ4.
M0Q8%HUCT1@7#%5;/SKM=89SI6ERNFV?!Z;-]-OO.^M#)Z?QB73!YOD5)M.8/
M[U7;"_L/,WBSM17:64_'VL=-B>7:&\&H:"R0J.,:N*/MMC<<G#R]OF/(^WOI
MIZI^CS\R/N0VA#PU92V%B7UCQYT^LJJ?48!,_=>(OE##VRXM>R'Z>V(R]D9U
M'S>H-<+T+767#KYV7TO0+^EO,H)0Q$U.IRN;OA2[4X.W;L1K\0/A[O+\/Q/'
M@IL[+N-1EL0(G++;:W6-[C5V6<*\9^JEET-QSS5]IPVLJ]O92_B32T=WU_9Z
MJT\@P\?TX:VU.@,DL=U=V/1L\'JPK&^.#L!Y'V>T=]=#^QT]QT/X^/TZ+19#
M*\J[)"_(#4^X\>=;V;*ZG/\ C[U6?5B5O[,>J=@T\=\#5?B>+M".T)G>@]$&
MD[!(%;-#V'7'9\?LD%QOU:6<'8]N_GIY_1_T?+L.)+A%E9[/J7(),)I.*4&G
MN,?H-7SW:Z;@VO(HM'-'M_)"JM3 IG_B:7\_;-Z6:WMN\3<T5-TBSBQW62ML
M7K@J_?7$ZG =/B?N^7E[UU'L'W-.-7X'QQUA>+#T]KU;'BUQ68'OK&%_);DN
M(8*>J98&1/1.L(XF.&!TC'>D"+,UJ^D2*[V?',N:PF*GY@RTFS*>D2YB\^L6
M0JQKUY+LK:Q@XQVC'4.J R.R#0%V(W'V[\-O$?GS&^$?(586^1QAZ/ASRM#T
M[W*.<N3#&UN6:*;+DD7.]:*U(*J;;#Q4Z\<[;RE:)6$2I";@PH>,(O2]5/6C
M4.F I;"N*P<X%O4'W63HK<6XL]#)Y,Q4@M?'CK:H&EM2M5[JVJGDSZ_)A^HK
MU5_(\#VMHL6I'GKLX834)(98XK4VL*5_S-DL3<66;I+6VRV0+1W2[9>&!O$+
M+0<O^D/C,%4@QF6BKR0/C.:JN2I7+^#QQCR%K,_T:(XT1.6YZ.-%Z?,F2EAW
M? HT-)IZ+&V'\=9#M18UF=WE+6R?37[*RUEY0:ZAN!<IHH\SK(\T,/W8Z6KA
MK-(@HUFV>IHF71+Q[,3[O WZV-#>PE.2O&;4N3F56A9T]/J"='GA::NUJ0X-
M&G8P%N@6FG,"%XAT=2ADO*_B/S'6S-Q,%4Y)QTLD%^*K9_,GS V+GK8K)1X[
M,1X2FOBA9BQ<,>42#Y16&ABURED0WV%\JME<F?@KQ/L&>NNW5&;ZSS6!&/YP
M:;/=\4U%NI#R@=5' P6,#N]"@;8&"O\ FK,\Y2'2M5BC)$K991@*..JXB..*
M.Z8S<MM\Y;@9PQCJAO66A&I4@+H-@(()+-J O/?C1S3S=EO$6S;R-KELVQRU
M@8"U+ Y.K7,,=O./&!!/S/=D$H:63>_I)5U*!8HRC&1Z08#8V7>KZB9M<$-M
M?K9:H[;0\.WP.5+UU-C^8;<JG%! \R&6$&E(P9>$?87Z9$,*]SM$_)6.B.%K
MVT<\B,4(K*=LYCTW",V82X1GFC#$G'D;!)U=J=0[78R! 6W<:2^5;[Y:5=<8
MMMF,;V1C<@D+V(J]"RR*B<R@B=JHIB2;T=1-!"*TDSHG2*[H,A<UD?(\HW64
MU/4W/2^AUV< U_/=V[-T&YY?U2@QJ_F9NB\^#*F]/M]X)5Z3FF:#37W15@-9
M7U7G:O3.MHY<K11,9WVR,RPQ[VCE@#M%-"SG9LQ@95$1*3.>FNTJC,R;=$4.
M6MQ+CZX%2.)KUH01V:^2:"&U2O00@SK/S<\<KM;2.Q3A'I#]17FCBCL&36R&
MWY]Y UF^\=IW];XZ05)V<N"N>W@6U@@%,?Q;L3W$FPKY(3R'C?11F#H' 16R
MH5.,6IJQ"2A&XJJ5%](98K.H@.NZS$=09H1H-*BZ'4@Z]^P(T[ZA5S#?S=B+
M'1S6<5M^4E93%B[:$.M&\06WYF0,NFX%0%.I#;M%*M+>3XW1Z'+5)'5-7RK=
MUHOYOOTJLMX];P,X+.YO":.RWUG:NG\TLC':97\FI:5.@RSCK5FJAMAZ:7-W
M,)$C!U=7ILYZ2RQGU5U:PA!9G41@ 4WT??H5?0;""V]3IK%<I+:6%#;>G.B]
M:3;%C["LL<=>4SL_].H=\/1WI+%N<2APAB<$Z>;<<MZ=;=!M<=?:;)Z:]O.,
M]--@F#Y;V&*DTN/N=31KOL)4#$>>=4P*XM+C29QT;S*REI!ZU:JLK]*%7Y^*
MOJJI)&(PZJZJLT0T,L)*NJMTW;\XG4 *WM+:ZDJ=Q)I/#:DG:*1X)7DIV@"*
MUX1R0R2QFQ H.?3:[O)'H61$5=B+*JQA4:_.JWO=]Q_&Z/+=:Y-#EM)@*;3T
M(NFX+U"WT8]+HJ*"\KQ;>TM/+W0F3V(XA\<$ZS6]K'!(SY Y4XT,*KBD,"S.
MKQ2[ED96V3Q*I96*DJ!44 :CMZH^@<*JTN1DIP/#:IB*6NDD8EHVY)0DJ!U#
MN^8D8L P!U=]-- Q '&9+PT]?W/_ !2]515_=LX9ZJB>B*O[,,OZJB*JJB>O
M\2>J^G]M?X_C9G'*;_;M_;-^$\4'\AZ3";3S9[EC.B\-[1VG/S>+OB->0B\F
MSV>O(*6SGT/XC_/6E7DM[?TL@%A#5]#MK?)&UJ/-K-)3 7HQ8A50.V<X-?5'
M]LW?[B?BXD2<YSH@H^UC\7?/4/1&]!.ZG'I1L7R];4#=%;H+I0MR+$5J2:>:
M*HVM:#=5U-9U5A1/>/\ 1V=98U\Q(LQQ37\&GWM.(>;&8V8.2O=PG\19!8ZC
M/45-ZXOB4I>:J:+FNMY037T=H0;-:QA:+)]#Z-+=!V!UB)#IM_I]CGH*'4$
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M3_[Q5'_%?2['J^I7];[7\XT_6[Z>K^=^_?MV]O;SXL^2L?\ .?GK)_-?HO\
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M"3G!^7Q^/W/R]_%_?@XIQH:T/_B9G^^#5_THN/CE[FK]4>:_?&S_  AX]P_
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MAHVD9TYZGKW5%_+T6Z55KLM6P+;25Z\E>SMMU:= \@=9U'QTIR==QT25_8;
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MHQ5V/H9)4(KEAJQ;UB58L=UMCKP3EI)T:7T69D=*]PATFL1(\,0.:4+*\TT
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ML#J-\4CQM[U8CV\9JOW.?%W^X=@/^!T_]K\2_P!-M_U^3Z^.7?S/X;]KJ_\
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M.<:TZI%!!\PXR1M')@B<7+8W+<F&!<YNO*S!F@/AA.I)IA^8FH(5@-^X8D!
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MN@[@=@P([#SVJES^@;35M5MZG824])EL'64M# !O<M#FJX"JOCIKM&QG U#
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M$A*P1O2!DT\,3Y?8V26-BJ],V/Y<QL>0HR+?O,R7*SJK4JZJS+.C $BZQ )
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MIWTT_6^[V>P:]M->(/1W@C:%U;O-G@0L?CJ;NH6J33<(\A+/-X/815OEB[L
M6E&%_$ZMX[+L6CK>=>1ZS]5H1-1:V3+87Y?38I-5FOJCBG;X^SMKW([::>K]
M';S^'#=YUBNBC=#\=[[&V7'IK'?%;Y^)Z(#R?7]'R55I*@KR!V6Q*Z))G_Q6
M-NNPO:^ZVO5W+NY:+H(.>U77QLZFMJ-#>%U=6<5[$'S[>S7WZ#]C]S3X=N-1
MEO;.K4V>;5%E<O(J:JF2O*<7A=3(V:N""^GG<3$WI*M>V0:)RS1M8K7(YS4:
MJ+Z?'*^;S&/7F/+P#&Y"2P,U?B#QY:O$'F].E4-&C8F0Q!G[JK2N4U ,C:;C
M[S^&'A=S79\&/#S,2\]<IT\//X8<IY*6M<\/LO?>KC9.5:%EX+5B+Q#J)=:"
MJ3'/-'1K+9*LZ5(0XA5,_MNOZ[)F1J%25U?(>M595BITT.T-),S-18QK:VZ>
M0,<)R?E.OJ!PI+.]EE%KX(<Z&D,LBU<BT9%9K\<:TC*Y@])BL+=IR0+&EZ:H
MW2@'*K3*1?:82+%4T9]UM]8EZXC<G(4F/Y5M7)^;(\?53*KA;N)FY6Y@IY.:
MY:Y7Q_,,'IV2?QZCQDR/RI'CI*LE[/%XH!%@8%CR,@Q3E&![=HFW-P;BX>80
M$,BEADE;G]A.''!8'.L;"*IH".R%24 Q%LCYC_IZ2G&L#XEF1QBQ,E1%E,LM
M>"N,AC,CI(050Y* /K&FR,RV1RZD5AA"1TPMF=XXG 81[BO$FY'\-9,SE,NW
M*7/O)[24TV2SCDK)2P&.W9:Q;2CA6\8[&0Q$!R"R"T\N%Q-:Y<B=X'N+&)1D
M$\.^M=Y.N.O'TU[R*NFF?@H#F6?,]E;12H.%I%%<(@O8Z9XRM;/,A"3.,^<J
MQ.C6!&/;)-N4^<JV+PB>CXJ=X[%^V=LV1C=U:..HI.],=$I5@PT&P%2#JS:Z
M#G/QQ\"\[E_$RW%D^=L2UJEROR\>O1Y.N5:\D5FYGRB>C6.<;TBR1-"Y>3TI
MEE$B 11&,M(W6]"Z&?V:[8TWF0^U(*>*?IA^=]<K\V3I:W-<\O2Z\:L!\JH8
MQ]$1B!\1%:7$.9%@OLL!-E+"\L066=')+&Y\85A9.(0HP5^G\HMU!&TLL"R$
M>@;-AFA=- ^\$!B@5@QT2G@*DF;FQ8YQTLH\D+6SRJZTVN14L??DJ)MYPZXL
MC'W*<YD-58)(1)"++R1R0A44NV''=DW4_P"S1[JWI=9DLTJ<][D6LY4$W)2*
M&_)^I\L9OO7,A)<[QI:%+CZ^B!:/DXZRD@B,C81G;G6==^[#QC95-E]<GIH%
MZNZ _G#^J%Z$^Z+V=*34^H>&N'P4QLGHW1YS9^KF8\17TY2L-U&?Y-Z.0&O.
M!WX=O3,5T;3:J?2JFR'YY-UK+C;^1NAZ-P&O(V7$QYUZP=/7$P\<W2Q#FQ<?
MZQZR&C/[VKS17!.,@0: JOE:5*,4I;HAI0B\N'YN7/VVQQQ[50T+RF46Q,1T
MV0[0GHL?GKY[NVGD>+>?/""[R-B:F=_-/5RA7*05%J_F?EI#6S5N@R&;Y>MD
MA%0^H(QN)!WJ 06'Y(%=*#S-5)U74\GU=8*NJMD RW$.G5AXN?J,3H"MY86S
MP_+_ "K[3)1X[[H)HLU*9:1Z*,P.MCS=V7(+!'*%J1J20\@[>W8?(@C36,Z$
M$:@]B/>.-/7K$^Q?2&K2*.HVV.K85@BQ/UBVW)1[H^D6#QDL'U Z;G0!=;^X
MTV$V6RO+_68R:QJVZ1UYKZOF/:DIX-I)SJXZ!95->V;S<KY:/>0<C?82U^V@
MJ*>KR_.VP8P?=T5!7CYX2X5%T"[GT[:#2/R!\C\WJ1J-=#J"W?0L=3BFLRPR
M2.[PZC>6D$%K8)3"\K!0<J-DPK%M)@J".#2(3)&H0/SEQ_;[CDU!:X7?<2K<
MA94AQM..=PK?GG$CDD'2D6D]VSRLT$.BEO"WDW/YMBO+\?5_7II8+JYAM&6)
M5IIQ[M2\A/;VKIVTT&FP::>6F@T\N%=>U<:NCPR5%C*DJ&J3,3W)+%QD7ZA<
MZN9-[]3=U-[;MQV%/#/U_<_\4O545?W;.&>JHGHBK^S#+>JHBJJHBK_$BJOI
M_%ZK_'\.7&AV\S])_#Q5'<4_2;[SS[]7XCC'"^P5D?B=X@36X_:>JZ;G,5,3
M9[K\0G)+]B#H> ]N@NVWF5T^NH+MYLF>4>IL2*UL5L+<FM#.+OUH[D>LVF@^
M"?$<&LO.NXV0)XTGAAX+%A&VUM:'JGE3TJ1)+\JT4VWMGDL\$5EBO4O!?KY[
M-DL=D+=",-:1#8#,FC.+>WO/U#\?$8?QCKMDD\=CX-^!Y<,U'ELQ(*1Y0]*D
M#9F\=66-%D\_"$[P0^D%I*6DN+NBKZH>&(%M->WU0L#Z^\M1C#BO;WM]7_S7
M! _!^0,T^B()\-?"$V?6:^HW6E?8>5?3K!;C;4,U.72:4UIO@B0V2\JI,_0/
M .1K2!HZ6HCB<V&N#9"<4[>\_5_\UP0X:M\I^;4S\_S[Q1\-<C2/*0N6MS_E
MMU6O%D+A!!J(99F#^";?FO#J:JKI TD5R 4U35TXB05M8$+ <';WGZA^/C3_
M /(?7]K&\K/+=MKS?EH]S)Y']#FN@Z_LFM/K +.1:M20ZNT)X76%6P$/\#Y%
MD734I!'N=\RJ%]B>_J#PK&7_ #(5_0Z>-F@-V]H]G*6JLI;K:,##%B+B  CL
M1.2P[E5\N-6\URT5S$BSS6TD$$&HBJ0RIH5.A#O=A;73S&SL?(GA+6MUT.[4
M%;GD_*+-:XMAM>IW4M$0HID?I[)H/F\5=['HJ-7T3]'*QBN158U4V!-5S-GI
M]?$8*;HN)(NIF;C;)%\F77ETZ'L/@=!KY#B/QW*$6[IW,BF]2K[:-<;E/L.F
M3_X]S[SQ!%!:,R1\I7$>-33O^A5\S^FZ'Y_NKHPX09$E3BJ2,D'BK:V)DK7-
MD='65S'.<VO$2%,^)O2$E\!RZS'I^L<O<W?-",1G=^9W<"HAB4,"#I#$"2(D
M"Y1DZR@ 7\F!ZV@]"KZ:,6+#0Y/0@EW.A[:NY\V;4S3;==:B-3G?-T1J(B)^
MUO3_ *(B>B)_(O\ V$^' #F #08[#:#L/Z>7O_D]PFZ^,/\ [1?_ ,@K_P#>
M? UQ3R0Z9A1>D4D')\+;O?UG76!1$O7[^M;"66/3_-$'C9QFQ4D>%(V?+,D<
M+).KW(X*!&(KX#7Y2S^8MYF['\CPALQ;C>-\A=;;(B0!@KKB?73N"KE8V/<%
M!IJ9@O..+Q%6A3DKWYRM*&19$CKH&21G*[D:RVUAWU 9A[F/#,O?)O8Z9M>W
M1>._++IM6='95S;/LMX6T,^-CXF$0)-P9R,D6.1\3T3^#)&]T<C7L54^%$GA
MSGY=O4."?8P9=UZ\=&\M1KB/CI\?(\ \1<2-=*>3[COHM7R_RCV?>X@">Y'%
MN-<5XO<<F?8AC5]@Z3KMRKS !A@0(A"G?L&]TPTH%765Y4,BNC/ K*\ UI @
M(L,6,^&F:)8LO+_< -K=O=QHJZ-_2CN"J*K:Z[E15;4* *_T1\5_8>3]OFM4
MC[]C3MK]S7MIKP>-\P.I,:UC.(<]8QK4:UK>WZ)K6M:GHUK6IPA$1J(B(B(B
M(B)Z)^GPH_H?<QCRDPG^7W_^Z.+?Z(F(_L+)?X-7_>..KQZ\DNLP#=;+K>/\
M[,9;]FT=H2TWM>EKG!%RYK'C2A0?(X5:(:-&P2*5ATB@RROFDB<!$D#9IX-^
M8#.6[N6VSXI&KY*2M(#9MD&1*]9R488_5D*R+H65&W;AMT +2RKSYCZ]2J12
MN.MF$64]:%657=T"L-Y&X&,GL2-"._GPY;_N71=2RO9I/'7C-XRJ/CLZUMIW
M#2F-"L(V21,)'2?QT>C)%BEDB>B?P98I'1R->QRM^+V\-,X=-UG#G0@C6Q<\
M_(::X_S]G&4^(F.;37'7#H=1Z\'8^_[;@<,Z)>'O-D.\5^"E2V P8ILL_9;^
M28B ):Q!&R2N\<ED]S$HZ2)94<DLT5)3P3/DBJ@&#VGPRS)UW3X74Z:ZSV_+
M50/_ )W^]5'Q*CW#BA\0L:>YQMLZ^W=![-/^E[@-?@!KV X/H/)7L8L$(PW#
M.4CC#Q1P#CP=YU,,$$$+$CBAABC\=6QQ111M:R.-C6L8QJ-:B-1$^,G]#7/#
MRM8C_*+G_=_%W]$7'_M?<_PX/]KC.]^"5HKC6^/7?M#?TU9G[:S\N=]*944]
MX5I*X)T7*^*C,8-=&T&7).;)%"R9[Y:(!8Y)'PHR1L:3R:9YDQ\V*SF1Q]AH
MGGK2QI(T+.T1+5X9!L9XXG(VNH.Z-3NU&A&A+C'?3*11WXXWB2PNY4<@NH5F
MC.XKJ-24)[$]B/;Q<#S&Q0'2;/Q=YU:EF 5>^[AT_%61U?\ (0\(#4^#'F-1
M&%@J3%.,A@PY\DPWU$$T'SF,^;%)'[F*R<9!Y-]'\HX$;[P<L-+L-+T*RZ^X
M+9[>MM(=?9YW$DTHA9T^4Z5CZL6F%7=&FU6-^V= #GU65/M;TS3660I#A-)G
M947Y1P:CW'Z_^'GYC[OUAIWX:^>MLML\>;UO05=/KZKH;59DLCG:MU??=)&Y
M6/:2)!H9=?7EX^FEXQ@K/-9-X,-C7VXEB>7K;%9:B*C.*[O+MY#3V^0U'L/Q
M/Y:ZE)O@+76.L=J;#I+K171/H9ZVSQ0THMGB1>^U7DI4UMR\+1U[CM6O2*F,
M'2:Z%@0U_B"2:8;-4>@0;7#G%-?AW[=_;V_D_E^';AE\D\5[7E_0ZO?2]DV>
MC4?*2YFWSY1^PDJ;88?2]%O,U4_*TF^UK%R.-!Z'+59FMNH=#L*M,W1.&Z#%
M5S7U)='!K_P^'U >X??[<7 ^#BG&H[^.5_7TYG_!-Y+_ )X/)+XT1XT?HG+G
M]IE?]+'<>IW_ )-S^HO%_P#=7(W\#S;QA5V&7365L0'UOT#X9C)&3.%:;$K+
M&DM\^8R09TPZ/7[?=&/&<LJ-A-8+/+&3#%*+/IW'7O0)FEZ75#+&I42&)@8K
M->W&0X5]!U:T:N-NK1%U5D8JZ^B7-G+2\T8^*EZ9Z$\,MN1)6K+<C9+^&RN!
MMI)7:6$.?0,Q;>LQE"PW4K3RQV88Y*L\/H\"S31S?7V+73MK65=7,@YL24\;
MSIB3BA'!6X1;SK 9E4*2^8QPLBU$+Y1)1RB@I%%/*FD5Z4.BF8SSKNB;T@B)
M4BC<25Y(Q%"YGD0+&' G8"17CCE#3S!R,G,4<WIN0!G7'+C<;,(+D1Q,3W9K
M%ZS5>EE:5MKE^LF+JV'EN-6<XJ%Y*DM>S:IRG@@L00@H</O^2(/"+%\QROD^
M5!&V*/WO7]7O]C$]SE_5R^JK^J_#7([22/(VFZ1V=M  -S,6.@'8#4G0#L!V
MXF]6O'4K5ZL6[I5H(J\6]B[].&-8TWN>[MM4;F/=CJ3W/"UPO_D>T_W]=._S
MDZSX<<Q_5</[UX/_ %+C^(KX>?J?O?W[^)O_ -<GFSCZLLJ\W2!Z."Q:-,'
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M1].C&_,25LBE+*JL<QT*-<U\DPK8Q\)6V5KRH+M\!6NUV;=LI%B6&/0$'4:
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M0_)!#%UGTZ^35*#>)@:R]6!86 #RWK=+ (5'C0S@T/N/U?6.W?0_<T[CX\7
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M NYWQ)Q%]+E8 X/-_P EYBY]1 &VQFS<(\??'32WT->]ATM.QCK",-[2GCI
MY'J<&I]P_P $?BX^P/%?PWM+JOSE9MN@V.AMJA-!5T('F[Y,F75E0JZ5B7=?
M5C]\D.,J%?#,Q+(>"0)712M^=ZQN1#@U/N'N^U'G[O+@Q_<2\=__ (%W+_C;
M>6G_ &W?!P:GX?4/Q<:UOXL'B[QW+^9M?0U@6_(KF^,7([=OYA[9VW7'L-L.
MJ^1817R[C5]#NK>,1T%0#\JM8<VM&F:24*)"4>?,3J7Q/M2UI,+TUK-O3(:^
MD4ZEO3::>FPVH)C'YG=LV[NV[7:NGH#]A!@Z69J>))MSY>$U['*@C^2N8,_@
M@PECYB+==<'DL<MDCIKTS9$IA!<1%!))NQNG<)XW6#N+LA;BO%:^*-Q)W3^A
MB#MDGD;##&Z:?8QQH^:9[(HF*[W22/:QB*YR(NK4R%V1MD=>C(Y!(5,+BG8A
M023M6B3H "2=.P!)[<=TV>4^7:<1GMY7F>K &1#-9\1>>((@\CB.-3)+S,J!
MI'9412=6=@J@D@<>,_C/#*N22*SD-KI81HS9HC^L;T.2(.8E@41<C"-I&Y@T
MIDC!(YW(D3R7L@:]97(Q;DNY"4 Q5*<@+% 4P>,<%PN\J"M @L$!8J.X4;B-
M._&"SRYRI2=X[F=Y@J/'"EB1+/B7SK Z5WF%=)W67FA"L+V&6!)6 1IF$08N
M0O$O^[URG_S1H_\ *-TG_2[XQ?*EG^M8[_,^)_W+A=^8G#?V;S=_]T#GS_Y2
M<-KQZ\3."Z3F,-O=8^V-L9MWV$64E>A]+'62&K[!NZL)'1B[""%7Q A#1/F6
M/YQ#V.()DF)EEF?(K5MR\!,&/8MC\6Q+8K&,=6QM1CW:H2%&NBJ-%10$0*J@
M#G^AC6@;,P09KF^"&'FSG2*.*#GCG*&-4CYNS: [8\ZH:1]-\TS RV)FDGG>
M2:221F]+XB>+L%@)4SY:>&T/B(G K9>J]+CL#8!$:I<P@;]TTDF(5'L4B2&-
M[(4>U9'-]R>N 6)BC2"ICRBD!G&'QA12WVH9A2T!;0Z D$^SA6T6R:.NW,W-
MZSRJ[Q0MX@\YK-*D>G4:.,\PAW5-1O95(74;B-1QYT\4/%%3AZM*%%LRR#A!
M:Y.N='4XDJLB819##B?GSZB8BN@ECF.ACC=()%(R0AL;'M<MW6GVE_0J.P!6
M+_(N-VA7)5&+>A: .P(4DZ,00-2.+-J=5(/S4\V=:1Y8TA_HA\X]5W@4/,B1
M_FAWL\*,KRJ 3&K!G !!X!.Y>(GC]1\4[#=U>,M1K.GY;T"TKB5Z)TPA!SZ_
M)VY8DZP%;&8:=(B(8Y%A(AE@D]OLEBDC<YJJ\5:8Y3&CT?'KK?IC<F+QJ.-;
M$8U5TJ*Z,/-61E93H5((!XC_ #O3F')?-Y;.<W2J.5\^3%8YVYPLP2 8FV3'
M/7L9R6"Q"X]62">.2&5"T<B.C,IS._NB<4_^!]9_XQ_D;_VK?$Q],G_^@_Y+
M6_F>.9_D2A_]/?YVRO\ OO$&OC9XW)]^];W>I^56^_4>OE+WW_W6V((IZOOO
M^^]_W':@**;[K#Z=/I$4GU^2BO\ B[TJSZOJQ^O]I^=*_K=]/5^9];OV[:]^
MW&/Y*Q?SGSMKYD:S?TYR?S0V[M9/S]Z@V^MZVGJ]_+B1B\5."SF$UT)/3IK
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MJN:URM5?15:U?3U1/AVP)/IDO<_U,_M/]=AX@_B8B# U-$4?TW@\E _]CO\
MN'&8#6Z0NKZ3I\=IK'APU)U&]\[\M7&](K+4(6CXXW:<O=Y 0["W)\A^7!68
M%F3+AS86Y')W^MJJ.KL21D !&O#C=B<<L#R]O8@]O?[/8?Y![/=K^I%F<6U_
M1JOIOCY8[NAI]AE!Y&T7E)+VBUN.NSZMQ5(4NK\C:_82]0O)N1[2DP5]K30=
M;@:FHU-1C]!C<M<7T9YP#W:'3S[GL-.^OVOQ^[KP.4=%'HIN4\M#=D"+2AX/
MW'CV>PKZGRLNB\!S[!Z@O%;SG6D;6^7-P!9;,[7\AM*CG^H#/UM^?8<CBLL1
MMH!,UF;%QP:@>SST/ZWZ1IZO;S\AH./.4-^0Z#E_;;)N&RF0VG%M/V'/=.6K
M\@V,!&/YOVCL.H/TXM1Y@E;']L,.'Z'V&VGZ;+064P5AM$SX?3(M#;Y2K><'
M;33N>_EJ"?8.QV_0.Q^]P7<ZS&V!Z)X\Z+(Y?F"V/09]FN)WXTNKZ)C@]34.
M\@MCJ3^@,SOG-MHM9J!S-IUJ>?H;J#<@UNAZN!GB=@!HK"&II3BO;OKK["1K
MW]GEZO;V#M[O=IQJR ^*&ZML4'JK3IV" J;/+P:&Q@(P%^3$'7&U3;(N*>1N
MX8I$8XTLC)7-@:LK6.5(D]WM^.8LS@L=+S!E91)D18DS-Z0=*:LH$SW96'3W
M5RR@.?4U8D=M23WX]N_#?QCYRQOA'R%C'Q_)LN'H>'/*U!O3J>9E>3&U>6:-
M<^F"+)I%(SU8SZ0(XEC<E]D:J0H2\OC1%5<TUVLL>@,J*7+S,&T-"3D-I+IR
MRR\UF+RM%1H'8S8K0@W*'YJ<-\EP]M15R2#V4]/]!;PAJ3@TER%95L22SR#=
M7F$.)]'C5+%H.R*V*585%IK+2!(E$TQZ@65FB)9AXO6J/*N7DDP=&GC*K;,K
M2;,<_G*W99L5A'K)8L0\[2S9"9L)7PT%26Q?D?'8Z,U&EHQ178T8F2\1[B7<
M;_,9SIN9;=YV#+G:>:7#;"6D?)?0VPM8)5-+Z9.)\ZM&SD@IL=<$,%7I]-71
MS/)'-$!07,%5EIT'M376A_/$=4+\G).%1UDE::2.@DLG5DG+AIY))'8O(>S*
MSRSE[QCS^/S_ #/#A,1RS%D'.+MYHR3<XV<<TD]>6G2BH5+G,MBE4]#J8M*I
MAQM2K6K0QP5(^\,D,%H_'3E_7N8ZWJ^<J-CS>R?*+S^T+,L<7IXVJI0^I'@A
M&@&W#5C2)H<CI7RS2_-65GL;$D;O>Y5*V-Q^+JPJMZ1&M79 6FKA@2M16!TK
M@:>J--!J.^I/;367.7,W-_.'/66REL\MT[$>"Y=IF.O0R<D+1Q3YR6-AU,J'
M5]TT@?5F4@)M"D-N,(P-4;V2X$C+Q0^RD*D@,T,%/TP'-S:>MS//KTVM$!#[
M#$R#1RX=,2MA9Q9\82WS(Q.=EN3HFWE.]U,L2T$;;8-<*"(B]1I1"\UF-79F
MI'6+TGTC:AE+)*1*(U^;DXUTL5R7F*Q&)<<F2,A62VE;-14VO0TL3:DA2*/F
M-0MPXOY,,TZTTCL4E:DUF519K%7 :F.&RH09C\O]?8]51SW6S][H8)]W367)
M,A6W-Y9IY W==L6U-IH.94P XAFI)S1XA<)M53F46F^B6/$VR1PLNU:9[(*T
M1%>1+TSI&AQL;5PZ16Y&8K"LJNI5Y%EBU8X[T:SU(FEI=6?/ ZS_ "I<1\K6
MFY?QT%FU/^:ZU#D1!8MX2M$D<EYZ4T<BRP5I*EWI6/UTW<:C9\./EO.43SP=
M5)0%D>0U\<32I>4]1B5Y:.W+WRCH*\I$CA?#)]0Z"195CCDBE>O#J*I=YF@K
M0"S#))5MZ22O%*@"QASJB1Q,2=N@.\::ZZ'RX8_'*;.TN25LW)\3/#'FL?\
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M7$CN=-9YN"O?6CB2R$O-5$,A(G:<0((I >>!0<@9T5Q?R^H]:1(I,<3X9?4
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M?US'AC_/KO?^:#Y1?#YRO^F$O[DD_A8.(!XL?J:K?OQ5_BE_C*;V3^2'JO\
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M/5)N:1]U9?6T]967S4@3=;SSMMS:W='4>8N)M+K-/#9HJBOXIDC+.B?8(5]
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MZ4TPRK.I-41MK^QFL[+#UT$=DXJ^VAL45X'SL((&FODLXKNIIEFI@"QK TP
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MMSYR298K4F1E,V1QR8>$VYIYN9GKWO05;#Q1PPSVK,<R]$5#:AO)&[NI57=
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M@C7S/\@TDHZ2N.(J["XN&+W3W5E4#9B%5QE@:D @IPQ D\S"(9(VG!J?</\
M!'XN/E/&#PC6S2E39:1;EU]895M2GFAY!K9NT]2*TZTSB )W3ZI;ZM">PRPI
MTB^X!BO:00/'$Y'J<&I^'^"/Q<2-'XD^'&G9329J^VNA9HJZXN,^^C\P_(RV
M9>U&>L0*>_M*9P'<"$LZZCMK6LJ[@X)9QJRQL0 C98"3!XI#@U/P^H?BX*OW
M#_&__P V=?\ ^-%Y1?\ ;)\'!J?A]0_%QBL\@O!3QDM?,3<T=SC=?>U]3XT^
M.]K7)H.U]SOS1#+SJ/E:':+%:W/23K3Z4B#/52,KW&NKQ98)B0Q8"#["4J)<
MT!":6Z*"7M8TZU>"?;WA^UZT;[=?;MTW:#770:;M\(+E^M'GQ2R>6QP=\9U!
MB\MD<6)2JW]IF&/M5A.4U;IF4.8][[-N]M0&[\#?"/- /M='AHZ"KBE'@DLK
MOLO5ZH".<J9@XL+S#NC0#LE)(DC@'C=(CYIGLBC1SW-:L55(V.BTZ3'OV7'T
MR>W<]A7U[#N>-ROF<S&I>3FCFF-00"S\V\PJH).@!9LH!J20!W[DZ#CPW7A#
MX(YMI[M%EJVA;5"5Y]HZZ[AT^K;6@VQD]=5&GJ=TJ! Q+.P%) KR2%CA-,&G
M%&?)/#(QM5C1M-M*FVI(&W'4SJ0 2!I7[D @D>P$$\6OF\O'N,G-7,\84*S;
M^;N84VJ[%$9MV5&@9@54G0,P(&I!'!)_K=_B!_<LLO\ *IV/_M ^+=L7]BT?
M\@I?S'&3Y5SO_.7FO_M7S'_WIQKV:KFV<RW0NO9G.'[NDH,]W/NU'2U%9U/I
MX@5?5U78MN""-###KVHJQCP1I+/)[R2YOF%%S3E3332:VYHSV4IYNU6K3PQ0
M10X\1QBC0(0-CJCD M68Z;F.@UT4:*H"@ =S>!/A9R1S-X7<O9S.XR]D<MD+
MG-,EV]-S'S,DMF2/F_/0+)*(<Q&C2&.) \FP/*P,DK/([NP[)1U$18]?+L=_
M$>6R644*3LO3F%DQP)ZSR#C.VJ33,A3]97QL<V-/U>J)\,0YBS[1O*LRM%&5
M#R#&T#&A;LH=Q3VJ6/902"?9QM1_!SPEBM049,48[ME))*U-^;>9DM6(X0#-
M)!7;/"65(@09'C1EC!!8CCPBC98Z2*('H.Q,EG()#@C%[AT8B28L.&(DL6)D
M.X>Z0@4>:&<F!B++!#+%+*UK)&.7*^=YEC#-(7C5421B^*IJ%CD9D1V+4@ C
MLK*C'U696 )((".MX6^"UQXXJD%2U)-8L5(HZW.V?G>6U4BCGM5HTBYB9GL5
MH)8IK$*@R0Q2QR2*J.I,+T?*BMYYO'.O^AS-;C-2KH2NJ=-+&E1*,Y5B($*U
MLPQ4$B?P9AR898)XU=%-&^-SFJLP?,>8FS>'ADLQ-'+E<?'(HI4%+));A5@&
M2LK*2I(W*P8>8(.AXC?BAX.>'6.\-/$/(4\%9BMT.1N;;E64\Q<SRB*S5P&0
MG@D,4V9DAD"2HK&.6-XWTVR(RDJ=I7]SSA/_ )NZ5_Q@/('_ +4/C;OI4ONA
M_P FK?S7'FY\CT?_ *<_SGD_]\X'7>-GBXQNC<^WU#&X^-9=<YWDWVYK<M$@
MKSEDT:KUE$I(T"BD+5]FHK4%C>0J_*8YZ7=>QZOJ1^O]I^=*_K=]/5^9];OV
M[:]^W&+Y-Q?SOST_S'>;^F^0^9&F[67\^_-^J"?7T[#7RX]0'B[XU6MA;5-6
M7LK*UH'!LO:P#R3[H984K[&%Y->RV"'ZM(37..'8^<-ID<*DPL?+ CV-5R4-
MB< ,5B ;7:35K@-IYZ$PZ'3VZ>7%RXO&NSHDEEWCVB1%RV19HRPU4.HN$IN
M)7<!J!J->#/E7 N9\P\K_#;18\/7P6L_9^AU4C[[J74MH%]$3XC^31,K65.U
MV>@J825E#@]AT0+#H8TE@A)C@))CE?.7IGDO2*PCT]&<^K##&=>I"/MHT5M.
M_EKI\.PXU]XFX^M5Y?KR0^D;CE:Z'JW+EA=IK7"=$L3RH&U4:,%# :@$!F!S
M1]D_DAZK_-ON?Z,6GQ,^-$+YCZ1^'C#URO4^,)_,^27JC>?5'HB N5[O3$9K
MP(\X;^FNR*;'\QCES <Q'B;I<\F5-+YY03NN<G)!:6(_UDH.ED@-%)@.*Z$>
M[VCN1[=?C\>)$*N\3*&C?F<=-^(5CL_-D1L:934GX;7F$E;9U9=#QG+[=+,8
MKPDG0IO2J'A6,!V@S7PC6"V>U(AC'FTSW!G!W^'T[AK]XCZ_/X\35D;XMVS)
M1C#/Q$G@3GWT<X;/PZ?-*+W8^[RO:\A'A&%1>%S#(ZBGK?(+ITM;=+,_82&6
M57+:Z*S93"1*<&G]K]8^ON?^'PX/.8].\<N9:S)Z\9WX@.A.Q^4W^2JPKC\.
M;S=$JT Z1MQ]W>Q('GO#JE:+6U]D%7 YFA!<+34=6 -!&(1+%'.PXIH?A_A#
M\?Y:GBSG[]W$O]P_F5_];G_$(_\ <8/@X-#\/K'X^-?7AGDMSX#E62$FR?D;
M-)%!9^Z2O\/_ "SM0W_,O+.5JP6%7Q,P E/:]$<X<F5&2(^)ZME8]C=4Y?'6
MI<G>D3T;:]F1EWWJ,;:$_KDDLJZGX,H(]HX[.Y+YCQE;E/EVO*F7,D.(I1N8
M>7N8+,19(5!Z=BOBY8)DU':2&1XV'=6([\=E_P!+Y3>]"J.CMK_+BJMZ<6J@
M@"!\+?*>6LF(HZ[HU15FS1V/CD<7\V&MZKLAYXHBXQR7SUD[HVOKO]DITIW4
M@:#9197+$L<E0#:.T#,O:X!H6KQ$'34:,-=&/#K-F<--=BO!^88Y8EC 1.5^
M83&QACO11L0^#=M0F1M!@& 8F,Z Q^L/4FNY95Z#+::QF\QM%;9?6ZK;?5VG
MA5Y.0$7E[J\X?E2I+TBI\:JZ4H0&DL/H:T(=PHX =7GZP%@M/3#UK[WK7&CD
MC6*@BO''%HN2HD(D;B0; UPZ$L-6/?4L['5F)&&+)X:.:O.\_,DTE>S8M[I.
M5\^&FFLP/78S-'@4+(D3[8T!58UCA1-L42Q\3W>O)7G]CPSM%>/DO(V*<_D_
M10H9;#P_\M*D".4K'W$$<AUK:\3"JZP-CWM<3861@@ 4*/),)@'CDE9CJ8RV
MMJLQ]%T6Q"QTR%!CH)%)T5;)9CH.P4$D]@">,V8YGQ<F(RL:QYD-)CKR*7Y:
MYCC3<]:51ODDQ*1QKJ?6>1E1!JS,%!(3N=\X_'0?/T8\MQU%)8*>LAD1GC?Y
M(RL22(*!CT;+%R5\4C4<U4;)&]\;T]',<YJHJLTD<?4?\_8C[=O/-8@'S/F#
M=!!^![CC=%7Y4-6L1REXA,#!"0R^&W/[*1TUT*LO+95E/F&4D$=P2.%[-Y'^
M,:[70;D+H'=:VRT =H+*(/XT=UG "?>4^"H[<@1A_!RR%>2#S/(K%&401",0
M-82QL5E@Z*#,)DZ,<)MX1EC*D$YO&!B$>9U!VY$#LUB7N "00/UNI;FPV1].
MLWTY;\38I;,<R%%\-.=VCC-B#'5YGC$G*3MJT>*I$!V=5=)" 1+M7QX?O_BO
MA;VDO0MSW6REH,IH<E7A6/C?Y ($P'3Z8'56;W-"X>(0]![&O@AIAW$.AK '
MSB^A**.\:LTZS(Z&WA%#RQRL5S6*W:QQM$H!;($:%6)<Z:LP![:'6RA@KU"Q
M7L)RSXF2FM3LTHHY/#7GH1B.W:CN2DB/E5&.R6)5@7=MBB+)H_JE2[>>9W!-
M#!A*NF.ZJ?8N[KXWG1!1>.'D>TDJ*G\@>9VYD 44O)XW'6,@8)#:ZI#2>TN3
MU'J:<,ZU-#"GS8N)#=C"W,9(S16E5(LOBY78M4G VQQW&<Z:ZDA2%4%F(4$A
MIY^>_%RKD);'+7/%.".SAWELW^0>=J%2)5S>.8F6W=P$%:+=ILC$DJF21DBC
M#2NB-E._>[Y5_N0\H_\ B/>:G_8!\/WH4_[*M_EM+_>.-*_+M#^MY3_,6<_[
MNXK@3JN(RUO6JL4KS7!'[!4:B@O%A\&O*6:2JI=7H^DZXT.F<7XKS^UXF@ZS
MM"0";#Z^=@Q%8&2XIE;[R%'2LZQ$BF>B49?S[5[LBQH"WYZ]JQ("!H-02//L
MV&SCBEQ!)FU%U)8Y-,#E3LCFEM3,L>N)/E)<G*E]QT**=0O=E8_O?+\OI=EJ
MCV^8.LMMDW.P32WO@KY9PI35V:$-@KZ6G=2>,]3)%3-*L[6V8"4\ML-M;W!T
M+VSVACI<;U9V5$ J($W?:WJGK%B-6;=9/K: #4::@ :: :*8,I2AEGF9\Q,\
M_2!ZF RX$:Q*P5$Z>+0A-6=]K$@.[L.[MKCW_%T\AL%N_&[$U%)G>Z@%C=OS
M=E)-L_%WR8YQ5N'AP?2A7QP7G0N29>E*/60R)T54+836DX["BX0Y! 39QW/"
MUI(K4C.82#7=?4LUY3J9(CW6*5V ['UB- = 3J0#%>>\I5M8BM'$EX,N2A<]
M?%Y.JFT5KBG22S3AC+:L-$#%R-6"E58C-/L+*=O2=-C]0)Q4FFZ+=>>>5K;+
MH1MI0P9WCQ6TY<SOY6KN9NK8*%HY!$N'>(3C*VYU]72#V9@T808]R<Z;<<^C
M[I[CRT\^^GL.OY=N.QD-#BWOZQ5].\>[GH%/4;"BBMQ+/N=GU:_TO4GZ^%D<
MU1;;T<D_J4J\QZ)F^;%7@ MIAZD/>Y_,RYW-VFC'(.#77V'3V]QI\?)?HU^Y
M\.$HV/$J*#BCUYM,3S3C-A36F-M-'U,?29 7EZ]M\?J>N=1,[L+=:_KN<?5=
M<Y=F-=SB#9D5XS*2VL=6-4OYSIO@X.WN/O\ ,=]=#^QT]W8]AQ^7$^1:A"ZF
MDR4<;:KJM-N%-B[F1&%TZ#][^/9U>H^P=F(6Q[>?/7>5T='K,C]VJ%+LJQU7
MJQI+'C#U.*^[S]A\_?II^M[^SMW\O+AR<UK)).J\)=68/A('8I]-VZ?*[+4Y
M[66G0@.A970=XJ>Q56]L >N76LM(1-1<=C)_,4(-WQP2[T]6-G-6(9J\176A
MQ3V'S\AJ-P\NVGL^CX_?XTV2\CMI:HDVPML3'72 3DFMFK+Q\; G#OE)27VV
M/JYC8%>C_1O\)J+Z)^OI\<BYY<:>9\SM7)^E?+V0"]&2J!Z0,A,!TMT9('4T
MV;B2.VIUX^A?PHS/.,/@?X;1S?F,.$B\*N3TE%^KFI'.*3E''!Q=Z5Q8W;T0
M'TGI($8[]BA2!PH4QUJ[%WI\:Q2UE7(KM+72NM8K5D#,_26L9MA/9;& 2:.#
M+,HWP2P63[$,21D+606C#&1+-U<9.HAE=;$R@49EBJF L;EN$Q0I#CV=2^0>
MWO1H1!+("S;X#$68A?R3<E9^9,7%+BJ,A;F?'S9#.1Y8PIR_@;T=W(V<ES;#
M7G%?E6M@16L0Y)LG2IE(8NAE4N"(ER6?N[/2WXE4=0P7%.#7"&PV-==I'6 R
MNFE'K!P6WL[Z=K9DDD8.8("X^%(R:QQ]3"//$@R$%2*C4:P;C5K$T\T;0M4#
M6)@%5[$DIK+Z2Q3:I=))1"Q9)Q#8>16E/*7-&<M\SY^+%5N7X<SBL?C<?;BR
M,6=:+%8YGFGK8FI0&:G;#1+.9)4@M5*+7X5AL8U[^)K598<IOX?V&[!/-VB.
MBN^;0K"=@U,6VIM1.CW2UN@^1],@=T.K$:UDB3?-^8KG*Q6*U$<BS#EJ''28
M.'I>FB-;UT#J- 7W&.F6U*IMTTVZ=@?/77MQS%X[9WFM/%*ZUY.7GLORIRT"
M:D622 1+=YBZ8"S6'DZFYI-Y+;2-FT AM;&Q<^UQW<KNN@N,6-M7&2M+N80N
MC"91^PKLES:YM:T$>+=(Z'4$<Y7 ?<"V4\%6?EVG5(=G,8[6 OE)KQ"HFK3&
M$+ZJD5S((FEL*I+='O&)VG*C>6$A5RN@B(T$N;MOG+#+6HI>:0F299LHE4W(
MZF,>58XQ<T6T^-BQR2R" 1R5%D@20L]Q'6S>?SQ6M1->DT(>QE[,#E30+T7I
M%EH2=;9Q<;M*X[4R5/1;6L.QT;*+ACB3WFSB!6<6>H+^.+0VF@J#L_1&QE5Y
M.D:Q<%165!$/2U81[H%99#U;@  U*L[QG8D;*V?*VD\4D].NMWY82*03SY66
MP]N3Y#FC>TT=Z6.6F/0, 68NR+)'7@L 3S6HI6SWO*=QI)..'G77*"5;UR.,
M.,2CU\*(7)S+IOHXETU]+[AT&0E%;$C9?GN@=[_EMD:Z5>&5>$<WT?1C()3!
M= ,Y5H]/19"VHC56UT';0Z:^?$5\<LSEK7(DT=V+'"!<ICG)JBR)=RM*% ,K
MLFWUCN[:^X^PU\[L5JVT%<_HD>'L (4TA#H<V+N1#69^#)W3]S+9.$U59(3F
MFY'[HRZ ;*02:KPH:@$J_6I8G2MZ&18U-@Q,HZATC68-TQ$YG+:2KK&(0^]=
M23VV*9-G'&"6-QT"$>7FVG<G0#R\R3V_#P"[2XM<;J--=VT],EE6/N;$Z]KB
M=ZZJ&VZXBRT,@E>PS;#CB[8?E[B8ZVPF"@I ,7&/1/MQXXV5_P 8)T,,LKNZ
M;DWLSKUM@GZ#2[5UF $PJZ[6("+#ZA<#U>+EF+ $)[?(MW\]NO93VU[=^^OD
M//AX8IG41.?5<>:=R\6C*J2[(6.9=%>E2.N7E6QQA-T!KKP"U,/.-*.*L!+>
MQ&*))EFB*EC>B_"V&O9$"]-JX0J6 .^0^N2Q)=9I%8LQ+%E=@2=03Q:;(#;2
MA/< D'\&H&GU#3W<;<'AGZ_N?^*7KZ>O[MG#/7T_B]?V89;U]/7U7T]?XO5?
MC2_%S>9^D_AXH3Y$9WF6[\U>Z8GJ?-^T=#H9?%WQ)O!(.28$W:L L2KK\2;G
M"DW<PM99I3G 5W1[&^R)4;13A-125=T&2J4TXI)Q=WVC3]DWM ]B>_S\N/:1
MA^'S6MCHX>3^=86LL.@F].36"\)7[V'JR>BU_51)1U)P1%9/54^XJPKBMH;.
MML*=70K!8AV$,LS)#BG?WCRT^V'NT]_GIVXC2.?\L)"^ADS7XB7RQ:2@SE#*
MO"Z24K+TM-S'9<H.KZ(HCDTTT8VHH.D=%MM#%8NLH_S5MK>^HVT<X>?CI3@[
M_#X]QW[Z^_3ZN)369#D6VOI;O1<]\^#86]9I.QU5"G!0(Z;-Z?.9; 8JCBS:
MMYI]XJ&U.7YMGJ:KTL%NO0ZH(G215FV#;J;Y#S@[CW>6GF/+O\?CK].G#=\?
M=ES;QMP2<[P?$_,@VA::&;$MYX^V4$@Z@9C.9$08,#)Y?*Y\$=M3EJR4Q0J0
M<FWNYK;1W9-E?W5K9%G%-#\/\(?CXU#?*'J8ECY=>75HF(Z>$VT\B]^>P&RP
M=R%: MG2K]!;0"5GS@#XO;_5Q)D26+U;[D_A)\=5^$V26KR;6B-+)3D7;[=2
MK2EGB.Z;R$B#:6'ZX>8]O&H.<ZAESDCBQ4CUKUQMEL)&XT0^:GOI[CY'BMVE
MNZ74.#<;FNIB_30FA3(#CRV)855HHBVE09]6 9[0K#Z$3YTH2AV420(@AXR/
ME22=WK-:_P!/JT.8(]BRQ-T<;(.M7GZ?I%:7J12:13=*/>T72G79\U-'JVZ/
M5HI:V_99QC;BCC?:4].6+=TY4VNGKIO?0/OC.X[D;0:#QT-(>39&2@]HC+LX
MD9-/%C1$=#+(F5^O)'CDS<D#9K1^.I)#&RQ2C1/C)6N' 0E[?A'*E:62>4P\
MT++.NC.N,B!5F&/ZTB*:3('L'&56E#(T:E7Z"0B1AQG1I46-!)B"D9U"FW)H
M0/2NFK$6 VD7I<P30ACJO4,FT<,I.D"HB(N1Z*JHB(JKB[7U7T_LKZ1HGJO\
M:^B(G]I$3]/A\^6T_:W-'_\ 1=C^0<-WH#?V70_RN/CNX7?6Q=7ORJ_GO3+,
M8CJ>KE;/7XNS)CC<L%2CAYE;Z?*)B5O]5@<B/8CFJO\ X2?$%I<T8VE:S<5F
M/(1RMF[DO3] LLRJ\=?:'"H0K]NZ$ZCMKY\3$\O9*[5QLM9()8ACX8^H+$05
MF1Y=Q4E@2O?3730G7A@ZRALMA&+%8<W[:&V"*Q#G^W88EBV%1<#()<4QBF!'
M>T&R@9$V>8) [.%86."L1'+(K[KW,F OJBROE8PJRQOTL?.#+!83ISUY#)7D
MTCF4*&:+IS+M'3E35MV6OR[G:Q8I7K,248;[,9V21MNCD7;*GKH2= ^Y#KZR
M-VT%[/G5E:DV9<^2\AHI[B%P]@L&%KFQD0EPY2"[AD@ES,P\@VCBQE)'=AS1
M2!3P(<((,&'8%CRHILOR_.\SM<SP:PI24KCAHRNM)+"E&Q[(4MKCZXL1LIB9
M1(B)''+(C9X\)G8UC5:5$B(ZIK9.H*FPT1!%H$-";,O2<$."5+,S(I#5;::5
MK6M7EW77JC417NP5FCG*B>BN<C&L8CG+^J^UK6^J_P %J)Z(CV.<\+I_\\#\
M3CK6I^)TB ^H ?#AO/*F:))Z$(U.NGI,/\KD_62?CPE^:]1K\Q9]:KKC)]$@
M.?UBZ*D%9BK::45LV<R;60%I&QR0%(D?S'P.7WMCDB>OZ/3X1X'*I8.9L5Z.
M4GAGS5ATDBH3,-!5I(0W8%7!0ZJ0" 03Y\6Y2FU5J=>S8J0S1485>-["!@3+
M,P/;4$$$:$'W\$&PWF)VD0D5C1]<"8/%9!$?;,0=&MC3W0J!7-(:IM8=[0+,
M=L39Y@4"M('0QO!L1'?,5[C>VWPBRX[/QA1+&W1Q[ RP3ILGKR=2.32.90H9
MH^G,NT&.6/OJDKS+6+%+>.;=L8;[&NQXVW1R+M9?60ZD!MR'4[D;MH*VUGB+
M@NY.(7N\)-] \:R<-APVLGA+'QX=S&L$V3F@=#?@X:B!N!)8Y Y0T/@%'$98
ME?,1S4UG>>1ZW,P:RI24KCHM&#I1CG&UJC+I9CQ]>.="#&T9E5$02OKFCN+&
ML:B?%$1$%-UB0D%38:/N)1WB:S*\;#1@VPDML71LQ]PSD<;&+F>ER*QC6+(_
M!V[7O5K417N2(>.-'.]/<Y(XV,155&,:WT:CR+\@ 'R7FCH -3C903H--2%
M )^  ]P [<(3'$23Z;1&I)T%E=!K[.^I[?$D^\GC9B_ 8NA]#XJ]JN!1;$,<
MWRTZ(^,>U"FKCXT9S7CD2H0$0B30.5S%<U'HBN8K7I_!<B_'*//SF3G#..8Y
M82UB ]*>,Q3)^<JPT>-NZD@;@#YJ0?;QMK  ##T KI(!$P#QL'1OGI>ZL.Q
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MTG,Z*I&H\U2X:RCZ/O*C?DRTM,X&VT.8$JK:J_J->-KS6V,TZ&V9)!#2$+.
MGMH!H//S/W_9][BW?P<4XQ2=U_KVNE?X+'C#_G:\Q_B)<T>=+Z+'X8.-S^$O
MZ'GO[?&_Z-[A,]BY7%UK-B4+[N2@F!,N9X#FUT-M"Z#1X?7\ZNX"*^<@5D[W
M9G;W<E7(XA(0;V*JL2Q;0$0JHL(U#+T6+;=VH7MJ1W61)%.HU_71KK[UU ()
M!&UKE46XQ'O,94N0VT.-)8)JS@J2-?FIY"G?19 C,'4-&P3L^':+4E:Z87<T
M=3!L<)5<^M(I,*8<2505VDL;$D4^QAW%861'<9:WL<=8$!/K+L> AMS2W=39
M00JR])U0)\V3LD,@^<[!B@&H!0C4, XUW+J-I4CC%/2DF,Q6>-!- E=@8&8F
M-969E9A.A(DB=X6*['&[J1R(P'%BH(UA@AB=\KUBBCC7Y$2P0>K&(U?DP+)*
ML,7JG]3B6618V>C%D?Z>Y4W#@.P [=A[!H/N#V#X<:K/2/Y7N\?X1/D/_GMW
MOQI[G+]45[^Y8[_5=+CTU^QL_P"1CE+]T\V?_&G,7"?M,BX_3!::"R46<. 1
MJ#O#0F-Q-<%K :^='H1 YD3(MG;/,']KGE/AKDB($CA*C-:(;_2IR4VA#K(T
MA+B0H0DTE&652-K L6Q\ C;4",--JCLT;1;&R/*YN\PU.88L@:TU2&LHKM56
M=&L4*G,U.C,'ZT3)&D?->3:U!M9K+PT-D]:.&S'<C8N?,@TP>GBO;.,QIMJ7
M:LCDGB9;L-GD>$(0R(J,9PU<&@-4UA@I[I:^IK&PN#+%0MV9LH6IR4FK0F,Q
MP) 2%8US&H$CJ60N'FDZDQ,;Q;99YMW4C81A#'R0L/,%7F&+,9!+2V\E:R2(
M\T:Y1;D\CU*TZ0VHZS5Z%7T3&JMNK>:2CC,>(VK6:_I+2'2OY.M]_O*U7_(1
M_P 7<O?I_@_WXQG\=@X3^+O_ "3^)_\ ]3SG7_X;R?&X;\;PX\HN*Q$^.3G!
M=@KA-A T3K-/HZ&:*SRL5E]EK=)JNI[N9WK'=@?<[ #6]=T9-:4J 0CU%=GZ
MY0WGBVEU<*?2.\)*=XBI[-IN*K%'[CH"D*@COJ2QUT(56HXSM<43C2XDL9WP
MAMB2S6[!\I%WLLUR4JWJZ(L:Z;@[NR\3@KS.:K6:O0:2JT9NEJ,=2#?09@K/
M24U7DA+)8JF%[]/=CEU<M[>Z30C?/#9=#EZ$X,^\N*\2E'J\;NK*JJI4*78Z
ML&U+D:G[5=#M55.AVD*"%!+%E->M)%---)*DIE2!!MA,1185;1 >JX9#))+(
M-5W@R,K2.H0*:57]<IX8?S\;S_F@>4GP]\M_U?)^Y9/X6'B >*OZFZW[[UOX
MK>XR?=D_DAZK_-ON?Z,6GQ...>U\Q](_#Q1/@?0/)3'\]Y[*9@[/:X;1 \4R
M'/H08X#ORWETY[RUAU^7746+JK.GIR/NFYLSM+J-GKJV4G- @#MR4I(M5?G!
M_P ?^ \_RU/L'$]K>G>5Z8O9D05&AJNE'>/O+]GC,WE.4Z";+4'8;BTVL^JP
M9.D.Q?31[\BL&,P=+>Q&%TPIZ!S&CG\O")TFESAP#3M]W7W^0^(^Y_+Y<+W9
M=,\_!;*__(N2T%K/%%I)\]4W.!SX](3T@/J5%6OYR1<."K?=R('B,]SL\IT6
M:ZK)])N!7T\O0+(I@>#/.*^K^/0_1W&OMU]GWO;P[.)ZCRCM.MU86REM;?DL
M])T.9MAK,3-A],RH W%P%SNZTH#>;YRK9NM'2QU<SJNEU +!,RA$^FY5E;Q0
M[6S.*'3V=OQ^WV^7MU/?V>_2]GP<4XUV_'/^1?#?_0=I_P O6OQJ_*_IE=_=
M$GX>.T.2?U)<N_O33_@EX\>JT72JWLF7 K@+F?FSJRMFNEKL]'9A$H14]5_,
M,Y=I&'.<%9TM_7<<'IP!S0W'@:C2$-K;R"O..RR=$B,#DE1+JVW5M#V,.P!=
M0"&4SEB=0"B#520'<YYKJ9&!460T]B&39"'5MT=_K%G"EU>.9,<L:AEW+/,=
MD@5V@6F:VG>C^B\ZKB@+^;'.UO70-T;884G-QET@VCZ"G/217FY]R1!"9T?
MD_63W68DGB-9 &_H]X7HP\=D=*XCE(*A]D)C D#Z,5CZ@.C^>[J#3:^A\^DH
M4NC@LY5[=-&24U_2,@MIGJM"&B$UOT-E+Q$!5A%1BQE@)#;5-V5IDK-SR/\
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M=%(I&@(*'4:%2U%_Q:.+QY+QSQ=DG5NZ:?Y_:\X#]!L^J:#1U</S,+TB?ZR
M$QR11'Q_3?)B+;_5&#D%0I_!G=\+,<4$[[8HE/2;NJ '3>G;4>SB.<Z5FBQ=
M=O2KDNM^)=LUAY$&M>T=P4]@PTT!]Q(]O&</5V1S^D:K':++<6N:??W?G?E:
MRVW^MTV6BHN/6&VY?%WXS76,-O1 5H3RY<*P6QS4MGJ0*>(\T-M>-'<D-E'&
MC!Y>9'<>0'GWT]H/OX@M#F,,M+8;FTO?&';7<--J:<FQ"['W2[Z3J=#T&PTA
M(DS!!7#V]CU<<_E6\I>5V;AQ=)@AJG?T.*(SM03I1GG%?AW]_P!J/9]WR\B?
M8>Q/LX\556R:*_I<RRIQI>FVG+>^9VYQRZ_R2N[2H&SO4-\=VF.]&H!KA]/U
M+5=H!WEF'=XDUUKT;8\U@LLE97H/.\G/6'!V\M3[/UH^YYGRT]_\IXA]%24U
M;CL7T3;8SG(?-.K<0VW34VMQM/(9<[=5^KYCWGJ6RN=<)4E27L/69^:]/[W?
M370M*R.N_,S*@>X%T$',*L,XKV_9'77V*.^GEIW\O</O<,'ENLUX?6>$UF6&
MYB'MS<[T2?)O)Z=T/5YLTOR#T?6NL:YNQLLW;:G.:/1=*ON!=,W,1]45<T=
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MXE-HUV3YTD1&SN$2P2-89]FTF%8 YD74EO5"(TO3''$D5M78A$8'M]L4TU+
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M(2-& ^:-[TD4<HDQJB3R5L;3W+J+1C!VX]EUD]#F"Z,0"4WE0Q*L7]E62_\
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M^\ST#^\_\@_\:_%?_P!R0^-R_(MO]G!_AO\ S?'"'YHD_:V__A4/]]X4,VC
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MJF3/:Y)"65=8PETK:\-(4[T<E)U-_+_+Y,JHDA&?R 9EC$(4%EY;!UTK5PS
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M:O6,+?$<LYLTLL3L1'%&Z4F>>5L0C(JZ-KVQUC(ZYHK&N5%<B<=":D&-]&>
MO$7M6PY63<Y)!H@ EF8@(!&-0(@(]HX3S2U_2'65K'4#A6TCB(U711WZVI[
M:D^L?-O6UXW>O#+U_<^\4?7T]?W:^%^OI_%Z_LORWKZ>OZ^GK_%\<CD:$CW'
M3C9#>9^D_AXQK>8E-R_<>77;^?\ 0_(?D_ )SO&KQ.T-6=TW6XG/NODB3\3_
M  PJ4U?M)4@LV4FMZ!DKFT,KHQ[BD%%2QS=YF]A'F[L*G%P^U&@)T9O+7W)[
MO+4:_EY=]A><C(CTK4\_O%"RHKWJ>EW)/+[;R7S,G.+[)77>@>XE<]NZR6VL
M*N)NI=#:8W4ZEV6N#746AMAI*R[IBC<_8'%""?UI\@/(^P:<+BUI.$VE*M//
MY7_A_P CP,/@\/&5'Y&9$$/;B9SBN_YVVQZ)5054I=Q=X/;= "VO-K>QO]!+
M74W*L!G*<?#7IM]MU.#UO<===3V\CKYC^7_PT:$N@\=EV=G</\G/ ZUH+[R!
MYOUNR^Z>1O+!=?6LYR0EC+J,K=4.$JZRJUN^M*K*R;6OLZ:\T=E2C;7/6G9[
MZ'8T!W.C@T/N/E[O_'Z/9IY@:CO:WA'=O"?C6-LJ$3RC\0ZX_1[37;F\%R'8
MN2T>:$.TMO++64U-6":  6&NRF5&SN.#+CKJ^:W%SL-U8B,M;$]SS@()/DWW
M0?R[^?&GKY2]AY):^7WE[<U?4N<V51<>1N_LJBU V^9,K;6N(2K^G/K3A[.0
M4X*?V/\ DE"RRP2^UWLD=[5].K?"3+8JGR;6@MY/'U9A>OL8;%VM!*%:;56,
M<LBN P[@D:$=QQI[G.C=FSDDD-.U*AKUP'BKS2(2$.HW(A&H]HU[<54W6FY_
MJ5J4#Z=S=C0W&,<ANQI&K7$%N"4;2U?R2I_=?T*"S)5,>HC5^XDJM@+[?26:
M9:_AK_H_2SN# BZH/5R=4&!Y#$8[]?;(^MRGTV%<'ICYZ3YZ/N&8J5:_6$N[
M&Y$E]A&RG,>HJ;]U:75!\Q/N4RZ;OT-=8W]@A<GY.SM[NZ;T7D;R;-@TD4,O
M0*^)'$(_"S1PE$QCRN<-GR,E934DGTTRROT,\JC5A$)$I[;9FQT]FU:&;Y<,
MDX1E0YF%07!Q+*LCJC$I3?'3M5;8^XW7;IUW5VF5PQVXXH83C\KMB+ L*$AT
M0^G E%+#UIUM1B8;@ ( -TBE51WIU/F7HGKT;!(OHGJB;#/JB+_91%6P151%
M_B543U_C]$_B^)5^:# ^W-XC_.5/^>'#-\EY+]K[W^26/YOA&8OHO/H#NANG
MW6.A:3TC1E#K+IZ2-"!I8*Q(R(5><B2P2*QR,E9[HWJUR-<OHOHV<NYW!QKF
M>IF<4F_/9"1-^1J+O1EK[77=,-R-H=&&H.AT/;B_-8S)/)0*8^\X7&55;;4L
M-M8&753I&=&&HU![C4:CCYW&DPFGAKX@^C\]C^G<<QRF:VG:@,QHJCC:"N^2
M3,KKNAD]9ZIC_IF.?/,OUPCD:]RC,W\-DD@6+/X)=AF4];)U!T'FB,<=^OMD
M<F[1;YRJ#TP6=_GXB Q3X^KD:C2L^*R9WB,_-TISU%C?<]:7<BCT>ROJ3'U]
M H^;<=@%7TF5NKTN[DZ'RB5A/U4A-45LZZ02W0^BH:J*OM)$9ZJ#F;"I)O*2
M3Z<AQ!A:)]-53H080T76QEN[+<;.\LNLG4,E67+0-%:$U*E66O98+WAQT]:6
M]38QR%YIM.E4??.[A6%RO76N,7F1MV!)DHRJ\!BL6)FEA&O:2W',E>P-R;8T
M)WS+MC5R@=$YT&"$)+TG&%R"B##2%S:NA^<4^"%D3R)?^Z+OZI.YJR/_ (3O
MX3E_A+_'\2V'/8&*&*)N8,3*T<4<;2ODZ6^1D4*9&^?/K.1N;N>Y/<\,,F+R
MCR2.,5?0.[.$6E9VH&8D*OS0[*#H.P[#RX!>?]#P Q?15(W./@0GHML2,LVF
MI8D(&?2YYC"(%>:U)8'OCD8V6/W1N?&]J.56.1&7!Y[!I-GR^9Q2"3/69(RV
M1IJ'0TL>H=-9AN0LK ,-02I&NH/#CD\7DV3%[<=>;;BX%;;4L':PGLDJVD9T
M8 @D'0@$'3N./5N-'A-/#7Q!]'Y['].XYCOK-;3M0&8T11Q=!7?))F5UW0R^
MI%6QWTS7/FF_V<(Y&O=DS-_#9)($BS^"789E)FR=0=!YHC''?K[9'UNT6^<K
M ],%G?Y^$@$V8ZKD:;2,^*R9W",_-TI_G%C?<]:75%^8L#U9CZ^@5?FW&H ;
M>39.XT!E[+T#E!$1+I)9ZDS9USQ+6,BJS%<RHM)$C?ZUU*91%WM7)].2LMC8
MJWZ2O>T@PIJN/C+5^6ZV<Y9D5R6:I-EH&AM*]7'0"K:;:WYWIS4I;U8B.7?8
ML$=*N1)+*NKK=@K)77&9E2F@69*$HDA*S6Y3/"-1I+8CL1UYAN32*+[>4%$1
MOU?0>>5]97 3=+QATP0(@DILVKHOG&2C#QPR%2^MD]?F$/8LLGJ]Z^YZ^KG+
M^JRFMG,%!7@A?F'$S/##%$\SY.EOE:-%1I7UL$[I""[:DG4GN?/ADFQF4EFE
MD7$WXUDD=UC6E9VHKL6"+\T.R@[1V'8>7&W%_J>ZRKK;PUZQ851X5F 1Y7](
M<.=7E0&B3M;SWD3'+"2-))#*C7M<QRL>Y$<U6K^J*GQQOXESP6N>N89ZTT5B
M"2Q5,<T$B2Q2 8ZFI*21LR, RLI*L=&!![@CC?7*<4D/+F*BFC>*5(90\<J-
M'(A-F<@,C ,I(((! U!!\CQD+\P<96='N/%CGEW.<+3;SNG3,9;DUDD$-D/6
M:CP:\Q:,^>OF)'+&B.A$.ED$D($)@9.V-TH\T:.C=!>)&/)OH_E' MHO V@U
MNIO=WH.EZ C9:VMN!M5= YK+@K8F6&5Z/C1HP(G"DSU.791]%?#>Y%AI0.MD
MRV:DOBB$@/:><&NGE^7?7X>[V:<#)7X;7.S\QK<@3T?<!4>IJ]Y$@F=K<?20
MU5WT03FH-U8" )0FTTE-4Q\@P!F2R\U6H.>NJ\ZXC)*+_+JY@X-?H\M/J&GY
M?5Y:CAEB>&P(&@K- 'T_51%UFFM+$<ME;5BW4.8L:WO $6="O:I:TP&VKY?(
M_I!XVQA8MJ\R#'3$#RRY\N6Z.*<%7&_%X3C%]G2:C?76BRF1IND5>5RF@HLX
M.F<GZCTRXZ3ISJD[,!9T*)9Y#*/-0#DT1;*V@RH(U%)3+<:E+PXKK^'7V_E_
M+Q:KX.*<:AOX[/\ 7TY/_!-Y1_G@\C_C1'C1^B<N?VF5_P!+'<>J7_DV/ZB\
M8?W5R+_ \V\82]5FHM0!$%(9."Z&8J2.>".&94:?46E$8QT4['QO5];<&I Y
MR*V$OZ<A[)XX7CS:<H76HRM*L:RAUC5D8LO>*S!;B(92&&D]:(L!W:/>@*E@
MZ^C/-/+4/-%"*E+;GHM!+;DCG@2&5@M_#Y3 W%:.='C8MC<Q>$#,"L-OT>=T
MGBB>M,&7O)J[0EW!1]U:Q_=ZJ:J>T1HL*PQ/6L^0OMDBG&(03[.#+"Z85QDA
M+7R$FSQ0U@]:Y5.8)Z4=9(JU=O1K"V 9.HVYAU]PU5DD7J>DRJP601A" D:,
MT[S0[/>$^-YBMYFU?S.5C.8Q,^(=:@JQ="&0XSHD)-#8K3>B'#T987GJO;DL
MAY+5RQ#!BZ^-:[&JQC&J]TBM:UJO?[?>]41$5[_8UC?<[T]7>UK6^JKZ-1/1
M$8"=23H!J2=!KH-?8-23H/(:DGWD\;452JJI9G*J%+OMW.0 "S;55=S>9VJJ
MZDZ*!H.&]P3^3:#_ 'Z=7_SK;7XF5S[:K^]6%_U/1XYSY?\ T'._W]>)'_UP
M>9^"JVQ$=EJP=9%;%!%@C!QM&8.+/ \FL!V-?6D^LS%D8V&'<WCB8$<J%RQU
MGI)!$,5$??%=,55ZIB5T=G)8LZL%D>H\B^J=#J:4(5C]H#)V8LI3#>Y<2WFZ
MV<2[/7GKPP((EBADC:6G6S]6G-K(I91''S+DVFCU(G=:>C1)#/':'\QRS\KS
MY]H^HM;"ISIA1@%1:1M*AAEDSH>6"E&(6=LXLPE2.:LC&*ZO*L+Z]L$KQY2@
MVU^>SE/25L;JT4<MA$1Y8B5) G>RX9=I#AY630G218X((S(P5^HU8;DKY%DQ
M:Q9F[;HXFQ/8K4;JB=(W?%5\+6>"8RB2!Z]&*P75-:L]K*9.UZ)$\U<5)7L'
M\DO4?YNMM_1JS^#!?IYAOWUQW\;AXIXH_P#)GXB?WB\W?_#^0XV7?C??'ESQ
M7)WCP+$5K"P-G;BOT>FH-2)'+651,56;F.MZON=0--ZQPS60:=&V5M(8Q9@Y
MI\M#7T,$PAT1M^?DZA]7U1V!![GN"BQGZ#M4>_OJ=/8$'H*@RE96!DDCE&JJ
M=IBM2W4!.@++UYGU&HUBVH-K;I&E./\  <WQPTPNCM+4YDN5RV0"$+GG8"'7
M9J,N4BQ2N:5)5PWNEM#B+30ETX%+6F$1CS14\![[2PM1Y&?ST\V;R&O?V:Z:
MZ   :ZD=^^F@%]6E'4),;,08XHE4G156,'5@H.P/(S%I"BHI.A" EF9Y9#^N
M?\,OY\=__P T/R@^%N,_JEO[DW^DG$1\0OTD@_?*#^+V^,L_9/Y(>J_S;[G^
MC%I\/_&FE\Q](_#QB*\>^8> 1N(R^>W'BGS>I+H<UR7*B:4S 69_YWT5OB.:
M3W)T93\L%0(P:WZ'G!)%JM+HC/FEESW0U"L0\)AQ74^\^T^>G\OWNWPXD]U7
M?AMX3G^FZ=9^'.#'R5;RGGO5\B5>9;(9@S>U/1BN@+4"5M?<V,)5%(-0\^L-
M46FE966*TL[FP5,ED*H$YP#<?:?;[2?+Z-??Q\V&>\ ZL:UN"O"/F4^>J'$W
M;R*FLSEI?V?.VR]&@@U]'G80V...#AY1N=)J<T39 29K%5@MP^UL+NR#RTAP
M$L/:?K/GYZ??'_AWX+N5<M\$.G;*FR,/A?RFK>>;=YBT/7.(DE!T.B"T-X?C
MK&@T68RFEBC SV<-=::">I%KQ]*L>>KX[822"^G.#5O>?+7S_P"/Y#OQ;O\
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M]&\@]775U>149>&LMA&R5$3Z7DP=4<4['7N?J'D-.WVVNGE^6O&GFO+^AV%
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ML@^;(6C>'D#DN)XELQQ/%S#DD:)+<T<]Q(V7EH%%LV(HIK*J0)IHHY)0SHK
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M6LVI.. 6NIJY>>- S^-_*5['1ZHXIH/;J3V]@^&GDWM&G\G?@GXM8]&K>O\
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M&V1L[-" BN_J(S$!F]523VX15O!7[&>Y/6JT^4/#NW9N36:]2O6M5)Y[5BG
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MHE*\B8>>*!ME],LTD,K(T<Z-Z-ITHOV"=O/L.W%GHU#U_5B^;(#_ #I]0DZ
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M'VNI'6D8GN"4"IJ""Q[^/< SO&;*\L:&]OK5;RBR=!.RX6O55%R ,H%81-]
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M*?.#Z*S@>374<_*L'%;'#QQF3.E% ?:(5.Q8:ZRF8L<3OF0UME*SW1UYCH4
MRP*-*,7K&A :03SE%)(&C-MT'=E'<^;*/-AK)6Y,*6(ZC\WNEJ92T5=J.,6:
M10)&)2(D.PVQ2L-H.JQ2L-1&Y6.KND=EMS1JVJ\MLC96!A%B**"#S' %&3D5
M$,!-G'&-!:OF501RA""5]B-C@,"F5WRS!G2WMDF12[8DJH"L6::< !R0I)*Z
M>L58#WE6]QTQQ\I1S2)%#SGU99&E1(XZ>+=V:!4:8!5)8F-9(V?MZJR1D]G0
MD9[F7Y'+Q/L*6/?PSZ]>6=!0X%.19$130UR5NA(B%1'.E&4B#WPH1$U9(5?\
MQB*YJ)\74\Q$]NJ@H(I>S H;TB4[=TJC70C0Z:ZZ'SX39WD:U#A,Q,>8[,@B
MQ60E,9QM%0XCJ3,4+*-RA@-I([C74=^*>TJ]N^S5/L[,.QGVP#V,_9MFG>QO
MTL7M;[E+]7>U/1/<OZKZ>J_K\0^3)T1)(/DI3H[C7TVP-=&(UTT]O'4='D7F
M)J5-ASS,H:K7(7\SN+.T&%"!J9-3H.VI[GSX\A&JZ6(79 %>0^?'-IJZ>WMA
M9\-CHB*VK%A@(*L#HGV#7BABCEB3DD3(R(>$P269S(RAW27BY"RQNN#=DE<1
M1,+5HK)(Q951"$T9F9655&I8HX&I5@,$G+EV&:W6E\3*\5BC5DNW89,-A$EJ
M4X4CDFLV$:<-#!#'-!)+(X58HYX'<JLT1?@.JZ99G1UE=Y#4)ME+7K:Q@#8/
M(3&/K$DAB4]HS#UF45LA ['3>SV-<1 CE3YT?N'MPQH9),&Z1A^F7:U:""30
MG86*Z;M%8[==?5;W'2E;ER[<L+4J^)D%BT];TQ:T6%PKSM5W1H; A68R=$-+
M$#)MVCJQZD=1-P%V\CLXO/WE%]<'.B&VO*B&#+SS.C(I4/4\9(#,Z6(I7JT4
MUHY3HO3VD-A4>14CE<J3;POLU;_B)R92BI"G);YAQM=+2V)9V@:6PJ=40R#I
MR%-=0C^J?(\:F^R,Y7SF%\$/$?+6>:Y,G#0P#67H/A,?42UT[E0K&UF!S-$N
M[:Q:,;M!IVUUX%?SWWC^ZO7?Y.J#_I?QZ=?F*M?\X;'^;J7'B'^;>;]K*W^/
MG_'Q".[!U=K+*1>Y9E&4\T8]H[\D9=4 GF)>'#"5Z'^L,LQL4H44;T1\AD4H
MC$<1%)&U*>6$ G)YL&E9E2P?1<=\R[2-$J2^MZC-*K1*K:%I5:, NI49_P U
MU\F(?(L>LP+1#?:^<4*'+)^R 0AR1V"$.=%()[:WK/7+EY$51V[-VD@L8TI+
M:_$9<Q88C&R.$ED^G/D]L1*0S?(D7^!*L,S6.5T4B-K!RL+1=:W-7I!C6-G$
M%3'2E%E#&)FV,VBR!'V-Y/L?:25;2V7G"["%,V&CB#E@ID>T@8H0' W::E-R
M[AYKN74#<-:[>66FZM;\YI1M-T$6Y 9M:Z>$4?&TU2^,MM%HXXYU)@FF>]K8
M92(U@5J-<LK9%<BQHBP;Q*Y9GQV"J3R9>:V'RT$0C>G6A"EJ=]]^Z/UB0$*[
M3V.XGS X?^5^:),CD)H&HPQ!:<DNY)96)*SUTVZ,2-#O)U\]0.-RW:TY6QZ;
MI\=H^'\:Z$W177GEC<!=;#L'6<M9U7/]GL^75G<]7<29'PX[!F^3$T!3L314
MNT/ZA5K)67AT[&I(2:'3\S\;,&H[CV$$_3WT]O?B T>#D.J+'K>@$\9]F=+4
M:>QL]_0^?&CT-YK=;=GZ=^0WM;F.=?A\.IM%TSGJ9GJF9X[68[&2"K'8=3II
M,AK+4JW4<X._EI]?L'G]P>\]OIX ;+&5UV=^;;CG/,677[->U=)M;PWR)[75
MWAEEB^B]9QG6-V86OX7PIP77,AU3R,W5=)R&B?6B+I;?/(-QRQ@H<V@AP=_K
M[=_N:=C[.P[Z<>G569I%7E2]=A\B/6VF>\H:\/3S=D[?4D3:B_3R%M_)"?1;
M:J_"C#MJK9PVB];*/XU875=S]VJI<I!4<C,NVXN TX._WAV[?#3M]7\O#9X
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M4;":>+S][Y#2QIG<4SFU<M?31>*+*NIDEYVV7!W$M4(%)H\8=:YC0OM*2XM
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MBTID)(F5K1IQB *L9?M3YK>225S_ *]BT+T\A&4:6*>& M"(J\45:*NUVQU
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MG*@V&U@M?(IN]S=GL8?PT<?-F-#CFZ?NX--PJ/48_/9*CKCR\_R\,:N;82G
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MQ'(R-L%9[6,185]K&^J^UJ>C4]5]$_7X9N7J=1OEO=5K-IS!D%&L$1T4)6T
MU7L![ .PX<\K9L 8S2>8:XJJ3I*XU)>;4GUNY/OX]&X-J<K#7R#YW.RO+<<]
MK301HD.D %4F*BKE9$U7WUV[_8]3&J2HKXIY/IB?E_*53F9:N,2%HZ%!C(9B
M!-#&HF:&(R+2KZ*-UVX04JKZVI5STY"H0X\>D]QI0]JT @C'S<KGIB1]C6)=
M20*]<>M,?5[%1O777@*OMQ45UZ76!4F(4!/JTAMS(AE$KXQ**BO!+&VE@](O
MH-*ZYDJ*-T<D"*8)',R>P4IX0C/=S-2"[+6AIX<PCJ;;<JQ]&ND5*E=BL6F3
MU>AD#;:I3*M&.M$K*]@R&&)?7Q\\M>.9[&0ZAV;H$9M\IDL6:[QP!B6ZE00"
M>P"&(C<@K%L#NY0*BC-!",DSE8(\L08EXLU:'\X9\\+)7#R_[';_ %2%7K&_
M^"W^$U?T3^+XEL-6G+#%*U"O$TD4<AC>O%OC+J&*-Z@]9"=K=AW![<,4D]B.
M21!:F<([H'6:3:X5B P]8]FTU'<]CP-<MH:.63I'S::ID^7TRYCC^97!O]D;
M:/-JV-GNA7VL17.5&M]&HJJJ)^J_$=PE.F9^80:M8A>8+"KK!$=J^@XXZ#5.
MPU).@[:DGS)X>,C9L"+$Z3S#7%0DZ2N-2;%O4G1NY/O\^)C>&T^2@KY1LWFI
M7EN/>UIP D33I !%*BH*U61L62_O7(HU1%Z3(KXB)/I2EC2%V7,2U<:D+1T:
M#&0S$":&->LT,1D6E7VJ"UVX?FZR^L-5=NG)MV&W'I/<:0-:M*$Z8^;D=B@D
M?8;$NI.E>#[:8]NS*-ZZZ\"5YM*&KL-3$/0X::OH*HJQA))^B@26,03$FQ$R
MDQP2P.'N4UI0-2QC(TD-H9D:63]7+'6-EW+4ZT^16.GB'AI5I+"O(8DW+%'B
M95D9U1EV6QDY(:H &LU-OG'ZK+75P4K$L51GL9 26)4C94+G0N]Y"BJ6#;X?
M1(Y)B2=L=@:HNQ3*Z6Y_./:U[*2D>Q[4<Q[:T!S7-<B*US7)"J.:Y%145%5%
M145%]/B5BE1(!%2H00""((2"#W!!":$$=P1Y\,9LV@2#8L @Z$&60$$>8(W=
MB.-J#\ ,<<7Q$Z_ +!"-!'Y8]&2.&")D,3$7G/'W*C(XVM8U%555?:U/555?
MXU^.+/$Q$CYZYB2-%1%M5PJ(H55!Q]0D!5  U)).@\R3[>-_\ILS\N8IF8LQ
M@E)9B22?29^Y)U)^[Q?_ ,N\?4=#OO%/ 7[BVT6Y[QTG'W;@)F#'MJ--X.>8
ME+9."(?%.P<M S9E&F?!,R*;V2.BD1JL6"\2,>WZ/Y1P-Z;\/_FFST5KL=5O
MNCW6MT-;=A:/0$"<KC.N2+C*]%Q;2Y&P<SC'KQ0\YTBQKB,Y3PU^4U$-%FV;
MBBU#!K-ML<&OP'Y:?B\_/V>6@XZZW\/[GM'4Z"DH.G=6HZW3":,&V#K(N4#A
M3@[<OER[RKCK4Y:M6-1;"DX_C<G9T @0]0)FUO0:<.MDN'SCG!K\![OO:#ZO
M9]_7CMTOX>O%MF60?J]-U6W,4F>&LE@V$&?AI\L1MM%T!^*BKLQ3TU5<4T=_
MK-$P>UTX-[L(*FS)JX],@\Q/U!P:GV:#R^]^7?W\'_)O#WG'(=WG^E4NCZ'<
M["AQ6SP*DW>C@BH3\YL]D#MW +C*"LH\;2!YNW$(9F:W+45#5"0VED58 VEQ
M+%:0G!K^'7Z/R_D'%L/@XIQJ;?C:_P!?/G_\$[D/^>#R5^-*>+WZ)@/[3)_Z
M5#CT]_\ )U?U'XM_NGDC^"YKXPXZO*B:VOA +,/ ^1,5-$57*&A#/KJ>TH3(
M_0X,X9S9ZNY/@]7#N?%))'/$YLD3%^-2T[CTI&D2..3<J*R2A]AZ<\-A#\W)
M&X*RP1MV< @%2"">/0KF3ERKS-2CI6;5RET9;$L=BB:HG7TS%Y'#6DTN5;D!
M6;'96[#JT!:-Y$FC99(U/$7>8(#0"V8I]G:*EG2)GOF-;5N<#5N.)-*B 9/6
M30PRFI(",7.^*26:*DIY'.^I&EG(RU\C)6>)XXH=8K'I.AZPZDH1$0RE9E9A
M'I(T:@@*UB<?:.%5OR_)E+-5\A7N9#(D9#$#![U&.9J>.:W/;L14DFH2Q127
M ]."U,T<DDL6)Q;L>O7DFF.(F)%''&CGO2-C&(^1ROD<C&HU'/>OZN>[T]7.
M7]7.55_L_" G<2= -23H!H!J== /8/<.)=&@CC2,,S"-%0,[;G8*H7<['NS'
M35F]I)/$KQ?_ &C2_P"_SK?^=C;?#[D/T:#][</_ *II<:<Y4_J#+?W[>(W_
M -<'F;@AM<0'::</5?=+8&P"&%ACA$6L<(^:O#U8-<9(PVM,F^>'!M+U6L9,
MT:>205Q,$K1D9)2*Z\59ZIBBDC=G)9NH' D>J\B I(HVNU.#S4LH#[64MJ+K
MW+5>]F:^<%Z]5MUHH(TCK^AM TE2OG*U2=ELT[$G4KQ\Q9,A5D6&5WA,T4BP
MA6',]R&CS4^>D!N+Z4?,6I-M5 D.IT&BE(S$63^G<X6G&)07[9%]02R,B.6Q
MMI9[.PE)((G^8HL9:>RM@/% &LQ+%*Z]7<0MDVBVC2LI8RG125(CB CC"JJZ
M-.)Y QF'EQ+ULAE'BPUV:]2K2M0$2/+ADP72)AH0S"'T-.K,J2H]N\\MRW)-
M++)OD>Q_R1=4_FXW']&+3XNY?_3["?OOC?X[#Q9XJ_\ )?XD?WA<X?\ P]D>
M,Z_QV3QXZ<(=_ Z5"=*4+KM>$_1W]/HTCB_*\L52=0=)T?7*N,#ZK,SRRBP[
M[46EK)'8RFR3AH+4R2J#"]DV/IC4D,02?AVT8L!Y?LB3W]G;A-Z,-6(D<;F5
MM-%(!69IQIJO]<<DZZZC0>0TX-L#S6CYX.Z"J+M;&1*''Y>$NYF$G*&SV(I&
MU%'50N"" B09A4]WH)_?"][[O2W4L3X0) :\&Y5"^6I[ =_8 - .WQU)^)/L
MTXR10K$.Q9O51-6()"QKHH[ >TLQ_P"D[>S0!X<4_KM_#K^>#HO_ #2_)7X2
MWOT)?[H/]%^&+F?]+D_=47\'-QG"[)_)#U7^;?<_T8M/AKX@2^8^D?AXQD<G
M71Z'C'#I['\.OOES)6Y_F>_%O:;NOCOG67.E"QV(C@N28PO*"C//H[%N4S1L
MV3T CJ$J2IK)K7/*<*GL.#RU\C[/_#4?B/!:5D2"A#J__6U/)$,"SQ47.[ &
MI\EN%4@9>-9G<?D2*2<:G\NP8'Q6N6Y]B,]H2U9]PTM-E:2NT!=F*!!$TX-3
M^7Y?5[O9Q(C4]V#: W5?^''Y.5EI6:H_95A=5Y.\.JY*VZL*W6U#XJYM?Y>#
M1@YX*OWVWAI,<*R+(9U^MT1%#1UI-N=-.<&I_P#'O^'Z."#(66XPM]3:7,_A
MX>30=Q0TVTHJZ<SR1X!=C?1=$VCNA[@FPK;WRSLJRXO-/LW)?6VFN S]&23'
M!"MJ@8PXT9P:_1]0X;W[P_D)_>#=]_RJ^(/_ +D9\'%.-)"H\MX\_ ;2'<7Z
M6XVLOM.(9\BUY@^)A46DM4GB:]=^WYGR)??"Z1J+&]S%?$Y\:L>[G3F.[AX\
M]ETGR]>&5;]D21-4R3M&W4.JEHJ3QL1Y$H[*?83Q[.>"W*WB/:\)O#RSC/#W
M*9+'S\IX>6G?BS_)E:.W7>HC1SI!=YCK6XED4@A+->&91V>-3VXBK'R<QUK>
MB:4SA'6%NPH(1ACAM1A0'1QC17$ SE@ Z@,-).-!H;T<8J6%Y(X]Q900S,B,
MG8]K7,8A(FA7/5>DQ)93C\FVI)C+=VQQ8!C#$64$*3&A()4$3JQX:^(EJ]%D
MIO"G.&[#&D<4\?.')L!58UN)$=D'.,<;/$F0O1Q2LC2QQW+,:.J32*T8#Y"<
M^K[INB&X%UMUW]8VPGL2]AC["<\V(%]8(3;?7]6)CN):P"206F=:L,^R122-
MJ$"5[E6]LWBGCZ+9^IT]NT(N-R*!%+B1A'LQJF,.X#2],KU2!U-W":#PIY\K
MW1D8_";.F[UA8>Q+SIRE8DGG6!JL4EOK\Z2K<:M79HJ9M";T)6;T3HDDGLZ;
MY@!6W-NA53>.]*$=9X?65Z%$6/-'#C*90GC(1.T?>SD.AA63YDJ00S3*QKDB
MBD?[6+?CKV$;(40F:K.YN50B"GE%+L9T"J&:B%!8Z#5B%&NI('?C!SEREXGQ
M<H<URV?#7+5ZT?+>=DL6'YCY&D6"!,7::69HX>9Y)I%BC#.4BCDE8*5C1G(4
MMBFY[Y OIZE\? =/)&^M!='(F[X^U'L<+$K'HU_06/1'-5'(CVM<B+Z.:B^J
M)9-RV&EE/ROCQK(YT,62U&K$Z'2CIV^'&.CXYI%2IQ'P^YO8Q5:\99;O)NUB
MD2+N&O- .ATU&H!T\P#Q"'<"Z[8FVM@9XW:V4J[#)K[1S>G\SAA+#-$K@#H7
MBP=1B$8AP515"FNB@CD,AK@F$OE0:'V*(\39B2&-,YC@D#K)$#5N,R.CRR1L
M';&ER8WFF>/<Q"-+(4 WMJT6O$SEZ[:OW+/AASI)/E*T]2^5S?+D4=FO:K4J
MEJ)Z\/.<==1:JX['P6BD2M9BI54G:001[?BG\?NM4%FMS5>-FM@LG1GQO*FZ
MAS0UTKK0F$NR(F8=U(F*8X\@>&4NQEC>>0L;6RDN9ZM6LV*M6(NA+G<<T6L9
M"+5N1@=)2D2@QXU2L<:L0D8(C74Z*#Q;C?$KES$7CDJ'A?SI%>9+:/8DSG+M
MII#?GCLW9I%M\YSQR6[<T4;V+CHUN78%>8KJI#^[9#MU'S8VWO>':6KJJ_4\
MV)*-?L^4EHQ6=*R/R(6C@;LHI\A9*PAQ*V%8HY9V2DR0C,FFCFOA-A&H^)G(
MUR.]5NR5^9L5(E2NEJ.>RXM(%AB>U7@K([L0JM/-%&"=7=1J>-7_ &3'BY'S
M'X#>)^$/)W,F(&1Y:FA.2OV>6I:=,+:JRF:Q'CL]>O/&!&1MK5)Y"2-(R-2$
MO^=];_<EUW_#W.O],OCU@^5<I_S8RG^6X'_O?CP*]!H_MS3_ ,FR?^Y<"3T(
M>I[OV,;ABV1D1Y:P[?*CJXN"T(O!Y85@Z''])]/<EE6HT8GR(Q[ D@N%C)YI
M'N;"DAZ__HGF ;$JSRE,OC$)E2R]Q&0IGE,73MRRV8UB*+'/))*BJ[L2L#1C
MI_T]H'I(8TW8^VVB-"M=E;=C3OW0(D+%]Q:-51B5  ]=$8=F5F^Q\5UH#9H8
M!EC;J,//#$./*3/'"+ 3NYH0XE(-+*F8(R!I)1$Q1"2D/=(N6DT^/W^A\I92
M .D<949'#.BI&TCJD4<F:=(5WS2R.(E022R/+)ND8MQ986*UM](SU.0JS-KZ
M'?5BS!%+.R8]6D(5$12Y8HBJBZ* .%%Y':C16.(JH3.>:*EB;J@96E'6^,(B
MDD;47C$':RKTIY"2/:]TB/?"V%&Q/1TK7NC8_7_BO?O3\NTDGPEZD@S59A+-
M9Q4JLPHY$",+5R$\@8@E@2@0!""P8J#*.2:M6/*V&CR=:=CCY042"\A ])J'
M<3+5C70$ : EM6! T!(W?=GFS-[TS3XR[XGSGH!&FO?._G7.+&YZCO*2Z$Q_
M1MGS"M[-L28<[XD]@J>76&6+&QN?HMM9]#J:U1-,4A4))%DP*IY+XW8/+S/F
M/8#]'F1\>W'G/X+K-+ 5TH[.\DU-B;4:O0V.ZIO-H$R30:8HC3664ZG!3Y#P
M0CRYFRY( +U:IYF/G\U'F7@:;IS=7DMQ<$D'UYQ74>7?M\/+WC[;VG37W'33
M3@-O[6TG R"6TV-@JKSAW7M'6F1>2UXVKTU9Y-WQ_DYI.CFVS?PW)1J[JES;
M\T*Z9AN?@G435K,.;!7<JLL_%=5QAQ4:'WGR]GNT'[+Z-?Y.!TSF$FLNZC22
M<]K)M/M<9W*CATHO;.A WVIO[ WRR*ZS7I;Q_AG1%5O7J:SZQY"'F<&J):8V
M0C+ R'<?M(,8.SX.#[I]GL'PT/VW;V=^WGY\,_A]ML\CO.#T6!I\18NS=!T&
MDYIR:Y\@+RFPM58:W7]IMM,+84D7X;6:DY/N*PG&=#PF7PL5QSLS)8[B]ISW
M*8^NIZ[HU=HSBA([ZZZ]O9[/\+N/;_+QJ)NR_3;&C<XO,8)M8=5*XE9^B74#
M6@E!JLRS2)SKVPH@[W?,>DGI&GN<C_1/=\<GYW'4?S2YBP,C=2Q\NY"8(F*A
MF5)OE"9PB,<I&90K]E8QH7 !*+KM'OKX7\S\U?T%O#O&R<G\N6L1_0OY1I26
M;//-Z@]C&_F4Q\#3V(DY,L+2:6KK)+&ER<5BS*MF4()63#\!>W62(29U/94Y
M-V%'8PDZ>R)LK>Z=14@=,,7EY^#.).EASX]1858L%#\J09PVH2.>:(2V'7)"
MM:^DD<QAGCK2+ T=#9%7KFU9GL-%<3F@")9+<MA)W-G<#U*.Y(VD@>,SW)<U
MRK9K6<>,EBK69J-DX[?,ZVKV8S"X/"X_$17N7;'@FYNR5L%3Q5O&UHL&(7C]
M&YE,4]N"GE:YAD,CKFZ2^DIJ_)6%T@0H-@TW:W(B/@K## I)&G,X_6.T1@=C
M$376IQ1UT;5G0OKRYP2I2(9V[(4():=6.>Y8BKK+)-%TL9&Y5ITCD"B)N8)E
MIQ/$4EAABBK12HPE5)%5&27\I\QY2KS%F[>*Y=Q-_+R4JE"\+G.5FL'@QEFS
M5:0W8O"S'3<P7:UU9Z61OY"]FKV/M1/2FGISS6HK%W?%/A?D+O;OJQ&6S7)W
M+6IA1[!EYU+45B,=.)HY17"/"Y#<_4M>QLOS_G,#6%S&(Q)TD<Z-^Q& JV</
M7$.1G*1W+OK28]$8LZ4]1L7(.  %!#;R6U(*KM!;4WB)XOYOEKQ%RZY/DW'M
M:N<N<LMTJ7-DT\,<4%GF%48V)N5ZKM)(TC[HQ758Q&I$DAD*QM.#Q0[>3V*X
MJ 2N2P[M)9;HN@AZSLW40EO#G,&+:H-<F^+D]=+HI<0W)I8YK\Q%68.<T#="
M/3 +8B74+\>7V]"CB:TK0JG2$IHL)6CZUF5%8+E%&Q+,LLBN(UW2(L;NZ*8S
MJ8>--8\R6LC#R[=BR$L_IKTTYFJ-2BNFAAL?9GB>;DR5S8L8?'4J<U9[DBQ5
M+,UJO7KV9H[D:Q$\3M9&N'G4CB)Z:#I=L9G)$W.FBCL=;E-U@>=G0(ZH\0PH
M\G0B=&J</3RV("YBET>AM:N8JTNOO=?+,K;#6SUM+S(/0Q7D @G.D,L5J35N
MIF',\I@LV-O6Z[0QZK&L>P\,$/BGRY&V-=N5#.5YA.9KL<KAX1+DJ=O!50B>
MA>']88RHF1PV):48WY-CR%PK+<FN-,AX)?*KA?D5S3)X/4:S+\C6NBZ8 %!'
M0]7U5F9,<9C=NV*.2([C=-# ,D+")9"&D3R-DCBA:*]LSIH-F?8^X63&^*G+
M]JI.MVP(,ND=>PAHQ/OQ-S<6LQM>=-J!F %:3<P"DJ#N&L/LOO%EN=/!/+X2
MUR]\C0-F<#:>]#EQE)%]'O K&M-L;C0_49P"YMIL&IVOY<4'Z45H2ZL7\TT=
M!2B+]U#<16;VTGE(KK"CL1[T0MJ\GME'JUJ/JBK"R;"(ZL8(PQ;()D;W/] L
M\]Z2O'\HU*-2,^DQ;Z^:LNSPS4YTN1R@\LV=E?T7J23SA(S76,2^D0A23Y-X
MM:J2OZ)8LSO\RX67'1*JRQSQM7=/Z<0AI>ML2.(EQ*7*=)R1I"V5C=U.G.,L
M8JL:S809>_3_ )W)E #OB,^53BDAS0\6EA)T8F1F2OJ\Y(6:0;5P#V)%'9FO
MELR$L\URMD)I)UJI8626YL^5Y6ABNR4I*L<D3IRDRO?CQCB"O1:65Y:R).].
MQ*S6),\4=::I&D33-$52N7] 59)*ZV$G=)%;. K6>XO5ELA(U25FB6>) (E-
M,I8;83&U-?3YO.6=75U*4PAMCO;*&R='3L?5N@L!V<MJT@L I!'AFC2 !3P%
M#RPDP1$,E1'7&2Y>+%U8*M''V*U:L*L<L^9LK8VU0:Q2=!RY7V3PM$8I8VAB
M=)$9)$5PPX0W8Z$EV>2:U:BFFE,[QQ8Z)HM9])0T;'+2[HY X=&$CJ58%6*D
M<?T*?#+U_<^\4?5$1?W:^%^J(OJB+^R_+>J(JHBJB+_$JHGK_'Z)_%\<)MYG
MZ3^'CHP^9^D_AXISU30:C(^<W?M'6^1?._'O/,\5O#.NMK+H?.A=N#=GKTC\
M0"\'^F.+WF+BHXZ2AH=+<VLCT-@;3B'VQL]<!3%3NIQ=^M'8GUF\OH3X'ATD
M1>0HF:M-<7YN<>&S51:7-'96I'C)!$-#<T.J)PUI4HR3MK9B+"+8"RYD<,:*
M8BQNG#UU=&606)',<6]O<?K_ /F> 4OI?0 @Y[ S\17QU@ &J,]HGF2^/]2@
MLE!J*B?145Z).O=%B.J"\^&7H'V83B P*,(RXL)Q*X0@F(XKV]S?7_\ ,\>R
M3==.CM)*63\0KQ]2W'U$6-EKE\>ZM3(M++:E9]E>Z%.YJ]J)H0C\T\[T2OBT
M@)V>E+9<AD@Q'%.WN/U__,\&V&#\C.F4JZ/G_FYQW7T:$H(MI1>- IXC9WA!
M6D#'21=P7VM,J;.KN:^1R)%8TEK57(#R*NS!+(.#M[C]8_%QI=>5F;ZP/Y@>
M78UKU"@L[<;R)WD%O:C\U96C6MBQE5\\\>K_ #B8E9#.BL1@*&F_)]B_[*D]
MWZ=8>$E?*R<F5&J9.O5A-W( 0R8WTEPPL'<3+Z;!J&/<#IC;Y:GSXTESU-03
MF"59Z4LTGHU761;AA!'3[#9Z/)II[3N.I]@\N*]V<6TID%6VZKF:]#26""*7
MAX8?GDO_ $;''[]4GJOZI[G+Z,9[F^]S?<WUV).,M5Z?I',6.AZT@BBZF("[
MY&\E77)]SY:GR&HU(U'$3B-&??T<1:DZ:%WV9 G:H\R=*GWO,]] =#Q&6%I?
M51)8=EV3'A% M:\L<C%CQS0M2* EWO8NJ]RK ,4*60UJ*X00H8LA(AYXI7X9
MK%ZO))'/S1BHI(0#(DF+173U4D.JG*:^JDL<LF@)CCDCEDVHZL<T<5>94DBP
MEV1)"1&ZWF(8AF7L?1-/6='1/V<B.B;G5@"9M%TES6N;T:D<UR(YKFX&-6N:
MJ>J.:J:E45%145%1?14_5/A=Z'GCY9NG_F7_ /Z7"3TC%CSQD_\ G$_[IPK,
M#0[^6;?+!NZF!6=&T49"OQ+9OGD-AK?F$,3\R1_)9(BM](/ZI\OVJOS7>[T1
MGP%3-GY9V9BHFF>OA]V(W[Y E?<X_I@NQ6[:)ZVW3[8Z]G;)2XTKC2V/F.N+
MK;=+Y&U=TVBG\['<1W];MK[O>768NPIF#R6W4LW7L+(:*.\O$Q0MFG<USTC8
MK]2B?P6,?)(Y?1D4;722.8QJN1XL#*U!&;/,6.@$L@BC,N("!Y""0HUR?L +
M$^2J"S$ $\(8Q0FW"+%6I"BEV"7V8JHT&ITJ>\@ >9)  ).G$<>;>U9!8ECV
M#)!E L8\L>?&PQS0M<P:7T=&NJ]RNCA-#GF8U'/'',$(G;'"5!))@FLW:SRQ
M3\T8J*2$ RQOBE5T!6-NZG)ZZJDL+N "4CEBD<*DB,V6."K*J/'AKCI(2$9;
MK%6(++Y^B: %D=5)(#.CJI+(P!$S/=#D:U[.B4CV/:U['LPC'->QR(K7-<FI
M5'-<BHK7(JHJ*BHOI\+A4SQ (SE(@@$$8;4$'N"",GH01W!'GPF,F+!(.-L
M@Z$'($$$>8(]%[$<+_GM?T.(KHL0FXI8?E]%M6D.EQ/S_J"?LF=<\AB?F6+Y
M#'L=&Q(/67VN8Y_S5^9[61_"T<T\V?*9FLA&>L"37$!P\@I4"7 -\; 5*J$U
M;3;KN)8Z.>2LXY$Q@;'3,/DR$K^?RNU?2+6BG\['<0=3N[:ZZ:=NYK9&;FG8
M/):]/RU>PHAHH[R\0R%LL[FN>D;%?K$3^"QCY'N7T9'&QTDCFL:KD=;$65J"
M-K/,E" 2R"*,RXA$#.03M!.1'DH+,?)5!9B ">$$4M*<L(<19D**78)?9BJC
M0$G2I[20 /,D@ $G3B/.T&HK"2A#^MX\0H*-DA0\V+C9-"QWTOHCH_S7[E<U
MIX,DD;4=)#$>%+*QD9@[Y<$TEVN\L<_-.-BDA4-*CXJ,.@/2\U^4==0)X"R@
M%E6>%F 66,MEC%>9$>+"7'21BJ,MYRK'U_(^B::'I2 $Z F.0 DHP$_&-TJ6
M-DL70L]+%*QLD<D>$1\<D;VHYCV/;JU:]CVJCFN:JM<U45%5%^%RT<XRAESU
M1E8!E9<,I5E(U!!&1T(([@CL1W'"8V\:"0<7.""00<@P(([$$&IJ"#V(/EQM
MJ_ZGO991^&W6&6Y\%G8)Y7](^I-&!^VPSN_9[R'V*P+ZHSY"-C]K%3ZF7W.:
MK_5/=[6\<>),<T7/',$=B9;$RV*W4F2'H+(3CZC B'J2[-%(73J-J5+=M=!O
MGE5XWY>Q;Q1M%&89=L;2=4J/29P09-B;N^I!VC0'3OIJ;Y>;>.Y=NS_$S.]I
MI,IH>7/\DM-<;*NW$04N3;5YGP]\L=*EE>_<7-!A!I"JD>Y>46]D ;@&%R/8
MV%7)!^)"/;]'\HXCZSP9_#ENK_0Y:H\</'2ST63CK)=/3 Y'/%6% VY^O^UI
M;#PQO>#(:E6>^"$A&3.C&?(K$8YCG'!J?>?K/ 3-XR?A0"IHE,Y7XB@_E"KM
MKO5-/$PX#\Y3T-F+375I=L,(@?65]5:'UH)Y9C88!9[6H;,]B6U<I1P:M[S]
M9X]L'BE^%>3;OSXW(O$J>^COKW+.I(1,-);KI<Q575YI*%E:PE3)+>@I\UH[
M*YKXX7%5@>?NYS(X65)ZCG%=6][??X^,QXK?A6[6TJJ3(<@\3M-<7L-W/2U=
M'6XRS/M8LU8G4^B?7BB2RS&?8;6KLJZX; Q[JTT P8Q(9AY6,.*:M[S]9X:7
M^MS>"/\ >G<-_P 0J;_V'P<&I]Y^L\:J7XV7C'X^<O\ ,[)YKG?'<#C* GQA
MYK>$5&=SP58!-<&]5[X 792#CL8QQ9 536BRS*BN="",Q5](V_&D?%_*9''2
MX 4;MBH)8\D91!*T?4*-1V;MI&NW<VFOEN/OX]./_)W\D<H<Y4_%EN:N6\/S
M V/L\DK1;+48;AJ"U%S4; @,RL8Q,:\!D"Z;C$FOVHXP_P!ASODM2.I=IF<E
M7"HY&*2<.(+ CE:YR-66=S&(OL8]ZI[OT8Q[U]&L<J:?@SW,]F015\EE9Y"-
M1'#--(Y&H&NU-3YD*.W=B%'<@'T7R7A/X'X:L;N7Y)Y#QE-6"-:OX[&5*X<J
MS[3-.(XP0B/(=6]6..20Z(C,/$;C>*ULTX]A38@&<:%LY$)?V\>6&%SX&)+*
MR61KF,]Q0J*YR(B?4CJOHDT2NRQ9;FZ=$DANYF5)',:/&]AU9P')52H()TCD
M[#SZ<@'=&T07_#O['W%3V*V3Y8\-\?8J0+9M07:^'K2UZ[/7C$TT<S(T<>^W
M44NP"J;5;<0+$)>:3E7-7(CFXO.N:Y$5KDKX5145/5%143T5%3]45/T5/A(>
M9>802#F,@".Q!LR:@^X]^'T>"GA"P#+X=<GLK %6&%I$$$:@@B/0@CN".Q''
M@Y_R[G96>(E(QU#-(W6= ':]X,3G)")OM**-$B^GZ,@'ABAC3^)L<;6I^B?#
MSE.8L['8A5,M?13C,,Y"V) "\F'HR2-Y^;R.SL?:S$GN>-><D^#OA9:Q&1EL
M^'_*D\B<Z>(]97EPU-V6O2\0N9Z=2$%HR1'7JP0UX5\DBB1%T"@<$\O.N10'
MC5<V9R,5F8Q\@E?) (PPEC&32.= ,YZ32HD8Y,GJQB^L8Q#T]6P3*Q&N>YG:
M)YUR>5:",A9)EFF,:$E5 =QZJ^LZ+W([N@\W4%_E\*O!&"_6Q4W)7(<63N(\
ME3'R8W&)=LHB32,T%9E$TH$=:S)JB-K'6LN-5KS%/(+B>*FO'C#I,05(85."
M)&/]!,\HP8/[B0,.R.5SIIX:]6GR1QHYS0G,*5/D/9(N23,\V1!VDO9B-8XU
MED+O841QO+T4D<D (C3 PAFT!E!C^W!'"2KX<^ =UZT=/E7PZM27+<]"I'7J
M8>9[5VM2^4K%6NB;FFGAQVF0>.,,RT62V1Z.Z2&)Z'RWG8F W)0V-H82!L?I
MB!YHP(FR130TILD4K'(G\%\<C6O:O]AR(OPX\M<PYR?F/ 0S96])#-FL5%+&
M]B1DDCDO0(Z.I.C*ZDJP/8@D'B*^+WA#X7XWPG\4,A0Y"Y6IWJ'AWSK=I6Z^
M'IQ3U;=7EK)SUK$$BQAHYH)HTEC=2&1U5@01QEA_=QX1_<HQ/_ @W_V/QZ@_
MF=P7[4T/\FC_ -GCYW/3KG]E6/\ '2?[7 V[D?BVW[U[L=RM/RY)!%?I\JH]
M::4HB8,6*R:DOJ'(2:,2".R=&.G.&(#B1Y,$L3,/R-RU\[^<,7\R0)?FH/FR
MS%5#]O5+,K* ="64J/6!'%WI=_M^>+7K?:_.R=]!J=._L!!/N!!\CQZZOBOC
M1=S2CTV$YE;3PU]3;315HM4=)%5W\1$]'8R-%DE5@-Q (5-5E.1(#X1YI17R
MLC<Y*QX3ER4D18[&2$)'(0D,+$1S!C$YV@^K(%8HWDP!*D@<4-R\OG9LCN1W
MED'=?MAW/F-1J/,:]^+C^ G).98;ST\2+G'X?.9RUEW/50)#ZFMA$*>'/XN=
M^FF&66-$<L4DH\#WL_B5T3%7^+XA_/>*QM'#P34Z-6M*V1AC:2&%(W,9K6V*
M%E .TLBDCRU4'V<*Z5FQ-(ZRSRR*(BP5Y&8:B2, Z,2-="1K\3QM2=D_DAZK
M_-ON?Z,6GQJ7AS7S'TC\/%$^!XORES7/>>Z7(Z.GT.=W87%'PT5U>WLWY,YP
M#SSEL!1@4&DO+[,A,^G WL7V7"Y3)V!MM=TY5V3H',2YSQP=OP_7^6GW]//C
MRW/(/,\H2YDO=AK-9>W_ #\.H+N<MUZ? 14.DT-+PD8FUR.5S$N$S#;;EFLS
MO?-+4M*AJ1MI2ZW"9C5:#2CD7GY4.*@CX#N3W[_</;73R'G[S[N&1I>?>5-G
MN2S<S:'5G/0_(<[;R45[U:V O;[G)6"P.=?34Y]%'>J)F&Z$?JMZ%SXVPS@T
M!M]BK8:PJB:,@& XMX+^"\F[%07>.T73M5J)79[)].!/JRNF[G1@Z*PVW6KF
M[P<-QF;/7Z:A&-Y?S(.NHT/(MMG:'FZR2MDV5\S%!W]R<5_'^7?M^#\)XN/\
M'%./YH5__MHVG^_O=_TON_CC;G3]5G,/[ZV_X4\?2M]C-_\ B^^#O_U/^7/]
M7Q<+NQ!T+M376(<LKZ<> =)Q6V,@\+U8-HX3HI@O7Y!$I)-AG219I(Y%A93F
M-285SXXCVVO-0&-G@E51;DD?9*8%=U!DQ[0LLOVZ+''#?CD12N\VHB5D +0S
M7*X[FE^=,5E:,TKX"K6K"S37*RU:\A2IS9!D89\=_4]J>W;R7*=NG8ECE->/
M!9!5GI-(D.3$J//;T.^J"3[@LJH&,+?/!/8SK)**^F:!Z6(_W R%Y$EG&ZU'
MCADL!5<2K((\^P5HQ#I<OX66E:C@JQ1VI(HU1T@C"I(+9FU@?T>)P@KL*SEA
M!*!&"[7FD,B0?EWE7Q,H<RX*WD\]=NX&GD+TMFO9RMIIK%&3E],9MRM;Y5O0
M/:DS,+9NM'!)E:):X8ZL/*T=-:EHTW7^TC9?[U=#_P D&?#1AOTXQ7[Y4?XU
M%QL#Q*_Y.N?O[RN:O]17^-D?,_[7,_\ ^I*K_P"8!_C;,GZ))_;M_I'CS6K_
M -3P?W&+_07A1E4'3(>C;"Z8\ZSR5C1W %16QZTT(5BGTG.QJ9@E4PL-E7:4
M]U1=%,,M@IJTZ<;7TZ06Y+QWQ4"L25C7A315E5T9V,2L3M>P7W.0VY'22NJH
M0R@POJBZ@RL9JY49:]8+R2T9:UB."$7)40=2OBDKJD(>,0S06*V6DDGC:*0I
M?K[9Y"K+4YS+$;NILZ2VV%W<S.J\=9U1 LVPT5P+<V=QJB2P2;2E.N+*J$LL
MKEZFH#A-A(NBRR]+=BDZ"Y2I&N+(LSP.LB0HGK3(X80QH45(MK!75%<K+*[,
M5(10(T(C3>44Q./R,,U>>]8G/1H35VC:]:G2>6>ZTD3SUY9IH8YZ5.""-95D
MLR2/<LQO;L"!+$XMYD_UO.N_WR<H_P [^#^)GX3_ /*9R)_?3AOX[%QK_P"R
M"_Y%_$;^]NU_"0\8O_CUGX\0>%,^FW#?S(UTQA$)]Q7SBMBT)$,RU@NQM+4^
M*LD66)]2X_'$U6>BA'GKV,LJ\B5[H(WI:E1DT\P/E &25UGM5WC"WI$?T>/+
M6;,Z5FW*:IGQ$E6BBQO !9@D<E PM2O(GQY]%.V-3'!*KDUE9>L]&&&,S#0B
M81WEFM%F64F*15 8CHI(8"FV-3]2FLL9+&=:\ >4EUH0>.:?"9:RN+#&F;&V
MNCBK"*NO)^6.*ZQ-#G+F@<Y&F&9L'3RU7J?*E@V)#!!&TGI$DT<LR2VF,L4;
MA175:TE6"3:D9GFBDE="0)IL>2GHS;?0HA$O5D8((5B:.-HX5V.ZDF4M,LLJ
M;F81(ZHK:$HB[\GO]H-1_OO _P"1;_XA'C#^IFC^_M7_ %?D^)#R'^G%G][9
MOXU3XW5=CFV[[I6FQFAXWE=R;I;KSSYQSFQ)W^FK+4/(](VG+:[L.VE^T^-/
M4JSF%ED2A<=GZ/9W.UJ:E8-.4A4!LI\8E9QMQOL?R@G7X:Z#X_\ C[N)*HQ>
MEP5A^\7$'S:RMZ^DW5]8;BN\K\M;5VBT>F@VH&;WP>4R7B"^DM=9SRFM>R97
MF-)E:)U5;LV_18]%E]YJYX[*N.#OY:>?L[^SV?1II]0X3+,2*5D\AGS4&EJ<
M)PDN\!@L?(%U3=!@>.>?V7C3-TZ]"?X* 'UO3^:P]),P=E@C:\",S6TE/':\
MQL;FIT$=@<5[^6@\_P )U \_+MK_ "]^Y#+NM;BDH]<ZTT^;#EPWD]+0Z"?>
MWKLYF]Y>6W>>I^0G18#[;\.@VARG>LM9T>_*(P]Y+!89D'FXN,&YRT#0:ZEW
M9P>?L'L^GR&@TUUT_+7@TP5;J,KUKAE</BAUV@>:RA&:PVP[%I<PS5F9ZI\E
M/R/?]&4[P<SEO1;@REU?;[ <*]N<K>]#GQ#M385NBM*+0V=N<4U\_P O+3MK
MKW'EYZ_#C4%DZQ>MH'TMG@*N0-M0ZKL'_GE\,3QD#40M_P Q<JUT3'1)([WJ
MYJQM7W>J*GK\<KYNQC4YCRY%RXMA,W?(2/')(%F6_*0J,;RF0!QHI**6[':-
M=![]^%O+O/%WP5\.E; <JR8:WX7<HJ9[?.5^C))BY^5,>.M9C3E&=*;O4??,
MBVIEKL646) G49'E;NJL,NYIU596 :WT1Q!!UU5&V!5Z/D:VH$EGSY/(I8YG
MC8:O:Z*-M'](^N*GT;XI)XP[(5:MM(KH1"\4HJE56.L$@2LU^1VVVTSX50V2
MD,;$VMXL*M,%=7A>*S\I7KO+#6;4N.NT?ER.2>6UEK-K*6<W#RK0KUC)RY/X
M.23S20\DU$N1(F#-9\18EYD9'1*^1KF.(Z775>BN#<]CA;"T6M% D6370LAB
M C(<XB4>P'P(?WPDP^-K[BR)/MBE,@C4B: N<MYB'(VH#5@%NQ<AA:5W72@A
M8R%!M62$Y5S55(F_.\0B@4Q,2BO&J;)9R9RIEXL_EGY>QW*V1R,./K592>;,
M@E9:2SOUIJF2C\.:L6=FGO1@9:\+V4FCNPJEJ2O;EL>DWP\2_."SXY<]8&*X
M^V^FT"X0KT&Z%""P-@ FC@:U7S8\A9W3K,YR^C(DB2-$]9%?_!=L9S!A,5B:
MZ22Y"59K=UD:.C""-J5%8,K7QIYC0@G74Z@:=]2>)7@WXG\[^(^7L5J/)]&6
MARYRS!/#/S1DY499K',$D,D4T?*:EB=LBR(\,>PJI5I YV,]OG_G'=AN-2!S
M78A:<RR=HY<]#TK,2YX+0NRO.\K<'"&'\:)FDL[# 9/.TI=--?%?055[:7@-
M<%9&UUO6O)YPQ0HI.T.1-8Z1K)Z)5ZA0RV=A:)<KU!$;"SJLQB$;2Q&+J,59
M#J9/L<?$"3F:QC8LER;\L1[[,M,9[-^BQSI3Q/I$:77Y%-5KPQDV.EFQRW7M
MPT;\=_T6..>&PJO&\TN<Z:RYS9$8WH5\;F.K[/>9)QO0\4)([3;334';+> 5
MT/!J^>L#<VKEBK[ZM?769>#V>HRKK\ZNTT,<2N7FRC66T)*F0C"5(S8(K56"
M0I*^,#';F&#.MC=%)%ZS1SP[VB0PN0QT/L>^;<S)AFIYWE"W):S=N+%!\SGH
M&L7YZ$'.$BQB7P^@:*O)A^G>JY =*"SC;_1@N3K>@5RKRU\Y+;NF.P>& XY'
MGC%Z=77 YIO18CAI'5^-V[7BR,'QD,L/S(B9)&SM25$?"V)8O27YD>S_ +'O
MF6AD_%7E^MBH[4UP09B2.*['%3@94Q-P/NL13770A6+*!7<,1M)77<-5?9>>
M"O//(O@IF,]S0_+<>)7,8&H[X;+7\G=$]B\O1VU+6$Q,+1EHR)'-Q60$$(_<
M#'ETLNY+K!?S/35E(*OW<)Q%;LRB)2*VQH[$:^%*8O.;7Z>M2H4DPVS2$;[6
MT2,M]@+"R5)?07F#TR2O%\H5JU.,^DQ=2OE9I'>">G.ER.1?D&SL@]%ZDLUC
M9'Z,(A*9XU#;O)W%M DS^B2SSO\ ,N%EI1*%EBL1O79#\J1;Y>MM2.+<_6+E
M!&[$:"VG:2ZYL8[Z*& OZ]=,@T>N510-+!4O$JS02H.4RQ$:"OS;1QJS-R%&
MS'UXL%B5269,LQY#?D(I3;G6X(TE$_RB$7)DQPY!*QCK2PR)RTRR7X*(1*^/
M:29YH(TGDIV'9IG55)HQ#$:^]DZ?HI9J:[Y*K3!YDD1LPI6M)9+/+:"(L<KM
M&L\2*L:L;,6>KAS*?:,U2V <TUZ9.:9LRX#9[0ZWLC;UQ@BX(!0C&W1%@PJO
M4(-0"&R!**.L"Q,?<<^33'CT:A3GB9[DKRRY69)GL36IYKAFB^1(>C,+;SB6
M PQ&"0-"8XRFT-MKT-K?S]BQ$ZK618THQM&L4<$4=?8_RE)U$,"QE)>I)U%(
MD#MNU/\ 0K\,O7]S[Q1]41%_=KX7ZHB^J(O[+\MZHB^B>J(O]GT3U_M)\<'-
MYGZ3^'CI)O,_2?P\8^?)BOXSK/-/N&'[-2=ZN*<SQ=\3KNN;Q'A':>R.8279
M_B5<R*70E\FYCT6#..%K^G%W-#!??:W6UO4COABMJJNO*^6G%WZU?+LS'OH
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M35F>"Q3GCN1R!L38"0>B]2::QLC]&6$3--&BON\(\7#''*WHMGKO\S(%DIN
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ME$:&"RS)%M,#S\*>*O>0()]6L<]6QSH8R#Z^.=S$=]/]> \A(V&BNEN2;(R
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M]SH)49=#A.5;!808O"S%4BD/2J5'TCF#-#)ZJ'5)0K&-QZK[6VDE3I1[^7C
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MQYRQ((1"Y89F23C0Q#S.?%&QB I40C1B]DQ&P4-&(H0C!264,HL[2%8EE!!
M))'<G@.<YD:Q':;E_D]K432/%9-N^;$;RHL4KQS'$]1&DC1(Y&5@7151B54
M!W:\AY/Q<:ZW+9UW!6UL7,M[)8.!U70I36A,RMJXM0XB,1#!(4D"2*/'/-%"
M^;V-DEC8KGIFI8[&I=J,EB\66U790T$ 4LLJ$!B)R0"0-2 2!Y#A#S#S/S=)
M@,Y'+C.7%B?#Y-)6CR.3:18VI3J[1JV-56<*255F52V@+ :GBV69\EO+*+.9
M^*'FWCLZ&.DJF1.EZ)TILKHF #MC=(UG.G,;(K$17M:YS4<JHURIZ*N[_P"A
MW*WK?*,8W>M^A-[>_OXX^3G^VJ(HQ=8[54:^F2C70 :_U-Q'F=?[]8VIMU8<
M#\2#[NQ'@&L+8S2;0JU.%&:D8HYI\_+7EDCCL:D<$4\KXXFM1L;6HGI\7#P\
ML !1E% '< (X )]H&N@U]_%AYZE9V=L+1+L &<V&+LH[ ,QJZD =@"2!QTY_
MK/=\J2*;EO'[Q"S9@=(S.A%Y_0[&G)%SD92',HA9Z[E@\L%(PU4,95PO: TI
M4(2!)O1_Q5O#ZR_9\J'!.[UDD;5M--W<G4Z'37ST/GQ2/GF2(@Q82A$53IJ8
MYV0K'NW=,%:HT3=ZVP>KN[Z:\ 7D'W+RGV?/*_+V>"\?ZX:ZZWX^"1& [WHI
M<\-@O?N9RU'S(", -&X*2UC"BL7ME^?#7O*F&BG)CB@D09'D=L=C[]V2^LD<
M%*T71(CO*O!)&VW<0NX!]0"0"1H2//ARQO.]ZYEL+!'C:B2-G<&\1>W-LZL6
M6IS1K)MK%A&SQJKLH+*A+*K$!2=_DWR[_P#-?CA_CCTW_0#XU'Z!C_Z_<_Q,
M'\]QTU^:/FG]K,!_G+(_]V<")/#^_&)9?6<V\02DMBGG7'U)VTG2S-D5LDAE
ME\WF;OK2GN1LCR"OF2N5&O<]51%^,HKUAMTNY$;!M318QM4>2KI/ZH^ T'"-
MLGF7$N_E_E1Q,YDGW6;3"60Z$R2ZXD[W/8EGU8]B3Q*5/*/)BAF.(HL9XJTT
M]DHZV4U3>[^NFL%#9)&(IT@?.(7E*+'+*P?Y[I/D,ED;%[6O<BVO4IR!0]J^
MX77:'2)@NO<[=9SIJ0-=//V\98<US!7:1H,)RS TNWJM#=NQM)L!"=0IBE+[
M 2%W$[02!H">*!?B<9WR&K>"Y*?=@\8@J']=H8AGY+1;BQLELG8W?/A;/!<9
M.I%:$HL9BR2QD/G;.@S&P.C?+)&^\MU:D-Z5H9;#,:DBD211!=IF@)(*RDZZ
M@>S337X<:V\6<QF[O+E**_2Q4$*YNM(KU+MN:4R"CDE"LDU*!0A5W)8.6#!0
M%()(V'=C0,WG2M/BKWBS=S8Z6]\[^8<YL0-ZVLM6YGJ.SY@!U?:0P1\DW$>"
ML<837Y*@JM;>W0%"Q^H<TR(V6Q#&%V9QQX/(]_:->P/OT'<C7WZ:'B*T_ [@
M:KM.I:G##0M&J-1JKW75/DARL&F(UDQNBM,1TJOSM'PZ6C9><J&N^IU6 HZ>
MMFHKUN^W$NQH-SHR8+$0X 1Y:D_<U]W;[;X#X]NVG"J+P^<T=[<ZE^.MH[X3
MF^VZ5N]6)U/-5Y5-+>[CR;?>[#7:,GQE=%B#:[INV[$Y>+:(RNKEW'+LX&=@
M2;3$7 MP<5U&GM]WE[@.WVWMT&O# R=;66?0,+:4.(L">Q6HW6[-EI8>2) ]
M=H+7?W'DZ?K*O:<UO^.1\JHKB@UU]Y(6%7SK2Y.IOQB,/M@+>HMH\3I?I#BG
ML]OL[[1J/+30ZZ^[Z_CQZ>,1Y4+<>-M[SS 0Z+:5@5S>\SEJO*LX/%:W.7</
MDI-39E<=2\PK^79W/4T>N[D_EN7"IZ&V3-<^M*ND==4. N$$. Z=]=?CZH]F
MFO?7Z-?I^/&N!2^ ?E)NL+4ZN#.<M@S.PR8.AA=8]2*!GAHM!3Q64:GJW%21
M"2Q@%HI2M(?&.]K_ $F<UB/7FW+\D3RY_)WXLK!&\F8NVXT-69S&SW99D4D-
MHQ4D Z#1B.PT/'L]X>_96X/%>$W)')]_D+,78,=X=\M\MW;,6;QU>.W#4Y;I
M8RS/&&CZD"3I&\B!FWQ*XU.Y2>$O!X!]HLN>6VE?I.4ORK+D(2YO[3H4@!@M
MT729NLI54"PY,&?6FEY6>D+J98ZZ,>WH[\?0QQGT=J-/*J'*5]+D4B6J*/'$
MR101PY#I&$V;-R6.0BV3+&UN9Y&5W+QM%&B-&\>[AD?[)#D^SR_=HV,#S;9@
MNW8K5_(VK_)YN_*$>#PW+E.Y65L#&F/NP\O8VO4BDKUT@LQ7K=BS!9K6NEPS
MLE^'7Y.2:?6 4 /-K&:EAI**S#;OKE*.GEJA9$'JA-"O,HZZQM1("T6VKH;<
M^PJUF&;9#ANFA21NM\D6;%>NDN2IJRRVK!F%>SU9WM.CR,\9E*HNJ#84C0'U
MM"WLF& ^RPY=PV7RMJCR7S--#/C\)B8\;)E<**6-K8*">&E#5M)12>>41VI!
M8%BU9D!,>X1Z#<V>1>*GDS@]WT_+F8O 'VL59SVV+07IDL8D(ME'K( 4CGFQ
MR/GED=7%K,SY,:0HV+T?)\U?8N@Y6]"QU6L^1C<K8N2[UK2:$2"L--"X((Z?
M?S!U'NXBF7^R*AYBYSSF<J\F7X(I\1R[0]'FS%'J(U&3-2&0NE=D991= 4#0
MJ8SKKN&DA#X]]=FZ];@  Y:/:?,ET).9CZ4))7AV;<]A:BV?#8S\Q?!):_DT
M7+(9GEMY["LJ=1'HGU\$5Q2GC.!Q#^A1QM/ 8@O1$IKSAVCZMF9%*K8  %B:
M5Q($ =HEC+%4D5X8/%6D>9K61APV6CO23F^:*Y;$O6AN-CL)C+4J228IG:27
M#XVE7>JUAS!'=FN+&LDU66NKJ_QET\AN8M(JK-P$ =%6I#:W2QT -1J;0GDY
M(6;E";QD ?GR:6?/\]?5$O2@77+M)WTIITFUJY&K&H6RDT9M1%9:P5M4L2,Z
M*+PZI=K;-9,:V[79^H(NC%O&E=@T;AYZY<6QC;8P.466CFGGB$=C"4J]>S8E
MY6E%."O%@88L*MJ3E[#DR55J27CD<@8Y6;*Q-$2>5?,>Z8?)86^T^"RHX$?2
MZX:'[=T1MB1,81D-JV*%8G98-L4:Q-GE=.LCO:L38_EN61'-VA]CSC)*'BMR
M_8K2)=F6OF%2NP:J'W8FX&)G82A=B;FTV'=IM&A.O&L_LQ/$U.;?!#,8B;!6
M,1&V:P%EKKWH+H7H7AHGH\443L9&<+N#@+YD'B@?22[@ZL$_,F?BH1G?=@'$
MB:\&1Y-=:TE@)>"S-ES!Z0"-J%*.)LDBA2J8$A\Y40D)+9/0G/R6IJ\8OTXZ
M4;>DUS)%DXV+PV:<\5R-PV,F"1"KU9Y+&U!6$'7DE6%) WD?B^BDK^B6&L..
MC(%>FX"RPV(WKNNEJ/>YFVQI#JQF,G35#(R$"^F:7)<V;+P604M#5UGTS=94
MM@K] +5O K#QR&8Z2.>TK\]'! 'GY9R93PQ664]:9)+,5*VY!9&MSK<3IR];
MY3$8R5<)!>BKM#7FCD&(97LP451(:#R2--%$MAZTS,\K*JCHL$1KMN3I^A;_
M $28M)6>422Q.AN@K#)9U:2R%18W8Q+*@"HK%S-IJ8,RB562&L1")KTZ8\C7
M"Q$3V5E;6-A=O(%;GA?HR&7!1[)Z]1AW@2L>%)#$^!S&OV.GR4= "MC8K$;O
M<F::3*(LCV+%J>>WU(QCXA#(+<DRO 8XS X,+(C1E0VVUJ-:/6MO$ZK7B6-:
M;E5BBABB@"N;#]13 D963>PE!$@9@VI_H=>&7K^Y]XH^J>B_NU\+]41?5$7]
ME^6]4]?1/7T_M^B>O]I/C@IO,_2?P\=)'S/TG\/&/;R=M.)8WS,[GONV7/>J
MNJ#\9O#C-T\/#_(3K/#)BS"=?^(OMS_O<?/.R\?J=1.REP%FR@$NC+J]GMI8
M<[C*\JYTJ5UA:1K[_K(_!Q</M1_;-YC7V)\#[_9\.#F:E\.HW7-=#T?S>+UU
M1L;?!0X>#SC\YX;RYU5?V"'B%=45=K8^2(&)8;I-H;52TXMOK:HH?.6L&AOX
M:2M#N):PT'Q^L_CXIW^'U+[M?=[ORUX%;*7Q7K 0#IG_ (B4R7>,H=[FA!/.
MGRO)-T.?ML9O=Y:N''9YB_\ <2PR=#R[H:V];L'9LN\/R%R!S^/:SP1I*:#X
M_6?Q\'?73U>WMT&GGIKY>7!;8YWQ'J[Z'-6&_P#-*NMBNHIRT*.\_$)\M,L+
M8%_E/G^S755]AK/+:B!-R[Z?J.(:% .1)LKDZ[@$H<A:.17?!H/C]9_'P=_/
M0>6OVH^/N'P/PX:''^!>.7;\F3M<1N_-1<_%I=+FQ2K?SN\Y*^2U_+EK/6-O
M:V%OD@0^6@OX(H+K/%D?3%F4IX))8(!,DHD)H/C]9_'Q34_#ZA^+C3;\KN.9
M2G\P?+JD%N^JS!TOD1O*P2>T[CV>[MYQQVU:QRVU]<[T^\O;!WO7Y]K=V%A9
MDHC$(+E1C/;UIX18:I=Y+JSS3Y9'-W(*5J9W-T(0%G(!%>CD*]=6(^V81AG/
M=RQ[\:2YZR-BOS!+'''1916JG6?%XRU)J8^^LMFI+*1[@7('L XK-HLKB\U]
M+];8]5(^HC**D0+K?4)%#K*]1DLK8KY^[&3Z*O\ K!?J&#*2<_Y[/I0B/;)[
M)]>QN(Q_3ZT_,C]1996Z7-',;=&M!T_2+4N_-1_,P=6+J"/J3'>.G#)HVV,U
MKE^UOZ<>(7:40=3"8<;Y9-W2A3;C6^<DV/MW;8_5.YUU&L!<08"FMIZ24CL1
M9\;["(=@76.D/983T]0!?7, <A'1!D22KJ+(4R?ZQ!(R$64:N>:9$\9$-M,)
M4M/39^:I9U,ZQK#S-GR+#U:L%VW'$SYZ/1JU6Q',_6Z2OZT<#32J8PH@?)3P
MK.%PB1GIER^%Q.L2S325X&<)BG.V6>)XUV;RIT:41HP<GX_,\L5! 3!=='D@
M(ACGAD3KW5T1\4S&R1O1';)%1',<UR(J(J>OZHB_#Y'R]C9$21+>?9)$5T;\
MU/,W=7 93WRVO<$'OPW-EKB,R-#BPRL58?(>$[,I(([8_P!A&G'7QR\W&1!W
M5#E.M=QR],'TO3_(J\YW3K]&#\R2*L?*3,-5[46(@V=R^I!Q#93"/:SY\\GL
M9[=>5O"OD/F"YG+^:P7RG=7-W*WI=O)9>6P\,"0")9)FO[Y2@8C?(SR$: L0
M !.X_$SGKEZEC<?A.8K>+HFA%8%2E'5KUEFFDEZKI#'76./>5!8(JKKJ0 2>
M#S1=IZ;F8X)3N[>3D[96&$RH%Y%=KD<)75L"$V=H2D_1Q_4*OA=&\AHZD&O6
M6-@H9+U5K;+_ (0^$N.5&FY0C<,LTC"*[E&,5>NG4LV9-^3C^9KH5,@C+S-N
M4112'4!55\7?%:V6$?.N24J8T'4>$!Y96V10IMK-Z\C:A2^V,:$NZCN8.U\A
M^B55O-1N[;Y4&6+7FPB1!>0_8W-LR:RMK;BU&"D)Z@,U):VKM1#"%-4.*9OS
MH092RH)($1V?"[PBK6WI'DMI; ,J1+#<R!%B2O6KW+,<+29>,!Z]6S%,_6Z*
MN-Z0--*C1A1#XJ>+$T"V!SO?2(B-G+NFL2S2RP0/($IN2)IH7C3I]1@=K2*B
M,&X.!.E]5.%&-%[_ .2$HQ@\)0\J>1O<VI) 1&V6%Z-=OD<B/C>UWHY$<GKZ
M*B+ZI\/,7@GX4S1QS1\J5FCE1)(V].RXW(ZAE;0WP1JI!T(!'M /#>_C-XIQ
MN\;\Y98.C,C#=7.C*2K#40Z'0@C4'3BMV=RT>PT/4;W3ZGIMU=$](M(S+8WK
MG47V)ZPT.;9'-8F-U[2+$M(_;"IITA!;H(H87SNB@A8QRY4Y0P>-@R^.QR9+
M'T*6<M05:E'/9VI7AC-6C*0(J^2C4LTDKLTC!I&)T9B  &+F+F;,9.S3R.2F
MJY&_=QT$UJY>QN-MV9Y.K8C#/-/4D?14C154$*H7L 22?5HLOC,S'!*=8=1G
M;*PPF5 ^L]/D<)75L'U-G:$I/NA_4.OA5CR&CJ0;(LL;!0R7JK6O5_'8G'*C
M33\QN&6:1NES-S$QBKUX^K9LR;\S'\U FA=8^I,VY1%#(=0&FK=OVRPCBPZE
M2BCJ87$ /+*VR*)=N.;UY&U"EML8T)=U'?B&LPL+67,U LW73;)DLPPL(75N
MC*VQ-$ I[4X(.0KH8K6SA5=Z ?,\SZ0:2%T\0I!)0\H[4EB'#5[CT=W-,UD,
M\<20\RY[2Q+%!4M30PM+G8AOAK78)W,O2C9"ZQ/))&T8412Y&6!;.S!QQ%5=
MVDPN*!BC>2>&.20)C'.V2:O+&HCWN&VEU1'5B9@\[R=D$'8AW/191#Q1S19?
MVM]79\P<J%D\$GL?L4<WWQ2-=[7(CF^OHY$5%3X=X<%C+$,4\5O//%/&DT3?
MFGYF&Z.10Z-H<J"-58'0@$:]P#P@DRMV*22*2OBE>-VC<?(F&.CHQ5AJ*.AT
M((U';C;I_P!3U5H]1X9=6KA9;": ;ROZ2V.6TM;.[.<CN>\B>OS[.Y+/LBG(
MKE1KB2I7-8C6-5&-:U..?$FO'5YXY@KQ-.Z16*P5K-FQ<G.['TW/4LVY9K$I
M!8@&25RJA44A54#>_*DK3\NXN5Q&K/#*2(88J\0TLSCU(8$CAC&@&H1%!.K$
M%B2<BGESD*CH.@\4<#H$*6AV_>ND9"[0&=!C5J-+X.^8E+9(&2K)4'*^B-F^
MGG6*1(I?9(K'^WVK!^)$/;]'\HX'M+X \NV6@M-;J]UTR]U=_77(>BT)D7*F
M6%V5;Y?HF,CL9VB\L'# 2OSG2;2M=GZ06KQVD@I\\S<YO5M%L6VAP:]M-!]_
MX?'VZ?D-.(B?\-WA)^=TV4M]'U4_/Z:KVPDM8%IZ/'C5=OO@<'7W>FJHN?Y7
M)1L.'@YEB)*3/GLL,#3&T0IX6.C,:V9AP;CKKVU\O?\ #VZ\,NF\/LG1:BJT
MU?TOK#8JC2#Z"#-%F<]L<X8-3Z7;Z_'YRXAL>=%VMS38/2](W%WE2[&W(T\5
MS=!WEQHKF\RF*LLX<&OY?<T^_P"WB5YCXE\\Y=M\GTD#2=(TNYR?/=-S!E[J
M-6QP]WE-)J@-<P:ZRV;K,WBDGS]D%,RCDI<U31>RTLCKF"XNY1[88X-?9VXM
M%\'%.,'/FG_7O:O_  5?'/\ SN>7/Q >=OM\;_:V_P -?CJ7[&_] YO_ +K@
M_P#0RW%3>C\YJNETHU+:V=U3M#*L"AK"AEK(SXEMLSH<=:0I]WJ[@!T1N=U%
MT"]9 7S0.)86'*.8/!/'"X)V@<NJJVH4$/NT]61)5/J,C AXU/9N^FAU!(XZ
M+R..BR4*PRRS0['D=9(#$)!U:MBG*/GHIHR'KVID[H2I8.A5U5@$ZS@E-M2;
M0B_V>V)8;01YRK&:W$-BR(#;6.TFFR4[L2^PJ;$[Y M?9GO-*GM*\&MAL5*E
MK*^<;+'<>(*$BB&C[V.LVLIVE0)-)0&4:EE&@"L6*Z;F!16\!#=>1K%VZ^ZN
M*T2Z4=*D8E$I:JQI&2*63:D<LA=VECCC$FXQ1E777@"58 58!"@X-<(, % U
MSWM@$#A8./"CI'/D<D4,;&(Y[G/5&^KG.<JJJ5F+,68ZEB6)]Y)U)^Z>'J.-
M(HTBC&U(T6-%[G:B*%4:GOV  []^/3XL_P DYW\]'DW_ ,Y7K7P[6/MHOW)1
M_B5?C54'V^1_?SF'_7N1X-=%R6IT&]J^B_F#2T]Y4@ "#CU;Z!]9(13U?1*B
MDM)Q[?/VI#CJD3J6P4>.,N*M*F+#DLP#DKQVM$G9(FBVHRL226W:Z,8F9?59
M>S&&/4Z;@ =I&IXQ2T8Y;26^K-'*B*H"=(H3&EN.-R)(I#OC6[8V@,$)92Z/
MM''QFN15.=L*VPFT6HT;J;5]%VM2+?/SJ!@:'I1Q)=F;#%19RC<]]*/:Z:IS
MLA$DQ M3KM +8SVKY*Z:M'G9PRA$0,D4;%=^I6$ */6=OMM$+Z=B44@+WUI#
M0CA=',T\QCGMV8Q*8=J2W&9G8"*&+4QK)-'"6)98YY5<R$H4"_,+^M(\I?\
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M?1J/;I\>),6P\"5Z56;JS_$=\"#P!=*^SLZ5.I<9;)=Q,[7ENROUMF7/U\F
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M;4W3"^PU&YK-=:FXFBTN]VDQN>NZ1!;4FA&)8/:C9UE%]3GQA:,_GAT^-J(
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MQ7@9NO9M$FETI&7;T+*2B!VJ9O TMPL=I-1*+-9-Q0F6<1G/N4MI4UNMBTI
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MZ$7<-$"M,'<YP:L*GV%- .5-06+C8<]/:Q4V:UIU1I<SGKNL(CW13OTWG/\
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MXF64H+/.5CKJ_!M>.<,#)IJB)]6PJRLHIB6N#"KVWE(3:D3HR.I!NJBPLG"
MV8)$YP:K^Q^^>.1D=)ELIJ=OXG&,2U'N]%G)ZZ3DG!8C([S(T]QH-56N'E-9
M+]1FZ3.Z"SO/1JLJPZ.XE-?"E:9\DX-1^P^^>._-1]9V5M4465_$CI;^XOP+
MFSI:ZKX9QDLJS"SMD13:&4..-R_.?0VXI-9=0,52*JP'F#/B'(C?&AP:C]A]
M\\-#]B'EG_?P6/\ Q=>1?_.^#@U7]C_[QXTA:H?L \1X\/8$;&/H-2.GNY_F
M'N>Z#2VT4DKE5R>BS2,=*K$3VQJ_V-_@M3XYPYDR5*+/Y>-\4DKI?LJTIN64
M+D2$%BBG:NOGHO8>SCV@\%>2N9+OA+X=VZW/=FA7L\I86:&DG+V&LK5CDIQL
ML"SSJ9IA&#M$DA+MIJW?CDUOTX>S%I9^Z5\5N;$Z82MDPV28:1$UA,OOA'=,
MDKT=$$=+&B-59(@3I(T<P,ET32+]9HFG7! PH=KRBY<**=4&A;70:&2,'W&2
M,'0NH.P9.5,U#?KXN7Q4,>1M(9*])^7N7ELS($GDW1PD;VW1U;<B #62.I;=
M RU9S'X1]7OBRP@!O("HG,L9"8J\:+$Y%\ISQ(Y9B$$:V9?J$CA@GE]T7O:^
M,<A\;G-@E5F1K42(\C\O%4C"F1C;N ('(5=YU]74LHT.A!900"PU20X*]8L5
MJD'B[%+9NO/'3ACP/+C26GKH\LPKJ/T;9'%+)K'N5DBE="RQ2%8KI;>N_LXZ
M!]7UII0OY)U?U(OY"S4'U(_V(_YP_P ^-ZR0_.C]T?S6(KX_=[V_PD3XR8W*
M46R-!5Q$:,UVJH<7;1*DSQ@-H3H=I.NA['30]N$G.?(O-$')_-<TOB#:L1Q<
MM9V62 \M82,3)'B[3O"9$4/&)%!0NA#J&W+W X"ZMG5EK*Y6=41C/H _8S\C
M9QWL;]/'[6^Y7>KO:GHGN7]5]/5?U^/8V# Y<P0D<QR@=*/0?)= Z#8O;4C4
MZ<?-7+S! )9!\E0G1W&OI5GV,?\ I<>>2\WL)1H4W;:V(NM#EL+ >7(92.0(
M&"."8@HIKY4^1 /"4+,1))[6CPEB2S*R,H=TF)L=;22:%^;E66O$T\\;8_&J
MT,**CO+("1L2-)8GD9M BRQ,VBR(6O&8W(DBX,,DKB.-A/;(>1BP5$T/K,S(
MZJ!J69'5=2C =0&CW%H4T*N[A6&F/'E+:*-D,K*1]/!.@I$BPME61OTQ*M@)
M8YJ2#S.;',V-[D1;8:-FQ((8.;TFE*-((H\?C6DV(_3D8H#N'3D(20$ HY"N
M 2!Q63+M$A>3!A$#!"[3VPNYEWJ-Q.AW+ZR$'1E[J2.)";)=%W-SS_$W/5YF
MUFQ[!Q/*ES"XG.1$B1Z'KV)J&GCN57-=/72&,.AAD:L,\@[8)T6&1Z?$;Y^A
MS?+W*.9ST6<-J;#15LG!7FQM-(I9Z-ZK8@65H]'Z?5C0N%(+*"NHUUXD7)$M
M+F7FS \NV* K5\Y?CQ-BQ!9F::*#(*]69XA)N3J+'*VS<" VAT[<9=/]:I3^
M^9W/^3[ _P#1_CEG_P YCQ"_K>&_R'_YOCK?_P UGD7]M,]_CJW\QP#3?A[\
MY&#UM@3YI'# 8))7;0TC-\P@$R[(2#@Y9+PB7V0U\<9]7:5SY2'LC;9U5I6J
M[Z^N-'@RC[)'Q()C KXDF73I@8\DOJ 1M ?4]F4_0P/D0>$Q^QE\.@L[G.Y<
M+5U])8W*86  LI,K&+1 &1T)8@!XY$^V1@)>L_#7S%S=WN:JO+74'7^9C ET
M%./AN?OL:B&TEL(*V<X7Z=)8(#YJFTB$F<WY1$M<;'$]SAID9:WV2GB*JJ[0
MX<*^NUC0[-H 2 =_<@,I(]Q'OXR)]C!X?R22PIF,VTL(0RQBQ6+QB0N$++T-
M0',<@4^1*. =5.E*?Q%? YW#N)Y?6-[=JM@MCU.DSOVRQR&1JH($+R6WLOKF
M$5H_SWRQ?:$';"_^I.85(]W\../X17/&KF[G.)<7EEQJUH)!?0UZO2?KQ*U=
M=6W'5.G:DU'M.T^SAMS7@5RMR15CRV-NY6Q/8L)CG2W+$T8AECELLRB.-#O#
MU(P"3IM9NVNA&S;L:ZHVO2-/B=)QO>:^YTEYYX<LYW8Y':8*I),H.K;/F ?3
M-A7#W$I!N=L<+/696C"O=&,-G83=,BD0V"F5S6M7$!'\H)U^&N@^/_C[N(S3
M<"EJJJTZ5JN4="I(JVIU&NT&BI^I^,N?R(^M:;H[?#='KLT%8DU-7+RD75=6
M"RN> 2>CT?[1=>=LP-;H)!+$4X->VG_C\?K]OT?$ZB]P/G=<#526F?UHY5-S
MKR&ZX5;!].\;,_M!!=9T;9G]BVFA>4<MC5XC(=BWA)DG+M/5K7T71,=GZ^WA
M-.R=W6$'!J?/Z/O>7EI[!^'B +SF0WT&JI[/)=2.J])@NM],ZC$N^X)5U%>?
MMB/+O(;;HNILK:*6MYQ%16G8>^T<V$V) \8%QS:IK+<&4O(;4;4'%=3V[>T:
M?'L-/I\A^1'#VY5>;/&;W@PHG,NG&CA574;'G',-7;<;R5"3I][H>H['5V^/
MKRRZ!V/O:^D+T&<PV0(^JMLSQG#7E7D!H:"RZ/<7QQ3OW^_I^7O\S[SW]G&(
M# _B,8^KX/C.7Z7@G4#A:[DF>P5^6#I><##&#B8\3/6I <\^M@(@@(CC(D'E
MFBBFBC>Q\C(WM5J:;R'-&&K92]"]B<3U[]F)U%61P)8K#HR@@Z,-ZD CS]GG
MQZ&<I?8_^)>9Y+Y9RU7&8EL9E>5\-D:\LV<J0,U&]B:UF&25' :%C7E5G5B#
M&20QU4GA&1^?G-DY'O*4:B[P55;F:*/;:E1.+FF2F@X[GF1J#DJJ^T@2I<+S
M_ T4:R-&966*W!6F^2@QE5$+F_-+C!;BB99EF"[HHFAD0,IEE#!7:0*QZ[.A
M4$NLB&(Z.CCA&/ OGDX.[DXY,5-C>KT[MV'*0V&A?T.H\;S5X*;30(<:E:TD
MSPK!+4M17T8UK%>0LKEWX@_+L]M+[35/,NRZHD>/6N IY;OCD0V33L.Q3JFX
M5) -+"<:[4:UL5H#':D3NHZP4>J":UB$SDIK/-6)CCCZS685D.BNU2;YWT8=
M#U=6(TC'J,5[,W?7V!VQ7V/7B'<LVQCHL'>EJ!7GABYAH,:8RQ^45$H6,.K6
M>TT:2G='& H5>^I'GOQ!*^\[+U;3@\*Z,L%CEN5UJA2Z'G49(LE._>R.EE<N
MI6!\926;4A2&5[V+!+\YL?NC]^"QG\/-5JS"U(J-)912U674LG1+=@#H!O7N
M?/7MY<*:?@MXCT,UE\;+B,>UJ"IB+,H3-4RBQ6CD5A(<@!F8UY=RC7: I)]8
M<!,?EMDU[5=:*OP?5X-.58OUS\DV\X\0&!?39+F^*O#8BIKAQ$KR,!DLY7K2
MR&R35,>J/T3XWOL\[+57G-X\4DD:1_1^T0F]&L#<O4G= 5'<+UC*%D*[7:$Q
M@DQR#A,GA+SBV?GIQ04#DP&N24!FL>>FXK8V&?20Q[3(M'T%I*O5::&&]';>
M,1V:KK"Y7S7P(8&';9XSJ.BK9NN[+JF9B).YE3@Z"\VUM9EC0%PMO$CL,Y3:
MWI<%CE[&3Y0SM&9B/EV)-D+6J9FER=0-8 9T:&LD,X$,KM$L:,6'8G24Q593
M)&-76*.=BBH'*M]3PXYF>'%2$49H<ADI[6+9\E7KQWI+EB%(F4/ HEI"[FJ4
M=2X=M:6Y=QL4=B2Q+7607\X/+$CJ?-\-F >.;.D*;U:GLXB;70X64:;Z/(;A
MCQ6_;M"7,R9[)W2L?)$V'TA>UTC7OC1VT?L?\M3E\5.7UH&2]96'+LE8(:Y=
M?DBZKD2V"D2[%8OHS L%VCN1QJC[*;P[YMY>\'LQD,]1J4,><IA(&LQY""ZR
M2RWT,2F"OK*0Y0J64$*2">W&*7I-D585@GYASEMGQG?=JUQ4=_DWJ37W%)8
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M6+QSXA];206;+"0)Y['8IK85FBJCYG,]RR00C_.G;%%)"^0XKO?]DW^$?Q\
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M*606:Y<FGAZ5>(RU(X^I(00H9U!.@!U('#OR9X7>(')?-G+W-?-'*V4PW+V
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MZC:QKQZ]MP .UEW'AWL8F&Q>CR'7LPSQ)&BB(P&,M#'D(H)66:O*=\*Y.YM
M81L9%,L<G330<I^'Y:GT=3IV7UZ4?4;+0;N"&8?%ABOO]+F&Y*T<GV;(U18
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M)E+I!(02-5TU(M!^Y+YH?WOA'^5+D'^FWQU!_P"<YR)^UW,7^24_]^X\\?\
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M'JY\/T*&L:R-_P ]\#UC8_<7ASC]>7&6&Y5LJN3MZRQ"VB;C#3]32Q4@DW
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MA;6,T<+H:VGKK&W/>/6UYA4$2CMY*5ML=NXS>X69O:0!WWZ#5B%'[)F51JS
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M))#<UN@CTH@M\#;UQPIU7;"CGUDX9,$4C#BFG_2'W_Q<0;^+:%X9]>O@99-
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MB[#F55GT<RYZ+GAO6CU^RL)I)SR=!!G9XQ!;"F@]P^H<5U8]]22=2>_TGW_
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M1'VG@7TJ*;<6#;<>UKBHSEWC*Z4KF@QE<?65;Z.NMBVD=2267.@TL,$=B,Z
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M2.';&\K&-6!E#>MV(!'MUX"OO_D+_P";N,_\(;?_ *N^.N?D[/?LL1_A7?\
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M22/Y2NML=DW+;L;6VL5W+\YY'34? \ G/L'AR"^C)/C,I,@_1K8<=)L[42)
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MGN9[O<ULC'*B(]JKH?QICDDDY<Z<;OHF5UV*S::MCM-=H.FNATU\]#QZA_\
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MDVC@LD2 $?K8_)F.4&RV1R<7B!RI6:_5LU5>'+8@7:RVJV(K,T5ILDR%JIQ
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M#ZOHO1*?:U/G0$!97D&KP@FHV+Z['Z=C[#0:TFR+")M12ZPXIIYZGW>_0?\
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M%]SF.)EB,,I4R.P<Y>V0>:]H>+U5Q";+>7#[0([G'T!95_:V-V=*$V'HIK6
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M]CK+:?J/HPDC1$"QG>[L6MS6MJJX"K%Y-WM1JT(4 =9>!=K?*L <$8\2RO3
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M-DW?HCQKZW"7Z-8D758-$?GM+FHI?NM.\JT=@I1RA]%2V%.6&*V?HM8R.U=
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MD::MB>Z[S6JKH_N>\HL320#3 5[KXRT&RT>HQK[Y-734XN[;1K^R;\"?$<-
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MTID  C[/*8ML3/I/+$0R]2Q$FC0P^OU"3\S)IH J^T&^^^E-JXK\?.R*4LA
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M;.:M1V;EJQ&,7.X2>Q-*@<6Z(#!9'90P#, P&H!(UT)XW0.R?R0]5_FWW/\
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M(^GA"^1=&9'H8Q61BK*:4>H9200>_F"".);A^HZ5CPNB462[!U7-5 W3[QZ
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M]$E<QK&/66)71.21&M=[FN1&/"9#*K+GMN L.6SUEG OXY>FYI8\&,[IQN(
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MUJ>+L69%KTJEJ[9=(62M2JV;<[1UZ\TJ> X3EU?*; 3G<[\VN%D,-:/D6&I
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M.8VLQL@W4!29<O-1<\=/6+]F&8FLMPRRBRAJ!E=:R7\RV:,"P&HFX($)%N$
MHLLTRML*DAA)-H3N(V*5 !;5=+_FZY;7)RW4O6='E:RL#8J<R*\M2A1E#2+9
M7=$8*.Y!T@18E5V9EA$<BXKNJB1RXV#37D-K-HNU2;;90B8*DJ)>G;'*DX,/
M)9O-QN[68^GGYX7G<V*+1UZ6QTY-#SJ"_F.E#TS=S>W+.6];94"GH&O!K>@;
MIANH)B?4'4,AE;<?5V]27:!O3II8^>L!^=^ODC+OR8R%[;AK$7IT\!J"HD?Y
M]?H"D:T01%ZC.:]+K,^RSZ7,^9^JTO8\7S3 8CD'6"M1;=>K)ZJO/HJ.M;8.
MKL%T0XL8<DC2H.A,8,!1B,FDB:^$6?VO61(XY)MX5H>1.=\3S/S'I5Q%"/()
M9GA_/,B&WC[-2#2&'=(P:>:-3M!V@ECV!XAOC3EZWB%R'>Y5Y8BM6\U?NXZ2
MK7FA%1)%IV!:G^?G=8E*P12. S#=MT!U(!QM]4\0_)8NI 2[XYL,>*60?FV&
M:(GGT(9TVNI[#/MKP%,Z)5QNOI4,5]1&V4AY#V3B('*TESX>H\SXT^&V7A6&
M'/6H6$=R*0MA,A8'0N4IZ<[(B]+9-&DV^.5BR@!XV7;*67CVCX,^).-?JS\N
MH5:2LT>N8Q<&L\%B.Q"A9[#AED:/8T:@.=5=3JFUH32>$'E5:7=@P[C^O!+^
MK7>PU\@^&;8"MJ:Y<V(2<R;IS9)\C"$T9+AB0"QD6ZDS1G@QD,$A0W?%_P .
MKTTLQYDG16OKD(@O+^18K:AJFE6@E<RZ2T_1E1K%91&\\_5D26%'$2*Z_@_X
MCU42$<L:NM5J\@;-XH$UGG%B:9%WZQS]8LL4Y++'%L1E=E+L?YOQ&\I0,JU\
M' >@VPQ_WK1):U[\-]L+;I;&PT;YZY8MT8UU9[K1R 2-))^8&V%_SI5=[G/%
M+QT\-*=4UFS=J65IKL\C+A[T2]:[;L7)42-E<I&DMADC5I'8(JAF9M26^QX(
M^)EF9;"\O*L0BJHA^5,9(3#6KQ01NSK84.SQQ*[,JA2S$J--.-YOPS_K/_%+
MU147]VSA?Z+_ !I_WK\M^B^GJGJG_H5?CE<]R3[R>-D-YGZ3^'BDGD!R'JG:
M?+;R%RG)-V7SR^%\;?$&U.OPM'H<R4@TC?Q2:#.PPGYJ6&P^8-T2^Q%NR7WN
M93OJVZ6 6QL*,&M,IQ7]:O\ ;-^!/@?JX:!W$O,"2+2B1]'$)Q5MU33:9W-H
M].+5-,YY;=["ZJ7GQMO6X@7= :30XIVAYS-')KW9,*KO%KF@P"11V09Q34>[
MV?'STT]^GGW^/"XM/&7RRL*1:U;XF$X'#8/(ERA^1W4H!MS9T_%-_F7:RTNE
M!2[I[G)]9U^(NA#*^N&.OZ3D\FVN"[G:;&/.41P:C\@.W?7[ON^ ]X[<->GX
M?Y2T6IO[W1;N'HTEMY'<ZZ16%5G0MQAJ^MY]3TKJ'44!F.4NQS:UC*0:JK1,
M:$--1W5P*7M[1B:RP)M9#@U'N]FGW=//^7[WLXL)XN\[WG*^5BX;>6MC=R4=
MJ0+F+/2:J7<;TS+1U]7' 5T?7MK:6LT&R,NH[PPJPHZ6KKG5!%-%,-);Q6IA
M1P'\O^'PXTF?,S^O<\T/\);H7_R-3\=D^"_ZA*?[OR7\8/&A/$#]4<W[EJ?P
M9XIYM:2_N5JTI2U'; XMLJMLS*Q1#)E$6ONE^C8[[DVI2$M%J"5:*<IC?F_I
M$CFSW+T[UOT;T.4QA.J&TLS5C%,YB]'N?-*?2!4V2_G232*<RC>=$!$:Q]BM
M!UO2$W%@FFL,<V^-=_5K^O\ H1GW)\^OKQB,@?;< VBQ^_MKLJR&*2$"=#G3
MU<>NN@&%L.S=.!4B1N"&:P#\LZ$2QN%('8QQ;"EFB:\DPH>-GOXK-V;LMB*;
MIP2"<O77*7(1()L=4KU8E,486#Y/OQ6+9DC ,HEWJ#)++&KA6O8V&O'$Z;I$
MZ868TJ\A0QVIY9G(D<]3TNJ\4&QB0A31B$C1F=HL<T0HT1$WU$\4$,<Y'M1G
MSYF1M;+-[$_1OS7HY_M3]&^[T3^+XE\:LL:*[[W5%5WT WL% 9]!V&XZG0=A
MKH.&!RK.[*NU2S%5UUVJ22%U]N@T&OPX7?-O_#Z#_.7IO_E%7\,/+_VV=_OA
MR'\'5X=,KY8O]Z:G^G-Q(;BDO[J&OCHRU&="XYKW)9FU:B&$"_*K+KW!,<ZP
M2F(]\ZU!'M&-65'2+[X(T7/F:=ZXD"TI>F5,P)%B:MTI7CVUK>L()G%235_1
M9-(IBP+>M&O&+'V*U=I383>"(R 8DFWHKZRP:2$"+KKHO67UXP"!V8\!5]D=
MY9WA=G"2C*Z=2GD5$6LN0&'0ET5$'6@1RAC,;7?EV]!M+;ZH9C%.88JM:LIY
ML,33=Q6:L79;*2[:[]0O57*7(!,LM*C#7A5HHP*WH-V"S;,D0!F$O;5IYD1?
M6NXZ&ND3+K*NT+,:4$AC9+%B260AW)E]*KR0P[')Z930Z+%&S.4"$@<$* LC
MZLN 0>$HKV^SZDB.%C)B/;_[[\Z1KI/;_8]WI_8^)7 LB0PI+)U94BC62733
MJ2*@#R:>S>P+:>S73ABD96DD9%V(SLR)KKL4L2JZ^W:-!K\.%]SG_P <Z9_.
M9<?\A9KX8\#^C<Q?WPV?XCCN'/*_:8G]Z8/XQ:XD=S27]W !'1%J,^)QS7N;
M9F5:B&$"K#677O"8]U@E,0KB%J9U:,:LB.D57P1)\*,S3NW$A6G*8RIF!(L3
M5C%*\16M;UA!,XJ2:R&I)I'-N!8[HUXQ8ZQ6KM*;"!P1&0#"DV]%?=+!HY B
MZZ^IUE]9--!V9N Z\R>YLK\RTBG1*R=TCYJ:/66X##19JK,"B5C)1!FMKUJ+
MBLN[=2AV-4EEDHZ>Y+"P9"TW<7F;%^6RD@]%<L7J+E+E<31O6QL45</%&/1_
M1;=>[;ZL0UE%CIC7TBP$75[N/BK)"RZS* %G-*"3IN)K;O,5D8F7K02UX-CD
MA#%N_P#51DMVK'+%K*X4\KZTX8 0<TWT5/JRX1XXR"O1?U3ZB9KY?1?U3W^B
M_$IK)+%7KQSR]::.&))IM-.K*B*LDNGLZC@MI[-=.&29D>:5XTZ<;R.T:?L$
M9B43M^Q4@?<XVN?]3_?UH'7?\+#H_P#F[Y!\<2>*7ZO^9/W34_U92XZ'Y._4
MSB/[A+_&K'%]_,</$VEQXH4G2#:P#!Z3R"W>6UD]Q<MS]=)2:CPI\O<^<'/=
M*6 ZN=80V3@("(31BFD$Q(),PE8E^(!Q)A[?H_E' 7:<;\.+T\ZXO^XU=U?7
M,)3]'>&]DQD=AI+M]-OL]5:BU:"H8#+O-4O2M57T$=8%6T<$$]>AU-8.J*UP
MQQ3B)-\>O!2VK])5775:6U"U0&R@LVN[T#4%,M^A@9JJW&I"LLW>TEH-?:6I
MQ>0K#&H:ZC%$H(VU=)7R7&FDO#BI)/N^'8=OA]'!'/RKP\(E]9>UT4@;KJVL
M9JV?K^,-%)I+JIZE2%X>:8]Y=DF18!V_KC!88K"*]&?NK!\5\BU682B.#7\O
M:/+V_<X(^59;Q:X[>5=WD.ZYGTJLWH,V/3672N:$436:S7G;G3VH5>,&'^7[
M71:$L8B^3*S4-7=PT67@M:LQN:I5".#7\?Y?E^$ZV*_;AQ7^Z_R[_*!D_P#K
M;X.*<:A'X\V_PE_YOXH^AVN2NP6>*G,Q'FU&DIK(1A<77/(.:45Q 9LT+2(X
M21Y9(5>DC(YX9'-1LK%=HKQGKSSR<N]"":;:F5W=*-Y-NK8[3=L4Z:Z'3737
M0Z>1X]7_ /R9V7Q6+H^,@R>3Q^.,]OD,PB]=K5#,(X>;^H8O2)8^IT]Z;]FN
MW>N[3<-<(EV1D+\1@AV@K6,CDEDCD%N@H)F*0$76E-:_YSD1I-<>:'(OM^8R
M,E\H[X2HX"(M-4TRE&4RPTK!+*JLLE29T.R:*Q&2-@[QSP0RKWT+1A7#QLZ-
MZ5<Q6>1.9Z4='(\SXA(XI9I8I:?,&/KV(S:Q][$7$603N MO%9/(4)3MZD<5
MMYJLE>Y%7LPQTP.#)-G/)NJF<@@-:V1ZV=1$YU=(8&82!+*.D,Y097V\,6:
MR4EC087"CI!&04D^=)LU'"D,=2RD:3>D*!6LL!.L4L4<RJY9(Y8NO+(CQ(C&
M9Q(Y=DCV--G&^&EW(V<I<Y@P=FW:QQQ$LC9C!Q,^)EOT+]O&335A!9N4;QQ=
M"E9K7Y[<2XZ!J=9:\5JZ+)5^9,[_ .?Z7_A0'_V_PV^@7O["M_Y--_L<37\U
MG*O_ #FY?_SSCO\ >>-EW\,KI7.:OPJY0#9[_$UQL-_VMTH9VJHA"HFS]ZZ>
M1 Z0<@^.5C9AY8IXE<Q$DADCE8JL>UR]!XJ&88G$@PR@KB<6I!C<$,*%<$$$
M:@@@@@]P00>_'B1XH7Z,OB?XE2Q7:DL4OB'SO+%+'9A>.2.3FC*O')&ZN5='
M0AD=2592&4D$'BTVA7@FCVM=OR>K9H'15E>*"/-5]%S0PSI*ROW%51V,H\A4
MZ*?0@=*WD-<K'QAROT<I-H'8EU.>GJ'-?2$0QB%BI))W1,3W*%AKH.S&--?;
MZN@(!8'7LAH23+.;40D50 5L1@:JLRHQ&XZE%L3A1]J>H2RLR1E!JGS'CO4:
M,;3KU^GLK"#26VIEAL.BXU #[&ROK[4A16(M?& TH/.:;5ZB^SL+G-D#L+TK
MZJ8T42I&KKBUDJ5Z+ %0O:-]0 H4Z$ZZ;E55;V$*- "23C5,>L@E],1F$CRD
M&Q#M9F>250RKMU$<LLLD?M#.=2P5 H_YF=1YF;X?^5H071,*687XV=T%$$%U
MV?()*)(Y?J8H!QX(K!\LT\TKV1Q11L=))(YK&-<YR(JC%12+E,:3&X OTR24
M8  6(R221H !W)/EPEY@M5FP.;5;$#,V(R2JJRQEF8TY@  &U))[ #N3V'&M
MK^:LQ_NCH?\ ABO_ .D?'JC\HX_^SJ?^4P?[?'E]Z);_ +&L?XF3_9X"G5G/
MEDL9(]4) ^R.%L7+%HJST%+"O#]0'(*R5TC%0?2V9UTV,II4<A,Z"SMEJX!Z
M^%J-?"ZSE<C$AGFCG.V[7TCEAN39&)HPVX>ID+$UL"02!I'Z;AZR1P(N$N1T
MC!J.PCC>,:UI?61X(ZKAB-.[5HHX"4VD*I92)6:0^G-B<\RBJE1H:MD31(PA
MAR-"$3"$.DBSD,%^80LB./,5QITLTDTLY2^Y'LC:R-M]"+"8T_G6[751$L,<
M;W8I$AC#;W$>YRP,TI,TS,SL\G?4* HMM/DK8^>K3$[S(S+6D4R-IM4OHNA$
M:?-Q@ !4['4DGC)7^%3>4MA^(QXJ#@6]6=/]^Z])\@.P$)F]C?&KMJ.?\N&9
M[_8U7-1SO;Z(JHBK^J?&K_&^U5GY2HI!9KS..8*;%8IHY&"BAE 6*HQ(4$@$
MZ::D#S(XF'AY!/%FK320RQJ<7. SQN@)]+I'0%@!KH"=//0'W<;E_9/Y(>J_
MS;[G^C%I\<J\;E7S'TC\/&,KD[.BZ+BO#)#_ ,/?<725>=YIO0+JO\C>3Y[[
MMHQ,?BXQ[LN 'I=64766#<OFSB,O=Q3T9!%/53V5+*;7PR1'!H/V0^_^+@H.
MPVG/:*UWX;W20&@UN7J@DHO+'GV<0,7&,PD>=D$3/]BK/IK$*/E_-XY[B'V6
MUG'@L?':FG,SM2T4X/\ K#M\#^+[W$BS/;R$\>T%_#OZM7V(FGLM@&;5>76$
MJ20KNUK=34$?135O9!7ATX]?N=K#4YD98LS0OUVF)HZBN*O;.8HX/NCW>1_V
M?O\ GQ/8R;K//SLA8Y7\/_K()&"Q!W.,E&;Y:<[O@:;%V-H%<%4D-7H.O6E8
M0Q3*NI9 ::(39!UU/34X9H]145H(IP?='U'_ &>&[^WKRC_O$]W_ )=_'O\
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M*$V:+F55JZ*ZP-EV@/:B/I&G!J?V1\O>?N?7^7;35S>*G&?"_P E.92;^R\
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M@\^-SK9X&F#QD-AF;]N]&RQ)(C)$_L/:J?$CK8#ENS6KV!R[AHQ8@BF"/B:
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M_;:<88SAYG6.."JS,0%'H8 ]9!(A+-"%59(SNB9B%F'Z$7X'?+OB7&*WQ/\
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M>&"*)BIJ7R5+(BDJ2 2-="0#IV'#YRU//+>F62:61?1)#M>1W&HFK@'1B1J
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MO(K#H.8FBY>^IVE(8!:1V,O/:.7F5<2?\@XD:IEW.@) /CF#&?<G![]=?/\
M'Y_'S[_3V]PIQJJ"SG:> ;X([I.G9G,UH]0)FJ7G!UI8Z^HLK_RD/2RK9'Z
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M^9P5168&OU  &8=/0D<9HVJN(VBQW,#JS2])H\I&P9F!ZW3*X4@LP!ZNW4D
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M'22"::%O:%D8H5D".H?J:SQMV;KINBZ[E+('09P/*6543T3%$UCZ4"^*T D
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MKFR2BRB>:Z:$<88>&S?-.1/,]D4,,3'R2R/:QC7.<B+FHJPO4R5( M5R200
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MYR.#M,^.T:Q!E^<WW(Z&=A(TGHWU]6.5&_Q)H'*8/(-F\C:C6JZ-E;<Z*]J
M;E-N215=2^HU&@92-1W!''K'R/XP\D5O#+E#E^W/GH+4'(N!P]F:K@\A*(9X
M\!4IS25IDBV2=.0,T,J':^BNIT(/"=!XUU,[!6D@7-]8:'87@]K%H:3+Z&LH
M<[H,]F\SSRM)J+*CT#$<X!V<G,.J"B6PRVA;L_._Y,<ADF<XN^+,;F)0(XFB
MV26J4KSQ2V+%N5)EE!'K&<1K(HU5%ZH&[1 SQ^)')S82U4%^5I+5Z#(1V:F!
MYDHU\9D<=AL1R]0LT'I3)(1!%BWNS5)FZ4MB<T'8PJUAVUF\%T<?9ZN<GEW4
M;O6,JLM7$@"X;Y-M3T H4Y I%M5CF/F$*T%\;?V3C$@$&- 94!1QR)2MF<WS
M8+)/!!"D5>*)7GE.MV%@\LC@>JQ?ND4*0QJIU*OU7U^=(XF6+\9.0*N6R>0L
MWLS<OSU<91C*<LWH9(*%*!I"T\21$"S>R=G(6IY4$:20>@5]I]!5V+.<;2PY
MQTOJ-;L.:=;JK(ZCYL9%7_L_N"2V"-39PQD$1C)+\B(B1LK1U>Y%E6";VIZ1
MJOQT-X.X^Y3Y>O0O \S'*2.36TL(H:M7 #/&2H8[2=NNNFAXXC^R<YSP?-/B
M-5RF+DM"J.5\74_/M.>E-UH+^7DDTAG57*;9X]KZ;6.X#NIXCDW%:SL-[HP:
MS=H663/J64B\PTS=2(/>97GO/;& GY!*2MS[*_!3VU<2@S6%Z>P ;.R&'/N6
MWV?Z-9])<BM8W:]79T'ZH#QQ0G4;M0FD1(.FA<@=MIW<Z>G5=2W570DZ':P]
MB@C73W GM[2.$UECZ6@M^=6P>AV EG368N8BCH<%JJT2X'SU9P[-60H=</<_
M37>BLZGCDU/;TEG">)30[5C6-++R(,]XECISH\+!)0P<1 )$RABBU495 ?UY
M"M<JR$$+U1V)C!>T6ZRD'K#U0-=$<:#11K]!"GS[=_AKQ<YO:*ZRZIX_L"Y]
MU\@@?JED2T1O-[Y"BT3CW6('0@Q/C:I)+4(^H= Q?>@L!,__ ($+OA#S7O@Q
M$DMB&>O$L\&Z6:)DC!+%0"W?N20 -.'_ )>M16,U1CK[YY2TY$<2%G8"I8U(
M7MKH.Y^ )X=WDK:2]$S%4 1B^KX^$A=9D)"M?R:^=72LZ=B-#SQT].UYH#'[
M"O;H%)SH[I7):-^XT*N$2X6Q"U@F0HDG2S$V@W';N) 4@D_:]AIYGV=CQL>]
M4MRQJIJVH@QDBUEKG:38B>$;-6764%]8QKZWK)H-VY5QT_*:K?W^R4W*=,J7
MZ VZVPJ,XOK6Z8.%.?'\A#IG&R622A9*'.&CZ4FW$A=-3](D=< !OBA&A?49
M&@ #Z5&0/5UU;34]_P!CY_#V@<89\==F>3=5M*7+2@>C/U HA-8*#OU$>Q@Y
M8#U)SN4>7#^Y7K+#$\FI\U-S;N.@4>OO3F7@?*M!,,</?6EK?"SR6;E62](8
M-:11GZHI(C-4;&3I3H!S+6>".QLA1W$>E1#OIH2VHT[::;>WT>SRX65ZUN*N
MJ>A77 5V#BNQ#!V9P=VX[^S#60]Y#K(0"Q'&P+X9KZ^'_BDOHJ>OC9PQ?1?X
MT]>89;]%]/5/5/[/ZK\/?'/S?;-])_#QCL\I@.,ZSS-[AA.P;#HN.".\7?%6
MXK"N=8+J.P/,4^7\37E9D!IO-\]=I6"B1=3;;2U=\Y*O605TV<M:NYSI]Z)\
M'%P^U'E]LWGH!Y)[_/R[Z?\ CY9H/&)+NRUP'9.KB; OIAW3Q+*3Q.\AIZR$
MYW9:?N]3E#ZN'$!F'X<+?45>4?2#75659C).^"TJ[1P]H,<4[_#V>T>P:>_B
M,M!?'XP04 +N.ZKQ:OF^"YU6/7PL\BRBY(<KS/O/++VZO7K0P@6QM]1>1N_*
MIPQ:VHKLN9580>0?05%!;5FD.#O\/:==PUU.GQ^ ^_Q$V&1\8#]!0W3NY]?A
MBR][224 T/BIY+#&AY7-=2W'6<^&=<@YD,S1:ZNO^BZ<$FUTS;GF^BKUHS];
MQ[0:O.U&E&.#O\/+3[9?H'O\AV]_GWXM+XV]T\?/'SF8'-YNL]KWXM4ZK'J#
M;[Q^\I)&4M+1Y+,Y"MI:>"^Q>KL 0I8,RFALQ6W3ZQ^KO]&;1UF?I"Z_/51Q
M33Z/\(?CXT]/+;L6"N_,7R[O*XS0R5MUY#[NSKY"<)O:\EX9#:M(G$UUAF1;
M&OF7V.]X=@(*9%Z)\V!GN;Z]:^$.9H4N2JL%A[(E6]D&(BQ^0L)HTY(^=KU9
M8B=/,!R1[0#QI+GK'6[',$LD2Q%#6J@%K56,ZB/OZDLR./@2NA\QJ.*K:G2X
MO3*&JW%Z$D0]A7%I^1=B3]156RAK80C^M-#]'8*H _T=BJ$M$19_4.=946.=
M9+(XG(&+\]7H0L<]>8?(F7DZE6T8382,^B(89ST(Q#8^<$6KZQ/N&V-TZF0J
M=3YB!]S1RIID**;)H=_29OGVWQ?./U(O5W^KZZ[>XG;+D[:W6\DU5Q$<QUK,
M.B<VV,@S"=#FJG+7KYX9 E<0/*!4Q3U0_P V):XR5[BIK05D0C&NT<9:M^FM
MDKBS V70#E[+M&)+^.JXRZ71H29(V@JJ]:/<OH\K,96LQA8E6P"[#!Z.*4#1
MD0JW]-*(8K5M37*X5@_JL)9BLS:'JQJ HB<ERU!>DXH08<6(J]6(:"(>-7Y#
M9/>L<,;8V>]ZT'JYWM:GN<OZN7U7^S\26/F#$11QQ+)>*QHJ*6Q.8+%44*-Q
M-'N=!W/M/?AG?%9!W9S'7U=F8Z7:(&K$DZ#TGL-3V'LX\O(EMKT/<VE#C.EW
M]85TC3/@L:#EG2+L%ZI%6-?$I=7EBQXR(G)Z3#22,(A56_-B9[F^L,H>(7)>
M)L9NKE.8*6/LMF[DXKW!/7G$4L=?INT,L*R('VD@.JMH-=-".)5-R1S;E:^-
MM8SE_)9"L,;!";%* V8#+&\O4030EXV9-0&"L="=#P6ZOGVMU$0T2X#LP2,@
MLZ\I?V%]9)^?5W(J"64,"+DH$$L%C9&H-BOU#0WI)[@R&RJUMF4\0_#K)+&O
MYM<3" EFO+ZSR=2K<BZ-A$&B=*<J%,-@]00D-K#(&T&6ER%S]39F_,;G9-6B
ME3\Y3)MF@?J1,QV-OCU)$D7JEQIHZZ=Q6RX[MK*Y^_OR/88[&*2P)$3]WSK4
MHD9EW04N=NI"1WY_W%C2A4D,U6+\Z%U<7-)).1901CCQ-UCG7P^GN>G'GS#+
M84SR1?,NT2RW*-/'W#)&9-TD;04T>M'U$->9V:22S&J1*MAY,Y\B@-8<D9YH
MF$2/^=Y@Y2O9GM5PK"#1&$DY69]K"6-0%6)BSEG YW55X08$',^TK "*.'"L
MO%NM/E6(:%D,:R/_ "6GOD5C$5[O1/<[U7T3U]/B10^*/AQ!#% G-V)V0QI$
MFZ:0MMC4(NX](:G0#4Z=SWX:)/#GG^61Y&Y1SFZ1V=M,?,!N=BQT&G8:GL/=
MPBLIL:?-773:O0"Z>FLV='M)9JVQQ&T$L!6RT6<6-I@4N?:2%,YJ))].7%"0
MD3HY5B2.6-SK^6N:L%:7-6ZER2W5M9RS-7LU*.0M031^B48]R35ZDD9T>-U*
M[@RE3J!VU1YS 9>I+0J6Z9J6JV-@BGK6YJ]:Q#)UK#[9(9YHY%)5U8:KH0P(
M)''=K-+B]1$-$MQ>A(R"SKR__=&V)/U%7<B('90P(M/ @AZQMC<#8K]0T-Z2
M*X,ALJM:XY/(XG)+&OI5Z$!+->7^DF7DZE6Y%T;")^=$Z4Y4*8;!Z@B(;6&0
M-H$-*I?ILS>CUY-6BD3^F%%-LT#[XF;Y]M\>I(DC]4N--)$(U(S8D98^\=HO
MS3;1V,<Y)PC7<UV4P<9UC3YVALGD#N#:\H.2OS8K@A$F@>&:1.3,2;&P8:!N
MGDQLUTY 9&VMA7>:$'EW+O"L\]2A1L-+&809HF@Q\9ABWQF&9WD>291'&BN)
M+L=?T7T*$Q%4C?3*4E<QQ3VK$05@Y".)+3B1]K"1%552,EV9CUG0</55M?5C
MF7[QZT$0"!TV0V+YG0AP1CQ.E>F?:CY%9&U7N1K4<Y55&IZ^GP_U\[AJU>"M
M')?,=>&*!"V)RY8I$BQJ6/H U8JHU.@U.ITX:YL9D9I99FCKAI9'D8+=HA0T
MC%B /2>P!)T'L'&W5_J>NR$N/#/JUB Z9XI/E?TET+B!# )E1O/N11K[Q3X!
MBHOX351$E@8KD]'-16JBKQWXE6(K7/',%B$N8I;%4H9(I87(7'TT.Z*9(Y4.
MY2-'121W (()WQRI$\'+N*BD"ATAE#!721=39G/9XV=&[$?:L=#V/<$<9!?,
ME,$RY\33NHU]%9\]I/(?;:37#::EAT-''2YCPM\NM 6>?33A6+#V5;*W[G%$
MP$HAI D4@L3B61)\0;B1#VZ>[Z/:./<H/@='M-7STW&^-U1L,57MM='3W_/\
M%GI ZYM;<7)A@Q-Y15X=J-44U#:6]]/4D&PT%8.AUP\(::&1YP:M[S]9X V[
MC\.N6NT-N#@>2755EJ73:.\L\UXY&ZJN%HL;+1MU=I ?FN;6PEB)GA=1F+>W
M?63&.K\]I*#1E,BHKBOL"#BNK>\_7\-??[OQ>?$DS1?A]R7D6:9SGDJWT]HE
M3!5+XYEH9--)KQ.>CV$,3N;I\W.G;\X7"UNK8KLQ9[.9,M7VY-ZUX#3@U;WG
MW^?_ !^OW>W@IRM5X4[2]SV;S_%^=SV^H$V1E-!8^-!] /,WGFB*R6X$-LM!
MS:KK*BVRVE$?375)<& 7 1LP$<@*)9USBC@U;WGZ_P#CY?'RX<?[M_CO_<%X
MO_DMP_\ U%\'%-3[S]9XQ#>3?#^*A>9^WK0N0<N$KHO&'QS.C %Y_DQPHS3.
MK>6D!9C!8JED#"BH  (22&QI+/$$)'*]S!H6LAG-DDD;4>G(Z:K8UV.RZZ&'
M37:1KIJ=->.@/!"K6M1<R>DUX+.R3$[.O#'-LW+D=VWJ*VW=M7=IIKM&OD.$
MKM<?XX\\ITO==S?FM96NFF@9)!S&JMRII!JVPN2T@K:7.6-D0P&FJ;6XL)8!
M)(@*FLL+,Q\ (1,\43CDMRMM2:8GL?T9E U(4:EG &K,JC4]V8*-20.-WVJN
M$IQ]6S1HQH20"*$<C$K&\K:)% [D)%')*Y"D)'&[L0JL1 ZH3Q;Q=BE3H^<X
M4.PEJWW((PW%Y;9UT!"56!E/SCZ?&'Q:4@"6YK'V8&?DLCZL0II]B,*#'*1'
M<AN2#<LTI&[:2;&W:2&(W[I!L!VMH7T!(T!)('&*PG+]5^G/1IJYC,J*N+,G
M50-&K&$QU7$Y0RQ]1(2[QJP9U502&$#R'A]D$'8U_+>6& 6 HYH1@V&R<HY8
MA43)QB8)65:LEAGAD9+%(U5:]CVN:JHJ+\8S8L@D&>8$$@@ROJ".Q!];V<+%
MQN)=5=,?CV1U#(RU*Q5E8 JRD1Z$$$$$=B#KQ7/B'(.2E9#22%<NYT3(SMOD
MH,R2?$YJ9[!@O(KJ088[7R5CG-@$$@@%&B14C@&AB@B:R*-C4VQB?6QE!F]9
MC5A)9NY),:ZDD]R?B>-"Y&M67)Y55KP!5R^555$48"JN0LJJ@!= J@  #L
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MWR3+N+%6>(C?[6(.HW>\^?%(<9GX9%EKU^48IA"L2R0P74D%<:%8U=%#"$$
MJ@.P:#0>7"H\H=#Y(U/&[6VNA>(35]5L^0VCX:N7>-,F)KNPX,ROB8XMBP-@
MEL(!6&.5%D:&XA846=(_B6>'T-2[SQRK3J&Q'9M9S'UX'L=,P)+-.D:-*(])
M#&I8%@A#$#MWXU]XR/S'2\,.<[E\862G4Q#6;"5#>%EXX+$$A2$S:Q!V*@ N
M"H!)T/%6?WH>[?[E.2_\(;'_ -E\>@?]#W/?MCB/\3=_'QY<_P!$:C^UMO\
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MT_*V$C7&Y;;-@,:BS0T+#@K)CH566)U0JP((=&4Z$:$'0\(=-_D8^+[[-/\
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ME03M)'L)&A(]G&>#\(W^MEU_\_\ U/\ ^2H?CS>\:_\ E,YH_=4/\5AX]$O
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M;R]+;$S@3S1^LO5FA31HH06,A)^;D"D -O=)N4T!D5</?#YQSY&N,%R19A(
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M-C7/>]S6M17*B?#CFN9>79</EHX\]AI)),9?2-$R=)G=WJRJJ(JS$LS,0%4
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M66CIR Z ]-9Y(B7"F1LKRZE^R=T?4FQ &42-*_?24@H&E4]]-Q0-JN[:&#Y
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M=2>/ 'QMK5H/&/Q5A@KP0PQ>(G.4<4444<<44:<P9!4CCC10B(B@*J* JJ
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MVT4/4KC7!PZGW&3S6T2.Y+UN'1M$MLWB,<94$)'AI?92!QX\S1 S(1+&=H3
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MR!XWO/J\O-:>2^4&3J=.#G-C1B\B>VJQTU?T ZFSAP?4-"#YKY]N_GY]OO\
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M-QU.GLUTXC[E6=RJ[5+,5777:I)(77VZ#0:^W3BPWB1_M(WG\[^V_P#E=/\
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M-*!H)9515DDTT&F]P6TT&FOEPRS,CRRO&NR-I':-/V",Q*+V_8J0/N<;4WX
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M$Q#4LQU))]I)U/'@KXVPQ0^,7BC%#%'%%'S_ ,V)'%&BI'&BYNZ%1$4!450
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MV:*,P>,AD<S4KU1LK&R(V1J*J(]%1%7^/X?ZW+_+-FO!87ES"HMB&*94?$4
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MDF\J+.YMA8R C1JVP +\V59/2]Y8$AEC&JEE#CF1,Z0I]&W3LMUA(G.CLXY
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MU![#L23W#$=@5S=ZPZQ)A*3GUA&I'SRBN&"H"96B#,Y5]BZ[&B1@K,1>4O\
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MKP6?2]97^*^YW_BEI?\ 37X<^GS/_9N!_P V9#_O;A%OPG]C97_+:G^X<+O
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MBBEBYCOI(Y(ZBO9)'(S*VSF/8]HZ.8]CD1S7-5'-<B*BHJ?";F"" 8'-D0Q
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M_L=;HYOO;Z.]KD1S?7T5/5%^/)V7!PF20_*< U=SIZ/:[:L3IVCTX]MJW/\
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M%T16;N,T<![Z^7L[ZC7M]WX?3W\]/.,QD,>;9PNQ(YKMY;[ >)^:\;NE_/\
M$KR_U--NZ3#\^Z=F<[D\ZS8?AY6MKCJ.PU>VK=3?:T6Q($L:..RQ&GY)MP1Z
MNS0X._P/?7[8>?;77OW^\>_'3QFB!YYT?BNJN<_U$BNYM$Y[[6M\.?-N;6YH
M""V\KB'X?(CA^'V4S16?T]?WO#-UAE0%S/.M.P1<6>YC3T*8RER)Q4]]?+N
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M/TNU';M[]>P_8@=_?W'M]_#8:]OY\;PRRRHZ@V)E]1;4DS#4(3'U(&2N5C[
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MFT!);B(B+/-M51Z23H"2=69FU)[Z: /+6\+YUB(0R-%UOLHT1KBE8HK\O9+
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MVZ?#X#@PFATDMA;6#?!SSH&=<]6S'9#!!.L^#XP#-ACJ"BRV>C$$C\RTC$H
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MUB/(;2_AYK;2ZFQTPKRN7="6QDVMD(/]VT [I=-]2_4G@M$^XVL:K;%"(/\
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M/$25XK-=! \S7H8H^L8F$G3#2!G"$,5!"D$Z\:Y\;?LM^:?$#PGY\Y.RG*6
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MA193&(Q)R6._6^60IG71@2IUL#U6 (/G[.Q' IH^A9/1;.XT(G0J?*3G&GN
MV F7ZC=ZBNS<N0.QD.)BKV8G,I'3%%31=(=-!J(6T^SE6 >NM%KX= 6GEQN4
MFL22K1R5<NS;;"XC,2SI":[5A7""C"!&Q(N:B8".P= CE!*UPRN*"!3DL<P
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M,X4!F ]@9M2![-=.&!RI=RB[4+,54G4JI)*J3[=!H-?;PN^;?^'T'^<O3?\
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MQ&6,G@\6!:@K^)=X?W\NBP;,-I[SIFIQW2]1HAKW.<'S'1R+'477D$+?.9K
MN(S&4?LL4ML-;]"T]I479)@5)*$:CWCZQP=_/:?/7R'W/UOU^_W<&>XV'@UM
M+W<WH_XB_ASBK/7=#W.QJM!AMED*'58VFZ)BN58S8T=02G>R<G9WFMCY:+::
M?9W^+L3I;6Z,N,Q79/1##WRFH]X^L<4T/N/W_P 7N_+V<'/$^U>$O*-KD]3:
M?B#>%&D!Q?.=GS_/UE3J,+F[BL$VW1';<T<?7V7<==;'9FHKJS(9G/Y[0PWI
MU9%0V5FS1/FT9(H1J/>/K'X^*D$_K3]_W=_K/?BXO^N&^!?]^?XM_P"7?F7^
MDOP:CWCZQQ30^X_4>- DOL7)EMM&].EX-63:[8$1/35T:ME@(U%O/!-&Y#?1
M\4T,D<L4C55LD;VO:JM<BKVSR1S)R]6Y0Y<KV,YB()X<12CEAFR-2.6*185#
M))&\JLC*>Q5@"#YCCGWF/#Y:;.Y66+&7I(Y+L[))'5G='4N2&5E0JRD=P02"
M.X/ )9[3EIVLKM3!UOG4$E= )&P8BWIBWK(()JPFNC+9?".A@GAU9#R8$A>L
MLP #TF8UCV/<;&7Y;FRD&23FG (T"1*(GN4Y26BBR<((E%Z(HCKDW,B;"6>"
M$[P 04D5#,QTI:;87*,)6<EU@G0:2/2D.J&NX9E:D@1MPT620;22"!+-D\GS
M]J#9+V7G1?TLU5,]C3J,:=%I<_\ E\5P!7YB(^@FLH50C22_))^\/9'$Q@+&
M>JMF/DY8HV8;'YK<!+TGJL0)Z4;CT.AZ!&8)?E!^@]A/7R#[)/2RJJ!"J]UM
MI,U9ADB^0LHA=9E!Z=AE_/%KTI^HGHR]18F]6JNY>@"6)D)TX.-WUKEI6'V0
MPW1<0023E-% /!#J*:6:>>:H,CBABC88Y\DLDCFLC8Q%<][D:U%543X=\WS/
MRW+A<O''G\,\DF+OHB)DZ;.[O4E5551,2S,Q 4 $DD <(,;A,PF1H.^+R"JM
MVJS,U2=555G0EF)0   $DD@ #4\9ZL[Y@^*$&?HH9O);A$4T--612Q2=7P[)
M(Y(PH&/C>QUXCFO8Y%:YJHBM<BHJ(J?'':H^@]5O(?K3[OHX[.7)XX*H-^F"
M% (-F'4'3R/K\(G4]+\5M#I^E:$?S%\=*YG1<?KLC+%)KL4;8U8VSRO.LM8R
M_=(^A -/@ CYP#8U 3P1F#&75U\^4ELT2QXS Y+D C>&'VA.FY57S]NFP'3X
MG77MQ@>YCF>5ADJ0ZB.A^>B)&](T/<2C4#I@@:?KF!\^"/GW8/#W%7L&D*\I
M/&ZQM1*G6UX+ZO:X"@B!EWO0+7>ZSY"IKK,E]7+*_,T]%5DDSNH@<Z0Z(TEU
MZ5&/<L+*=2I) 8#1"--S%F]_8^J /9IKJ=3Q='=QJ,&-^B2%<#2>%=.I(TCZ
M?.'MW55'L"GOZW82\P/*?QGTWC]KJ7.>07%[ZX*O^82C5=1TS'6-@1&#U?$6
M!LD(8EQ*1*P0$4DPES(U2$4>:>16Q1/<CWRZZ5^8N7K%AE@@@SV%EFFE(CBB
MBCR=5Y)))'T5$106=V(55!)( X9^:[E2URUGJU:S!8L38F_'#!!*DLTLC5I
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MPB?]AGQ>C90R_P"HS,:[XK1R='(G\ZLSJ8EF1VADC26-CM8QF15W&*3YJ9=
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MSO\ 7[."BHJ.P41-T+0O_#PIS--TB-NB&J,YJ*\G0=?"M/SA$VZA#NX9;;I
METOYIC0YI&G'M%^]M]A:_5?!Q74>YO+W^SZO+AETP_F"D1[L]8>':027%JZS
M=34G4$B??M,EBO''J#?>QUPVPBFBM5(534,CE89Z3L>B'%.WN/UC\7&D1Y<,
M[$GF/Y>)=$<T=>)Y$;M+IU6)J653K/VU?U#JMA9KRV K_ ^2TN20A/X7O>OJ
MGIUMX0C-?F*J>A-BQ!Z=D-!:2VTV[KG=J89%3;K]KH-=//C2//7R=^:"7T@7
M3+Z-5UZ+0!--ATTWJ6U]_P![BN%F-MYE 6Y_9;*L=B.ZK6S"MY%CMOX?TC@%
M**7VV/\ X?TZC^A/_A_*7^/XV-8CS3]#TL\M/ML1M6](@MMMM=^DT'5E.EC[
M;IF/YSSV^WB*1/CUZG0^6%UB83=*2 :P]MXDV+WB\MP;U/+7V<0Y=1;QJ7"<
M)Q6-605T9T1=44Q6#,=&/4,+9-.BM@8^&*"N;,B1M=%'$,B*QK422U+:]59H
MN3QM2NLZRU91I&"(ZBRAY.R HJ5PXV@J%C[J ,Z3P$(8WSY!:4QE)D(+D%IB
MA5>[$$M*5[D$E_/@L]O4?_@V!_\ C;1?]+^'/3F7]G@_\5?_ )[A%KA_V.2_
MPJO^QPN^>MZ1[]W]--B$_P"^)HOJ/GCWR^I/R:WYJP_+*3T@]/;\M'^LB+[O
M<J_I\,6#',&N:Z;X;]/KW4WQW3\[LK[MFV4:1Z;=H;5M==3Y<.F3.*TQN\9#
M]*ZNW:U;[3=-INU7[;SUT[>6G!A:#;>=H7WK]ELS8[ 9]=]T"MY&QVOJY@;P
MOJRE1EAZN>T9T'H3ZN<V)?553X=+,>9<0^EGEI@L\;5_28+3!;7<1-#U93I/
MW81E-).Y"^9X0POCUZG0^6%+1.)>B\ UA[%Q)L7O%V!<-ZG8:^SB'+J;>)#8
M3Q.*QHP:N98Q%U13$8'$^."I8:R:=/:-')!##7-G1(F/ACC&1'1M1$DM6VO6
M2>+D\ 1UUL++5E&D2E4JB97D[1JR*E<.-H**L?=0!G2> ]-HWSYU>4Q%)D.K
MD%IC&57NY!+2[>Y!)?L3P6>SJ*?Q38'_ .-=#_TOX=-.9?V>#_Q5_P#GN$6N
M(]V2_P .K_L<+O -Z/\ 5]$^FFQ*._:);?5?/'O512OLN>]ZC_+*14'^7\KV
M))ZR>_YBJOM5J(PX0<P=7/=-\-K\O6>KOCND=3T*AKLVRC1-NW0-JV[=WTTX
M=,F<5LQ>]<A^E<&S:U;[3KV=-VJ?;:ZZZ=M-/CP86@VWG:%]Z_9;,V.P&?7?
M= K>1L=KZN8&\+ZLI498>KGM&=!Z$^KG-B7U54^'6S'F7$/I9Y:8+/&U?TF&
MVP6UW$30]64Z3]V$93YSN0OF>$,+X]3)Z/\ +"DQ,)>C) "8>Q<2;%[Q=@6#
M>KV!/LXAS*FXC^NBL!.*Q^T0)ME&95%-]H#)HV5S3F3SIZ"-(@A:$A"?);-#
M&V#T?&U&I9:MQ>LL\?* ^:A%A9:LH^85U%<3!Y/T(21J(0_J!T4)ZRC3-'-
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MV&C#+!*4:EGJM$\ZX&L8D.CN+62T!U13_P"V:D*TD2L0"%:6(,09$#1@;C+
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M&2'1[M1"J!+"=3Z=2;3M(=.RDZG0=O?IP.](M -16B"4]A&Z1GW9BM-#T ;
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MH(1A_(/A4(X\4<$$,75L$R.*&)B1Q11L;?(C61L:UC&HB(UJ(B)Z)\*1E,6
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M1IH.X()T&XG0<6K<P2,CKDZ6Z.6:9=<HK*)+&[JL5:R5(;<Q"L"B%F**I)/
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MN8XNF2Q^ST5)PE].="#OK#>:JW7$:JP[Z-OZTC06D&@S66HYLY!0GZ#/3S'
M-/;_ "_'\0^OOKIPX#+WR/FZ$93B#]>#RO[P5FZMTC\]Q6?/1<3'Y_@32ZRP
M!2M?I[&$OH,VTSV"/&EI+X&L0S3[2YOXZ:@SFL.#\M/R^L_3V^'FX1?>6IV_
MP\/5J73)@Y>/U@VA*OA>8TY,70@;#017.@T+<J,\PG36L@E,,/09B*EQD5%8
MCWHK8CH+*K<<!T[Z>_M]'Y?R?'2]'P<4X_G&&?\ EC3_ ._/;?TMNOCO+D']
M17*_[RT/X!>.;.9_U0YC]WV/],\ 5I/JX=?6*%$9-F&C#..B'CJ'0RO474-/
M6:0I663"834R*AL&FCAD@EL5<R9(YU@=K#Y1<K6Z*RMCA'&9E052K$Q9(3;V
MD(L"1)ODKI"-T1D:P2'"2%$4*TVI2]1HUMEW$9=I@RC?3,>T)K$5:/TT.74D
M,(M"I*[@_-3=4=;5Z7R6"5[B*Y9TD@RS1E8M"OYECL7A1H:R 6_]C,N^N5LY
M4;I'6+RPD9-\-6/;F8VH?3NL("]?<"N-$>GH7],5G,*]8)'>T7&FN0\BEFL-
M+!M?A=:7#B"7T;I]4+-M(:V7U])_.AC#GIEGK:^EB3U4('2"2$KP<=#_ -H&
MY_WGZ;_D4WX=\_\ I%FOWIR/\3FX;\7^F6._=U3^,1\;565_VL9S_P!0T_\
MR>/\>1[_ &[?VS?A/'M97_J>#^XQ?Z"\),VT[$!TW=235NNL><Q9R^;FA,V+
MSM\RFKG^92YLNAFNY1;"712:#]KHI@VE*FH(V#9AY04 9 \YJ@" Q1Z%!+N7
M>7,H&F^;>&V@C9MZ!!0;_M]"2" U/)DTOVR8[+TA!-T%@6D27,- P-"92KF?
MK?*2NL[&$!:Y9 C*S]O+#NNNOJ0?=KJ":TOFWUUK);5>,%KZS9)JC%BK7FT
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M)!."4T.I(C8^:+NVQDA2S4?IZ#9KKN;74'[7L5\SIV[CMW.FIT[#BMWXC/\
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M@<_I_#,_:VT9W1GB9:EEJZ$QEW8V=3'5J4EH"LYQ3_JC[_M&OO\ =P.FZW,
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MZ'9@@UM=>^3]19W5?<4FEJ3 +>E"L:\>NE+TES/4Y"LLM$(<&X^Y?+7[1/\
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M$V19'9^7?4W Q8EC-!V\(1Y YR5[#8_4390)$I8U355Y#X$BDFJJRNJ)'NK
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M2[$\VQ+9.<5.0^R;[&#Q)L:=;(8.31F;5K3[BS!5+,PA#.=J(H+EBJ*J+HH
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MM+FXF#U3K*R?GABXZMXU0EU#0OK(K_[(,/1NO6V+J2"&J<'&W,FJQZ,-" P
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M@,=EHB*=F<F2/K4Z\NK6:P$W6#)^=YPNT8L?)4C:4V@A&D>@DB,H>(/K/%&
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M,L,,321E':O%'7+&!%C&9*G,<:JB4+H1--%] !70!P%93"0Z@R.X5PRB5WE
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MI#N0?AV3Y?ZC1$Z*0LK:2T'U<)Y+=9/=/FYJZN^HBLPBVZ*4Y?FL/$)2R<A
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M@89Y+,F[$$Z7SVZ9"2"&#/3:J,J,]9L[LQLR<5T\O9KW^Y[_ /P[\%A/EQS
M6:U:^LW$@=/?"4QED-GH"17B6NDU.*SVD '@LY+:UH-)M,1KLW4OK*TNW8[/
MV.EM:BLPT3=4\X-#^1^@_@/M_#Q,<S\H>6=7TE)D<I91RZ&ZP[-^M9)H<$:3
M74A%[?9\.*>.AV5TZSL9CLS>*=!F&W\&90)@VP)SMD?6 &G%.+%?!P<:C/XY
MW]?3E_\ !-Y-_G@\D?CI3['W]"YK_NF%_P!'*\:E\3_M\)_:Y#\-+C"_HM$!
MF06G6#2I&2231QPAPI.1)]* ;:EN9&Y\;5:+5UIYTB*]))(A7Q#,G*D@'FZ
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M[#R_+SX;/#N \I\<,<1@N/9J7+98JZFOYJ^>]T.BE=8RUE31PJEAIK6XL6C
M4-#1TE<&TM!0JRI"'AB16222' 23Y\.3X.*<<^#@XY\'!QSX.#@ QG_E_JG^
M_P#"_P VG._@X.#_ .#@XY\'!QSX.#A5<9_VE$_[_P#KG^=C:_!P<-7X.#CG
MP<''/@X..?!P<<^#@XY\'!QSX.#CGP<''/@X..?!P< '1_\ R)3?[_\ F?\
MG S?P<'!_P#!P<<^#@XY\'!QSX.#CGP<''/@X..?!P<<^#@XY\'!QSX.#CGP
M<''/@X..?!P<<^#@XY\'!QSX.#CGP<''/@X..?!P<<^#@XY\'!QSX.#CGP<'
M'/@X..?!P<<^#@XY\'!QSX.#CGP<''/@X..?!P<<^#@XY\'!QSX.#CGP<''/
M@X..?!P<<^#@XY\'!QSX.#CGP<''/@X..?!P<<^#@XY\'!QSX.#CGP<''/@X
9..?!P<<^#@XY\'!QSX.#CGP<''/@X./_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>g383050g29k08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383050g29k08.jpg
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M P$1  (1 0,1 ?_$ !X  0 " P$! 0$!           '" 4&"00* @,!_\0
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MV=+0YC*WOSVS."!6VM[TK=VLS1.8ZH$1*] :I#&[/,JJB+E.*8SZ4)Q
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MBQN7M"Q5'Y4T(WQF4*VEU3HW1K5'-RY,8I;7)(E<$)VVZ5:F(4E&E:#$VT
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MZ<3V5[,-^<&7FEFRR#>P'<J?977),!6(7_V8SOX)['[X/\"UUPI\)TVSDKL
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MJJNX8I,?H4T78TN4QA9L4)+)<&W5O:Y2XM3RWR0!CH7F5>'1GQ^(OD!
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M!>'32L6LJ&4[7MC[S;M;*OVE17(BXQE,Y3L(*&7H
M        ,1(&!EE3([1N1MB-Z87Q I:W=I<"=5")P;UA6Q*E*H)WQV;EFE[[
M:Y[.S;7/9OIMKOKKM@#+@#^?>BL&Y/P47@_8O4K)W<:]]R5KMMOJ5DSL[O)>
MN^^^^NF<]SC;;;;&,9VSG('] !B$K RHGEWD25K1DOS\E:D+P\:DZY<G! Q>
M'Y96]0LVQD_9N:3'5V4-Z#&^$:-6[NZP@C14Z.!R@#+@    Q+T^LT<1EN+\
MZ(6A"<Y,S,2J7J"TQ)SO(WA#'V!K)W,VUP<X/3ZYMS.UHR^Z4+W)<D1)BS%!
MY1>P$6,/(_C_ "B!3"TXW=-7OM:U\J<D4YGC3-XZOB435-")&YKR7]^3.!C:
MU[E-;BVNA?A:@O"IK<VQQ2Y/1.*(\\3A>A2L4>9^";_?C/-H7<T<.NB\F;2P
M(*QQ._W3&L@;7-1%G:22ZN8(WRW9F0F62@H1K0SE='&=.=-H_ 9PD6:J$RBR
M]W$-_.G#I3]^,\Z?)N\1DBJ4XC4/K&:8F%H.:%?<5WQFX8)#[9O1^=7^6W'!
M;:9K<3/4-2RB0;.2M8OM=='7"2(VS&Z.1O3LQ,#D2J,=6QN4AO7R)CAS8QO\
MG261>N0U%QN2S>'2&W*^8I/6L143ZPF5WE+2W+81"DJ)$Y*91*M%:DG1B9"&
MYR;UQK@X[IR-$:Q,IVWP2=IOD0;+ ;5K6U&XIWK:=Q6<MA[4V/A*V+O:!Y3F
M,[PJ=T#8YZ[HCS<> K'*/R!J)4?Z++O'WYIVVU<65S2I0-^    !6SF _P \
MB_&RUWVMU3^W2=O8T.QCS$V[=WED=BI[^T); E,3:RT+H<X2F+0$^2R*-I"&
MMS4'O;8A+3MJ\[;1(<)3BG[^'E\72<U7Z\989Q^K=I=;FNMCK<KDA<J>47%'
M4\G.N//%CP'EFGXM2]?("HVLD*EIF=H5I6D3CTPV1JG>T&E-$RY$>^(K07.+
MV)QA5W<$3CTIC/5ORA7%'?',U3NP[VK-+NAL\=MHFGYL1-C97ELC''^F3[*X
M?-K?.ZW/;X[LFAKN]5[*[G7/<LBK@H>2T#G<4C.4%+J)9S((&[CP3?CJ=Q\>
M<>3!O7&R[^7$@Y?\>([,Y9:*^OW!0:S%H)27*6:0S6D=:FY&/,-LF2UABOTD
M+<H]*%C91K_-+_?)M&K'BUNEYIHBMM&*4G.#@&["]*=6<IS\>"+NWISY3"H?
M0B!B           !!G&[XG(S])S?[?2@9/\ ?+Y/0A"</*[TJ3F,22L?,_\
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M0>&J0Q-4= (H:IB[^PL;5&&-\CI^[3L:R/#-&F)CCS4YMNZ9:W,;,U-*,\E
MW)$Y($H "#.-WQ.1GZ3F_P!OI0,G^^7R>A"$X>5WI4G,8D@ 5#Y8?_-^)_\
M6VKG[)V$.>:^_P 9Y/\ _6#9_NV\G:>1S_$^6+_4QJC[ZTP6\'0SBP ',#EQ
M_P (CTD_^O/,[^ZA)Q<;'^2NN/ZMI_[[A*??/RIT1_6+_P#<LIT_%.+@
M
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MEPN].8R0P,P
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MSMN:5_AR2.\YRK^\L\+=B*)G@QL;YK43]QG!\SZ
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M3UE/%41)(U&O1DK$<UKVHJHCFHN'(CG)E%PY4PJRD/$>P
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M4+)I^EHY(9(*FS/DLM;%(Z-^S66[9BGV'Q/>Q\>539<CL*N<9:B.=TN%1+:
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M-4;4                               !C&,8[,8[,8^#&,?HQC^8
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MA"Y:[_GR/]#V/[JI2GZ'_F27],7O[TJ3I\*:7
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M<8WHO-OWICJ7)VJ Q     (,XW?$Y&?I.;_;Z4#)_OE\GH0A.'E=Z5)S&)(
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M3]T2*18Y8E58I7PR(L<S(Y6*V6-[51[&JN,IEJHJR\/ >X
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M^>G-HHFY^R5#0V[3[&?YNY7IG5=ZU?\ F.GPIQ;P
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MM;0W.C=M-J**_7B.>%[7L?%W:LDJ855'M3+98962L<U7-<UR*CN*)U.%++D
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M5=?2UH_VN3P<[Y*?R#LW]8OO]HKL=K_PB/Z7M3_U+2/]BM.EO!T0XH
M          !S X*_K5=4_P#K4P#^[W6PN.I/YDT7^AJO[UJRH:<_GG67Z9I?
MNNC.GXIQ;P
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MBV.IJ"@@934=-WQ8[953-IZ>-$CB8Z>:6388B-17KLHB;BT(O1R0
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M<+B\@KA8@
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MV%/\[?+U)YD%!&5"B]UK:^K_ )NR6:/Y-N>NDQY>)T]%.+>
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MPJ>ZQE,VY&B-X
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M(C^HIQ__ +7[8%QJOR$M/ZQW7_@:$J%-^7-T_5RV?\=7'3\4XMX
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M72/JZE9$@BDM]RINZ+%&Z5Z-DJ:.&++8V.=A7HJXPF55$6_HK!9@
M                            *V\M%TX;J/>54!,FQ*_VZTXGE:FM6QY>
M+!15(LN6 H[P7PQMC2!TE2F0H:;/G:MNS$&Y;,TYQ.%4-3'R@AH*W+^/Q^/+
MP)3CU\>G&[ZRDZFQ[;,K?A@2\*N6K9;A-L0QHECJU4M=;A'=JR32"'3>0NW(
M]KBU6.K.J>9I192"ML&N!2)MAMR6;)U:[2.OM8R]PKP3T\-WC3Y-W3O7.-_#
MB=:@,2#.-WQ.1GZ3F_V^E R?[Y?)Z$(3AY7>E2<QB2          >96B1N"?
M=*O2)EJ4S.N3$RL@I2G,SIOC?3.Y)VFY>V=-]==]<[:Y[G?7&V.S.,9&$D<<
MK%CEC9*Q<99(QKV+A<IEKD5%PJ(J93<J9/K#//32-FIYI8)6YV989'Q2-VD5
MKME[%:Y,M547"IE%5%W*8;VH1/\ U7CO^Q&W_P!L/-['6_X#1_LT'J'N]FKS
M\;7/]OJO^J/:A$_]5X[_ +$;?_;!['6_X#1_LT'J#V:O/QM<_P!OJO\ JE7*
M*1I$')[F>D0I4R)*4[4'WI,D(*3)R^^5,29OWLDG70O3NS-]S-^YUQW6^VVV
M>W;;.<T32L<<.N>4N.*-D4;:C26RR-C6,3.GFJN&M1&IE555PF]555WJ==Y0
MIYJGDFY"9JB:6>9]%RC;<LTCY9'[.LY&-VI'JYSMEK6M3*KAJ(B;D1"XHZ.<
M/                    .7_ #1_7?Z4/].'(?\ NS3<7'3_ .3FMOT=:OOB
MF*??_P HM%?I"Z_=%0=0!3BX
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M>C5;+'&[>U<HJ(K5WHBY142Q8U1M0
M        "#.-WQ.1GZ3F_P!OI0,G^^7R>A"$X>5WI4G,8D@
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M:Q15SY8Z.6XTCX(ZB2!K'2QQO7+5>QLC'*W*.V5RB*B+B41OBH@
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M;M*^&VW*DK9HX^ZOC@E1[VQ[36*]6[EV4<YK5<B817-1<;29LV-.;<
M       (,XW?$Y&?I.;_ &^E R?[Y?)Z$(3AY7>E2<QB2
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M^5O^E/E(_7K5?WY7$["UG/0
M  #F(>E6%=9E X;H'+V-5=,MP;2735N7&-67$CE(A6FH#70M/L@(682;:J-4
MQZ@HXPK;78O3?&<=MP16KH%S4>S;;J]KU9MM2386S.:CT8J[:MVMVTB*B+N5
M4*BJ.37C7*U^R[23F(_8<K-M+PURM5Z)LH[9W[*JBJG!%.G8IY;@
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MI0;IE XN4;TL*'^RJ3/>--S716E;#W%7'90G9!.-V?QU<>8FD"
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M7")S_(=Q ,0
M                           *B\VOB9C7]9+A]_>LIL"4X^1WH4MT!
M 5'O/]9'A'_2%=']WNP0)3@[Y/WH6X @
%   #_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>g383050g35a01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383050g35a01.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( 14"70,!$0 "$0$#$0'_Q  ?  $
M @,!  ,! 0          !P@%!@D$ 0(#"@O_Q !%$  !! ,  0 '!04& P4)
M 0 % P0&!P ! @@)$1(3%!46&E98E]87&"&5U"(C,5&8UPHD<24G-Y&V)C@Y
M07-X@;>X,__$ !T! 0 " P$! 0$            !!0,$!@((!PG_Q !0$0 "
M @(! @,#" 4(!@D#! ," P$$  41!A(3%"$Q49$5%R)!56&4TP<C<8'P)#)3
ME:&QP=$6-39"U-4E,W6$L[2UX?$(4F(F-$2%0U1R_]H # ,!  (1 Q$ /P#A
MOGWAGP_C&,S,<CIR7R$#$XP+>')+*#(N.QX*.2VN0,'#;Y :)%L4.?[2SP@_
M<MVC9+G^*BZW'&OX[S&YRJZFO<8J2A9N:PYX%:EC)L,I^H0 9(I^J(F<R*4Q
M[5H2!,:Y@*4L8Y)C&%   Q]9$4P,1]<S$9;:\O"684,V7''+D\=)O9HN5C8/
M*:,JRRG<VMZ)RPBJNT4 D@36--09HB(+-^@9YM"9+*U YKM-@]Y34ZWOFBUG
M4=?:%WJU^WK4CKG:3L[M**VO?7"(*' TG2U0,67BJ*TFO#%Q)CS'MO-ET]8U
MD2#+^JLW >%9VMI7)LWDO.9&5&H4PMAK./";%=SI6R8 N)R%$/'3R#=24K#&
MU$W(XF )(<L;BB%83962AT3"3E<0J5!)@^B@](HBS=K#E';5'E\DU<J-MJ\(
M*[YL9V^J%(6"V>OBNV3A3YNUH2R5S$,@&RWL.0DA@X$ID9*(+B9C*Z-5M)<=
M>-;?EZH"6(BG8ERX9$RN35"^\(.(F0DACNB)D>>)S )4_;2_:7"%76*MVNUC
M3Y#A*$R53M9C,R78:'O$N>!G6U&LL,)*"HTXXUM$Z23[8B^W3KCI+66;]&.>
M;M2."<,\V4QP5<(98&>3]"0N88Z)]5!,$<",\YBBA>GB(IVYF1241%=T\C8.
M5H*/H>HO9$@F?8PXD0[BCC,@M1-WMBC@&XINU4#;4_\ 2CH.M7DN2*-I3\B6
ME/TTX']A^7:)_P"F6Z\B^3J(\D?D2"Q?X;Y>GVXY\1L]:2X:.PHRHE>/#(MU
MY7*/%A'C0<,[95XTPGQ(GL\687W=\Q&>YUNQ@Y5.ONPR&^!*YJO@X?X4N\&0
ME?=#?!B6^',=_A1+..R)G+%>*G@3;'EY')')X!,JHB;"/V'7U4HHV0?DX9W(
M9]:/)CZ+CP'F/PR4M^EBJP1XUZ=EW(A@U7Z0^)=)H]]K)U.\ZHH:!R46J]YY
MMJ6[TS34E@JJTO#\RUOBV$3P$,$NU8L,HB>!F8B)M=+TU=WJG.JV*2!5:JTH
MBVURR;9N>)Y=2H57=$R<K(>3D!B>.9B)YBN,GI.VH@VF!([7<O;@(%-BM<RR
M7-@)(A"@\V"D5!+^-N)DP;.(ST3X?)[11;)E.^W6NTE6VE4EDN^[=&QHV"K@
MJV@FVJP6T5Y: V65F!X@NBN4P[LD?62D.!XF"XF)XJ7:^ZB+!MJOA56P=1[X
M495UV%G($J; Q*>^"CB(@^2])CF)C,AUX\7_ ,&M1ONC;AYD748ZF_('JLYK
MR:ZAG*FTNI=H7L)I]N,<J\])]'](?*M*<[XV[]K6]9X^5M5*O&C9Z^4^/Y;Q
M?.UO"\SQSY?Q/$[?'XF)\+GQ./7MSW.JV<,A,ZV_#93YB%33L>)->)XE\!X?
M=X//IXO'9SZ=V>XWX\6F+%UJ7%1@U,V=I1V,'(_W#8O-"NFI&9'YC'HU#""K
MB,,&Z\S-.8,=="A0!<XU*LD?:%D7KMJ4:#O*]M2,[BV.76*BYZG18?67,A65
M7<ZP,0XBBNL;2A8;842SF88 Q($?IFJN@%-@)98&ZI+%37389P=AMA2:Y3*1
MB;#)K,( 5+(,8^@9$)B&M_L6N/32,O\ =369IC-5"B4->_0DI^$EJH-!PZ-)
MQEQ\J]R>4$-F;MP4X%=N^AZ#5PL[TBF@KUSF^4=?W.'S]+NK0$V!\TCN1#)@
M5RZ/$Y5#"(8"3@>^9B!YF8S%\G;#M27D;G;8DXKEY9W:^5Q),A,]G#97 E)P
M$E(P,R7$1.>-M4]IO)QQ632M)^ZLE32.TZ];0V1+SA33@8D:;[XB:0WH]WI<
M.NB61WRPW[T8LD_X]IJIPKOT5ZD-;SI7*HTXYYME83%:.#E4_KY/PO1D2N?I
M^AQ(3]*)C/ TKA6(IC4M%;GCBJ-=LV)Y"&1PB \7U7,''T?4)@OYL\YD4Z0N
ME8/*)"C4-H*Q^#NS ^:'$X!*^P\0?Q[EIV?92@GR)VRC[L'P08=&&Q9=HL,Y
M>M.GO"&G*.^_$[+70Q"9OTH;9%95E3:1#+ N[O") 2SN:+>P_#E<%!]I=LSV
MSQ[C7;"5N;%&Y*JQ,&PR*K_#02NV6BX^SM42X,99!R,AW#W1'='/X]4Q</*,
M8<]5197+>;!BDCAB_4%E&D9='@8_LN;/1A78KV#X8.*34)E"@KIVQ'CT^WKM
M=%MSTKJ?E'7\O'SU/FLP$V8\RCFNYI^&M3X[^5,8<P  SM(SGM&)GTR/D^_P
MF?)6^+"S;7GRSN'J4'>QJ9[.&K6$29F'<(!](IB/7,TMXZ>03?ALHYHRX&B+
MR7-( U7=UI,VK=>=/GW QE#$W#@*DCU*G1)3A@WC^E/FJKSOEMPTVMO7&8XV
M^J*9@=GKRD4%:F!N5RF*HA)E8F(9,^ (1)RWCPX&.Z2X]<R3JMH/$EK;XP3Q
MJQ)5+ Q-DC\,:_)+B/&(_H0KGODOH]O/IGLE'C/Y#0PY84=DE)6D/*51M;JR
M.-0:1O&<,:I=NN.2I\HQ'N1C $[Y9.G T^J\T&*LD>GXU\Z9[Y7WY3N=3874
M:G943"]Q%.?,I$K)3V_JU 1B9M'N&#5 ^(!3 F EZ9Z=I]K79:4W771.CSYN
M(K-(:XQ)<,:8@0"HNV9!LEX9C'<!$/KFC&*SLB/" T@/U]-P8&1K,6\>-F(H
M>&"#K@H(82 8@&)/6"#,HL1 E19MBDQ67[=B"3 DWY49O&ZRFRNY3<QB56JS
M6J@I:I;U&Q4 PU'+ $Y((!JS44E$0+ ,)X(9B-=E.VI:VMJV5J=(PIC$-!;9
M-8-"%F0P)R:C!@P,S)+,#CD2B9M=;W@19%(@GW$YM3Q]YM\1S$N3?C$"L=V?
M\AQ+^:$0HT2!4AXV-+1XE*D.SXYV6B0"8%Y,+'=.7SH3P@S<])4=#JBILFCY
M6CMIH,\Q*]TVF*M2P*P,,W18-T.!!0HQ78;76DS[1%DD8Q-U?Z9MZY1>9NZO
MSX>!#-.JV3=J!V#6 *FN"94;H\4"-"GL: =Q2' EQ6<=2ERF'*;(14EFE'BR
MY-LBT'0*5/G*KD+(AL/,-TT&PI57M<3+3(B+DTN>-J,)$5&A'7*1-\U:JW)[
M'7K&29?I+&("9([2!&(8D["YF29$1#$+8\)]A)6;!Y 2**@-=L&% KHW#*9.
M($*KR*96X*[(B!"9F5O8M)Q[1<8++@R$9;I2Y=/=C=U+9NB/.XQKIAN!RK3W
MG<V<+M(9K;7Y5[_6Y<[:NFL8UM/UGW#9=$5\6HBISR^4=?V]_GZ?9/C\'YI'
M;_)H@K'TN_C^3C,$_P!?U43$L[8F,?)]_N[/(W._]3]'RSN[^43(U_H]G/Z\
MA(4^GZV8F [IB<]L3HJV9C<4?H(;!I /MR22<=$&D)DHYU%S+ R2Z2WQP?:G
M4F"H!HS:J?,RCXOPT:C!*2Y-ZHBR146Y\OV=&OKV[4[*CH*0=@K*3%RS4'/,
MJ)4G#2(H[ %?<1LF &)*8C/2-;>??5K!K-"\YP(&NX"2P&'QQXHM@94(C/>9
M' P"XDRF!B9RW@[T9MV2"BW=_P 3L&CY;%.8/>5GA00>52]M+976OCO,BT,L
MN<1UD>@ 4*J(9.!"AH4R*'Q4A+ W;'M +R654$HT#.LM:G9CJGU-DA_F=928
MUB*\H1<VU==BG6<2K3&0PH9"V$M3$K:)\ME<0R;P.D-BW6ELT6M<]$5MC<6M
M;GP]U356#KV["A;56N0&0E@";0::R'A?B3X<5KKOQ5\AK0FM40*+U)-TS=WN
M^T*O=2*/DHM'I<U;,5"Q,T)DTA;#@;N/A0J#DX;-MWRH\8&;."#I?ANGOK=Q
M;WFII5K]I]^M*]8,3>%30>ZN1%"P6Q*I-HM:R14I<C!FPH 8F9RIJZ7:7+%*
MLFC8AFQ+BF35&E3Q@98; <V 62EKB6,9!2 +&3*8B,F(OX)RC4H&0BN[_P#%
MV\YD9#V 0%QBF+--RHN^+5P!U)S$1:($(2"3<R P#1+.X<X;JJQB8.P9 $ D
MCV1. P@KH+ZF3*&6;>KW6LKJ94 W;&DM"Q"XWP5O*1LLD5+;(#8B8AU<6"UJ
M13#&+WSZ;=XP5ZNTTVRL,7:,$Z^XQ[".HN',0,%77RUBX,D3$^"\EFM3B;*P
M.'ZU\7KCN"IK*N"M8N^F8*J91!XM*P$9%R"03+A6>"9N:'&V8(&%(\]QL2R@
M)GJ1%GCUEP+[<#/4DX3<JJ-M^YNM?K[U.A<>%9MY%EZ&N-2J_%5E59K)K6!^
MN85M?@K$2D^#]8D8@M"II[]^E;OU$E872=62]20:VQ$V0L,!@K6L^5 -9GBF
M1# 3(>DP4S&B)4U;ZX6)21&JK)6CT_+HQ^"'DH-)U LU/.>U4VX2)%.!>V,D
M+N.T%^$1H==Z\5[15Y31ZVGWK6U.PH"RPF;U.'5%RZTJ;*8964,1,ML+D^Y*
MXB8F39 C$3',^L9K10ORM#HI6Y5:9"JS8K.\.PV>>%H/L[7,GB> 7)%/$\1Z
M3GW(4K<@AG,B)6I;,&#ZZ?-QE@OB$#E+)G!"3SE#MH/F3ER*20C#YUPY;=MV
MAOMBNORX0Z23ZTJGOJ V.O85<%WZ9G;&3J"%I!%9 >8(ZXB<RX8F)B27!1'$
M\SZ3DGK[X#8(Z-P!J$(6B.LX1K&41(C8F0B$D43$B+)&9B8XCUS=YCXP7%7M
M(12_9U%G\.ALVGY*OHN.E J0Q^4&7(Z( 9KS*!PLP%9-7\*)"9"U0$R%@2=)
MOB#4@W3;\I-M.%-6ONM?;V;]55>-BQ6JA;>:#4U"Q.PVMX!FMA$%D&**6)(!
MD0D9F>2XC8L:;85-<C9V4'7KV+1U4@X&J<P@0JQ#A!BQ@JY@T86T3*"(3CCB
M.9T[]AUU^U$N/V/VE[<_&/S4$X_9_+/:FH84.[,$RT2Y^4>N2#!PA-0J_?A]
M/6K,<GV^<*IMN.E=;/REKOY1/GZ7%4P7:GS2/Y,PSA8+L?K/U)FR8  9VD1S
M Q$EZ9K_ "=L.41Y"[S: F5H\J_FPL \0V(_5_K0!<29$ON$0^E,P/KFUUGX
MTVQ9E[Q[QPX +0.TY"\=L4P=FL3D.5$.&D=>RG?)YFZ#N#8S3D.RZ<--=B%.
ME].&G>N=(+Z7U@N;BC3UC=OXL6J*A@_%IDJQ#!EPHY40LA9]K"[2X9$1VE'M
MCC,]/47KFR5J85-:ZTB&%W!97E<BHG_K1)<L#E8\CRN>>1GV3SGZ'/%^ZQW3
M#N/P.66*/=P&#V([-5["9\?#@Q$\@[:PA[$X]6B8_EF3&1Q=9R8[3X<!N>1Y
M!X+,%1+?YEW"]UKB[X;:14,;5FH*[=FJIC&5;,U#)8P\^X#=$"N)[6<F FL&
M%V9+-/L![956?; JM:V3*M>TU:UVJPV@%A2@>TP5,RR8Y7]$R!AA'?.B-*>M
MM^,B!IC5MC/0U@DU D"+-(1)G(R;F4>E>%1$0?HC.VLE)I=H+\*, RKUUQTB
MKSTEK:?>N=HK]$3L+*[4%E0(;:65E,'67,1,,L#)]R0F"B8-D",Q,>OK&:HT
M+Q A@T[9+M'*ZS!KND+#(YY6@X#M:<<3R*Y(HXGT])SVN*,NUHZDC%W3MIM7
MT-65;2]FXKZ6HNHHX0 /)6LA)&Z@CE8&LC%QQ"2*I%.&O:8!@\,=\Z'-5W/'
MF-GK2%)#L*1#9B)KE%M$B^):*(E,PSAL2\P3$AW1+2%<?3*(GW.MV,$X9H78
M*O,P\9JO@D3"B?,.B5\KF$ 3I@^V84),GZ$3,19F[FEC&,ZZ>@E_^*AXP_\
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M5)CNQY)=$>]X>-4>FKY9)HOI-=3A/>V=NHM(6&6JZT-[96\W+!+(,9,)!A%
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M0(V#.PXI\1A\3SV9AJ=1+#J*CMGI8-:NOR9J&:Y-7396=2.5Q7JTJ\FA#RE
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M,KVFRVRTK+8$1XA8*F*[C/&G1=*V;EQ";5H4U-K&M:QVUUR?#I0=V7;T".K
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M"EO21V&6==>6-FPO9LJNJUBKML^%V4@"S7<:V>:ERW0E20:K)?TUTXH=G,;
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MM*A!*$+4A("M8QF3J?J.QU/LANMJ4M;4JUE:[4ZG7)A-#4ZJL;3K4*PSW-9
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M3#!+U<N$BGYQUMMK?1+HN6*:]GTO<IN^1^HM>YA5W;E*76!T^T1*9?I[=@
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M%FS9L&JK3IUE";K5RVY-6LD":]JUC)1KKJO$S-BB[!-GBI)M&QVTH5$?9VP
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MMPZ:-0P%_P N]M2Q1RZ9/&R#!@JNZ57:N$DTNNT5.><@[K4'7IVQVFN*IL+
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M/?'QC/7]51C[Q@?YP/\ ZC'$^Z?A..8]\?&,U67#JAG[%F+GC&MYL-'D4B[
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MP/\ .!_]1CB?=/PG',>^/C&/JJ,?>,#_ #@?_48XGW3\)QS'OCXQCZJC'WC
M_P X'_U&.)]T_"<<Q[X^,8^JHQ]XP/\ .!_]1CB?=/PG',>^/C&/JJ,?>,#_
M #@?_48XGW3\)QS'OCXQCZJC'WC _P X'_U&.)]T_"<<Q[X^,8^JHQ]XP/\
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MTQWI8R";.U"+#A/105\3M=OQ\)LJ*TZ]SLDQTX8XGV\>GOR1L8QC&,8S'&#
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M%)$[ATB%2)N$DH])NX> RBPITZ39$D&SQHZVU7ZX5Z:.VKI/GMNX14[8S?\
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M'[ BH:\)OW.;"3AAH*.T7=JT4!\>E 7;,K&S8A:-?1$9!EFPT@-?+#9R,'3
M4\8E18KIBR8GC]WL^[UY_OS5#O@G )!&WD->6?<B445)VJX& VQ"MM(1X%>
MV8L+:A@AZXK%R75C<T6FY4FJJ:(F)-''C46UA<CC01IV(78Y]8GB/3CW_5[/
MKS*#?!RI!\Y"3A0]8A)2'3253JO8V0-@_IROB]A6N*N^RVP#EC&&)TD-L"T
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J,6;QDB73==:FCB5]MV2C5B9Y_B?\9^OVY:G&1C&,8QC&,8QC&,8QG__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>g383050g41w28.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383050g41w28.jpg
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M/])R?T?X^^7?^LU7^OC_ .$:?>25OV2'_P"R:_\ F+3Z;C?OWJ('^DY/Z/\
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MT^\DK?LD/_V37_S%I]-QOW[U$#_2<G]'^/OEW_K-5_KX_P#A&GWDE;]DA_\
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M;!B82$AHH4^<L5AF#76PH>O0$;)3<L6M(T< 2]G".3*&/N9.R%2B@[%@X(H
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M*ANG;T-IK>^KY#=7?-^K3>N&-02VD+[)58-HJ00&77ED<&O4'<EHUE<"*_U
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MMY?=PD37"CM2<P\ Y6^#E1@PF<RL6B_=;2&\[+I3&+)QC+[E4IMCE'2N'G!
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M^_\ #_T]/H[.C?\ =+U _@3HW]_O'WAF_/UY[5_<,I_9]/[IE[._V.MX?O\
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MI;6DQ:E-J&=8Q6!",> I7'$B,#$=8I?F0U TXTTXTTXTUZE_F6[_ "Z=5/\
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M-$W'_%9%!"'!SW*!!C.(])6IA<^G$W93@X&H?N%&0NR'@***..&#! 9\KB0
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MKLS5IRS1SH[3T/&W&KO.Y<5)*;'K86;4(R5RY,G9.K #<<1^4#)<1Q#..K&
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M "DF?]%93\?B.:WNG_!@_P#Q2O\ <;K.;?\ [^+_ .'9_OKU9?5S_P";J/\
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M8\W=#9ZJ&3;6[6H\=5=;YEGS?,$_'##&5%SW,>?G=H[5.DGY0V_^1@/QY?-
MW;_>U3_/G_)ZW;;GZ/9_S0?[^G5M\H:A_(Q_X\CC:7][6_\ /A_)Z;C_ $>M
M_FC_ -_75W;NG6!ME@V9:WB8ABTWV.@X>&L[M8%.L5#C0X)RM3KE:EGCD$"2
M\M#F2C<?*B9!<ABC$$*9DFFG!B-]5D#4NLJ(.5()A&N&2*WR1PP(8,1Q("8C
MV&>T' \<C/'&ENQX-99;R$->*P!LKB6(& E;/$?;D3-9% F/60(HG@N.)Q[7
M3-#0@L_"TZS3$-5K#-:=LI,'.&6"ZNBV'4EQKLTW( S%BLI,BRU/U2JUVDO
M9=6'%"0$*>"UG Q0!U7RB9RLW+ VK"VN#" 3$KM)8'606N!_!M:QT%QR4L,2
MGUB8IC&@N& EA@IC*;9!A,=,,J.6?838R2B&)4M,C\ A8$,>DC/$V7TVNWVV
MO6QN<I[^7+G"VW%>O6OB+K6W<1.M9W7F0C8\:XUATIU69OWX&:DIC 10;0ZA
M"L*R^GVMD(0KQ2#8_!$KR)?"F1VL _M$RID1'S>DQQZQ//,?#5-G'2]WF@T3
M/F!WCL5Y>N>M8Z_61ARIF?G=Q+F.)CCB?CKC73I;$N=)V' KM;=<M=R+ERH6
MX5FNI"14QK%K.IZUL=<;A"I@S$Q4)T"LJ=D( N391Y+\8H8H>>KD/8V*DY.4
MNKGXO(I,!!J8?/EE=EME;.\"/1H$R.IP,^L%S$@PER=BX<FR'EA;7$<@Y:^O
MBAE5-9B^DF7=+!5,DN2^$C,3#%@R+TCZ3D'8\]L#WGAW$W0J72?=/H_!D;-0
MGKU-9D_7>J7YV)#X:8&P'Z-KTONW+WJB?6>4+!)W:N".O'1[G=N?CY02'7KQ
MZ=?#SSSZ]N.(XYF<*>MAC^W/="$]>../"=@^W;GU[>?CCB..O/,\\16?T/T>
M/M:9W-%RX@-XE;['V#$DJ"P0I5(SKFCZ]L&O)'.9-I1PLC\#U6>(FVLA$0$Z
M4)A 1\>Q+AV"3[^4U0ID!$D$D'7O,1YO.YZWC\WTD?+XS">8,(GU@I"0B_)X
MQ;9=$X%YV 9VZ<_@/=D5V5R^=\Z"\/E XZRMDQZ$,'#*K@>DN9@=0C:F%G].
MML#1-9B?A*%I*8C)X@NM0;\0#=R#1-N),;V/'E*'FX6TQID=[MD,R?\ @+^9
M%A^-DEE *W[U(6^9-A>.;8$$"PX*4P,UNLH*.0-9078>O!1UGM%7B6!3BI#*
M<0(+"&C2,&3*UR ODHM]HLC/!@X2'J7;YD]HD;$9Z7Z6J)V V>L0FXW>PR,^
MQLEF BF;I!O.2D+.PR&Y(E!N#LQ,Y7XF4?9<0/%R[PC31D6D=.&^6)R3NZ)'
MD5) 0FOY"\)Q F!?-CCB"!AC'Q((*9@N?74GY,3(6.TQ+GL)D68 8<$]EL#Y
MT\\]&+$ICT YCB1X]-?FRZ-NNQ$$O[(V+ 2,D'5Y>LU;%3H1U9AXM=@.@RIN
M?E@).\VD^:EB1X 0 !EB7B(R+%)D>X9Q)#)0Q=U%?B*U=@B3!8SS/%AET$X
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MJGH_Z6Z5':E65M)B7@8%6Q=W6JGFS&Y(;558F'YFKVX*P9I4?(6!E_Z_]?\
MK[-.OI/U\Q]D1P4SS^WQ'IQS\)^G5^ZNZ]:3N.UTFE:^T[N^<GK/$E6"R>2+
MJ3W-K&O1FSK%J:8G[?9$[=77[#%1]HKCI@Y.I)+9BK+5Y$"S4UNQQ34L]%M>
M<?MQQ]?KZSZ>GP^/K]/'TZWKXUYIQIKIR?ZUMZB^TJENFD<N-+UAC?\ 7]0L
MPLQJJ1AZ\+4"^B*M=1DO.Q?4$_98^!/W"S?Y9(D7IMB"LEAG=>/2LX/#QL7!
M25NB&JY&.L3]<<_&/CVD?A\>.(^/U_&?A&IZQ[7+IYD:3/[ @Z'MZ=J\7)4%
MJ%F 7]("P5GK.R)VQ5ZMWTBW3.[(ND:KK&3J[A4D-OZS:BML8S8Z<@NL-F6:
M/$4UYUGGCF.?7T]>?3_1_%SSJQ9GVDVF*E,WL6^T+<]%JE+L.S:5';)F*_29
MJG["V%J.H.WJY:]HP-&V%;K\NVIK(DF?7Q+;2*D!:UP\F'6Y*3+80RZTZS/'
MP]>/R3]/V?7]6OI->T-JL!)-4N2Z=^I!C<RK(57R=%K"T:F_ B-ZJMNY(^UO
M3V=Z_.B+JLY2Z+;/=1D1L^3DOA#!G5>1B8^=96"EKSC]N./K]>/HCZN?I^K5
M4;"]IO4<3.GIW6];NKFBWMC0 V[MZSD#5F:'!5.<Z+[SU>HJ$5&$7=C:95Y$
MH3FM+;(R,)K:9J( DD?5WK)\)VCXL!KWCX\_'Z(^GXQ'V?7&IS4/:::WV )6
M!Z/HWJ MMWN5GDJS6M<5Y&AY6=D\QNMD;77,8MP>^'=0BQKM01(>,4S98]@C
M+%$F52;A(NP$PX$JTZ_MQQ],\_#_ ,_X-=DN/K?6[?P9[=\?P9[9SC_JSG'\
M/&J=.--.--:#=5GRN@OY&7^-.<W7:'PR'VU?XK&M6W)\:?V/_C3K5CFYZUC6
M-FIB.KT/+3\P3@.(@XT^8E"\M/OX%CHP5TTXG+(S;Q#V&!F'7<M#LNON>'P-
M-K<RE.:@ F&(!')&0@,<Q')%,0,<S,1',S$<S,1'TSJDS%8&PYX !(RGB9X$
M8DBGB(F9XB)GB(F9^B)G579WYJU,N5#N3<PPL&6B8(Z9)I%\&IP$S.QT/*1$
M6??"*RU20CC@K!"*9'*L#3GGR@82TI->2/R5[A:ZP7C&>0,X"'(ET@!&)E"(
M9YI@9 ^9A<^@D4?-B9U%]_J]Y#N<=3!9'*'PD3,0( )\JA D4,#B)9$\E _C
M3QJ!2EVZ7P)V[[!G*U  2M=-+K=VVC,:8L(86#$34;K"0B2MGG4AJ(F\MR!H
M59.8#L4@TW%,%*(PF"BI @.\*<D0)K@PR%HPQ-8+BYGB0*P)Q6%TD'(P3!DE
MC,E,1'SS&"CF[%B;[#%+$EE*WVCIL$>T&-4@*T2( ^"(5%$,+@(GG\&!2.?O
MS_3W$2<;)W2E5V>FJA6XR;AS0-226PI:M51!)B(R1BG:S4;&;$P@1,64MMX/
M+ D9EEI]S(R'QG':$1D"$P2YBP:PEF)6AKBQO$=A*&-7!&4%',3S)<S'KQ,1
M<?./ Q-R%F:5@8$-0K!J5R70@E26$(#(3ZCP(3$3/'(S/\7NG1N8*3F2D2 L
M7=(]<Y)CRFIM@1TE=8YQZC4)$BY79&E#3EM9/S;J-5P'6XR2S*ADBQX'J@8@
MU #W.[W$(ZR22Z#(VJY"DN'OD?(+I!4CXG,*)(>LQ)%P1CV]]]H^,CGM .'N
M4'4L"3AY0CM*R3#&P7E0H9ZEWB8$>1">O-<V#HZ.KTP :&'"0PH]<LTM5)?7
M%B@3GWKM9[!'5=W%&E*L%-2=BL=IJ$U[LB180JQG'@#'M@KP?%DETQ7NDP"&
M2,YEBQ:%@&#$)6!-_# PA%:UM#L4G"X@I'GT*(]]XI"LQF( !A;"2==BRF7,
M8*OP!J$R8UJ3Z! 2PB&"@9[#,_ VWZ%%H3]\L4'%UJE4-UJ!6_>-7SE.?J_O
M&5K9;((E>MM4B9L $Z9^"YK2P8I,>4>)&&-N./1S;PWL)O2_W=9DQSHD^$60
M;#.HLB9EBFD!2(>09Y+M$20_XW$TRZA%>;# %243"^7U33*NQJ*!A;E 8B1^
M(HD1ZR0B7/(<QC+;+=/,[=\T"Y:X;L]MFSF)E0TOT^72T1\L_$-Q];;LZ[*Y
MKR1K9P,&-80(5^UJF'8V$#E$ADR88KSB.5*"^"?.FQXE!$AR%]*B&"[,\?C]
MX%@D<K(X5T@CD>8&9C5+3QYO]W=6\K6%!\'CWM$Y"!7#9;[N2B$(8(2WO(@)
M<241SHK:73O%QE>7' !G1DC%US:$8/4-46JRHAHLF-:#JUYG0*K3I-VEI]TQ
MB X>9LH\(0S'Q+PXSK8\20@5[K?(F=BD2$F5BEMI2Y,X+EJ%DQP^:>Q<F"Y.
M)(HF8Y*.4VL< +ZC! 0KM#":C6P =8A3V"I)>'@ B -D!,"$Q'H$Q%J0>SJ!
M9;([4(&V0\M8FZI!WE$:$1EU1E/L;C[4-8XPG"/1RT26L?*5%Q9!;8OG@Y,R
M/B2C\DQCK/6ORL48+\IIDBCCAJ^.ZRCXB4<_ HCG@N.>I<2PLUV,E*V@;(4#
M^HSSREDS ,&?Q3"9CB9&9Z\CVX[#S(:U8H:WUR ME=-Q(U^T0L58H*0PP2+@
M^&FP6)*,-P,:R,8/@H(EA_#!8[!+.%^6^RTZE:$VV+-3&*9'5BC)9CS$]3 I
M$HY&9&>"B8YB9B?C$S&KBF Y:W++LMH Q9<3'8#&" N"B"CD9B>)B)CX3$3K
M-<HU7K9+I9_RDF?]%93\?B.:WNG_  8/_P 4K_<;K.;?_OXO_AV?[Z]67U<_
M^;J/_'9W_P"1%\QFT?T2]_V*_P#O-U.W)^)4_P"T[^)6NI'J)C=K6X&N4/4R
M78R3/(/M<M;2)F4K$5#MU% S]7CLS\=7["IR0D+P?6YE^OY"RS8:G6+7#'NC
M"2'F*Z1CRJJ)C[7SA&!4"H 6$?EYAL^,C#@83# AG;E;6+,>2'C6AY$;3A6B
MI$B1233;W)0AXN)4/D@&<D3B6<KF.&*4T"F(+UB;&U-US*Y!;%4DJG*N%ZR!
MAJG+ZGN\T(T!8I/705\LTE> S@:\ZJIG3=\C?@^@@ MR)JS-K0X]"%LR#]WW
M6F'7EHM"(LR;1M)">P"^4+%,Q+/PH@DN_!1V9*YX*)&+7O5TY+A1*.9K0"BJ
M.,>K"K#8:3H(5SX28\?'R,R"H;S(%VGZEV?J*@)N1C(>IBV]D^SR$=B:)!FH
M@!MVM5&G65V3;'EK%),1L!L!IBW4^#5$O8A:S=,1#Y34GZR74YY"\>P!(V2J
M16)=!("F88UJ^G(@,D:)E33[QW8GO$2,P&DMR*S(04+H)I#WD3 ?P:4MD^#8
M<"NQPU*^OS%.Z24'R>HT1M3J.)BY1^ K>)+W96K#8&)0_2VP:L[*V&'II,ZW
M06*E/V%,TG+UA'"A@K,R\^-.M2[D3"CDR\,5*/W?=<>)C#&=>S%KD1N(9 @3
MO'+Y8 =/1?)$N>)"1['(B4#%OWK(R)RM??HMC(,J=A4FP$RSP0DV0<?A.HBW
MF19!R"XDPD]6#OR:V0@NN5^J!S;$))D5DTJ0KU0LUGD9"2%V%4L&P9,K7G/(
MI,8-6U2<F;+3@R@I1G#HS90S4<<.?'HA7^>;9"3'R#$&Y2A$90W@X%D<N*6=
M1$0GF/IB9(9B3>.QV4M0G '*BD@2UI$0V$]@(U^B!A?8I(XF#CF(F.LP6!?V
M1O:#@ZO)R]=5*G6VL3TA[LAM96]:ZM9A;#KP&%@)WT4E,/!L%5^0O$N_)S#<
M,&I^.2C#PZ!6QBJXKTC-@B<#"FK&2*PO\(LEO(S#L(Q,P8I"!"3+B?A/,S%J
M;-Y8*,U]Y<IA=%UG<J;#*X@#.".1B5FXR(^D<CQ''$07+U)M/9VRJ/LF;&?J
M)-KCVD%4*!3%%Q(Q#:HPA^,+-P1.R!IU/N,H&6Q4+@K,6N6@VE3/N41YMP%/
MEJM6KNK+F&PLO2PSM!\3VB"@> &(:D9B6J^= G\SN7QU54M6K*+)Q*9:,1*%
M]"")CK,B4\L(B2XAF$N^;W")/H,\A$69V!U,65"""M;YJ;3$B))0B% SCYI0
M=QAIN=JXLZ)&3X;+)^NAAA*QL2-E''X*6M!XY >1&&!\8NRC'+F(BQ#9D2 Y
M[!UB4F(,()()F!L3,L1(Q# 4,Q,S,S,VH?DF\3-;PQV$E^C)*8<LV*AD"P8@
MJ\1"K G)+-QQ(]8$=9'4T_N9ZU1,O.(FI. N-@KL19DSFN+74"(S VF)N8D;
M"&',E#JKH UXK<94WFG8C$;(R$TZ4T2IZ4B4,TVEU(48A(":082NEA;>W-P
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MQL:\J$_4H>'#9M*[-4',3TQ:8-%F]>6!+/UUUR*)CSNR1/!IT@; R4P<.1!
M=NL4*7[PP&F<RKQMB5BL_'Q!##(@H*)B9J*[>)4E <A*;'4PIVAE[?=TL2 1
M#?(GYYM#RP1"<J^9(3\+'=V-OMF8\[%>A':_\*)D7$>G7MR5+)KD/OAO6;/B
MF$VYP9T^7H1;>P1)5,&D/ L>0:W%E0Q7JA(_N]'KQW/O*QGM[PGIW.C[SSU\
M4<"#XE)#WYY*!DH(>)D39R'>)\8=/*42,5W2?C&_%:/G^;CL:"BQ!^/B!&9@
M9">T?G3]]V7?K]!F6Z&GHB-C*OM )QQREVJA0\KZ['3M8:J;*5Z<E[".'/AH
MFKK CMXGY1:%PUCP&\WC,DRA;170DQ48%),K3QYE/,.OOZVP+%@N9 NBCF?&
M$?/#F)X&=*;[+WA+@8 @NR,SX6H NWR>Q4DMALB&#W>N(\AS\QG$Q\Z-8"/V
MEU @ANOC4!N5&#S/ AU\NLW5,[*2#6NMEW*)*5:92Q&-L@DVFJUFH^41$/(P
MNSL,-2#)+D<,NLJU$BB)?TF861,AB?&(^>NDX\0+'YT+:QO,%S/C]1F.Q:H&
MS?&)F$08QY!A<J=Y"**]EH%Y2;,0,M4I7J$^K>(*)ZQJ,1.Q=TQ<Y<)- TQ.
M1DE9G?!;CM6;;$@("'7&Z)B2)*,U078%3SD>"X3;U9CF#,R&)0>>L"31X@>P
M"N73KTR6D>0 Q7^A19JR;"@[I"!687T[3$*^=,=9&5KX[2N=60L708XN#,"9
MZ-*K;%:PD:(R8U)9WZC,NF1B9+O#&1(A#(U));<NY\R<['Q,>I$7&$:[(8M1
M.@]EM-9C3K1#1-V=:K_PN,D9<=$3,B3@S+;L1.1 #,NV3'%,"IGV+8U*?4".
M?GE#X\47J\\E"S),>2%"(3V"0YGN!SUX*)GI-P[MR2,0C@1FO/EFA9B.I- '
MS"Y;)''4X.!B18$0<2)1'DCZ#;>W2!E@1BD$J=26I(,#(4+94K(66-.LMC&D
M+"B\O2V82J#U2,&$D7ZW8AS)2:8%;"B7HS%FJ[:4U*93,RZ../5@OK@*R%:Y
M%?A@>[):13$&' A/)%!>-LZ]BW<&8B$S/$_-62+)$T28R"9YY/HJ$C E*V1)
M'$=1D?*K67AMK;P;FJ1'6:M +$F+;#1,Z3":ROB2<1<_2]=3S9 K9-C+B(0.
MN3]EM$+9IR7GB'F!X9!<?6CW(2S#CVSK4I!Q+842"C(!.PGCN#GAQ,P$$<L
M%$L!"(F2D99'=<S6%J]!H%JQF#<(,D*K^>AHK,B1Y9(+%9M:#3,YF(7R*YZ-
MB.?=]K;<C-F2],J5:P9#*)I\=&SDEK&Y%1T25*7;2\-.FO3D=:&8NV1C-4V%
M<IU+["*BB'-I1P1;LDQ$RI3GB:M0JP.:S@XAQ&L;*H(X%-PUQ $N244MKJ7,
M?A9,7"40,F$:J?:MC9-"5]AY2(F55Q"$FZD!E)@V!:,*L.9S^"Z$DHGL(%,Q
MP>_[FLETU9%3T.;6P1[;&+FFHBB7L<>SC#1VQHZ7FB++[U(@*S74'1L&\W4)
M],M)*4='GYE2!C8E]=V:]-:K1+.&3X3@))Z)\4S*" (7UAC3F"./*'4?21ZQ
M(G&J!?=8ZJ+ E8PT?) (?$,B L"9RWO*U+["'"601\D)=I@@F=T.8;68UO\
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MI;=:0%1M[]ZK,9;6YI$\TH]< 7I-GA!JR;RS\&)C)\J@B;\V)Y_!P)2ST^9
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M /\ '/.:[D_PJ_\ [*?Y!6MWPG]XU_M=_*LUM%S ZS.G&FJ-N/RCD?\ 4_Q
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M(T;(H+KG>=*>.'F,"0&(A3%8"2X= R( L0C]';,\1\Z2Y+F8'BB-IO\ G<J
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M[O=L+>6W]WHHJR1X.[[S-%SF5HLJ8EM9X*MJ$VTK4(>PJ5Y:V,HVQ1;!3"3
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M3$=$V[6V=O%*MQ9G:^/RF]:E7(XY]C'L34L4:UKSUVY8567A.,#L;B(A79L
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M<ZXAUE_!7B\OE%?Y8/&4\7A:843QUA$7*HWSL3DR9"V]VXZ5DV0@9*":-<I
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M3CUCGHGW(]-M>_NRFE-BK2PE/'U+(6I)C79%S7C9E#3.994!B88IA /(D(
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MYH1#:H][/.LUMZ]2+W,JWRE@F>9M2O3=(,K]0AS5>4#!@V527C4ES1Z!$,3
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M\:EV.H3!2SJGU-;0-74[YX4J//W:T7:%@X<?7T2XNL#.Y/>!C,V0H@,^9E[
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M1G]3J=^:6E^DVO\ PJ_KM/G?S/[9C/NQ7_<N/D*W^G5?W1G]3I^:6E^DVO\
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M3[X_ND$-Q!I1!&'W7G4J3K5O+;BNY-V3??>DK>(K8@*6-Q]+'TAQ]6XFX-:
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M48PVZ=E97)[O]H+:UVM63MVSA;CHMW4UV/HYS'20'4$.)L<L\8?@U%R!Q+9
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M>5+?,4-(Q[H46,L*,CA!GU(9DL2;AP+F6$2%QV0R5+835<.<?$$M:H(5 41
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MF15JS_Z2\KSG/QY[\C'1KE\(()_ZI3_$7:./VHXU)&_8'XR)_P#:'_S'KJ9
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MZ7UN.1Y2AF62_5+RZKLRA64N>$E;>'D)7XW66UX2ZE/;9;1WTPNU+(BO80H
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M0,QXF;(L>?J*! )^'F;(L_:F5@MD#!1Q,03(.(F.X 7(Q_?'8?VO"?[<?_\
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M 9$2LY'YT 13$3/I/3?9QN7&;/WSMK<V9QDYC&8?)+MVJ(!68XAA;%KM55W
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MRTW(NX5E/A6I3Q/CSC*>[:,_4-Y+*;5?573M1[Y-:^LW5_S@$M'K,"X'BI\
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M.2>:H*>HC),*!UXW(UJQ4U2#(BT 2KH*H!8$RNA<$,L$_5EA00*0;(QV(H$
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M0Y]W<VJ-DH%!B=33NUIV3=5)_!-NKT(B3: AX&LR"K+)FW>RP=5!$!%OT3$
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M7+D%'OC^XI/(JT^CPRCW4:2D-:7'W1VEO-LR*05-.^8\O+9#[RDH;4VYS/\
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MRLI Q@$B(]X,2ADSR<L@I.9/F=;6=)%[G8N_"4PZ3.77;)%2:HZ,)=<<"9E
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MBJMO%V_ C)8^Q)A[U[E9KA9JOKF$FM:F#)!(Q.W]OV75W("(B*I=&I1P\YA
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M8;"'WPRUC,.J4ZTM _0\3[.MZ.I94[%FMB,0SW4KF-NEX;4$D660MRDX%AB
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M;KZ\0VJI0A>):U2AK9DF#V--=2#DF>3GPB* )2BF0"#:$ST\<+CL/2D!DUP
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MYN,J\7DX<B0W6QO%WSW],VM#'Q9RG'E]D?483S7[)BQIF$<#)3Q^WQ Q)?\
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MW?\ U>GP4FOL(W^W@_\ >./DNY_D+_?"/ZS3Y:H?IC?WN_\ J]/@I-?81O\
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M(S8<0F.=0*.Z;C(:7H%98134R6\7D%)+46Z^$@M2W\*9:;BGM_)C*$B-8ZZ
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MIY]!CZ",O26LXB3+CX# ".QENI5<OH<$+8AG3!H"V5:\1.&2B!,LV&GS L]
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MAS 013 @,S,")%/'$1,\1K!;HJ6+^VMP4:BI=;N87*5:R8(!EKWTGJ2N",A
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M7W[E\+CF2%C;J5;NS-'&V!I*Q]9&,M/K6@.K8L'8)C_.@_>;1P+;+9L+.O\
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MQIW!"=1:L26IY9:=<4?!2R5RCA"R,5F+P\HAR<'#FG'E.>++JY@0644YE2I
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MSG&/L5VUF>)PP)R ,ZP8'P+!@PYD"*(F1F)D9F"CGUB-3D/59#R)*2#N8=I
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M"6<(<M;0D6R!&$]QDI7Y%BT0[=0=$M"!,B*8K,=48\[,K(+!POERF,4SE0F
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MA()<1$47736QLR4B\LQZV3(^KH\EXAH1*\WA'%,Z%9"HN:=*AEI@ 6L;Y>[
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MJ'V Z^*=?'W154QKQFD-D*-"9!\4H9CTA1)L5;HA*GG6MN,6V6RU;P7*$RS
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MQSY&1A0O>\JR%0R%1WRCLO9FPK]K=X*R=W,V*=+#*,FV,G8D1%-6M4QM,>T
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M0)V%K$(,S;'6(F_\JD=3'.15\EG)S UZYN\:PGP,L,)]B%,D%K4HN2!##(Y
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M6H#K"35)3Q_(_IEV!7I2\2-AU!J/?(]^!V;!1</>K$T!'Z_1:.H#>NS&U_\
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MI@Z%&10+&&R;JQ*3196R.VMV-):XOE5VKLVW2U/@J;5+Z*/8B8Q5@A;E.-;
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ME/'^*&"J6>^5^D-(#8*Y+R=880+88A,P1 LRB)@9F,3M39?3.::!1-G[CU;
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M9Q]2]G'Q\QS<C,\PD>/^N?Q^V!CTC]KF9Y^F(UD58^(XEQ<_]0?2/])?&?\
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ME4R1.B&NE[HQ\*.5UG6(4KWN8LA6;,-#@Q0@GDYR98?8'S6-;+J%P?RIN/\
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MS8+/&;0I<7'42Q[+AGKCJ^X0#]XI=3"8DIZ1I8!<;@^4E@8XH60533!HV\N
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MK%25K4H(X!:@%:PCX\" 1 C',S/$1$>NJOZ=_P#(O0OY+*_K60Y+RG]_V?\
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MP:HT!7-/7;8]HJLO+>XKU&TV*B*.5@94#KR-J<G?)M4+3G&T(*%K1TWL&=E
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ML28B)&D)DY9+8F,^##]:E6W##M2,KL&)IYW4X:#LV]:TUI"S*=A O=)&FX"
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M>H#X ZTV+80KU9>JZUZV5FA,V<SYY1.Q-/$ZK.D!R"7LP%/DM?/[-*"&*6U
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MLL1O^KE^X=GF6&G4"?UVQ7M4B^]43<;K[7,9>9H:86$RP D6NG>XU.VJELK
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M7'6#Y;P_5FNY1X&,YQV4@)I2LX93CXTY>SW?7C*NZD(5Y6+%BV;_ $CYB_\
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M^L(6)44@ZNUA"2U"KT,+*HF)@8GB0YB>?6=<WW7U!_NYTW^"J[?WR<I[XO\
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633C33C33C33C33C33C33C33C37__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>g383050g44x13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383050g44x13.jpg
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M$0 "$0$#$0'_Q  =   " P$! 0$!            " <)"@4&! (#_\0 -A
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MP5RVW\83/)K9B/?%2A-I?[(3U&YG*(PN*OY2QMXJ5=CN,SM+&1'%*1G\$YQ
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MQ34%5QDUFE*E..O-/KUN.W1=?O\ S;N74M#T4WSF9@ZXY]HX3:(Z^72R\U5
M;#JNO;]:H*K&=L.$S8PQB(FUD8X./8YBI"6@ E^"\F3Z+U,BD;:V5HW;.1G*
M+*UD[#*A5T*RSS)UJLDO$M7TR<EX0EDJ';=IP43'D?2-C(+3;PV1Q]7%QAV!
M3Q-55\+=EV%K@**EMX>9K8Y"$#YSA4.+E$*7(3!4[?J/.B[#:7N>O7IJC[@Q
M>-O6FOWJY@1;GQF$TRSCE0T_35I0K+;O[DN#I@V_"?\ I.QY5;J\[&%,RT*\
MN/;/&*3&2U)<V77I*970P_Z0XKAUU_OW'B3 +@HWB8:X?N/5$[N99KYQ6E*.
M[+-]ZK-A03')G)DUZ%:?Q^]8DVR,[3!)07])=0UJ[U'>\W2E(#ZVU)VKK375
M" *(+#5&I[PVV'!C7"Q*68)KC08FG$,MN3BD^9.E.8QE;TF0ZZM2LJ^/G;;U
MCH&\\[5S!VK-AG'R.=0J&PN B 1)%=F9@0$1&/M Q$1ZCJ/I:$[DXZLNG0U%
M3J55<Y771DKZU!+#)AR(CC]HDC(B*?R4S/2%^P'UZ>SSF*!7>ZNDMTU/;MBU
M[;]?!HFQ*G?+C<KU29< O*)T4Z2?M%!JK;((5:41!L.6F?-D1S1D/$3#5&D*
M<CV'3NH]*Y4F8#%T74U64V3*LZNE%=XD$!86,*L-F6&F2(HXC$@!SRWB(FL:
MITIK+#"K4V7R*+[:MBHL;:+5FQ9K$#".JTY?51$*!\" E!%,,8L>.T[QJ1V-
MTY_:U]-&Y^C-;Y2P:O\ QOMR::&BG%J?K5N&4*Q!-F 8N<*5*0Y7RX^QQ1SZ
MODE2(D>$192G[EE6515Q7Z/K:CC+7L*^;IB!%]FI.PME5D_C9@$HBCW$%)#,
M^IZ=-S,_KO;[(Y:GZ9:T_?)@!ONEX56KN*';ZMU&+A"8]S B4?>.DV_3+LT5
M'#^S'P6!^;R]T-9$7U2?I?F,1V:71_VBW)_XG\,F X0<$_-_=/R+MA^V_O&9
M_DUW2FQ^O589R^/&-5\?[\-Y?8\TQ^/))<8/;WPA6_KCU7^SL5OY;N2KC\F<
MJZ+4^O)M%>MX(G\^. DY7_V><MV]R76C7Q:=-KK(#[JJZ&M_N=];]2L<".5K
MUH@\S5TZ,EMI=BD@QOJNZ#2D"2TO"D.1YD&2_'>;7C*5MN*2K&<9SCQS:&8:
M=$:F<HI!BBRC%F,[$!AB$$!#/XD2B)B?Q,=(7N(I;^X.D4-&#4X<.IH%&XFM
MF;L 8E'Y@AF8F/S$]:_O$ST^NLFWZI__  9Q=_U/O+_*M6^.#M+_ )N=_P"'
MCO\ W7>D=WK_ .C:>_X^1_Y=/K0QUCS77NO.1]F<\V+[9E&Q-=H@@"DIO+C=
M>N@V/%,T>R?!*5.Y0"M8\01DMLY2Y*A,28658;DN8RML-E&X;,5,DK>?C6.3
M C[M0<R%A7OUNQ)&,3/H2F"^\1TU<[ATY[!7,4[C$6ZG%1E&\*LA LK.^V_[
M3P6<Q&TD,$.^TSUB)U][(-A<W>M3J;UR6R.<";@9VE-UG4VY"'L/T_7EO('D
M= U:4ZC/VT3\2<KI4(F*IS,N9)VV3DQ,.1PCRF'O8TS6R>J,3J9,K93FI%IV
MVVSK*17..='Y+F#19,_:(IA$^SC?SC5U=;Q&D,UI%XL7?BZ5).\3_AZCS;^J
MH*8G89!JC5QF=RF^9#O"IVT8\^<I6CBCT;;LK00;*%[RN_,&[-S7Y<9I;)V#
M=[GJ\G*CB481C[EDQ1J;%!UQMAE;F,'PDR7#Q]29G"EID<NK.Z]H-84%0KY6
MC1KQ,[K)"+8Q)S^)"P^39,S$?ML$2]#TVL5@WZ=[;9%*@E>3LX;(Y&U(QLT;
M-BD9"O\ [T,K5Q4F(B9_=41#[+J+_P!,>.U^SQCMXH#2.5L2=T$6B7Y[&&<&
M\!Q](ISE'BR<X_O.032)]DDA\N8^WR4F69+"LNIE)1U]TRL3FZ0,Y?&''!->
M/?C\A6'Q8F/QY)XJAFWO@*M_QUQ=G JQIZ^:X#Y995@VI]>7QC6KS6$OSXH@
MFRO?US)VWOEM=_UP,UX8Y:Z)';9;&N:V?TMLI5S46PS]G'!1ZD5DRYOSO_TL
MRQ^&4SATIO*),0C'BR8CC<MIE::'ASLAEL:5.2BU%ZKX.&_*62X(@=H]R);\
M3'[$$D)1(S,=,?/!49A<L%Z FG..N38\FW&%"AA$4S/VD-N0E'U"400S!1$]
M9[?TSD^T/<D]:#9JI2J;!VDQ*KV',KS$18I^MXR+8B-\W]&'?Q\&GKE(1GXX
MPY'6O&,KQE3&[I"J,QB"';S%3F&?;>5C9+P[_G;D3MM_]=NE7V=-TX/.@6_Q
MQO"2O[0XZ8^>(_&_ :\S_OB9^\=>'_2O?X6[7_Y_H/\ R[;OG3W:_P S _\
MZ9+_ -U'KF[*?Y&HO^+B_P#V7^O7?JE&&5::Y,DJ;1E]K9NQ6&WLIQEQ#,BJ
M@G'VTJ_TX0ZN-'4M./Y*4RWG/\TX\T=IYGYV8C?U-6M,Q^-X<R(G_P!-Y_\
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M2+\"(0'#DS&GO.>WWJQ+M.9C/:;P>8SAX;,5<39IL3-*=K?FE>0\J@OD-(_
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MDC&),I(XB!*(ZLNGZTT\-CZLA=7"$>,%Y$JY75J$S\*WS5(ZXD"N B"R*%A
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-1T>'1T>'1T>'1U__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>g383050g46m46.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383050g46m46.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1_B4&AO=&]S:&]P(#,N,  X0DE-! 0
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M<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F
M"7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT3W5T
M<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !2
M9W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O
M;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M      !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M    4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;VP!
M %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M          !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F-
M60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1"
M;W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P
M4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE-
M ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M #^    X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         ".$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             #
MAP  !M8          0                         !              ;6
M   #AP                     !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   #AP    !29VAT;&]N9P  !M8    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   X<     4F=H=&QO
M;F<   ;6     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    %.$))300,     !5_     0   *    !3   !X   FZ   !5C !@
M ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" !3 * # 2(
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M9IVV5UML>YKGES3HUCW_ )Y+?IM8J^1CL=E,HISA6ZQI=!%9U_1BIK&-]/\
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MW%V9II)DL:2>20%P?U(?OQ:*!+O4R
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$!_\  $0@!(0(P P$1  (1 0,1 ?_$ !\   $$ @,! 0
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M/\/]=-,]^Z9YZO'_ ,7L\]@]N8?%XZ_'>S%XCIH_=,\]7_:]WO\ \X;%W_\
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MG%W_ #-PP/M_>?\ 731^2[.?^J>G_P#BIQ=_S-PP/M_>?]=-'Y+LY_ZIZ?\
M^*G%W_,W# ^W]Y_UTTWU_<6/%+>,=Y.YXHC'K6:=+,8=Q=*AA6LH2KUNW.[<
M-(Y689,R/7*#5,[E9%N*BB2!#+*%*F FX8'V_O/^NFFV_+91_P#ME^+/_$Y>
M>(>GY_\ W1_UTU]_+91Q]OM+L6#_ /L^7KB. >Q)_P#4?]=0)Q\_W$_RT?EK
MI'_;+L6__P /EZX8'V_O/^NF1]O[C_IK25;FZH=5SS7Z;:.<S$.2,=S^*+[9
MGLP\E,75TD#<ZW;\91=>BRS-:?M&0_&H.SVMT:,?D4<N?@OJV1TTF+XJD=/W
MG\/O]L#\X_&4G[KSE5_U2&#O^-*E_P#//#3(^W]Q_P!-'[KSE5_U2&#O^-*E
M_P#//#3(^W]Q_P!-'[KSE5_U2&#O^-*E_P#//#3(^W]Q_P!-+:B9RPQE&2?P
MV-<KXZO\O%LDI*2BZ=<J_9)"/CUUC-D7[UG$/W;ALS5<%,W3=+)D0.N HE.*
MGR\-1SG_ *$?STZ?#31PTT<--'#31PTT<--'#31PTT<--'#31PTT<--'#31P
MTT<--<3_ *)O]B/^ >&FO%=S6\PG-)%<[O,OAZKYNS7$4:<YY\&9/CE8F_6]
MI'4W'.$)+&V.LGXR@EVTBFA 4Z]6GF.P4[G*FQ5;QDX<DBJY:* =<%'Y_/Y.
MGY_/Y_YSUY0LX\R==YJ;EA68K_,AS#1?V=_Y1^7JVQE>M:+V4NSSF0SW)6_
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M(RK2E>YGL;<OD),,Y)JG.W6IU^UDLDD\08O89S /K!=:S%(!'1R,HZ5:BSF
MD@=M' G;-V"R+_IEDM]=U$A:PT%7>U:FBJD>UPRUJ_#3;6AJ@:9)0]/*&41R
M@^6^X%6/&>?WJ_\ 3_2D<IZJN%!8_,DDHH)+Q<8+2L5?$P,L1%64$TT:)(KT
MQ*.A.YL;<&%TR[E+379J-L'VP,,RE'[*3C6:M*JO*;7ZP+%ZT!%()Z!L5=N\
M[).B*JNR.W$1<:\DY8"T;M6T<]0<23S._J-UIC/ZI]1?_.:X?_2^?X:U3_:?
MX;__ #?='$'Y=1V@_N(J_P#G_#$EL"(T=E/42I8GYRI'*M;H=:4BWF+W\SA.
MW%=U&)@4J[!'3?46E5>SQBM??J0CDTJX?R*3XB9F3UN8[\'26.N/3G4%GA2H
MNMDNUMIWE$*35UOJJ6)I65F"!YHD4L51B!DG"D^VLM9^L>D^H:AZ2P]2V*]5
M44+5$E-:[K0U\Z0*RHTKQ4T\KK&&=5+, ,L!GG3<9:R1BPUBRO6[)]ILTP]8
MG$V[9PM/@KKRYU=;%0MH2(9(0K]E;JE/VR4?-I]G(3DFK)3D>J[1EQADV[!N
MU36/<TG1_5E?30UE%TS?ZNEJ(_,@J::TU\T$T9)7?')' R,"0<%6/ SG&HU7
M6/2=#434=;U-8*2JIW,<]/4W:@@GBD !*21R3JZ, 1E6 .?;.HY1+'EH9Y%J
MF1IS[8JZ7&2KU+N%-7;3F=N5]@91O;I&E2SM>)=T_'=95CDQ?TIBJX9O F2N
M2"@FFHT,V.HZN#T+UJ._274@_P#V)<>/WTVJ ZYZ*)P.K^F?_G[:Q_$U6-6-
MX9BG"./+I-T[F.D<RURYKNIW%]_M3F NS"J-"5F.@CMR3-7/ LKI!M;9#R]D
M5(#B,7*,B\@@?(I-$G1=8N$<MIEJH+K%+;9J'>:R&NC>EEIA&AD<S).J-&%C
M4R$L  @+=AG6Q4=537&GAJ[?405U+4*&IZFDE2I@F4G;NBFB9TD&[TDJQP00
M3G.&!D(O-DO(MCN/M(:E P*R*C>584K#.'(R:!,T<^21>5^=N4[?VL7($E%(
M]XH>7@;&Q49M7;%./05>)/67-6\9?"(D%/$OH- 0.#U=8V/WG-:"#]A (]]9
MBHIGD<&GH:BGCV@%'D:<ELG+;_+C(!! V[>""<\X&-2,3MJW;KG=K#]H9DZX
M6:U1]6KJ$P8>6"!=M*C4DYA[$03UK&8;^#R"[6RVNY2Z4NTBHEX=I-M8EZ5Z
M2(:NU)?]L?A(2!_M-Z"R3@?^UMB[G@?_ !]]OOQ^[5#X.J_^1Y?_ '#^?S[:
MD7D"RV'&F(*<G.<PN-:1;6[6L0<OES+558K5ZX3#2(,$R]1JL??,>1T=+V=R
MR<RZ#)A8#LHM 7:#9BZ02341WR>XT%-3I5U%9304LNPQU$LR)#()%WQE)"P5
MQ(HW(5)#+R,ZPUTNMKLM/\5>+E0VFF,JP"HN-73T4)F8,5B$M2\:&1@K$("6
M(!P.-1H_+[9P4/O[1#DD[8D3Z #%!.X4X"IW3&,/-D)!(8!2 A2)IB0Q5!,H
MH!R G9_K%T_W^G+3\O\ XHT@_#^^[_QUKI\0^@02#UMTJ" <CZ?M61S_ /I/
M<=L?PUV\MT]/Q<O!8^K?.[RO97;O+K>KS-5"I8Q!"VSB=YO=BR/<6D$]8<Q]
MB/$HMI"SR:,2]6@)WX8P1:!(I2:B+A9>M37FTUDH@H[G054QSB*FJZ>:0@#+
M,$CD9BJCDD @>^K^V=7])WBI2BM'4UAN=8Z.Z4E!=J"KJ'CB&9'6""=Y&1!]
M9@NU?LU924!   1V/XC[_P O&3UL>FJS-EVMX3HK^]65)[((-73%A'5Z%]"X
MM=KE7ZW0VKM*A7K^/6M-M>(D<N(>J1!W,_/J-%(^$8/I%5!LHTU!'E3YD\R\
MP7,7?YIQ5I&+Q$R@AK$>R&4?N*M&MX2<EY&#O4))HL/@=@GKPA+H0TLU(^57
M&.@&DG&EB&$:Y1LS\_Z::M$X::.&FFZRYD%+%.,KWDA:)<3R=(JLU91A6KI!
MDYEC1+)5TG'(O'(&;M%'BA"H%<KE,DAU]U0ABE$HM.VHM2/V@V!:'+SU,S?-
MAB3)%3<SC>T5)VA,6]I&$B:V6Y1[I&S5B%=1;M.V5=0CVHLUPCYNP2I'58CX
MA>QMAC#M-;V!Y[\ 7.3@(6B3LY:I*P6*K5QOJF72OQ2;^Q3M6@WS#[PV2OQ<
M YL54/;X9U:*BUDE;-$(JJE=QB)VSL&[4"<8^TXTLG'-[@UM<EJ ,]975M0M
M!:I\)C,;9)E5';HDS.5N3FXY:-J;IK(TJMV.MSE?MU\9+N*=4YE@,?8IN-<.
MF)'34=2; =@ A["&P^GO^H?(?R\--'#31PTT<--'#31PTT<--'#31PTUQ.8"
ME,81T!2F,(_@  (B/\P<0) !)X !)/V#OJ(!) '))  ^T]M4093YNN3S)D59
M*=<.>SFB3@Y6<;.Y"!BL=XO:L&AH:S-+ SC(YR?EH=R9&#%]&M&S=1:6>/%&
MK<OJ7SI4ZBRF@2^*/1L+%)+C-N5G1@+=6N T9"N,BF((!.-W8_/7IV']#WQ[
MGCCFBZ3HC',@DC+=16%2495<$JU?E25=>#@@Y'<'6^+SY\KH*&-_\(1S6"F!
M"%! ,88=Z2F**@F.!B\JXJ")P$I1 QQ*7ME$H%$RG53/BKT5@_\ :4^ K,2+
M9<. H+'!%+DG@@!<DG '<:J']#CQ^ )/2= !D#)ZEZ?P,L%!)^D>!DCDD<<]
MLZLOE7L5*\MR$ZKFC*+.O'J,+=5LQ13:JQF2GE8(#*V%>';LZ*E7&KJ5A.B)
MD4XVD,7/HG+DK1%E+B5ZEM-TZAM=GL57U)7SO%:**VO=JBH6":61:)(5G:1:
M>)&G=_+=2(4C,I.5V;@1KSQ'TY=I.HSTHL"M>Q=Y+&:9I8HT%QBJ7HWB-0[+
M (Q.C+Y^_P DC#;]O.JZ8RU\L,/;K/=H_G2YP&\Y<F%?86)0'L.=.1^ZY'Z$
M*X5 V&S*IKLFDDZ: 1%5)N=$P&40.X#O#Q'_ .%/X,?_ #15@^^Q7I<_;S0C
M/']/LUU/_P"#UXI?_*2F.![76VD_PJ??/V=].!CS+V(HFY1 L>>KFRMYY6T0
MY6U3N4'C&4KKTB\XD9"M++?N>HZ=;1+Y-<L,[?-K$SG 8&]2$VE(IE?A=6_]
M)KP?N=?1VZCZ@K)*NNJH:2FC^@[RH>>HD6*-2QH@J*789=B$499B "=6M9X"
M^)E!255=4V6G2GHZ>:JG?Z4MI*P01M+(RJ*HLQ"(Q"J"S$;5!) T^?.C?L3T
M]2F-<J<Q6=\'L9^,L32.8X8?IQ![ HU<PBCR0DI=E2[%8&;V**NV;1YF$M$(
M"A(O3*(.E0(JV]4],=$]0]8FK^@:2.J^!\CXCS*NGI0OQ!D$04U$L8<DQOG;
MG:,$X!&?+G7/B;T=X<I0OU;<C;4N(J32N*:HJ WP@B:;>*>.0Q[1-'C>!N.0
MN2K#5=K6Y<AS26=V9#G7Y[2W&3CJ]!3%Q+EC+!9V7K56GIJ>B:Z^!. )$EC4
M%++8693-(MJ]20FGSMJ[;RPHR*&V_P"Q'Q%_^4T7'M])T'_TQ_/6BG])7PC_
M /F@J3]UEO']:(:GWR;7K!]DGLA*XBY@.8/+J;*#KBL["9GM]LML=72%=SPM
MI>O*V^-1DVCR8 56LJFVDEF2B,3''*Q;N 77=:KU-T/U'TB*/Z>HHZ7X^5X:
M;RZNFJ2\D80LK"FED,6/,3F38#G ['&]]&^)G2'7S5J=-5T]6UOIX:JJ::AK
M:-5@J))XHG1JN&%9,O33 K'N*A0Q 5ES!8G/#]DBSAF4.2Y/R2<7F1MFU.WD
MP_*DN9[@SS6.=BH.+ 6BE>*11K288=5 .AX>K",8#\'.WX[3'X*>(3HCK:J8
MJZJZYNMN)*NH93Q4'ZP.>^<Y! UB7\:/#Q'96O9W#>A!I*N,AHY&C92DD2$8
M9#C*X*X(XY&\R']H!]D;EC(+#)&59>/R3)0].-3H>)ON#Y.W0$2R&<"Q+RD=
M'SU+?J,II9TFFBJ];.$B*M&Z"9D142(H$P\$O$,C(M=*.XYNMN'L3QFH[\?]
M<\07QG\/WPJ7>20G_P NCJY".>Y*1-M&<#+$#V]M63QF+,54[E6C*# 6B]U#
M$4>SB[+'35-G7]/MK*KOKNVR$G!14M4V\1*0,+()NQJJS*")&/VM1>+Q+1VS
M<@5\GPKJ_J&U=#6.]]1=2SM16JP1237.9(9:AX$AF6!MD-.DDT[^:P54A1W<
MD!%.>>K4G]M$#0$.*B-9(B2%#*Z>8I);&,KSSC]_&JPLR\AGV8.=LGHY;NTW
MS"J6M./BF;@\?F_/BK24>0ZHF92\[\;LDT]G7Q&)&$1Z:5>.X8D3&LVB46F'
MJCN/.S_IE^ ,9*MU57*5)!#=.=19RK%3C%M((RIP1G/?G(.LHMFN##*0JZ]L
MK)&1VS_F^1_?]HT^N..6;[.ROU&DXHI5.8H3T-88(:?D52D1+?*#)^PNK:RU
MMLG=4JFT52+%J),JVV>J)%=C6VQ&SQXNZ,N_5R=A_2R\$>IKU:^G[/U)65-T
MO-=36V@A-AOM.CU59*D$"O/4T$4,*-+(JF66143.YV502(2V>OAC>66-411D
MDRQDG[AOR3]P)^S3\<ZF0L1TE6F-\K<QF?,'L;#&SS2+CL,/_@OQU5@\AW#N
M1?RS"F3]@:/(\JS5LS%E,1C4[9X\3.V<F.8Q.Z7GJ6S]/K3&YU$D0J@_DF."
M>IW",+N+&!)-N-P&6QDG Y!US[JGK?ISHP4C=05KT?QWG_"[:6IJ/,^':-9<
M_#Q2[-IE3&_;O!)7(!U6W/VW[/:WQ3F$NW.QS^7"*E3E:V&)FL^<P"$%:*\=
M_P!U_59VM0B</7',),1'<K4H+6*:2CN(76<?$23A_BY<'_M*Z2YQ73GWR+=7
M$?\ ]OC'Y]M:>/'+PWX'TU+R0!BVW+\ !\+R?D-60\G5[Y>;_<;S(X'S+GJ_
MA%5V"C[+6<JY(R[?*Y&"\D9)U&3D,EEJ3FWD=,N@0=1[Q2%D4&J[)% KQD=4
MB*P9VR]36?J$U M50\YI1&9MU-/3[1*7"$>=%'OR8W^KG&.<9UMW2_7/3?6+
M5J6"LEJC0"!JKS*2JI=@J/,$6/B(H]^[RGSLSC'JQD9GV[?M&1"F<NFS?N&.
M1,7"R:13G216<JE*)SEZC)MF[AP<I1$2(HJJF $TSF#/:V_/&?;OJDWFPYCL
MH9PRM(\N_+]8K5$+IS2M&^[C)FO4IJ\6ZL(H7.Q3=;N;]>LC"P]6B(Z>JUMC
M).4>)$4<P=T58 1&CT+F!::M Y9L.O,%XBKU D)@\H]9=UVY:MGKYY7*\LZ(
MB"E=IH21$WS:KQIDA]$DNFV!=TL^D&\;"MGR4+'M-/\ <--'#34;.8'*60L?
MNZ9%XZBJ5)2<['Y"L$D:]24S%1816/ZT2?78(2$,W=J1SN6462:A+NV;]I%(
ME5=*1K\2E0,TU&&*^U$PU*O(^.0Q[F47CR6DF*A0I[11-O$P,^PIEDLW4$T"
MKJ/KUW?IUV7BVB*UH:(D&RK0!*PNUEEVGYXY[_=IQ*3SOPMP<95<N,=W&MHX
MKIV+)B0JLL>N+7=]:,LR<PG4JNB$39)*E"I/PSB@R47(C;BQS!>W'9V9[!JP
MTJ5DTTZ.$.9V"SK8+7!5ZD7.!+2)*4JEGE;(>H(L8[(U8+ FNF.TV\3;)>7D
M)BH_>6(*_GHZ,=4>1,LL$!:I8$0%1IJ3G#31PTT<--'#31PTT<--'#37S8#[
M" Z]_/#([9Y^6FC8?B'\X<--<#@FH42F$HE$?(; ?(>0\#L-@/G^3B'!X![_
M "/.G_7\1R#^!YU6%S6X,QB^S-B]*(P+BRU63*SJXV+(=HL.+1R%,K15)+1&
M!C'*3(N.B0Z*[6P=IW9%%[(K&$9- 0J\IW5 3P%7TGTW7SRU=99;?4U,S;YI
MY:='D=L ;G8@Y. !DZZ79O&;Q4Z<M='9+'U]U+:K1;XFAH;=1W.:GI*6)Y7F
M>.&*,A45I99)&[Y9V)[ZAU@>F8YO]8I$K:.4WEU6&;R#R[P=J>OL9S>+Y&)@
MLV51&PO4JQ2GUOR0ZM244YDZZW@KX[L5:KD^B_L:+:,4EZ4]CI.V_4CI+G_V
M>M7/_P":1?SVY_CK)_[?O&K_ .J;UCS[B\U0^9R<./NY]_;DZO-I..:/CFK1
MM*HM=C*M4X<KP(JO1")6L7'A(.G+]Z#5J&RI X>O';I76]KN%C_PQ#C.TEOH
M:"DCH:.EAIJ2$.(H(D"QQA]^_:O.-WF/GY[C\SGG-\Z@O?4UVJK]?[I6W>\5
MK1-57&NF,U7.T$,-/"TDQ];&.&GAC4D\*@!SC567,3$U[&]WRXQI6"<4O*SC
M##M>OBBTEAZ=MII.RVM2_-6C1W98G)M72BT6KNN12K6 2JLD^G^X[8(3<2H\
M;NF'-7\#O"-V9V\/^FBSL68F@3)+$ECG/<DDD]R>_)SK:$\5O$:-5CCZRORH
MBA51:^4!5 P !NX & !V P!QK#Q PKF0+QCVMO\ !N"GK25M.28"WQ#3'UBJ
ME\:5:AO+?!OLG3=9F+=.ABF+9W*'KE(C:=8WEIL=X?SDC-Q:T'$PZY20'@9X
M1 @CP_Z;!!!!^ 3.1^.IO]K/B3V_73J 9!!_M\OOW'<_Z?CC5F61L.XIO=58
MQ%ZH5;MD+5&QW,!$3;%-TPC56D<9JCZ9(==H"M"@VV79BHB)2^_'9>G[K<>D
MHUCZ<KJBR1I2PT*K02&F HZ<*(*8;<8AB"KY:=A@=\#'(NJ.F[#UL%7JVTT/
M4*K5S5ZK=(%J@M;49$]2 _'G2AF#OW()'&=461!4FL?A&4G^6W!2WY1Z;3K[
M+QQ^7>2K35-C>[7C2IP\.ZLH\PMFC*17B.[?)KDR;,MYM!QT-4W-&8F9B27V
M?_:1UV0&'5E[()&&%=*?XY]M:=_L6\*B,_[/NF2,'GZ,BQVS[<<#GD=N_&K&
M>0>$ILS7[#>U\+X]Q/D]B_9PDJPH\'7T&L;5K;4J=D2 CFMJJ^2\I0%U9.XJ
M?BWOWFCI>"+)]*2AZE"D*B9[C+MU;U-?:9*.\WRY7&F29:A(*NH>6-9D5T5P
M&SAE61QD'W.LY8/#_HGI2KDK^F^F+/9*R6!J:2IMU(E/*\#,CM&S+C*%HT."
M,#' '.FAYQN7C#A,Q4I>"Y;,+VJ>R'7,O91R9:[5B(V091\%!EL6M3&>.DLE
MX\& ;2:=ZD%)2S"E;W+$S-D+>L/2BJ0UW0]>=9VRD@H;?U+=Z2CI8Q%!305;
MQQ1("2%51P!DD_B=3UO0O1URJIZRNZ=M5755,AEGGFIU:620J 78^Y("Y^??
M4'*%5\(R=JQW3[3R4X&/\4M=>+>+<&"ON4G$5V:/@6,-'N*5+YHL%BB"K3&>
M81*N7F+<W0\\J@S F.6]>&;MD5=_[2NOS_\ E;?/_P"-D/O\CW&>/Y:M?]FO
M0><CI2S!O8BD4-GL"I!R"/8^V/GKT14G'5%QY38N@4>M1%8I<.R68159AVY&
ML1'LG*SARX;-6I?D1167=N55"%T G64$?<>-+NTLM]FKJB\R/<I[DLBUTE6Q
ME:I66)H9%E)[AHF9"!CTLP&,ZVVWT5)::6GH;=!'14E*-M/!  D<8+;B$7_>
M8EF/)).2<ZJ\S+-V:LWO,4=1L8XX+4L?77"&.(11YA21NJ[^<RQ+X9C73M2;
M99LIRTC+1:64'CF.IK>I1[>03BV@JW-LHX722XJ?T>?!%0/_ ,&720'MFUP_
MS)R>?O)/XZS'TA<#VJ)NW'/L/P[ #\,:W. +A'9(N6)XRWXVQ(2LY'JF1D#A
M#5=:%LT7=:/8EQB$K5!N;Y9)C'\[;:*V=V%_BZ=AWCJC.XV3AI[(![,V2K#B
M*_H]>"0PX\,NDN""&%KB[JW!R,<@CY\'3X^X8YGFQ[Y[<]_;!^7R.K",MXQQ
MQD2EN(O(-,@+O#5]-:>C8:Q-2O8]&3C(]ZFU<E2$0$JJ3=PY;E5 >LJ*ZI0'
MYAWU.IM%LK:6*AJZ*"HI(?+$4$J!HXQ$GEQ!1QQ&AVKDGC@YUKUXLMJZ@IA1
MWNWTMTI5F6H6GK(5FB$Z!E28(PP)%5F"L,$!B!JB6,91C%CAB4LG+-@E<F0*
MA1+U-,1Y=)6MM$F60;A0ZA%0[BS!S"6>.I$*@M9)%PVR',-IY.35%FT4I<>N
M@5*5Q0Z.Z4)XL5L)[X$"'^'RUKO^SCH3()Z2L?N>;? <_:<ISGN>?ZZL%Y"8
M_ F46U\S%1L)8_QS,4[*]KI%2<U^%=QEC94U6LU2;A/O*20(DZC[5)P=F05M
M,.1!)*%D%5H$1<GCE7KN]HNG+%;9Q54%KHZ.H4,!+!"L;A77:RY'^%AC/S^X
MG.1MO1W2]FK$K[78+7;ZV..2*.IIJ.*&9(I5VRQJZJ"$<'U 'DG.IIYTR8YQ
M#C*>OK2+CI9>*=UQ@FE.3*E;K;$;):(6L?'K;9$HN;5KE.K7QG[PV^?)#28P
MU;C)22]$N#82<9H8_#[.?ZC./OULHP2 Q(7(W$*&(&>2%+*&('(4LH)XW#N*
MQ[CC_/?-1E<V*;^:H35=PO=8-O<K=#&D"5>.1L]"CIRT0)ZK8:TO7+CD!M3+
MQ",8:<4AXN!,TG7Z[^*LU)O5\Q51X\>Q/?Y8X]CW//V?Q.HL$P=K.3N(&4"@
MI[,2';:Y]T ('M(V-2*',=,Y4&$S58+'*#7 >#9*C4'+&2"32RU_3NUJJ%5E
M(J?4I474'#K)"SR.LE*5N]P4L3&Q/)>P+.&D',A$RBJ4-2=OQ_B<?Z#2T3^T
M%Y8'=JFJ5$7*2G[/!2XP3J)@:W+RCMQ*EL%<KIT&"+=N*KIF"]OK4FE-@0E?
M>0,J6982SIDPE5&#4=:>,^T>Y7YJ01A(B=N,E8W#%O((U5G0;,O:C-UZK&WH
M_>KA&0R[%1K3IJ(L#DDBT9B#5]Z1#ORK&5CV#\_GY_AJ(&<]N!GE@,X^62-Q
M_P!T9)&3C .D9D_GMY,+U5+CC"[72?3@[C6[=!R*"$98ZX_EX!-Y=*O)2T#+
MH&C9&,C%'-$O"C"[@XBX2+;5Q:?>SL5'.89^_:E[Y'X']P_UU&F3NWV8=CD5
M59-_?KG8#5R9:V9^K(9=LEJL\2YI5GN<W8<A.0D'$])O,>U1G9I%G*VCM.ZF
MHT;L*N0SV/KK-LU'2"5LG)=6VLNX>CG$EQG9&N6&KTX]]R)!S6.V=1N^+<6N
MKY'SD-,R#U%TZL-,K%MLUUBHUU*/H%X_JC#XC\.DH4'Y_/Y.FG_A9+D8<6ZO
M'37S*YN,S+PDA%RYIC-K@7$#-9"=5)X_2FSNFYCXEOV7IZ95MP.2H0EUM;MW
M8IB/<1Z4>]0:?A^?^7_35NI==)=;UH-;]]:^OZ_QX::^\--'#31PTT<--'#3
M1L!WH0'7O^K]O#31L ]QUPTU\V'XA_/PTU\$Q! 0$Q=" @("(>P^/KPTQG54
M_-1 9M97G,\EBE-]&52CX&I\G6V<,:DLT'&1+5)95C'"B4#,X+OKRRNTDV-8
M6%XC<HMI63-F3]S59Y,[AI)V_P +3$Y^'IR<L3_9X"26;<Q.8SDYY/VY/?.K
MY;G<APM?6G;V45,V%&6;@!^!Z\<>P4?X=*G #?+SFYX\@LEE9_"F<MS"5>WU
M67IU:EK T=U61J"F.Y&?R7"T^C0,\@\KSU[-P3BOT2NM):'M4<C).9&9@GBR
M[X2F'_QO3C/N((@2.Q'U.Q&0<8R"0>>=!<[HK!A<:X,#D$54X(^X[\C'W^V,
M:L@+&1X-/0@@CZ,4^SZ;H3[ HB3M]KL]/:!+M@"8)E(! ( $  +XXJ-%&T;0
MLB/$R&-HW1'1HR,%&1U9"F.-I4KCC&.-6>]O,\W<PEWF3S S+()"2?,WJ0V\
ML2=^=Q.3G.JG\C*\S:MMR(ZJ"=@5@5^8".QO2(>%D,1Q0K5I"L,9N2)&H6SE
M[LBM=55?LW:'WPLELN<6^!XX8DC851=J\BK1K5;9!ZJ"C<#G!IH2![9^I^<_
M=JZ-?7__ "74\<X,KG]^3G[OMQ]FEMRCY!M.1<B-H^V7B/L3^$PU5Y#)=,D:
MG5*DYK.39.,H;Y".KD*2L0-Q?/:R1Q8U<FVF2;1U26LMOKU6J\)%OJK8(N'E
M%LM4;#;;[>CH0RL*6G#JRG(8$ID,IP0W<$ ^VI375C @U=258$$>?)@@X!!P
MPX(XP.,$CWYE-S9!96?+[E&8Q^@8^06-4<I4YRW:,';YI+O'+9HBJQ^(0%H:
M-EP[PCZM:N3:+3H!VK$R!6XME,I%/+'N:">6/> ':&9TW8[;MC $C.1D9!Y&
M-8^:GIY@OGP12^6&">;&CE-^-VTR [=W )]P #QJL:_.^:^@V.XM4YM: @V#
MM]0F=TM+6J7^G0DVIRW5VZMU'\=3N5UK97+EM>9F5GF>63M$Z.DA49*FSM#(
M^DHII)5?C*P__'E3D=O6.3Q]G(_>">,?*B+?:]K;J"C7 &/[/&<MN&59BPVX
M7)W ,<@+CU%EM)Y;'![!B"G6278';3\E'.VDE)."Q@N+"6*F96-:61!U'4ZA
M(/(6S-FR=DKB_P!SJX9:"EHY=6'9N%%4PIR2SRJ%EFFD )*F21WP6QN*!B53
M. ?0% ]@  !/#2TD#,U/!3P,X"L8(8HRRJTC!6*(&<*9'QO+'GG)SF$O,G6\
MVAD+*TCC%L[C*G5ZAB**K+&$4HL8V6M=XM3^%GUTH.9P->W<FLE'/6CA2SA<
MB1]34:-GSBE3"#-RA)SFNJLD&MJMQQD?&5 /8 8 E&. .P'S[Z?!40'_ '*E
M YY%/&@[_P"XJJ3D\DY/(SGC2!P!:LW.N8/'V/\ *E:+\"16N-9EX-]'5*0G
M4?2O,WO$YFUN8W"56A;5#PC"DX[8!D*JSM*:(N[K2V@U&?;WD9YU$5U7Z@M;
M5@GOMK*C(YY_\4X/?G&>3R-&H*/ W4-+C/&ZFC;/'8%T/V'\/LXN1.V9F:E9
MJ)H&:@0B8('*D*7;2T)2=L0[8D(!0T7IZ0 -:  XLYHHIXWBJ(UEBD&)(Y0'
M5QD'#A\A@2!G=G/<\ZN4)4 H<;1@%>,#&W Q@#CCC'RU3QD0G-TDB_F::>\S
M2EFYD\UP%;K-=N>,8-Z]QWCMAS*.JY$1@V7EIF6%!"3=4O'C..=V*7O25M.H
MP,-CKZ4JL=W8BU6I.!;[>.W>DI2254*3ZHB<D*"<'EB3@$G,_FN>?,?!X&'8
M X[CTL ?D?\ EJ0O*G=[==,CVAC9K6ID*#-BG%=G"5+1STV/K>07!9%K:8]I
M R5)JDW4V,\U+"V"MP\K*W%_*QH/+ L]K[=PRC7LQM%KWQO]&T2R0NDD4BTD
M"21R(ZNKHZQJRLKHI!!!&,#C(T$KXR&.&SV9BI]O<D''/;L<Z?OFS)8V'+UE
M2:H+4%LAQ=/D?N2[38QSZ093;M5LV;K,#25?M+=NL!E"F%RK7IM%N! <K1,B
M1#TJMTT$+;?,19-BE5\U4DP"1GZZMR< $GDXYR>=47CCE(,D43LI)1GBCD*9
M'JV^8KXS[^QP,]M5O^HYL\<Y+EDAJ<[D&&BK2XHL;#NW>-[9"34NYY>H.ZQ4
M&L:/P5BB145/>YIW-ADX]GK]<-&5&8QP-;4MDQ66\Q#X2D[FEILCL?AXLC\0
MH(P.W?[O?4#!3,&#04_ R M)2X+$@8<^6I52I)R Q+!5*X8LMB_)Z]G+!RS8
M%N-YBW<?D>S8?Q]*7Y:7KL559U[:75;CUIQY+PD00C*+=/)0SIZ>-;]*+(7'
M8(DB!12+.L446=D<<9[,514[9/.T#L2>.PYT2"&(GRX8HR>YBBCC)^0/EJN<
M>P/;)QR3J/G-[C+(=NG;FY3Q_>LOPTOB<C#"L!5[H,'4Z3FR.-<4T9*]UP]F
MK+4P3YY^KNXG)*Y+ 6HH5B79+MX1NZ*2V5-5.VG^Y=^62J<OD=-/FTI)7&Y6
M%K$M9NU2_5ZD8BLQY8NN5R CU%W7P2OPT>F"#&*3>.2H"<&395O"L(2(B6FH
MNP_/G8:BGCJ0RC"0=J99UJ="M^/(_%D<Y0D*+/9--*-*?B*^N)JR2:$K,S<Q
M&C7H*](MJFPF+,WFXMQ4X8L:111I^3_4_<.^M=3_ +4:M7I@VE8'!>5DXXR,
M'(O'%@;-:JLWA;/&1EF@Y)I%V)&/F9DJU1>O99S\)CG+,[Z(=1D(_G47<1)R
M+37UI]J+6W<,:9+@O*39--**9JLI;X3690;+:(2_6.FPC6&MQJ]..&<W$8]E
MA>6-2*;0T7(.62"*LI&E>S#1IIK,H\_7+-D^"92.:^5ZYVRH4N7L4VC(W7':
MDG$P[&/:OHE*<B0LT(Q9/7-G<-WT(Q;D53@9@5&5>;3\E<9^!I<HT_/]?S]N
MM5)YYY>[F(R2/)K#Q-CF\J5E:5L5RAJ[4)-GD"Q94QKCFX6,Q;!#PULCYN*K
MM[2O$/8)^'B6S^7C&SB01:/!!\#OICY?+^6?;[-,Y1<Z\ILE9:C2*]R45%G"
MPX4;#$4VL=1K[>QS5BS ROC>(JCUY--ZXWC:K+I/:_)2EO?1,W'KIS]C2AH^
M1ACQ%C=M-3YY0,K<OV1<BR"6*^7=CB:4;8_1BH^W(1=':.I:!I[/&R\Y4P4K
M#IX[2CZZYR!3V#5X9PYCK*>*7>,7+B*BH1Z]::LE#P !^'#31PTT<--'#31P
MTU\$0#W'6_\ V?Y0X::X*'T41 0'R&P#SX_O_P#M]N)6[??G^1_/O]V@&2!\
M^-5T6;F;SK'\OB6=ZG2,=V1U(7\M(B<?.'\S%R3]U*9D5PU $2L;I^C#>K?3
MBT4Z7%^VC&#5LZ='5>E3: HMO%-TQ81U&>GJJJN=/$E"]?+<4^&\F-8K,+W4
MM)21Q^:8T@66(")9I7<+F+:Y9<<U9,U#'6A8@7E6'8RDY+SF!-K&5!DD*S,<
M!?GZ03&_(//KSJXJ>P[/(O*_B*C_ !5RD4QIK-M:D7K2/72?]F8/6J7+VZY.
MXU1ZP-&@]CJT]:)NU0*X<($24,79[?T'T/=1,;;U)=ZPPHYS36&=8GE1X4-.
MU764M-0PS 3!Q'-5QN45B%8*Q6QJ;G74QA$D%&C2L@<23AF2-M^95BIIIYY%
M7: 1'$Q)88Q@Y;WEE^UGRES%Y'L6.$L2TNF.HV&KKF.L;MW:GK4DC-9;QECE
MVR=P\HUK#ARDQC\B$G3=F39'!0D>DJ=-%T)^,9XH>'E%X?=(MU327)KC+%4I
M"U)5? 4\9@DIJNH&*N*?RH<RTK("^4=MPW'&HV:\372XRT$D4<:K"TBR(E0I
M!66.+&R959LJX8A<L,C*@@ZLT?2V;5WK21.[PQ)/VK9^S:/349R9XR;2'I1?
MMV[ISF%-5NWD/1L_6(I'!-R+1L+@IA01Z?'U7XO7&%HEAZ9M\XD&[ ZQZ2B*
MC&3GSKU&1N^152/\0'.MYCLZ.2)*ORMO8M25C ]P?[N"3&/GD^_R.-,W:Y50
M]*JC$800%BV@FC(Z.*WQ2,FE94<JUIHT51RB*:+>O*O':D&BU,*$2HZ<*1X-
MS+J&-3'B[?67>.@YPHQ^U%YLLE-CVVU,%=-%(,^\1D YY]C VB$$@5T9QQQ3
MU . 2!P\<9'OP?M[>^JNF;<ST5.//,RN,>F1,X(B"%#M#@ %L5(3A_6V3G.O
M"I0^<J>MZ*(CO5A5^.59;O+^/Z.$/F!O*SU)T\A?;CG$U?" IS\R1[J-;#8>
MA:KJ!JE:.NB_LJ1O(?))'[4D*!OEB)'I.Y@#CW&HG3//%+N+;*5&0QT$T\FW
M476I>6)RFYDEZM.(MW!_AA7]K-/J5R1A(]:1<JH/7DF>)CA7>K>H;E,X/QCY
M/T@]NYOU:MV "2GZV]-M.=HR0(HZYV=CCTJFXN2JJ"2-=#B\ [E+1"M/5O2\
M7[%Y6@FN$"5*",,2C4XG:;S,#"QJC.Q("J20"H3Y;(6[H9-<8=QPMD=$QA:W
M^,Y4+59;RW,=DI'*&&RP=S?V)@4\:HHP[BSQ$BS-11D!C)"=+BG'^D,TI(BZ
M5A+ C(:_V=&(/^(!ZI2<?XB 0"<9SK6+CX4UEN6-CU)T]+O)_P#COR" ,#(\
M\Q[\Y[+G ^MC(R_T/DSFKN<8VFZ^G@)"MR(J@BE>8+)E*M1$$5CM'99:I24J
MLXCE#+(N!:)KNCIO&0MG8*%2<@ ;Q;O$R[7.W17**RV6&&8N$6;J>@C="AP1
M+M8O&S$$C"LA'(<@C.(;I[I:A5Z:XW+J":YT^3,UHMUNK[6Y;#1_#UPNL7F#
M:1O_ &68VW(02O/4]9\PKAF#)I"\HKYL2%"L"QDH6RILR58I4RA7TD&\I)E&
M% R#</@PHECM))F[6TR%&X3Q%NAW>=;NGEVAV8KU315!VC))) #$D<D8./F>
M!JTBL_2I9Y*NLZHC1E(A>+I^WSL7XVAV>[P$KN[[6##& 1]9>FIEYCJ"P>15
M6@.42I1[N1=2[V.J4;:H=@ZDY!3N/I([-J]BDG$H],4IW;I5+ONEBE,LX,(=
M7%E-XGW=))/(LW3T\4:AS(>JZ*!WR,D1QR1>M^PV^8"<^VJCV3I+:3'=>JF=
M@?+,O3M!%&&QR&'T_,2I)'K# K@[E;/"TD9[-SHZ4A(EPB_>DCWT21=>CS#E
MRC%S!F:DM&$64R:JL5A)*1T>:1:%$$'AF+,SE,XM4!)K\WCC6P M+TM2A5;;
MD=1V<X[CZHJ68#CMM]N<8P<2MCIV/_?I5X[M0R-V]CY<C9."<X]/R.-(R2&^
M/7\5,2=8Y='TM6UXU_ R#W%3Q_)P3J%1<-X=U"NE<A'=1KN+;NG2,8JR,BNS
M2<KIM13(NH!\3)^D2T<ODKTQ3,X*@*O4%J!9F4%0-TJKD[L#)49/) YU<ITW
M X7^VR$$@;Q22 ')P3M9]V%^[G3/YHYWLPX<J"=L<5IE:4C3+&&",J^#LH3<
MF O$7BQ70,X^\.5Q;) S,558$P23,HD!S%%0G5=P^/5TE+!NCZ.B54,C37'J
M>UP4P7@C]O3M5C>P[(RAB.0#WUT+I_P=2]5S4LW5%LH8TI)*II9&9P=AC BQ
M3QU$@+;SEUC8(5P0<\1&3^U-M;])VY=85*U.]E8Z8>I3/+=DQ@[?3,(:/4AY
MER@\M(.'+Z-/$Q0Q,JJ4RS0\6Q](ND9@W[=.I\?Z^G)V].6=A@G=%U=1G*D?
M5&R$,Q(/U3@8'JQVUT^A_116XPO/2]=6%XTEDC(8".5Y(MI(1*B& R-R" H+
MD#*Y .UQF'.586-B-;H>@<NC"XNV;E@M9V5-,WLBL?)R:L[(,7$PE>4)!1H\
MF7*\N^:*.Q17E%EGZZ1W1U%!MX_TAKI*P4=%H'VDDS7R-%XR%S.U.T.TC'K:
M8*JGU%<$#"M^C7L9E_6&8%6(+"RRJ"0V,A@@Q\P2VTCD-@ZE!C3FERGD*#E'
MTG8L$0(-Y!2-,QDHQ[_72'I&ZQE@ ^5F_6DH*YTC%%,Q=D$O4/S &5A\=Y63
M-79+-1.<8CFZJM89@1DL-[Q\ G&0",CG!UHG5/@]6V"L@I:2HN=U2:F$[ST]
MCN$B1LSLOE9IH)E# +N.YE)!4@8.2XLI+W>/@A=3;_EF9UM"OM8 QWU"?!%I
M5@PH%90/0?)0M @A,+<&\7XCM@CVT=@GQ4G\;*^EA>JJ;+833(-[&#J^BK92
M&("LM+3QS2,3D#TK@9P6[:T*#IF:KJ114<5PJ*MF913Q6^J\TE"0XV-&" N#
MNR 1@@@8.L.-S?86H/EXC*'+"U4DGAY&3.VB#QRKZ0410;&>O2GR\@9V\4;-
M&J!W:PG5,@V00,<2(I@$E+XYU%>C245BLTD:,JN9NJ+=02!G 9 L=<L!QAAN
M>0)&AR&; W'+-X==1)O#67J!2G# 66OE"$KD%S'"5 ((;.1E2#J%EV^T&YCY
MB[1..*53<.V(EK@:8R2B)*KV.>)9I:Z13<RS5N<E_BHWX-)+OB(-6SD'2161
MQ%Y).DC**E]"6N5J^WT=9($ADJ:6FJ'B22.H2,U%/%/L6HA=H)U3S=@DB=D?
M;O!PPUH$Z/32O!*C++&\J.C JR-'/+ 58$9#9B)92,J3M.2,Z6W)%S$9&3S@
MIRURF*,+XJKK-OD!]-5O&=&DZ<[C+C7U69'YW ??&?B79U5B*M':I6ASKIHL
MQ;/O2-TDU+QX]@!W @GC ^\YSR.VJ2MDXQC[SD_=]_\ IJ761G>#_P!T.T93
ME'A9K(,7 T^=DWTSDB-K4.JC*J7.!@W[C'4K9FD5>[16X9I9!92Z]4EIV"B9
M-NRAY)#UA&Z=/Y_G\_\ 74^FDCWO('0JNC::#4U7A*W!UZOUZH5J,RJV77"K
M5O&:E+[=6E"LHJ.>R<(;$,-&Y'LC2/1L#=>F1$A;GR)&;4D./;'V:=S]O?\
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M7.HJ/AF$!EJ"E).TI2+:I9N%!89!X!\6C;F-YGY$!<JU*[KF 1*!Y:&G[ Z
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M"=AGG[LZ#>.DD[3%13"K689:$0?R2D*_?OX,LVJR</')RC*]2;ETGI<]^Q;
MSG 8\9)'/((_B-60VD\8SW[?AJ169Y*MQN=+?4FQ+9+&OT-CZ.R1!0>648"4
MED,BDEL71R%5Q\%7DI2=6@(*.&?G73*T5EG#-%DYOO$<F>K'IZB<?+.,_;^<
MZ54KC_!5IGLDR=-B+-/7>I3,*_NM8"7L='K=AD("9JYJ]&S\O/,&L"\J===X
MXAUUCQ!Y%%K!QCU(6<PWD"Q<@U'3%%Q_15'N+IN-@+E,0EAQ.SK,I5);(CQ%
MJM6+A9:A2:/4I*PN&3EQ:,<2TE!U^ ;L4HN(Z*DXF+=**RTE8):)EFFM11*I
MAV3OL/!N:.6B-I#'$?+.K)(9OE5'T;7G4/+0$78(%LZI!&M@86"K8U@9&8"S
MSL3$N&$Y*IR-97&:MC2PM0^?MG\#]_;@_P"@UNGZ6%J!8$<6/,431F$Q:H^G
ME<DR0ZG$EZW<V-"Q\1]*!&,7[2(F'M>H],>_=5R]9PD5C^SH.G-CA)&W)59R
MU'\_/^.I3$Y(\%@=ZJ9C951DP60?@M8W9Q>Q3B*O$*I#NS] +.6QXS(EH:.'
MZZBD^^(] \A,.UQ757:?ZY_/V?9VTYD9R_4",J4]1"_>%]4Y]XP66A9.QRK]
MDQC(R4)+LZU%-EEQ0CZXFX*JW7CD4^N18.5V<FX>)"F";3\_NTGIGE3P[.VQ
MG<9"%>J2;*<E)Y%$LDN# CF7E8VQOV:+00-Z*.<VN,3M2[:-59&=33V8%XJX
MCIF3CW+36NK_ "A8BK)V:D0-Q9J(Q,5 R2C6X3+%2Q0<%6*A4H2(G3QRS,SF
M/BHNBULS9LU%FFHX:+F> Z;R$@W<M-8K#D\Q+'*MWK=>[A-,W,6Z:6$]SE_C
M""\4QJ$4@H@JF<C5J4\50ZM'"BU9HMVR$2V5CT&3U%%VDTUN(#E/PW6X^,BX
MR$D4F40E&MVB"DW)."F;Q,AC*0:(.3++&.Y1Z<04&,726$Q'$-##&+ =N\=E
M5:?G\_G[M22*4"E H>=?7ZC^L?U_CPTU#"O1[![S]9S]:R:.^WRF\K8I^I;(
MK]'5EOFVZNCND/T]6@ZM:WH-^P<--,!DCE S17D&L91LDV;(N)7_ #$7G,-C
MP9#GB,03!HK)=JO][GHEAEJNV2M6%PPB;5<"J-(M9\R)(1[9!!TH86I1/L?3
M-=3T%;6RU,]-2M-:*NFI*FKML=VAIKA)/1O!.U+)%,'VPQU46?+.#.'RI49M
M:J.21(UC+X61"Z1SR4S.@=-R^?$RR*-H/"YW=C\C6+EKD%PI>83G-M3'!2-7
MY@)?.^&\(U9M=<G76V*)(Y4HV ()N%IEXG(_I[@+B6R'+33)Q:96<9,@?HLI
M9D\A8\T-QUBU]334U?TC%5S6^OLL_3U[O-ZJZ7IBUTIJA:*N_NRYJ;8TD$8I
MZ"&F:*%$ED5"\3H\GG:P-72"6.Y*C30UBU--3TT35\[B,SQT:B10LR8(9IW\
MS#^O(*X(Q%O+_P!DCR?8ZN,#5)WE_LN/)>PTVKM*?#SU^Q<\8W?)5JS-CG&B
M*(VB!QK>204/$Q5MEYYTP/#J2KUM&"JS34(BX#C-V?JP7.BJ*RGI.DZ^&EKZ
MMJR6#I$I+16NCLMRN3$TE14T)GFFJ**.GCE2;R@91N(R#JUJ;>89DB-5=O7#
M$(A],R$2U$E3#3["XIV*!?-+^I,\ 8Y&GCY6N0^F<I7-SDW$D(%'B%K?BW![
MR69X\ML79[+4RO\ FIPHB6+L-@)C/'JD?).R(-9R/8/:B8A8QZS=%6>)K)G#
MG/C#)9O$#PB?%B2DBK[O/:9I!;(>FC7T[VZID<T\L,MVQ'"ZE&F26:-IX<!5
M*YUG.E9ZGIWJ5*A:EJLTU/#60PULLESA$HF 59HG6C)616 *C:0K;F+ A1Z%
MH?EYAH(JR:-MR*H"Y@4'KR"HRUH-: (:%ATCE'7_ %4BRH>Q3E*  '@^#P6L
M-O!2%:^A#D.13=811!R!C+J.GXU+>^2"W?/!UVBM\1KE<9$EEL_30:-/+!_5
MN*7(SGDU=758/_#M^W.MK(X0C7L:NU5LE_415(0IBGR*_*42@H0X;6,Q4/Y$
MH#LXG$PAH1\B/$:SP=M4M))DW>I1POHJNM$-'(!(O]XHL1&T'U(,8WJOVZM*
M?KJM@J$FCMG32RHS$']6J/@E6!]'FA.Q/90!Q@#&M%$X<2J@."PGQJ6(]%,S
MGXY?DW_9,CU@F#8TC#*]KN H;O ET@;I3ZP-HNM6G\'8:<Q_1UDCG#M^V9>M
MZ.%8QG@@5'3,A+#Y*PSP,#G-S6=82WIHFN7T90_#Y6(6_I_R?,67^\,GPE;
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MR' KX@QJ9IQ-(Z8"*9B^Z6Y5&'/H7<V "Q(') P,D]\<<]_EPOU!F4GD$K@
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M)"^4#L8L2ZD@'5<$9]@IC5FAT-LTY% #*&$PGJ\K'CH0*!A CJT]PP^"[$H
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MC22,)6MM(7W2R/),YR!DR2,V>2223KS=<!Y-741RQ2PLD\RF-QB1"LA5D=6
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M]H2''4_4ZL[DYVG;!4@<^VU0.X;L-75*+PGENE#-N0* 9+;22ICV.V5&4Y
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MZQQQ-:89)Y96(5(O+>M2H=W;"(@0.Q*J@.5S8BCJ]H?$X0 DL&8* ,DD$)M
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M[]_E(/W\?S&M6K,59LJ*"SDK)4!* M5'J2"A.LH&+^:,U(H'6 @8/S>QZBB
M" @(XB2_]"TLAI'D^!F3 -$U7%!+$7 91Y'P*S*T@82*!'N;>"N<@FX2EN#J
M'2,R(<_M%1BI .#ZBQ'!R#EO8]L<09^T0H:63L#-*_&OY>&<)WZN2)GC.3-%
M+&2;,9Q,R(NWD<5,45!7*8Z1=BH)"F P=L=Z-XF7>S0=-AJ&EJ3--=+=$!6+
M.T0BD-096"U%%1(Q,:\+\6@<8]+YUZ$_1CZG7I#Q(FN]71T5<GZMW6D$-31&
ML DEJK8P:.*.=")-D<BAL$[6=1@,<TFLN6&RQJ7:0_*'8DS',?XBRGE'R!#'
M  %N#EFP!(JB8 4_:$ACE[G4(B!BB/G,7Z+TEEA@R,>6Q2)26'_EDN,\<@G.
M,#)U[ZG\7;17RB=QTQ:G">6U)56Y*64A3RYCEFE)5B<*PD&=I (.X%[\8<N^
M3K#;6,0O/9NBFZK604![(*H.&"?IVIQ31,DW@JHL(*"4$R"$ZF &$O4DY$1*
M:$K2UD;)26N*IF?)"00^<[*JG)55,A=B!@+L9F)& Q &N==9^*_2-NLE75P6
M_H2NJ(YZ1!#3TM733,9IUWR)4S55YA1E!)8_1\J\$;X<$+6]]IYA;-6.<TTB
M'@'=CM3-YB]A(K/IU&1*X;N#VFTMU&B)6UF<]*!2MR+Z,H(BHX4'0@;8];\/
M8;#3VBJ/5-%6VJJFN4TE+$(*>D\RE\BF4/MJJ5RX\P.!L5 I!#+E@3OO@EXF
M5_4?3UTK.GX.E+-1QWEZ:: RR[7JEHJ21I!\,UD5B()($+&FD;"JGF )L6 S
MW'G-'58P;1+H251AVZ;90]D=HW2*9L2/C)-FQCR<A.A&H%<G<I-4C&,0JRBY
M$D#"=5,IMN2X^'E7(:>FHY:^7.[R(TMKR.J'&XBGL"OP2-S,[H"?46]+#K<5
MZNETF- >H>A'EF9@8X:]ZV=74Y;^S2]6U:DK@@_V4,C9 V<KIOYC+_,G47":
M%?SHY9D=)@NX)'Y.EH0JBQ!Z$Q439W-N597H*4"G.W4T'2 ]0!L=BL]I\.*^
M*J-7TW<8'5T$(-E2O]. )&>1+2C*NXMR K!3A&W<G5NKNG;W+443M_LTN)BA
M=#],/;K;*@W$^72I4WI'97'<^1)$7)WJW8^A'&[Q_(8[Q2_E7AW\H]P5@)W)
M/5'!WAWD@YP]3EWKP[M1191THZ<J*KG<J+*G7,<53*',<3#ZBM*TZV^D6E#)
M3K3PK#&R/$R1+$B1 QNJLA$:J-I *A0N!@ ?%+KI&CZOZDC?X4/'?;Q'(M$T
M;T:2I<ZL2"E:-F5H<GT."59<%68<ZG9R-_OGJ2 _PJQ?@_FAT#?Y/Y!XNY_J
MC_B'\FUKL6-HSW&3^'8<_+GMJ^SBUU6T<--'#31PTT<--'#31PTT<--'#31P
MTT<--0^J/[_7/?\ %2Y6?Z5N;7AIJ1-GQCC6[/49&YX]H]ND&S8&;=_9ZG 3
M[UNS*HHL5JBZE8]VNDV*LJJJ"":A4@4444 G4<PBTTV#BE4'%M\KL[3\915>
M9.JU:(R8<8[H#9!9==Q(5=Q&(22=6B2+JI]+.0.W,Z*9-,Q5 ()3''=E.VVI
M@;:Y"1S$E8W< L %!*J>20>._P \ YULELB6KLMSH5JZ*GJ7N-JJHXZRK@I!
M)#34]UCG:-ZB2-&9&JH!Y:DNV\%5(1L84K9V<_E?%*;>.L#06Z=Z4.::KLQ"
M)J=4,S+THJ2;-L1<_G1BI"<Q2@)C  #YMGG22X6]%$JL&KR2\<B @1,,995!
MPR@XSG&#R #K/45MEH>CNLFDJ;?.)'Z74+1U]'6L UVJ-Q84TLA5?3@[@!EE
M!Y(&M9E>FJ6C(M2>QC1FO.5&'+:HH'3Y2*0,=A;((DDDL^;LGZJ9',4L[1*4
M&RQ1<>G.<@@GL)*ZG^)K*8X7S8$%1&6 ;A)%61.0<*8V92.,@DC(XU<])WH6
MCIF]4\\LD=OO%:;96>5"M0X>:T5TE')'$\T"%TJTA9F\Q2J*X!W-@P(Q>O$J
M6-I(1D1*19'K[E_>/BOI,LFV?R1.8+&\=*2$<H:/8+(H.Y*/=F61<&?'!X#@
MP.C)&(0-:LTT-//4U8AD11:7:<,<JTB!*>H*9R!NDA;<H)#D;^0P)ZSXR1UD
M/2E'2U=;25CT_5]530-3T_PTT%']&5-10T]7_:*@.\5-5Q"+:8E%.8D6,%"=
M6LREA@&RR?J$UBJG((@8J:/48A3:V("!A$-^Q@T'X<:_U%U[TA;):9+M\1')
M)"6BVI3.6C#[,A2K83<,!@ #[>^O.%/0U4F\Q$<<' *\GG'(&>W;D_;H&9A%
M6O4!!(F<A1!3MM>[H3!H=& 0WOP.R>P[U]>*?ZX=(5% )%C*0S1HZS&.WF0*
M74AB&0KN/ P5/?'!QI\+5+)M."5)&WU#/'V=OGQ[_/WUHOXE0P W],J : X/
MH]JY-\W4!.T)%&X$\@.QZ1'ZB;6@#$M?.F:AA\(]NJ K1^:MQM%!7298D1^0
MR2TZQ$-D@A"5)SO.5 JB"H7.X2+G. DKJ,<9R.<_(]AVXUH#OHP[@Z7:@3KB
MJ8H :+1 !/O6C$%X(B'CR AK]0:WQITO4-A>NDIXHNDVJO.90&L$*JS@'C;\
M<A[>_(^_.KQ(:@("7JMH'^&=QCW[CL,?+G@XSK DE6*1TP78UC9@$P :%;;\
M#T[#\^<? B'CVUL!T'MA[_>J2CDIOBZ7H5&E5G59.GJ7)52 6&:URH!.2"I+
M<C&,G5Q )V#^7+<#@'ZM1+W/."1_$_ZG*76@8AVHJY4;K:6.8W4Q19M$OF\[
M:]L_=32_N!*<!$/<!\\<ZJNF+#<JRHN<]%7M'62><\EMH;116]R0OJHU><F.
M#&%4#'(;TYY.36Y5D2QH)HW=%&%G9IV!' WJX8%L##$@]N#GNA;3"51HNU*]
M3L)1.FH9($92;0$ ZR@8#"P>D*<W5KI,J'5KR40+OC2>I;3TQ9IJ:*&W7-?.
MC+GXUE9@0VPJIA8GA@<[\>Q!QDZV"T5][G65Z=[: A4$R4-MD(') #5=-*
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MU!2&,R)6T%#=*6MD8B).*EUBEV-*V,R[1C"+9B"*IP'KBH)0P!\H&DW*HEV
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MNJ#@'%&SSM4_LAZ9_/C12_U2W?69I+/\53I4+>[/2*S8$%=5&.K0@]Y(E1@
M3DJ<@XP0/8:Q"R.G9S(_<&XL2E)L5'9FK1,=](=( VD2B8^C;Z1$ .4!V8!\
M\:K67N9D*KX<]5TY .UOCY(!(0.%*4T]-&03P0TB!O\ $RG)U<RVI*=0QZ@L
ML_<%8))Y67N22/A' 'VEA@GVUK7SZ>%8R+1%U%M%RE3,V45Z'"8G#1U 7"P$
M.43=0F*H1(.V/D.HP /&N5-UZM:4PVVQ72T4$Q6(PS5DT9A\Q&265R>H).VX
MMYA$:IP<')(G@I;>L9DFEBJI4/F&2,R&,^6P9%93;G##(PZ[P& .2.X0Z^&T
MRI *.0,CMC;+^=5R5(R28E$/T0:S+Y^R 3>!!0&X+D -$4*4QP-B:GHFX)'F
MJZHNB0Y7A.KJ7()SM %17;0/O8M]IY.MCAZY<$!NG.EIU"XVGINEIF.. QJ*
M.&*I<_,,Y5SRX)&=8HX4:J$%5?*.2RJ" B8$<F*L41Z=@732/=-6Q-@ =0IH
M%,H/S&$QAZAD3H59:<R'K"O1-CD^=U39B4"[AEF2L:?N,Y0F0 X7' U<?K],
M/2G2/283VSTU!4-]O[:I@ED8Y)QOD8 >D (,#FRBXJA.1F;'9;)9X\R(L0C)
MM_;;JR*Y<#U).OA .YHH*H@@<J;OT( W!0Q17)W0 ]/I.CN,%W:2[]00=74H
MH98?H7J&NCK+?'(Q&VLVU5UIZ7S8%39#O@E<!G"L-Q&K*ONE1?(A1T-GMMJF
M$D<HJK?16RT383=NB^(2DIQL??ED,J;L+Z6"Y"[BI.I65KZ^*JM3<M2JJ-S.
M):NC"/ 52 ICD*UFD8EV9$ 5*)%02,@H;J!,YS$4 FZUMQHA.%7HSPL6/ ;?
M-]"02+R<%1]/4TA4DG&UBIP0 Q&1K\@NU WD3W:\!^^RGKI9HO8 [Z))8,G[
M#N'O@=^B'G:"Y?@WJQ,2K3FE.VC%R%>%\)$?F7 I&DNJY A"@/<Z4A A?)Q*
M!2B%6.N:,B2W=->&25C$;3+54""2(Q@R*A7JIR28R2"(W!0Y*LO&KBNMO4,5
M*DUV7JF*WEH\RU=)<33@R,6B99*NC$.YBV4(=2Q.58$[M>2[^J%59Q7FOQ&=
M.?9P!1P!%=32&BHR5;+".0<@?GSKN77454P:(*11$G20H_4=[O8*FJDI)1<K
M!8C.L\J+^K-UK::E"!FVB?Z-J:V.2;OAIFC;;V4@MCV/^C%25<G1=Z:W]33V
MJ(]22;HZGI^S71Y7-JMF7$ER>.2)5[".,%6[L<@**,R7*])))IO+]>09)E*G
MI"@2!DQ*0O20I#$8=HR90 !()!,00*4Q!$-'"#0]-%V,/3]H,X9B=_5OED$D
MAMQ>0LK!B,@J''()!R=>I4J;S18GN'4E^AHX@ \]-X1L@(QM4I4QV<1F-L\2
M1RE'X*LP(.E!$V3%;PBILJS&79F13,*,4M$XWKRR)6)RB99!4UIK[MR50ZPA
MHS=QV"@(]0D,'26E/1W*1H'L5NZ?M]-'EJD/U/>)LE26#B6BN4$2*&R79$RO
M)QO!)QM??Z%Y% N%UO)VR1+/<O#> &(2XW0QBLZ1N3N')!8O5Q("0"T:KA?4
M)@"B6+(],QC$X[A7\V+3E\P1+(M7*L5&/6\ CB2B((N9#U+EA'-UT@>,T72#
M<Y2)+JB1%($B"!/0EM+Q4%)'-L#K30AMDLE0@8H,[:F=WJ)T/=7F<M[ GDZ^
M/W6FZ;JOJ&0LK,U[N[/B 4I#-<JO*M21P4\5,5  $201A>00  -3@Y1ZE8Z/
MS;5*O6R'=PDPVJ5U749.^T8PMW,(U6;N4%VZBS5TV72,4R3EJNL@IL2E4$Q3
M 6[F8%!@Y&[N/N.M>12"." ![ZL+S!SC4;#EER'5IJ!GY22HN-XZ^,TXL8\3
M6V5D9!9G]Q8-%PZ15&>8,U(>>E'#@J<>PK\P667<%;1[\R-MJH3CO_(ZS8[G
M#Q4LXM"$LI/Q253"45DI!M5K//1?HX%:54L4BD[AH1T<8NL1#*+F;+,'0)"1
M;6T5TA9)T>39BNU'69:N;G%-86CC'4M$A%+O+%\5G6-*MZL1%UVJ5RZST_<V
MSLL&<EDK$8XI#V(=R=:&4:H.'L>Z47!B\9+NVFMR\YJL*LER-E;-*K.%G#A&
M/294NZOS3Z39K<7J\A6A9U]<M@AD&^/[>=:;B3.HE,D,HJ9Z"+R.5=M-:=[S
M=XC1LU9KK%U8Y5*T(S0QLS'4VV.XYZ_AYVL5DT1#"C"*+6*2-/6=&->HP:;T
ML"M%S@SZD:2*>"BT_/Y^6N<'S<X<F8F+EOCDFDC-(Q*T29K4KG)M98\_*U")
MAH^'>M*WVIB;<+9 I8OH2.*XDX<TYVI-LV-&2PLFFG[IMN@[Y6(:WUITJ]@Y
MYIZR.=+,GL<LHCW5$3=YC(MVKYJJFJDHFHBY;I*D.00$NM"+32FX::.&FCAI
MHX::A]4?W^N>_P"*ERL_TK<VO#34P>&FNLZ13CLV]@&@]O'OY#8#Y\C_ ).'
MY^_4" ?P[<#@_,?;IE;<7>5<2@(&\$O^O @ ?YB-.C8@&OFZ=AOR(%$2_P +
M>.J-WQUNQG >LW'C S X S\_8#W^TXUN=E/_ +(]:C(Y/338P!DK=9CD8 )V
MY4MC( (W<D:U\-9V=BRT<&+23*E&U*S0ZKEXQ4;-7+R,N,='/3,%C"(.D6[Y
M@X2.J0.G92B'Z10XA'/'/7@IOS%331R95D!85$:,$8\. P92RD@$$ $@G4];
M:Y[9T@HJ9*9GK+U:*V*.&<2R10U5CJ*J SQA/V3-%/'+M9\[7'?C4/)"&&K9
M%9TT(Y^QCX"?QB,8G()?G7<;+\W\!*,G3=<3"+MDLR7: DH)2"54JZ9P Y#"
M.*IHXX:Z6B>)FA6V53>6R$EU:KF]1+ ;M_?(PK<'[M[ZOK#=_#ZBODE7#45-
MPZGM JFIV?9'4VWHJ@II(Y4=08Y_.A<U"@LK@HP/.K"Y%A""=(7D,J]-TB!#
M T(L"91-U"7>]!YUX]P#\0XUZ^6/I>HEI_I+I4W1DC(A=[=!5&&)GW[ S[@H
MW9(  (X&0-<@@EJER(ZD1Y.3Z\9/ /MQ@_A^ &@S.(.T%(L$H5,2% @ Q2#I
M*!@'6NZ4P>W]T'[=<1FL_33VUJ=>D9$IC$BK$MKIU"HKJRJ$^+AP 1G *8[\
M]C 2U(EWFHRP))8N<DX.22%/V]A^[VZV49%%%3MQ"I1 2&'^M2D$>D1$-""Y
M]^=@.Q#]6O(C0M73W342RBGZ8EA!9'8-;XXR3'R"-M=4 @YP>03CL, F:6HJ
M&()J%/&,A\@#[RJG(_C\S[8X1T."XG"">^5!$#>B.'S:T)MBKX#WUK6O?7%J
MO3O2RUAE'1M9YGG;Q+]&<YQ@?X^P))'''?/<ZF,U25Q\6F,8(\Q?OSGC\>!W
M!]SK'D(>#6 AC03PYB%. &%H ].S (@'6<1$1$/&A#8#^(AQ:7SICI.K:&6I
MZ0KIWB214)MB.XWG<0%DEC!+, ,>8HVD\GMJI3U-8F[RZM5SS@2D9'(Y*Y/V
M>_W$:8FUQ^47(S4=589W7TA662AK 0D._48-TUQ["Z<5)'5:JF42()!2<I@3
M\\*A>DX%$. W^P>(M-7W;]6^F[G1VZ"MJ4M+&GICY=!%.P@2-?CY(%C:,;QN
M3<69WQ@J-;I:9NE8OA*F[5:W!E59*NV;:BE2H<@AHVJX@)XBN=Q=%(( 4=SA
MCYBF9^141^(S\I9S"0X)*+UAHQ%J7J*)BD+4IROHG!41ZA,\2=*@!0!$Z:8G
M*;EW4'2OBA=9H'O'3]\D:%&$)6JI3PS%V),48!))')]A@ZZ%;+QX;_M334-/
M:@" \9N4E3YI(/(-VL]:%5<9'DF/._UEL+C;42(S,TM\&M8FK-:O(N%O6HKP
MJZ'4W!HY*W*HX=S;PJ9@6%$3&7!8QC% HF$Y@4"YZ0Z7ZJMW4UIKKATU4RTD
M-0[3I<JFE:C96IY8U,Z2O'$0CLK+N*X<*1Z@ :'4=3T!)8Z];7-,;HT<?D%:
MN)P9?/A,A6**WTVY=GF8$8C4 \(  FI*R !TI :&BR"'5L/5>E*.]['H;N@3
M-O\ $Y1'0:WH X[)>0C_  WQ'2?3L.)9& %T-!Z2[$'RJ"N6!NQ(<@NV<-E
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M6#B1#YV4>.M^>R@/D/8-=H->/J(>/;BR'373S "2W6<@>ZT]'D\_,0@'&#D
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M#W8-3]01I@\@*20" <'OKECM?+SZU(-[3/,4886KTZI(V43<.BJ@C_6Y2EE
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MUB :UY]AI7KQ!KS)3O!:6C4+(S-4J:<'8=F=[2",YSD$2X+ *I=F"F:&@3U
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M0Z$/ Z$! =?4!#W#AIKZ51,YCE(<IC)B!5"E, B0PE P 8 \E$2B!@ =")1
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M:^43*$((>^AZ@*.@_@[ 0XFJ++XD&.5*6@Z7C9HV6$U%PK6D20H0C.T5.(R
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MF F%IEUW\!=[%9(&,N6.V+C(1HZ>R]]U6#YW<Y5.50A!,Z1<(2+%1PC3U/\
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MN[!&ZWLQ;WV_]B75"5'S*J <<^^I&&F9X3#T,HL/8-&7(([_ %;<)B8?P$
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MY0 *H+/QG#,>=7<4JQ 1Q5E0J+D;4<J,'YA2,?(\#V^W.(#:0:!W&24:"@[
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MBB 9+R2J*JQT%D0!?OJK$$#]9@(0H_*&@XZ_9>INI:JC#QV&VU!#LK&.Y+&
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M>(7&VFH\TQ,49MT"4BA0058/"R  Y)]6O6-AY-LEB3"B3,QCLT>7CES1:',
M%$[5+"E)(@<2^>D3) 01*(CH=AL??CK=$9C3Q?$((Y_+0S(IW!)64%T5O\2J
MV0&]QSDY&OEIU;#1TW4M[I[=))+;X;G7QT<DBHC24\=;411.8UY1GCC0LK<[
ML]CG4_\ D<_?.4O_ 'K7O_DAMQ4G^H/^(?R.L-'W7[OZ:OKXM=5]'#31PTT<
M--'#31PTT<--'#31PTT<--'#34/JC^_USW_%2Y6?Z5N;7AIJ8/#31PTTU.9*
M]#S./K8O*LF[P\36+,^CCKE$3LG@5Z22*NW.!BF(<2',0P"(D.0PD,4Q1$.+
M6KBCE@D#IO(BE*<GAC&R\8(]1#$#'."=;-T?75=#U'9EI9Y(5J[O:H*E4( G
M@-QIG,3C!!7>B,#C(95(.0-1"NT1<%(AW/X]4R$E ($MSMX+V:BXB(AW2LT\
MD9><C5HK(=+7*V1>IR %^\K2<*DV.*G;1(3H'7:I*MXEEI!.J>4Q;S)56%)!
MM9Y-N_<0)$(7<,(^.  0>N]/UMC-=3VSJ=.G7KFEL\,(IZ&KK:VLC2AAIZ2V
MU<51TU?D:40/2J5MM1;MTF!ERX!BK41O\G)3L@I)E&XRLIA(\1.RL@ZM+554
MG,%C5)DNJ1*8[ZS) I2MTFS26;@9-(ADE"B8QC:G-%>)K9U&MJGD@ODUBJS3
M5D+EZI9BR@2!R6+;HU"J=F2H(![8W+Q8'3U+TSTY2T],QLU)U3BJH:"D@M4R
M2&T5AES(]''$9&8B2:5Z+>=SJ5&T*+&8%EF9LDL%QF23CA0Q3M%*TVF*NBV3
MZ-'1=)O']F%XJ)_F*LFJT*F79!(IOJ#C7POB]2G-55]87/S,LK0WP6\0<9\D
MK'9JCS",Y#D)GMD^_"*V?I265#9Z22C@5,.ER:GN,KR9Y998(**-5]BOE'!Y
MWXX"J-'W11N)D'M@;K"4O28\F=R5,PB #M,[0G<\;*'40H@(@80#6N+F>U^*
M]31L:6OZNHJF1$,;2WX5BQ-O4D-3FWP-+Z 5P1&5)WXPN#CEGM:2X:&CDC!.
M5$'E[A@XY5QMYP2!SQC6I7A,AK"43SEC'I 0_K5V1EL1T(]8 U."@@(!TB)2
MZV/OOY<,+'XY0\&_=45/R6.O6D'/&3F-22,9W?;W.,"Y2NLL9;%OMN&X/G12
MS>_<8D&T_9G&?X[1&(N7:314=V0-)@47!I9(ZP&   5#=+<2F..MFZD^V)M[
M)Y  R4'3_BS*R)47#K1%=0TKKU+"K@XR3Z*1< X&0>.<!<X&K5JFU@LXAH@-
MQ(0P.$.<G: K]AGY@_(_/7O(&[@*9F\_9TP*!@,'JX]83#O0" G8%Z!'>@+H
M0]A'7OQ1N/2OBFAA6AO_ %X 5(<CJ**1B3G!!D@ 4*/F!D#N=7$-RL^',UMM
MK9(VX6J4>PQA9B&)/8_,COQJ)%BYS<+T.T354O60I^-D:M*O82Q'='LZ:+9_
M'*F;N2J+,8 8X/ZY().M%P9$3F $SF3Z XY>W574MLO36Z\U_7]3\!5RT=P*
M]9F*1Y(LAL)#'B+#, R+C:V1@:[+:/ KQ!ZCM%#>K!TQ2U5+>*2.OM@A>UDR
M4TP)C*K/<(IR2B[P'CWE"&)YR$C-_:&\IR1V_I\P2:O413J[%IG612CLF@."
M\.0R@#L="4# GHQ1ULH#?W#K EHS10^*;H4]8C\0ZE=K<G# 4!&>"0#^[YYV
MW_HS>,\@E$O0\*$,N/.H:&HSN&<+Y->VT\C.<9XQG6I9\Y?+/GIZAAVO7-:W
MSMS4&-85Z41);H^47CP-+'3<0S]D+:5*BE&J.D_4ET15 CH0 Z0#QB:Z\WJ^
M44UKI:;Q!DEJT58X:Z_P7:(B-UF*ST[4D<U6V(SM8X?S0LI&5P;JK\!_%KPZ
MIY>N+MT^UFMMA"U=3<J6>2T2TT=0RT:F*M@FWTAE>I2#*-RLABW8<Z<.-Y9\
M.+%.>UX9J\H8O2+0S?$L7#^G V^Z!OA4>'J!4,!/*X#V^D 3UUGWB+58KA3+
M*+W8^J3E5\AH+949#;B'W>13NI;C WYVXR1@\ZK4^*G7T 467KB\V^-\FI7]
M=*JM$G+,A'GU2[-JG:0J^HY+$G3/S7+!R=-Y*17_ ',-:DI$KYV=5 ^-6H&<
MNQ7.90YU31BIA%=4QU#*"D83@/68FQWQ+455=%/*J1==FG@?RQ3B6.+;&AP$
M\PVT;  ,#=@C&,]];C0>*/C?-#2;?%&OIH9(E9)OUG,01".#@3J2R\ C)8=O
MM*IH-=C\3DD4>7[$JN(V$PY;N+.VK5#1!*9=-TE4XY1P)9^C@(LR.' $3%)[
MHS@Y@71#J25G3J'J" 2BPW'KFQ(ZCSE-\GE$SHWIDE0QTT8<#*H(F1 , +@
M'%]25]5U7+2S>)?60ZQJJ)9(K3+7]3A7H:>5U-7 F;+>69*BH5*ABTT#,T9?
M#$\2IA[G9'$4R1D["[1EE6Z8/$A!DP>(O.D!5(9@I8I8S50O3\Z'=?=OYA!0
MVQZ<FWB!UK'0I'^ME]=UC56+W&$U'FY]2LSW-7WXQVC.,D@ ]N.UUFH8ZVI>
MGHXWHED)AD02U$7D_P"%A4-14WF1\_WGEQ*==Z]EL#7HZYR?<B81$!27(?H
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M2SE*^WRU3DE I,9BH:G:N -P8H2W(##)'G,#*<B+8J RE353!,I1*@P406
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M2SL<#OP(S_TY[:B5FZT5V:R;1E(:;BI;TKC%1ER1L@S>G3_Z9O">NX5NNH)
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MO)3PN"#V\M2H P3N4#(&/PX^6JGE)C )'!QQ@?+'!_T^_MKK-+%24 JI4"F
M ,/4\[0]("&]?*<#![;T)=>-^_%*7J5(7VSPTQ:/#G=7K3%4]^?)DW]\D9!4
M#D$$8E6G+#T,P!SW4L.,_,Y ]C\S]N=9@61BO^;*8@F  ':3UL(@ !^)3=73
MY\^!XOX^L[96O\/$RNZJ&/PMTH6;"CV*R!]N#D\#L,@'C4GPD@]1XR<$M X
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M66H,;S>2A/J?RHR'DVCG:IR?;4@?RU\T'^HPFO\ CXQ!_P X<7'E4W_R7_\
MT)/]=9_Z+Z=_^:D?_.6O_P#]]8SW./-,@U75;\E<RLN1(YDDASQB(0.<I1$
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MMUK$?:)D\;;)BG55W'MXNHN4DR+05:</U7TZR?LG ?UK;GCJ0=*MNVDXKW<
MZY[E/"BFLXFO5%;K;5BDHTDI::IN]OJ4GKU;R_B:A(ZIH9U\MY%$7E/M+%S,
MN3G'1>'5WH^I?-M-ZH))::_3ST,];TA?HJGX$(1!1O+]$6VC,REMS5F^FW$D
MK3H,;9^?9E35:@9K("]!YI<BS"*5BJTK=&5\IA)!*7J!0LB,75():=M$2:NR
M1%SKN)*TL1DSR'0B48*/ NUM&ZXKHA%2_2G2=+:=].T5">FZP@QUBD&>JK!&
MT1>-D 1*9&2, J%DQ& =#\=ND/$"MAZ:%X-KO6RMN<BN+?7T1AAD@HHQ"I4S
MC_P4/F88[BN\-G5JL3<\G ]JR#G(=AL[9K;IQ]8)AIC&L,(^WU23$Y*] ,P0
MR*HZ@%*\HHD+VQM57KN>(W4)Z"+%4#IZ%)7]&M%6?V?J&.HEHH(J6*:ZT[1T
M]=$4,U1*CR?&3PU15P:9621(Y D4KA$)\]-T!<XHS/57/I6DEA#R2V\T]6M3
M&$&X4_F/3R@3;5 \UT=2Q#&( %=<5,B9AQL6BNYFZRE[*VFK*>YMXW"C9JI:
MXATDH>NQC<R.4)T:@K7SJ)=Z4;)22D^"1DUFS/KV7,6:YVQ7N0Z=Z6J*R6>C
MI88_CZFY5JT4L<@DJ*AFB0!UJ &1(BL1B&3YL@RHIVOPUJ.HG:&3J>P6P4H,
M[/45*P+.KL(UB3-'2J2G=F/FX_RH&),F,)53-V0:7BVZS.7A33ZKFI>8=SBM
M&L.[:DX>R#"K(,VJ%Z>EI(UDR#==P9$9S[S(EVNG%^H$Q.Z6;PWK.J;6U\,E
MRL:W=%-/04]SN<<=N\F<QSK&9'I8YEJ/+8@".$QJX4"7:6/+^J:<=*7ZNL#5
M-ONS6UHT>OHML]/4&:&.=#'*5SE!)L?EQN4\C.-.)"8-SLR"D_&\]Q%A&&C[
M4A>B_DI9PQ;M(28+_=.0C01O;X:<C5.X@+Q@B:;)9O3F[KF*[X@GLLW@G S5
M(IJ^XN)6B:&"ON\[+3($42IZ)5>42MELLX !QC'&M9%Y( WQH,9SY<87/)QG
M(/MQD]_D,\?(K$_,-#M*HPD\T5>Q(Q=:M<=<5@Q)%QGWQL$L*QZ]8F&[A)FJ
M;2L)F13=0* S"=A!)0RDE&F4 $ZLW0W4%II*RT6N@ML])(96I)ZNH@J7I*>5
M,U<(FJ8)I,A%;:ZNNT;O0<Y$R5U-)*D[M*C*5)$8(P58,K+D%2>. 4))(((
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M-)#/+\32TU?'''6PM'MA"E98%A,+#<S^7-N.%&WN:)N*0^F*=IP1D,Z<@_\
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M/W&2&%@J+EX\BVK!NQKRI,<N'%CGUI&K6)*%M1VN<ZTPMM5G6S4.?L_K[?\
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M)+#?QG)*CVR.=>:V)_M9%?[FLO?W_P!#$]^/:2#"(,8PJC'RP!QK39.#&/\
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MC<H41X R$(&PX"6KJ9BIE0>@%5*32XQSG .XJ"<\=AV.>XQG44V RRHNFYA
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MZQ*NF E =CM4P%$-GT " VM2]$*.IITLU[=7IJE3)#9+BT< ,#@L&S4(-H/
M64A_<C;@U88Y2\;K+ &61&"M-&"6#@@88HQ)(QG'S(SV,36\%C*L'^(2<^>7
M1,06WII :25 #J"4Y5?F1BC=U/MZ#^N!$"G/M,XCLOE&"V]+4$YJ:^KNL\&&
M0Q"VV]7$C'(8^36P3 J0P(>3(YWJ3KL$ERZQO$:4M/1RT) 219Z0WQG947&!
MDU4>UPV3MB"]MI51I6,7>/';8BT9)RC%D8QRD;1:M2*R Q3=*HI@BX<EZCF
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MA^O&UTW0G2C6Z"27IR7#T\1:5Z6W-)ZU7EI!3&9F8GU,26))W<$ZM6K:KS&
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MDI>H:*BAA)R_H@2N7RC(Q,C$ ;F<N>^=1-;)(VYTH96)Y>2G,C'@+ZF*$D
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M94SQG. ?XZ7T)>:<9TR9EQ#2UUPVGUJ,JQM4Q$3F$QB J0>H2E$X?,'D/?W
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M&57;4!<8",_"M4$\84'X>)CCDX0L?F=O)S]F/]==2D ]+L!L3C]JJJZ@C[^
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M=IE.[=2)2EFQC.VXQQ2C(X4*-O![$:6C/!UY1*@/WMHSENF4-'323.LJF)3
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M(^W&(^ ?G]8<=SG)]^-=97DZR$57+-VB00$ ,L[:'+L=B =I==N4_@!UH_@
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M(#O[OU 1 = /F";AYUL-^!\!O6O?Z\=BH<FFB)#*6BC)20!9%)7G>%+("?\
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MW\1IY/[>T\H#4RDA\'<=P!*K@$C.O1^H^*DD<Q(MH)P#Y2]E4 $?IU&58GT
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M$(F&TQ/3^;N(P6^$OOD-_NG [Y4<ZPIJ?C'/QU#YX',9M[BFP3@$OY]'4 \
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MWCCXB3RN)K58H BDAZBUU\&< $%3/- 964=HX&,C'TIZL:QDOAEX65>8J'Q
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MV.@(0_RB!NZ41T$)/$NZ!5S=+!(K;L;:ZT2,_."JKG#,>0%#X)X+ G5"2BL
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MQ%R)Z,!0!43NP*43"(= %*H(Z'Z^UQ%^DKTP>7M%_1"0J/'%"5!8A4# UTP
M);;S XQ\OK"E3]#UT^XM7VBF9?:IJO+9B0>% 61NW^?:?NTX49>(=_&-I'U'
MI/6-D7(LGB1$GJ +I%4*BZ2(L<4W!"&*51,="4P"&]:,/3Z#Q+Z>N%GI+G]*
MT].E=205C4DZQQU,*5$8DCCJ!$TBB4(R[TW9!.,<#.N5-KJZ>IEIC'YI@D>+
MS(2)8W*GED<$ J?8^G(P<#.N[[Y0R?RB\1'Q[ 0IM:_450=?S!^KB@?$_I:
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MP,<W=-#6C<1&1@ <GOWSC*D^Q'V\Y[:732=BT(AJF1T4A$V:)"B*9Q'0)E
M_2, B/MKJ-[^X^_'7+3U=TY2=.6Y(;G M-!;:5(V=&.V)8D5-T9,JYQ@$&23
M!Y#L0"<;)2U+5$A,3$F1B<8[Y/MGY^WMV.D^_FF#@Y#]]$Y2(F*/YQVW$H]6
M_P!!%)0HAH/<1V.A#0AKC3;UUAT_6/$Z5U%.$I74GXJOI%5F;*_L:6FEB8
MG/<@XQ[:N8::H4<HZ9(_PHQSCN"S*>_L/YZ:+-4NV<4>&0372,)\L<O_ &R
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MC(V@C!UN/3UUJK9%11K;[-7I#5I():BW&IG.V9)-NYPR,F%V^6ZR1L#^TB?
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M\1A3("P.01(Q!.=QP"5"\G:^U4*1&O$6*8O5U$@6SD \B&A-\/7 IM@/47J
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M_,-T:BX<"JF4&(GJ5)G'YA,F8[@"N4",_P T!A<%7*BDIK5/X8V17YZRE].
MK;*60D9&3B6X/* ,9)>0C .T#*@9JL_1PIZ.GB-/9.H+JZ,BF%Z.6HV=QN,=
M5 J!R ,LLK,Q;(Y) Y(?:@W26MT0W5P_C2SI.Y2):*V68J5_F9("+.4$3"$M
M/52$>&!D)Q32[S)%)J0@"14Y"=9H2^&5F1VD2_\ GHLBL\X>U L.,AH6KI)"
M%XVCD8X(4$$3)X 1K:9YFNO6_3DJTM:[6."&Z4D"%8)63"TEO>$+42[2[K(^
M$!R03@>HZP/J7',$U&\W&O50622%NT6@VS@I>@XB8YY*;:MQ HDT<"J H)A
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MH9*RBDIKIMP"#-;OC"(Y1_BB2ID"\_M6.0O6QR+<; *GQ5B[I8MN@4@2E23
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MX+\?;COD?9I/#;J V<G9!-N4NPJ9 2$K,SV$Q3$2=)7":!FYB )>DJA %(P
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M3/ 1Y;^;N89SZ%P, XD:>XX@B3$:NVKF+5-I46KEE,HJ=)P$ 5$H*: IQ((
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M9!2)F)!<[D%_3@4ATB)=H53"IU@4HY*5MP QSG.?PY_F-48^_P N/ZCY:O\
MXV'BH=J9E%1K"-:'>2,@HV8-$&C=1_+R#J6E7QT4"$3.[DY5Z\DG[DQ16=OW
M;EVN=1==10U#577-]&1LHT48R;!G(,EC)'5:/FR+ILJ9!9-R@91!<BB9S(N$
MDETA,41363(H71R%$&FD/+X@Q3/K/7$WC:B2Z\BFDD_6DZG!/U'J:$NWL")7
M9W3!4[CMSK1K,D%4QA+)MFSX!]2@DH1IK-K^,<=5*1<R]5HE0K<J\;^D>24%
M7(F)?NVFVX^F<.F#1NLLAU-6QNTH<Q.IN@;74D00::4+2NP# (<K&$B69:\P
M-%P!6L<T0+"1IT&S8\?$ DD4(YD=LS:(&:LP10,BU;I"02(IE*TUN.&FCAIH
MX::.&FCAIHX::U\G$14VU,PF8R/EV)CD5,SDV39^T,HD/4FH9NZ351,=,WS$
M,)!,0?)1 ?/#34-<?PD+ \^6>&D'$1<,T/RI\K;@[:)CVD<W.N;+/-J0RQT6
M:**9E3$(0IE!*)Q*0H"(@4 !IJ;7#332X^_^6&7_ /?E"_T;T/C0^DO_ ,8O
M$O\ _6ZW_P#WD=):V6^?_$KI#_[!5?\ ]\E]TXTVT;OXB18NTTUFKQJJV<)+
M%ZTE$5R]M0BA-AU%,0P@(;#?XA[\;A<*6&MH:RCJ(UE@JZ::FFB=2Z2Q3QM$
M\;H""Z.KE6CSZP2AR&(U@*>9Z:>*HC9DD@=9D=6*,K1G>&##E<;<[AR.XU4!
M4F<TDM30F55U4V<7AZNL45VK=H=FQJ/-Y78!NQ["222XF2:LT%5E'AEESN%U
MB]T4R$(3P)X.4-R2\U4=UJ)JJ&E\&[I8J..II8:;X>@Z7\4+C;EIU@CBCD&R
M*EAJ'^+,E3YM5(&D,:QJOI;Q2J;?+9*D4)7?-X@TMVGF2:25*BHO/1M!75,Z
M,Y*K&U14RHJ1X54C4$9))L4,S4#6FYE0WY$2"0N@]NGI(H&_K^B >^A'Z]#E
ML[*!Y5OJ*T$CE(M@4CWRBU)). ,%4Q_F/OPXR@YRX7' )).<CCN!_!N?<<ZR
MA16,CTA%% = '=.HMY\ALPE!#>A_P" ^W&5,-:U&(1TR8TV(OG32R&,8(P71
M:(OSC  !*DC/;5,$;]WQ [YP%4GMGONS]^?QU@+-?;OQ9%1'P0R9U@']9!V*
M _@/@H@._<=:# U-L4MFLZ<IZC*D1M U2K @D["'^%/OG(B(]6-QQM2NLS#.
MR8K[G(7Y]\ ,#]O?VSC&=8OP1H8>\,)'E$PB<!5.[[H;\CUB4I!*?\2]0A^(
M?4+(]+4DCFK/2]HC\P^:!4U%W:10?_-5#$JS'W 8CN,9.=5OC9P @JZDKCV*
M;?EP23^\C &,ZQG$8TZ0 8N-U]!$[H0#I'?L;]GU4\[^NP#BUK;#0N4WV3IY
M<@L"[70A0O)&,22,3C"Y)(;#$\9$!5S ,/B*INP)+(!CY#+ 8!^T XP.2=>'
MGG7OZ\)S>\RC16WJ-HJ.S3D% 8QF[;I*LT4["^*1H@568:B1-'Y2E*=(AP#J
MV(?H!>ITO+4B,TMB=2T2>3*D5;)3*/JY5GI'D*9W %F!Q_AS@G[=^"%\M-N\
M'O#J:JKK),8ND+(9Z=H;.E8SFWPC9([5D;[AZ26>G9RV[>Q'"Q[C,O-UB*C%
MW9XD4#D*L61^[;Q0!$-E[8NW,H9$H@(B;MG;@8VAT;IZ@MJSH^X4K*E19#(S
M98&.FNL Q]K)'3EOD 2V.PP==3I;ST??@\RUM!2?#LD>(+E:Z0MN4, RT;MN
M [ N?;TGDZF[R#VF"GN;_!T=+6F1G&SZQ2H/8=5PT(U=@-3L"QDA(U?JF*FF
MH4JA"HM=%[9>A-(H?)@+C9H8*2I:X625Z5% FCC6KIW;UJ$45/ERRKB0KEF0
MLX!#G+'7*OTA+A2Q^#/7<5K>T)51VRC%)40U5!55A,=WMQ#@>4DDDC1@F1O,
M!.6+$C(/J\-6*680&*AF;$O2'J 6%ZX[AO(DZ1!5$2@4.K8;,!M[T'2.^?34
M?2\Y7;TU5H.S;WN-3QD\F5E@&,$@KL.WON(/'R'CO74* +7SU%2"JLGDK2IA
MO\2G]E,3C"\@\>PSSIMY=KCDBDDT=UN4<&3570<*1J#),RYTCF(J=HI\03<E
M YRB9(1/W>D0ZM&$0XP;_0U-(ZT]F$:I*RQ$T]>HP& *^9%.FU0.QF.W&,#O
MK;:.?JAEI9Z>Y6R%759(!5LS[0P!5)PM$4+ 8#@J5R.,GC3N8+95\C"?"I0<
M_'H^J8B]+-+.!.HKV5P0%O\ ,_#H(43@H)3D#J$H@!@T(=9\-HIJZ&[M1VET
M$<]*TGEM6+&[-&PR66DJ ^&]6[S6S@$NP]1TKQ"J+Q+5VYKW76NJE%-,(6MJ
MPA4C\P9$H41,6R>-R @>PYT_GPR1UY322 WG1C*F-L0UL3'23-[>/ :\>!_#
MI;].WQGWFGI(2WJPXJ2__$Q:GA;\<=QD'(XYX)X@-NYROOC;W^6"V ,\X/[M
M83N.ED>D$2=\3 (F%$5%-?[+O&, ;\ZZ=#^/C7&*NMEZG@:+X2G%66R7^%DG
M<("!@M\8[#!.<%,-WSD8U5CEIGSN?  X#X]_D4V^V.QQ^[28D("S.D72;-XF
MR=+D4!!9&,3!TW4/OI,5=PPDFH*%WY.LS=)&\B=%0!$O&K?JSU?4U# %8))7
M;,;VMIFC+9RK2+;)XY2!D%@TJGN&(YUD:>LMT+1.],)UC*LZ/4.(I0#EE(A>
M"95;D82=&&1ZC@@],#6[G&)KEDI-28444VDN^29)G1(!"@9(H1=9A$NCK#KV
MLBN<#".E0)\H7OZH]:T3"-#23;SG+VVIB*D \?L;5!$N?\S8'8LV <5:^Y6B
MND22GI4H$52K1T\D\B,<YR?BZRIDR, 8#@8YV@G2.S!'3"53@UG*B8MRY9P"
M90@$$XA_G\8V#0'$P:T.@ P%#?N( 'CC>>@+!U9!U;8:BO: TL55OF58$W!4
M4X59.&4')Y]\?9D8*NDI'I9XXMP9UV[RY.<'(.SMDX/N>#C5%.*LUTZMX?BL
M9WO#L5DR*0LRUZCG3ZZ62K+,)&3K4% .$2DKY4Q<I@VAR' SA<Y>M80*B4R8
M*']=*BE8R"<*B@ ]\;1@Y/.<8S_UUJ3Y9W.#DLQ('L23JVK[*=PT=XPSB[CX
M\L3'NL\RCEC%)N%GA(QFOCG'"K2.([<B+EV5BW,1J1RX'OKE2!58>Z<P\4)%
MVN1G/ _/\-3H?3]QQ_7^NI0XXY:E(" 75N%^MEAMTE%9$)ZA)^P9P%,F<M3#
MRQWUW1$(B&@99/U,V\,I'R5CD)B;:-T0*S?,1=O 6DU/K,M>$+']PJA1*Q.I
M2A8>PM))];+E+3KBRL"M[0PM3=^T=$/)'L;=N[CR,W],G56\-8V)FC9[*,FT
M?Z5XU#'X_?\ DZ1TQR^VBSSV1I.4+6(YG=S5F>58%L5KM$<\NL,ZQ^NRGSPD
M^V^#UF1J#*G/H2&F*LU9K6-O),I.581#V+02%J.E?BO%5XJREBB;/)D&L/+%
M89%)FWN#^XQ]DA9V:L[XT(]JMGI[-G2F0-)IH9RVKDW(&=.6WIE'?HB&!U#[
M??M^1G]_OI^?S[_G[M-)%\L%L5K$M0K'%8R6K;+!K;&=*?1RC@H-;&,#3FC^
MPSU85J":+MZ,M4($L1-EL:Z\%"5"N-(R&0=KO7*4=-3^*&@ /_?\=<--?>&F
MCAIHX::.&FCAIHX::.&FF4RY05K*VBIZ,9+/K'6Y2%=1;=*:=1*+IDWM]<GI
M1@Z*5=*/=).&\"@HD221<I(NVZ"B0$4*!^.9^(?2,M^IZ.\6^FGJ>H+)4VU[
M;#'>ZFTTL]'%U+8;U<*:K5)4I)O.BLD'E&ICFV3*K(%8AAM72U\%JGJ:>IE2
M*WU]%<J:H=J%:Z6*:IM%PH*:>')61#')6>IHV0^4T@)*DJ6TM,J>1M[!UDFH
M+P%=K^.L@V)PB,PE-). BW])57=%:0B@*G<,&1W((AT*+']0H1 O6;I'2[]6
M-<>IK?-UYTXUGL5JZ+ZRO+Q"\2W:*3X"IZ:-14&*SF(H]'1S2R1R%)9V#2&,
M%E ;8;73_#V2KBZ;NGQ=SN'4G3=OBF:A^CC&*FFOT:PO/6AH%CJ9!&L@:18U
MV+YK!5W!E[SCW"247&N8Y'(-%"#<MU2*SD%D=_75$5%T!482L>YDHE59-8G2
M@V(VFF*R9URF*"X@5(.3=9=#>$4=OH*BF'571BVB7XWS+K;>IY[+44T^)FBN
MU)-=+7)5"??$*6 7*&J;XL"*.0R$)NM@ZKZY2KKDD?I^]FY1-%*E#7V!+@LT
M1:!9:&HCIZV)&B8'<PHYHO3SLR"T>J\E66&3U7L3-I2$*[D<*O2NUX>SUV,8
M-@YB<) 5!&)M[U^X9MQ*0[XZS>;?(.2O.H3MRII(EU7P3INGZ;QHZEEMMSHJ
MNV5?AW77 2RV*\6"DI*6:ZV.-*=;7U!4U%5#20M#+4)-%=*R.1*MD5U2,0C/
M^)KWB;P]M=/<*26"MCZKIX%IS66>Y5E1(M'=09#5V2.CCJ7[Q[)K9#/$5"M)
M*V6:S"0O^/H7L_$+O1(@7 '! %Y")8@J*72!Q3[\NF)Q*)B]9B 8"@8#&]PW
MZ<-XZ;A\L4][Z8A9O\-%11X7/'J"W)0KM@;CW)PQY[<-ING.I*WS#2V&^U8B
M*^:8:"LE,9;ZF\I 67<2=A*\\[2<:QI"^T5K&+3,A:*NV@DV@OEI]X9HC"HL
M *!A?*S*\F6.(SZ#%-ZL[@B'2)3=?2(#QAIK]T[5224K7#IZ=W*@O-9(V^WU
M2O=V# ]RVU%XYR,84]AODM;'0P6NZRW!I?(2WQ"9JZ2;G,:48@-0[@K@HD;$
M'"D D TP_::YR.]1Q ? /,*E%*@O<OO..([)'2*BR1DZ[\*+/! SP'1*D<K_
M .'@[V!Q.[%#?2IKD_B8+$(;2(H+-6>NH+&C2&F*;MJKN\F6<'=M($9P !G?
MQ@^Z_P!$GP^ITGZV'B5X8FXI)#9&L_ZXV6LI%B,;W(5BT,MPMYCD=_,@\U4*
ML=J_64#%4)\T\R39HLY5R_S&N44$E5E9]%$4XL4R$.=1\$HM(KF2;(E(<ZCQ
M0%>P5,ZA@,"?')A2VEF5UH+*KEE*JRF2<$, H!"J6?@;<%<G !'M[.'A_P"%
M,LZ01>'WA;&\DBQQT$DD'Q>]V"K3M1I21L\LC, L2H#*7"J?5G6MC,Q9INBB
MC9UGS+$V5DF"Y4GLLYL)6XK#T&4(E#M'JC43@7H$RX)D. =!3&.30*NFHR$W
M6VW]V]3Q;  0#C,LN#VR2!D=O?!O:CH/H+I\)(OAGT3;FJ&,8>GHX*!I-GJP
MSU[4JN%!'U&?:3DX!!+P57$_-#:_@]I@,,9CR0S=O$5V-^0ON,*\REA9N^P+
MGX9:\62ML8DCEVYF)Q>2*RZGHE'+)1%%1JFE>T]HMM321OY]%"\T<@$:B4DL
MI*JJ%+E'$2N.-N!DX 7U <MZAZX\)[-47"T5W6W0/2TL$ CGZ='3?6%SJ:+S
M(PQCDJ+%U1'9*J69&61!34L2QK(%F8OO)E1+X.YW[8V(S'%+Q(&QA=]=PRM!
M3+$=IG2$K5NCC@BK9V)51#U(#X0[Q $.[Q:TG23I)(ZP5DTA7=FD50QQC:-K
M7HANRD!F.X@;ADG'*HNO_ "V,U2.K+?,7PN;3T==+94 J"#)+/)U1-)L])Y"
M+(OH(!V\Y5>QSSWTMQ'UY''%])&MWS9=T-*OV/"U1)%V[(X=F*A*8\)*F."?
M<.]ZEDS**E5%!0A3;+7?HNKJI6E%M+)(8TE6K@>2=8T*G)\J[E4Y!&69AQZ=
MH&!0KNIOT<+U3SW!NI^F!<)Z6LCABNW3O54UU:9()?(/G1=1R6Y9))0@IY)Z
M9EY]4;^H&X618TU)$#'6:N_S@ "5>GK%'/\ 9@-\YU4;JB(-P !!5/JZ1,9(
M>GY UL<]HL%%F2FI(S.&*;:"HKQ4!2?7Z9>I7C" @;EV @@8 QKQ+35-\E<+
M'!+3 IE9KI;:&KHRHQ@!).GRID8$>7(2>,X))!UKDZY6'I!70&QE(?P5!:WW
MQ4!$OR=(J-K6X2$IQ#8]*IA #:-TB @%HU)%.LA07%$*-_9WHKI4MC:0R^?3
MWPQMN&6&TC;NVMAEU7:Z7BF<QR_1#^7@M+'8NF5P#ZLJL]G2;*@XY"\@[3C!
MTHZC3(=G*"J]C"MD ;+$!23E+1-MQ,8R>M,9R1D&9%>D#=*I6H+D#K!-0I3*
M +HZR6?Z7*W"AH[=2>1,_P 1<Z2>>)G#@ K2U%SN89^3RU$Q ) .3C6'O5\N
M%12)''4AY/-4@4=#;+8V #WGMU+32L,D#:TZCMZ3QIU"L8-J3MH"Q30V(]*$
M8B@@!M>3=(IH%$P@  (ALP@'U /'0*BV](4W J+*T(.X.G3D<$&XYP"SBF4L
M02<!?5SA>#C56FKY"&=JEWR!N>I#.!S[EG.!]IXSWR3I(,JO263H'4>PK#9T
M(*=*S>#:E6*4^^YHP)"81.(B)@ VS;$ $.-66W=+O+A:GI$LY<@Q6*D:<#<0
M-K&,OO'U1Z^. "!P,S4WF_5,(@GKKE+ "G[.2L9D!4#&07(VCL!V^SMG9.;M
MC>GF*QL9GI7;I/UB0Q-%N4VW%N8YT2]QS6(A\S16ZTC[0<+%<@3H4Z 2.0QN
MD]*4_0-'1U"7*.TR5#U+2!H+350J8V'I!%$8U+#G/F E3D*=NJ--8NH[RK36
MTTOEPD1O\;>[-;Y Y]0"1W.OI9)$QW:-&C7L2#D:U!I? R@"Z-7*^<5MKBH?
M'$JD[.*H]8G6%6#*Y*J;J$RH*Z6ZA$JH=?4'%5H_"P,SMT_9)1N)Q^IU>K,6
M)RWFR1*&)!.3N+MDG!!)U>+2]>*WE+<;DNP;-J]14CQ +Z<*%K&B*<87;N7;
MRI*X)R6MKQ R(8L/!I-RJFVJ6+H%I,03_H *H,XH"";I$.DJH=0A].D=C9O#
MX:2$-2=)6J- K!_*Z6N)"#)]06.543W8G8>&)(/),DEJZPJ6W556\K(.&J;[
M;58  <@25:LP [!>^ !@Z\[>;U$E<DN5D"B1!:JTA9$@HJ-S$14K3,Z13(+%
M(LB)2"4HI+%*JD("FH4#E$ ]8V81?1E%Y"+%3?"4ZP0HAC2.)8P$58&YB 4
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M._$%TP?3\QT6^H1S>>3RPA*F2C'Y))KZ.1QECKTIO5)D3**A@0.)TP+^;#I
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MLA>GG@DSY4L4@]<<F"&V,H(.UE8'#!E(SJJQ[8N9FO2BN/H"TR";BG1LBQ]
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MCBDD>XT\YF6G9S&-F\^9Z1WFLKXJ[PGZ4>5U)H;_ &NWU7EO!YZBE_6IH(Y
MI,@7X22D\L2A0RF4#@DEU+E5K?+A'B1W9H_T_J.HM6=10G5[@(;&0^,HJ?H
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M4R]:S=(RZJA$3GV9),7"IB$$H=TP_,.8CK%@I(Y%AHW,<0!$8!9F'?:O&1[
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M%=M$YCLRID/ZH&JP* "8E'W@H.54'V.23D\8]P3DGY@D'OSQK0VR7F)[O(Q
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MY^V/;OJ0U2ORR,".!ZB?_P#(?UUV&'F0,&BT#"@#[[_*[<CAKV$-#@K7G?T
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M+'T]]"KJJ3J+9 '!G[JT2I"IM2(&,*(,Q,J8Y-*$ H[J-(6&"!P<^_\ 4G4
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M_P 0\--?>(#M^+?S.FNH_N'[/\8\1TT']P_9_C'AJ [M]_\ 0:Y_P/\ P?\
M%Q)[K][_ ,SH>WXK_,:ZS_I#_)_@#B8=OQ;^9U'7=Q'31PTT<--<2^X_^_\
M"-PTURX:@>WXK_,:Z#_I$_V8?_WFX:#NWW_T&N_AJ.CAIKJ/[A^S_&/#4#W7
M[_Z'7;PU'7P/<W[?\0<0;L?N/\M-<2>X_L+_ (.(#N/_ %__ $0TU]_@?^#_
M (N)!]?\6_KIK@'Z?\IO\?%737;Q(?KK]W^NFCB?31Q2'U_Q;^NFCBKIHX::
M.&FCAIKX/N7]O^(>*;?X_P#TZ:"^P?L#_!Q.O8?</Y::^%^G^Q+_ (^(Z:Y<
=--'#31PTT<--'#31PTT<--'#31PTT<--'#37_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>g383050g52e38.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383050g52e38.jpg
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M 0            4!! (#!@<("?_$ & 1  (" 0(# @8*#@@$ P4$"P$" P0
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MI-@\]P63$D'97VCLS$5+ \'BE,W/&R% 4D*=1XDTTR00H;G;6HK4T"RZ7JL
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MWHF#>CT_&.L6C=AGL2RZ5<JRTTT1[5IM+IP=FJ4A3JM,8XGTYHJ\M60*6,D
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M1XG5E!SJU+HSV?JUET3..SVN)\#1<Q"6*%K\QN&VN1CLRP)MZ*M[L*,QUY:
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M !!X=8E"(6NO')>0 E[)#D%%96I:O )C&,)QY#4;"7-0O6TYN2U;L65YT$;
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MZU;$U8^(HM\!UH 5"1-@F8U=;1IRHTRFZP+I<L$6Q-UJ5I(&OJA)0,P%)9E
M[#"BS:"_;4^?FJW$>JO<JWY)TDM5'NNLLD,;B;VQL6;-Y;,;*8IX[+V["2QL
MG(T,K1%>7IFTO#^EI4LTHX&CK64IH8XY9$,(T^"O7I-7=6$D+UEJP/%(K\ZR
MQK)S<V1W]A+JY0@A3UNW"3L 79\?MW[,A.Q#GMJ/7",UU8]1!^,\H/X*%@&=
M7V^T4MFM1L"#!C S\K+AA#VDU^>7W?TFO!F45].6HU%]/]KEIH*(KR7(=1;[
M5S<[2^'5X+/;22O*6ACC9F@419U?T=I;*QGOM:6ZE_VP:VQNFPE26@OVTKR+
M%X%/-7[%(EC"RO(JK.QES\M=(-0M0=CJ3=AV\BDRDJW8*I2F=HV0:N:ELPM]
MCMGQ=DU.P*ZP=5)>OWJ)!F:RXZ?)BUD-)-8@1(^H2,E7RQXGU RPV##IWA,<
M?8SV31A:;4(#4>B\%\L"MB*:J[1S@(AG8B>5GL)',H<.4!%-!VM_P9Y!+!6%
MV98:$RVDNI-1"D-!)%9C62$EG$*AH8E2N[Q-W8;I5IF*>D),M^]6:U3\5MF,
MM]WM5P.FK;='-S5>@TFWR=BD76FV%FC4_6%&K-88BPXN(K,- "A1,6PWE>%<
M9.)=1D"HHJPP1/0>O5@KK%7K#39[5FND* DA6L7;4\Y=GDGEF9Y')VVS'P[I
MZ%G8VIIY4O)/9GL-)/8.HP5:UAY7("EA7IUH80BI'#'$JQH!OG;-Z7Z)E):'
MEI:#EI;,,%28QN-D)EY^)/C:#J/;.D(6/E0O5I2:(10-U7N/EFE+1[>66":K
M+;@#:5\4XDU2..1(Y8X^T:RY=(P)$>UJ%#4Y'1MSRLMO3:KQG;W"JZ]0QVY-
MP]ICNCR1/)V:5X^1Y"8V2K0O:;&CKM[I35U&TD@)]VS*W0J,BTMT5UI8M=1F
MIK/L??EIUY$R<.0)6K)M,^8'S!5]42Y!U @TR/<E2(F(=A(XB,G7CE;  *:<
M+$NK)1)+SO?'Q1=AN/J$%/2H+DB2!IX:*QMVLW:=K8"JX022"5U>(+X(ZGE:
ML0J@=,G#5.:HE&:WJD]6-XV6&:ZT@[*(QF.N69"[1H8D*2EC;4[LMD,Q)NMS
MS6>BPXQAQC#C&'&,.,8<8PXQE4NWW8>>ZV:R1>JS6J?<IGU\^\W5+3:[=6SY
MX"JTBT7N9!J M'UIM.=G+#\$U8Q]QM^"C*[7X)F9MMEL4=%0+S!M[A[1XM:O
M&K//8K1[0@SP05YDB>Q:@J1O8:U>H110]I.H&TKS32F.O#"\DH*Q->U672*7
MA,,->Q)O*1!-//"\JP5I[4BUQ6IW9))>S@8D&)(HHA)/-,D<1#( COK:6K?-
M*^Q52 M3QNVF-,,W2Q;=,K\\U9I3I=!]PXNP6*%>UP57*Y1A )15(L4UFYR9
M\8I6;2W$$!@/QA58<*P&O'_Q]E[[Z>=2-:'3UEB,"<22<.O##*+BS36F=/"H
M8_!HT<?:#(KL'$L\33BQ+M1K+1CO#3Q9FOM#*)GX>BU])IHS3:&&LJ2>#32>
M$2,GW\1LJE"H'^ZVZ+O*T.PUC6ZB+CK>_=B:I9M0U"X78.N[G73^LU.W=5FH
M(R^:SH-I]IE(*^Q2:L):M?QS#EM8:=8,S GB3O*(X:TVJEN&>YRUKM31[$.H
M6*]9IM-%C6[&F3F5:MVW!M'+4D[=J]MV%<D%>U1HLT#Q%J%EZTL%3FL4[.K0
M34*]BRL.H&OHU?4H!&UJE5GYI(K4?8K-54=N 0W9,LN-:N>D$G+N=IFYU34T
M8-UMW9M.8HM3WI<+7;8<0B#9M5&U[2I@VMPNK[*359+;EWE[\#JSX\G5FCV=
M%1J,8_?(J?VI @1D^;A**LNI5I]0=M:TRC':L:76@KRL)3!:MV8TGDO0K833
MZL51[W@JS6H#9L.*LD6GRM)NQ<4R6&T^Q!10:1J-UZT&IV)YXU,8GK5*TC0Q
MTIFA>_8DLK1\):&M,(($-I);T2)#J]Z1+<MQU;*[8JG5.1DZO*0U?N="D$SF
MQW<8HYET^+]M)N,0QI95DE+71:PZ-=YFK:2A]Q.O-HL%>8-P57&Y&=V9N$-.
MK7TT^QKJ)8CEFK6T[*F/^*6MVU85Y#J0@2O;G#58Y]2ETX F&9EY9BD6O%Q9
MJ%BD]Z#1'>"2.*Q5?M;AVK-8[*8V(UTTS//6A(LR0:='J!($L*MS1!I=G-!M
M8=\HE*O,<7!GQ]SJ5<M8)U8F';#6C0[%#ARXI=>GR(R%?G(,E@Q#T3,/0T2[
M)@+'-<C %OJ%:\3;KM5M6:KK*CUK$U=TGC$,RM#(T;+-"'E$4JE2)(Q)($<%
M0[@<Q]E5G6U6K64:)DL00SHT,AEA99HUD5HI2D9EB(8&.0QQEU(8HA/*);S7
MSOPXQAQC#C&'&,K/VXV78=7Z8=/J!*XZV7O9.DM(UN<0VRZNK2N_-R47335Q
M;04V^$LJGM7AZS1[)[#X!<E%!AF#OCD.-+M\/TH;VI!+"AZ]6EJ>IS1$D=O'
MI.FVM2-8E2&"V#5$#E"'5)&92&4'(^NW):6GEX"4GLV].TZ&0 'L9-4U"MIX
MG (*[UQ9,RAP59T56!#;&E\1VUVUKFS;DHT'3!MT2H>YNU!5;3?ML2=&$JNN
MNO6O-&SSE<'F6M>[*DY4R55>S,1."Q&$XE5+<E)) YI!X/HY.']/N0:;:ELM
MIL;:;H:S>"4$M-/<U>[JL(F,1N4DC6,5%[3E8_:QLB%E"/YV/7;U2;4:T===
M1=-1UHPBU>>L(*FE4M,F,*R"I<>1I/"7Y.8#W9)=]F++GG_2#W\<3:=K;TA6
M).B0MYZ\:UU.H+8EW)N]INO8JAZ;OM8'N]5KFE+<NN5R.A]L9<F)BG$[ LJ9
M.$Q7*_0[07)AR*^H<(U"U" ZG.EJ6KK%W4.>G56K7JZ/;U*I.U6>;4Z_;3/)
M0VCBL+4@*2]M-;@6-D':>*K06]/[70-6BLZ53H\MNRUF>QJU:A9@%F&'3I^R
MB2.]O(]=K4P>/L8JTS.KYD"^_P#L>.==S+]97*\/3J;KF[[<'M6QK'5;%7X:
M_=@]CZ$9+H%6L&EXZ6NHCGV/OLCUIRYHU(?/TV> 8EHNIV%MR)7P7A.FX'9Z
MV)C9LW*NGF"G#/#-+4TBEJI6W/#J3QU6'AG@4_@QU!8;,3F-YX3V@YMQ1;0G
MM-',8KUZEF^)K<L$T4=K5;>EAJL$VGH]A2*OAD/A'@#RUY4#I!*.0K3:??2^
MUBZP.WWZ'F*Z[TT'NQ&BQ4/L$N4OVV[%UVG ]<OYM="3K\:%H46F]0DXNL&H
MOMPEFH4M,O8:_ EY?AQ]VCPI5GK3:<+7::Q8;AER\E18ZE"'6(FN#L+?A;26
MW\%EB[=34KQF1>2&69>60Z=WB>U#8AOFKV>E0+Q&BQI:9[5^7295J'MZW@@C
MJIX3%(86%F>01MSRQ1L3&&%9^ZF\)>M2-#A.NK50W9+5/?=B%5<M@;$U]KP>
MA:<I^K9.8V)2K;=.N\'LBS22IK=54KD'69+2E5]IL5=O+SLVQ6X&/L,]IP\-
MZ9',EN36#8TR.?2H6\&IT[=PVM1L7DCJ6:U;6):<"=EIL\TDR:G/M#-5 C,T
MKPQ;<W$.I21-5CTD0:E)!J<R^$6K=6H*NGUZ3R6J\]G28K<SF748(8X7TZ'>
M6&R3+V,22RV#IN]9.LZBZ.OV,$JW3W8G[&%"F)\J52$3'34SU\NFUY"VF(S'
MEXF7C3-?OQKL>ER,RLB>Q(8.Q@'V(R38TM)]0XG$++7BT?PZW'$L?,KQ1ZO6
MH)77W:]F%6V'#[/LL7)R^ZYEJP:F\-'APRJ9Y=6-.K)*TG*R22:78NM.PY&[
M0LU4H4W3K+S\WN>5J]8])(Y&CQ=LN&EU5+5TCHC9.Y@;65=YH^9N<IJR$VO9
MK;K35T6'J[-+M5SAJUK%NP2,%9=E4*UO0=@<GJW4K+7ZO898:O\ T-#EX*^I
M>$7DU6EIKUQ5B2.LEZ33X:]V\[7O"8*\D]XPI+#2MUQ+#V4UB":>&-I7]+B@
M2>?3NPI/IES4$F:S(TMEZ,=Z:>G21:7@\]B.&D)7BFN59S'-VL,$T4,L@M!U
MVWQL7==7N$C:-+$ZSL<"F*)K8Q\IL#-)NH-AKZ)>)(BK5?=-ZMM&,@R*28*T
M/"ZXDXN->99/@92U!F,YQ#UC2J>FSUT@U(789>T68K'4%JL\,QCD62O5U&]!
M[I.66 -<1W!*RI RG+.DZG;U&&P\VG&G+%V;0AGM>#V%FB$D92:UI]*;W+[Q
M3%:CQJ0&B>=6&4WJ?>K>LQK/56W#]%M3MJV/U*C>PT1I[66R)&U54VO62^:-
MB4V28=1UX(VT+9:G6=BSMFFZQ0Q-B9'@8"7@ZY6]G6Z3@2P/1V.%]+CNW]/3
M5.R@I\0/H\FI7:203K-#5U20PQ@ZN-/:">>G%#%/::GS2RQRS3T:Z2JWGX.)
M=3DJ4KS:8)9[>A1ZM'0IW'G@:&>SIJ":3;23?6:"&W+-)#6%O:.)XH8;L\D3
M+*;?Z1J1IL-9[6=JBG'4V*ZEV'LS2[/&;=LK\/NB3J6M9?8MIHVHIMW1[%6G
M@JVW%?!T[(3]BJ^S8X MFVNZ3S6VR#&NBOP<EF6"NM^REF37X=$LP2:? LNF
MI8NQTX+6H1#5&GB:8N7B2&&>B[J:XU/MBJ'NL<6O7CGG:C7>O'H4NL5IH[\Q
M347@IR6YJM"0Z:(95A"<DCR30W$5A.=.[$%A-MO=[)2A;+L.G:7IM^^; C]F
M#T" '>G[NS"S8@^@ZKO>=FCEZVT[M^WQ1@@5L"K<1# 4FPL21#3\[*S=<AAS
M7 ]73^%TM4H=1LZB*E1Z1MS,(:QEB8ZK/I<42BYJ.G5Y%9H'FDD:S"4!$213
M2%0VS?XE>K<ET^OIYM6EN"K$#+9$<JKI<.IRR,:FGWYT95G6&.-:\H=@9'DA
MC#%6!HC=-GMN]MA4&P15HA(RQZ ZY]H*O5[FQABUZS7N%S9%+N&JYYC"EY"=
MKDYJ<:<2(Z\4L:=M-KC17VXF*C Q=35--@KZ54MPO!*\.K:QH<\]8DU[OM<*
M5FO>B)VYA-%?:+F"J&BKP.RF221FVM,U&:QJ=NK+'-$DVEZ3K4$-D;3T_#S<
MK6*4J]>0Q245E"DDB2>= 0D:*MSN><ST.'&,.,8<8PXQAQC#C&'&,.,8<8PX
MQAQC#C&'&,.,8<8PXQAQC#C&'&,JUVJOL]5(?35-KAQT,;O+L%KC3A]AC"7@
MI*"J\HS/W.ZNQD@,MHJ+E9JG4:>J<1,AOCR,)*V(*8BR&I,$1>+FA5(K$FI6
M)D61=+TBYJ*PN R2SH8JU8.I!5XXK-J*Q)&P*2QPM&X*.V1=;LRP1Z?7A9HV
MU+5:FGO*A*O% XEL62CK[J-Y*]:6".12&CDF61&#JIRA$%WBVUJNG;E(72X[
M;@FL+#Z1K>-PG;GL^9KDW&ZCZ[=S=B486BTL%BB7!F7E8VBI%CJ>#*2M;A 1
MH$")=,'%4VXUZR7A>A?L::!9?3VO0\':77BK48YHGU#6.&Z=IK5ES:KF.-[1
M9[+)'-*[2O(%9MP?+P\2WJ=:^372^*<G%VIV);%R2&1:&D\0W*PK5U6K8$CI
M6"I75WAC58U0L%ZAM3_>+=%6-NH4CIW7<J[(]NY;JQIAN!O&RI4DXNOZ]L^R
M)FP;)C8#3=CF8[S5RI/Y@@Z5&6DF7L<Z!72Q86*C2+D?/AX8TV=:[)J-R,1\
M/1Z[J1FJTD55FMP4XX:3RZE#')]NL#M6LO L<,3S*TDCK67?EXDU"%["/0J.
M7UY]$T_L[-MRS15)KDDMM(M/FD3[3 W9K62=I)9%B98T0V'R4?WKV<18H<>7
MZ^1=4KL=.=1ZGLX>?V7*,7ZJ6KMCL=_4<9'P%63K5,;/1]'NJH\J5.G+%4)*
M4K+[I3<#&2[2XAOK?A:B(9&CU=YYGAX@L43%20U9X-!IC4'>:?PWGB>U6#K&
ML4-A(YP%,KQD2'FO$UPS1K)I201)+H,%T2W'%J"?7;9H(D4'@?)*E:R4+O)-
M7=X26$22 QA 37?S:T;;*1OF1H,<-JF^==[)*:EUC$;)L\N98)R]]J>LNDJ#
M8]QQX.M5L4:>KR]BH*L =3!V9,5F,E[96PV9>;C6F)VM'PI0>O9TI+;F_5U>
M%-0O24H8UABJZ%K>IVX=.=K@:U%,*96%K#4HYY(Z\S&.*0F*7)Q1>2>MJ;U4
M%&UI4ST*<=N:1I9+6MZ-IU6?4$6GM6DA\,#3+ ER2!))XE$DB 29?LCW4[#2
M77?L#6JCJ034VW*?U2[)[8M]FGMB7&GD5& I TY6:M<=,,$ZM$NMELTEY6;L
M"#;H+6?Q0>;AHF5DG'IN.F,=>B\-Z0FL:1-8U!K^GV=>T:A7@BIU[ L36C%-
M/6U(B\U:"!-S69Z\MWP@&22--HGCSGJ_$6K/I6JP5Z*4;]?0]7O6)I;=B P1
M5A)#!8TX&DMF:9]A859XJ?@Y$<<C[RH^;'=H;LSK6_:AI*X%F38V@)M(AZ8?
ME_@[$)G6U"(NV$8&R 4@_,N@9T1Q2B@_8&D.&X27AM3//'4-,\-J:A9$I0T6
MH*(Q'S]KX;:%;??G4IV98,/<MSDA?<[@YZZ[J/@=JA6[(.+HNDR&3E[/P.JU
MGNY6Y^<*5.[+RC=O=;;91%?I,K#"U:0OETTA&5BLF]7J#V"UL*1?+.3+[1D+
M?1=96::A*Y(A:H*IK$%KZQ[(35[ZZ99L;(K\+$#;&:U=*U.Q@."^J_H5#).M
M2MJCSSIKEO2+K"I L=%*]J]!%+,C:@MDRW(:1GJ*L'@4TLC4S?CL0N#YD\82
MQP/:L::D,+:+5U6F#9F9[KSUJ<TD43+1:N(JLUL0V2T_A<4:+;%)X)D*VDKW
M8?:<AUVWEM.RZ@#J&P=/Q]^?CJO+3%PCZC>L56A1UZAYR+D[1KZJWV+@)5J5
M1!G)F]> 2(DW$32(YJ7A/@B?E(4ND4%UC2Z$.HO8IZ@]0//'%7:Q5\(M/5DB
M>.&W/5>:,QF13%<=&BDB+F.7M(8[46JW6TK4KLU!(+5!+12%Y)UKV>PJI9CE
M1YJL%J.)PXC82U$=9(Y.021=G-)623[G;YJ(,U89;4\+:;?']>>JFU+95JAL
M"QS^K*=7MP7_ +-A3U^BPH71<ANB6>@*AK"&FKM'0<)=R?8WA1H"N,@TNP7&
MYVTX;TJP\<,=^6"N^KZ]0KSV*D,5^S-IU31&BJ.TNJIID8FL7I(ZSRRU1S!C
M+,7LPUJT:3B'4ZZ23248YIUTK1+L\$%J66E7BU"UK"RVD6/37U%S%!3CDLI'
M'9;E($4(6O+8L2Z=[^V&M6>\1\SK*F,UR.K.JK=JN8#V393L[JJ-\MFCJ?8[
M]0I9.J&:++4FE3.X28Z:2/<57F'(A*J;9*1"0FS823BM>+A.&:"J\5ZRTSSW
MZ]^-J4*>UMBK!JEB&I;C\/-J.S9BTY9(B:_@L@EL)#9DEHRI)WR<4RPS64DI
MUQ"D-&>C(MR5CJ->U/IM>:U5<416>M6DU I)M8\)C,<#35HH[L3IU=C>D#N4
M%?YS5^MM#YV+=82U;Z"9C4V6W-M6&N:#"TVN6:AG*CJZ\OCW*T2VY(N,CPIP
M:+IU<8B2Y&SW,/)<<$5RI\)5I:D5Z[JO@=:6#2F+]A78PS:LVI=F9!8O50U:
M"/39'=XF>Q,9%2"LW*[+BWQ38BM24J>F>%V8YM4 3MIP)H=+73^T$9@I62MB
M=]0C1%E5*\(1GFL+S(K6'Z][*G;#MGL[K*6)EY"+H-KUS=J63.NY(EX>K;NU
MW&W0BE212GRE$/5BZBW-V+:P2XQ#569K=9!3B.@@W'H^K4HH:&B78UC22U!<
MK65B'+')/IEMZRV479=A/6:L)"5!EL1S3M[N5@*NE7)9;VLTI#(R59ZEFN92
M6DCAU*HEAJSL2VYALK8*#F(C@DAA7W$:DVUY R[AQC(9=MCZ^UK'C2VQ+S4:
M+&FD^Q!'6^QQ%<&..RC*T@@NRY@B#3EIQG+80N7BG?DPVTK.<8SLUJ=NZ[1T
MZMBTZKS,M>&29E7?;F81JQ5=^]FV4>,YKV;=6F@DMV8*R,W*K3S1PJS>)5,C
M*&8^)5W8^(8LL]HM(?.W;),A&<8RA\2B;"-%=3GY4N,%B51X8AI6/E0ZPZXV
MM.<*2K.,XSS>]HM4_LZ ^,-;IJP\Q5K 8'S$ YI>W6F_VACYQ7M,#YP1"01Y
M""0?%G'[*/27^,\W^;O97ZH<>T6I_P!1%^>4OK./;O3?Z]_S6W_H8?LH])?X
MSS?YN]E?JAQ[1:G_ %$7YY2^LX]N]-_KW_-;?^AA^RCTE_C/-_F[V5^J''M%
MJ?\ 41?GE+ZSCV[TW^O?\UM_Z&'[*/27^,\W^;O97ZH<>T6I_P!1%^>4OK./
M;O3?Z]_S6W_H8?LH])?XSS?YN]E?JAQ[1:G_ %$7YY2^LX]N]-_KW_-;?^AA
M^RCTE_C/-_F[V5^J''M%J?\ 41?GE+ZSCV[TW^O?\UM_Z&'[*/27^,\W^;O9
M7ZH<>T6I_P!1%^>4OK./;O3?Z]_S6W_H9V1>SV@2"A0B]I5BN%GOM"QP]W>*
MH#LH6^YAID2*3=Q:_F4+=<5A#8L?[2^O/]ZWGPSX<6T/5E#,M&>94!9S5"VP
MB@;EI#5:;D4#O9^51XSG)=:THD*UZ"(L0J"RQJ\[,=E6/PD1=HQ/<J<S'R8]
M\9QG&,XSC.,XQG&<9\<9QGY<9QG'R9QG'RXSCY^2LIYSQC#C&'&,.,8EY_L/
MI:N3,A6B;_$2]IB'\C3%2IC$GL&WPS_EPK#4S5*(!8[#$J4E6,HQ(QHWGQXY
M1E7E5X4H='U*:))UJ21P2#FCL62E2O*IWZQSVGAAD'0[E';;QY.EU;3HI'A-
MJ.2>,\LD%</:L1MMOM)!66:6,D=P=%)\6^8?]DWJG_B;4_\ N?=__P#PRYV>
MTE__ / _I;2OKN</;BEY+WZ*U7ZED#V!LGJYMB,!A=I:XG-D0\7(+EHV*O?5
M/<5MC8^4<C9"&<D0@I_49XPQKD1+2D4X4RTAYR-DCP5K4*80TYM5*6N4'>6C
M<CI2.@C>2KKNGUW= Z2A&>'4$9E$D<<@4D@.B.!S*I&K:MZ->18[M.6W&CF1
M$LZ'J$Z(Y1XRZK+08*QCD="P /([KORL0<0+:.GP,.FO!Z<<%@$28TTF$'Z?
M[59B<3 =#'U8)+?!R-.)$S)C:Q$%UTP?EG);5%&8J2'4P#3<>GL:#B%Y#,VH
M\TI1HS*W$-$R&-K1O-'SG4>;D:ZS7"F_*;3&P1VQ+YP6;05C[)=/*Q<XD[,:
M!>$?:+5%(/R>U_+SBFJU VW,*P$&_9#EQ>S '4P"C7&LZ;H<AH6TV2"GXN%V
M/K?IELV*L])F)^GXH;EPKRP=0QV&[/'59+$7&GNO9P@8($0MLR.'4 [N1OK[
MVJ\^HVEU6"&6&26G<XCI20VHX;/A8KS<VH/O \^[NH'W3,RE7/.-21-#6M8A
MT^K)IDTT4J1VZ?#UV.:O)+7\%-B(K03:9( $1B>Y55@RCE,G")Z6!Q^H8]S3
M9TKC0</!P6FI">ZF[@GIG6T=7!HH6'13YJ6U$7)P+X>(2((03&E#/Y.C 3U.
M9,$'>;Z&7B1GU!QJ*I[:R2RZBD6O:?%'=>8NTAL11Z@J2ANUD!5U9>5V7;E8
M@]RGAY4H(=.=_:N..+3VET+4)9*:0JBQBO))09XBO9QGF1@>9%;?F (PYT%Z
M/Z35<W)'K-5SG-C2+4O?W"NC^P'W;K*L2#LNS)VEQS22ESQ[4L^1+(,DU$D)
ME"")'#F#'WGE]BR\6H*P36["BFACJ!>)ZH%:,H(RD &I[1(8U6,K'RKR*$VY
M0 .#1<+.;!?1H6-M@]HMPW:)L.',@><G3?MK"0F0,_,><E]^8DX^(SL1I>$C
M8^&AHO8T1#Q (D9%149URWN!&QD: .V*#'QX(NKFA0@0A6FAA!!FFAQAVFV6
M6T-H2G$I](U*5WDD>G))(S/)(^L:6[N[DL[NS7BS,S$LS,26)))).4TU73XT
M2...Y''&JI'&FD:FB(B *J(JT@JJJ@!5       SO?LF]4_\3:G_ -S[O_\
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MR!1#O7*O$,TJS2ZO5DE25YDD?B;1F=)9*\55W4G4R59JT$-?W.VT,4<8V1%
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MF4!@%8E@ 23G=5M\.T8&JTHZU2LQ9FKUJ$D$+,ZA79HHZRHQ9556)!)50IZ
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MOF:A3YU]9]AJ]:F2<!, K-F82+D7\1P<J'/C!K).&><P$+.1L?-,#Y7ZAB5
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MFC-3CDS9864D ()@ =-^A\?7;IU\W3N'R[CNWR,R/??;%,LJY(_9.BX[5,A
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MC-6Z!)GCA&I_#4=)Q,,*S(V/?L.H\O4>/R_Y9^NMW8KM'M/L/OJ.A]AU:ZP
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MM"]1U<[MV:#S9KO90KB+:-3V;L[>-7P-C@6JB.%*U:9J>FB:=%Q]-L$O/C)
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MI]K$&*]F>20/[2PT_P"H(1_>/L^M0KU3R/\ @NH\JT_N*QQC/F]&QQ#+0Q
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MX<8PXQAQC*_=3/P5NL_Y/VFOJYK?*VO_  [K7I;4?7)LE:%\!Z-Z*T[U2'+
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M(/K_ !FF8461"VA7NQ 89=21L6X7Z#I]2DK C:YQ=BFHN5UQB$?D_+T_?O\
MJS(Y3M^0;=?R[^+YO-W=<F\W5/27Y@G6H/.\\9<C=B-]?&']@=8TVC7%T<NJ
MUZYEN[Q[TX[$;*UV'7/84+B]+F;'L?Q.Q8@K/'6+9I%>LH#'N?YWZC;Q>??R
M_LZ8TY72W;)A>K]@3EP['W"4#[Q[KM&Q=94/;NMJZPUUB^,O;J(T$-7A9&P4
MNN&UYB'NG7B?N=6F+B58B:S!K:-B"K;6!8)ACW/7N^Y&VXWZD+O\W7;_ 'Q2
M4K77I'ZQ!ZGK6 K_ !-C@*3U[BH\NM6_KO'=>ZI58>@0(78FH[1J+<HU?)S;
MLU9Q[OC7%BUU"3-&BB3=3O!66LPD1LAB68/+U_+Y=^\[;>+;NWW\AVSOQNM?
M2+U%O3C"Y?=6P41E^ZYVJ\QYNR]0)$E,R6MJG#=B@;?<EWRL66&J56O2)^X0
M,%5JUM"NS)S$Q6HW7A4%/5N?J3'3KW=WG[^OF/3;R['?KOY;'=I83N3(;@CR
M-'YV(NHYI>MV=;G4FTZ=@M>5#:P^R+0_MB:[,P>P9 *\736DQK9Z@1U9BM7Q
M=PFQ?@_8V!8NN6N0I]F99CIMY^O?OYMMMO&.O?TZXYNDNG+'H;KE4=;6_P"&
M_C+'6'9DS+?&&P!VB56[:]G7"T#%%38!!0QCL@#+B23RL$NOI?,>29E)F"&T
M,,022.[I^S+7\9C#C&(/3OTA]K/?Y7?T7>MO*VH^\] ]$S?3NM9*T[WWKOI6
M'Z#T;.-4_2MV?]YM'^HC5/,7_>&B?B5KZ4OYRH^_=9_':_T90Q^\E93PXQAQ
MC#C&'&,.,8<8PXQAQC#C&'&,0'6KZ.K'[_\ MA^E-N3E76??</HK0OH/3LEZ
M/[TF]*:Y]-:AC_Y*RIB#[6?@N]DO<'N+ZO+%RMH'P[HOI;3O7(<E:[\!ZSZ*
MU'U2;'YR3E7#C&'&,.,8<8PXQAQC#C&'&,.,8<8SA7S9_@S_ #<8Q#=5OP7^
MM_N%T_\ 5[7>5==^'-9]*ZCZW-DO0_@71_1>G^J0X^N2LJ97WL9][FMOR@M
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MSPX!*VT.8$*<;VX:S2,H*LB[G=^4$'HVW*K,G..;E4\A.S/&#MSC?5FG6)6
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MC\BJY8GS $GQ#'M_HWQA /.Q=0/E9E  \Y(&-ND;)UWLR.?F-<7RF7^)%?\
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M)3A2EL+7[.E3&"5!^5CKX]UO2-"?3Q+I=.N;+:@P\'ILX85S5+<W95H@ HE
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M23.A-KL]R1MH=!NO&P9OK'<ZA0H^KZOZMZ<*N-FLIC]RC;*.,&#!"Q#X;$M
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M*:YE41<[&L5E3=.WY0R!ET+&G:CIC:2L;5[A.J2RR2T]#JU%KQC3K*JS+$+
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MY*G6L)PKS+;SC*D)QC/BM.,>&>>1U($6B#T(AK;_ )O%GRBH=X-QOUEF\_\
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M,\9PS]<8Q =:OHZL?O\ ^V'Z4VY.5=9]]P^BM"^@].R7H_O2;TIKGTUJ&/\
MY*RIB#[6?@N]DO<'N+ZO+%RMH'P[HOI;3O7(<E:[\!ZSZ*U'U2;'YR3E7#C&
M'&,.,9#K]1H39%4DJ=8ER+<1*NQKI2XB0?BI)"XJ5"F!5AR8N4E@/I, 8RDP
M)Q@X;PR\"4(6ADEIC%(UUHJK8\B$N][C? /?9<9%<V7.(5$L,Y3X!Q,B-ZB8
M8;REMIMLQ^1)E@T-Y^#Y$-1!BB<;?+\_ES._R?,/W9U'^JNO23&CW[/MUU\<
MWVX5+FV+HX,([ZDD;+0H3DFH,<58Y*T.C-L):?=Q@U]+D@X^6]G&_P GS#)5
MKO0E.UE(#R-?FM@'/#(DD-LV2^6*P!*Q+.9>.4\%(F.#/N.O>1_UCS:UX);2
M5XY*4Z\XS!.^.WC&'&,.,9PKYL_P9_FXQB&ZK?@O];_<+I_ZO:[RKKOPYK/I
M74?6YLEZ'\"Z/Z+T_P!4AQ]<E94ROO8S[W-;?E!:!^M2L\K:/]^N^B=5]2FR
M7JWWFIZ4TOUV'+!<DY4PXQAQC#C&'&,.,8<8PXQAQC#C&'&,.,97[J9^"MUG
M_)^TU]7-;Y6U_P"'=:]+:CZY-DK0O@/1O16G>J0Y8'DG*N'&,UL:9SG-5L6<
MYSG.=R]B,YSGY<YSG?\ LS.<YS\^<YSG.<YS\N<Y\<\^AW/NZWHS1_HFEG@Z
M7WNQZ2U?Z5NY(-D['I>H:%;=G;%G1:S2*/!G6*RSAB7G&@(P!K+CJT#C-O%F
M%/*\@P( 3!!T@:\.$$.^40RROC3IV+]J"E4C,UFS*L4,8(!9W.PW+$*J@;LS
M,0J*"S$*"<[+=NO1K3W+4@AKUXVEED;<A47R  LS$[*JJ"S,0J@L0#3+7'I%
M=;7:[:VI]MT[V,T8'NLI,?I>\;LUS'56C[,EB!/A"+@X>7B[1828B=L$?C)]
M<B[3'P3\T/EEL/*SB1PG/0V^$[=:M<L0:AI.I-IPYM1K:=;>:S30-R/(\;P1
M"2*)_<S/"T@C();W*LP@5.*:MFQ4@GH:IIRZ@>73[.H54AKVW*\R1I(DTI22
M5?=1)*J&0$<ONB%R[4+>J39#'8ZNW&JST@P#B3?!A;#$2AC,:HET),@Z*"8^
M^V"HQEX3!:T88R2TZQASUK:T8\Y)6LPJ'EKSQ(6Y TD4B*7V#<H9E +<I#<H
M.^Q!VV.>ACLUY6*13PRNJ\Y6.5'8)N5YBJL2%Y@5YB-MP1ON#F/;VAK-V#DK
M.UL2BNUN&-^#I>PMVV 7!Q4AYT-^P24LF0R ";ZQUM'LI1#3_G<0GU?F6G&>
M1I7!(D)J61-(O.D1@E$CI_U(G)S,O_S $>?. NTS&\PMUC#&W*\HGB[-&[N5
MWY^56WZ;$@^;*V;Q[N:_TQLG76GXNA[/W7LO9U2DK_7*GIX"FRA2Z1%/Y'?L
M/M]QNU*AY%);C9.(N,@I&6ECTB/NI":'RP\_8TWARUJ%2W?>S3TZG3G2K-/?
M:P@%AQS"+DKU[$B<H*\[R(B+S <Q.X$G4>(:M"W5HI6MZA;N0-:BAHK Y-=#
MMVO-/8@1^8@]FD;.[\I/*!L2W*7OFNVR0NPDI6[;K@*B5[6EBEYG9C%?JP&6
M=F5Q5C$C5L*L1DK#S-7PG$+;@+-'0>0)U> XUV692X4C0LZ7+ E9DF@MM:EN
M11QTS+.V]*;L6<$1*DD<W66!H7E#1#F?D)Y<WJ^I13M8#PSU%K15)9'MB*%=
MK<7:A".U9XWA^]SK*L?+)[E2X'-DO5MO5*0\2"MG:]2 I"W$G*NE;P&IMLL6
M/<7@G,EZG*$'G!!+5A?E268*,K.'B&D+U_ ;W-R^!VN;NY?!YN;?E+;;<F_W
M*LW=]RI/<"<[_#J07F-RJ%(W#>$0\I 8(3OS[;<S*O?]T0.\@9GG+E4&K&/3
MW;76V[:6(H\2K.3D6BQE H;6\LT>$45B3>$2TVMU1#8JF4MH6O*\)3G..L5[
M!A-@03&!6Y6G$3F%6W Y3)R\@;<@;%M]R!MUSL-B 2B SPB=EYEA,B=JR[;\
MPCYN<KMUW"[;>/(;1-Z:<V<%F0H.S*5:!?C),U%M4788UYQ^Q0,Q.P4A&BCJ
M(004XJ1K,]\'.CM.CS 4:1*1+IL9Y#%[%G3-0IMRVJ=B$]C'.>>)P!%+''*C
ML0"%')-'SAB#&SA) K[KG16U*A<7FK7*\P[5X!R2IN98Y)(V102"V[PR<A4$
M2*A>,LGNLDCFQM>LLMD/7NF-#O-./M/N6B$;9=89FFJV\\VZH["%M-6)]F!<
M<2K*$33S46I6#G$,9Z13MDD"K8)!V($$I()C,H! 7<$Q R[=_9@O]R-\[3;J
M@ FS7 ()!,T8! D$1(/-U E(C)\4A"?=';,+:-Q:UJ,/;IF2ML09BC.1XEDB
M( IJQV4&7FCQXBO5W%:A5FS;MDLLV:#!UR!0%F3FYDX.-CQGRB&VU=L&GW+$
ME>-*\B^$AFADE4PPM'&ADEF[:0+&(88E:667FY(XU9V(4$YUS7ZD$<\CSQMX
M,56:.)A+,LDC*D4791EI.UED98XH^7GDD954$D8D-.]S-:;CL<;68^)F:X5/
MK4/6#SK1J*YPLY)XA3[,BO+E-0;-V4+7;,55XF7LL7"VQ4$]/P<--FUMR9Q
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MLV9K,+M)$LSHO.P$ATK7!UV32J>FK[46F@CM%;%I;L,U">S9DG5M.FK$OV$
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M#M5U"Y,(8HI*LZS]LW)$X[6LR*Y*R$MNO[C*_<,G5U\V%;"]3)U9XY@=E9#
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MH4.780"$-$9:RROU/"VC5=4L7;&I"S[5Z93:S;-0;SR22,(JL$7N'^V22%G
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M9&.S*8]PP!W7<$D$!MCN1MXP.[-KO<STB-0KOHM/1;;9D>@71>U0NY)#M!)
M:3FM:VL'3VISZ#LQJJ9(U75JS<85J"5:6YJ0E;9\+2!HY\@04\PIE9*VWO+#
M2X9+.H06YIS/!-!&@5U:1NT$CS/(63>40K&J$PG?F=95!KK)+'B].AK5XYJZ
M2QVGD5U&P$79*\ZNJ]JDS,#$.4UA).)2DJQJB.\>G%WTLFL'VUM%^B@]&N^D
MM'F6AW7FV'&W,8?R_E!'K=P*QY5/IP0IO'G2M_&'%XRZG/DM)HD36?!5NV8I
M3*BS]J:L<9_X;>+F*AN5^5XXGAD5AV8;G;I&C3(*NEP2(]71].KM4DW1HZL<
M1C8U^R$M=HALK+ YKEB$<0L\8(BZ2?)'I5=4^H<4WZ)3T:*1V4LCKPUK7;#:
M$+6I;K32D(VYA.5^<=;N/'[M2FE+2I64+4C+:-3LA$?4YGAK0)X,HEB4JQ>.
M.1(84K;,Y60GD1NTED<<SL3(R]KV*$TL0EJTI9Y5EFA65>:1H@J03RH7+$1=
ME8AC;E 4B=4<+VF;?O2 ^DPJ^G.M?HOS"/1X= -LP6S^HK.Q(.I;?TS*WBN:
M>Q(3;,:34M5,2EH497ZJ2S% O/AF%G&$OB#+(.=]0WA,^IIL,LNHP1:C9CAA
MM.B)VIB>U&GWN9HR@)(!;F+HBH9(E#!F"FH9TBCK((H5+QEDC]SLJ@@,(QS=
M$4LH'*=EYE4A>@S5RWZ:6B8RWC/HA/1()]7YEI\O5YQ&&E9RAS"O'%J7E'BM
M.%97A*O!?D^92?-FU!IO*T)GU?58V56=#%:D'@^XAD4S%*TTD!:5%8M'%,H;
ML@6YHF8ZYM;<Y-:$CN79"Y9=^4@@[=1OW ]5#$ @';]8]-#1\N(PCT0/HE//
ME+F$>'5TA2E^T95[1ZO*;.GRH>RI?K,?+E6<J\^%*4I.-P:*QD01:GKPF)=8
MT\*L,\R6BPMO"? (@D,Q[;MG)9FYPTD+OVL:\O"AL28*_>/^3;JO13L3U/0!
M3TZ#H2.4G^D3USL+5MZ]Z(M;$! U1FS::UA86:O5@O@VL5MJ:I$')-P%<CO.
M[[! PZ"<1T0%ZQSV6/&'8\Z_5^;/S.RG9V+$>Y;DFE3F8AF;E=EW9AT).VY(
MZ$]1EA#S(C=VZJ=AT W /=XL<O.G.65^ZF?@K=9_R?M-?5S6^5M?^'=:]+:C
MZY-DK0O@/1O16G>J0Y8'DG*N'&,UKZ9^]2P^^3L/]?VS.?0[GW=;T9H_T32S
MP='[W8]):O\ 2MW&QS4S<PXQAQC#C&5KV=U'T)NO:E8VWM^AQ&SYBFTN6I%:
MK%^ C;;KV+#G)4>6E)IFDSH!T,Y:"EB"AYG'VG2&H\9@=E+:FD.XL4M>U33J
M,U"A9>E'8L)9FGJN\%MVC0HD9LQ.L@A4$MV8(!8DG??;)-S1--U"[#>O5DN2
M5Z[UXH;*I/519'#O(*\B,AF) 7M""0H &VV^)69]&KUDDZ9>]9QH-WIVK=D7
MV3V):M74FVNUS7C\U-1\7&2PD951 <QD%$%#PT;D46%:!?@G1_65LN&]<_AV
MC'QAK*6*MQVK6+M.JE2&[8@[:T(XW=T9YV?GED#._,TA82[_ &Y9-AM/DX2T
MEX+%1!9@IVK+VIJ=>?LJIDD5$=5@"<D:%8TY1&%,1&\31DG?L[ ]'#UPVA/7
MNR7;&QIJ5O54%I&7W[]*_P#@I5@KI5K^)!U17J\NL18EEIE<?#CIQV>CP8X!
M4("*-#EF D8J\7:O2BJPUO!(TJSM9V%5/M\[5YJK2S]=B[16)0SQ")F=NU8F
M0*PS9X4TJW)9EL&W(]F%:^YLO]HA6>&RL<'3<(LM>(JDIE557LT58RRE76/T
M;52<OFCX^MO-R&E:EV2MO;3:H>PK1-VN[SNVW(8A%3CZ>R5"OQ055FK9*&6G
M9+9LN*Y,KBH8# <BQE.8[=AXOG%74GF!349])@T.DU2&."O'1$@,[V&$G:-/
M%"BPU"L9[,22-S*?NM.7A2$V=.2$AM/@U6?6KJVII)K$MTQD0K #&46&29VE
MM<T@Y^1%Y7&W+M&YXK/8X<8PXQAQC$KV3_!TW[[E=I_U&G>4-)^%=,](4O68
MLGZM\%:GZ/N^K2YLZY\WSZ!AQC(];OO4L_\ %Z:_HTGG=7]\0?AHO\:YU3_>
M)OP4G^!L@N@?H(TI[I-;_P!3H;FUJWPKJ?I"[ZS+FMI?P;IWXC4]7CQM\GYO
M8<8PXQAQC#C&'&,.,8<8PXQAQC#C&'&,0>G?I#[6>_RN_HN];>5M1]YZ!Z)F
M^G=:R5IWOO7?2L/T'HV<:I^E;L_[S:/]1&J>8O\ O#1/Q*U]*7\Y4??NL_CM
M?Z,H8_>2LIX<8PXQAQC$=L>V;Y@+$(/K?4%4V%5G!(=TV4DMGMTR:'-(DI!F
M:#9B"JM*B/LQT6/'FAFJE6LGE23@2A!D1RB2V,A!&R^UOL,*X-U=J/PF6]*9
MF0WNPD3D"+$&8B$Q>$2:-?)(*+DBI,Y:VV8EQ@,6M2:7'UO24-DEC+3XSG.,
M9SCRYSC&<I\<9\,YQ\N/''R9\/F\<?)G]SC&<\8PXQAQC#C&(#K5]'5C]_\
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M6,T@?*A5'$8>4MT<5UQ8J<(%2AI1YGG]BR[ZM@=MS""'WEY<(55GCNUHYIY
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MUJ9B(?5%PLUOU1"=8X=E&C;H)M(X4&,L6PK!*BV^F/N8DZU'%38484RSGTV
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M&99-I 9U,CKVAYW9"$96A!A5%^UD,&D#L>SSEG7AQC#C&'&,0'6KZ.K'[_\
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MGN4VG_46=Y\VTKX6TWTC3]9CSV6K?!6I^C[OJTN;.^?-L^@8<8R/6[[U+/\
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M=:#8RIONLUSLKJ5@^5"KN2RZS'YV&+'3\:*\(,6#7*OXA@ 6"8&-:2BTIDT
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MHQ$U UV-B+%:CKM,!(?;,M$G&PT1(2WG+?='=+CZ^%'0[#PXKC :E @BMO\
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M&AQF72'W%*SY6V64*<=6KY/F0A*E9_R8YQ/N06/<H)/NV[@-SXLR'8D +U)
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M/R+""B' O%UQACUZTVTV:#7M BL:GI^GA%M6YH&6LMPP_;EY-TF6)4FC9F9
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M_"4)+2U,(#9QE'FRVEUU0S:EY6@4MLI"7&N3VXH )9XY!"O5WDC=(O%[EF8
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MY6;B=HVMS0>S-70FZY^H!ZHHH5=V?,W:W5B_VT^9E]KW-R7JT9/&[;MED@(
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M@\,<02-89MH2ZQK((XXT3ZSI7&1T7B233+N@KIZWX-(732DNJ7M4K)%$NO\
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MG\N(2T>DLV!5 ;O-L]=ZY.TW7U([+[!D9\S>Q<5:)6H=1&M;F;?-35A=&&1
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MK)2,<R*V-)&&./GMDK2UE#,;GRYGG:+27V"AGJ=57AC0YZ.-'=KT0XP7'VE
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M(I!7IP2V9C&E*KSN(HE9^5=QS-ML-QOGT74;U+3D>S?MUJ5<,B&>U-'!$'<
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MH5A2593G&>,V 01N#N#U!'<1Y<^W&,.,8<8PXQG"OFS_  9_FXQB&ZK?@O\
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M>U(KN4KF!33A2"!5B+TH[3!IW9A(8[?.LXT,&)BZWN(0( (<.. %ZV]A$,C
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M:?\ @H3C'[G&8SM<8PXQE?NIGX*W6?\ )^TU]7-;Y6U_X=UKTMJ/KDV2M"^
M]&]%:=ZI#E@>2<JX<8S6OIG[U+#[Y.P_U_;,Y]#N?=UO1FC_ $32SP='[W8]
M):O]*W<[>X->QVT]>6FBRC:71I^(+"\%8^3#CK3B6U8S\Z<X5G&<*Q\N,XQG
M'R^&><:T\]26"W5D,-FI8BM5Y5VWCG@=98W&X(/*R@[$;'N.X)&=\\$-J">K
M902U[,,D$\9[I(9D,<B$]XYD9AN.H/4$'8CRD;@U3;]+7&3J5L )8R(4\W'R
M2VEI%DQ4KSZA]IWP2WZY3?AEUG'AE*\+RWA37E7G]:<(<8:=Q925X9(J^J0Q
MK[8:8Q7MH)  'EA5CS34W;K%.O,%#+'*5E#+GYMXEX;O<-VVCG5Y:$KGP'4.
M0F*Q&=RB2LON8K:KTE@;E)(,D0>$JY5?M7^7_M_^;GL.0^4?W1GF^8?]0_NG
M]^'M7^7_ +?_ )N.0^4?W1CF'_4/[I_?A[5_E_[?_FXY#Y1_=&.8?]0_NG]^
M'M7^7_M_^;CD/E']T8YA_P!0_NG]^'M7^7_M_P#FXY#Y1_=&.8?]0_NG]^'M
M7^7_ +?_ )N.0^4?W1CF'_4/[I_?A[5_E_[?_FXY#Y1_=&.8?]0_NG]^'M7^
M7_M_^;CD/E']T8YA_P!0_NG]^<I(4I24)\RUK5A"$(QE2UK5GP2A"4YRI2U9
MSC"4IQE2LYQC&,YSX<X2%(HWEEDCBBB1I))9.1(XT4;L\CL0J(H!+,Q"J 22
M!G)>9V5$!=W8(B)&[N[L=E1$7=F9B0%5068D  G-TGHV>LLY'R[NZ;G'.@9P
M(L*L!%M*;?0R^I"R#%H7C&4N/Y;;QC'BK+;;:4Y\JUNIQ^9_9'XTAXDM0Z7I
M4G:Z/ITS326E&T>H7@IC5XAL.:M5C>1(9#MVSRRR*&B6%V^\<"\*3:+!)J6I
M1]GJ=V(115CMSTJ?.LA678D+9LND;2Q@DPI%&A(D:9%VD=DOP<]^>Y3:?]19
MWGS[2OA;3?2-/UF//8ZM\%:GZ/N^K2YL[Y\VSZ!AQC(];OO4L_\ %Z:_HTGG
M=7]\0?AHO\:YU3_>)OP4G^!L@N@?H(TI[I-;_P!3H;FUJWPKJ?I"[ZS+FMI?
MP;IWXC4]7CQM\GYO8<8Q>7#7Z[<?'')O6PJJV#AA+L=3Y\:(CY-L<E96$2+3
MT8<^KUKF6VR'0R WWAF4!K=]E=*9(9D';Q _+GUIE%*J#A:G[[?KBT2PR.T-
M<Y.'DV@4LJ4KU@KD? Q):GW?-E+SIA):G$^7&?#RIRE@_(!\_P#F3D^XS&'&
M,.,8<8R&W'7M+V .P)<Z\!811FWVF1S\/*92V2\$0^A3;3K:7$N/QP+N<.87
MC#@S2D^7.,^+&92KU>!I<!&5>L1K,1 PS&1HV.86\XV,RIUQ]>,.DNOD.K<>
M==>==?>=>==<6XXM2U9SEC,]QC#C&(/3OTA]K/?Y7?T7>MO*VH^\] ]$S?3N
MM9*T[WWKOI6'Z#T;.-4_2MV?]YM'^HC5/,7_ 'AHGXE:^E+^<J/OW6?QVO\
M1E#'[R5E/,'9D(<KTVA:4K0N+-0M"TX4E:%#N84E2<XSA258SG"DYQG&<9SC
M./#FQ4]]5_PT?^,9T6?>\_X)_P#"<7=&U#&T :XX@RPVI"UD%E(D&8(,1R.<
M(0]Y$Y0TZK)K33SJ'E(<<92ZIK'FQC.?,G7SO_G^?YZ9\1@;FTM\[&P&_720
MX3RDO5>/4R/G$:TWE32?;E80A9+F7GTMK\GK14,9\%DI<RS'C'R;>?QD$_KZ
MGJ>@S@8.TE33!Q=N;2.VL)AIQ%>C1BW_ &)!$?(LI0XI]>'"B9!9;><HSD3.
M&V6&'&'G'"^2E1S<R<WN2 >8J5;IUV Z[;=03U\VV^<9!,0JI*8ANK..4.&1
ME5@/NN4$CE).QVV7?<J-LY*1,ID^:*Q)N"P;D*TP!@H(7*Q91TGUI!J73"_:
MY%]E0@^6Q)(9L5U#R!QWL-LK;?X%E4#F(4$@;L0 2>@ \>_BV[R>X9V;L>X;
MG;Q*IVV4ITW'3H2=QM[H!C[H Y\H*)G@<R9S5DEC3Y :('Q R0L.J)@41Z$L
M/DP8(S,:6RX;AU9,H#(3D@VP0IMJ-6R(T,DWML2=K5A@BAKUYH2[&VBS/-8Y
MV# 6%>R8"(P.2/LHX" 3VA<C<:<%22'4;]R;4[UN&WV1CHSFH*=-H8V5FI&*
ME%=#7'/:3^&VK?VPCLA70%,CPU9)D"]CQ,38K**W/%M2:K(W(P<J'%FY]6V5
M7PH>2-E305-9:*:+&-B01DL^ S2LK':\N@*\J+,8[4QDE8,IF6.:.'W18B*/
MEB/+L2 ))7(V4@[@[[XD&Z'D0!.[L^:-V(\;R D\X(&S +MXADSU_.Q-A!FC
MX:6^'!&9W,8Y)Y3Y%DG1,+"QL@IU.&V4X>28,\E[U;:&O685ZM.$>7'*<P(A
MHACNPJMN=N7<^%VMR!N=@>\#<[>4YIPD&6X1W>$KTWWV_P"%K=-_-W?DR?<U
M\V,.,8@.M7T=6/W_ /;#]*;<G*NL^^X?16A?0>G9+T?WI-Z4USZ:U#'_ ,E9
M4Q!]K/P7>R7N#W%]7EBY6T#X=T7TMIWKD.2M=^ ]9]%:CZI-C\Y)RKAQC#C&
M)[;&Y*3K2#F$25MKH5M^""B(*LORX'QAD"%80.,0' 8?S+&BCDD,.ENC".H:
M8PI2U)QG'CNZ?5-VY!7 )5WWDVWW$2 O(=QW'D4A?*Q [R,T=2MK1I6+)(!C
M39 ?'(_N(]QN.@8@MX^4,1W9_*<[]:GNVA^VVVZE:WTF!N[#L5[UZ3)Q31\#
M9:+LB3/L UH240LML]21RX\&0<2F17B6&/&0^.3#9&1WZI#-5M25W 6&*5Y(
M%,86-HY2"3MWL"0JN"=U(;E"[;9*H3/;CBDC#,MRC-4O:DUP-=KVZQC6I%%6
M:&96[1+=Z6.T[1F#L(8S%.)5,%=)4.S.Q)LMF+2J)+$*6DR)&,3'MK;4ZU((
M'$DRE%/H4*Z*3(2.&E_!8QP>5)9')&4_JM,1'(3V.\BL Z[J8^UWC90KNO:-
M)&BMOL[JD@([P%3M3H/12Q=6I#/>IZ7#'-=@<7+R0S7:57FC9IHI:S^&5J]:
M0PK.T+QHC=K$9_2-_<K/7&V[ [?W7L:]%$-:RT'KJ8BAK"0+E;16V-CBN5D*
MMQ<@L9IM33%$(M<U.A#/OO *75%F8PW*"JYJ =QWWW Z'9@""W53MNN^Y)Y=
MB0?=ENFUM(E[=IAVBL%DC*\Y[%Q+X.[2",$H7'8QQ=H5#A8S&-D YOZ!/,YL
M8<8PXQAQC.%?-G^#/\W&,0W5;\%_K?[A=/\ U>UWE77?AS6?2NH^MS9+T/X%
MT?T7I_JD./KDK*F5][&?>YK;\H+0/UJ5GE;1_OUWT3JOJ4V2]6^\U/2FE^NP
MY8+DG*F'&,.,8<8PXQAQC#C&'&,.,8<8PXQAQC*_=3/P5NL_Y/VFOJYK?*VO
M_#NM>EM1]<FR5H7P'HWHK3O5(<L#R3E7#C&:V--IRBKV5M6/!;6Z.QC+B?W4
M.L]@MG-.MJ_>4VXA2%X^=*DYQGY<<^AW.KUCXCI>C$?(=)I$?JSP=+I'8'DU
M/6 ?E&K70<::TYSGY,?N?Y/\O.A6 '4^/S^;-S$OMK0>N=SQJX^ZP IJ_(I#
M1N&T)*:\V/#Y',>&58^;/@KS8^3'R<RK&*6.Q7FEK6(F#Q6*\DD$T;#IS)+&
M5=#MN-U(/7,.L<L<D,T44\$HY98)XTFAE7??EDBD5D<;@=&!RALIZ*75!13C
MP,_*!,+4I2&,87Y6\9S\B<8;?;3X8_<\$_Z^>FBX[XVA0)'Q/=91L 9XZUF3
MIT]U+8K32L?*6<DGJ<\[)P;PE*Q=] J*3OT@FN5HQN=_<Q5[$<2CS*@ \0 Z
M9CO]R<UK_C5*_P"9[_:^=GV0>.?_ (EG_--/^HYU_P!">#_B&+\^U/ZYA_N3
MFM?\:I7_ #/?[7Q]D'CG_P")9_S33_J./Z$\'_$,7Y]J?US#_<G-:_XU2O\
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M->B D@JET]TC>[5U.W4H>TV(.WW)5XV(V(! VZJ>FP5.UB\)U!8+"<LZP3-
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M1OW$$@C8@D=<^FDGH >FP^8C?YC^[Q#I =.;$VU<Z%7;:QO/;-2M"71JZ/*
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M %,=@W]?/\\?^GAB'<QGQ^&9KY/E^4D?./\ UXR)X9_@S\G'A _L]?\ N/\
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M"I\#&5Z,2YX8PI]8D6,,T\4[X>9\IY+A+Z\J<>=<6I2L]1)/4G<^4YV  =P
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MD8F*/M0I*76+";&1Y4NV8^&,XVS&?>L:_H=)%B@:92:C40H*%^+D&'6*W#0
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M-*I%UZUR*117/*VYZN+^9II&7\?(!XJREW*DX^3Y5>*$^.4\QOMY!Y-SMO\
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M]BQ=M3W=H?ZH_+>>LPXQE?NIGX*W6?\ )^TU]7-;Y6U_X=UKTMJ/KDV2M"^
M]&]%:=ZI#E@>2<JX<8PXQAQC#C&'&,.,8<8PXQAQC#C&'&,.,8<8PXQAQC#C
M&'&,CUN^]2S_ ,7IK^C2>=U?WQ!^&B_QKG5/]XF_!2?X&R"Z!^@C2GNDUO\
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M+?89&M R,1'2<S;YD]H!^7P9Z\1<'[0U##QR \^2-;#CV&1U(7AWS.>J4O\
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MVC]GT&ESM8D9F#N=&M%C4= K8(L*+ #MC0^I:I7XZ*.(CHTAJ=G=VB.&GFS
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M2_78<?SK2'D*;<QG*58RG/@K*5>"L93GRK3G"DY\,_(I.4JQGY<9QGY>2?\
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MP U:_;O,\2::M66*&ZEJ&9;LCW*L#K97LG6#PQ')::J:J^S_ '+]Z4##C6$
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M<E5G9416=V8*JJ"S,S'9551N2Q)   )).PZYAF5%9W8*J@LS,0JJJC<LQ.P
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MZUC[%7#_ ,8<0?I*/ZIA]KX]./QQ]S/S[@?J'Q]EKB+XNX<_13?6L?8JX?\
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*PB+LD:I&JJ/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>g383050g91s91.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383050g91s91.jpg
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M=I.8XA<C)#1U>;2XU3(S072SM1DF)S8U0E%R<[)#4U3_Q  > 0$   <! 0$
M             0,$!08'" ()"O_$ %\1  $$ 0(" @81#P@) P4!  (  0,$
M!081$A,'(107,39!M D5(C4W4515875V=Y.SM=35"!8R-#A2<7-T@96AMM'P
M(R1RD9*QLL$S0E9XE[?3X?$E8F-#1$53A93_V@ , P$  A$#$0 _ -#]=X+C
M]*(E$2B)1$HB41*(E$2B)1$HBG'/0,SM-9A T'@5X<ANODMBO,6:A5=(D+7C
M0"4("P^& F[QT<69R)BT2:*M6[90A@NC@\R2LBNM;&RM=ZU>TXR#%9MO4'B:
M-G VFEA<Y'>3A&)BA(G)B<F#9^'?=FK_ "NGY\U=B I(*S62X>-V,'BCE8 \
MQQ/([2B+,XLSDSMOML[UN"\4]X3B<AM>7@DJB<H-O0R;<=+H7.QSQ,.6;R=Z
MK*+CF<6(E7($4.ALF?O,V#%V2>I!GZ $:9>LW35"7:SF-JUI+?9,$\,8R.YP
M6*IB\D90BT'&4X ,IG8A >,A 7D%Y3C$A=_=?$WK$X5N1+#*;AL,T%@7X#:4
MGEX1A,WC 8)2)Q%R)@)HQ,A)FL0EIC9[-V*P90&=F1<H<&+00\R@DR;C9^."
MH+OW9B(8$@;)\688AT,C2]DFEG3 9>[@DW:635LG5!D:1#(Y6JL9P-'V5$5J
MNYU#D=A&.PX2D,9\Q^6VY<)'U Y;MO3G2M"0L->Q($KGV/(->9AL#&SD1PL4
M8D8\#<;[-N(]9,.S[52W'+D)?/%.VB-RW4S)/ V"=M7S>^>9@=F13("L<; ^
MUD289B"V#QC:UW37,81Q72PNR<V2\>6^*]<\?]@,GV[6_P!&7!PG_I?L"Y@<
M)?8OQAL[\3;^_*W(^H+OV3A]JS_9CQ<0?Z/[(> ]Q[K<);MYE]JKJ3C[)-OC
M'1 7)8C&UW4I%:_A(J3K'TB.R-CG!A0H)@L3L%CYIFB5>)C46%R,E=Q^/-"Y
M^,,7YAKB8\8;2[^5AH&(G#/,S0':L20M$X5*D9QQR69WEEB)P%S<^"$992CB
MF((RY>Q>Z>.DNBY!+#$Y2A7@"5Y.*S9D$C"O#RXY&8R86'BE>.-CDB$C;CW9
M!^/LCG>OG\]92:(BL[X[+SBD1+K'\)//,--0@;L?:.<>N/CY"/,<(I#"S,KA
M>5GHY\I''C(6*>6S;1P.36<K#6MC5*&<V_F?/L T7)J^6%DZE+F\<H2GS[$9
M _(CEY+;23\N,F)T&.EL5BL#+"#OV5R83>1I;#48!LVWC<8RC'DPF)-S9(^:
M3O'#S)!<6\6V]!2K4VPA&KEB#6934O88D@&BL?GJ#E0D:<)M1 P:E+(A&5Y(
MJ4<*X)"W\62-AR:F5L!Y%SG?'&\:&5@OU#O,!5Z\?&Y23RU79@C%R,S>"Q,T
M+ S.YC,\<@-UD I<QTM.P%5R:><V#8(HK OQ2.S  \Z&)Y>-WV HF,"?J$G7
MN3+BWOB!B!)>0:QFR%GY%Z$)LDHA*%7<5D+:5*0]G'I/EY&Q9#C1XM9K\GF.
M#MPH8;DQF;+O%'R"67FOF\9:DDCBN5GX &0#>Q PSQ/ U@I8?Y3B..*/BYQ.
M+-&0&Q;,+NHSXG(5@ Y:L[,9$!"T,KE#(TSP#'+YCA$Y#9N4+$_&Q"X[N3,K
M)(Z6W&'8%"A?4VS!8P&B&<&R)&"2EBP#H2/!NI'ERCQR*2;CT3V#QIF&4=J(
MX%,'3?)CDO9=*^52&1Q\A $=ZF9R/(T8!9@(I'AW:5@$3=R>)Q)I&%GX.%^+
M;9U(*C= 3,Z=H1C8',BKRB(-+L\;F[@S"TC.W!N[<>[<.^[*ZB_&O=H*%OYJ
M6UO-F#4&>/ Y6&=PV6M3\+2 QV*2=4],&+D&BG'8\0%R\>H+)$G*.+J[9^ID
MFDW207<28\QCI; 5X[E8GEBBD@D&Q 45AY9IH6BKD,CO-*,D!,8 S\/$#;N[
MNS33QEZ.$ISJSBT<D@3 4$PR0-''%*\DPO&S1Q$$PN)D[;[$_4S,[T=AHS9J
MR2KDU%#L-9J0"1[)"OID D !E*HU&1K8L]<19R[%=T:NNS>LE&:[3+(>I9XU
MS5>H).$E,_9Y.DSL,<\5@NRH:D@5Y8I2@FF,@%IA$]XV8@)B8MB\R3,+NSLO
M T+3L[G#) /8\MH"GCDC&6*(6,GB<@VDW8AV<?,^:9W)F=G5=D/&/>D8!@C1
M76,[16- I5*G("\)F"4BCD4B+YD/)RJ2C'()#,5&LUWR?BYQ13,;?%-7QARW
MSQQPRE19G&S2RQ!<K.T<L$ R]DUWBFGL"1A!";2OQS,P/O$S,?<V9V[DR3%W
MXHP,JMAG..69X^1-S(H82$2FE%XVX(G<NJ1W<=F?=V[B@6KHK>E$2B)1$HB4
M1*(E$2B)1$HB]AI_6VO_ #"/_4QKR?V!?T2_N=1'NM^%O[U]="N$5U^E$2B+
MG;\)H\P36WVKM?>ZO=M;7Z'>^FW[26_',<M<])_>]6]MJ_BMY<)==,K0J41*
M(E$2B)1$HB41*(I^B'&7;NP=:@]I08"WE0,]M$GJ1$4(((*2<?)!HR"D?*I<
M,OW&0^&NE-B1P3:8*.,@0LTX3'2)V%5)Q^YFUV,S0J7):5F4H)(J07W,P=H3
MA,[(<N.1M^.PW8DI]CLW-DC;CA&1@EY=PAQ=RS5CMP1M-');*FP 3/*,HA 7
M&8/MPPOV3$'.=^6!NPR.#E'Q^E.N.VT8/-S\ Q"VFYR.G),">9ZXL]F;%PI$
MU4TRI)DH+8Y.E0M\%;.69-9HW0=M,5'*?\SAEE:-7+TK-:*US.QHI8H91[,X
M:Y,T[.\8%QEP\SJV(&)W$MA?K=0L8RW!.=?E\^2,Y8W[%XIQ=XG;C(> =W#P
MB3LS$S.[=3*R,=9SU="SL;$SQQGB)%&W#T *?FV3!B92'J,<B+H:W<H,%L[E
M1J&:#K-)1-R^:-\L;*N4<<ZKLRJS\)SQ1%S)(V&60(R(HW)BX!,F<F\P;L[,
M[.(D_<9]I'8MAVXAADD'@"1RC I!$387'B(&=A?S0L[.[.SDS=UVWHS^(RL4
M]=#2D8D(TBQ<F63U@_"DF;UF\CK)(C(&CIJX;)KMW((>NB_,H*IX*C&2R3I[
M@@@I@I?V-B Q$PGA,"&,A,9 (2&8G"(A)B=G&4F<8W9W8R9V%W=G92RAF G$
MXI (7,2$HR$A*(6*479V9V>,78C9VW 79RV9]U5"NMMB@F3TB<@,U##QK48^
M(ORL5.CF0]D:>.1X9X]=.V"*#5J6?LGC$8X7431?O&CELUS5605PP\1W*<I"
M$5JM(1D8 ,<\1D9QB)2"(B;N11B0D8LSN(D+DS,[._LZMF,2.2O. BPN1'#(
M(BQDX@Y.0LS,9"0B[OL1,[-N[.I?#<7II(-?QN>BI1!'"DEC8R;IPS)[)V\L
M%P4OO-QQS92XFHYB:40S'Y[610"YBA,M*RM)@^;'%([B(3?NV5!)FJT-J:K)
M#:9H9CK/888'@.S'C&RY5P9IWL<;47>1I)( @<A>)IN8XB5:&)GDKQ6 EKN\
ML03M!Q2M,%<[[XP9C=X6AX>RV:-P"8Y6$FD>/@XG:H3+AYNR C=VFY2+!C0F
MBU1&!TS<ZV6&S-(Y*(A&1[_5SE%/.TZ%_P#GR(GB)4;C@/" )"#6-N!Q(\"%
MD_%?4&-M'CHX#D.7)M(\4?*)CKO'#8F(;HN_\V/^:SQ !^:EEBE:)C"*4PC/
MA;U<+TDH1C'0<.8?,9QG:26&(2J.WVP'\XAD(Q\R$<D;R.)21@4(#];;%+L&
M945 9J3%D;/[CR0^*G7K!]86PR*D[LWC9@JW<V'"\,R3_N%,_$V&&3QQW;?&
MZEKF=RI&91G:K 8</&!SQ"8\9< <0N3./&;L [LW$3\+;OU*A&K9,1,*\Y 7
M%PD,4A"7 /&7"3"[/PAYHMG?8?-/LW6J7>(RO$.)D648D-H^>(K!P9VX4E8.
M9+-\NPN+$D[MO$B)%'/\19BS76<IY?BYI8W^BO?9$',.'G1<V(&DDBY@<R,'
MZV,PXN( =G9V(F9GW[J\<F;@"3E2<N0G".3@+@,V?9Q MN$B9^IQ%W=G\"ON
M7:*VM",&%S\)DC=PXA"6PBS#&/GL2$0C*\B.QA)W,VC@6W5C=U",?=*89O[8
M-<FCD>MBYOFZ[I.E@R=&RY<JS"[-9>H!/+%P3S-%%,XUR8W:;891;8?-<3$W
M#U;O434+<'#S()6=X&LF/+DXH8GDDB9YQ<&>+S49/YKJX7%]^M4HSJB="]@E
M-8,@3Z53(4LHBJ*AS E(G#FZ+' DNHQ:LF-W[E%NSSNLX4LSQLBFFJIGU)X7
MSKW'?JR5([I2C!7D9G:2P00LVYN#,1$7"SN3;,W%UN[,W6Z\'3L!9.H,933@
M^SA )RN^PL;N+"/$[,+[OYGJ;??N*@6A$TR'A2V,0E&0N2.WC".DK "UQY]\
M.RRP(,@KRS3Q8H[8YXY8/&S%1=9KECEBOAA>U[5-[)K<<@=D0<<(B<P<V/CB
M ^L"D'BW 2;[$B9F+P.ZE\B?A ^3+P2D0Q'RSX9"'[(0+AV,A_UF%W=O#LOX
M*0N8@WZXHU$Y,'*-5":3H:4 E![]LJ%&H&3":[-VU1<(J"0[IJ5)X*)XY,!K
ME!\ZLDU635RB%FO(+''8AD!V!V,)8R%VD-XXW8A)V=I)!*,'9_-F+B.Y,[(<
M$T9.$D,H&+DSB<9B3. L9LXDS.S@#L9;MYD78GV9V=>=_ IR*<-F9.%RP<[>
MY@DV;5_'##-P[4E"3I>,IMD'#--5?.1(,GJP+!+'/(NDT=*#[.,&ZM\(#:JF
MQ$%F Q%I7)QFC)A:%Q:9R=B=F:)R%I=]N6Y#Q;;LHE7G%V$H)A(GC86*,V=W
ME9WB9F<6=WE82>-F^S87<=]G4JZHXYRO;P$@9 R6%AWJ4I;0>/1F2N9.T.S2
M8.X\:DS<  5%Q4Q'6#E0<!>86>S(_%!&+O-LWR(XW4SR3H;V7@H2A%+#8D%X
M'LRS0C"45>N,T<+RRL<\<I,QRCYFO%/)P[OP=775U,9-<C*2.6 ":9J\<4KR
MC)-,\9RM'&X0G&+N,9>:FDB#BV;BZU48OQEDLD9PM!Q/M816<;-8M"6LM72H
MU(V,UF[(J\7'1Q9!XPB9.!0_*6/FRJ470V9-X.X--<QYAHCD"-@BA/Q-F882
MLNU6[/6IF4=R[!%$=>L0"QS,XE.%J=H!)GG>G6LC$3'&3\V.0 ]18N61H&>Q
M5BGM"QU:LIR#/.)NXQ.SC$<$/.)G:%K,\#FW";-RSC,J*KH5^'BHZ0SK8>NM
M:F#X5_(HIKZ9*SF\YD@9DZ(CT7N+.+P63 (G8N2$D&8-OL610QT4321+MD,H
M^_&EWDQLH$LQQ5:ENY'%(,,]JNU;L:&0A W'BFLPRS\L)!*1ZD-A@=WC)^:)
M@/A\>01#)8LUJIR1E+%7G>?GR )$+/PQ02QP\9 31M9D@<V9C9N60&4#U=%;
MTHB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(LO6G*9B.<J3)AK
M-!';A:(0> RB9J2YXM&W\:A6$19*/P<(L&27!S.7!H4,#RLT]ED@CZB!*0NH
M]#XZ_?L'(FP%A",6KG=)Z$=BS:@KM +3!-8>P7#+9YCM+7@DLG)!&,$4K.$3
M2V)1$FDO+981?GC59KAP05Y9WF)XBB@Y(N4<# SQS31P $QE+)%L4A1PQD0N
M'OC>9,A'A\Q.<-&.[J3*13"[M<P^NMWLA<[.=JC_ *6V76@W<;.)*X*=KM**
M,L%,L,<WB^6/@]/0G(TC6#':O#7X6C';^1&F+']DW6XT@9V\#%LS["R]CFY!
M!P> 2WFEFW>0MVYKVB<?L7ZF>T;[^%Q9]NMU_6',%^P;2!R#A%ADGG8;)C/C
M6<M?.6+HJ/X_[/X^1LM!PR0IGE"$!P#:Q^0D1:I22X+F6@P=&'4,BR"@!6+X
M 2>(9+/'#5EXZL?(%B:,\K2RLT=F1Y"[)<I:440&P0NT9&<PV)G:1H>7)",C
MQP<$TX<-B3G$XN8XZUCHC@#@9Z[#';DD,>.7<V$(GAA9XWM".<GY%'!,5$H
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MF.MQ.$1[%#L8V8R;B&WNY;X45D:L:41*(E$2B)1$HB41*(E$2B+V&G];:_\
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MO5,# ^QH3,YL@#XVU.5FM/%9Y146F9HG",;?#+"3E.VT9%/@Q52)YWY<]@"
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M$\9;#RQ9I=DUW4GG/)I34.M=42;:42Y".(+'(G%- Z@D*\=X_,)%LGOS.O\
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MQ[%(O#<L7$=)6C"VPI)WT/8W?(92Q5N-7C:!F8*91PRA(5C(%:LR0314G&0
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M[=N@CWG=I88XW:&K6KG8DKUX(#M3=D6CABCB.S.X!&\TY (O-*\<8!S)'(^
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MZ^YU=7X/P]7]2SXHH)1$HB41*(M?4._]>>?>PYWG_3-?\+((GI&'9_[U@[Y
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M0'B=G:-Q;;PNW@6!8#H]N8?+TLE+D:TT=4Y#*..*5C-CADB9A<GX6V<V=]_
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MB)1$HB@T;OV+/<@A%^#E$;@LJR?VB.T)%A&64$DB3(03D*;Y!PA)WDC!B2@
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MN8.SB$PR2PLTG7N+'-$\49;.QF0,.[&SJLL:.U!4ELU[E&2G9KX.OJ$*M@9
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MC$"DX&;J9R[C.1 +F[<(N8\7=;>=#$QD#R$45=YHHIK#1G($+2.[\3B/61,
M22#&SL<C1FP]QW:/M8L]FX"B!;:I82K(#Y&Y)K%(ZW0N @(NZ"2+2,LC639
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ME6)#R;T8#0/),-E0V:28 _&!7$!@DLB\GGCB1')>$U\#CJ4;:&L7#(D3G4D
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M68Y)'YEBK%$W" N^Q&SOML.[[,M?:-TGJ#$YZM=R%#L>M'%9$Y>RJ4NQ20&
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MV^]/^PZ;-Z;?K_<GCGZ*\_8?Q4XV^]/^PZ;-Z;?K_<GCGZ*\_8?Q4XV^]/\
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MNH]8-.B=7I>E_P!_ZW])V5,RTWS/Q7.92'9'RV!OI(N0# 06V)!JLJ* W&[
M:"A"TI!0H@0SR'34K&=@O7%E'=W,3=LM5$,94QT[8GOXF[=75^?N^'TO2V\'
MI[OOU[*_XKKCDE XU*#\NV42G<I?:QWYC),AA4V]:OYS:4CR6BB6O(4NV5'1
M'Q&'J2MB8$QS!IDX*/ 3!Y\I;BQCY@1MG=M]MMV_JW_CN]?LK]UCK_DVKIF0
MLGLXQALB,=F0:]%R\U*=F2R+/6^O8&H"&238!=\,*YAWFX0LODDMCAL7.'+F
M#RK*%LRX)LW0%!2/M_'5^K\'I;?G\,22O0/,>7E6+$E.HU8.Y"ZZ+GRN4ZFC
MUOCLP!NOC[N%T? Q9\V6 AAT-<Q;=4:A@P,$#/U(T_@:<@D\B56NP@A&=F[N
M[]W];.W[OUJY!FLN;I784&D\FFH<%$6,QC[TW$0.Q#9%9@)%1G0@T\NZ<6C@
M 3*Q<L=Q#=22L?,"'^ ?.<,C E)C)C"<HUP3J_\ /Y^ON]75MU=STU+07CC/
MA\%W!$2.XGI![LK74BA00ZV);](.X<3-AR@QO(V>&W>2.ZFF#D<J01>(W LX
MV^R5:X6<$7"5DDD2@HH&:&W,RC91>VN-3BW+_>^O-XX:I#3M]>"-FVK-?:0U
M>-@C<BKKQFFI9WG 3VU(D4RC[-D$DH""""C)%=X3/A2CNV[=;]Q^OP]>_L^S
MU]?IJ+=<<2^0FFQK+./QC2LODT(B[\O$BI23&$6,AF1C4>B=;"-=FVB\+2=M
MM9:X/ZJQDPM[@^L2?@=>:<',6 T]B6(1DF^_=_!W/9W=^[W?U=?@7Z9X7G8Q
M#DWHEH8'!(KQW-@&^L0TA%2DS.=^/-))<98:0Q,C]=@"<:%LM:"(^W?W&29K
M!'4G>!)3>&09;7Y*2RLF[=?AW?\ 5OOX7?K?V=_S[K:L*1?MQ8UN5=IOR:#!
MFB1?))602>/TFZ>#QVFACU8HIN'&*BV"5K6LGCG;"WT8T4%[]$2B)1$HB41*
M(E$2B)1$HB41*(E$2B)1$HBLG8<$%;)B;V'FG1!F.?OX\05<"U&R3W!:-R,3
M)F6">;ML\0LDL]#MT75LF^66351;!+-%;)-9,C=7Z_UMLHIEW'$/--@M)\8G
MDYPR\JZ_?GHRRQAK8#*V.H)_GM/4(,PK\DE#[9AKO8#HL?&.01L06.IG"8>8
M$9$'NQ9,2CO[#?G\"R,HH)1$HB411GM'6C?98R/I)2:0PB20Z4-)E#)K%DP#
M@[&9 @*,QUTY:,Y4#DD;?MS$5DDEBQ5F7!OTE0Y\A=IXD3P8D69%CT;X0:Z.
M*Z.3=2Z;>2>/;:(B-<"5VFO2=Q,;A2VHB0D0U.&((0D@=^X/:=#DRLQCI@--
M7[:22H-D?3&6B:,4*._=ZFZ_P]6^_<Z_96:-%!*(E$2B*.=H:X:;.CK,,H>-
MQ,J&DD<F$9E<<Q#J&H[(XN40),'K1"0"C85VW>))N@IAB1%.T'X(H4987;+K
MHO&Q%C3*>">LY>*U4',RN9NV^G1CL!#GCP;K0D:9@3..LGTHQ0-DM>NR(652
M25:M#S-;8T87 S\">,2#Y(2*/#UQ;(24=_S?P_[W6;E%!*(E$2B*/]GZ]'[1
MA[F)$"I<#?RW#Y0)/ ;CO*X*40"8 9[$#3)(P/+"'>8J4QH._5'EA9 620;J
MCR+-RS<KI9D_C^M043X9:@D\*$0F?-,MCI1\_E+ 4CFT=@)65").:G([9>QC
M0XLG#VN+%QMB<,,CDZ:,FK88M=VH- L 0EH,8L2CN[=Q]OX_R\'I++6B@E$2
MB)1%8FRX ,V?#2,/*$"H?!R^CQL6=!YL<#4<D\/D8F8P^3B+%&)02J2C4L A
M3S%L8%% [MR/2;%AA$<LY9KD4#F.*N1'7XS7++=FT0P-O-\=CGLVHS53U>93
M![/9KM.4O)(B6UP_'JB)CL28-9,;C YD/CR=HD CPP<PB;R5 9(4=_8;]?\
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/$2B)1$HB41*(E$2B+__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>g383050g93i64.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383050g93i64.jpg
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M 0$! 0'_P  1" '+ EX# 1$  A$! Q$!_\0 '@ !  (" P$! 0
M  @)!@<$!0H# @'_Q !J$  !! ,  0$%  H)#0D*"@L% P0&!P ! @@2"1$3
M%!46%R$B.%1W>+;2"B,Q-SE7E):W&!DD-%9T=I6SM+74U24R,S9UDY>XUB=!
M0E%887)SLM,F.D1%4E-QD9*8L2@U0T95@<+1U\;_Q  > 0$  04! 0$!
M         0($!08' P@)"O_$ &81  $# P(" P<*#PT%!0@!!0$  @,$!1$2
M(08Q$T%1!Q05(F%QD39U@:&QL[3!T? (%B,E-3=2571VDI25M=,7&"0R,S14
M5G)SLM3A"4+2U?$X8I.6PT535[;"Q,76)D-$1H*#_]H # ,!  (1 Q$ /P#W
M\81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3
M")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81
M,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$5>_M)_P!XR*?E8!?H
M?.\K9S/F^,*A_(>?XBK",H5:81,(F$3"+HR<GC84I' 9@^&%&9B0>B8D)(DF
M;,E)R@T,1D9$< 9.%DW)=\PCX<L<>-6";A=L)&/R*W'#1HNJF1:9>>67BX/C
MD_E[[R,HYG%*JE*<'LR2.;3A*(. 3-9]],1BDQ*=F^64=D2Q/78U(.56:D%2
M"2[+AOTZ062X*<';8[\MCOYNU;X8OF)1BS)C'C4B-(M6[X>08N$7;%\Q=H\.
M&CQF[;]J(.FKI!1-=NX04[161[X43[ZXZYZV4+#;%M.L:@CVI;;5C0.KHIT_
M;"N9-8LOC\)CW11[PNHS&Z-24B,&[?NTVKE1LSTY^87X;K]I)]\I*;YN:2BK
M*^7H*&DJ:R?27]#202U$NAI <_HX6/?I:7 %V, D9.X5M55M'0Q=/75=-1P:
M@SIJJ>*GBUNR6LZ29[&:G '#<Y.#@;%:*_J]O!C_ ,M#Q.__ #%T_P#]L<R7
MTL\1_P!7[W^BJ_\ RZQOTS<.?U@LGZ5H/\PG]7MX,?\ EH>)W_YBZ?\ ^V./
MI9XC_J_>_P!%5_\ ET^F;AS^L%D_2M!_F%O.N+6JZX@"LKJ.R8#:<60). RT
MEKB8QV< $2[-%JY=BE3,9(E!R9)JW>LEW#'MSIT@B[:JJI<\.$NN\=5T5;02
MB"NI*JBF+!((:NGEII3&XN:UXCF8QY8YS7 . TDM< <@XR5)6T=?$9Z&KIJV
M$/,9FI)XJB(/: 7,,D+WL#VAS26YR X$C!"S[+57*81,(F$3")A$PB81,(F$
M3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB8
M1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(J]_:3
M_O&13\K +]#YWE;.9\WQA4/Y#S_$581E"K3")A$PB811JN2LY7,[J\19L":M
M5P%06G8\JFRZ[U!LNS#R3QZMJNQ2K)LKUI4@LK)Y<%;*H-M=*(MEEGG>M(MU
M-Z*1U^4?&%4]6_A7Y65M(/&VRG%5162O_#.#^/\ 3"=?L;)C35[Y3-*AJ?S,
MJ<S<:9@DU2 Q=5R^\G(W8\:#SY="0\DV=H,R*#0BXC!,R4EW,=1)(SU9((Y=
M>V#U>C:W7Q/J@]1'C#X]TK*2 \K):HIFMZ^/O0_;A0(H8B<2%!"*0'MXBW=]
M &KIFJT!?-H(.="4&>G"*2VN^.2@G))'6254)^R2OX.MC^<)67^@IYG3NY+Z
MJW>M=9[Y3+F7=8]2S/72D]ZJ5X&\^FE\UIA%[T?V--_!ZRC\Y>Q_T)JW/FCN
MN^JF'UHI/A%8OI+N3>I>7UVJ_>*->@_.7+IR81,(F$3")A$PB81,(F$3")A$
MPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$
M3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(J]_:3_ +QD
M4_*P"_0^=Y6SF?-\85#^0\_Q%6$90JTPB81,(F$3")A$PBH#_9)7\'6Q_.$K
M+_04\SIW<E]5;O6NL]\IES/NL>I9GKI2>]5*\#>?32^:TPB]Z/[&F_@]91^<
MO8_Z$U;GS1W7?53#ZT4GPBL7TEW)O4O+Z[5?O%&O0?G+ETY,(F$3")A$PB81
M,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A
M$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F
M$5>_M)_WC(I^5@%^A\[RMG,^;XPJ'\AY_B*L(RA5IA$PB81,(F$3")A%0'^R
M2OX.MC^<)67^@IYG3NY+ZJW>M=9[Y3+F?=8]2S/72D]ZJ5X&\^FE\UIA%[T?
MV--_!ZRC\Y>Q_P!":MSYH[KOJIA]:*3X16+Z2[DWJ7E]=JOWBC7H/SERZ<F$
M3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB8
M1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")
MA$PB81,(F$3"*O?VD_[QD4_*P"_0^=Y6SF?-\85#^0\_Q%6$90JTPB81,(F$
M3")A$PBH#_9)7\'6Q_.$K+_04\SIW<E]5;O6NL]\IES/NL>I9GKI2>]5*\#>
M?32^:TPB]Z/[&F_@]91^<O8_Z$U;GS1W7?53#ZT4GPBL7TEW)O4O+Z[5?O%&
MO0?G+ETY,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%HZ[O
M(VHO'9E&']KG#XA*9%"HB.-XU7=D644(.@,<*R\\MV&K*)3 NP% HN#+GC1T
MDQ9A!(L>Z=D"#9)/?6,^WLI )Y+;8$\%E((+)XV58'([(Q(X\!-BW*3T88"E
MV:) 65'/$.NT'; @Q<(.V;E'OM)=NLFJGUUQWK>RA=GI1/:G26E.-J\<)J=I
M:ZYVIPFKTIRDIUQK?JYX4Z15Y3ZWK7/?22FN=[WQUK1%^\(F$3")A$PB81,(
MF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$P
MB81,(J]_:3_O&13\K +]#YWE;.9\WQA4/Y#S_$581E"K3")A$PB81,(F$3"*
M@/\ 9)7\'6Q_.$K+_04\SIW<E]5;O6NL]\IES/NL>I9GKI2>]5*\#>?32^:T
MPB]Z/[&F_@]91^<O8_Z$U;GS1W7?53#ZT4GPBL7TEW)O4O+Z[5?O%&O0?G+E
MTY,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%7YYY^+,V\F
M4Z+[B(N-R1C6DUG9B71&07[=?C7N31V;U#.*T68L;/H6,R><M=(.)6B\* /E
MFHB2B$7H<HZTV==I]E(.,^;;8'?(/61V*&P?V;'DHS<GD)O:8:T>#5' ZWYD
MP.V2=!/&*;'QGB](EJK916-^.%C]-:N=3D 1N &^3GFXL&EA_P"J%:!E!5@4
M=RDIR.S&_+&=LYYY'FY;XY@%2H\0/$JSJ'M0C8EAAJ2,%Y=X^U/74DFD$,24
M<>C\DK=8JR=1&.P]Q7PF-/X <%*QXHO(QQ:O^&\@C_;81400,0:HAB@G( WV
M)P.K!]D[]ODQOLM!65[-BT"]?U^QB$M$.YDWE5U%[=16MB5P1.;NI])#I&JK
M$%6*4J&\2H:P:&!$E D!^0KX4]!H'7W$1F\04C4<>=E((WR.SVL<QD<\;K6M
MJ^&?D4,M$4P:P2O+1A5M^8%AV2Q!F[8M9L@*:F/'WRI>O9E<=MPJD&$ABHAI
M-9' '55P[L1-7T%D[0? @%V:BW%8AZ])GV"&CJZP1C;/LD]>YQG.<XDWL\_+
M L+DX#[=\<D,L*5S+XYUY/'['MD;;$OX/^(1.@V-42>L!X(A!@M=)VZ]:WFY
MEPJ9F'K<TQT495GNQW3FPU(ZL9ZN?QJ=0[.O.,#[K//S;#99T<\ K@%VG%I!
M5LG@T8AD7OLM/(FF0F,J>MJTK>94QXR0^Q&<<K C7A\.;L@[:%5VK8\8E(ZP
MZW>Q ]-UBY0W-X_8EM5H=E1D8QCJW\IR3VC;D#SY=1P5(3P$\9[.\8Z]D<5M
M T/-&B;J+]+$ MCOIV(DI4!&6H Y8B@U]3E1JPR26"Z9H&I6(<N+,,/RW'1:
M0V=+C;IZ4<%!(/+D,]6.9SCF>74IZX4)A$PB81,(F$3")A$PB81,(F$3")A$
MPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%7O[2?]XR*?E8!?H?.\K9S
M/F^,*A_(>?XBK",H5:81,(F$3")A%#;KSFIS4+>3I./W(Z%*V6_J.&#A]0S,
ME)+8G0AQ-.#0RIHZ/'NBDX0",JZG!PP1&M],1T?C)8RZ738MNE=E.#Y.6?-G
MMSR4GH).(I9L(A]CP0TUDD(G\7 32'R%CI;ED=C$H%-38$NUY<)(..&Y$6]:
MNTN'"**_'"VN%DDE==<<E')47?LDK^#K8_G"5E_H*>9T[N2^JMWK76>^4RYG
MW6/4LSUTI/>JE>!O/II?-:81>]']C3?P>LH_.7L?]":MSYH[KOJIA]:*3X16
M+Z2[DWJ7E]=JOWBC7H/SERZ<F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB8
M1,(F$3")A$PBBCY)6Q*81+?'JO(B[Z#N[=L":HG)%RU9NEAL6JVF[#MMX,&\
M$6[UALC*ST0C49>\N&:JO$.)R]V+68&F@PBT*<<_)\N%7=X[>:?D<\Y]F=4%
M_FVG%M>0YF-S5_8@.*AQL0\FZ*->$M\VX2<M&? Y9A!+*K2TQ%:LK7B\:4#?
M$73BTNBORL#L1_#H^51 \; Y#R['4!SV&_5SYXYC*GB;OFY1_DJC4[&M?FJV
M4.1\=W-?M:>1+KTL2<?&DR#K[-QM7.Z;Y^4(.W+3YI2=\#&?P/DRSMD50>,T
M"IQMG;TC/HYK6]VVQ.ZW\O:S$0VVYO/6CV#V'8-J^*PJ/U,[&,*@C-92]I#S
M4)>JQD/9RUX61Y M(C'X"',6;W%9;$VEJI-(PUY@KZ0#BD8QR'/ ._,GKZL
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M3;[CKS>DAZIWM@DITX[[73;<K]\I]*;2XS5U[OU9;*BGI_I9IIS-:K-<'/\
M"DL0#[I::.Y/C:SO*0AL+JHQ-<7DO:P/(!<6C5N'_H/+9?J.LK!QW74C::_\
M3V9D1L-/4.='P_Q'=+''.Z7PI "^I9;VU#V",-C?*Z-I<&AQP[^O$2+^(<+_
M #_??]E,QO[X^L_JG3?IB7_EZSG[R*V__$2N_P#+=/\ \Y7<QSVN4@/2$"#[
MHX,VY,F18KISS/'JO3?DB^09[7Y2W%N-*;2TMM32>^^-=[Y].^N??[]7-%]$
M/5U=924AX6IF"JJJ>G+Q=I7%@FE9&7AO> U%NK.,C.,9'-6-T^@NMUNMEQN
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M_P!XMR;8+%@?66T\A_[.H^S^Y7\^RZ5_W3R'_'1+_6<CPE<?Z?6_G4_[13X
ML7WEM/Z.H_V*W!4DHDJS>V-K2(ZKM&GY0LEM0L_[^$MP4CNN%4_4XWZ%>===
M:Y4Y]W7.NNM:WK6]^_8^';A7N9Q!JK:MVGARX.;JJ9CI<)J/#AE^SADX(W&3
M@K2>,[)962<':+1:V:^-K.Q^F@I&ZV&EN1+'8B&II(!+3D$@9&P6G_LNE?\
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M;>MLY\:+]!$PBW'?7[Y+G_ ZK/Z+(9FR\7?9R3UNL/ZAMBT;N<^I6'U[XO\
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MD1A?+32.B>Z)SV/,9<W!+"^-CB.66M/4K.MM]%<HFPU]+#5Q,D$K8YV"1C9
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MA3)=,]KV2GZYXZ2F#3'3X CT/=T[)GZ7MJ-!,23X5N(R^%^!WA@")KFNC&:
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MDG#9R@IPLBLGPHGWSWSK>GTE\(4F:JEX7L%/4TP,]/40VBABF@FB!?%-%(R
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M:.\<_P"[BZ_YP07_ /UUG"/WO/!GWTXG_/+5_P F7UO^_0[J'W@X"_1G$/\
M^T)_6CO'/^[BZ_YP07__ %UC][SP9]].)_SRU?\ )D_?H=U#[P<!?HSB'_\
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M?IMZU]>C?^&:.P36R[/JJF<U(M,[JQAHHY644;:EH;44DCB2^<,Z/&-!!>\
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MA>3^0\_Q%6$90JTPB815_>TIE'EK%/'-L^\,A4Z)VL[LF&,3"E9PRLY_.QL
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M,(F$3")A$PB81,(F$3")A$PBBCYATQ,+SK,'$H3V'X*CIT,D3C9IZLP:['M
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MY<>UE=\E[1(4=?59'H/3LEDTOM\%6I:*!'<KCD?9H.+-4\DTQS,V9=<.DV"
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M]Z67*[;E+MXQEL,E('KL'-I@4>P8F@&;R.*LN?I;,XHP)2!$R0.(.>O 'L#
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M4< C.Y(.LB%S=1U7\DM*-1B!S&)2:7SV!1!L\>221UY'VAWEU-6 ML.(;47
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M$CO<8#2V;\\**(G^![ F=L>7/N\NSGOVJ;.%"KID_A%.N [8C5UT@(;: CR
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M4-,5NF7C,/C/V&516:\NG'<3C:W<14FA]+4C<\';'F$YE:;05P?Y%LR@G/\
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MJIW])!411SPR .:'Q2M#XWZ7AKVZFN!PYH<,X(!V68Y;KV4<O(3RU\>O%;B
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M^E\RSKW"?VM^-_[P>\4ZYIQ)ZNN$_P"P??IEZ3<Y"NEIA%YLO9U_PXOM4?\
MD3?Z6PC.N\5_:VX)_O7>\U*YIPWZNN+/[ ]^A7I-SD2Z6OPI_P &I_Z'7_L[
MPH=R/F/N+S<?L8K\#:]_SHCW]%E69U[NR_9^U^LL7PVM7-.Y;]A:_P!='_!*
M1>DK.0KIB\W'[)X_ GI/\Z6.?T36]G7>XUZH[CZR3?#[>N:]U'[!47KM#\#K
M5Z0&O]K-_P#U"/\ D^<Y&[F?.?=726\AYA[B^^0I5,'M4OW[?9Y?EM*_I;3&
M<4[K'V<[G/K[+\+LJP=W_G%L_"#_ (X%<_G:UG$PB\WGF_\ P_WLSOR1$_\
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M6-=/Q$H&C9Y'C<B8E7H->XIMU&R9'S SU_$1U'VM[;Z9$3:/5!50"ROH7VQ
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MM,P\VN P'="(4=W!5#.Y(.T?U(>H4]!Z0U&M]?4MM_GUD^/FM<_"^'O:OO\
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M Y\Y(!'&G39RVVB3;M5-.&ZZ.^?B)*<\W$M)5P11334U1##.-4$TL,D<4S2
MX.BD>T,D&DAV6%PP0>1"\(ZFFFDEBBJ()983IFBCEC?)$[)&)6-<71G((P\
MY!',%9GENO=<5\^9#&3PD2>-1XX>U</G[]\X2:,F+)HEVNZ>/'2_::#9JV03
M46<.%E.$D4N.U%.^>.>NM5-:Y[FL8USWO<&L8T%SG.<<-:UH!+G.)   )).
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M#9JV0346<.%E.$D4N.U%.^>.>NM5-:Y[FL8USWO<&L8T%SG.<<-:UH!+G.)
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M;,>KQ59>SS_?@\X/RML/THM?/63E'_8'N!><?7['QJTW/)>B81-_N;^Y[_\
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M(VC 9\8!O&47ERNY-$77PP)99/EL0[^79NEO2AWUOX;=7K]SC>=.XDNENJ>
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M' R""KD8-ML53P #'IK'.U&J5APSZ0/(=H3JN(XP,Q@^WGV,Y'Q!3J!Y]3<
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M=I?'0TJII)7U<:4[USZMV]72RT554T<^GIJ6>6GET'4WI(7NC?I=@9;J:<'
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MO^#@&?ELM/\ ]J/YOG=:]5TGK=1>Y*M/[FWJ:;^'5?\ Z:OBSF2WY5Q^UF_
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MFJYV@@NMI'GO:2*G?IXZNJ&=M+6T=4\.<RFJJ>=[6XU.;#,R1P;D@:B&D#)
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MJ=6W$OJ)U AO;9F[^6KEB[^$P]R/QR+OC_@TD<W7B?A:GL-IX8N,-5-4/OU
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M_O>$\T/@_BZIXEN7%-#/204S.'[BVBA?"^1SJACI[A#KE#]FN HVG#-LO=U
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M9Z'->4>4N2A9UA$PB81>;+V^O[]7LHOSGR?Z64;G7^Y=]CN./6:/WBYKFG=
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MF=SMOYLXY?&I!3'P6H>8UNSK%5B="AP=SG[\B!$0Z#.2<+LB2\2MD5( 64C
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MUEE.^OJ'N;VBU57!UJGJK9;ZF=[[AKFGHJ::5^FXU;&ZI)(G/=I:T-;DG#0
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M^&%,9"R29#!4QD0X>S3Z "%.DVK)F11;-^.E.^U-\))<<[[[Z[WKU=;WN[B
M,;<@=?5Y2O%_\8^Q[@4UR]MRD/XV>#3.9W9(Z2J>U948CU[^0R9L8./ VS6,
M3<O!(@\LF7M"XRMF]GS4<)C*]ADM-WR:J#*#1LR$ETXCA)M;R;/=R S\_;7K
M'NWM.-AV[XZM]AV?$N5,?/.#>-P?<:JNRHEY21&+PB56>ZG-F>2D;=3*PN \
MMYC1&AO'4I$J_D;>];H O=<M/L/.&AYQF>D];PXQ(W+J=HD8M0JPTGJ(]@[
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(1,(F$3"+_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
